<SEC-DOCUMENT>0000950170-24-031529.txt : 20240314
<SEC-HEADER>0000950170-24-031529.hdr.sgml : 20240314
<ACCEPTANCE-DATETIME>20240314162547
ACCESSION NUMBER:		0000950170-24-031529
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		82
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240314
DATE AS OF CHANGE:		20240314

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Larimar Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001374690
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				203857670
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36510
		FILM NUMBER:		24750565

	BUSINESS ADDRESS:	
		STREET 1:		THREE BALA PLAZA EAST. SUITE 506
		CITY:			BALA CYNWYD
		STATE:			PA
		ZIP:			19004
		BUSINESS PHONE:		844-511-9056

	MAIL ADDRESS:	
		STREET 1:		THREE BALA PLAZA EAST. SUITE 506
		CITY:			BALA CYNWYD
		STATE:			PA
		ZIP:			19004

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZAFGEN, INC.
		DATE OF NAME CHANGE:	20100301

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZAFGEN INC
		DATE OF NAME CHANGE:	20060906
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>lrmr-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:lrmr="http://www.larimartx.com/20231231" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_753c0b7c-04b8-4625-9acc-6491696a4c32" name="dei:DocumentFiscalPeriodFocus" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8">FY</ix:nonNumeric><ix:nonNumeric id="F_3e826b8f-62f8-4539-8051-933f165e12de" name="dei:EntityCentralIndexKey" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8">0001374690</ix:nonNumeric><ix:nonNumeric id="F_479d3e40-b888-40c6-bf71-cd23683a2f76" name="dei:AmendmentFlag" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonFraction id="F_68573a87-9368-4180-b1d5-870fdebccda7" name="us-gaap:CommitmentsAndContingencies" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_5793ff2a-5e93-4e6d-badc-77a0ddfc5bbb" name="us-gaap:CommitmentsAndContingencies" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_b02ed5cb-0a60-495a-a92c-8887d3f31d3b" name="us-gaap:PreferredStockValue" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_9e6f1fc1-938c-4d9f-b37c-b85697a3850a" name="us-gaap:PreferredStockValue" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_79196bf3-be5b-4806-9ec5-5fed79d1cfbe" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_bcdb66fd-e3ec-478b-b8b2-8edf5a625608">P5Y</ix:nonNumeric><ix:nonNumeric id="F_1743f7c9-4f07-468e-8ed1-5de01b765813" name="us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" contextRef="C_786b0fcb-721f-4485-992a-f6eb8aa02bf3">http://fasb.org/us-gaap/2023#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember</ix:nonNumeric><ix:nonFraction id="F_8cb91d11-91f9-408e-87be-ef7e83759a47" name="us-gaap:ProceedsFromWarrantExercises" contextRef="C_4d0e0e4e-6b0a-403d-87e1-7dc7a011b1ec" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">6,284</ix:nonFraction><ix:nonNumeric id="F_1adadb6d-a5ef-4cd0-b448-c546eec4b594" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="C_b59bebb3-ca2d-4a96-ba24-a2513f6be665">P3Y</ix:nonNumeric><ix:nonNumeric id="F_54780bae-ad9f-44bf-b3f5-82dab5b666a1" name="us-gaap:LeaseExpirationDate1" contextRef="C_25c4d6a9-6524-4f9f-84fa-c1a37a44ade0">2023-08-31</ix:nonNumeric><ix:nonNumeric id="F_ed24bfd5-a8ef-478d-bee3-0b02edde6a19" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="C_c656e41d-74c1-416b-8d9c-5d87a8f0183d">P2Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="lrmr-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="C_e3617796-30ca-4ac0-abe2-0626ffe07078"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">lrmr:Ircsection174Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">lrmr:PerformedInUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_80781f96-9385-4dd5-8eb7-f026c92fd2c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_69cb0fb5-da69-40e6-80bc-099615cd64ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dac4deed-8338-46b9-9588-adb96f059754"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">lrmr:WakeForestUniversityHealthSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a74f39df-acd1-4d8b-9dba-1fd17150fcb5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c9852892-0da8-479d-83c0-1ee02dd67583"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_783e630c-cae9-4de1-9bdf-0cc7dfa2bdb8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:AdditionalOfficeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-09</xbrli:startDate><xbrli:endDate>2023-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a2ca56a1-3b79-4526-a05b-9dc40fc95833"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b1cbaf6b-72b0-4de8-aef3-35073ff760cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">lrmr:NoExpirationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5ea5486f-6817-49ce-bca9-bd58ccc45608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e9f9b4ac-b65e-40cf-8ab9-8f0d09a73535"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8bce919e-849a-4aa5-be5e-b7af4b9b190d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bb598509-13da-4a32-959a-d65c251e001c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_095c643d-76db-4c04-8cbb-33eef107ab9e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-28</xbrli:startDate><xbrli:endDate>2020-05-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_79fb8102-e267-43bc-9f8f-f08e3d54c866"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_df56d690-57ac-45e5-928f-f00b6eb9e578"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_78ca8c58-4724-4fdd-b217-9f4c3b5b885f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lrmr:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9e62e2a7-281f-4efe-9952-2af3980d814c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d735f0e0-bd1f-4ef9-b8c9-2c828c14ca2f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:LabSpaceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8f177c92-7fde-43e5-bb65-ae7ee79f52cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lrmr:ZafgenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4df7afcb-4d0e-4162-9cf0-4e8b3712bbec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cf00efe6-6c32-4b41-a584-da4e540323ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeSubleaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lrmr:FirstSubleaseYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4e7af380-9c31-42f4-a857-43c89ba539c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bcdb66fd-e3ec-478b-b8b2-8edf5a625608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lrmr:EquipmentFurnitureAndFixturesAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1f994bce-c827-41bc-8923-a0b663b5dccb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-01</xbrli:startDate><xbrli:endDate>2023-09-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c10d75ec-25a9-4bc3-b1d5-100a6af3fb57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-08</xbrli:startDate><xbrli:endDate>2019-08-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_71666c3b-3ed8-4c95-870d-c95adde92612"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cb46581b-8c63-4fee-b4c7-cc9ee9a93a21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7a4395b1-58c4-4b3b-bac0-3280e7df8802"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4d0e0e4e-6b0a-403d-87e1-7dc7a011b1ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-01</xbrli:startDate><xbrli:endDate>2023-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_89695345-0b21-49a0-8d47-0e33cf4abec6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeAndLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-04</xbrli:startDate><xbrli:endDate>2020-08-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fe994e7e-b8ca-4866-b2b8-f68f8a9ef323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lrmr:InducementStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_24df9b26-5847-47e5-b4ad-c48348d08414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a8e69aee-3f52-42fe-9a00-5c7054b2ba1f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8cd23ff2-fd7c-4814-976b-44a4de8fb1e2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-28</xbrli:startDate><xbrli:endDate>2020-05-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d4d4aee3-9c3b-49c7-bff2-63ffe90e6e2e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f93fcf7c-172c-4854-bab6-8d8a70725f95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ccc62b5b-71d4-486d-aec0-66d4350d7baf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lrmr:ZafgenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c597ff2c-39de-40dd-b55f-1bcc76bd4dc7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">lrmr:MTSHealthPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-28</xbrli:startDate><xbrli:endDate>2020-05-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f1c3acf0-ab7f-4fb7-b405-7bbdf99bfc05"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_32800e6f-ee7b-44d6-a810-966628d6e119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cf8be5df-f0b1-4821-a7e8-f9b1795798f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lrmr:FromExerciseOfWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0899eeab-0bfd-49a2-8a22-1c41967d8084"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2a37f99b-d107-4e6e-89a3-1dc033f729cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-11</xbrli:startDate><xbrli:endDate>2023-08-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_600d2614-95f3-40e4-a75b-3d7d2462a2d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeSubleaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lrmr:FirstSubleaseYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_393eb466-a24d-43ed-9e90-d9f5eb33fa0b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b8fdf4b9-43b7-4ab7-8542-b3d410371289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6dc50be6-f9ce-45f0-896b-c14acf174567"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_039998c9-136d-4c84-92be-a69133fb0a75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lrmr:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_510b971c-d3fe-4984-9d53-6865328abecd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e619f4e9-77cd-449f-8ab2-c55b57519206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a9f53337-4c5c-4958-98a5-a81a54dd3435"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d800893b-5211-4ef0-8aeb-b28cb9dd18ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeAndLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-05</xbrli:startDate><xbrli:endDate>2018-11-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_530aece5-55e1-42ca-83b2-fdd8cc766346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4b113e78-3130-4612-8c3b-467b2bc9cf25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8ad4ebd6-202a-41f5-854f-4158140e7f04"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f4ad8f7d-6e13-40e8-9f2e-5b7b5f6addd0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeAndLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-09</xbrli:startDate><xbrli:endDate>2021-08-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7edb1b10-e53a-422a-9a1e-e81b7d59c086"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_73fffb18-77da-4d3d-8982-345e143a5dd4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">lrmr:NoExpirationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a82c95f9-c18c-445c-a45f-cb3e1f90d580"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ce01a5a3-0bd6-4643-a592-16b822a79946"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_faa2d74d-3a2d-47fb-a723-778c940b635d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lrmr:EquipmentFurnitureAndFixturesAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_47c297aa-bca8-4b02-b5a1-b4f42c32fbc2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lrmr:USGovernmentSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7461d392-dc75-45e2-93a6-6a4655ad44cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lrmr:FromPriorPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b6f1f981-2a41-46ca-88f7-657876f052f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c1455b06-7113-45cb-ac47-8e1eb7003ee1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_026fc58b-40b7-41a5-a024-519b8180c981"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0042b997-c48a-4b61-bc0b-c18adeff5e3f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_69f61fa0-0ce7-4f9f-b5a6-b3da5b3c716c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeSubleaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-27</xbrli:startDate><xbrli:endDate>2020-10-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a3c09498-0d4a-46e4-b3c4-1c97a4ae24dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c1f2a4df-aa2f-4030-a1d3-a3da85f2634e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3d5bafd5-20d4-4026-a715-daa85bdc64bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">lrmr:IndianaUniversityResearchAndTechnologyCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_41a0d33b-53ab-4ae8-bdba-87ffec128add"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_112cf294-81d1-4c4c-ba37-b763be85def2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_786b0fcb-721f-4485-992a-f6eb8aa02bf3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3e015593-165f-45fc-9cb4-52b758b04a99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_196f20b7-7250-4fea-befc-99827d01c86b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lrmr:InducementStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5c533b45-4872-44aa-8eba-29efd92ddf96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">lrmr:EmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e779eef1-f227-4303-a5d4-03032bdb61b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_26cd9754-8143-4a1f-93ac-b42a31563c34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeAndLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_485ac229-ff1e-4d6d-89fa-970087d282fe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:AdditionalOfficeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bdabb33a-7162-4c37-8a9a-3a553319cde1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">lrmr:WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-11</xbrli:startDate><xbrli:endDate>2019-12-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e5052803-8e24-4b5c-bf1d-feeb356d8445"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_25c4d6a9-6524-4f9f-84fa-c1a37a44ade0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-09</xbrli:startDate><xbrli:endDate>2023-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d39d1e4b-8b4a-4b1b-9377-433018f6afff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_02732bcd-6e0a-478e-b53c-e115414d242b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">lrmr:WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a4f1b737-b155-4ae3-9c2f-2c7f4437ce11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4d67c562-0e3a-4233-a627-82c574413619"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">lrmr:EmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-17</xbrli:startDate><xbrli:endDate>2024-01-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f2aae2bb-8999-4b7a-9f12-440a582140f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lrmr:SixthSubleaseYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeSubleaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cfbfa2af-4b87-40ab-a789-900833fd126d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c68ae4ef-38ed-4e5e-950b-6c460b173668"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8d3107c2-8938-4cdd-a26e-1dde989d7e23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2066b280-00da-4f34-bd69-b3d154d32fd8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_04fe8bd0-766a-4741-afc3-501f8a39c817"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">lrmr:DomesticAndStateLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b59bebb3-ca2d-4a96-ba24-a2513f6be665"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_94e051e5-07aa-4e1e-a62e-12871b5fe6b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_860248e3-56cf-4688-98a3-19daf6e5ff6f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">lrmr:EmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">lrmr:FirstAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5b2496bb-0283-4097-be94-f3832f36eb00"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lrmr:InducementStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9592d411-a0cd-4a54-9714-8ba1a249205b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1efd9ede-f9a2-45c2-93a1-636a41f2a1f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:AdditionalOfficeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_17f828a8-cd38-4b18-ac31-c79bc0508443"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fa925083-1371-4656-ab14-7ea6e7f54fb3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">lrmr:EmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-17</xbrli:startDate><xbrli:endDate>2024-01-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5c3f05e5-8f01-4df5-a495-e7063f7dcbec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_953fc3f7-0bdc-46a5-a81f-b24a2a0ecad9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lrmr:InducementStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_740659e5-2866-4797-81d2-afb8bf9c13fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4b5e3f0d-190b-43a0-915d-81748af18c9f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_995af330-bf27-4e38-9645-1ac883fd043e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lrmr:USGovernmentSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b9dcce0a-1f1b-450f-80d2-41ae1be44f56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cf75de90-0aaa-46d6-bc15-445c359ea784"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0247df73-9c90-49d2-a664-08a0e4028d55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b312098e-3ef4-4545-b143-2d83afce1c16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0bbb406f-e95b-44a2-aa20-069ec9f8367d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b094896e-8ca7-4bae-b10c-753cf6471626"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeSubleaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lrmr:FinalSubleaseYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_88192957-9603-4bc3-a321-f4c70d5a065f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5baad777-d068-4ce3-be35-c76ec7ffb655"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">lrmr:EmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">lrmr:FirstAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-17</xbrli:startDate><xbrli:endDate>2024-01-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a3395847-e949-4251-a28f-6484e3b7556e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">lrmr:FirstAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lrmr:InducementStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b696efd6-314c-4861-aaea-8e43ed271ae6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f0f9091f-cf20-4767-8991-bfab4c73cc6d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_846f3ecc-8d1c-4bc9-aa46-2d08b1bb1e55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3b388c97-79fa-4717-81b4-abd04c453ac4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_59823e91-6700-4233-b1ac-e431259ec4c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lrmr:USGovernmentSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d76e4f25-f643-4f25-bc71-be694bd78953"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7c80164a-e618-431e-908f-17026b8e4ae2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_37911699-3824-4881-9471-81254e29f4ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7812fd06-a01a-48d2-ab1b-3ad1ddddf263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5602ff77-c44f-4314-9ff2-70c3f8d3ba31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e879db45-fbcf-422c-84ea-f7c96123af6f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">lrmr:DomesticAndStateLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_26ed7eb8-3335-4a45-993d-30b861b1ef11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c656e41d-74c1-416b-8d9c-5d87a8f0183d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeAndLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_279e75b7-f67a-4ee0-b268-adff2a559757"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">lrmr:IndianaUniversityResearchAndTechnologyCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_064057be-fcdf-4308-890d-a8ada4719458"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lrmr:FromPriorPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3beedc45-1504-486d-95b7-175808b52042"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9d1af696-7d08-4f42-87a7-b186b43ac50d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-28</xbrli:startDate><xbrli:endDate>2020-05-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_22aa2b7d-3358-4d02-ae96-34174231f4a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lrmr:USGovernmentSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_95b87097-23b2-4be8-a5a4-68ffcb45d537"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">lrmr:WakeForestUniversityHealthSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f1669ee1-0407-437f-848e-7c1d63a35e33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a0d3bc37-c2c5-449e-9b72-d46590f710ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ba0cb289-2a01-465c-bc0c-d7869d54c786"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">lrmr:Ircsection174Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">lrmr:PerformedOutsideUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4a47b017-2508-45fe-a4d9-e2f06dcde4b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1c1b0f6e-ec81-493a-a1e1-b384f3fff492"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">lrmr:EmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <div style="min-height:0.5in;"></div>
  <p style="border-top:2.25pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">t</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">Form </span><span style="font-size:16pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b98e6082-3d13-4fd6-9232-c9585c8e9c72" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">10-K</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">(Mark One)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"/>
    <td style="width:96%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_0c3fc938-3933-4b12-825f-44d07629e7bf" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="dei:DocumentAnnualReport" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fb500297-b998-40fb-bcb1-73678eedc0bd" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2637af49-1bb6-4a66-b19d-11539426bcac" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3ace50fb-f126-46da-b935-85db70e4a6f2" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">2023</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">or</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"/>
    <td style="width:96%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_7d9dde10-6809-4bba-92b6-4f8c783710a3" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="dei:DocumentTransitionReport" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">For the transition period from to</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Commission File Number </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8f1edc67-46ff-4a62-b699-4d9b9c2c7c05" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">001-36510</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:16pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d3489c83-1a01-46c3-b7d1-e43424924498" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">LARIMAR THERAPEUTICS, INC.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:22pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:0.04%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.5%;"/>
    <td style="width:1%;"/>
    <td style="width:49.5%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;text-align:left;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_adf7578f-92eb-4f63-ab9b-a5ce87e37e8d" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_420e8e5a-d83a-49e1-8876-29791c7ec8a0" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">20-3857670</span></ix:nonNumeric></span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Identification No.)</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;text-align:left;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:left;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;text-align:left;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_c36a549d-2fab-4e11-bf69-bea85e1c8cfd" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Bala Plaza East</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;min-width:fit-content;">, </span><span style="font-size:8pt;"><ix:nonNumeric id="F_69761ab6-49b1-4410-9142-85523e058f77" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Suite 506</span></ix:nonNumeric></span></p><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_76ef918c-fa2a-4f9b-9510-04b01270508e" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Bala Cynwyd</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;min-width:fit-content;">, </span><span style="font-size:8pt;"><ix:nonNumeric id="F_b9507bfd-de3e-487e-9f52-75aa829e9875" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Pennsylvania</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;min-width:fit-content;"> </span></p><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_fa873981-2a3e-4b29-9e96-f395ff4ace33" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">19004</span></ix:nonNumeric></span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Zip Code)</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8bb275aa-a6b0-4904-b9da-61e38787b955" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">844</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">) </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6c74f906-ad39-4af9-9df8-c5ef31805312" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">511-9056</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Registrant&#8217;s telephone number, including area code)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:40%;"/>
    <td style="width:20%;"/>
    <td style="width:40%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="border-top:0.75pt solid #000000;border-right:0.75pt solid #000000;border-left:0.75pt solid #000000;vertical-align:middle;border-bottom:0.75pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title of each class</span></p></td>
    <td style="border-top:0.75pt solid #000000;border-right:0.75pt solid #000000;vertical-align:middle;border-bottom:0.75pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Trading Symbol(s)</span></p></td>
    <td style="border-top:0.75pt solid #000000;border-right:0.75pt solid #000000;vertical-align:middle;border-bottom:0.75pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="border-right:0.75pt solid #000000;border-left:0.75pt solid #000000;vertical-align:middle;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_343b3a00-9e09-4fba-83c2-7323c588098b" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common Stock, par value $0.001 per share</span></ix:nonNumeric></span></p></td>
    <td style="border-right:0.75pt solid #000000;vertical-align:middle;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_2845f6f3-0b25-4497-85db-39eb45a0091d" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">LRMR</span></ix:nonNumeric></span></p></td>
    <td style="border-right:0.75pt solid #000000;vertical-align:middle;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_8aebbd9b-93d9-4ddb-acb8-8e333f293b09" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The Nasdaq Global Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. &#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Yes &#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;"> </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_067a50c5-8ac0-4010-8871-0bce984ce18a" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="dei:EntityWellKnownSeasonedIssuer"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">No</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. &#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Yes &#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;"> </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_189824df-86bc-41d7-9b39-f66d38948d4a" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="dei:EntityVoluntaryFilers"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">No</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2b5a366e-3069-48fe-8727-c4d416ba7c93" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> &#9746; No &#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_da285eff-2238-41da-9a41-5446ef9f1fe3" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> &#9746; No &#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:25%;"/>
    <td style="width:5%;"/>
    <td style="width:40%;"/>
    <td style="width:25%;"/>
    <td style="width:5%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_539c227f-5815-40b0-b5ce-14321b71ccc4" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><ix:nonNumeric id="F_949a7a64-9fcb-408d-9d9e-309432cb5399" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><ix:nonNumeric id="F_795e25dc-771f-4c85-900d-da3e71efb3af" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d9b4c90b-bce4-4d3d-aec3-764eb6cd5575" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><br/>If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a90156c2-442d-49e0-8062-b21b9025df47" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#9744;<br/></span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"><br/><br/>Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; No </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_081f134e-fbc7-4045-b9ec-995b95b3688c" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">On the last business day of the most recently completed second fiscal quarter, the aggregate market value (based on the closing sale price of its common stock on that date) of the voting and non-voting stock held by non-affiliates of the registrant was $</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e30fbad2-51dc-4112-8671-a4ccc1f80872" contextRef="C_c68ae4ef-38ed-4e5e-950b-6c460b173668" name="dei:EntityPublicFloat" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,218,629</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">As of March 12, 2024, the registrant had </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_39852e52-2a46-416f-9dbc-b2776b6363f6" contextRef="C_0247df73-9c90-49d2-a664-08a0e4028d55" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">63,800,017</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> shares of the registrant&#8217;s Common Stock, $0.001 par value per share, outstanding.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d0b6873f-1276-49d7-90b8-3b954fb8dee6" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Part III of this Annual Report on Form 10-K incorporates certain information by reference from the registrant&#8217;s proxy statement for the 2024 annual meeting of shareholders to be filed no later than 120 days after the end of the registrant&#8217;s fiscal year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.36pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="toc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TABLE OF CONTENTS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:13.3%;"/>
    <td style="width:78.52%;"/>
    <td style="width:8.18%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Item No.</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Page No.</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="3" style="padding-top:0.007in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="#parti_291637"><span style="color:#0000ee;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART I</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item1business_796317"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">ITEM 1.</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item1business_796317"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">BUSINESS</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item1ariskfactors_798482"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">ITEM 1A.</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item1ariskfactors_798482"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">RISK FACTORS</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item1bunresolvedstaffcomments_265117"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">ITEM 1B.</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item1bunresolvedstaffcomments_265117"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">UNRESOLVED STAFF COMMENTS</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item1ccybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">ITEM 1C.</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item1ccybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">CYBERSECURITY</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item2properties_264380"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">ITEM 2.</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item2properties_264380"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">PROPERTIES</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item3legalproceedings_49550"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">ITEM 3.</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item3legalproceedings_49550"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">LEGAL PROCEEDINGS</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item4minesafetydisclosures_57184"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">ITEM 4.</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item4minesafetydisclosures_57184"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">MINE SAFETY DISCLOSURES</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="3" style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="#partii_672268"><span style="color:#0000ee;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART II</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item5marketforregistrantsscommonequity_9"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">ITEM 5.</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item5marketforregistrantsscommonequity_9"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">90</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item6selectedconsolidatedfinancialdata_6"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">ITEM 6.</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item6selectedconsolidatedfinancialdata_6"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">SELECTED FINANCIAL DATA</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">90</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item7managementsdiscussionandanalysis_41"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">ITEM 7.</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item7managementsdiscussionandanalysis_41"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">91</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item7aquantitativeandqualitativedisclosu"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">ITEM 7A.</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item7aquantitativeandqualitativedisclosu"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">98</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item8financialstatementsandsupplementary"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">ITEM 8.</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item8financialstatementsandsupplementary"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">98</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item9changesinanddisagreementswithaccoun"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">ITEM 9.</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item9changesinanddisagreementswithaccoun"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">98</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item9acontrolsandprocedures_737107"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">ITEM 9A.</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item9acontrolsandprocedures_737107"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">CONTROLS AND PROCEDURES</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">98</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item9botherinformation_654168"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">ITEM 9B.</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item9botherinformation_654168"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">OTHER INFORMATION</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item9cforeignjurisdictions"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">ITEM 9C</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item9cforeignjurisdictions"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="3" style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="#partiii_936646"><span style="color:#0000ee;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART III</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item10directorsexecutiveofficersandcorpo"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">ITEM 10.</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item10directorsexecutiveofficersandcorpo"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item11executivecompensation_214372"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">ITEM 11.</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item11executivecompensation_214372"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">EXECUTIVE COMPENSATION</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item12securityownershipofcertainbenefici"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">ITEM 12.</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item12securityownershipofcertainbenefici"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item13certainrelationshipsandrelatedtran"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">ITEM 13.</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item13certainrelationshipsandrelatedtran"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item14principalaccountingfeesandservices"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">ITEM 14.</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item14principalaccountingfeesandservices"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">PRINCIPAL ACCOUNTING FEES AND SERVICES</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="3" style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="#partiv_994849"><span style="color:#0000ee;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART IV</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item15exhibitsfinancialstatementschedule"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">ITEM 15.</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item15exhibitsfinancialstatementschedule"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">EXHIBIT AND FINANCIAL STATEMENT SCHEDULES</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16_form_10k_summary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">ITEM 16.</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16_form_10k_summary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">FORM 10-K SUMMARY</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures_181481"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">SIGNATURES</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">105</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Statements made in this Annual Report on Form 10-K that are not statements of historical or current facts are &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements discuss our business, operations and financial performance and conditions, as well as our plans, objectives and expectations for our business operations and financial performance and condition. In some cases, you can identify forward-looking statements by terminology such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;assume,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;design,&#8221; &#8220;due,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;positioned,&#8221; &#8220;potential,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. In addition, statements that &#8220;we believe&#8221; or similar statements reflect our beliefs and opinions on the relevant subject only. These forward-looking statements, which are subject to risks, uncertainties and assumptions about us, may include projections of our future financial performance, our anticipated growth strategies and anticipated trends in our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">You should understand that the following important factors could affect our future results and could cause those results or other outcomes to differ materially from those expressed or implied in our forward-looking statements:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">uncertainties in obtaining successful non-clinical or clinical results that reliably and meaningfully demonstrate safety, tolerability and efficacy profiles that are satisfactory to the FDA, European Medicines Agency ("EMA") and other comparable regulatory authorities for marketing approval for nomlabofusp (nomlabofusp is the International Nonproprietary Name and the United States Adopted Name for CTI-1601) or any other product candidate that we may develop in the future and unexpected costs that may result therefrom;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in patient recruitment for our clinical trials (including as a result of the impact of FDA approval of competitive products for the treatment of Friedreich's ataxia ("FA"), and/or the impact of other clinical trials of competitive products), delays as a result of clinical and non-clinical results and/or FDA's request for additional information or studies (whether clinical or non-clinical), changes in clinical protocols, unexpected adverse events, regulatory restrictions, including additional clinical holds, and milestones for nomlabofusp;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to successfully execute our open label extension trial (&#8220;OLE&#8221;), including the timing of site initiation and rate of patient enrollment, and our ability to pursue dose escalation;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">uncertainties associated with the clinical development and regulatory approval for nomlabofusp, including potential delays in the commencement, enrollment and completion of clinical trials, the timing of a potential Biologics License Application (&#8220;BLA&#8221;) submission for accelerated approval, including our ability to supply to the FDA all required data for FDA to review and accept an accelerated application, or any other product candidate that we may develop in the future;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the difficulties and expenses associated with obtaining and maintaining regulatory approval for nomlabofusp or any other product candidate we may develop in the future, and the indication and labeling under any such approval;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">how long we can continue to fund our operations with our existing cash, cash equivalents and marketable securities and our estimates regarding future results of operations, financial position, research and development costs, capital requirements and our access and needs for additional financing;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability, and the ability of third-party manufacturers we engage, to optimize and scale nomlabofusp or any other product candidate&#8217;s manufacturing process and to manufacture sufficient quantities of clinical supplies, and, if approved, commercial supplies of nomlabofusp or any other product candidate that we may develop in the future and our ability to maintain our relationships and contracts with our key vendors and to identify and contract with alternate or secondary key vendors;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to realize any value from nomlabofusp and/or any other product candidate we may develop in the future in light of inherent risks and difficulties involved in successfully bringing product candidates to market and the risk that the product candidates, if approved, will not achieve broad market acceptance;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to comply with regulatory requirements applicable to our business and other regulatory developments in the United States and other countries;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the size and growth of the potential markets for nomlabofusp, if approved, or any other product candidate that we may develop in the future, the rate and degree of market acceptance of nomlabofusp, if approved, or any other product candidate, that we may develop in the future and our ability to serve those markets;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">given competing therapies and products for the treatment of FA, our ability to obtain and maintain designations or eligibility for expedited regulatory programs, and to commercialize current and future product candidates, if approved, (including the impact of potential barriers to entry if a competitor is able to establish a strong market position before we are able to commercialize our products);</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain and maintain patent protection and defend our intellectual property rights against third parties;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the performance and compliance with the rules and regulations of the FDA (and all other regulatory authorities) of third parties upon which we depend, including third-party contract research organizations ("CROs"), consultants and third-party suppliers, manufacturers, distributors, and logistics providers;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to recruit and retain key scientific, technical, commercial, and management personnel and to retain our executive officers;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to maintain proper functionality and security of our internal computer and information systems and prevent or avoid cyber-attacks, malicious intrusion, breakdown, destruction, loss of data privacy or other significant disruption;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent to which geopolitical tensions including regional conflicts around the world, adverse macroeconomic events, including those due to inflationary pressures, rising interest rates, banking instability, economic slowdowns or recessions, health epidemics, unforeseen emergencies and other outbreaks of communicable diseases could disrupt our operations, the operations of third parties on which we rely or the operations of regulatory agencies we interact with in the development of nomlabofusp and any other product candidates that we may develop; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the potential impact of healthcare reform in the United States, including the Inflation Reduction Act ("IRA") of<br/> 2022, and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the other risks and uncertainties included under the section titled &#8220;Risk Factors.&#8221;</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These forward-looking statements are based on management&#8217;s current expectations, estimates, forecasts and projections about our business and the industry in which we operate, and management&#8217;s beliefs and assumptions are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Although we believe the expectations reflected in the forward-looking statements are reasonable, the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements may not be achieved or occur at all. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this Annual Report on Form 10-K or to reflect the occurrence of any unanticipated events. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless expressed as such, and should only be viewed as historical data.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SUMMARY RISK FACTORS</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The risk factors summarized and detailed below could materially harm our business, operating results and/or financial condition, and may impair our future prospects and/or cause the price of our common stock to decline. These are not all of the risks we face, and other factors not presently known to us or that we currently believe are immaterial may also affect our business if they occur. Material risks that may affect our business, operating results and financial condition include, but are not necessarily limited to, those relating to:</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Financial Position and Need for Capital</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred significant losses since our inception and anticipate that we will incur continued losses for the foreseeable future.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have no commercial revenue and may never become profitable.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2024, we completed an underwritten public offering of common stock raising net proceeds of approximately $161.6 million We anticipate that this amount, combined with our current cash, cash equivalents and marketable securities will fund operations into 2026. We may need to raise additional funding in order to continue our planned operations. This funding may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed would force us to delay, limit or terminate our product development efforts or other operations.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Product Development and Regulatory Approvals</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An FDA partial clinical hold remains in place for the nomlabofusp development program. While the FDA agreed to allow us to conduct the Phase 2 dose exploration trial up to a dose of 50 mg daily for 14 days followed by every other day for 14 days for a total of 28 days, and that we can begin an OLE trial of nomlabofusp at a daily dose of 25 mg, there is uncertainty as to when, or if, the FDA will allow an OLE dose above 25 mg, or allow further clinical development of nomlabofusp beyond the OLE study. </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot be certain data from the OLE study or prior clinical studies will provide the FDA with adequate data to allow the nomlabofusp development program to proceed as planned in part or in full, and even if so, that we will ultimately be successful with our clinical development or that we will ever be able to obtain regulatory approval for nomlabofusp.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may experience difficulties identifying and enrolling patients in our clinical trials given the limited number of patients who have the disease for which nomlabofusp is being studied or for any other product candidate. Difficulty in enrolling patients could delay or prevent clinical trials of nomlabofusp or any future product candidate. There is also a competing approved FA therapeutic, other competing studies and potentially other FA therapeutics that could be approved that may also limit the availability of participants for nomlabofusp clinical trials.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additional competing technologies could emerge, adversely affecting our opportunity to generate revenue from the sale of nomlabofusp.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Failures or delays in the completion of our clinical trials could result in increased costs and could delay, prevent or limit our ability to generate revenue and continue our business.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Nomlabofusp may cause adverse events or undesirable side effects in non-clinical or clinical trials that could delay or prevent its regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following regulatory approval, if any. Because we anticipate that nomlabofusp will require chronic dosing over the lifetime of patients and because we have only tested nomlabofusp in a limited number of patients for a maximum of 14 days daily and every other day from day 15 to day 28, there may be undesirable side effects as of result of long-term exposure to nomlabofusp that we have not seen to date in our clinical trials.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We intend to pursue an accelerated approval from FDA for nomlabofusp for the treatment of FA using FXN levels, supportive pharmacodynamics ("PD") and clinical information, and safety data from the OLE study, along with additional nonclinical pharmacology information needed to use FXN levels as a novel surrogate endpoint. Although we have initiated discussions with FDA regarding our surrogate biomarker </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">approach, there can be no assurance that data we intend to generate will be successful in establishing, among other things, that dose-dependent increases in FXN levels are reasonably likely to predict or demonstrate a clinical benefit.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in regulatory requirements, FDA guidance, guidance from other regulatory authorities or unanticipated events during our non-clinical or clinical trials of nomlabofusp or future product candidates may result in changes to clinical trial protocols or additional non-clinical or clinical trial requirements, which could result in increased costs to us and could delay our development timeline.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell nomlabofusp in the US and/or foreign markets, if approved, we may not be able to generate any revenue.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we receive marketing approval for nomlabofusp, we may not achieve broad market acceptance, which would limit the revenue that we generate from our sales.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we obtain regulatory and marketing approval for a product candidate, our product candidates will remain subject to regulatory oversight.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Business</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to manage expected growth in the scale and complexity of our operations, including attracting and hiring additional qualified management, including commercial, sales and marketing management, our performance may suffer.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to healthcare laws and regulations, and health information privacy and security laws, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Reliance on Third Parties</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have limited experience in conducting or supervising clinical trials and must outsource all clinical trials. As a result, many important aspects of our drug development programs are outside our direct control.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely on third-parties to manufacture the materials for our research and development, including our non-clinical and clinical study drug substance and drug product. </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are undertaking a program with a third party to produce a lyophilized version of nomlabofusp that, once available, we intend to use in our planned clinical trials. If we are unable to successfully produce a lyophilized version, our ability to execute our clinical trials and commercially launch nomlabofusp could be adversely affected.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not yet manufactured or formulated nomlabofusp on a commercial scale and we may not be able to do so. As a result, our ability to adequately commercially launch and/or supply nomlabofusp could be adversely affected. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Intellectual Property Rights</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If, in the United States and other countries, we are unable to adequately protect our proprietary technology or maintain issued patents which are sufficient to protect nomlabofusp or potential product candidates, third parties could compete against us more directly, which would have a material adverse impact on our business, results of operations, financial condition and prospects.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our key patent, which we license related to nomlabofusp, will expire in 2040 and we will lose our ability to rely upon this patent to prevent competing products from entering the market.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Common Stock</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our stock price is highly volatile, and purchasers of our common stock could incur substantial losses.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We must maintain effective internal controls over financial reporting, and if we are unable to do so, the accuracy and timeliness of our financial reporting may be adversely affected, which could have a material adverse effect on our business and stock price.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ownership of our common stock is highly concentrated, and it may prevent other stockholders from influencing significant corporate decisions.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="parti_291637"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART I</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item1business_796317"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 1. BUSINESS</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using our novel cell penetrating peptide ("CPP") technology platform. Our lead product candidate, nomlabofusp (nomlabofusp is the International Nonproprietary Name ("INN") and the United States Adopted Name ("USAN") for CTI-1601), is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin ("FXN"), an essential protein, to the mitochondria of patients with Friedreich's ataxia (&#8220;FA&#8221;). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Currently, there are no treatment options that address the core deficit of FA, low levels of FXN. Nomlabofusp represents the first potential therapy designed to increase FXN levels in patients with FA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that our CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. We intend to use our proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since our inception, we have devoted substantially all of our resources to developing nomlabofusp, building our intellectual property portfolio, developing third-party manufacturing capabilities, business planning, raising capital, and providing general and administrative support for such operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had cash, cash equivalents and marketable securities of $86.8 million. In February 2024,we raised net proceeds of $161.6 million in an underwritten public offering of common stock, We anticipate the $161.6 million in net proceeds, together with $86.8 million of cash, cash equivalents and marketable securities on hand will fund operations into 2026.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Nomlabofusp Program Update</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Trials</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have completed two Phase 1 clinical trials and a Phase 2 dose exploration trial, and recently initiated a Phase 2 OLE trial in patients with FA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2021, we reported positive top-line data from our Phase 1 FA program after completing dosing of the single ascending dose ("SAD") trial in December 2020 and of the multiple ascending dose ("MAD") trial in March 2021. Data from these trials demonstrated proof-of-concept by showing that daily subcutaneous injections of nomlabofusp for up to 13 days resulted in dose-dependent increases in FXN levels from baseline compared to placebo in all evaluated tissues (buccal cells, skin, and platelets). There were no serious adverse events associated with either the MAD or SAD trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2023, we reported preliminary unblinded top-line data from the 25 mg cohort of our Phase 2 four-week, placebo-controlled, dose exploration trial of nomlabofusp in FA patients. Data from the cohort indicated nomlabofusp was generally well tolerated and showed increases in FXN levels from baseline compared to placebo in all evaluated tissues (skin and buccal cells) at day 14.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2023, following the FDA&#8217;s review of our complete response to the partial clinical hold, the FDA cleared initiation of a second cohort (50 mg) of our four-week, placebo-controlled, Phase 2 dose exploration trial of nomlabofusp in patients and the initiation of our OLE trial with daily dosing of 25 mg.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2024, we reported positive top-line data and successful completion of our four-week, placebo-controlled Phase 2 dose exploration study of nomlabofusp in participants with FA. Nomlabofusp was generally well tolerated and demonstrated dose dependent increases in FXN levels in all evaluated tissues (skin and buccal cells) after daily dosing of 14 days followed by every other day dosing until day 28 in the 25 mg and 50 mg cohorts. Participants in the 25 mg (n=13) and 50 mg (n=15) cohorts were randomized 2:1 to receive subcutaneous injections of nomlabofusp or placebo. Participants treated with 50 mg had individual frataxin levels in skin increase from less than 17% relative to healthy volunteers at baseline, to 33% to 59% of healthy volunteers after 14 days of treatment. Patients treated with placebo showed no increase in their frataxin levels during this period. Additionally, the majority of treated patients in both cohorts with quantifiable levels of frataxin at baseline and day 14 achieve at least</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a 100% increase in tissue frataxin in skin cells, and at least a 30% increase in tissue frataxin levels in buccal cells. With both skin and buccal cells, when dosing is switched to every other day the magnitude of the increase declines.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2024, we initiated the OLE trial evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver, with the first patient dosed in March 2024. Participants who completed treatment in the Phase 2 dose exploration trial, or who previously completed a prior clinical trial of nomlabofusp are potentially eligible to screen for the OLE. The OLE will evaluate safety, tolerability, pharmacokinetics ("PK") and measures of frataxin levels in peripheral tissues as well as other exploratory PD (lipid profiles and gene expression data) following long-term subcutaneous administration of nomlabofusp. Clinical measures collected during the trial will be compared to data from a matched control arm derived from participants in the Friedreich&#8217;s Ataxia Clinical Outcome Measures Study (FACOMS) database. Dose escalation in the OLE trial will be considered based on safety, tolerability, PK, and tissue FXN levels from the Phase 2 trial&#8217;s 50 mg cohort as well as available data from the 25 mg dose of nomlabofusp in the OLE trial, and is contingent on FDA review as part of the partial clinical hold. Initial data from the OLE trial is expected in the fourth quarter of 2024.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Strategy</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our strategy is to become a leader in the treatment of rare diseases by leveraging our technology platform and applying our management team&#8217;s know how and expertise to the development of nomlabofusp and other future pipeline programs. Key elements of our strategy include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Advance nomlabofusp through clinical development and regulatory approval in the United States the European Union and other foreign jurisdictions</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We have completed two Phase 1 clinical trials and a Phase 2 dose exploration trial in patients with FA in the United States and have initiated an OLE study in the U.S with patients age 18 or older to be dosed 25 mg of nomlabofusp daily. Expansion of this OLE to doses above 25 mg as well as the initiation of additional U.S. clinical trials evaluating nomlabofusp are contingent on FDA review as part of the FDA&#8217;s partial clinical hold. We do not know if, or when, the FDA will lift the partial clinical hold on our nomlabofusp program or if it will ever allow further clinical development of nomlabofusp beyond the current OLE study that we recently initiated. We also are planning to include in our clinical studies, individuals between the ages of 2 and 17 and are currently in discussions with FDA as to what additional clinical trial data in adults would inform inclusion of those pediatric individuals in our studies. We are continuing to collaborate with key opinion leaders and seek guidance from regulatory authorities to develop and execute a clinical development plan for regulatory approval of nomlabofusp in the United States, the European Union, the United Kingdom ("UK"), Australia, Canada and potentially other countries. </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intend to pursue the use of tissue frataxin levels as a novel surrogate endpoint to support a potential Biologics License Application (&#8220;BLA&#8221;) submission for accelerated approval</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Recently, we had discussions with the FDA regarding the potential use of tissue FXN levels as a novel surrogate endpoint. The FDA has acknowledged that frataxin deficiency appears to be critical to the pathogenic mechanism of FA, and that there continues to be an unmet need for treatments for FA patients that address the underlying disease pathophysiology. We intend to pursue an accelerated approval using FXN levels, supportive PD and clinical information, and safety data from the OLE study, along with additional non-clinical pharmacology information needed to support the novel surrogate endpoint approach. We are beginning to plan for a confirmatory study and are targeting a BLA submission in the second half of 2025. </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If nomlabofusp receives regulatory approval(s), commercialize nomlabofusp in the United States, the European Union, and other relevant countries independently or with third parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We intend to evaluate commercialization options in the United States, the European Union, the United Kingdom and in other foreign jurisdictions throughout the world where FA patients can benefit, if we are successful in obtaining regulatory approval. We may build our own internal sales force; partner with a contract sales organization, and/or enter into a joint marketing partnership with another pharmaceutical or biotechnology company, whereby we may jointly sell and market nomlabofusp, if approved; or we may seek to out-license nomlabofusp, whereby other pharmaceutical or biotechnology companies sell and market nomlabofusp and pay us milestone and/or royalty payments on sales. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expand our product candidate pipeline to treat a variety of rare diseases. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We intend to expand our pipeline to treat additional rare diseases. A key component of this strategy is to utilize our novel protein replacement therapy platform technology to deliver FXN or other molecules to intracellular targets. We employ a rational approach to selecting disease targets, and take into account many scientific, business, and indication specific factors before choosing each indication. </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Continue to improve our novel protein replacement therapy platform. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We continue to improve the scientific understanding of our platform, including how our technology allows enhanced delivery of cargo proteins, thereby impacting the biological processes associated with the diseases we seek to treat. In addition, with our expertise in the use of a CPP to effectively deliver proteins to intracellular targets, we believe that our scientists are well positioned to design and develop additional therapies that will address unmet medical needs associated with other rare diseases and develop other therapeutics with potentially disease modifying therapeutic action. We also plan to continue to build our intellectual property portfolio to expand our protein replacement therapy platform. </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Opportunistically evaluate enabling, adjacent or potential competing technologies, and where advantageous, seek licenses or collaborations regarding those technologies, to advance our platform.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We will continue to evaluate technologies that may enable or enhance our product candidates or our rare disease focus. To facilitate the advancement of our CPP platform, we periodically engage in partnering and licensing discussions with a range of biotechnology or pharmaceutical companies and academic institutions and maintain awareness of complementary technologies, synergistic opportunities and "tuck-in" options. </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Continue to strengthen key relationships.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We partner with experts in every aspect of development. We believe this expertise, along with our technology platform, will provide us with the ability to develop and commercialize the drug and biologic candidates we have under development and to maximize the value of our platform. In addition to partnering with experts in drug and biologic development, we collaborate with key opinion leaders, academic institutions, experts in the field of rare diseases and with patient advocacy groups associated with the diseases that are being targeted. We have established a scientific advisory board and we regularly seek advice and input from these experienced thought leaders on matters related to our research and development programs. The members of our scientific advisory board consist of distinguished research scientists, professors and industry experts recognized as key opinion leaders in the fields of rare disease, pediatrics and mitochondrial disease. We build these relationships to enhance our knowledge of the patient&#8217;s needs and utilize that knowledge to design development programs intended to address unmet medical needs and add value for potential patients. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Platform Technology for Treatment of Rare Genetic Diseases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are estimated to be over 9,500 rare genetic diseases, which, collectively affect hundreds of millions of people worldwide. Of the hundreds of millions of individuals suffering from these rare genetic diseases, only approximately 5% have therapeutic options available to manage their disease. Many of these diseases result from a deficiency in the amount or the function of a particular target molecule, often a protein. Particularly challenging to treat are those diseases that result from the deficiency of a molecule that is active within a cell or within a cell-based organelle. The challenge to providing treatment of these diseases is the need to improve the amount or function of the therapeutic target by transporting a therapeutic element across the cell membrane and potentially the membrane of the organelle where the target is active in the diseased patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The ability to transport therapeutic proteins across biological membranes has, to date, not been reproducibly achieved. The collective population of people with rare diseases stands to benefit from the emergence of a scalable treatment platform that can transport therapeutic proteins across cell membranes to deliver them to the intracellular site of activity. In addition, traditionally, medical treatment for each rare genetic disorder has been approached on a disease-by-disease basis. This approach is inefficient, as there are thousands of diseases, each with a distinct patient population, that cannot be addressed by traditional therapeutic approaches and are in need of treatment options. Our understanding of our therapeutics derived from proprietary gene expression data across several disease models supports the concept that product candidates based on our platform technology could significantly impact common pathological mechanisms in various diseases with comparable etiologies. We are utilizing this approach to identify therapeutic opportunities where our molecules and technology are more likely to be impactful.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Nomlabofusp For the Treatment of Friedreich&#8217;s ataxia</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Friedreich&#8217;s ataxia</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Friedreich&#8217;s ataxia is a rare genetic disease that is the most commonly inherited ataxia in humans, with approximately 20,000 individuals living with Friedreich&#8217;s ataxia globally, and of these individuals, approximately 5,000 are in the United States and the majority of the remaining individuals are primarily in Europe. Friedreich&#8217;s ataxia results from a deficiency of the mitochondrial protein, FXN. FXN is an essential and phylogenetically conserved protein that is found in cells throughout the body, with the highest levels found in the heart, spinal cord, liver, pancreas, and skeletal muscle. FXN is encoded in the nucleus of the cell, expressed in the cytoplasm and transported into the mitochondria, where it is processed to the mature form. As part of this process the mitochondrial targeting sequence is cleaved off in the mitochondria by a naturally occurring enzyme.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Friedreich&#8217;s ataxia is a progressive multi-symptom disease typically presenting in mid-childhood that affects the functioning of multiple organs and systems. It is a debilitating neurodegenerative disease that results in poor coordination of legs and arms, progressive loss of the ability to walk, generalized weakness, loss of sensation, scoliosis, diabetes and cardiomyopathy as well as impaired vision, hearing and speech. Patients suffer from progressive neurologic and cardiac dysfunction. Key among these is a primary neurodegeneration of the dorsal root ganglia and the dentate nucleus of the cerebellum, which leads to the hallmark clinical findings of progressive limb ataxia and dysarthria. A hypertrophic cardiomyopathy is common and associated with early mortality, typically between 30 and 50 years of age. Omaveloxolone, the first drug approved for the treatment of FA, was approved by the FDA and the European Commission in February 2023 and February 2024, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Nomlabofusp</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Nomlabofusp, an investigational biologic fusion protein that is administered subcutaneously, consists of a CPP genetically fused to human FXN, and includes a mitochondrial targeting sequence. Using our proprietary peptide delivery technology, nomlabofusp is designed to carry the molecule from the intravascular space across the cell membrane and into the mitochondria where the CPP and the mitochondrial targeting sequence are cleaved off to yield mature FXN. See Figure 1.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 1.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img131876768_0.jpg" alt="img131876768_0.jpg" style="width:504px;height:188px;"/>&#160;</p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have completed two Phase 1 nomlabofusp clinical trials, and a Phase 2 dose exploration trial and have initiated an OLE study in the U.S with patients to be dosed 25 mg of nomlabofusp daily. The nomlabofusp program remains under a partial clinical hold imposed by the FDA, and expansion of the OLE study above the 25 mg dose level as well as further clinical development of nomlabofusp is contingent upon FDA agreement based on its review of data from the 50 mg cohort of the Phase 2 dose exploration study and review of the available data from the OLE study at the current 25 mg dose level. Based on the results of our non-clinical development program as well as results from our Phase 2 clinical trials, we believe that administering nomlabofusp may increase FXN levels in the mitochondria of patients with Friedreich&#8217;s ataxia and patients could potentially experience:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">improved cellular function; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a positive impact on Friedreich&#8217;s ataxia symptoms; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a slowing of progression of the disease, potentially prolonging life. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In our Phase 1 clinical trials, nomlabofusp appeared to increase FXN levels in the peripheral tissues that were tested (buccal cells, skin biopsies and platelets) and data from our Phase 2 dose exploration study demonstrated dose dependent increases in FXN levels in all evaluated tissues (skin and buccal cells) after daily dosing of 14 days followed by every other day dosing until day 28 in the 25 mg and 50 mg cohorts. Based on this, we believe that our technology may allow us to address other rare genetic diseases that either require the replacement of molecules that need to target specific intracellular organelles, or that share similar clinical symptoms that overlap with Friedreich&#8217;s ataxia. Finally, the use of nomlabofusp to improve mitochondrial function in other rare diseases that demonstrate evidence of mitochondrial dysfunction is also being explored.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Development of Nomlabofusp</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Non-clinical Development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Knock-Out Mice and Other Non-clinical Studies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Nomlabofusp has been demonstrated to prolong the life of knock-out ("KO") mice whose heart and skeletal muscles were deficient in FXN. These mice, when untreated, develop a severe hypertrophic cardiomyopathy similar to patients with Friedreich&#8217;s ataxia and, like many Friedreich&#8217;s ataxia patients, die early in life. In non-clinical studies of nomlabofusp, the median survival in animals treated with vehicle of 98 days was extended to a median survival of 166 days in animals treated with nomlabofusp subcutaneously three times per week (p=0.0001). Furthermore, 87.5% of mice treated with nomlabofusp survived beyond the mean age of death in the vehicle treated group (107.5 days) whereas only 33% of vehicle treated animals survived. Results are reflected in Figure 2.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 2.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img131876768_1.jpg" alt="img131876768_1.jpg" style="width:290px;height:202px;"/>&#160;</p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In a separate study conducted at an independent laboratory, a similar mouse model was studied. In this study doses of 2 mg/kg, 10 mg/kg, 30 mg/kg, 60 mg/kg and 100 mg/kg administered subcutaneously every other day were compared to vehicle. After 2 weeks of dosing, mitochondrial extracts from cardiac tissue were analyzed for the presence of human FXN. In addition, activity of succinate dehydrogenase ("SDH") an enzyme whose activity is dependent on the presence of FXN, was also analyzed. Human FXN was found in the mitochondria of the cardiomyocytes and increased with increasing dose. SDH activity which was suppressed to near zero in vehicle treated animals was also suppressed to near zero in the 2 mg/kg dose group. In the 10 mg/kg dose group activity was increased and in the 30 mg/kg dose group the activity was returned to that of wild type animals. There was no further increase in activity when the animals were dosed with 60 mg/kg or 100 mg/kg but the effect was maintained at levels equivalent to that of wild type animals. See Figures 3 and 4.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 3.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img131876768_2.jpg" alt="img131876768_2.jpg" style="width:280px;height:183px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 4.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img131876768_3.jpg" alt="img131876768_3.jpg" style="width:262px;height:170px;"/>&#160;</p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Another study, also performed at an independent laboratory, demonstrated the maintenance of cardiac function when the same KO mouse model was studied. These mice were treated with nomlabofusp at doses of 10 mg/kg every other day for 6 weeks. Echocardiograms were performed prior to initiating dosing and after 4 weeks of dosing. When compared to vehicle, mice treated with nomlabofusp maintained their left ventricular volume and ejection fraction while vehicle treated mice deteriorated over the same 4-week period. See Figures 5 and 6.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 5.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img131876768_4.jpg" alt="img131876768_4.jpg" style="width:510px;height:193px;"/>&#160;</p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 6.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img131876768_5.jpg" alt="img131876768_5.jpg" style="width:495px;height:198px;"/>&#160;</p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Using a neurologic mouse model, treatment with nomlabofusp prevented the development of ataxia in mice whose nervous system was deficient in FXN compared to those treated with placebo.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In multiple non-clinical studies in rodents and non-human primates ("NHPs"), human FXN was found to be distributed into all tissues tested following nomlabofusp dosing. See Figure 7.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 7.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:84.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:3.321%;"/>
    <td style="width:1%;"/>
    <td style="width:29.012%;"/>
    <td style="width:1%;"/>
    <td style="width:3.321%;"/>
    <td style="width:1%;"/>
    <td style="width:37.015%;"/>
    <td style="width:1%;"/>
    <td style="width:3.321%;"/>
    <td style="width:1%;"/>
    <td style="width:19.008%;"/>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="11" style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Observed hFXN across all tissue and cell types tested:</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#10003;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Brain</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#10003;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Spinal Cord</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#10003;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Skin</span></p></td>
   </tr>
   <tr style="height:3.6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#10003;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Heart</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#10003;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cardiac Mitochondria</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#10003;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Buccal Cells</span></p></td>
   </tr>
   <tr style="height:3.6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#10003;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Liver</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#10003;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">CSF (Cerebrospinal Fluid)</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#10003;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Platelets</span></p></td>
   </tr>
   <tr style="height:3.6pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#10003;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dorsal Root Ganglia</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#10003;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Skeletal Muscle</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Non-Human Primate and Rat Toxicology Studies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We previously conducted 28-day and 13-week GLP toxicology studies of nomlabofusp in two species, rat and NHP. In the rat studies, some injection sites showed edema and erythema with associated histologic changes localized to the injection site. The rat studies showed no significant clinical observations and no significant systemic histopathological findings. In the NHP studies, some injection sites were raised and firm with dose dependent histologic changes localized to the injection sites. The NHP 28-day study showed no systemic toxicity. The NHP 13-week study showed no systemic toxicity in the low and mid-dose groups, and minimal to mild histopathological findings in the high dose group. There were also several episodes of occasional transient muscle rigidity in some animals observed immediately after dosing in the two highest dose groups at very high exposures. These clinical observations resolved with no intervention and all of the NHPs who experienced these clinical observations received all doses and completed the in-life portion of the study.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To support extended dosing of patients with nomlabofusp, we conducted a 26-week NHP toxicology study in 2021. In May 2021, we notified the FDA of certain mortalities which occurred at the two highest dose levels in the then-ongoing study. On May 25, 2021, the FDA placed a clinical hold on the nomlabofusp clinical program. In the clinical hold letter, the FDA stated that it needed to review a full study report from the then-ongoing NHP study and that we could not initiate additional interventional clinical trials until we submitted such report and received notification from the FDA that additional clinical trials could commence. At the time of the FDA clinical hold, we had no interventional clinical trials with patients enrolled or enrolling.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2021, we completed dosing in the 26-week NHP toxicology study. The study included four dose groups in addition to vehicle. Data from the study were collected throughout the second half of 2021 and included in the complete response to the clinical hold submitted to the FDA in January 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2022, in response to the complete response to the clinical hold we submitted to the FDA, the FDA stated that it was maintaining the clinical hold and that additional data were needed to resolve the clinical hold. We</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">subsequently submitted a request to the FDA for a Type C meeting, which was granted and held in July 2022. We submitted a complete response to clinical hold incorporating additional information requested by the FDA at the meeting as well as information on the proposed study in August 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2022, following the Type C meeting and the submission of the Company's complete response to clinical hold, the FDA allowed the 25 mg cohort of a Phase 2, four-week, placebo-controlled, dose exploration trial of nomlabofusp in FA patients discussed above to proceed. In connection with this decision, the FDA lifted its full clinical hold on the nomlabofusp clinical development program and imposed a partial clinical hold.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2023, we met with the FDA. Following that meeting, we submitted a complete response to the FDA&#8217;s partial clinical hold that included unblinded safety, PK and frataxin data from the Phase 2 trial&#8217;s completed 25 mg cohort.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2023, following the FDA&#8217;s review of our complete response to the partial clinical hold, the FDA cleared initiation of a second cohort at 50 mg of our four-week, placebo-controlled, Phase 2 dose exploration trial and initiation of our OLE trial with daily dosing of 25 mg.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Non-Interventional Studies</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have conducted non-interventional studies to examine the range of tissue FXN concentrations in individuals who are homozygous for the normal FXN gene. Tissue samples in these studies were collected using the same sampling techniques and proprietary assay used in the interventional studies. In a 2020 study we obtained data from 8 healthy adults, but the study was then terminated early by the study site due to competing priorities during the COVID-19 pandemic. In 2021 we initiated a second study that enrolled approximately 60 healthy adults. Enrollment in this study was completed in 2022 and data has been used for comparison purposes in the Phase 2 clinical study described below. See Figure 8.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 8.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img131876768_6.jpg" alt="img131876768_6.jpg" style="width:624px;height:303px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">FXN concentrations were measured in skin and buccal cells from 60 homozygous healthy volunteers utilizing the same sampling technique and assay as clinical trials of nomlabofusp; FXN levels measured via detection of peptide derived from mature FXN; FXN concentrations normalized to total cellular protein content in each sample. 1. E.C. Deutsch et al. Molecular Genetics and Metabolism 101 (2010) 238&#8211;245. 2. Friedreich&#8217;s Ataxia Research Alliance</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical Trials</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Completed Phase 1 Clinical Studies in Adults with Friedreich&#8217;s Ataxia</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We submitted our investigational New Drug application ("IND") application for nomlabofusp and began Phase 1 clinical trials in 2019 in patients with FA. We completed two clinical studies of nomlabofusp in adult subjects with FA, a SAD study (completed in 2020) and a MAD study (completed in 2021). The primary objective</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for the SAD and MAD studies was to assess the tolerability of nomlabofusp at doses ranging from 25 mg to 100 mg administered via subcutaneous injection ("SC"). The secondary objectives were to establish the PK of nomlabofusp administration in humans and to explore the PD of nomlabofusp administration by measuring tissue FXN concentrations in accessible tissues, namely buccal and skin cells, and in platelets. Administration of nomlabofusp via SC injection appeared to be well tolerated up to doses of 100 mg administered daily for up to 13 days. No SAEs were reported in either study. The most common treatment emergent adverse events ("TEAEs") were injection site reactions ("ISRs") that were generally mild, self-limited, and usually resolved within approximately 1 hour. Patients in the 25 mg cohort were dosed once a day for the first 4 days followed by 1 dose every third day through day 13 for a total of 7 doses, while the patients in the 50 mg cohort were dosed once a day for the first 7 days followed by 1 dose every other day through day 13 for a total of 10 doses, and patients in the 100 mg cohort were dosed once a day for 13 days consecutively for a total of 13 doses (see Figures 9 and 10). The study was designed in this fashion to ensure that the PK of nomlabofusp in patients with FA were characterized at the lower doses before the dose was escalated. This is typical of first in human studies such as multiple-ascending dose trials that evaluate a study drug&#8217;s clinical safety profile.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There was rapid uptake of nomlabofusp into the circulation following subcutaneous injection, and exposure appears to be proportional to dose.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 9.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img131876768_7.jpg" alt="img131876768_7.jpg" style="width:624px;height:301px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 10.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img131876768_8.jpg" alt="img131876768_8.jpg" style="width:624px;height:310px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">*FXN levels measured via detection of peptide derived from mature FXN; FXN concentrations are normalized to total cellular protein content in each sample; Data represent median and 25th and 75th percentiles; FXN levels from day 4, &amp; day 13 measurements are shown for data derived from the 25 mg cohort; FXN levels from day 7 &amp; day 13 measurements are shown for data derived from the 50 &amp; 100 mg cohorts.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Completed Phase 2 Dose Exploration Study</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Phase 2 randomized, double-blind, placebo controlled dose exploration study evaluated the safety, tolerability, PK and PD of two doses of nomlabofusp. Cohort 1 evaluated 25 mg and Cohort 2 evaluated 50 mg. Participants in either the 25 mg or 50 mg cohorts were randomized 2:1 to receive daily subcutaneous injections of either nomlabofusp or placebo for 14 days, and then every other day for an additional 14 days for a total 28-day dosing period.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2023, we reported preliminary unblinded top-line data from the 25 mg cohort of the Phase 2 trial. Data from the cohort indicated nomlabofusp was generally well tolerated and showed increases in FXN levels from baseline compared to placebo in all evaluated tissues (skin and buccal cells) at day 14.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2023, we met with the FDA. Following that meeting, we submitted a complete response to the FDA&#8217;s partial clinical hold that included unblinded safety, PK and frataxin data from the Phase 2 trial&#8217;s completed 25 mg cohort.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2023, following the FDA&#8217;s review of our complete response to the partial clinical hold, the FDA cleared initiation of the second cohort (50 mg) of our four-week, placebo-controlled, Phase 2 dose exploration trial and the initiation of our OLE trial with daily dosing of 25 mg.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2024, we reported positive top-line data and successful completion of our four-week, placebo-controlled Phase 2 dose exploration study of nomlabofusp in participants with FA. Nomlabofusp was generally well tolerated and demonstrated dose response in FXN levels in all evaluated tissues (skin and buccal cells) after daily dosing of 14 days followed by every other day dosing until day 28 in the 25 mg and 50 mg cohorts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">With regard to safety in the Phase 2 dose exploration trial, there were a total of 28 participants (19 received nomlabofusp and 9 received placebo). There were no serious adverse events reported. There was one allergic reaction which was considered to be a severe adverse event in the 25 mg cohort that resolved with standard treatment. This participant withdrew from the trial. The most common adverse events reported were mild and moderate injection site reactions which resolved without any intervention and there were no study discontinuations due to injection site reactions. Consistent with findings in our Phase 1 study, nomlabofusp demonstrated quick absorption after subcutaneous administration and had dose proportional increases in exposure.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Participants treated with 50 mg for 14 days daily had frataxin levels in skin cells increase from less than 17% at baseline relative to healthy volunteers, to 33% to 59% of healthy volunteers after 14 days of treatment. Patients treated with placebo showed no increase in their frataxin levels during this period. Additionally, the majority of treated patients in both cohorts with quantifiable levels of frataxin at baseline and day 14 achieve at least a 100% increase in tissue frataxin in skin cells, and at least a 30% increase in tissue frataxin levels in buccal cells. Figures 11 and 14 show a clear dose response and increase from baseline in skin tissue and buccal tissue frataxin levels respectively.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The graph on the left in both Figures 12 and 15 show a dose dependent increase in frataxin levels after 14 days of treatment. With both skin and buccal cells, when dosing is switched to every other day the magnitude of the increase in frataxin levels declines.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The waterfall plots on the right in both Figures 12 and 15 depict the individual changes in frataxin levels from baseline in skin cells and buccal cells at day 14 respectively. Each bar represents an individual patient, with placebo treated participants in grey, the 25 mg cohort in aqua, and the 50 mg cohort in blue. The majority of patients treated with nomlabofusp had significant increases in frataxin levels while placebo patients were basically unchanged. Importantly, there also appears to be a dose response as frataxin levels are notably increased in most of the 50 mg cohort over the 25 mg cohort.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 11.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img131876768_9.jpg" alt="img131876768_9.jpg" style="width:624px;height:307px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Only participants with quantifiable levels at baseline and day 14 and day 28 are included in the tables.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 12.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img131876768_10.jpg" alt="img131876768_10.jpg" style="width:624px;height:314px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">*FXN levels measured via detection of peptide derived from mature FXN; FXN concentrations are normalized to total cellular protein content in each sample. Data represent median and 25th and 75th percentiles. Only participants with quantifiable levels at both baseline and day 14 are included in the figures.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">**Median baseline FXN levels in patients were 3.5 pg/&#181;g for the placebo, 3.7 pg/&#181;g for the 25 mg cohort and 2.1 pg/&#181;g for the 50 mg cohort.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figures 13 and 16 depict how many people had a shift in frataxin levels in skin cells and buccal cells as a percentage of average healthy volunteers after 14 days of treatment. On the left is the 25 mg cohort and on the right is the 50 mg cohort. On the far left of each figure are categories of the percentage of average healthy volunteers. Figures in black to the left of the black vertical line represent patients at baseline. Figures to the right of the black</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">vertical line represent day 14 frataxin levels as a percentage of average healthy volunteers. In blue are individuals that increase by 25% to 50% and in green are individuals that exceeded 50% of average healthy volunteers.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 13.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img131876768_11.jpg" alt="img131876768_11.jpg" style="width:624px;height:324px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Only participants with quantifiable levels at baseline and day 14 are included in the figures.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">*% of healthy volunteer FXN level is calculated by dividing each participant's FXN level by the average FXN level (16.34 pg/&#181;g) from the noninterventional healthy volunteer study (N=60).</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 14.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img131876768_12.jpg" alt="img131876768_12.jpg" style="width:624px;height:321px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Only participants with quantifiable levels at baseline and day 14 and day 28 are included in the tables.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 15.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img131876768_13.jpg" alt="img131876768_13.jpg" style="width:624px;height:302px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">*FXN levels measured via detection of peptide derived from mature FXN; FXN concentrations are normalized to total cellular protein content in each sample. Data represent median and 25th and 75th percentiles. Only participants with quantifiable levels at both baseline and Day 14 are included in the figures.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">**Median baseline FXN level in patients were 2.1 pg/&#181;g for the placebo, 1.8 pg/&#181;g for the 25 mg cohort and 1.6 pg/&#181;g for the 50 mg cohort.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 16.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img131876768_14.jpg" alt="img131876768_14.jpg" style="width:624px;height:333px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Only participants with quantifiable levels at baseline and day 14 are included in the figures.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">*% of healthy volunteer FXN level is calculated by dividing each participant's FXN level by the average FXN level (8.24 pg/&#181;g) from the noninterventional healthy volunteer study (N=60).</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Open Label Extension</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2024, we initiated the OLE trial evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver, with the first patient dosed in March 2024. Participants who completed treatment in the Phase 2 dose exploration trial, or who previously completed a prior clinical trial of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">19</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">nomlabofusp are potentially eligible to screen for the OLE. The OLE will evaluate the safety, tolerability, PK, and measures of frataxin levels in peripheral tissues as well as other exploratory PD (lipid profiles and gene expression data) following long-term subcutaneous administration of nomlabofusp. Clinical measures collected during the trial will be compared to data from a matched control arm derived from participants in the Friedreich&#8217;s Ataxia Clinical Outcome Measures Study (FACOMS) database. Further dose expansion in the OLE trial will be considered based on safety, tolerability, PK, FXN levels from the 25 mg dose of nomlabofusp in the OLE trial, as well as data from the Phase 2 trial's 50 mg cohort and is contingent on FDA review as part of the partial clinical hold. Initial data from the OLE trial is expected in the fourth quarter of 2024. We also are planning to include in our clinical studies, individuals between the ages of 2 and 17 and are currently in discussions with FDA as to what additional clinical data in adults would inform inclusion of those pediatric individuals in our studies.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success depends in large part upon our ability to obtain and maintain proprietary protection for our current and future products and technologies, and to operate without infringing the proprietary rights of others. Our policy is to protect our proprietary position by, among other methods, filing for patent applications on inventions that are important to the development and conduct of our business with the U.S. Patent and Trademark Office and its foreign counterparts. We also intend to rely on regulatory exclusivity (also called data package exclusivity), which is separate and distinct from the protection afforded by patents, to protect our products. We further protect our proprietary information by requiring our employees, consultants, contractors and other advisors to execute nondisclosure and assignment of invention agreements upon commencement of their respective employment or engagement. Agreements with our employees also prevent them from bringing the proprietary rights of third parties to us. In addition, we require confidentiality or service agreements from third parties that receive our confidential information or materials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of February 23, 2024, our intellectual property portfolio was composed of numerous international Patent Cooperation Treaty ("PCT"), foreign, and United States non-provisional patent applications, a United States patent and United States provisional patent applications that we own or co-own, and six issued United States patents and additional non-provisional patent applications in the United States and in certain foreign jurisdictions that we license from academic institutions. The issued patents in the United States licensed by us, which include issued patents covering the composition of matter for nomlabofusp and methods for treating FA, have expiration dates between 2024 and 2040 without taking potential patent term extension into consideration. The international and the United States non-provisional patent applications licensed by us relate to composition of matter and methods of use for nomlabofusp.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The additional patent applications we own or co-own which include PCT, foreign and United States non-provisional patent applications a United States patent, and United States provisional patent applications are related to the development of nomlabofusp, including methods of use of nomlabofusp, and to our peptide-delivery platform technology.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A provisional patent application allows for an effective filing date to be established with regard to an invention, but once a provisional patent application is filed, either a corresponding non-provisional patent application or a petition to convert the provisional patent application into a non-provisional patent application must be filed within 12 months or such effective filing date will be lost. If we or our licensor timely files non-provisional patent applications in the United States and in countries outside of the United States with regard to our provisional patent applications and these non-provisional patent applications result in issued patents, such patents are expected to expire in 2044 or 2025, without taking potential patent term adjustment or patent term extension into consideration.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Nomlabofusp is covered by licensed issued patents (composition of matter and methods of use) in the United States which, if properly maintained, will expire in 2024, 2025 and 2040, excluding any patent term extensions that might be available following the grant of marketing authorizations. We also possess an exclusive license to non-provisional applications in the United States and certain countries outside the United States for nomlabofusp (composition of matter and methods of use). If these patent applications in the United States and other countries result in issued patents, those patents would be expected to expire in 2040. This estimated expiration excludes any patent term adjustment that might be available following the grant of the patent and any patent term extensions that might be available following the grant of marketing authorizations. We cannot predict whether the patent applications we and our licensors are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors or other third parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patents extend for varying periods according to the date of patent filing or grant and the legal term of patents in various countries where patent protection is obtained. The actual protection afforded by a patent, which can vary from country to country, depends on the type of patent, the scope of its coverage and the availability of legal remedies in the country.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also use other forms of protection besides patent protection and regulatory exclusivity, such as trademark, copyright, and trade secret protection, to enhance our intellectual property, particularly where we do not believe patent protection is appropriate or obtainable. We aim to take advantage of all of the intellectual property rights that are available to us and believe that this comprehensive approach will provide us with proprietary exclusive positions for our product candidates, such as nomlabofusp, where available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In-License Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are party to a License Agreement dated November 30, 2016 with Wake Forest University Health Sciences ("WFUHS") and a License Agreement dated November 30, 2016, as amended, with Indiana University ("IU"). Such agreements provide for a transferable, worldwide license to certain patent rights regarding technology used by us with respect to the development of nomlabofusp.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In partial consideration for the right and license granted under these agreements, we will pay each of WFUHS and IU a royalty of a low single digit percentage of net sales of licensed products depending on whether there is a valid patent covering such products. As additional consideration for these agreements, we are obligated to pay each of WFUHS and IU certain milestone payments of up to $2.6 million in the aggregate upon the achievement of certain developmental milestones, commencing on the enrollment of the first patient in a Phase 1 clinical trial. We will also pay each of WFUHS and IU sublicensing fees ranging up to a low double-digit percentage of sublicense consideration depending on our achievement of certain regulatory milestones as of the time of receipt of the sublicense consideration. We are also obligated to reimburse WFUHS and IU for patent-related expenses. In the event that we dispute the validity of any of the licensed patents, the royalty rate would be tripled during such dispute. We are also obligated to pay to IU a minimum annual royalty of less than $0.1 million per annum starting in the 2020 calendar year for the term of the agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the event that we are required to pay IU consideration, then we may deduct 20% of such IU consideration on a dollar-for-dollar basis from the consideration due to WFUHS. In the event that we are required to pay WFUHS consideration, then we may deduct 60% of such WFUHS consideration on a dollar-for-dollar basis from the consideration due to IU.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Competition</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The biopharmaceutical industry is characterized by intense and dynamic competition to develop new technologies and proprietary therapies. Any product candidates that we successfully develop into products and commercialize may compete with existing therapies and new therapies that may become available in the future. While we believe that our platform technology, product candidates and scientific expertise in the field of rare diseases provide competitive advantages, we face competition from various sources, including larger and better-funded pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies, as well as from academic institutions, governmental agencies and public and private research institutions. We expect to compete with Biogen&#8217;s SKYCLARYS</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (omaveloxolone), which was approved for the treatment of FA in adults and adolescents aged 16 and older by the FDA and the European Commission in February 2023 and February 2024, respectively. Other competitors currently developing therapeutics to treat FA include, but are not limited to Design Therapeutics, Lexeo Therapeutics, Neurocrine Biosciences/Voyager Therapeutics and PTC Therapeutics. Many of our competitors have significantly greater financial, technical and human resources than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated amongst a smaller number of our competitors. Our commercial opportunity could be reduced or eliminated if our competitors develop or market products or other novel therapies that are more effective, safer or less costly than our product candidates or obtain regulatory approval for their products more rapidly than we may obtain approval for our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Manufacturing and Supply</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Nomlabofusp is a biologic fusion protein that is produced in E. coli. We have worked with contract manufacturers to develop, in accordance with cGMPs a manufacturing process and analytical methods for drug substance to support clinical trials. We also use third party manufacturers for the clinical packaging, storage and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">21</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">distribution of nomlabofusp. We rely on third parties to store the nomlabofusp master cell bank and working cell bank, each stored at a different location. We continue to advance the manufacturing of nomlabofusp, obtain stability data, and produce drug product for future clinical trials. We are continually trying to optimize our manufacturing process to increase yields, decrease costs and increase reliability in supply chains. The final process will need to be successfully scaled up to support commercial manufacturing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The drug substance which is in frozen liquid form for nomlabofusp is currently manufactured for us by KBI Biopharma, Inc. ("KBI"). We are party to a Master Services Agreement, as amended, with KBI, pursuant to which KBI provides biological development and clinical manufacturing services with respect to nomlabofusp. We currently produce a frozen liquid form of drug product at another manufacturer. We have also begun a program with a third-party manufacturer to produce a lyophilized version of the drug product from the same KBI drug substance, that, once available, we intend to use in certain of our future planned clinical trials and ultimately, commercial use, assuming nomlabofusp receives required regulatory approvals.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Human Capital Resources</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Employees and Compensation</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order to achieve the goals and expectations of our Company, it is crucial that we continue to attract and retain top talent. To facilitate talent attraction and retention, we strive to make our company a safe and rewarding workplace, with opportunities for our employees to grow and develop in their careers, supported by strong compensation, benefits, paid time-off and health and wellness programs, including programs that build connections between our employees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we employed 42 full-time employees in the United States, of which 32 are directly engaged in research and development with the rest providing administrative, business and operations support. None of our employees are represented by a labor organization or under any collective-bargaining arrangements. We consider our employee relations to be good.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants. The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel through the granting of stock-based and cash-based compensation awards, in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Diversity and Inclusion</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We value the diversity of our employees and take pride in our commitment to diversity and inclusion across all levels of our organizational structure and with respect to our board of directors. We are committed to developing strategies for building diverse teams and promoting the advancement of employees from diverse backgrounds.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Scientific Advisors</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have established a scientific advisory board and we regularly seek advice and input from these experienced thought leaders on matters related to our research and development programs. The members of our scientific advisory board consist of distinguished research scientists, professors and industry experts recognized as key opinion leaders in the fields of rare disease, pediatrics and mitochondrial disease. Their scientific perspectives will be invaluable to determine our strategic scientific pathway and support the development of other potential treatments for complex rare diseases to help fill unmet medical needs in this space. We intend to continue to leverage the broad expertise of our advisors by seeking their counsel on important topics relating to our product development and clinical development programs. Our scientific advisors are not our employees and may have commitments to, or consulting or advisory contracts with, other entities that may limit their availability to us. In addition, our scientific advisors may have arrangements with other companies to assist those companies in developing products or technologies that may compete with ours. All of our scientific advisors are affiliated with other entities and devote only a small portion of their time to us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our scientific advisors are set forth in the table below:</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:25.64%;"/>
    <td style="width:1.98%;"/>
    <td style="width:71.38%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marni Joy Falk, MD</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Executive Director, Mitochondrial Medicine Frontier Program at Children&#8217;s Hospital of Philadelphia; Professor, Department of Human Genetics and Department of Pediatrics, University of Pennsylvania Perelman School of Medicine</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Giovanni Manfredi, MD, PhD</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finbar and Marianne Kenny Professor of Clinical and Research Neurology, Weill Cornell Medicine; Professor of Neuroscience, Weil Cornell Medicine</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Jill Ostrem, MD</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Medical director and division chief of University of California San Francisco (UCSF) Movement Disorders and Neuromodulation Center. Carlin and Ellen Wiegner Endowed Professor of Neurology.</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Mark Payne, MD</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Professor of Pediatrics, Indiana University School of Medicine</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Facilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We lease office and laboratory space, which consists of approximately 8,000 square feet and 1,750 square feet located in Bala Cynwyd, PA and Philadelphia, PA, respectively. We are currently on a month-to-month lease on this Philadelphia lab space. We, as well as our landlord, can terminate the lease with four months notice.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have entered into a lease for 3,927 square feet of new laboratory space in King of Prussia, PA to replace the Philadelphia lab space, but this lease has not yet commenced with expected occupancy in the second quarter of 2024.As part of the Merger (as defined below) with Zafgen, Inc ("Zafgen"), we acquired a non-cancellable operating lease for approximately 17,705 square feet of office space at 3 Center Plaza, Boston, Massachusetts (the "Boston Lease"). The Boston Lease expires on October 30, 2029. On October 27, 2020, we entered into a sublease agreement whereby we subleased all 17,705 square feet of office space leased under the Boston Lease until October 30, 2029.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Legal Proceedings</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Corporate Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We were founded in 2005 as a Delaware corporation under the name Zafgen, Inc. ("Zafgen"). On May 28, 2020, Zafgen completed a reverse merger with Chondrial Therapeutics, Inc. ("Chondrial") in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated December 17, 2019, by and among Zafgen, Zordich Merger Sub, Inc., Chondrial and Chondrial Therapeutics Holdings, LLC, pursuant to which Zordich Merger Sub, Inc. merged with and into Chondrial, with Chondrial surviving as our wholly owned subsidiary. Following completion of the merger, Zafgen, Inc. changed its name to Larimar Therapeutics, Inc.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our principal executive offices are located at Three Bala Plaza East, Suite 506, Bala Cynwyd, PA 19004, and our telephone number is (844) 511-9056. Our website address is www.larimartx.com. The information on, or that can be accessed through, our website is not part of this Annual Report on Form 10-K and is not incorporated by reference herein. We have included our website address as an inactive textual reference only.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Available Information</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We file annual, quarterly, and current reports, proxy statements, and other documents with the Securities and Exchange Commission ("the SEC") under the Securities Exchange Act of 1934, as amended ("the Exchange Act"). The SEC maintains an internet website, www.sec.gov, that contains reports, proxy and information statements, and other information regarding issuers, including us, that file electronically with the SEC.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Copies of each of our filings with the SEC on Form 10-K, Form 10-Q and Form 8-K and all amendments to those reports, can be viewed and downloaded free of charge at our website, www.larimartx.com as soon as reasonably practicable after the reports and amendments are electronically filed with or furnished to the SEC.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our code of ethics, other corporate policies and procedures, and the charters of our Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee are available through our website</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">23</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">at </span><span><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">www.larimartx.com</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. We intend to post information regarding any amendments to, or waivers from, our code of ethics on our website.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government Regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, drug and biologic products are subject to extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;) and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products. Biological products used for the prevention, treatment, or cure of a disease or condition of a human being are subject to regulation under the FDCA, with the exception that the section of the FDCA that governs the approval of drugs via new drug applications (&#8220;NDAs&#8221;), does not apply to the approval of biologics. In contrast, biologics are approved for marketing under provisions of the Public Health Service Act (&#8220;PHS Act&#8221;), via a Biologics License Application (&#8220;BLA&#8221;). However, the application process and requirements for approval of BLAs are very similar to those for NDAs. FDA approval or licensure also must be obtained before the marketing of drug and biological products. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">U.S. Development Process</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The process required by the FDA before a drug or biologic product may be marketed in the United States generally involves the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">completion of non-clinical laboratory tests and animal studies according to Good Laboratory Practices ("GLPs"), and applicable requirements for the humane use of laboratory animals or other applicable regulations; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preparation of clinical trial material in accordance with cGMPs; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">submission to the FDA of an IND, which must become effective before human clinical trials may begin; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">approval by an institutional review board ("IRB") reviewing each clinical site before each clinical trial may be initiated; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">performance of adequate and well-controlled human clinical trials according to Good Clinical Practices ("GCPs") and any additional requirements for the protection of human research subjects and their health information, to establish the safety, purity, potency, and efficacy, of the proposed drug or biological product for its intended use; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">submission to the FDA of an NDA or BLA for marketing approval that includes substantive evidence of safety, purity, potency, and efficacy from results of non-clinical testing and clinical trials; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">satisfactory completion of an FDA inspection prior to NDA or BLA approval of the manufacturing facility or facilities where the drug or biological product is produced to assess compliance with cGMPs, to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s identity, strength, quality and purity; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential FDA audit of the non-clinical and clinical study sites that generated the data in support of the NDA or BLA; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential FDA Advisory Committee meeting to elicit expert input on critical issues and including a vote by external committee members; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FDA review and approval, or licensure, of the NDA or BLA, and payment of associated user fees, when applicable; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compliance with any post approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategies ("REMS") and the potential requirement to conduct post approval studies. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Before testing any drug or biological product candidate in humans, the product candidate enters the non-clinical testing stage. Non-clinical tests include laboratory evaluations of product chemistry, pharmacology, toxicity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and formulation, as well as animal studies to assess the potential safety and activity of the product candidate. The conduct of the non-clinical tests must comply with federal regulations and requirements including GLPs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The clinical study sponsor must submit the results of the non-clinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. Some non-clinical testing typically continues after the IND is submitted. An IND is an exemption from the FDCA that allows an unapproved product to be shipped in interstate commerce for use in an investigational clinical trial and a request for FDA authorization to administer an investigational product to humans. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA places the clinical trial on a clinical hold within that 30-day time period. In such a case, the IND sponsor must resolve any deficiencies to the satisfaction of the FDA, and the FDA must lift the clinical hold before the clinical trial can begin. The FDA may also impose clinical holds on a drug or biological product candidate at any time before or during clinical trials due to safety concerns or non-compliance. If the FDA imposes a clinical hold, trials may not recommence without FDA authorization and then only under terms authorized by the FDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical trials may involve the administration of the drug or biological product candidate to healthy volunteers or subjects under the supervision of qualified investigators, generally physicians not employed by or under the study sponsor&#8217;s control. Clinical trials involving some products for certain diseases, including some rare diseases may begin with testing in patients with the disease. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters to be used to monitor subject safety, including stopping rules that assure a clinical trial will be stopped if certain adverse events should occur. Each protocol and any amendments to the protocol must be submitted to the FDA as part of the IND application. Clinical trials must be conducted and monitored in accordance with the FDA&#8217;s regulations comprising the GCP requirements, including the requirement that all research subjects or his or her legal representative provide informed consent. Further, each clinical trial must be reviewed and approved by an independent IRB, at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of study participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the form and content of the informed consent that must be signed by each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. Additionally, some trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a data monitoring committee. The data monitoring committee may review safety data and/or efficacy data.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Phase 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The drug or biological product is initially introduced into healthy human subjects and tested for safety. In the case of some products for rare diseases, the initial human testing is often conducted in patients. </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Phase 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The drug or biological product is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule. </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Phase 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Clinical trials are undertaken to further evaluate dosage, clinical efficacy, potency and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the product and provide an adequate basis for product labeling. In most cases, the FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the safety and efficacy of the drug or biologic. In rare instances, a single Phase 3 trial may be sufficient when either (1) the trial is a large, multicenter trial demonstrating internal consistency and a statistically very persuasive finding of a clinically meaningful effect on mortality, irreversible morbidity or prevention of a disease with a potentially serious outcome and confirmation of the result in a second trial would be practically or ethically impossible, or (2) the single trial is supported by other confirmatory evidence. In drugs and biologics for rare diseases where patient populations are small, Phase 3 trials might not be required if substantial evidence of effectiveness and an acceptable risk/benefit profile can be demonstrated from Phase 2 trials. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An OLE study may also be conducted. An OLE study typically enrolls participants from previous clinical trials and is designed to gather the long-term safety and tolerability data on a potential new medicine beyond the time period of the original studies.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">25</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Post-approval clinical trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication in real-world scenarios. They provide additional information regarding risks, benefits and best use, including longer term safety data. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA or BLA.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data, and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA and the investigators for serious and unexpected adverse events, any findings from other studies, tests in laboratory animals or in vitro testing that suggest a significant risk for human subjects, or any clinically important increase in the rate of a serious suspected adverse reactions over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#8217;s initial receipt of the information. The FDA or the sponsor or its data safety monitoring board may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug or biological product has been associated with unexpected serious harm to patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the physical characteristics of the drug or biological product as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. To help reduce the risk of the introduction of adventitious agents with use of biological products, the PHS Act emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the sponsor must develop methods for testing the identity, strength, quality potency and purity of the final biological product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the drug or biological product candidate does not undergo unacceptable deterioration over its shelf life.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are also various laws and regulations regarding laboratory practices, the experimental use of animals, and the use and disposal of hazardous or potentially hazardous substances in connection with the research. In each of these areas, the FDA and other regulatory authorities have broad regulatory and enforcement powers, including the ability to levy fines and civil penalties, suspend or delay issuance of approvals, seize or recall products, and withdraw approvals.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Information about certain clinical trials must be submitted within specific timeframes to the NIH for public dissemination on its clinicaltrials.gov website. Sponsors or distributors of investigational products for the diagnosis, monitoring, or treatment of one or more serious diseases or conditions must also have a publicly available policy on evaluating and responding to requests for expanded access requests.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">U.S. Review and Approval Processes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">After the completion of clinical trials of a drug or biological product, FDA approval of an NDA, or BLA, must be obtained before commercial marketing of the product. The NDA or BLA must include results of product development, laboratory and animal studies, human studies, information on the manufacture and composition of the product, proposed labeling and other relevant information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Prescription Drug User Fee Act, as amended, ("PDUFA") each NDA or BLA may be accompanied by a significant application fee. The applicant for an approved application is also subject to an annual program fee. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on NDAs or BLAs for product candidates designated as orphan drugs, unless the product candidate also includes a non-orphan indication.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Within 60 days following submission of the application, the FDA reviews an NDA or BLA submitted to determine if it is substantially complete before the agency files it. The FDA may refuse to file any NDA or BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the NDA or BLA must be resubmitted with the additional information. The resubmitted application is</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">26</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">also subject to review before the FDA files it. Once the submission is filed, the FDA begins an in-depth substantive review of the NDA or BLA. The FDA reviews the NDA or BLA to determine, among other things, whether the proposed product is safe and effective (for drugs) or safe, potent, and effective (for biologics), for its intended use, and has an acceptable purity profile, and whether the product is being manufactured in accordance with cGMPs to assure and preserve the product&#8217;s identity, safety, strength, quality, potency and purity. One of the performance goals agreed to by the FDA under the PDUFA is to review standard NDAs or BLAs in ten months from filing and priority NDAs or BLAs in six months from filing, whereupon a review decision is to be made. The review process may be extended by three months if the FDA classifies a response to an FDA request for additional information or clarification as a major amendment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA may refer applications for novel products or products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the review, the FDA will also determine whether a REMS is necessary to assure the safe use of the biological product. If the FDA concludes a REMS is needed, the sponsor of the NDA or BLA must submit a proposed REMS; the FDA will not approve the NDA or BLA without a REMS, if required.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Before approving an NDA or BLA, the FDA may inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA or BLA, the FDA will typically inspect one or more clinical trial sites to assure that the clinical trials were conducted in compliance with IND study requirements and GCP requirements. To assure cGMP and GCP compliance, an applicant must incur significant expenditure of time, money and effort in the areas of training, record keeping, production, and quality control.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the submission of relevant data and information, the FDA may ultimately decide that the NDA or BLA does not satisfy its regulatory criteria for approval and deny approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than the sponsor interprets the same data. If the agency decides not to approve the NDA or BLA in its present form, the FDA will issue a complete response letter that usually describes all of the specific deficiencies in the NDA or BLA identified by the FDA. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example, requiring additional clinical trials. Additionally, the complete response letter may include recommended actions that the applicant might take to place the application in a condition for approval. If a complete response letter is issued, the applicant may either resubmit the NDA or BLA, addressing all of the deficiencies identified in the letter, or withdraw the application.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. The FDA may impose restrictions and conditions on product distribution, prescribing, or dispensing in the form of a risk management plan, or otherwise limit the scope of any approval. In addition, the FDA may require post marketing clinical trials, sometimes referred to as Phase 4 clinical trials, designed to further assess a drug or biological product&#8217;s safety and effectiveness, and testing and surveillance programs to monitor the safety of approved products that have been commercialized. As a condition for approval, the FDA may also require additional non-clinical testing as a Phase 4 commitment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Post-Approval Requirements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Maintaining substantial compliance with applicable federal, state, and local statutes and regulations requires the expenditure of substantial time and financial resources. Rigorous and extensive FDA regulation of drug and biological products continues after approval, particularly with respect to cGMP. We will rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of any products that we may commercialize. Manufacturers of our products are required to comply with applicable requirements in the cGMP regulations, including quality control and quality assurance and maintenance of records and documentation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Following approval, the manufacturing facilities are subject to periodic inspections by the FDA and such inspections may result in an issuance of FDA Form 483 deficiency observations, untitled letter, or a warning letter, which can lead to plant shutdown and other more serious penalties and fines. Prior to the institution of any manufacturing changes, a determination needs to be made whether FDA approval is required in advance. If not done</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">27</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in accordance with FDA expectations, the FDA may restrict supply and may take further action. Annual product reports are required to be submitted annually. Other post-approval requirements applicable to drug and biological products, include reporting of cGMP deviations that may affect the identity, potency, purity and overall safety of a distributed product, record-keeping requirements, reporting of adverse events, reporting updated safety and efficacy information, and complying with electronic record and signature requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">After an NDA or BLA is approved, the product may also be subject to official lot release. As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#8217;s tests performed on the lot. The FDA may also perform certain confirmatory tests on lots of some products, before releasing the lots for distribution by the manufacturer. In addition, the FDA may conduct laboratory research related to the regulatory standards on the safety, purity, potency, and effectiveness of drug and biological products. Systems need to be put in place to record and evaluate adverse events reported by health care providers and patients and to assess product complaints. An increase in severity or new adverse events can result in labeling changes or product recall. Defects in manufacturing of commercial products can result in product recalls.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Manufacturers must also comply with the FDA&#8217;s advertising and promotion requirements, such as those related to direct-to-consumer advertising, the prohibition on promoting products for uses or in patient populations that are not described in the product&#8217;s approved labeling (known as &#8220;off-label use&#8221;), industry-sponsored scientific and educational activities, and promotional activities involving the internet. Discovery of previously unknown problems or the failure to comply with the applicable regulatory requirements may result in restrictions on the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant or manufacturer to administrative or judicial civil or criminal sanctions and adverse publicity. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval or license revocation, clinical hold, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors, debarment, restitution, disgorgement of profits, or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Drug and biologic product manufacturers and other entities involved in the manufacture and distribution of approved drug and biological products are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMPs and other laws. Accordingly, manufacturers must continue to expend time, money, and effort in the areas of production and quality control to maintain cGMP compliance. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer, or holder of an approved NDA or BLA, including withdrawal of the product from the market. In addition, changes to the manufacturing process or facility generally require prior FDA approval before being implemented and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Orphan Drug Designation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Orphan Drug Act, the FDA may grant Orphan Drug Designation ("ODD") to a drug or biologic product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making a drug or biologic product available in the United States for this type of disease or condition will be recovered from sales of the product. ODD must be requested before submitting an NDA or BLA. After the FDA grants ODD, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. ODD does not convey any advantage in or shorten the duration of the regulatory review and approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a product that has ODD receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same drug or biological product for the same indication for seven years, except in limited circumstances, such as showing clinical superiority to the product with orphan exclusivity by means of greater effectiveness, greater safety or providing a major contribution to patient care or in instances of drug supply issues. Competitors, however, may receive approval of either a different product for the same indication or the same</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">28</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product for a different indication but that could be used off-label in the orphan indication. Orphan drug exclusivity also could block the approval of our products for seven years if a competitor obtains approval before we do for the same product as defined by the FDA for the same indication we are seeking approval, or if our product is determined to be contained within the competitor&#8217;s scope of product for the same indication or disease. If we pursue marketing approval for an indication broader than the orphan drug designation we have received, we may not be entitled to orphan drug exclusivity.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expedited Review and Approval Programs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA has various programs, including fast track designation, priority review, accelerated approval, and breakthrough therapy designation, that are intended to expedite or simplify the process for the development and FDA review of drug and biological products that are intended for the treatment of serious or life-threatening diseases or conditions and demonstrate the potential to address unmet medical needs. The purpose of these programs is to provide important new drug and biological products to patients earlier than under standard FDA review procedures. To be eligible for a fast track designation, the FDA must determine, based on the request of a sponsor, that a drug or biological product is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need. The FDA will determine that a product will fill an unmet medical need if it will provide a therapy where none exists or provide a therapy that may be potentially superior to existing therapy based on efficacy or safety factors. In addition to other benefits, such as the ability to have greater interactions with the FDA, the FDA may initiate review of sections of a fast track NDA or BLA before the application is complete, a process known as rolling review.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA may give a priority review designation to drug or biological products that treat a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. A priority review means that the goal for the FDA to review an application is six months, rather than the standard review of ten months under current PDUFA guidelines. Most products that are eligible for fast track designation may also be considered appropriate to receive a priority review.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, drug and biological products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may be approved on the basis of adequate and well-controlled clinical trials establishing that the drug or biological product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require a sponsor of a drug or biological product receiving accelerated approval to perform post-marketing studies with due diligence to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the drug or biological product may be subject to accelerated withdrawal procedures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Food and Drug Omnibus Reform Act (&#8220;FDORA&#8221;) was recently enacted, which included provisions related to the accelerated approval pathway. Pursuant to FDORA, the FDA is authorized to require a post-approval study to be underway prior to approval or within a specified time period following approval. FDORA also requires the FDA to specify conditions of any required post-approval study, which may include milestones such as a target date of study completion and requires sponsors to submit progress reports for required post-approval studies and any conditions required by the FDA not later than 180 days following approval and not less frequently than every 180 days thereafter until completion or termination of the study. FDORA also provides the FDA increased authority for expedited procedures to withdraw approval of a drug or biologic or indication approved under accelerated approval if, for example, the confirmatory trial fails to verify the predicted clinical benefit of the product. FDORA also enables the FDA to initiate enforcement actions for the failure to conduct with due diligence a required post-approval study, including a failure to meet any required conditions specified by the FDA or to submit timely reports. In addition, the FDA generally requires, unless otherwise informed by the agency, pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, a sponsor can request designation of a product candidate as a &#8220;breakthrough therapy.&#8221; A breakthrough therapy is defined as a drug or biologic product that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug or biologic product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">29</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA must take certain actions, such as holding timely meetings and providing advice, intended to expedite the development and review of an application for approval of a breakthrough therapy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. Furthermore, fast-track designation, priority review, accelerated approval and breakthrough therapy designation, do not change the standards for approval and may not ultimately expedite the development or approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Rare Pediatric Disease Vouchers</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Rare Pediatric Disease Voucher Program is intended to encourage development of new drug and biological products for prevention and treatment of certain rare pediatric diseases. Although there are existing incentive programs to encourage the development and study of drugs and biologics for rare diseases, pediatric populations, and unmet medical needs, this program provides an additional incentive for the development of drugs and biologics for rare pediatric diseases, which may be used alone or in combination with other incentive programs. A rare pediatric disease is defined as a disease that is a serious or life-threatening disease in which the serious or life-threatening manifestations primarily affect individuals aged from birth to 18 years, including age groups often called neonates, infants, children, and adolescents; and is a rare disease or condition as defined in the FDCA, which includes diseases and conditions that affect fewer than 200,000 persons in the United States and diseases and conditions that affect a larger number of persons and for which there is no reasonable expectation that the costs of developing and making available the product in the United States can be recovered from sales of the product in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The sponsor of an application for a drug product that obtains rare pediatric disease designation may be eligible for a voucher that can be used or sold to obtain a priority review for a subsequent application submitted under section 505(b)(1) of the FDCA or section 351 of the PHS Act. A rare pediatric disease drug product must meet certain eligibility requirements for a priority voucher at the time the sponsor seeks approval. The rare pediatric disease priority review voucher program was most recently re-authorized by Congress through September 30, 2024, with the potential for priority review vouchers to be granted through September 30, 2026.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pediatric Information and Pediatric Exclusivity</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Pediatric Research Equity Act (&#8220;PREA&#8221;), certain NDAs and BLAs and certain supplements to an NDA or BLA must contain data to assess the safety and efficacy of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of pediatric data or full or partial waivers. A sponsor who is planning to submit a marketing application for a drug that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration must submit an initial Pediatric Study Plan (&#8220;PSP&#8221;) within 60 days of an end-of-Phase 2 meeting or, if there is no such meeting, as early as practicable before the initiation of the Phase 3 or Phase 2/3 study. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA and the sponsor must reach an agreement on the PSP. A sponsor can submit amendments to an agreed-upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from preclinical studies, early phase clinical trials and/or other clinical development programs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Best Pharmaceuticals for Children Act (&#8220;BPCA&#8221;), a drug or biologic product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods for all formulations, dosage forms, and indications of the active moiety and patent terms for drugs and six months to exclusivity periods for all formulations, dosage forms, and indications for biologic products. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued &#8220;Written Request&#8221; for such a study, provided that at the time pediatric exclusivity is granted there is not less than nine months of term remaining.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Biosimilars</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Biologics Price Competition and Innovation Act of 2009 ("BPCIA") created an abbreviated approval pathway for biological products that are demonstrated to be "biosimilar" or "interchangeable" with an FDA-licensed reference biological product via an approved BLA. Biosimilarity to an approved reference product requires that there be no differences in conditions of use, route of administration, dosage form, and strength, and no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency. Biosimilarity is demonstrated in steps beginning with rigorous analytical studies or "fingerprinting", in vitro studies, in vivo animal studies, and generally at least one clinical study, absent a waiver from the Secretary of the U.S. Department of Health and Human Services ("HHS"). The biosimilarity exercise tests the hypothesis that the investigational product and the reference product are the same. If at any point in the stepwise biosimilarity process a significant difference is observed, then the products are not biosimilar, and the development of a stand-alone BLA is necessary. In order to meet the higher hurdle of interchangeability, a sponsor must demonstrate that the biosimilar product can be expected to produce the same clinical result as the reference product, and for a product that is administered more than once, that the risk of switching between the reference product and biosimilar product is not greater than the risk of maintaining the patient on the reference product. Complexities associated with the larger, and often more complex, structures of biological products, as well as the process by which such products are manufactured, pose significant hurdles to implementation that are still being evaluated by the FDA. Under the BPCIA, a reference biologic is granted 12 years of exclusivity from the time of first licensure or BLA approval, of the reference product, and no application for a biosimilar can be submitted for four years from the date of licensure of the reference product. The first biologic product submitted under the biosimilar abbreviated approval pathway that is determined to be interchangeable with the reference product has exclusivity against a finding of interchangeability for other biologics for the same condition of use for the lesser of (i) one year after first commercial marketing of the first interchangeable biosimilar, (ii) 18 months after the first interchangeable biosimilar is approved if there is no patent challenge, (iii) 18 months after resolution of a lawsuit over the patents of the reference biologic in favor of the first interchangeable biosimilar applicant, or (iv) 42 months after the first interchangeable biosimilar is approved if a patent lawsuit is ongoing within the 42-month period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regulation Outside of the United States</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to regulations in the United States, we are subject to a variety of regulations in other jurisdictions governing clinical studies, commercial sales, and distribution of our products. Most countries outside of the United States require that clinical trial applications be submitted to and approved by the local regulatory authority for each clinical study. In the European Union, for example, an application must be submitted to the national competent authority and an independent ethics committee in each country in which we intend to conduct clinical trials, much like the FDA and IRB, respectively. Under the Clinical Trials Regulation (EU) No 536/2014, which replaced the Clinical Trials Directive 2001/20/EC on January 31, 2022, a single application is now made through the Clinical Trials Information System (&#8220;CTIS&#8221;), for clinical trial authorization in up to 30 European Union/European Economic Area ("EU/EEA") countries at the same time and with a single set of documentation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The assessment of applications for clinical trials is divided into two parts (Part I contains scientific and medicinal product documentation and Part II contains the national and patient-level documentation). Part I is assessed by a coordinated review by the competent authorities of all European Union Member States in which an application for authorization of a clinical trial has been submitted (Member States concerned) of a draft report prepared by a Reference Member State. Part II is assessed separately by each Member State concerned. The role of the relevant ethics committees in the assessment procedure will continue to be governed by the national law of the Member State concerned, however overall related timelines are defined by the Clinical Trials Regulation. The new Clinical Trials Regulation also provides for simplified reporting procedures for clinical trial sponsors.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, whether or not we obtain FDA approval for a product, we must obtain approval of a product by the comparable regulatory authorities of countries outside the U.S. before we can commence clinical studies or marketing of the product in those countries. The approval process and requirements vary from country to country, so the number and type of non-clinical, clinical, and manufacturing studies needed may differ, and the time may be longer or shorter than that required for FDA approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To obtain regulatory approval of a product under the European Union's regulatory system, we submit a Marketing Authorization Application ("MAA"), to be assessed in the centralized procedure. The centralized procedure allows applicants to obtain a marketing authorization ("MA") that is valid throughout the European Union and the additional Member States of the European Area (Iceland, Liechtenstein and Norway) ("EEA"). It is</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">31</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compulsory for medicinal products manufactured using biotechnological processes, for orphan medicinal products, for advance therapy medicinal products (gene-therapy, somatic cell-therapy or tissue-engineered medicines) and for human products containing a new active substance which are not authorized in the European Union and which are intended for the treatment of HIV, AIDS, cancer, neurodegenerative disorders, auto-immune and other immune dysfunctions, viral diseases or diabetes. The centralized procedure is optional for any other products containing new active substances not authorized in the European Union or for products which constitute a significant therapeutic, scientific or technical innovation or for which a centralized authorization is in the interests of patients in the European Union. When a company wishes to place on the market a medicinal product that is eligible for the centralized procedure, it sends an application directly to the EMA, to be assessed by the Committee for Medicinal Products for Human Use ("CHMP"). The CHMP is responsible for conducting the assessment of whether a medicine meets the required quality, safety and efficacy requirements, and whether the product has a positive risk/benefit/risk profile. Full copies of the MAA are sent to a rapporteur and a co-rapporteur designated by the competent EMA scientific committee. They coordinate the EMA's scientific assessment of the medicinal product and prepare draft reports. Once the draft reports are prepared (other experts might be called upon for this purpose), they are sent to the CHMP, whose comments or objections are communicated to the applicant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The rapporteur and co-rapporteur then assess the applicant's replies, submit them for discussion to the CHMP and, taking into account the conclusions of this debate, prepare a final assessment report. Once the evaluation is completed, the CHMP gives a favorable or unfavorable opinion as to whether to grant the authorization. When the opinion is favorable, it shall include the draft summary of the product's characteristics, the package leaflet and the texts proposed for the various packaging materials. The time limit for the evaluation procedure is 210 days (excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP). The EMA then has fifteen days to forward its opinion to the European Commission which will make a binding decision on the grant of an MA within 67 days of the receipt of the CHMP.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The European Commission has fifteen days to prepare a draft decision. The medicinal product is assigned an EU registration number, which will be placed on its packaging if the MA is granted. During this period, various European Commission directorates-general are consulted on the draft MA decision. There are two other procedures in the European Union for the grant of an MAA in multiple European Union Member States. The decentralized procedure provides for approval by one or more other, or concerned, Member States of an assessment of an application performed by one member state, known as the Reference Member State. Under this procedure, an applicant submits an application, or dossier, and related materials including a draft summary of product characteristics, and draft labeling and package leaflet, to the Reference Member State and Concerned Member States. The Reference Member State prepares a draft assessment and drafts of the related materials within 120 days after receipt of a valid application. Within 90 days of receiving the reference member state's assessment report, each Concerned Member State must decide whether to approve the assessment report and related materials. If a member state cannot approve the assessment report and related materials on the grounds of potential serious risk to the public health, the disputed points may eventually be referred to the European Commission, whose decision is binding on all member states. Where a product has already received an MA in one Member State, another Member State can recognize that MA under the mutual recognition procedure.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regulation (EC) No. 141/2000, as amended, provides that a product may be designated as an orphan medicinal product if its sponsor can establish that it is intended for the diagnosis, prevention, or treatment of life-threatening or chronically debilitating conditions that affect not more than 5 in 10,000 persons in the European Union when the application is made. In addition, orphan designation can be granted if the product is intended for a life threatening, seriously debilitating, or serious and chronic condition in the European Union where without incentives derived from orphan designation.it is unlikely that sales of the product in the European Union would be sufficient to justify the necessary investment in its development. Orphan designation is only available if there is no other satisfactory method approved in the European Union of diagnosing, preventing, or treating the condition, or if such a method exists, the proposed orphan product will be of significant benefit to patients over the existing options. We have obtained orphan drug in the European Union for nomlabofusp.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Orphan designation provides opportunities for fee reductions, protocol assistance and access to the centralized procedure in the European Union. Fee reductions are not limited to the first year after an MA for small and medium enterprises. In addition, if a product which has an orphan designation subsequently receives a centralized MA for the indication for which it has such designation, the product is entitled to orphan market exclusivity, which means the regulatory authorities in the European Union may not approve any other application to market a "similar medicinal product" similar drug for the same indication for a period of 10 years. A &#8220;similar medicinal product&#8221; is defined as a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">32</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. The exclusivity period may be reduced to six years if the designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity. Additionally, an MA may be granted to a similar medicinal product for the same indication if:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the second applicant can establish that its product, although similar to the authorized orphan product, is safer, more effective or otherwise clinically superior; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the MA holder of the authorized orphan product consents to a second orphan medicinal product application; or </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the MA holder of the authorized orphan product cannot supply enough orphan medicinal product.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The EMA offers a scheme to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist. The PRIority MEdicines, or PRIME, scheme is intended to encourage drug development in areas of unmet medical need and is intended to reinforce early dialogue with, and regulatory support from, EMA in order to stimulate innovation, optimize development and enable accelerated assessment of such product candidates. It is intended to build upon the scientific advice scheme and accelerated assessment procedure offered by the EMA. The scheme is voluntary and eligibility criteria must be met for a medicine to qualify for PRIME.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The PRIME scheme is open to medicines under development and for which the applicant intends to apply for an MA through the centralized procedure. Eligible products must target conditions for which there is an unmet medical need (there is no satisfactory method of diagnosis, prevention or treatment in the European Union or, if there is, the new medicine will bring a major therapeutic advantage) and they must demonstrate the potential to address the unmet medical need by introducing new methods or therapy or improving existing ones. Applicants will typically be at the exploratory clinical trial phase of development and will have preliminary clinical evidence in patients to demonstrate the promising activity of the medicine and its potential to address to a significant extent an unmet medical need. In exceptional cases, applicants from the academic sector or SMEs (small and medium sized enterprises) may submit an eligibility request at an earlier stage of development if compelling non-clinical data in a relevant model provide early evidence of promising activity to establish proof of principle, and first in man studies indicate adequate exposure for the desired pharmacotherapeutic effects and tolerability.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a medicine is selected for the PRIME scheme, EMA:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Appoints a rapporteur from the CHMP or from the Committee for Advanced Therapies ("CAT") to provide continuous support and to build up knowledge of the medicine in advance of the filing of an MAA; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Issues guidance on the applicant&#8217;s overall development plan and regulatory strategy;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Organizes a kick-off meeting with the rapporteur and experts from relevant EMA committees and working groups; Provides a dedicated EMA contact person; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Provides scientific advice at key development milestones, involving additional stakeholders, such as health technology assessment bodies and patients, as needed.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For SMEs who enter the scheme based on data showing proof of principle, the appointment of the rapporteur occurs once they have generated data confirming eligibility at proof of concept stage. They are required to submit relevant data and justification as the product development reaches this stage.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Medicines that are selected for the PRIME scheme are also expected to benefit from EMA&#8217;s accelerated assessment procedure at the time of application for marketing authorization. Where, during the course of development, a medicine no longer meets the eligibility criteria, support under the PRIME scheme may be withdrawn.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A Pediatric Investigation Plan ("PIP") in the European Union is aimed at ensuring that the necessary data are obtained to support the authorization of a medicine for children, through studies in children. All applications for marketing authorization for new medicines have to include the results of studies as described in an agreed PIP, unless the study results are deferred, or the medicine is exempt because of a waiver. This requirement also applies when a marketing-authorization holder wants to add a new indication, pharmaceutical form, or route of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">33</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">administration for a medicine that is already authorized and covered by intellectual property rights. Several rewards and incentives for the development of pediatric medicines for children are available in the E.U. Medicines authorized across the E.U. with the results of studies from a PIP included in the product information are eligible for an extension of their supplementary protection certificate by six months. This is the case even when the studies&#8217; results are negative. For orphan medicines, the incentive is an additional two years of market exclusivity. Scientific advice and protocol assistance at the Agency are free of charge for questions relating to the development of pediatric medicines.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aforementioned European Union rules are generally applicable in the EEA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The UK left the European Union on January 31, 2020 and the UK and the European Union concluded a trade and cooperation agreement (&#8220;TCA&#8221;), which was provisionally applicable since January 1, 2021 and has been formally applicable since May 1, 2021. The TCA includes specific provisions concerning pharmaceuticals, which include the mutual recognition of cGMP, inspections of manufacturing facilities for medicinal products and cGMP documents issued, but does not provide for wholesale mutual recognition of UK and European Union pharmaceutical regulations. At present, Great Britain has implemented European Union legislation on the marketing, promotion and sale of medicinal products through the Human Medicines Regulations 2012 (as amended) (under the Northern Ireland Protocol, the European Union regulatory framework continues to apply in Northern Ireland). Except in respect of the new European Union Clinical Trials Regulation, the regulatory regime in Great Britain therefore largely aligns with current European Union medicines regulations, however it is possible that these regimes will diverge more significantly in future now that Great Britain&#8217;s regulatory system is independent from the European Union and the TCA does not provide for mutual recognition of UK and European Union pharmaceutical legislation. However, notwithstanding that there is no wholesale recognition of European Union pharmaceutical legislation under the TCA, under the new framework mentioned below which will be put in place by the Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;), the UK&#8217;s medicines regulator, from January 1, 2024, the MHRA has stated that it will take into account decisions on the approval of MAs from the EMA (and certain other regulators) when considering an application for a Great Britain MA. On February 27, 2023, the UK government and the European Commission announced a political agreement in principle to replace the Northern Ireland Protocol with a new set of arrangements, known as the &#8220;Windsor Framework&#8221;. This new framework fundamentally changes the existing system under the Northern Ireland Protocol, including with respect to the regulation of medicinal products in the UK. In particular, the MHRA will be responsible for approving all medicinal products destined for the UK market (Great Britain and Northern Ireland), and the EMA will no longer have any role in approving medicinal products destined for Northern Ireland. Once the Windsor Framework is approved by the EU-UK Joint Committee, the UK Government and the European Union will enact legislative measures to enact it into law. The MHRA has introduced changes to national licensing procedures, including procedures to prioritize access to new medicines that will benefit patients, an accelerated assessment procedure and new routes of evaluation for novel products and biotechnological products. All existing E.U. MAs for centrally authorized products were automatically converted (grand fathered) into UK MAs free-of-charge on January 1, 2021. For a period of three years from January 1, 2021, the MHRA may rely on a decision taken by the European Commission on the approval of a new MA in the centralized procedure, in order to more quickly grant a new Great Britain MA. A separate application will, however, still be required. On January 24, 2023, the MHRA announced that a new international recognition framework will be put in place from January 1, 2024, which will have regard to decisions on the approval of MAs made by the EMA and certain other regulators when determining an application for a new Great Britain MA.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is now no pre-marketing authorization orphan designation in Great Britain. Instead, the MHRA will review applications for orphan designation in parallel to the corresponding MA application. The criteria are essentially the same, but have been tailored for the GB market, i.e. the prevalence of the condition in GB (rather than the EU) must not be more than 5 in 10,000. Should an orphan designation be granted, the period or market exclusivity will be set from the date of first approval of the product in GB or EU/European Economic Area, wherever is earliest.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may also apply for access to the UK&#8217;s Innovative Licensing and Access Pathway (&#8220;ILAP&#8221;) which aims to accelerate the time to market and facilitate patient access to certain types of medicinal products in development which target a life-threatening or seriously debilitating condition, or where there is a significant patient or public health need in the UK. To access the ILAP, an applicant applies for an Innovation Passport designation. Once an Innovation Passport designation is granted, the MHRA and its partner agencies (including The All Wales Therapeutics and Toxicology Centre, National Institute for Health and Care Excellence and the Scottish Medicines Consortium) will work with the Innovation Passport designee to define a Target Development Profile, (&#8220;TDP&#8221;). The</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">34</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TDP sets out a unique product-specific roadmap towards patient access in the UK and provides access to a toolkit to support all stages of the design, development and approvals process, including continuous benefit-risk assessment, increased support for novel development approaches and enhanced patient engagement. However, although the goal of the ILAP is to reduce the time to market and enable earlier patient access, access does not accelerate conduct of clinical trials or mean that the regulatory requirements are less stringent, nor does it ensure that a marketing authorization application will be approved or that any approval will be granted within a particular timeframe or at all.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Healthcare Laws and Regulations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Coverage and Reimbursement</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to successfully commercialize our product candidates will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is also significant uncertainty related to the insurance coverage and reimbursement of newly approved products and coverage may be more limited than the purposes for which the medicine is approved by the FDA or comparable foreign regulatory authorities. In the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;), an agency within the U.S. Department of Health and Human Services. CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare and private payors tend to follow CMS to a substantial degree. Factors payors consider in determining reimbursement are based on whether the product is a covered benefit under its health plan; safe, effective and medically necessary; appropriate for the specific patient; cost-effective; and neither experimental nor investigational. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Outside of the United States, the pricing of pharmaceutical products is subject to governmental control in many countries. For example, in the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular therapy to currently available therapies or so-called health technology assessments, in order to obtain reimbursement or pricing approval. Other countries may allow companies to fix their own prices for products, but monitor and control product volumes and issue guidance to physicians to limit prescriptions. We cannot be sure that reimbursement will be available for any of our product candidates that we commercialize and, if reimbursement is available, the level of reimbursement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Healthcare Laws</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sales of our product candidate, if approved, or any other future product candidate will be subject to healthcare regulation and enforcement by the federal government and the states and foreign governments in which we might conduct our business. The healthcare laws and regulations that may affect our ability to operate include the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal Anti-Kickback Statute prohibits, among other things knowingly and willfully, directly or indirectly, soliciting, receiving, offering, or paying any remuneration that is in exchange for or to induce the referral of business, including the purchase, order, lease of any good, facility, item or service for which payment may be made under a federal healthcare program, such as Medicare or Medicaid. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Patient Protection and Affordable Care Act as amended by the Health Care and Education Reconciliation Act (collectively, the &#8220;ACA&#8221;), amended the intent element of the federal Anti-Kickback Statute so that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to commit a violation; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">35</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Federal false claims and false statement laws, including the federal civil False Claims Act, prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, for payment to, or approval by, federal programs, including Medicare and Medicaid, claims for items or services, including drugs, that are false or fraudulent. The ACA amended the federal Anti-Kickback Statute such that a violation of that statute can serve as a basis for liability under the federal civil False Claims Act; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal Health Insurance Portability and Accountability Act of 1996 ("HIPAA") created additional federal criminal statutes that prohibit among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors or making any false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 ("HITECH") and their implementing regulations, impose obligations on healthcare providers, health plans, and healthcare clearinghouses, known as covered entities as well as their business associates and their subcontractors that perform certain services involving the storage, use or disclosure of individually identifiable health information; including mandatory contractual terms, with respect to safeguarding the privacy, security, and transmission of individually identifiable health information, and require notification to affected individuals and regulatory authorities of certain breaches of security of individually identifiable health information. HITECH increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal Physician Payments Sunshine Act enacted as part of the ACA, and its implementing regulations requires certain manufacturers of approved drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to collect and report annually to the Centers for Medicare and Medicaid Services, the agency that administers the Medicare and Medicaid programs ("CMS") information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, certified nurse-midwives) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. The reported data is made available in searchable form on a public website on an annual basis. Failure to submit required information may result in civil monetary penalties; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Foreign Corrupt Practices Act ("FCPA") prohibits U.S. businesses and their representatives from offering to pay, paying, promising to pay or authorizing the payment of money or anything of value to a foreign official in order to influence any act or decision of the foreign official in his or her official capacity or to secure any other improper advantage in order to obtain or retain business. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many states have similar laws and regulations, such as anti-kickback and false claims laws that may be broader in scope and may apply regardless of payor, in addition to items and services reimbursed under Medicaid and other state programs. Additionally, we may be subject to state laws that require pharmaceutical companies to comply with the federal government&#8217;s and/or pharmaceutical industry&#8217;s voluntary compliance guidelines, state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures. Certain states and local jurisdictions also require the registration of pharmaceutical sales representatives. Further, certain states require the posting of information relating to clinical studies and their outcomes. A growing number of states require the reporting of certain drug pricing information, including information pertaining to and justifying price increases and the price set for newly launched drugs, or to prohibit prescription drug price gouging. We may also be subject to state and foreign laws governing the privacy and security of health information, many of which differ from each other in significant ways and often are not preempted by HIPAA. In the United States, there are numerous federal and state privacy and data security laws and regulations governing the collection, use, disclosure and protection of personal information, including federal and state health information privacy laws, federal and state security breach notification laws, and federal and state consumer protection laws. Each of these laws is subject to varying interpretations and new laws continue to be proposed. At the state level, numerous states have or are in the process of enacting or considering comprehensive</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">state-level data privacy and security laws, rules and regulations while other states have focused on more narrow aspects of privacy. In the state of Washington, for example, the My Health My Data Act will require regulated entities to obtain consent to collect health information, grant consumers certain rights, including to request deletion of their information, and provide for robust enforcement mechanisms, including enforcement by the Washington state attorney-general and a private right of action for consumer claims. Other states have also enacted, proposed, or are considering proposing, data privacy laws, which could further complicate compliance efforts, increase our potential liability and adversely affect our business. Additionally, to the extent that our product is sold in a foreign country, we may be subject to similar foreign laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Healthcare Reform</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system. The United States government, state legislatures and foreign governments also have shown significant interest in implementing cost-containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical or biological products, medical devices, and medical services, in addition to questioning safety and efficacy. CMS also has authority to revise reimbursement rates and to implement coverage restrictions for some drugs. Cost reduction initiatives and changes in coverage implemented through legislation or regulation could decrease utilization of and reimbursement for any approved products. While Medicare regulations apply only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, although private payors have their own methods and approval process apart from Medicare determinations, any reduction in reimbursement that results from federal legislation or regulation may result in a similar reduction in payments from private payors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Affordable Care Act substantially changed the way healthcare is financed by both governmental and private insurers, included provisions that affected the pharmaceutical industry. Among other things, the Affordable Care Act expanded manufacturers&#8217; rebate liability under the Medicaid Drug Rebate Program, expanded the 340B program, and increased the amount of Medicaid drug rebates manufacturers are required to pay to states. Since that time, several healthcare reform proposals recently culminated in the enactment of the Inflation Reduction Act (&#8220;IRA&#8221;) in August 2022, which, among other things, allows HHS to directly negotiate the selling price of a statutorily specified number of drugs and biologics each year that CMS reimburses under Medicare Part B and Part D. Only high-expenditure single-source biologics that have been approved for at least 11 years (7 years for drugs) can be selected by CMS for negotiation, with the negotiated price taking effect two years after the selection year. Negotiations for Medicare Part D products take place in 2024 with the negotiated price taking effect in 2026, and negotiations for Medicare Part B products will begin in 2026 with the negotiated price taking effect in 2028. In August 2023, HHS announced the ten Medicare Part D drugs and biologics that it selected for negotiations. HHS will announce the negotiated maximum fair prices by September 1, 2024, and this price cap, which cannot exceed a statutory ceiling price, will go into effect on January 1, 2026. A drug or biological product that has an orphan drug designation for only one rare disease or condition will be excluded from the IRA&#8217;s price negotiation requirements, but will lose that exclusion if it receives designations for more than one rare disease or condition, or if is approved for an indication that is not within that single designated rare disease or condition, unless such additional designation or such disqualifying approvals are withdrawn by the time CMS evaluates the drug for selection for negotiation. The IRA also imposes rebates on Medicare Part B and Part D drugs whose prices have increased at a rate greater than the rate of inflation. The IRA also extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. Manufacturers that fail to comply with the IRA may be subject to various penalties, including significant civil monetary penalties. These provisions have been and may continue to be subject to legal challenges. For example, the provisions related to the negotiation of selling prices of high-expenditure single-source drugs and biologics have been challenged in multiple lawsuits brought by pharmaceutical manufacturers. Thus, while it is unclear how the IRA will be implemented, it will likely have a significant impact on the biopharmaceutical industry and the pricing of prescription drug products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. For example, the FDA released a final rule in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">37</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 2020 providing guidance for states to build and submit plans for importing drugs from Canada, and FDA authorized the first such plan in Florida in January 2024. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect that additional federal, state and foreign healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in limited coverage and reimbursement and reduced demand for our products, once approved, or additional pricing pressures.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">38</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item1ariskfactors_798482"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 1A. RISK FACTORS</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">You should consider carefully the following risks and uncertainties when reading this Annual Report on Form 10-K, as well as the other information contained herein, including our audited consolidated financial statements and the related notes and the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operation.&#8221; If any of the following risks occur, our business, financial condition and results of operations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">could be materially and adversely affected. Although we believe that we have identified and discussed below the key risk factors affecting our business, there may be additional risks and uncertainties that are not presently known or that are not currently believed to be significant that may adversely affect our performance or financial condition. In that event, the trading price of our common stock could decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Financial Position and Need for Capital</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have incurred significant losses since our inception and anticipate that we will incur continued losses for the foreseeable future.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since our inception we have devoted substantially all of our resources to the development of nomlabofusp. We have incurred significant losses in each year of operation since our inception in 2016. For the years ended December 31, 2023 and 2022, we had net losses of $36.9 million and $35.4 million, respectively, and, as of December 31, 2023, we had an accumulated deficit of $188.6 million and we expect to continue to incur significant expenses and net operating losses ("NOLs") for the foreseeable future.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have devoted substantially all of our financial resources and efforts to research and development, including non-clinical studies, our clinical development program, the development of manufacturing processes as well as the manufacture of initial lots of clinical trial material. We expect to incur significant losses for the foreseeable future to further develop and commercialize our lead drug candidate, nomlabofusp.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect that our expenses will increase substantially if and as we:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">continue clinical development efforts for nomlabofusp;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seek regulatory and marketing approvals in the United States and in foreign jurisdictions for our product candidates that successfully complete clinical trials, if any;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish sales, marketing, distribution and other commercial infrastructure to commercialize various products for which we may obtain marketing approval, if any;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">contract for the manufacture of larger quantities of product candidates for clinical development and potentially commercialization;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maintain, expand and protect our intellectual property portfolio;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">hire and retain additional personnel, such as clinical, manufacturing, quality control, regulatory and finance personnel; and; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">experience any delays or encounter issues with any of the above.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently have no sales, marketing or medical affairs infrastructure and have no experience in the sales, marketing, or distribution of pharmaceutical products. Assuming nomlabofusp ultimately is approved for marketing in the US and elsewhere, we will need to establish commercial capabilities as well as customer service and support, logistics, and other related functions, or make arrangements with third parties to perform these services.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net losses and negative cash flows have had, and will continue to have, an adverse effect on our liquidity and potentially the ability for us to raise capital due to our unfavorable operating results.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have no commercial revenue and may never become profitable.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To date, we have not generated any commercial revenue. Our ability to generate revenue and become profitable depends upon our ability to obtain regulatory approval for, and to successfully commercialize, nomlabofusp or other product candidates that we may develop, in-license or acquire in the future.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This will require success in a range of challenging activities, including completing numerous clinical trials of nomlabofusp or any future product candidates, obtaining marketing approval for nomlabofusp and any future product candidates, manufacturing, marketing and selling those products for which we, or any future collaborators</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">39</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">or partners, may obtain marketing approval, satisfying any post-marketing requirements and obtaining reimbursement for our products from private insurance and/or government payors. Even if we are able to successfully achieve the above, we do not know what the reimbursement status of nomlabofusp or any other future product candidates will be or when any of these products will generate revenue for us, if at all. We have not generated, and do not expect to generate, any product revenue for the foreseeable future, and expect to continue to incur significant operating losses for the foreseeable future due to the cost of research and development, non-clinical studies and clinical trials and the regulatory approval process for nomlabofusp and any future product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to generate revenue from nomlabofusp or any future product candidates also depends on a number of additional factors, including our ability to:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">successfully complete development activities, including the remaining non-clinical studies and planned clinical trials for our product candidates;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">complete and submit BLAs to the FDA and MAAs to the EMA and obtain regulatory approval for indications for which there is a commercial market;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">complete and submit applications to, and obtain regulatory approval from, other foreign regulatory authorities;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">manufacture or have manufactured any approved products in commercial quantities and on commercially reasonable terms;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">develop a commercial organization, or find suitable partners, to market, sell and distribute approved products in the markets in which we have retained commercialization rights;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">achieve acceptance among patients, clinicians and advocacy groups for any products we develop;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtain coverage and adequate reimbursement from third parties, including government payors; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">set a commercially viable price for any products for which we may receive approval.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of the uncertainties and risks associated with these activities, we are unable to accurately predict the timing and amount of increased expenses, and if or when we might achieve or maintain profitability. We and any future collaborators may never succeed in these activities and, even if we do, or any future collaborators do, we may never generate revenues that are large enough for us to achieve profitability. Even if we are able to complete the processes described above, we anticipate incurring significant costs associated with commercializing nomlabofusp or any of our future product candidates. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our failure to become and remain profitable could decrease the value of our business and could impair our ability to raise capital, maintain our discovery and clinical development efforts, expand our business or continue our operations and may require us to raise additional capital that may dilute the ownership interest of shareholders. A decline in the value of our business could also cause shareholders to lose all or part of their investment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may need to raise additional funding to complete the development and commercialization of nomlabofusp. This funding may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed would force us to delay, limit or terminate our product development efforts or other operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, our existing cash, cash equivalents and marketable securities were $86.8 million, excluding restricted cash of $1.3 million. In February 2024, we completed an underwritten public offering of 19,736,842 shares of our common stock at an offering price of $8.74 per share with net proceeds, after deducting underwriting commissions and offering costs, of approximately $161.6 million. Together with our existing cash, cash equivalents and marketable securities, we have adequate resources to fund our operations into 2026.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to continue to spend substantial and increasing amounts to conduct clinical trials of nomlabofusp and further research and development activities for nomlabofusp, and for any additional product candidates that we may develop, in-license or acquire in the future. In addition, raising funds in the current economic environment may present substantial challenges, and our expenses will increase as we expand, through development, in-license or acquisition, our pipeline of product candidates. If we obtain marketing approval for any of our product candidates, we will likely incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution to the extent that such sales, marketing, manufacturing and distribution are not the responsibility of a future collaborator. Accordingly, we will need to obtain additional funding in connection with our continuing operations. Our current cash, cash equivalents and marketable securities may not be sufficient to fund all of the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">40</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">efforts that we plan to undertake or to fund the completion of the development and commercialization of nomlabofusp. Accordingly, we may be required to obtain further funding through public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources. The incurrence of indebtedness would result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If additional capital is needed to complete the development and commercialization of nomlabofusp, there can be no assurance that we will be able to raise sufficient additional capital on acceptable terms or at all. If such additional financing is not available on satisfactory terms, or is not available in sufficient amounts, or we do not have sufficient authorized shares, we may be required to delay, limit, or eliminate the development of business opportunities and our ability to achieve our business objectives, our competitiveness, and our business, financial condition, and results of operations will be materially adversely affected. We could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results, financial condition and prospects. In addition, geopolitical tension including, for example, the broader impact of the ongoing conflict between Russia and Ukraine and the current conflict in Israel and Gaza (including any escalation or expansion), and the impact of a future pandemic, epidemic or outbreak of an infectious disease, such as COVID-19, or recent liquidity constraints, failures and instability in U.S. and international financial banking systems on the global financial markets may reduce our ability to access capital, which could negatively affect our liquidity.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If additional capital is needed to complete the development and commercialization of nomlabofusp, and if we are unable to obtain funding when needed and/or on acceptable terms, we may be required to significantly curtail, delay or discontinue one or more of our research and development programs, the manufacture of clinical and commercial supplies, product portfolio expansion or pre commercialization efforts, which could adversely affect our business prospects, or we may be unable to continue operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies, nomlabofusp or other product candidates that we may develop, in-license or acquire in the future.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may seek additional capital through a combination of private or public equity offerings, debt financings, collaborations and licensing arrangements or other sources. To the extent we raise additional capital through the sale of equity or convertible debt securities, existing ownership interests will be diluted and the terms of such financings may include liquidation or other preferences that adversely affect the rights of existing stockholders. Debt or equity financings may be coupled with an additional equity component, such as warrants to purchase shares, which could also result in dilution of our existing stockholder&#8217;s ownership.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights, including future revenue streams, to nomlabofusp or other product candidates that we may develop, in-license or acquire in the future, or grant licenses on terms that are not favorable to us.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our ability to use our NOLs and certain other tax attributes may be limited.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 we had NOL carryforwards that expire for U.S. federal income tax purposes of $179.0 million, a portion of which begin to expire in 2026. Our NOLs could expire unused and be unavailable to offset future income tax liabilities because of their limited duration or because of restrictions under U.S. tax law. NOLs generated in taxable years beginning before January 1, 2018 are permitted to be carried forward for 20 taxable years under applicable U.S. federal income tax law. Under current U.S. federal income tax law, NOLs arising in tax years beginning after December 31, 2020 may not be carried back. Moreover, NOLs generated in taxable years beginning after December 31, 2017 may be carried forward indefinitely. As of December 31, 2023, the Company had federal net operating loss carryforwards that were generated after December 31, 2017 of $140.3 million that do not expire, however these carryforwards are limited to 80% of the taxable income in any one tax period.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In general, under Section 382 of the Internal Revenue Code (the "Code") if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50% change (by value) in its equity ownership over a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">41</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three-year period, the corporation&#8217;s ability to use its pre-change NOLs and other pre-change tax attributes (such as capitalized research and development costs and research tax credits) to offset its post-change income may be limited. We believe that as a result of our merger with Zafgen, our ability to utilize NOLs acquired in the transaction and our other NOLs is expected to be severely limited by Section 382 of the Code. Additionally, our July 2021, September 2022 and February 2024 equity transactions could also limit our ability to utilize NOLs in the future. We may also experience ownership changes in the future as a result of subsequent shifts in our stock ownership. As a result, if we earn net taxable income, our ability to use our pre-change NOLs to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed and would adversely affect our business, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in tax laws and regulations may have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could affect the tax treatment of any of our future domestic and foreign earnings. Any new taxes could adversely affect our domestic and international business operations, and our business and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, under Section 174 of the code, in taxable years beginning after December 31, 2021, expenses that are incurred for research and development in the U.S. are capitalized and amortized, which may have an adverse effect on our cash flow. In addition, it is unclear how these U.S. federal income tax changes will affect state and local taxation. Generally, future changes in applicable U.S. tax laws and regulations, or their interpretation and application could have an adverse effect on our business, financial conditions and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Product Development and Regulatory Approvals</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The FDA has placed a partial clinical hold on nomlabofusp and there is uncertainty as to when, or if, the FDA will lift the partial clinical hold on our nomlabofusp program, or if it will ever allow further clinical development of nomlabofusp beyond our currently ongoing OLE study at the 25 mg dose level.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To support extended dosing of patients with nomlabofusp, we conducted a 26-week NHP toxicology study. In May 2021, we notified the FDA of certain mortalities which occurred at the two highest dose levels in the then ongoing study. On May 25, 2021, the FDA placed a clinical hold on the nomlabofusp clinical program. In the clinical hold letter, the FDA stated that it needed to review a full study report from the then-ongoing NHP study and that we could not initiate additional interventional clinical trials until we submitted such report and received notification from the FDA that additional clinical trials could commence. At the time of the FDA clinical hold, we had no interventional clinical trials with patients enrolling or enrolled.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2021, we completed dosing in the 26-week NHP toxicology study. The study included four dose groups in addition to vehicle. Data from the study were collected throughout the second half of 2021 and included in the complete response to the clinical hold submitted to the FDA in January 2022.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2022, in response to the complete response to clinical hold, we submitted to the FDA, the FDA stated that it was maintaining the clinical hold and that additional data were needed to resolve the clinical hold. We subsequently submitted a request to the FDA for a Type C meeting, which was granted and held in July 2022. We submitted a complete response to clinical hold incorporating additional information requested by the FDA at the meeting as well as information on the proposed study in August 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2022, following the Type C meeting and the submission of the complete response to clinical hold, the FDA allowed the 25 mg cohort of a Phase 2, four-week, placebo-controlled, dose exploration trial of nomlabofusp in FA patients discussed above to proceed. In connection with this decision, the FDA lifted its full clinical hold on the nomlabofusp clinical development program and imposed a partial clinical hold.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2023, we met with the FDA. Following that meeting, we submitted a complete response to the FDA&#8217;s partial clinical hold that included unblinded safety, PK and frataxin data from the Phase 2 trial&#8217;s completed 25 mg cohort.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">42</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2023, following the FDA&#8217;s review of our complete response to the partial clinical hold, the FDA cleared initiation of a second cohort (50 mg) in our four-week, placebo-controlled, Phase 2 dose exploration trial and the initiation of our OLE trial with daily dosing of 25 mg.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2024, we initiated the OLE trial evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver, with the first patient dosed in March 2024. Dose escalation in the OLE trial will be considered based on safety, tolerability, PK, and tissue FXN levels from the Phase 2 trial&#8217;s 50 mg cohort as well as available data from the 25 mg dose of nomlabofusp in the OLE trial, and is contingent on FDA review as part of the partial clinical hold. Initial data from the OLE trial is expected in the fourth quarter of 2024.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2024, we reported positive top-line data and successful completion of both the 25 mg cohort and the 50 mg cohort of our four-week, placebo-controlled Phase 2 dose exploration study of nomlabofusp in participants with FA. Nomlabofusp was generally well tolerated and demonstrated dose dependent increases in FXN levels in all evaluated tissues (skin and buccal cells) after daily dosing of 14 days followed by every other day dosing until day 28 in the 25 mg and 50 mg cohorts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business may be adversely affected if the FDA partial clinical hold does not enable the development program to proceed as planned, if the FDA places a full clinical hold on the development of nomlabofusp, or, if additional non-clinical or clinical studies are required. This may cause significant delays or expense in developing nomlabofusp.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our success is currently dependent upon the success of our lead product candidate, nomlabofusp. We cannot be certain that data from both cohorts of our Phase 2 dose exploration study augmented by data from the OLE trial will provide the FDA with adequate data to remove the partial clinical hold on nomlabofusp, allow the nomlabofusp development program to proceed as planned in part or in full, or that we will ultimately be successful with our clinical development or that we will be ever able to obtain regulatory approval for nomlabofusp.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently have no drug products for sale and our business is currently wholly dependent on our successful clinical development, regulatory approval and commercialization of nomlabofusp, our lead product candidate and our only product candidate in clinical development, for which we have completed two Phase 1 studies and a four-week, placebo-controlled Phase 2 dose exploration study in patients with FA. In January 2024, as permitted by the FDA, we initiated the OLE trial evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver, with the first patient dosed in March 2024. Participants who completed treatment in the Phase 2 dose exploration trial, or who previously completed a prior clinical trial of nomlabofusp are potentially eligible for the OLE. Dose escalation in the OLE trial will be considered based on safety, PK, and tissue FXN levels from the 25 mg dose of nomlabofusp in the OLE trial, as well as other data from the Phase 2 trial&#8217;s 50 mg cohort, and is contingent on FDA review as part of the partial clinical hold. We cannot provide any assurance that the data from our Phase 1 and Phase 2 trials augmented by data from the OLE trial will prove the FDA with adequate data to remove the partial clinical hold, allow us to continue our development of nomlabofusp, or that we will ultimately be successful in our clinical development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the regulatory and manufacturing hurdles faced by our product candidate, the administration of a protein such as nomlabofusp, may cause an immune response, resulting in the creation of antibodies directed against the protein. These anti-drug antibodies can have no effect or can neutralize the effectiveness of the protein or require that higher doses be used to obtain a therapeutic effect. Neutralizing antibodies may be detected at a later date or upon longer exposure periods and there can be no assurance that neutralizing antibodies will not be detected in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our efforts to develop and commercialize nomlabofusp for the treatment of FA are unsuccessful, or we experience significant delays in doing so, our business could also be substantially harmed. The success of nomlabofusp will depend on several factors, including the following:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maintaining our IND with the FDA in order to continue to conduct clinical trials in the United States, including our ability to expand to higher doses or have the partial clinical hold lifted by the FDA on a timely basis, if at all;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">successfully submitting a BLA for accelerated approval;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">43</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">successfully recruiting, enrolling and retaining patients in and completing any clinical trials, if allowed to continue, including trials in pediatric patients;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">demonstrating long-term chronic daily dosing safety, tolerability and efficacy profiles that are satisfactory to the FDA, EMA and other comparable regulatory authorities for marketing approval;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">successfully completing all necessary toxicology studies to support clinical development and regulatory approval for nomlabofusp;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">receiving timely marketing approvals from applicable regulatory authorities;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">managing the extent and cost of any required post-marketing approval commitments to applicable regulatory authorities;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establishing and maintaining arrangements with third-party manufacturers for nomlabofusp, including developing, validating and maintaining a commercially viable manufacturing process that is compliant with cGMPs;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maintaining and growing an organization of scientists and business people who can develop our product candidates and technology;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtaining, maintaining and protecting our patents, trade secrets and regulatory exclusivity in the United States and other countries;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">successfully launching commercial sales following any marketing approval, including establishing a specialty sales organization, or successfully partnering with another organization, if applicable;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtaining commercial acceptance of our product candidates, if approved, by patients, the medical community and third-party payors and obtaining and maintaining healthcare coverage and adequate reimbursement;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maintaining an acceptable safety profile following any marketing approval; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">competing with other therapies.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of these factors are outside of our control, including the clinical development and regulatory approval processes, results of non-clinical and toxicology studies and clinical trials, potential threats to our intellectual property rights and the manufacturing, marketing and sales efforts, respectively. The process of obtaining regulatory approval is expensive and time consuming. The FDA and foreign regulatory authorities may never approve nomlabofusp for sale and marketing, and even if nomlabofusp is ultimately approved, regulatory approval may be delayed or limited in the United States or in other jurisdictions. Even if we are authorized to sell and market nomlabofusp in one or more markets, there is no assurance that we will be able to successfully market nomlabofusp or that nomlabofusp will achieve market acceptance sufficient to generate profits. If we are unable to successfully develop and commercialize nomlabofusp due to failure to obtain regulatory approval for nomlabofusp, to successfully market nomlabofusp, to generate profits from the sale of nomlabofusp, or due to other risk factors outlined in this report, it would have material adverse effects on our business, financial condition, and results of operations as nomlabofusp is currently our sole product candidate.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical development is a lengthy and expensive process with an uncertain outcome, and the results of non-clinical studies, toxicology studies or clinical trials may not be predictive of future non-clinical studies, toxicology studies or clinical trial results.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical development is expensive and can take many years to complete, and its outcome is inherently uncertain. We cannot guarantee that any non-clinical studies, toxicology studies or clinical trials will be conducted as planned or completed on schedule, if at all, and failure can occur at any time during the non-clinical study, toxicology study or clinical trial process. Despite promising non-clinical, toxicology or clinical results, any product candidate can unexpectedly fail at any stage of non-clinical, toxicology or clinical development. The historical failure rate for product candidates in our industry is high, especially for products in early stages of development.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The results from non-clinical studies, toxicology studies or clinical trials of a product candidate may not predict the results of later non-clinical or clinical trials of the product candidate, or in clinical trials with different patient populations such as children and adolescents and interim results of a clinical trial are not necessarily</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">44</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">indicative of final results. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy characteristics despite having progressed through non-clinical studies and initial clinical trials. It is not uncommon to observe results in clinical trials that are unexpected based on non-clinical studies and early clinical trials, and many product candidates fail in clinical trials despite very promising early results. Favorable safety and efficacy outcomes in adult clinical trials may not be seen in pediatric clinical trials.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, current and future non-clinical and clinical data may be susceptible to varying interpretations and analyses. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving promising results in earlier studies. Furthermore, we cannot provide assurance that we will be able to successfully progress any future non-clinical programs from candidate identification to Phase 1 clinical development. As is typical in candidate development, we have a program of toxicology studies in animals for nomlabofusp and cannot provide assurance that the findings from such studies or any ongoing or future clinical trials will not adversely affect the clinical development of nomlabofusp. For the foregoing reasons, we cannot be certain that our non-clinical studies and clinical trials will be successful. If non-clinical studies or clinical trials for nomlabofusp or any future product candidates or indications fail to demonstrate safety or efficacy to the satisfaction of the FDA or the equivalent regulatory authorities in other countries, the FDA or equivalent regulatory authority will not approve our product candidates in those and other indications, which could have a material adverse effect on our business, financial condition results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not know whether any ongoing or future clinical trials for nomlabofusp will be completed on schedule, if at all, as the commencement and completion of clinical trials can be delayed, prevented or terminated for a number of reasons, including as a result of safety concerns, or ambiguous or negative interim results. In addition, a clinical trial may be suspended or terminated by us, the FDA, other regulatory authorities, IRBs or ethics committees, an independent data monitoring committee, or safety review committee, overseeing the clinical trial at issue or other regulatory authorities due to a number of factors, including, among others:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">inspection of the clinical trial operations or trial sites by the FDA, the EMA, or other applicable regulatory authorities that reveals deficiencies or violations that require us to undertake corrective action, including the imposition of a partial clinical hold or a full clinical hold;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unforeseen safety issues, including any that could be identified in our prior or future toxicology studies, adverse events or lack of effectiveness;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in government regulations or administrative actions;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">problems with clinical supply materials;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">lack of adequate funding to continue the clinical trial;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">challenges in recruiting and enrolling patients to participate in clinical trials, including the size and nature of the patient population, such as pediatric patients, the proximity of patients to clinical trial sites, eligibility criteria for the clinical trial, the nature of the clinical trial protocol, the availability of approved effective treatments for the relevant disease and competition from FDA-approved therapeutics for FA, other clinical trial programs for similar indications, and the resurgence of vaccine resistant, more deadly or more contagious variants of COVID-19</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and the efforts to mitigate those effects;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">difficulties in retaining or recruiting clinical investigators in our ongoing or future clinical trials;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">difficulties retaining patients who have enrolled in a clinical trial but may be prone to withdraw due to rigors of the clinical trial, perceived lack of efficacy, side effects, screening and monitoring measures, personal issues or loss of interest;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">severe, serious or unexpected drug-related adverse events experienced by patients in clinical trials;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unanticipated negative effects of chronic long-term daily patient dosing;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">45</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA, the EMA, or other applicable regulatory authorities may disagree with our clinical trial designs, our interpretation of data from clinical trials, or may change the requirements for approval even after it has reviewed and commented on the design for our clinical trials;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinical sites and subjects may deviate from trial protocol or drop out of a trial; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reports from non-clinical studies or clinical testing of other therapies that raise safety or efficacy concerns.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Failures or delays in the completion of our clinical trials could result in increased costs and could delay, prevent or limit our ability to generate revenue and continue our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For our lead product candidate nomlabofusp, we have completed two Phase 1 clinical trials in patients with FA and our four-week, placebo-controlled Phase 2 dose exploration study of nomlabofusp in FA patients. The FDA has agreed that we may commence our OLE study in patients who previously participated in one of our previous nomlabofusp clinical trials at the 25 mg level. We cannot be certain that data from both cohorts of our Phase 2 dose exploration study augmented by data from the OLE study will provide the FDA with adequate data to remove the current partial clinical hold on nomlabofusp.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical trials may also be delayed or terminated as a result of safety issues in non-clinical or clinical trials, ambiguous or negative interim results or events outside of our control.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If future clinical trials of nomlabofusp fail or further delays occur in the United States and or other countries, we may not be able to develop and commercialize nomlabofusp and could fail to realize the potential advantages of doing so, and it could materially adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, disruptions caused by future pandemic, epidemic or outbreak of an infectious disease, such as the COVID-19 pandemic may increase the likelihood that we encounter such difficulties or delays in initiating, enrolling, conducting or completing our planned and ongoing clinical trials. Further, FA is a rare disease, there are a limited number of patients in close proximity to clinical trial sites and clinical trial patients may need to travel from other countries to the clinical trial sites in order to participate. In addition, given the limited number of FA patients, the recent approval of a competing therapy for the treatment of FA may make patients less likely to enroll in our clinical trials or less likely to be eligible for our clinical trials. Any inability to successfully initiate or complete clinical trials could result in additional costs to us or impair our ability to generate revenue from product sales. In addition, if we make manufacturing or formulation changes to our product candidates, we may be required to or we may elect to conduct additional studies to bridge our modified product candidates to earlier versions. Clinical trial delays could also shorten any periods during which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may seriously harm our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be successful in our efforts to identify, discover or acquire additional product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently only have one product candidate nomlabofusp in clinical development, although we have other product candidates in pre-clinical development. Therefore, the success of our business largely depends upon our ability to identify, develop, in-license or acquire and commercialize products targeting rare diseases. We may focus our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful. In addition, our research methodology may be unsuccessful in identifying potential product candidates or our potential product candidates may be shown to have harmful side effects or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research programs to identify new product candidates require substantial technical, financial and human resources. We may focus our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful. If any of these events occur, we may be forced to abandon our development efforts for a program or programs, which would have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have no marketed proprietary products and have not yet advanced a product candidate beyond Phase 2 clinical trials, which makes it difficult to assess our ability to develop nomlabofusp or any future product candidates and commercialize any resulting products independently.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have little experience in later stage clinical development, and related regulatory requirements or the commercialization of products. As a result, we have not yet demonstrated our ability to independently and repeatedly conduct clinical development after Phase 1, successfully conduct an international multi-center clinical trial, conduct a pivotal clinical trial, obtain regulatory approval, manufacture drug product on a commercial scale or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">46</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">arrange for a third party to do so on our behalf, and commercialize therapeutic products. We will need to develop such abilities if we are to execute on our business strategy to develop and independently commercialize product candidates for orphan and niche indications. To execute on our business plan for the development of independent programs, we will need to successfully:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtain the FDA's permission to continue with the clinical development of nomlabofusp beyond our currently ongoing OLE study at the 25 mg dose level;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">execute our clinical development plans for product candidates;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtain required regulatory approvals in each jurisdiction in which we will seek to commercialize products;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">build and maintain appropriate sales, distribution and marketing capabilities;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">gain market acceptance, including reimbursement, for our future products, if any; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">manage our spending as costs and expenses increase due to clinical trials, regulatory approvals and commercialization activities.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unsuccessful in accomplishing these objectives, we will not be able to develop and commercialize any product candidates independently and could fail to realize the potential advantages of doing so, and it would materially adversely affect our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We cannot be certain that we will be able to successfully complete clinical trials for nomlabofusp or any other product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have advanced only one product candidate into clinical development, nomlabofusp. Our business currently depends primarily on nomlabofusp&#8217;s successful clinical development, regulatory approval and commercialization. We submitted our IND and it was accepted, permitting the conduct of clinical trials. We completed two Phase 1 and our four-week, placebo-controlled Phase 2 dose exploration study. As a result of certain mortalities in a non-clinical study of NHPs, the FDA issued a clinical hold in May 2021.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2022, following a Type C meeting and the submission of our complete response to the partial clinical hold, the FDA allowed the 25 mg cohort of a Phase 2, four-week, placebo-controlled, dose exploration trial of nomlabofusp in FA patients to proceed. In connection with this decision, the FDA lifted its full clinical hold on the nomlabofusp clinical development program and imposed a partial hold.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2023, we met with the FDA. Following that meeting, we submitted a complete response to the FDA&#8217;s partial clinical hold that included unblinded safety, PK and frataxin data from the Phase 2 trial&#8217;s completed 25 mg cohort.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2023, following the FDA&#8217;s review of our complete response to the partial clinical hold, the FDA cleared initiation of a second cohort at 50 mg of our four-week, placebo-controlled, Phase 2 dose exploration trial and to initiate our OLE trial with daily dosing of 25 mg.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2024, we reported positive top-line data and successful completion of our four-week, placebo-controlled Phase 2 dose exploration study of nomlabofusp in participants with FA. Nomlabofusp was generally well tolerated and demonstrated dose dependent increases in FXN levels in all evaluated tissues (skin and buccal cells) after daily dosing of 14 days followed by every other day dosing until day 28 in the 25 mg and 50 mg cohorts. Participants in the 25 mg (n=13) and 50 mg (n=15) cohorts were randomized 2:1 to receive subcutaneous injections of nomlabofusp or placebo. The initiation of additional U.S. clinical trials evaluating nomlabofusp are contingent on FDA review of data under the partial clinical hold.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA has agreed that we may commence our OLE study in patients who previously participated in one of our previous nomlabofusp clinical trials at the 25 mg level dosed daily. We cannot be certain that data from both cohorts of our Phase 2 dose exploration study augmented by data from the OLE study will provide the FDA with adequate data to remove the current partial clinical hold on nomlabofusp, allow the nomlabofusp development program to proceed as planned in part or in full, or that we will ultimately be successful with our clinical development or that we will be ever able to obtain regulatory approval for.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In clinical development of any product candidate, the outcome of toxicology studies and early clinical trials may not be positive and may not be predictive of the success of later non-clinical studies or clinical trials. Adverse toxicology or safety results could lead to clinical holds or other developmental delays. Interim results of clinical</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">47</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">trials do not necessarily predict success in those or future clinical trials. Success in adult clinical trials may not predict the outcome of pediatric clinical trials.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Published clinical data or case reports from third parties or early clinical trial data of nomlabofusp or any future product candidates may not be predictive of the results of later-stage clinical trials. Interpretation of results from early, usually smaller, studies that suggest a clinically meaningful response in some patients, requires caution. Results from later stages of clinical trials enrolling more patients, or different patient populations, such as pediatric patients, may fail to show the desired safety or efficacy results or otherwise fail to be consistent with the results of earlier trials of the same product candidate. Later clinical trial results may not replicate earlier clinical trials for a variety of reasons, including differences in trial design, different trial endpoints (or lack of trial endpoints in exploratory studies), different patient population, number of patients, patient selection criteria, trial duration, drug dosage and formulation and lack of statistical power. These uncertainties are enhanced where the diseases under study lack established clinical endpoints, validated measures of efficacy, as is often the case with orphan diseases for which no drugs have been developed previously and where the product candidates target novel mechanisms. For example, to our knowledge, nomlabofusp is the only protein replacement therapy being developed for the treatment of FA and therefore non-clinical studies may not be adequate to predict efficacy in a clinical trial due to our novel protein replacement therapy platform.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, such as pediatric patients, variability of the disease being studied, changes in and adherence to the dosing regimen and other clinical trial protocols and the rate of dropout among clinical trial participants. If we fail to ultimately receive positive results in clinical trials of nomlabofusp, the development timeline and regulatory approval and commercialization prospects for nomlabofusp, and, correspondingly, our business, financial prospects and results of operation would be negatively impacted.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, nomlabofusp or any future product candidates may not be approved even if they achieve their primary endpoint in clinical trials. The FDA, EMA or foreign regulatory authorities may disagree with our trial design and our interpretation of data from non-clinical studies and clinical trials. In addition, FDA, EMA or foreign regulatory authorities may disagree with the extent of population exposure to assess clinical safety. Any of these regulatory authorities may change its requirements for the approval of a product candidate even after reviewing and providing comments or advice on a protocol for a pivotal clinical trial that, if successful, would potentially form the basis for an application for approval by the FDA, EMA or another regulatory authority. Furthermore, any of these regulatory authorities may also approve nomlabofusp or any future product candidates for a narrower indication than we may request or may grant approval contingent on the performance of costly post-marketing clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may experience difficulties identifying and enrolling patients in our clinical trials given the limited number of patients who have the disease for which nomlabofusp is being studied or for any other product candidate we may study in the future. Difficulty in enrolling patients could delay or prevent clinical trials of nomlabofusp or any future product candidate. There are also competing FA therapeutics, other competing studies and potentially other FA therapeutics that could be approved</span><span style="color:#ff0000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">that may also limit the availability of prospective participants in nomlabofusp clinical trials.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Identifying and qualifying patients to participate in clinical trials of nomlabofusp is critical to our success. The timing of our clinical trials depends in part on the speed at which we can recruit patients to participate in testing nomlabofusp, and we may experience delays in our clinical trials if we encounter difficulties in enrollment, such as difficulties with enrollment in pediatric clinical trials.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The conditions for which we are planning to evaluate nomlabofusp and any product candidates we may evaluate in the future, are rare genetic diseases. Accordingly, there are limited patient pools from which to draw for clinical trials. Arranging for investigative sites and recruiting patients for clinical trials in this disease may be very difficult. The recent FDA approval of a product for the treatment of FA may impact our ability to enroll patients in our clinical trials as patients using other FA treatments may be excluded from participation in our nomlabofusp studies or may be less likely to participate in our nomlabofusp clinical trials due to the availability of another FA therapy. If other companies are studying their investigational products in Friedreich&#8217;s ataxia and/or if other companies have their products approved for the treatment of FA, it may be more difficult to enroll eligible patients into our clinical trials. Competing priorities at sites and participation of subjects in other studies may limit our ability to execute clinical trials in a timely fashion, if at all.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">48</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the rarity of FA and other diseases that we are studying, the eligibility criteria of our clinical trials will further limit the pool of available study participants as it will require patients to have specific characteristics that we can measure to assure their disease is either severe enough or not too advanced to include them in a clinical trial. The process of finding and diagnosing patients may prove costly, especially since the diseases we are studying are rare. We also may not be able to identify, recruit, and enroll a sufficient number of appropriate patients to complete our clinical trials because of demographic criteria for prospective patients, the perceived risks and benefits of the product candidate under study, the proximity and availability of clinical trial sites for prospective patients, and the patient referral practices of physicians. The availability and efficacy of approved and competing therapies and clinical trials can also adversely impact enrollment. Furthermore, our inability to enroll a sufficient number of patients for our clinical trials, including pediatric clinical trials, could result in significant delays or may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for nomlabofusp or any future product candidates, and jeopardize our ability to achieve our clinical development timeline and goals, including the dates by which we will commence, complete and receive results from clinical trials. If patients are unwilling to participate in our trials for any reason, the timeline for recruiting patients, conducting trials, and obtaining regulatory approval of potential products may be delayed. Enrollment delays in our clinical trials may also jeopardize our ability to commence sales of and generate revenues from nomlabofusp, which could cause the value of our company to decline and limit our ability to obtain additional financing, if needed. Any of these occurrences may harm our business, financial condition, and prospects significantly.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">FA has no FDA-approved therapies that address frataxin deficiency, which is the underlying cause of the disease, and clinical endpoints required to obtain approval are not well defined.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are currently no FDA-approved products to treat FA that are designed to increase frataxin levels. We have concentrated our research and development efforts on developing a novel, FA therapy designed to address frataxin deficiency, which is the underlying cause of the disease, and our future success depends on the success of this therapeutic approach. The clinical trial requirements of the FDA and other comparable regulatory agencies and the criteria these regulators use to determine the safety and efficacy of any product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recently, we had discussions with the FDA regarding the use of tissue FXN levels as a novel surrogate endpoint. The FDA has acknowledged that frataxin deficiency appears to be critical to the pathogenic mechanism of FA, and that there continues to be an unmet need for treatments for FA patients that address the underlying disease pathophysiology. We intend to pursue an accelerated approval using FXN levels, supportive PD and clinical information, and safety data from the OLE study, along with additional non-clinical pharmacology information needed to support the novel surrogate endpoint approach. We are beginning to plan for a confirmatory study and are targeting a BLA submission in the second half of 2025. The FDA or other regulatory authorities may not agree with this approach.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regulatory authorities in the United States, the United Kingdom and the European Union have not issued definitive guidance as to how to measure and achieve efficacy in treatments for FA. As a result, the design and conduct of clinical trials of nomlabofusp may take longer, be more costly or be less effective as part of the novelty of development in FA. The FDA may not accept that the supportive PD and clinical information, and safety data from the OLE study, along with additional non-clinical pharmacology data we ultimately submit in our BLA, adequately supports the use of FXN levels as a novel surrogate endpoint. Even if the FDA supports the use of FXN levels as a novel surrogate endpoint, the FDA may not agree with the adequacy of the design of clinical trials intended to assess this novel surrogate endpoint.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if applicable regulatory authorities do not object to our proposed endpoints in an earlier stage clinical trial, such regulatory authorities may require evaluation of additional or different clinical endpoints in later-stage clinical trials.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Nomlabofusp, including the effects of long-term daily patient dosing, may cause adverse events or undesirable side effects in clinical trials that could delay or prevent its regulatory approval, limit the commercial profile of approved labeling, or result in significant negative consequences following regulatory approval, if any.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any adverse events or undesirable side effects caused by, or other unexpected properties of, nomlabofusp in non-clinical or clinical studies could cause us, any future collaborators, an IRB or ethics committee or regulatory authorities to interrupt, delay or halt clinical trials of our product candidate and could result in a more restrictive</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">49</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">label or the delay or denial of regulatory approval by the FDA or other regulatory authorities. Should the FDA permit us to continue with the clinical development of nomlabofusp, it is possible that as we progress nomlabofusp through clinical trials and toxicology studies, or as the use of nomlabofusp becomes more widespread if it receives regulatory approval, illnesses, injuries, discomforts and other adverse events that were not observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, may be reported by patients. If such side effects become known later in development or after approval, such findings may harm our business, financial condition and prospects significantly. Further, if a serious safety issue is identified in connection with the use of nomlabofusp commercially or in third-party clinical trials elsewhere, such issues may adversely affect the development potential of nomlabofusp elsewhere or result in regulatory authorities restricting our ability to develop or commercialize nomlabofusp, if approved.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, if nomlabofusp were to receive marketing approval and we or others identify undesirable side effects caused by the product (or any other product) after the approval, a number of potentially significant negative consequences could result, including:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities may request that we recall or withdraw the product from the market or may limit the approval of the product through labeling or other means;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities may require the addition of labeling statements, such as a &#8220;boxed&#8221; warning or a contraindication or a precaution, or labeling restrictions based on patient population;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be required to change the way the product is distributed or administered, conduct additional clinical trials or change the labeling of the product;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may decide to recall or remove the product from the marketplace;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we could be sued or held liable for injury caused to individuals exposed to or taking our product candidates; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we could be required to conduct expensive post-marketing studies;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we could lose our commercial market opportunity and our revenues could decrease substantially;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">damage to the public perception of the safety of nomlabofusp; and </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our reputation may suffer and physicians or patients might be less likely to use our product or may refer patients to products produced by our competitors.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any of these events could prevent us from achieving or maintaining market acceptance of the affected product candidate and could substantially increase the costs of commercializing our product candidates and significantly impact our ability to successfully commercialize our product candidates and generate revenues, all of which would materially adversely affect our business, financial condition and results of operations. In addition, the patient populations under investigation with nomlabofusp have many co-morbidities that may cause severe illness or death unrelated to our product candidate, which may be attributed to nomlabofusp in a manner that negatively affects the safety profile of our product candidate.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interim, &#8220;top-line,&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available or as additional analyses are conducted, and as the data are subject to audit and verification procedures that could result in material changes in the final data.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may publish interim, preliminary or &#8220;top-line&#8221; data from our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or &#8220;top-line&#8221; data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Material adverse changes between interim, preliminary or &#8220;top-line&#8221; data and final data could significantly harm our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our approach to discover and develop fusion proteins for delivering proteins is novel and may never lead to marketable products.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">50</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have concentrated our efforts and research and development activities on delivering proteins (FXN or other) to intracellular targets. Our future success depends on the successful development and manufacturing of such therapeutics and the effectiveness of our platform. The scientific discoveries that form the basis for our research are relatively new.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Nomlabofusp uses a novel and unproven approach and mechanism to treat FA and therefore its efficacy and safety are difficult to predict, and there is no guarantee that nomlabofusp will be approved by the FDA, the EMA, or any other regulatory authorities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If nomlabofusp proves to be ineffective, unsafe or commercially unviable, it is possible that our platform and pipeline would have little, if any, value, which would substantially harm our business, financial condition, results of operations and prospects. In addition, our approach may expose us to additional financial risks and make it more difficult to raise additional capital than other, more advanced proven technologies, which would materially adversely affect our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Protein replacement therapies are novel, complex and difficult to manufacture. We could experience manufacturing problems that result in delays in the development or commercialization of our protein replacement therapy platform or product candidates or otherwise harm our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The manufacture of fusion proteins, such as nomlabofusp and any fusion protein candidates, is technically complex and necessitates substantial expertise and capital investment. Production difficulties caused by unforeseen events may delay the availability of material for clinical trials and commercial products for nomlabofusp or any fusion protein product that may receive regulatory approval in the future. Additionally, because biologic products are complex, the manufacture of such products and product candidates is more difficult and costly. We may not be able to have such products reliably manufactured in accordance with the applicable regulatory requirements in sufficient quantities to support our development programs and, if ultimately approved, commercial supply.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are a limited number of contract manufacturers who specialize in the manufacture of biologic products and those that do may still be developing appropriate processes, controls and facilities for large-scale production. While we believe that there will be sufficient sources of supply that can satisfy our clinical and commercial requirements, we cannot be certain that we will be able to identify and establish additional relationships with such sources, if necessary, in a timely manner or at all, and what the terms and costs of such new arrangements would be, or that such suppliers would be able to supply our potential commercial needs. Furthermore, in the event our primary manufacturer cannot meet our needs, any switch to an alternative manufacturer, if available, would result in a significant delay, would require FDA approval, and cause material additional costs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As further described in these risk factors, the manufacturers of biologic products must comply with strictly enforced cGMP requirements, state and federal regulations, as well as foreign requirements when applicable. Any failure by us or our contract manufacturing organizations to adhere to or document compliance to such regulatory requirements could lead to a delay or interruption in the availability of our program materials for clinical trials or commercial use, among other consequences. If we or our manufacturers fail to comply with the FDA, EMA, or other regulatory authorities, it could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, clinical holds or termination of clinical trials, Form 483s, warning or untitled letters, regulatory communications warning the public about safety issues with a product, import or export refusals, license revocation, seizures, detentions, or recalls of product candidates or product, operating restrictions, criminal prosecutions or debarment, suits under the civil False Claims Act, corporate integrity agreements, or consent decrees any of which could significantly and adversely affect supplies of our product candidates and our business, financial conditions and results of operations could be materially adversely affected.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our current dependence upon others for the manufacture of our product candidates may also adversely affect our business, results of operations, financial condition, and our ability to commercialize any product candidates that receive regulatory approval on a timely and competitive basis.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fast track designation by the FDA or any future expedited program designations may not lead to a faster development, regulatory review or approval process and it does not increase the likelihood that any of our product candidates will receive marketing approval.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have received fast track therapy designation for nomlabofusp for the treatment of FA. We may, in the future, apply for other expedited program designations from the FDA (such as breakthrough therapy) for nomlabofusp or future product candidates. Designation for these programs is within the discretion of the FDA. Accordingly, even if we believe nomlabofusp or a future product candidate meets the criteria for designation, the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">51</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FDA may disagree. The receipt of a designation may not result in a faster development process, review or approval compared to products considered for approval without these expedited program designations and, in any event, does not assure ultimate approval by the FDA. In addition, even though nomlabofusp has obtained fast track designation, the FDA may later decide that it no longer meets the criteria for designation and revoke it. Approval of other therapies for the treatment Friedreich&#8217;s ataxia could negatively impact our continued fast track therapy designation for nomlabofusp for the treatment of FA. In addition, if we apply to the FDA for other designations for nomlabofusp or future product candidates, the FDA might not grant such designations. If we apply for any similar programs in foreign countries for nomlabofusp or future product candidates, those designations also might not be granted by the regulatory authorities of those countries. Any of the above could adversely affect our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We intend to pursue accelerated approval from FDA for nomlabofusp for the treatment of Friedreich&#8217;s ataxia, however this may not lead to a faster development or regulatory review or approval process and does not increase the likelihood that we will receive marketing approval. If we are unable to obtain approval under an accelerated pathway, we may be required to conduct additional clinical trials beyond those that we contemplate, which could increase the expense of obtaining, reduce the likelihood of obtaining, and/or delay the timing of obtaining, necessary marketing approvals.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We intend to pursue an accelerated approval from FDA for nomlabofusp for the treatment of FA using FXN levels, supportive pharmacodynamic and clinical information and safety data from the OLE study, along with additional non-clinical pharmacology information needed to support our surrogate biomarker approach. Under the FDA&#8217;s accelerated approval program, the FDA may approve a drug or biologic for a serious or life-threatening illness that provides meaningful therapeutic benefit to patients over existing treatments based upon a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. Although we have initiated discussions with FDA concerning our surrogate biomarker approach, there can be no assurance that data we intend to generate will be successful in establishing that increases in FXN levels are reasonably likely to predict clinical benefit. In addition, future nonclinical pharmacology and clinical studies may not provide adequate information or may fail to support the predictive value of increases in FXN and, therefore, its ability to serve as a surrogate endpoint. Even if these evidentiary requirements are met, we may not be able to accrue adequate exposures to assess clinical safety or expedite the scale up of manufacturing or meet other CMC requirements in a timeframe commensurate with the expedited assessment of clinical efficacy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Approval of other therapies for the treatment of FA, including the approval of omaveloxolone for the treatment of FA, could negatively impact our ability to utilize the accelerated approval pathway, and/or get approval for nomlabofusp. For drugs or biologics granted accelerated approval, post-marketing confirmatory trials are required to describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. These confirmatory trials must be completed with due diligence and, in some cases, the FDA may require that the trial be designed, initiated and/or fully enrolled prior to approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, the FDA may withdraw approval of any product candidate approved under the accelerated approval pathway if, for example:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the trial or trials required to verify the predicted clinical benefit of the product candidate fail to verify such benefit or do not demonstrate sufficient clinical benefit to justify the risks associated with such product;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">other evidence demonstrates that the product candidate is not shown to be safe or effective under the conditions of use;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we fail to conduct any required post-approval trial of our product candidate with due diligence; or</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we disseminate false or misleading promotional materials relating to the relevant product candidate.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the FDA may terminate the accelerated approval program or change the standards under which accelerated approvals are considered and granted in response to public pressure or other concerns regarding the accelerated approval program. Changes to or termination of the accelerated approval program could prevent or limit our ability to obtain accelerated approval of any of our clinical development programs. Recently, the accelerated</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">52</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">approval pathway has come under scrutiny within the FDA and by Congress. The FDA has put increased focus on ensuring that confirmatory studies are conducted with diligence and, ultimately, that such studies confirm the benefit. In addition, the Food and Drug Omnibus Reform Act (&#8220;FDORA&#8221;), included provisions related to the accelerated approval pathway. Pursuant to FDORA, the FDA is authorized to require, as appropriate, that a post-approval study to be underway prior to approval or within a specified time period following approval. FDORA also requires the FDA to specify conditions of any required post-approval study and requires sponsors to submit progress reports for required post-approval studies and any conditions required by the FDA. FDORA also gives the FDA increased authority to withdraw approval of a drug or biologic granted accelerated approval on an expedited basis if the sponsor fails to verify the drug or biologic&#8217;s predicted clinical benefit. FDORA enables the FDA to initiate enforcement action for a sponsor's failure to conduct with due diligence a required post-approval study, including a failure to meet any required conditions specified by the FDA or to submit timely reports.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to maintain orphan drug designation or other regulatory exclusivity for nomlabofusp or obtain such exclusivity for any of our other product candidates in the future, our competitive position would be harmed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We received orphan drug designation from the FDA for nomlabofusp for the treatment of FA in July 2017. In the United States, orphan drug designation entitles a party to financial incentives such as tax advantages and user-fee waivers. In addition, if a product candidate that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications, including an NDA or BLA, to market the same drug for the same indication for seven years, except in limited circumstances, including if the FDA concludes that the later drug is clinically superior to the approved drug. A drug is clinically superior if it is safer, more effective, or makes a major contribution to patient care. In the case of a biological product, whether a drug is the same drug is based on the principal molecular structural features of the product. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, we may lose orphan drug exclusivity if we are unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. Moreover, orphan drug exclusivity may not effectively protect our product candidates from competition because different drugs can be approved for the same condition. Further, even after an orphan drug is approved, the FDA or comparable foreign regulatory authority can subsequently approve another drug for the same condition if such regulatory authority concludes that the later drug is clinically superior, if it is shown to be safer, more effective or makes a major contribution to patient care.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have also received orphan drug designation for nomlabofusp in the European Union. In the European Union, the European Medicines Agency, or EMA&#8217;s Committee for Orphan Medicinal Products grants orphan drug designation to promote the development of products that are intended for the diagnosis, prevention or treatment of life threatening or chronically debilitating conditions affecting not more than five in 10,000 persons in the European Union. Additionally, designation is granted for products intended for the diagnosis, prevention or treatment of a life threatening, seriously debilitating or serious and chronic condition and when, without incentives, it is unlikely that sales of the drug in the European Union would be sufficient to justify the necessary investment in developing the drug. In the European Union, orphan drug designation also entitles a party to financial incentives such as reduction of fees or fee waivers and ten years of market exclusivity following drug approval. This period may be reduced to six years if the orphan drug designation criteria are no longer met, including where it is shown that the product is sufficiently profitable so that market exclusivity is no longer justified. Loss of orphan drug designation for nomlabofusp or the failure to obtain such designation in other countries or for any future product candidates could adversely affect our business, financial condition and results of operation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If another product has received approval in the indications for which we have received orphan drug designation, we may still receive approval in that indication if we can demonstrate that our product candidate is clinically superior to the existing orphan product. This demonstration of clinical superiority may be done at the time of initial approval or in post-approval studies, depending on the type of marketing authorization granted. Having to comply with these additional requirements to obtain orphan drug exclusivity could adversely affect our business, financial condition and results of operation.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Although we have obtained rare pediatric disease designation for nomlabofusp, we may not be eligible to receive a priority review voucher in the event the FDA determines we no longer meet the criteria for designation, revokes the designation or FDA approval does not occur prior to September 30, 2026.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">53</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The sponsor of an application for a rare pediatric disease drug product may be eligible for a voucher that can be used or sold to obtain a priority review for a subsequent application submitted under section 505(b)(1) of the FDCA or section 351 of the PHS Act. The rare pediatric disease priority review voucher program was most recently reauthorized by Congress through September 30, 2024, with the potential for priority review vouchers to be granted through September 30, 2026. We received rare pediatric disease designation from the FDA for nomlabofusp in 2019. We may, in the future, apply for rare pediatric disease designation from the FDA for future product candidates that may qualify for designation. Vouchers for rare pediatric disease drugs are awarded for qualifying applications when the drug receives approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although nomlabofusp has received rare pediatric disease designation, nomlabofusp may not receive a priority review voucher for a number of reasons: nomlabofusp may not receive approval; nomlabofusp may receive approval in adults, but not pediatric patients; nomlabofusp may not meet the eligibility requirements for a priority voucher at the time we seek approval for nomlabofusp; or we may not meet the current deadline for receiving a priority review voucher (September 30, 2026), in which case we would not be able to obtain a voucher unless Congress further reauthorizes the program. Finally, a rare pediatric disease designation does not necessarily lead to faster development or regulatory review of the product or increase the likelihood that it will receive marketing approval. If we apply for designation for future product candidates as drugs for rare pediatric diseases, the FDA may not grant the designation. The failure to maintain rare pediatric disease designation for nomlabofusp or if FDA approval does not occur prior to September 30, 2026 could result in the inability to receive a priority review voucher which could adversely affect our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to maintain PRIME designation in the European Union for nomlabofusp, our competitive position would be harmed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The PRIME scheme is open to medicines under development and for which the applicant intends to apply for an initial MAA through the centralized procedure. Eligible products must target conditions for which where is an unmet medical need (there is no satisfactory method of diagnosis, prevention or treatment in the European Union or, if there is, the new medicine will bring a major therapeutic advantage) and they must demonstrate the potential to address the unmet medical need by introducing new methods or therapy or improving existing ones. Applicants will typically be at the exploratory clinical trial phase of development and will have preliminary clinical evidence in patients to demonstrate the promising activity of the medicine and its potential to address to a significant extent an unmet medical need. In exceptional cases, applicants from the academic sector or SMEs may submit an eligibility request at an earlier stage of development if compelling non-clinical data in a relevant model provide early evidence of promising activity to establish proof of principle, and first in man studies indicate adequate exposure for the desired pharmacotherapeutic effects and tolerability.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a medicine is selected for the PRIME scheme, the EMA:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">appoints a rapporteur from the CHMP or from the CAT to provide continuous support and to build up knowledge of the medicine in advance of the filing of an MMA;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">issues guidance on the applicant&#8217;s overall development plan and regulatory strategy;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">organizes a kick-off meeting with the rapporteur and experts from relevant EMA committees and working groups;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">provides a dedicated EMA contact person; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">provides scientific advice at key development milestones, involving additional stakeholders, such as health technology assessment bodies and patients, as needed.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For SMEs who enter the scheme based on data showing proof of principle, the appointment of the rapporteur occurs once they have generated data confirming eligibility at proof of concept stage. They are required to submit relevant data and justification as the product development reaches this stage.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Medicines that are selected for the PRIME scheme are also expected to benefit from EMA&#8217;s accelerated assessment procedure at the time of application for marketing authorization. Where, during the course of development, a medicine no longer meets the eligibility criteria, or if a medicine granted early access to the PRIME scheme cannot later demonstrate proof of concept, support under the PRIME scheme may be withdrawn. Approval of other therapies for the treatment Friedreich&#8217;s ataxia, including the recent approval of omaveloxolone could negatively impact our continued access to this and similar programs. Loss of PRIME designation for nomlabofusp or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">54</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the failure to obtain such designation for any future product candidates could adversely affect our business, financial condition and results of operation.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in regulatory requirements, FDA guidance, guidance from other regulatory authorities or unanticipated events during our non-clinical or clinical trials of nomlabofusp or future product candidates may result in changes to clinical trial protocols or additional non-clinical or clinical trial requirements, which could result in increased costs to us and could delay our development timeline.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in regulatory requirements, FDA guidance or guidance from EMA or unanticipated events during our non-clinical or clinical trials may force us to terminate or adjust our clinical programs. The FDA, or other applicable regulatory authorities may impose additional clinical trial and/or non-clinical study requirements. Amendments to our clinical trial protocols would require resubmission to the FDA, or the applicable regulatory authorities as well as IRBs and ethics committees for review and approval, which may adversely impact the cost, timing or successful completion of a clinical trial. If we experience delays completing, or if we terminate, any of our clinical trials, or if we are required to conduct additional clinical trials, or non-clinical studies and/or post-market studies, the commercial prospects for nomlabofusp or any other potential product candidates may be harmed and our ability to generate product revenue will be delayed or eliminated, and it would materially adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order to market any product outside of the United States, we must comply with numerous and varying regulatory requirements of other countries regarding drug development and commercialization. The approval processes varies from country to country and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may negatively impact the regulatory process in others. Even if we receive marketing approval for nomlabofusp in the United States, we may never receive regulatory approval to market nomlabofusp outside of the United States.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The ability of the FDA to review and/or approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s ability to hire and retain key personnel, and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. Furthermore, government shutdowns could also impact the ability of regulatory authorities and government agencies to function normally and support our operations. For example, the U.S. federal government has shut down repeatedly since 1980, including for a period of 35 days beginning on December 22, 2018. During a shutdown, certain regulatory authorities and agencies, such as the FDA, have had to furlough key personnel and stop critical activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a prolonged government shutdown occurs, or if global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Regulatory requirements governing biologic products have changed frequently and may continue to change in the future. Such requirements may lengthen the regulatory review process, require us to perform additional non-clinical studies or clinical trials, and increase our costs, or may force us to delay, limit or terminate certain of our programs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regulatory requirements governing biologic drug products are evolving and may continue to change in the future. As a result, it is difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for nomlabofusp for the treatment of FA or any other future protein replacement therapy product candidates in any indication, if at all. Regulatory review agencies and the new requirements and guidelines they promulgate may lengthen the regulatory review process, require us to perform additional or larger studies, increase</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">55</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval studies, limitations or restrictions. Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Delays, failure or unexpected costs in obtaining, the regulatory approval necessary to bring our product candidates to market could have a material adverse effect on our business, results of operations, financial condition and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the clinical trial requirements of the FDA, the EMA and other regulatory authorities and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of such product candidates. The regulatory approval process for novel product candidates such as ours can be more expensive and take longer than for other, better known or more extensively studied product candidates.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The clinical trials of nomlabofusp and any future product candidates are, and the manufacturing and marketing of nomlabofusp and any future product candidates, will be subject to extensive and rigorous review and regulation by numerous government authorities in the United States and in other countries, such as within the European Union, where we intend to seek regulatory approval of, and market, any product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Before obtaining regulatory approvals for the commercial sale of any product candidate, we must demonstrate through non-clinical testing and clinical trials that the product candidate is safe and effective for use in each target indication. This process can take many years. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions, which may cause delays in the approval of or may result in the decision not to approve our product candidates. We have not obtained regulatory approval for nomlabofusp, and it is possible that this product candidate or any product candidates we may seek to develop in the future will never obtain regulatory approval. If marketing approval is obtained, it will likely include post-marketing studies, and other post-marketing requirements, and surveillance such as REMS which will require the expenditure of substantial resources beyond the proceeds we currently have on hand.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, we are not permitted to market nomlabofusp in the United States, or the European Union until we receive approval of a BLA from the FDA or a MAA from the EMA, or in any other foreign countries until we receive the requisite marketing approval from such countries. The development of drugs for FA or other rare diseases may require initial non-clinical studies, early and usually smaller, clinical trials and randomized, double-blind placebo controlled long-term safety and efficacy trials in order to test the safety and efficacy of the drug.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Nomlabofusp requires substantial further clinical development before we can submit a BLA to the FDA. Development and/or regulatory programs for nomlabofusp in any countries other than the United States (such as a MAA to the EMA) are only in very preliminary stages and may require substantial further development in those countries prior to regulatory submissions seeking regulatory approval for marketing.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even after successful completion of clinical trials, there is a risk that the FDA or other regulatory agencies may request further information from us, disagree with our findings or otherwise undertake a lengthy review of our submission.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA and certain European regulatory authorities may delay, limit or deny testing or approval of nomlabofusp for many reasons, including, among others:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may not be able to demonstrate that nomlabofusp is safe and effective to the satisfaction of the FDA or the EMA;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the results of our clinical trials may not meet the level of statistical or clinical significance required by the FDA or the EMA for marketing approval;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA or the EMA may disagree with the number, design, size, duration, conduct or implementation of our clinical trials;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">56</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA or the EMA may require that we conduct additional non-clinical studies and/or clinical trials;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA or the EMA may not approve the formulation, manufacturing, labeling or specifications of nomlabofusp;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the CROs that we retain to conduct our clinical trials may take actions outside of our control that materially adversely impact our clinical trials;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA or the EMA may find the data from non-clinical studies and clinical trials insufficient to demonstrate that nomlabofusp&#8217;s clinical and other benefits outweigh its safety risks;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA or the EMA may disagree with our interpretation of data from our non-clinical studies or clinical trials;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA or the EMA may not accept data generated at our clinical trial sites;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">if and when our BLA is submitted, the FDA could require an FDA advisory committee assessment, or the advisory committee may recommend against approval of our application or may recommend that the FDA require, as a condition of approval, additional non-clinical studies or clinical trials, limitations on approved labeling or distribution and use restrictions;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA or the EMA could require development of a REMS as a condition of approval or post-approval, or may not agree with our proposed REMS, or may impose additional requirements, including requirements that limit the promotion, advertising, distribution, or sales of nomlabofusp;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA or the EMA may find deficiencies with or not approve the manufacturing processes or facilities of third-party manufacturers with which we contract; or</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA or the EMA may change their approval policies or adopt new regulations rendering our clinical data insufficient for approval.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any of these factors, many of which are beyond our control, could jeopardize our ability to obtain and/or maintain regulatory approval for and successfully market nomlabofusp. Any delay or failure in obtaining required approvals could have a material adverse effect on our business, financial condition and results of operations. This process can take many years and will likely require the expenditure of substantial resources. Of the large number of drugs in development in the United States, only a small percentage will successfully complete the FDA regulatory approval process and be commercialized. It is possible that the FDA or other regulatory agencies will not approve any application that we submit. It is possible that our product candidates may not obtain appropriate regulatory approvals necessary for us to commence clinical trials for our product candidates. Accordingly, even if we are able to obtain the requisite financing to continue to fund our development and clinical trials, we cannot ensure that nomlabofusp, or any other of our potential product candidates will be successfully developed or commercialized.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are subject to healthcare laws and regulations, and health information privacy and security laws, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Healthcare providers, physicians and others will play a primary role in the recommendation and prescription of nomlabofusp or any potential product candidates, if approved. Our future arrangements with third-party payors will expose us broadly to applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute nomlabofusp or potential product candidates, if we obtain marketing approval. In addition, we may be subject to patient privacy regulation by both the federal government and the states or other countries in which we conduct our business. For more information, see the section of this report titled &#8220;Business &#8211; Healthcare Laws and Regulations &#8211; Other Healthcare Laws.&#8221;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ensuring that our future business arrangements with third parties comply with applicable healthcare laws and regulations could be costly. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations, including anticipated activities to be conducted by our sales team, were found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines and exclusion from</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">57</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">government funded healthcare programs, such as Medicare and Medicaid, any of which could substantially disrupt our operations and would materially adversely affect our business, financial condition and results of operations. If any of the physicians or other providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs, which could have a material adverse effect on our business, results of operations, financial condition and prospects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Healthcare legislation, including potentially unfavorable pricing regulations or other healthcare reform initiatives may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The commercial potential for our approved products, if any, could be affected by changes in healthcare spending and policy in the United States and abroad. We operate in a highly regulated industry. New laws, regulations or judicial decisions or new interpretations of existing laws, regulations or decisions, related to healthcare availability, the method of delivery or payment for healthcare products and services could adversely affect our business, operations and financial condition. The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system that may affect our ability to profitably sell our product and product candidates, if approved. The United States government, state legislatures and foreign governments also have shown significant interest in implementing cost-containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. The pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. Previously, in March 2010, the ACA was enacted, which was intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for health care and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. Healthcare reform initiatives recently culminated in the enactment of the IRA Inflation Reduction Act of 2022 or IRA, which, among other things, allow allows HHS to directly negotiate the ceiling price of a statutorily specified number of drugs and biologic each year that CMS reimburses under Medicare Part B and Part D, requires the payment of rebates on Medicare Part B and Part D drugs whose prices have increased at a rate faster than the rate of inflation, and redesign the Medicare Part D cost sharing structure, including revising manufacturer financial liability for covered products. For more information, see the section of this report titled &#8220;Business &#8211; Healthcare Laws and Regulations &#8211; Healthcare Reform.&#8221;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect that additional federal, state and foreign healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in limited coverage and reimbursement and reduced demand for our products, once approved, or additional pricing pressures.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if approved, reimbursement policies could limit our ability to sell product candidates that we elect to sell on our own.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If approved by regulatory authorities, market acceptance and sales of product candidates that we elect to sell on our own will depend on reimbursement policies and may be affected by healthcare reform measures. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels for those medications. Cost containment is a primary concern in the U.S. healthcare industry and elsewhere. Government authorities and these third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. We cannot be sure that reimbursement will be available for nomlabofusp, if approved, or future product candidates that we elect to sell on our own and, if reimbursement is available, the level of such reimbursement. Reimbursement may impact the demand for, or the price of, product candidates that we elect to sell. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize product candidates that we elect to sell. For more information, see the section of this report titled &#8220;Business &#8211; Healthcare Laws and Regulations &#8211; Coverage and Reimbursement.&#8221;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In some foreign countries, particularly in Canada and European countries, the pricing of prescription pharmaceuticals is subject to strict governmental control. In these countries, pricing negotiations with governmental authorities can take six to 12 months or longer after the receipt of regulatory approval and product launch. To obtain favorable reimbursement for the indications sought or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of product candidates that we elect to sell on our own</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">58</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">with other available therapies. If reimbursement for product candidates that we elect to sell on our own is unavailable in any country in which we seek reimbursement, if it is limited in scope or amount, if it is conditioned upon our completion of additional clinical trials, or if pricing is set at unsatisfactory levels, our business, financial conditions and results of operations could be materially adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if we obtain marketing approval for a product candidate, our product candidates will remain subject to regulatory oversight.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we receive marketing approval for nomlabofusp or a future product candidate, regulatory authorities may still impose significant restrictions on the indicated uses or marketing or impose ongoing requirements for potentially costly post-approval studies. Nomlabofusp or future product candidates will also be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping and submission of safety and other post-market information. The FDA has significant post-market authority, including, for example, the authority to require labeling changes based on new safety information and to require post-market studies or clinical trials to evaluate serious safety risks related to the use of a drug. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval. Any regulatory approvals that we receive for nomlabofusp may also be subject to a REMS, limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including post-approval clinical trials, and surveillance to monitor the quality, safety and efficacy of the product, all of which could lead to lower sales volume and revenue. For example, the holder of an approved BLA or NDA is obligated to monitor and report adverse events and any failure of a product to meet the specifications in the BLA or NDA. The holder of an approved BLA or NDA also must submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, product manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP requirements and adherence to commitments made in the BLA or NDA or foreign marketing application. If we, or a regulatory authority, discover(s) previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured or if a regulatory authority disagrees with the promotion, marketing or labeling of that product, a regulatory authority may impose restrictions relative to that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we or our contractors fail to comply with applicable regulatory requirements following approval of nomlabofusp, a regulatory authority may:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">issue a warning letter, or untitled letter asserting that we are in violation of the law;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">require us to enter into a consent decree, which can include imposition of various fines, reimbursements for inspection costs, required due dates for specific actions and penalties for non-compliance;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">request voluntary product recalls;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seek an injunction or impose administrative, civil or criminal penalties or monetary fines;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">suspend or withdraw regulatory approval;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">suspend any ongoing clinical trials;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refuse to approve a pending BLA or NDA or comparable foreign marketing application (or any supplements thereto) submitted by us;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrict the marketing or manufacturing of the product;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seize or detain the product or otherwise require the withdrawal of the product from the market;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refuse to permit the import or export of product candidates; or</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refuse to allow us to enter into supply contracts, including government contracts.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">59</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize nomlabofusp, if approved, and adversely affect our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the FDA&#8217;s policies, and those of equivalent foreign regulatory agencies, may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of nomlabofusp. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would materially and adversely affect our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if we receive marketing approval for nomlabofusp in the United States, we may never receive regulatory approval to market nomlabofusp outside of the United States.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may pursue marketing approval for nomlabofusp in the United States, the European Union and in other jurisdictions worldwide. In order to market any product outside of the United States, we must establish and comply with the numerous and varying safety, efficacy and other regulatory requirements of other jurisdictions, including potential additional clinical trials and/or non-clinical studies. Approval procedures vary among jurisdictions and can involve additional testing and additional administrative review periods. The time required to obtain approvals in other jurisdictions might differ from that required to obtain FDA approval. The marketing approval processes in other jurisdictions may implicate all of the risks detailed above regarding FDA approval in the United States as well as other risks. In particular, in many countries outside of the United States, products must receive pricing and reimbursement approval before the product can be commercialized. Obtaining this approval can result in substantial delays in bringing products to market in such countries. Marketing approval in one jurisdiction does not necessarily ensure marketing approval in another, but a failure or delay in obtaining marketing approval in one country may have a negative effect on the regulatory process or commercial activities in others. Failure to obtain marketing approval in other countries or any delay or other setback in obtaining such approval would impair our ability to market a product candidate in such foreign markets. Any such impairment would reduce the size of our potential market, which could have a material adverse impact on our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our future growth depends, in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The prevalence of FA is estimated to be approximately three times greater in the European Union than in the United States, and, therefore, represents our largest potential market for nomlabofusp. Our future profitability will depend, in part, on our ability to commercialize nomlabofusp and future product candidates in the European Union and other foreign markets for which we may rely on collaborations with third parties. If we commercialize a product candidate in foreign markets, we would be subject to additional risks and uncertainties, including:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our customers&#8217; ability to obtain reimbursement for a product candidate in foreign markets;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compliance with the FCPA;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our inability to directly control commercial activities because we may need to rely on third parties;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">different medical practices and customs in foreign countries affecting acceptance in the marketplace;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">import or export licensing requirements;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">longer accounts receivable collection times;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">longer lead times for shipping;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">language barriers for technical training;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">60</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reduced protection of intellectual property rights in some foreign countries;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">foreign currency exchange rate fluctuations; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sales in the European Union and other foreign markets of a product candidate could also be adversely affected by the imposition of governmental controls, political and economic instability, trade restrictions and changes in tariffs.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell nomlabofusp, if approved, we may not be able to generate any revenue.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not currently have an established infrastructure for the sales, marketing and distribution of biologic or drug products in the United States or foreign countries. In order to market a product candidate, if approved by the FDA or any other regulatory authority, we must build our sales, marketing, managerial and other non-technical capabilities or make arrangements with third parties to perform these services. If we are unable to establish adequate sales, marketing and distribution capabilities, whether independently or with third parties, or if we are unable to do so on commercially reasonable terms, our business, results of operations, financial condition and prospects will be materially adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if we receive marketing approval for nomlabofusp, we may not achieve broad market acceptance, which would limit the revenue that we generate from our sales.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The commercial success of nomlabofusp, if developed and approved for marketing by the FDA or EMA or other applicable regulatory authorities, will depend upon the market size for, and the awareness and acceptance of nomlabofusp among the medical community, including physicians, patients, advocacy groups and healthcare payors. Market acceptance of nomlabofusp, if approved, will depend on a number of factors, including, among others:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">if the actual number of patients with FA is lower than we believe;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the relative convenience and ease of subcutaneous injections as the necessary method of administration;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the prevalence and severity of any adverse side effects associated with nomlabofusp;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">limitations or warnings contained in the labeling approved for nomlabofusp by the FDA, EMA, or other regulatory authorities, such as a &#8220;boxed&#8221; warning or if any approval that we obtain is based on a narrower definition of possible patient populations;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">availability of alternative treatments, including any competitive FA therapies approved or in development that have been or could be approved or commercially launched prior to approval of nomlabofusp;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the strength of marketing and distribution support and timing of market introduction of competitive products;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">publicity concerning our products or competing products and treatments;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">pricing;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">patient acceptance of the cost and inconvenience associated with refrigerated storage for nomlabofusp;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">payor acceptance;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">increased political pressure on pharmaceutical pricing;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">increased pressure on orphan drug pricing for affected patient groups;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the impact of any future changes in U.S. healthcare, including medical financial assistance or a transition to a single-payor system;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effectiveness of our sales and marketing strategies;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to increase awareness of nomlabofusp through marketing efforts;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">61</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain sufficient third-party coverage or reimbursement;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the willingness or ability of patients to pay out-of-pocket in the absence of third-party coverage; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the likelihood that the FDA may require development of a REMS, as a condition of approval or post-approval or may not agree with our proposed REMS or may impose additional requirements that limit the promotion, advertising, distribution or sales of our product candidates.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If nomlabofusp is approved but does not achieve an adequate level of acceptance by patients, advocacy groups, physicians and payors, we may not generate sufficient revenue from nomlabofusp to become or remain profitable and our business, financial condition and results of operations could be materially adversely affected. Our efforts to educate the medical community and third-party payors about the benefits of nomlabofusp may require significant resources and may never be successful.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. If we are found to have improperly promoted off-label uses, we may become subject to significant liability.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products, such as nomlabofusp or any potential product candidates, if approved. If we receive marketing approval for nomlabofusp, or any potential product candidates, physicians may prescribe our product candidates to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion and required that they enter into corporate integrity agreements with the Office of Inspector General of the Department of Health and Human Services. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of nomlabofusp or any potential product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Additional competing technologies could emerge, adversely affecting our opportunity to generate revenue from the sale of nomlabofusp, if approved.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. For example, omaveloxolone, was approved for the treatment of FA in adults and adolescents aged 16 and older by the FDA and the European Commission in February 2023 and February 2024, respectively. We expect nomlabofusp, if approved, will compete with omaveloxolone and other new, future approved products and may need to demonstrate compelling advantages in efficacy, convenience, tolerability and safety to be commercially successful. Other competitive factors, including biosimilar and gene therapy competition, could force us to lower prices or could result in reduced sales. Many of our current or potential competitors, either alone or with strategic partners, have significantly greater financial resources and expertise in research and development, manufacturing, non-clinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. New products developed by others could emerge as competitors to nomlabofusp or any other potential product candidates, resulting in nomlabofusp or other product candidates being obsolete before we are able to recover expenses incurred in connection with their development or realize revenues from any commercialized product. The pricing of our current product candidate, if and when approved for marketing, will depend, in part, on the pricing strategies adopted by our competitors. If these or other companies enact pricing strategies that impact the price we can charge for our product candidate, if approved, we may reduce our prices and our revenue and results of operations could be affected. Any new product could also affect our ability to recruit and retain clinical trial patients, to obtain and maintain designations or eligibility for expedited regulatory pathways, and to commercialize current and future product candidates. Given that we are still in a relatively early phase of development for nomlabofusp, the recent approval and commercialization of omaveloxolone and the approval of any future competing technologies could provide competitors with a significant competitive advantage and may create an additional barrier to market acceptance of nomlabofusp. If we are not able to compete effectively against our current and future competitors, our business will not grow and our financial condition and results of operations will be adversely affected.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">62</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop. Our competitors also may obtain FDA, EMA or other regulatory approval for their products more rapidly than we may obtain approval for ours and may obtain orphan product exclusivity from the FDA for indications our product candidates are targeting, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, products or technologies developed by our competitors may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing any product candidates we may develop against competitors.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may face competition from biosimilars and may face increasing competition over time.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may face competition from biosimilars in both the United States and Europe, and over time we may face increasing biosimilar competition. To the extent that governments adopt more permissive approval frameworks and competitors are able to obtain broader or expedited marketing approval for biosimilars, the rate of increased competition for our biologic drug products could accelerate. Expiration or successful challenge of applicable patent rights could trigger such competition, and we could face more litigation regarding the validity and/or scope of our patents. Our products may also experience greater competition from lower cost biosimilars or generics that come to market when branded products that compete with our products lose their own patent protection.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the European Union, the European Commission has granted marketing authorizations for biosimilars pursuant to a set of general and product class-specific guidelines for biosimilar approvals issued in 2005. In addition, in an effort to spur biosimilar utilization and/or increase potential healthcare savings, some countries in the European Union have adopted biosimilar uptake measures such as requiring physician prescribing quotas or promoting switching or pharmacy substitution of biosimilars for the corresponding reference products, and other countries may adopt similar measures. Some countries in the European Union may impose automatic price reductions upon market entry of the second or third biosimilar competitor.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, the ACA authorized the FDA to approve biosimilars via a separate, abbreviated pathway. A growing number of companies have announced that they are in varying stages of development of biosimilar versions of existing biotechnology products. Some companies pursuing development of biosimilars may challenge our patents well in advance of the expiration of our material patents. The U.S. pathway includes the option for biosimilar products meeting certain criteria to be approved as interchangeable with their reference products. Some companies developing biosimilars may seek to register their products as interchangeable biologics, which could make it easier for prescribers or pharmacists to substitute those biosimilars for our products. In addition, critics of the 12-year exclusivity period in the biosimilar pathway law will likely continue to seek to shorten the data exclusivity period and/or to encourage the FDA to interpret narrowly the law&#8217;s provisions regarding which new products receive data exclusivity. While we are unable to predict the precise impact of biosimilars, we expect in the future for there to be greater competition in the United States as a result of biosimilars and downward pressure on product prices and sales. These biosimilars or generics may affect the tier designation by third party payors and may require prior authorization for use of nomlabofusp, thereby adding barriers to access. This additional competition could have a material adverse effect on our business, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Business</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to manage expected growth in the scale and complexity of our operations, including attracting and hiring additional qualified management, our performance may suffer.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are an early-stage clinical biotechnology company with a small number of employees, and our management systems currently in place are not likely to be adequate to support our future growth plans. As a result, we are highly dependent on our management and scientific personnel. The loss of the services of any of our executive officers, other key employees or consultants and other scientific advisors in the foreseeable future, might impede the achievement of our research, development and commercialization objectives. Competition for qualified personnel in the biopharmaceutical field is intense due to the limited number of individuals who possess the skills and experience required by our industry. We will need to continue to hire additional personnel as we expand our clinical development and if we initiate commercial activities. We may not be able to attract and retain quality personnel on acceptable terms, or at all. In addition, to the extent we hire personnel from competitors, we may be</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">63</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">subject to allegations that they have been improperly solicited or that they have divulged proprietary or other confidential information, or that their former employers own their research output.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely on consultants and advisors, including scientific, non-clinical, manufacturing and clinical advisors, to assist us in formulating our development and commercialization strategy. These consultants and advisors may be employed by other employers and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. In addition, a possible future pandemic, epidemic or outbreak of an infectious disease may pose a risk to our ability to retain and rely on our executive officers and key employees, including the potential that one or more of such employees or members of their families may contract the virus, which could impact the ability of such employees to perform as expected, which in turn would adversely impact our current and planned operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recruiting and retaining qualified scientific, medical clinical, manufacturing, quality assurance, regulatory, legal, public company financial, business, sales, marketing and commercial personnel and implementing and improving our operational, financial and management systems will be critical to our ability to grow and succeed. These demands also will require the hiring of additional executive or management-level personnel or the development of additional expertise by our senior management personnel. Hiring a significant number of additional employees, particularly those at the executive or management level, would increase our expenses significantly. In addition, we may not be able to attract and retain these personnel on acceptable terms given the competition among numerous pharmaceutical companies for similar personnel. We also experience competition for the hiring of scientific personnel from universities and research institutions. Moreover, delays or failures in clinical trials may also make it more challenging to recruit and retain qualified scientific personnel. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our business strategy will be limited and our business, financial condition and results of operations would be adversely affected.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, if we fail to expand and enhance our operational, financial, management and compliance systems in conjunction with potential future growth, such failure could have a material adverse effect on our business, financial condition and results of operations. We may be unable to successfully implement these tasks on a larger scale and, accordingly, may not achieve our research, development, business and growth goals.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may acquire businesses or products, or form strategic alliances, in the future, and we may not realize the benefits of such acquisitions or alliances.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may acquire additional businesses or products, form strategic alliances or create joint ventures with third parties that we believe will complement or augment our existing business. If we acquire businesses with promising markets or technologies, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate such businesses with our existing operations and company culture.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may encounter numerous difficulties in developing, manufacturing and marketing any new products resulting from a strategic alliance or acquisition that delays or prevents us from realizing their expected benefits or enhancing our business. We cannot be certain that, following any such transaction, we will achieve the expected synergies to justify the transaction and it could adversely affect our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may seek to establish collaborations and, if we are not able to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans or expand our internal efforts and growth.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our development programs and the potential commercialization of our product candidates will require substantial additional cash to fund expenses. For nomlabofusp, and any future product candidates, we may decide to collaborate with pharmaceutical and/or biotechnology companies for the development and potential commercialization of those product candidates in some or all markets.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration for nomlabofusp or other potential product candidates will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the applicable product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">64</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such collaboration could be more attractive than the one with us for our product candidate. The terms of any collaboration or other arrangement that we may establish may not be favorable to us.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may also be restricted under existing license agreements from entering into future agreements on certain terms with potential collaborators. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable or unwilling to do so, we may have to curtail the development potential product candidates for which we are seeking to collaborate, reduce or delay our development program or one or more of our other development programs, delay potential commercialization in some or all markets or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense, including potentially increasing our infrastructure and investment outside the United States. If we elect to increase our expenditures to fund development or commercialization activities on our own, we will need to obtain additional capital, which may not be available to us on acceptable terms if at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue. In addition, such efforts may require diversion of a disproportionate amount of our attention away from other day-to-day activities and require devotion of a substantial amount of our time to managing these activities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, any future collaborations that we enter into may not be successful. The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborators generally have significant discretion in determining the efforts and resources that they will apply to these collaborations. Disagreements between parties to a collaboration arrangement regarding clinical development and commercialization matters can lead to delays in the development process or commercializing the applicable product candidate and, in some cases, termination of the collaboration arrangement. These disagreements can be difficult to resolve if neither of the parties has final decision-making authority. Collaborations with pharmaceutical or biotechnology companies and other third parties often are terminated or allowed to expire by the other party. Any such termination or expiration could adversely affect our business, financial condition, results of operations and could harm our business reputation.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We face risks related to health epidemics, and/or other outbreaks of communicable diseases, which could significantly disrupt our operations and may materially and adversely affect our business and financial conditions.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business could be adversely impacted by the effects of a global pandemic, epidemic or outbreak of an infectious disease, such as, for example, a possible resurgence of vaccine resistant or more highly contagious or deadly variants of COVID-19 and the efforts to mitigate such outbreaks. Such global outbreaks of communicable diseases globally could materially and adversely impact our operations, including without limitation, our manufacturing and supply chain for nomlabofusp and our planned clinical trials, which could continue to face, enrollment difficulties as hospitals or clinical trials sites experience closures. Because FA is a rare disease, there are a limited number of patients in close proximity to clinical trial sites and clinical trial patients travel from throughout the United States to clinical trial sites to participate. Any travel advisories or infection risks could present increased risks to patients traveling to a clinical trial site for dosing if clinical trials are allowed to continue. These events could delay our clinical trials, increase the cost of completing our clinical trials and negatively impact the integrity, reliability or robustness of the data from our clinical trials. In addition, employee health and availability could be impacted, which may have a material and adverse effect on our business, financial condition and results of operations. Future pandemics could adversely affect global economies and financial markets resulting in an economic downturn that could have a material adverse effect on our business and prospects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are subject to stringent and evolving U.S. and foreign laws, regulations and rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse business consequences.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">65</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of business, we collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, process) personal data and other sensitive information, including proprietary and confidential business data, trade secrets, intellectual property, data we collect about trial participants in connection with clinical trials, sensitive third-party data, business plans, transactions, financial information and medical information collected by our patient access management team (collectively, sensitive data). Our data processing activities may subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements, and other obligations relating to data privacy and security.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), and other similar laws (e.g., wiretapping laws). For example, HIPAA, as amended by HITECH, imposes specific requirements relating to the privacy, security, and transmission of individually identifiable health information. Additionally, in the past few years, numerous U.S. states&#8212;including California, Virginia, Colorado, Connecticut, and Utah&#8212;have enacted comprehensive privacy laws that impose certain obligations on covered businesses, including providing specific disclosures in privacy notices and affording residents with certain rights concerning their personal data. As applicable, such rights may include the right to access, correct, or delete certain personal data, and to opt-out of certain data processing activities, such as targeted advertising, profiling, and automated decision-making. The exercise of these rights may impact our business and ability to provide our products and services. Certain states also impose stricter requirements for processing certain personal data, including sensitive information, such as conducting data privacy impact assessments. These state laws allow for statutory fines for noncompliance. For example, the California Consumer Privacy Act of 2018, as amended by the California Privacy Rights Act of 2020 (CPRA) (collectively, CCPA) requires businesses to provide specific disclosures in privacy notices and honor requests of California residents to exercise certain privacy rights. The CCPA provides for fines of up to $7,500 per intentional violation and allows private litigants affected by certain data breaches to recover significant statutory damages. Although some U.S. comprehensive privacy laws exempt some data processed in the context of clinical trials, these laws may increase compliance costs and potential liability with respect to other personal data we may maintain about California residents. Similar laws are being considered in several other states, as well as at the federal and local levels, and we expect more jurisdictions to pass similar laws in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Outside the United States, an increasing number of laws, regulations, and industry standards may govern data privacy and security. For example, the European Union&#8217;s General Data Protection Regulation (EU GDPR), United Kingdom&#8217;s GDPR (UK GDPR) (collectively, the GDPR), Brazil&#8217;s General Data Protection Law (Lei Geral de Prote&#231;&#227;o de Dados Pessoais, or LGPD) (Law No. 13,709/2018), and China&#8217;s Personal Information Protection Law (PIPL) impose strict requirements for processing personal data. For example, under the GDPR, companies may face temporary or definitive bans on data processing and other corrective actions; fines of up to 20 million Euros under the EU GDPR / 17.5 million pounds sterling under the UK GDPR or 4% of annual global revenue, whichever is greater; or private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Swiss Federal Act on Data Protection, or the FADP, also applies to the collection and processing of personal data, including health-related information, by companies located in Switzerland, or in certain circumstances, by companies located outside of Switzerland. The FADP has been revised and adopted by the Swiss Parliament. Companies must comply with the revised version of the FADP and its revised ordinances from September 1, 2023, which may result in an increase of costs of compliance, risks of noncompliance and penalties for noncompliance.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we may be unable to transfer personal data from Europe and other jurisdictions to the United States or other countries due to data localization requirements or limitations on cross-border data flows. Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries. In particular, the European Economic Area (EEA) and the UK have significantly restricted the transfer of personal data to the United States and other countries whose privacy laws it believes are inadequate. Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border data transfer laws. Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the United States in compliance with law, such as the EEA standard contractual clauses, the UK&#8217;s International Data Transfer Agreement / Addendum, and the EU-U.S. Data Privacy Framework and the UK extension thereto (which allows for transfers to relevant U.S.-based organizations who self-certify compliance and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">66</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">participate in the Framework), these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the United States. If there is no lawful manner for us to transfer personal data from the EEA, the UK, or other jurisdictions to the United States, or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including by limiting our ability to conduct clinical trial activities in Europe and elsewhere, the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions (such as Europe) at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business. Some European regulators have ordered certain companies to suspend or permanently cease certain transfers of personal data to recipients outside Europe for allegedly violating the GDPR&#8217;s cross-border data transfer limitations. Additionally, companies that transfer personal data to recipients outside of the EEA and/or UK to other jurisdictions, particularly to the United States, are subject to increased scrutiny from regulators individual litigants and activist groups.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to data privacy and security laws, we may be contractually subject to industry standards adopted by industry groups and may become subject to such obligations in the future. We are also bound by other contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful. We publish privacy policies, marketing materials, and other statements, such as compliance with certain certifications or self-regulatory principles, regarding data privacy and security. If these policies, materials or statements are found to be deficient, lacking in transparency, deceptive, unfair, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators, or other adverse consequences.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, under various privacy laws and other obligations, we may be required to obtain certain consents to process personal data. For example, some of our data processing practices may be challenged under wiretapping laws, if we obtain consumer information from third parties through various methods, including chatbot and session replay providers, or via third-party marketing pixels. These practices may be subject to increased challenges by class action plaintiffs. Our inability or failure to obtain consent for these practices could result in adverse consequences, including class action litigation and mass arbitration demands.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Obligations related to data privacy and security (and consumers&#8217; data privacy expectations) are quickly changing, becoming increasingly stringent, and creating uncertainty. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. Preparing for and complying with these obligations requires us to devote significant resources and may necessitate changes to our services, information technologies, systems, and practices and to those of any third parties that process personal data on our behalf.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may at times fail (or be perceived to have failed) in our efforts to comply with our data privacy and security obligations. Moreover, despite our efforts, our personnel or third parties on whom we rely on may fail to comply with such obligations, which could negatively impact our business operations. If we or the third parties on which we rely fail, or are perceived to have failed, to address or comply with applicable data privacy and security obligations, we could face significant consequences, including but not limited to: government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-action claims) and mass arbitration demands; additional reporting requirements and/or oversight; bans on processing personal data; and orders to destroy or not use personal data. In particular, plaintiffs have become increasingly more active in bringing privacy-related claims against companies, including class claims. Some of these claims allow for the recovery of statutory damages on a per violation basis, and, if viable, carry the potential for monumental statutory damages, depending on the volume of data and the number of violations. Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to loss of customers; inability to process personal data or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or substantial changes to our business model or operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our internal computer systems, as well as those of CROs, CMOs, vendors, contractors, and consultants, and potential collaborators may experience failures, unauthorized access, or security breaches, potentially causing a material disruption in our product development programs, operations, harm to our brand, significant liabilities, loss of revenue, and additional costs.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Despite implementing comprehensive security measures, both our internal computer systems and those of our contracted third party service providers are susceptible to various threats, including cyber-attacks, computer viruses,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">67</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unauthorized access, natural disasters, terrorism, war, and telecommunication and electrical failures. The extensive use of mobile devices accessing confidential information further heightens the risks, leading to potential device loss, security incidents, and data breaches that could result in the loss of confidential information and intellectual property. Any system failure, accident, or security breach causing interruptions in our operations may lead to a material disruption in our product development programs and business operations, potentially requiring substantial resources for recovery. For instance, the loss of clinical trial data from completed trials could lead to delays in regulatory approval efforts and significantly increase costs for data recovery or reproduction.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are exposed to risks stemming from misappropriation, misuse, leakage, falsification, or intentional or accidental release or loss of information maintained in our information systems and networks, including personal information of our employees. External parties may attempt to penetrate our systems or induce our employees or those of our vendors to disclose sensitive information. As with other companies, we face threats to our data and systems, including malicious codes, viruses, and cyber-attacks. The increasing number and complexity of these threats over time pose a challenge. A material breach in our security or that of our vendors, contractors, or consultants could harm the market perception of our security measures, resulting in business loss and damage to our reputation and credibility. This could significantly adversely affect our business, financial condition, and results of operations, necessitating substantial amounts of money and resources to repair or replace information systems or networks. Despite our continuous efforts, the possibility of such events occurring cannot be entirely eliminated.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In our endeavor to protect systems storing critical information, we have implemented security measures. However, given their size and complexity and the increasing amounts of information maintained, these systems, including our internal information technology systems and those of third-party entities like Contract Research Organizations, Contract Manufacturing Organizations, contractors, and consultants, remain potentially vulnerable to breakdowns, interruptions, and security breaches. Incidents such as service interruptions, system malfunctions, natural disasters, terrorism, war, telecommunication, and electrical failures, as well as security breaches from inadvertent or intentional actions by employees, contractors, consultants, and other third parties, including cyber-attacks by malicious entities, may compromise our system infrastructure. This could lead to the loss, destruction, alteration, or unauthorized access to our data, including trade secrets, confidential information, intellectual property, proprietary business information, and personal information, or data processed or maintained on our behalf. Such incidents could result in financial, legal, business, and reputational harm.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The rise in phishing and social engineering attacks and the increase in remote working further elevate security threats. Any disruption or security incident could lead to loss, damage, or unauthorized access to data, potentially exposing us to litigation and governmental investigations, delaying the development and commercialization of our product candidates, and subjecting us to fines or penalties for noncompliance with privacy and security laws. Notifications and actions following a security incident could impact our reputation and incur significant costs, including legal expenses and remediation. Significant efforts and costs are expected for detection and prevention. Our reliance on third parties for manufacturing introduces an additional layer of risk to our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Insurance policies, including a specific policy related to cybersecurity losses, may be insufficient, with potential availability issues in the future, high deductibles, and limitations in coverage, posing challenges in mitigating losses from disruptions, failures, or security breaches.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If our information technology systems or data, and/or those of third parties upon which we rely, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions, interruptions to operations or clinical trials, reputational harm, litigation, fines and penalties, disruptions of our business operations, and a loss of customers or sales.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of our business, we, or the third parties upon which we rely, process proprietary, confidential, and sensitive data, including personal data (such as health-related data), intellectual property, and trade secrets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cyberattacks, malicious internet-based activity, online and offline fraud and other similar activities threaten the confidentiality, integrity, and availability of our sensitive data and information technology systems, and those of the third parties upon which we rely. These threats are prevalent, continue to rise, and are becoming increasingly difficult to detect. These threats come from a variety of sources, including traditional computer &#8220;hackers,&#8221; hacktivists, threat actors, personnel misconduct or error (such as through theft or misuse), organized criminal threat actors, sophisticated nation-states, and nation-state-supported actors. Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">68</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">conjunction with military conflicts and defense activities. During times of war and other major conflicts, we and the third parties upon which we rely may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our goods and services.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We and the third parties upon which we rely are subject to a variety of evolving threats, including but not limited to, social engineering attacks (including through deep fakes, which may be increasingly more difficult to identify as fake, and phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-of-service attacks, credential stuffing, credential harvesting, personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunction, software or hardware failures, loss of data or other information technology assets, adware, attacks enhanced or facilitated by AI, telecommunications failures, earthquakes, fire, flood, and other similar threats.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ransomware attacks, including by organized criminal threat actors, nation-states, and nation-state-supported actors, are becoming increasingly prevalent and severe and can lead to significant interruptions, delays, or outages in our operations, disruption of clinical trials or otherwise affecting our ability to provide our products or product candidates, loss of sensitive data (including data related to clinical trials) and income, significant extra expenses to restore data or systems, reputational harm and the diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments (including, for example, if applicable laws or regulations prohibit such payments). Remote work has become more common and has increased risks to our information technology systems and data, as more of our employees work from home, utilizing network connections, computers and devices outside our premises, including at home, while in transit or in public locations. Future business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies. Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely on third-party service providers and technologies to operate critical business systems to process sensitive data in a variety of contexts, including, without limitation, cloud-based infrastructure, drug suppliers, data center facilities, encryption and authentication technology, employee email, content delivery to customers, and other functions. Our ability to monitor these third parties&#8217; information security practices and posture (including whether any unremediated vulnerabilities exist or have been exploited) is limited, and these third parties may not have adequate information security measures in place. In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties&#8217; infrastructure in our supply chain or our third-party partners&#8217; supply chains have not been compromised.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. We take steps designed to detect, mitigate, and remediate vulnerabilities in our information security systems (such as our hardware and/or software, including that of third parties upon which we rely). We and the third parties upon which may rely may not, however, detect and remediate all such vulnerabilities including on a timely basis. For example, we have identified certain vulnerabilities in our information systems, and we have taken steps to mitigate the risks associated with known vulnerabilities. These steps include implementing compensating controls and other protective measures. Further, we and the third parties upon which we rely may experience delays in developing and deploying remedial measures and patches designed to address identified vulnerabilities. Vulnerabilities could be exploited and result in a security incident.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any of the previously identified or similar threats could cause a security incident or other interruption that could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our sensitive information or our information technology systems, or those of the third parties upon whom we rely. A security incident or other interruption could disrupt our ability (and that of third parties upon whom we rely) to provide our products.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may expend significant resources or fundamentally change our business activities and practices (including our clinical trials) to try to protect against security incidents. Certain data privacy and security obligations may require us to implement and maintain specific security measures or industry-standard or reasonable security measures to protect our information technology systems and sensitive data.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">69</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Applicable data privacy and security obligations may require us to notify relevant stakeholders, including affected individuals, customers, regulators, and investors, of security incidents. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences. If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences. These consequences may include: government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive data (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; diversion of management attention; interruptions in our operations (including availability of data); financial loss; and other similar harms. Security incidents and attendant consequences may prevent or cause customers to stop using our products, deter new customers from using our products, and negatively impact our ability to grow and operate our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to experiencing a security incident, third parties may gather, collect, or infer sensitive data about us from public sources, data brokers or other means that reveals competitively sensitive details about our organization and could be used to undermine our competitive advantage or market position. Additionally, sensitive information of the Company could be leaked, disclosed, or revealed as a result of or in connection with the use of generative AI technologies.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, our insurance coverage may not be adequate or sufficient in type or amount to protect us from or to mitigate liabilities arising out of our privacy and security practices. The successful assertion of one or more large claims against us that exceeds our available insurance coverage, or results in changes to our insurance policies (including premium increases or the imposition of large deductible or co-insurance requirements), could have an adverse effect on our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We face potential product liability exposure, and, if claims are brought against us, we may incur substantial liability.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The use of nomlabofusp and other potential product candidates in clinical trials, if any, and the sale of nomlabofusp and other potential product candidates, if developed and approved, exposes us to the risk of product liability claims. Product liability claims might be brought against us by patients, healthcare providers or others selling or otherwise coming into contact with nomlabofusp or other potential product candidates. For example, we may be sued if any product we develop allegedly causes injury or death or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Physicians and patients may not comply with any warnings that identify known potential adverse effects and patients who should not use our products. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to stop development or, if approved, limit commercialization of our product candidates. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, including as a result of interactions with alcohol or other drugs, negligence, strict liability and a breach of warranties. Claims could also be asserted under consumer protection acts in other jurisdictions. If we become subject to product liability claims and cannot successfully defend ourselves against them, we could incur substantial liabilities. In addition, regardless of merit or eventual outcome, product liability claims may result in, among other things:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">withdrawal of patients or clinical investigators from our clinical trials;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delay or termination of clinical trials;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">substantial monetary awards to patients or other claimants;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">decreased demand for nomlabofusp or our other potential product candidates following marketing approval, if obtained;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">damage to our reputation and exposure to adverse publicity;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">increased FDA warnings on product labels;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">70</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">initiation of investigations by regulators or ethics committees;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product recalls, withdrawals, or labeling, marketing or promotional restrictions;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">litigation costs;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">distraction of management&#8217;s attention from our primary business;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">increased product liability costs;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">loss of revenue; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inability to successfully commercialize nomlabofusp or other potential product candidates, if approved.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We maintain product liability insurance coverage for our clinical trials with a $5 million aggregate coverage limit. Nevertheless, our insurance coverage may be insufficient to reimburse us for any expenses or losses we may suffer. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses, including if insurance coverage becomes increasingly expensive. If we obtain marketing approval for nomlabofusp or other potential product candidates, we intend to expand our insurance coverage to include the sale of commercial products; however, we may not be able to obtain this product liability insurance on commercially reasonable terms. Large judgments have been awarded in class action lawsuits based on drugs that had unanticipated side effects. The cost of any product liability litigation or other proceedings, even if resolved in our favor, could be substantial, particularly in light of the size of our business and financial resources. A product liability claim or series of claims brought against us could cause our stock price to decline and, if we are unsuccessful in defending such a claim or claims and the resulting judgments exceed our insurance coverage, our financial condition, business, results of operations and prospects could be materially adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Reliance on Third Parties</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have limited experience in conducting or supervising clinical trials and must outsource all clinical trials. As a result, many important aspects of our drug development programs are outside of our direct control.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have limited experience in conducting or supervising clinical trials that must be performed to obtain data to submit in concert with applications for approval by the FDA, the EMA or other comparable foreign regulatory authorities. As a result, we expect to continue to rely on CROs, clinical trial sites, clinical data management organizations and consultants to design, conduct, supervise and monitor our non-clinical studies and clinical trials. We, our CROs, and contractors are required to comply with various regulations, including the FDA&#8217;s regulations regarding current Good Clinical Practices ("cGCPs") which are enforced by regulatory agencies, including the FDA, and comparable foreign regulatory authorities to ensure the health, safety and rights of patients are protected in clinical development and clinical trials, and that trial data integrity is assured. Regulatory authorities ensure compliance with these requirements through periodic inspections of trial sponsors, principal investigators and clinical trial sites. Our expected reliance on third parties that we do not control does not relieve us of these responsibilities and requirements. If we or any of our CROs, contractors, or clinical trial sites fail to comply with applicable requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, EMA or other comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot ensure that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with such requirements. In addition, our clinical trials must be conducted with products produced under cGMP requirements, which mandate, among other things, the methods, facilities and controls used in manufacturing, processing and packaging of a drug product to ensure its safety and identity. Failure to comply with these regulations may require us to repeat non-clinical studies and/or clinical trials, which would delay the regulatory approval process, and could also subject us to enforcement action, up to and including, civil and criminal penalties, which would materially adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our CROs and contractors are not our employees, and except for remedies available to us under our agreements with such CROs and contractors, we cannot control whether or not they devote sufficient time and resources to our ongoing clinical and non-clinical programs. If our CROs and contractors do not successfully carry out their contractual duties or obligations or meet expected deadlines or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">71</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed or reduced. In addition, operations of our CROs and contractors could be affected by earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or man-made disasters or business interruptions. If their facilities are unable to operate because of an accident or incident, even for a short period of time, some or all of our research and development programs may be harmed or delayed, and our operations and financial condition could suffer.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have less direct control over the conduct, timing and completion of these clinical trials and the management of data developed through the clinical trials than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. These factors may materially adversely affect the willingness or ability of third parties to conduct our clinical trials and may subject us to unexpected cost increases that are beyond our control. Nevertheless, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on CROs and contractors does not relieve us of our regulatory responsibilities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we must, at times, share confidential information with third parties. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements, or other similar agreements with our collaborators, advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, such as trade secrets, intellectual property, data from clinical studies and future development plans. Despite the contractual provisions employed when working with third parties, the need to share confidential information increases the risk that such confidential information become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our confidential information, a competitor&#8217;s discovery of our confidential information or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, because we have relied on third parties, our internal capacity to perform these functions is limited. Outsourcing these functions involves risk that third parties may not perform to our standards, may not produce results in a timely manner or may fail to perform at all. We currently have a small number of employees, which limits the internal resources we have available to engage new third-party providers, if necessary, and monitor existing third-party providers. To the extent we are unable to engage new third-party providers, if necessary, and successfully manage the performance of third-party service providers in the future, our business may be adversely affected. Though we carefully manage our relationships with CROs, and contractors there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition, results of operation and prospects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We rely on third-party supply and manufacturing partners for drug supplies for our research and development, non-clinical activities, and clinical activities, and may do the same for any commercial supplies of our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely on third-party supply and manufacturing partners to supply the materials and components for, and manufacture, our research and development, non-clinical and clinical study drug substance and drug product. We have not yet manufactured or formulated nomlabofusp or any other product candidate on a commercial scale and may not be able to do so for any of our product candidates. We will work to develop and optimize our manufacturing process; however, we cannot be sure that the process will result in therapies that are safe, potent or effective. Given our reliance on third parties and the risk of manufacturing commercial scale quantities, our ability to adequately commercially launch and/or supply nomlabofusp could be adversely affected.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not own manufacturing facilities or supply sources for such components, non-clinical and clinical study drug substance, product and materials, including devices that may be required for administration, but may develop these capabilities in the future. There can be no assurance that our supply of research and development, non-clinical and clinical development of drugs and other materials will not be limited, interrupted, restricted in certain geographic regions or will be of satisfactory quality or continue to be available at acceptable prices. In particular, replacement of any product formulation manufacturer we may engage could require significant effort and expertise</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">72</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">because there may be a limited number of qualified replacements. For example, we rely and expect to continue to rely on a small number of manufacturers to supply us with our requirements for drug substance and formulated drug product related to our nomlabofusp clinical program. The drug substance which is in frozen liquid form for nomlabofusp is currently manufactured for us by a third-party manufacturer, and the frozen liquid form of drug product is made at another manufacturer. We are undertaking a program with a third party manufacturer to begin to produce a lyophilized version of the drug product from the same drug substance, that, once available, we intend to use in certain of our future planned clinical trials. Our research and development programs could be adversely affected by a significant interruption in these manufacturing services or in the supply of drug substance and formulated drugs. In addition, because we rely on multiple manufacturers for our nomlabofusp clinical program, termination of our agreements with any of these manufacturers could significantly adversely impact our current and planned operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the event that any of our suppliers or manufacturers fails to perform their obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third party, which we may not be able to do on reasonable terms, if at all. In some cases, the technical skills or technology required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills or technology to another third party and a feasible alternative may not exist. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third party manufacture our product candidates. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates in a timely manner or within budget.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also rely on third parties to store master and working cell banks. We currently have one master cell bank and one working cell bank for nomlabofusp and believe we would have adequate backup should any cell bank be lost in a catastrophic event. However, it is possible that we could lose multiple cell banks and have our manufacturing severely impacted by the need to replace the cell banks, which could materially and adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may rely on third party manufacturers if we receive regulatory approval for any product candidate. To the extent that we have existing, or enter into future, manufacturing arrangements with third parties, we will depend on these third parties to perform their obligations in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance. If we are unable to obtain or maintain third party manufacturing for product candidates, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our product candidates successfully. Our or a third party&#8217;s failure to execute on our manufacturing requirements could adversely affect our business, financial condition and results of operations in a number of ways, including:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">an inability to initiate or continue clinical trials of product candidates under development;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delay in submitting regulatory applications, or receiving regulatory approvals, for product candidates;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">loss of the cooperation of a collaborator, including termination or nonrenewal of the agreement at a time that is costly or inconvenient for us;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in manufacturing associated with having to change manufacturers;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">subjecting our product candidates to additional inspections by regulatory authorities;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">requirements to cease distribution or to recall batches of our product candidates; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in the event of approval to market and commercialize a product candidate, an inability to meet commercial demands for our products.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We and our contract manufacturers are subject to significant regulation with respect to manufacturing our products. The manufacturing facilities on which we rely may not continue to meet regulatory requirements and have limited capacity.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">73</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All entities involved in the preparation of therapeutics for clinical trials or commercial sale, including our existing contract manufacturers for nomlabofusp, are subject to extensive regulation. Some components of a finished therapeutic product approved for commercial sale or used in late-stage clinical trials must be manufactured in accordance with cGMP. These regulations govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of adventitious agents or other contaminants, or to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing. We or our contract manufacturers must supply all necessary documentation in support of a BLA or NDA on a timely basis and where required, must adhere to the FDA&#8217;s or other regulator&#8217;s GLPs and cGMP regulations enforced by the FDA or other regulators through facilities inspection programs. The facilities and quality systems of some or all of our third party contractors must pass a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of nomlabofusp or any of our other potential products. In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of nomlabofusp or our other potential products or the associated quality systems for compliance with the regulations applicable to the activities being conducted. If these facilities do not pass a pre-approval plant inspection, the FDA or other regulatory approval of the products will not be granted.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The regulatory authorities also may, at any time following approval of a product for sale, audit the manufacturing facilities of our third party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time-consuming for us or a third party to implement and that may include the temporary or permanent suspension of a clinical trial or commercial sales or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we or any of our third party manufacturers fail to maintain regulatory compliance, the FDA or other regulators can impose regulatory sanctions including, among other things, refusal to approve a pending application for a biologic product, or revocation of a pre-existing approval. As a result, our business, financial condition and results of operations may be materially harmed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, if supply from one approved manufacturer is interrupted, there could be a significant disruption in commercial supply. The number of manufacturers with the necessary manufacturing capabilities is limited. In addition, an alternative manufacturer would need to be qualified through a BLA or NDA supplement or similar regulatory submission which could result in further delay. The regulatory agencies may also require additional studies if a new manufacturer is relied upon for commercial production. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates in a timely manner or within budget.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These factors could also cause the delay of manufacturing development, clinical trials, regulatory submissions, required approvals or commercialization of nomlabofusp or any other product candidates, cause us to incur higher costs and prevent us from commercializing our products successfully. Furthermore, if our suppliers fail to meet contractual requirements, and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical trials may be delayed, or we could lose potential revenues. Any of the above would materially adversely affect our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in methods of product candidate manufacturing may result in additional costs and/or delays.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As product candidates progress through clinical to late-stage clinical trials to marketing approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods, are altered along the way in an effort to optimize yield, manufacturing batch size, change drug product dosage form, minimize costs and achieve consistent quality and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commercialize our product candidates and generate revenue.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">74</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We enter into various contracts in the normal course of our business in which we indemnify the other party to the contract. In the event we have to perform under these indemnification provisions, it could materially increase our costs and potential liability.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the normal course of business, we periodically enter into academic, commercial, service, collaboration, licensing, consulting and other agreements that contain indemnification provisions. With respect to our academic and other research agreements, we typically indemnify the institution and related parties from losses arising from claims relating to the products, processes or services made, used, sold or performed pursuant to the agreements for which we have secured licenses, and from claims arising from our or our sublicensees&#8217; exercise of rights under the agreement. With respect to our collaboration and contract service agreements, we typically indemnify our collaborators from any third party product liability claims that could result from the production, use or consumption of the product, as well as for alleged infringements of any patent or other intellectual property right by a third party. With respect to consulting agreements, we typically indemnify consultants from claims arising from the good faith performance of their consulting services.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Should our obligation under an indemnification provision exceed applicable insurance coverage or should we be denied insurance coverage, our business, financial condition and results of operations could be adversely affected. Similarly, if we are relying on a collaborator to indemnify us and the collaborator is denied insurance coverage or the indemnification obligation exceeds their applicable insurance coverage, and if the collaborator does not have other assets available to indemnify us, our business, financial condition and results of operations could be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">To the extent we are able to enter into collaborative arrangements or strategic alliances, we may be exposed to risks related to those collaborations and alliances.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Biotechnology companies sometimes become dependent upon collaborative arrangements or strategic alliances to complete the development and commercialization of product candidates. In seeking collaborative arrangements and strategic partners, we face significant competition from other companies as well as public and private research institutions. There can be no assurance that we will be able to enter into or maintain strategic alliances on terms favorable to us, or at all. If we elect to enter into collaborative arrangements or strategic alliances, these arrangements may place the development of our product candidates outside our control, may require us to relinquish important rights or may otherwise be on terms unfavorable to us, which could adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dependence on collaborative arrangements or strategic alliances would subject us to a number of risks, including the risk that:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may not be able to control the amount and timing of resources that our collaborators may devote to the relevant product candidates;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our collaborators may experience financial difficulties;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be required to relinquish important rights, such as marketing and distribution rights;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">business combinations or significant changes in a collaborator&#8217;s business strategy may also adversely affect a collaborator&#8217;s willingness or ability to complete its obligations under any arrangement;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a collaborator could independently move forward with a competing drug candidate developed either independently or in collaboration with others, including our competitors; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborative arrangements are often terminated or allowed to expire, which would delay the development and may increase the cost of developing our drug candidates.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Intellectual Property Rights</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If, in the United States and other countries, we are unable to adequately protect our proprietary technology or maintain issued patents which are sufficient to protect nomlabofusp or potential product candidates, third parties could compete against us more directly, which would have a material adverse impact on our business, results of operations, financial condition and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial success will depend in part on our success in obtaining and maintaining issued patents and other intellectual property rights in the United States and elsewhere and protecting our proprietary technology. If we do not adequately protect our intellectual property and proprietary technology, competitors may be able to use our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">75</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">technologies and erode or negate any competitive advantage we may have, which could harm our business and ability to achieve profitability.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">With respect to our patent portfolio, we in-license from WFUHS certain issued U.S. patents that relate to nomlabofusp and its use for treating FA. We also in-license from IU a United States patent and pending non-provisional applications in the United States and certain foreign countries that relate to the composition of nomlabofusp and methods of use, and certain U.S. patents relating to materials and methods of use relating to the development of nomlabofusp. We also own or co-own pending international PCT, foreign and United States non-provisional applications, a United States Patent, and United States provisional applications relating to the development of nomlabofusp, including methods of use of nomlabofusp, biomarkers and to our peptide delivery platform technology.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In some cases, we have only filed provisional patent applications on certain aspects of our technologies and each of these provisional patent applications is not eligible to become an issued patent until, among other things, we file a non-provisional patent application within 12 months of the filing date of the applicable provisional patent application. Any failure to file a non-provisional patent application within this timeline could cause us to lose the ability to obtain patent protection for the inventions disclosed in the associated provisional patent applications.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">With respect to both in-licensed and owned intellectual property, we cannot predict whether the patent applications we and our licensors are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors or other third parties.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot provide any assurances that any of our pending patent applications that mature into issued patents will include claims with a scope sufficient to protect nomlabofusp, or other potential product candidates. Other parties have developed technologies that may be related or competitive to our approach and may have filed or may file patent applications and may have received or may receive patents that may overlap or conflict with our patent applications, either by claiming the same methods or formulations or by claiming subject matter that could dominate our patent position. The patent positions of biotechnology and pharmaceutical companies, including our patent position, involve complex legal and factual questions, and, therefore, the issuance, scope, validity and enforceability of any patent claims that we may obtain cannot be predicted with certainty. Patents, if issued, may be challenged, deemed unenforceable, invalidated, or circumvented. U.S. patents and patent applications may also be subject to interference proceedings, ex parte reexamination, or inter partes review proceedings, supplemental examination and challenges in district court. Patents may be subjected to opposition, post-grant review, or comparable proceedings lodged in various foreign, both national and regional, patent offices. These proceedings could result in either loss of the patent or denial of the patent application or loss or reduction in the scope of one or more of the claims of the patent or patent application. In addition, such proceedings may be costly. Thus, any patents that we may own or exclusively license may not provide any protection against competitors. Furthermore, an adverse decision in an interference proceeding can result in a third party receiving the patent right sought by us, which in turn could affect our ability to develop, market or otherwise commercialize nomlabofusp, and other potential product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, though an issued patent is presumed valid and enforceable, its issuance is not conclusive as to its validity or its enforceability and it may not provide us with adequate proprietary protection or competitive advantages against competitors with similar products. Competitors may also be able to design around our patents. Other parties may develop and obtain patent protection for more effective technologies, designs or methods. The laws of some foreign countries do not protect our proprietary rights to the same extent as the laws of the United States, and we may encounter significant problems in protecting our proprietary rights in these countries. If these developments were to occur, they could have a material adverse effect on our potential future sales.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to enforce our patent rights depends on our ability to detect infringement. It is difficult to detect infringers who do not advertise the components that are used in their products. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor&#8217;s or potential competitor&#8217;s product. Any litigation to enforce or defend our patent rights, even if we were to prevail, could be costly and time-consuming and would divert the attention of our management and key personnel from our business operations. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded if we were to prevail may not be commercially meaningful.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, proceedings to enforce or defend our patents could put our patents at risk of being invalidated, held unenforceable, or interpreted narrowly. Such proceedings could also provoke third parties to assert claims against us, including that some or all of the claims in one or more of our patents are invalid or otherwise unenforceable. If any of our patents covering nomlabofusp are invalidated or found unenforceable, our financial</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">76</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">position and results of operations would be materially and adversely impacted. In addition, if a court found that valid, enforceable patents held by third parties covered nomlabofusp, our financial position and results of operations would also be materially and adversely impacted.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The degree of future protection for our proprietary rights is uncertain, and we cannot ensure that:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any of our patents, or any of our pending patent applications, if issued, will include claims having a scope sufficient to protect nomlabofusp or any other products or product candidates;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any of our pending patent applications will issue as patents;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we will be able to successfully develop and, if approved, commercialize nomlabofusp before our relevant patents expire;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we were the first to make the inventions covered by each of our patents and pending patent applications;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we were the first to file patent applications for these inventions;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">others will not develop similar or alternative technologies that do not infringe our patents;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any of our patents will be found to ultimately be valid and enforceable;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any patents issued to us will provide a basis for an exclusive market for our commercially viable products, will provide us with any competitive advantages or will not be challenged by third parties;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we will develop additional proprietary technologies or product candidates that are separately patentable; or</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">that our commercial activities or products will not infringe upon the patents of others.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely upon unpatented trade secrets, unpatented know-how and continuing technological innovation to develop and maintain our competitive position, which we seek to protect, in part, by confidentiality agreements with our employees and consultants. We also have agreements with our employees and selected consultants that obligate them to assign their inventions to us and have non-compete agreements with some, but not all, of our consultants. It is possible that technology relevant to our business will be independently developed by a person that is not a party to such an agreement. Furthermore, if the employees and consultants who are parties to these agreements breach or violate the terms of these agreements, we may not have adequate remedies for any such breach or violation, and we could lose our trade secrets through such breaches or violations. Further, our trade secrets could otherwise become known or be independently discovered by our competitors. If we are unable to adequately protect our proprietary technology or maintain issued patents which are sufficient to protect nomlabofusp or potential future product candidates, third parties could compete against us more directly, which would have a material adverse impact on our business, results of operations, financial condition and prospects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our key patent, which we license relates to nomlabofusp will expire in 2040 and we will lose our ability to rely upon this patent to prevent competing products from entering the market, which may impair our ability to generate revenue.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have in-licensed certain patents relating to nomlabofusp from WFUHS. The U.S. patents relating to nomlabofusp and its use for the treatment of FA expire in 2024 and 2025, respectively. When these patents expire, we will be unable to use these patents to try to block others from marketing nomlabofusp in the United States We have also in-licensed an issued United States patent and pending non-provisional patent applications in the United States and certain foreign countries relating to the composition of nomlabofusp and methods of use from IU. This United States patent will expire in 2040 at the earliest. Pending applications if issued as patents, would also expire in 2040 at the earliest. We cannot predict whether these patent applications we and our licensors are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors or other third parties. When these various patents, if issued, expire, we will be unable to use the patents to try to block others from marketing nomlabofusp in the United States.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We own a certain United States provisional application and certain United States and foreign non-provisional applications and a United States patent relating to our platform technology. The United States Patent will expire in 2041 at the earliest, and the pending applications, if issued as patents, would be expected to expire in 2041-2044. The provisional application may not be timely converted into a non-provisional application, and we cannot predict</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">77</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether these provisional applications and non-provisional patent applications will issue as patents in any particular jurisdiction, or whether the claims of any issued patents will provide sufficient protection from competitors or third parties for potential product candidates. When these various patents expire, we will be unable to use the patents to try to block others from marketing products pertaining to our platform technology.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Once our patents expire, we will be subject to competition from third parties who will be able to use the intellectual property covered by these patents, which could impair our ability to generate revenue and could adversely affect our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may infringe the intellectual property rights of others, which may prevent or delay our product development efforts and stop us from commercializing or may increase the costs of commercializing nomlabofusp or other potential product candidates, if approved.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success will depend in part on our ability to operate without infringing the intellectual property and proprietary rights of third parties. We cannot ensure that our business, products and methods do not or will not infringe the patents or other intellectual property rights of third parties.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The pharmaceutical industry is characterized by extensive litigation regarding patents and other intellectual property rights. Third parties may allege that nomlabofusp or our other potential product candidates or the use of our technologies infringes patent claims or other intellectual property rights held by them or that we are employing their proprietary technology without authorization. Patent and other types of intellectual property litigation can involve complex factual and legal questions, and their outcome is uncertain. Any claim relating to intellectual property infringement that is successfully asserted against us may require us to pay substantial damages, including treble damages and attorneys&#8217; fees if we are found to be willfully infringing another party&#8217;s patents, for past use of the asserted intellectual property and royalties and other consideration going forward if we are forced to take a license. In addition, we may also be required to indemnify certain of our licensors, vendors or suppliers from any damages they incur related to any infringement of any third party intellectual property by our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, if any such claim were successfully asserted against us and we could not obtain such a license, we may be forced to stop or delay developing, manufacturing, selling or otherwise commercializing nomlabofusp.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we are successful in these proceedings, we may incur substantial costs and divert management time and attention in pursuing these proceedings, which could have a material adverse effect on us. If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, defend an infringement action or challenge the validity of the patents in court, or redesign our products. Patent litigation is costly and time consuming. We may not have sufficient resources to bring these actions to a successful conclusion. In addition, intellectual property litigation or claims could force us to do one or more of the following:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cease developing, selling or otherwise commercializing nomlabofusp;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cease preparations or development of our other potential product candidates;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">pay substantial damages for past use of the asserted intellectual property;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtain a license from the holder of the asserted intellectual property, which license may not be available on reasonable terms, if at all; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in the case of trademark claims, redesign or rename the trademarks or trade names of our product candidates to avoid infringing the intellectual property rights of third parties, which may not be possible and, even if possible, could be costly and time-consuming.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any of these risks coming to fruition could have a material adverse effect on our business, results of operations, financial condition and prospects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">78</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may also be subject to claims that former employees or other third parties have an ownership interest in our patents or other intellectual property. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business, financial condition and results of operations. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have systems in place to remind us to pay periodic maintenance fees, renewal fees, annuity fees and various other patent and application fees, and we employ an outside law firm to pay these fees. The U.S. Patent and Trademark Office and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ an outside law firm and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If this occurs, our competitors may be able to enter the market, which would have a material adverse effect on our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Competitors may infringe on our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of our or our licensors is not valid, is unenforceable and/or is not infringed, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing which could materially adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interference proceedings provoked by third parties or brought by us may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to us from the prevailing party. Our business, financial condition and results of operations could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States, which could adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we or one of our licensing partners initiated legal proceedings against a third party to enforce a patent covering our product candidate, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include alleged failures to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement. Grounds for unenforceability assertions include allegations that someone connected with prosecution of the patent withheld relevant information from the U.S. PTO, or made a misleading statement, during prosecution. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">79</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">litigation. Such mechanisms include re-examination, post grant review and equivalent proceedings in foreign jurisdictions, e.g. opposition proceedings. Such proceedings could result in revocation or amendment of our patents in such a way that they no longer cover our product candidates or competitive products. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to validity, for example, we cannot ensure that there is no invalidating prior act, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection would have a material adverse impact on our business, financial condition, and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We do not seek to protect our intellectual property rights in all jurisdictions throughout the world and we may not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek protection.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Filing, prosecuting and defending patents on product candidates in all countries and jurisdictions throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States could be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. For example, an April 2020 report from the Office of the United States Trade Representative identified a number of countries, including India and China, where challenges to the procurement and enforcement of patent rights have been reported. Several countries, including India and China, have been listed in the report every year since 1989. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license, which would materially adversely affect our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are dependent on licensed intellectual property for nomlabofusp. If we were to lose our rights to licensed intellectual property, we may not be able to continue developing or commercializing nomlabofusp, if approved.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have an exclusive license with WFUHS, pursuant to which we exclusively license certain patent rights relating to the TAT-frataxin fusion protein and its use, on a worldwide basis. We have an exclusive license with IU, pursuant to which we exclusively license certain patent rights relating to nomlabofusp and its use for the treatment of mitochondrial diseases, on a worldwide basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our license agreements with WFUHS and IU impose, and we expect our future license agreements will impose, various development, diligence, commercialization, and other obligations on us in order to maintain the licenses. In spite of our efforts, WFUHS, IU, or a future licensor might conclude that we have materially breached our obligations under such license agreements and seek to terminate the license agreements, thereby removing or limiting our ability to develop and commercialize products and technology covered by these license agreements. If these licenses are terminated, or if the underlying patent rights licensed thereunder fail to provide the intended exclusivity, competitors or other third parties would have the freedom to seek regulatory approval of, and to market, products identical to ours and we may be required to cease our development and commercialization of certain of our product candidates or of nomlabofusp. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, disputes may arise regarding intellectual property subject to a licensing agreement, including:</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">80</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the sublicensing of patent and other rights under our collaborative development relationships;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether and the extent to which inventors are able to contest the assignment of their rights to our licensors; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the priority of invention of patented technology.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize nomlabofusp, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Some intellectual property may have been discovered through government funded programs and thus may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with non-U.S. manufacturers.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our in-licensed patent rights from WFUHS and IU were funded in part by the U.S. government and are therefore subject to certain federal regulations. When new technologies are developed with U.S. government funding, the U.S. government generally obtains certain rights in any resulting patents, including a non-exclusive license authorizing the U.S. government to use the invention or to have others use the invention on its behalf. The U.S. government&#8217;s rights may also permit it to disclose the funded inventions and technology to third parties and to exercise march-in rights to use or allow third parties to use the technology we have licensed that was developed using U.S. government funding. The U.S. government may exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of the government-funded technology, or because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In addition, our rights in such inventions may be subject to certain requirements to manufacture products embodying such inventions in the United States in certain circumstances and if this requirement is not waived. Any exercise by the U.S. government of such rights or by any third party of its reserved rights could have a material adverse effect on our competitive position, business, financial condition, results of operations, and prospects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have not yet registered trademarks for a commercial trade name for nomlabofusp or other potential product candidates and failure to secure such registrations could adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not yet registered trademarks for a commercial trade name for nomlabofusp or other potential product candidates. Any future trademark applications may be rejected during trademark registration proceedings. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, the U.S. PTO and comparable agencies in many foreign jurisdictions give third parties an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. Moreover, any name we propose to use with our product candidates in the United States must be approved by the FDA, and similarly in many foreign jurisdictions regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">81</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">evaluation of potential for confusion with other product names. If the FDA or a foreign regulatory authority objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA or other regulatory authorities.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Any trademarks we have obtained or may obtain may be infringed or successfully challenged, resulting in harm to our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to rely on trademarks as one means to distinguish any of our products that are approved for marketing from the products of our competitors. Once we select new trademarks and apply to register them, our trademark applications may not be approved. Third parties may oppose or attempt to cancel our trademark applications or trademarks, or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we could be forced to rebrand our drugs, which could result in loss of brand recognition and could require us to devote resources to advertising and marketing new brands. Our competitors may infringe our trademarks and we may not have adequate resources to enforce our trademarks.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we do not obtain additional protection under the Hatch-Waxman Amendments and similar foreign legislation by extending the patent terms and obtaining data exclusivity for nomlabofusp, our business may be materially harmed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depending upon the timing, duration and specifics of development and FDA marketing approval of nomlabofusp or our other potential product candidates, one or more of our U.S. patents may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, (the "Hatch-Waxman Amendments"). The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, we may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain a patent term extension or restoration or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our ability to generate revenues, business, financial condition and results of operations could be materially adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our proprietary rights may not adequately protect our technologies, which may adversely affect our position in the market, business, financial condition and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely on unpatented trade secrets, know-how, and technology, which are difficult to protect, especially in the pharmaceutical industry, where much of the information about a product must be made public during the regulatory approval process. We seek to protect trade secrets, in part, by entering into confidentiality agreements with employees, consultants and others. These parties may breach or terminate these agreements or may refuse to enter into such agreements with us, and we may not have adequate remedies for such breaches. Furthermore, these agreements may not provide meaningful protection for our trade secrets or other proprietary information or result in the effective assignment to us of intellectual property and may not provide an adequate remedy in the event of unauthorized use or disclosure of confidential information or other breaches of the agreements. Despite our efforts to protect our trade secrets, we or our board members, employees, consultants, contractors or scientific and other advisors may unintentionally or willfully disclose our proprietary information to competitors.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we fail to maintain trade secret protection, our competitive position may be adversely affected. Competitors may also independently discover our trade secrets. Enforcement of claims that a third party has illegally obtained and is using trade secrets is expensive, time consuming and uncertain. If our competitors independently develop equivalent knowledge, methods and know-how, we would not be able to assert our trade secrets against them and our business, financial condition and results of operations could be harmed.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. The Leahy Smith America Invents Act ("the Leahy Smith Act") enacted in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">82</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 2011, brought significant changes to the U.S. patent law system. These include provisions that affect the way patent applications are prosecuted and may affect patent litigation. The United States Patent Office continues to develop and implement new regulations and procedures to govern administration of the Leahy Smith Act, and many of the substantive changes to patent law associated with the Leahy Smith Act became effective on March 16, 2013. The Leahy Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of our issued patents, all of which could harm our business, results of operations, financial condition and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. Additionally, there have been recent proposals for additional changes to the patent laws of the United States and other countries that, if adopted, could impact our ability to enforce our proprietary technology. Depending on future actions by the U.S. Congress, the U.S. courts, the U.S. PTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed alleged trade secrets of our employees&#8217; former employers.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of our employees have been previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we are not aware of any claims currently pending against us, we may be subject to claims that we or our employees inadvertently or otherwise used or disclosed the trade secrets or other proprietary information of our employees&#8217; former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. If we fail in defending such claims, in addition to paying monetary claims, we may lose valuable intellectual property rights or personnel. A loss of key personnel or their work product could hamper or prevent our ability to develop and commercialize nomlabofusp or our other potential product candidates, which would materially adversely affect our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Common Stock</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our stock price could be highly volatile, and purchasers of our common stock could incur substantial losses.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The market price of our common stock could be subject to significant fluctuations. Market prices for securities of early-stage pharmaceutical, biotechnology, and other life sciences companies have historically been particularly volatile. Some of the factors that may cause the market price of our common stock to fluctuate include:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain regulatory approvals for product candidates, and delays or failures to obtain such approvals;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the results of, and delays in, current, and any future, non-clinical or clinical trials of nomlabofusp or any of our future product candidates, including any delays related to a future pandemic, epidemic or outbreak of an infectious disease;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">geopolitical tension, including the potential impact of ongoing conflict between Russia and Ukraine and the current conflict in Israel and Gaza (including any escalation or expansion);</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the entry into, or termination of, key agreements, including key licensing or collaboration agreements;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the failure of nomlabofusp or any of our future product candidates, if approved for marketing and commercialization, to achieve commercial success;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">issues in manufacturing our approved products, if any, or product candidates;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the initiation of material developments in, or conclusion of, disputes or litigation to enforce or defend any of our intellectual property rights or defend against the intellectual property rights of others;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">announcements by us or our commercial partners or competitors of new commercial products, clinical progress (or the lack thereof), significant contracts, commercial relationships, or capital commitments;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">83</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adverse publicity relating to our markets, including with respect to other products and potential products in such markets;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the introduction of technological innovations or new therapies competing with our potential products;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the loss of key employees;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">general and industry-specific economic conditions potentially affecting our research and development expenditures;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">general economic conditions in the United States and abroad (including the potential failure of the United States Congress to raise the debt ceiling);</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in the structure of health care payment systems;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adverse regulatory decisions;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">trading volume of our common stock; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">period-to-period fluctuations in our financial results.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is no guarantee that our common stock will appreciate or even maintain the price at which our holders have purchased it. Therefore, there is a risk that investors may lose all or part of their investment in our securities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies or the biotechnology sector. These broad market fluctuations may also adversely affect the trading price of our common stock.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management&#8217;s attention and resources, which could significantly impact our profitability and reputation. Any lawsuit to which we are a party, with or without merit, may result in an unfavorable judgment. We also may decide to settle lawsuits on unfavorable terms. Any such negative outcome could result in payments of substantial damages or fines, damage to our reputation or adverse changes to our offerings or business practices.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We must maintain effective internal controls over financial reporting, and if we are unable to do so, the accuracy and timeliness of our financial reporting may be adversely affected, which could have a material adverse effect on our business and stock price.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We must maintain effective internal control over financial reporting in order to accurately and timely report our results of operations and financial condition. In addition, as a public company, the Sarbanes-Oxley Act requires, among other things, that we assess the effectiveness of our disclosure controls and procedures quarterly and the effectiveness of our internal control over financial reporting at the end of each fiscal year.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The rules governing the standards that must be met for our management to assess our internal control over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act are complex and require significant documentation, testing and possible remediation. These stringent standards require that our audit committee be advised and regularly updated on management&#8217;s review of internal control over financial reporting.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management may not be able to effectively and timely implement controls and procedures which respond to the increased regulatory compliance and reporting requirements that are applicable to us as a public company. If we fail to staff our accounting, finance and information technology functions adequately or maintain internal control over financial reporting adequate to meet the demands that are placed upon us as a public company, including the requirements of the Sarbanes-Oxley Act, or to otherwise prevent material weaknesses in internal control over financial reporting, our business and reputation may be harmed and our stock price may decline. Furthermore, investor perceptions of us may be adversely affected, which could cause a decline in the market price of our common stock.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">84</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Ownership of our common stock is highly concentrated, and it may prevent other stockholders from influencing significant corporate decisions.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Entities affiliated with Deerfield Management Company beneficially own or control approximately 38.6% of our outstanding common stock (assuming full exercise of our outstanding pre-funded warrants and no exercise of outstanding options) as of December 31, 2023, on a fully-diluted basis. Accordingly, such entities have substantial influence over the outcome of a corporate action by us requiring stockholder approval, including the election of directors, any merger, consolidation or sale of all or substantially all of our assets or any other significant corporate transaction. These stockholders also may exert influence in delaying or preventing a change in control of the combined company, even if such change in control would benefit our other stockholders.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are a smaller reporting company. We cannot be certain whether the reduced disclosure requirements applicable to smaller reporting companies will make our common shares less attractive to investors or otherwise limit our ability to raise additional funds.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are currently a &#8220;smaller reporting company&#8221; as defined in the Exchange Act of 1934 and have elected to take advantage of certain of the scaled disclosures available to smaller reporting companies, including simplified executive compensation disclosures in our filings, exemption from the provisions of Section 404(b) of the Sarbanes-Oxley Act requiring that an independent registered accounting firm provide an attestation report on the effectiveness of internal control over financial reporting and certain other decreased disclosure obligations in our SEC filings, including, among other things, only being required to provide two years of audited financial statements in annual reports. Reduced disclosure in our SEC filings due to our status as a smaller reporting company may make it harder for investors to analyze our results of operations and financial prospects. We cannot predict whether investors will find our common stock less attractive because of our reliance on any of these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our management.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Provisions in our certificate of incorporation and bylaws may delay or prevent an acquisition or a change in management. These provisions include a classified board of directors, a prohibition on actions by written consent of our stockholders, and the ability of the board of directors to issue preferred stock without stockholder approval. In addition, because we are in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law ("DGCL") which prohibits stockholders owning in excess of 15% of our outstanding voting stock from merging or combining with us. Although we believe these provisions collectively will provide for an opportunity to receive higher bids by requiring potential acquirers to negotiate with our board of directors, they would apply even if the offer may be considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove then current management by making it more difficult for stockholders to replace members of the board of directors, which is responsible for appointing the members of management.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We do not anticipate that we will pay any cash dividends in the foreseeable future.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The current expectation is that we will retain our future earnings to fund the development and growth of our business. As a result, capital appreciation, if any, of our common stock will be stockholders&#8217; sole source of gain, if any, for the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our failure to meet the continued listing requirements of The Nasdaq Stock Market LLC could result in a delisting of our Common Stock.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we fail to satisfy the continued listing requirements of The Nasdaq Stock Market LLC ("Nasdaq") such as the corporate governance requirements or the minimum closing bid price requirement, Nasdaq may take steps to delist our common stock. Such a delisting would likely have a negative effect on the price of our common stock and would impair a stockholders ability to sell or purchase shares of common stock when they wish to do so. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow the common stock to become listed again, stabilize the market price or improve the liquidity of the common stock, prevent the common stock from dropping below the Nasdaq minimum bid price requirement or prevent future noncompliance with Nasdaq&#8217;s listing requirements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General Risk Factors</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">85</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial reporting obligations of being a public company in the United States are expensive and time-consuming, and our management will be required to devote substantial time to new compliance matters.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The obligations of being a public company in the United States require significant expenditures and place significant demands on our management and other personnel, including costs resulting from public company reporting obligations under the Securities Exchange Act of 1934, as amended, and the rules and regulations regarding corporate governance practices, including those under the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (the "Dodd-Frank Act") and the listing requirements of Nasdaq on which our securities are listed. These rules require the maintenance of effective disclosure and financial controls and procedures, internal control over financial reporting and strong corporate governance practices, among many other complex rules that are often difficult to implement, monitor and maintain compliance with. Our management and other personnel devote a substantial amount of time to ensure that we comply with all of these requirements and to keep pace with new regulations, otherwise we may fall out of compliance and risk becoming subject to litigation or being delisted, among other potential problems.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our employees may engage in misconduct or other improper activities, including violating applicable regulatory standards and requirements or engaging in insider trading, which could significantly impact our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional, reckless or negligent failures to comply with the regulations of the FDA and applicable non-U.S. regulators, provide accurate information to the FDA and applicable non-U.S. regulators, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. Employees may also unintentionally or willfully disclose our proprietary and/or confidential information to competitors. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use of, including trading on, information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a code of conduct, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may be ineffective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. In addition, we are subject to the risk that a person or government could allege fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our results of operations could be adversely affected by general conditions in the global economy, geopolitical events and general conditions in the global financial markets. A severe or prolonged economic downturn due to geopolitical tension resulting from ongoing conflict between Russia and Ukraine and the current conflict in Israel and Gaza (including any escalation or expansion) or other factors could result in a variety of risks to our business, including, weakened demand for our product candidates and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our products. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Adverse developments affecting the financial services industry, including events or concerns involving liquidity, defaults or non-performance by financial institutions or transactional counterparties, could adversely affect our business, financial condition or results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. For example, in early 2023, several financial institutions closed and were taken into receivership by the Federal Deposit Insurance Corporation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">86</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(&#8220;FDIC&#8221;). Although we assess our banking and customer relationships as we believe necessary or appropriate, our access to funding sources and other credit arrangements in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that affect us, the financial services industry or economy in general. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all. Any decline in available funding or access to our cash and liquidity resources could, among other risks, adversely impact our ability to meet our operating expenses, financial obligations or fulfill our other obligations, result in breaches of our contractual obligations or result in violations of federal or state wage and hour laws. Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors not described above, could have material adverse impacts on our liquidity and our business, financial condition or results of operations.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">87</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item1bunresolvedstaffcomments_265117"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 1B. UNRESOLVED STAFF COMMENTS</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item1ccybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 1C. CYBERSECURITY</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cyber Risk Management and Strategy</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have implemented and maintain various information security processes designed to manage cybersecurity risks relating to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical data, including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and data related to our clinical trials and products (Information Systems and Data).</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Director of Information Technology, assisted by our managed information technology service provider and other third party service providers, lead the Company&#8217;s cybersecurity risk management processes. This group works to identify and assess risks from cybersecurity threats by monitoring and evaluating our threat environment and the Company&#8217;s risk profile using various methods in certain contexts, including, manual tools, subscribing to reports and services that identify cybersecurity threats, analyzing threat intelligence reports and feeds, conducting scans of certain environments, and other tests.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We implement and maintain various technical, physical, and organizational measures, processes, standards and policies designed to manage risks from cybersecurity threats to our Information Systems and Data, as applicable depending on the environment, including incident detection and response, disaster recovery/business continuity policies, network security controls and data segmentation, access controls, physical security, asset management and tracking, systems monitoring, and employee training.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our assessment and management of risks from cybersecurity threats are part of the Company&#8217;s overall risk management processes. Our Director of Information Technology works with management to prioritize our risk management processes and mitigate cybersecurity threats that are more likely to lead to a material impact to our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We use third-party service providers to assist us to identify, assess, and manage risks from cybersecurity threats. These third-party service providers may include threat intelligence service providers, cybersecurity consultants, cybersecurity software providers, managed cybersecurity service providers, and dark web monitoring services.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also have established a process to conduct diligence on certain third parties before engaging with those third parties, such as those that support our GxP processes, which may include a security assessment.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not identified any cybersecurity incidents or threats that have materially affected us or are reasonably likely to materially affect us, including our business strategy, results of operations or financial condition; however, like other companies in our industry, we and our third-party vendors may, from time to time, experience threats and security incidents relating to our and our third-party vendors&#8217; information systems and infrastructure. For more information, please see our risk factors under Part 1 Item 1A. Risk Factors.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Governance</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our board of directors holds oversight responsibility over the Company&#8217;s cybersecurity risk management as part of its general oversight function. The audit committee of the board of directors is responsible for overseeing the Company&#8217;s cybersecurity risk management processes, including oversight of the Company&#8217;s processes for monitoring and controlling cybersecurity risks.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including our Director of Information Technology, who has over 10 years of information technology management experience.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Director of Information Technology, along with management, is responsible for helping to integrate cybersecurity risk considerations into the Company&#8217;s overall risk management strategy and communicating key priorities to relevant personnel. Management is responsible for approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security-related reports.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have processes designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including our Vice President Legal and Compliance, Vice President Finance and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">88</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Administration, Chief Financial Officer and Director of Information Technology. In addition, the Company&#8217;s incident response policy includes a process for reporting to the audit committee of the board of directors for certain cybersecurity incidents.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The audit committee receives reports from members of the Company&#8217;s management concerning the Company&#8217;s significant cybersecurity threats and risk and the processes the Company has implemented to address them, as applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item2properties_264380"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 2. PROPERTIES</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently lease 1,750 square feet of laboratory space in Philadelphia, PA. We are currently on a month-to-month lease on this Philadelphia lab space. We, as well as our landlord, can terminate the lease with four months notice.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have entered into a lease for 3,927 square feet of new laboratory space in King of Prussia, PA to replace the Philadelphia lab space, but this lease has not yet commenced with expected occupancy in the second quarter of 2024.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are party to an operating lease for approximately 17,705 square feet of office space in Boston, Massachusetts, which we refer to as the Boston Lease. The Boston Lease expires in October 2029. On October 27, 2020, we entered into a sublease agreement whereby we subleased all 17,705 square feet of office space leased under the Boston Lease until October 2029.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that we will need to increase our lease space</span><span style="color:#0000ff;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in the near and intermediate term. We believe that both appropriate office and laboratory space will be readily available on commercially reasonable terms.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item3legalproceedings_49550"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 3. LEGAL PROCEEDINGS</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may be subject to other legal proceedings and claims in the ordinary course of business. We cannot predict the results of any such disputes, and despite the potential outcomes, the existence thereof may have an adverse material impact on us due to diversion of management time and attention as well as the financial costs related to resolving such disputes.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item4minesafetydisclosures_57184"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 4. MINE SAFETY DISCLOSURES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">89</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:-15.385%;padding-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;" id="partii_672268"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART II</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item5marketforregistrantsscommonequity_9"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Market Information</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our common stock is publicly traded on the Nasdaq Global Market under the symbol &#8220;LRMR.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Holders</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 14, 2024, we had approximately 62 record holders of our common stock.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dividends</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not declared or paid any dividends since our inception nor do we expect to pay dividends in the foreseeable future.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recent Sales of Unregistered Securities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There have been no sales of unregistered securities other than as previously disclosed by us in our Current Reports on Form 8-K as filed with the SEC.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Issuer Purchases of Equity Securities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item6selectedconsolidatedfinancialdata_6"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 6. [Reserved.]</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">90</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item7managementsdiscussionandanalysis_41"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> RESULTS OF OPERATIONS</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">You should read the following discussion and analysis of our financial condition and results of operations together with the audited consolidated financial statements and the related notes included elsewhere in this Annual Report on Form 10-K. In addition to historical financial information, the following discussion contains forward-looking statements based upon our current plans, expectations and beliefs that involve risks, uncertainties and assumptions. Our actual results may differ materially from those described in or implied by these forward-looking statements as a result of many factors, including those set forth under the section titled &#8220;Risk Factors&#8221; and in other parts of this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using our novel cell penetrating peptide ("CPP") technology platform. Our lead product candidate, nomlabofusp (nomlabofusp is the International Nonproprietary Name ( "INN") and the United States Adopted Name ("USAN") for CTI-1601), is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin ("FXN"), an essential protein, to the mitochondria of patients with Friedreich's ataxia (&#8220;FA&#8221;). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Currently, there are no treatment options that address the core deficit of FA, low levels of FXN. Nomlabofusp represents the first potential therapy designed to increase FXN levels in patients with FA.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that our CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. We intend to use our proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since our inception, we have devoted substantially all of our resources to developing nomlabofusp, building our intellectual property portfolio, developing third-party manufacturing capabilities, business planning, raising capital, and providing general and administrative support for such operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Nomlabofusp Program Update</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Trials</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have completed two Phase 1 clinical trials and a Phase 2 dose exploration trial in patients with FA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2021, we reported positive top-line data from our Phase 1 FA program after completing dosing of the single ascending dose ("SAD") trial in December 2020 and of the multiple ascending dose ("MAD") trial in March 2021. Data from these trials demonstrated proof-of-concept by showing that daily subcutaneous injections of nomlabofusp for up to 13 days resulted in dose-dependent increases in FXN levels from baseline compared to placebo in all evaluated tissues (buccal cells, skin, and platelets). There were no serious adverse events associated with either the MAD or SAD trials.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2023, we reported preliminary unblinded top-line data from the 25 mg cohort of our Phase 2 four-week, placebo-controlled, dose exploration trial of nomlabofusp in FA patients. Data from the cohort indicated nomlabofusp was generally well tolerated and showed increases in FXN levels from baseline compared to placebo in all evaluated tissues (skin and buccal cells) at day 14.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2023, we met with the FDA. Following that meeting, we submitted a complete response to the FDA&#8217;s partial clinical hold that included unblinded safety, PK and frataxin data from the Phase 2 trial&#8217;s completed 25 mg cohort.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2023, following the FDA&#8217;s review of our complete response to the partial clinical hold, the FDA cleared initiation of a second cohort (50 mg) of our four-week, placebo-controlled, Phase 2 dose exploration trial and to initiate our OLE trial with daily dosing of 25 mg.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2024, we initiated the OLE trial evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver, with the first patient dosed in March 2024. Participants who complete treatment in the Phase 2 dose exploration trial, or who previously completed a prior clinical trial of nomlabofusp are potentially eligible to screen for the OLE. The OLE will evaluate the safety and tolerability and PK and measures of frataxin levels in peripheral tissues as well as other exploratory PD (lipid profiles and gene expression data) following long-term subcutaneous administration of nomlabofusp. Clinical measures collected during the trial will be compared to data from a synthetic control arm derived from participants in the Friedreich&#8217;s Ataxia Clinical Outcome Measures Study ("FACOMS") database. Dose escalation in the OLE trial will be</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">91</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">considered based on safety, tolerability, PK, and tissue FXN levels from the Phase 2 trial&#8217;s 50 mg cohort as well as available data from the 25 mg dose of nomlabofusp in the OLE trial and is contingent on FDA review as part of the partial clinical hold. Initial data from the OLE trial is expected in the fourth quarter of 2024.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2024, we reported positive top-line data and successful completion of the two cohorts (25 mg and 50 mg groups) of our four-week, placebo-controlled Phase 2 dose exploration study of nomlabofusp in participants with FA. Nomlabofusp was generally well tolerated and demonstrated dose dependent increases in FXN levels in all evaluated tissues (skin and buccal cells) after daily dosing of 14 days followed by every other day dosing until day 28 in the 25 mg and 50 mg cohorts. Participants in the 25 mg (n=13) and 50 mg (n=15) cohorts were randomized 2:1 to receive subcutaneous injections of nomlabofusp or placebo.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recently, we had discussions with the FDA regarding the use of tissue FXN levels as a novel surrogate endpoint. The FDA has acknowledged that frataxin deficiency appears to be critical to the pathogenic mechanism of FA, and that there continues to be an unmet need for treatments for FA patients that address the underlying disease pathophysiology. We intend to pursue an accelerated approval using FXN levels, supportive PD and clinical information, and safety data from the OLE study, along with additional non-clinical pharmacology information needed to support the novel surrogate endpoint approach. We are beginning to plan for a confirmatory study and are targeting a BLA submission in the second half of 2025.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Nomlabofusp has been granted Orphan Drug (U.S. and Europe), Rare Pediatric Disease (U.S.), Fast Track (U.S.), and PRIME (Europe) designations for FA. We have also begun to engage with regulators and investigators outside the U.S. as we prepare to expand our clinical program to additional geographies. With approximately 75% of individuals with FA living outside the U.S., establishing global clinical trial capabilities is important for addressing the pressing unmet needs of the FA community.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financing Activities, Including Recent Material Financings</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have funded our operations to date primarily with proceeds from sales of common stock, proceeds from the sale of prefunded warrants for the purchase of common stock, the acquisition in 2020 of cash, cash equivalents, marketable securities and restricted cash upon the merger with Zafgen, Inc. ("Zafgen") and, prior to the 2020 merger with Zafgen, capital contributions from Chondrial Holdings, LLC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2022, we sold 25,558,750 shares of common stock in an underwritten offering for net proceeds of $75.2 million, after issuance costs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2024, we sold 19,736,842 shares of common stock in an underwritten public offering, for net proceeds of approximately $161.6 million.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Critical Accounting Policies and Significant Judgments and Estimates</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our consolidated financial statements are prepared in accordance with GAAP. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amount of assets, liabilities, costs and expenses, and related disclosures. We believe that the estimates and assumptions involved in the accounting policies described below may have the greatest potential impact on our consolidated financial statements and, therefore, consider these to be our critical accounting policies. We evaluate these estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions and conditions.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expense</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Costs for certain research and development activities, such as manufacturing, non-clinical studies and clinical trials are generally recognized based on the evaluation of the progress of completion of specific tasks using information and data provided by our vendors and collaborators, and accordingly, are considered an area of significant judgment and management&#8217;s review of manufacturing, non-clinical and clinical expenses. This process involves reviewing open contracts and purchase orders, communicating with our personnel and outside vendors to identify services that have been performed on our behalf and estimating the level of service performed and the associated costs incurred for the services when we have not yet been invoiced or otherwise notified of the actual costs. We work with vendors and suppliers to ensure that our estimates of our research and development expenses are reasonable. We expect to increase our investment in research and development in order to advance nomlabofusp through additional clinical trials. As a result, we expect that our research and development expenses will increase in the foreseeable future as we pursue clinical development of nomlabofusp and/or any other product candidates we develop.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">92</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Compensation Expense</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We measure all stock-based awards granted to employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires the use of highly subjective assumptions which determine the fair value of stock-based awards. The assumptions used in our option-pricing model represent management&#8217;s best estimates. These estimates are complex, involve a number of variables, uncertainties and assumptions and the application of management&#8217;s judgment, and thus are inherently subjective. If factors change and different assumptions are used, our stock-based compensation expense could be materially different in the future.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to May 28, 2020, we were a private company and lacked company-specific historical and implied volatility information for our common stock. Prior to January 1, 2023, the Company estimated its expected common stock price volatility solely based on the historical volatility of publicly traded peer companies with comparable characteristics including enterprise value, risk profiles and position within the industry. Beginning on January 1, 2023, the Company began blending its historical data starting in June 2020 (following its merger with Zafgen in 2020) with its historical peer group. We regularly evaluate our peer group to assess changes in circumstances where identified companies may no longer be similar to us, in which case, more suitable companies whose share prices are publicly available would be utilized in the calculation. We expect to continue to do so until we have full historical data regarding the volatility of our own traded stock price.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The expected term of our stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield considers the fact that we have never paid cash dividends on common stock and do not expect to pay any cash dividends in the foreseeable future.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Compensation expense of those awards is recognized over the requisite service period, which is generally the vesting period of the respective award. Typically, we issue awards with only service-based vesting conditions and record the expense for these awards using the straight-line method. We account for forfeitures as they occur.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We classify stock-based compensation expense in our consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial Operations Overview</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To date, we have not generated any revenue from product sales, and do not expect to generate any revenue from the sale of products in the foreseeable future. If our development efforts result in clinical success and regulatory approval or collaboration agreements with third parties for our product candidates, we may generate revenue from those product candidates or collaborations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The majority of our operating expenses since inception have consisted primarily of research and development activities, and general and administrative costs.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses, which consist primarily of costs associated with our product research and development efforts, are expensed as incurred. Research and development expenses consist primarily of:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">third-party contract costs relating to research, formulation, manufacturing, non-clinical studies and clinical trial activities;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">employee related costs, including salaries, benefits and stock-based compensation expenses for employees engaged in scientific research and development functions;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">external costs of outside consultants and vendors;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">payments made under our third-party licensing agreements;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">sponsored research agreements;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">93</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">laboratory consumables; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">allocated facility-related costs.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the clinical and commercial development of nomlabofusp, or any other product candidates we develop. We are also unable to predict when, if ever, material net cash inflows will commence from sales of our product candidates. The duration, costs, and timing of clinical trials and development of nomlabofusp or any other product candidates we develop will depend on a variety of factors, including:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope, rate of progress and expense of clinical trials and other research and development activities;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinical trial results; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">uncertainties in clinical trial enrollment rate or design;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">significant and changing government regulation;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing and receipt of any regulatory approvals;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the influence of the FDA or other regulatory authorities on our clinical trial design and timing;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establishing manufacturing capabilities or making arrangements with third-party manufacturers and risk involved with development of manufacturing processes, FDA pre-approval inspection practices and successful completion of manufacturing batches for clinical development and other regulatory purposes;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain and maintain patent and trade secret protection and regulatory exclusivity for our product candidates; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to recruit and retain key research and development personnel.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A change in the outcome of one or more of these variables with respect to the development of a product candidate could significantly change the costs, timing and viability associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to require us to conduct additional non-clinical or clinical trials beyond those that we currently anticipate will be required for the completion of clinical development of a product candidate, or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses consist primarily of personnel costs, consisting of salaries, related benefits and stock-based compensation, costs related to our executive, finance, information technology, and costs related to other administrative functions. General and administrative expenses also include insurance expenses and professional fees for auditing, tax, and legal services, including legal expenses to pursue patent protection for our intellectual property. We expect that our general and administrative expenses will increase in the foreseeable future as we hire additional employees to implement, improve and scale our operational, financial, commercial and management systems.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Results of Operations</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following commentary is a discussion and analysis of our financial condition as of December 31, 2023 and results of operations and cash flows for the year ended December 31, 2023 compared to the year ended December 31, 2022 and should be read in conjunction with the consolidated financial statements and accompanying notes.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The discussion and analysis of our financial condition as of December 31, 2022, and results of operations and cash flows for the year ended December 31, 2022, compared to the year ended December 31, 2021, is included in item 7, Management&#8217;s Discussion and Analysis of Financial and Results of Operations of our Annual Report on Form 10-K for the year ended December 31, 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">94</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comparison of the years ended December 31, 2023 and 2022</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our results of operations for the years ended December 31, 2023 and 2022:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.552%;"/>
    <td style="width:1.26%;"/>
    <td style="width:1%;"/>
    <td style="width:10.842%;"/>
    <td style="width:1%;"/>
    <td style="width:1.28%;"/>
    <td style="width:1%;"/>
    <td style="width:10.862%;"/>
    <td style="width:1%;"/>
    <td style="width:1.28%;"/>
    <td style="width:1%;"/>
    <td style="width:10.922%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Increase</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Decrease)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Statement of Operations Data:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,670</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,250</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,420</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,088</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,276</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,812</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">41,758</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,526</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,232</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(41,758</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(36,526</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(5,232</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income (expense), net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,809</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,171</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,638</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(36,949</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(35,355</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1,594</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and development expenses</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses for the twelve months ended December 31, 2023 increased $3.4 million compared to the twelve months ended December 31, 2022 due to continued and increased clinical development of nomlabofusp and related regulatory and bioanalysis. The increase in research and development expenses compared to the prior year period was primarily driven by an increase of $1.9 million in personnel expense, an increase of $1.3 million in clinical expense, an increase of $1.1 million in regulatory and statistical consulting expenditures, an increase of $0.5 million in assay development costs, and an increase of $0.3 million in stock-based compensation expense associated with stock option grants made in 2022 and 2023, partially offset by a decrease of $2.0 million in drug manufacturing costs.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and administrative expenses</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses for the twelve months ended December 31, 2023 increased $1.8 million compared to the twelve months ended December 31, 2022. The increase in general and administrative expense was primarily driven by an increase of $0.7 million in stock-based compensation expense associated with stock option grants made in 2022 and 2023, an increase of $0.5 million in personnel expense, an increase of $0.5 million in operational costs primarily related to technology and an increase of $0.4 million in professional fees primarily related to legal, accounting and consulting services, partially offset by a decrease of $0.3 million in insurance expense.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other income (expense), net</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other income (expense), net was $4.8 million of income in the twelve months ended December 31, 2023 compared to $1.2 million in the twelve months ended December 31, 2022. The increase primarily relates to interest income on a higher investment base and higher investment yields on that base during the current period.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Liquidity and Capital Resources</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since our inception, we have not generated any revenue from any sources, including from product sales, and have incurred significant operating losses and negative cash flows from our operations. We have devoted substantially all of our resources to developing nomlabofusp, building our intellectual property portfolio, developing third-party manufacturing capabilities, business planning, capital raising, and providing general and administrative support for such operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our sources and uses of cash for each of the periods presented below:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.033%;"/>
    <td style="width:1.5%;"/>
    <td style="width:1%;"/>
    <td style="width:12.963000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.52%;"/>
    <td style="width:1%;"/>
    <td style="width:12.983%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(33,459</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(27,569</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by (used in) investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,353</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(90,960</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75,257</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net decrease in cash, cash equivalents and restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(76</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(43,272</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">95</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net cash used in operating activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2023, net operating activities used $33.5 million of cash, resulting from our net loss of $36.9 million, adjusted for noncash expenses of $6.0 million, and changes in our operating assets and liabilities of resulting in a use of cash of $2.5 million. Our net loss was attributed to operating expenses of $41.8 million offset by other income (net) of $4.8 million. The change in operating assets and liabilities was primarily due to a decrease in accounts payable and accrued expenses and an increase in prepaid assets.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2022, operating activities used $27.6 million of cash, resulting from our net loss of $35.4 million, adjusted for noncash expenses of $6.1 million, and changes in our operating assets and liabilities resulting in a use of cash of $1.7 million. Our loss was primarily attributed to operating expenses of $36.5 million. The change in operating assets and liabilities was primarily due to an increase in accrued expenses due to the growth in our operating activities following the partial release of the clinical hold in late 2022.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net cash provided by (used in) investing activities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2023, investing activities provided $33.4 million of net cash, resulting from $134.8 million of maturities and sales of marketable securities, which was offset by purchases of $101.2 million in marketable securities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2022, investing activities used $91.0 million of net cash, resulting from purchases of $133.6 million in marketable securities, which was offset by $42.8 million of maturities and sales of marketable securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net cash provided by financing activities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2023, financing activities provided less than $0.1 million of cash from the exercise of stock options and warrants.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the year ended December 31, 2022, financing activities provided $75.3 million of cash from sale of common stock in an underwritten public offering, net of issuance costs.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Capital Requirements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not yet commercialized any products and do not expect to generate revenue from the commercial sale of any products for several years, if at all.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have to date incurred net losses. We incurred net losses of approximately $36.9 million and $35.4 million for the twelve months ended December 31, 2023 and 2022, respectively. As of December 31, 2023, we had an accumulated deficit of $188.6 million and a cash, cash equivalents and marketable securities balance of $86.8 million, excluding restricted cash of $1.3 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Losses have resulted principally from costs incurred in connection with research and development activities, and general and administrative costs associated with the development of nomlabofusp and our operations. We expect to incur significant expenses and operating losses for the foreseeable future as we expect to continue to incur expenses in connection with our ongoing activities, if and as we:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">continue to advance the development of nomlabofusp through additional clinical trials, including related manufacturing costs;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seek to identify and advance development of additional product candidates into clinical development and identify additional indications for our product candidates;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seek to obtain regulatory approvals for nomlabofusp and other potential product candidates;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">identify, acquire or in-license other product candidates and technologies;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maintain, leverage and expand our intellectual property portfolio; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expand our operational, financial, commercial and management systems and personnel, including personnel to support our clinical development and future commercialization efforts and our operations as a public company.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2024, we sold 19,736,842 shares of common stock in an underwritten public offering, net of underwriting discounts and commissions and offering costs of approximately $161.6 million. We anticipate that</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">96</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">these net proceeds, together with our current cash, cash equivalents and marketable securities will fund operations into 2026. If we encounter unexpected delays in our clinical trials or if there are other unanticipated changes to our operating plan from our current assumptions that negatively impact our operations, we may reduce expenditures in order to further extend our existing cash resources. Until we can generate substantial revenue, if ever, we expect to seek additional funding through a combination of public or private equity offerings, debt/royalty financings, collaborations, strategic alliances and licensing arrangements or other sources. The incurrence of indebtedness would result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, minimum cash balances, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There can be no assurance that we will be able to raise sufficient additional capital on acceptable terms, if at all. If such additional financing is not available on satisfactory terms, or is not available in sufficient amounts, or we do not have sufficient authorized shares, we may be required to delay, limit, or eliminate the development of business opportunities and our ability to achieve our business objectives, our competitiveness, and our business, financial condition, and results of operations will be materially adversely affected. We could also be required to seek funds through arrangements with collaborative partners, strategic alliances or otherwise at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects. In addition, geopolitical tensions, volatility of capital markets, and other adverse macroeconomic events, including those due to inflationary pressures, rising interest rates, bank instability and the ability of the U.S. government to manage federal debt limits, as well as the potential impact of health crises on the global financial markets may reduce our ability to access capital, which could negatively affect our liquidity and ability to continue as a going concern.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to obtain sufficient funding when needed and/or on acceptable terms, we may be required to significantly curtail, delay or discontinue one or more of our research and development programs, the manufacture of clinical and commercial supplies, product portfolio expansion and/or pre commercialization efforts, which could adversely affect our business prospects, or we may be unable to continue operations. Certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recently Issued Accounting Pronouncements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Please read Note 2 to our audited consolidated financial statements included in Part IV, Item 15, of this Annual Report for a description of recent accounting pronouncements applicable to our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other Company Information</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">97</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item7aquantitativeandqualitativedisclosu"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not<br/> required to provide the information required under this item.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item8financialstatementsandsupplementary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our audited consolidated financial statements and the report of our independent registered public accounting firm are included in this Annual Report on Form 10-K on the pages indicated in Part IV, Item 15.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item9changesinanddisagreementswithaccoun"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item9acontrolsandprocedures_737107"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 9A. CONTROLS AND PROCEDURES</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We maintain &#8220;disclosure controls and procedures,&#8221; as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our principal executive and our principal financial officers, as appropriate, to allow timely decisions regarding required disclosure.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">With respect to the year ended December 31, 2023, under the supervision and with the participation of our management, we conducted an evaluation of the effectiveness of the design and operations of our disclosure controls and procedures. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of December 31, 2023 to provide reasonable assurance that the information required to be disclosed by us in this Annual Report was (a) reported within the time periods specified by SEC rules and regulations and (b) communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding any required disclosure.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control &#8211; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on our evaluation under that framework, our management concluded that our internal control over financial reporting was effective as of December 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended December 31, 2023, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">98</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item9botherinformation_654168"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 9B. OTHER INFORMATION</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(a) None.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(b) During the fourth quarter of the fiscal year ended December 31, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_45bce1aa-6082-4606-8a7a-92a065c00edf" contextRef="C_f1669ee1-0407-437f-848e-7c1d63a35e33" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_76f715a8-955e-452d-a468-0ed5fa1f47ea" contextRef="C_f1669ee1-0407-437f-848e-7c1d63a35e33" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_b92fa2ca-85d5-4b95-8753-a8d31193fb23" contextRef="C_f1669ee1-0407-437f-848e-7c1d63a35e33" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_5f166b7e-d5cd-4976-9a1e-d9fe39fab658" contextRef="C_f1669ee1-0407-437f-848e-7c1d63a35e33" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">no</span></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> director or &#8220;officer&#8221; as defined in Rule 16a-1(f) under the Exchange Act adopted or terminated any Rule 10b5-1 trading plan or arrangements or any non-Rule 10b5-1 trading plan or arrangements, in both cases as defined in Item 408(a) of Regulation S-K.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item9cforeignjurisdictions"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">99</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="partiii_936646"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART III</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item10directorsexecutiveofficersandcorpo"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 10.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by Item 10 of Form 10-K is incorporated by reference to the information contained in our definitive proxy statement for the 2024 annual meeting of stockholders.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item11executivecompensation_214372"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 11.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">EXECUTIVE COMPENSATION</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by Item 11 of Form 10-K is incorporated by reference to the information contained in our definitive proxy statement for the 2024 annual meeting of stockholders.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item12securityownershipofcertainbenefici"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by Item 12 of Form 10-K is incorporated by reference to the information contained in our definitive proxy statement for the 2024 annual meeting of stockholders.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item13certainrelationshipsandrelatedtran"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by Item 13 of Form 10-K is incorporated by reference to the information contained in our definitive proxy statement for the 2024 annual meeting of stockholders.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item14principalaccountingfeesandservices"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 14.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PRINCIPAL ACCOUNTING FEES AND SERVICES</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our independent accounting firm is </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f1855b0b-3ca7-4a7b-8855-ffed8b4570f3" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PricewaterhouseCoopers LLP</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f242e56a-b88f-40b4-81c8-131db9a5e644" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Philadelphia, Pennsylvania, USA</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, PCAOB Auditor ID: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c0fc958d-7725-48b9-a820-d4a9d5562e01" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="dei:AuditorFirmId"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">238</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by Item 14 of Form 10-K is incorporated by reference to the information contained in our definitive proxy statement for the 2024 annual meeting of stockholders.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">100</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="partiv_994849"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART IV</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item15exhibitsfinancialstatementschedule"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 15.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">EXHIBITS, FINANCIAL STATEMENT SCHEDULES</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Financial Statements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See Index to the Consolidated Financial Statements on page F-1 of this Annual Report.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. Financial Statement Schedules</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None, as all information required in these schedules is included in the Notes to the Consolidated Financial Statements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3. Exhibits</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Reference is made to the Exhibit Index below for a list of exhibits required by Item 601 of Regulation S-K to be filed as part of this Annual Report.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item6_exhibits"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following exhibits are being filed herewith:</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">101</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="exhibit_index"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> INDEX</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">* Filed Herewith</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">+ Certain confidential portions (indicated by brackets and asterisks) have been omitted from this exhibit</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">** Furnished herewith. This certification will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, except to the extent specifically incorporated by reference into such filing.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:17.18%;"/>
    <td style="width:1.18%;"/>
    <td style="width:81.64%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;text-indent:7.2pt;padding-left:0.003in;vertical-align:top;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;text-align:center;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit No.</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;border-bottom:1pt solid #ffffff03;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.007in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.007in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.1</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001374690/000119312519316828/d845901dex21.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Agreement and Plan of Merger, dated as of December 17, 2019, by and among Zafgen, Inc., Chondrial Therapeutics, Inc., Chondrial Therapeutics Holdings, LLC, and Zordich Merger Sub, Inc. (incorporated by reference to Exhibit 2.1 of the Company&#8217;s Current Report on Form 8-K filed on December 18, 2019).</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.2</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001374690/000119312520065288/d846972dex21.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amendment No. 1 to Agreement and Plan of Merger, dated as of March 6, 2020, by and among Zafgen, Inc., Chondrial Therapeutics, Inc., Chondrial Therapeutics Holdings, LLC, and Zordich Merger Sub, Inc. (incorporated by reference to Exhibit 2.1 of the Company&#8217;s Current Report on Form 8-K filed on March 6, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1374690/000119312514247362/d747935dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Ninth Amend</span><span style="color:#0000cc;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">ed </span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">and Restated Certificate of Incorporation of Larimar Therapeutics, Inc. (formerly known as Zafgen, Inc.) (incorporated by reference to Exhibit 3.1 of the Company&#8217;s Current Report on Form 8-K filed on June 24, 2014).</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.2</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1374690/000119312520157924/d936040dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certificate of Amendment of Ninth Amended and Restated Certificate of Incorporation of Zafgen, Inc. related to the Reverse Stock Split, dated May 28, 2020 (incorporated by reference to Exhibit 3.1 of the Company&#8217;s Current Report on Form 8-K filed on June 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.3</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1374690/000119312520157924/d936040dex32.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certificate of Amendment of Ninth Amended and Restated Certificate of Incorporation of Zafgen, Inc. related to the Name Change, dated May 28, 2020 (incorporated by reference to Exhibit 3.1 of the Company&#8217;s Current Report on Form 8-K filed on June 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.4</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1374690/000119312514247362/d747935dex32.htm"><span style="color:#0000cc;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated By-laws of Larimar Therapeutics, Inc. (formerly known as Zafgen, Inc.) (incorporated by reference to Exhibit 3.2 of the Company&#8217;s Current Report on Form 8-K filed on June 24, 2014)</span></a><span style="color:#0000cc;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1374690/000156459021011003/lrmr-ex42_407.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Description of the Company&#8217;s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (incorporated by reference to Exhibit 4.2 of the Company&#8217;s Annual Report on Form 10-K filed March 4, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1374690/000119312520257168/d887315dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Larimar Therapeutics, Inc. 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Current Report on Form 8-K filed on September 29, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1374690/000119312520257168/d887315dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Larimar Therapeutics, Inc. Form of Stock Option Grant Notice and Award Agreement under its 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 of the Company&#8217;s Current Report on Form 8-K filed on September 29, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.3*</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lrmr-ex10_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Restricted Stock Award Agreement for Company Employees under the Larimar Therapeutics, Inc. 2020 Equity Incentive Plan.</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.4*</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lrmr-ex10_4.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Non-Qualified Stock Option Grant Notice and Award Agreement.</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.5</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001374690/000119312520157924/d936040dex102.htm"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Registration Rights Agreement, dated as of June 1, 2020, by and among the Company and certain Investors (incorporated by reference to Exhibit 10.2 of the Company&#8217;s Current Report on Form 8-K filed on June 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.6</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001374690/000119312520181162/d926045dex103.htm"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Registration Rights Agreement, dated as of June 8, 2020, by and among the Company and certain Investors (incorporated by reference to Exhibit 10.3 of the Company&#8217;s Registration Statement on Form S-3 filed on June 26, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.7</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001374690/000119312520157924/d936040dex103.htm"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Indemnification Agreement between the Company and its directors (incorporated by reference to Exhibit 10.3 of the Company&#8217;s Current Report on Form 8-K filed on June 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.8</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1374690/000119312520211426/d82303dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Employment Agreement, dated July 31, 2020, by and between the Company and Carole Ben-Maimon (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Current Report on Form 8-K filed on August 6, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.9</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001374690/000119312520157924/d936040dex104.htm"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Employment Agreement, dated June 1, 2020, by and between the Company and Michael Celano (incorporated by reference to Exhibit 10.4 of the Company&#8217;s Current Report on Form 8-K filed on June 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.10</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1374690/000119312523026958/d399840d8k.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Employment Agreement, dated February 7, 2023, by and between the Company and Gopi Shankar (incorporated by reference to Exhibit 10.10 of the Company&#8217;s Annual Report on Form 10-K filed on March 14, 2023).</span></a></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">102</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:17.18%;"/>
    <td style="width:1.18%;"/>
    <td style="width:81.64%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.11</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1374690/000095017023041293/lrmr-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Employment Agreement dated May 23, 2023, by and between the Company and Russell Clayton (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Quarterly Report on Form 10-Q filed on August 10, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.12**</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1374690/000156459020040314/lrmr-ex106_306.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">License Agreement, by and between the Company and Wake Forest University Health Sciences, effective as of November 30, 2016. (incorporated by reference to Exhibit 10.6 of the Company&#8217;s Quarterly Report on Form 10-Q filed on August 14, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.13**</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1374690/000156459020040314/lrmr-ex107_305.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amendment 1 to License Agreement, by and between the Company and Wake Forest University Health Sciences, effective as of November 28, 2017 (incorporated by reference to Exhibit 10.7 of the Company&#8217;s Quarterly Report on Form 10-Q filed on August 14, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.14**</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1374690/000156459020040314/lrmr-ex108_304.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amendment 2 to License Agreement, by and between the Company and Wake Forest University Health Sciences, effective as of March 29, 2019 (incorporated by reference to Exhibit 10.8 of the Company&#8217;s Quarterly Report on Form 10-Q filed on August 14, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.15**</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1374690/000156459020040314/lrmr-ex109_303.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">License Agreement, by and between the Company and Indiana University Research and Technology Corporation, effective as of November 30, 2016 (incorporated by reference to Exhibit 10.9 of the Company&#8217;s Quarterly Report on Form 10-Q filed on August 14, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.16**</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1374690/000156459020040314/lrmr-ex1010_302.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">First Amendment to License Agreement, by and between the Company, the Trustee of Indiana University and Indiana University Research and Technology Corporation, effective as of August 16, 2019 (incorporated by reference to Exhibit 10.10 of the Company&#8217;s Quarterly Report on Form 10-Q filed on August 14, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.17</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1374690/000095017022016917/lrmr-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Second Amendment to License Agreement, by and between the Company and The Trustees of Indiana University, effective as of May 28, 2020 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed on August 11, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.18</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1374690/000095017022016917/lrmr-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Third Amendment to License Agreement, by and between the Company and The Trustees of Indiana University, effective as of June 9, 2022 (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed on August 11, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.19</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001374690/000119312520181158/d913803dex45.htm"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Notice of Substitute Option Grant between the Company and a certain Optionee (incorporated by reference to Exhibit 4.5 of the Company&#8217;s Registration Statement on Form S-8 filed on June 26, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.20*</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lrmr-ex10_20.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Lease, dated as of August 8, 2019, by and between Larimar Therapeutics, Inc. and Bala Plaza Property, Inc.</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.21*</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lrmr-ex10_21.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">First Amendment to Lease, dated as of March 9, 2023, by and between the Company and Bala Plaza Property, Inc.</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;min-width:fit-content;">10.22</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1374690/000156459019018086/zfgn-ex104_74.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Commercial Lease by and between the Company and Shigo Center Plaza Owner, LLC dated as of February 12, 2019 (incorporated herein by reference to Exhibit 10.4 of the Registrant&#8217;s Form 10-Q filed on May 9, 2019)</span></a><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;min-width:fit-content;">10.23</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1374690/000119312520282731/d37391dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Sublease, dated October 27, 2020 by and between the Company and Massachusetts Municipal Association, Inc. (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on October 30, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;min-width:fit-content;">10.24</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001374690/000156459021026084/lrmr-ex101_148.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Master Services Agreement, dated as of September 20, 2017, by and between the Company and KBI Biopharma, Inc. (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed on May 10, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;min-width:fit-content;">10.25</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001374690/000156459021026084/lrmr-ex102_147.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">First Amendment to Master Services Agreement, dated as of November 9, 2018, by and between the Company and KBI Biopharma, Inc. (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed on May 10, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;min-width:fit-content;">10.26</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1374690/000095017023007855/lrmr-ex10_23.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Second Amendment to Master Services Agreement, dated as of September 20, 2022, by and between the Company and KBI Biopharma, Inc. (incorporated by reference to Exhibit 10.23 to the Company&#8217;s Form 10-K filed on March 14, 2023)</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.1*</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lrmr-ex21_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Subsidiaries of Larimar Therapeutics, Inc.</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23.1*</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lrmr-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm.</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.1*</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lrmr-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Rule 13a-14(a)/15d-14(a) certification of Principal Executive Officer.</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.2*</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lrmr-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Rule 13a-14(a)/15d-14(a) certification of Principal Financial Officer.</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32.1**</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="lrmr-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Section 1350 certification of the Principal Executive Officer and Principal Financial Officer, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97.1*</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lrmr-ex97_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Larimar Therapeutics. Inc.&#8217;s Compensation Recovery Policy</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.INS</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Instance Document</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.SCH</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.CAL</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.DEF</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.LAB</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Label Linkbase Document</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.PRE</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">103</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16_form_10k_summary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 16. Form </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10-K Summary</span></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">104</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span><span id="signatures_181481"></span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"/>
    <td style="width:3.78%;"/>
    <td style="width:46.22%;"/>
   </tr>
   <tr style="height:0.7pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:0;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:0;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:0;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">LARIMAR THERAPEUTICS, INC.</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Carole S. Ben-Maimon, M.D.</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.007in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name: Carole S. Ben-Maimon, M.D.</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title: President and Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:33.14%;"/>
    <td style="width:2.7%;"/>
    <td style="width:40.48%;"/>
    <td style="width:2.7%;"/>
    <td style="width:20.98%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Signature</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;border-bottom:1pt solid #ffffff03;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;border-bottom:1pt solid #ffffff03;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.007in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.007in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.007in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Carole S. Ben-Maimon, M.D.</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;border-bottom:1pt solid #ffffff03;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;border-bottom:1pt solid #ffffff03;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">President, Chief Executive Officer and Director (principal executive officer)</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 14, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.007in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Carole S. Ben-Maimon, M.D.</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Michael Celano</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;border-bottom:1pt solid #ffffff03;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;border-bottom:1pt solid #ffffff03;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer<br/>(principal financial and accounting officer)</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 14, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.007in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Michael Celano</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Joseph Truitt</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;border-bottom:1pt solid #ffffff03;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;border-bottom:1pt solid #ffffff03;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chairman, Board of Directors</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 14, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.007in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Joseph Truitt</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Thomas E. Hamilton</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;border-bottom:1pt solid #ffffff03;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;border-bottom:1pt solid #ffffff03;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 14, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.007in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Thomas E. Hamilton</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Jonathan Leff</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;border-bottom:1pt solid #ffffff03;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;border-bottom:1pt solid #ffffff03;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 14, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.007in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Jonathan Leff</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Jeffrey W. Sherman, M.D., FACP</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;border-bottom:1pt solid #ffffff03;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;border-bottom:1pt solid #ffffff03;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 14, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.007in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Jeffrey W. Sherman, M.D., FACP</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Frank E. Thomas</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;border-bottom:1pt solid #ffffff03;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;border-bottom:1pt solid #ffffff03;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 14, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.007in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Frank E. Thomas</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">105</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INDEX</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:93.94%;"/>
    <td style="width:6.06%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#report_independent_registered_public_acc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Report of Independent Registered Public Accounting Firm (PCAOB ID </span><span><ix:nonNumeric id="F_7b60c641-7d69-4e20-a393-d202db5b3b10" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="dei:AuditorFirmId"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">238</span></ix:nonNumeric></span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">)</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_consolidated_balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Balance Sheets as of December 31, 2023 and 2022</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_consolidated_statements_operat"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2023 and 2022</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_consolidated_statements_change"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Changes in Stockholders Equity for the years ended December 31, 2023 and 2022</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_consolidated_statements_cash_f"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Cash Flows for the years ended December 31, 2023 and 2022</span></a></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_condensed_consolidated_financia"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">106</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="report_independent_registered_public_acc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the Board of Directors and Stockholders of Larimar Therapeutics, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Opinion on the Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Larimar Therapeutics, Inc. and its subsidiary (the &#8220;Company&#8221;) as of December 31, 2023 and 2022, and the related consolidated statements of operations and comprehensive loss, of changes in stockholders' equity and of cash flows for the years then ended, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis for Opinion</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Critical Audit Matters</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accrued Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As described in Notes 2 and 6 to the consolidated financial statements, the Company recognizes external research and development costs based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its key service providers. Within accrued expenses, total accrued research and development expenses amounted to $4.6 million as of December 31, 2023. Management&#8217;s process involves reviewing open contracts and purchase orders, communicating with personnel and outside vendors to identify services that have been performed, and estimating the level of service performed and the associated costs incurred for the services when invoices or other notification of actual costs have not been received.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The principal considerations for our determination that performing procedures relating to accrued research and development expenses is a critical audit matter are (i) the significant judgment by management in developing the estimates of accrued research and development expenses and (ii) a high degree of auditor judgment, subjectivity and effort in performing procedures and evaluating audit evidence for these accrued research and development expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">related to management&#8217;s estimates of the level of service performed and the associated costs incurred for the services when invoices or other notification of actual costs have not yet been received.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the financial statements. These procedures also included, among others; (i) testing management&#8217;s process for estimating accrued research and development expenses; (ii) evaluating the appropriateness of the method used by management to develop the estimate; (iii) testing the completeness and accuracy of the data used by management to develop the estimates related to the level of service performed and the associated costs incurred for the services when invoices or other notification of actual costs have not yet been received; (iv) evaluating the reasonableness of the estimated costs incurred for the services which have not been invoiced or other notification of actual costs have not yet been received, on a sample basis, by tracing to underlying supporting documentation, such as underlying contracts, invoices and information received from certain third party service vendors, where applicable, and; (v) testing a selection of invoices received by the Company subsequent to December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ PricewaterhouseCoopers LLP</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Philadelphia, Pennsylvania</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 14, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have served as the Company&#8217;s auditor since 2020.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">LARIMAR THERAPEUTICS, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_consolidated_balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDAT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ED BALANCE SHEETS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(In thousands, except share and per share data)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current assets:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dfaa878d-5bc2-462f-b591-fb10c89d4d67" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,749</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f124128-b4cc-47ea-ab13-8ca4f6c6f8f3" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,825</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95c01a93-2c9a-44bf-b1f5-72a4e4d143d9" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60,041</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_54270f3c-f6e0-4956-8699-8cc5d7e17274" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91,603</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_86a858b6-8ac6-4c76-bc63-f174acc58def" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,385</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dc1c6733-8fe1-4174-99ea-d1865309d15b" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,311</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd19c352-460c-4179-9de9-70dd1bd083cd" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">90,175</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c045896-df20-4935-a754-c37ca5779469" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">120,739</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_92451b4d-f1c3-4b10-9da5-ae8fdfcbc984" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">684</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d0181589-5ff3-4c86-af29-f1a0c27a009d" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">831</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a9d3d5f-96fd-41bd-b000-973ef5ea239a" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,078</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34b828a6-c496-4956-9d17-a91b8d5e60d6" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,858</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_75238b7f-bd0a-44f5-b47c-6fe5bb1fb79c" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,339</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_85f2bb5b-2c51-4bc8-9b42-d349a39dbb03" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,339</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e643ddba-2f99-48f8-bab3-6ebe330628b9" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">659</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be8c00cd-b0fe-4390-84c0-57324f431338" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">638</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d3a1b56-d3ca-4710-b8d1-5a7b70001f1a" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">95,935</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a65aa946-2896-4691-b2c5-4eb7887eed26" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">126,405</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Liabilities and Stockholders&#8217; Equity</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_53bc8a20-de14-4c50-b4bf-c4a5c470ed47" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,283</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7db7ca2a-0859-45b6-9721-000f98d14cb3" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,686</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_23d7e63e-5437-4b0f-b3ba-c73374a19578" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,386</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5b5619c7-d573-4e2e-aae9-b3de0ee48c39" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,408</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities, current</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a33b8df1-cc46-4749-b39b-696b68bfe45f" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">837</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f7f11077-e90a-446f-b9e7-381e9fe6492b" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">611</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3590a564-05e3-4215-a751-8d953e4959f4" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,506</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_66511f24-c4d7-4097-999e-385daaf50bcf" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,705</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_06e6eaeb-1cc2-4d67-8327-2c375fb9c6d2" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,709</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be934d7b-e80a-4a39-be6b-c36e706b68fc" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,797</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_457c1c10-195d-4194-acf1-c38ac2e5e2a6" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,215</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1182dd4d-c964-43a1-92e9-4eceb2f30f5e" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,502</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_68573a87-9368-4180-b1d5-870fdebccda7;"><span style="-sec-ix-hidden:F_5793ff2a-5e93-4e6d-badc-77a0ddfc5bbb;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commitments and contingencies (See Note 8)</span></span></span></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stockholders&#8217; equity:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Preferred stock; $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de52b56d-15e8-499b-8782-d487729c50a2" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_22e53b8d-74b9-4abb-b2b2-0d717eb2de2c" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value per share; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_613d8687-10da-4b7f-bccb-9be0ff18aa38" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_105bd887-fc19-4854-863b-449627f2d879" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares authorized<br/>&#160;&#160;&#160;as of December 31, 2023 and December 31, 2022; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0fab3a0c-babc-4966-b945-b2721b61f137" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_81cae4ed-c208-4f42-869e-2edabd042b89" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_156d7866-c581-45e1-9c93-96e6ba68c6c9" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_3a45f377-0560-41cd-995b-0f7361e024c0" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares issued and<br/>&#160;&#160;&#160;outstanding as of December 31, 2023 and December 31, 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_b02ed5cb-0a60-495a-a92c-8887d3f31d3b;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></span></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_9e6f1fc1-938c-4d9f-b37c-b85697a3850a;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></span></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock, $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e2fa6ea5-9223-4cc3-9096-7f80e957ad97" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b41e191b-6811-4d6b-90cb-60724b5a65bd" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value per share; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_996c550a-7074-4535-b71a-63dec6a67a5d" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_5505976f-7dc5-41ae-b7bb-2670c2eda425" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">115,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares<br/>&#160;&#160;&#160;authorized as of December 31, 2023 and December 31, 2022; <br/>&#160;&#160;</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8cb3ed0d-c5dd-4d49-9a0b-c87088e7402e" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_df58f490-55b8-422f-a128-fb6c8737de45" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">43,909,069</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;and </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ea3ea2e-31c4-42bd-9d9c-53ed4d8d603e" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_4349e05e-d30f-4eb4-9484-d3510a0d1905" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">43,269,200</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares issued and outstanding as of <br/>&#160;&#160;&#160;December 31, 2023 and December 31, 2022, respectively</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_19082c79-4363-4152-bc8e-d65b00bb53e7" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_079049b3-0a79-4603-9cdb-c9515fb8499c" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_71f8fc97-83ff-4ebd-a710-a8a9c6e3aeef" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">270,150</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ca472570-c1c9-485b-a92d-71497a72af43" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">262,496</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_85a801cf-ec43-46f8-9146-1a7d80e05746" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">188,554</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1692723b-bda1-4bfc-bbce-afe219e07df9" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">151,605</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated other comprehensive gain (loss)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_115ceedf-6940-4669-907b-b49030210ff6" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4109db41-21af-47bb-81d4-faf451e46807" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">31</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stockholders&#8217; equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9021bdf2-9444-4efe-8acd-9ff34d5d54dc" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81,720</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_750df9ed-3449-41ec-bbe1-612ba603a02d" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">110,903</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities and stockholders&#8217; equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9dc3ef48-ba59-46f9-a6ac-6d4769eb05b0" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">95,935</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_890308ad-c6dc-48d6-8acf-58a4c610fdf1" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">126,405</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">LARIMAR THERAPEUTICS, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_consolidated_statements_operat"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED STATEMENTS OF</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> OPERATIONS AND COMPREHENSIVE LOSS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(In thousands, except share and per share data)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e5c4502c-3d7d-4d35-892b-828449eacd22" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,670</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4bfe56de-dd62-48f9-8923-fd0d5f1e6a0c" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,250</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a07bf621-2467-4fa5-a8d4-08117dfdafe4" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,088</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8e1fc070-0e6e-4e4e-8541-b19aecc199f0" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,276</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9fc8feca-83fb-4985-a18b-16d5ccae9832" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,758</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_604df18e-9da7-4047-8bd1-345064119460" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,526</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_093c07c8-a971-46ea-8b00-1329019cc009" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">41,758</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_50b61f38-6fbd-42b0-bdb5-743ee8a9aa81" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">36,526</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income (expense), net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_85c9ce68-3dbd-4a26-aa68-364bf330e1e0" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,809</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34b6af8d-4872-4637-befe-2ebd3134762b" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,171</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9869b22e-af9a-4e21-a007-293715151054" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">36,949</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_75273e31-44f1-4243-a5d5-f2942c64d59f" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">35,355</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d5f72b20-727d-429f-8b46-b068f6e884c2" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_922c9206-1887-4d8a-88e3-89a685071165" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.84</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_594bb64b-2347-410a-9645-814ca4f241dd" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_cff1cbd2-bb26-4d63-b1d1-4bb4cc8ebf32" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.37</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average common shares outstanding, basic and diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3cfdf0af-35de-4304-8280-a04c6e79a088" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_2477610f-ed1f-4eab-941c-aa58211add59" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">43,901,241</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5b0e8153-225c-4e23-a0f9-9d1ac006ea62" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_2e0815f4-3289-4cd8-87c1-eaad9c3aa082" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">25,761,394</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Comprehensive loss:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c04e520e-c9c5-4a86-87d5-0c37646e2e02" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">36,949</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_edbe7dcb-ba1c-4f5e-adb0-06328c7f76c4" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">35,355</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other comprehensive loss:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized gain (loss) on marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27f0ea33-ecce-4220-9bf4-e2a14d37972f" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">112</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6db9509d-a0fa-4dd7-b6ef-eb1698c72255" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">31</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total other comprehensive gain (loss)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_703428ee-fe16-4ef4-88a8-16e6e0d0f540" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">112</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f7fed643-f2c7-4c41-8a34-6e0cfea6c537" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">31</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c20f0e88-87fe-453d-bb15-268d4481f507" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">36,837</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ebce6160-e757-44d0-84c4-1814afa940d0" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">35,386</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">LARIMAR THERAPEUTICS, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_consolidated_statements_change"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED STATEMENTS O</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F CHANGES IN</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">STOCKHOLDERS&#8217; EQUITY</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(In thousands, except share data)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:39.828%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.441%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.941%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.941%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.941%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.941%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.961%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additional</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Other</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Paid-in</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Comprehensive</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Stockholders&#8217;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Par Value</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Capital</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deficit</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gain (Loss)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Equity</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balances as of December 31, 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ee5e293-662d-46e6-bb52-fc1b7e9f56ae" contextRef="C_7edb1b10-e53a-422a-9a1e-e81b7d59c086" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">43,269,200</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11bfc6b9-bd7f-47e9-b7d9-ee402a164902" contextRef="C_7edb1b10-e53a-422a-9a1e-e81b7d59c086" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_16517f5f-07c9-480f-baa6-6416639150b6" contextRef="C_b312098e-3ef4-4545-b143-2d83afce1c16" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">262,496</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4787f92e-3aef-4090-aa5f-7715855965e8" contextRef="C_88192957-9603-4bc3-a321-f4c70d5a065f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">151,605</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_68a7dd57-672f-44e4-aa54-0ffd8b8f456e" contextRef="C_8d3107c2-8938-4cdd-a26e-1dde989d7e23" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">31</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_447b6ee2-f238-4563-ba85-08fbd807b8ab" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">110,903</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd21daff-b46d-4e67-9d93-a65b552edced" contextRef="C_df56d690-57ac-45e5-928f-f00b6eb9e578" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,615</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2dd44e6d-0709-4ff1-83c9-9bbc5f2333e2" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,615</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise of stock options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a3564b8-741a-48bd-aba8-33dc3d6c5f6a" contextRef="C_9592d411-a0cd-4a54-9714-8ba1a249205b" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">11,466</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ff6d0b8-25dd-4468-8ce9-b21eab46a2bf" contextRef="C_df56d690-57ac-45e5-928f-f00b6eb9e578" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aed69174-2077-44b3-8beb-1792de8da006" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise of warrants</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f3fc9b6e-5463-4e32-99b9-0cbaa0b654ce" contextRef="C_9592d411-a0cd-4a54-9714-8ba1a249205b" name="lrmr:StockIssuedDuringPeriodSharesExerciseOfWarrants" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">628,403</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a0c2069-2a82-4418-9320-f20d9efe7e41" contextRef="C_df56d690-57ac-45e5-928f-f00b6eb9e578" name="lrmr:StockIssuedDuringPeriodValueExerciseOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d432360a-f11a-4640-9482-efdac3581d16" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="lrmr:StockIssuedDuringPeriodValueExerciseOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized gain on marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b3646b6a-e581-4478-9e60-ce7f6983e0ff" contextRef="C_7c80164a-e618-431e-908f-17026b8e4ae2" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">112</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_143ccab9-a094-45c9-9c2d-1dfac4859641" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">112</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_14ab6502-1582-487a-b528-431e3fd2247a" contextRef="C_5602ff77-c44f-4314-9ff2-70c3f8d3ba31" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">36,949</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a78c2291-e72f-4eec-ae52-7b33cd812d61" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">36,949</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balances as of December 31, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_83b53ca4-f27a-4b75-87c0-060f0f69e2df" contextRef="C_69cb0fb5-da69-40e6-80bc-099615cd64ea" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">43,909,069</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_71e4aaa8-f057-47a2-86d2-cb4b0a469ebc" contextRef="C_69cb0fb5-da69-40e6-80bc-099615cd64ea" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_92c4ce5e-467f-42fe-a4eb-b69deecd64cf" contextRef="C_b9dcce0a-1f1b-450f-80d2-41ae1be44f56" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">270,150</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a20d510-73f0-4277-acb7-4a8d691d1b2c" contextRef="C_cfbfa2af-4b87-40ab-a789-900833fd126d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">188,554</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_886255c1-5abe-431f-ae38-77e1e3bfda7b" contextRef="C_41a0d33b-53ab-4ae8-bdba-87ffec128add" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b9a128e-092d-46f1-ab0c-a3cf4d3c2552" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81,720</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:39.828%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.441%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.941%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.941%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.941%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.941%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.961%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additional</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Other</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Paid-in</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Comprehensive</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Stockholders&#8217;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Par Value</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Capital</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deficit</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Loss</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Equity</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balances as of December 31, 2021</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c297dec2-847c-4e50-bab9-8f9840bb02f9" contextRef="C_f93fcf7c-172c-4854-bab6-8d8a70725f95" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">17,710,450</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_85c98b8e-a5c1-48d0-acc5-e565e8b65e92" contextRef="C_f93fcf7c-172c-4854-bab6-8d8a70725f95" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_517bc8dc-5165-4459-a2b9-5e151a2e5c76" contextRef="C_510b971c-d3fe-4984-9d53-6865328abecd" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">180,645</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ea54650-900b-461b-8465-48fcd746f647" contextRef="C_8ad4ebd6-202a-41f5-854f-4158140e7f04" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">116,250</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_32ae919f-867a-4bf7-a69b-b903f9b93967" contextRef="C_cb46581b-8c63-4fee-b4c7-cc9ee9a93a21" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,413</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of Common Stock, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d9cc242-e715-4b97-b3e4-c729e7059f7d" contextRef="C_4b5e3f0d-190b-43a0-915d-81748af18c9f" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">25,558,750</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_881a1ef8-6e55-4fb1-8a2d-5c31a149467d" contextRef="C_4b5e3f0d-190b-43a0-915d-81748af18c9f" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ff26bd5-4388-472a-80f0-b80a8178d40b" contextRef="C_e5052803-8e24-4b5c-bf1d-feeb356d8445" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75,232</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0b94d19c-9320-40c4-9cd6-cda49bdc6c7c" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75,257</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef674291-af7f-4c30-82c5-89c59a4f06d0" contextRef="C_e5052803-8e24-4b5c-bf1d-feeb356d8445" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,619</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e200929c-a99c-4186-8b6b-0aefc91e785e" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,619</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized loss on marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc7748e6-46d8-422e-bf69-58a7f1d180ce" contextRef="C_e9f9b4ac-b65e-40cf-8ab9-8f0d09a73535" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">31</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80b45e78-7feb-48f3-bce0-53cbc45edbea" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">31</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1281c0b1-8f11-4256-8ff8-13ea06dec0b6" contextRef="C_7812fd06-a01a-48d2-ab1b-3ad1ddddf263" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">35,355</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e44cc253-9574-4dd2-8eb1-fe2d3b659887" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">35,355</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balances as of December 31, 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f5b0447e-0b68-4c31-96f8-83030c545fba" contextRef="C_7edb1b10-e53a-422a-9a1e-e81b7d59c086" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">43,269,200</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f74d457-637e-4aab-899d-a7197070fbd8" contextRef="C_7edb1b10-e53a-422a-9a1e-e81b7d59c086" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_66049c01-aa36-4100-9984-284ee69d3b37" contextRef="C_b312098e-3ef4-4545-b143-2d83afce1c16" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">262,496</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e46b3686-1add-4d33-897b-cb354ff7d797" contextRef="C_88192957-9603-4bc3-a321-f4c70d5a065f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">151,605</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_96d8f92d-3137-493f-a578-466e99f82ea3" contextRef="C_8d3107c2-8938-4cdd-a26e-1dde989d7e23" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">31</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bdf25206-ab3a-4756-81f2-f77ab18e1bf7" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">110,903</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">LARIMAR THERAPEUTICS, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_consolidated_statements_cash_f"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED ST</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ATEMENTS OF CASH FLOWS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(In thousands)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:72.995%;"/>
    <td style="width:1.32%;"/>
    <td style="width:1%;"/>
    <td style="width:10.182%;"/>
    <td style="width:1%;"/>
    <td style="width:1.32%;"/>
    <td style="width:1%;"/>
    <td style="width:10.182%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">   </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">  </span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash flows from operating activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27c1b753-4ac2-4f45-8144-f7ec9c1efd41" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">36,949</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dca4a8a7-65c6-4960-8903-0434d2254c1b" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">35,355</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">   </span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">   </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f8cb40ac-c2b3-4fdc-bd3d-0b0ec1750f13" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,615</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a5c69306-475e-4dcb-aea8-ddd0f5a008ae" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,619</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease expense</span></p></td>
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a207d581-e53f-462b-98f4-e839778637d6" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="lrmr:CashAndNonCashOperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">82</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_70c72613-7dc1-4068-a1f3-3be17c8123ec" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="lrmr:CashAndNonCashOperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">46</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation expense</span></p></td>
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f2fff81-2ae4-40d9-812c-a4d956bef6d8" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">311</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_971ca7e3-c0be-47ae-88c8-7c2fe4527e49" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">318</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization of discount on marketable securities</span></p></td>
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29fe295a-8c62-46e1-8e06-6c8bda20818b" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:AmortizationOfDebtDiscountPremium" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,843</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8108fbcd-dc13-469f-8a04-62dcb666d143" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:AmortizationOfDebtDiscountPremium" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">774</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">   </span></p></td>
    <td colspan="2" style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11816cbb-3edc-4dc1-b397-ccd7b54608f2" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,065</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f37ffd55-827a-4448-a89f-69a1f10fff91" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">204</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ef7fb04-acc6-4efd-ab9a-3c5f8e53b753" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">403</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ade19061-aa90-43ea-b19e-7f4325fdbce3" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses</span></p></td>
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c8964aea-cd95-4871-8705-2874f2dc022f" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,022</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_149da19d-124e-4add-aa83-98613f8a514f" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,816</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets</span></p></td>
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_52e78546-a047-4247-9440-ba78549af8f8" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e23efc6e-9785-4b97-a661-a7f5d8820358" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">31</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in operating activities:</span></p></td>
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4a6213e-eeb6-4a63-9831-cea7ef850d70" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">33,459</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d074ad88-bb2b-4cc9-8e34-5c56379203cf" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">27,569</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash flows from investing activities:</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">   </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">   </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchase of property and equipment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7759c14-e778-49e8-b856-a42a734e1607" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">164</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e55551b5-7391-4902-b985-b137d5d468a5" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchase of marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d9b18d70-6c34-49fd-a02b-f896f3331d62" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">101,233</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_30aedbd3-4e36-4636-b2da-9508a4d600c0" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">133,610</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Maturities and sales of marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a79a0d2b-7eaf-4f2e-a7fa-90cea5448e5e" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">134,750</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb4fbf76-caf0-4803-9fb7-5ab135b88b08" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,750</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by (used in) investing activities</span></p></td>
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce03c79c-9668-41ab-a80f-ae8420bbdeec" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,353</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b6c0201-bfae-44cf-9d5a-6812d45bb357" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">90,960</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash flows from financing activities:</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">   </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">   </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from sale of common stock, net of issuance costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_841e95a5-a037-4d6a-81eb-cee484f277fc" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75,257</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from exercise of stock options and warrants</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e43600e8-d8c0-4926-bcac-2df3ffef6356" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="lrmr:ProceedsFromExerciseOfStockOptionsAndWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2589bb3a-e132-4b3c-90dd-dc4698f7cbb6" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0be1031f-81c3-4fdc-a42e-f6e64fb17ed3" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75,257</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Net decrease in cash, cash equivalents and restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd745cc2-94dd-4526-b2ee-13beaaa99ccb" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">76</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b3d483f6-0016-44bb-813a-f54033542417" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">43,272</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash, cash equivalents and restricted cash at beginning of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_535f6701-d8f3-49ef-9236-0577e8a23769" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,164</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_60616a61-e970-4bb7-a67b-7beac17cda2a" contextRef="C_cb46581b-8c63-4fee-b4c7-cc9ee9a93a21" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,436</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash, cash equivalents and restricted cash at end of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f8a0ed2a-2650-422c-bd67-79eea518e25c" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,088</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e738841-7031-43c5-9b97-15536a6f2231" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,164</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Supplemental disclosure of non-cash investing and financing activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leased assets obtained in exchange for new operating lease liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cefd22bf-4508-42ce-a635-9ad6f12673b3" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">790</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from exercise of stock options included in other current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3937e938-0e13-47cb-9fc5-315df4619ea5" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="lrmr:ProceedsFromExerciseOfStockOptionsIncludedInOtherCurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">LARIMAR THERAPEUTICS, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_to_condensed_consolidated_financia"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONSOLID</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ATED FINANCIAL STATEMENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_31f51cb1-d352-4c6f-8a31-050841828027" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" escape="true"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Description of Business and Basis of Presentation </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Larimar Therapeutics, Inc., together with its subsidiary (the &#8220;Company&#8221; or &#8220;Larimar&#8221;), is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Larimar's lead product candidate, nomlabofusp (nomlabofusp is the International Nonproprietary Name ("INN") and the United States Adopted Name ("USAN") for CTI-1601), is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin ("FXN"), an essential protein, to the mitochondria of patients with Friedreich&#8217;s ataxia ("FA"). FA is a rare, progressive and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has completed two phase 1 studies of nomlabofusp and a Phase 2 dose exploration study in patients with FA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2021, after reporting positive top-line data from the Company&#8217;s Phase 1 FA program, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) placed a clinical hold on the Company&#8217;s nomlabofusp clinical program after the Company notified the FDA of mortalities at the highest dose levels of a 26-week non-human primate toxicology study that was designed to support extended dosing of patients with nomlabofusp. In August 2022, the Company submitted a complete response to the clinical hold following a Type C Meeting with the FDA, and proposed as nomlabofusp's next clinical trial a Phase 2, four-week, dose exploration study in FA patients starting at the lower dose levels tested in the Company&#8217;s Phase 1 multiple-ascending dose clinical trial. In September 2022, the FDA lifted its full clinical hold on the nomlabofusp program and imposed a partial clinical hold.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2023, the Company announced top-line data from its completed 25 mg cohort of a Phase 2, four-week, dose exploration trial of nomlabofusp in patients with FA and provided a complete response to the FDA in June 2023, which included unblinded safety, pharmacokinetic ("PK"), and pharmacodynamic ("PD") data from the Phase 2 trial&#8217;s completed 25 mg cohort. Data from the completed 25 mg cohort (n = 13) indicated that nomlabofusp was generally well tolerated and showed increases in FXN levels from baseline compared to placebo in all evaluated tissues (skin and buccal cells) at day 14 (the final day of daily dosing in the trial).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2023, the Company met with the FDA. Following that meeting, the Company submitted a complete response to the FDA&#8217;s partial clinical hold that included unblinded safety, PK and frataxin data from the Phase 2 trial&#8217;s completed 25 mg cohort.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2023, following the FDA&#8217;s review of the Company's complete response to the partial clinical hold, the FDA cleared initiation of a second cohort at 50 mg of our four-week, placebo-controlled, Phase 2 dose exploration trial and initiation of the OLE trial with daily dosing of 25 mg.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2024, the Company reported positive top-line data and successful completion of their four-week, placebo-controlled Phase 2 dose exploration study of nomlabofusp in participants with FA. Nomlabofusp was generally well tolerated and demonstrated dose dependent increases in FXN levels in all evaluated tissues (skin and buccal cells) after daily dosing of 14 days followed by every other day dosing until day 28 in the 25 mg and 50 mg cohorts. Participants in the 25 mg (n=13) and 50 mg (n=15) cohorts were randomized 2:1 to receive subcutaneous injections of nomlabofusp or placebo. The initiation of additional U.S. clinical trials evaluating nomlabofusp are contingent on FDA review of data under the partial clinical hold.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2024, the Company initiated an OLE trial evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver, with the first patient dosed in March 2024. Participants who complete treatment in the Phase 2 dose exploration trial, or who previously completed a prior clinical trial of nomlabofusp are potentially eligible to screen for the OLE. The OLE will evaluate the safety, tolerability and PK and measures of frataxin levels in peripheral tissues as well as other exploratory PD (lipid profiles and gene expression data) following long-term subcutaneous administration of nomlabofusp. Clinical measures collected during the trial will be compared to data from a synthetic control arm derived from participants in the Friedreich&#8217;s Ataxia Clinical Outcome Measures Study (FACOMS) database. Dose escalation in the OLE trial will be considered based on safety, tolerability, PK, and tissue FXN levels from the Phase 2 trial&#8217;s 50 mg cohort as well as available data from the 25 mg dose of nomlabofusp in the OLE trial and is contingent on FDA review as part of the partial clinical hold. Initial data from the OLE trial is expected in the fourth quarter of 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to risks and uncertainties common to pre-commercial companies in the biotechnology industry, including, but not limited to, development and commercialization by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with governmental</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulations, failure to secure regulatory approval for its drug candidates or any other product candidates and the ability to secure additional capital to fund its operations. Product candidates under development will require extensive non-clinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, infrastructure and extensive compliance-reporting capabilities. Even if the Company's drug development efforts are successful, it is uncertain when, if ever, it will realize significant revenue from product sales.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_48b38935-2f3d-476d-bfbe-e541f7df1b87" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consolidated financial statements include the accounts of Larimar and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated. The accompanying consolidated financial statements have been prepared in conformity with GAAP.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f3261750-8be3-4ee8-91b7-c077f28eed06" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:LiabilityReserveEstimatePolicy" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity and Capital Resources</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s consolidated financial statements have been presented on the basis that it will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since its inception, the Company has incurred significant recurring operating losses and negative cash flows from operations. The Company has incurred net losses of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_38bce3ab-557b-44aa-8cc7-b263438ddf8e" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">36.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd03d9a8-6a4e-4c83-a787-0387c160548d" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">35.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the years ended December 31, 2023, and 2022, respectively. In addition, as of December 31, 2023, the Company had an accumulated deficit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_31c6dc8a-94d7-4e88-a1fa-ae5df80c870d" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">188.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company expects to continue to generate operating losses for the foreseeable future. As of December 31, 2023, the Company had approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c434db06-28cb-4c03-bf4c-db1c2b57fb83" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">86.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of cash, cash equivalents and marketable securities available for use to fund its operations and capital requirements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has funded its operations to date primarily with proceeds from sales of common stock and proceeds from the sale of prefunded warrants for the purchase of common stock, the acquisition in 2020 of cash, cash equivalents and marketable securities upon the merger with Zafgen, Inc. ("Zafgen") and, prior to the 2020 merger with Zafgen, capital contributions from Chondrial Holdings, LLC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2024, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6baff0d9-449a-4e12-a0c2-acbe00269041" contextRef="C_3e015593-165f-45fc-9cb4-52b758b04a99" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">19,736,842</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock in an underwritten public offering at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e496e3b9-4d03-4209-987f-3feaefc5f392" contextRef="C_530aece5-55e1-42ca-83b2-fdd8cc766346" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.74</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and received net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aed7f46d-3a49-426c-907a-38ab6394698d" contextRef="C_3e015593-165f-45fc-9cb4-52b758b04a99" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">161.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In accordance with Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-15, "Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern", the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. As of the issuance date of these consolidated financial statements, the Company expects its cash, cash equivalents and marketable securities, including its net proceeds from the February 2024 public offering, will be sufficient to fund its forecasted operating expenses and capital expenditure requirements into 2026. If the timing of the Company's clinical assumptions are delayed or if there are other forecasted assumption changes that negatively impact its operating plan, the Company would reduce expenditures in order to further extend cash resources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has not yet commercialized any products and does not expect to generate revenue from the commercial sale of any products for several years, if at all. The Company expects that its research and development and general and administrative expenses will continue to increase and, as a result, that it will need additional capital to fund its future operating and capital requirements. Unless and until the Company can generate substantial revenue, management continuously evaluates different strategies to obtain the required funding for future operations. These strategies include seeking additional funding through a combination of public or private equity offerings, debt or royalty financings, collaborations and licensing arrangements, strategic partnerships with pharmaceutical and/or larger biotechnology companies, or other sources. The incurrence of indebtedness would result in increased fixed payment obligations and the Company may be required to agree to certain restrictive covenants, such as limitations on its ability to incur additional debt, limitations on its ability to acquire, sell or license intellectual property rights, minimum required cash balances and other operating restrictions that could adversely impact the Company's ability to conduct its business. Any additional fundraising efforts may divert the Company's management from their day-to-day activities, which may adversely affect its ability to develop and commercialize its product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There can be no assurance that the Company will be able to raise sufficient additional capital on acceptable terms, if at all. If such additional financing is not available on satisfactory terms, or is not available in sufficient amounts, or if the Company does not have sufficient authorized shares, the Company may be required to delay,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">limit, or eliminate the development of business opportunities and its ability to achieve its business objectives, its competitiveness, and its business, financial condition, and results of operations will be materially adversely affected. The Company could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable and it may be required to relinquish rights to some of its technologies or product candidates or otherwise agree to terms unfavorable to it, any of which may have a material adverse effect on the Company's business, operating results and prospects. In addition, geopolitical tensions, volatility of capital markets, and other adverse macroeconomic events, including those due to inflationary pressures, rising interest rates, bank instability and the ability of the U.S. government to manage federal debt limits as well as the potential impact of other health crises on the global financial markets may reduce the Company's ability to access capital, which could negatively affect its liquidity and ability to continue as a going concern.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the Company is unable to obtain sufficient funding when needed and/or on acceptable terms, the Company may be required to significantly curtail, delay or discontinue one or more of its research and development programs, the manufacture of clinical and commercial supplies, product portfolio expansion, pre commercialization efforts and/or commercial operations, which could adversely affect its business prospects, or the Company may be unable to continue operations.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b6a41464-d5f3-4dff-a896-eb06dd677789" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Summary of Significant Accounting Policies </span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_aa283011-7f49-4ee3-bbc0-c285b7082a8e" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. This process involves reviewing open contracts and purchase orders, communicating with our personnel and outside vendors to identify services that have been performed on our behalf and estimating the level of service performed and the associated costs incurred for the services when we have not yet been invoiced or otherwise notified of the actual costs. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expense, the recording as prepaid expense of payments made in advance of the actual provision of goods or services, valuation of stock-based awards and valuation of leases. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_74409b8f-c929-4a68-8b03-12a423787164" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk and Significant Suppliers</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and marketable securities. Cash balances may be held in financial institutions which may exceed federally insured limits. The Company has not experienced realized losses related to its cash, cash equivalents or marketable securities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is highly dependent on third-party manufacturers to supply products for research and development activities in its programs, to scale and optimize their manufacturing processes and, ultimately, to provide commercial supply. The Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for drug substance and formulated drugs related to these programs. The drug substance which is in frozen liquid form for nomlabofusp is currently manufactured for the Company by a third-party manufacturer, and the frozen liquid form of drug product is made at another manufacturer. The Company is undertaking a program with a third manufacturer to begin to produce a lyophilized version of the drug product from the same drug substance, that, once available, the Company intends to use in certain of its future planned clinical trials. The Company&#8217;s research and development programs could be adversely affected by a significant interruption in these manufacturing services or in the supply of drug substance and formulated drugs.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1079a47e-b891-4960-96aa-735d43f27e2c" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company considers all highly liquid investments with maturities of three months or less at the date of purchase to be cash equivalents. Cash equivalents consisted of money market funds as of December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></ix:nonNumeric></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4c1cce6c-7107-4a88-a8d9-c13d03c02ea4" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:MarketableSecuritiesPolicy" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Marketable securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Marketable securities consist of debt investments with original maturities greater than ninety days. The Company classifies its marketable securities as available-for-sale. Accordingly, these investments are recorded at fair value, which is based on quoted market prices. When the fair value is below the amortized cost the amount of the expected credit loss is estimated. The credit-related impairment amount, if any, would be recognized in net income; the remaining impairment amount and unrealized gains are reported as a component of accumulated other comprehensive income in stockholders&#8217; equity. Credit losses, if any, are recognized through the use of an allowance for credit losses account and subsequent improvements in expected credit losses are recognized as a reversal of the allowance account. If the Company has the intent to sell the security or if it is more likely than not that the Company would be required to sell the security prior to recovery of its amortized cost basis, the allowance for credit loss would be written off and the excess of the amortized cost basis of the asset over its fair value is recorded in net income.</span></p></ix:nonNumeric></div><div style="font-size:11pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6d53943c-13f0-48ff-a90d-8bd2dec39051" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_79196bf3-be5b-4806-9ec5-5fed79d1cfbe;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> or</span><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0e90f192-a118-4d6a-a6c7-8084f45f8c70" contextRef="C_faa2d74d-3a2d-47fb-a723-778c940b635d" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seven-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> estimated useful life for equipment, furniture and fixtures and office equipment. Leasehold improvements are amortized over the shorter of the asset life or the term of the lease agreement. Expenditures for repairs and maintenance of assets are charged to expense as incurred. Upon retirement or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain or loss is included in loss from operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e9f289ab-6a4d-4ea9-a17a-e58d14b7f551" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Long-lived assets consist of property and equipment, net&#184; and right-of-use assets. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. Any impairment loss, if indicated, is measured as the amount by which the carrying amount of the asset exceeds the estimated fair value of the asset.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_87793d10-8884-4e70-8fac-c2532b3943d8" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions. The Company&#8217;s focus is on the research, development and commercialization of novel therapeutics for the treatment of rare diseases.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_875981ff-a58a-4e90-9ebb-c2e21152eee8" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Costs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Costs associated with internal research and development and external research and development services, including drug development, clinical studies and non-clinical studies, are expensed as incurred. Research and development expenses include costs for salaries, employee benefits, subcontractors, facility-related expenses, depreciation, stock-based compensation, third-party license fees, laboratory supplies, and external costs of outside vendors engaged to conduct discovery, non-clinical and clinical development activities and clinical trials as well as to manufacture clinical trial materials, and other costs. The Company recognizes external research and development costs based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its key service providers.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such prepaid expenses are recognized as an expense when the goods have been delivered or the related services have been performed, or when it is no longer expected that the goods will be delivered, or the services rendered.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upfront payments, milestone payments and annual maintenance fees under license agreements are currently expensed in the period in which they are incurred.</span></p></ix:nonNumeric></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8c4cb1cd-7cf3-417b-b92f-e1e027404b2e" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent Costs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e4853bca-806c-4cdf-9338-270f611e3749" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company measures all stock-based awards granted to employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model. Compensation expense of those awards is recognized over the requisite service period, which is the vesting period of the respective award. Typically, the Company issues awards with only service-based vesting conditions and records the expense for these awards using the straight-line method. The Company accounts for forfeitures as they occur.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to May 28, 2020, the Company had been a private company and lacked company-specific historical and implied volatility information for its common stock. Prior to January 1, 2023, the Company estimated its expected common stock price volatility solely based on the historical volatility of publicly traded peer companies. Beginning on January 1, 2023, based on the availability of sufficient historical trading data of the Company's own common stock on the Nasdaq Global Market to calculate accurately its volatility, the Company began blending its volatility starting from June 2020 (following its merger with Zafgen in 2020) to the date of each stock-based award, and weighing the volatility of its peer group for the amount of time from May 31, 2020 backwards so that the blended volatility equals the expected term of the related stock-based award. The expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield considers the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fa71842c-da21-45ef-9af4-70cca577afb5" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a134382-473b-4518-af46-067f55096911" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="lrmr:LikelihoodPercentageMinimum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_affe2350-e55d-4c2a-b63c-8fb692320df6" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comprehensive Gain (Loss)</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comprehensive gain (loss) includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and economic events other than those with stockholders. For the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company&#8217;s only element of other comprehensive loss was unrealized loss on marketable securities.</span></p></ix:nonNumeric></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_75cbd8e2-565d-4fe8-a1dd-addd219308a0" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss Per Share</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Prior to August 11, 2023, basic shares outstanding includes the weighted average effect of the Company&#8217;s prefunded warrants issued in June 2020, the exercise of which requires little or no consideration for the delivery of shares of common stock. These prefunded warrants were exercised on August 11, 2023 and the Company received cash proceeds of less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0d8e9634-c02a-4379-bdb2-d1188ebfec6a" contextRef="C_2a37f99b-d107-4e6e-89a3-1dc033f729cc" name="us-gaap:ProceedsFromWarrantExercises" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Accordingly, the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ede818e7-2b40-4dcc-be53-36f8ecf595c3" contextRef="C_cf8be5df-f0b1-4821-a7e8-f9b1795798f9" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_1a72dc75-2c0f-4dc2-97c4-319a1f79b0d8" contextRef="C_cf8be5df-f0b1-4821-a7e8-f9b1795798f9" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">628,403</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares were issued upon the exercise of these warrants and are included in issued and outstanding common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares, including potentially dilutive common stock equivalents assuming the dilutive effect of outstanding stock options, outstanding restricted stock units, and unvested restricted common shares, as determined using the treasury stock method. For periods in which the Company has reported net losses (all periods since inception), diluted net loss per common share attributable to common stockholders is the same as basic net loss per common share attributable to common stockholders, since dilutive common stock equivalents are not assumed to have been issued if their effect is antidilutive.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company excluded </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fca4116a-e6d7-44bd-961b-1e0587d04615" contextRef="C_9e62e2a7-281f-4efe-9952-2af3980d814c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,888,502</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c88a8d00-f9e6-4bb4-bc66-c2e3fe04654b" contextRef="C_393eb466-a24d-43ed-9e90-d9f5eb33fa0b" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,071,528</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> options to purchase common stock, outstanding as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 respectively, from the computation of diluted net loss per share for the twelve months ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, because they had an anti-dilutive impact due to the net loss incurred for the periods.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c2f6075a-d1c8-41d8-95a9-d3230a21448a" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently Issued and Adopted Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, new accounting guidance is issued by the FASB or other standard setting bodies that is adopted by us as of the effective date or, in some cases where early adoption is permitted, in advance of the effective date. We have assessed the recently issued guidance that is not yet effective and believe the new guidance will not have a material impact on the consolidated results of operations, cash flows or financial position.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_41dcfb5b-84f9-4cfd-b0bb-8798c6974563" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair Value Measurements and Cash Equivalents/Marketable Securities</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value Measurements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2023 and December 31, 2022 are measured in accordance with the standards of ASC 820, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value Measurements and Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which establishes a three-level valuation hierarchy for measuring fair value and expands financial statement disclosures about fair value measurements. The valuation hierarchy is based on upon the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:11.54%;"/>
      <td style="width:88.46%;"/>
     </tr>
     <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level &#8211; 1</span></p></td>
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></p></td>
     </tr>
     <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:middle;"><p style="font-size:1pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:middle;"><p style="font-size:1pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level &#8211; 2</span></p></td>
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.</span></p></td>
     </tr>
     <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level &#8211; 3</span></p></td>
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inputs to the valuation methodology are unobservable and significant to the fair value measurement.</span></p></td>
     </tr>
    </table><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s financial instruments consist primarily of cash and cash equivalents, marketable securities, accounts payable and accrued liabilities. For accounts payable and accrued liabilities, the carrying amounts of these financial instruments as of December 31, 2023 and 2022 were considered representative of their fair values due to their short term to maturity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_75168287-982c-422a-85fc-4cb77832509e" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables summarize the Company&#8217;s cash equivalents and marketable securities as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted<br/>Prices in<br/>Active<br/>Markets <br/>(Level 1)</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs <br/>(Level 2)</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs <br/>(Level 3)</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds invested in government securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_da05cfd5-9611-4e81-ad79-3ba10527b26a" contextRef="C_b696efd6-314c-4861-aaea-8e43ed271ae6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,701</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_37d2b70a-60de-402f-8d46-0d46cce05968" contextRef="C_80781f96-9385-4dd5-8eb7-f026c92fd2c7" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,701</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ff4e4f3-12e8-430f-b448-0dbf42c2e9c5" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,701</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7bccad0-6ccd-4762-94cc-a2b6cb412bfd" contextRef="C_a9f53337-4c5c-4958-98a5-a81a54dd3435" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,701</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury Bills</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_08439506-756c-4fdd-bf7b-b46dd6ef1ada" contextRef="C_e619f4e9-77cd-449f-8ab2-c55b57519206" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,334</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b95f1cf4-ff2f-4dd7-89cd-40162ba6fb92" contextRef="C_f0f9091f-cf20-4767-8991-bfab4c73cc6d" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,334</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Government securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_47ec9e13-74b1-49fc-a944-dd93a0cf0322" contextRef="C_47c297aa-bca8-4b02-b5a1-b4f42c32fbc2" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,719</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d70b75e5-f6a7-481f-a6fc-8b18321365bd" contextRef="C_22aa2b7d-3358-4d02-ae96-34174231f4a5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,719</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cbc61258-54ea-4f90-b434-23af7ec7911a" contextRef="C_112cf294-81d1-4c4c-ba37-b763be85def2" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,988</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3857454f-4628-4995-9e46-16c01b63d7c9" contextRef="C_846f3ecc-8d1c-4bc9-aa46-2d08b1bb1e55" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,988</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ba107f7e-e247-457b-89f1-ab7591aadf0a" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60,041</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ceff5667-31b2-456d-9a11-46090d6e9c4d" contextRef="C_a9f53337-4c5c-4958-98a5-a81a54dd3435" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,334</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0abc302c-23c3-43c7-8a2a-62ebe9f22c73" contextRef="C_a4f1b737-b155-4ae3-9c2f-2c7f4437ce11" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,707</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Total cash equivalents and marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_584ac7db-b800-43d9-a1e1-db5a2d91950e" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,742</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a7833c7-fc00-49d7-9f5e-287ffc501747" contextRef="C_a9f53337-4c5c-4958-98a5-a81a54dd3435" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,035</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2efd4645-616a-435d-8803-790467f9434c" contextRef="C_a4f1b737-b155-4ae3-9c2f-2c7f4437ce11" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,707</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds invested in government securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_acd03ac6-2dee-4701-b876-8382fc5bd506" contextRef="C_b6f1f981-2a41-46ca-88f7-657876f052f8" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,184</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_88465c87-4e61-4e8a-9413-4b42da093791" contextRef="C_3b388c97-79fa-4717-81b4-abd04c453ac4" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,184</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_78c39102-d351-4b19-ab9a-6d7451eec5da" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,184</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_62b11e40-2b4b-42e8-8590-083c8e506ea2" contextRef="C_d4d4aee3-9c3b-49c7-bff2-63ffe90e6e2e" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,184</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Government securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c2f2fd77-1047-4955-a693-748be4af8cfc" contextRef="C_59823e91-6700-4233-b1ac-e431259ec4c1" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91,603</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_91e56672-b297-4a69-bbfb-c8efc7403b26" contextRef="C_995af330-bf27-4e38-9645-1ac883fd043e" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91,603</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_62c6ffb8-4fe1-49c5-b62a-359886c34bd8" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91,603</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22cf74c5-2959-40ed-abd8-4b733d848f80" contextRef="C_ce01a5a3-0bd6-4643-a592-16b822a79946" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91,603</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Total cash equivalents and marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a4768bea-78c5-43ad-930c-8b18b7fb4417" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113,787</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_882e19b5-a606-4843-9828-c206d5ff95a6" contextRef="C_d4d4aee3-9c3b-49c7-bff2-63ffe90e6e2e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,184</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e49a62b2-6145-4340-b630-4db2e9078c22" contextRef="C_ce01a5a3-0bd6-4643-a592-16b822a79946" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91,603</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accrued interest receivable related to the Company&#8217;s investments was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa01df17-67b5-4e9b-afbb-ea1a9be8045f" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:InterestReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9de88772-8aa8-462c-b084-9445c1433db9" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:InterestReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, respectively, and is included in prepaid expenses and other current assets on the consolidated balance sheet.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company classifies its money market funds and U.S. treasury bills, which are valued based on quoted market prices in active markets with no valuation adjustment, as Level 1 assets within the fair value hierarchy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company classifies its investments in U.S. government and agency securities, corporate commercial paper, and corporate bonds, if any, as Level 2 assets within the fair value hierarchy. The fair values of these investments are estimated by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2022, the unrealized loss for available-for-sale investments were non-credit related, and the Company does not intend to sell the investments that were in an unrealized loss position, nor will it be required to sell those investments before recovery of their amortized cost basis, which may be maturity. As of December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_038f9d0b-a66a-49e8-97a8-2d5202ed75fe" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_629330aa-4c1e-4a3f-840a-674b2f1dc7d2" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> allowances for credit losses for the Company&#8217;s investments were recorded. During the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">twelve months ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_df44f736-51d6-4836-a9e4-f1b4a1eb3e49" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:AssetImpairmentCharges" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_a96a60e8-1276-4221-8383-e16674976f12" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:AssetImpairmentCharges" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recognize any impairment losses related to investments.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company's cash equivalents and marketable securities consisted of a U.S. government money market fund, U.S. Treasury Bills, U.S. government and agency securities and corporate bonds, all held in our name in a separate custody account with U.S. Bank. The U.S. government money market fund has same-day liquidity access and the U.S. government and agency securities all have maturities of 90 days or less.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Marketable Securities</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a92628a0-f6f8-41b6-94db-3bd2490e964a" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables summarize the Company&#8217;s marketable securities as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized <br/>Losses</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury Bills</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d963915b-b433-4c7a-968d-d3738a689244" contextRef="C_e619f4e9-77cd-449f-8ab2-c55b57519206" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,330</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_827a6a67-f4de-446f-b46d-ae5718c88f2a" contextRef="C_e619f4e9-77cd-449f-8ab2-c55b57519206" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc424484-ed3f-4109-b93c-686c34b0ea5d" contextRef="C_e619f4e9-77cd-449f-8ab2-c55b57519206" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,334</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Government securities (due within 1 year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b096e49b-f9d6-484a-9dd6-f0736d6fbb2f" contextRef="C_47c297aa-bca8-4b02-b5a1-b4f42c32fbc2" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,653</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05aaee7d-05eb-46e2-bd12-f6e94d4f6619" contextRef="C_47c297aa-bca8-4b02-b5a1-b4f42c32fbc2" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e323b63-4d7a-493a-b467-0be2a9228e82" contextRef="C_47c297aa-bca8-4b02-b5a1-b4f42c32fbc2" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,719</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper (due within 1 year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd25d45d-e48d-483b-ad70-4233ae00ed39" contextRef="C_f1c3acf0-ab7f-4fb7-b405-7bbdf99bfc05" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,977</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_225018bc-7fda-4470-91ba-b33c3d64de23" contextRef="C_f1c3acf0-ab7f-4fb7-b405-7bbdf99bfc05" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d813c27a-dc7c-4c9c-b28c-83af4c108aab" contextRef="C_f1c3acf0-ab7f-4fb7-b405-7bbdf99bfc05" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,988</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6b39e1d4-afbb-4816-bb40-cdb58eeb2c85" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,960</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_43519dc9-7b56-42f8-b038-7d8fdabcb72c" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_09bc7d2a-4c5f-4882-82d1-b9f083766aeb" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60,041</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Government securities (due within 1 year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_73e8e9fb-a9cd-48db-826f-f7f7f6aa345e" contextRef="C_59823e91-6700-4233-b1ac-e431259ec4c1" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91,634</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e40e3e9-7865-48d4-bf29-54070ee9c6eb" contextRef="C_59823e91-6700-4233-b1ac-e431259ec4c1" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b2895f4c-cedd-4ffe-aaec-411b8db48d2a" contextRef="C_59823e91-6700-4233-b1ac-e431259ec4c1" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a22b4f68-b577-492c-83c4-30c6351cceaf" contextRef="C_59823e91-6700-4233-b1ac-e431259ec4c1" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91,603</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5e2b72ca-8ced-424d-8993-f09f0c732941" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91,634</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f14155d3-850c-4d65-b278-553e5f4c99e6" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_373524ed-99ac-4ad7-be47-0b13f9916965" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_65db60b8-6868-46f6-a517-aae6a5f598c1" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91,603</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_36d3d127-05a7-4df5-a410-112877f326a2" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="lrmr:PrepaidExpensesAndOtherCurrentAssetsTextBlock" escape="true"><div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prepaid Expenses and Other Current Assets</span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2f93bd2f-2f07-46eb-a503-2eb8e633ca75" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="lrmr:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prepaid expenses and other current assets consisted of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid research and development expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bd889bed-5593-4ccd-87f6-81b3d070a8dd" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="lrmr:PrepaidResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,994</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed73c1c0-47e9-4bbc-a57b-50f5fd0c589e" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="lrmr:PrepaidResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,394</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid insurance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a212893-2020-413e-845a-cdf7ccd60ea5" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">682</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_85a1e95c-69bf-42c4-8f12-89518e0037f5" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">679</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other prepaid expenses and other assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98d6b844-490c-4ed0-ab0f-ba4d6908e490" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="lrmr:OtherPrepaidExpenseAndOtherCurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">709</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6d70a6c2-3489-4bd3-821f-3cb9c5a5285c" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="lrmr:OtherPrepaidExpenseAndOtherCurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">238</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total prepaid expenses and other assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa7f45bf-f08e-4a79-b049-f3b1744d4a26" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,385</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e6c11938-9862-4a3a-9db9-cc13a3e596dc" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,311</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_95e31d73-1d7f-4231-b533-f5831e6ba3a3" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">5.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fixed Assets</span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_36600fc8-b485-4400-9cee-5d2d273ffca4" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fixed assets, net consisted of the following:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.477%;"/>
        <td style="width:1.399%;"/>
        <td style="width:12.775%;"/>
        <td style="width:1.399%;"/>
        <td style="width:1%;"/>
        <td style="width:10.776%;"/>
        <td style="width:1%;"/>
        <td style="width:1.399%;"/>
        <td style="width:1%;"/>
        <td style="width:10.776%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Useful Life</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_3f2b881d-39b4-4757-9c54-41e8a1a4a4f1" contextRef="C_4a47b017-2508-45fe-a4d9-e2f06dcde4b3" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5 years</span></ix:nonNumeric></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27f77186-6d9d-491c-ae00-b30aa9e1bb35" contextRef="C_4a47b017-2508-45fe-a4d9-e2f06dcde4b3" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">117</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e472ad16-4bb2-4273-98ae-91775106ebee" contextRef="C_a2ca56a1-3b79-4526-a05b-9dc40fc95833" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lab equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_a69265d9-5c33-49e9-958f-fa03ae2c9b63" contextRef="C_026fc58b-40b7-41a5-a024-519b8180c981" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5 years</span></ix:nonNumeric></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b43a8c0e-7adb-466a-8d65-7ca02146fb31" contextRef="C_026fc58b-40b7-41a5-a024-519b8180c981" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,192</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bfc3e6ef-646f-4790-b320-13f25af51c25" contextRef="C_32800e6f-ee7b-44d6-a810-966628d6e119" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,192</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_fea2306c-389a-475f-8394-2373bb2ba54c" contextRef="C_4b113e78-3130-4612-8c3b-467b2bc9cf25" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7 years</span></ix:nonNumeric></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c51e21f-e27f-47bc-9490-a69ee68a19c5" contextRef="C_4b113e78-3130-4612-8c3b-467b2bc9cf25" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">555</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7462da63-e8b8-466d-9ee4-753ca09d8793" contextRef="C_4df7afcb-4d0e-4162-9cf0-4e8b3712bbec" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">456</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="-sec-ix-hidden:F_1743f7c9-4f07-468e-8ed1-5de01b765813;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">lease term</span></span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af25b1e8-32b2-4e36-85a5-933c17096276" contextRef="C_786b0fcb-721f-4485-992a-f6eb8aa02bf3" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_835437f5-831b-43ac-8bbb-748f831f5348" contextRef="C_a3c09498-0d4a-46e4-b3c4-1c97a4ae24dd" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Total property, plant and equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d1cdc41e-1344-4b9d-b512-d00d3ca635f6" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,909</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed034083-f856-494f-b382-82cad0da49ad" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,745</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Accumulated depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ffa6d2e5-50a9-4292-9cff-c3ffd52f51f3" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,225</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5007f546-ca58-4a69-ad35-c17b61b1adb0" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">914</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Property, plant and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_553d891a-90b4-4812-aead-c90ee8cdb258" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">684</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_59146f0b-ce30-45f2-b9fa-06171b799089" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">831</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation expense was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8fa60bec-2d97-4889-a706-16299e0923a2" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="lrmr:DepreciationExpenseExcludingLeasedAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_4d597278-77b1-4536-baf9-65e947f0f1bb" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="lrmr:DepreciationExpenseExcludingLeasedAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, respectively. In addition, for the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4bbbe297-f55a-40ea-9ff5-c88264289a99" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="lrmr:DepreciationExpensesRelatedToSubletAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_39bcd4fb-1515-46f3-a46f-6f184d20ee2a" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="lrmr:DepreciationExpensesRelatedToSubletAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of depreciation related to sublet assets recorded as other expense.</span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6d2d1cba-af8b-4dc0-acc3-a12c265c78b3" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" escape="true"><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">6.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued Expenses</span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a7d2ba33-b563-47fa-88f9-fb2759771797" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses consisted of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued research and development expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_84cbfd71-1ede-4cb3-9041-d4198ac8c7e7" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="lrmr:AccruedResearchAndDevelopmentExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,594</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_44730009-215e-4f98-97fa-8555fa6beeca" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="lrmr:AccruedResearchAndDevelopmentExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,921</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued payroll and related expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_43346046-9053-4b16-810c-276a4efd6145" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,365</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de4750a9-77d2-434f-8229-36aea391c785" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,046</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_273ebda0-afdd-4fbd-a43c-682ce143f331" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">427</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80992495-1a8f-40f2-a1a8-aa70f27840f5" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">441</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Total accrued expenses and other current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc7f1165-5f2f-4084-b81a-1e98486b7d14" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,386</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8272fdaf-499e-441f-8884-7b2675273ccd" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,408</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b061d5be-fa65-4cfd-b66c-5d1fa2418584" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">7.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stockholders&#8217; Equity and Stock Options</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Common Stock and Prefunded warrants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 28, 2020, the Company entered into a securities purchase agreement with certain accredited investors (the &#8220;Purchasers&#8221;) for the sale by the Company in a private placement of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_70db5bb7-16e3-40e3-a4e1-a18e2a0506e3" contextRef="C_8cd23ff2-fd7c-4814-976b-44a4de8fb1e2" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,105,359</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock and prefunded warrants to purchase an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_07461840-c97a-4f49-8465-11e396e260d3" contextRef="C_a74f39df-acd1-4d8b-9dba-1fd17150fcb5" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">628,403</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock, for a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c523676-4bd3-4a1b-b4d9-34f4549806ca" contextRef="C_a74f39df-acd1-4d8b-9dba-1fd17150fcb5" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">11.88</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share of the common stock and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_06f0a520-9277-404b-92aa-88f08b828958" contextRef="C_26ed7eb8-3335-4a45-993d-30b861b1ef11" name="lrmr:WarrantsIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">11.87</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per prefunded warrant. The prefunded warrants were exercisable at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_31f715c0-6549-4afb-b4e8-0b4bd6948614" contextRef="C_26ed7eb8-3335-4a45-993d-30b861b1ef11" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.01</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and were exercisable indefinitely. In August 2023, the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5dbde661-40b3-4eaa-894b-b6d3e35e5643" contextRef="C_4d0e0e4e-6b0a-403d-87e1-7dc7a011b1ec" name="lrmr:StockIssuedDuringPeriodSharesExerciseOfWarrants" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">628,403</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of prefunded warrants were exercised and the Company received cash proceeds of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_8cb91d11-91f9-408e-87be-ef7e83759a47;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six thousand two hundred and eighty-four dollars</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The private placement closed on June 1, 2020. The aggregate gross proceeds for the issuance and sale of the common stock and prefunded warrants were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0231dd17-0ec3-47f6-bf4f-6d33890d27af" contextRef="C_9d1af696-7d08-4f42-87a7-b186b43ac50d" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">80.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, transaction costs totaled $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34cff39c-f214-4ae4-a2aa-34534cace9f9" contextRef="C_9d1af696-7d08-4f42-87a7-b186b43ac50d" name="lrmr:StockAndWarrantIssuanceTransactionCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and resulted in net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_df9275d2-d171-487c-a5c9-2d45e5ccc1ae" contextRef="C_9d1af696-7d08-4f42-87a7-b186b43ac50d" name="lrmr:ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">75.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company&#8217;s Registration Statement on Form S-3, filed with the SEC on June 26, 2020, registered the resale of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f9b16062-a8e6-4bfb-813a-f6b25a86c7b9" contextRef="C_8cd23ff2-fd7c-4814-976b-44a4de8fb1e2" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,105,359</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock sold and the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f8def0f-a4ee-45fd-8149-c0649d1706d7" contextRef="C_a74f39df-acd1-4d8b-9dba-1fd17150fcb5" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">628,403</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock underlying the prefunded warrants. MTS Health Partners served as placement agent to the Company in connection with the private placement. As partial compensation for these services, the Company issued MTS Health Partners </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e06e73cb-14bb-4f5a-9cfc-0dc17e2cbc0c" contextRef="C_c597ff2c-39de-40dd-b55f-1bcc76bd4dc7" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">35,260</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company&#8217;s Amended and Restated Certificate of Incorporation, authorized the Company to issue up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ee458a5-ed00-42ab-8745-7a37f38f77bd" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">115,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3cab3754-c043-4310-99dc-ceb35d6335ad" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> par value common stock, of which </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f0e354a-1c0b-4872-80c7-9c431a45c973" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_f29bed71-dceb-4138-bfb0-901617746638" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">43,909,069</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares were issued and outstanding, and up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c0631842-5e57-4290-9cf2-dd34df4f59fc" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f46ebd5-cbeb-4a35-8125-fd5c36e7af6d" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> par value undesignated preferred stock, of which </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c6a44aab-5bd2-4100-857b-bb8d214e33c7" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_9ee1d560-fc38-42b2-b060-473af60c2e2d" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares were issued or outstanding. The voting, dividend and liquidation rights of the holders of the Company&#8217;s common stock are subject to and qualified by the rights, powers and preferences of the holders of the preferred stock. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8f8f9b17-9a46-4515-9b95-89fc295fd606" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:CommonStockVotingRights"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Common stockholders are entitled to receive dividends, as may be declared by the board of directors of the Company (the &#8220;Board&#8221;), if any. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc70025d-27ea-47ee-bb70-1a39f09ffb7e" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:DividendsPayableCurrentAndNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cash dividends have been declared or paid to date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2022, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d912091a-ddfb-4586-a626-1e76fced428f" contextRef="C_94e051e5-07aa-4e1e-a62e-12871b5fe6b5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">25,558,750</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock in an underwritten public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f4c329b9-a407-4fe9-8b97-0bdd74ab7b46" contextRef="C_5c3f05e5-8f01-4df5-a495-e7063f7dcbec" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">3.15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and received net proceeds, net of underwriting discounts and commissions and offering costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec4f3ff2-1cc6-469c-ae02-debc5310245c" contextRef="C_94e051e5-07aa-4e1e-a62e-12871b5fe6b5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">75.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2024, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0c73161-b062-4ede-8612-a5c189cbbea2" contextRef="C_e779eef1-f227-4303-a5d4-03032bdb61b2" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">19,736,842</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock in an underwritten public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_08231669-60b5-475d-b31d-708ee571a40a" contextRef="C_24df9b26-5847-47e5-b4ad-c48348d08414" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">8.74</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and received net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cad30f38-6977-496e-b97d-870797617cee" contextRef="C_e779eef1-f227-4303-a5d4-03032bdb61b2" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">161.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2022 ATM Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2022, the Company entered into a sales agreement (the "ATM Agreement") with a Guggenheim Securities, LLC in connection with the establishment of an &#8220;at-the-market&#8221; offering program under which the Company could sell up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9eb2be57-27aa-4520-b52c-a6f16393853d" contextRef="C_039998c9-136d-4c84-92be-a69133fb0a75" name="lrmr:AggregateGrossSalesProceedsUnderSalesAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of shares of common stock (the &#8220;ATM Shares&#8221;) from time to time.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2024, in connection with the underwritten public offering described above, the Company terminated the ATM Agreement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9dd8c17a-bebd-4061-9c0a-2d5d37fe4fc5" contextRef="C_78ca8c58-4724-4fdd-b217-9f4c3b5b885f" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ATM Shares were ever sold pursuant to the ATM Agreement.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2020 Equity Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Board adopted the 2020 Equity Incentive Plan (the "2020 Plan") on July 16, 2020 and the stockholders of the Company approved the 2020 Plan on September 29, 2020. The 2020 Plan replaced the predecessor plans (the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">"Prior Plans") that the Company assumed following its merger with Zafgen in May 2020. Options outstanding under the Prior Plans will remain outstanding, unchanged, and subject to the terms of the Prior Plans and the respective award agreements, and no further awards will be made under the Prior Plans. However, if any award previously granted under the Prior Plans, expires, terminates, is canceled, or is forfeited for any reason after the approval of the 2020 Plan, the shares subject to that award will be added to the 2020 Plan share pool so that they can be utilized for new grants under the 2020 Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2020 Plan provides for the grant of incentive stock options (&#8220;ISOs&#8221;), nonstatutory stock options (&#8220;NSOs&#8221;), stock appreciation rights, restricted stock awards, restricted stock unit awards, and cash or other stock-based awards. ISOs may be granted only to the Company&#8217;s employees, including the Company&#8217;s officers, and the employees of the Company&#8217;s affiliates. All other awards may be granted to the Company&#8217;s employees, including the Company&#8217;s officers, the Company&#8217;s non-employee directors and consultants, and the employees and consultants of the Company&#8217;s affiliates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f18d22f0-5bfd-46a7-addb-3133c98688d3" contextRef="C_37911699-3824-4881-9471-81254e29f4ad" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The maximum number of shares that may be issued in respect of any awards under the 2020 Plan is the sum of: (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d2903e25-3ec4-43ad-a7f1-a2377cf9adab" contextRef="C_37911699-3824-4881-9471-81254e29f4ad" name="lrmr:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,700,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares plus (ii) an annual increase on January 1, 2021 and each anniversary of such date thereafter through January 1, 2030, equal to the lesser of (A) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28f81010-1576-4a03-b0a0-334ac96bf43a" contextRef="C_37911699-3824-4881-9471-81254e29f4ad" name="lrmr:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the shares issued and outstanding on the last day of the immediately preceding fiscal year, or (B) such smaller number of shares as determined by the Board (collectively, the &#8220;Plan Limit&#8221;).</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The maximum aggregate number of shares that may be issued under the 2020 Plan is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf1fa9ce-36ec-4b0d-9485-009dc54e3df5" contextRef="C_4e7af380-9c31-42f4-a857-43c89ba539c2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> over the </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_97bf7aa3-a084-410a-aa85-f296a4494185" contextRef="C_37911699-3824-4881-9471-81254e29f4ad" name="lrmr:ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> term of the 2020 Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As permitted by the 2020 Plan, the Company added </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4425ddf1-a359-4299-b637-d0797cb7bcef" contextRef="C_a8e69aee-3f52-42fe-9a00-5c7054b2ba1f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,756,363</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d92c5d01-ed74-42a6-ac25-31bd0e3f42a8" contextRef="C_b8fdf4b9-43b7-4ab7-8542-b3d410371289" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,730,768</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares available for grant to the 2020 Plan on January 1, 2024 and January 1, 2023, respectively, increasing the maximum number of shares of the Company&#8217;s common stock that may be issued under the 2020 Plan as of January 1, 2024 to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c6e6c73-3c2d-4121-b310-ce170bcb6b77" contextRef="C_7a4395b1-58c4-4b3b-bac0-3280e7df8802" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,042,968</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the twelve months ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, options to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e13290b-0388-4f64-9e28-bf5733d51afb" contextRef="C_7461d392-dc75-45e2-93a6-6a4655ad44cb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">224,437</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7dbe08af-399a-4873-bf10-07b1baced462" contextRef="C_064057be-fcdf-4308-890d-a8ada4719458" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">148,623</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares issued under the Prior Plans were canceled and became available for grant under the 2020 Plan. In addition, as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed9bb3df-0f78-46e6-b66b-9d821bcbb7ef" contextRef="C_6dc50be6-f9ce-45f0-896b-c14acf174567" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,286,605</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock were available for grant under the 2020 Plan.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Valuation</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4ae884be-8e5b-47a6-b682-14fc58cc4d8d" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted to employees:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.357%;"/>
        <td style="width:1%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.357%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c87bd4b-2e9a-47db-9935-22deeb78ba79" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.72</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b014603d-0ad2-4151-9420-a61b60eed52e" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_6f899d2c-b3df-40c3-b593-89da9c1ff437" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.23</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_25883e93-bb09-4f15-8006-f01eeb60881a" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.21</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a3dbab5-6204-4842-bda2-4baf9330d23d" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">94</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5928f1e7-8a8e-464d-9806-d49700b9b550" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">89</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_92a8f7c5-9437-4721-b8c9-da03d09cbeea" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_74186fcc-764b-4da5-a907-1bf513f784cb" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Options</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dbfb4874-9d4a-423a-8aa3-3d65a34889b4" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the Company&#8217;s stock option activity for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">twelve months ended December 31, 2023 (amounts in millions, except for share and per share data):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.11%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.662%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:8.942%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.662%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.182%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Average</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Average</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Remaining</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Intrinsic</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exercise</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Contractual</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Value (a)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Term (in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in millions)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Outstanding as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b143184e-0985-45c0-a230-1d37fefe7e3b" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,071,528</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d15d83a6-fe64-47ba-9c70-5b90ce0f82f6" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">12.13</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_2ea5d8e9-bb66-4a87-823d-4c07ec12ed76" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.6</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d40b75a1-3be1-4151-9e90-c755832ea9b0" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,748,200</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f530709-a4b1-45b7-aad4-8efe105b4bb0" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.68</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd5c3775-94f0-4ce9-9728-7ea7baabeeb6" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">11,466</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_607a5230-ccb1-49c8-a22f-43a7b93940d4" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.93</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited/Expired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b960c3d-7a84-4a5a-a011-c3c13d78629b" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">534,760</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_84aba926-5bc7-415e-921b-12c0508c7334" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">12.52</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4f0f69e-978d-4828-9010-5f2f6216382a" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,273,502</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_74327eba-9a4f-4542-a40d-8f87bbada95a" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">9.06</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_cdf3657f-4e52-4191-9366-4c66de7d93c4" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.8</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a0e901be-0e80-445c-8eab-603fcfba7fa0" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exercisable as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cef4d872-6ecb-4055-81bb-d20a947864b4" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,930,100</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9d9a2d4a-a35a-4c35-9e23-8d9dc176ddb3" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">12.55</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_bcc4a2b4-5a28-484b-8670-abe99547aaaa" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.6</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a7a8494-b1c0-4bf7-990c-2815f6ffb81b" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Vested and expected to vest as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f8c9ccf-0df1-4df1-a537-d8a184c1f8e2" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,273,502</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e1a33dd-a87b-413b-99bc-548adf783af1" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">9.06</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_79bde6e8-0607-47e8-a44c-ca008348af2f" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.8</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a5e0733a-0fcb-411e-a311-de741fa48d8d" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(a)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were in the money at December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></div></div></ix:nonNumeric></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2023 Option Grants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the twelve months ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company granted options to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d0c1d712-36e6-476f-89c5-6d9ce73f85cd" contextRef="C_1c1b0f6e-ec81-493a-a1e1-b384f3fff492" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,388,200</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock to employees under the 2020 Plan. The options have an exercise price equal to the closing stock price as of the grant date, and vest over </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ac4bb259-73f7-4ea3-9dcb-aca75a2b4901" contextRef="C_1c1b0f6e-ec81-493a-a1e1-b384f3fff492" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f2f807e2-7da4-417f-89ae-a66b82dee8ea" contextRef="C_860248e3-56cf-4688-98a3-19daf6e5ff6f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% vesting on the first anniversary of the grant and the remainder vesting in equal monthly installments thereafter. The weighted-average grant date fair value of options granted under the 2020 Plan during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">twelve months ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cb0157a6-91f0-43e4-b13e-63ff5bd94b4e" contextRef="C_37911699-3824-4881-9471-81254e29f4ad" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.70</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1159bf4f-a7dc-42e1-85c6-bb37788e5f3a" contextRef="C_c1455b06-7113-45cb-ac47-8e1eb7003ee1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.21</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, total unrecognized compensation expense related to unvested stock options granted under the 2020 Plan was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ae4fdb7-6274-4de9-9c55-33def823a20d" contextRef="C_a82c95f9-c18c-445c-a45f-cb3e1f90d580" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which is expected to be recognized over a weighted average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_34d9408e-f94a-4508-b450-4ed2610bf3d6" contextRef="C_37911699-3824-4881-9471-81254e29f4ad" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.91</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inducement Stock Option Grant</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the twelve months ended December 31, 2023, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Company granted options to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d221071c-a1c9-4bf5-8912-adb75a44eda1" contextRef="C_196f20b7-7250-4fea-befc-99827d01c86b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">360,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock granted outside of the 2020 Plan. These grants were made pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq listing rule 5635(c)(4). The options issued under this inducement grant have an exercise price equal to the closing stock price as of the grant date, and vest over </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2b3fbd19-4960-45ca-bed0-e446244eb169" contextRef="C_196f20b7-7250-4fea-befc-99827d01c86b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f55fb8a-6909-469e-91fc-c96e364b5b6a" contextRef="C_a3395847-e949-4251-a28f-6484e3b7556e" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% vesting on the first anniversary of the grant and the remainder vesting in equal monthly installments thereafter. The weighted-average grant date fair value of options granted under this inducement grant during the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> twelve months ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e8908944-ad14-48e7-b865-c95c519b475f" contextRef="C_196f20b7-7250-4fea-befc-99827d01c86b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.59</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_999a1b73-d798-41c0-8e57-142d6dfa0eaa" contextRef="C_fe994e7e-b8ca-4866-b2b8-f68f8a9ef323" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> inducement grants in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">twelve months ended December 31, 2022.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, total unrecognized compensation expense related to unvested inducement options granted under the 2020 Plan was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_15ad8156-d06b-463c-ac45-6ec87155e743" contextRef="C_5b2496bb-0283-4097-be94-f3832f36eb00" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which is expected to be recognized over a weighted average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c77e89b1-c6fa-4d4a-aaf4-2b30533c23e4" contextRef="C_953fc3f7-0bdc-46a5-a81f-b24a2a0ecad9" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3.28</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock Units</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2023, RSUs were granted under the 2020 Plan to the Company's employees in order to maintain retention of key employees. The value of an RSU award is based on the Company's stock price on the date of the grant. The shares underlying the RSUs are not issued until the RSUs vest.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_66aab9fb-b891-4635-b595-c42bee288355" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Activity with respect to the Company's RSUs during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">twelve months ended December 31, 2023 was as follows (in millions, except share, contractual term, and per share data):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.11%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.662%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:8.942%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.662%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.182%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Average</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Average</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Remaining</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Intrinsic</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Grant Date</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Contractual</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Value (a)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Term (in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in millions)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Outstanding as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_deab8a33-8043-4470-8c4f-945c451ff751" contextRef="C_79fb8102-e267-43bc-9f8f-f08e3d54c866" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted stock units granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ed8847f-796a-4af6-bc3a-ce841d942629" contextRef="C_0899eeab-0bfd-49a2-8a22-1c41967d8084" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">650,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_85870ae7-74d1-4029-87da-21b6300ba4d3" contextRef="C_0899eeab-0bfd-49a2-8a22-1c41967d8084" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.94</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted stock units forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_02a19866-7357-4d03-8727-4c59b020782c" contextRef="C_0899eeab-0bfd-49a2-8a22-1c41967d8084" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">35,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e9b7a6f-8e2e-49b9-bd5b-ff1ff6989781" contextRef="C_0899eeab-0bfd-49a2-8a22-1c41967d8084" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.94</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_855faaee-0fb2-4175-bc7c-180e6424cdc6" contextRef="C_a0d3bc37-c2c5-449e-9b72-d46590f710ec" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">615,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6100e162-f6c5-4b7b-8231-906351e67849" contextRef="C_a0d3bc37-c2c5-449e-9b72-d46590f710ec" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.94</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_cbb1e5ce-131e-42ac-9d92-1bf7bcdb39d5" contextRef="C_0899eeab-0bfd-49a2-8a22-1c41967d8084" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.6</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_164c7670-1773-4ea0-bc96-16940116e0b8" contextRef="C_a0d3bc37-c2c5-449e-9b72-d46590f710ec" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.8</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unvested and expected to vest as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8d583880-1d75-4ccc-90cb-0e737264cde1" contextRef="C_a0d3bc37-c2c5-449e-9b72-d46590f710ec" name="lrmr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">615,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_853a574b-7dd6-4f18-a82e-c3cca649617c" contextRef="C_a0d3bc37-c2c5-449e-9b72-d46590f710ec" name="lrmr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.94</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_8d9f46fd-08e9-4322-bb3b-a1501cd61914" contextRef="C_0899eeab-0bfd-49a2-8a22-1c41967d8084" name="lrmr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.6</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5b764b46-9a7b-4714-a785-c5f83160ea55" contextRef="C_a0d3bc37-c2c5-449e-9b72-d46590f710ec" name="lrmr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.8</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock Unit Grants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The RSUs vest annually over </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_027e1196-c40b-455e-bcc7-21b958be9295" contextRef="C_5c533b45-4872-44aa-8eba-29efd92ddf96" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and have a weighted-average grant date fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64b4ba6b-e999-49a8-88d5-bb5c604ddac1" contextRef="C_5c533b45-4872-44aa-8eba-29efd92ddf96" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.94</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per unit.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, total unrecognized compensation expense for RSUs was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8da64e55-294f-4481-951a-804ff5fa70d1" contextRef="C_a0d3bc37-c2c5-449e-9b72-d46590f710ec" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which is expected to be recognized over a weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1eecdf9c-db5b-4ebe-b51f-12bb2f30ebb0" contextRef="C_0899eeab-0bfd-49a2-8a22-1c41967d8084" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3.09</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">January 2024 Option and Restricted Stock Unit Grants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 17, 2024, the Company granted options to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_50656af7-151c-4ad6-af56-c0719a743fc1" contextRef="C_fa925083-1371-4656-ab14-7ea6e7f54fb3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,472,175</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d2406cf0-1faa-4615-80e3-162ef73a387f" contextRef="C_4d67c562-0e3a-4233-a627-82c574413619" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">245,363</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of restricted stock to employees under the 2020 Plan. The options have an exercise price equal to the closing stock price as of the grant date, and vest over </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4d3f23e6-1522-4b97-9640-918a1f88d2e5" contextRef="C_fa925083-1371-4656-ab14-7ea6e7f54fb3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5a3c0704-d9a0-4fc7-a2fa-8b7c8bf3e0e8" contextRef="C_5baad777-d068-4ce3-be35-c76ec7ffb655" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">vesting on the first anniversary of the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">grant </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and the remainder vesting in equal monthly installments thereafter. The shares of restricted stock will vest annually over </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0f96c300-547e-45ee-9b5c-b5ce5992dcc0" contextRef="C_4d67c562-0e3a-4233-a627-82c574413619" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d75b0896-eda6-4467-ac4f-7c7168217753" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense was classified in the consolidated statements of operations as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.92%;"/>
        <td style="width:1.6%;"/>
        <td style="width:1%;"/>
        <td style="width:12.64%;"/>
        <td style="width:1%;"/>
        <td style="width:1.6%;"/>
        <td style="width:1%;"/>
        <td style="width:12.64%;"/>
        <td style="width:1%;"/>
        <td style="width:1.6%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f74923b1-cff2-41f0-b611-532d7187359f" contextRef="C_c9852892-0da8-479d-83c0-1ee02dd67583" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,077</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5b074bd9-f704-49b7-81d3-62f9a9be68a6" contextRef="C_740659e5-2866-4797-81d2-afb8bf9c13fd" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,771</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b99a8d9-6214-4297-bbf4-8d13828bf996" contextRef="C_d39d1e4b-8b4a-4b1b-9377-433018f6afff" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,538</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_894eec86-e005-4cf9-833e-8fcbb2f9fa31" contextRef="C_0042b997-c48a-4b61-bc0b-c18adeff5e3f" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,848</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c6c3c64-d6dd-4863-ba5d-a7ed2dd11398" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,615</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e6145afa-f3a4-4349-99de-779e1e774285" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,619</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_abe5ea53-4227-46eb-a3ed-3ee74991f954" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">8.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commitments and Contingencies </span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intellectual Property Licenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is party to an exclusive License Agreement (the &#8220;WFUHS License&#8221;), dated November 30, 2016, as amended, with Wake Forest University Health Sciences (&#8220;WFUHS&#8221;) and an exclusive License Agreement (the &#8220;IU License&#8221;), dated November 30, 2016, as amended, with Indiana University (&#8220;IU&#8221;). Such agreements provide for a transferable, worldwide license to certain patent rights regarding technology used by the Company with respect to the development of nomlabofusp. Both agreements continue from their effective date through the last to date of expiration of the licensed patents, unless earlier terminated by either party in accordance with their terms.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In partial consideration for the right and license granted under these agreements, the Company will pay each of WFUHS and IU a royalty of a low single digit percentage of net sales of licensed products depending on whether there is a valid patent covering such products. As additional consideration for these agreements, the Company is obligated to pay each of WFUHS and IU certain milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0464cf26-8788-4e39-ad32-38bad4829e7c" contextRef="C_95b87097-23b2-4be8-a5a4-68ffcb45d537" name="lrmr:MilestonePaymentAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_1a54c308-4d82-48b6-873e-c242fc35f91a" contextRef="C_3d5bafd5-20d4-4026-a715-daa85bdc64bd" name="lrmr:MilestonePaymentAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.6</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in the aggregate upon the achievement of certain developmental milestones, which commenced with the enrollment of the first patient in a Phase 1 clinical trial. The Company enrolled the first patient in its SAD trial on December 11, 2019 and paid WFUHS and IU less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a955a41b-7003-47b0-9a7d-6fd2dc508095" contextRef="C_bdabb33a-7162-4c37-8a9a-3a553319cde1" name="lrmr:PaymentForLicenseAgreements" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company will also pay each of WFUHS and IU sublicensing fees ranging from a high-single digit to a low double-digit percentage of sublicense consideration depending on the Company&#8217;s achievement of certain regulatory milestones as of the time of receipt of the sublicense consideration. The Company is also obligated to reimburse WFUHS and IU for patent-related expenses. In the event that the Company disputes the validity of any of the licensed patents, the royalty rate would be tripled during such dispute. The Company is also obligated to pay to IU a minimum annual royalty of less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ee09bc3a-c8c6-4890-8638-e9bedf9a6e05" contextRef="C_3d5bafd5-20d4-4026-a715-daa85bdc64bd" name="lrmr:MinimumAnnualRoyaltyObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million per annum.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the event that the Company is required to pay IU consideration, then the Company may deduct </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_13bf1c34-09fe-4b36-afea-0522acfd3c64" contextRef="C_279e75b7-f67a-4ee0-b268-adff2a559757" name="lrmr:LicenseAgreementConsiderationDeductionPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">20</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of such IU consideration on a dollar-for-dollar basis from the consideration due to WFUHS. In the event that the Company is required to pay WFUHS consideration, then the Company may deduct </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1134c9be-02d1-4d55-a025-8868e3883624" contextRef="C_dac4deed-8338-46b9-9588-adb96f059754" name="lrmr:LicenseAgreementConsiderationDeductionPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">60</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of such WFUHS consideration on a dollar-for-dollar basis from the consideration due to IU.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2022, the Company initiated dosing of a Phase 2 study. Pursuant to the terms of both the WFUHS License and the IU License, the company recognized milestone expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d73b9865-c289-41f6-8d98-122b5e8b3fa3" contextRef="C_02732bcd-6e0a-478e-b53c-e115414d242b" name="lrmr:MilestoneExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million within research and development expenses.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Both agreements continue from their effective date through the last date of expiration of the licensed patents, unless earlier terminated by either party in accordance with their terms.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Bala Cynwyd Office Space</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 8, 2019, the Company entered into an operating lease for office space in Bala Cynwyd, Pennsylvania, effective as of December 15, 2019, for a period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_20dae8a3-cdaa-4f76-b746-185e6628cc24" contextRef="C_b59bebb3-ca2d-4a96-ba24-a2513f6be665" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three years and six months</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> with an option to extend the lease for </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_1adadb6d-a5ef-4cd0-b448-c546eec4b594;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> additional years. Due to required tenant improvements to be completed by the landlord, the Company did not take immediate possession of the leased property and the lease term commenced on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_18d98bc9-dfd1-44f7-83e9-a80a54b1af3c" contextRef="C_c10d75ec-25a9-4bc3-b1d5-100a6af3fb57" name="lrmr:LeaseTermCommencementDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">February 15, 2020</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 9, 2023, the Company executed a lease extension agreement on its original </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c0c10150-0a35-4236-ab1b-7eb3355286e7" contextRef="C_25c4d6a9-6524-4f9f-84fa-c1a37a44ade0" name="lrmr:AreaOfOfficeSpace" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">4,642</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square footage of office space in Bala Cynwyd, Pennsylvania (which was set to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_54780bae-ad9f-44bf-b3f5-82dab5b666a1;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">August 2023</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) and agreed to lease an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_741cae72-c104-48df-920f-f82c0d405b36" contextRef="C_783e630c-cae9-4de1-9bdf-0cc7dfa2bdb8" name="lrmr:AreaOfOfficeSpace" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">3,462</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of office space from the same landlord.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The lease extension on the original </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_650c29a6-9a07-4a96-bb65-caf7769f9bc1" contextRef="C_1f994bce-c827-41bc-8923-a0b663b5dccb" name="lrmr:AreaOfOfficeSpace" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">4,642</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square footage commenced on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_29abee27-b299-4925-bcc8-257ee8fa2492" contextRef="C_25c4d6a9-6524-4f9f-84fa-c1a37a44ade0" name="lrmr:LeaseTermCommencementDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 1, 2023</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and the Company recorded a right of use asset and lease liability of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d8c25d1-4604-42e8-9ff9-0e0ce505573e" contextRef="C_8bce919e-849a-4aa5-be5e-b7af4b9b190d" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_f0f9e090-e96b-4429-ab7b-7de236846746" contextRef="C_8bce919e-849a-4aa5-be5e-b7af4b9b190d" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of that date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The new lease on </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b237ab66-00dd-414d-951e-c1976dc22cd7" contextRef="C_1efd9ede-f9a2-45c2-93a1-636a41f2a1f2" name="lrmr:AreaOfOfficeSpace" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">3,462</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> additional square footage commenced on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e292e4fd-bf2e-45f4-bc00-b6584585b691" contextRef="C_783e630c-cae9-4de1-9bdf-0cc7dfa2bdb8" name="lrmr:LeaseTermCommencementDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">October 1, 2023</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and the Company recorded a right of use asset and lease liability of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4cfb248e-cd80-4090-8447-f549bea9af3a" contextRef="C_485ac229-ff1e-4d6d-89fa-970087d282fe" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d3dcabe2-db31-49c1-8a75-d70349fa51a2" contextRef="C_485ac229-ff1e-4d6d-89fa-970087d282fe" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of that date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The right of use assets and lease liabilities with both these leases are reflected in the financial statements for the year ended December 31, 2023 as are the right of use asset and lease liability of the Company's Boston office space discussed below.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Boston Office Lease</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Company's 2020 merger with Zafgen described in footnote 1, on May 28, 2020, the Company acquired a non-cancellable operating lease for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_162157b3-8b8c-4fbd-bb48-421948038faa" contextRef="C_095c643d-76db-4c04-8cbb-33eef107ab9e" name="lrmr:AreaOfOfficeSpace" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">17,705</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of office space (the &#8220;Premises&#8221;). The lease expires on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_182d1e70-b5d2-403b-936e-62b190151118" contextRef="C_095c643d-76db-4c04-8cbb-33eef107ab9e" name="us-gaap:LeaseExpirationDate1" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">October 30, 2029</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. As part of the agreement, the Company is required to maintain a letter of credit, which upon signing was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2fa88c0c-f0ad-44cd-95df-a798c9f3c81f" contextRef="C_5ea5486f-6817-49ce-bca9-bd58ccc45608" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and is classified as restricted cash within the condensed consolidated financial statements. In addition to the base rent, the Company is also responsible for its share of operating expenses, electricity and real estate taxes, which costs are not included in the determination of the leases&#8217; right-of-use assets or lease liabilities. The right-of-use asset is being amortized to other income/(expense) over the remaining lease term as a result of the sublease described below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 27, 2020, the Company entered into a sublease agreement (the &#8220;Sublease&#8221;) with Massachusetts Municipal Association, Inc. (the &#8220;Subtenant&#8221;), whereby the Company sublet the entire Premises to the Subtenant. The initial term of the Sublease commenced on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c8b74739-bf79-4ae4-8382-f0918e8716fa" contextRef="C_69f61fa0-0ce7-4f9f-b5a6-b3da5b3c716c" name="lrmr:LeaseTermCommencementDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 4, 2020</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and continues until </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0aab6cd5-5527-4d30-8084-5c6c42dc2bc4" contextRef="C_69f61fa0-0ce7-4f9f-b5a6-b3da5b3c716c" name="us-gaap:LeaseExpirationDate1" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">October 30, 2029</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In connection with the Sublease, the Company evaluated the need for impairment under ASC 360 "Impairment Testing: Long-Lived Assets Classified as Held and Used," and determined there was no impairment.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Sublease provided for an initial annual base rent of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de53f237-aa5d-4b21-afe7-c41fef13750f" contextRef="C_600d2614-95f3-40e4-a75b-3d7d2462a2d9" name="lrmr:SubleaseAnnualBaseRent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which increases annually up to a maximum annual base rent of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c97484ee-a8d1-442b-90e6-b28ec9ad7a7d" contextRef="C_b094896e-8ca7-4bae-b10c-753cf6471626" name="lrmr:SubleaseAnnualBaseRent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Subtenant also is responsible for paying to the Company future increases in operating costs (commencing on January 1, 2022), future increases in annual tax costs (commencing July 1, 2021) and all utility costs (commencing March 1, 2021) attributable to the Premises during the term of the Sublease. As part of the Sublease, the subtenant deposited a letter of credit in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e33a740-46af-484a-b972-2892ee5f1c8d" contextRef="C_cf00efe6-6c32-4b41-a584-da4e540323ec" name="us-gaap:SecurityDepositLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to assure their performance under the sublease. If there are no uncured events of default under the sublease, the amount of this security deposit decreases over time to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb2c4107-29c6-4e4a-88c1-c4c2c4f74a07" contextRef="C_f2aae2bb-8999-4b7a-9f12-440a582140f9" name="us-gaap:SecurityDepositLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million on the sixth anniversary of the Sublease. The Company records sublease income on this sublease on a straight-line basis as a component of other income/(expense).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Lab Space</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 5, 2018, the Company entered into an operating lease for office and lab space in Philadelphia, Pennsylvania, effective as of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_10cd939f-6314-4f2e-ab15-81748ad2b921" contextRef="C_d800893b-5211-4ef0-8aeb-b28cb9dd18ee" name="lrmr:LeaseTermCommencementDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 1, 2019</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and expiring on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b5914cbb-b88f-40a8-839c-f1b6ac82fc52" contextRef="C_d800893b-5211-4ef0-8aeb-b28cb9dd18ee" name="us-gaap:LeaseExpirationDate1" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2020</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> with an option to extend the lease for </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_ed24bfd5-a8ef-478d-bee3-0b02edde6a19;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">two</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> additional years. On August 4, 2020, the Company executed the first option to extend the lease for an additional year, expiring on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_63119ee8-d7be-4bc2-ae8b-8a9fcbe819de" contextRef="C_89695345-0b21-49a0-8d47-0e33cf4abec6" name="us-gaap:LeaseExpirationDate1" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2021</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. On August 9, 2021, the Company executed the remaining option to extend the lease for an additional year, expiring on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9a247719-3080-489e-ac75-32c8c364fcb9" contextRef="C_f4ad8f7d-6e13-40e8-9f2e-5b7b5f6addd0" name="us-gaap:LeaseExpirationDate1" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In January 2023, the Company executed an extension of this lease for an additional year, expiring on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c0ae6d51-bfef-4a5e-b3e0-18bf06197721" contextRef="C_26cd9754-8143-4a1f-93ac-b42a31563c34" name="us-gaap:LeaseExpirationDate1" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company has determined this lease extension qualifies as a short-term lease and have applied the accounting policy election to not record the related right-of-use asset and lease liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 16, 2023, the Company entered into an operating lease for lab space in King of Prussia, Pennsylvania for a period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b6a273c4-8c30-4808-9b8e-f68f9d080813" contextRef="C_d735f0e0-bd1f-4ef9-b8c9-2c828c14ca2f" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Due to required tenant improvements to be completed by the landlord, the Company did not take immediate possession of the leased property and the lease term is expected to commence in the second quarter of 2024, no right of use asset or lease liability will be recorded until the lease commencement date.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Lease Expense</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expense arising from operating leases was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8d18ce1a-0e0b-4142-abbe-8d3c20b92ff4" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7e064f7-1e14-4806-97aa-808e8209231c" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">twelve months ended December 31, 2023 and 2022, respectively. For operating leases, the weighted-average remaining lease term for leases at December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ac057305-b916-4b0c-9161-9a72aca16a87" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5.5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5e274e9f-e5e3-4fa1-bcad-e66db0051d4b" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6.8</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">respectively. For operating leases, the weighted</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">19</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">average </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">discount rate for leases at December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_acc06655-4300-4f18-ae16-10a819c64062" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_6699385d-ee4b-4268-b8d4-4152e8bd3acf" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">11.0</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%. The Company has not entered into any financing leases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_69b513e9-5b5c-4a44-83a4-9f110b4d9c28" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Maturities of lease liabilities due under these lease agreements as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 are as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.1%;"/>
        <td style="width:1.94%;"/>
        <td style="width:1%;"/>
        <td style="width:15.96%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">Year Ending December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Operating</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Leases</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c4c34187-45f0-4feb-a5d9-a77505d2984a" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,380</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a50a5ddd-64d1-4e37-b297-d39ffff2d3c3" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,403</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d08e7df-7ae0-4738-b663-525232d4939b" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,328</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_afc7dff9-53a7-436d-94c1-42881075282b" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,118</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_df222110-d8f3-45ff-929f-8c62b8ce32b1" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,136</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_15f3ff11-d2ca-451c-9599-055139efe9c8" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">959</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_47f1018c-d571-4870-bd9c-c12a043ca6b3" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,324</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c9e56b8-5590-46c6-9017-3efa1a55eb82" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,778</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Present value of lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f75888c7-e637-48fd-9e0e-e992ab1615d3" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,546</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Legal Proceedings</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is not currently a party to any litigation, nor is management aware of any pending or threatened litigation against the Company, that it believes would materially affect the Company&#8217;s business, operating results, financial condition or cash flows.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_65e10f47-5b92-4c7c-91ad-5c21a5d81a2d" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">9.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income Taxes </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the years ended December 31, 2023, and 2022</span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company recorded </span><span style="font-size:10pt;font-family:Times New Roman;color:#333333;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5b38321f-5207-4f1a-af92-c3af61a152b5" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_93c09c5c-f301-4cc9-a822-cf3b9db4d30a" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> income tax benefits for the net operating losses incurred in each year due to its uncertainty of realizing a benefit from those items.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_40358b79-ed06-44fe-aebd-84aaa67863b5" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The domestic and foreign components of loss before income taxes are as follows.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Domestic</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dfb6a0f6-0cc4-48ef-83b2-12250336e388" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">36,948</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ecff1b5-e3e3-4c4a-9e11-ffc1cc1a047f" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">35,339</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e8fd37f-5490-4bf4-8949-ea7fe1a3d5e8" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9beae1ce-47a6-4702-a43a-9c859cb5c120" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9d30f437-e8e8-4fd0-851b-2efb606bb6e9" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">36,949</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_07c67a87-67c9-4774-aa39-537946bf1a9f" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">35,355</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_27362e81-d24a-4e0f-8f68-30dc93e68a77" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A</span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.343%;"/>
        <td style="width:1%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.343%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal statutory income tax rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28bf7cc8-d8b4-450f-a584-8f75249b56a3" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e3a2760-87e0-4a56-a79b-7eb21612b767" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State taxes, net of federal benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb93b7ae-174b-4aa1-8ace-370103378546" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.9</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0b1b8f80-6c4c-499f-be27-6842153e9307" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">6.2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in state tax rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a860ff1-cce8-4113-ac69-e83476cc6765" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="lrmr:EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.7</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fefd4e00-bee3-4b5e-ad82-d2f6d5343579" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="lrmr:EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">7.9</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal and state research and development tax credit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_85de52cf-fa02-41c7-82cc-374e3cc9c00b" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">8.2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ab1816b-4140-4951-b523-2cce43d11788" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nondeductible permanent differences</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8d6d0c6-6323-467a-be45-e6412d3cdaca" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7dc10fa-a1a7-4ba4-8a22-45690bbe51a4" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock compensation forfeitures - DTA Write Off</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_589ca90a-3678-49a0-9273-c72657623766" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="lrmr:EffectiveIncomeTaxRateReconciliationStockCompensationForfeituresPercent" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.8</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in deferred tax asset valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_01b3b85f-6255-4fe6-b86a-e6b24d00a4ce" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">29.6</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_04b2bcf2-8b55-4320-93b7-ce317aa740c6" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">19.3</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Effective income tax rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_813d097e-63b8-42dd-9a4d-3766ae2d9da6" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_626334ba-6f38-4180-af92-4e8d6795e381" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude></ix:nonNumeric></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c6dac32b-c8b9-42e1-8236-e5cb94ad399d" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net deferred tax assets as of </span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 consisted of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized R&amp;D - acquired in merger with Zafgen</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd1368a9-7218-4c00-a63d-7f89c95d166f" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66,678</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd9c85cd-10f6-4b6c-8917-86551421d8b2" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66,941</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized R&amp;D - Section 174 Costs post 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_81fd4183-1843-4b95-a991-120d36d1a9ea" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="lrmr:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,411</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d8ed426-2d97-49ea-beb6-fb5d524e7b3a" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="lrmr:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,019</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27abb52f-d60a-4183-8b54-1e1dafaef8de" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,490</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a5cca039-6a9e-42f1-8096-8b254b337d05" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,709</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f0b29fab-0a7b-4dc4-80b6-341d061aad34" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,195</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6497b23a-faa7-4b29-bb22-202fc6c0497a" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,204</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax credit carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b28dab93-d5d3-4ac8-ae8c-bebb55e23a7f" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,319</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ba15aabd-a451-43d2-ae82-ff74d90682cf" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,284</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other temporary differences</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1422d989-c73c-490b-9272-12a928835bd9" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1807014c-e7e4-477e-8e03-e905d8a482db" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accruals &amp; reserves</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f4277ef4-a187-4b3e-a017-31068256315b" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fdf1f1d1-0619-44c6-879d-7bcf942623c3" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fixed assets &amp; intangibles</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_db5088f8-2300-4786-a720-570b65d7eb5c" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="lrmr:DeferredTaxAssetsFixedAssetsAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">107</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bfce9afa-5d2f-496a-a8f2-5fd3cc8df034" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="lrmr:DeferredTaxAssetsFixedAssetsAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_569c8978-34bb-4a7c-8025-a80f5a13e158" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="lrmr:DeferredTaxAssetsOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,298</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c2949e0-341e-40c2-af10-d0209cd66a37" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="lrmr:DeferredTaxAssetsOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,355</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2db2b1a4-e50c-4980-a2b2-191001d43b92" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">142,538</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1dc795e0-11b4-4e99-89e7-e25a36b901d6" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">131,632</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating right of use asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_88c9fc52-d523-4ee0-b400-1c5897f6273f" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">768</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05152b9f-8505-40d8-bfe8-65bad7ad42b5" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">801</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c357bfdc-f30f-4cff-9bef-756aecd97187" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">768</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f4c9677f-e014-4bf6-96be-a694cf2b9cfe" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">801</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c8cf427e-d809-46f2-a399-5999bd3a265c" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">141,770</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7307a544-756f-4f94-bdbe-0dce56d49155" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">130,831</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets / (liabilities)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in the valuation allowance for deferred tax assets during the year ended December 31, 2023 and 2022</span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> related primarily to the increase in net operating loss carryforwards and tax credit carryforwards and a decrease other deferred tax assets associated with a reduction in the Company&#8217;s effective state rate. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cf9213d8-36c6-4c13-9c53-755f3e465d7a" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:SummaryOfValuationAllowanceTextBlock" escape="true" continuedAt="F_cf9213d8-36c6-4c13-9c53-755f3e465d7a_1"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes to the valuation allowance were as follows:</span></ix:nonNumeric></span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_cf9213d8-36c6-4c13-9c53-755f3e465d7a_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valuation allowance as of the beginning of the year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3325cd8a-e598-4ccf-b8fc-e3029648c2f7" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">130,831</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_21be415b-6787-435f-9448-00fae66d3a94" contextRef="C_cb46581b-8c63-4fee-b4c7-cc9ee9a93a21" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">124,016</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increases recorded to income tax provision</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27b7336f-e6e7-46eb-88c2-f7873f642a1a" contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,939</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_814ef94a-baa3-4f24-98ab-6ddc1ed62e64" contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,815</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valuation allowance at end of year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_66ad2a29-d680-44d8-a3b3-af4b1b007bfc" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">141,770</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ee98ab93-3722-4a80-ae88-d34d85e1d369" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">130,831</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had net operating loss carryforwards that expire for federal, foreign and state income tax purposes of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#333333;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34707822-016a-4241-b464-e7a8343743e5" contextRef="C_0bbb406f-e95b-44a2-aa20-069ec9f8367d" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">179.0</ix:nonFraction></span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#333333;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_86ab5acc-90b5-4e6c-b765-fa34d3529691" contextRef="C_bb598509-13da-4a32-959a-d65c251e001c" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#333333;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ddd1b745-b3c4-4b3a-a34f-dd02562ccab4" contextRef="C_d76e4f25-f643-4f25-bc71-be694bd78953" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">148.1</ix:nonFraction></span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. The federal and state operating losses begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f2abf064-a220-4237-b1d7-8d506373100b" contextRef="C_17f828a8-cd38-4b18-ac31-c79bc0508443" name="lrmr:NetOperatingLossCarryForwardExpirationYearBegin"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2026</span></ix:nonNumeric></span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d7fb0ec4-b9c8-4605-836b-27d7f20212c5" contextRef="C_c1f2a4df-aa2f-4030-a1d3-a3da85f2634e" name="lrmr:NetOperatingLossCarryForwardExpirationYearBegin"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2030</span></ix:nonNumeric></span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, while the foreign net loss carryforward can be carried forward indefinitely. As of </span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had federal net operating loss carryforwards that were generated after December 31, 2017 of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#333333;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_00f2111d-a00e-4d90-a159-7b5756c9ac7d" contextRef="C_b1cbaf6b-72b0-4de8-aef3-35073ff760cf" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">140.3</ix:nonFraction></span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million that do not expire, however these </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_76b7936f-06fd-44d8-b31c-b34748172b71" contextRef="C_73fffb18-77da-4d3d-8982-345e143a5dd4" name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">carryforwards are limited to </span><span style="font-size:10pt;font-family:Times New Roman;color:#333333;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c7cb695-3546-44a1-acba-8da764123c04" contextRef="C_73fffb18-77da-4d3d-8982-345e143a5dd4" name="lrmr:OperatingLossCarryforwardsMinimumPercentageOfTaxableIncomeInTaxPeriod" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">80</ix:nonFraction></span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the taxable income in any one tax period.</span></ix:nonNumeric></span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> As of </span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company also had available tax credit carryforwards for federal and state income tax purposes of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#333333;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95ac9944-1097-4636-b3a9-e4814b1b1888" contextRef="C_e879db45-fbcf-422c-84ea-f7c96123af6f" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">16.3</ix:nonFraction></span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million which begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_245637dc-6dc1-4f6a-972f-df290bc3bd37" contextRef="C_04fe8bd0-766a-4741-afc3-501f8a39c817" name="lrmr:TaxCreditCarryForwardExpirationYearStart"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2039</span></ix:nonNumeric></span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Utilization of the pre-Merger net operating loss carryforwards attributable to Zafgen, of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#333333;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ce8c0e9-737b-45cf-b779-54a27a3fbdaa" contextRef="C_8f177c92-7fde-43e5-bb65-ae7ee79f52cb" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">33.5</ix:nonFraction></span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, are subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986 due to ownership changes occurred during the tax year associated with the Merger. In addition to the limitation of the pre-Merger NOL&#8217;s of Zafgen, the net capitalized R&amp;D deferred tax assets in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#333333;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d1611073-2c69-4100-8ff1-bd607485684e" contextRef="C_8f177c92-7fde-43e5-bb65-ae7ee79f52cb" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">66.9</ix:nonFraction></span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_373c08e7-3af1-4fea-af88-25958810a79a" contextRef="C_ccc62b5b-71d4-486d-aec0-66d4350d7baf" name="lrmr:NetCapitalizedRDDeferredTaxAssetsRealizationDescription"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">is subject to the built-in loss rules under Section 382 and may not be realized if the underlying asset associated with the R&amp;D is disposed within five years of the Merger, or May 28, 2025</span></ix:nonNumeric></span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. The ownership changes will limit the amount of pre-merger Zafgen carryforwards that can be utilized annually to offset future taxable income with an annual limitation of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#333333;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0d1b1e5f-8bee-4ba6-94ae-45c187869da5" contextRef="C_ccc62b5b-71d4-486d-aec0-66d4350d7baf" name="lrmr:NetOperatingLossCarryforwardsAnnualUtilizationLimitChangeInOwnership" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35</ix:nonFraction></span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thousand per year. The Company has reduced their NOL and R&amp;D tax credit deferred tax assets associated with the pre-Merger Zafgen operations as a result of the 382 analysis.</span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">21</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company believes that as a result of its merger with Zafgen, its ability to utilize NOLs acquired in the transaction and our other NOLs is expected to be severely limited by Section 382 of the Code. Additionally, the Company&#8217;s July 2021, September 2022 and February 2023 equity transactions could also limit its ability to utilize NOLs in the future. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception. If the Company experienced a change of control, as defined by Section 382, at any time since inception, utilization of its net operating loss carryforwards or tax credit carryforwards would be subject to an annual limitation under Section 382, which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, our July 2021, September 2022 and February 2024 equity transactions could also limit our ability to utilize NOLs in the future. </span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any limitation may result in expiration of a portion of the net operating loss carryforwards or tax credit carryforwards before utilization. Further, until a study is completed, and any limitation is known, no amounts are being presented as an uncertain tax position.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Tax Cuts and Jobs Act ("TCJA") requires taxpayers to capitalize and amortize research and experimental expenditures under IRC Section 174 for tax years beginning after December 31, 2021. This rule became effective for the Company during the year ended December 31, 2022 and resulted in the capitalization of research and development costs in both 2023 and 2022. The Company is amortizing these costs for tax purposes over </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e7f8a078-9e40-465b-aa1c-7a4f231b7056" contextRef="C_e3617796-30ca-4ac0-abe2-0626ffe07078" name="lrmr:CapitalizedResearchAndDevelopmentAmortizationPeriod" format="ixt-sec:durwordsen"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> if the research and development was performed in the U.S. and over </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a5fbc33e-6f7d-464a-910a-a7bab8eb420d" contextRef="C_ba0cb289-2a01-465c-bc0c-d7869d54c786" name="lrmr:CapitalizedResearchAndDevelopmentAmortizationPeriod" format="ixt-sec:durwordsen"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15 years</span></ix:nonNumeric></span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> if the research and development was performed outside the U.S.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022</span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company&#8217;s net deferred tax asset balance before the valuation allowance was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#333333;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a32a0ef-cef6-4886-a8ec-88bcaa184298" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="lrmr:DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">141.8</ix:nonFraction></span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#333333;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f8d08d42-4ee5-4a4f-b955-69aa59acad5c" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="lrmr:DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">130.8</ix:nonFraction></span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, and was comprised principally of net operating loss carryforwards, capitalized research and development expenses and tax credit carryforwards. During the years ended </span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, gross deferred tax assets increased due to deferred tax assets acquired as a result of additional net operating loss carryforwards and research and development tax credits generated.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets. Management has considered the Company&#8217;s history of cumulative net losses incurred since inception and its lack of commercialization of any products or generation of any revenue from product sales since inception and has concluded that it is more likely than not that the Company will not realize the benefits of the deferred tax assets. Accordingly, a full valuation allowance has been established against the deferred tax assets as of December 31, 2023 and 2022. Management reevaluates the positive and negative evidence at each reporting period.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#333333;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d7a2ea2-782f-4eb8-af0c-184c42fe8e2b" contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_1b6b2159-68d4-4378-81b4-06b2f19d1d48" contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recorded any amounts for unrecognized tax benefits as of </span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending income tax examinations. The Company&#8217;s tax years are still open under statute from </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3121b984-6f0a-44ed-9156-cfd2472adee9" contextRef="C_3beedc45-1504-486d-95b7-175808b52042" name="us-gaap:OpenTaxYear"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2019</span></ix:nonNumeric></span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to the present. Earlier years may be examined to the extent that tax credit or net operating loss carryforwards are used in future periods. The Company&#8217;s policy is to record interest and penalties related to income taxes as part of its income tax provision.</span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span></p></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>2
<FILENAME>lrmr-ex10_3.htm
<DESCRIPTION>EX-10.3
<TEXT>
<html>
 <head>
  <title>EX-10.3</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">GOODWIN PROCTER DRAFT:  2/15/2023</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;min-width:fit-content;">RESTRICTED STOCK UNIT AWARD AGREEMENT<br>FOR COMPANY EMPLOYEES<br>UNDER the larimar therapeutics, inc.<br>2020 equity INCENTIVE PLAN</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Name of Grantee:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No. of Restricted Stock Units:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Grant Date:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Larimar Therapeutics, Inc. 2020 Equity Incentive Plan as amended through the date hereof (the &#x201c;Plan&#x201d;), Larimar Therapeutics, Inc. (the &#x201c;Company&#x201d;) hereby grants an award of the number of Restricted Stock Units listed above (an &#x201c;Award&#x201d;) to the Grantee named above.  Each Restricted Stock Unit shall relate to one share of common stock, par value $0.001 per share (a &#x201c;Share&#x201d; or &#x201c;Shares&#x201d;) of the Company.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Restrictions on Transfer of Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  This Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of by the Grantee, and any Shares issuable with respect to the Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of until (i) the Restricted Stock Units have vested as provided in Paragraph 2 of this Agreement and (ii) Shares have been issued to the Grantee in accordance with the terms of the Plan and this Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Vesting of Restricted Stock Units</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The restrictions and conditions of Paragraph 1 of this Agreement shall lapse on the Vesting Date or Dates specified in the following schedule so long as the Grantee remains an employee of the Company or a Subsidiary on such Dates.  If a series of Vesting Dates is specified, then the restrictions and conditions in Paragraph 1 shall lapse only with respect to the number of Restricted Stock Units specified as vested on such date.</font></div></div>
  <table style="margin-left:6.667%;border-spacing:0;table-layout:fixed;width:83.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:58.46%;"></td>
    <td style="width:41.54%;"></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Incremental Number of<br></font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Restricted Stock Units Vested</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Vesting Date</font></p></td>
   </tr>
   <tr style="height:15.1pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="text-indent:0.6pt;vertical-align:top;"><p style="margin-left:0.6pt;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">_____________ (___%)</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">_______________</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="text-indent:0.6pt;vertical-align:top;"><p style="margin-left:0.6pt;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">_____________ (___%)</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">_______________</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="text-indent:0.6pt;vertical-align:top;"><p style="margin-left:0.6pt;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">_____________ (___%)</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">_______________</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="text-indent:0.6pt;vertical-align:top;"><p style="margin-left:0.6pt;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">_____________ (___%)</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">_______________</font></p></td>
   </tr>
  </table>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Administrator may at any time accelerate the vesting schedule specified in this Paragraph 2.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Termination of Employment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  If the Grantee&#x2019;s employment with the Company and its Subsidiaries terminates for any reason (including death or disability) prior to the satisfaction of the vesting conditions set forth in Paragraph 2 above, any Restricted Stock Units that have not vested as of such date shall automatically and without notice terminate and be forfeited, and neither the Grantee nor any of his or her successors, heirs, assigns, or personal </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.8in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">ACTIVE/121521257.3</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">representatives will thereafter have any further rights or interests in such unvested Restricted Stock Units.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Issuance of Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  As soon as practicable following each Vesting Date (but in no event later than two and one-half months after the end of the year in which the Vesting Date occurs), the Company shall issue to the Grantee the number of Shares equal to the aggregate number of Restricted Stock Units that have vested pursuant to Paragraph 2 of this Agreement on such date and the Grantee shall thereafter have all the rights of a stockholder of the Company with respect to such shares. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Incorporation of Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Notwithstanding anything herein to the contrary, this Agreement shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Committee set forth in Section 2 of the Plan.  Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tax Withholding</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.   The Grantee shall, not later than the date as of which the receipt of this Award becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, and local taxes required by law to be withheld on account of such taxable event.  To the extent authorized by the Committee, the required tax withholding obligation may be satisfied, in whole or in part, by withholding from Shares to be issued to the Grantee a number of Shares with an aggregate Fair Market Value that would satisfy the withholding amount due. The Company has the right to deduct any such taxes from payment of any kind otherwise due to the Grantee.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tax Consequences</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The Grantee acknowledges that the Company has not advised the Grantee regarding the Grantee&#x2019;s tax liability in connection with this Award. The Grantee acknowledges that the Grantee has reviewed with the Grantee&#x2019;s own tax advisors the tax treatment of this Award (including the issuance of any Shares in settlement of the Restricted Stock Units hereunder) and is relying solely on those advisors in that regard. The Grantee understands that the Grantee (and not the Company) will be responsible for the Grantee&#x2019;s own tax liabilities arising in connection with this Award.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 409A of the Code.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  This Agreement shall be interpreted in such a manner that all provisions relating to the settlement of the Award are exempt from the requirements of Section 409A of the Code as &#x201c;short-term deferrals&#x201d; as described in Section 409A of the Code.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Continuation of Service</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. This Agreement will not confer upon the Grantee any right to continue in the employment or service of the Company or any of its Affiliates, or limit in any respect the right of the Company or its Affiliates to discharge the Grantee at any time, for any reason.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Entire Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. This Agreement represents the entire agreement between the parties with respect to the subject matter hereof and supersedes any prior agreement, written or otherwise, relating to the subject matter hereof.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.8in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">ACTIVE/121521257.3</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Data Privacy Consent</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the &#x201c;Relevant Companies&#x201d;) may process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the &#x201c;Relevant Information&#x201d;).  By entering into this Agreement, the Grantee (i) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii) waives any privacy rights the Grantee may have with respect to the Relevant Information; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate.  The Grantee shall have access to, and the right to change, the Relevant Information.  Relevant Information will only be used in accordance with applicable law.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">12.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Electronic Delivery of Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The Grantee authorizes the Company to deliver electronically any prospectuses or other documentation related to this Award and any other compensation or benefit plan or arrangement in effect from time to time (including, without limitation, reports, proxy statements or other documents that are required to be delivered to participants in such arrangements pursuant to Federal or state laws, rules or regulations). For this purpose, electronic delivery will include, without limitation, delivery by means of e-mail or e-mail notification that such documentation is available on the Company&#x2019;s Intranet site. Upon written request, the Company will provide to the Grantee a paper copy of any document also delivered to the Grantee electronically. The authorization described in this Paragraph may be revoked by the Grantee at any time by written notice to the Company.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.8in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">ACTIVE/121521257.3</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:36pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Larimar Therapeutics, Inc.</font></p>
  <p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">By:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	Title:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:36pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned.  Electronic acceptance of this Agreement pursuant to the Company&#x2019;s instructions to the Grantee (including through an online acceptance process) is acceptable.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Dated:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Grantee&#x2019;s Signature</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Grantee&#x2019;s name and address:</font></p>
  <p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.8in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">ACTIVE/121521257.3</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>3
<FILENAME>lrmr-ex10_4.htm
<DESCRIPTION>EX-10.4
<TEXT>
<html>
 <head>
  <title>EX-10.4</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;min-width:fit-content;">larimar therapeutics, inc.</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;min-width:fit-content;"><br>NON-QUALIFIED stock option grant notice</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;min-width:fit-content;">and award agreement</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;min-width:fit-content;">NON-PLAN INDUCEMENT AWARD</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Larimar Therapeutics, Inc., a Delaware corporation (the &#x201c;Company&#x201d;), hereby grants to the individual listed below (&#x201c;Participant&#x201d;) an non-qualified stock option to purchase the number of Shares set forth below (the &#x201c;Option&#x201d;). The Option is subject to the terms and conditions set forth in this Non-Qualified Stock Option Grant Notice (the &#x201c;Grant Notice&#x201d;) and the Award Agreement attached hereto as Exhibit A (the &#x201c;Agreement&#x201d;), which is incorporated herein by reference. This Option has been granted as an employment inducement grant pursuant to Rule 5635(c)(4) of the Marketplace Rules of NASDAQ Stock Market, Inc., is not issued under the Company&#x2019;s 2020 Equity Incentive Plan, as amended through the date hereof (the &#x201c;Plan&#x201d;), and does not reduce the share reserve under the Plan. However, for purposes of interpreting the applicable provisions of this Option, the terms and conditions of the Plan (other than those applicable to the share reserve) shall govern and apply to this Option as if this Option had actually been issued under the Plan. This Option is not intended to be an &#x201c;incentive stock option&#x201d; under Section 422 of the Internal Revenue Code of 1986, as amended. Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Grant Notice and the Agreement.</font></p>
  <p style="margin-left:0.987%;font-size:10pt;margin-top:6.05pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Participant:	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">]</font></p>
  <p style="margin-left:0.987%;font-size:10pt;margin-top:5.85pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Grant Date:	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">]</font></p>
  <p style="margin-left:0.987%;font-size:10pt;margin-top:5.8pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exercise Price Per Share:	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">]</font></p>
  <p style="margin-left:0.987%;font-size:10pt;margin-top:5.8pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Total Number of Shares Subject to Option:	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">]</font></p>
  <p style="margin-left:0.987%;font-size:10pt;margin-top:5.8pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Expiration Date:	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">]</font></p>
  <p style="margin-left:0.987%;font-size:10pt;margin-top:6.2pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Vesting Schedule:	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">]</font></p>
  <p style="margin-left:0.987%;text-indent:4.175%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.611%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">By Participant&#x2019;s signature below, Participant agrees to be bound by the terms and conditions of the Agreement and the Grant Notice, and, for purposes of interpreting the provisions of the Option, the terms and conditions of the Plan (other than those applicable to the share reserve) shall govern and apply to this Option as if this Option had actually been issued under the Plan. Participant has reviewed the Agreement, the Plan and the Grant Notice in their entirety, has had an opportunity to obtain the advice of counsel prior to executing the Grant Notice and fully understands all provisions of the Grant Notice, the Agreement and the Plan. This document may be executed, including by electronic means, in multiple counterparts, each of which will be deemed an original, and all of which together will be deemed a single instrument.</font></p>
  <p style="margin-left:0.987%;font-size:10pt;margin-top:6.2pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">LARIMAR THERAPEUTICS, INC.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">PARTICIPANT</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">ACTIVE/121518754.3</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:0.987%;font-size:10pt;margin-top:6.2pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.987%;font-size:10pt;margin-top:6.2pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">_____________________________________	________________________________<br>Name:	Name:</font></p>
  <p style="margin-left:0.987%;font-size:10pt;margin-top:6.2pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Title:	Title:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">ACTIVE/121518754.3</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;min-width:fit-content;">exhibit a<br>to NON-QUALIFIED stock option grant<br><br>Notice Award agreement</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Grant Notice to which this Agreement is attached, the Company has granted to Participant an Option under the Plan to purchase the number of Shares set forth in the Grant Notice.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Award of Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  In consideration of Participant&#x2019;s employment with or service to the Company and for other good and valuable consideration, effective as of the Grant Date set forth in the Grant Notice, the Company has granted to Participant the Option to purchase part or all of the aggregate number of Shares set forth in the Grant Notice, subject to the terms and conditions set forth in the Grant Notice and this Agreement, and, as set forth above, for purposes of interpreting the provisions of the Option, the terms and conditions of the Plan (other than those applicable to the share reserve) shall govern and apply to this Option as if this Option had actually been issued under the Plan.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Date of Grant; Term of Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The Option is granted on the Grant Date and may not be exercised later than the Expiration Date, subject to earlier termination in accordance with this Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Option Exercise Price</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The exercise price per Share of the Option (the &#x201c;Exercise Price&#x201d;) is set forth in the Grant Notice.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Vesting and Exercise of Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Vesting</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Subject to the continued service of the Participant with the Company through the relevant vesting dates, the Option shall become vested and exercisable in such amounts and at such times as set forth in the Grant Notice.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Service with Affiliates</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Solely for purposes of this Agreement, service with the Company will be deemed to include service with an Affiliate of the Company (for only so long as such entity remains an Affiliate of the Company).</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Effect of Termination of Service on the Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. If the Participant&#x2019;s service ceases for any reason, the termination or survival of the Option will be determined in accordance with Section 7 of the Plan.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Method of Exercise</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The Participant may exercise the Option by delivering a payment of the Exercise Price, any required tax withholding and written notice of exercise to the Company in accordance with Section 5(d) of the Plan. To the extent permitted (and subject to procedures established) by the Committee in its discretion, the Participant may also pay the Exercise Price (i) by surrendering previously acquired Shares to the Company, which Shares have an aggregate Fair Market Value on the date of exercise equal to the aggregate </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">ACTIVE/121518754.3</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:left;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exercise Price then due (or by means of attestation, whereby the Participant identifies specific previously acquired Shares having an aggregate Fair Market Value on the date of exercise equal to the aggregate Exercise Price then due and the number of Shares actually delivered upon exercise is reduced by the number of such identified Shares), or (ii) by means of a broker-assisted cashless exercise. The notice of exercise must also be accompanied by any further documents or instruments necessary or desirable to carry out the purposes or intent of this Agreement.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Partial Exercise</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The minimum number of Shares with respect to which the Option may be exercised at any one time shall be the lesser of (i) 100 Shares, or (ii) the total number of Shares as to which the Option is then exercisable.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Restrictions on Exercise</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The Option may not be exercised, and any purported exercise will be void, if the issuance of Shares upon such exercise would constitute a violation of any law, regulation or exchange listing requirement. The Committee may from time to time modify the terms of the Option or impose additional conditions on the exercise of the Option as it deems necessary or appropriate to facilitate compliance with any law, regulation or exchange listing requirement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Investment Representations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The Participant represents and warrants he or she is acquiring the Option (and upon exercise of the Option, will be acquiring the subject Shares) for investment for the Participant&#x2019;s own account, not as a nominee or agent, and not with a view to, or for resale in connection with, any distribution thereof. As a further condition to the exercise of the Option, the Company may require the Participant to make any representation or warranty as may be required by or advisable under any applicable law or regulation.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Non-Transferability of Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Except as may be permitted by the Committee in accordance with Section 14 of the Plan, the Option may not be sold, pledged, assigned, hypothecated, gifted, transferred or disposed of in any manner, either voluntarily or involuntarily, other than by will or by the laws of descent and distribution.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Adjustments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The Exercise Price, as well as the number and kind of shares subject to the Option, are subject to adjustment at the discretion of the Committee, including, but not limited to, in accordance with Section 3(d) of the Plan.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tax Consequences</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The Participant acknowledges that the Company has not advised the Participant regarding the Participant&#x2019;s tax liability in connection with the Option. The Participant acknowledges that the Participant has reviewed with the Participant&#x2019;s own tax advisors the tax treatment of the Option (including the purchase and sale of Shares subject hereto) and is relying solely on those advisors in that regard. The Participant understands that the Participant (and not the Company) will be responsible for the Participant&#x2019;s own tax liabilities arising in connection with the Option.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Continuation of Service</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. This Agreement will not confer upon the Participant any right to continue in the employment or service of the Company or any of its Affiliates, or </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">ACTIVE/121518754.3</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">limit in any respect the right of the Company or its Affiliates to discharge the Participant at any time, for any reason.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. As set forth above, this Option is not granted pursuant to the Plan.  Instead, this Option is granted as an &#x201c;employment inducement award&#x201d; pursuant to the exemption provided by Rule 5635(c)(4) of the Marketplace Rules of NASDAQ Stock Market, Inc.  However, for purposes of interpreting the provisions of this Option, the terms and conditions of the Plan (other than those applicable to the share reserve, but, including the powers of the Administrator set forth in Section 2 of the Plan) shall govern and apply to this Option as if this Option had actually been issued under the Plan.  The Participant has received a copy of the Plan, has read the Plan and is familiar with its terms, and hereby accepts the Option subject to the terms and provisions of the Plan only for purposes of interpreting the provisions of this Agreement, including that the Committee is authorized to interpret this Option and the Plan and to adopt rules and regulations not inconsistent with the Plan as it deems appropriate. The Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee with respect to questions arising under the Grant Notice or this Agreement, or any interpretations of the Plan or the Plan&#x2019;s governance and applicability to this Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Entire A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">g</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">reement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The Grant Notice and this Agreement represent the entire agreement between the parties with respect to the subject matter hereof and supersede any prior agreement, written or otherwise, relating to the subject matter hereof.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">12.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Amendment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. This Agreement may only be amended by a writing signed by each of the parties hereto; provided that the Company may amend this Agreement without the Participant&#x2019;s consent, if the amendment does not materially impair the Participant&#x2019;s rights hereunder.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">13.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Governin</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">g</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> Law</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. This Agreement will be construed in accordance with the laws of the State of Delaware, without regard to the application of the principles of conflicts of laws.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">14.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Headin</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">gs. The headings in this Agreement are for convenience only. They form no part of the Agreement and will not affect its interpretation.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">15.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Data Privacy Consent</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.	  In order to administer the Option and to implement or structure future equity grants, the Company, its affiliates and certain agents thereof (together, the &#x201c;Relevant Companies&#x201d;) may process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Option (the &#x201c;Relevant Information&#x201d;). By entering into this Agreement, the Participant (a) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (b) waives any privacy rights the Participant may have with respect to the Relevant Information; (c) authorizes the Relevant Companies to store and transmit such information in electronic form; and (d) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Participant shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">ACTIVE/121518754.3</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">16.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Electronic Delivery of Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The Participant authorizes the Company to deliver electronically any prospectuses or other documentation related to the Option and any other compensation or benefit plan or arrangement in effect from time to time (including, without limitation, reports, proxy statements or other documents that are required to be delivered to participants in such arrangements pursuant to Federal or state laws, rules or regulations). For this purpose, electronic delivery will include, without limitation, delivery by means of e-mail or e-mail notification that such documentation is available on the Company&#x2019;s Intranet site. Upon written request, the Company will provide to the Participant a paper copy of any document also delivered to the Participant electronically. The authorization described in this paragraph may be revoked by the Participant at any time by written notice to the Company.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">6</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">ACTIVE/121518754.3</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.20
<SEQUENCE>4
<FILENAME>lrmr-ex10_20.htm
<DESCRIPTION>EX-10.20
<TEXT>
<html>
 <head>
  <title>EX-10.20</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">LEASE</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">between</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">BALA PLAZA PROPERTY, INC.,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Landlord,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">and</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CHONDRIAL THERAPEUTICS, INC.,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">a Delaware corporation,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:36pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tenant</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">August 8, 2019</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.75in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;" id="mptableofcontents"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">TABLE OF CONTENTS</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Page</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:18.736%;"></td>
    <td style="width:77.924%;"></td>
    <td style="width:3.339%;"></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:90pt;vertical-align:top;"><p style="text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ARTICLE 1	BASIC LEASE PROVISIONS</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:90pt;vertical-align:top;"><p style="text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ARTICLE 2	PREMISES, TERM, RENT</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 2.1	Lease of Premises</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 2.2	Commencement Date</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 2.3	Payment of Rent</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 2.4	First Month&#x2019;s Rent</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 2.5	Area of Premises and Building</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:90pt;vertical-align:top;"><p style="text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ARTICLE 3	USE AND OCCUPANCY</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 3.1	Permitted Uses</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 3.2	Parking</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:90pt;vertical-align:top;"><p style="text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ARTICLE 4	CONDITION OF THE PREMISES</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 4.1	Condition</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:90pt;vertical-align:top;"><p style="text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ARTICLE 5</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ALTERATIONS</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 5.1	Tenant&#x2019;s Alterations.</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 5.2	Manner and Quality of Alterations</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 5.3	Removal of Tenant&#x2019;s Property</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 5.4	Mechanic&#x2019;s Liens</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 5.5	Labor Relations</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 5.6	Tenant&#x2019;s Costs</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 5.7	Tenant&#x2019;s Equipment</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 5.8	Legal Compliance</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 5.9	Floor Load</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:90pt;vertical-align:top;"><p style="text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ARTICLE 6	REPAIRS</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 6.1	Landlord&#x2019;s Repair and Maintenance</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 6.2	Tenant&#x2019;s Repair and Maintenance</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 6.3	Restorative Work</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:90pt;vertical-align:top;"><p style="text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ARTICLE 7	INCREASES IN TAXES AND OPERATING EXPENSES</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 7.1	Definitions</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 7.2	Tenant&#x2019;s Tax Payment</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 7.3	Tenant&#x2019;s Operating Payment</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14</font></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">i</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.75in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <table style="border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:97.416%;"></td>
    <td style="width:2.584%;"></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 7.4	Non-Waiver; Disputes.</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 7.5	Proration</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 7.6	No Reduction in Rent</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:90pt;vertical-align:top;"><p style="text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ARTICLE 8	REQUIREMENTS OF LAW</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 8.1	Compliance with Requirements.</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 8.2	Fire and Life Safety</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:90pt;vertical-align:top;"><p style="text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ARTICLE 9	SUBORDINATION</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 9.1	Subordination and Attornment.</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 9.2	Mortgage or Superior Lease Defaults</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 9.3	Tenant&#x2019;s Termination Right</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 9.4	Provisions</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 9.5	Future Condominium Declaration</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:90pt;vertical-align:top;"><p style="text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ARTICLE 10	SERVICES</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 10.1	Electricity</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 10.2	Excess Electricity</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 10.3	Elevators</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 10.4	Heating, Ventilation and Air Conditioning</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 10.5	Supplemental Heating, Ventilation and Air Conditioning</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 10.6	Overtime HVAC</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 10.7	Cleaning</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 10.8	Water</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 10.9	Refuse Removal</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 10.10	Directory</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 10.11	Tenant Access to Premises</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 10.12	Telecommunications</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 10.13	Service Interruptions</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 10.14	Service Additions and Omissions</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:90pt;vertical-align:top;"><p style="text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ARTICLE 11	INSURANCE; PROPERTY LOSS OR DAMAGE</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 11.1	Tenant&#x2019;s Insurance.</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 11.2	Waiver of Subrogation</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 11.3	Restoration.</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 11.4	Landlord&#x2019;s Termination Right</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26</font></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ii</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.75in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <table style="border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:18.736%;"></td>
    <td style="width:77.924%;"></td>
    <td style="width:3.339%;"></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 11.5	Tenant&#x2019;s Termination Right</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 11.6	Final 18 Months</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 11.7	Landlord&#x2019;s Liability</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:90pt;vertical-align:top;"><p style="text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ARTICLE 12	EMINENT DOMAIN</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 12.1	Taking.</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 12.2	Awards</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 12.3	Temporary Taking</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:90pt;vertical-align:top;"><p style="text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ARTICLE 13	ASSIGNMENT AND SUBLETTING</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 13.1	Consent Requirements.</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 13.2	Tenant&#x2019;s Notice</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 13.3	Conditions to Assignment/Subletting.</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 13.4	Binding on Tenant; Indemnification of Landlord</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 13.5	Tenant&#x2019;s Failure to Complete</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 13.6	Profits</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 13.7	Transfers.</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 13.8	Assumption of Obligations</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 13.9	Tenant&#x2019;s Liability</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 13.10	Listings in Building Directory</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 13.11	Lease Disaffirmance or Rejection</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:90pt;vertical-align:top;"><p style="text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ARTICLE 14	ACCESS TO PREMISES AND SUBSTITUTION OF PREMISES</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 14.1	Landlord&#x2019;s Access.</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 14.2	Building Name</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 14.3	Substitution of Other Premises.</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 14.4	Light and Air</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:90pt;vertical-align:top;"><p style="text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ARTICLE 15</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">DEFAULT</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 15.1	Tenant&#x2019;s Defaults</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 15.2	Landlord&#x2019;s Remedies.</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 15.3	Landlord&#x2019;s Damages.</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">41</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 15.4	Interest</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 15.5	Intentionally Omitted.</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 15.6	Other Rights of Landlord</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="text-indent:90pt;vertical-align:top;"><p style="text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ARTICLE 16	LANDLORD&#x2019;S RIGHT TO CURE; FEES AND EXPENSES</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43</font></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">iii</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.75in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <table style="border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:97.416%;"></td>
    <td style="width:2.584%;"></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:90pt;vertical-align:top;"><p style="text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ARTICLE 17	NO REPRESENTATIONS BY LANDLORD; LANDLORD&#x2019;S APPROVAL</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 17.1	No Representations</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 17.2	No Money Damages</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 17.3	Reasonable Efforts</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:90pt;vertical-align:top;"><p style="text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ARTICLE 18	END OF TERM</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 18.1	Expiration</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 18.2	Holdover Rent</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:90pt;vertical-align:top;"><p style="text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ARTICLE 19	QUIET ENJOYMENT</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:90pt;vertical-align:top;"><p style="text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ARTICLE 20	NO SURRENDER; NO WAIVER</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 20.1	No Surrender or Release</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 20.2	No Waiver</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:90pt;vertical-align:top;"><p style="text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ARTICLE 21	WAIVER OF TRIAL BY JURY; COUNTERCLAIM</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 21.1	Jury Trial Waiver</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 21.2	Waiver of Counterclaim</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:90pt;vertical-align:top;"><p style="text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ARTICLE 22	NOTICES</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:90pt;vertical-align:top;"><p style="text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ARTICLE 23	RULES AND REGULATIONS</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:90pt;vertical-align:top;"><p style="text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ARTICLE 24	BROKER</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:90pt;vertical-align:top;"><p style="text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ARTICLE 25	INDEMNITY</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 25.1	Tenant&#x2019;s Indemnity</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 25.2	Landlord&#x2019;s Indemnity</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 25.3	Defense and Settlement</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:90pt;vertical-align:top;"><p style="text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ARTICLE 26	MISCELLANEOUS</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 26.1	Delivery</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 26.2	Transfer of Property</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 26.3	Limitation on Liability</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 26.4	Rent</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 26.5	Entire Document</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 26.6	Governing Law</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 26.7	Unenforceability</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 26.8	Lease Disputes.</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 26.9	Landlord&#x2019;s Agent</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 26.10	Estoppel</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49</font></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">iv</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.75in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <table style="border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:97.416%;"></td>
    <td style="width:2.584%;"></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 26.11	Certain Interpretation al Rules</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 26.12	Parties Bound</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 26.13	Memorandum of Lease</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 26.14	Counterparts</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 26.15	Survival</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 26.16	Inability to Perform</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 26.17	Lien for Payment of Rent</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 26.18	Financial Statements</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 26.19	Changes to Property</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:126pt;vertical-align:top;"><p style="margin-left:36pt;text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Section 26.20	Tax Status. Tax Status of Beneficial Owner</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:90pt;vertical-align:top;"><p style="text-indent:-90pt;padding-left:90pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ARTICLE 27	SECURITY DEPOSIT</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EXHIBITS<br>Exhibit A	Floor Plan<br>Exhibit Al	Land<br>Exhibit B	Definitions<br>Exhibit C	Work Letter Agreement<br>Exhibit D	Design Standards<br>Exhibit E	Cleaning Work<br>Exhibit F	Rules and Regulations<br>Exhibit G	[Intentionally Omitted]<br>Exhibit H	Construction Rules and Regulations</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">RIDER</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Rider 1	ADDITIONAL PROVISIONS<br>R1-A	OPTION TO EXTEND TERM<br>R1-B	DISPOSAL OF MEDICAL, INFECTIONS AND CHEMOTHERAPEUTIC</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">MATERIALS AND WASTE<br>R1-C	EARLY ACCESS</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">v</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">LEASE</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Lease (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Lease</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">is made as of the 8 day of August, 2019 (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), between Bala Plaza Property, Inc., a Delaware corporation (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Landlord</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and Chondrial Therapeutics, Inc., a Delaware corporation </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tenant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Landlord and Tenant, intending to be legally bound, hereby agree as follows:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARTICLE 1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br><br></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">BASIC LEASE PROVISIONS</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:40.577%;"></td>
    <td style="width:59.423%;"></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.007in;vertical-align:top;padding-right:0.007in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PREMISES</font></p></td>
    <td style="text-indent:14pt;padding-left:0.007in;vertical-align:top;padding-right:0.007in;"><p style="margin-left:14pt;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">A portion of the fifth floor of the Building, as more particularly shown on </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit A</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.007in;vertical-align:top;padding-right:0.007in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">BUILDING</font></p></td>
    <td style="text-indent:14pt;padding-left:0.007in;vertical-align:top;padding-right:0.007in;"><p style="margin-left:14pt;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The building, fixtures, equipment and other improvements and appurtenances now located or hereafter erected, located or placed upon the Land and known as Three Bala Plaza, Bala Cynwyd, Pennsylvania</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.007in;vertical-align:top;padding-right:0.007in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">COMPLEX</font></p></td>
    <td style="text-indent:14pt;padding-left:0.007in;vertical-align:top;padding-right:0.007in;"><p style="margin-left:14pt;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">One, Two and Three Bala Plaza, as further defined on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Exhibit B</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.007in;vertical-align:top;padding-right:0.007in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">LAND</font></p></td>
    <td style="text-indent:14pt;padding-left:0.007in;vertical-align:top;padding-right:0.007in;"><p style="margin-left:14pt;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The real property described on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Exhibit A-l</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;to this Lease</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.007in;vertical-align:top;padding-right:0.007in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PROPERTY</font></p></td>
    <td style="text-indent:14pt;padding-left:0.007in;vertical-align:top;padding-right:0.007in;"><p style="margin-left:14pt;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The Building, the Common Areas and the Land</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.007in;vertical-align:top;padding-right:0.007in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">COMMENCEMENT DATE</font></p></td>
    <td style="text-indent:14pt;padding-left:0.007in;vertical-align:top;padding-right:0.007in;"><p style="margin-left:14pt;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The later to occur of (a) December 15, 2019 or (b) five (5) days following the date on which the Initial Installations (as defined in Exhibit C) are Substantially Completed in accordance with the terms of this Lease.</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.007in;vertical-align:top;padding-right:0.007in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">RENT<br>COMMENCEMENT<br>DATE</font></p></td>
    <td style="text-indent:14pt;padding-left:0.007in;vertical-align:top;padding-right:0.007in;"><p style="margin-left:14pt;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The day following the expiration of the two (2) month period that begins on the Commencement Date.</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.007in;vertical-align:top;padding-right:0.007in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">EXPIRATION DATE</font></p></td>
    <td style="text-indent:13.7pt;padding-left:0.007in;vertical-align:top;padding-right:0.007in;"><p style="margin-left:13.7pt;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The last day of the 42 month (three years and six months) period that begins on the Commencement Date, or the last day of any renewal or extended term, if the Term of this Lease is extended in accordance with any express provision hereof.</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.007in;vertical-align:top;padding-right:0.007in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">TERM</font></p></td>
    <td style="text-indent:14pt;padding-left:0.007in;vertical-align:top;padding-right:0.007in;"><p style="margin-left:14pt;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The period commencing on the Commencement Date and ending on the Expiration Date</font></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:23.504%;"></td>
    <td style="width:17.073%;"></td>
    <td style="width:59.423%;"></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-left:0.007in;vertical-align:top;padding-right:0.007in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PERMITTED USES</font></p></td>
    <td style="text-indent:14pt;padding-left:0.007in;vertical-align:top;padding-right:0.007in;"><p style="margin-left:14pt;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Executive and general offices</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-left:0.007in;vertical-align:top;padding-right:0.007in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">BASE YEAR</font></p></td>
    <td style="text-indent:14pt;padding-left:0.007in;vertical-align:top;padding-right:0.007in;"><p style="margin-left:14pt;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Calendar year 2020</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.007in;vertical-align:top;padding-right:0.007in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#2c2c2c;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">TENANT&#x2019;S<br>PROPORTIONATE<br>SHARE</font></p></td>
    <td colspan="2" style="text-indent:14pt;padding-left:0.007in;vertical-align:top;padding-right:0.007in;"><p style="margin-left:14pt;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#2c2c2c;white-space:pre-wrap;min-width:fit-content;">1.2057%</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.007in;vertical-align:top;padding-right:0.007in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#2c2c2c;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">AREA OF BUILDING</font></p></td>
    <td colspan="2" style="text-indent:14pt;padding-left:0.007in;vertical-align:middle;padding-right:0.007in;"><p style="margin-left:14pt;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#2c2c2c;white-space:pre-wrap;min-width:fit-content;">The rentable area of the Building shall be deemed 385,012 square feet, as agreed by Landlord and Tenant.</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.007in;vertical-align:middle;padding-right:0.007in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#2c2c2c;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">AREA OF PREMISES</font></p></td>
    <td colspan="2" style="text-indent:14pt;padding-left:0.007in;vertical-align:middle;padding-right:0.007in;"><p style="margin-left:14pt;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#2c2c2c;white-space:pre-wrap;min-width:fit-content;">4,642 rentable square feet</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">FIXED RENT</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:33.687%;"></td>
    <td style="width:22.104%;"></td>
    <td style="width:22.104%;"></td>
    <td style="width:22.104%;"></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease Year</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Annual Fixed Rent</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Monthly Fixed Rent</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Annual Fixed Rent per Rentable Square Foot</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1*</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$135,391.67*</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#2c2c2c;white-space:pre-wrap;min-width:fit-content;">$13,539.17</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#2c2c2c;white-space:pre-wrap;min-width:fit-content;">$35.00</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#2c2c2c;white-space:pre-wrap;min-width:fit-content;">$164,791.00</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#2c2c2c;white-space:pre-wrap;min-width:fit-content;">$13,732.58</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#2c2c2c;white-space:pre-wrap;min-width:fit-content;">$35.50</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#2c2c2c;white-space:pre-wrap;min-width:fit-content;">$167,112.00</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#2c2c2c;white-space:pre-wrap;min-width:fit-content;">$13,926.00</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#2c2c2c;white-space:pre-wrap;min-width:fit-content;">$36.00</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4 through Expiration Date**</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#2c2c2c;white-space:pre-wrap;min-width:fit-content;">$84,716.50</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#2c2c2c;white-space:pre-wrap;min-width:fit-content;">$14,119.42</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#2c2c2c;white-space:pre-wrap;min-width:fit-content;">$36.50</font></p></td>
   </tr>
  </table>
  <p style="margin-left:27.507%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#2c2c2c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">*There are two (2) months of free Fixed Rent in Lease Year 1 and, therefore, the Annual Fixed Rent for this period reflects ten (10) months of Month Fixed Rent in lieu of twelve (12).</font></p>
  <p style="margin-left:27.507%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#2c2c2c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">** There are six (6) months in Lease Year 4 and, therefore, the Annual Fixed Rent for this period reflects six (6) months of Monthly Fixed Rent in lieu of twelve (12).</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:28.84%;"></td>
    <td style="width:71.16%;"></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.007in;vertical-align:top;padding-right:0.007in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#2c2c2c;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">ADDITIONAL RENT</font></p></td>
    <td style="border-top:0.5pt solid;text-indent:13.7pt;padding-left:0.007in;vertical-align:top;padding-right:0.007in;text-align:right;"><p style="margin-left:13.7pt;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#2c2c2c;white-space:pre-wrap;min-width:fit-content;">All sums other than Fixed Rent payable by Tenant to Landlord under this Lease and any work letter, exhibits, riders or other attachments hereto, including Tenant&#x2019;s Tax Payment, Tenant&#x2019;s Operating Payment, late charges, overtime or excess service charges, supplemental chilled water charges, damages, and interest and other costs related to Tenant&#x2019;s failure to perform any of its obligations under this Lease</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.007in;vertical-align:top;padding-right:0.007in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#2c2c2c;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">RENT</font></p></td>
    <td style="text-indent:11pt;padding-left:0.007in;vertical-align:top;padding-right:0.007in;"><p style="margin-left:11pt;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#2c2c2c;white-space:pre-wrap;min-width:fit-content;">Fixed Rent and Additional Rent, collectively</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.007in;vertical-align:top;padding-right:0.007in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#2c2c2c;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">INTEREST RATE</font></p></td>
    <td style="text-indent:11pt;padding-left:0.007in;vertical-align:top;padding-right:0.007in;"><p style="margin-left:11pt;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#2c2c2c;white-space:pre-wrap;min-width:fit-content;">The lesser of (i) 4% per annum above the then-current Base Rate, and (ii) the maximum rate permitted by applicable law</font></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:28.84%;"></td>
    <td style="width:71.16%;"></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.007in;vertical-align:top;padding-right:0.007in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#2c2c2c;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">SECURITY DEPOSIT</font></p></td>
    <td style="text-indent:11pt;padding-left:0.007in;vertical-align:top;padding-right:0.007in;"><p style="margin-left:11pt;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#2c2c2c;white-space:pre-wrap;min-width:fit-content;">$67,695.85, as may be reduced pursuant to the terms of Article 27</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.007in;vertical-align:top;padding-right:0.007in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#515151;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">TENANT&#x2019;S ADDRESS<br>FOR NOTICES</font></p></td>
    <td style="text-indent:11pt;padding-left:0.007in;vertical-align:top;padding-right:0.007in;"><p style="margin-left:11pt;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#2c2c2c;white-space:pre-wrap;min-width:fit-content;">Until Tenant commences business operations from the Premises:</font></p><p style="margin-left:10.8pt;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chondrial Therapeutics, Inc.<br>150 Monument Road, Suite 207<br>Bala Cynwyd, PA 19004<br>Attention:  Carole Ben-Maimon, MD</font></p><p style="margin-left:10.8pt;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Thereafter:</font></p><p style="margin-left:10.8pt;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chondrial Therapeutics, Inc.<br>Three Bala Plaza East, Suite 506<br>Bala Cynwyd, PA 19004<br>Attention:  Carole Ben-Maimon, MD</font></p><p style="margin-left:10.8pt;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Copy to:<br>Lundy Beldecos &amp; Milby PC<br>450 N Narberth Avenue<br>Suite 200<br>Narberth Pennsylvania 19072<br>Attention:  Anthony J. Beldecos<br>abeldecos@LBMlaw.com</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.007in;vertical-align:top;padding-right:0.007in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">LANDLORD&#x2019;S ADDRESS<br>FOR NOTICES</font></p></td>
    <td style="text-indent:10.8pt;padding-left:0.007in;vertical-align:middle;padding-right:0.007in;"><p style="margin-left:10.8pt;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Bala Plaza Property, Inc.<br>c/o Tishman Speyer Properties, L.P.<br>45 Rockefeller Plaza<br>New York, New York 10111<br>Attn:  Chief Financial Officer</font></p><p style="margin-left:10.8pt;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Copies to:</font></p><p style="margin-left:10.8pt;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Bala Plaza Property, Inc.<br>c/o Tishman Speyer Properties, L.P.<br>One Bala Plaza<br>Suite 501<br>Bala Cynwyd, Pennsylvania 19004<br>Attention Property Manager<br>and:</font></p><p style="margin-left:10.8pt;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tishman Speyer Properties, L.P.<br>45 Rockefeller Plaza<br>New York, New York 10111<br>Attn:  Chief Legal Officer</font></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:28.84%;"></td>
    <td style="width:71.16%;"></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.007in;vertical-align:top;padding-right:0.007in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">LANDLORD&#x2019;S ADDRESS<br>FOR PAYMENT</font></p></td>
    <td style="text-indent:10.8pt;padding-left:0.007in;vertical-align:top;padding-right:0.007in;"><p style="margin-left:10.8pt;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Bala Plaza Property, Inc.<br>c/o Tishman Speyer Properties, L.P.<br>75 Remittance Drive<br>Suite 1152<br>Chicago, Illinois 60675-1152</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.007in;vertical-align:top;padding-right:0.007in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#2c2c2c;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">TENANT&#x2019;S BROKER</font></p></td>
    <td style="text-indent:10.8pt;padding-left:0.007in;vertical-align:top;padding-right:0.007in;text-align:right;"><p style="margin-left:10.8pt;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p><p style="margin-left:10.8pt;text-indent:0;font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#2c2c2c;white-space:pre-wrap;min-width:fit-content;">Tactix Real Estate Advisors, LLC</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.007in;vertical-align:top;padding-right:0.007in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#2c2c2c;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">LANDLORD&#x2019;S AGENT</font></p></td>
    <td style="text-indent:10.8pt;padding-left:0.007in;vertical-align:middle;padding-right:0.007in;text-align:right;"><p style="margin-left:10.8pt;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#2c2c2c;white-space:pre-wrap;min-width:fit-content;">Tishman Speyer Properties, L.P. or any other person designated at any time and from time to time by Landlord as Landlord&#x2019;s Agent and their successors and assigns</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.007in;vertical-align:top;padding-right:0.007in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#2c2c2c;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">GROUND LEASE</font></p></td>
    <td style="text-indent:10.8pt;padding-left:0.007in;vertical-align:bottom;padding-right:0.007in;text-align:right;"><p style="margin-left:10.8pt;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#2c2c2c;white-space:pre-wrap;min-width:fit-content;">That certain Ground Lease dated December 10, 2003 between Bala Plaza, Inc. (&#x201c;Prime Landlord&#x201d;), as fee owner and ground landlord, and Bala Plaza Property, Inc., as ground tenant, pursuant to which Landlord has acquired the right to use and operate the Complex, including, without limitation, entering into leases for space in the Building, as the same may be amended from time to time.</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">All capitalized terms used in this Lease without definition are defined in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARTICLE 2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br><br></font><font style="color:#2c2c2c;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">PREMISES, TERM, RENT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 2.1	Lease of Premises.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Subject to the terms of this Lease, Landlord leases to Tenant and Tenant leases from Landlord the Premises for the Term.  In addition, Landlord grants to Tenant the right to use, on a non-exclusive basis and in common with other tenants, the Common Areas.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 2.2	Commencement Date.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Upon the Effective Date, the terms and provisions of this Lease shall be fully binding on Landlord and Tenant, including prior to the occurrence of the Commencement Date.  The Term of this Lease shall commence on the Commencement Date and, unless sooner terminated or extended as hereinafter provided, shall end on the Expiration Date.  If Landlord does not tender possession of the Premises to Tenant on or before any specified date, for any reason whatsoever, Landlord shall not be liable for any damage thereby caused, this Lease shall not be void or voidable thereby, and the Term shall not commence until Landlord tenders possession of the Premises to Tenant.  Landlord shall be deemed to have tendered possession of the Premises to Tenant upon the giving of notice by Landlord to Tenant stating that the Premises are vacant, in the condition required by this Lease and available for Tenant&#x2019;s occupancy.  No failure to tender possession of the Premises to Tenant on or before any specified date shall affect any other obligations of Tenant hereunder.  There shall be no postponement of the Commencement Date (or the Rent Commencement Date) for (i) any delay in the tender of possession to Tenant which results from any Tenant Delay or (ii) any delays by Landlord in the performance of any Punch List Items related to the Initial Installations.  Once the Commencement Date is determined, Landlord and Tenant shall execute an agreement stating the Commencement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Date, Rent Commencement Date and Expiration Date, but the failure to do so will not affect the determination of such dates.  Notwithstanding anything to the contrary contained in this Lease, Tenant and Landlord hereby agree that if the Commencement Date shall not have occurred within nine (9) months following the Effective Date, as may be extended by Unavoidable Delays and Tenant Delays, Tenant may terminate this Lease by giving written notice to Landlord in which case this Lease shall terminate and neither party shall have any further liability to the other except </font><font style="color:#2c2c2c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(i) those obligations expressly intended to survive the termination of this Lease, and (ii) an obligation on the part of Landlord to return to Tenant any amounts deposited by Tenant under this Lease.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 2.3	Payment of Rent.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tenant shall pay to Landlord at Landlord&#x2019;s Address for Payment or at such other place as Landlord shall designate in writing from time to time, without notice or demand, and without any set-off, counterclaim, abatement or deduction whatsoever, except as may be expressly set forth in this Lease, in lawful money of the United States by wire transfer of funds or by good check (i) Fixed Rent in equal monthly installments, in advance, on the first day of each month during the Term, commencing on the Rent Commencement Date, and (ii) Additional Rent, at the times and in the manner set forth in this Lease.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 2.4	First Month&#x2019;s Rent.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tenant shall pay one month&#x2019;s Fixed Rent on or prior to the Commencement Date </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Advance Rent</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If the Rent Commencement Date is on the first day of a month, the Advance Rent shall be credited towards the first month&#x2019;s Fixed Rent payment.  If the Rent Commencement Date is not the first day of a month, then on the Rent Commencement Date Tenant shall pay Fixed Rent for the period from the Rent Commencement Date through the last day of such month, and the Advance Rent shall be credited towards Fixed Rent for the next succeeding calendar month.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 2.5	Area </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Premises and Building.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Landlord and Tenant agree that the Area of the Premises and the Area of the Building set forth in Article 1 shall be conclusive and binding on both parties regardless of any measurement of the Premises and/or of the Building after the date hereof.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARTICLE 3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br><br></font><font style="color:#2c2c2c;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">USE AND OCCUPANCY</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 3.1	Permitted Uses.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tenant shall use and occupy the Premises for the Permitted Uses and for no other purpose.  Tenant shall not use or occupy or permit the use or occupancy of any part of the Premises in a manner constituting a Prohibited Use.  If Tenant uses the Premises for a purpose constituting a Prohibited Use, violating any Requirement, or causing the Building to be in violation of any Requirement, then Tenant shall promptly discontinue such use upon notice of such violation.  Tenant, at its expense, shall procure and at all times maintain and comply with the terms and conditions of all licenses and permits required for the lawful conduct of the Permitted Uses in the Premises.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 3.2	Parking.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If the Property now or hereafter contains, or Landlord has obtained the right to use for the Property, a parking garage, structure, facility or area, the following shall apply therein:</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">5</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)	Parking shall be available in areas designated by Landlord from time to time.- Parking for Tenant and its employees and visitors shall be on a &#x201c;first come, first served,&#x201d; unassigned basis, in common with Landlord and other tenants at the Property, and their employees and visitors, and other persons to whom Landlord shall grant the right or who shall otherwise have the right to use the same.  However, in no event shall Tenant and Tenant&#x2019;s employees and visitors use more spaces than the number derived by applying Tenant&#x2019;s Proportionate Share (as defined in this Lease) to the total number of unassigned spaces in the area or areas designated by Landlord from time to time to serve the Premises.  In addition, Landlord reserves the right to:  (x) adopt additional requirements or procedures pertaining to parking, including systems with charges favoring carpooling, and validation systems, (y) assign specific spaces, and reserve spaces for small and other size cars, disabled persons, and other tenants, customers of tenants or other parties, and (z) restrict or prohibit full-size vans and other large vehicles.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)	Monthly fees, if applicable, shall be paid in advance prior to the first day of each month.  Failure to do so will automatically cancel parking privileges, and incur a charge at the posted daily parking rate.  No deductions from the monthly rate will be made for days on which the garage or parking area facilities are not used by Tenant or its designees.  In case of any violation of these rules, Landlord may also refuse to permit the violator to park, and may remove the vehicle owned or driven by the violator from the Property without liability whatsoever, at such violator&#x2019;s risk and expense.  Landlord reserves the right to close all or a portion of the parking areas or facilities in order to make repairs or perform maintenance services, or to alter, modify, re-stripe or renovate the same, or if required by casualty, strike, condemnation, act of God, Requirements, termination or modification of any lease or other agreement by which Landlord obtained parking rights, or any other reason beyond Landlord&#x2019;s reasonable control.  In the event access is denied for any reason, any monthly parking charges shall be abated to the extent access is denied, as Tenant&#x2019;s sole recourse.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(c)	Hours shall be reasonably established by Landlord or its parking operator from time to time; cars must be parked entirely within the stall lines, and only small or other qualifying cars may be parked in areas reserved for such cars; all directional signs, arrows and speed limits must be observed; spaces reserved for disabled persons must be used only by vehicles properly designated; washing, waxing, cleaning or servicing of any vehicle is prohibited; every parker is required to park and lock his own car, except to the extent that Landlord adopts a valet parking system; parking is prohibited in areas:  (a) not striped or designated for parking, (b) aisles, (c) where &#x201c;no parking&#x201d; signs are posted, (d) on ramps, and (e) loading areas and other specially designated areas.  Any vehicle not parked in a proper manner may be issued a violation and towed at the vehicle owner&#x2019;s expense.  Delivery trucks and vehicles shall use only those areas designated therefor.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(d)	There shall be no overnight parking at the Property, and at the end of each day Tenant shall, and shall cause its personnel and visitors to, remove their automobiles from the parking garages, structures, facilities and areas at or serving the Property.  If any automobile owned by Tenant or by its personnel or visitors remains in any such parking garage, structure, facility or area overnight and the same interferes with the cleaning or maintenance thereof (snow or otherwise), any costs or liabilities incurred by Landlord in removing said automobile to effectuate cleaning or maintenance, or any damages resulting to said automobile or to Landlord&#x2019;s equipment or equipment owned by others by reason of the presence of or removal of said automobile during</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">6</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">such cleaning or maintenance shall be paid by Tenant to Landlord, as Additional Rent, on the rent payment date next following the submission of a bill therefor.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(e)	Parking stickers, key cards or any other devices or forms of identification or entry shall remain the property of Landlord.  Such devices must be displayed as requested and may not be mutilated in any manner.  The serial number of the parking identification device may not be obliterated.  Devices are not transferable and any device in the possession of an unauthorized holder will be void.  If an employee of Tenant has more than one vehicle, he or she may use the same parking device for all registered vehicles.  Such employee may also purchase additional parking devices.  In any event, all vehicles must be registered with Landlord or any garage manager.  Loss or theft of parking identification, key cards or other such devices must be reported to Landlord or any garage manager immediately.  Any parking devices reported lost or stolen which are found on any unauthorized car will be confiscated and the illegal holder will be subject to prosecution.  Lost or stolen devices found by Tenant or its employees must be reported to Landlord or the office of the garage immediately.  If an employee of Tenant does not have his or her card, he or she should obtain a one-day visitor pass from the Landlord or garage manager.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(f)	Tenant agrees that it and its employees shall observe reasonable safety precautions in the use of the parking areas or facilities garage and shall at all times abide by the foregoing rules and regulations as well as any additional rules and regulations promulgated by Landlord governing the use of the parking areas or facilities.  It is understood and agreed that Landlord does not assume any responsibility for any damage or loss to any parked automobiles or to any personal property located therein, or for any injury sustained by any person in or about the parking areas or facilities.  Except in connection with a permitted assignment of this Lease or a permitted sublease of the Premises or a portion thereof, neither Tenant nor any Tenant employee nor any other party claiming by, through or under Tenant shall assign, sublet, license or otherwise transfer or allow the use of any of Tenant&#x2019;s parking rights under this Lease.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARTICLE 4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br><br></font><font style="color:#2c2c2c;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CONDITION OF THE PREMISES</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 4.1	Condition.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tenant has inspected the Premises and agrees (a) to accept possession of the Premises in the condition existing on the Commencement Date &#x201c;as is&#x201d;, and (b) that except for the Initial Installations described in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit C</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, Landlord has no obligation to perform any work, supply any materials, incur any expense or make any alterations or improvements to prepare the Premises for Tenant&#x2019;s occupancy.  Tenant&#x2019;s occupancy of any part of the Premises shall be conclusive evidence, as against Tenant, that Landlord has Substantially Completed the Initial Installations described on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit C</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> (excluding Punch List Items) and that Tenant has accepted possession of the Premises in its then current condition and at the time such possession was taken, the Premises and the Building were in a good and satisfactory condition as required by this Lease.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">7</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:15pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARTICLE 5</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br><br></font><font style="color:#2c2c2c;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ALTERATIONS</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 5.1	Tenant&#x2019;s Alterations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)	Tenant shall not make any alterations, additions or other physical changes in or about the Premises, including without limitation any initial tenant fit-out work to ready the Premises for Tenant&#x2019;s occupancy (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Alterations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">other than decorative Alterations such as painting, wall coverings and floor coverings (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Decorative Alterations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), without Landlord&#x2019;s prior consent, which consent shall not be unreasonably withheld if such Alterations (i) are non-structural and do not affect any Building Systems, (ii) affect only the Premises and are not visible from outside of the Premises, (iii) do not affect the letter of compliance issued for the Building or the Premises, and (iv) do not violate any Requirement.  Tenant shall give Landlord not less than 5 Business Days&#x2019; notice prior to performing any Decorative Alteration, which notice shall contain a description of such Decorative Alteration.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Plans and Specifications.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Prior to making any Alterations, Tenant, at its expense, shall </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">i) submit to Landlord for its approval, detailed plans and specifications </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Plans</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">of each proposed Alteration (other than Decorative Alterations), and with respect to any Alteration affecting any Building System, evidence that the Alteration has been designed by, or reviewed and approved by, Landlord&#x2019;s designated engineer for the affected Building System, (ii) obtain all permits, approvals and certificates required by any Governmental Authorities, (iii) furnish to Landlord duplicate original policies or certificates of worker&#x2019;s compensation (covering all persons to be employed by Tenant, and Tenant&#x2019;s contractors and subcontractors in connection with such Alteration), commercial general liability (including property damage coverage) and business auto insurance and Builder&#x2019;s Risk coverage (as described in Article 11) all in such form, with such companies, for such periods and in such amounts as Landlord may reasonably require, naming Landlord, Landlord&#x2019;s Agent, any Lessor and any Mortgagee as additional insureds, and (iv) furnish to Landlord reasonably satisfactory evidence of Tenant&#x2019;s ability to complete and to fully pay for such Alterations (other than Decorative Alterations).  Landlord shall have 10 Business Days after receipt of the Plans within which to approve or disapprove of the Plans.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Governmental Approvals.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tenant, at its expense, shall, as and when required, promptly obtain certificates of partial and final approval of such Alterations required by any Governmental Authority and shall furnish Landlord with copies thereof, together with &#x201c;as- built&#x201d; Plans for such Alterations prepared on an AutoCAD Computer Assisted Drafting and Design System (or such other system or medium as Landlord may accept), using naming conventions issued by the American Institute of Architects in June, 1990 (or such other naming conventions as Landlord may accept) and magnetic computer media of such record drawings and specifications translated in DFX format or another format acceptable to Landlord.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 5.2	Manner and Quality of Alterations.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">All Alterations shall be performed (a) in a good and workmanlike manner and free from defects using union labor, (b) substantially in accordance with the Plans, and by contractors approved by Landlord, and (c) in compliance with all Requirements, the terms of this Lease and all construction procedures and regulations then prescribed by Landlord, including, without limitation, the construction rules and regulations set</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit H</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, and (d) at Tenant&#x2019;s expense.  All materials and equipment shall be of first quality and at least equal to the applicable standards for the Building then established by Landlord, and no such materials or equipment (other than Tenant&#x2019;s Property) shall be subject to any lien or other encumbrance.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 5.3	Removal of Tenant&#x2019;s Property.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tenant&#x2019;s Property shall remain the property of Tenant and Tenant may remove the same at any time on or before the Expiration Date.  On or prior to the Expiration Date or the effective date of an earlier termination of this Lease, Tenant shall, unless otherwise directed by Landlord, at Tenant&#x2019;s expense, remove any Specialty Alterations and close up any slab penetrations in the Premises.  Tenant shall repair and restore, in a good and workmanlike manner, any damage to the Premises or the Building caused by Tenant&#x2019;s removal of any Alterations or Tenant&#x2019;s Property or by the closing of any slab penetrations, and upon default thereof, Tenant shall reimburse Landlord for Landlord&#x2019;s cost of repairing and restoring such damage.  Any Specialty Alterations or Tenant&#x2019;s Property not so removed shall be deemed abandoned and Landlord may retain or remove and dispose of same, and repair and restore any damage caused thereby, at Tenant&#x2019;s cost and without accountability to Tenant.  All other Alterations shall become Landlord&#x2019;s property upon expiration or any termination of this Lease.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 5.4	Mechanic&#x2019;s Liens.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tenant, at its expense, shall discharge any lien or charge recorded or filed against the Property in connection with any work done or claimed to have been done by or on behalf of, or materials furnished or claimed to have been furnished to, Tenant, within 10 days after Tenant&#x2019;s receipt of notice thereof by payment, filing the bond required by law or otherwise in accordance with law.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 5.5	Labor Relations.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">All workmen and mechanics performing any Alterations must work in harmony and not interfere with labor employed by Landlord, Landlord&#x2019;s contractors or by any other tenants or their contractors.  To that end, unless otherwise permitted by Landlord in writing, all Alterations shall be done by union labor having the same or a compatible union affiliation as other workmen or mechanics performing work for Landlord, Landlord&#x2019;s contractors or by any other tenants or their contractors.  If at any time during the course of the Alterations, any workmen or mechanics performing the Alterations are not of the same union affiliation or are unable to work in harmony, or interfere, with labor employed by Landlord, Landlord&#x2019;s contractors or by any other tenants or their contractors, then the approval granted by Landlord to Tenant for the subject Alterations may be withdrawn by Landlord upon 48 hours, written notice to Tenant, and Tenant shall thereafter cause the Alterations to cease and shall restore the Premises to the condition as existed prior to the commencement of such Alterations.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 5.6	Tenant&#x2019;s Costs.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tenant shall pay promptly to Landlord, upon demand, all out-of-pocket costs actually incurred by Landlord in connection with Tenant&#x2019;s Alterations, including costs incurred in connection with (a) Landlord&#x2019;s review of the Alterations (including review of requests for approval thereof) and (b) the provision of Building personnel during the performance of any Alteration, to operate elevators or otherwise to facilitate Tenant&#x2019;s Alterations.  In addition, Tenant shall pay to Landlord, upon demand, an administrative fee in an amount equal to 5% of the total cost of such Alterations, At Landlord&#x2019;s request, Tenant shall deliver to Landlord reasonable supporting documentation evidencing the hard and soft costs incurred by Tenant in designing and constructing any Alterations.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">9</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 5.7	Tenant&#x2019;s Equipment.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tenant shall provide notice to Landlord prior to moving any heavy machinery, heavy equipment, freight, bulky matter or fixtures (collectively, &#x201c;Equipment&#x201d;) into or out of the Building and shall pay to Landlord any costs actually incurred by Landlord in connection therewith.  If such Equipment requires special handling, Tenant agrees (a) to employ only persons holding all necessary licenses to perform such work, (b) all work performed in connection therewith shall comply with all applicable Requirements and (c) such work shall be done only during hours designated by Landlord.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 5.8	Legal Compliance.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The approval of Plans, or consent by Landlord to the making of any Alterations, does not constitute Landlord&#x2019;s representation that such Plans or Alterations comply with any Requirements.  Landlord shall not be liable to Tenant or any other party in connection with Landlord&#x2019;s approval of any Plans, or Landlord&#x2019;s consent to Tenant&#x2019;s performing any Alterations.  If any Alterations made by or on behalf of Tenant, require Landlord to make any alterations or improvements to any part of the Building in order to comply with any Requirements, Tenant shall pay all costs and expenses incurred by Landlord in connection with such alterations or improvements.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 5.9	Floor Load.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tenant shall not place a load upon any floor of the Premises that exceeds 80 pounds per square foot &#x201c;live load&#x201d;.  Landlord reserves the right to reasonably designate the position of all Equipment which Tenant wishes to place within the Premises, and to place limitations on the weight thereof.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARTICLE 6</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br><br></font><font style="color:#2c2c2c;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">REPAIRS</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 6.1	Landlord&#x2019;s Repair and Maintenance.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Landlord shall operate, maintain and, except as provided in Section 6.2 hereof, make all necessary repairs (both structural and nonstructural) to (i) the Building Systems, and (ii) the Common Areas, in conformance with standards applicable to Comparable Buildings.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 6.2	Tenant&#x2019;s Repair and Maintenance.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tenant shall promptly, at its expense and in compliance with Article 5, make all nonstructural repairs to the Premises and the fixtures, equipment and appurtenances therein (including all electrical and plumbing systems in and serving the Premises from the point of connection to the Building Systems) and all Specialty Alterations; but excluding repairs, maintenance and replacement of exterior windows, atrium windows, exterior signs, the base Building heating, ventilation and air conditioning systems located in the Premises, the base Building life safety systems located in the Premises and non-Specialty Alteration lightbulbs, lamps and ballasts located in the Premises, which shall be repaired, maintained and replaced as necessary by Landlord and, to the extent applicable, the cost of such repairs, maintenance and replacements will be included in Operating Expenses (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tenant Fixtures</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">as and when needed to preserve the Premises in good working order and condition, except for reasonable wear and tear and damage for which Tenant is not responsible.  All damage to the Building or to any portion thereof or to any Tenant Fixtures requiring structural or nonstructural repair caused by or resulting from any act, omission, neglect or improper conduct of a Tenant Party or the moving of Tenant&#x2019;s Property or Equipment into, within or out of the Premises by a Tenant Party, shall be repaired at Tenant&#x2019;s expense by Tenant or by Landlord in</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">10</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">accordance with the allocation of repair responsibilities set forth above.  All Tenant repairs shall be of good quality utilizing new construction materials.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 6.3	Restorative Work.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Landlord reserves the right to make all changes, alterations, additions, improvements, repairs or replacements to the Building and Building Systems, including changing the arrangement or location of entrances or passageways, doors and doorways, corridors, elevators, stairs, toilets or other Common Areas (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Restorative Work</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">as Landlord deems necessary or desirable, and to take all materials into the Premises required for the performance of such Restorative Work, provided that (a) the level of any Building service shall not decrease in any material respect from the level required of Landlord in this Lease as a result thereof (other than temporary changes in the level of such services during the performance of any such Restorative Work) and (b) Tenant is not deprived of access to the Premises.  Landlord shall use reasonable efforts to minimize interference with Tenant&#x2019;s use and occupancy of the Premises during the performance of such Restorative Work.  There shall be no Rent abatement or allowance to Tenant for a diminution of rental value, no actual or constructive eviction of Tenant, in whole or in part, no relief from any of Tenant&#x2019;s other obligations under this Lease, and no liability on the part of Landlord by reason of inconvenience, annoyance or injury to business arising from Landlord, Tenant or others performing, or failing to perform, any Restorative Work.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARTICLE 7</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br><br></font><font style="color:#2c2c2c;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">INCREASES IN TAXES AND OPERATING EXPENSES</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 7.1	Definitions.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">For the purposes of this Article 7, the following terms shall have the meanings set forth below:</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)	&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Assessed Valuation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">shall mean the amount for which the Property is assessed by any Governmental Authority for the purpose of imposition of Taxes.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)	&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Base Operating Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">shall mean the Operating Expenses for the Base Year.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(c)	&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Base Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">shall mean the Taxes payable on account of the Base Year.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(d)	&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Calendar Year</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">shall mean each calendar year all or any portion of which occurs during the Term and &#x201c;Comparison Year&#x201d; shall mean any Calendar Year commencing subsequent to the Base Year.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(e)	&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Operating Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">shall mean the aggregate of all costs and expenses paid or incurred by or on behalf of Landlord in connection with the ownership, operation, repair and maintenance of the Property, including, but not limited to, the following:</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(i)	capital improvements incurred after the Base Year only if such capital improvement either (A) is reasonably intended to result in a reduction in Operating Expenses (as for example, a labor-saving improvement) provided, the amount included in Operating Expenses in the Base Year or any Comparison Year shall not exceed an amount equal to the savings reasonably anticipated to result from the installation and operation of such</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">11</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">improvement, and/or (B) is made during the Base Year or any Comparison Year in compliance with Requirements.  Such capital improvements shall be amortized (with interest at the Base Rate) on a straight-line basis over such period as Landlord shall reasonably determine, and the amount included in Operating Expenses in the Base Year or any Comparison Year shall be equal to the annual amortized amount; and</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(ii)	costs of maintaining and operating (including the reasonable rental value thereof) the management and engineering offices, if any, for the Building.</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Operating Expenses shall not include any Excluded Expenses.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If during all or part of the Base Year or any Comparison Year, Landlord shall not furnish any particular item(s) of work or service (which would otherwise constitute an Operating Expense) to any leasable portions of the Building for any reason, then, for purposes of computing Operating Expenses for such period, the amount included in Operating Expenses for such period shall be increased by an amount equal to the costs and expenses that would have been reasonably incurred by Landlord during such period if Landlord had furnished such item(s) of work or service to such portion of the Building.  In determining the amount of Operating Expenses for the Base Year or any Comparison Year, if less than 95% of the Building rentable area is occupied by tenants at any time during the Base Year or such Comparison Year, then Operating Expenses shall be determined for the Base Year or such Comparison Year to be an amount equal to the like expenses which would normally be expected to be incurred had such occupancy been 95% throughout the Base Year or such Comparison Year.  If in any Comparison Year the cost of premiums for insurance coverage with respect to terrorist acts and occurrences is less than the cost of such premiums included in Base Operating Expenses, Landlord may subtract from Base Operating Expenses an amount equal to the difference in such cost of premiums commencing with such Comparison Year.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(f)	&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Statement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">shall mean a statement containing a comparison of (i) the Taxes payable for the Base Year and for any Comparison Year, or (ii) the Base Operating Expenses and the Operating Expenses payable for any Comparison Year.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(g)	&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean (i) all real estate taxes, assessments, sewer and water rents, Business Improvement District assessments and charges, and other governmental levies, impositions or charges, whether general, special, ordinary, extraordinary, foreseen or unforeseen, which may be assessed, levied or imposed upon all or any part of the Property or in connection with the use thereof (including any transit, personal property, sales, rental, use, gross receipts, or occupancy taxes, vault rental and other taxes and assessments), and (ii) all expenses (including reasonable attorneys&#x2019; fees and disbursements and experts&#x2019; and other witnesses&#x2019; fees) incurred in contesting any of the foregoing or the Assessed Valuation of the Property (but such expenses will not be included in Base Taxes if incurred during the Base Tax Year).  Taxes shall not include (x) interest or penalties incurred by Landlord as a result of Landlord&#x2019;s late payment of Taxes, (y) franchise, transfer, gift, inheritance, estate or net income taxes imposed upon Landlord, or (z) deed transfer, transfer of economic interests or recordation taxes.  For purposes hereof, &#x201c;Taxes&#x201d; for any Calendar Year shall be deemed to be the Taxes which are assessed, levied or imposed for such Calendar Year regardless of when due or paid.  If any Taxes are assessed on a fiscal year (rather than a Calendar Year), Landlord shall have the right to equitably allocate such Taxes on a Calendar Year basis.  If Landlord elects to pay any assessment in annual installments, then (i) such</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">12</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">assessment shall be deemed to have been so divided and to be payable in the maximum number of installments permitted by law, and (ii) there shall be deemed included in Taxes for each Comparison Year the installments of such assessment becoming payable during such Comparison Year, together with interest payable during such Comparison Year on such installments and on all installments thereafter becoming due as provided by law, all as if such assessment had been so divided.  If at any time the methods of taxation prevailing on the Effective Date shall be altered so that in lieu of or as an addition to the whole or any part of Taxes, there shall be assessed, levied or imposed (1) a tax, assessment, levy, imposition or charge based on the income or rents received from the Property whether or not wholly or partially as a capital levy or otherwise, (2) a tax, assessment, levy, imposition or charge measured by or based in whole or in part upon all or any part of the Property and imposed upon Landlord, (3) a license fee measured by the rents, or (4) any other tax, assessment, levy, imposition, charge or license fee however described or imposed, including business improvement district impositions then all such taxes, assessments, levies, impositions, charges or license fees or the part thereof so measured or based shall be deemed to be Taxes.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 7.2	Tenant&#x2019;s Tax Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)	If the Taxes payable for any Comparison Year exceed the Base Taxes, Tenant shall pay to Landlord Tenant&#x2019;s Proportionate Share of such excess (&#x201c;Tenant&#x2019;s Tax Payment&#x201d;).  For each Comparison Year, Landlord shall furnish to Tenant a statement setting forth Landlord&#x2019;s reasonable estimate of Tenant&#x2019;s Tax Payment for such Comparison Year (the &#x201c;Tax Estimate&#x201d;).  Tenant shall pay to Landlord on the 1st day of each month during such Comparison Year an amount equal to 1/12 of the Tax Estimate for such Comparison Year.  If Landlord furnishes a Tax Estimate for a Comparison Year subsequent to the commencement thereof, then (i) until the 1st day of the month following the month in which the Tax Estimate is furnished to Tenant, Tenant shall pay to Landlord on the I st day of each month an amount equal to the monthly sum payable by Tenant to Landlord under this Section 7.2 during the last month of the preceding Comparison Year, (ii) promptly after the Tax Estimate is furnished to Tenant or together therewith, Landlord shall give notice to Tenant staling whether the installments of Tenant&#x2019;s Tax Estimate previously made for such Comparison Year were greater or less than the installments of Tenant&#x2019;s Tax Estimate to be made for such Comparison Year in accordance with the Tax Estimate, and (x) if there shall be a deficiency, Tenant shall pay the amount thereof within 10 Business Days after demand therefor, or (y) if there shall have been an overpayment, Landlord shall credit the amount thereof against subsequent payments of Rent due hereunder, and (iii) on the 1st day of the month following the month in which the Tax Estimate is furnished to Tenant, and on the 1st day of each month thereafter throughout the remainder of such Comparison Year, Tenant shall pay to Landlord an amount equal to 1/12 of the Tax Estimate.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)	As soon as reasonably practicable after Landlord has determined the Taxes for a Comparison Year, Landlord shall furnish to Tenant a Statement for such Comparison Year.  If the Statement shall show that the sums paid by Tenant under Section 7.2(a) exceeded the actual amount of Tenant&#x2019;s Tax Payment for such Comparison Year, Landlord shall credit the amount of such excess against subsequent payments of Rent due hereunder.  If the Statement for such Comparison Year shall show that the sums so paid by Tenant were less than Tenant&#x2019;s Tax Payment for such Comparison Year, Tenant shall pay the amount of such deficiency within 10 Business Days after delivery of the Statement to Tenant.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">13</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(c)	Only Landlord may institute proceedings to reduce the Assessed Valuation of the Property and the filings of any such proceeding by Tenant without Landlord&#x2019;s consent shall constitute an Event of Default.  If the Taxes payable for the Base Year are reduced, the Base Taxes shall be correspondingly revised, the Additional Rent previously paid or payable on account of Tenant&#x2019;s Tax Payment hereunder for all Comparison Years shall be recomputed on the basis of such reduction, and Tenant shall pay to Landlord within 10 Business Days after being billed therefor, any deficiency between the amount of such Additional Rent previously computed and paid by Tenant to Landlord, and the amount due as a result of such recomputations.  If Landlord receives a refund of Taxes for any Comparison Year, Landlord shall credit against subsequent payments of Rent due hereunder, an amount equal to Tenant&#x2019;s Proportionate Share of the refund, net of any expenses incurred by Landlord in achieving such refund, which amount shall not exceed Tenant&#x2019;s Tax Payment paid for such Comparison Year.  Landlord shall not be obligated to file any application or institute any proceeding seeking a reduction in Taxes or the Assessed Valuation.  The benefit of any exemption or abatement relating to all or any part of the Property shall accrue solely to the benefit of Landlord and Taxes shall be computed without taking into account any such exemption or abatement.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(d)	Tenant shall be responsible for any applicable occupancy or rent tax now in effect or hereafter enacted and, if such tax is payable by Landlord, Tenant shall promptly pay such amounts to Landlord, upon Landlord&#x2019;s demand.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(e)	Tenant shall be obligated to make Tenant&#x2019;s Tax Payment regardless of whether Tenant may be exempt from the payment of any Taxes as the result of any reduction, abatement or exemption from Taxes granted or agreed to by any Governmental Authority, or by reason of Tenant&#x2019;s diplomatic or other tax-exempt status.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(f)	Tenant&#x2019;s obligations to pay Taxes (or any other amounts) accruing during, or relating to, the period prior to expiration or earlier termination of this Lease, shall survive such expiration or termination.  Landlord may reasonably estimate all or any of such obligations within a reasonable time before, or any time after, such expiration or termination.  Tenant shall pay the full amount of such estimate, and any additional amount due after the actual amounts are determined, in each case within 30 days after Landlord sends a statement therefor.  If the actual amount is less than the amount Tenant pays as an estimate, Landlord shall refund the difference within 30 days after such determination is made.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 7.3	Tenant&#x2019;s Operating Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)	If the Operating Expenses payable for any Comparison Year exceed the Base Operating Expenses (excluding any Base Operating Expenses that are non-recurring), Tenant shall pay to Landlord Tenant&#x2019;s Proportionate Share of such excess </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tenant&#x2019;s Operating Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">For each Comparison Year, Landlord shall furnish to Tenant a written statement setting forth Landlord&#x2019;s reasonable estimate of Tenant&#x2019;s Operating Payment for such Comparison Year (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Expense Estimate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tenant shall pay to Landlord on the first day of each month during such Comparison Year an amount equal to 1/12 of the Expense Estimate.  If Landlord furnishes an Expense Estimate for a Comparison Year subsequent to the commencement thereof, then (a) until the 1st day of the month following the month in which the Expense Estimate is furnished to Tenant, Tenant shall pay to Landlord on the 1st day of each month an amount equal</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">14</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">to the monthly sum payable by Tenant to Landlord under this Section 7.3 during the last month of the preceding Comparison Year, (b) promptly after the Expense Estimate is furnished to Tenant or together therewith, Landlord shall give notice to Tenant stating whether the installments of Tenant&#x2019;s Operating Payment previously made for such Comparison Year were greater or less than the installments of Tenant&#x2019;s Operating Payment to be made for such Comparison Year in accordance with the Expense Estimate, and (i) if there shall be a deficiency, Tenant shall pay the amount thereof within 10 Business Days after demand therefor, or (ii) if there shall have been an overpayment, Landlord shall credit the amount thereof against subsequent payments of Rent due hereunder, and (c) on the 1st day of the month following the month in which the Expense Estimate is furnished to Tenant, and on the 1st day of each month thereafter throughout the remainder of such Comparison Year, Tenant shall pay to Landlord an amount equal to 1/12 of Tenant&#x2019;s Operating Payment shown on the Expense Estimate.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)	On or before May 1st of each Comparison Year, Landlord shall furnish to Tenant a Statement for the immediately preceding Comparison Year.  If the Statement shows that the sums paid by Tenant under Section 7.3(a) exceeded the actual amount of Tenant&#x2019;s Operating Payment for such Comparison Year, Landlord shall credit the amount of such excess against subsequent payments of Rent due hereunder.  If the Statement shows that the sums so paid by Tenant were less than Tenant&#x2019;s Operating Payment for such Comparison Year, Tenant shall pay the amount of such deficiency within 10 Business Days after Tenant&#x2019;s receipt of the Statement.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(c)	Tenant&#x2019;s Proportionate Share Adjustments; Allocations Within Complex.  Landlord may separately determine Taxes and Operating Expenses for the Property and other buildings in the Complex.  If any Taxes or Operating Expenses (or components thereof) apply to the Property and other areas of the Complex (including, without limitation, costs of shared parking facilities and other common areas, and a shared management office), Landlord shall allocate the same in accordance with sound accounting and management practices and any instruments or agreements pertaining to the sharing or allocation of the same.  In the alternative, Landlord shall have the right to determine, in accordance with sound accounting and management practices, Tenant&#x2019;s Proportionate Share of Taxes and Operating Expenses (or components thereof) based upon the combined total of the same for the Property and all or any such other buildings and areas of the Complex, in which event Tenant&#x2019;s Proportionate Share shall be based on the ratio of the rentable area of the Premises to the rentable area of such buildings.  If the Property or Complex shall contain non-office uses during any period, Landlord may determine, in accordance with sound accounting and management practices, Tenant&#x2019;s Proportionate Share of Taxes and Operating Expenses for only the office portion of the Property or Complex (or for only the non&#x1f;office portion, if this Lease permits non-office use of the Premises); in such event, Tenant&#x2019;s Proportionate Share shall be based on the ratio of the rentable area of the Premises to the rentable area of such portion for such period.  Tenant&#x2019;s Proportionate Share shall be subject to such other adjustments for such periods as may be applicable pursuant to Section 7.1(e)(ii), above, and pursuant to the definition of Tenant&#x2019;s Proportionate Share in Article 1.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(d)	Tenant&#x2019;s obligations to pay Operating Expenses (or any other amounts) accruing during, or relating to, the period prior to expiration or earlier termination of this Lease, shall survive such expiration or termination.  Landlord may reasonably estimate all or any of such obligations within a reasonable time before, or any time after, such expiration or termination.  Tenant shall pay the full amount of such estimate, and any additional amount due after the actual</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">15</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">amounts are determined, in each case within 30 days after Landlord sends a Statement therefor.  If the actual amount is less than the amount Tenant pays as an estimate, Landlord shall refund the difference within 30 days after such determination is made.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 7.4	Non-Waiver; Disputes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)	Landlord&#x2019;s failure to render any Statement on a timely basis with respect to any Comparison Year shall not prejudice Landlord&#x2019;s right to thereafter render a Statement with respect to such Comparison Year or any subsequent Comparison Year, nor shall the rendering of a Statement prejudice Landlord&#x2019;s right to thereafter render a corrected Statement for that Comparison Year.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)	Each Statement sent to Tenant shall be conclusively binding upon Tenant unless Tenant (i) pays to Landlord when due the amount set forth in such Statement, without prejudice to Tenant&#x2019;s right to dispute such Statement, and (ii) within 60 days after such Statement is sent, sends a notice to Landlord objecting to such Statement and specifying the reasons therefor.  Tenant agrees that Tenant will not employ, in connection with any dispute under this Lease, any person or entity who is to be compensated in whole or in part, on a contingency fee basis.  If the parties are unable to resolve any dispute as to the correctness of such Statement within 30 days following such notice of objection, either party may refer the issues raised to a nationally recognized public accounting firm selected by Landlord and reasonably acceptable to Tenant, and the decision of such accountants shall be conclusively binding upon Landlord and Tenant.  In connection therewith, Tenant, such accountants and all other persons to whom Tenant gives any of the information obtained in connection with such review shall execute and deliver to Landlord a confidentiality agreement, in form and substance reasonably satisfactory to Landlord, whereby such parties agree not to disclose to any third party any of the information obtained in connection with such review.  Tenant shall pay the fees and expenses relating to such procedure, unless such accountants determine that Landlord overstated Operating Expenses by more than 5% for such Comparison Year, in which case Landlord shall pay such fees and expenses.  Except as provided in this Section 7.4, Tenant shall have no right whatsoever to dispute, by judicial proceeding or otherwise, the accuracy of any Statement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 7.5	Proration.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If the Rent Commencement Date is not January 1, the Additional Rent for the applicable Calendar Year shall be apportioned on the basis of the number of days in the year from the Rent Commencement Date to the following December 31.  If the Expiration Date occurs on a date other than December 31st, any Additional Rent under this Article 7 for the Calendar Year in which such Expiration Date occurs shall be apportioned on the basis of the number of days in the period from January 1st to the Expiration Date.  Upon the expiration or earlier termination of this Lease, any Additional Rent under this Article 7 shall be adjusted or paid within 30 days after submission of the Statement for the last Calendar Year.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 7.6	No Reduction in Rent.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In no event shall any decrease in Operating Expenses or Taxes in any Comparison Year below the Base Operating Expenses or Base Taxes, as the case may be, result in a reduction in the Fixed Rent or any other component of Additional Rent payable hereunder.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">16</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:15pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARTICLE 8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br><br></font><font style="color:#2c2c2c;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">REQUIREMENTS OF LAW</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 8.1	Compliance with Requirements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tenant&#x2019;s Compliance.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tenant, at its expense, shall comply with all Requirements applicable to the Premises; and/or Tenant&#x2019;s use or occupancy thereof; provided, however, that Tenant shall not be obligated to comply with any Requirements requiring any structural alterations to the Building or any alterations or repairs to any Building System unless the application of such Requirements arises from (i) the specific manner and/or nature of Tenant&#x2019;s use or occupancy of the Premises, as distinct from general office use, (ii) Alterations made by Tenant, or (iii) a breach by Tenant of any provisions of this Lease.  Any repairs or alterations required for compliance with applicable Requirements shall be made (1) at Tenant&#x2019;s expense by Tenant in compliance with Article 5 if such repairs or alterations are nonstructural and do not affect any Building System, and to the extent such repairs or alterations do not affect areas outside the Premises, or (2) at Landlord&#x2019;s expense, by Landlord if such repairs or alterations are structural or affect any Building System, or to the extent such repairs or alterations affect areas outside the Premises.  If Tenant obtains knowledge of any failure to comply with any Requirements applicable to the Premises, Tenant shall give Landlord prompt notice thereof.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Hazardous Materials.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tenant shall not cause or permit (i) any Hazardous Materials to be brought onto the Property, (ii) the storage or use of Hazardous Materials in or about the Building or Premises (subject to the second sentence of this Section 8.1(b)) or (iii) the escape, disposal or release of any Hazardous Materials within or in the vicinity of the Building.  Nothing herein shall be deemed to prevent Tenant&#x2019;s use of any Hazardous Materials customarily used in the ordinary course of office work, provided such use is in accordance with all Requirements.  Tenant shall be responsible, at its expense, for all matters directly or indirectly based on, or arising or resulting from the presence of Hazardous Materials at the Property which is caused or permitted by a Tenant Party.  Tenant shall provide to Landlord copies of all communications received by Tenant with respect to any Requirements relating to Hazardous Materials, and/or any claims made in connection therewith.  Landlord or its agents may perform environmental inspections of the Premises at any time.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Landlord&#x2019;s Compliance.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Landlord shall comply with (or cause to be complied with) all Requirements applicable to the Property which are not the obligation of Tenant, to the extent that non-compliance would materially impair Tenant&#x2019;s use and occupancy of the Premises for the Permitted Uses.  Landlord represents to Tenant that as of the date of this Lease, Landlord has not received any written notice of any asbestos or other Hazardous Materials in the Building in violation of any applicable Requirement.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(d)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Landlord&#x2019;s Insurance.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tenant shall not cause or permit any action or condition that would (i) invalidate or conflict with Landlord&#x2019;s insurance policies, (ii) violate applicable rules, regulations and guidelines of the Fire Department or any other Governmental Authority having jurisdiction over the Building, (iii) cause an increase in the premiums of fire insurance for the Building over that payable with respect to Comparable Buildings, or (iv) result in Landlord&#x2019;s insurance companies&#x2019; refusing to insure the Building or any property therein in</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">17</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">amounts and against risks as reasonably determined by Landlord.  If fire insurance premiums increase as a result of Tenant&#x2019;s failure to comply with the provisions of this Section 8.1, Tenant shall promptly cure such failure and shall reimburse Landlord for the increased fire insurance premiums paid by Landlord as a result of such failure by Tenant.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 8.2	Fire and Life Safety.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Any modifications to the Building fire alarm and life safety systems required by Tenant or completed as part of the Initial Installations shall be at Tenant&#x2019;s sole cost and expense, subject to the terms of the Workletter attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit C</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  If the Fire Insurance Rating Organization or any Governmental Authority or any of Landlord&#x2019;s insurers requires or recommends any modifications and/or alterations be made or any additional equipment be supplied in connection with the sprinkler system or fire alarm and life-safety system serving the Building by reason of Tenant&#x2019;s business, any Alterations performed by Tenant or the location of the partitions, Tenant&#x2019;s Property, or other contents of the Premises, Landlord (to the extent outside of the Premises) or Tenant (to the extent within the Premises) shall make such modifications and/or Alterations, and supply such additional equipment, in either case at Tenant&#x2019;s expense.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARTICLE 9</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br><br></font><font style="color:#2c2c2c;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">SUBORDINATION</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 9.1	Subordination and Attornment.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)	This Lease is subject and subordinate to all Mortgages and Superior Leases, and at the request of any Mortgagee or Lessor, Tenant shall attorn to such Mortgagee or Lessor, its successors in interest or any purchaser in a foreclosure sale.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)	If a Lessor or Mortgagee or any other person or entity shall succeed to the rights of Landlord under this Lease, whether through possession or foreclosure action or the delivery of a new lease or deed, then at the request of the successor landlord and upon such successor landlord&#x2019;s written agreement to accept Tenant&#x2019;s attornment and to recognize Tenant&#x2019;s interest under this Lease, Tenant shall be deemed to have attorned to and recognized such successor landlord as Landlord under this Lease.  The provisions of this Section 9.1 are self-operative and require no further instruments to give effect hereto; provided, however, that Tenant shall promptly execute and deliver any instrument that such successor landlord may reasonably request (i) evidencing such attornment, (ii) setting forth the terms and conditions of Tenant&#x2019;s tenancy, and (iii) containing such other terms and conditions as may be required by such Mortgagee or Lessor, provided such terms and conditions do not increase the Rent, materially increase Tenant&#x2019;s obligations or materially and adversely affect Tenant&#x2019;s rights under this Lease.  Upon such attornment this Lease shall continue in full force and effect as a direct lease between such successor landlord and Tenant upon all of the terms, conditions and covenants set forth in this Lease except that such successor landlord shall not be:</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(i)	liable for any act or omission of Landlord (except to the extent such act or omission continues beyond the date when such successor landlord succeeds to Landlord&#x2019;s interest and Tenant gives notice of such act or omission);</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">18</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(ii)	subject to any defense, claim, counterclaim, set-off or offset which Tenant may have against Landlord;</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(iii)	bound by any prepayment of more than one month&#x2019;s Rent to any prior landlord;</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(iv)	bound by any obligation to make any payment to Tenant which was required to be made prior to the time such successor landlord succeeded to Landlord&#x2019;s interest;</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(v)	bound by any obligation to perform any work or to make improvements to the Premises except for (x) repairs and maintenance required to be made by Landlord under this Lease, and (y) repairs to the Premises as a result of damage by fire or other casualty or a partial condemnation pursuant to the provisions of this Lease, but only to the extent that such repairs can reasonably be made from the net proceeds of any insurance or condemnation awards, respectively, actually made available to such successor landlord;</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(vi)	bound by any modification, amendment, or renewal of this Lease made without successor landlord&#x2019;s consent;</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(vii)	liable for the repayment of any security deposit or surrender of any letter of credit, unless and until such security deposit actually is paid or such letter of credit is actually delivered to such successor landlord; or</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(viii)	liable for the payment of any unfunded tenant improvement allowance, refurbishment allowance or similar obligation.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(c)	Tenant shall from time to time within ten (10) business days of request from Landlord execute and deliver any documents or instruments that may be reasonably required by any Mortgagee or Lessor to confirm any subordination.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 9.2	Mortgage or Superior Lease Defaults.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Any Mortgagee may elect that this Lease shall have priority over the Mortgage and, upon notification to Tenant by such Mortgagee, this Lease shall be deemed to have priority over such Mortgage, regardless of the date of this Lease.  In connection with any financing of the Property, Tenant shall consent to any reasonable modifications of this Lease requested by any lending institution, provided such modifications do not increase the Rent, materially increase the obligations, or materially and adversely affect the rights, of Tenant under this Lease.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 9.3	Tenant&#x2019;s Termination Right.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">As long as any Superior Lease or Mortgage exists, Tenant shall not seek to terminate this Lease by reason of any act or omission of Landlord until (a) Tenant shall have given notice of such act or omission to all Lessors and/or Mortgagees, and (b) a reasonable period of time shall have elapsed following the giving of notice of such default and the expiration of any applicable notice or grace periods (unless such act or omission is not capable of being remedied within a reasonable period of time), during which period such Lessors and/or Mortgagees shall have the right, but not the obligation, to remedy such act or omission and thereafter diligently proceed to so remedy such act or omission.  If any Lessor or Mortgagee elects to remedy such act or omission of Landlord, Tenant shall not seek to terminate this Lease so long as such Lessor or Mortgagee is proceeding with reasonable diligence to effect such remedy.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">19</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 9.4	Provisions.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The provisions of this Article 9 shall (a) inure to the benefit of Landlord, any future owner of the Building or the Property, Lessor or Mortgagee and any sublessor thereof and (b) apply notwithstanding that, as a matter of law, this Lease may terminate upon the termination of any such Superior Lease or Mortgage.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 9.5	Future Condominium Declaration.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Lease and Tenant&#x2019;s rights hereunder are and will be subject and subordinate to any condominium declaration, by-laws and other instruments (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Condominium Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">which may be recorded in order to subject the Building to a condominium form of ownership pursuant to the laws of the Commonwealth of Pennsylvania, provided that the Condominium Documents do not by their terms increase the Rent, materially increase Tenant&#x2019;s non-Rent obligations or materially and adversely affect Tenant&#x2019;s rights under this Lease.  At Landlord&#x2019;s request, and subject to the foregoing proviso, Tenant will execute and deliver to Landlord an amendment of this Lease confirming such subordination and modifying this Lease to conform to such condominium regime.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARTICLE 10</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br><br></font><font style="color:#2c2c2c;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">SERVICES</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 10.1	Electricity.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Subject to any Requirements or any public utility rules or regulations governing energy consumption, Landlord shall make or cause to be made, customary arrangements with utility companies and/or public service companies to furnish electric current to the Premises for Tenant&#x2019;s use in accordance with the Design Standards set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit D </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Design Standards</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">for electrical usage.  If Landlord reasonably determines by the use of an electrical consumption survey or by other reasonable means that Tenant is using electric (including overhead fluorescent fixtures) in excess of 4 watts per useable square foot of demand load </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Excess Electrical Usage</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), then Landlord shall have the right to charge Tenant an amount equal to Landlord&#x2019;s reasonable estimate of Tenant&#x2019;s Excess Electrical Usage, and shall have the further right to install a separate electric current meter, submeter or check meter in the Premises (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Meter</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">to measure the amount of electric current consumed in the Premises, The cost of such Meter, special conduits, wiring and panels needed in connection therewith and the installation, maintenance and repair thereof shall be paid by Tenant.  Tenant shall pay to Landlord, from time to time, but no more frequently than monthly, for its Excess Electrical Usage at the Premises, plus Landlord&#x2019;s charge equal to 10% of Tenant&#x2019;s Excess Electrical Usage for Landlord&#x2019;s costs of maintaining, repairing and reading such Meter.  The rate to be paid by Tenant for submetered electricity shall include any taxes or other charges in connection therewith.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 10.2	Excess Electricity.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tenant shall at all times comply with the rules and regulations of the utility company supplying electricity to the Building.  Tenant shall not use any electrical equipment which, in Landlord&#x2019;s reasonable judgment, would exceed the capacity of the electrical equipment serving the Premises or which interferes with the electrical service to other tenants of the Building.  If Landlord determines that Tenant&#x2019;s electrical requirements necessitate installation of any additional risers, feeders or other electrical distribution equipment (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Electrical Equipment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">or if Tenant provides Landlord with evidence reasonably satisfactory to Landlord of Tenant&#x2019;s need for excess electricity and requests that additional Electrical Equipment be installed, Landlord shall, at Tenant&#x2019;s expense, install such additional Electrical Equipment, provided that Landlord, in its sole judgment, determines that (a) such installation is</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">20</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">practicable and necessary, (b) such additional Electrical Equipment is permissible under applicable Requirements, and (c) the installation of such Electrical Equipment will not cause permanent damage to the Building or the Premises, cause or create a hazardous condition, entail excessive or unreasonable alterations, interfere with or limit electrical usage by other tenants or occupants of the Building or exceed the limits of the switchgear or other facilities serving the Building, or require power in excess of that available from the utility company serving the Building.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 10.3	Elevators.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Landlord shall provide passenger elevator service for the Premises 24 hours per day, 7 days per week; provided, however.  Landlord may limit passenger elevator service during non-Ordinary Business Hours.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 10.4	Heating, Ventilation and Air Conditioning.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Landlord shall furnish to the Premises heating, ventilation and air-conditioning </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">HVAC</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">in accordance with the Design Standards for HVAC usage during Ordinary Business Hours.  Landlord shall have access to all air-cooling, fan, ventilating and machine rooms and electrical closets and all other mechanical installations of Landlord (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Mechanical Installations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">and Tenant shall not construct partitions or other obstructions which may interfere with Landlord&#x2019;s access thereto or the moving of Landlord&#x2019;s equipment to and from the Mechanical Installations.  No Tenant Party shall at any time enter the Mechanical Installations or tamper with, adjust, or otherwise affect such Mechanical Installations.  Landlord shall not be responsible if the HVAC System fails to provide cooled or heated air, as the case may be, to the Premises in accordance with the Design Standards for HVAC usage by reason of (i) any equipment installed by, for or on behalf of Tenant, which has an electrical load in excess of the average electrical load and human occupancy factors for the HVAC System as set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit D,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> or (ii) any rearrangement of partitioning or other Alterations made or performed by, for or on behalf of Tenant.  Tenant shall install, if missing, blinds or shades on all windows, which blinds and shades shall be subject to Landlord&#x2019;s approval (not to be unreasonably withheld), and shall keep operable windows in the Premises closed, and lower the blinds when necessary because of the sun&#x2019;s position, whenever the HVAC System is in operation or as and when required by any Requirement.  Tenant shall cooperate with Landlord and shall abide by the rules and regulations which Landlord may reasonably prescribe for the proper functioning and protection of the HVAC System.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 10.5	Supplemental Heating, Ventilation and Air Conditioning.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If, at Tenant&#x2019;s request or due to Tenant&#x2019;s particular use or occupancy of the Premises, the Premises or any portion thereof is at any time served by any supplemental heating, ventilation and air conditioning unit(s) that taps into the base Building HVAC System condenser water loop (whether one or more, but exclusive of any units that are part of the base Building HVAC System, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Supplemental HVAC Units</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a) Tenant shall pay Landlord within thirty (30) days after Landlord gives Tenant an invoice therefor, on a monthly basis, a charge of $10.00 per ton for each Supplemental HVAC Unit; (b) Tenant, at Tenant&#x2019;s expense, shall install an electric submeter for the Supplemental HVAC Unit(s) concurrently with Tenant&#x2019;s installation of such Supplemental Units(s):  (c) Landlord shall read the submeter (with Tenant providing Landlord with reasonable access thereto) and Tenant shall pay to Landlord all electricity charges (including any taxes and other fees associated with such electricity charges) measured on such submeter within thirty (30) days after receipt of an invoice therefor; (d) Tenant, at Tenant&#x2019;s expense, shall at all times maintain a Supplemental HVAC Unit(s) service contract with a firm and upon such terms as may be reasonably satisfactory to Landlord; (e) Tenant shall provide Landlord with such documentation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">21</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">and other evidence as Landlord might reasonably request from time to time to demonstrate Tenant&#x2019;s proper maintenance of the Supplemental HVAC Unit(s) including, without limitation, Tenant&#x2019;s compliance with all of the equipment manufacturer&#x2019;s warranties, rules and requirements with respect to the Supplemental HVAC Unit(s); and (f) in no event shall Landlord be liable for, and Tenant hereby waives any claim for, any Losses and other damages whether direct, indirect, consequential or punitive damages, including loss of profits or business opportunity to persons, property, equipment or otherwise arising in connection with the base Building HVAC System including any failure of the base Building HVAC system condenser water loop and/or any equipment related thereto to operate as such loop and/or equipment was designed to operate and regardless of the cause of such failure.  Notwithstanding the foregoing subpart(a), in the event that Tenant installs a Supplemental HVAC Unit of five (5) tons or less in the Premises, other than for its computer room, then Tenant shall not incur fees for tapping into the Building HVAC condenser water loop for such Supplemental HVAC Unit.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 10.6	Overtime HVAC.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Fixed Rent does not include any charge to Tenant for the furnishing of HVAC to the Premises during any periods other than Ordinary Business Hours </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Overtime Periods</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If Tenant desires HVAC services during Overtime Periods, Tenant shall deliver notice to the Building office requesting such services by 2:00 p.m. of the Business Day on which or preceding the date such services are to be provided; provided, however, that Landlord shall use reasonable efforts to arrange such service on such shorter notice as Tenant shall provide.  If Landlord furnishes HVAC service during Overtime Periods, Tenant shall pay to Landlord the cost thereof at Landlord&#x2019;s then established rate for such service in the Building, presently estimated at $203 per hour.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 10.7	Cleaning.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Landlord shall cause the Premises (excluding any portions thereof used for the storage, preparation, service or consumption of food or beverages, as an exhibition area or classroom, for storage, as a shipping room, mail room or similar purposes, for private bathrooms, showers or exercise facilities, as a trading floor, or primarily for operation of computer, data processing, reproduction, duplicating or similar equipment) to be cleaned, substantially in accordance with the standards set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit E</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Landlord reserves the right to modify such standards from time-to-time provided that Landlord&#x2019;s cleaning standards shall be reasonably consistent with those provided in Comparable Buildings.  Any areas of the Premises which Landlord is not required to clean hereunder or which require additional cleaning shall be cleaned, at Tenant&#x2019;s expense, by Landlord&#x2019;s cleaning contractor for such charge as Landlord establishes from time to time, Landlord&#x2019;s cleaning contractor and its employees shall have access to the Premises at all times except between 8:00 a.m. and 5:30 p.m. on weekdays which are not Observed Holidays.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 10.8	Water.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Landlord shall provide water in the core lavatories, drinking fountains and janitor&#x2019;s closets on each floor of the Building.  If Tenant requires water in excess of that used by a normal office building tenant of similar size using its premises for normal office use, Tenant shall pay for the cost of bringing water to the Premises and Landlord may install a meter to measure the water.  Tenant shall pay the cost of such installation, and for all maintenance, repairs and replacements thereto, and for the reasonable charges of Landlord for the water consumed.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">22</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 10.9	Refuse Removal.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Landlord shall provide refuse removal services at the Building for ordinary office refuse and rubbish.  Tenant shall pay to Landlord, Landlord&#x2019;s reasonable charge for such removal to the extent that the refuse generated by Tenant exceeds the refuse customarily generated by general office tenants.  Tenant shall not dispose of any refuse in the Common Areas, and if Tenant does so, Tenant shall be liable for Landlord&#x2019;s reasonable charge for such removal.  Tenant shall, at its sole cost and expense, comply with all present and future Requirements regarding the collection, sorting, separation, and recycling of trash.  Each separately sorted category of trash shall be placed in separate receptacles as directed by Landlord.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 10.10	Directory.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Landlord shall list Tenant on at least one of the Building directories located in the first floor lobbies of the Building.  The Building directory listing Tenant&#x2019;s name will be shared with other Building tenants and space on the directory shall be equitably apportioned amongst the tenants.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 10.11	Tenant Access to Premises.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tenant shall have</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">access to the Premises 24 hours a day, seven days a week.  Outside of Ordinary Business Hours, Building access will be monitored by an electronic card or key security and access system or any such successor system installed and maintained by Landlord.  Tenant shall be responsible for access control to the Premises at Tenant&#x2019;s sole cost and expense.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 10.12	Telecommunications.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If Tenant requests that Landlord grant access to the Building to a telecommunications service provider designated by Tenant for purposes of providing telecommunications services to Tenant, Landlord shall use its good faith efforts to respond to such request within 30 days.  Tenant acknowledges that nothing set forth in this Section shall impose any affirmative obligation on Landlord to grant such request and that Landlord, in its sole discretion, shall have the right to determine which telecommunications service providers shall have access to Building facilities.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 10.13	Service Interruptions.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Landlord reserves the right to suspend any service when necessary, by reason of Unavoidable Delays, accidents or emergencies, or for Restorative Work which, in Landlord&#x2019;s reasonable judgment, are necessary or appropriate until such Unavoidable Delay, accident or emergency shall cease or such Restorative Work is completed and Landlord shall not be liable for any interruption, curtailment or failure to supply services.  Landlord shall use reasonable efforts to minimize interference with Tenant&#x2019;s use and occupancy of the Premises as a result of any such interruption, curtailment or failure or defect in any such service, or change in the supply, character and/or quantity of, electrical service, and to restore any such services, remedy such situation and minimize any interference with Tenant&#x2019;s business.  The exercise of any such right or the occurrence of any such failure by Landlord shall not constitute an actual or constructive eviction, in whole or in part, entitle Tenant to any compensation, abatement or diminution of Rent, relieve Tenant from any of its obligations under this Lease, or impose any liability upon Landlord or any Indemnified Party by reason of inconvenience to Tenant, or interruption of Tenant&#x2019;s business, or otherwise.  Landlord shall not be liable in any way to Tenant for any failure, defect or interruption of, or change in the supply, character and/or quantity of electrical service furnished to the Premises for any reason except if attributable to the gross negligence or willful misconduct of Landlord.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">23</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 10.14	Service Additions and Omissions.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Except with respect to the services that Landlord otherwise agrees to provide as set forth in this Article, Landlord shall have the right to add, modify and/or curtail any Building services as Landlord determines appropriate from time to time in Landlord&#x2019;s sole discretion.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARTICLE 11</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br><br></font><font style="color:#2c2c2c;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">INSURANCE; PROPERTY LOSS OR DAMAGE</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 11.1	Tenant&#x2019;s Insurance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)	Tenant, at its expense, shall obtain and maintain in full force and effect the following insurance policies throughout the term of the Lease:</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(i)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Commercial General Liability (</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CGL</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;</font><font style="color:#2c2c2c;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">)</font><font style="color:#2c2c2c;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> Insurance</font><font style="color:#2c2c2c;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#2c2c2c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">on an occurrence basis covering liability arising from premises operations, independent contractors, product-completed operations, personal injury, advertising injury, bodily injury, death and/or property damage occurring in or about the Building, under which Tenant is insured and Landlord, Landlord&#x2019;s Agent and any Lessors and any Mortgagees whose names have been furnished to Tenant are named as additional insureds (the &#x201c;Insured Parties&#x201d;).  Such insurance shall provide primary coverage without contribution from any other insurance or self-insurance carried by or for the benefit of the Insured Parties, and such insurance shall include blanket broad-form contractual liability coverage.  The minimum limits of liability applying exclusively to the Premises shall be $3,000,000.00 per occurrence and $5,000,000.00 aggregate.  If CGL contains a general aggregate limit, it shall apply separately to this location.  Landlord shall retain the right to require Tenant to increase such coverage at the time of Lease renewal to that amount of insurance which in Landlord&#x2019;s commercially reasonable judgment is then being customarily required by landlords for similar office space in Comparable Buildings.  There shall be no deductible or self-insurance without prior written consent of Landlord.</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(ii)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">All-Risk Commercial Property Insurance (Including the Perils </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Flood and Earthquake</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">insuring Tenant&#x2019;s Property and Above Building Standard Installations, for the full replacement value thereof, having a deductible amount, if any, not in excess of $25,000 without prior written consent of Landlord.  Flood and Earthquake coverage with a limit as close to the full replacement cost of the property covered as is reasonably available shall be provided.  The Insured Parties shall be included as Loss Payee(s) with respect to all Alterations.</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(iii)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Builder&#x2019;s Risk</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> during the performance of any Alteration, including without limitation any initial tenant fit-out work to ready the Premises for Tenant&#x2019;s occupancy, until completion thereof, on an &#x201c;All Risk&#x201d; basis including a permission to complete and occupy and flood including resulting water damage endorsements, for full replacement value covering the interest of Landlord and Tenant (and all respective contractors and subcontractors) in all work incorporated in the Building and all materials and equipment in or about the Premises or evidence of coverage under the &#x201c;All Risk&#x201d; property insurance policies.  The Insured Parties shall be named as additional insureds.</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(iv)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Business</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Interruption Insurance</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">covering a</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">minimum of one year of anticipated gross Rent.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">24</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(v)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Workers&#x2019; Compensation Benefits insurance</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">as required by law or by statute, and Employer&#x2019;s Liability with a limit not less than $1,000,000 each accident for bodily injury by accident or $1,000,000 each employee for bodily injury by disease.  A deductible or self&#x2011;insured retention for such policy shall not exceed $25,000 without prior written consent of Landlord.</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(vi)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Commercial Automobile Liability Insurance</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(if the Tenant is operating a fleet out of the Premises) covering any auto including owned, hired, and non-owned autos, as applicable, with a combined single limit with respect to each occurrence in an amount of not less than $1,000,000.  The Commercial Auto policy shall include contractual liability coverage.  The Insured Parties shall be named as additional insureds.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)	All insurance required to be carried by Tenant shall contain a provision that the Insured Parties receive thirty (30) days prior written notice in advance of any termination or material change (except that notice of termination for nonpayment of premium shall be 10-days) of the policies that would affect the interest of any of the Insured Parties and shall be effected under valid and enforceable policies issued by reputable insurers authorized to do business in the Commonwealth of Pennsylvania and rated in AM Best&#x2019;s Insurance Guide, or any successor thereto as having an AM Best&#x2019;s Rating of &#x201c;A&#x201d; or better and a Financial Size Category of at least &#x201c;X&#x201d; or better, or if such ratings are not then in effect, the equivalent thereof.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(c)	On or prior to the Commencement Date, Tenant shall deliver to Landlord appropriate certificates of insurance, that evidence insurance required to be covered by this Article 11, the waivers of subrogation required by Section 11.2, the Insured Parties are named as additional insureds/loss payees as required pursuant to this Article 11, and the commercial general liability is primary, non-contributory, and not excess of any other valid and collectible insurance.  Evidence of each renewal or replacement policies shall be delivered by Tenant to Landlord at least ten (10) days after the expiration of the policies.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(d)	By requiring insurance herein, Landlord does not represent that coverage and limits will necessarily be adequate to protect Tenant, and such coverage and limits shall not be deemed a limitation on or transfer of Tenant&#x2019;s liability under the indemnities granted to Landlord in this contract.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(e)	All rights that inure to the benefit of the Landlord shall not be prejudiced by the expiration of the Lease.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:15pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(f)	Tenant may satisfy the limits of liability required herein with a combination of umbrella and/or excess policies of insurance where applicable, provided that such policies comply with all of the provisions hereof (including, without limitation, with respect to scope of coverage and naming of the Insured Parties as additional insureds).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 11.2	Waiver of Subrogation.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Landlord and Tenant shall each procure an appropriate clause in or endorsement to any property insurance covering the Property and personal property, fixtures and equipment located therein, wherein the insurer waives subrogation or consents to a waiver of right of recovery, and Landlord and Tenant agree not to make any claim against, or seek to recover from, the other for any loss or damage to its property or the property of</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">25</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">others resulting from fire or other hazards to the extent covered by such property insurance, regardless of whether such loss or damage is caused by the negligence of Landlord or Tenant, arising out of any of the perils or casualties insured against by the property insurance policies carried, or required to be carried, by the parties pursuant to this Lease.  In addition, Landlord and Tenant shall have no liability to one another for any deductible amount carried under any policy.  Tenant acknowledges that Landlord shall not carry insurance on, and shall not be responsible for, (i) damage to any Above Building Standard Installations, (ii) Tenant&#x2019;s Property, and (iii) any loss suffered by Tenant due to interruption of Tenant&#x2019;s business.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 11.3	Restoration</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)	If the Premises are damaged by fire or other casualty, or if the Building is damaged such that Tenant is deprived of reasonable access to the Premises, the damage shall be repaired by Landlord, to substantially the condition of the Premises prior to the damage, subject to the provisions of any Mortgage or Superior Lease, but Landlord&#x2019;s repair obligation shall be limited to base level Alterations and improvements that are typically performed in connection with the initial occupancy of tenants in the Building </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Building Standard Installations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">and Landlord shall have no obligation to repair or restore (i) Tenant&#x2019;s Property or (ii) except as provided in Section 11.4(b), any Alterations or improvements to the Premises, to the extent such Alterations or improvements exceed Building Standard Installations (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Above</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Building Standard Installations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">So long as Tenant is not in default beyond applicable grace or notice provisions in the payment or performance of its obligations under this Section 11.4, and provided Tenant timely delivers to Landlord either Tenant&#x2019;s Restoration Payment (as hereinafter defined) or the Restoration Security (as hereinafter defined) or Tenant expressly waives any obligation of Landlord to repair or restore any of Tenant&#x2019;s Above Building Standard Installations, then until the restoration of the Premises is Substantially Completed or would have been Substantially Completed but for Tenant Delay, Fixed Rent, Tenant&#x2019;s Tax Payment and Tenant&#x2019;s Operating Payment shall be reduced in the proportion by which the area of the part of the Premises which is not usable (or accessible) and is not used by Tenant bears to the total area of the Premises.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)	As a condition precedent to Landlord&#x2019;s obligation to repair or restore any Above Building Standard Installations, Tenant shall (i) pay to Landlord upon demand a sum </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tenant&#x2019;s Restoration Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">equal to the amount, if any, by which (A) the cost, as estimated by a reputable independent contractor designated by Landlord, of repairing and restoring all Alterations and Initial Installations in the Premises to their condition prior to the damage, exceeds (B) the cost of restoring the Premises with Building Standard Installations, or (ii) furnish to Landlord security (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Restoration Security</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">in form and amount reasonably acceptable to Landlord to secure Tenant&#x2019;s obligation to pay all costs in excess of restoring the Premises with Building Standard Installations.  If Tenant shall fail to deliver to Landlord either (1) Tenant&#x2019;s Restoration Payment or the Restoration Security, as applicable, or (2) a waiver by Tenant, in form satisfactory to Landlord, of all of Landlord&#x2019;s obligations to repair or restore any of the Above Building Standard Installations, in either case within 15 days after Landlord&#x2019;s demand therefor, Landlord shall have no obligation to restore any Above Building Standard Installations and Tenant&#x2019;s abatement of Fixed Rent, Tenant&#x2019;s Tax Payment and Tenant&#x2019;s Operating Payment shall cease when the restoration of the Premises (other than any Above Building Standard Installations) is Substantially Complete.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">26</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 11.4	Landlord&#x2019;s Termination Right.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding anything to the contrary contained in Section 11.4, if the Premises are totally damaged or are rendered wholly untenantable, or if the Building shall be so damaged that, in Landlord&#x2019;s reasonable opinion, substantial alteration, demolition, or reconstruction of the Building shall be required (whether or not the Premises are so damaged or rendered untenantable), then in either of such events, Landlord may, not later than 60 days following the date of the damage, terminate this Lease by notice to Tenant, provided that if the Premises are not damaged, Landlord may not terminate this Lease unless Landlord, similarly terminates the leases of other tenants in the Building aggregating at least 50% of the portion of the Building occupied for office purposes immediately prior to such damage.  If this Lease is so terminated, (a) the Term shall expire upon the 30th day after such notice is given, (b) Tenant shall vacate the Premises and surrender the same to Landlord, (c) Tenant&#x2019;s liability for Rent shall cease as of the date of the damage, and (d) any prepaid Rent for any period after the date of the damage shall be refunded by Landlord to Tenant.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 11.5	Tenant&#x2019;s Termination Right.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If the Premises are totally damaged and are thereby rendered wholly untenantable, or if the Building shall be so damaged that Tenant is deprived of reasonable access to the Premises, and if Landlord elects to restore the Premises, Landlord shall, within 60 days following the date of the damage, cause a contractor or architect selected by Landlord to give notice (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Restoration Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">to Tenant of the date by which such contractor or architect estimates the restoration of the Premises (excluding any Above Building Standard Installations) shall be Substantially Completed.  If such date, as set forth in the Restoration Notice, is more than 12 months from the date of such damage, then Tenant shall have the right to terminate this Lease by giving notice (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Termination Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">to Landlord not later than 30 days following delivery of the Restoration Notice to Tenant.  If Tenant delivers a Termination Notice, this Lease shall be deemed to have terminated as of the date of the giving of the Termination Notice, in the manner set forth in the second sentence of Section 11.5.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 11.6	Final 18 Months.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding anything to the contrary in this Article 11, if any damage during the final 18 months of the Term renders the Premises wholly untenantable, either Landlord or Tenant may terminate this Lease by notice to the other party within 30 days after the occurrence of such damage and this Lease shall expire on the 30th day after the date of such notice.  For purposes of this Section 11.7, the Premises shall be deemed wholly untenantable if Tenant shall be precluded from using more than 50% of the Premises for the conduct of its business and Tenant&#x2019;s inability to so use the Premises is reasonably expected to continue for more than 90 days.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 11.7	Landlord&#x2019;s Liability.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Any Building employee to whom any property shall be entrusted by or on behalf of Tenant shall be deemed to be acting as Tenant&#x2019;s agent with respect to such property and neither Landlord nor its agents shall be liable for any damage to such property, or for the loss of or damage to any property of Tenant by theft or otherwise.  None of the Insured Parties shall be liable for any injury or damage to persons or property or interruption of Tenant&#x2019;s business resulting from fire or other casualty, any damage caused by other tenants or persons in the Building or the parking garage or by construction of any private, public or quasi-public work, or any latent defect in the Premises or in the Building or the parking garage (except that Landlord shall be required to repair the same to the extent provided in Article 6).  No penalty shall accrue for delays which may arise by reason of adjustment of fire insurance on the part of Landlord or Tenant, or for any Unavoidable Delays arising from any repair or restoration of any portion of the</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">27</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Building, provided that Landlord shall use reasonable efforts to minimize interference with Tenant&#x2019;s use and occupancy of the Premises during the performance of any such repair or restoration.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARTICLE 12</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br><br></font><font style="color:#2c2c2c;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EMINENT DOMAIN</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:15pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 12.1	Taking</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Total Taking.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If all or substantially all of the Property, the Complex, the Building or the Premises shall be acquired or condemned for any public or quasi-public purpose (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Taking</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">this Lease shall terminate and the Term shall end as of the date of the vesting of title and Rent shall be prorated and adjusted as of such date.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Partial Taking.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Upon a Taking of only a part of the Property, the Complex, the Building or the Premises then, except as hereinafter provided in this Article 12, this Lease shall continue in full force and effect, provided that from and after the date of the vesting of title, Fixed Rent and Tenant&#x2019;s Proportionate Share shall be modified to reflect the reduction of the Premises and/or the Building as a result of such Taking.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Landlord&#x2019;s Termination Right </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Whether or not the Premises </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">are </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">affected, Landlord may, by notice to Tenant, within 60 days following the date upon which Landlord receives notice of the Taking of all or a portion of the Property, the Complex, the Building or the Premises, terminate this Lease, provided that Landlord elects to terminate leases (including this Lease) affecting at least 50% of the rentable area of the Building.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(d)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tenant&#x2019;s Termination Right </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If the part of the Property so Taken contains more than 20% of the total area of the Premises occupied by Tenant immediately prior to such Taking, or if, by reason of such Taking, Tenant no longer has reasonable means of access to the Premises, Tenant may terminate this Lease by notice to Landlord given within 30 days following the date upon which Tenant is given notice of such Taking.  If Tenant so notifies Landlord, this Lease shall end and expire upon the 30th day following the giving of such notice.  If a part of the Premises shall be so Taken and this Lease is not terminated in accordance with this Section 12.1 Landlord, without being required to spend more than it collects as an award, shall, subject to the provisions of any Mortgage or Superior Lease, restore that part of the Premises not so Taken to a self-contained rental unit substantially equivalent (with respect to character, quality, appearance and services) to that which existed immediately prior to such Taking, excluding Tenant&#x2019;s Property and Above Building Standard Installations.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(e)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Apportionment of Rent </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Upon any termination of this Lease pursuant to the provisions of this Article 12, Rent shall be apportioned as of, and shall be paid or refunded up to and including, the date of such termination.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 12.2	Awards.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Upon any Taking, Landlord shall receive the entire award for any such Taking, and Tenant shall have no claim against Landlord or the condemning authority for the value of any unexpired portion of the Term or Tenant&#x2019;s Alterations; and Tenant hereby assigns to Landlord ail of its right in and to such award.  Nothing contained in this Article 12 shall be deemed</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">28</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">to prevent Tenant from making a separate claim in any condemnation proceedings for the then value of any Tenant&#x2019;s Property or Above Building Standard Installations included in such Taking and for any moving expenses, provided any such award is in addition to, and does not result in a reduction of, the award made to Landlord.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 12.3	Temporary Taking.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">all or any part of the Premises is Taken temporarily during the Term for any public or quasi-public use or purpose, Tenant shall give prompt notice to Landlord and the Term shall not be reduced or affected in any way and Tenant shall continue to pay all Rent payable by Tenant without reduction or abatement and to perform all of its other obligations under this Lease, except to the extent prevented from doing so by the condemning authority, and Tenant shall be entitled to receive any award or payment from the condemning authority for such use, which shall be received, held and applied by Tenant as a trust fund for payment of the Rent falling due.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARTICLE 13</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br><br></font><font style="color:#2c2c2c;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ASSIGNMENT AND SUBLETTING</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:15pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 13.1	Consent Requirements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Assignment or Subletting.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Except as expressly set forth herein, Tenant shall not assign, mortgage, pledge, encumber, or otherwise transfer this Lease, whether by operation of law (including by merger) or otherwise, and shall not sublet, or permit, or suffer the Premises or any part thereof to be used or occupied by others (whether for desk space, mailing privileges or otherwise), without Landlord&#x2019;s prior consent in each instance, which consent shall not be unreasonably conditioned, withheld or delayed.  Any assignment, sublease, mortgage, pledge, encumbrance or transfer in contravention of the provisions of this Article 13 shall be void and shall constitute an Event of Default.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Collection of</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Rent.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If, without Landlord&#x2019;s consent, this Lease is assigned or transferred, or any part of the Premises is sublet or occupied by anyone other than Tenant or this Lease is encumbered (by operation of law or otherwise), Landlord may collect rent from the assignee, subtenant or occupant, and apply the net amount collected to the Rent herein reserved.  No such collection shall be deemed a waiver of the provisions of this Article 13, an acceptance of the assignee, transferee, subtenant or occupant as tenant, or a release of Tenant from the performance of Tenant&#x2019;s covenants hereunder, and in all cases Tenant shall remain fully liable for its obligations under this Lease.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Further Assignment/Subletting.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Landlord&#x2019;s consent to any assignment, transfer or subletting shall not relieve Tenant from the obligation to obtain Landlord&#x2019;s consent to any further assignment, transfer or subletting.  In no event shall any permitted subtenant assign, transfer or encumber its sublease or further sublet any portion of its sublet space, or otherwise suffer or permit any portion of the sublet space to be used or occupied by others.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 13.2	Tenant&#x2019;s Notice.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If Tenant desires to assign or transfer this Lease or sublet all or any portion of the Premises, Tenant shall give notice thereof to Landlord, which shall be accompanied by (a) with respect to an assignment or transfer of this Lease, the date Tenant desires</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">29</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the assignment or transfer to be effective, and (b) with respect to a sublet of all or a part of the Premises, a description of the portion of the Premises to be sublet and the commencement date of such sublease.  Such notice shall be deemed an irrevocable 30 day offer from Tenant to Landlord of the right, at Landlord&#x2019;s option, (1) if the proposed transaction is an assignment or transfer of this Lease, to terminate this Lease with respect to the entire Premises, (2) if the proposed transaction is a sublease of 75% or more of the rentable square footage of the Premises and the term of such sublease (including any extension options provided for under the sublease) would either be for 75% or more of the then remaining Term of this Lease (without regard to any then unexercised extension options under this Lease) or for a period expiring during the last 18 months of the Term of this Lease (without regard to any then unexercised extension options under this Lease, but considering all extension options granted under the proposed sublease), to terminate this Lease with respect to the entire Premises, or (3) if Landlord elects not to exercise its termination right under clause (2) or if the proposed transaction is a sublease that does not fall within the criteria set forth in clause (2), to terminate this Lease with respect to the space that Tenant proposes to sublease (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Partial Space</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Such option may be exercised by notice from Landlord to Tenant within 30 days after delivery of Tenant&#x2019;s notice.  If Landlord exercises its option to terminate all or a portion of this Lease, (a) this Lease shall end and expire with respect to all or a portion of the Premises, as the case may be, on the date that such assignment, transfer or sublease was to commence, provided that such date is in no event earlier than 90 days after the date Landlord receives the above notice unless Landlord agrees to such earlier date, (b) Rent shall be apportioned, paid or refunded as of such date, (c) Tenant, upon Landlord&#x2019;s request, shall enter into an amendment of this Lease ratifying and confirming such total or partial termination, and setting forth any appropriate modifications to the terms and provisions hereof, and (d) Landlord shall be free to lease the Premises (or any part thereof) to Tenant&#x2019;s prospective assignee, transferee or subtenant.  Tenant shall pay all costs to make the Partial Space a self-contained rental unit and to install any required Building corridors.  Notwithstanding anything to the contrary in this Section 13.2, Tenant may withdraw its request to assign or transfer this Lease or sublet all or any portion of the Premises within five (5) days following Tenant&#x2019;s receipt of Landlord notice of Landlord&#x2019;s exercise of its rights under this Section 13.2.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 13.3	Conditions to Assignment/Subletting</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)	Provided that no Event of Default then exists, Landlord&#x2019;s consent (if required under this Article 13) to the proposed assignment, transfer or subletting shall be granted or denied within 15 days after delivery to Landlord of (i) a true and complete statement reasonably detailing the identity of the proposed assignee, transferee or subtenant </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Transferee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the nature of its business and its proposed use of the Premises, (ii) current financial information with respect to the Transferee, including its most recent financial statements, (iii) a copy of the assignment or sublease document, and (iv) any other information Landlord may reasonably request.  Such consent shall not be unreasonably withheld, conditioned or delayed, provided that Landlord shall base its decision upon relevant factors which may include the following:</font></p>
  <p style="text-indent:26.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">a.	in Landlord&#x2019;s reasonable judgment, the Transferee is engaged in a business or activity, and the Premises will be used in a manner, which (1) is in keeping with the then standards of the Building, (2) is for the Permitted Uses, (3) does not violate any restrictions set forth in this Lease, any Mortgage or Superior Lease or any negative covenant as to use of the Premises required by any other lease in the Building, and (4) will not attract a volume,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">30</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">frequency or type of visitor or employee to the Building which is not in keeping with the then standards of the Building and will not impose an excessive demand on or use of the facilities or services of the Building;</font></p>
  <p style="text-indent:26.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">b.	the Transferee is reputable with sufficient financial means to perform all of its obligations under this Lease or the sublease, as the case may be;</font></p>
  <p style="text-indent:26.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">c.	if Landlord has, or reasonably expects to have within two months thereafter, comparable space available in the Building, neither the Transferee nor any person which, directly or indirectly, controls, is controlled by, or is under common control with, the Transferee is then an occupant of the Building;</font></p>
  <p style="text-indent:26.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">d.	the Transferee is not a person or entity (or affiliate of a person or entity) with whom Landlord is then or has been within the prior six months negotiating in connection with the rental of space in the Building;</font></p>
  <p style="text-indent:26.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">e.	there shall be not more than two subtenants on each floor of the Premises;</font></p>
  <p style="text-indent:26.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">f.	Tenant shall, upon demand, reimburse Landlord for all reasonable expenses incurred by Landlord in connection with such assignment or sublease, including any investigations as to the acceptability of the Transferee and all legal costs reasonably incurred in connection with the granting of any requested consent, not to exceed $2,500; and</font></p>
  <p style="text-indent:26.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">g.	the Transferee shall not be entitled, directly or indirectly, to diplomatic or sovereign immunity, regardless of whether the Transferee agrees to waive such diplomatic or sovereign immunity, and shall be subject to the service of process in, and the jurisdiction of the courts of, the Commonwealth of Pennsylvania.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)	with respect to each and every subletting, transfer and/or assignment approved by Landlord under the provisions of this Lease:</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(i)	the form of the proposed assignment, transfer agreement or sublease shall be reasonably satisfactory to Landlord;</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(ii)	no sublease shall be for a term ending later than one day prior to the Expiration Date;</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(iii)	no Transferee shall take possession of any part of the Premises, until an executed counterpart of such sublease, transfer agreement or assignment has been delivered to Landlord and approved by Landlord as provided in Section 13.8;</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(iv)	if an Event of Default occurs prior to the effective date of such assignment, transfer or subletting, then Landlord&#x2019;s consent thereto, if previously granted, shall be immediately deemed revoked without further notice to Tenant, and if such assignment or subletting would have been permitted without Landlord&#x2019;s consent pursuant to Section 13.7, such permission shall be void and without force and effect, and in either such case, any such assignment, transfer or subletting shall constitute a further Event of Default hereunder; and</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">31</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(v)	each sublease shall be subject and subordinate to this Lease and to the matters to which this Lease is or shall be subordinate; and Tenant and each Transferee shall be deemed to have agreed that upon the occurrence and during the continuation of an Event of Default hereunder, Tenant has hereby assigned to Landlord, and Landlord may, at its option, accept such assignment of, all right, title and interest of Tenant as sublandlord under such sublease, together with all modifications, extensions and renewals thereof then in effect and such Transferee shall, at Landlord&#x2019;s option, attorn to Landlord pursuant to the then executory provisions of such sublease, except that Landlord shall not be (A) liable for any previous act or omission of Tenant under such sublease, (B) subject to any counterclaim, offset or defense not expressly provided in such sublease, which theretofore accrued to such Transferee against Tenant, (C) bound by any previous modification of such sublease not consented to by Landlord or by any prepayment of more than one month&#x2019;s rent, (D) bound to return such Transferee&#x2019;s security deposit, if any, except to the extent Landlord shall receive actual possession of such deposit and such Transferee shall be entitled to the return of all or any portion of such deposit under the terms of its sublease, or (E) obligated to make any payment to or on behalf of such Transferee, or to perform any work in the subleased space or the Building, or in any way to prepare the sublet space for occupancy, beyond Landlord&#x2019;s obligations under this Lease.  The provisions of this Section 13.3(b)(v) shall be self-operative, and no further instrument shall be required to give effect to this provision, provided that the Transferee shall execute and deliver to Landlord any instruments Landlord may reasonably request to evidence and confirm such subordination and attornment.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 13.4	Binding on Tenant; Indemnification of Landlord.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding any assignment, transfer or subletting or any acceptance of rent by Landlord from any Transferee, Tenant shall remain folly liable for the payment of all Rent due and for the performance of all the covenants, terms and conditions contained in this Lease on Tenant&#x2019;s part to be observed and performed, and any default under any term, covenant or condition of this Lease by any Transferee or anyone claiming under or through any Transferee shall be deemed to be a default under this Lease by Tenant.  Tenant shall indemnify, defend, protect and hold harmless Landlord from and against any and all Losses resulting from any claims that may be made against Landlord by the Transferee or anyone claiming under or through any Transferee or by any brokers or other persons claiming a commission or similar compensation in connection with the proposed assignment, transfer or sublease, irrespective of whether Landlord shall give or decline to give its consent to any proposed assignment, transfer or sublease, or if Landlord shall exercise any of its options under this Article 13.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 13.5	Tenant&#x2019;s Failure to Complete.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If Landlord consents to a proposed assignment, transfer or sublease and Tenant fails to execute and deliver to Landlord such assignment, transfer or sublease within 90 days after the giving of such consent or the amount of space subject to such sublease varies by more than 10% from that specified in the notice given by Tenant to Landlord pursuant to Section 13.2, or the net effective rent payable under such Sublease is less than the Market Sub-rent, then Tenant shall again comply with all of the provisions and conditions of Sections 13.2,13.3 and 13.4 before assigning or transferring this Lease or subletting all or part of the Premises.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 13.6	Profits.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If Tenant enters into any assignment, transfer or sublease permitted hereunder or consented to by Landlord, Tenant shall, within 60 days of Landlord&#x2019;s consent to such assignment, transfer or sublease, deliver to Landlord a list of Tenant&#x2019;s reasonable third-party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">32</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">brokerage fees and legal fees paid or to be paid in connection with such transaction (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Transaction Costs</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">together with a list of all of Tenant&#x2019;s Property to be transferred to such Transferee.  The Transaction Costs shall be amortized, on a straight-line basis, over the term of any sublease.  Tenant shall deliver to Landlord evidence of the payment of such Transaction Costs promptly after the same are paid.  In consideration of such assignment or subletting, Tenant shall pay to Landlord:</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)	In the case of an assignment or transfer, on the effective date of the assignment or transfer, 50% of all sums and other consideration paid to Tenant by the Transferee for or by reason of such assignment or transfer (including, except to the extent prohibited by Section 26.20, sums paid for the sale or rental of Tenant&#x2019;s Property, less, the then fair market or rental value thereof, as reasonably determined by Landlord) after first deducting the Transaction Costs; or</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)	In the case of a sublease, 50% of any consideration payable under the sublease to Tenant by the Transferee which exceeds on a per square foot basis the Fixed Rent and Additional Rent accruing during the term of the sublease in respect of the subleased space (together with, except to the extent prohibited by Section 26.20, any sums paid for the sale or rental of Tenant&#x2019;s Property, less, the then fair market or rental value thereof, as reasonably determined by Landlord) after first deducting the monthly amortized amount of Transaction Costs.  The sums payable under this clause shall be paid by Tenant to Landlord monthly as and when paid by the subtenant to Tenant.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 13.7	Transfers</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Related Entities.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tenant is a legal entity, the transfer (by one or more transfers), directly or indirectly, by merger, consolidation, operation of law or otherwise, of a majority of the stock or other beneficial ownership interest in Tenant or of all or substantially all of the assets of Tenant (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Ownership Interests</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">shall be deemed a voluntary assignment or transfer of this Lease; provided, however, that the provisions of this Article 13 shall not apply to the transfer of Ownership Interests in Tenant if and so long as Tenant is publicly traded on a nationally recognized stock exchange.  For purposes of this Article the term &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">transfers</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">shall be deemed to include (x) the issuance of new Ownership Interests which results in a majority of the Ownership Interests in Tenant being held by a person or entity which does not hold a majority of the Ownership Interests in Tenant on the Effective Date and (y) except as provided below, the sale or transfer of all or substantially all of the assets of Tenant in one or more transactions and the merger or consolidation of Tenant into or with another business entity.  The provisions of Section 13.1 shall not apply to transactions with a business entity into or with which Tenant is merged or consolidated or to which all or substantially all of Tenant&#x2019;s assets arc transferred so long as (i) such transfer was not made for the sole purpose of assigning or transferring this Lease, (ii) the successor to Tenant has a net worth computed in accordance with generally accepted accounting principles at least equal to the net worth of Tenant on the Effective Date, and (iii) proof, reasonably satisfactory to Landlord, of such net worth is delivered to Landlord at least 10 days prior to the effective date of any such merger, consolidation, assignment or transfer.  Tenant may also, upon prior notice to Landlord, permit any business entity which controls, is controlled by, or is under common control with the original Tenant (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Related Entity</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">to sublet</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">33</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">all or part of the Premises for any Permitted Uses, provided the Related Entity is in Landlord&#x2019;s reasonable judgment of a character and engaged in a business which is in keeping with the standards for the Building and for so long as such entity remains a Related Entity.  Such sublease shall not be deemed to vest in any such Related Entity any right or interest in this Lease nor shall it relieve, release, impair or discharge any of Tenant&#x2019;s obligations hereunder.  For the purposes hereof, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">control</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">shall be deemed to mean ownership of not less than 50% of all of the Ownership Interests of such corporation or other business entity.  Notwithstanding the foregoing, Tenant shall have no right to assign or transfer this Lease or sublease all or any portion of the Premises without Landlord&#x2019;s consent pursuant to this Section 13.7 if Tenant is not the initial Tenant herein named or a person or entity who acquired Tenant&#x2019;s interest in this Lease in a transaction approved by Landlord.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:15pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Applicability.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The limitations set forth in this Section 13.7 shall apply to Transferee(s) and guarantor(s) of this Lease, if any, and any transfer by any such entity in violation of this Section 13.7 shall be a transfer in violation of Section 13.1.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:15pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Modifications, Takeover Agreements.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Any modification, amendment or extension of a sublease and/or any other agreement or transfer by which a landlord of a building other than the Building or its affiliate agrees to assume the obligations of Tenant under this Lease shall be deemed a sublease for the purposes of Section 13.1 hereof.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 13.8	Assumption of Obligations.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No assignment or transfer of this Lease by Tenant shall be effective unless and until the Transferee executes, acknowledges and delivers to Landlord an agreement in form and substance reasonably satisfactory to Landlord whereby the Transferee (a) assumes Tenant&#x2019;s obligations under this Lease and (b) agrees that, notwithstanding such assignment or transfer, the provisions of Section 13.1 hereof shall be binding upon it in respect of all future assignments and transfers.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 13.9	Tenant&#x2019;s Liability.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The joint and several liability of Tenant and any successors-in-interest of Tenant and the due performance of Tenant&#x2019;s obligations under this Lease shall not be discharged, released or impaired by any agreement or stipulation made by Landlord, or any grantee or assignee of Landlord, extending the time, or modifying any of the terms and provisions of this Lease, or by any waiver or failure of Landlord, or any grantee or assignee of Landlord, to enforce any of the terms and provisions of this Lease.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 13.10	Listings in Building Directory.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The listing of any name other than that of Tenant on the doors of the Premises, the Building directory or elsewhere shall not vest any right or interest in this Lease or in the Premises, nor be deemed to constitute Landlord&#x2019;s consent to any assignment or transfer of this Lease or to any sublease of the Premises or to the use or occupancy thereof by others.  Any such listing shall constitute a privilege revocable in Landlord&#x2019;s discretion by notice to Tenant.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 13.11	Lease Disaffirmance or Rejection</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  If</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">at any time after an assignment by Tenant named herein, this Lease is not affirmed or is rejected in any bankruptcy proceeding or any similar proceeding, or upon a termination of this Lease due to any such proceeding, Tenant named herein, upon request of Landlord given after such disaffirmance, rejection or termination (and actual notice thereof to Landlord in the event of a disaffirmance or rejection or in the event of</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">34</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">termination other than by act of Landlord), shall (a) pay to Landlord all Rent and other charges due and owing by the assignee to Landlord under this Lease to and including the date of such disaffirmance, rejection or termination, and (b) as &#x201c;tenant,&#x201d; enter into a new lease of the Premises with Landlord for a term commencing on the effective date of such disaffirmance, rejection or termination and ending on the Expiration Date, at the same Rent and upon the then executory terms, covenants and conditions contained in this Lease, except that (i) the rights of Tenant named herein under the new lease shall be subject to the possessory rights of the assignee under this Lease and the possessory rights of any persons or entities claiming through or under such assignee or by virtue of any statute or of any order of any court, (ii) such new lease shall require all defaults existing under this Lease to be cured by Tenant named herein with due diligence, and (iii) such new lease shall require Tenant named herein to pay all Rent which, had this Lease not been so disaffirmed, rejected or terminated, would have become due under the provisions of this Lease after the date of such disaffirmance, rejection or termination with respect to any period prior thereto.  If Tenant named herein defaults in its obligations to enter into such new lease for a period of 10 days after Landlord&#x2019;s request, then, in addition to all other rights and remedies by reason of default, either at law or in equity, Landlord shall have the same rights and remedies against Tenant named herein as if it had entered into such new lease and such new lease had thereafter been terminated as of the commencement date thereof by reason of Tenant&#x2019;s default thereunder.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARTICLE 14</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br><br></font><font style="color:#2c2c2c;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ACCESS TO PREMISES AND SUBSTITUTION OF PREMISES</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 14.1	Landlord&#x2019;s Access</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)	Landlord, Landlord&#x2019;s agents and utility service providers servicing the Building may erect, use and maintain concealed ducts, pipes and conduits in and through the Premises provided such use does not cause the usable area of the Premises to be reduced beyond a </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">de minimis</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> amount.  Landlord shall promptly repair any damage to the Premises caused by any work performed pursuant to this Article 14.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)	Landlord, any Lessor or Mortgagee and any other party designated by Landlord and their respective agents shall have the right to enter the Premises during normal business hours, upon reasonable notice (which notice may be oral) except in the case of emergency, to examine the Premises, to show the Premises to prospective purchasers, Mortgagees, Lessors or tenants and their respective agents and representatives or others and to perform Restorative Work to the Premises or the Building.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(c)	All parts (except surfaces facing the interior of the Premises) of all walls, windows and doors bounding the Premises, all balconies, terraces and roofs adjacent to the Premises, all space in or adjacent to the Premises used for shafts, stacks, stairways, mail chutes, conduits and other mechanical facilities, Building Systems; Building facilities and Common Areas are not part of the Premises, and Landlord shall have the use thereof and access thereto through the Premises for the purposes of Building operation, maintenance, alteration and repair,</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 14.2	Building Name.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Landlord has the right at any time to change the name, number or designation by which the Building or the Complex is commonly known.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">35</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:15pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 14.3	Substitution of Other Premises</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)	At any time and from time to time whether before or after the Commencement Date, upon at least 90 days prior written notice, Landlord shall have the right to substitute other space in the Building or Complex </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Substitute Space</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">for the Premises by notice (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Substitution Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">given to Tenant designating the space so substituted for the Premises.  The Substitute Space shall have a rentable area and configuration substantially similar to the Premises.  Notwithstanding such substitution of space, this Lease and all the terms, provisions, covenants and conditions contained in this Lease shall remain and continue in full force and effect, except that the Premises shall be deemed to be the Substitute Space, with the same force and effect as if the Substitute Space were originally specified in this Lease as the Premises demised hereunder.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)	In the event of the substitution of space as provided in this Section, the following provisions (i) through (iv) shall apply:</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(i)	If the Substitute Space has less square footage than the Premises, then effective on the date the Substitute Space is available for occupancy by Tenant (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Substitution Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the Fixed Rent and the Additional Rent payable under this Lease shall be decreased proportionately.  If the Substitute Space has more square footage than the Premises, then effective on the Substitution Date, the Fixed Rent and the Additional Rent payable under this Lease shall be increased proportionately, but not by more than 5%.</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(ii)	Landlord shall, at Landlord&#x2019;s expense, prepare the Substitute Space in substantially the same manner as the Premises were prepared for Tenant&#x2019;s initial occupancy (including the Initial Installations by Landlord and Tenant&#x2019;s Alterations).  Landlord shall have the right to move any millwork, floor covering, cabinet work, and any other decoration as well as telephone lines and any other communication line and other reusable items, from the Premises to the Substitute Space, subject to Tenant&#x2019;s prior approval, which approval shall not be unreasonably withheld, conditioned or delayed.  In addition, Landlord shall reimburse Tenant for Tenant&#x2019;s reasonable documented costs to relocate Tenant&#x2019;s fixtures, equipment and other personal property from the Premises to the Substitute Space using a moving company approved by Landlord, which approval shall not be unreasonably withheld, conditioned or delayed.</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(iii)	As soon as Landlord has Substantially Completed preparing the Substitute Space, Tenant, upon 45 days&#x2019; prior written notice, shall vacate and surrender the Premises within such 45 day period in the condition required by </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 18.1,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> and any failure to do so shall be subject to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 18.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Tenant shall move to the Substitute Space, at Landlord&#x2019;s reasonable cost and expense.  If Tenant fails to move to the Substitute Space within such 45 day period, Landlord, as Tenant&#x2019;s agent, may remove Tenant from the Premises to the Substitute Space.  The failure of Tenant to move to the Substitute Space pursuant to this Section within 5 days after the expiration of such 45 days&#x2019; notice shall be an Event of Default, and Tenant shall pay Rent with respect to both the Premises and Substitute Space until Tenant has moved to the Substitute Space.</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(iv)	Promptly after Tenant shall enter into occupancy of the Substitute Space, Landlord shall reimburse Tenant for Tenant&#x2019;s reasonable, direct, out-of-pocket moving</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">36</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">expenses, unless Landlord moved Tenant into the Substitute Space pursuant to Section (iii) above.  Upon request from Landlord, Tenant shall supply Landlord with satisfactory evidence of direct out-of-pocket expenses incurred by Tenant in moving from the Premises to the Substitute Space.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(c)	Following any substitution of space pursuant to this Section 14,3, Landlord and Tenant, promptly at the request of either party, shall execute and deliver a supplementary agreement setting forth such substitution of space, the Substitution Date and the decrease (if the Substitute Space is less square footage than the Premises) or the increase (if the Substitute Space is more square footage than Premises) in the Fixed Rent and Additional Rent.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(d)	Notwithstanding anything in this Section 14.3 to the contrary, if Tenant is relocated to Substitute Space by a Substitution Notice during the final 365 days of the Term (with Tenant having no valid unexercised extension options remaining as of the Substitution Date), and Tenant is not satisfied, in its reasonable discretion, with the Substitute Space as identified by Landlord in the Substitution Notice, Tenant may, as its sole remedy, notify Landlord in writing </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tenant&#x2019;s Substitution Termination Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">no later than ten (10) days after Tenant&#x2019;s receipt of the Substitution Notice, time being of the essence, that Tenant elects to terminate this Lease, in which event, this Lease shall be deemed terminated as if by lapse of time, with no termination fee, penalty or payment due Landlord whatsoever on the Substitution Date, unless, Landlord revokes the Substitution Notice by delivering written notice of such revocation to Tenant within ten (10) days after Landlord&#x2019;s receipt of Tenant&#x2019;s Substitution Termination Notice, in which event this Lease shall continue in full force and effect as if Tenant&#x2019;s Substitution Termination Notice had not been delivered and Landlord&#x2019;s Substitution Notice shall be deemed void.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 14.4	Light and Air.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If at any time any windows of the Premises are temporarily darkened or covered over by reason of any Restorative Work, any of such windows are permanently darkened or covered over due to any Requirement or there is otherwise a diminution of light, air or view by another structure which may hereafter be erected (whether or not by Landlord), Landlord shall not be liable for any damages and Tenant shall not be entitled to any compensation or abatement of any Rent, nor shall the same release Tenant from its obligations hereunder or constitute an actual or constructive eviction.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARTICLE 15</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br><br></font><font style="color:#2c2c2c;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">DEFAULT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 15.1	Tenant&#x2019;s Defaults.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Each of the following events shall be an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Event of Default</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">hereunder:</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)	Tenant fails to pay when due any installment of Rent and such default shall continue for five days after written notice of such default is given to Tenant except that if Landlord shall have given two such notices of default in the payment of any Rent in any 12 month period, Tenant shall not be entitled to any further notice of its delinquency in the payment of any Rent or an extended period in which to make payment until such time as 12 consecutive months shall have elapsed without Tenant having failed to make any such payment when due, and the occurrence of any default in the payment of any Rent within such 12 month period after the giving of two such notices shall constitute an Event of Default; or</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">37</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)	Tenant fails to observe or perform any other term, covenant or condition of this Lease and such failure continues for more than 30 days (10 days with respect to a default under Article 3) after notice by Landlord to Tenant of such default, or if such default (other than a default under Article 3) is of a nature that it cannot be completely remedied within 30 days, failure by Tenant to commence to remedy such failure within said 30 days, and thereafter diligently prosecute to completion all steps necessary to remedy such default, provided in all events the same is completed within 90 days; or</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(c)	if Landlord applies or retains any part of the security held by Landlord hereunder, and Tenant fails to deposit with Landlord the amount so applied or retained by Landlord, or to provide Landlord with a replacement Letter of Credit (as hereinafter defined), if applicable, within ten (10) days after notice by Landlord to Tenant stating the amount applied or retained; or</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(d)	Tenant files a voluntary petition in bankruptcy or insolvency, or is adjudicated a bankrupt or insolvent, or files any petition or answer seeking any reorganization, liquidation, dissolution or similar relief under any present or future federal bankruptcy act or any other present or future applicable federal, state or other statute or law, or makes an assignment for the benefit of creditors or seeks or consents to or acquiesces in the appointment of any trustee, receiver, liquidator or other similar official for Tenant or for all or any part of Tenant&#x2019;s property; or</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(e)	a court of competent jurisdiction shall enter an order, judgment or decree adjudicating Tenant bankrupt, or appointing a trustee, receiver or liquidator of Tenant, or of the whole or any substantial part of its property, without the consent of Tenant, or approving a petition filed against Tenant seeking reorganization or arrangement of Tenant under the bankruptcy laws of the United States, as now in effect or hereafter amended, or any state thereof, and such order, judgment or decree shall not be vacated or set aside or stayed within 60 days from the date of entry thereof.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 15.2	Landlord&#x2019;s Remedies</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)	Upon the occurrence of an Event of Default, Landlord, at its option, and without limiting the exercise of any other right or remedy Landlord may have on account of such Event of Default under this Lease or applicable Requirements, and without any further demand or notice, may give to Tenant notice of (i) the termination of this Lease, in which event this Lease and the Term shall come to an end and expire (whether or not the Term shall have commenced) upon the termination date set forth in such notice with the same force and effect as if the date set forth in the notice was the Expiration Date stated herein, and/or (ii) the termination of Tenant&#x2019;s right of possession of the Premises, in which event Tenant&#x2019;s right of possession of the Premises shall come to an end and expire (whether or not the Term shall have commenced) upon the termination date set forth in such notice; and Tenant shall then quit and surrender the Premises to Landlord, but Tenant shall remain liable for damages as provided in this Article 15 and/or, to the extent permitted by applicable Requirements, Landlord may, pursuant to legal process, remove all persons and property from the Premises, which property shall be stored by Landlord at a warehouse or elsewhere at the risk, expense and for the account of Tenant.  Any termination notice may be given simultaneously with any notice of default given to Tenant.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">38</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Possession/Reletting.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If this Lease and the Term, or Tenant&#x2019;s right to possession of the Premises, terminate as provided in Section 15.2(a):</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(i)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Surrender of Possession.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tenant shall quit and surrender the Premises to Landlord, and Landlord and its agents may immediately, or at any time after such termination and pursuant to legal process, re-enter the Premises or any part thereof, without notice, either by eviction or ejectment proceedings, or by any other applicable action or proceeding, or by force (to the extent permitted by applicable Requirements) or otherwise in accordance with applicable legal proceedings (without being liable to indictment, prosecution or damages therefor), and may repossess the Premises and dispossess Tenant and any other persons from the Premises and remove any and all of their property and effects from the Premises.</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(ii)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Landlord&#x2019;s Reletting.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Landlord, at Landlord&#x2019;s option, may relet all or any part of the Premises from time to time, either in the name of Landlord or otherwise, to such tenant or tenants, for any term ending before, on or after the Expiration Date, at such rental and upon such other conditions (which may include concessions and free rent periods) as Landlord, in its sole discretion, may determine.  Landlord shall have no obligation to accept any tenant offered by Tenant and shall not be liable for failure to relet or, in the event of any such reletting, for failure to collect any rent due upon any such reletting; and no such failure shall relieve Tenant of, or otherwise affect, any liability under this Lease.  However, to the extent required by taw, Landlord shall use reasonable efforts to mitigate its damages but shall not be required to divert prospective tenants from any other portions of the Building.  Landlord, at Landlord&#x2019;s option, may make such alterations, decorations and other physical changes in and to the Premises as Landlord, in its sole discretion, considers advisable or necessary in connection with such reletting or proposed reletting, without relieving Tenant of any liability under this Lease or otherwise affecting any such liability.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tenant&#x2019;s Waiver.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Upon the occurrence of an Event of Default, Tenant, on its own behalf and on behalf of all persons claiming through or under Tenant, including all creditors, hereby waives all rights which Tenant and all such persons might otherwise have under any Requirement (i) to the service of any notice of intention to re-enter or to institute legal proceedings, (ii) to redeem, or to re-enter or repossess the Premises, (iii) to restore the operation of this Lease, after (A) Tenant shall have been dispossessed by judgment or by warrant of any court or judge, (B) any re-entry by Landlord, or (C) any expiration or early termination of the term of this Lease, whether such dispossess, re-entry, expiration or termination shall be by operation of law or pursuant to the provisions of this Lease, and (iv) to any notice to quit the Premises.  Tenant hereby waives all errors and defects of a procedural nature in any proceedings brought against it by Landlord under this Lease.  Tenant further waives the right to any notices to quit or otherwise as may be specified in the Landlord and Tenant Act of Pennsylvania of April 6, 1951 (68 P.S.C.A. Section 250.101 et seq.), as the same may have been or may hereafter be amended, including, but not limited to, the three months and 15 or 30 days notices, and agrees that the notices provided in this Lease shall be sufficient in any case where a longer period may be statutorily specified.  The words &#x201c;re-enter,&#x201d; &#x201c;re-entry&#x201d; and &#x201c;re-entered&#x201d; as used in this Lease shall not be deemed to be restricted to their technical legal meanings.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(d)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tenant&#x2019;s Breach.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Upon the breach or threatened breach by Tenant, or any persons claiming through or under Tenant, of any term, covenant or condition of this Lease,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">39</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#2c2c2c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Landlord shall have the right to seek to enjoin such breach.  Upon the occurrence of an Event of Default, Landlord shall have the right to invoke any other remedy allowed by law or in equity as if re-entry, eviction or ejectment proceedings and other special remedies were not provided in this Lease for such breach.  The rights to invoke the remedies set forth above are cumulative and shall not preclude Landlord from invoking any other remedy allowed at law or in equity.</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(e)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CONFESSION OF JUDGMENT FOR POSSESSION OF PREMISES.  FOLLOWING THE OCCURRENCE OF AN UNCURED EVENT OF DEFAULT, TENANT HEREBY EXPRESSLY AUTHORIZES THE PROTHONOTARY, CLERK OR ANY ATTORNEY OF ANY COURT OF RECORD TO ACCEPT SERVICE OF PROCESS FOR, TO APPEAR FOR, AND TO CONFESS JUDGMENT AGAINST TENANT AND ALL PERSONS CLAIMING UNDER TENANT IN ANY AND ALL ACTIONS BROUGHT HEREUNDER BY LANDLORD AGAINST TENANT TO RECOVER POSSESSION OF THE PREMISES (IN EJECTMENT OR OTHERWISE</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, WITHOUT ANY LIABILITY ON THE PART OF SAID ATTORNEY, FOR WHICH THIS LEASE SHALL BE SUFFICIENT WARRANT, AND TENANT AGREES THAT UPON THE ENTRY OF SUCH JUDGMENT, A WRIT OF POSSESSION OR OTHER APPROPRIATE PROCESS MAY ISSUE FORTHWITH (WITHOUT ANY PRIOR WRIT OR PROCEEDING WHATSOEVER</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">IN ANY SUCH ACTION, LANDLORD SHALL FIRST CAUSE TO BE FILED IN SUCH ACTION AN AFFIDAVIT MADE BY LANDLORD OR SOMEONE ACTING FOR IT SETTING FORTH FACTS NECESSARY TO AUTHORIZE THE ENTRY OF JUDGMENT, OF WHICH FACTS SUCH AFFIDAVIT SHALL BE CONCLUSIVE EVIDENCE, AND IF A TRUE COPY OF THIS LEASE BE FILED IN SUCH ACTION (AND OF THE TRUTH OF THE COPY SUCH AFFIDAVIT SHALL BE SUFFICIENT EVIDENCE</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, IT SHALL NOT BE NECESSARY TO FILE THE ORIGINAL, AS A WARRANT OF ATTORNEY, ANY RULE OF COURT, CUSTOM OR PRACTICE TO THE CONTRARY NOTWITHSTANDING.  TENANT AND ALL PERSONS CLAIMING UNDER TENANT HEREBY RELEASE LANDLORD FROM ANY CLAIMS ARISING FROM ANY ERRORS OR DEFECTS WHATSOEVER IN ENTERING SUCH ACTION OR JUDGMENT, IN CAUSING SUCH WRIT OF POSSESSION OR OTHER PROCESS TO BE ISSUED OR IN ANY PROCEEDING THEREON OR CONCERNING THE SAME, AND HEREBY AGREE THAT NO WRIT OF ERROR OR OBJECTION SHALL BE MADE OR TAKEN THERETO.</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">THIS WARRANT OF ATTORNEY SHALL NOT BE EXHAUSTED BY ONE EXERCISE, BUT JUDGMENT MAY BE CONFESSED FROM TIME TO TIME, AS OFTEN AS OCCASION THEREFOR SHALL EXIST.  SUCH POWERS MAY BE EXERCISED DURING AS WELL AS AFTER THE EXPIRATION OR TERMINATION OF THE TERM AND DURING AND AT ANY TIME AFTER ANY EXTENSION OR RENEWAL OF THE TERM.</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">THIS SECTION 15.2(e</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> SETS FORTH A WARRANT OF ATTORNEY FOR AN ATTORNEY TO CONFESS JUDGMENT AGAINST TENANT.  IN</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">40</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">GRANTING THIS WARRANT OF ATTORNEY TO CONFESS JUDGMENT AGAINST TENANT, TENANT, FOLLOWING CONSULTATION WITH (OR DECISION NOT TO CONSULT WITH</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> SEPARATE COUNSEL FOR TENANT AND WITH KNOWLEDGE OF THE LEGAL EFFECT HEREOF, HEREBY KNOWINGLY, INTENTIONALLY AND VOLUNTARILY WAIVES UNCONDITIONALLY ANY AND ALL RIGHTS TENANT HAS OR MAY HAVE TO PRE-JUDGMENT AND PRE-EXECUTION NOTICE AND AN OPPORTUNITY FOR HEARING UNDER THE RESPECTIVE CONSTITUTIONS AND LAWS OF THE UNITED STATES OF AMERICA, THE COMMONWEALTH OF PENNSYLVANIA, OR ELSEWHERE.</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:15pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">TENANT SPECIFICALLY ACKNOWLEDGES THAT LANDLORD HAS RELIED ON THE WARRANT OF ATTORNEY SET FORTH IN THIS SECTION 15.2(e</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> IN ENTERING INTO THIS LEASE WITH TENANT AND THAT THE LANDLORD-TENANT RELATIONSHIP CREATED HEREBY IS COMMERCIAL IN NATURE.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 15.3	Landlord&#x2019;s Damages</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Amount of Damages.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">this Lease and the Term, or Tenant&#x2019;s right to possession of the Premises, terminate as provided in Section 15.2(a), then:</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(i)	Tenant shall pay to Landlord all items of Rent payable under this Lease by Tenant to Landlord prior to the date of termination;</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(ii)	Landlord may retain all monies, if any, paid by Tenant to Landlord, whether as prepaid Rent, a Security Deposit or otherwise, which monies, to the extent not otherwise applied to amounts due and owing to Landlord, shall be credited by Landlord against any damages payable by Tenant to Landlord;</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(iii)	Tenant shall pay to Landlord, in monthly installments, on the days specified in this Lease for payment of installments of Fixed Rent, any Deficiency; it being understood that Landlord shall be entitled to recover the Deficiency from Tenant each month as the same shall arise, and no suit to collect the amount of the Deficiency for any month, shall prejudice Landlord&#x2019;s right to collect the Deficiency for any subsequent month by a similar proceeding; and</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(iv)	whether or not Landlord shall have collected any monthly Deficiency, Tenant shall pay to Landlord, on demand, in lieu of any further Deficiency and as liquidated and agreed final damages, a sum equal to the amount by which the Rent for the period which otherwise would have constituted the unexpired portion of the Term (assuming the Additional Rent during such period to be the same as was payable for the year immediately preceding such termination or re-entry, increased in each succeeding year by 4% (on a compounded basis)) exceeds the then fair and reasonable rental value of the Premises, for the same period (with both amounts being discounted to present value at a rate of interest equal to 2% below the then Base Rate) less the aggregate amount of Deficiencies theretofore collected by Landlord pursuant to the provisions of Section 15.3(a)(iii) for the same period.  If, before presentation of</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">41</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">proof of such liquidated damages to any court, commission or tribunal, the Premises, or any part thereof, shall have been relet by Landlord for the period which otherwise would have constituted the unexpired portion of the Term, or any part thereof, the amount of rent reserved upon such reletting shall be deemed prima facie, to be the fair and reasonable rental value for the part or the whole of the Premises so relet during the term of the reletting.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Reletting.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If the Premises, or any part thereof, shall be relet together with other space in the Building, the rents collected or reserved under any such reletting and the expenses of any such reletting shall be equitably apportioned for the purposes of this Section 15.3.  Tenant shall not be entitled to any rents collected or payable under any reletting, whether or not such rents exceeds the Fixed Rent reserved in this Lease, Nothing contained in Article 15 shall be deemed to limit or preclude the recovery by Landlord from Tenant of the maximum amount allowed to be obtained as damages by any Requirement, or of any sums or damages to which Landlord may be entitled in addition to the damages set forth in this Section 15.3.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 15.4	Interest.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If any payment of Rent is not paid when due, interest shall accrue on such payment, from the date such payment became due until paid at the Interest Rate.  Tenant acknowledges that late payment by Tenant of Rent will cause Landlord to incur costs not contemplated by this Lease, the exact amount of such costs being extremely difficult and impracticable to fix.  Such costs include, without limitation, processing and accounting charges, and late charges that may be imposed on Landlord by the terms of any note secured by a Mortgage covering the Premises.  Therefore, in addition to interest, if any amount is not paid when due, a late charge equal to 5% of such amount shall be assessed; provided, however, that on 2 occasions during any Calendar Year of the Term, Landlord shall give Tenant notice of such late payment and Tenant shall have a period of 5 days thereafter in which to make such payment before any late charge is assessed.  Such interest and late charges are separate and cumulative and are in addition to and shall not diminish or represent a substitute for any of Landlord&#x2019;s rights or remedies under any other provision of this Lease.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 15.5	Intentionally Omitted</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 15.6	Other Rights of Landlord.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If Tenant fails to pay any Additional Rent when due, Landlord, in addition to any other right or remedy, shall have the same rights and remedies as in the case of a default by Tenant in the payment of Fixed Rent.  If Tenant is in arrears in the payment of Rent, Tenant waives Tenant&#x2019;s right, if any, to designate the items against which any payments made by Tenant are to be credited, and Landlord may apply any payments made by Tenant to any items Landlord sees fit, regardless of any request by Tenant.  Landlord reserves the right, without liability to Tenant and without constituting any claim of constructive eviction, to suspend furnishing or rendering to Tenant any property, material, labor, utility or other service, whenever Landlord is obligated to furnish or render the same at the expense of Tenant, if (but only for so long as) Tenant is in arrears in paying Land lord for such items for more than five days after notice from Landlord to Tenant demanding the payment of such arrears.  If Tenant fails to pay any Rent when due or Tenant otherwise fails to fully and timely perform its obligations under this Lease and Landlord engages an attorney in connection with such failure, Tenant shall pay upon demand the reasonable attorneys&#x2019; fees incurred by Landlord regardless of whether Landlord initiates legal action in connection with such failure.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">42</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARTICLE 16</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br><br></font><font style="color:#2c2c2c;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">LANDLORD&#x2019;S RIGHT TO CURE; FEES AND EXPENSES</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If Tenant defaults in the performance of its obligations under this Lease, Landlord, without waiving such default, may perform such obligations at Tenant&#x2019;s expense:  (a) immediately, and without notice, in the case of emergency or if the default (i) materially interferes with the use by any other tenant of the Building, (ii) materially interferes with the efficient operation of the Building, (iii) results in a violation of any Requirement, or (iv) results or will result in a cancellation of any insurance policy maintained by Landlord, and (b) in any other case if such default continues after applicable notice and cure periods, or if no such period is specified, then 10 days from the date Landlord gives notice of the defaulted obligation.  All costs and expenses incurred by Landlord in connection with any such performance by it and all costs and expenses, including reasonable counsel fees and disbursements, incurred by Landlord in any action or proceeding (including any unlawful detainer proceeding) brought by Landlord or in which Landlord is a party to enforce any obligation of Tenant under this Lease and/or right of Landlord in or to the Premises, shall be paid by Tenant to Landlord on demand, with interest thereon at the Interest Rate from the date incurred by Landlord.  Except as expressly provided to the contrary in this Lease, all costs and expenses which, pursuant to this Lease are incurred by Landlord and payable to Landlord by Tenant, and all charges, amounts and sums payable to Landlord by Tenant for any property, material, labor, utility or other services which, pursuant to this Lease, attributable directly to Tenant&#x2019;s use and occupancy of the Premises or presence at the Building, or at the request and for the account of Tenant, are provided, furnished or rendered by Landlord, shall become due and payable by Tenant to Landlord within 10 Business Days after receipt of Landlord&#x2019;s invoice for such amount.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARTICLE 17</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br><br></font><font style="color:#2c2c2c;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">NO REPRESENTATIONS BY LANDLORD; LANDLORD&#x2019;S APPROVAL</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 17.1	No Representations.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Except as expressly set forth herein, Landlord and Landlord&#x2019;s agents have made no warranties, representations, statements or promises with respect to the Building, the Property or the Premises and no rights, easements or licenses are acquired by Tenant by implication or otherwise.  Tenant is entering into this Lease after full investigation and is not relying upon any statement or representation made by Landlord not embodied in this Lease.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 17.2	No Money Damages.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Wherever in this Lease Landlord&#x2019;s consent or approval is required, if Landlord refuses to grant such consent or approval, whether or not Landlord expressly agreed that such consent or approval would not be unreasonably withheld, Tenant shall not make, and Tenant hereby waives, any claim for money damages (including any claim by way of set-off, counterclaim or defense) based upon Tenant&#x2019;s claim or assertion that Landlord unreasonably withheld or delayed its consent or approval.  Tenant&#x2019;s sole remedy shall be an action or proceeding to enforce such provision, by specific performance, injunction or declaratory judgment.  In no event shall Landlord be liable for, and Tenant, on behalf of itself and all other Tenant Parties, hereby waives any claim for, any indirect, consequential or punitive damages, including loss of profits or business opportunity, arising under or in connection with this Lease.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">43</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 17.3	Reasonable Efforts.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">For purposes of this Lease, &#x201c;reasonable efforts&#x201d; by Landlord shall not include an obligation to employ contractors or labor at overtime or other premium pay rates or to incur any other overtime costs or additional expenses whatsoever.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARTICLE 18</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br><br></font><font style="color:#2c2c2c;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">END OF TERM</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 18.1	Expiration.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Upon the expiration or other termination of this Lease, Tenant shall quit and surrender the Premises to Landlord vacant, broom clean and in good order and condition, ordinary wear and tear and damage for which Tenant is not responsible under the terms of this Lease excepted, and Tenant shall remove all of Tenant&#x2019;s Property and Tenant&#x2019;s Specialty Alterations.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 18.2	Holdover Rent.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Landlord and Tenant recognize that Landlord&#x2019;s damages resulting from Tenant&#x2019;s failure to timely surrender possession of the Premises may be substantial, may exceed the amount of the Rent payable hereunder, and will be impossible to accurately measure.  Accordingly, if possession of the Premises is not surrendered to Landlord on the Expiration Date or sooner termination of this Lease, in addition to any other rights or remedies Landlord may have hereunder or at law, Tenant shall (a) pay to Landlord for each month (or any portion thereof) during which Tenant holds over in the Premises after the Expiration Date or sooner termination of this Lease, a sum equal to two times the Rent payable under this Lease for the last full calendar month of the Term, (b) be liable to Landlord for (1) any payment or rent concession which Landlord may be required to make to any tenant obtained by Landlord for all or any part of the Premises (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">New Tenant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">in order to induce such New Tenant not to terminate its lease by reason of the holding-over by Tenant, and </font><font style="color:#515151;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(2) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the loss </font><font style="color:#515151;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">of </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the </font><font style="color:#515151;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">benefit </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">of </font><font style="color:#515151;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">bargain </font><font style="color:#515151;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">if any New </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tenant shall terminate its lease by reason of the holding-over by Tenant, and (c) indemnify Landlord against all claims for damages by any New Tenant.  No holding-over by Tenant, nor the payment to Landlord of the amounts specified above, shall operate to extend the Term hereof or to establish a month to month or any other tenancy.  Nothing herein contained shall be deemed to permit Tenant to retain possession of the Premises after the Expiration Date or sooner termination of this Lease, and no acceptance by Landlord of payments from Tenant after the Expiration Date or sooner termination of this Lease shall be deemed to be other than on account of the amount to be paid by Tenant in accordance with the provisions of this Section 18.2.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARTICLE 19</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br><br></font><font style="color:#2c2c2c;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">QUIET ENJOYMENT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Provided this Lease is in full force and effect and no Event of Default then exists, Tenant may peaceably and quietly enjoy the Premises without hindrance by Landlord or any person lawfully claiming through or under Landlord, subject to the terms and conditions of this Lease and to all Superior Leases and Mortgages.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARTICLE 20</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br><br></font><font style="color:#2c2c2c;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">NO SURRENDER; NO WAIVER</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">44</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 20.1	No Surrender or Release.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No act or thing done by Landlord or Landlord&#x2019;s agents or employees during the Term shall be deemed an acceptance of a surrender of the Premises, and no provision of this Lease shall be deemed to have been waived by Landlord, unless such waiver is in writing and is signed by Landlord.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 20.2	No Waiver.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The failure of either party to seek redress for violation of, or to insist upon the strict performance of, any covenant or condition of this Lease, or any of the Rules and Regulations, shall not be construed as a waiver or relinquishment for the future performance of such obligations of this Lease or the Rules and Regulations, or of the right to exercise such election but the same shall continue and remain in full force and effect with respect to any subsequent breach, act or omission.  The receipt by Landlord of any Rent payable pursuant to this Lease or any other sums with knowledge of the breach of any covenant of this Lease shall not be deemed a waiver of such breach.  No payment by Tenant or receipt by Landlord of a lesser amount than the monthly Rent herein stipulated shall be deemed to be other than a payment on account of the earliest stipulated Rent, or as Landlord may elect to apply such payment, nor shall any endorsement or statement on any check or any letter accompanying any check or payment as Rent be deemed an accord and satisfaction, and Landlord may accept such check or payment without prejudice to Landlord&#x2019;s right to recover the balance of such Rent or pursue any other remedy provided in this Lease.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARTICLE 21</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br><br></font><font style="color:#2c2c2c;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WAIVER OF TRIAL BY JURY; COUNTERCLAIM</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 21.1	Jury Trial Waiver.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Landlord and Tenant hereby waive trial by jury in any action, proceeding or counterclaim brought by either party against the other in connection with any matters in any way arising out of or connected with this Lease, the relationship of Landlord and Tenant, Tenant&#x2019;s use or occupancy of the Premises, any guaranty of all or any portion of Tenant&#x2019;s liabilities under this Lease or the enforcement of any remedy under any statute, emergency or otherwise.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 21.2	Waiver of Counterclaim.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If Landlord commences any eviction or ejectment action against Tenant, Tenant will not interpose any counterclaim of any nature or description in any such proceeding (unless failure to interpose such counterclaim would preclude Tenant from asserting in a separate action the claim which is the subject of such counterclaim), and will not seek to consolidate such proceeding with any other action which may have been or will be brought in any other court by Tenant.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:15pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARTICLE 22</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br><br></font><font style="color:#2c2c2c;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">NOTICES</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Except as otherwise expressly provided in this Lease, all consents, notices, demands, requests, approvals or other communications given under this Lease shall be in writing and shall be deemed sufficiently given or rendered if delivered by hand (provided a signed receipt is obtained) or if sent by registered or certified mail (return receipt requested) or by a nationally recognized overnight delivery service making receipted deliveries, addressed to Landlord and</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">45</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tenant as set forth in Article 1, and to any Mortgagee or Lessor who shall require copies of notices and whose address is provided to Tenant, or to such other address(es) as Landlord, Tenant or any Mortgagee or Lessor may designate as its new address(es) for such purpose by notice given to the other in accordance with the provisions of this Article 22.  Any such approval, consent, notice, demand, request or other communication shall be deemed to have been given on the date of receipted delivery, refusal to accept delivery or when delivery is first attempted but cannot be made due to a change of address for which no notice is given or three Business Days after it shall have been mailed as provided in this Article 22, whichever is earlier.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARTICLE 23</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br><br></font><font style="color:#2c2c2c;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">RULES AND REGULATIONS</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">All Tenant Parties shall observe and comply with the Rules and Regulations, as supplemented or amended from time to time.  Landlord reserves the right, from time to time, to adopt additional Rules and Regulations and to amend the Rules and Regulations then in effect.  Nothing contained in this Lease shall impose upon Landlord any obligation to enforce the Rules and Regulations or terms, covenants or conditions in any other lease against any other Building tenant, and Landlord shall not be liable to Tenant for violation of the same by any other tenant, its employees, agents, visitors or licensees.  Landlord agrees not to enforce the Rules and Regulations more stringently against Tenant than against other tenants of the Building in general.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARTICLE 24</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br><br></font><font style="color:#2c2c2c;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">BROKER</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Each of Landlord and Tenant represents and warrants to the other that neither it nor its agents have dealt with any broker in connection with this Lease other than Landlord&#x2019;s Agent and Tenant&#x2019;s Broker and that no other broker, finder or like entity procured or negotiated this Lease or is entitled to any fee or commission in connection herewith.  Each of Landlord and Tenant shall indemnify, defend, protect and hold the other party harmless from and against any and all Losses which the indemnified party may incur by reason of any claim of or liability to any broker, finder or like agent (other than Landlord&#x2019;s Agent and Tenant&#x2019;s Broker) arising out of any dealings claimed to have occurred between the indemnifying party and the claimant in connection with this Lease, and/or the above representation being false.  Landlord shall pay Landlord&#x2019;s Agent and Tenant&#x2019;s Broker their respective commissions earned in connection with this Lease pursuant to separate agreements.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:15pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARTICLE 25</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br><br></font><font style="color:#2c2c2c;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">INDEMNITY</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 25.1	Tenant&#x2019;s Indemnity.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tenant shall not do or permit to be done any act or thing upon the Premises or the Building which may subject Landlord to any liability or responsibility for injury, damages to persons or property or to any liability by reason of any violation of any Requirement, and shall exercise such control over the Premises as to fully protect Landlord against any such liability.  Except to the extent of any such injury or damage resulting</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">46</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">from the gross and sole negligence or willful misconduct of Landlord or Landlord&#x2019;s agents or employees, Tenant shall indemnify, defend, protect and hold harmless each of the Indemnitees from and against any and all claims and Losses, resulting from any claims (i) against the Indemnitees arising from any act, omission or negligence of all Tenant Parties, (ii) against the Indemnitees arising from any accident, injury or damage to any person or to the property of any person and occurring in or about the Premises, and (iii) against the Indemnitees resulting from any breach, violation or nonperformance of any covenant, condition or agreement of this Lease on the part of Tenant to be fulfilled, kept, observed or performed.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 25.2	Landlord&#x2019;s Indemnity.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Landlord shall indemnify, defend and hold harmless Tenant from and against all Losses incurred by Tenant arising from any accident, injury or damage to any person or the property of any person in or about the Common Areas (specifically excluding the Premises) to the extent attributable to the gross negligence or willful misconduct of Landlord or its employees or agents.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 25.3	Defense and Settlement.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If any claim, action or proceeding is made or brought against any Indemnitee, then upon demand by an Indemnitee, Tenant, at its sole cost and expense, shall resist or defend such claim, action or proceeding in the Indemnitee&#x2019;s name (if necessary), by attorneys approved by the Indemnitee, which approval shall not be unreasonably withheld (attorneys for Tenant&#x2019;s insurer shall be deemed approved for purposes of this Section 25.3).  Notwithstanding the foregoing, an Indemnitee may retain its own attorneys to participate or assist in defending any claim, action or proceeding involving potential liability in excess of the amount available under Tenant&#x2019;s liability insurance carried under Section 11.1 for such claim and Tenant shall pay the reasonable fees and disbursements of such attorneys.  If Tenant fails to diligently defend or if there is a legal conflict or other conflict of interest, then Landlord may retain separate counsel at Tenant&#x2019;s expense.  Notwithstanding anything herein contained to the contrary, Tenant may direct the Indemnitee to settle any claim, suit or other proceeding provided that (a) such settlement shall involve no obligation on the part of the Indemnitee other than the payment of money, (b) any payments to be made pursuant to such settlement shall be paid in full exclusively by Tenant at the time such settlement is reached, (c) such settlement shall not require the Indemnitee to admit any liability, and (d) the Indemnitee shall have received an unconditional release from the other parties to such claim, suit or other proceeding.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARTICLE 26</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br><br></font><font style="color:#2c2c2c;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">MISCELLANEOUS</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 26.1	Delivery.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Lease shall not be binding upon Landlord or Tenant unless and until Landlord shall have executed and delivered a fully executed copy of this Lease to Tenant.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 26.2	Transfer of</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Property.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Landlord&#x2019;s obligations under this Lease shall not be binding upon the Landlord named herein after the sale, conveyance, assignment or transfer (collectively, a &#x201c;Transfer&#x201d;) by such Landlord (or upon any subsequent landlord after the Transfer by such subsequent landlord) of its interest in the Building or the Property, as the case may be, and in the event of any such Transfer, Landlord (and any such subsequent Landlord) shall be entirely freed and relieved of all covenants and obligations of Landlord hereunder arising from and after the date of Transfer and the transferee of Landlord&#x2019;s interest (or that of such subsequent Landlord)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">47</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#2c2c2c;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">in the Building or the Property, as the case may be, shall be deemed to have assumed all obligations under this Lease arising from and after the date of Transfer.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 26.3	Limitation on Liability.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding anything appearing to the contrary in this Lease, no Landlord Party shall be personally liable for any debts or other obligations of Landlord or in respect of any claims against Landlord arising under this Lease, and any such debts, obligations or claims shall be satisfied solely out of the interest of Landlord in the Building.  No personal judgment shall be sought or obtained against any Landlord Party.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 26.4	Rent.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">All amounts payable by Tenant to or on behalf of Landlord under this Lease, whether or not expressly denominated Fixed Rent, Tenant&#x2019;s Tax Payment, Tenant&#x2019;s Operating Payment, Additional Rent or Rent, shall constitute rent for the purposes of Section 502(b)(6) of the United States Bankruptcy Code.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 26.5	Entire Document.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Lease (including any schedules and exhibits referred to herein and all supplementary agreements provided for herein) contains the entire agreement between the parties regarding the Premises and all prior negotiations and agreements arc merged into this Lease.  All of the schedules and exhibits attached hereto are incorporated in and made a part of this Lease, provided that in the event of any inconsistency between the terms and provisions of this Lease and the terms and provisions of the schedules and exhibits hereto, the terms and provisions of this Lease shall control.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 26.6	Governing Law.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Lease shall be governed in all respects by the laws of the Commonwealth of Pennsylvania (but not including the choice of law rules thereof).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 26.7	Unenforceability.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If any provision of this Lease, or its application to any person or circumstance, shall ever be held to be invalid or unenforceable, then in each such event the remainder of this Lease or the application of such provision to any other person or any other circumstance (other than those as to which it shall be invalid or unenforceable) shall not be thereby affected, and each provision hereof shall remain valid and enforceable to the fullest extent permitted by law.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 26.8	Lease Disputes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)	Tenant agrees that all disputes arising, directly or indirectly, out of or relating to this Lease, and all actions to enforce this Lease, shall be dealt with and adjudicated in the courts of the Commonwealth of Pennsylvania or the United States District Court for the Eastern District of Pennsylvania and for that purpose hereby expressly and irrevocably submits itself to the jurisdiction of such courts.  Tenant agrees that so far as is permitted under applicable law, this consent to personal jurisdiction shall be self-operative and no further instrument or action, other than service of process in one of the manners specified in this Lease, or as otherwise permitted by law, shall be necessary in order to confer jurisdiction upon it in any such court.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)	To the extent that Tenant has or hereafter may acquire any immunity from jurisdiction of any court or from any legal process (whether through service or notice, attachment prior to judgment, attachment in aid of execution, execution or otherwise) with respect to itself or its property, Tenant irrevocably waives such immunity in respect of its obligations under this Lease.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">48</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 26.9	Landlord&#x2019;s Agent.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Unless Landlord delivers written notice to Tenant to the contrary, Landlord&#x2019;s Agent is authorized to act as Landlord&#x2019;s agent in connection with the performance of this Lease, and Tenant shall be entitled to rely upon correspondence received from Landlord&#x2019;s Agent.  Tenant acknowledges that Landlord&#x2019;s Agent is acting solely as agent for Landlord in connection with the foregoing; and neither Landlord&#x2019;s Agent nor any of its officers, directors, agents, managers, employees, and direct and indirect shareholders, partners, members and owners (nor any officer, director, agent, manager, personal representative, trustee or employee of any direct or indirect shareholder, partner, member or owner of Landlord&#x2019;s Agent) shall have any liability to Tenant in connection with the performance of this Lease, and Tenant waives any and all claims against any and all of such parties arising out of, or in any way connected with, this Lease, the Building or the Property.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 26.10	Estoppel.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Within 10 days following request from Landlord, any Mortgagee or any Lessor, Tenant shall deliver to Landlord a statement executed and acknowledged by Tenant, in form reasonably satisfactory to Landlord, (a) stating the Commencement Date, the Rent Commencement Date and the Expiration Date, and that this Lease is then in full force and effect and has not been modified (or if modified, setting forth all modifications), (b) setting forth the date to which the Fixed Rent and any Additional Rent have been paid, together with the amount of monthly Fixed Rent and Additional Rent then payable, (c) stating whether or not, to the best of Tenant&#x2019;s knowledge.  Landlord is in default under this Lease, and, if Landlord is in default, setting forth the specific nature of all such defaults, (d) stating the amount of the security, if any, under this Lease, (e) stating whether there are any subleases or assignments affecting the Premises, (f) stating the address of Tenant to which all notices and communications under the Lease shall be sent, and (g) responding to any other matters reasonably requested by Landlord, such Mortgagee or such Lessor.  Tenant acknowledges that any statement delivered pursuant to this Section 26.10 may be relied upon by any purchaser or owner of the Property or the Building or all or any portion of Landlord&#x2019;s interest in the Property or the Building or any Superior Lease, or by any Mortgagee, or assignee thereof or by any Lessor, or assignee thereof.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 26.11	Certain Interpretation al Rules.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">For purposes of this Lease, whenever the words &#x201c;include&#x201d;, &#x201c;includes&#x201d;, or &#x201c;including&#x201d; are used, they shall be deemed to be followed by the words &#x201c;without limitation&#x201d; and, whenever the circumstances or the context requires, the singular shall be construed as the plural, the masculine shall be construed as the feminine and/or the neuter and vice versa.  This Lease shall be interpreted and enforced without the aid of any canon, custom or rule of law requiring or suggesting construction against the party drafting or causing the drafting of the provision in question.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The captions in this Lease are inserted only as a matter of convenience and for reference and in no way define, limit or describe the scope of this Lease or the intent of any provision hereof.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 26.12	Parties Bound.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The terms, covenants, conditions and agreements contained in this Lease shall bind and inure to the benefit of Landlord and Tenant and, except as otherwise provided in this Lease, to their respective legal representatives, successors, and assigns.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 26.13	Memorandum of Lease.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Lease shall not be recorded; however, at Landlord&#x2019;s request, Landlord and Tenant shall promptly execute, acknowledge and deliver a memorandum with respect to this Lease sufficient for recording and Landlord may record the</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">49</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">memorandum.  Within 10 days after the end of the Term, Tenant shall enter into such documentation as is reasonably required by Landlord to remove the memorandum of record.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 26.14	Counterparts.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Lease may be executed in two or more counterparts, each of which shall constitute an original, but all of which, when taken together, shall constitute but one instrument.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 26.15	Survival.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">All obligations and liabilities of Landlord or Tenant to the other which accrued before the expiration or other termination of this Lease, and all such obligations and liabilities which by their nature or under the circumstances can only be, or by the provisions of this Lease may be, performed after such expiration or other termination, shall survive the expiration or other termination of this Lease.  Without limiting the generality of the foregoing, the rights and obligations of the parties with respect to any indemnity under this Lease, and with respect to any Rent and any other amounts payable under this Lease, shall survive the expiration or other termination of this Lease.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 26.16	Inability to Perform.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Lease and the obligation of Tenant to pay Rent and to perform all of the other covenants and agreements of Tenant hereunder shall not be affected, impaired or excused by any Unavoidable Delays.  Landlord shall use reasonable efforts to promptly notify Tenant of any Unavoidable Delay which prevents Landlord from fulfilling any of its obligations under this Lease.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 26.17	Lien for Payment of Rent.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In addition to and not in lieu of any similar statutory or common law lien or security interest to which Landlord may be entitled, Tenant hereby pledges and assigns to Landlord, as security for the payment of any and all rental or other sums or amounts due from Tenant hereunder, all of the furniture, fixtures, goods and chattels of Tenant which shall or may be brought or put on or into the Premises.  Notwithstanding the forgoing, if Tenant&#x2019;s Property is financed or owned by someone other than Tenant, Tenant shall have the right to grant liens to lenders with respect to Tenant&#x2019;s Property and to lease Tenant&#x2019;s Property.  Upon prior written request by Tenant, Landlord agrees to acknowledge (a) the aforesaid waiver of any landlord lien with respect to Tenant&#x2019;s Property at the Premises, and (b) reasonable rights of such lender or lessor in and to Tenant&#x2019;s Property on terms and conditions acceptable to Landlord in its discretion.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 26.18	Financial Statements.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tenant shall from time to time, within 10 business days after request by Landlord, deliver to Landlord financial statements (including balance sheets and income/expense statements) for Tenant&#x2019;s then most recent full and partial fiscal years immediately preceding such request, certified by an independent certified public accountant or Tenant&#x2019;s chief financial officer and in form reasonably satisfactory to Landlord.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 26.19	Changes to Property.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Landlord shall have the following rights (a) to rearrange, change, expand or contract the Common Areas; (b) to use Common Areas while engaged in making improvements, repairs or alterations to the Property; and (c) to do and perform such other acts and make such other changes to the interior of the Building (including, without limitation, the lobbies, entrances, passageways, doors, doorways, atriums, corridors, elevators, stairs, public restrooms, loading docks and parking garage) and the exterior of the Building (including, without limitation, the facade, roof, sidewalks, exterior windows and arcade), all as Landlord may from lime to time in its sole judgment deem to be appropriate, provided no such</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">50</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">change serves to limit Tenant&#x2019;s access to the Premises.  Landlord may exercise any or all of the foregoing rights without being deemed to be guilty of an eviction, actual or constructive, or a disturbance of Tenant&#x2019;s business or use or occupancy of the Premises.  Tenant shall have no claim for damages or indemnification against Landlord nor shall Tenant be entitled to any diminution or abatement of Rent arising from Landlord&#x2019;s exercise of any or all of the foregoing rights.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 26.20	Tax Status. Tax Status of Beneficial Owner.  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tenant recognizes and acknowledges that Landlord and/or certain beneficial owners of Landlord may from time to time qualify as real estate investment trusts pursuant to Sections 856 et seq. of the Code and that avoiding (a) the loss of such status, (b) the receipt of any income derived under any provision of this Lease that does not constitute &#x201c;rents from real property&#x201d; (in the case of real estate investment trusts), and (c) the imposition of income, penalty or similar taxes (each an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Adverse Event</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">is of material concern to Landlord and such beneficial owners.  In the event that this Lease or any document contemplated hereby could, in the opinion of counsel to Landlord, result in or cause an Adverse Event, Tenant agrees to cooperate with Landlord in negotiating an amendment or modification thereof and shall at the request of Landlord execute and deliver such documents reasonably required to effect such amendment or modification.  Any amendment or modification pursuant to this Section shall be structured so that the economic results to Landlord and Tenant and the rights of Landlord and Tenant shall be substantially similar to those set forth in this Lease without regard to such amendment or modification.  Without limiting any of Landlord&#x2019;s other rights under this Section, Landlord may waive the receipt of any amount payable to Landlord under this Lease and such waiver shall constitute an amendment or modification of this Lease with respect to such payment.  Tenant expressly covenants and agrees not to enter into any sublease or assignment which provides for rental or other payment for such use, occupancy, or utilization based in whole or in part on the net income or profits derived by any person from the property leased, used, occupied, or utilized (other than an amount based on a fixed percentage or percentages of receipts or sales), and that any such purported sublease or assignment shall be absolutely void and ineffective as a conveyance of any right or interest in the possession, use, occupancy, or utilization of any part of the Premises.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARTICLE 27</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br><br></font><font style="color:#2c2c2c;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">SECURITY DEPOSIT</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tenant shall deposit with Landlord the amount set forth in Article 1 (&#x201c;Security Deposit&#x201d;), upon Tenant&#x2019;s execution and submission of this Lease.  The Security Deposit shall serve as security for the prompt, full and faithful performance by Tenant of the terms and provisions of this Lease.  If Tenant commits an Event of Default, or owes any amounts to Landlord upon the expiration of this Lease, Landlord may use or apply the whole or any part of the Security Deposit for the payment of Tenant&#x2019;s obligations hereunder.  The use or application of the Security Deposit or any portion thereof shall not prevent Landlord from exercising any other right or remedy provided hereunder or under any Requirement and shall not be construed as liquidated damages.  In the event the Security Deposit is reduced by such use or application, Tenant shall deposit with Landlord within 10 days after notice, an amount sufficient to restore the full amount of the Security Deposit.  Landlord shall not be required to keep the Security Deposit separate from Landlord&#x2019;s general funds or pay interest on the Security Deposit.  If, at or prior to the end of the 14th month following the Commencement Date, no Event of Default shall have occurred, then the amount of the Security</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">51</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.94in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Deposit shall be reduced as of that date by $27,078,34 to an amount equal to $40,617.51.  Further, if, at or prior to the end of the 26th month following the Commencement Date, no Event of Default shall have occurred, then the amount of the Security Deposit shall be reduced as of that date by $13,539.17 to an amount equal to $27,078.33.  The reductions set forth above shall be effectuated by Landlord returning to Tenant the reduced amounts of security within thirty (30) days of the reduction date.  Any remaining portion of the Security Deposit shall be returned to Tenant (or, at Landlord&#x2019;s option, to the last assignee of Tenant&#x2019;s interest in this Lease) within 60 days after Tenant (or such assignee) has vacated the Premises in accordance with the terms of Article 18 of this Lease.  If the Premises shall be expanded at any time, or if the Term shall be extended at an increased rate of Rent, the Security Deposit shall thereupon be proportionately increased.  Tenant shall not assign, pledge or otherwise transfer any interest in the Security Deposit except as part of an assignment of this lease approved by Landlord under Article 13, and any attempt to do so shall be null and void.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[SIGNATURES FOLLOW]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.38in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">52</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">IN WITNESS WHEREOF, Landlord and Tenant have executed this Lease as of the day and year first above written.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">LANDLORD:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:36pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">BALA PLAZA PROPERTY, INC.<br>a Delaware corporation</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">By: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">/s/ Steven Wechsler	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Name:</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> Steven Wechsler	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Title: Senior Managing Director</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">THE UNDERSIGNED TENANT ACKNOWLEDGES THAT IT FULLY UNDERSTANDS THE CONFESSIONS OF JUDGMENT AND WAIVERS CONTAINED IN SECTIONS 15.2(e</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> HEREOF AND KNOWINGLY, INTENTIONALLY AND VOLUNTARILY ENTERS INTO THIS LEASE FULLY COMPREHENDING THE RELINQUISHMENT OF CERTAIN RIGHTS BY VIRTUE OF SUCH CONFESSIONS OF JUDGMENT AND WAIVERS.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">TENANT</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:36pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CHONDRIAL THERAPEUTICS, INC.,<br>a Delaware corporation</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">By: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">/s/ Carole S. Ben-Maimon, M.D.	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Name:  </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Carole S. Ben-Maimon, M.D.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Title:  </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">President and CEO</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">53</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Floor Plan</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[Omitted]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT A-1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Land</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[Omitted]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT B</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Definitions</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[Omitted]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT C</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Workletter Agreement</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[Omitted]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT D</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Design Standards</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[Omitted]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT E</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Cleaning Work (&#x201c;Work&#x201d;)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[Omitted]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT F</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Rules and Regulations</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[Omitted]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT G</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[Intentionally Omitted]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[Omitted]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT H</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Construction Rules and Regulations</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[Omitted]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">RIDER ONE</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ADDITIONAL PROVISIONS</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[Omitted]</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.21
<SEQUENCE>5
<FILENAME>lrmr-ex10_21.htm
<DESCRIPTION>EX-10.21
<TEXT>
<html>
 <head>
  <title>EX-10.21</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">FIRST AMENDMENT TO LEASE</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">This First Amendment to Lease (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">Amendment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">is made as of this 9th day of March, 2023 (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">by and between Bala Plaza Property, Inc., a Delaware corporation (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">Landlord</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#x201d;),</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">and Larimar Therapeutics, Inc., a Delaware corporation (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">Tenant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#x201d;).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">RECITALS</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">A.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Landlord and Tenant, as successor by name change to Chondrial Therapeutics, Inc., entered into a certain Lease, dated as of August 8, 2019 (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">Lease</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#x201d;),</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">under which Landlord leased to Tenant 4,642 rentable square feet of space on the fifth floor of the Building, as more particularly described in the Lease (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">Original Premises</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#x201d;).</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">B.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Landlord and Tenant desire to amend the Lease to (i) expand the Original Premises by adding thereto 3,462 rentable square feet of space, being a portion of the space known as Suite 505E and 504E and located on the fifth floor of the Building, as such space is shown outlined and hatched in black on the floor plan attached hereto as </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">Exhibit A </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">(the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">Additional Space</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#x201d;),</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">(ii) extend the Term of the Lease for the Original Premises for three (3) years commencing September 1, 2023 and expiring August 31, 2026, (iii) provide for the performance by Landlord of certain improvements to the Additional Space, (iv) set the Fixed Rent and Additional Rent for the Additional Space and adjust the Fixed Rent and Additional Rent payable under the Lease, and (v) otherwise amend the Lease as set forth herein.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">NOW, THEREFORE, the parties hereto, intending to be legally bound, hereby agree as follows:</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:4.533%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Arial;min-width:fit-content;">Defined Terms</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">.  Capitalized terms used but not defined in this Amendment shall have the same meanings as set forth in the Lease.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:4.533%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Arial;min-width:fit-content;">Extended Term</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">.  The Term of the Lease is hereby extended for a period of three (3) years (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">Extended Term</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">commencing September 1, 2023 and expiring August 31, 2026 (hereinafter the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">Expiration Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#x201d;).  All provisions of the Lease, as amended hereby and except as otherwise expressly set forth herein, shall apply to the Extended Term.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:4.533%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Arial;min-width:fit-content;">Condition of the Original Premises</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">.  Tenant accepts the Original Premises for such extended term in their &#34;AS IS&#34; condition as of the commencement of the Extended Term.  Tenant acknowledges that neither Landlord, nor Landlord's agents, representatives, employees, servants or attorneys have made any representations or promises, whether express or implied, concerning the condition of the Original Premises, and agrees that, Landlord shall have no obligation to make any alterations or improvements to the Original Premises for or during the Extended Term, other than Landlord's repair and maintenance obligations under the Lease.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:4.533%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Arial;min-width:fit-content;">Demise of Additional Space</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Landlord hereby leases, demises and lets unto Tenant the Additional Space, and Tenant hereby takes and hires the Additional Space from Landlord, for the period commencing on the date that Landlord's Work (defined in Section 7 below) to be completed by Landlord pursuant to Section 7 below is Substantially Completed, except for any Punch List Items, (the &#34;Additional Space Commencement Date'') and terminating on August 31, 2026 (being the Expiration Date of the Lease).</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Tenant shall, within ten (10) business days after request from Landlord, execute a confirmation of the Additional Space Commencement Date, and other matters as Landlord may reasonably request, which confirmation shall be in substantially the form of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Arial;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">attached hereto; any failure to respond within such time shall be deemed an acceptance of the matters as set forth therein.  If Tenant disagrees with Landlord's determination of the Additional Space Commencement Date, Tenant shall pay Fixed Rent and Additional Rent, and shall perform all other obligations relating to the Additional Space commencing on the date determined by Landlord, subject to refund or credit when the matter is resolved.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Except for Landlord's Work to be made by Landlord pursuant to Section 7 of this Amendment, Tenant accepts the Additional Space in its &#34;AS IS'' condition as of the Effective Date.  Tenant acknowledges that neither Landlord, nor Landlord's agents, representatives, employees, servants or attorneys have made any representations or promises, whether express or implied, concerning the condition of the Additional Space, and agrees that Landlord shall have no obligation to make any alterations or improvements to the Additional Space for or during the remainder of the term of the Lease, except for Landlord's Work to be made by Landlord pursuant to Section 7 of this Amendment, other than Landlord's repair and maintenance obligations under the Lease.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Landlord and Tenant agree that effective on the Additional Space Commencement Date, (i) the Additional Space shall be deemed to be part of the &#34;Premises&#34; leased by Tenant from Landlord under the Lease, (ii) the combined Premises shall consist of approximately 8,104 rentable square feet, and (iii) the Additional Space shall be governed by all of the provisions of the Lease, as amended hereby.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:4.533%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Arial;min-width:fit-content;">Adjustment of Base Rent and Additional Rent</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Effective on September 1, 2023 and continuing through the Expiration Date, Tenant shall pay Landlord annual Fixed Rent and monthly installments thereof with respect to the Original Premises only as follows:</font></div></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:46.1%;"></td>
    <td style="width:19.24%;"></td>
    <td style="width:18.26%;"></td>
    <td style="width:16.4%;"></td>
   </tr>
   <tr style="height:12pt;background-color:#244c6f;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="border-left:0.5pt solid;padding-left:0.007in;vertical-align:bottom;padding-right:0.007in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#ffffff;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Period</font></p></td>
    <td style="border-left:0.5pt solid;padding-left:0.007in;vertical-align:bottom;padding-right:0.007in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#ffffff;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Annual Fixed Rent</font></p></td>
    <td style="border-left:0.5pt solid;padding-left:0.007in;vertical-align:bottom;padding-right:0.007in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#ffffff;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Monthly Fixed Rent</font></p></td>
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:bottom;padding-right:0.007in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#ffffff;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Fixed Rent Per RSF</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="border-left:0.5pt solid;padding-left:0.007in;vertical-align:bottom;padding-right:0.007in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">September </font><font style="color:#2d2d2d;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">1, </font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2023 - August 31, 2024*</font></p></td>
    <td style="border-left:0.5pt solid;padding-left:0.007in;vertical-align:bottom;padding-right:0.007in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$163,823.92</font></p></td>
    <td style="border-left:0.5pt solid;padding-left:0.007in;vertical-align:bottom;padding-right:0.007in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$14,893.08</font></p></td>
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:bottom;padding-right:0.007in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$38.50</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:bottom;padding-right:0.007in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#2d2d2d;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">September 1, 2024 </font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">- </font><font style="color:#2d2d2d;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">August 31, 2025</font></p></td>
    <td style="border-top:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:bottom;padding-right:0.007in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$182,198.50</font></p></td>
    <td style="border-top:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:bottom;padding-right:0.007in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$15,183.21</font></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:bottom;padding-right:0.007in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$39.25</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.007in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">September </font><font style="color:#2d2d2d;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">1, </font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2025 - August 31, 2026</font></p></td>
    <td style="border-top:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.007in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$185,680.00</font></p></td>
    <td style="border-top:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.007in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$15,473.33</font></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.007in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$40.00</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">* Tenant does not have an obligation to pay Fixed Rent for the first (1st) month of this period (the Fixed Rent being abated), and, therefore, the Annual Fixed Rent amount for this period reflects eleven (11) months' of monthly Fixed Rent instead of twelve (12) months' of monthly Fixed Rent.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">2</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Effective on September 1, 2023, Tenant's Base Year under Article 1 of the Lease applicable to the Original Premises shall be the 2023 calendar year.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Effective on September 1, 2023, with respect to the Original Premises only, Tenant's Proportionate Share under Article 1 of the Lease shall continue to be 1.2057%.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:4.533%;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Arial;min-width:fit-content;">Annual Fixed Rent and Additional Rent for Additional Space</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Effective on the Additional Space Commencement Date and continuing through the Expiration Date, Tenant shall pay Landlord annual Fixed Rent and monthly installments thereof with respect to the Additional Space only as follows:</font></div></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:42.74%;"></td>
    <td style="width:20.76%;"></td>
    <td style="width:18.6%;"></td>
    <td style="width:17.9%;"></td>
   </tr>
   <tr style="height:12pt;background-color:#244c6f;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="border-left:0.5pt solid;padding-left:0.007in;vertical-align:bottom;padding-right:0.007in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#ffffff;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Period</font></p></td>
    <td style="border-left:0.5pt solid;padding-left:0.007in;vertical-align:bottom;padding-right:0.007in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#ffffff;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Annual Fixed Rent</font></p></td>
    <td style="border-left:0.5pt solid;padding-left:0.007in;vertical-align:bottom;padding-right:0.007in;"><p style="text-indent:14pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#ffffff;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Monthly Fixed Rent</font></p></td>
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:bottom;padding-right:0.007in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#ffffff;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Fixed Rent Per RSF</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="border-left:0.5pt solid;padding-left:0.007in;vertical-align:bottom;padding-right:0.007in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Additional Space Commencement Date - August 31, 2024*</font></p></td>
    <td style="border-left:0.5pt solid;padding-left:0.007in;vertical-align:bottom;padding-right:0.007in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$122,179.75</font></p></td>
    <td style="border-left:0.5pt solid;padding-left:0.007in;vertical-align:bottom;padding-right:0.007in;"><p style="text-indent:14pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$11,107.25</font></p></td>
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:bottom;padding-right:0.007in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$38.50</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:bottom;padding-right:0.007in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#2d2d2d;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">September </font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">1, </font><font style="color:#2d2d2d;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2024 - August 31</font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">, </font><font style="color:#2d2d2d;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2025</font></p></td>
    <td style="border-top:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:bottom;padding-right:0.007in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$135,883.50</font></p></td>
    <td style="border-top:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:bottom;padding-right:0.007in;"><p style="text-indent:14pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$11,323.63</font></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:bottom;padding-right:0.007in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$39.25</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="border-top:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.007in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#2d2d2d;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">September </font><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">1, </font><font style="color:#2d2d2d;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">2025 - August 31, 2026</font></p></td>
    <td style="border-top:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.007in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$138,480.00</font></p></td>
    <td style="border-top:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.007in;"><p style="text-indent:14pt;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#2d2d2d;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$11,540.00</font></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.007in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.007in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$40.00</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">* Tenant does not have an obligation to pay Fixed Rent for the first (1st) month of this period (the Fixed Rent being abated), and, therefore, the Annual Fixed Rent amount for this period reflects eleven (11) months' of monthly Fixed Rent instead of twelve (12) months' of monthly Fixed Rent.  In the event the Additional Space Commencement Date is delayed beyond September 1, 2023, the above rental period dates shall be correspondingly adjusted.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Effective on the Additional Space Commencement Date, Tenant's Base Year under Article 1 of the Lease applicable to the Additional Space shall be the 2023 calendar year.  The Base Year for the entire Premises </font><font style="color:#2d2d2d;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">will </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">therefore be the 2023 calendar year.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Effective on the Additional Space Commencement Date, with respect to the Additional Space only, Tenant's Proportionate Share under Article 1 of the Lease shall be 0.8992%.  Effective on the Additional Space Commencement Date, the total rentable square footage of the Premises shall be 8,104 rentable square feet and Tenant's Proportionate Share for the entire Premises shall be 2.1049%.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Landlord currently holds $27,078.34 as the Security Deposit under Articles </font><font style="color:#2d2d2d;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">1 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">and 27 of the Lease.  That amount is subject to reduction in accordance with, and subject to, the provisions of Article 27.  As an additional Security Deposit, on or before the Effective Date, Tenant shall deposit with Landlord an amount equal to $22,214.50 to be held by Landlord as a Security Deposit pursuant to Article 27 of the Lease except that this additional Security Deposit shall be in addition to the initial Security Deposit under the Lease and shall not be subject to the reduction terms and conditions set forth </font><font style="color:#2d2d2d;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">in </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Article 27.  As of the Effective Date, Landlord will hold a combined security deposit of $49,292.84 through the remainder of the Term.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">3</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:4.533%;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Arial;min-width:fit-content;">Landlord's Work.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">At Landlord's expense, Landlord agrees to construct Landlord's Work and improvements to the Additional Space (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">Landlord's Work</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">in Landlord's Building standard manner, in a good and workmanlike manner, in compliance with all applicable laws and in accordance with (i) Nelson Architecture and Interiors space plan dated November 10, 2022 and revised January 6, 2023 - Project #PR1 R10/5 Plan #22.0022013.013/JNP/CFA including all Alternates on the Alternates list except for Alternate #5 attached hereto and made a part hereof as </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Arial;min-width:fit-content;">Exhibit C</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">(the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">Plans</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#x201d;),</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">and (ii) mechanical and engineering drawings (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">MEPs</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">to be prepared based upon the Plans.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Neither the preparation of the Plans and the MEPs, nor the review or approval thereof by Landlord constitutes a representation or warranty by Landlord that any such documents (i) are complete or suitable for their intended purpose, or (ii) comply with Requirements; it being expressly agreed by Tenant that Landlord assumes no responsibility or liability whatsoever to Tenant or to any other person or entity for such completeness or suitability.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">If Tenant requests any changes to the Plans, Landlord shall not unreasonably withhold its consent to any such changes, provided the changes do not adversely affect the Building's structure, systems, equipment, appearance or value.  Upon such a request by Tenant, and prior to Tenant being bound by the applicable proposed change order, Landlord shall reasonably promptly provide Tenant with written estimates of the increased construction costs and the time delay associated with any proposed change order.  If ordered by Tenant, Landlord shall implement such change order and Tenant shall bear such costs and shall pay such estimated increased costs to Landlord within 10 days of receipt of an invoice therefor at such time as the request is approved by Landlord.  If the actual increased costs are greater than the estimated increased costs, Tenant shall pay the difference in increased costs to Landlord within 30 days of an invoice promptly upon demand therefor.  The costs charged by Landlord to Tenant caused by Tenant's requesting changes to the Landlord's Work or the Plans shall be equal to the sum of (i) the amount of money Landlord has to pay to cause the Landlord's Work, as reflected by revised Plans, to be constructed above the costs that Landlord would have had to pay to cause the Landlord's Work to be constructed if no changes had been made to the Plans (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">Differential</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#x201d;),</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">(ii) any cancellation fees, reshipping charges or any other similar costs incurred by Landlord in connection therewith, and (iii) an amount equal to 5% of the Differential to compensate Landlord for its time and effort in connection with such changes.  If such changes delay Landlord's performance of the work shown on the Plans, then such delay shall constitute a Tenant Delay.  Any other actions of Tenant, or inaction by Tenant, which delays Landlord in completing the Landlord's Work shown on such Plans shall also constitute a Tenant Delay.  Whenever possible and practical, Landlord will utilize, for the construction of the Landlord's Work, the items and materials designated in the Plans; provided, however, that whenever Landlord reasonably determines in its judgment that it is not practical or efficient to use such materials, Landlord shall have the right to substitute comparable items and materials (or of better quality at no cost to Tenant if no such comparable item exists or is readily obtainable; at no time shall Tenant be required to accept an inferior substitute because of the unavailability of the item specified).  If Tenant refuses to grant such consent, and Landlord is reasonably delayed in causing the Premises, or any part thereof, to be Substantially Complete because of Tenant's failure to permit the substitution of comparable items and </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">4</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">materials (or of better quality at no cost to Tenant if no such comparable item exists or is readily available), such delay shall constitute a Tenant Delay.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Tenant shall pay to Landlord a sum equal to any actual cost to Landlord in completing the Landlord's Work resulting from any Tenant Delay.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Except as hereinafter provided, no Tenant Parties shall enter the Additional Space during the performance of the Landlord's Work.  Tenant hereby designates John Berman as its authorized agent (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">Tenant's Construction Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">for the purpose of submitting to Landlord and authorizing any Change Orders and for the purpose of consulting with Landlord as to any and all aspects of Landlord's Work.  Tenant's Construction Agent shall have the right to inspect the Additional Space during the course of the Landlord's Work provided Tenant's Construction Agent shall make a prior appointment with Landlord and/or its contractor at a mutually convenient time.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Subject to a mutually acceptable schedule, Tenant will have access to the Additional Space ten (10) days prior to the Additional Space Commencement Date, solely for the purpose of installing telephone and communication systems, security equipment, related cabling, moving furniture, and other similar requirements, at no charge to Tenant.  If Tenant enters upon the Additional Space prior to the completion of the Landlord's Work, (a) Tenant shall comply with the provisions of this Lease, and (b) Tenant shall indemnify and save Landlord harmless from and against any and all Losses arising from or claimed to arise as a result of (i) any act, neglect or failure to act of Tenant or anyone entering the Additional Space with Tenant's permission, or (ii) any other reason whatsoever arising out of Tenant's entry upon the Additional Space prior to the Additional Space Commencement Date.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:6pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Because Tenant will be in possession of the Premises during the performance of the Landlord's Work and a portion of the Landlord's Work will impact the Original Premises, Tenant shall (i) not interfere with the execution and performance of any of the Landlord's Work, and (ii) take all reasonable steps requested by Landlord or its contractor(s) to provide working areas within the Original Premises required by Landlord or its contractors, so that the Landlord's Work will not be delayed by the presence of Tenant's personnel in the Original Premises.  Landlord shall use reasonable efforts to minimize interference with Tenant's use and occupancy of the Original Premises during the performance of the Landlord's Work.  Notwithstanding anything to the contrary contained in the Lease, in no event shall Landlord's (or its contractors') entry upon the Original Premises for the purposes of performing the Landlord's Work be deemed to be an eviction, actual or constructive, of Tenant from the Original Premises or any portion thereof, nor shall anything contained in this Section 7 or any action of Landlord in accordance herewith relieve or excuse Tenant from its obligations and duties under the Lease, as amended by this Amendment.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(h)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Tenant hereby assumes all risk to Tenant's trade fixtures, fixtures and other personal property (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">Tenant's Property</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">arising in connection with the performance of the Landlord's Work, except to the extent caused by the gross negligence or willful misconduct of Landlord, its agents, employees or contractors.  Tenant hereby releases Landlord, its agents, employees and contractors, from and against any claim, loss, cost or liability for damage to Tenant's Property or for injury to any persons resulting or claimed to have resulted in connection with the Landlord's Work, except to the extent caused by the gross negligence or willful misconduct of Landlord, its agents, employees or </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">5</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">contractors.  In accordance with the foregoing, Tenant shall (i) obtain property and liability insurance, or confirm that its current insurance policies are effective, against such risks in the amounts required under the Lease, and Tenant shall provide Landlord with evidence of such insurance prior to the commencement of the Landlord's Work, which insurance policies shall include a waiver of subrogation in favor of Landlord whereby Tenant and its insurer(s) each waive any right of recovery against Landlord for any loss or damage suffered in connection with the performance of the Landlord's Work, whether or not such loss or damage is caused by the fault or negligence of Landlord, and (ii) indemnify and hold harmless Landlord, its agents, employees and contractors from any claim, loss, cost or liability for damage to Tenant's Property or, except to the extent caused by the gross negligence or willful misconduct of Landlord, its agents, employees or contractors, for injury to any persons resulting or claimed to have resulted in connection with the performance of the Landlord's Work.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Landlord shall use commercially reasonable efforts to Substantially Complete Landlord's Work on or prior to September 1, 2023.  Landlord and Tenant further agree that if the Additional Space Commencement Date does not occur by March 1, 2024, as may be extended by Unavoidable Delays and Tenant Delays, Tenant may, at any time thereafter until the Additional Space Commencement Date, terminate this Lease by giving written notice to Landlord in which case this Lease shall terminate and neither party shall have any further liability to the other except (i) those obligations expressly intended to survive the termination of this Lease, and (ii) an obligation on the part of Landlord to return to Tenant any amounts deposited by Tenant under this Lease.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">(j)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Landlord warrants that the Landlord's Work shall be free from defects in design, materials and workmanship that arise during the Warranty Period.  If Tenant gives Landlord written notice during the Warranty Period (time being of the essence) of any such defect, as Tenant's sole remedy and Landlord's sole obligation, Landlord shall perform (or cause to be performed) the work necessary to correct or fix such defect at Landlord's sole cost and expense and as soon as practicable under the circumstances, but in any event, within 30 days following receipt of the notice, subject to Tenant Delays and Unavoidable Delays.  As used in this Amendment, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">Warranty Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">means the one year period that begins on the date that the Landlord's Work is Substantially Completed.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:4.533%;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Arial;min-width:fit-content;">Reserved Parking</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">.  At no cost to Tenant throughout the Term of the Lease, Landlord shall reserve for Tenant's exclusive use two (2) of the parking spaces in the reserved parking area at the back of Three Bala East, as such spaces are outlined and hatched on the drawing of such lot attached hereto and made a part hereof as </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Arial;min-width:fit-content;">Exhibit D</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">.  by identifying each such space with a Building standard sign with Tenant's name.  Tenant shall comply with the reasonable rules and regulations relating to the use of such reserved parking areas that are established from time to time by Landlord.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:4.533%;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Arial;min-width:fit-content;">Substitution of Other Premises</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">.  Notwithstanding anything to the contrary contained in the Lease, including, without limitation, Section 14.3 of the Lease, Landlord may exercise its substitution right under the Lease no more than once during the Term.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:4.533%;display:inline-flex;justify-content:flex-start;">10.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Arial;min-width:fit-content;">Restatement of Remedy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">.  Section 15.2(e) of the Lease is hereby restated in its entirety as follows:</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">6</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">&#x201c;15.2(e)	CONFESSION OF JUDGMENT FOR POSSESSION OF PREMISES.  TENANT HEREBY EXPRESSLY AUTHORIZES THE PROTHONOTARY, CLERK OR ANY ATTORNEY OF ANY COURT OF RECORD TO ACCEPT SERVICE OF PROCESS FOR, TO APPEAR FOR, AND TO CONFESS JUDGMENT AGAINST TENANT AND ALL PERSONS CLAIMING UNDER TENANT IN ANY AND ALL ACTIONS BROUGHT HEREUNDER BY LANDLORD AGAINST TENANT TO RECOVER POSSESSION OF THE PREMISES (IN EJECTMENT OR OTHERWISE), WITHOUT ANY LIABILITY ON THE PART OF SAID ATTORNEY, FOR WHICH THIS LEASE SHALL BE SUFFICIENT WARRANT, AND TENANT AGREES THAT UPON THE ENTRY OF SUCH JUDGMENT, A WRIT OF POSSESSION OR OTHER APPROPRIATE PROCESS MAY ISSUE FORTHWITH (WITHOUT ANY PRIOR WRIT OR PROCEEDING WHATSOEVER).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">IN ANY SUCH ACTION, LANDLORD SHALL FIRST CAUSE TO BE FILED IN SUCH ACTION AN AFFIDAVIT MADE BY LANDLORD OR SOMEONE ACTING FOR IT SETTING FORTH FACTS NECESSARY TO AUTHORIZE THE ENTRY OF JUDGMENT, OF WHICH FACTS SUCH AFFIDAVIT SHALL BE CONCLUSIVE EVIDENCE, AND IF A TRUE COPY OF THIS LEASE BE FILED IN SUCH ACTION (AND OF THE TRUTH OF THE COPY SUCH AFFIDAVIT SHALL BE SUFFICIENT EVIDENCE), IT SHALL NOT BE NECESSARY TO FILE THE ORIGINAL, AS A WARRANT OF ATTORNEY, ANY RULE OF COURT, CUSTOM OR PRACTICE TO THE CONTRARY NOTWITHSTANDING.  TENANT AND ALL PERSONS CLAIMING UNDER TENANT HEREBY RELEASE LANDLORD FROM ANY CLAIMS ARISING FROM ANY ERRORS OR DEFECTS WHATSOEVER IN ENTERING SUCH ACTION OR JUDGMENT, IN CAUSING SUCH WRIT OF POSSESSION OR OTHER PROCESS TO BE ISSUED OR IN ANY PROCEEDING THEREON OR CONCERNING THE SAME, AND HEREBY AGREE THAT NO WRIT OF ERROR OR OBJECTION SHALL BE MADE OR TAKEN THERETO.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">THIS WARRANT OF ATTORNEY SHALL NOT BE EXHAUSTED BY ONE EXERCISE, BUT JUDGMENT MAY BE CONFESSED FROM TIME TO TIME, AS OFTEN AS OCCASION THEREFOR SHALL EXIST.  SUCH POWERS MAY BE EXERCISED DURING AS WELL AS AFTER THE EXPIRATION OR TERMINATION OF THE TERM AND DURING AND AT ANY TIME AFTER ANY EXTENSION OR RENEWAL OF THE TERM.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">THIS SECTION 15.2(e) SETS FORTH A WARRANT OF ATTORNEY FOR AN ATTORNEY TO CONFESS JUDGMENT AGAINST TENANT.  IN GRANTING THIS WARRANT OF ATTORNEY TO CONFESS JUDGMENT AGAINST TENANT, TENANT, FOLLOWING CONSULTATION WITH (OR DECISION NOT TO CONSULT WITH) SEPARATE COUNSEL FOR TENANT AND WITH KNOWLEDGE OF THE LEGAL EFFECT HEREOF, HEREBY KNOWINGLY, INTENTIONALLY AND VOLUNTARILY WAIVES UNCONDITIONALLY ANY AND ALL RIGHTS TENANT HAS OR MAY HAVE TO PRE-JUDGMENT AND PRE-EXECUTION NOTICE AND AN OPPORTUNITY FOR HEARING UNDER THE RESPECTIVE CONSTITUTIONS AND LAWS OF THE UNITED STATES OF AMERICA, THE COMMONWEALTH OF PENNSYLVANIA, OR ELSEWHERE.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">TENANT SPECIFICALLY ACKNOWLEDGES THAT LANDLORD HAS RELIED ON THE WARRANT OF ATTORNEY SET FORTH IN THIS SECTION 15.2(e) IN</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">7</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">ENTERING INTO THIS LEASE WITH TENANT AND THAT THE LANDLORD-TENANT RELATIONSHIP CREATED HEREBY IS COMMERCIAL IN NATURE.&#x201d;</font></p>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:4.533%;display:inline-flex;justify-content:flex-start;">11.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Arial;min-width:fit-content;">Exercise of Option to Renew</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">.  Tenant and Landlord acknowledge and agree that the extension of the term of the Lease pursuant to this Amendment is in lieu of an exercise by Tenant of Tenant's renewal option under Section R1-A of Rider One of the Lease and, therefore, Section R1-A of Rider One of the Lease is hereby deleted from the Lease and rendered of no further force or effect.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:4.533%;display:inline-flex;justify-content:flex-start;">12.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Arial;min-width:fit-content;">Option to Renew</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">.  Provided and upon the conditions that, (a) at the time Tenant exercises its right and option (described below) to extend the term of the Lease and immediately prior to the commencement date of the applicable extension term, the Lease shall be in full force and effect and Tenant shall not be in breach of any of the provisions of the Lease (whether or not the same constitutes an &#34;Event of Default&#34; as defined in Article 15 of the Lease), and (b) during the twelve (12) months prior to such commencement date no such Event of Default shall have occurred, Tenant shall have the right and option, exercisable by giving Landlord prior written notice thereof at least nine (9) months before the commencement date of the extension term, to extend the term of the Lease for one term of three (3) years, commencing on September 1, 2026 and expiring on August 31, 2029, at a monthly Fixed Rent (expressed as an annual amount per square foot of the total rentable square feet of the Premises) equal to the greater of (1) the monthly Fixed Rent payable by Tenant for the month immediately preceding the commencement date of the extension term, and (2) the Fair Market Rent (defined below) as of the commencement date of the extension term, but otherwise upon the same terms, conditions and provisions contained in the Lease including, without limitation, the obligation of Tenant to pay Additional Rent under Section 2.3 of the Lease (except that (A) Landlord shall have no obligation to perform any improvements to the Premises or provide any contribution therefor, (B) there shall be no waiver or abatement of Rent, and (C) there shall be no further right and option to extend).  As used herein, &#34;Fair Market Rent&#34; means the monthly base rent, per square foot (with a tenant to pay Additional Rent of the same types described in the Lease), for a lease term equivalent to the extension term, at which Landlord is renewing leases for comparable improved office space in the complex of which the Building is a part and landlords are leasing comparable improved office space in buildings that are comparable to the Building and located in the Bala Cynwyd and Conshohocken, Pennsylvania markets (with appropriate adjustments to take account of variations in location, size and tenant fit-up costs undertaken by Landlord and such landlords) as provided to Tenant by Landlord's written notice within thirty (30) days of receipt of Tenant's notice of exercise.  Within ten (10) days after Tenant's receipt of such notice from Landlord to Tenant, Tenant shall give notice to Landlord either accepting or rejecting the Fair Market Rent (if greater than the monthly Fixed Rent payable by Tenant for the month immediately preceding the commencement date of the extension term).  If Tenant rejects such terms or if Tenant fails to notify Landlord within such ten (10) day period, then the Lease shall terminate absolutely, without the necessity of any further notice from either party, at the end of the then existing Term of the Lease.  If Tenant accepts such terms, then Landlord shall prepare, and the parties shall execute, an appropriate amendment to the Lease reflecting the amendment.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:4.533%;display:inline-flex;justify-content:flex-start;">13.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Arial;min-width:fit-content;">Brokers</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">.  Tenant represents and warrants that Tenant has not dealt with any broker, agent, finder or other person in connection with the negotiation for or the obtaining of this Amendment, and that no broker, agent, finder or other person brought about the </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">8</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:4.533%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">transaction contemplated by this Amendment, other than Tishman Speyer Properties, L.L.C. and Tactix Real Estate Advisors, LLC.  Tenant shall indemnify, defend and hold Landlord harmless from and against any and all claims, lawsuits, liabilities, damages and costs, including attorneys' fees, incurred by Landlord by reason of any breach of Tenant's foregoing warranty.  Landlord shall pay Tishman Speyer Properties, L.L.C. and Tactix Real Estate Advisors, LLC. the respective commissions earned by them (if any) in connection with this Amendment pursuant to separate agreements.  Landlord shall indemnify, defend and hold Tenant harmless from any claim of any other broker, agent, finder or other person with whom Landlord may have dealt in connection with this Amendment.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:4.533%;display:inline-flex;justify-content:flex-start;">14.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Arial;min-width:fit-content;">Ratification of Lease</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">.  Except as specifically modified by this Amendment, all of the provisions of the Lease are hereby ratified and confirmed to be in full force and effect, and shall remain in full force and effect, including, without limitation, all remedies reserved to Landlord, with which remedies Tenant hereby acknowledges complete familiarity, and which remedies are incorporated herein by reference as though set forth in their entirety.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:4.533%;display:inline-flex;justify-content:flex-start;">15.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Arial;min-width:fit-content;">Acknowledgements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">.  Tenant hereby acknowledges that, as of the date of this Amendment, (a) except as modified by this Amendment, the Lease is in full force and effect; (b) the Lease has been assigned or encumbered by Tenant; (c) Tenant knows of no current defense or counterclaim to the enforcement of the Lease; (d) Tenant is not currently entitled, to Tenant's knowledge, to any offset, abatement or reduction of rent under the Lease; (e) Landlord has completed all work to be performed by Landlord, except for the work to be performed by Landlord in accordance with the provisions of this Amendment and paid all contributions and other sums due to Tenant under the Lease, if any, and (f) there are no existing defaults by Tenant or, to Tenant's knowledge, by Landlord in the performance of their obligations under the Lease, nor to the best of Tenant's knowledge, is there now any fact or condition which, with notice or lapse of time or both, will become such a default, and to the best of Tenant's knowledge there is no offset, defense, counterclaim or credit against any rental or other payment due under the Lease.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:4.533%;display:inline-flex;justify-content:flex-start;">16.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Arial;min-width:fit-content;">Limitation of Liability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">.  Notwithstanding anything appearing to the contrary in the Lease or this Amendment, the officers, directors, agents, managers, employees, and direct and indirect shareholders, partners, members and owners of Landlord and Landlord's Agent, respectively (or any officer, director, agent, manager, personal representative, trustee or employee of any direct or indirect shareholder, partner, member or owner of Landlord or Landlord's Agent, respectively) (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">Landlord Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#x201d;),</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">shall not be personally liable for any debts or other obligations of Landlord or in respect of any claims against Landlord arising under the Lease or this Amendment, and any such debts, obligations or claims shall be satisfied solely out of the interest of Landlord in the Building.  No personal judgment shall be sought or obtained against any Landlord Party.  &#34;Landlord's Agent&#34; means Landlord's agent for leasing and management functions at the Building, Tishman Speyer Properties, L.L.C., and any successor thereto.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:4.533%;display:inline-flex;justify-content:flex-start;">17.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Arial;min-width:fit-content;">Binding Effect</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">.  This Amendment shall be binding upon, and shall inure to the benefit of Landlord and Tenant and their respective heirs, executors, personal representatives, administrators, successors and permitted assigns.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">9</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.75in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:4.533%;display:inline-flex;justify-content:flex-start;">18.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Arial;min-width:fit-content;">Governing Law</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">.  This Amendment shall be governed by and construed in accordance with the laws of the Commonwealth of Pennsylvania.</font></div></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:4.533%;display:inline-flex;justify-content:flex-start;">19.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Arial;min-width:fit-content;">Counterparts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">.  This Amendment may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which shall constitute one and the same instrument.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;font-style:italic;min-width:fit-content;">[Signature page follows.]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">10</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">IN WITNESS WHEREOF, Landlord and Tenant have caused this Amendment to be executed by their respective duly authorized officers as of the day and year first above written.</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">LANDLORD:</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Bala Plaza Property, Inc.,</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">a Delaware corporation</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">By: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Arial;min-width:fit-content;">/s/ Paul A. Galiano	</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Its:</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Arial;min-width:fit-content;">  Senior Managing Director	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">THE UNDERSIGNED TENANT ACKNOWLEDGES THAT IT FULLY UNDERSTANDS THE CONFESSION OF JUDGMENT CONTAINED IN SECTION 15.2(e) OF THE LEASE, AS RESTATED BY THIS AMENDMENT, AND KNOWINGLY, INTELLIGENTLY AND VOLUNTARILY ENTERS INTO THIS AMENDMENT FULLY COMPREHENDING THE RELINQUISHMENT OF CERTAIN RIGHTS BY VIRTUE OF SUCH CONFESSION OF JUDGMENT.</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">TENANT:</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Larimar Therapeutics, Inc.,</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">a Delaware corporation</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">By:  </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Arial;min-width:fit-content;">/s/ Carole Ben-Maimon	</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">Its:  President and CEO</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">11</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Arial;min-width:fit-content;">EXHIBIT A</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Arial;min-width:fit-content;">Additional Space</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">[Omitted]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Arial;min-width:fit-content;">EXHIBIT B</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;">CONFIRMATION OF ADDITIONAL SPACE COMMENCEMENT DATE AND EXPIRATION DATE</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">[Omitted]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Arial;min-width:fit-content;">EXHIBIT C</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Arial;min-width:fit-content;">Space Plan</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">[Omitted]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Arial;min-width:fit-content;">EXHIBIT D</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Arial;min-width:fit-content;">Reserved Parking</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">[Omitted]</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>6
<FILENAME>lrmr-ex21_1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html>
 <head>
  <title>EX-21.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 21.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">LIST OF SUBSIDIARIES</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:73.333%;text-indent:25%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.32%;"></td>
    <td style="width:33.34%;"></td>
    <td style="width:33.34%;"></td>
   </tr>
   <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Subsidiary</font></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Ownership Percentage</font></p></td>
    <td style="border-top:0.5pt solid;border-right:0.5pt solid;padding-left:0.075in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Jurisdiction of Incorporation or Organization</font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#bdd6ee;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Zafgen Australia Pty Ltd.</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100%</font></p></td>
    <td style="border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Australia</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>7
<FILENAME>lrmr-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.39in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Georgia',serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:24pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Georgia',serif;min-width:fit-content;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Georgia',serif;min-width:fit-content;">We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos. 333-239510, 333-268312) and Form S-8 (Nos. 333-239509, 333-249287, 333-270535, 333-270536) of Larimar Therapeutics, Inc. of our report dated March 14, 2024 relating to the financial statements, which appears in this Form 10-K.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Georgia',serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Georgia',serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Georgia',serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Georgia',serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Georgia',serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Georgia',serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Georgia',serif;min-width:fit-content;">/s/ PricewaterhouseCoopers LLP</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Georgia',serif;min-width:fit-content;">Philadelphia, Pennsylvania</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Georgia',serif;min-width:fit-content;">March 14, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Georgia',serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Georgia',serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Georgia',serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.39in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Georgia',serif;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Georgia',serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>8
<FILENAME>lrmr-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.88in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Carole S. Ben-Maimon, M.D., certify that:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. I have reviewed this Annual Report on Form 10-K of Larimar Therapeutics, Inc.;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4. The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:4pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:4pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:4pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:4pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5. The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:4pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:4pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Date: March 14, 2024</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:44.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Carole S. Ben-Maimon, M.D.</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Carole S. Ben-Maimon, M.D.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">President and Chief Executive Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:0.88in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>9
<FILENAME>lrmr-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.88in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Michael Celano, certify that:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. I have reviewed this Annual Report on Form 10-K of Larimar Therapeutics, Inc.;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4. The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:4pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:4pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:4pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:4pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5. The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:4pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:4pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Date: March 14, 2024</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:44.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"></td>
   </tr>
   <tr style="height:9.35pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Michael Celano</font></p></td>
   </tr>
   <tr style="height:2.9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Michael Celano</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Financial Officer and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:0.88in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>10
<FILENAME>lrmr-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:0.88in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Larimar Therapeutics, Inc. (the &#x201c;Company&#x201d;), does hereby certify, to the best of such officer&#x2019;s knowledge, that:</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(1)	The Annual Report on Form 10-K for the period ended December 31, 2023 (the &#x201c;Report&#x201d;) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48.88%;"></td>
    <td style="width:1.12%;"></td>
    <td style="width:3.34%;"></td>
    <td style="width:1.12%;"></td>
    <td style="width:45.54%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 14, 2024</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;/s/ Carole S. Ben-Maimon, M.D.</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;Carole S. Ben-Maimon, M.D.</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;President and Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;(Principal Executive Officer)</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 14, 2024</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;/s/ Michael Celano</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;Michael Celano</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:0.88in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>11
<FILENAME>lrmr-ex97_1.htm
<DESCRIPTION>EX-97.1
<TEXT>
<html>
 <head>
  <title>EX-97.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">LARIMAR THERAPEUTICS, INC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">COMPENSATION RECOVERY POLICY</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Adopted as of September 21, 2023</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Larimar Therapeutics, Inc., a Delaware corporation (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), has adopted this Compensation Recovery Policy (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) as described below.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">1.	Overview</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Persons (as defined below) in accordance with rules issued by the United States Securities and Exchange Commission (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">SEC</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) under the Securities Exchange Act of 1934, as amended (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and the Exchange. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in Section 3 below.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2.	Compensation Recovery Requirement</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In the event the Company is required to prepare a Financial Restatement, the Company shall recover reasonably promptly all Erroneously Awarded Compensation with respect to such Financial Restatement.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">3.	Definitions</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Applicable Recovery Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the three completed fiscal years immediately preceding the Restatement Date for a Financial Restatement. In addition, in the event the Company has changed its fiscal year: (i) any transition period of less than nine months occurring within or immediately following such three completed fiscal years shall also be part of such Applicable Recovery Period and (ii) any transition period of nine to 12 months will be deemed to be a completed fiscal year.</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Applicable Rules</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any rules or regulations adopted by the Exchange pursuant to Rule 10D-1 under the Exchange Act and any applicable rules or regulations adopted by the SEC pursuant to Section 10D of the Exchange Act.</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">c.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Board of Directors of the Company.</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">d.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Compensation Committee of the Board or, in the absence of such committee, a majority of independent directors serving on the Board.</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">e.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Covered Person</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any Executive Officer. A person&#x2019;s status as a Covered Person with respect to Erroneously Awarded Compensation shall be determined as of the time of receipt of such Erroneously Awarded Compensation regardless of the person&#x2019;s current role or status with the Company (e.g., if a person began service as an Executive Officer after the beginning of an Applicable Recovery Period, that person would not </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">be considered a Covered Person with respect to Erroneously Awarded Compensation received before the person began service as an Executive Officer, but would be considered a Covered Person with respect to Erroneously Awarded Compensation received after the person began service as an Executive Officer where such person served as an Executive Officer at any time during the performance period for such Erroneously Awarded Compensation).</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">f.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means October 2, 2023.</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">g.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Erroneously Awarded Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the amount of any Incentive-Based Compensation received by a Covered Person on or after the Effective Date and during the Applicable Recovery Period that exceeds the amount that otherwise would have been received by the Covered Person had such compensation been determined based on the restated amounts in a Financial Restatement, computed without regard to any taxes paid. Calculation of Erroneously Awarded Compensation with respect to Incentive-Based Compensation based on stock price or total shareholder return, where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in a Financial Restatement, shall be based on a reasonable estimate of the effect of the Financial Restatement on the stock price or total shareholder return upon which the Incentive-Based Compensation was received, and the Company shall maintain documentation of the determination of such reasonable estimate and provide such documentation to the Exchange in accordance with the Applicable Rules. Incentive-Based Compensation is deemed received, earned or vested when the Financial Reporting Measure is attained, not when the actual payment, grant or vesting occurs.</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">h.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exchange</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Nasdaq Stock Market LLC.</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">i.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">An &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Executive Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any person who served the Company in any of the following roles at any time during the performance period applicable to Incentive-Based Compensation such person received during service in such role: the president, principal financial officer, principal accounting officer (or if there is no such accounting officer the controller), any vice president in charge of a principal business unit, division, or function (such as sales, administration or finance), any other officer who performs a policy making function, or any other person who performs similar policy making functions for the Company. Executive officers of parents or subsidiaries of the Company may be deemed executive officers of the Company if they perform such policy making functions for the Company.</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">j.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Financial Reporting Measures</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; mean measures that are determined and presented in accordance with the accounting principles used in preparing the Company&#x2019;s financial statements, any measures that are derived wholly or in part from such measures </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(including, for example, a non-GAAP financial measure), and stock price and total shareholder return.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">k.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Incentive-Based Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any compensation provided, directly or indirectly, by the Company or any of its subsidiaries that is granted, earned, or vested based, in whole or in part, upon the attainment of a Financial Reporting Measure. </font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">l.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">A &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Financial Restatement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a restatement of previously issued financial statements of the Company due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required restatement to correct an error in previously-issued financial statements that is material to the previously-issued financial statements or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period. </font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">m.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Restatement Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, with respect to a Financial Restatement, the earlier to occur of: (i) the date the Board, a committee of the Board or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare the Financial Restatement or (ii) the date a court, regulator or other legally authorized body directs the Company to prepare the Financial Restatement.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">4.	Exception to Compensation Recovery Requirement</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Company may elect not to recover Erroneously Awarded Compensation pursuant to this Policy if the Committee determines that recovery would be impracticable, and one or more of the following conditions, together with any further requirements set forth in the Applicable Rules, are met: (i) the direct expense paid to a third party, including outside legal counsel, to assist in enforcing this Policy would exceed the amount to be recovered, and the Company has made a reasonable attempt to recover such Erroneously Awarded Compensation; or (ii) recovery would likely cause an otherwise tax-qualified retirement plan to fail to be so qualified under applicable regulations.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">7.	Tax Considerations</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">To the extent that, pursuant to this Policy, the Company is entitled to recover any Erroneously Awarded Compensation that is received by a Covered Person, the gross amount received (i.e., the amount the Covered Person received, or was entitled to receive, before any deductions for tax withholding or other payments) shall be returned by the Covered Person.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">8.	Method of Compensation Recovery</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Committee shall determine, in its sole discretion, the method for recovering Erroneously Awarded Compensation hereunder, which may include, without limitation, any one or more of the following:</font></p>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">requiring reimbursement of cash Incentive-Based Compensation previously paid;</font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">seeking recovery of any gain realized on the vesting, exercise, settlement, sale, transfer or other disposition of any equity-based awards; </font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">c.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">cancelling or rescinding some or all outstanding vested or unvested equity-based awards; </font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">d.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">adjusting or withholding from unpaid compensation or other set-off;</font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">e.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">cancelling or offsetting against planned future grants of equity-based awards; and/or </font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">f.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">any other method permitted by applicable law or contract.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the foregoing, a Covered Person will be deemed to have satisfied such person&#x2019;s obligation to return Erroneously Awarded Compensation to the Company if such Erroneously Awarded Compensation is returned in the exact same form in which it was received; provided that equity withheld to satisfy tax obligations will be deemed to have been received in cash in an amount equal to the tax withholding payment made.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">9. 	Policy Interpretation</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Policy shall be interpreted in a manner that is consistent with the Applicable Rules and any other applicable law. The Committee shall take into consideration any applicable interpretations and guidance of the SEC in interpreting this Policy, including, for example, in determining whether a financial restatement qualifies as a Financial Restatement hereunder. To the extent the Applicable Rules require recovery of Incentive-Based Compensation in additional circumstances besides those specified above, nothing in this Policy shall be deemed to limit or restrict the right or obligation of the Company to recover Incentive-Based Compensation to the fullest extent required by the Applicable Rules.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">10.	Policy Administration</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Policy shall be administered by the Committee. The Committee shall have such powers and authorities related to the administration of this Policy as are consistent with the governing documents of the Company and applicable law. The Committee shall have full power and authority to take, or direct the taking of, all actions and to make all determinations required or provided for under this Policy and shall have full power and authority to take, or direct the taking of, all such other actions and make all such other determinations not inconsistent with the specific terms and</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">provisions of this Policy that the Committee deems to be necessary or appropriate to the administration of this Policy. The interpretation and construction by the Committee of any provision of this Policy and all determinations made by the Committee under this policy shall be final, binding and conclusive.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">11.	Compensation Recovery Repayments not Subject to Indemnification</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding anything to the contrary set forth in any agreement with, or the organizational documents of, the Company or any of its subsidiaries, Covered Persons are not entitled to indemnification for Erroneously Awarded Compensation or for any claim or losses arising out of or in any way related to Erroneously Awarded Compensation recovered under this Policy.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img131876768_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img131876768_0.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1:"4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %F:^5S0X0DE-! 0      &$< 5H  QLE1QP"   "Z:8< E  "')R,CDS
M.3DX' (% $!-:6-R;W-O9G0@5V]R9" M(%!R;VIE8W0@6F]R9&EC:" M(%!R
M96QI;6EN87)Y(%!R;WAY(%-T871E;65N=%]' #A"24T$)0      $+KC1,8D
M!!COD?'4<#WU46$X0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q 9G]9(         IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-
M!"8       X             /X   #A"24T$#0      !    '@X0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              %@   #L          !
M      $              [    %@                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     ,X0DE-! P     "^8    !    H
M #P   '@  !P@   "\H &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( #P H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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M]!<?U'KKL;/R:*\3 ]&JYU=9=0#('T9=O:W<DR8\4LA(CT%ZZ
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MGG4/Y,X=T_DW?K'^>=WAX^'2G_H_^0?\[Q__ /J<?_D_V?14>TVXXPY_9VE
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M]#^-&<=?]7U[N_IZ*@?AW/A-^?\ 9\:ARWY8]H7( _XB_IX>.@XC%C;AG#?
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MK&^P??B\N^^_LQTV\S@/7OZ=._H=CW[T]I+QK\O[.<OY#^QFB]?,?V,#MO\
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MPUYW?]O]7HQG:K]^+RZQG[86G=_F4'?W=/TX&#['M)>-?J&<Y<?^3-&\^?\
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MU>)H)5CCF:-UBD>2-)"I"O)$(S(@; !9!)&6&Y42*6^<,^T1';D&WS!X\]_
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MZOK^K>FX>8]=O+^(.G,/Y3;:8[L=WLW[NG3QZ=U,]^>_V[=_7KX=>^G+?KS
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MZ:>/7QP-QTZ]??L<>BH\.8;!TZ<^G7J(AS#W]-_>#O\ CXV_3[W=\?&_Z/<
M0V'PV^C8-N74 ^K8>?NTQGU;C'OWV_7](IG'KZY]VV_ZOH--^O7<-M_'GX
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M#/\ N36W\)ENY_/^OO=X;:OGZ_D_AGYFNWJ[7I[\TY+[_NJ[W_UW_#]>:GV
MGP9_W)K;^$RW_P"?>/\ 5J>?+^3^&=_^:+W_ /6[N[NIR7_I5W_??\/=_C3V
M GP9_P!R:V_A,M_^??TVT\^7\G\,_-%_VO7MTWV'3#DO_2KO^^_X:>P$^#/^
MY-;0_P"<RW_QOAT\^7\G\,/KM%_0P-.2_P#2KL_]M^I13V GP9_/^Q-;>?\
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MQXM]A.TX@O"^%<-6Q3CEG%8\.MC%92+P[6B2SQR22O--<E2]W)+([3N[:CC
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MX96FE92#(Y(]8KBD*%</ PQJ\"!6WJ(T8R-#^CE-VRH>K#("R[DI_MBI]SV
M-]L ;@ Z-%$Z<IXT:,8 C9%9!I(*X1@5[) *C&%P,8P*+?7RW?GZWEVM]K,G
MGBW$PNN8P*L_G <3:RI(+:\D'!.*]K2)C&&_H,>R9[MFS+]:M4$/UFR*H5FU
M#NB%V;M"JK V0_\ 1( JJ"92]X;?051G  U8U8 &K  &< 9V &^V !TKE)/-
M+^%FEE[<DGRDCO\ *2D&63M$]N0JI=OG,5743@8Z/4$(+<K08F-]%*DT0(V]
M!:]P5&/7])8(E1[KNRI,G'ZNT3 H$;K"*J0$4^VU.7'@#0N %&-(QA!A!@C
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MAM;2[8!3@GY*[4XQD"-V.RG%(^:5[8:V%WJ7M*L1N)[;+$; <R C.<9=!G)
M-?4S?AI)%5PIE;'9&Z,.E85G!KC7P02@5I8L"C,J+"_[HD8K-F+$IOC'!N>1
M,5F505S 09D8SG;,0SW9G56A&>F9E=&B'6174ID,"9Z,')YA (.?D2PFP.IY
M11Q)C.@HP;!4XK%1R?CB_JND:-?*?<%F+1F_>HUJQ1,TJT92!W"3)VY3CG;@
MZ#=TJT=)(*JE*115LNF41.D<I;@Z0V#I) #8[)+*'4 ],LA##?=2&&V]3(R
M2,G5@="=+:6V._98A6\&V.#M5 6SSA)NO*-E\NXU1<0CI=E,(*W6ND5C';61
MCXARV?$-(@9LNA*RL9&+)J@4R<@_:,C #E=-,V00RAU(96P%9>TK$K(P"D9!
M)6*5@!G*QN1LC8T00Q0@AQG*D$,,%0<J=Q@N@.VQ=0=V&;3R'Q/8>Q_78:>-
M<JW9%;(K4S5F%KUDK[N7L<;;K9%U!E-0C4\DEZQBFS^3[YRZ;&.0463TJ(JK
MHBEJJ"\T=NH/,EEMH@,'L>=$<IW'4(RD2!L89"",C>LL0L,LY_!Q17$I;;#>
M:HSRHI) +@J4*YR'[) (->7,G%-B'"$RRJUPLK!*WR#.M2[:K ]9-90U=L>0
M*_COXQ"+]RU;%C(J6L2#N1,9<%@CF4@X;IK>C'*"'$TW(1@&5H%D8_-B%R)^
M4[_U&-O(I*Y(8H,9D7*3,4?-8$@I.\:@',GFRHTJJ>FO3("H.,A7Z:2:R*EF
M/$RQJP1/)=$.>[%.>G$):H036<B:YFJAH,H/1&3 CM-1F86?>@#M,[;?ORF3
M!@ZBF#K""73CM"(H7$F.N@HK.'(QI!;.D9J]%UGYNMH]7XO,5@C1ZAMK5R%9
M<Y#$ C)JIU')6/+^G(*T:\U*X)1/HWK-2LV&*FTX\'B1EV@O#QSIP5N5RB11
M1 RHE*J5)7L"84E *P= DQ\F20'_ !"0B2$!OFDA)(W(SLCHW1E)'9RAV<=4
M.SCM,FZGM#MHZ[CYRLO52!066<\+R1VZ<?EC'3U1W)/X=H1K<J^X,ZE8H&)I
M./;@E(&%=W'DDHX[Q%+M';)OFBBP%(X2,9D8#9V*&0'N,:JS,X/0HJJS%OFA
M58DX!--\E<'(95(P<AF;2JG;9F;8*=R=@*[8[-F'IAK%OHG*6/Y)E-S2U;AW
M3&W0+IO)V!NDDNO"L54'QR.9-)!=!8[)(3."I+H*"0"+I"=OV1@@NCRJ"/G1
MQG$CCQ2,[.P[*G8D&A.-6=M+*C9_%=R0B-_)9BK:5."<' V-3]FO#WH4')?9
M2Q_ZOL\@XB:Z^^-T$#2<DFBZ;5TQBG'IW=/W+=RLB@LDV.H9-99),X 95,#
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MI%"!;QQ%S0R$FG,G!^S9N"(*&0(<0,*A]$"QB8(-//GY\AU$DMYI:6FC)/S
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M\38Z1@$8;>M,2RW2MAO.F9B2-X]?"7X2P3T&%Q+UQS47(( Q;U<^#^Q]7E)
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M".,\4.1LN#9);%93 LF%,MWQ"W9P0H4</X1<\19]]OE)(HT [HS)G?3C4D3
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M(M .S9&;Q<KRSU:-&CUMEG>,F B*5CEI8P;:!@C$A6B4J!DD]&.K4"  [:R
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M+8G7L#V$>V AIQ1"YK^LYEM+M1L31T:/DXQ%X4[A=3O$]Q,T>IACFF]FNU;
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MN\J>&01W#13*Y5DF4%(IF/R;F:1XM/+TC9W/'$XSPG*'B$J3*7%Y'XSN66[
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M8G1Q YSHN$LIH5(9>:EW)?1J&;'R:JW#;H.Y!VY052\A1+QIO$?/1_#1PUY
MLD0I=,DYJK&/FC9@W?P56CI*X6.E*VJ3<R$PY%.!@8XC6,E7!5$B+)K."MV$
M<U75<H$"RC%PD,>"6MQ.<L%&B.VCFF=2WSB2V5C49!;<HBLRR'+PRS,2%CE:
M/&G)[=V;>)=O E0SD[@%@"Q"G$][XZ7[Z S5#TJ@W.O3E%I^0CQ-\>1B4Q6&
MMUQ^P04FV+E8K%6&4CT9!99E#RH/GK&=49F.1!LW?1BC[GAF0R1NND7$2KK!
M0RP#C"\+EV?24E+B0A-R(M3E@T;*-#8A6!9F@9B$.H1ROPQ[^(Y4$-$ $5I,
M %V4*I1@U;:<.UWL=_H]BFK0\3?2,?F//%1:JIM6[,J<%1LRWFGUQJ9)LFDF
M=1I PL<V57,45W*B1G#@ZBZJAS=G4!(&'62!9&]+%Y%R-S@84;>.3WU7P)75
M?FB*Q=>G\?PVRN7)Q_*DF=O1G2   !G?7.I32E-*4TI32E-*4TI32E-*4TI3
M2E-*58USQECS(H1@7RDUBX!#.1>17QBAF$MZO<& @*':B\15%(%033!=,H@F
MN"9"K$.4A0" 8=9!LZE2K#J-+K(N_P#5=%<>#*&&" :'=&C.Z/\ .7N.S+O_
M -5F4^(8@[$UV3N.*!9V,]&6.F5F=CK0O%NK(PEH6/?M)UU!E:%AG,LW<MU$
MWZ\65BR+'JN2J':%:-BH&(""8%$ Z<[Z9&F7/XLKHL;2#P9D54+#<JH!S5R1
MWG\&(NIQR@[R"/'30'D=PO34S-C)S7KK%&IU*;F:U"KP59;&;-&9T(.+9QB1
MVC#T@6+8Y&B*13(-!=NA;)& 2(BX6%,"]X?>C88&PR#CN)")&"?2(XXT!_DH
MJ]%&,X&<XWQC/?C4[X]6N1VQ_*8GJ:\4WC7']EL41;;!3:W,V> % T-/240Q
M=RD:+5<7306KQ9$ZR?HCLQG;0.T(-70^DM^[7 % )\FQ9.RQ&"PV)&"O4=^E
MF7(WTL5S@D56&M0C=I <Z3N,Y!Z>&0"1T) )&0,>]K2:@QC8^&9UF#:Q$3*!
M.1<8A&,TF$?,E?+2995FT(B"#>0+(N'#\KM(A5P>+*. ."IQ-J  &(C8PIRX
MB.L<?):WT)_)7D.\.D8'+9E&QH=^9G?FMKD_KOS5FU/_ "FYR++DY)=0QW&:
MZ'6/Z,]%D9Y4*VZ&-=.'T>*\+'J"R>.IIE8W+IJ)FX]PX<3\;'32RR?945E&
M#1^<QG+=)4I1H*LF5**J(5."J)\Q5(Z*OXH&,=U&[897[2LQ9@VX9BI0L0>K
M%6923N02#M5*=8BQ<]6KCAYCVFNEZ>L=Q5E5ZY$JGKRRCSUB=2($[0?0#&D/
MU_\ K?NP]- KH [\I5 JY5E=25=8XX5920RQ1)RXHP0<Z(T["+T525& 3DPU
M!E;M*[O(X.X>25B\CM_*9W)9R<ZF.3DU,;B7%\.^=2<5CZG1\B^E',X[?,Z[
M%-W2\P\CI*(=R:BR34IQ>NHN8EF#AQOWJS23D$%#&3>."J3 Y;0X'*9'B:/\
M1HY"A>,KT*/RX]2_-.A!C"K@<E^:23(&5PY)+!USI8$[AE))!Z@DGJ2:I_V#
ML-^E.'OV+:!Z6[A$JTZ<?%.$[U>OHMD&24,J?T+=2.39M6S0K0VZ(-4$6_9[
ME(A"[UOJ=]1U/(DSL226ECD69)&)W+K*B2ACN)%5\ZE!$  "J-E1&C11L%1D
M>-E [@8W=".FEF48#'/IG<-XGL^_QBQO29OM2$I*F]:5F'?=N1G&Z;29>G](
M:*=MQ+-D44)%0_:,]322(Y%0$DP+@#&/ZJ/&.GS'D:5EQTTF5FD(QCF$O\[>
MMEF/5CUC;K^-$BQQ,/ HBJBD;A!I'9VJO%H=+(0I"52O%(2;)9"%+#L *6P)
M1Q8=.;*4&_9"4)%%+&E?;>D@Q &H*=R $"MVL:CJP)@,[X%R)A<8\.>)YA+C
MY_-DU9UMG/<1T!6)<#8:8&C:$>J)HHF0?BF-2,$"J%!X<Q/63IJUW'%*A%4G
M;%^DK%UJ(8J)/8QP]=1KE,[9HF9-:/<2+]9B<@@+0[UT9OW8KJ=JAF&G#,-&
MK3@X^=&\+>DEHI)(R3N4=E)*DBLE58L6 )<@MG?.F2.51ZA+%'(!T#QHPW48
MN.:IE3LAW2E@K<)-G>P<C679Y6,9/S.:[++-7$G!KBZ15%6)D'#%DN\8'$S5
MPJT;**I&,BF)<D JRGYKF,N.FHPF0Q$_UHC+(8V&&0NQ4@DUI<J5*D@H'"D$
M@@2!1(!CN<(@<=&TC.<52*_BW'%3,52KT:K5Y4B;Y$JT+!QL:N"<FVBVDB4%
MFK9)0?3FL'#-W8B;=PC%QY%A.5H@!#9<$,204>,@].7(XD=,=-+2 2,"""X#
M8SO0;$, ,AUD!\)$5D1O051F52-U5B!L36',=<(>&,=HVYLG"!;&US;P["4:
MVV.K3MDG$5^2DIB$BV["*@(=DH2.DY9Z^2DG[=]-JN#I*.9186Z )T$B%83@
MJKK+D@:C(L0A5NF 1&-/9P#J<D'(P))E:0$C*2($!.D+-())%&^X=U4D-G&A
M,8().9DL88Y1;I-4:-4TFR#.#CT4"0$65)-C659%:O-2I@U[(-X1:7E5HM(
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M/<MG*^><654169@+;B\%N-( QR5BO@8LE1HMB2ZJ^I=Q+/GG)C/"V%KU"T&
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M*\SEDS>@D#QHV=@@L1P@#E!)<$5TQW362[TAN[5(/,BA-CE'H(:R6*]H;$'
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M*S=!5)<=UTE$DSIK#]J&ZI#%$J@[%+S. C]J7R#9@'J,TKB+9L0  K9
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H-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*5__]D!              $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img131876768_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img131876768_1.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1K04&AO=&]S:&]P(#,N,  X0DE-! 0
M    &K2^:#8X0DE-! 0      &$< 5H  QLE1QP"   "Z:8< E  "')R,CDS
M.3DX' (% $!-:6-R;W-O9G0@5V]R9" M(%!R;VIE8W0@6F]R9&EC:" M(%!R
M96QI;6EN87)Y(%!R;WAY(%-T871E;65N=%]' #A"24T$)0      $+KC1,8D
M!!COD?'4<#WU46$X0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q 9F            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-
M!"8       X             /X   #A"24T$#0      !    '@X0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              %Y   "'          !
M      $              AP   %Y                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     4X0DE-! P     $#0    !    H
M '    '@  #2    $!@ &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( '  H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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M]GYON6)E?4=U]V1:,[8+GW!H]$.VTY+LVW,J=-OZ2[?U6_[/D;?T.RK]7O\
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MT_33
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! ?_  !$( ,H!(@,!$0 "$0$#$0'_Q  >  $  00# 0$
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M"4);:ZY57BI-2)?K1DD1N=R@V5Y92#==FMREQ[9,Q2F]!R+G-82'.:T@9()
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MDD@F94Q/ECJ8?]U-"]T3P?86$.''&0<Y&,\G$2GC"P4'&]&\TX;0\-'F)?\
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M^]]S($9\ ?//E[CGZN/K4#X<!W(Z]/KZ'^'UCJN@:.*<XF,DF #_ *I0(/F
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MT0!Y!#96M:0*=6U_2:TE(.)9*O5&MP:4J[9ECG<DG$P[1B1^Z8%31*R<.RH
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MJY.7"\9,(F$3")A$PB81?DHB53D1$2CVB'(>G ^H_ >?W^0XP1D$>?">&/\
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M2DCGJ)W;Y)(X(:1T;&.>7$-:,#/&!@*X"FH?$\,!_P#SQ=-=P$,)2$T8V#N
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M?07U!,8'4:&V=R0.L+.33S)K !8;5%669&/:NEJ<T$%#-YIRQ1% KQL3WM-
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?81,(F$3")A$PB81,(F$3")A%_]D!              $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img131876768_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img131876768_2.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1OZ4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &]Z^<30X0DE-! 0      &$< 5H  QLE1QP"   "Z:8< E  "')R,CDS
M.3DX' (% $!-:6-R;W-O9G0@5V]R9" M(%!R;VIE8W0@6F]R9&EC:" M(%!R
M96QI;6EN87)Y(%!R;WAY(%-T871E;65N=%]' #A"24T$)0      $+KC1,8D
M!!COD?'4<#WU46$X0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q 9B            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-
M!"8       X             /X   #A"24T$#0      !    '@X0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              %1   "!0         !
M      $              @4   %1                      $
M                $     $       !N=6QL     @    9B;W5N9'-/8FIC
M     0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N
M9P          0G1O;6QO;F<   %1     %)G:'1L;VYG   "!0    9S;&EC
M97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L
M;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%
M4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%
M4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q
M    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL
M;VYG   !40    !29VAT;&]N9P   @4    #=7)L5$585     $       !N
M=6QL5$585     $       !-<V=E5$585     $       9A;'1486=415A4
M     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4
M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     4X0DE-! P     $5T    !    H
M &@   '@  ##    $4$ &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( &@ H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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M +2>K>E/3I*CT.^[)Z-@9%X
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 1$  A$! Q$!_\0 'P !  $"!P$               @)"@$" P0%!@<+_\0
M5Q    8! P("!@0'"P8+"0   0(#! 4&!P ($0DA$C$3%!5!47$*%F&Q%R(Y
M@9&AMQ@9,C8X4W-XDL'1(R0E)B?P,T)'2%)66&)WAI8H1F-F<M+6X?'_Q  >
M 0$  04! 0$!             0($!08' P@)"O_$ #D1  (! P($! ,&!P !
M!0     ! @,$$04A!A(Q00<34? B87$4@9&AL<$(%3)2T>'Q%B,S0F)R_]H
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M7'ER^HUPCV5MM-GKFV ^>9+(V*EK5D%O*7&E3D\G[)J=/B<>2\^_QTY#();
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M:-X^.C8YLBRCX]@S1(W:,F+-N1-LT:-6Z2:#=LW331013(DD0I"E* '(: :
M: : : : : : : : : : : : : : : : : : : : I/;\MON1<H[A]O-LJ<:[
ME*]+X WS;79EZ1B^?QM#L^XW&U%>T&]3WLY!TXB:U[2Q9)5.;G#ME46BUDAF
MYA*=Z4BP$!+]T'Q6QSCZL83GJWBNTI[#;YMSRS9E[;E"W-K=EB?<8$F(^191
MEED)EK'X[FI+%MN@[:RB48)4U:MOJZ4"_(3V>V#W[_XCRC.O1<WCY=PFUQI
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M: : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
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M*HE$DP 'D 'X@ _I#GW\#^H- 8Z : : : : : : : : : : : : : : : :
M: : : : : : : : : : : : : MWMUUC<M^IY@FE8\IK:SE1LN&I6Z.U#YP6
M"HSMDR@PEI:Q6<D388Z&/'KTB&=HX_+7(F;J*5D&8-D<K:&B72;</?OW]2NM
MD#"^'<LN8!YE/$V-,EO*HNX<U9WD"B5:Y.:TY=J,U73B 7L<5)*PZ[E6/8*N
M%8X[9191BS.H8QFR(D ZZ^VT;<I1E88V3P%A:1CK=<&N0[6P?8NI#ME9[^QY
M]2O%A:N(-1":M[/D1:V22(YF6XB(I/2: CKGXA"[V>GT0I"E*"VZD *!0 H
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M@X\F:7%?6]:(9V((F D90A49U=.LR]<LJX-/^!A+57) PF1E6QC 2HT T T
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M:6Q;/U+*=9R')[BL=5R72Q4@C8HZ[REBH.+]LEER! P$I*1M2C([*]O1?6&
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MU(15-G9VNC+R:(WB=@YYDM.)09W;:'++NBM9IJS; !3-;;6NI!<XC'L6VO\
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M6(N5:UYE%*.[K33>W79/"6SR>PY./_MQOIA$1\63K&("'_%#ZU.P$ Y#R$0
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M(0 *4H%  T!K^B2_FT_[!?\ #0&/HDOYM/\ L%]WE[O=H!Z-/^;)_8+_ (:
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6 : : : : : : __9              $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img131876768_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img131876768_3.jpg
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M ?_$ !X  0 #  (# 0$            '" D%!@,$"@(!_\0 /1   @(" P
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M6;][^T_!6\LC%HHKSUJC0%VMTM3LCU%7 .5JS;&S##F(!1!LG98"9>4V*CB
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M]NM)["T-@L9/JO:==S &DZ&'+18AIO"Y \F CL9N9]&<N/W;FPS0 C J$ZT
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MI\6REH+D-CT+]I)E;U9JBQ5HH:J>DGFY,4[C1ROFC8V=I?&USWQ1>NZ/1*
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M=%24;+D^[8HZ:"*.G<ZLDCCE>_ ,9$O,E/+$CY7ND..Z'AQL 30)92X(CA"
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M6PQP4\]9)'50WB)E6YKZ0AU(YM!%=*.65\T#7.DDM^LU%3'!)V[T#47&+_2
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MHI8\9<<)9,,9.L>L\<),\>LNNL\NN_2.66%VN&62)^"W5&]T;M)P2-32#@D
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M%:/2=HW<XV2NL2S&E%UVPBK+-+7FZZP/MEG7 M\VGD-H:=J.4 97!B@XE;6
M&&9C/E('WUE%UUQ[T776KXBJ;U-<(:F+[&^GJ&QU/V>6.HGN+ZMT\KB^@AE:
MZ-].US!%*UC3([+,871^/*"GLT-LCHI('FI;-"Y\'.C?%%1-IVQ1@-JY(W->
MV9S7&2-SR&##NJW;QFBS[^KA+'GE]'T_1CGCEW]'_P _1UWWW]'.V+F"\G")
MPB<(G")PB<(G")PB<(G")PB<(HZV]JRH;QU5L?36P!"3J1M.D6?7]L%"*S!.
ME06Q.8D:?('1XYR GX"&RR FX8Y9B%X0D8XY91]==DZ*!A_!'CPJNI*]>?.F
MFMPYH&=]<+[!N?5NO-F6:)EL[8UKVS>9X6UFJY?:X=]L&[VBR2JD\*U,(6VG
MC 7"CXQPX%.IPZ$C..A(Z=/)>JH^'AX21.G+Y7Y#\\#E/0@EYH.>J:>56X P
M(OL8(DU0,5D52N=R8?1\[)7DJN5EGUU(QD*DZZSZV:+C3BR"@HK93<17>EH;
M?J%'!25T])R6N)):)*=\4SV-)/+9)(]D0.(FL&RQK[1:Y)YJF6@I99JC'.?+
M"R760,9+9 YH<?O.:T.=U<25T?77PN?"6O *C%EYRUI>W54UK7=7S678U2KM
MI+MBFO+@UW5BM]<E5#:_;7MWT'T78;G#3@GK0D@O&0K 2?(7KVEX[XRGMSK3
M-Q->):%[WR21R5LSYI>8PQR12U;G&LEIWM<X.I9)W4Q)+C%JW56V6TLJ!5,M
MU(R=H :YL+&M9I(+7,B Y37MP,2-8) !C5A=]_=Y>!<?_P"H?$7D<27K_;&4
MO\Y:@7'#Y]?^V80\&GCFAD1]_1E$2+/#/#GUUG%)AGUUEUIT\$-3#+3U$3)H
M)XW1312-#XY(W@M>Q[3D.:YI((.Q!6RVF\76Q7.WWJS7&LMEVM593W"VW&BG
MDIZRAK:25LU-54T\;@^&>"5C9(I&$.8]H<#D+IU^^'7X:N:^K42?1VJ:;*#;
M%6Q0A*95*;6[+91*8R79N4K$S!-,[:45EBU 2W!<-+%#\LY"PB,6,2%Q>."?
MPCPP^(0NL-K$8?S &4D4;M6DMWDC:V0MP3ZA<69P=.0".N4O_$IZ?J.O?<H?
M3!Q^ZKDI31N=4\27"M@Y!D9+AM'633T;)=<;<5+*=M0&ZHQ*(WO:[NX_P_?#
M, ,BV;R#YO; 3?*]R#633="M4>60?6>(\G_J5&URZFQ^TS[SFZ[ZFFS[ZSGS
MDSQQRZ^NAL%DMDG.M]JH*2<-T">&EB9,&D8+1-IY@#AL\!WK_>SA:YQ=Z9?2
MQQY0FU\9>D7C'B.UF<5+K7=+_<:BUNJ&O#XYGVXSBB>^%PS3N= 339(@Y8<X
M'P_N\/ 'Y&O'GZ9M*_T3S+KFVM_XG?Y'YJ/E7PSOAVS[&L^PE_D[RZTF)J];
MURRIF&A]'&T6O&U%Q:K%FW#K\-#[R57EO'=XU]G/G,RE/1HZB)D$-TMZF*)K
M=^)WOR<^[KT4@_N\/ 'Y&O'GZ9M*_P!$\)K?^)W^1^:]-CX!^'@H7G-FWBCQ
M@K5*PR6+)DQ\WZ/" 7@!0YDF''&$TR(<0,0>*2<DF>2.&"&/.67/###++HFM
M_P")W^1^:ZIKSX7GP_-?UC"M1>0?-5PC^_KE8.GEY\_Z4?V'+NYW%]<LE/;+
M'7X?7:2N9O\ *N50'[#Z5%44I5'<Q/8/9,Q-;OQ.'N)^?FN[_N\/ 'Y&O'GZ
M9M*_T3PFM_XG?Y'YJ/=D_#.^';=4(U*.\G>7:.6]>UU@K8T_0^CJW;#2:98%
M=WF4JBYJ&5(0 U%KLRRU CBRYFU(QV'GF-&1D5"36_\ $X]>I/C^:D+]WAX
M_(UX\_3-I7^B>$UO_$[_ "/S3]WAX _(UX\_3-I7^B>$UO\ Q._R/S4>%?#-
M^'8;MA#;^O)_EZ!U6=>6RMYZZ$T/HZ.ILU=XLE+9QW6P5/JAYE&6)$7KV5%3
M[%D1 .M6V*\K<82Y&N<@1-;_ ,3O#?)SMGV^U2'^[P\ ?D:\>?IFTK_1/":W
M_B=_D?FG[O#P!^1KQY^F;2O]$\)K?^)W^1^:Z32/A=_#]I$-GAP\@>:K/^)[
MM9[ME);_ #]I1S*CSLYWSV59KV?6OQ?NVHH^_P#_ "UY-WU/VM#_ /)[*G_]
M_":W?B</S._M._53KK7R1Y3TQ9<;II[S)Y[U1<< "U>-LUKI?7%%LN*P_P"R
M^>78O:O6U;3$ W[&'YL3HKH<C[&+[://[/#Z"@N<>KB?>2?W5A.%"<(G")PB
M<(G")PB<(G")PB<(G")PB]<DL4*/&8PD<2'.<47"4F:."/(HXJ$$$;'.7+#'
M*<PT@<06'KON0@J>$>''.67##(BQH]$^A;KZ?V(3YX\QVC9VN-EHJ;>5]@ZC
M2-G5!M05WFEK ZNXVNET_:-%UZA;TH:;9&F?13-N57 +J+W4%:?9EBJ.\="3
ME<  9(!!QC??Q\QD8(\1XC(*U)T=KAAJ'4M#UFSM1%U+I5?#0?B,A4 D[,%
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E$3A$X1.$3A$X1.$3A$X1.$3A$X1.$7__V0$!              $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img131876768_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img131876768_4.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[16$4&AO=&]S:&]P(#,N,  X0DE-! 0
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M>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    * $$ 4 !. "
M+0 @ #0 ,P X       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\
M;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N
M=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT
M   0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O
M;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP
M $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B
M;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P
M  ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+
M   *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=0
M0P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M  H  0         !.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F
M9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    ! "T    &
M       !.$))30/X      !P  #_____________________________ ^@
M    _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@  #A"24T$
M"       $     $   )    "0      X0DE-!!X       0     .$))300:
M      ,U    !@             "7   !CH          0
M           !              8Z   "7                      !
M                     !     !        ;G5L;     (    &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   "7     !29VAT;&]N9P  !CH    &
M<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC
M94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T
M   ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T
M   *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   EP     4F=H=&QO;F<   8Z     W5R;%1%6%0    !
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M3001       ! 0 X0DE-!!0       0    &.$))300,      KG     0
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M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M P$1  (1 0,1 ?_$ !X  0 " P # 0$            '" 4&"0$#! (*_\0
M5!   00#  $" P,&"@<#!1$ !0(#! 8  0<($1()$R$4%5@6%Q@B,34C.4%1
M87B6F+?7,G&1L<'5X8&A\"0E-T*"*#-(5FAU=G>&AXB2I[.UT?'_Q  < 0$!
M  (# 0$              0(% P0&!PC_Q ! $0 ! P,!!08$! 4"!04!
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M8579K==CRFT<HN-<BD93((]>J^5-5P*\[ACZ^F%7T/SROXHWG07'<EM5KI?
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MU*GWMIUMQ:MZU@%&/A^?N+RU_K^^7/\ B*O(GU7CXK[3N*O'R;\D+^Y2# &
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M & , 8 P!@# & 4"^'Y^XO+7^O[Y<_XBKR)]5^>A5X^3?DA?W*08 P!@# &
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M?5?=;)Q:\:-!:X6*"&96W$09Q$"(F2&-(<?@1G-[;U??OWXD7CY)\D.D6"#
M& , 8 P!@# & , 8 P!@# & , 8 P"$>G>0W,.0&1("\SK+")'4,J$($4*\6
M>-/>D*FZ9@L3JW7RL)1-Q(Z8]H9]HU/U'85)W'TQO3F]#=MI;39)X*:X25<<
MM4B?ET@MMQK&2N=VF(V24E+/&LV(9'K#O=JC&J]6;F''OME/PTVLVUH:VX[/
MT]JGI;<Z1*UU;M%L_:9:=D24ZR5$E/=;E1U"4C5JH&+5]G^6[61(NU[3+4F6
M'+9GQ(LV/\W3$N.S)9^<R[&>^5(;2ZW\V.^AM]ASV+3[V7VVWFE>J'$(6G:=
M;QCD>UKVYW7-:Y-YKFKAR(J9:Y$<U<+JBHBHN45$5%0\-/"^GFF@DW.T@EDA
MD[.1DK-^)ZL=N2QN?'(S>:N[)&YS'IAS'.:J*OTYD<0P!@# & , 8 P!@# &
M , XH_%M!>7I<]P=?C"CR+W%;&W1@[^8VPVP3#DVE^Y\D=K< Q^1I <V".R*
MW'O2@EYZ<W8.1 !S1X=8:S-*FQ$N%%\<>_?=U13),:Y\O?SQKTYGF@@_-YOX
MG=A)'U]L_,M^7=^E/NE#IM[@;GCV]P7G<+G T*.3,5SY/0F>[L6N202(%M=&
M;C;)3"[VZS*C[?>^Y/+Z\?+A-,)P[^N<KKUQA/#S-N\>I_32/Q9_)I_J]5HM
M0LVO"?Q[;8%\^OA[H@-P0CK/7=PIKIVQ<YYA/9(ONJE(E#$5Z1%BMM1W6BTM
M4EQF*YKX)]??M2_T_P!W/1>'1%7YG7_*8C & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , H%\/W]Q>6O]?WRX_Q%5@J\?)OR0O[@@P!@# &
M , 8 P!@# & , 8 P!@# /2_(9C-+>D.ML,MI4MQUU:&VFT)UZJ4MQ:DI0G6
MOKM2MZUK6M[WO(JHU%<Y4:U$RJJJ(B)U55T1/$R8Q\CVQQL=(]RHUK&-5[W.
M5<(C6M155571$1%55(*.^2_(!4UX,'L4GH5D:]Z=UCE88ITDTEUO>DJ9F-U*
M*4@AW$JW[5*.SA;*-I5MQU*4[WKS]1M3989'005+[E5-RBTEG@FNM0BHN%21
MM"R=E/A<HJU+X6HJ:N0^A6_\*]MJRG975ULBV9M;MU?XMMA74>RU K'(KDDA
M=>IJ2HK6*B91+?3U;W93=8N4.4WFUT7RQ/\ 4N<3J/S_ *U1*NQ- 2N?BIH>
MOE9DSHZ8UM;8G,:KSUEBQK!( O$D(KLHH_.9@QW)<F QM2-I^-?B#==MYKQ9
MY+7:[S;Z-CX)+=#)34E1))=49<&[Z?E7UC&U#Z-\R)2OF=(V)BR.C8JZ?L/\
M MF?P9MVR.U-/M!M)L9M#>)(+A#M+605URHX(-EUELKI:>1;FRU2RVR*XLI'
M+=(:2.G?42-ABJ9%1R+V@YN\?D\\H<BUIE(M+],J[UE1.9U&FIL#@2"LRF7'
M2AO3$E)%4G3[.FV]-.Z6WI"-)TG7WFV.J7VZWOK$<E8ZBI752/:C7I4K!&LZ
M/:B(C7)+OHYJ(B-7*(B8/PIM/';8MI=H8K,L3K1'?+M':G4\BRP.MK*^H;0K
M#*KG+)$M*D2QR*YRO9NN5RYRNZ9W31C & , 8 P!@# & , 8 P!@# .7?/?X
MX7R5_J*^.'^+G9<G-?!/FXR_I_N^AU$RF(P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P#\K6AM"W'%)0VVE2UK6K24(0G6U*6I2MZTE*4ZVI2
MM[UK6M;WO (SYMVKCW9&C;_).I<^Z:S6B"15A=H5P 6QL(26E2VX118*?.3!
MD.H0M;*)&V_G(0M;.UI2K>@PO0JA\/S]Q>6O]?WRY_Q%7D3ZKP\5]KWE7CY-
M^2%_<I!@# & , 8 P!@# & , 8 P#3K;T.B4*+N;=KC6JI&]BG$.'S0\5M[2
M?I[8S<R0T[*<5O7M0U'0ZXM?HA"5+WI.=*MN-OMT?:U];2T;.3JF>*%%[F]H
MYJN5>2-155=$15-U9MF]H=HIDI[#8[M>9=Y&JVVT%36(Q5YRNAC>R)N-5?*Y
MC&IESG-:BJ1 [Y%,G_:WR7F72>IJ6II*2\4"Y1Z@E+NE;^=^5'0=UR-/CMIU
MI:W0,4U[DK1\E+JE>FM,NTK:E$_@UJNEW55:B3,IG6^BP[.7?G+G^49*QJ85
M74K*G.41N5RB>U;^&<EMR[;+:O9;9!&MD5U%-<6[07M7,W42/^$;-?Q2:FE>
MJJC67&6@PK7;ZL1,K[=#/)>X:0HC8>=<A%NH6I<&M#9W1K:WI>_1#2CIW[@K
M420A'^DMFMEV4N;W[5NI3I2KV6U-;A9*JV66)4SN4L4EUK$1>"?F*E*6DC<B
M8SBDJ&[V<.5,&*U7X565'-IK9M/MM6,<B-J+K5T^RUE<K4U>ENMW\2NTT;G<
M&R76B>K43>1BJJ'YA^,7/YKNI?1B=S[+-][3^T]2LLJP 6I+>O7;T6E16QM)
MB^Y6]J]C=>VE.O1.M[]/7<;LI;9%5UTEKKZ]<*K;Q5OJJ;>3FVWL2*W,UU3%
M)E-,*67\6-I*=BP;,4EBV&@W7QYV0M,-MN+XGZ)'-?IG5=_FPF$5SKFBN7+E
M37"3P&!!*Y 8%5\0,!BXJ?9%&!X$08/C(WO:MH8APF6([2=[WO>](;3KUWO?
M[=[ST$%/!31MAIH8J>%B89%!&R*)B<D;'&C6-1.2(B8Y'SRNKZ^YU,M;<JVK
MN%9,N]-5UU3-5U,KL(F9)YWR2R+A,9>]R\LX.;'G-(J;'2N+I/\ DF/Y1*=L
MP-N/6Y5G:#.5IO<"[*3U9N,NT!]Z4RI#U9U,<BLL[U)5'V0VO:8ZO/7_ &(V
MFVFJ;/6V:"_5%-!<8:=SK71U\\%!.D%4]]P?)22-CCECAE2%5D:U$9,UJR?K
M:T[-%^)FUFPL26[9VFV1FI-I)_X5>G7W92GOM7_#*F-:F9LU3)5P._A?YFW4
M.:1[&P-J52994>J-7I)7_9]Q!MM$TFFMBQ^VS"7-/)+-_8V?832ZEU_3J9Z?
M25IS3SNEZ=]VG7-;]^_2MCDA:V&57++"B12J]KFO62--QZO:Y5<URN:N\CE5
M47**JKJ:U\CIGNE>D37RN=(Y((TA@1SU5SDAB17)%$BJJ1QHYR,9NM151,F8
MS(Q& , 8 P!@# & , 8 P!@&J6N^4>ALC)%XN=4ID<T38"AG[78A%=9+&9*5
MJC"1CI>9#1/)R$H6IB!%4[*=2A>VVE:3O>@/:U=::_:Y-$8MM9>O$,6V<ETU
MH\*<M<4*ZZEEHQ)KJ)>R[ MUY:&FR#L-,1;JTMI>VI6M; YP<]_CAO)77_R%
M/''_ +NN]D__ +R<U\$^;B_THG>OHB?<ZBY2# & , 8 P!@# & , 8 P!@#
M& , 8 P".NKV.W5"B'[13!-?-%*_ EFI(^R%2 > Z)%PI,XC\F6-%EW]S_DQ
M])B,+BH8=6K>G9#.M:WO6W>IK*.WU%50P4]1/3QOF6*JGDIXG11,?))B2*"H
M<DFZW$:+'NN<J(YS4U/3['VRS7K:&VVB^UERH*2Y5,%!%4VNCIJZH965D\5/
M2]I!55=%'^6WY<SR-E=(QJ?HBD5<)\/&;;;[[SNM72Y!J\!FVL4,L0T=7"Q
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MTOMU6/.Z2I26*6T6O#KFT^NMMIW4QQAE+F]Z]-(<=0K?JG>M>BD[WE/LSM+
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M'R;\DY\#I)E(, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M <N^>_QPODK_ #?H*^.'^+G9<G-?!/FXR_I_N^G^3J)E,1@# & , 8 P!@#
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M%/S&(ZW-QGW&Y*%M)>OO_'Q'3O\ NJ?0EO\ 2$[;^"'O?[/_ (]^,O[?YO\
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M6O%P3\"V\[Y780I:-+AK=*A25(%.#YC[K33A"/\ *(2:%3"X\/>F4]2U>"#
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MY$-I$AM*),=3L5YAYP#7K9UGG%%MM HMOMPJO6OJ4LZ/Y^()K>8<M,^LAW;
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MF-%XYT^GKY(5+ _#T^(4<XW0*Q8>C]%#]+#^1?BM?9]HNW4:MU(=2"G,:AT
M1TWL_/A9DN8>=U..6 $0V(*EHY&UO0&""J>"D,R6Y+'>O+IU[L>?=YYN415T
MT5'>N%1%3XZ^6<$O7WQ0\^2-!\5IM2BWECJG..=0J=T6M3O)>PN<E.7@7TZ$
M4-]&LI,3T&I]004NH1B6?C7(79KU.'P)+5&G\U1%:<DO7'O*^/OX<!E-<_),
M\%3N[NG5,+Q_H$1I6D(TKT]VDITKTWO>O7TUZZUO?UWKU_9O?UWKZ[^N#$_6
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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E & , 8 P!@# & , 8 P!@# & , 8 P#_V0$!              $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img131876768_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img131876768_5.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[15H4&AO=&]S:&]P(#,N,  X0DE-! 0
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M>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    * $$ 4 !. "
M+0 @ #0 ,P X       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\
M;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N
M=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT
M   0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O
M;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP
M $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B
M;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P
M  ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+
M   *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=0
M0P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M  H  0         !.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F
M9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    ! "T    &
M       !.$))30/X      !P  #_____________________________ ^@
M    _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@  #A"24T$
M"       $     $   )    "0      X0DE-!!X       0     .$))300:
M      ,U    !@             ":@  !@L          0
M           !              8+   ":@                     !
M                     !     !        ;G5L;     (    &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   ":@    !29VAT;&]N9P  !@L    &
M<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC
M94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T
M   ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T
M   *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   FH     4F=H=&QO;F<   8+     W5R;%1%6%0    !
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M3001       ! 0 X0DE-!!0       0    *.$))300,      K,     0
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M\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                _^%! 6AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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M 0$! 0$! 0'_P  1" #& >\# 1$  A$! Q$!_\0 '@ !  (" P$! 0
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M:_0%V=?RV&D,M^]SGED6XOV-I2GW+7O:UJ]/52M[4K>][WO"K>(\Q]5. +^
MPW]E#O\ *,X465PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81:;O
MB6\VE6OL_C<5#<LNG1;06$] YU6EO\OX'V3D<>:69@VZ4..5?NUEKHJK7F9
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M2:>XCN&\ZODP,_I).5^-W?M-9UINZ<FBVN,VGU>L')[%#F:VG6]^YQRI6]P
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MG.#0RYT[Z>(N.,;M8-^A>"3AI;5'>[M=%L;=I+<QPCKQ56B7(!;=*:2FA!/
M"N ?;GZ\-RK=SX$*9!Y(<6B,D!4^$3@2$^^/-'RF)L1]&_U+9DQG'&74[_\
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M]IJJN&WTD%&?@[A6544L;!%77!WP(C8USZ=C9*N4]DS=.TH/UWE-A3[@/3*
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M?H'P_JMT48W$,],NC<XOR3H?+[]/4Y+,QK-)Z#)YX=E6@"(LYHY H'VJW\T
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M?J#6[L9WOU;W $+5JQY6>8*_*A?,5<80JB)L3X_0S066AW4) !<]*?TD[?\
MPQOTE:T[]Q^1]*M/_4])^=O6\^1LVPVX.V;K.=GQ_*14OC_]VF!$8I#*";J7
M?!',F/ZFYND8C W^/Z\D_@[_  2;_!]NU@V[<-HC;(ZDU?QT#F=NZY"G)&RH
M9_-AF+,?PO:]LTYF+MP+:6#F%2 :!--A]@"TB-IR<&U/C%-CI&]JUN-]PB:3
M%E[3K2=_-9U\O>U>FO7T]<^NP/EDAC?-#\/*YH,D/:-E[-QXL[1@#7X_Y-&"
MOR%<8*2FK:F"@KA<J.*0MIZ[X:6D%5& ,2_"S$S0@G(W'DN&,]Z_FKY)Y#^:
M\&D\M^1*[+:K9X^\>N]M*ZM@2ZF8?:+KV_QEZCWCF86SQFVXA&\?HKDU493$
MCM2USF3).$/6]LZN.O.S7!XDX\M<=VF/KA>4XUS@ GN[@-.[/=[\>X V=NWF
M[WK5ELO2ZK9U0N<M >EUOGH=CB)^PB;4\-ZMR,(%OCT@]>^?0&&1-:M18I.-
M$BD 0BL1YM@9;E06ELO533H^!/+&O+CW<\8H]Y?^<%[XB_9@4(-5I]IX9: ^
MQ0#C]U7>A/6)'C1Y%= 9ME>FRK4K8MX1?^65,,.J$NNE)29]A=&O%USOMB7I
MKW>/GGNY=>ZH ^8[QC&1Z\"3W<//%F>R7_MM,"<DOM N%AZ([Y+\" >/]?F5
MX$:360?D-:=0R_+>YHK"91A%,K#PJQ=$-7^;.FN[9'56FBIA1]Z-&<VZX=_X
MZRIYCAQ^X\^7WT4#Q>W>7Y6_V'@8B=!K 3EO6N><_JMC.@>E'^CQ0U2[!5:-
M7[ETXBLC ']&KW9J!]PZ*27*/U=V>W(:9C.'!BC9(:_;KB$T',^P'#Q!X9^_
M>N\-\R/)I%4'VXB'%4HC:7N9-66UE.3]FZ!5Q997(;38-U\5SFN'YAD7(Z5>
M@@NHB%@OFR1LXTQ =AVVSS!#4JIC4Z'3.F=>/EW#CY$K(>'GDSY3F>M<CXQ<
MQ4+\#N@C*S<R_"[S+Z?:A*Q=VL*.DBK6MJ2+V,%6N&+YN\(-Q(T%AN!)?=L;
M)4K6 LYU]?'R[OV$ >>3H.'$<_7QX>NZ3"B81,(F$3")A$PB81,(F$3")A$P
MB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A$PB81,(F$3")A$PB81,(F$3>]:_/>_37\^\(L7HV'V857M%1^SR!R3"@V
MI;&R:12I.X:22H7O^HU"5+2J,F3MO3.WT[:TO:];UG5V\)F-,)8_B!$)C!OM
M[40EVX)3'G>$9>"T/QNEPQG*Z?B(.W-+VT7Q(B[<P;[>V$)?V8E,>=_LR_\
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M$8EAE;NR,)(#AD$#+2'#! .A&H714TT%9!)35,8F@F;NR1N+@'M!#L$M(=Q
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M")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$7_]D!
'          $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img131876768_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img131876768_6.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0+R17AI9@  34T *@    @ ! $[  (
M   -   !2H=I  0    !   !6)R=  $    :   "T.H<  <   $,    /@
M   <Z@    $
M
M
M
M
M
M1G)A;FL@0V]N=V%Y    !9 #  (    4   "II $  (    4   "NI*1  (
M   #-3<  )*2  (    #-3<  .H<  <   $,   !F@     <Z@    $
M
M
M
M
M
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MH=**=F@CC:\DI*H[>K,;_A#?#'_0N:3_ . ,7_Q-'_"&^&/^A<TG_P  8O\
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MA<TG_P  8O\ XFC_ (0WPQ_T+FD_^ ,7_P 36S11[.'8/K>(_P"?DOO9C?\
M"&^&/^A<TG_P!B_^)H_X0WPQ_P!"YI/_ ( Q?_$ULUG:QK5OHL,<MTDKK(VT
M>6 3G'N135*,G91)GCJ\(\TJC2]65_\ A#?#'_0N:3_X Q?_ !-'_"&^&/\
MH7-)_P# &+_XFK>D:O!K-HUQ:I(B*Y0B0 '. >Q/K6=)XQT^/4FLFAN?,64Q
M$A5VYSC^]TJEA[MI1,WF52,5)U79[:LF_P"$-\,?]"YI/_@#%_\ $T?\(;X8
M_P"A<TG_ , 8O_B:V:*CV<.QM];Q'_/R7WLQO^$-\,?]"YI/_@#%_P#$T?\
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M;-%'LX=@^MXC_GY+[V8W_"&^&/\ H7-)_P# &+_XFC_A#?#'_0N:3_X Q?\
MQ-;-%'LX=@^MXC_GY+[V8W_"&^&/^A<TG_P!B_\ B:/^$-\,?]"YI/\ X Q?
M_$ULUB:GXKL=)OFM;B*X:10"3&JD<_4BJC14G91,ZF/K4US3JM+U8[_A#?#'
M_0N:3_X Q?\ Q-'_  AOAC_H7-)_\ 8O_B:U;>9;FVBG0$+(@< ]<$9J2I]G
M#L:+&8AJZJ/[V8W_  AOAC_H7-)_\ 8O_B:/^$-\,?\ 0N:3_P" ,7_Q-;-%
M'LX=@^MXC_GY+[V8W_"&^&/^A<TG_P  8O\ XFC_ (0WPQ_T+FD_^ ,7_P 3
M6M--';PM+.ZQQH,LS' %+%(DT*2Q'<CJ&4^H/2CV<>POKF(O;VC^]F1_PAOA
MC_H7-)_\ 8O_ (FC_A#?#'_0N:3_ . ,7_Q-;-%'LX=A_6\1_P _)?>S&_X0
MWPQ_T+FD_P#@#%_\31_PAOAC_H7-)_\  &+_ .)K9HH]G#L'UO$?\_)?>S&_
MX0WPQ_T+FD_^ ,7_ ,31_P (;X8_Z%S2?_ &+_XFMFBCV<.P?6\1_P _)?>S
M&_X0WPQ_T+FD_P#@#%_\31_PAOAC_H7-)_\  &+_ .)K9HH]G#L'UO$?\_)?
M>S&_X0WPQ_T+FD_^ ,7_ ,31_P (;X8_Z%S2?_ &+_XFMFBCV<.P?6\1_P _
M)?>S&_X0WPQ_T+FD_P#@#%_\31_PAOAC_H7-)_\  &+_ .)K9HH]G#L'UO$?
M\_)?>S&_X0WPQ_T+FD_^ ,7_ ,31_P (;X8_Z%S2?_ &+_XFMFBCV<.P?6\1
M_P _)?>S&_X0WPQ_T+FD_P#@#%_\31_PAOAC_H7-)_\  &+_ .)K9J)[J".Z
MCMGE432@E(\\D#J?TH]G'L)XS$+>H_O9E_\ "&^&/^A<TG_P!B_^)H_X0WPQ
M_P!"YI/_ ( Q?_$U=U34H=)L6NKE9&12 1& 3S]2*@T;7K77/.^R1S)Y.W=Y
MJ@9SG&,$^E5[%<O-RZ$/,*JFJ;JN_JR'_A#?#'_0N:3_ . ,7_Q-'_"&^&/^
MA<TG_P  8O\ XFMFBI]G#L:?6\1_S\E][,;_ (0WPQ_T+FD_^ ,7_P 31_PA
MOAC_ *%S2?\ P!B_^)K9HH]G#L'UO$?\_)?>S&_X0WPQ_P!"YI/_ ( Q?_$T
M?\(;X8_Z%S2?_ &+_P")K9HH]G#L'UO$?\_)?>S&_P"$-\,?]"YI/_@#%_\
M$T?\(;X8_P"A<TG_ , 8O_B:V:*/9P[!];Q'_/R7WLQO^$-\,?\ 0N:3_P"
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M=4^SAV+^N8C_ )^/[V8W_"&^&/\ H7-)_P# &+_XFC_A#?#'_0N:3_X Q?\
MQ-;-%'LX=@^MXC_GY+[V?.WQITRPTKQG:0:796]E$VGHYCMXEC4MYD@SA0.<
M <^U%6?CQ_R/5G_V#4_]&RT5\UBDE6DD?M^12E++*,I.[L>S^#?^1%T'_L&V
M_P#Z*6MFL;P;_P B+H/_ &#;?_T4M;-?2T_@7H?B&+_WBIZO\SD?&^LR6\::
M=;-M,J[I6!YV] /QYJGX:\)P7UDM[J)8I(?W<2G&0#U)K.\9$GQ/.#V5 /\
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MIQ@IR$\3B)UI4J:6G4V=+\2Z=JTGE6[LDO:.48)^G8UK5Y;KFG-H&N>7;2,
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M+249.[.G"1Y\2ZM)6@/U/6K+2(PUY+AF^[&HRS?A67#XYTF60*PN(@3C<Z#
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M&;=C=G^[UKK[J)I[.:),!I(V4$],D8IUYQDXV88&E4IPFI*USSGP=_R-%O\
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M5-LFO"NZL,1&-[+5?UZD_CV^@D2VM(Y%>5'+.JG.WMS^M7O 7_(!F_Z^6_\
M05K/;P%,M@0ES&]V7'+9"*O.>Q)/2M_PSI$^BZ;);W3QN[3%P8R2,8 [@>E$
MY05'DB[CHTZTL7[6I&UT<%;L-*\3H;D$"WN?G^@/6O2+S5;2TTUKQIXVCVDH
M0P.\]@/6LKQ!X4CU>7[3;2"&YQAMP^5_KZ&L>T\ W)G7[==0K$#R(<DG\P,5
M4I4JJ4I.UB*4,3A92A"-T]F8WAG_ )&6R_ZZ?T->@^(-/_M/0[B!1F0+OC_W
MAS^O3\:Y_2_!]]8:W#=O+;&&.0MM5F+8Y]J[*HKU$YJ46:X'#RC1E3J*U_\
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M11169TA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW%8W&IZC=W,K2ZJJC:).2(S]Y@3WS@'_ .O2?$K3?[8^)VE:<7\LW-FD8?\
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M5VDDG!!8="3@@]Z],HH XVRLO%U[X0UF#Q&UO+=75K+';01!0P)1A@L/EY)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /G_P"/'_(]6?\ V#4_
M]&RT4?'C_D>K/_L&I_Z-EHKY?%_QY'[MD'_(KH?X3V?P;_R(N@_]@VW_ /12
MULUC>#?^1%T'_L&V_P#Z*6MFOI:?P+T/Q+%_[Q4]7^844459S!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% 'S_ /'C_D>K/_L&I_Z-EHH^/'_(]6?_
M &#4_P#1LM%?+XO^/(_=L@_Y%=#_  GL_@W_ )$70?\ L&V__HI:V:QO!O\
MR(N@_P#8-M__ $4M;-?2T_@7H?B6+_WBIZO\PHHHJSF"BBB@ HHHH **** "
MBN&U#XLZ%INI75C/::BTMM,\+E(T*DJ2#C+].*K_ /"YO#W_ #YZG_WZC_\
MBZZ5A:[5U$YWBJ*=G(]!HKS[_A<WA[_GSU/_ +]1_P#Q='_"YO#W_/GJ?_?J
M/_XNCZI7_E8OK5#^8]!HKS[_ (7-X>_Y\]3_ ._4?_Q='_"YO#W_ #YZG_WZ
MC_\ BZ/JE?\ E8?6J'\QZ#17GW_"YO#W_/GJ?_?J/_XNC_A<WA[_ )\]3_[]
M1_\ Q='U2O\ RL/K5#^8]!HKS[_A<WA[_GSU/_OU'_\ %T?\+F\/?\^>I_\
M?J/_ .+H^J5_Y6'UJA_,>@T5Y]_PN;P]_P ^>I_]^H__ (NC_A<WA[_GSU/_
M +]1_P#Q='U2O_*P^M4/YCT&BO/O^%S>'O\ GSU/_OU'_P#%T?\ "YO#W_/G
MJ?\ WZC_ /BZ/JE?^5A]:H?S'H-%>??\+F\/?\^>I_\ ?J/_ .+H_P"%S>'O
M^?/4_P#OU'_\71]4K_RL/K5#^8]!HKS[_A<WA[_GSU/_ +]1_P#Q='_"YO#W
M_/GJ?_?J/_XNCZI7_E8?6J'\QZ#17GW_  N;P]_SYZG_ -^H_P#XNC_A<WA[
M_GSU/_OU'_\ %T?5*_\ *P^M4/YCT&BO/O\ A<WA[_GSU/\ []1__%T?\+F\
M/?\ /GJ?_?J/_P"+H^J5_P"5A]:H?S'H-%>??\+F\/?\^>I_]^H__BZ/^%S>
M'O\ GSU/_OU'_P#%T?5*_P#*P^M4/YCT&BO/O^%S>'O^?/4_^_4?_P 71_PN
M;P]_SYZG_P!^H_\ XNCZI7_E8?6J'\QZ#17GW_"YO#W_ #YZG_WZC_\ BZ/^
M%S>'O^?/4_\ OU'_ /%T?5*_\K#ZU0_F/0:*\^_X7-X>_P"?/4_^_4?_ ,71
M_P +F\/?\^>I_P#?J/\ ^+H^J5_Y6'UJA_,>@T5Y]_PN;P]_SYZG_P!^H_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /G
M_P"/'_(]6?\ V#4_]&RT4?'C_D>K/_L&I_Z-EHKY?%_QY'[MD'_(KH?X3V?P
M;_R(N@_]@VW_ /12ULUC>#?^1%T'_L&V_P#Z*6MFOI:?P+T/Q+%_[Q4]7^84
M4459S!1110 4444 %%%% 'S/XJ_Y'+6O^O\ G_\ 1C5DUK>*O^1RUK_K_G_]
M&-637U]/X%Z'R=3XV%%%%60%%%% !1110 4444 %%%% !1110 4444 %%%%
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M>60< ' !XX^N;_P^EN-)^*4=CX5\/>*-+\)WUFYGMM7LIHX;2X7)5HV<G:&
MQC/4_3 ![763XJUP>&?"6J:V8/M/]GVLEQY.[;YFU2<9P<9]<5Y!\-_ASHOC
M&#Q5=>*XYM0MU\17L5M9M<.D,/S LX52/G).,G. HQBLZWM$U/X(?$70]9>7
M4;?POJE]%ILES(S/$(E_=\YYQDXSZX["@#W'PMJTNO>#]&UBXC2*74+""Z=$
MSM5I(U8@9[ FM6O"YO"-U8_L\^'?^$&TRX8WHL+_ %JUL)V2:^B,*F8*V<AF
M.WA>V>.U5/!UU\/XO'^C#PO)J_@751(4N-'U&"55U$$8"'<Y4-GH<Y)[$XH
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MOQ=X;NG$&F:E'_PD%DQR%7/RW _ @''HM7?@U:RZAI>L>-KZ,I=^*+Y[E X
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MD/A&>VMM3ED1$N+E-Z0H6&]]O<A<X'<XKBL?%[PI.#G3?'UHXY7$>FW,9_\
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M:)[91117RQ],%%%% !5>=BMW;^A+ _E5BJEW_P ?5K_O'^5 %NBBB@ HHHH
M**** ,[7?$.D^&=+?4=?U""PM$.#+,V,GT ZD^PYK(\-_$GPCXNOC9:!K45Q
M=A=XMY(WAD9>N5615+#W -<CXUBAO_VA/ MEK"A]/2UNI[6*091[D#N#QD *
M1[XH^-\4-O/X,U.R55UV/Q#;0V;H/WCHV=Z>I4\9'3\Z .<\3>.=+\2_&4Z'
M<^,-<T?1;.S$2II*W$#RWIE*%694)*@=_N\#!ZY]X5=J!02<#&2<DUYS9?\
M)S&J?]BS#_Z4&O1Z .$?XU_#V.QMKP^(XS#<J7C*VTS,%#%"64)E!N4\L!GK
MTKKH=:TRXT1=8AO[=]-:+SA=B4>7L_O;NF*\X_9WTJRA^!^FRK;1%M0>X>Y)
M0?O2)GC&[U^50.:\R1V3]FC3K*1VCTIO%(MKW!XCM?.8GGTW;?SH ]LT_P",
M'@+4]4CT^S\1VYGE?RXC)')''(V<861E",<\<&M;Q#XX\.>%+JWM_$6J1V$E
MQ%)+%YB-AE3&[Y@" >0 "<DG S6'\6-*T8_!?7K>[MK>.TM-/=[50@"Q2*O[
MK;Z?-M QZXK@?*FUKQY\$VU]#+</I<UQ+Y@Y:1+975CGON4'Z^E 'IL/Q0\'
M36-G>?VTD5M>O,D$L\$L2DPIOD!+J-N%_O8ST&34.F_%OP+JR7;6GB.V46<7
MG3?:$>#"9 W#S%7<,D#C/4>M8'Q0T^VU/XF?#:VO8EEA;4;F1D=00Q2)6&1W
MY455\?Z=9W_[0OPX2\MXY5,=ZY#H#DQQ%TS]&&1[T =MX9^(GA7QC>SV?AW5
MTNKJW7?) T4D3A>/F"NJDCD<CCD56U_XJ>"_#.I2:?K&NQQW<(S+###).T7?
MYA&K;?QQ7.>(46/]ICPA)&H1YM*NTD91@NH!(!]0#S5#POXBU*\GUB;X4^!K
M8:;<:A*UQJNIZD8_M=P#AV"89\?B!R> <T =/XM\5V6L?!KQ#KGA+5Q,B:?.
M8;NSE*M&ZIGJ,%6'![$<5L^ ;F>\^&WAJZO)I)[B;2;62665RSR,85)9B>22
M3DDUXGX::X7X7_&.&Z^QK*EW=F1+'=Y"R&,A_+W<[<CCZ5[1\./^26>%/^P+
M9_\ HA* /.?BYX^LHO'?A_PJ?$FI:+9++,^M3:;%,DR 1*\*HZH2P;<0=F<9
MYQBNOB^(_@GPOI\>F7OB2XDDM+>!BUXDTUQ*LJ[HV/R;G8KR< D=\51\;?\
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M^QC\P>PQ6O\ $+2KS3_B1\-_#OA^+37M[*VF^PV^K,ZVSRQH "VP$E@ "/\
M:QZT >E^&OB3X2\77K6>@:S'<7:KO^SR120R,OJ%D52P]P#7/^%-5OY_CO\
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MZUN<31['CDC]-R. P'!YQ6?JWQ6\$:'K;Z1JGB""&]C(65%C=UA/H[JI5/\
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MN;>0QS6TG]Y''(/Z<#TK(T3X6Z1I6O6^MZAJ6L>(-2M%*VMQK-YYYM@>NP
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M\DUZ%10!X]X-^$.B:O\ #GP\T^J:[#I][IMM<76DP:BRVD\C1*SEDQD;F))
M(&:]"UWP1X?\1>&(O#^HZ>G]GP!/LZ0_NVMR@PIC(Y4@<<=N.E;]% '!V'PC
MT:#6++4=7U;7?$,FGN'LXM8OO/C@8=&"A0"1ZG)X%=#%X5LH?',_BI9;@WT]
MBMBT99?*$:OO! QG=D^N/:MNB@#!D\'V$GQ"C\8M-<_VA'IW]G"(,OE>7YA?
M.-N=V3USC':N?O\ X0:'<ZG>W>GZGKFBQ:BYDOK/2[\PP73'[Q9<'&>AVD=3
M7:W^HV6E6ANM4O+>RMPP4S7$JQH"3@#+$#)) %6: .*L?A7H&F^ =5\'V4M[
M'I>IRR228D4R1;\95#MP -H R"?4FM2X\%:=<Z]X:U9YKH3^&XYH[10Z[9!+
M$(V\P;<DX48P1SZ]*Z&B@#!UWPA8>(=>T/5KV:Y2?0YWGMEB90KLP (<%22.
M.Q%>7^-+WPI!\2;^;Q7<ZYX&U!42.#6=,N76/5H=O1B(V7*],'G@<\"O;J*
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M)YS,4D,8"G"Y+$# XZ]>]9D_Q3U[2;!-9\3^ +[2_#[%2]ZM]'-+ C$!7D@
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M'_$)_$.L:MHFN:)/H&LZ2B2W-M+,LR&-AD,DB\,/P[CWQQNI^+=7U[XE^(-
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M(>)&>7YB3TX&,C\* .LA^+,EUX!\0ZY;^&[A-4\.2M%?Z3<7 0H5P7(D"L"
MNXYQSM/L:Z'5O'.G:9\,Y?&B_OK);%;N)-^WS"P&Q,\X)9@O3@FO-_@/]CU+
M5OB L5S=ZG8W%Y$JW&H,6ENHRCC>Q('WAST'!%<]HMO>W^KZ7\'+L226^B:Y
M-=W;L<A]/BQ+"&]G:0#VP* /H'1+VYU+0;&^OK/[#<W-NDLEKYF_R690=A;
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MJ6(_E_%'E%%>K_\ "D?^I@_\DO\ [91_PI'_ *F#_P DO_ME'U[#_P WX/\
MR#ZEB/Y?Q1Y117J__"D?^I@_\DO_ +91_P *1_ZF#_R2_P#ME'U[#_S?@_\
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M3Y';4445X![H4444 %5+O_CZMO\ >/\ *K=5;K_CZMOJW\J +5%%% !1110
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ME#!7$G'SC!(^;/!-/?2=.ET@:5+86KZ<(A"+-H5,/E@8";,8V@ #&,<5;HH
MJ7&DZ==Z4=,NK"UGT\H(S:20JT6T8PNPC&!@8&.U<?X@\*W>H?%3PIJ,.G12
MZ-I]E>6]UDILC\Q%5%V$Y(.,< @5T&E^*['5_%FO>'K:*X6[T+[/]I>15$;^
M<A==A!). .<@<^M;= %#2M"TC0HGCT32K+3HY#N=;.W2(,?4A0,TY-%TN)KU
MH]-LT;4/^/PK H-SQC]YQ\_!(YSP:NT4 4?[#TG[/90?V79>3I[*]G']G3;;
M,HPIC&,(0. 1C%27^EV&J+"NIV-M>+;S+/"+B%9!'(N=KKD'##)P1R,U:HH
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M /12ULU]+3^!>A^)8O\ WBIZO\PHHHJSF"BBB@ HHHH **** "BBB@ HHHH
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M+ 8'7J/0G<^#=A>:7\(- L]3M)[.ZBA<207$9C=#YC'E3@C@T <I-\7-5F^
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MGVD+<3$Q.CC^)6!YX(]CFM"[-CJEO!8^%/@?;V^L2R*LLFMZ#%#9VRY^9C(
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5!-_Q^6__ OY5/4$O_'Y!]&_E0!/
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 ?/_P >/^1ZL_\ L&I_Z-EHH^/'_(]6?_8-3_T;
M+17R^+_CR/W;(/\ D5T/\)[/X-_Y$70?^P;;_P#HI:V:QO!O_(BZ#_V#;?\
M]%+6S7TM/X%Z'XEB_P#>*GJ_S"BBBK.8**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHKAM0\:ZC::E=6\<-J4AF=%+(V2
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M5BLFG.(8MK222?[J("Q'/4"I/#7B_0/%]F]SX;U.&^CC;;($RKQGT9& 9?Q
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M,+RS.L<:*6=W. H'4D]A7%0?&7X?W&I"QB\36WF,_EB1HY%A+>@F*B,_]]4
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7DFL_\
M(>O_ /KYD_\ 0C7K=>2:S_R'K_\ Z^9/_0C7;A/B9XV;?!'U*5%%%>B?/A11
M10 4444 %%%% !1110 4444 >@^ O^0#-_U\M_Z"M=/7,> O^0#-_P!?+?\
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MH!TK4%Z!IU&;>3W;DI]* /2:*** "BBB@ HHHH **** "BBB@ HHHH ****
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MHH **** "BBB@ HHHH **** "HV_X^$_W6_I4E1M_P ?$?\ NM_2@"2BBB@
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M2M(HQDCY0/0GIW]"G@ANH'@N8DFBD&'CD4,K#T(/6@#PO6]+\%SZQH&F7'Q
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MQ4]7^844459S!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "HW_P"/F/\ W6_I4E1/_P ?47^ZW]* ):*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !7#_%WQKJ/@'X?S:YH\-K-=1SQQA+I&9,,<'A64Y_&NXKR7]I7_ )(S<_\
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M@_\ 8-M__12ULU]+3^!>A^)8O_>*GJ_S"BBBK.8**** "BBB@ HHHH ****
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MB@#R_3O _C;P-<W]K\/M0T6?1+R=KB*RUE90UD[<L$:,'<N>QQ^>2;5Q\/\
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M&93/9AXW$:[5.2-AX) Y'-='X]\)WOBA?# TV2WB&D>(+34YA,S+NBBW;E7
M/S?,, X'N*ZZB@#@-:\'^(HOBU:^,_#$^F.LFG#3;ZVU R*1%YH<O&4!^;@#
M!XX]^-/PCX6O= \2>*]0O);=XM9U!;JW6)F+*H0+AL@8.1VS7644 <9X4\'W
M^A?$3QGK]W-;/:Z]):-;)$S%T$2,K;P5 '+#&"?PJ;XI>%+[QO\ #75/#VE2
MV\-W>>3Y;W+,L8V3(YR5!/13VZUUM% 'G'B7P)XB/C;1_%_A"[TO^U+'3O[.
MFM=45_(DCR3N5D&Y6RQ[<\>X-*3P!XTU7XB>&O%OB'5])F?2I9 ^GVB21Q0Q
M.A&8V(9G<DC.[:.!C%>J44 <!'X.\0:5\7M3\3:/-I<^E:[';IJ,%V9%FB\I
M-@,6T%6R!GYL5FZ5X'\<^ UNM,\ ZCHESH4LSS6UMK*S"2R+<E5:/.]<Y.#C
MZ]2?4:* .<\$^'M5\/:++'XAUZYUS4KJ=KB>>5CLC+?P1*?N(.P^O08 B\?^
M"H_''A^.S6\:POK.Y2\L+U$#&"=/NM@]1R<C_"NHHH \LUCP7\0_'&G1Z%XT
MU?0K31#(C7C:1'*9[Q58$*=^%C!(!.,\^W%=(_A"Z7XL:?XDMVMH]-M-%?3O
M)W-Y@8R!A@8QMP,=<^U=?10!QNK^$+^_^+GA_P 4PS6RV.F6=Q!-&[-YK-("
M 5&W!'KDBLQ="^)N@WU]%X>UO1M7TVYG::!M>:?S[3=_ "F0ZCMG%>BT4 >7
M6OP6MQ\,;KPW>:HW]I76H-JQU&WB""&\.,,B=E  &..,XQVDNO#OQ6UNPBTC
M5/$FBZ;9[E$^IZ2LRWLR @\ X6,G')!_3BO3:* . \;>"M=O_$OA?Q'X1N[$
MZCH"SQB+5FD,<Z2Q["2Z MN SVY)]N>\B\PPIYX42[1O"'*@]\9[4^B@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** /G_X\?\CU9_\ 8-3_ -&R
MT4?'C_D>K/\ [!J?^C9:*^7Q?\>1^[9!_P BNA_A/9_!O_(BZ#_V#;?_ -%+
M6S6-X-_Y$70?^P;;_P#HI:V:^EI_ O0_$L7_ +Q4]7^844459S!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>2:S_R'K__
M *^9/_0C7K=>2:S_ ,AZ_P#^OF3_ -"-=N$^)GC9M\$?4I4445Z)\^%%%% !
M1110 4444 %%%% !1110!Z#X"_Y ,W_7RW_H*UT]<QX"_P"0#-_U\M_Z"M=/
M7CUOXC/KL'_N\/0*S]?_ .1:U/\ Z])?_0#6A6?K_P#R+6I_]>DO_H!J*?QH
MZ)_"SPZBBBOJSY@**** "BBB@ HHHH **** "BBB@ KW'0/^1:TS_KTB_P#0
M!7AU>XZ!_P BUIG_ %Z1?^@"O+S'X(GI9?\ '(T****\4]@**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ JM<_\ 'Y;?5OY59JK<_P#'W:_[S?RH
M M4444 %%%% !1110!R7Q)\47'ACPJ/[*VG6-4N8].TQ6&0;B4X5C[*,M^&.
M]7S>:;X%\'V[>(=:*V]G$L<M_J$Y9YGQR26)+,3DX'T'2N-^)67^+7PQBE_X
M]3?7;L#T\Q8E\O\ 4FK_ ,4=6TFQO/#=I=>')/$FMW%ZTNCV"S^2GFQ@$R,Q
M.T!0PZ@]>G4T :.B?%?P3XBU>/2]*UV-[V7_ %4,T$L!E_W?,5=W0],UYQXU
M\>Z9K7QDC\/7/BW6M&T.PL7$_P#9*7$,LE\)C&8RRH6*A<'</EXZ\U7^)M]X
MPN-2\$W7BC2=&TE4\1VGV9;:Z:>YW9R?FVA0G S[[:[;_FZ;_N3/_;V@#(\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 ?/_QX_P"1ZL_^P:G_ *-EHH^/'_(]6?\
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M'0/^1:TS_KTB_P#0!7EYC\$3TLO^.1H4445XI[ 4444 %%%% !1110 4444
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MT=2K*PR"#U%>>6WP5T*SC>SM=:\1PZ-([,=&CU-DM,,<E< !MIR>-W->BT4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% 'S_ /'C_D>K/_L&I_Z-EHH^/'_(]6?_ &#4_P#1LM%?+XO^/(_=L@_Y
M%=#_  GL_@W_ )$70?\ L&V__HI:V:QO!O\ R(N@_P#8-M__ $4M;-?2T_@7
MH?B6+_WBIZO\PHHHJSF"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *\DUG_ )#U_P#]?,G_ *$:];KR36?^0]?_ /7S)_Z$
M:[<)\3/&S;X(^I2HHHKT3Y\**** "BBB@ HHHH **** "BBB@#T'P%_R 9O^
MOEO_ $%:Z>N8\!?\@&;_ *^6_P#05KIZ\>M_$9]=@_\ =X>@5GZ__P BUJ?_
M %Z2_P#H!K0K/U__ )%K4_\ KTE_] -13^-'1/X6>'4445]6?,!1110 4444
M %%%% !1110 4444 %>XZ!_R+6F?]>D7_H KPZO<= _Y%K3/^O2+_P! %>7F
M/P1/2R_XY&A1117BGL!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %5+S_CZMO\ >/\ *K=4[S_CYMO]X_RH N4444 %%%% !1110 4444 %%%%
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MB@ HKCXOB1IUWXUG\-:7I6L:C+:SK!=WMK:AK6U<C.'<L,8[X!KL* "BBB@
MHHHH **** "BBB@#Y_\ CQ_R/5G_ -@U/_1LM%'QX_Y'JS_[!J?^C9:*^7Q?
M\>1^[9!_R*Z'^$]G\&_\B+H/_8-M_P#T4M;-8W@W_D1=!_[!MO\ ^BEK9KZ6
MG\"]#\2Q?^\5/5_F%%%%6<P4444 %%%% !1110 4444 %%%% !1110 4444
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M'+=,*,=N0>/0/"&FWUM\9_B+?7-G<0VEY_9GV:XDB98Y]ENP;8Q&&P>#CH:
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M=V>,=<UQ;^%?$-GX,^&OB;2-*FN-6\+VH6ZTM_W4TD,D0610&Z. .A]3UZ4
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MYS<LZ;B"I)R2.1DGVQN^"_!=KX-L;M8[NXU"_P!0N#<WU_=$>9<2'N0.  .
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ME]'+%#+(F6$L:R$D] ,X'?'4UE:A:Z)INM:V?C-X8\03W<U[,]MX@A:62"*
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M1MX*@#D<8)_"@"3XK^);OPA\+=;UK33MN[>%4A? .QY)%C#8/'&_/X5S-O\
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MO#WC>Z\70ZYXTUVUA@M8FC@T?17E%L[-_'*7P7/H".#T[Y /,=-_Y(1\6?\
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M4-<USQ#/:3:SKMQ'+<"S5O*B2--D<:EN6P,_,0,YZ4 =;1110 4444 %%%%
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M_%CPO>_#*))#:^=_:]]8P-%;_9BGRQ2-@*[%L;5Y(QGBO8Z* ..\23Z=X_\
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M87>V<C'Y5U] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS ) [!B1VK:\1?#[3O$/B2PU]=0U/2M4L8O(6YTV<1F2+=N\MP58%<Y...M
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M?_T4M;-8W@W_ )$70?\ L&V__HI:V:^EI_ O0_$L7_O%3U?YA1115G,%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Q_B/\
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M4\E<*VXDY ZY)/!K8^+NEZGM\.^*=%L9=1G\-ZB+J:TA&9)8&&)-@[M@#]:
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M_P#Z.6JWQ*T>R^']YH_C_P -6$&GKIMVD&KQV<0C6XLY#L8LJC#,I(P??V%
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M5/5_F%%%%6<P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% ''^(_^2F^"_P#M^_\ 1(KL*Y;Q7H>M7^M:+JWAZ2P6YTPS_)?%
M]C"10O\  ,\ 'TJ#_BY/_4J_^3-=DH*I3A:25E;7U;_4XHS=.I.\6[N^B\DO
MT.PK.OM)>]N-XU"[MXF WQ0/MRP^ZP/48[@<' SQD' _XN3_ -2K_P"3-'_%
MR?\ J5?_ "9K)X=/>2^\WABY0=XQ?W&O_8$[_P"NUJ_;?\TVQPNYQ]TK@?(!
M_='!P,Y^;<?V!._^NUJ_;?\ --L<+N<?=*X'R ?W1P<#.?FW9'_%R?\ J5?_
M "9H_P"+D_\ 4J_^3-3]4C_,OO-O[2J_RO\ \!7]?\,NR-?^P)W_ -=K5^V_
MYIMCA=SC[I7 ^0#^Z.#@9S\VX_L"=_\ 7:U?MO\ FFV.%W./NE<#Y /[HX.!
MG/S;LC_BY/\ U*O_ ),T?\7)_P"I5_\ )FCZI'^9?>']I5?Y7_X"OZ_X9=D:
M_P#8$[_Z[6K]M_S3;'"[G'W2N!\@']T<' SGYMQ_8$[_ .NUJ_;?\TVQPNYQ
M]TK@?(!_='!P,Y^;=D?\7)_ZE7_R9H_XN3_U*O\ Y,T?5(_S+[P_M*K_ "O_
M ,!7]?\ #+LC7_L"=_\ 7:U?MO\ FFV.%W./NE<#Y /[HX.!G/S;J=GX*MK&
M1GMKVXMVE7]_]FVQ!V#%E*A1\@#,3M'!/7.6W5/^+D_]2K_Y,T?\7)_ZE7_R
M9H^J1_F7WA_:57^5_P#@*_K_ (9=D:_]@3O_ *[6K]M_S3;'"[G'W2N!\@']
MT<' SGYMQ_8$[_Z[6K]M_P TVQPNYQ]TK@?(!_='!P,Y^;=D?\7)_P"I5_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 ?/_QX_P"1ZL_^P:G_ *-EHH^/'_(]6?\ V#4_]&RT5\OB_P"/(_=L
M@_Y%=#_">S^#?^1%T'_L&V__ **6MFODF'Q7XBMH(X+?7]4BBC4(D:7DBJB@
M8  !X ':G_\ "9>)_P#H8]6_\#I?_BJ]F&)M%*Q^:8C).:M.7M-V^GGZGUG1
M7R9_PF7B?_H8]6_\#I?_ (JC_A,O$_\ T,>K?^!TO_Q57]:\C#^PO^GGX?\
M!/K.BODS_A,O$_\ T,>K?^!TO_Q5'_"9>)_^ACU;_P #I?\ XJCZUY!_87_3
MS\/^"?6=%?)G_"9>)_\ H8]6_P# Z7_XJC_A,O$__0QZM_X'2_\ Q5'UKR#^
MPO\ IY^'_!/K.BODS_A,O$__ $,>K?\ @=+_ /%4?\)EXG_Z&/5O_ Z7_P"*
MH^M>0?V%_P!//P_X)]9T5\F?\)EXG_Z&/5O_  .E_P#BJ/\ A,O$_P#T,>K?
M^!TO_P 51]:\@_L+_IY^'_!/K.BODS_A,O$__0QZM_X'2_\ Q5'_  F7B?\
MZ&/5O_ Z7_XJCZUY!_87_3S\/^"?6=%?)G_"9>)_^ACU;_P.E_\ BJ/^$R\3
M_P#0QZM_X'2__%4?6O(/["_Z>?A_P3ZSHKY,_P"$R\3_ /0QZM_X'2__ !5'
M_"9>)_\ H8]6_P# Z7_XJCZUY!_87_3S\/\ @GUG17R9_P )EXG_ .ACU;_P
M.E_^*H_X3+Q/_P!#'JW_ ('2_P#Q5'UKR#^PO^GGX?\ !/K.BODS_A,O$_\
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M6O(/["_Z>?A_P3ZSHKY,_P"$R\3_ /0QZM_X'2__ !5'_"9>)_\ H8]6_P#
MZ7_XJCZUY!_87_3S\/\ @GUG17R9_P )EXG_ .ACU;_P.E_^*H_X3+Q/_P!#
M'JW_ ('2_P#Q5'UKR#^PO^GGX?\ !/K.BODS_A,O$_\ T,>K?^!TO_Q5'_"9
M>)_^ACU;_P #I?\ XJCZUY!_87_3S\/^"?6=%?)G_"9>)_\ H8]6_P# Z7_X
MJC_A,O$__0QZM_X'2_\ Q5'UKR#^PO\ IY^'_!/K.BODS_A,O$__ $,>K?\
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MR#^PO^GGX?\ !/K.BODS_A,O$_\ T,>K?^!TO_Q5'_"9>)_^ACU;_P #I?\
MXJCZUY!_87_3S\/^"?6=%?)G_"9>)_\ H8]6_P# Z7_XJC_A,O$__0QZM_X'
M2_\ Q5'UKR#^PO\ IY^'_!/K.BODS_A,O$__ $,>K?\ @=+_ /%4?\)EXG_Z
M&/5O_ Z7_P"*H^M>0?V%_P!//P_X)]9T5\F?\)EXG_Z&/5O_  .E_P#BJ/\
MA,O$_P#T,>K?^!TO_P 51]:\@_L+_IY^'_!/K.BODS_A,O$__0QZM_X'2_\
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M"?6=%?)G_"9>)_\ H8]6_P# Z7_XJC_A,O$__0QZM_X'2_\ Q5'UKR#^PO\
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M?^!TO_Q5'_"9>)_^ACU;_P #I?\ XJCZUY!_87_3S\/^"?6=%?)G_"9>)_\
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M_P"$R\3_ /0QZM_X'2__ !5'_"9>)_\ H8]6_P# Z7_XJCZUY!_87_3S\/\
M@GUG17R9_P )EXG_ .ACU;_P.E_^*H_X3+Q/_P!#'JW_ ('2_P#Q5'UKR#^P
MO^GGX?\ !/K.BODS_A,O$_\ T,>K?^!TO_Q5'_"9>)_^ACU;_P #I?\ XJCZ
MUY!_87_3S\/^"?6=%?)G_"9>)_\ H8]6_P# Z7_XJC_A,O$__0QZM_X'2_\
MQ5'UKR#^PO\ IY^'_!/K.BODS_A,O$__ $,>K?\ @=+_ /%4?\)EXG_Z&/5O
M_ Z7_P"*H^M>0?V%_P!//P_X)]9T5\F?\)EXG_Z&/5O_  .E_P#BJ/\ A,O$
M_P#T,>K?^!TO_P 51]:\@_L+_IY^'_!/K.BODS_A,O$__0QZM_X'2_\ Q5'_
M  F7B?\ Z&/5O_ Z7_XJCZUY!_87_3S\/^"?6=%?)G_"9>)_^ACU;_P.E_\
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MX'2__%4?6O(/["_Z>?A_P3ZSHKY,_P"$R\3_ /0QZM_X'2__ !5'_"9>)_\
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-GZSD]+V. I4[WLC_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img131876768_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img131876768_7.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ) !*H# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MGPN"/$, /4!__0344X2C"5S:O6A5K4W!WU_R+OC3_C_MO^N7]:WK#_D5(_\
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MK_6JW@K_ (\;G_KH/Y5FOX#]3IE_OJ]#!,:R^+F1AE6OB"/4;Z[77>=#O/\
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M+Q>![).?G<9^AW'_  K.M[:]\1ZJ97!VL1YD@'RH/0?X5V.KZ6+W1FM(0 R
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6/8CA@AMTV011Q)G.U%"C/X5Y]H__(S0?]=C_6O1:K)I]E'*)4L[=9 <AUB
M(/UQ6E.IRIWZG/7P[J2@UIRL5["SDE\U[2!I,YW&,$_G5BBBL[LZ4DMBO)86
M<TIEEM('D/5VC!)_'%6***+L$DMBO+86<[[YK2"1O5XP3^M2Q0Q0)LBC2-?[
MJ* *?11=@HI.Z05#/:6USM^T6\4NWIYB!L?G4U%*]@:3T9'#!%;Q^7#$D:9S
MM10!^E2444#2ML036-I<OOGM897QC<\88X_&I8XXX8Q'$BHB]%48 _"G44[L
M2BD[V*K:98.VYK*V8^IB4_TJ>.*.%-D4:HO]U1@4^BB[8E&*U2"JTFGV4KEY
M+.W=SR6:)2?Y59HH3:V&TGN-CCCB0)&BHHZ*HP*<0""",@]1112&5?[-L-V[
M[%;;O7RES_*K( 4    < "EHIMM[B44MD5Y;"SN)#)-:02.?XGC!/YFIP H
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MZ7Y<^/X$0#_OH<_I5#PW9RWVMB\9"(HV,C-CC=V'YUV/]EZ?G/V&VSZ^2O\
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M_H+?^2TO_P 31_PLKPC_ -!;_P EI?\ XFOGVBJ]E$GVC/H+_A97A'_H+?\
MDM+_ /$T?\+*\(_]!;_R6E_^)KY]K;\1>%K[PS]D^VRV\GVI"Z>2S' &.N0/
M6E[*(^=GL_\ PLKPC_T%O_):7_XFC_A97A'_ *"W_DM+_P#$U\^UL^'_  QJ
MGB:Y>'3H5*QC,DLAVHGID_T%#I10<[/:?^%E>$?^@M_Y+2__ !-'_"RO"/\
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M+?\ DM+_ /$T?\+*\(_]!;_R6E_^)KY]HH]E$/:,^@O^%E>$?^@M_P"2TO\
M\31_PLKPC_T%O_):7_XFOGVBCV40]HSZ"_X65X1_Z"W_ )+2_P#Q-'_"RO"/
M_06_\EI?_B:^?:*/91#VC/H+_A97A'_H+?\ DM+_ /$T?\+*\(_]!;_R6E_^
M)KY]HH]E$/:,^@O^%E>$?^@M_P"2TO\ \31_PLKPC_T%O_):7_XFOGVBCV40
M]HSZ"_X65X1_Z"W_ )+2_P#Q-'_"RO"/_06_\EI?_B:^?:*/91#VC/H+_A97
MA'_H+?\ DM+_ /$T?\+*\(_]!;_R6E_^)KY]HH]E$/:,^@O^%E>$?^@M_P"2
MTO\ \31_PLKPC_T%O_):7_XFOGVBCV40]HSZ"_X65X1_Z"W_ )+2_P#Q-'_"
MRO"/_06_\EI?_B:^?:*/91#VC/H+_A97A'_H+?\ DM+_ /$T?\+*\(_]!;_R
M6E_^)KY]HH]E$/:,^@O^%E>$?^@M_P"2TO\ \31_PLKPC_T%O_):7_XFOGVB
MCV40]HSZ"_X65X1_Z"W_ )+2_P#Q-'_"RO"/_06_\EI?_B:^?:*/91#VC/H+
M_A97A'_H+?\ DM+_ /$T?\+*\(_]!;_R6E_^)KY]HH]E$/:,^@O^%E>$?^@M
M_P"2TO\ \31_PLKPC_T%O_):7_XFOGVBCV40]HSZ"_X65X1_Z"W_ )+2_P#Q
M-'_"RO"/_06_\EI?_B:^?:*/91#VC/H+_A97A'_H+?\ DM+_ /$T?\+*\(_]
M!;_R6E_^)KY]HH]E$/:,^@O^%E>$?^@M_P"2TO\ \31_PLKPC_T%O_):7_XF
MOGVBCV40]HSZ"_X65X1_Z"W_ )+2_P#Q-'_"RO"/_06_\EI?_B:^?:*/91#V
MC/H+_A97A'_H+?\ DM+_ /$T?\+*\(_]!;_R6E_^)KY]HH]E$/:,^@O^%E>$
M?^@M_P"2TO\ \31_PLKPC_T%O_):7_XFOGVBCV40]HSZ"_X65X1_Z"W_ )+2
M_P#Q-'_"RO"/_06_\EI?_B:^?:*/91#VC/H+_A97A'_H+?\ DM+_ /$T?\+*
M\(_]!;_R6E_^)KY]HH]E$/:,^@O^%E>$?^@M_P"2TO\ \36KHOB72/$/G_V5
M=_:/(V^9^[=-N[./O 9Z&OFBO5_@M_S'/^V'_M2IG325RHS;=CU:BBBL30*^
M??B5_P E U/_ +9?^BDKZ"KY]^)7_)0-3_[9?^BDK6E\1%38Y2BBBMS$****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT^\>T@@GPR##* 2._+C\C4.I6VF>(OAW/XBATRVTZ^L;@0R+:)LCDR4'W?\
M@8]^#67I?CB73[O51-817>G:E*\LMG(^,%CGAL>G'3L.E1ZUXQ%_HD>B:9ID
M6F::K;WB20R-(>HRQ ^M59W%=6.P\>:AI/A;5;>VL?#FC2R2P>9)YUH" -Q"
MX P.H;/<\4WXL:AML-+M?L=H?M$)?SC%^\CP5.$.> >XKB?&'B?_ (2S5XK_
M .Q_9?+@$.SS=^<,QSG _O?I5WQ!XSA\1:-;6MWI""^MXUC2\$YX&1N^3&.<
M>O%)1:L#EN<E1116A 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P _FI_]_8__ (BO0:*.>7<.5'GW_"GO#_\ S^:G_P!_8_\ XBC_ (4]X?\
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M/_O['_\ $5Z#11SR[ARH\^_X4]X?_P"?S4_^_L?_ ,11_P *>\/_ //YJ?\
MW]C_ /B*]!HHYY=PY4>??\*>\/\ _/YJ?_?V/_XBC_A3WA__ )_-3_[^Q_\
MQ%>@T4<\NX<J//O^%/>'_P#G\U/_ +^Q_P#Q%'_"GO#_ /S^:G_W]C_^(KT&
MBCGEW#E1Y]_PI[P__P _FI_]_8__ (BC_A3WA_\ Y_-3_P"_L?\ \17H-%'/
M+N'*CS[_ (4]X?\ ^?S4_P#O['_\11_PI[P__P _FI_]_8__ (BO0:*.>7<.
M5'GW_"GO#_\ S^:G_P!_8_\ XBC_ (4]X?\ ^?S4_P#O['_\17H-%'/+N'*C
MS[_A3WA__G\U/_O['_\ $4?\*>\/_P#/YJ?_ ']C_P#B*]!HHYY=PY4>??\
M"GO#_P#S^:G_ -_8_P#XBC_A3WA__G\U/_O['_\ $5Z#11SR[ARH\^_X4]X?
M_P"?S4_^_L?_ ,11_P *>\/_ //YJ?\ W]C_ /B*]!HHYY=PY4>??\*>\/\
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M['_\11_PI[P__P _FI_]_8__ (BO0:*.>7<.5'GW_"GO#_\ S^:G_P!_8_\
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M]C_^(KT&BCGEW#E1Y]_PI[P__P _FI_]_8__ (BC_A3WA_\ Y_-3_P"_L?\
M\17H-%'/+N'*CS[_ (4]X?\ ^?S4_P#O['_\11_PI[P__P _FI_]_8__ (BO
M0:*.>7<.5'GW_"GO#_\ S^:G_P!_8_\ XBC_ (4]X?\ ^?S4_P#O['_\17H-
M%'/+N'*CS[_A3WA__G\U/_O['_\ $4?\*>\/_P#/YJ?_ ']C_P#B*]!HHYY=
MPY4>??\ "GO#_P#S^:G_ -_8_P#XBC_A3WA__G\U/_O['_\ $5Z#11SR[ARH
M\^_X4]X?_P"?S4_^_L?_ ,11_P *>\/_ //YJ?\ W]C_ /B*]!HHYY=PY4>?
M?\*>\/\ _/YJ?_?V/_XBC_A3WA__ )_-3_[^Q_\ Q%>@T4<\NX<J//O^%/>'
M_P#G\U/_ +^Q_P#Q%'_"GO#_ /S^:G_W]C_^(KT&BCGEW#E1Y]_PI[P__P _
MFI_]_8__ (BNA\,>#]/\)_:OL$UU)]IV;_/93C;NQC"C^\:Z"BAR;W&HI!11
M14C"H+F21#"D10-(^W+*2 -I/3(]*GJO<?Z^T_ZZG_T!J #9>?\ />#_ +\G
M_P"*HV7G_/>#_OR?_BJY[6O$]UI^IR6L$,)$8&6D!.20#V(]:S_^$SU'_GC:
M_P#?+?\ Q5;*A-JZ..>.HPDXOH=CLO/^>\'_ 'Y/_P 51LO/^>\'_?D__%5Q
MW_"9ZC_SQM?^^6_^*H_X3/4?^>-K_P!\M_\ %4_JTR?[0H>9V.R\_P">\'_?
MD_\ Q5&R\_Y[P?\ ?D__ !5<=_PF>H_\\;7_ +Y;_P"*H_X3/4?^>-K_ -\M
M_P#%4?5IA_:%#S.QV7G_ #W@_P"_)_\ BJ-EY_SW@_[\G_XJN._X3/4?^>-K
M_P!\M_\ %4?\)GJ/_/&U_P"^6_\ BJ/JTP_M"AYG8[+S_GO!_P!^3_\ %4;+
MS_GO!_WY/_Q5<=_PF>H_\\;7_OEO_BJ/^$SU'_GC:_\ ?+?_ !5'U:8?VA0\
MSL=EY_SW@_[\G_XJC9>?\]X/^_)_^*KCO^$SU'_GC:_]\M_\51_PF>H_\\;7
M_OEO_BJ/JTP_M"AYG8[+S_GO!_WY/_Q5&R\_Y[P?]^3_ /%5QW_"9ZC_ ,\;
M7_OEO_BJ/^$SU'_GC:_]\M_\51]6F']H4/,['9>?\]X/^_)_^*HV7G_/>#_O
MR?\ XJN._P"$SU'_ )XVO_?+?_%4?\)GJ/\ SQM?^^6_^*H^K3#^T*'F=CLO
M/^>\'_?D_P#Q5&R\_P">\'_?D_\ Q5<=_P )GJ/_ #QM?^^6_P#BJ/\ A,]1
M_P">-K_WRW_Q5'U:8?VA0\SL=EY_SW@_[\G_ .*HV7G_ #W@_P"_)_\ BJX[
M_A,]1_YXVO\ WRW_ ,51_P )GJ/_ #QM?^^6_P#BJ/JTP_M"AYG8[+S_ )[P
M?]^3_P#%4;+S_GO!_P!^3_\ %5QW_"9ZC_SQM?\ OEO_ (JC_A,]1_YXVO\
MWRW_ ,51]6F']H4/,['9>?\ />#_ +\G_P"*HV7G_/>#_OR?_BJX[_A,]1_Y
MXVO_ 'RW_P 51_PF>H_\\;7_ +Y;_P"*H^K3#^T*'F=CLO/^>\'_ 'Y/_P 5
M1LO/^>\'_?D__%5QW_"9ZC_SQM?^^6_^*H_X3/4?^>-K_P!\M_\ %4?5IA_:
M%#S.QV7G_/>#_OR?_BJ-EY_SW@_[\G_XJN._X3/4?^>-K_WRW_Q5'_"9ZC_S
MQM?^^6_^*H^K3#^T*'F=CLO/^>\'_?D__%4;+S_GO!_WY/\ \57'?\)GJ/\
MSQM?^^6_^*H_X3/4?^>-K_WRW_Q5'U:8?VA0\SL=EY_SW@_[\G_XJC9>?\]X
M/^_)_P#BJX[_ (3/4?\ GC:_]\M_\51_PF>H_P#/&U_[Y;_XJCZM,/[0H>9V
M.R\_Y[P?]^3_ /%4;+S_ )[P?]^3_P#%5QW_  F>H_\ /&U_[Y;_ .*H_P"$
MSU'_ )XVO_?+?_%4?5IA_:%#S.QV7G_/>#_OR?\ XJC9>?\ />#_ +\G_P"*
MKCO^$SU'_GC:_P#?+?\ Q5'_  F>H_\ /&U_[Y;_ .*H^K3#^T*'F=CLO/\
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MW3/5]EY_SW@_[\G_ .*HV7G_ #W@_P"_)_\ BJ\H_P"%JZY_SZ:=_P!^W_\
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MK_OU)_\ %T?V-BNR^\/[+Q'9?>>V;+S_ )[P?]^3_P#%4;+S_GO!_P!^3_\
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M !=']C8KLOO#^R\1V7WGMFR\_P">\'_?D_\ Q5&R\_Y[P?\ ?D__ !5>)_\
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M>N&KN?BK_P C1;?]>2_^AO7#5[^&_@Q/&K_Q&%%%%;F04444 %%%% !1110
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MKR>]D1[B3>R($4X P!VXK;_X0S4?^>UK_P!]-_\ $T?\(9J/_/:U_P"^F_\
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M[Z;_ .)H4Z2V8ITL3-W<68ZZC=H+H++C[5_KOE'S=?;CJ>E5:Z+_ (0S4?\
MGM:_]]-_\31_PAFH_P#/:U_[Z;_XFJ56FNI#PV(>\6<[5ZSUG4+"$Q6URR1Y
MSM*A@/ID<5J?\(9J/_/:U_[Z;_XFC_A#-1_Y[6O_ 'TW_P 30ZE-Z-CCAL1%
MWBFC.34E31KFU_>-<7,H:1VZ%1SUSDG-9U=%_P (9J/_ #VM?^^F_P#B:/\
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MUC4#IT]@URS6T\WGRJP!+/Q\Q8C/8=ZLGQ/K)U&#4/MSBZ@B$*.JJ/D&3M(
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M (.1G:<=Z?I/B?6=#O+B[TV^>":X_P!:0JLK\YY4@C/7G'&3ZUV'_"E_$?\
MS^Z5_P!_9/\ XBC_ (4OXC_Y_=*_[^R?_$4WC,%)6E)/IJ#Q.%:LY)G)6GBO
M7;'6)]6M]2E6^N,^;*0&W^Q4@C [#'':J6J:K?:U?O>ZC<O<7#X!=L#@=@!P
M!["NZ_X4OXC_ .?W2O\ O[)_\11_PI?Q'_S^Z5_W]D_^(IK&8)2YE)7V&L3A
M4^9-7.33Q;KD=QILZ7V)=,C,5HWE)^[4KMQTYX]<T6OBC4H8VMI9C+937BWE
MQ H"&5PP)(<#<N=HZ$8KK/\ A2_B/_G]TK_O[)_\11_PI?Q'_P _NE?]_9/_
M (BI^M8'NA?6,)W1?USXGZ7>Z3J4-HNK237=L;9(KGREBA###$%<L3W^;/X5
MYSI6LW^B3RSZ=/Y,DL30NVQ6RAQD?,#Z"NW_ .%+^(_^?W2O^_LG_P 11_PI
M?Q'_ ,_NE?\ ?V3_ .(K.C6P%&+A&2L^YG2J8.E%QC)69Q$FM:A)HD6C/<9T
M^*;STAV+P^",YQGN>]4*]&_X4OXC_P"?W2O^_LG_ ,11_P *7\1_\_NE?]_9
M/_B*Z%C\)'::-EC,,MI(\YJ]:ZS?V6F7FG6\^RTO-OGQ[%._:<CDC(_ UW'_
M  I?Q'_S^Z5_W]D_^(H_X4OXC_Y_=*_[^R?_ !%$L?A)*SF@>,PST<D<K8>,
M/$&EZ0^E66IRPV;;OW8"DKNZ[6(ROKP1R2>IJ2XU^#_A!K/0+6.59/M3W5V[
M8"NWW4 P>1MQG..0*Z;_ (4OXC_Y_=*_[^R?_$4?\*7\1_\ /[I7_?V3_P"(
MK)XK WOS+>_S\R'B,)>_,M[_ #/.:*]&_P"%+^(_^?W2O^_LG_Q%'_"E_$?_
M #^Z5_W]D_\ B*V_M'"_SHT^NX?^='G-%>C?\*7\1_\ /[I7_?V3_P"(H_X4
MOXC_ .?W2O\ O[)_\11_:.%_G0?7</\ SH\YHKT;_A2_B/\ Y_=*_P"_LG_Q
M%'_"E_$?_/[I7_?V3_XBC^T<+_.@^NX?^='G-%>C?\*7\1_\_NE?]_9/_B*/
M^%+^(_\ G]TK_O[)_P#$4?VCA?YT'UW#_P Z/.:*]&_X4OXC_P"?W2O^_LG_
M ,11_P *7\1_\_NE?]_9/_B*/[1PO\Z#Z[A_YT==\%_^1.N_^P@__HN.N^?_
M )",/_7*3^:5S_@/PO/X3\/-8W,\<T\D[3.8L[5)"K@$@$\*.W>N@?\ Y",/
M_7*3^:5\EC:D:F(G*+NFSYS%3C.M*4=KEBBBBN4YPJO<?Z^T_P"NI_\ 0&JQ
M5>X_U]I_UU/_ * U 'GOC#XC:CH7B*?3+&TM62 +N><,Q8LH;C##'6L'_A;N
MO_\ /GIO_?J3_P"+K+^(_P#R/NI_]LO_ $4E<K0!WW_"W=?_ .?/3?\ OU)_
M\71_PMW7_P#GSTW_ +]2?_%UP-% '??\+=U__GSTW_OU)_\ %T?\+=U__GST
MW_OU)_\ %UP-% '??\+=U_\ Y\]-_P"_4G_Q='_"W=?_ .?/3?\ OU)_\77
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MN)20B;@N< D\D@= : .T_P"%NZ__ ,^>F_\ ?J3_ .+H_P"%NZ__ ,^>F_\
M?J3_ .+K(E^'OBF"%YI-+VQQJ68_:(C@#D_Q5S% '??\+=U__GSTW_OU)_\
M%T?\+=U__GSTW_OU)_\ %UP-3V=G<:A>16EI"TT\K;411R30!V__  MW7_\
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M +]2?_%T?\+=U_\ Y\]-_P"_4G_Q=<#5V\TB^L+*SO+J#RX+Q2T#[U.\#&>
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M]?:?]=3_ .@-0!Q7COQW?>&-3M[&QM;>1GA$S/.&(P6(  !']TURG_"W=?\
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M_P#BZX&B@#OO^%NZ_P#\^>F_]^I/_BZ/^%NZ_P#\^>F_]^I/_BZX&B@#Z/\
M#&L/K_ARSU.2)8GF#;D4Y *L5./RS5]/^0C-_P!<H_YO7/?#C_D0M,_[:_\
MHUZZ%/\ D(S?]<H_YO0!8HHHH *KWO\ J%_ZZQ_^AK5BJ][_ *A?^NL?_H:T
M <5X[\=WWAC4[>QL;6WD9X1,SSAB,%B   1_=-<I_P +=U__ )\]-_[]2?\
MQ='Q=_Y&NU_Z\4_]#DK@: .^_P"%NZ__ ,^>F_\ ?J3_ .+H_P"%NZ__ ,^>
MF_\ ?J3_ .+K@:* .^_X6[K_ /SYZ;_WZD_^+H_X6[K_ /SYZ;_WZD_^+K@:
M* .^_P"%NZ__ ,^>F_\ ?J3_ .+H_P"%NZ__ ,^>F_\ ?J3_ .+K@:* .^_X
M6[K_ /SYZ;_WZD_^+H_X6[K_ /SYZ;_WZD_^+K@:* .^_P"%NZ__ ,^>F_\
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M_P 71_PMW7_^?/3?^_4G_P 77 T4 =]_PMW7_P#GSTW_ +]2?_%T?\+=U_\
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MUS2_#,%MJ>E?9[=&M;7='Y&ERF:$A<AWF&0RYSG.!ZG@UY!6Y=>,?$%[I?\
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MOVFDSI#.DK.R[L1J#@9QW(]*7LIWM8%B:33DI:(\K_X5%K__ #^:;_W]D_\
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M3?\ O[)_\17JYUJV!(V2GW '^-)_;=M_<E_(?XT >4_\*BU__G\TW_O[)_\
M$4?\*BU__G\TW_O[)_\ $5ZW;ZI!<S")%D#'IN _QK/N?%=A:W4MNT=PS1L5
M8JHQD=>IJHQ<MB*E6%-7F['FG_"HM?\ ^?S3?^_LG_Q%'_"HM?\ ^?S3?^_L
MG_Q%>C?\)GIW_/&Z_P"^5_\ BJEMO%EA=745NL=PK2,$4LHQD].AJO93[&2Q
M5%NRD>:?\*BU_P#Y_--_[^R?_$4?\*BU_P#Y_--_[^R?_$5Z[=:A#:2!) Y8
MC/R@5!_;=M_<E_(?XUF=!Y3_ ,*BU_\ Y_--_P"_LG_Q%'_"HM?_ .?S3?\
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M_P#$4?\ "HM?_P"?S3?^_LG_ ,17K]I>Q7@<QAAMQD,*KG6K8$C9*?< ?XT
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MY#_A46O_ //YIO\ W]D_^(H_X5%K_P#S^:;_ -_9/_B*Z_\ X6KH?_/IJ/\
MW[3_ .+K9U?QCIFC6%C>3K<21WJ;X1$@)*X!R<D8^\*'0JII..XU6IM-IGF_
M_"HM?_Y_--_[^R?_ !%'_"HM?_Y_--_[^R?_ !%=?_PM70_^?34?^_:?_%T?
M\+5T/_GTU'_OVG_Q=/ZM6_E)]O3[G(?\*BU__G\TW_O[)_\ $4?\*BU__G\T
MW_O[)_\ $5Z1<>,=,MO#=OKKK<&UN'V(BH-^[GC&<?PGOVK&_P"%JZ'_ ,^F
MH_\ ?M/_ (NE&A4EM$IUJ:W9R'_"HM?_ .?S3?\ O[)_\11_PJ+7_P#G\TW_
M +^R?_$5U_\ PM70_P#GTU'_ +]I_P#%ULVWC'3+GPW<:XJW"VMN^QU9!OW<
M<8SC^(=^]$J%6.\05:F]F>;_ /"HM?\ ^?S3?^_LG_Q%'_"HM?\ ^?S3?^_L
MG_Q%=?\ \+5T/_GTU'_OVG_Q='_"U=#_ .?34?\ OVG_ ,73^K5OY2?;T^YR
M'_"HM?\ ^?S3?^_LG_Q%'_"HM?\ ^?S3?^_LG_Q%>F^'?%-AXF2X:R2=# 5#
MK,H!YS@C!/H:PW^*>A)(RBWOW .-RQI@^XRU2J%1MQ2U13JP23;W.._X5%K_
M /S^:;_W]D_^(H_X5%K_ /S^:;_W]D_^(KK_ /A:NA_\^FH_]^T_^+K0T7Q]
MI.N:I'I]M#=QS2!BIE10IP,D<,>P--X>JE=Q$JU-NR9P'_"HM?\ ^?S3?^_L
MG_Q%'_"HM?\ ^?S3?^_LG_Q%=QJ'Q(T73M0N+*2"]DD@D,;M'&NW<#@XRP[U
M6_X6KH?_ #Z:C_W[3_XNFL-5:NH@Z]-:7.0_X5%K_P#S^:;_ -_9/_B*/^%1
M:_\ \_FF_P#?V3_XBNXT_P").BZCJ%O91P7J23R"-&DC7;DG SAB>M3ZUX^T
MG0M3DT^YBNY)HP"QB12!D @<L.Q%+V%6_+RZC]M3M>^AP'_"HM?_ .?S3?\
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M!8BI%2C!M,Z(82M./-&+L<[_ ,*BU_\ Y_--_P"_LG_Q%'_"HM?_ .?S3?\
MO[)_\171?\+H\.?\^6J_]^H__BZZ?6/%^F:+X=M=<N!.]I=;/*$2 NV]=PX)
M'8'O2G@Z\&E*+N]A2PM:+2<=SS;_ (5%K_\ S^:;_P!_9/\ XBC_ (5%K_\
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MJ_[.Q7\C*^I8C^1G._\ "HM?_P"?S3?^_LG_ ,11_P *BU__ )_--_[^R?\
MQ%=]X7\?Z1XLOIK.QBNXIHHO-(G10"N0#C#'N1^=8LGQE\-I(R"UU-PI(#+$
MF#[C+U"P6(<G!0=T2L+6<G%1=T<W_P *BU__ )_--_[^R?\ Q%'_  J+7_\
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M:M+Q1X^TCPG?0V=]%=RS2Q^:! BG"Y(&<L.X/Y5#P==34'%W9+PM924''5G
M?\*BU_\ Y_--_P"_LG_Q%'_"HM?_ .?S3?\ O[)_\171?\+H\.?\^6J_]^H_
M_BZ/^%T>'/\ GRU7_OU'_P#%UI_9V*_D9?U+$?R,YW_A46O_ //YIO\ W]D_
M^(H_X5%K_P#S^:;_ -_9/_B*] USQYI&@:9IU_<K<RQ:@GF0"% 6*X!R<D8X
M8?G6#_PNCPY_SY:K_P!^H_\ XNHA@L14CS1@VB886M-7C%V.=_X5%K__ #^:
M;_W]D_\ B*/^%1:__P _FF_]_9/_ (BNB_X71X<_Y\M5_P"_4?\ \76]=>/-
M(M/"=KXC=;DV=R_EQHJ#S-V6!&,XXVMW[42P6(A;F@]= EA:T;7B]3S_ /X5
M%K__ #^:;_W]D_\ B*/^%1:__P _FF_]_9/_ (BNB_X71X<_Y\M5_P"_4?\
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M_"HM?_Y_--_[^R?_ !%'_"HM?_Y_--_[^R?_ !%=%_PNCPY_SY:K_P!^H_\
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MU/\ KF/YFIM/AB:UC+11$LY#&0<L/]FO+/IS'K2U+_CRL/\ KG_1:SY !(P
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MD[4\;_&H_P"+]!XK^+2]3R*BNF\%SV<5]<(VC_VMJ<T8CL+>2(21;SU+@D<
M#KVY/'6E\?#2E\53)I,4$4:1HLRV_$8E ^;;CC'0<=P:ZO;?OO96Z7N='M?W
MGL[';?\ -NW^?^?NO(J]=_YMV_S_ ,_=>=^&'6'65N&T1]9$*,_V502./XF
M4Y4>F,5Q8&7+&M+^_+]#EPDN6-5_WF8U>C?#K_D3O'/_ &#Q_P"BYJRO'L-H
MW]D7]GI]K;Q75KEIK--D$[C&XHGWE )Q\P!]NYU?AU_R)WCG_L'C_P!%S56*
MJ>TPG/:VJ_\ 2D5B)^TP_-YK\T><T5>T?2KG6]7MM-M #/</M7)P .I)]@ 3
M^%=SX^\/6>E>%M';3=+FA2&6:*>XE@VR2$, &<XSAB"5SV(Q754Q,(5(TGO(
MWG7C"<:;W8GP7_Y'&[_[![_^C(Z\YKT;X+_\CC=_]@]__1D=>= ;B ,<\<G%
M94?]ZJ^D?U,Z?^\5/2/ZB5UWPP_Y*+I7_;;_ -%/75>*;+1[GPQJ$'AS^P;C
M^SXH?M+16>)U7@EUG!VL21R .A;G/!Y7X8?\E%TK_MM_Z*>LYXA5\+4E:VC_
M "(E657#S=K:/\C(\5_\CCK?_80G_P#1C5D5K^*_^1QUO_L(3_\ HQJ]$7P_
M:Q^$+>VM-(T:\DGTA;R023;+\NP!WQ_*?D7ICC)X^NDL1&C3A=;V+E75*$+]
M3SOPI_R..B?]A"#_ -&+77_&C_D<;3_L'I_Z,DKD/"G_ "..B?\ 80@_]&+7
M7_&C_D<;3_L'I_Z,DK.I_OT/\+(J?[W#T9YS17?>#=4@CT.^EO="T.XL=*@+
MO-/:!IYI'8^6F\G'WCC.#P,>]<+/*9YY)2B(78MMC7:HR<X [#VKKIU7.<HM
M6L=,*CE*4;;'H7Q%_P"1.\#?]@\_^BX:\YKT;XB_\B=X&_[!Y_\ 1<-+\.+"
MQGT;4;JXLM,>=+F&-9]60&#8QY5<_P ?7\UKAP]94<(IM7U?_I3.2C55+#<S
M75_^E,\XKT;6/^2%>'_^P@__ *%/7+>,K6WL?&&J6UI:O:P1SD)$PQC@=/\
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M!HK\JAH/!>T=9.=]$1PSM") H!\Q"ASZ&B&=H1(% /F(4.?0TOV2Y_Y]Y?\
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MIY+A!&S74;-M7N!AAP>,_052UG5?[8O1<_8+&QP@3RK*'RDXSSC)YY_2I_\
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MXA*7DFMV11F-@.2!W(IU_84\-4C3:6C_ "'6]E"A-0LM'^1ROBO_ )''6_\
ML(3_ /HQJTK;Q]J]KHZ6$<5EYD<!MH[TP?Z1'$?X%?/3\/UJ3Q1X7U^7Q9J\
ML6B:C+%)>2R))';.RLK.2""!@\&LG_A%/$?_ $ -5_\  .3_  K2+H5*<5-I
MV2+BZ,Z<5)I[!X4_Y''1/^PA!_Z,6NO^-'_(XVG_ &#T_P#1DE8WA?POK\7B
MO2)9=$U&**.]AD=Y+9U55#@DDD8Z"NI^+>A:MJ/B>TN;'3+NZA^QK&7@A:0!
M@[D@X!QP17-4JP^NP?,MF83J0^MP=^C//8==NH/#ESH:)#]FN)EFD<@[\C&!
MG.,<>E9=:_\ PBGB/_H :K_X!R?X4?\ "*>(_P#H :K_ . <G^%=\:E&-[-:
M^9V*=-7LUJ=?\1?^1.\#?]@\_P#HN&N9T#Q??>'[2:TBM;&\M97$IAO(?,57
M'1AR.>!^5=OX^T#5[KPIX0AMM-NIY;6S\J>.&(NT;;(A@@9_NG\J\_\ ^$4\
M1_\ 0 U7_P  Y/\ "N'!NC/#*,VMW_Z4SDPSI2H*,FMW^;*NK:I=:WJMQJ5Z
MP:XG;<Q48 XP !Z  #\*[G6/^2%>'_\ L(/_ .A3UR'_  BGB/\ Z &J_P#@
M')_A7H&K>']7?X,:+8)IMTUY#>&22W6(F15+2X)4<_Q+^=5B:E).DHM64E^3
M'7G37LTFM)+\F>?:!XAN_#MW+/:QP3)-$T,T%RF^.5#V9<C/^?>F:[KMYXAU
M+[;>")6""-(X4VI&@Z*H].M2?\(IXC_Z &J_^ <G^%'_  BGB/\ Z &J_P#@
M')_A75>AS^TNK]SHO1YN>ZN=?H__ "0KQ!_V$$_]"@KC=)UZZT:VU&"WCA9;
M^W-M*9 20I[K@CGZYKT/2?#^KI\&=;L'TVZ2\FO!+';M$1(R@Q9(7K_"WY5Y
M_P#\(IXC_P"@!JO_ (!R?X5R8:=*3JJ35N;]$<]"5-^T4FOB_1&AI'CO5M%T
MF.PMX;)_(\P6UQ+!NEMM_P![8V>,GGD'\N*W_AU_R)WCG_L'C_T7-7(?\(IX
MC_Z &J_^ <G^%>@> /#^KVWA7Q?#<Z;=02W=GY<"31%#(VR48 /NP_.EC/81
MHR<&KMK_ -*0L5[*-*3C:[:_-'G.@ZU<^'M:M]5M$B>>#=M64$J=RE3D @]"
M>]&@ZU<^'M:M]5M$B>>#=M64$J=RE3D @]">]3?\(IXC_P"@!JO_ (!R?X4?
M\(IXC_Z &J_^ <G^%=DI4)7NUJK/7I_39U-TI7NUKH=?\%_^1QN_^P>__HR.
MN8UV[DL/B!J=Y$%,EOJDLJ!QD$K*2,^W%=O\)-"U?3?$]W<WVF7EK";)HP\\
M+1@L70@#(&> :Y;Q1X7U^7Q9J\L6B:C+%)>2R))';.RLK.2""!@\&N*%2F\;
M4NU;E1R0G!XJ=VK61'I_CS4-.U[4=9CL=.ENK_\ UGFQ,50=POS9 /&<D]!2
M:;JW]L^/M"N?[/L+'%Y;IY5C#Y2'$H.<9///7V%9W_"*>(_^@!JO_@')_A6M
MX7\+Z_%XKTB671-1BBCO89'>2V=550X)))&.@K>:P\8RE%J]K;^1M-48Q<DU
M>W<7XG_\E%U7_MC_ .BDJM)XYU=_$\&OJ+>.ZBB$.Q%;RW0#&&!)R#]?IBMW
MXC^'-;O/'>H75II%]<02B(I)#;LZG$:@\@>H-<I_PBGB/_H :K_X!R?X5.'=
M"6'I\[7PI?@KDT'2E1AS-;6_#4=X@\2WGB)[;[1#:V\%JFR"WM8MD<8/7 R>
MN!^5?0>M_P#'ZG_7,?S-?/B>$O$CN%&@:GDG S:.!^9'%?0^L6\TETC1Q.Z[
M,952>YKR,Z]FE3C3M97V^1YN:<B4(PV5_P!"@]U*RP@':8AA2N0:62\FFMUA
M=R54YR2<GZTW[)<_\^\O_?!H^R7/_/O+_P!\&O"/).DM/^/*#_KFO\J:_P#R
M$8?^N4G\TI]LI2UA5AA@B@CTXIC_ /(1A_ZY2?S2@18HHHH *KW'^OM/^NI_
M] :K%5[C_7VG_74_^@-0!8HK/N]<TZRN#!<7(25<$KL8XS]!4'_"3Z/_ ,_G
M_D)_\*I0D]D9.O23LY+[S7HK/M=<TV]N%@M[D/*V2%V,,X^HK0I--;EQG&:O
M%W"BBBD4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5=/^0C-_UR
MC_F]6*KI_P A&;_KE'_-Z +%%%% !5>X_P!?:?\ 74_^@-5BJ]Q_K[3_ *ZG
M_P! :@"Q163JWB;1]#G2'4;P0RNN]5\MF)&<9^4'T-9__"P?"_\ T%/_ "7E
M_P#B:T5*HU=1?W$.I!.S:.FHK$T[Q?H6K7J6=E?B6X<$JAB=<X&3R0!TK;J9
M1E%VDK%1DI:IA1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH L4444 %5[C_7VG_74_^@-5BJ]Q_K[3_KJ?_0&H \H^*O\ R-%M_P!>2_\
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MB53L944AXPWKNYQWW5SSPR+H6E7)MY+>WO/&45S:QR*5(B:7Y3M/W<X)Q[T
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M4J3$0HW;3T#,K-^.>] '6573_D(S?]<H_P";U8JNG_(1F_ZY1_S>@"Q1110
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M'YV K[BV",D';C@'J:[NN4D\,WK^%/#6EB6W\_2YK&29MQVL(2N[;QDYP<9
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M9,LAP=N>BG''6NSH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "JZ?\ (1F_ZY1_S>K%5T_Y",W_ %RC_F] %BBBB@ JO>_ZA?\
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M_P#0&JQ44\'G;/WCQLC;E9<9S@CN#ZF@".:PMIY#))%ECU.2*9_95E_SQ_\
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M7_G]G_)/_B: +%%5_L\O_/[/^2?_ !-'V>7_ )_9_P D_P#B: +%%5_L\O\
MS^S_ ))_\31]GE_Y_9_R3_XF@"Q15?[/+_S^S_DG_P 31]GE_P"?V?\ )/\
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MP_\ \^>I_P#?J/\ ^+HY)=@YD>@T5Y]_PN'P_P#\^>I_]^H__BZ/^%P^'_\
MGSU/_OU'_P#%T<DNP<R/0:*\^_X7#X?_ .?/4_\ OU'_ /%T?\+A\/\ _/GJ
M?_?J/_XNCDEV#F1Z#17GW_"X?#__ #YZG_WZC_\ BZ/^%P^'_P#GSU/_ +]1
M_P#Q=')+L',CT&BO/O\ A</A_P#Y\]3_ ._4?_Q='_"X?#__ #YZG_WZC_\
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M'_\ GSU/_OU'_P#%T<DNP<R/0:*\^_X7#X?_ .?/4_\ OU'_ /%T?\+A\/\
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M^_4?_P 71_PN'P__ ,^>I_\ ?J/_ .+HY)=@YD>@T5Y]_P +A\/_ //GJ?\
MWZC_ /BZ/^%P^'_^?/4_^_4?_P 71R2[!S(]!HKS[_A</A__ )\]3_[]1_\
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MW_"X?#__ #YZG_WZC_\ BZ/^%P^'_P#GSU/_ +]1_P#Q=')+L',CT&BO/O\
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M\]3_ ._4?_Q=')+L',CT&BO/O^%P^'_^?/4_^_4?_P 71_PN'P__ ,^>I_\
M?J/_ .+HY)=@YD>@T5Y]_P +A\/_ //GJ?\ WZC_ /BZ/^%P^'_^?/4_^_4?
M_P 71R2[!S(]!HKS[_A</A__ )\]3_[]1_\ Q='_  N'P_\ \^>I_P#?J/\
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MO:YXAO?#OP_\,3Z>R)<R0QKYC1AL($!(Y]>/RK1$UEX;T?0(8-8CT_[6HED
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M_DS+_P#%4?\ "M?"/_0)_P#)F7_XJCVL0]FSY]HKZ"_X5KX1_P"@3_Y,R_\
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M_DS+_P#%4?\ "M?"/_0)_P#)F7_XJCVL0]FSY]HKZ"_X5KX1_P"@3_Y,R_\
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M.(I._P#P.LS3/B#J^F:=;V)@L;R.V.;=KN$NT6.FT@CIVKU?_A6OA'_H$_\
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MT9)8HH&09;.YN&SN.>IS7J/_  K7PC_T"?\ R9E_^*H_X5KX1_Z!/_DS+_\
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MP%:&F?$'5],TZWL3!8WD=L<V[7<)=HL=-I!'3M7J_P#PK7PC_P! G_R9E_\
MBJ/^%:^$?^@3_P"3,O\ \51[2'8.21X[8^--:L==N=72=)+BZXG65<I(.P(&
M.G;%3:EXXU'4-)DTN&TT_3[25MTL=C!Y>_Z\GV_*O7/^%:^$?^@3_P"3,O\
M\51_PK7PC_T"?_)F7_XJCVD.P<DCRVT^)&MVMI;0O#87,MLI2&YN("TL8QCA
ML]<<9QSWS6?I7C'4]*?5)$$$\FIC%P\ZDG^+D8(Q]XU[%_PK7PC_ - G_P F
M9?\ XJC_ (5KX1_Z!/\ Y,R__%4N>'8.67<\8L?%%[I_AR]T.**W:UO&+2.Z
ML7!P!P<X_A':K3>-M1E\.Q:--;6,T,*>7#-)$3+&.Q5LX!'KBO7?^%:^$?\
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M;!HW16#DX(Y.<?Q'M6)7T%_PK7PC_P! G_R9E_\ BJ/^%:^$?^@3_P"3,O\
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MPC_T"?\ R9E_^*H_X5KX1_Z!/_DS+_\ %4>UB'LV?/M%?07_  K7PC_T"?\
MR9E_^*H_X5KX1_Z!/_DS+_\ %4>UB'LV?/M%?07_  K7PC_T"?\ R9E_^*H_
MX5KX1_Z!/_DS+_\ %4>UB'LV?/M%?07_  K7PC_T"?\ R9E_^*H_X5KX1_Z!
M/_DS+_\ %4>UB'LV?/M%?07_  K7PC_T"?\ R9E_^*H_X5KX1_Z!/_DS+_\
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M (3:+_GQ?_OX/\*/^$VB_P"?%_\ OX/\*/8S[!];H?S(ZJBN5_X3:+_GQ?\
M[^#_  H_X3:+_GQ?_OX/\*/8S[!];H?S(ZJBN5_X3:+_ )\7_P"_@_PKIK>7
MS[>*7&W>@;&<XR*F4)1W1I3K0J? [DE%%%2:!116'XF\30^&;:">>WDF65R@
M"$ @XSWIQBY.R$VHJ[-RBO/O^%L:?_T#;K_OI:/^%L:?_P! VZ_[Z6MOJU;^
M4R]O3[GH-%>??\+8T_\ Z!MU_P!]+1_PMC3_ /H&W7_?2T?5JW\H>WI]ST&B
MO/O^%L:?_P! VZ_[Z6C_ (6QI_\ T#;K_OI:/JU;^4/;T^YZ#17GW_"V-/\
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M]+1_PMC3_P#H&W7_ 'TM'U:M_*'MZ?<]!HKS[_A;&G_] VZ_[Z6C_A;&G_\
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MX6QX5_Y^IO\ OP_^%'U/$?\ /M_<P^JU_P"1_<SN**X?_A;'A7_GZF_[\/\
MX4?\+8\*_P#/U-_WX?\ PH^IXC_GV_N8?5:_\C^YG<45P_\ PMCPK_S]3?\
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M?0_] %>3G/\ NK]4>?FG^[OU1Z=1117R)\T%>?>*O^0_-_NK_*O0:\^\5?\
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M<=LCWKK]"\1V7BWQ/)80QE;2XT46<\4[B.61D+D^5C()PW0D<9/\->.T4ZF
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MAO3MVH ]>\U?^>8H\U?^>8KC-'\<QW=GX5&H6%Q;7WB")VBC504C*+N)))!
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M !'Q@A#SUSC',_ASQEK6L&7[=X.OK!7LQ>63K.LJ7*GHA;"K&YRN%8^N<8Y
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M0VRRQK(AEY5AD'Y&JY52^^]:_P#77_V1J (OLFG_ /0/MO\ OTO^%'V33_\
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MC+?,H8@^U4K'P?)!IWC.*728]"TV^MX9+()+&?(,49PS;2<.&57)Y'/WCR:
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MI3:;IURNLPZ58+"9M0O#L$H^4;0OF*8U!))8D<  #KD/\':G=:OX?6ZNI//
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MX&<@]3T'K^S_ &E_.C9_M+^= $, E6",3,K2A0'91@%L<D5)3MG^TOYT;/\
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MG0 VBG;/]I?SHV?[2_G0 VI;#_D'6W_7)/Y"F;/]I?SI]A_R#K;_ *Y)_(4
M6**** "J5U_Q^P?]<Y/YI5VJ=R,WT&2!^[DZ_5* $HIVT?WQ^M&T?WQ^M #:
M*=M']\?K1M']\?K0!PFK>&O$^G^*;_7?"%WI2MJD<:WMMJBR;-\8VK(A3G.T
MX(Z=^<\9/B+X::QKWA+1[6_U2UU;6+":2:1K_P Q()O,^\A,9#@+Q@CKM[ X
M'J.T?WQ^M&T?WQ^M 'F6G_#>[L-)\.6\":7:R6.L+J5W';/.8R NTA#(78G
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MRU.V^S7]G;W<&X-Y5Q$LBY'0X(QFK>P^J_G1L/JOYT -HIVP^J_G1L/JOYT
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MTC3-'B>+3-.M+&-VW.EM L08^I"@9-7: "BBB@ HHHH **** "BBB@ HHHH
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M7.<M[[>*^K1+<76JPN6"R7^A(2C%6 .T<$<@^XKU:U\/Z+8V5Q9VFD6%O:W
M(G@BMD1)01@[E P>..:E;2--=F9M.M&9FC=B85)+1_<)XZKV/;M0!YAXG7_A
M&KOQ59:!!'86TFGV,TD=L?(CCW3O'+(-H^0^6.6 R-H/.*V] LGTGQM9V]M8
MZ+I,$^GR/+9:;<R3"=0R;)2/)15()8;B<MNQSMKNOL=K]IDN?LT/VB2,1/+L
M&YD!)"D]2!D\>YJC!X>TJPL;NUTO3-/L5N4*R"&T14?@@;U  8<]#0!H3_\
M'O+_ +A_E7$>&+ZUTSX*6%Y>NJ6T6E ON/7Y<!1ZDD@ =R0*[*QLH[#3;:QC
MRT5O"L*[N254 #/Y5GVWA'PU97,=S:>'M)@N(SNCEBLHU9#Z@A<@T >>VFER
MWB6.D7MCI\MSI6AV?VE]<;S+>T# [VC@VC>V$(9C(N,+S@$&MHNL/H'@[PIX
MRN7DGC6RGT^[<DDLF6:'/4\/&$'_ %TKU6^T32=3N(;C4-+LKN:'_527%NDC
M1\Y^4D$CGTK.U3PO#J,5I81FUMM'CN!<W%G%:@&9U?S!A@P"@O@M\I+<\C-
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M_97\J &T4[?_ +*_E1O_ -E?RH ;13M_^ROY4;_]E?RH ;13M_\ LK^5&_\
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M8JR,(V(((Y!![US>I6$FA^"1XCTW4-4%_96BWC+<:C/<13A5#.C)([+AAD9
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MP #U  (% &_1110 4444 %%%% !1110 46O_ !^S_P#7./\ F]%%K_Q^S_\
M7./^;T 7:*** "L\?\?5U_UT'_H"UH5GC_CZNO\ KH/_ $!: 'T444 <CXB\
M'+XA\9:'J=W!8W6FV,-PD]O=)OWLX&TA2I4X([D4OBCP>-1T#3]+T2"QL8K7
M4(;KRE3RHPJ/N8*%7J<GMUKK:* /*-4^'7BK4]=>YN=0TBZMX=734+6:=9#<
MK$'!, 8@B.,#D!0<D#.,U/K7PXUK5KGQ7:_:M-72M6DCO+<MYAE%PFS"N!@"
M,X<$@D\@CTKU"B@#R&U^$^H0^!O$&EI;:%8ZEJ0B2/[%+=-%M1P^7:5F.>N
M%&/4YX37O@_<:GXPN-22#1+NRO7CDF:_>Z$T!P%<(L3JKCC(W$'G';)]?HH
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MWVBR1HA&T:*$.Y>"0 Z_>.0>^5KN@?:4\'>&Q<VYU:&%+/4H8'W$V(53*QR
M0I:)%!('+8%>IT4 %8-GHEU;^*M>U0S1K#J%O;10E.71HQ)DD$8_C&.O0YK>
MHH Y :)XDU.;2+?7)].:VTVX6Y:[MV8S7CID(3&4"Q9SN;#-R,#@Y'7T44 %
M%%% !1110 4444 %%%% !4MA_P @ZV_ZY)_(5%4MA_R#K;_KDG\A0!8HHHH
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M>*]%HH \PTGP=?V]EH^D7&DWC26$\/FWEQK$SV;)$V0\<(FSO.U<*4"J<]0
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M&#*R_P!T#N1Z5H44 9^9_P#GSF_[Z3_XJC,__/G-_P!])_\ %5H44 9^9_\
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M"B@#/S/_ ,^<W_?2?_%49G_Y\YO^^D_^*K0HH S\S_\ /G-_WTG_ ,51F?\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img131876768_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img131876768_8.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $V G # 2(  A$! Q$!_\0
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M1F/0#-1&*LM#IK5JBJ2]Y[OJ4?[$TG_H%V7_ (#I_A1_8FD_] NR_P# =/\
M"LZ/Q7'+$98].O7C'!=4! _6M33M3MM4M_.MF) .&5A@J?>M)47'5HY88US=
MHS?WL9_8FD_] NR_\!T_PH_L32?^@79?^ Z?X5?HJ.6/8V]M5_F?WE#^Q-)_
MZ!=E_P" Z?X4?V)I/_0+LO\ P'3_  J_11RQ[![:K_,_O*']B:3_ - NR_\
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M/\*/[$TG_H%V7_@.G^%7Z*7+'L/VU7^9_>4/[$TG_H%V7_@.G^%']B:3_P!
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ML*N.0N<_X?E7444_:.S7<7U>*E%K:.R"BBBLSH"BBB@ HHHH **** "BBB@
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MT]-8U Y_Z>&_QH_X2/71UUC4/^_[?XUU47B/09+V"[\PV:6MS=2+!Y!.]9%
M!&.!R,D>]+X@U*WM]'^QSW;2&?2K=8;/RN$DX/F[NG3CUHY]4N3^ON#ET;YC
ME/\ A(]<_P"@S?\ _@0W^-'_  D>N?\ 09O_ /P(;_&LRBNCDCV,>>7<V]/\
M0ZT^IV:/J]\RM/&"#.V""PXZU[[7SCIO_(6L?^OB/_T(5]'5YF812<;([\$V
MT[GSSJUY=KK-^!=W  N90 )6X^<^]5/MMY_S^7/_ '^;_&I=7_Y#>H?]?4O_
M *&:IUZ<4K(\^3=R?[;>?\_ES_W^;_&M:WTC7+G2TU%+T);N&*F6^V,VTX.
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M?#+WSR,D)TQ($M3(AB9UD'0!L[CSD$<<\UA>+/$=KK<426JO@3/,?,C*E-P
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M@#4?^O67_P!!-3+X6:T?XL?5!HG_ " -._Z]8O\ T$5?JAHG_( T[_KUB_\
M015^B/PH*W\67JPHHHJC(*^<=3_Y"]]_U\R?^AFOHZOG34H9CJUZ1#)C[1)_
M ?[QKTLNWD<.-VB4J*?Y$W_/&7_O@T>1-_SQE_[X->I<\\913_(F_P">,O\
MWP:/(F_YXR_]\&BX#**?Y$W_ #QE_P"^#1Y$W_/&7_O@T7 913_(F_YXR_\
M?!H\B;_GC+_WP:+@,I220 22!T!/2G>1-_SQE_[X-'D3?\\9?^^#1<!E%/\
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MDXVQ$'>YRWX5<?:<VKT_X'^8I<EM$:FHZ1HNFQ2V,MS>G5XX$E+! 869@#L
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M_0+OO_ =_P#"MN>/<RY7V*-%7O[%U;_H%WW_ (#O_A1_8NK?] N^_P# =_\
M"CFCW#E?8HT5>_L75O\ H%WW_@._^%']BZM_T"[[_P !W_PHYH]PY7V*-%7O
M[%U;_H%WW_@._P#A1_8NK?\ 0+OO_ =_\*.:/<.5]BCBBKW]BZM_T"[[_P !
MW_PH_L75O^@7??\ @._^%'-'N'*^Q1HJ]_8NK?\ 0+OO_ =_\*/[%U;_ *!=
M]_X#O_A1S1[AROL?0\7^I3_=%/IL?$2 _P!T4ZOFSW0JAK?_ " -1_Z]9?\
MT$U?JAK?_( U'_KUE_\ 034R^%FM'^+'U0:)_P @#3O^O6+_ -!%7ZH:)_R
M-._Z]8O_ $$5?HC\*"M_%EZL****HR"BBB@ HHHH **** "@D#J<5SP\3'^T
M?LIM-X,PC$L4FY2-RKZ=06Y'HI-277D7_B6TMYK=V2.WG.)8R%)W1C(SU[_G
M0!N;E_O#\Z-R_P!X?G5+^QM-_P"?*'_OFC^QM-_Y\H?^^: +NY?[P_.C<O\
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M !114-X;A;*<VBHUR(V\H.< MCC/XT +<W,-G;O<3OLB099L9Q^55O[6M/\
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M/5/^/'_MK%_Z,6@"Y1110 4444 %%%% !1110 4444 %%%% !1110!E^(O\
MD W/_ ?_ $(5J5E^(O\ D W/_ ?_ $(5J4 %%%% !1110 44V1BD;,J%V )"
MCJ?;FLV'5YIKM[8:9<J\>WS"73"ANA^][&FHM[#46]C4HHHI""BBB@ HHHH
M**** "BBB@ HHHH *IV'W[S_ *^&_D*N53L/OWG_ %\-_(4 7**** "BBB@
MHHHH *H:W_R -1_Z]9?_ $$U?JAK?_( U'_KUE_]!-3+X6:T?XL?5!HG_( T
M[_KUB_\ 015^J&B?\@#3O^O6+_T$5?HC\*"M_%EZL****HR"BBB@ HHHH **
M** "LR?_ )&:Q_Z]9_\ T**K7]H6>]$^U1;WD,2KO&2XZK]1WJK<?\C+8_\
M7K/_ .A14 :=%%% !1110 4444 %%%% !1110 4444 9;_\ (TP?]>4G_H:5
MJ5EO_P C3!_UY2?^AI6I5RZ%2Z!1114$A1110 4444 %4]4_X\?^VL7_ *,6
MKE4]4_X\?^VL7_HQ: +E%%% !1110 4444 %%%% !1110 4444 %%%% &7XB
M_P"0#<_\!_\ 0A6I67XB_P"0#<_\!_\ 0A6I0 4444 %%%% !699_P#(>U/_
M '(?Y-6G699_\A[4_P#<A_DU5'9_UU14=G_75&G1114DA1110 4444 %%%%
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M  E5KYQB,?V:?R]@(.-T?7-;-9D__(S6/_7K/_Z%%0!IT444 %%%% !1110
M4444 %%%% !1110!REQX8T:7QK%=/8QF5H&N&Y.#(&4!B.F>:ZNLM_\ D:8/
M^O*3_P!#2M2M*DFTKOH:3DVE=] HHHK,S"BBB@ HHHH *IZI_P >/_;6+_T8
MM7*IZI_QX_\ ;6+_ -&+0!<HHHH **** "BBB@ HHHH **** "N:TIY&\8ZH
M&NM\?E@I$&R%!V\XSC^O/-=+7*:,B_\ "8:J%N6="C 1G<=O*YP>F/;MT[4
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M(T;WEQ%$R[62,J ><YY!-6+6W>W1E>YEG).=TF,CVX JW;E2+=N5(GHHHJ"
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M()O+<AFR> <CCWJE&ZN)NVAJ4445(PHHHH **** "BBB@ JGJG_'C_VUB_\
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M; SBN'\&^+;O5==N+6:UC"7!:<M'G]V0 ,'VX_.NRCOI+B 26]I(=RAE\PA
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M6\39<,N7&W;@Y]*N4 %%%% !1110!E^(O^0#<_\  ?\ T(5J5E^(O^0#<_\
M ?\ T(5J4 %%%% $<XE,+"(1ESVDSBLW2],ETZ23;!9HDKEV,2D'V'X5K44
M%%%% !1110 4444 %%%% %*YL9;F56^V2(J.'10B\$#Z5:B1TC"R2&1AU8@#
M/Y4^B@ HHHH **** "J=A]^\_P"OAOY"KE4[#[]Y_P!?#?R% %RBBB@ HHHH
M **** "J&M_\@#4?^O67_P!!-7ZH:W_R -1_Z]9?_034R^%FM'^+'U0:)_R
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MXFCZ@$\\^@J7[=J/_0'D_P"_\?\ C0!I45F_;M1_Z \G_?\ C_QH^W:C_P!
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MG'3O725#=VL-[:R6TZEHI!A@"0?S'2JG]CP_\_-]_P"!<G^- &C16=_8\/\
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MGD^^* ):*BFN8+>&2:::...,9=F8 +]:1;NW>:2%9XS+'MWH&&5W?=R/?'%
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M*/"C>0;\W,MQ< R&)?/"$/Y>%Z*,[!QT'I2*(8? %V]AY4M_;P2-*68109!
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M][_WPG_Q5%%'M)=P^IT?Y?Q8?\+"TG_GWO?^^$_^*H_X6%I/_/O>_P#?"?\
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%[U\S_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img131876768_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img131876768_9.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $S G # 2(  A$! Q$!_\0
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M^%_PIU_J5MID:273E5=MJX4GG\*MCD9I<BM>PUB)MM*3NO,I?V/I?_0-L_\
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M_O*7]CZ7_P! VS_[\+_A1_8^E_\ 0-L_^_"_X5=HHY5V#VU3^9_>4O['TO\
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MQWES:1R7SLD2P12'897. -Q'3)ZXKG8_%.K6&IZRM_;![E9+2WMK*.4&,22
M\A\ X/4Y% '>T5QEQXTO+&VNXKS34BOK2XBBG*R,\,:."1*2%W;>,8QUJ6+Q
M++>2Z _[DB\N98V-I=;XR%0D$_+STZ'!% '745Q&F>.;RX^Q3W^F106=Y!/+
M')'/O;]T"6RN!P0..:LZ3XLU*]U/2;>[TJ*WAU.&2XAD6?>0@4$ C YY'YT
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M^>US_P!^&H_X69X;_P">US_WX:CZO5_E8>VI_P R.PHKC_\ A9GAO_GM<_\
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M^>US_P!^&H_X69X;_P">US_WX:CZO5_E8>VI_P R.PHKC_\ A9GAO_GM<_\
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M/_X69X;_ .>US_WX:C_A9GAO_GM<_P#?AJ/J]7^5A[:G_,CL**X__A9GAO\
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M^QO"7_0U2_\ @$U']C>$O^AJE_\  )JKVT>S^Y_Y"]F^Z^]'+T5U']C>$O\
MH:I?_ )J/[&\)?\ 0U2_^ 34>VCV?W/_ "#V;[K[T<O174?V-X2_Z&J7_P
MFH_L;PE_T-4O_@$U'MH]G]S_ ,@]F^Z^]'+T5U']C>$O^AJE_P# )J/[&\)?
M]#5+_P" 34>VCV?W/_(/9ONOO1R];7A#_D<-)_Z^!_(U>_L;PE_T-4O_ (!-
M6GX<TOPU#XCT^2U\1R7%PLP,<1M&4.<'C/:HJ58N#T>W9E0IOF6WWH]=KA_B
MI_R*T'_7VG_H+5W%<MX^MM.NM!BCU._:R@%PI$BQ&3+8;C _'\J\?#NU6+/3
MK*]-H\0HKJ/[&\)?]#5+_P" 34?V-X2_Z&J7_P  FKV_;1[/[G_D>5[-]U]Z
M.7HKJ/[&\)?]#5+_ . 34?V-X2_Z&J7_ , FH]M'L_N?^0>S?=?>CEZ*ZC^Q
MO"7_ $-4O_@$U']C>$O^AJE_\ FH]M'L_N?^0>S?=?>CEZ*ZC^QO"7_0U2_^
M 35)+H'A6$1[_%$H\Q!(O^A-RIS@_I1[:/9_<_\ (/92\OO1R=:-CKVK:9;F
M"QU&>WA+%MD9P,GJ:U_[&\)?]#5+_P" 34?V-X2_Z&J7_P  FI.I!Z-/[G_D
M"A);-?>C&M];U6T>9[?4+B-IVWRL'Y=O4^_O5L>(I%T6_L_*9KO4'!NKMY22
MZ@Y VXP#ZFKW]C>$O^AJE_\  )J/[&\)?]#5+_X!-2<J;Z/[G_D4HS75?>C!
ML=2O=,F::QNI+>5EVEXS@D=<?I5H^)-;-X+O^U+G[1L\OS-_.W.<?3-:G]C>
M$O\ H:I?_ )J/[&\)?\ 0U2_^ 34.=-N[C^#_P A*,UL_P 5_F<W+<3SW+7,
MLSO.S;VD9OF+>N?6KMUX@UB^2-+K4[F9(V#HKOD!AT/N16O_ &-X2_Z&J7_P
M":C^QO"7_0U2_P#@$U/VD'T?W/\ R#DEW_%&,-;U179Q?S[FF^T$[O\ EIC&
M_P"N*:FL:E&\#)>S*UNSO"0?N,_WB/KGFMO^QO"7_0U2_P#@$U']C^$O^AJE
M_P# )J7/3[/[G_D')/O^*_S.>M[RYM)))+>=XGD1D=E/+*W4'ZT6U]=623+:
MSO")D\N38<;E]#[5TLV@>%K>4QR>*)5< ''V)CU (_0U'_8WA+_H:I?_  ":
MG[6#Z/[G_D'LY+JOO1B1:QJ4$,,,5[,D4*LL2@\(&^\![&H6OKIK!+%KB0VD
M;;TA)^56]1^9KH?[&\)?]#5+_P" 34?V-X2_Z&J7_P  FH]I#L_N?^0<DN_X
MHR;/Q#K.GVRVUGJ5Q! I)$:,,#)R::NNZLEK+;)J5RL$Q9I(P_#%OO?G6Q_8
MWA+_ *&J7_P":C^QO"7_ $-4O_@$U+GI_P OX/\ R#EGW_%?YG.M>7+V2633
MN;6-RZ1$_*K'J0*MRZ]J\\<$<VI7,B0,KQ*SY"L.A^H]ZU_[&\)?]#5+_P"
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M?\BM!_U]I_Z"U=Q7#_%3_D5H/^OM/_06KP\-_&B>M7_A2/'Z***]\\<****
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M-8W:+.S6LZK;D"8F,CRR>@;T_&JVX8SD8]:%=]0^1>_LY?\ H(Z?_P!_6_\
MB:/[.7_H(Z?_ -_6_P#B:KSVMQ;#,\$L0W;<R(5YP#CGO@@_C4.1ZBA)OJ&G
M8O?V<O\ T$=/_P"_K?\ Q-']G+_T$=/_ ._K?_$U2HIV?<+KL:"Z2S0O,+^P
M,:$*Q\T\$YQ_#[&F?V<O_01T_P#[^M_\31!_R!;W_KM#_)ZI5*N[ZC=NQ=_L
MY?\ H(Z?_P!_6_\ B:/[-4_\Q'3_ /OZW_Q-4JE@MY[J80VT,DTI!(2-2S'\
M!3L^XM.Q8_LU<8_M'3\?]=6_^)H_LU<8_M'3\?\ 75O_ (FJ[6\Z6ZW#PR+
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M4DT,D:2KNC9U(#CU!/44M=KA\BS_ &:O_01T_P#[^M_\31_9J9S_ &AI^?\
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M[QJG.ST9S%7=&GBMM<T^>=PD45S&[L?X5# DU?\ ^$-\1_\ 0(N/_'?\:/\
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MC_Z!%Q_X[_C1[6'\R^\/9S[,PZ*W/^$-\1_] BX_\=_QH_X0WQ'_ - BX_\
M'?\ &CVL/YE]X>SGV9AT5N?\(;XC_P"@1<?^._XT?\(;XC_Z!%Q_X[_C1[6'
M\R^\/9S[,PZ0_=/TK=_X0WQ'_P! BX_\=_QH/@WQ'@_\2BX_\=_QH]K3_F7W
MB]G/LRCK'_(3?_KG%_Z+6J-=1JGA+Q!-?L\>E3LI2,9&WLB@]_453_X0WQ'_
M - BX_\ '?\ &IC5ARKWE]Y4J<[O1C/"U_#I?B&"\GD$:1)*0Q!/S&-@OZXK
MK7\2>'GBM[9RAMENEN"A4D!W1RS$8Z*[+_\ 7KE?^$-\1_\ 0(N/_'?\:/\
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M1\0'2((AI4_F+/(Q7Y> 53!Z^QINK#3WE]XE3GKHSF**W/\ A#?$?_0(N/\
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M):__ %Z0?S2O&*[,M_@_/]$<N9?[P_ZZL3 ]!1@>@I:*] X!,#T%&!Z"EHH
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M)%Y>R5X6"R"12RG!*N.&7W^OI6C6=H^E+I-O-'YYF>>9IY&$8C7<0!A4'"C
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M2GZGX=BU*],XNI((94CCN8$0%9DC<N@R>5P21QU!Q1J!MD8)![4E!.22>]%
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MP/H: *MOJ]C=7L]G;WL,MS!_K8D8%DYQS^/!]*6;4[2WEEBFO(8Y(8?/E5V
M*1Y(WGT&01GVKEM T?5]&O=TD$T\4"3JVZY1A.7E#(8@3^[P,[LXR<=>M5[O
MPKK3ZAJ4YFL[K[3 K;]AC:1UG#K&26( "KMZ8_6D!V=G?V^H6RW-G<)/ Q(#
MH<C(X(^OM5C>WK61H=M<PKJ%S=0?9Y+V\:X$&X,8UVJH!(XR=N3C/6M6F [>
MWK3HF)E7GO4=/B_UJ_6@"[7#_%3_ )%:#_K[3_T%J[BN'^*G_(K0?]?:?^@M
M5X;^-$BO_"D>/T458L[1[VX\E)(8OE+-),^Q5 &22:]]NVIX^Y7HK;?PKJ$4
M5W+*T"16I4,Y9B&W+O!7"GC'<XZUGVFE:C?PM-:6-Q/&APS1H6 .,XX]JE3B
M];E.,EI8J45>&C:HUT]J-/N3<(@D:,1G<%/0X]*J30R6\SPS1M'+&Q5T88*D
M=0::DGL)IK<97MG@QB/!VF8/_+,_^A&O$Z]K\&?\B=IG_7(_^A&N/'?PUZG3
MA/C?H;^]O6C>WK3:*\H]$CN;R*RM9;JZF2&WA0O)(_ 11U)J&PU>RU42?8+R
M.X\L@.$ZJ3TR#R,U5\26=QJ'AC4[.U027$UNR1H6"[F(X&3P*PM5L=:U.\N=
M2CTMHMUO%:BWDN0))5$N]V)1P.!P%+#.3T[@'9Y?W_*J5QK-A:7L-E<7T$5U
M-CRXG8!FR<#\SP,]37&:=8:Q;W>D:7<SR"2<2->Q^>6,4$4QDB(()QN!$9YZ
M<<XK<UB"^O=;M[?^S&?2LQ2W$\+QAYG5]RHVX@A%(#'&2>@QSD V;35[*_GG
MAM+V&>6 [94C8$H<D<_B"/J*M[V]:X[PIH>IZ9JCS7L15!;-"Q:574N92X\D
M#E8^3D-S]WTKKZ ';V]:3>WK244 /9FW=:3>WK0_WJ;0 [>WK37F$4;22.$1
M%+,S8  '))HK+U_3;K5=-^RVT\,0+AI4FC+K,@S\AP00"<9YZ#'>@"W)JMG#
MIRZC)>0K9,JNLY/RL&^Z1ZYR,>N:B_M_2_,M4_M*VW78W6XWC]X"< C\>/KQ
M67:0:K9^&;&QETY+FYM[>$.8Y$0!AP?+W$X=0 03@$]"*YW_ (1+6?L$%FB2
M1"X1([B03QMA4N&D7S<C)<*QRR?>8G..M(#T;>WK1O;UI&.6)]324P';V]:7
M<VP<]Z93OX!]: #>WK1O;UIM% #M[>M,2=9'=$E1GC(5U4@E21D CL<$&FS>
M;Y$GD%!-M/EEQE0V.,X[9KE_#NG:MHQU9+NUBF>ZFC99879O.D,8#2.3@A<C
MG'(Z 8 H Z$:OIYMYK@:C:&"!MDL@F7;&WHQS@'ZU:242(KHZNC %64@@@]"
M#7F^D:%JMB;2XGTRZGAM#:F6"1(@[&-95*QA3AT4N"&;YCZG%=IX;LY]/\/6
M=M<1^5*H8F+(/EAG9@G'H"!^% &MO;UHWMZTVB@":!B9>3VIFL_\@/4/^O:3
M_P!!-.M_];^%-UG_ ) >H?\ 7M)_Z":SJ;,VH?Q(^J.;\2_\DM?_ *](/YI7
MC%>S^)?^26O_ ->D'\TKQBO6RW^#\_T1YN9?[P_ZZLGLWMH[V%[R%I[96!DB
M5MI<>F:Z3_A*K/\ MHW_ )&H;5,;0Q)<+&J;"=L>U1@ICCUZ^M<I17;*G&6Y
MQ1FX[&[I/B%=.^V&2V9VN;F&?$;!0NR3>1^/05IVWB*UU&1[6YQ;0RP74<DD
MLNTGS9!( K '!XQR,&N/HJ948O4:J26AL^*KVWU#Q%<7%H_F0;8T5\YW;4 )
MR>O(ZUC445I&/*E%="9/F;9Z3\.AJM_HUS!:ZA#;0VT^%5K7S"2P#$YW"NR_
MLK7/^@Y;_P#@ /\ XNN7^$G_ "#-4_Z^5_\ 0!7HM>'B9-59)'K4(ITT87]E
M:Y_T'+?_ , !_P#%T?V5KG_0<M__   '_P 77)Z4;7_A*3_:(US_ (2/[=-G
MR_-\CR,MLS_RS\K;MZ<YK/TO5]>TCP_#";B]>.33895=X1FV8SE&Y*DX"\G(
M8C&<5/O?TBM#O/[*US_H.6__ ( #_P"+H_LK7,8_MRW_ /  ?_%UQ'_"0>*9
MM%6=;ZX2>WTZZN&*6@_?21SA4!#+D97L ">O%6;_ ,2Z_%KK117$OVEKR2*+
M3S;CRWB%NSQD/C)+,/[WM@8HM+R"\3KO[*US_H.6_P#X #_XNC^RM<_Z#EO_
M .  _P#BZR?"&H:QJFA:@]_?>:VP>5+'&5DC8IE@<QJ"0W0 ''0DXKG?#K^(
M-/T(BQFO)7@T2.]2WEB#>=<R&3=N)&XXP/E!!Z9I>]J&AW']E:Y_T'+?_P
M!_\ %T?V5KG_ $'+?_P '_Q=<@NM:_<R0V]IJEY)9/<LJ7YM%6211;,[+@IC
M D &<>W.*W/!6IZQ?33)JL\DP:QM+I2\ CV/(K;U& . 5'!R10^9*^@+E;L:
M?]E:Y_T'+?\ \ !_\70=+UPX_P")Y;\?]. _^+K=HJ.=E\B,+^RM<_Z#EO\
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M]E:Y_P!!RW_\ !_\76[11SL.1&%_96N?]!RW_P#  ?\ Q=']E:Y_T'+?_P
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MM<_Z#EO_ .  _P#BZ/[*US_H.6__ ( #_P"+K=HHYV'(C"_LK7/^@Y;_ /@
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M<S+WVNQ_Z!2?^!#T?:['_H%)_P"!#U1HHY5_3#F9>^UV/_0*3_P(>C[78_\
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M.< 'C'?0@BWB#2^:P1<R8QO./O?CUHY@L4/LFM?]#"__ (!QT?9-:_Z&%_\
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MK7_0PO\ ^ <=+]CUK;G_ (2%^O\ SYQUHT[^ ?6B_P#5@L9?V36O^AA?_P
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MR]SKWAZ[M9K:75[3RIHVC?;-@[6&#@]N#43:MX9>*&%M4LV@A3RU@,P,;+@
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M,5[/XE_Y):__ %Z0?S2O&*]7+?X/S_1'G9E_O#_KJPHHHKT#@"BBB@ HHHH
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M)1_^@/5W6?\ D!ZA_P!>TG_H)JEXA_UVB_\ 82C_ /0'J[K/_(#U#_KVD_\
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M#_Y_U_[]O_A1_P );H?_ #_K_P!^W_PK:HHO'M_7W![QB_\ "6Z'_P _Z_\
M?M_\*/\ A+=#_P"?]?\ OV_^%;5%%X]OZ^X/>,7_ (2W0_\ G_7_ +]O_A1_
MPENA_P#/^O\ W[?_  K:HHO'M_7W![QB_P#"6Z'_ ,_Z_P#?M_\ "C_A+=#_
M .?]?^_;_P"%;5%%X]OZ^X/>,7_A+=#_ .?]?^_;_P"%'_"6Z'_S_K_W[?\
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MPLSDYKWP7<PRQ3)9R1RA!(K6['=L&$[=AP*OP^)O#UO"D,-W%'%&H5$2)@%
MZ #'%;M%%X_TPLS%_P"$MT/_ )_U_P"_;_X4?\);H?\ S_K_ -^W_P *VJ*5
MX]OZ^X/>,7_A+=#_ .?]?^_;_P"%'_"6Z'_S_K_W[?\ PK:HHO'M_7W![QB_
M\);H?_/^O_?M_P#"C_A+=#_Y_P!?^_;_ .%;5%%X]OZ^X/>,7_A+=#_Y_P!?
M^_;_ .%'_"6Z'_S_ *_]^W_PK:HHO'M_7W![QB_\);H?_/\ K_W[?_"C_A+=
M#_Y_U_[]O_A6U11>/;^ON#WC%_X2W0_^?]?^_;_X4?\ "6Z'_P _Z_\ ?M_\
M*VJ*+Q[?U]P>\8O_  ENA_\ /^O_ '[?_"C_ (2W0_\ G_7_ +]O_A6U11>/
M;^ON#WC%_P"$MT/_ )_U_P"_;_X4?\);H?\ S_K_ -^W_P *VJ*+Q[?U]P>\
M8O\ PENA_P#/^O\ W[?_  H_X2W0_P#G_7_OV_\ A6U11>/;^ON#WC%_X2W0
M_P#G_7_OV_\ A1_PENA_\_Z_]^W_ ,*VJ*+Q[?U]P>\<KJ6N:=J=]HT%E<^=
M(+]'*A&& $?)Y%;NL_\ (#U#_KVD_P#035VJ6L_\@/4/^O:3_P!!-3-IQT-:
M":J1OW1YK9>*]:CL+>-+W"K$H \I.  /:I_^$NUS_G^_\A)_\3117E*I.V[/
MNIX3#\S_ ':^Y!_PEVN?\_W_ )"3_P")H_X2[7/^?[_R$G_Q-%%/VD^[)^IX
M?_GW'[D'_"7:Y_S_ '_D)/\ XFC_ (2[7/\ G^_\A)_\3111[2?=A]3P_P#S
M[C]R#_A+M<_Y_O\ R$G_ ,31_P )=KG_ #_?^0D_^)HHH]I/NP^IX?\ Y]Q^
MY!_PEVN?\_W_ )"3_P")H_X2[7/^?[_R$G_Q-%%'M)]V'U/#_P#/N/W(/^$N
MUS_G^_\ (2?_ !-'_"7:Y_S_ '_D)/\ XFBBCVD^[#ZGA_\ GW'[D'_"7:Y_
MS_?^0D_^)H_X2[7/^?[_ ,A)_P#$T44>TGW8?4\/_P ^X_<@_P"$NUS_ )_O
M_(2?_$T?\)=KG_/]_P"0D_\ B:**/:3[L/J>'_Y]Q^Y!_P )=KG_ #_?^0D_
M^)H_X2[7/^?[_P A)_\ $T44>TGW8?4\/_S[C]R#_A+M<_Y_O_(2?_$T?\)=
MKG_/]_Y"3_XFBBCVD^[#ZGA_^?<?N0?\)=KG_/\ ?^0D_P#B:/\ A+M<_P"?
M[_R$G_Q-%%'M)]V'U/#_ //N/W(/^$NUS_G^_P#(2?\ Q-'_  EVN?\ /]_Y
M"3_XFBBCVD^[#ZGA_P#GW'[D'_"7:Y_S_?\ D)/_ (FC_A+M<_Y_O_(2?_$T
M44>TGW8?4\/_ ,^X_<@_X2[7/^?[_P A)_\ $T?\)=KG_/\ ?^0D_P#B:**/
M:3[L/J>'_P"?<?N0?\)=KG_/]_Y"3_XFC_A+M<_Y_O\ R$G_ ,3111[2?=A]
M3P__ #[C]R#_ (2[7/\ G^_\A)_\31_PEVN?\_W_ )"3_P")HHH]I/NP^IX?
M_GW'[D'_  EVN?\ /]_Y"3_XFC_A+M<_Y_O_ "$G_P 3111[2?=A]3P__/N/
MW(/^$NUS_G^_\A)_\31_PEVN?\_W_D)/_B:**/:3[L/J>'_Y]Q^Y!_PEVN?\
M_P!_Y"3_ .)H_P"$NUS_ )_O_(2?_$T44>TGW8?4\/\ \^X_<@_X2[7/^?[_
M ,A)_P#$T?\ "7:Y_P _W_D)/_B:**/:3[L/J>'_ .?<?N0?\)=KG_/]_P"0
MD_\ B:/^$NUS_G^_\A)_\3111[2?=A]3P_\ S[C]R#_A+M<_Y_O_ "$G_P 3
M1_PEVN?\_P!_Y"3_ .)HHH]I/NP^IX?_ )]Q^Y!_PEVN?\_W_D)/_B:/^$NU
MS_G^_P#(2?\ Q-%%'M)]V'U/#_\ /N/W(/\ A+M<_P"?[_R$G_Q-'_"7:Y_S
M_?\ D)/_ (FBBCVD^[#ZGA_^?<?N0?\ "7:Y_P _W_D)/_B:/^$NUS_G^_\
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M?_$T?\)=KG_/]_Y"3_XFBBCVD^[#ZGA_^?<?N0?\)=KG_/\ ?^0D_P#B:/\
MA+M<_P"?[_R$G_Q-%%'M)]V'U/#_ //N/W(/^$NUS_G^_P#(2?\ Q-'_  EV
MN?\ /]_Y"3_XFBBCVD^[#ZGA_P#GW'[D'_"7:Y_S_?\ D)/_ (FC_A+M<_Y_
MO_(2?_$T44>TGW8?4\/_ ,^X_<@_X2[7/^?[_P A)_\ $T?\)=KG_/\ ?^0D
M_P#B:**/:3[L/J>'_P"?<?N0?\)=KG_/]_Y"3_XFH+WQ5K4MA<1O>Y5HF4CR
5DY!!]J**3J3MNRH83#\R_=K[D?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img131876768_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img131876768_10.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $Z G # 2(  A$! Q$!_\0
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MO3_^?&V_[]+_ (4?V7I__/C;?]^E_P *MT4<J[![6?=E3^R]/_Y\;;_OTO\
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MO3_^?&V_[]+_ (4?V7I__/C;?]^E_P *MT4<J[![6?=E3^R]/_Y\;;_OTO\
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MO3_^?&V_[]+_ (4?V7I__/C;?]^E_P *MT4<J[![6?=E3^R]/_Y\;;_OTO\
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MO3_^?&V_[]+_ (4?V7I__/C;?]^E_P *MT4<J[![6?=E3^R]/_Y\;;_OTO\
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MCP9I(AFB;[2ZS1QQ.7G8G:ARH_#%6+SPOIE]]L,R2[KN6.:1EE((=!A2N.E
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MI?\ 7U+_ .AFJ-7M;_Y#^I?]?4O_ *&:HU[</A1Y,MV%%%%4(**** "BBB@
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M*Q.23SP:HKXBTI](EMKIWG8)*L*^04=-S$J X/*]R#74?\*HTK_H(7WYI_\
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M_P"1-TG_ *]UKHBW]7DO-?E(74W:***YQA1110 4444 %%%% !1110 4444
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M ,A2^_ZYQ?\ H=>LZI_R";S_ *X/_P"@FOA<]_WR?HOR.W#;Q]0TO_D$V?\
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M$C!/!KJ>&:H*OK9Z;:7]2>;6QOT445RE!1110!1E_P"0W:_]<)?YI5ZJ,O\
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M2^_ZYQ?^AUZSJG_()O/^N#_^@FOA<]_WR?HOR.W#;Q]0TO\ Y!-G_P!<$_\
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ME=2S*HRQ 'J30!F*\S>(\21!$6W;8V[.X;E[=JU*H/\ \A^+_KV?_P!"6K]
M!1110 4444 %%%% !6?K-U+9V!EA(#[@,D9K0K)\1_\ (*/^^M5'=&5=M4Y-
M&)_PD&H?\]%_[Y%8MS*\]S++(<N[$DU-59_OM]:NHDEH<>"J3E-J3N,/44M(
M>HI:R/1+,?\ JU^E.[BFQ_ZM?I3NXKJ6Q\_4^-^H4444R#GO&'_((C_ZZC^5
M</7<>,/^01'_ -=1_*N'KZ_)?]U7JSOP_P !Z;I/_(&LO^N*_P JN=Q5/2?^
M0-9?]<5_E5SN*^4K_P 67JSAENP[UYAJ7_(4N_\ KLW\Z]/[UYAJ7_(4N_\
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M?:M75+29XK2YMK>*>:!2%#J'P& S@$CGCU%:4EG;3.7DMX79A@ED!)J8  8
MP!0!3TM)8K%$EB,9&3M. >3GH.!UZ9-7" 00>AHJ"]N&M+&>X2)IFBC9Q&O5
MB!G H ([2WMK1;:&"-((UPD:J-JCV%4?#?\ R+]K]&_]"-.M-4>YT]KB2TF4
M^8T85%+9 )^8>QIOAHY\/6AP1D,<'_>- &K1110 4444 4IM2\AT5[6XR[[%
M("_,?S]JLPRF5-QB>,YQA\9_0U4U+_7V'_7R/_035^@ HHHH **** "BBB@
MHHHH ***0C<"#T- "U1U+[MK_P!?*?UJM+:1KJUM ))@CQNS+Y[\D8QWIUVV
M$MXHH+EA%.K$[&;@9YR>M..YG5?NFK14<,PF4D)(N#C#J5J2D6G<****!A11
M10!1E_Y#=K_UPE_FE7JHR_\ (;M?^N$O\TJ]0 5@/%-+XA<HJ)"LB,^,&20A
M1Z]$&1GOGT[[]4'T:SDU,:@PF^T @@B=PO Q]S.T]/2@"GISW":M-:O$PACW
M%,0,H 8[LER<'Z#\<5H:A9F]@6,2;"&W9QGL1_6K=075TEK&&;DEE&T'GD@9
M_6@#G==CEL[PW$%W<))]G./GR!\ZC@5B?VOJ?_00G_2MOQ'/%+/+''(K/'!A
MP/X?G6N8H M_VOJG_00G_2C^U]4_Z"$_Z53R.>>]3VEK)?7*V\.WS&R1DXZ"
M@";^U]3_ .@A/^E(-7U3_H(3_I5__A%]2](O^^ZVK+PW9K9QB[MU:?'SD.>3
M0!RQU?4_^@A-^E']KZG_ -!";\Q7:1:%IL,@=;521_>)(_(U8_LZR_Y](/\
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M_?U?\: +-%5O[0LO^?RW_P"_J_XT?VA9?\_EO_W]7_&@"S15;^T++_G\M_\
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M)'V@@@YJMI[2-K5X6)V"1E53;A1C R0XY//KCZ5/KH7^SP6&<2*PPI)R.1C
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M2=I^G6@#3A<R01N0 64$@'(Z>M4[6[\W4)XOL\:$?><3*Q;' RHY'XU;M_\
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MXT?VE?\ _/[<_P#?UO\ &CVGD'U/^]^!Z317FW]I7_\ S^W/_?UO\:/[2O\
M_G]N?^_K?XT>T\@^I_WOP/2:*\V_M*__ .?VY_[^M_C1_:5__P _MS_W];_&
MCVGD'U/^]^!Z317FW]I7_P#S^W/_ '];_&C^TK__ )_;G_OZW^-'M/(/J?\
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M/:>0?4_[WX'I-%>;?VE?_P#/[<_]_6_QH_M*_P#^?VY_[^M_C1[3R#ZG_>_
M])HKS;^TK_\ Y_;G_OZW^-']I7__ #^W/_?UO\:/:>0?4_[WX'I-5-4_Y!-Y
M_P!<'_\ 037 _P!I7_\ S^W/_?UO\:@O-1OFLIP;RX(,;9!E;T^M)U--BZ>#
']]>]U['_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>img131876768_11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img131876768_11.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %$ G # 2(  A$! Q$!_\0
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M1F)89(R<8H<(W;?D.-:=DH]>;>_0ZJ.[@EM1=)*I@*[M^>,50C\1Z5('(NE
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M498@ =S2-(B %W5<^IQ7$?$QM%BTRQEUE[B95G*V^G0S>6+R4C"JQR.!USG
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M^!_\51_;K?\ 0(U3_OP/_BJ -:BLG^W6_P"@1JG_ 'X'_P 51_;K?] C5/\
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M^!_\51_;K?\ 0(U3_OP/_BJ -:BLG^W6_P"@1JG_ 'X'_P 51_;K?] C5/\
MOP/_ (J@#6HK)_MUO^@1JG_?@?\ Q5']NM_T"-4_[\#_ .*H UJ*H:?JB:A+
M/$+:Y@D@V[EG3:3N'&.3GI5^@ HHK(.OKY\\46G:A,(9#&SQP@J2.N#F@#7H
MK)_MUO\ H$:I_P!^!_\ %4?VZW_0(U3_ +\#_P"*H UJ*R?[=;_H$:I_WX'_
M ,51_;K?] C5/^_ _P#BJ -:BLG^W6_Z!&J?]^!_\51_;K?] C5/^_ _^*H
MUJ*R?[=;_H$:I_WX'_Q5']NM_P! C5/^_ _^*H UJH)H>E1ZL^JIIUJNH.NU
MKD1#S"/KUJ#^W6_Z!&J?]^!_\51_;K?] C5/^_ _^*H L66BZ7IUW<75EI]M
M;W%R<S211A6<^Y%-N-#TN[-V;BP@D-X$%QN3/FA/N[O7':H?[=;_ *!&J?\
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MNM_T"-4_[\#_ .*ID&M163_;K?\ 0(U3_OP/_BJ/[=;_ *!&J?\ ?@?_ !5
M&M163_;K?] C5/\ OP/_ (JC^W6_Z!&J?]^!_P#%4 :U%9/]NM_T"-4_[\#_
M .*H_MUO^@1JG_?@?_%4 :U%9/\ ;K?] C5/^_ _^*H_MUO^@1JG_?@?_%4
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MV_DI8GJA5VE8N@3.T*2> ,GCW-31^!O#T4EHRV VV@ BC+DJ,9P2#U(W'\Z
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M\Y@#L+'D,!&/I@"M&TTWP?!:631*JP70)B:1V (B\QB23TQO<\^M)%\-M,2
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M*DH **** "BBB@ HHHH **** "BBB@#,L_\ D/:G_NP_R:M.LRS_ .0]J?\
MNP_R:M.@ K,T;I?_ /7Y)_2M.LS1NE__ -?DG]* -)F"J6/0#)KSS[3X FTI
M9S&8;%+J1Q*4=%,C\L,]PV.G0]*]"==\;(3@,"*Y.;X>Z5+X>AT42316J/YL
MOE85IG'W68X['!^H% %%;/P-?:DL2KBZBG6 PY=2))%9UROT+8/;I5TZ1X.O
M'=)# &25X626;;N:.,(PP3R H&?IFG)X"LAK-KJTE[<R7L%R+AI#M'FD(5"L
M .1R3]34%S\-M-NO$,6KRWET66>25X#M,<@=BVTC' R3TYQ0!9'AGPC'):IB
MU$@B:TB!G&Z0.I.WK\QPQ/KS6]I%U9WND6MQI[[[-XQY+<\J.!U^E<HWPPTT
MMIC"_O0UC<M<$DJ3-EPP5LCH, #&#@5U.BZ5'HFC6NFPR/)';IL5WQN/UQ0!
M?HHJ,2YN6AQT0-GZDC^E $E%<_JWCCPSH>KPZ5J>L6]M>RXVQ.3QGID@87/O
MBN@!! (.0: "BLCQ!XIT3PM:QW.M:A%9QR-M3?DEC[  DU>T_4+/5;"&^L+B
M.XM9EW1RQG(84 6:*K7^H6FEV$U]?7$=O:PKNDED. HJAX?\4Z)XIMI+C1-1
MBO(XFVR;,@J?<$ T ;%%!( R>!7/Z5XX\,ZWK$NDZ;K%O<7T6=T2$\XZX)&&
MQ[9H Z"BBB@ HHHH ***:[;(V?&=H)Q0 ZBF1/YL*28QN4-CTS3Z "BBB@ H
MHHH **** "BBB@ HHHH **** "L*+_D7-2_W[K_T-ZW:PHO^1<U+_?NO_0WI
M2V9I2^./JC2TK_D$6?\ UP3^0J&#_D8K[_KV@_\ 0I*FTK_D$6?_ %P3^0J&
M#_D8K[_KV@_]"DHCL@J_'+U9HT444S,**S4UB.=KY+>)G>T4[@YV;FP>/4#C
MKC'IFJ]GKDMU<V*"VCV7-HMRY67)BR,\\=,G />@#:HKE9?%\ULA:XTXKL=D
ME DYC/\ #GCG(R<C@ 5TT$JSP1RHP974,".AS0!)52YD6*YBD<X5%=B?0 5;
MKC_B5J_]A^"]3O@VV06LD<9_VV&!_.@#P+XD_%>+QE<FS30[-K*VD/D339,I
M]\@C /I7>?!WXK)JEY:^$[G2K6R C(M7M<JG S@J>YYYKY_U#39-.CLFDZW5
MNMPO^Z20/Y&MSPB\N@ZSH/B1<F%;\1M[$8R/R)H ^U:*16#*&4Y!&0:6@ HH
MHH **** "BBB@ HHHH **** *]E_Q[G_ 'V_]"-6*KV7_'N?]]O_ $(U8H *
M*** "BBB@ HHHH **** "BBB@#,L_P#D/:G_ +L/\FK3K-L_^0]J?^[#_)JT
MJ "LS1NE_P#]?DG]*TZS-&Z7_P#U^2?TH TZ**0D*I)Z 9X% "T5C2>($;1Y
M]1M;=I$BD";9&"$_, 3W(Z]#@TX:O.UWJ,"6J2?9HM\;))]]\'$9XX;@>O6@
M#7HKED\7D26R36@C$S;"^\X1Q]X$8SP<CZCTKJ0<C(Z4 %4Y9HK:[GFGD2.*
M.!6=W. H!;))JY7EGQTU?^S/ E[ K8DOO)MP.^W<S'_T''XT >/_ !);PIKW
MQ$EU"S\2;K2Z9?M#BW9O*( !VGC<.*^F?"^M:/K6AV\NB:@E[:Q(L6\'Y@0,
M88'D'ZU\.RQ/!*T4BE70X93U!KU?X+>)&\,3^)(K@^6&TMKR,-W9!E<?4-0!
MT'Q[O_#6M7-E%#KR?VG8%HY+=$,BX;&<L. 1BNZ^#.I^'$\'VVAZ5K*WMW &
MDF1U,;@L<G"GL,]LU\H3B5G\^4-F;+AC_%R<G\P:ZSX8ZE)HGQ"T+4&RL$EU
M]G9NQ##:?RW T ?0WQEU+P\?!MSHFKZP+&YN@LD"JA=F*MD94?PY&.:X#X!W
MWAK1KZ\BFUU3J=^5BBMVC**0"<8)X+'-<+\6-4/B+XA:Y>+(#;V++:Q$]#M.
MW ^IW&N-L?.@?[?;OMEM)$D&.HYX/YX_.@#[<\2ZQI.BZ'<7&LWR6=HZF(R$
M\DD$84#DGZ5\P_#EO"F@_$6'4+OQ(5L[5V-NYMV7S200-W]T<UT/QJ\3KXI/
MAC3[64"*6S%_-SPA<<9_W0&_.O&K6W:ZG$*$!V!V@]SC@?C0!][0S17$$<T,
MBR12*&1U.0P/((-/KSKX(ZY_;/PULHW;=-8NUJ^3S@<K^A _"O1: "BBB@ J
M.?\ X]Y?]P_RJ2HY_P#CWE_W#_*@!MI_QYP?]<U_E4U0VG_'G!_US7^534 %
M%%% !1110 4444 %%%% !1110 4444 %847_ "+FI?[]U_Z&];M8<7_(N:E_
MOW7_ *&]*6S-*7QQ]4:.E?\ ((L_^N"?R%0P?\C%??\ 7M!_Z%)4VE?\@BS_
M .N"?R%0P?\ (Q7W_7M!_P"A241V05?CEZLT:***9F1R013(Z21HZNNU@1G<
M/0U4CT72XF5H]/MD94\L%8P,+_=^G)J_10!432[".)HDLX!&Q8LH08)/7\ZM
M(BQHJ(H55&  . *6B@ K*UG2K'6HUT_4K9+FTF5@\3C@UJU6E_X_K?Z-_*@#
MYX\?Z+IK?&W3-(-G'_9\>FJBP 84*J2$#\Q6S\"-!TK7_!-W%JMC#=I!J(FB
M$JYV.%'(JMX]5C^T)8$*<?8.N/\ 8DK;_9R!'@[4L@C_ $SN/]D4 >R@   #
M %%%% !1110 4444 %%%% !1110 4444 5[+_CW/^^W_ *$:L57LO^/<_P"^
MW_H1JQ0 4444 %%%% !1110 4444 %%%% &99_\ (>U/_=A_DU:=9EG_ ,A[
M4_\ =A_DU:= !69HW2__ .OV3^E:=9FC=+__ *_)/Z4 :=%%% %>YL;6\@>"
MYMXI8G.61U!#'W%1+H^FJTK+8VX:4YD(C'S'ISZ]35VB@"HNF6*1)$MG (T
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M@_[^G_XFF0&8ZA)YR(I\I<;&)[M["KM9FHZE::/]LU&_F6"UM[97DD;HHRU
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M^^W_ *$:L57LO^/<_P"^W_H1JQ0 4444 %%%% !1110 4444 %%%% &99_\
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M'0_&?@[0-7N[F[M[E]+CB;R6 !('#'(].,4 ?.EQ;S1)#-*,"X4R(?4;BO\
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MHH **** "BBB@ HHHH **** "L*+_D7-2_W[K_T-ZW:PHO\ D7-2_P!^Z_\
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MVH+:7JV32^<UON7<6SG .>!FIM2UQKGP'I.E1MNDAFD.SU4?<_4USQWI&=X
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MC=+_ /Z_9/Z4 6?L7_3U<_\ ??\ ]:C[%_T]7/\ WW_]:K5% %7[%_T]7/\
MWW_]:C[%_P!/5S_WW_\ 6JU10!5^Q?\ 3U<_]]__ %J/L7_3U<_]]_\ UJM4
M4 5?L7_3U<_]]_\ UJ9!#Y6I2_O97S"OWVSW:KM5E_Y"4G_7%?YM0!9HHHH
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M?^0E)_UQ7^;4 6:*** "BBB@ HHHH **** "BBB@ HHHH *CG_X]Y?\ </\
M*I*CG_X]Y?\ </\ *@#R3XG7$M[=Z1I5LP,B6_F >CD<?H#7GR!I(E"MAG4
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MY_T%9_\ OVG^% &A16?]AO/^@K/_ -^T_P */L-Y_P!!6?\ []I_A0!/9?\
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MV[=IC3I^54_^$6MA$(MZ>6&W!?LT> ?7[M=V#QGU=/W;ZI_=?_,F4;FM8_\
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MU?\ Z!5]_P" [_X4?V%J_P#T"K[_ ,!W_P *^[MJ_P!T?E1M7^Z/RIF9Y5\
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MWR,\C.S'  R6)/0 5=H 0@'J!52/2K**_>^2W47+ @OZ9QG'IG S]*N44
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::?<H8K?#1,#A3Z?6BBAR=MRZ=*'.O=6Y_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>img131876768_12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img131876768_12.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %! G # 2(  A$! Q$!_\0
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M9_\ ?A?\*/['TO\ Z!MG_P!^%_PJ[11RKL'MJG\S^\I?V/I?_0-L_P#OPO\
MA1_8^E_] VS_ ._"_P"%7:*.5=@]M4_F?WE+^Q]+_P"@;9_]^%_PH_L?2_\
MH&V?_?A?\*NT4<J[![:I_,_O*7]CZ7_T#;/_ +\+_A1_8^E_] VS_P"_"_X5
M=HHY5V#VU3^9_>4O['TO_H&V?_?A?\*/['TO_H&V?_?A?\*NT4<J[![:I_,_
MO*7]CZ7_ - VS_[\+_A1_8^E_P#0-L_^_"_X5=HHY5V#VU3^9_>4O['TO_H&
MV?\ WX7_  H_L?2_^@;9_P#?A?\ "KM%'*NP>VJ?S/[RE_8^E_\ 0-L_^_"_
MX4?V/I?_ $#;/_OPO^%7:*.5=@]M4_F?WE+^Q]+_ .@;9_\ ?A?\*/['TO\
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MR$$0KP=I]JV:I:S_ ,@/4/\ KVD_]!-3**L]#2C6J>TC[SW74-'_ .0)8?\
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M1@C;P38SE/WD8 5O0$\UJCPAIP5U\RX*G[JF3A3Z@8Z_6K[:/;/I"Z:Y=H5
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M !1110 4444 %%%% !1110 52UG_ ) >H?\ 7M)_Z":NU2UG_D!ZA_U[2?\
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M,+8X)SC.>@H ]7HK/T%G?P]IK2,S.;6(L6.23M'4UH4 %%%% !1110 4444
M%%%% !5+6?\ D!ZA_P!>TG_H)J[5+6?^0'J'_7M)_P"@FE+9FE'^)'U0:/\
M\@2P_P"O:/\ ]!%7:I:/_P @2P_Z]H__ $$5=HCL@K?Q)>K"BBBF9A1110 4
M444 5+#3+;3?M/V967[3.UQ)EB<NV,GGITZ5;HHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^>EK_P!^/_KT?4*OD'URGYGM-%>+?\++\2?\]+7_ +\?_7H_X67XD_YZ6O\
MWX_^O1]0J^0?7*?F>TT5XM_PLOQ)_P ]+7_OQ_\ 7H_X67XD_P">EK_WX_\
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MJG\OXARP_F_ YJ&YDMIEF@F:*5>5=&VL/H137E,DC222%W8Y9F;))]2:Z?\
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M/0=JL7OBZ.=@;>R:/9!<1Q$E 5:8C<Q"J!P,^Y)R:K]\1^Z.6!R,T4=**Z3
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M;D8.%''O52#PIJMS;V<\20-'=N(XR)>C%2P!]. ?6CGI]_Q#DGV_ H_;+/\
MZ!4/_?Z3_P"*H^V6?_0*A_[_ $G_ ,52:AIEQICPK.8F6:,2QO$X=67)&0?J
M#5.M$DU=?F2VUHS1M[BREN88VTJ'#R*IQ-)T)Q_>I;BXLH;J:)=*A*I(RC,T
MG0'']ZJ=G_Q_VW_79/\ T(4M[_R$+K_KL_\ Z$:7+J%]";[99_\ 0*A_[_2?
M_%4?;+/_ *!4/_?Z3_XJJ5%/E0N9EW[99_\ 0*A_[_2?_%4?;+/_ *!4/_?Z
M3_XJNDM/ 3W4VF 7^V&\MO/>3RO]4V%PF,\YW"L=O"^J+9PW1BC$,S(H+. 5
M#DA"WH#BLU4IOK^9HX370I_;+/\ Z!4/_?Z3_P"*H^V6?_0*A_[_ $G_ ,56
MBWA#54N'AD-K'L2.3>\VU2)&VK@D=R,8K&N;>6TNIK:==LL+F-UST(.#51<)
M;/\ $EJ2W7X%C[99_P#0*A_[_2?_ !5'VRS_ .@5#_W^D_\ BJI457*B>9GN
M_@=TD\':<T<0B4JV$4D@?,>YYKH:YOP%_P B3IO^XW_H9KI*^?K?Q)>K/:I?
M O0^;+K_ (_;C_KJ_P#Z$:BJ6Z_X_;C_ *ZO_P"A&HJ^B6QXC.Q\/ZC!!HFG
MQ_VZFG/;7[3SQEGW2QX7@!1ALX/!H?4-"FTVX8"UCCDCG+6[0YF,[29C8-C[
MH7'0]B,5QU%8NBKWN:^U=K6.^EU'PX^H0S,UEYOD2JBHH\F-SC:2WE\?Q !E
M;%<?K,MO/K%U+:1PQP,^56$G9TY*Y ."<GH*HT4X4E!W3)G4<E8*NQ?\@.Z_
MZ^(O_07JE5V+_D!W7_7Q%_Z"]:2V)6Y2HHHIB"K.G7TFFZE;7T7WX)%D ]<'
MD?B.*K44-75F"=M3MK[5=%6YN+*RFC.G1V,YB+J<//*X;&/4#"_A3[[4]$,S
M3PS6:RFQN$$<,8*!B!L .Q3R<X# X]:X:BL/81[FOMGV-SQ=?1:CXAFN[>>*
M:&1$V&,8P-H!!X'(.:PZ**UC%1BHKH9R?,VV%%%%4(T[.6*+1;HRVR3@W$6%
M9F7'ROSP14/VRS_Z!4/_ '^D_P#BJ(_^0%<_]?,7_H+U2J$DVRF]$7?MEG_T
M"H?^_P!)_P#%4?;+/_H%0_\ ?Z3_ .*JE7867@-[U]*(OML-[;F:23R\^2<#
M"XSSG</2IG*$/B?YCC&4OA7Y'.?;+/\ Z!4/_?Z3_P"*H^V6?_0*A_[_ $G_
M ,55W_A%-7-M%<);ATE=510WS8=BJ$CL"1ZU8G\*26^G?:3=Q2OY,LI$)#(-
MDBIC=GU;\,4<]/O^(^6?8ROMEG_T"H?^_P!)_P#%4?;+/_H%0_\ ?Z3_ .*K
M0D\(ZK#(%D-JJ&!I_-,P"!%(#<X[9']*R[^QGTR^FL[I0LT1PP4Y'3((/<8-
M.+A+9_B)J2W7X$GVRS_Z!4/_ '^D_P#BJLV,EC=78B?2X@NQVXFD_A4D=_:L
MFKVD?\A$?]<I?_1;4Y1LF*+U0@O+/'_(*A_[_2?_ !5'VRS_ .@5#_W^D_\
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M5I1-+($8&5Q&8\MSZ-VQS2Q^,]0C2W M[4M T;!B&RQ1"BY&< 8/08YKL/\
MA6.D_P#/]??^.?X4?\*QTG_G^OO_ !S_  H]OANP>RKGF]YJ,M]!90R*@6S@
M\B/:#DKDGGWYJI7J?_"L=)_Y_K[_ ,<_PH_X5CI/_/\ 7W_CG^%6L716Q#PU
M5[GF5G_Q_P!M_P!=D_\ 0A2WO_(0NO\ KL__ *$:].A^&FE13QR"]O24<, =
MG8Y]*6;X:Z5+/+(;V]!=RQ V]SGTH^N4KWN/ZM4L>4T5ZG_PK'2?^?Z^_P#'
M/\*/^%8Z3_S_ %]_XY_A3^N4NXOJM0X^W\::G;)"B)!LB\G:"#SY0P._?O\
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M_GVO/^_Z_P#Q%?0IZ;'BM>92HJ[YFE?\^UY_W_7_ .(H\S2O^?:\_P"_Z_\
MQ%',^P6\RE15WS-*_P"?:\_[_K_\11YFE?\ /M>?]_U_^(HYGV"WF4JNQ?\
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M\YJ2H>Y:/FRZ_P"/VX_ZZO\ ^A&HJENO^/VX_P"NK_\ H1J*OI5L>"PHHHH
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MUJH-5TW</^)C9]?^>Z_XT'5=-W'_ (F-GU_Y[K_C19A=%JBJG]JZ;_T$;/\
M[_K_ (T?VKIO_01L_P#O^O\ C19A=%+Q%J5]I-@UY:QV9BB1GE:Y=AN/&R-
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M(U'E7:*S!,8#=<@D9(/7O2LPNC*_X3BZ6335>SMU^TJC-R_[T-,8@T9QA00
MX+XR" /6NV(P2*YJ?3/#]TZO<:P9251)MU\N+A48L@D QN ).,8X.*VCJVG$
MY.HV>3_TW3_&FDPNBW153^U=-_Z"-G_W_7_&C^U=-_Z"-G_W_7_&BS"Z+O\
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M8=V;$_B.ZGT-=)\J)( J*Q5G)(4Y'!)"\]< 9K'HHHC%1V!R;W)K-0VH6:L
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M25]T4O[(TS_H'6G_ 'X7_"C^R-,_Z!UI_P!^%_PJ[12NQV12_LC3/^@=:?\
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M ,)+H7_09L/_  (3_&C_ (270O\ H,V'_@0G^-+EEV*YEW-2BLO_ (270O\
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MB_\ Z E;58/AB>&Z.L3V\J2Q/J+E71LJPV)T-;U$]Q1V/FRZ_P"/VX_ZZO\
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M&!?$%@^"P9M^6R0#R3T'I5I*UFB&W?1DT_C^UM-2U.VNK*6%+&%Y@7<"24*
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M)="_Z#-A_P"!"?XU7OD^Z&@Z.-$TYK;SS.\DTD\C[-B[G;)"K_"OH*U*R_\
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MFN0 XSZ)N'U8U)IFGO92ZA/,ZR3WETTS,HZ)@*B_@H _.EJ,N^3#_P \8_\
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MM&&;[JG&3]!WHKDM<@M[SQ3:6YTZ=) T,LNI"V=\!')2*-@"%)/WFR  >^>
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M *"&F_\ @(__ ,<H^S^(_P#H(:;_ . C_P#QRMFBCF8<IC?9_$?_ $$--_\
M 1__ (Y1]G\1_P#00TW_ ,!'_P#CE;-%',PY3&^S^(_^@AIO_@(__P <H^S^
M(_\ H(:;_P" C_\ QRMFBCF8<IC?9_$?_00TW_P$?_XY1]G\1_\ 00TW_P !
M'_\ CE;-%',PY3&^S^(_^@AIO_@(_P#\<H^S^(_^@AIO_@(__P <K9HHYF'*
M8WV?Q'_T$--_\!'_ /CE'V?Q'_T$--_\!'_^.5LT4<S#E,;[/XC_ .@AIO\
MX"/_ /'*/L_B/_H(:;_X"/\ _'*V:*.9ARF-]G\1_P#00TW_ ,!'_P#CE'V?
MQ'_T$--_\!'_ /CE;-%',PY3&^S^(_\ H(:;_P" C_\ QRC[/XC_ .@AIO\
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M_B/_ *"&F_\ @(__ ,<K9HHYF'*8WV?Q'_T$--_\!'_^.4?9_$?_ $$--_\
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+M_*BBD]AQ^)'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>img131876768_13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img131876768_13.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $N G # 2(  A$! Q$!_\0
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M9 V"<=J6&Y@N,^3,DF.NULXI<B[%JO+^;\2'^R]/_P"?&V_[]+_A1_9>G_\
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 54U3_D$WG_7!_\
MT$U;JIJG_((O/^N#_P#H)I2V-*7QQ]4&E_\ ()L_^N"?^@BK=5-+_P"039_]
M<$_]!%4];\2:=X>$)OW=1,2$VH6Z4Z<7*R1-:2C.3?<UZ*Y'_A97AS_GO/\
M]^31_P +*\.?\]Y_^_)K;ZO5_E9A[:G_ #(ZZ@@$$'D&N1_X65X<_P">\_\
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MN9H6N[9!$R1ESN(,C#(08'49Y/2HD\6RP:W;ZE;V:((49#"TSR"0'KDMD_\
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MM[I5HHHK8S"BBB@ HHHH ****  ]*]_C_P"1.'_7C_[)7@!Z5[_'_P B</\
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M\&CRI?\ GE)_WP: &'I7O\?_ ")P_P"O'_V2O C%+C_52?\ ?!KWZ/CP</\
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M]3VH TZSM5_UNG?]?:_^@M6C6=JO^MT[_K[7_P!!:@#1HHHH **** "BBB@
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MQ_Y"\7_7$?S-<]7U>7?[K#T.ZC\"/4/A7_QYW'_7U_[(*]#U3_D$7G_7!_\
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M"1IQ3J+1([(PE971IZ!_R ;/_<K2J;3/"VL66FP6TD,+-&N"1+P:M_V!JO\
MSPB_[^BODJ]2$JLI)Z-O\S@EAZKD_=,X45H?V!JO_/"+_OZ*7^P-5_YX1?\
M?T5ESQ[D_5JO\IG"BM#^P-5_YX1?]_!2_P!@:K_SPB_[^BCGCW#ZM5_E/+?%
M'_(?N/HO\A6/7H6L?#O7]1U.6YC%JJ/C :3G@51_X5=XB];3_OY_]:OK\+F6
M$A0A&4U=)'?3IR44FCBAU/UI:[,?"WQ'D\VG_?W_ .M2_P#"KO$7K:?]_/\
MZU=']JX/_GXB^278XH=3]:6NS'PM\1Y/-I_W]_\ K4O_  J[Q%ZVG_?S_P"M
M1_:N#_Y^(.278E\'_P#((D_ZZFN@IFA>#M:TNQ:"6.!F+ELK+6I_8&J_\\(O
M^_HKY+&UH3Q$Y1=TV<%3#U7-M(\V\8_\A>+_ *XC^9KGJ](U[P#KVJWR3PK;
M*JQA<-)SG)K+_P"%7>(O6T_[^?\ UJ^BP.8X6GAX0E-)I'72IS4$FC<^%?\
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M\%7=[>0W3WB,I&S :%(^><XV]1[FNJH Q]/U6\NKVXBFL'C2-20WN&("GU)
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M\< $#YO05U0Y7"=VE?\ S1EAX.%.*O<Z.BBBN0Z HHHH IZO_P @>]_ZX/\
MR-6U^Z/I535_^0/>_P#7!_Y&K:_='TH 6BBB@#F?%\L*KIT4BR,S7 90DK(>
M.^0,'KT/K5B]OI8?%-C9HL8BE0NY*#<3]?PJ/Q=;^?!I_7Y;I3@!3G@\<_S[
M5#=7MK)XYLX-P^T1(5QN3=R,]"=V/H.U '45DZ__ *BU_P"N_P#[(]:U9.O_
M .HM?^N__LCT <*.@H/2@=*#TH ***!R0!WH$]BW16F- U @'RTZ?WJ4>']0
MR/W:=?[U=/,NYX7L*G\K*8L;L@?Z-+_WS1]@N\?\>TO_ 'S7=H"$4'J!3JS]
MJSN^H1[GFH^$ELXWG5IP6^8CREXS2_\ "H;7_H+S_P#?I:])HKM_M?&_S_@O
M\CM]G$RK?P]IL%M%$;9',:!2QZM@8S4O]A:9_P ^<?ZUH45YS=W=EC418T5$
M&%48 ]*=112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M13("BBB@ K(TS_D.ZW_UVB_]%+6L&5B0&!(Z@'I63IG_ "'=;_Z[1?\ HI:
M->BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV'_/&Y_[Y7_&C_A+[#_GC<_]\K_C1SQ#ZM5['045S_\ PE]A_P \;G_OE?\
M&C_A+[#_ )XW/_?*_P"-'/$/JU7L=!17/_\ "7V'_/&Y_P"^5_QH_P"$OL/^
M>-S_ -\K_C1SQ#ZM5[#F\(:8]JUN[73(> 3.V5&2=H]LD\59TC0[?2);IX2?
MW[+QG[JJH 'X\D^Y-5/^$OL/^>-S_P!\K_C1_P )?8?\\;G_ +Y7_&CGB'U:
MKV+D7A_389K.9+?][9C$3[CD#:5P?7ACUJK+X4L[B!H7FN8U9RQ,$IC+C>7
M;'4 D_@:;_PE]A_SQN?^^5_QH_X2^P_YXW/_ 'RO^-'/$/JU7L6K+P_;:<4-
MM+."G"^9(6"J3DA0>F35N73;6:\-U)&6E**G+'&%)8<?4FLK_A+[#_GC<_\
M?*_XT?\ "7V'_/&Y_P"^5_QHYXA]6J]BY-X?TZ<JSP9D2?[0CECE7W!ORR!Q
M5NPM%L;*.W4[MN69O[S$EF/XDDUD?\)?8?\ /&Y_[Y7_ !H_X2^P_P">-S_W
MRO\ C1SQ#ZM5['045S__  E]A_SQN?\ OE?\:/\ A+[#_GC<_P#?*_XT<\0^
MK5>QT%%<_P#\)?8?\\;G_OE?\:/^$OL/^>-S_P!\K_C1SQ#ZM5[&KJ&GPZC%
M'',TB^7()4:-RK!AT.1]:R;GP?I\RLR-,)MI 9Y68;BI7>1W;#'GUI?^$OL/
M^>-S_P!\K_C1_P )?8?\\;G_ +Y7_&CGB'U:KV+9\/V9BTZ,/.B:>NV%4E(7
MH!DCN<#]33$\.6D%H\-NTBL71T=VW;2ARO7L*K_\)?8?\\;G_OE?\:/^$OL/
M^>-S_P!\K_C1SQ#ZM5[#V\)Z<UX+DR764!\I//;9"2?O(/X3UY'K3_\ A&+#
MSO-+W)=E"RDS']Z V[Y_7D_E4/\ PE]A_P \;G_OE?\ &C_A+[#_ )XW/_?*
M_P"-'/$/JU7L:TEC'<6D=O<LT@1TDSG'*L&'Z@51?PU8/#/&QN"TR[#+YS!U
M7G"JW8#)Q]:K_P#"7V'_ #QN?^^5_P :/^$OL/\ GC<_]\K_ (T<\0^K5>Q(
M_A>SP6B>99/*\D%G+#;@KT]<$BMF&)8((X4X2-0J_0#%87_"7V'_ #QN?^^5
M_P :/^$OL/\ GC<_]\K_ (T<\0^K5>QT%%<__P )?8?\\;G_ +Y7_&C_ (2^
MP_YXW/\ WRO^-'/$/JU7L=!17/\ _"7V'_/&Y_[Y7_&C_A+[#_GC<_\ ?*_X
MT<\0^K5>QT%%<_\ \)?8?\\;G_OE?\:/^$OL/^>-S_WRO^-'/$/JU7L=!17/
M_P#"7V'_ #QN?^^5_P :/^$OL/\ GC<_]\K_ (T<\0^K5>QT%%<__P )?8?\
M\;G_ +Y7_&C_ (2^P_YXW/\ WRO^-'/$/JU7L=!17/\ _"7V'_/&Y_[Y7_&C
M_A+[#_GC<_\ ?*_XT<\0^K5>QT%%<_\ \)?8?\\;G_OE?\:/^$OL/^>-S_WR
MO^-'/$/JU7L=!17/_P#"7V'_ #QN?^^5_P :/^$OL/\ GC<_]\K_ (T<\0^K
M5>QT%%<__P )?8?\\;G_ +Y7_&C_ (2^P_YXW/\ WRO^-'/$/JU7L=!17/\
M_"7V'_/&Y_[Y7_&C_A+[#_GC<_\ ?*_XT<\0^K5>QT%%<_\ \)?8?\\;G_OE
M?\:/^$OL/^>-S_WRO^-'/$/JU7L=!17/_P#"7V'_ #QN?^^5_P :/^$OL/\
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M?\\;G_OE?\:.>(?5JO8Z"BN?_P"$OL/^>-S_ -\K_C1_PE]A_P \;G_OE?\
M&CGB'U:KV.@JIJG_ ""+S_K@_P#Z":RO^$OL/^>-S_WRO^-5M1\66,FF72"&
4XRT+ 95?0^])SC8NEAJO.M.I_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>img131876768_14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img131876768_14.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %- G # 2(  A$! Q$!_\0
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M52 6 )Z FDZ?*[-#AB93CS1D[>I4_L?2_P#H&V?_ 'X7_"C^Q]+_ .@;9_\
M?A?\*36+]M,TV2Z2,2%2!M)QU.*I:AKLEEI-G>K KM<;<J6P!D9IQI<VR)GC
M'!M2D]->I>_L?2_^@;9_]^%_PH_L?2_^@;9_]^%_PJXIRH/J*P]2UR[M=773
M[6S2=V0,N7P3U_PHC3YG9(JIBI4U>4G^)H?V/I?_ $#;/_OPO^%']CZ7_P!
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M_?A?\*N@@C(.114\J[&GMJG\S^\I?V/I?_0-L_\ OPO^%4]7TG34T6^9=/M
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M-*6S:^>G];B:9;BS\92VJ2N\4<)VAFS@8!Q^&:BL--@U/Q!JT=R7,2R$[%;
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MFS.[.[D^WM6GD9QFN0T1UC37F:X^S@2',N,[.6YK)NTM[:TBN;+[>90XS=2
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M !1110 4444 %%%% !1110 52UG_ ) >H?\ 7M)_Z":NU2UG_D!ZA_U[2?\
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MTJ^JA5"J % P .U"N3+EZ"T444R0HHHH **** "BBB@ JEK/_(#U#_KVD_\
M035VJ6L_\@/4/^O:3_T$TI;,TH_Q(^J#1_\ D"6'_7M'_P"@BI[NZALK5[FX
M8K$@RQ"ECZ=!R:@T?_D"6'_7M'_Z"*@\1?\ (#G_ -Z/_P!#6B.R"M_$EZL?
M_;5M_P \+_\ \ 9O_B:/[:MO^>%__P" ,W_Q-:-9UOKNF75X]I!>1O<)*T+1
MC.0X!)'X 'GIQCK3,P_MJV_YX7__ ( S?_$T?VU;?\\+_P#\ 9O_ (FK5S>6
MUE!+/<SI%'#&99&8XVH.K'VJM:ZWIMX]JD%VC-=0?:85(*EX\@;AD>K#WYH
M3^VK;_GA?_\ @#-_\31_;5M_SPO_ /P!F_\ B:O&:(#)E0#=M^\.OI]:S3XE
MT4<'4K<-YWV?;N^;?YGEXQU^^"N>F: )/[:MO^>%_P#^ ,W_ ,31_;5M_P \
M+_\ \ 9O_B:OB1&QAU.>F#UXS_*G4 9W]M6W_/"__P# &;_XFC^VK;_GA?\
M_@#-_P#$U6\5^(%\+^'+G5VM_M A:-?+,@C!W.J9+$' &[.?:L>Q^)&E2Z F
MK:A'):QF>:$^4#<)B(X:0.@QL[Y('TH Z'^VK;_GA?\ _@#-_P#$T?VU;?\
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M10!G?VU;?\\+_P#\ 9O_ (FC^VK;_GA?_P#@#-_\36C10!G?VU;?\\+_ /\
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M+_Z :NQ?ZE/]T52UW_D7M2_Z]9?_ $ U=B_U*?[HH ?1110 4444 %9FN?\
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MX>^(VBSR,!;:D&M6.?[QP ?^!A: /KNBBB@#/UW_ )%[4O\ KUE_] -78O\
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M]H*.)8(A'_9SG8$&W/V>4YQ70_LX0Q'P?J<QC0RB_90^T;@/+3C/I0![0,@
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M3_=% #Z*** "BBB@ K*UXE;2U(4L1>P<#J?W@K5K,US_ (][3_K]@_\ 1@H
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M4?2F_"Q-37P_.;UI3:M+FT$I)(7'S8SR%ST_&CZNOJ_MN9;VMU'?6QW59?\
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M[/;0R32LI(CC&6; YP._'/X5K[*G]3Y++DV^6U_OUN%WS'TW67_S-8_Z\?\
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M:ZCDG:<O, ""548X_P!VNHH **** "BBB@ HHHH **** "N!^)O_ "1G5_\
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MH).,G/>IZ* "BBB@"KIW_(/@_P!VK55=._Y!\'^[5J@ HHHH **** "BBB@
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M  IU% !1110 4444 %9NMQS/9PM#"\S17,4I2/&XJK@G&2.U:5% &7_;$O\
MT"-1_P"^$_\ BZ/[8E_Z!&H_]\)_\76I10!E_P!L2_\ 0(U'_OA/_BZ/[8E_
MZ!&H_P#?"?\ Q=:E% &7_;$O_0(U'_OA/_BZ/[8E_P"@1J/_ 'PG_P 76I10
M!E_VQ+_T"-1_[X3_ .+H_MB7_H$:C_WPG_Q=:E% &+:ZE-!:QQ-I&HY5<'Y$
M_P#BZF_MB7_H$:C_ -\)_P#%UJ44 9?]L2_] C4?^^$_^+H_MB7_ *!&H_\
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M $VPDNF^Q!MUTT<)C;)CADV<L6 R?49/(PIYIMUXXO[>24K%8O\ +-BVR1+
M4GCB#2$MC;ARQ^[T'..:[EH(GQOB1MI)&5!P3UJC;Z'96VHS7RK(\TJLO[R0
MN%5B"P4'H"0/R Z4 ,\/:E<:II?VBY2!9!*\>8) ZL%8@'@D ^HR<'O6K341
M8T"(H50,!5& *=0 4444 %<AXJ\=Q^%]3BLFTY[DR0B7>LH7&21C&#Z5U]>-
M_%E@/%%KD@?Z&O\ Z&U>EE.'IXC$JG45U9D5&TKHV/\ A;\/_0$E_P# @?\
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M_P#8UC&O3LM3T*N58MSDU#KW7^9VE5#I>GDY-C:DG_IBO^%<M_PG_P#U#/\
MR/\ _8T?\)__ -0S_P C_P#V-/V]/N1_96,_D_%?YG4_V5IW_/A:_P#?E?\
M"@:9IZD$6-L".01"O^%<M_PG_P#U#/\ R/\ _8T?\)__ -0S_P C_P#V-'MZ
M?</[*QG\GXK_ #.HU#3+?4_LOV@,1;3B= ,8+ $#.>H^8U1O_#%AJ-RUQ.TP
MF"HMNR,!]EVMNS'Q\I)QD\YP!TXK%_X3_P#ZAG_D?_[&C_A/_P#J&?\ D?\
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M_(__ -C1[>GW#^RL9_)^*_S.TJ.2WAE;=)#&YQC+*#7'_P#"?_\ 4,_\C_\
MV-'_  G_ /U#/_(__P!C36(@MF']E8O^3\5_F=;]BM?^?:'_ +]BC[%:_P#/
MM#_W[%<E_P )_P#]0S_R/_\ 8T?\)_\ ]0S_ ,C_ /V-/ZU'^;\Q?V3B_P"3
M\5_F=DD:1+MC147T48%58=+L;:^EO8+:.*XF7;(Z#;O&<\@<$^_6N7_X3_\
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M_P#V-'MZ?</[*QG\GXK_ #.THKB_^$__ .H9_P"1_P#[&C_A/_\ J&?^1_\
M[&CV]/N']E8S^3\5_F=I17%_\)__ -0S_P C_P#V-'_"?_\ 4,_\C_\ V-'M
MZ?</[*QG\GXK_,[2BN+_ .$__P"H9_Y'_P#L:/\ A/\ _J&?^1__ +&CV]/N
M']E8S^3\5_F=I5+6?^0'J'_7M)_Z":YC_A/_ /J&?^1__L:JZCX[\_2[N+^S
=<;X77/G],J1_=I2KT[/4NEE6+52+<.JZK_,__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>27
<FILENAME>lrmr-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-03-14T16:10:28.3903+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.larimartx.com/20231231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:lrmr="http://www.larimartx.com/20231231" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" namespace="http://xbrl.sec.gov/country/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" namespace="http://xbrl.sec.gov/stpr/2023"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" namespace="http://xbrl.sec.gov/ecd/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" namespace="http://fasb.org/srt/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail2" id="DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail2">
        <link:definition>100020 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Lease Liabilities Due Under Lease Agreements (Detail) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100030 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100040 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" id="StatementConsolidatedStatementsOfChangesInStockholdersEquity">
        <link:definition>100050 - Statement - Consolidated Statements of Changes in Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100060 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20231231/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganization" id="DisclosureDescriptionOfBusinessAndOrganization">
        <link:definition>995455 - Disclosure - Description of Business and Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>995465 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecurities1" id="DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecurities1">
        <link:definition>995475 - Disclosure - Fair Value Measurements and Cash Equivalents/Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" id="Role_DisclosurePrepaidExpensesAndOtherCurrentAssets">
        <link:definition>995485 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureFixedAssets" id="Role_DisclosureFixedAssets">
        <link:definition>995495 - Disclosure - Fixed Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureAccruedExpenses" id="Role_DisclosureAccruedExpenses">
        <link:definition>995505 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptions" id="Role_DisclosureStockholdersEquityAndStockOptions">
        <link:definition>995515 - Disclosure - Stockholders&#8217; Equity and Stock Options</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>995525 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>995535 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" id="Role_DisclosureRelatedPartyTransactions">
        <link:definition>995545 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>995555 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesTables" id="DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesTables">
        <link:definition>995565 - Disclosure - Fair Value Measurements and Cash Equivalents/Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" id="Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables">
        <link:definition>995575 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureFixedAssetsTables" id="Role_DisclosureFixedAssetsTables">
        <link:definition>995585 - Disclosure - Fixed Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesTables" id="Role_DisclosureAccruedExpensesTables">
        <link:definition>995595 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsTables" id="Role_DisclosureStockholdersEquityAndStockOptionsTables">
        <link:definition>995605 - Disclosure - Stockholders&#8217; Equity and Stock Options (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>995615 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>995625 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20231231/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail" id="DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail">
        <link:definition>995635 - Disclosure - Description of Business and Organization - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>995645 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesAdditionalInformationDetail" id="DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesAdditionalInformationDetail">
        <link:definition>995655 - Disclosure - Fair Value Measurements and Cash Equivalents/Marketable Securities - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail" id="DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail">
        <link:definition>995665 - Disclosure - Fair Value Measurements and Cash Equivalents/Marketable Securities - Summary of Cash Equivalents and Marketable Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail" id="DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail">
        <link:definition>995675 - Disclosure - Fair Value Measurements and Cash Equivalents/Marketable Securities - Summary of Marketable Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" id="Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail">
        <link:definition>995685 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail" id="Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail">
        <link:definition>995695 - Disclosure - Fixed Assets - Schedule of Fixed Assets, Net (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureFixedAssetsAdditionalInformationDetail" id="Role_DisclosureFixedAssetsAdditionalInformationDetail">
        <link:definition>995705 - Disclosure - Fixed Assets - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" id="Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail">
        <link:definition>995715 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail" id="Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail">
        <link:definition>995725 - Disclosure - Stockholders Equity and Stock Options - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsAssumptionsUsedToDetermineFairValueOfStockOptionsGrantedDetail" id="DisclosureStockholdersEquityAndStockOptionsAssumptionsUsedToDetermineFairValueOfStockOptionsGrantedDetail">
        <link:definition>995735 - Disclosure - Stockholders Equity and Stock Options - Assumptions used to Determine Fair Value of Stock Options Granted (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail" id="DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail">
        <link:definition>995745 - Disclosure - Stockholders Equity and Stock Options - Summary of Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails" id="DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails">
        <link:definition>995755 - Disclosure - Stockholders Equity and Stock Options - Summary of Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockbasedCompensationExpenseDetail" id="DisclosureStockholdersEquityAndStockOptionsSummaryOfStockbasedCompensationExpenseDetail">
        <link:definition>995765 - Disclosure - Stockholders Equity and Stock Options - Summary of Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" id="DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
        <link:definition>995775 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail" id="DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail">
        <link:definition>995785 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Lease Liabilities Due Under Lease Agreements (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" id="Role_DisclosureIncomeTaxesAdditionalInformationDetail">
        <link:definition>995795 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfLossBeforeIncomeTaxesDetail" id="Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfLossBeforeIncomeTaxesDetail">
        <link:definition>995805 - Disclosure - Income Taxes - Schedule of Domestic and Foreign Components of Loss Before Income Taxes (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail" id="Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail">
        <link:definition>995815 - Disclosure - Income Taxes - Reconciliation of Federal Statutory Income Tax Rate (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail" id="Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail">
        <link:definition>995825 - Disclosure - Income Taxes - Schedule of Net Deferred Tax Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfChangesInValuationAllowanceForDeferredTaxAssetsDetail" id="Role_DisclosureIncomeTaxesSummaryOfChangesInValuationAllowanceForDeferredTaxAssetsDetail">
        <link:definition>995835 - Disclosure - Income Taxes - Summary of Changes in the Valuation Allowance for Deferred Tax Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>995845 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="lrmr-20231231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="lrmr-20231231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:href="lrmr-20231231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="lrmr-20231231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="lrmr-20231231.xsd#StatementConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:href="lrmr-20231231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20231231/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganization" xlink:href="lrmr-20231231.xsd#DisclosureDescriptionOfBusinessAndOrganization" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="lrmr-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecurities1" xlink:href="lrmr-20231231.xsd#DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecurities1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:href="lrmr-20231231.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureFixedAssets" xlink:href="lrmr-20231231.xsd#Role_DisclosureFixedAssets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureAccruedExpenses" xlink:href="lrmr-20231231.xsd#Role_DisclosureAccruedExpenses" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptions" xlink:href="lrmr-20231231.xsd#Role_DisclosureStockholdersEquityAndStockOptions" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="lrmr-20231231.xsd#DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="lrmr-20231231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:href="lrmr-20231231.xsd#Role_DisclosureRelatedPartyTransactions" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="lrmr-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesTables" xlink:href="lrmr-20231231.xsd#DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="lrmr-20231231.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureFixedAssetsTables" xlink:href="lrmr-20231231.xsd#Role_DisclosureFixedAssetsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesTables" xlink:href="lrmr-20231231.xsd#Role_DisclosureAccruedExpensesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsTables" xlink:href="lrmr-20231231.xsd#Role_DisclosureStockholdersEquityAndStockOptionsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:href="lrmr-20231231.xsd#DisclosureCommitmentsAndContingenciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="lrmr-20231231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20231231/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail" xlink:href="lrmr-20231231.xsd#DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="lrmr-20231231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesAdditionalInformationDetail" xlink:href="lrmr-20231231.xsd#DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail" xlink:href="lrmr-20231231.xsd#DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail" xlink:href="lrmr-20231231.xsd#DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:href="lrmr-20231231.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail" xlink:href="lrmr-20231231.xsd#Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureFixedAssetsAdditionalInformationDetail" xlink:href="lrmr-20231231.xsd#Role_DisclosureFixedAssetsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" xlink:href="lrmr-20231231.xsd#Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail" xlink:href="lrmr-20231231.xsd#Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsAssumptionsUsedToDetermineFairValueOfStockOptionsGrantedDetail" xlink:href="lrmr-20231231.xsd#DisclosureStockholdersEquityAndStockOptionsAssumptionsUsedToDetermineFairValueOfStockOptionsGrantedDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail" xlink:href="lrmr-20231231.xsd#DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails" xlink:href="lrmr-20231231.xsd#DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockbasedCompensationExpenseDetail" xlink:href="lrmr-20231231.xsd#DisclosureStockholdersEquityAndStockOptionsSummaryOfStockbasedCompensationExpenseDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="lrmr-20231231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail" xlink:href="lrmr-20231231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="lrmr-20231231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfLossBeforeIncomeTaxesDetail" xlink:href="lrmr-20231231.xsd#Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfLossBeforeIncomeTaxesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail" xlink:href="lrmr-20231231.xsd#Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail" xlink:href="lrmr-20231231.xsd#Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfChangesInValuationAllowanceForDeferredTaxAssetsDetail" xlink:href="lrmr-20231231.xsd#Role_DisclosureIncomeTaxesSummaryOfChangesInValuationAllowanceForDeferredTaxAssetsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="lrmr-20231231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail2" xlink:href="lrmr-20231231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail2" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_TaxCutsAndJobsActOf2017CapitalizationOfResearchAndDevelopmentCostsUnderIrcSection174" xlink:label="lrmr_TaxCutsAndJobsActOf2017CapitalizationOfResearchAndDevelopmentCostsUnderIrcSection174"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_LabSpaceMember" xlink:label="lrmr_LabSpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_MilestonePaymentAmount" xlink:label="lrmr_MilestonePaymentAmount"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_LeaseTermCommencementDate" xlink:label="lrmr_LeaseTermCommencementDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_EmployeesAndDirectorsMember" xlink:label="lrmr_EmployeesAndDirectorsMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_PrivateOfferingMember" xlink:label="lrmr_PrivateOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_IncomeTaxesDisclosureTable" xlink:label="lrmr_IncomeTaxesDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_VestOverFourYearsMember" xlink:label="lrmr_VestOverFourYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_LaboratoryEquipmentMember" xlink:label="lrmr_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_PrepaidResearchAndDevelopmentExpenses" xlink:label="lrmr_PrepaidResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="lrmr_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_PA" xlink:label="stpr_PA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_AreaOfOfficeSpace" xlink:label="lrmr_AreaOfOfficeSpace"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_FirstAnniversaryMember" xlink:label="lrmr_FirstAnniversaryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="lrmr_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_PerformedOutsideUsMember" xlink:label="lrmr_PerformedOutsideUsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_PerformedInUsMember" xlink:label="lrmr_PerformedInUsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="lrmr_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_WarrantsIssuedPricePerShare" xlink:label="lrmr_WarrantsIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDepositLiability" xlink:label="us-gaap_SecurityDepositLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_SubleaseAnnualBaseRent" xlink:label="lrmr_SubleaseAnnualBaseRent"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_Ircsection174Member" xlink:label="lrmr_Ircsection174Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_AdditionalOfficeMember" xlink:label="lrmr_AdditionalOfficeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_VestOneYearMember" xlink:label="lrmr_VestOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_TwoThousandSixteenEquityAndIncentivePlanMember" xlink:label="lrmr_TwoThousandSixteenEquityAndIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_SalesAgreementDescription" xlink:label="lrmr_SalesAgreementDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_NoExpirationMember" xlink:label="lrmr_NoExpirationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="lrmr_TwoThousandTwentyEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_MA" xlink:label="country_MA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_MTSHealthPartnersMember" xlink:label="lrmr_MTSHealthPartnersMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_AccruedResearchAndDevelopmentExpenseCurrent" xlink:label="lrmr_AccruedResearchAndDevelopmentExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_MilestoneLiability" xlink:label="lrmr_MilestoneLiability"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_TwoThousandFourteenStockOptionAndIncentivePlanMember" xlink:label="lrmr_TwoThousandFourteenStockOptionAndIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_USGovernmentSecuritiesMember" xlink:label="lrmr_USGovernmentSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_NetOperatingLossCarryforwardsAnnualUtilizationLimitChangeInOwnership" xlink:label="lrmr_NetOperatingLossCarryforwardsAnnualUtilizationLimitChangeInOwnership"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_AtTheMarketEquityDistributionAgreementMember" xlink:label="lrmr_AtTheMarketEquityDistributionAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_LicenseAgreementConsiderationDeductionPercentage" xlink:label="lrmr_LicenseAgreementConsiderationDeductionPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityReserveEstimatePolicy" xlink:label="us-gaap_LiabilityReserveEstimatePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_VestAnnuallyOverFourYearsMember" xlink:label="lrmr_VestAnnuallyOverFourYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_PercentageOfCompensationForServicesEqualToGrossProceeds" xlink:label="lrmr_PercentageOfCompensationForServicesEqualToGrossProceeds"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember" xlink:label="lrmr_WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_SixthSubleaseYearMember" xlink:label="lrmr_SixthSubleaseYearMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_IncomeTaxesDisclosureLineItems" xlink:label="lrmr_IncomeTaxesDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_ZafgenMember" xlink:label="lrmr_ZafgenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_ChondrialMember" xlink:label="lrmr_ChondrialMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_DomesticAndStateLocalJurisdictionMember" xlink:label="lrmr_DomesticAndStateLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_MergerAgreementMember" xlink:label="lrmr_MergerAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_OperatingLossCarryforwardsMinimumPercentageOfTaxableIncomeInTaxPeriod" xlink:label="lrmr_OperatingLossCarryforwardsMinimumPercentageOfTaxableIncomeInTaxPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="lrmr_StockIssuedDuringPeriodValueExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_FirstSubleaseYearMember" xlink:label="lrmr_FirstSubleaseYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarliestTaxYearMember" xlink:label="us-gaap_EarliestTaxYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_FromExerciseOfWarrantsMember" xlink:label="lrmr_FromExerciseOfWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_MinimumAnnualRoyaltyObligation" xlink:label="lrmr_MinimumAnnualRoyaltyObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_WakeForestUniversityHealthSciencesMember" xlink:label="lrmr_WakeForestUniversityHealthSciencesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:label="lrmr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_NetCapitalizedRDDeferredTaxAssetsRealizationDescription" xlink:label="lrmr_NetCapitalizedRDDeferredTaxAssetsRealizationDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_OtherPrepaidExpenseAndOtherCurrentAssets" xlink:label="lrmr_OtherPrepaidExpenseAndOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_ResearchAndDevelopmentCostsCapitalized" xlink:label="lrmr_ResearchAndDevelopmentCostsCapitalized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_AtTheMarketEquityOfferingProgramMember" xlink:label="lrmr_AtTheMarketEquityOfferingProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_DepreciationExpenseExcludingLeasedAssets" xlink:label="lrmr_DepreciationExpenseExcludingLeasedAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_ProceedsFromExerciseOfStockOptionsIncludedInOtherCurrentAssets" xlink:label="lrmr_ProceedsFromExerciseOfStockOptionsIncludedInOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_EffectiveIncomeTaxRateReconciliationStockCompensationForfeituresPercent" xlink:label="lrmr_EffectiveIncomeTaxRateReconciliationStockCompensationForfeituresPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_TwoThousandFourteenEquityIncentivePlanMember" xlink:label="lrmr_TwoThousandFourteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_PaymentForLicenseAgreements" xlink:label="lrmr_PaymentForLicenseAgreements"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_LikelihoodPercentageMinimum" xlink:label="lrmr_LikelihoodPercentageMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_ProceedsFromExerciseOfStockOptionsAndWarrants" xlink:label="lrmr_ProceedsFromExerciseOfStockOptionsAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_EmployeesMember" xlink:label="lrmr_EmployeesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_CashAndNonCashOperatingLeaseExpense" xlink:label="lrmr_CashAndNonCashOperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_FromPriorPlansMember" xlink:label="lrmr_FromPriorPlansMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_OfficeMember" xlink:label="lrmr_OfficeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_OfficeAndLabMember" xlink:label="lrmr_OfficeAndLabMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_MilestoneExpenses" xlink:label="lrmr_MilestoneExpenses"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="lrmr_DeferredTaxAssetsOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_IndianaUniversityResearchAndTechnologyCorporationMember" xlink:label="lrmr_IndianaUniversityResearchAndTechnologyCorporationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_PayrollTaxesReceivable" xlink:label="lrmr_PayrollTaxesReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_CapitalizedResearchAndDevelopmentAmortizationPeriod" xlink:label="lrmr_CapitalizedResearchAndDevelopmentAmortizationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_InducementStockMember" xlink:label="lrmr_InducementStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_AggregateGrossSalesProceedsUnderSalesAgreement" xlink:label="lrmr_AggregateGrossSalesProceedsUnderSalesAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_FinalSubleaseYearMember" xlink:label="lrmr_FinalSubleaseYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_EquipmentFurnitureAndFixturesAndOfficeEquipmentMember" xlink:label="lrmr_EquipmentFurnitureAndFixturesAndOfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_DepreciationExpensesRelatedToSubletAssets" xlink:label="lrmr_DepreciationExpensesRelatedToSubletAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_TaxCreditCarryForwardExpirationYearStart" xlink:label="lrmr_TaxCreditCarryForwardExpirationYearStart"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_NetOperatingLossCarryForwardExpirationYearBegin" xlink:label="lrmr_NetOperatingLossCarryForwardExpirationYearBegin"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts" xlink:label="lrmr_ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_MA" xlink:label="stpr_MA"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_StockAndWarrantIssuanceTransactionCosts" xlink:label="lrmr_StockAndWarrantIssuanceTransactionCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_OfficeSubleaseMember" xlink:label="lrmr_OfficeSubleaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate" xlink:label="lrmr_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_SummaryOfSignificantAccountingPoliciesTable" xlink:label="lrmr_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_DeferredTaxAssetsFixedAssetsAndIntangibleAssets" xlink:label="lrmr_DeferredTaxAssetsFixedAssetsAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance" xlink:label="lrmr_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term, outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized R&amp;D - acquired in merger with Zafgen</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net capitalized R&amp;D deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, in Process Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_TaxCutsAndJobsActOf2017CapitalizationOfResearchAndDevelopmentCostsUnderIrcSection174_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax cuts and jobs act of 2017, capitalization of research and development costs under irc section 174.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_TaxCutsAndJobsActOf2017CapitalizationOfResearchAndDevelopmentCostsUnderIrcSection174_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Cuts and Jobs Act of 2017, Capitalization of Research and Development Costs Under IRC Section 174</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_TaxCutsAndJobsActOf2017CapitalizationOfResearchAndDevelopmentCostsUnderIrcSection174_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalization of research and development costs under IRC Section 174</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_LabSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lab Space [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_LabSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lab space.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period of stock option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units (RSUs)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Quoted Prices in Active Markets, (Level 1) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_MilestonePaymentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_MilestonePaymentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_MilestonePaymentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of payment due upon reaching milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_LeaseTermCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease term commencement date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_LeaseTermCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Term Commencement Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_LeaseTermCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease term commencement date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements and Cash Equivalents/Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed assets, useful life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Estimated useful life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increases recorded to income tax provision</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Debt, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_EmployeesAndDirectorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employees and Directors [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_EmployeesAndDirectorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employees and Directors [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_EmployeesAndDirectorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employees and directors.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_PrivateOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_PrivateOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_PrivateOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Private offering of securities, as part of a merger agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_IncomeTaxesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_IncomeTaxesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_IncomeTaxesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income Taxes Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_VestOverFourYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vest over four years,</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_VestOverFourYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vest Over Four Years [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_VestOverFourYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vest Over 4 Years [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities Available For Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_PrepaidResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_PrepaidResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Research And Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_PrepaidResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of asset related to consideration paid in advance for costs related to research and development.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Capitalized Research and Development Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized R&amp;D - Section 174 Costs post 2021</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other temporary differences</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Common Stock. Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant date fair value of options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value, Unvested and expected to vest as of December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options Unvested And Expected To Vest, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Per share or unit weighted-average fair value of awards that are unvested and expected to vest under share-based payment arrangement. Excludes share and unit options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total prepaid expenses and other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated Entities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease term expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Tax Authority [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Loss [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_PA_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pennsylvania [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_PA_lbl" xlink:role="http://www.xbrl.org/2003/role/label">PENNSYLVANIA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average discount rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_AreaOfOfficeSpace_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of office space</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_AreaOfOfficeSpace_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area Of Office Space</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_AreaOfOfficeSpace_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Area of office space.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease extension period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Renewal Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Fixed Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Forfeited/Expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">U.S. Government and agency securities (due within 1 year) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Corporations and Agencies Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_FirstAnniversaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First Anniversary [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_FirstAnniversaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First Anniversary [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_FirstAnniversaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First anniversary.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Undesignated preferred stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses and Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses And Other Current Assets [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The entire disclosure for prepaid expenses and other current assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Vested and expected to vest as of December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_PerformedOutsideUsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performed outside US [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_PerformedOutsideUsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performed outside US.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, plant and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, Vested and expected to vest as of December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal statutory income tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrant issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_PerformedInUsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performed in US [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_PerformedInUsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performed in US.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term, Outstanding as of December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents and marketable debt securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash equivalents and marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Undesignated preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_WarrantsIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_WarrantsIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Issued Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_WarrantsIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Per unit amount of prefunded warrant issued.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDepositLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Deposit Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDepositLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease security deposits letters of credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_SubleaseAnnualBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Annual base rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_SubleaseAnnualBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublease annual base rent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_Ircsection174Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IRC Section 174 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_Ircsection174Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IRCSection174 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_Ircsection174Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">IRCSection174.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Disposition of Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Disposition of Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gain on disposal of fixed asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_AdditionalOfficeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Office [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_AdditionalOfficeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Office [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_AdditionalOfficeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional office.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Present value of lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Lease, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adoption Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Total deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_VestOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vest one year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_VestOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vest One Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_VestOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vest 1 Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_TwoThousandSixteenEquityAndIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2016 Equity and Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_TwoThousandSixteenEquityAndIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Sixteen Equity And Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_TwoThousandSixteenEquityAndIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand sixteen equity and incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_SalesAgreementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Sales agreement, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_SalesAgreementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Agreement Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_SalesAgreementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of sales agreement..</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of common stock, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares available for grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating right of use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Leasing Arrangements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Real Estate, Type of Property [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value per share; 115,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 43,909,069 and 43,269,200 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in deferred tax asset valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_NoExpirationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">No Expiration [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_NoExpirationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">No Expiration [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_NoExpirationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">No expiration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Expense (Benefit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2020 Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and Development Expenses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Threshold Number Of Shares Allowed To Issue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The minimum threshold number of shares used to determine the maximum number of shares that may be issued under the Plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum level of maximum number of shares allowed to be issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities and sales of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_MA_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Massachusetts [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_MA_lbl" xlink:role="http://www.xbrl.org/2003/role/label">MOROCCO</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Award vesting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock option vesting percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_MTSHealthPartnersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MTS Health Partners [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_MTSHealthPartnersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">M T S Health Partners [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_MTSHealthPartnersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">MTS Health Partners.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expense Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying value as of the balance sheet date of obligations incurred through that date and payable for expenses related to research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of warrants, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Exercise of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares of issued as a result of the exercise of warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, outstanding as of December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Aggregate intrinsic value, outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Aggregate intrinsic value, outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_MilestoneLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments due</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_MilestoneLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_MilestoneLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of payment due for milestones that have been achieved</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_TwoThousandFourteenStockOptionAndIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2014 Stock Option and Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_TwoThousandFourteenStockOptionAndIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fourteen Stock Option And Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_TwoThousandFourteenStockOptionAndIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand fourteen stock option and incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_TwoThousandFourteenStockOptionAndIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2014 Stock Option and Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain (loss) on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_USGovernmentSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government securities (due within 1 year) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_USGovernmentSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">U.S. Government Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_USGovernmentSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">U.S. Government securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options to purchase shares of common stock granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity and Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity Type of Counterparty [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Maturities of Lease Liabilities Due Under Lease Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_NetOperatingLossCarryforwardsAnnualUtilizationLimitChangeInOwnership_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The annual limitation amount of net operating loss carryforwards that can be utilized to offset taxable income due to changes in ownership.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_NetOperatingLossCarryforwardsAnnualUtilizationLimitChangeInOwnership_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Operating Loss Carryforwards Annual Utilization Limit Change In Ownership</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_NetOperatingLossCarryforwardsAnnualUtilizationLimitChangeInOwnership_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards, change in ownership, annual utilization limit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Credit Risk and Significant Suppliers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Consideration Received on Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_AtTheMarketEquityDistributionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At the market equity distribution agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_AtTheMarketEquityDistributionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Equity Distribution Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_AtTheMarketEquityDistributionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At The Market Equity Distribution Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_AtTheMarketEquityDistributionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Prior ATM Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_LicenseAgreementConsiderationDeductionPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement consideration deduction percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_LicenseAgreementConsiderationDeductionPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Consideration Deduction Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_LicenseAgreementConsiderationDeductionPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount that may be deducted from consideration due to Licensor 2 as a percentage of consideration paid to Licensor 1, whereby Licensor 1 is the identified party.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilityReserveEstimatePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidity and Capital Resources</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilityReserveEstimatePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liability Reserve Estimate, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (See Note 8)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, Vested and expected to vest as of December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_VestAnnuallyOverFourYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vest annually over four years.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_VestAnnuallyOverFourYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vest Annually Over Four Years [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_VestAnnuallyOverFourYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vest Annually Over 4 Years [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_PercentageOfCompensationForServicesEqualToGrossProceeds_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Percentage of compensation for services equal to gross proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_PercentageOfCompensationForServicesEqualToGrossProceeds_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Compensation For Services Equal To Gross Proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_PercentageOfCompensationForServicesEqualToGrossProceeds_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The fee for services as a percentage of gross proceeds resulting from the sale of shares of common stock under a sales agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Wake forest university health sciences and indiana university research and technology corporation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Wake Forest University Health Sciences And Indiana University Research And Technology Corporation [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">WFUHS and IU [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_SixthSubleaseYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sixth sublease year member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_SixthSubleaseYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sixth Sublease Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_SixthSubleaseYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sixth Sublease Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, Unvested and expected to vest as of December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options Unvested And Expected To Vest, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Intrinsic value of awards that are unvested and expected to vest under share-based payment arrangement. Excludes share and unit options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards, Limitations on Use</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unrecognized Tax Benefits, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unrecognized Tax Benefits, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Federal and state research and development tax credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal and state research and development tax credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_IncomeTaxesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_IncomeTaxesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_IncomeTaxesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income Taxes Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Open tax year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Open Tax Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, Exercisable as of December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Common Stock, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Common Stock, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury Bills [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ZafgenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Zafgen [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ZafgenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Zafgen [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ZafgenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Zafgen.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Changes in Valuation Allowance for Deferred Tax Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Valuation Allowance [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Stockholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ChondrialMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Chondrial [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ChondrialMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Chondrial [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ChondrialMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Chondrial.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Over-Allotment Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwritten Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Real Estate [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares, Restricted stock units granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options to purchase shares of stock granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allowance for credit loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Allowance for Credit Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_DomesticAndStateLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Domestic and state local jurisdiction.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_DomesticAndStateLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic And State Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_DomesticAndStateLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal and State [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_MergerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Merger Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_MergerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Merger Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_MergerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of common stock shares issued in exchange for one share of the other company's common stock as part of a merger agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_OperatingLossCarryforwardsMinimumPercentageOfTaxableIncomeInTaxPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards, minimum percentage of taxable income in tax period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_OperatingLossCarryforwardsMinimumPercentageOfTaxableIncomeInTaxPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Minimum Percentage Of Taxable Income In Tax Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_OperatingLossCarryforwardsMinimumPercentageOfTaxableIncomeInTaxPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of limitation on operating loss carryforwards as a percentage of taxable income in any one tax period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Exercisable as of December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_DirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Director [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_DirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Director [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Exercise of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Value of stock issued as a result of the exercise of warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_FirstSubleaseYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First Sublease Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_FirstSubleaseYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First Sublease Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_FirstSubleaseYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First sublease year member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarliestTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earliest Tax Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarliestTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earliest Tax Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accumulated other comprehensive gain (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation expense recognized period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term, Vested and expected to vest as of December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum number of shares that may be issued under stock option incentive plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum level of maximum number of shares allowed to be issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_FromExerciseOfWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">From Exercise of Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_FromExerciseOfWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">From exercise of warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Gross proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive loss:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_MinimumAnnualRoyaltyObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual royalty pay obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_MinimumAnnualRoyaltyObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Annual Royalty Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_MinimumAnnualRoyaltyObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The minimum annual royalty payment that is required under a contractual arrangement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Unobservable Inputs (Level 3) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Debt, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_WakeForestUniversityHealthSciencesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Wake Forest University Health Sciences (WFUHS) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_WakeForestUniversityHealthSciencesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Wake Forest University Health Sciences [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_WakeForestUniversityHealthSciencesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">WFUHS [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net decrease in cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Percentage of outstanding shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Additional Shares Percentage Of Outstanding Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The maximum number of shares that may be added annually to the threshold number of shares issued under the Plan, as a percentage of the shares issued and outstanding on the last day of the immediately preceding fiscal year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchased of equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction, Purchases from Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Financial Statement Error Correction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Prepaid Expenses and Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Prepaid Expenses And Other Current Assets Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of the carrying amounts of prepaid expenses and other current assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, Outstanding as of December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Letter of Credit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock voting rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Voting Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Accumulated depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average common shares outstanding, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_NetCapitalizedRDDeferredTaxAssetsRealizationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net capitalized R&amp;D deferred tax assets realization description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_NetCapitalizedRDDeferredTaxAssetsRealizationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Capitalized R D Deferred Tax Assets Realization Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_NetCapitalizedRDDeferredTaxAssetsRealizationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of the limitation that a capitalized research and development deferred tax asset may be subject to.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Commitments [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assumptions used to Determine Fair Value of Stock Options Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_OtherPrepaidExpenseAndOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other prepaid expenses and other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_OtherPrepaidExpenseAndOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Prepaid Expense And Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_OtherPrepaidExpenseAndOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, not separately disclosed.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ResearchAndDevelopmentCostsCapitalized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of research and development costs capitalized during the period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ResearchAndDevelopmentCostsCapitalized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Costs Capitalized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ResearchAndDevelopmentCostsCapitalized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalization of research and development costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total potentially dilutive shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_AtTheMarketEquityOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ATM Offering Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_AtTheMarketEquityOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Equity Offering Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_AtTheMarketEquityOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At-the-market equity offering program.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Net Deferred Tax Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Commitments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_DepreciationExpenseExcludingLeasedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_DepreciationExpenseExcludingLeasedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation Expense Excluding Leased Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_DepreciationExpenseExcludingLeasedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of depreciation expenses recognized in the period, excluding depreciation for leased assets as part of a sublease agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-Based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Bonds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Bond Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, exercisable as of December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Domestic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ProceedsFromExerciseOfStockOptionsIncludedInOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options included in other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ProceedsFromExerciseOfStockOptionsIncludedInOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Exercise Of Stock Options Included In Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ProceedsFromExerciseOfStockOptionsIncludedInOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from exercise of stock options included in other current assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_EffectiveIncomeTaxRateReconciliationStockCompensationForfeituresPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deferred tax asset write-offs from stock compensation forfeitures.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_EffectiveIncomeTaxRateReconciliationStockCompensationForfeituresPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock compensation forfeitures - DTA Write Off</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_EffectiveIncomeTaxRateReconciliationStockCompensationForfeituresPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Stock Compensation Forfeitures, percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patent Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity of Counterparty, Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity of Counterparty, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value, Restricted stock units granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other comprehensive gain (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total other comprehensive income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued and Adopted Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Undesignated preferred stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Undesignated preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Cash Equivalents and Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leased assets obtained in exchange for new operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition, Acquiree</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Acquiree [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforward</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_TwoThousandFourteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">2014 Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_TwoThousandFourteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand fourteen equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_PaymentForLicenseAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment for license agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_PaymentForLicenseAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment For License Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_PaymentForLicenseAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment for license agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_LikelihoodPercentageMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of likelihood to be realized upon ultimate settlement, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_LikelihoodPercentageMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Likelihood Percentage Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_LikelihoodPercentageMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The minimum likelihood percentage threshold used to determine the amount of tax benefit to be recognized.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ProceedsFromExerciseOfStockOptionsAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options and warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ProceedsFromExerciseOfStockOptionsAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Exercise Of Stock Options And Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ProceedsFromExerciseOfStockOptionsAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The cash inflow from the exercise of options under share-based payment arrangements and exercise of stock warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accruals &amp; reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average grant date fair value, balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Valuation allowance at end of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Valuation allowance as of the beginning of the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_EmployeesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employees [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_EmployeesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employees [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_EmployeesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employees.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_CashAndNonCashOperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_CashAndNonCashOperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Non Cash Operating Lease Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_CashAndNonCashOperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of lease expense, both cash and non-cash, related to operating leases.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term, Unvested and expected to vest as of December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options Unvested And Expected To Vest, Weighted Average Remaining Contractual Terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average remaining contractual term for equity-based awards excluding options that are unvested and expected to vest, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock; $0.001 par value per share; 5,000,000 shares authorized as of December 31, 2023 and December 31, 2022; no shares issued and outstanding as of December 31, 2023 and December 31, 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrant exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, Forfeited/Expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Paper [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Commercial paper (due within 1 year) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_FromPriorPlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">From Prior Plans [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_FromPriorPlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">From Prior Plans [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_FromPriorPlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">From Prior Plans [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_OfficeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_OfficeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_OfficeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Office.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term of plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Duration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The term of the plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Debt Discount (Premium)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of discount on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_OfficeAndLabMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Office and Lab.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_OfficeAndLabMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office And Lab [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_OfficeAndLabMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office and Lab [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid insurance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Insurance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Other Observable Inputs (Level 2) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, Unvested and expected to vest as of December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options Unvested And Expected To Vest, Outstanding Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of equity-based payment instruments, excluding stock (or unit) options, that are unvested and expected to vest as of the balance sheet date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_MilestoneExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_MilestoneExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_MilestoneExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of expense recognized during the period related to milestones. Such amount may include, but is not limited to, amounts due for attainment of milestones as well as deductions granted as part of a license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating lease liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_IndianaUniversityResearchAndTechnologyCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Indiana University Research and Technology Corporation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_IndianaUniversityResearchAndTechnologyCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indiana University Research And Technology Corporation [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_IndianaUniversityResearchAndTechnologyCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IU [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nondeductible permanent differences</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_PayrollTaxesReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payroll tax receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_PayrollTaxesReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payroll Taxes Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_PayrollTaxesReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying amount as of the balance sheet date of payroll taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_CapitalizedResearchAndDevelopmentAmortizationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized research and development amortization period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_CapitalizedResearchAndDevelopmentAmortizationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Research and Development Amortization Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_CapitalizedResearchAndDevelopmentAmortizationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortization period for capitalized research and development costs, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_InducementStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inducement Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_InducementStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Inducement Stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share-based compensation arrangement by share-based payment award, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_AggregateGrossSalesProceedsUnderSalesAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate sale of shares of our common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_AggregateGrossSalesProceedsUnderSalesAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Gross Sales Proceeds Under Sales Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_AggregateGrossSalesProceedsUnderSalesAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The potential aggregate gross sales proceeds available under a sales agreement to sell shares of the Company&#39;s common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_AggregateGrossSalesProceedsUnderSalesAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate sale of shares of our common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term, Exercisable as of December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value, Restricted stock units forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_FinalSubleaseYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Final Sublease Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_FinalSubleaseYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Final Sublease Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_FinalSubleaseYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Final sublease year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash proceeds from exercises of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Warrant Exercises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_EquipmentFurnitureAndFixturesAndOfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equipment, Furniture and Fixtures and Office Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_EquipmentFurnitureAndFixturesAndOfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equipment Furniture And Fixtures And Office Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_EquipmentFurnitureAndFixturesAndOfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equipment, furniture and fixtures and office equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_DepreciationExpensesRelatedToSubletAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of depreciation expense recognized in the period related to leased assets as part of a sublease agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_DepreciationExpensesRelatedToSubletAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation Expenses Related to Sublet Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_DepreciationExpensesRelatedToSubletAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expenses related to sublet assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_TaxCreditCarryForwardExpirationYearStart_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credit carry forwards, beginning of expiration period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_TaxCreditCarryForwardExpirationYearStart_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carry Forward Expiration Year Start</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_TaxCreditCarryForwardExpirationYearStart_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The first year in which a tax credit carryforward begins to expire.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_NetOperatingLossCarryForwardExpirationYearBegin_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards, beginning of expiration period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_NetOperatingLossCarryForwardExpirationYearBegin_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Operating Loss Carry Forward Expiration Year Begin</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_NetOperatingLossCarryForwardExpirationYearBegin_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The first year in which a net operating loss carryforward begins to expire.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, Restricted stock units forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, Restricted stock units forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Increase in shares reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of non-cash investing and financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Noncurrent Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accrued Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Domestic and Foreign Components of Loss Before Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense), net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Nonoperating Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Credit Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance common stock and warrants net offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Common Stock And Warrants Net Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock and prefunded warrants to purchase common stock, net of offering costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_MA_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Massachusetts [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_MA_lbl" xlink:role="http://www.xbrl.org/2003/role/label">MASSACHUSETTS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_StockAndWarrantIssuanceTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_StockAndWarrantIssuanceTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock And Warrant Issuance Transaction Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_StockAndWarrantIssuanceTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Costs incurred during the period related to the issuance of stock and warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Asset Impairment Charges, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Impairment Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment losses on investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated Entities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_OfficeSubleaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Office Sublease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_OfficeSubleaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office Sublease [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_OfficeSubleaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Sublease [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of Business and Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Description and Basis of Presentation [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to a change in the state tax rate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in state tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change in State Tax Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State taxes, net of federal benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average common shares outstanding, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Federal Statutory Income Tax Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective income tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining lease term in years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average exercise price, balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average exercise price, balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_DeferredTaxAssetsFixedAssetsAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed assets &amp; intangibles</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_DeferredTaxAssetsFixedAssetsAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Fixed Assets And Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_DeferredTaxAssetsFixedAssetsAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible fixed assets and intangible assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Common Stock. Net, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued payroll and related expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net deferred tax assets before the valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net Of Liabilities Before Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount, after allocation of deferred tax liability but before allocation of valuation allowances, of deferred tax asset attributable to deductible differences and carryforwards.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Loss Carryforwards, Total</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_TaxCutsAndJobsActOf2017CapitalizationOfResearchAndDevelopmentCostsUnderIrcSection174" xlink:to="lrmr_TaxCutsAndJobsActOf2017CapitalizationOfResearchAndDevelopmentCostsUnderIrcSection174_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_LabSpaceMember" xlink:to="lrmr_LabSpaceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_MilestonePaymentAmount" xlink:to="lrmr_MilestonePaymentAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_LeaseTermCommencementDate" xlink:to="lrmr_LeaseTermCommencementDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_EmployeesAndDirectorsMember" xlink:to="lrmr_EmployeesAndDirectorsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_PrivateOfferingMember" xlink:to="lrmr_PrivateOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_IncomeTaxesDisclosureTable" xlink:to="lrmr_IncomeTaxesDisclosureTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_VestOverFourYearsMember" xlink:to="lrmr_VestOverFourYearsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_LaboratoryEquipmentMember" xlink:to="lrmr_LaboratoryEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_PrepaidResearchAndDevelopmentExpenses" xlink:to="lrmr_PrepaidResearchAndDevelopmentExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:to="lrmr_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue" xlink:to="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ConsolidatedEntitiesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_PA" xlink:to="stpr_PA_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_AreaOfOfficeSpace" xlink:to="lrmr_AreaOfOfficeSpace_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_FirstAnniversaryMember" xlink:to="lrmr_FirstAnniversaryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="lrmr_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_PerformedOutsideUsMember" xlink:to="lrmr_PerformedOutsideUsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_PerformedInUsMember" xlink:to="lrmr_PerformedInUsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lrmr_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_WarrantsIssuedPricePerShare" xlink:to="lrmr_WarrantsIssuedPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDepositLiability" xlink:to="us-gaap_SecurityDepositLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_SubleaseAnnualBaseRent" xlink:to="lrmr_SubleaseAnnualBaseRent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_Ircsection174Member" xlink:to="lrmr_Ircsection174Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_AdditionalOfficeMember" xlink:to="lrmr_AdditionalOfficeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_VestOneYearMember" xlink:to="lrmr_VestOneYearMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_TwoThousandSixteenEquityAndIncentivePlanMember" xlink:to="lrmr_TwoThousandSixteenEquityAndIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_SalesAgreementDescription" xlink:to="lrmr_SalesAgreementDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_NoExpirationMember" xlink:to="lrmr_NoExpirationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_TwoThousandTwentyEquityIncentivePlanMember" xlink:to="lrmr_TwoThousandTwentyEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue" xlink:to="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_MA" xlink:to="country_MA_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_MTSHealthPartnersMember" xlink:to="lrmr_MTSHealthPartnersMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_AccruedResearchAndDevelopmentExpenseCurrent" xlink:to="lrmr_AccruedResearchAndDevelopmentExpenseCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:to="lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_MilestoneLiability" xlink:to="lrmr_MilestoneLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_TwoThousandFourteenStockOptionAndIncentivePlanMember" xlink:to="lrmr_TwoThousandFourteenStockOptionAndIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_USGovernmentSecuritiesMember" xlink:to="lrmr_USGovernmentSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_NetOperatingLossCarryforwardsAnnualUtilizationLimitChangeInOwnership" xlink:to="lrmr_NetOperatingLossCarryforwardsAnnualUtilizationLimitChangeInOwnership_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_AtTheMarketEquityDistributionAgreementMember" xlink:to="lrmr_AtTheMarketEquityDistributionAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_LicenseAgreementConsiderationDeductionPercentage" xlink:to="lrmr_LicenseAgreementConsiderationDeductionPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:to="us-gaap_DividendsPayableCurrentAndNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilityReserveEstimatePolicy" xlink:to="us-gaap_LiabilityReserveEstimatePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_VestAnnuallyOverFourYearsMember" xlink:to="lrmr_VestAnnuallyOverFourYearsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_PercentageOfCompensationForServicesEqualToGrossProceeds" xlink:to="lrmr_PercentageOfCompensationForServicesEqualToGrossProceeds_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember" xlink:to="lrmr_WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_SixthSubleaseYearMember" xlink:to="lrmr_SixthSubleaseYearMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue" xlink:to="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="lrmr_IncomeTaxesDisclosureLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_ZafgenMember" xlink:to="lrmr_ZafgenMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_ChondrialMember" xlink:to="lrmr_ChondrialMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_DomesticAndStateLocalJurisdictionMember" xlink:to="lrmr_DomesticAndStateLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_MergerAgreementMember" xlink:to="lrmr_MergerAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_OperatingLossCarryforwardsMinimumPercentageOfTaxableIncomeInTaxPeriod" xlink:to="lrmr_OperatingLossCarryforwardsMinimumPercentageOfTaxableIncomeInTaxPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:to="lrmr_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_FirstSubleaseYearMember" xlink:to="lrmr_FirstSubleaseYearMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarliestTaxYearMember" xlink:to="us-gaap_EarliestTaxYearMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_FromExerciseOfWarrantsMember" xlink:to="lrmr_FromExerciseOfWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_MinimumAnnualRoyaltyObligation" xlink:to="lrmr_MinimumAnnualRoyaltyObligation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_WakeForestUniversityHealthSciencesMember" xlink:to="lrmr_WakeForestUniversityHealthSciencesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock" xlink:to="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="lrmr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LetterOfCreditMember" xlink:to="us-gaap_LetterOfCreditMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_NetCapitalizedRDDeferredTaxAssetsRealizationDescription" xlink:to="lrmr_NetCapitalizedRDDeferredTaxAssetsRealizationDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_OtherPrepaidExpenseAndOtherCurrentAssets" xlink:to="lrmr_OtherPrepaidExpenseAndOtherCurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_ResearchAndDevelopmentCostsCapitalized" xlink:to="lrmr_ResearchAndDevelopmentCostsCapitalized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_AtTheMarketEquityOfferingProgramMember" xlink:to="lrmr_AtTheMarketEquityOfferingProgramMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_DepreciationExpenseExcludingLeasedAssets" xlink:to="lrmr_DepreciationExpenseExcludingLeasedAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateBondSecuritiesMember" xlink:to="us-gaap_CorporateBondSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_ProceedsFromExerciseOfStockOptionsIncludedInOtherCurrentAssets" xlink:to="lrmr_ProceedsFromExerciseOfStockOptionsIncludedInOtherCurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_EffectiveIncomeTaxRateReconciliationStockCompensationForfeituresPercent" xlink:to="lrmr_EffectiveIncomeTaxRateReconciliationStockCompensationForfeituresPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_TwoThousandFourteenEquityIncentivePlanMember" xlink:to="lrmr_TwoThousandFourteenEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_PaymentForLicenseAgreements" xlink:to="lrmr_PaymentForLicenseAgreements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_LikelihoodPercentageMinimum" xlink:to="lrmr_LikelihoodPercentageMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_ProceedsFromExerciseOfStockOptionsAndWarrants" xlink:to="lrmr_ProceedsFromExerciseOfStockOptionsAndWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_EmployeesMember" xlink:to="lrmr_EmployeesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_CashAndNonCashOperatingLeaseExpense" xlink:to="lrmr_CashAndNonCashOperatingLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms" xlink:to="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_FromPriorPlansMember" xlink:to="lrmr_FromPriorPlansMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_OfficeMember" xlink:to="lrmr_OfficeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration" xlink:to="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_OfficeAndLabMember" xlink:to="lrmr_OfficeAndLabMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber" xlink:to="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_MilestoneExpenses" xlink:to="lrmr_MilestoneExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="lrmr_DeferredTaxAssetsOperatingLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_IndianaUniversityResearchAndTechnologyCorporationMember" xlink:to="lrmr_IndianaUniversityResearchAndTechnologyCorporationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_PayrollTaxesReceivable" xlink:to="lrmr_PayrollTaxesReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_CapitalizedResearchAndDevelopmentAmortizationPeriod" xlink:to="lrmr_CapitalizedResearchAndDevelopmentAmortizationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_InducementStockMember" xlink:to="lrmr_InducementStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_AggregateGrossSalesProceedsUnderSalesAgreement" xlink:to="lrmr_AggregateGrossSalesProceedsUnderSalesAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_FinalSubleaseYearMember" xlink:to="lrmr_FinalSubleaseYearMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_EquipmentFurnitureAndFixturesAndOfficeEquipmentMember" xlink:to="lrmr_EquipmentFurnitureAndFixturesAndOfficeEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_DepreciationExpensesRelatedToSubletAssets" xlink:to="lrmr_DepreciationExpensesRelatedToSubletAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_TaxCreditCarryForwardExpirationYearStart" xlink:to="lrmr_TaxCreditCarryForwardExpirationYearStart_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_NetOperatingLossCarryForwardExpirationYearBegin" xlink:to="lrmr_NetOperatingLossCarryForwardExpirationYearBegin_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts" xlink:to="lrmr_ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_MA" xlink:to="stpr_MA_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_StockAndWarrantIssuanceTransactionCosts" xlink:to="lrmr_StockAndWarrantIssuanceTransactionCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivable" xlink:to="us-gaap_InterestReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_OfficeSubleaseMember" xlink:to="lrmr_OfficeSubleaseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate" xlink:to="lrmr_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lrmr_SummaryOfSignificantAccountingPoliciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_DeferredTaxAssetsFixedAssetsAndIntangibleAssets" xlink:to="lrmr_DeferredTaxAssetsFixedAssetsAndIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance" xlink:to="lrmr_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="lrmr_StockIssuedDuringPeriodValueExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_11"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_12"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_StockIssuedDuringPeriodValueExerciseOfWarrants" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_12" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_ProceedsFromExerciseOfStockOptionsAndWarrants" xlink:label="lrmr_ProceedsFromExerciseOfStockOptionsAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_ProceedsFromExerciseOfStockOptionsIncludedInOtherCurrentAssets" xlink:label="lrmr_ProceedsFromExerciseOfStockOptionsIncludedInOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_CashAndNonCashOperatingLeaseExpense" xlink:label="lrmr_CashAndNonCashOperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lrmr_ProceedsFromExerciseOfStockOptionsAndWarrants" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lrmr_ProceedsFromExerciseOfStockOptionsIncludedInOtherCurrentAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lrmr_CashAndNonCashOperatingLeaseExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20231231/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganization" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecurities1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="lrmr_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="lrmr_PrepaidExpensesAndOtherCurrentAssetsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureFixedAssets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureAccruedExpenses" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptions" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityReserveEstimatePolicy" xlink:label="us-gaap_LiabilityReserveEstimatePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LiabilityReserveEstimatePolicy" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:label="lrmr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="lrmr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureFixedAssetsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20231231/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_ZafgenMember" xlink:label="lrmr_ZafgenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_PrivateOfferingMember" xlink:label="lrmr_PrivateOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_MergerAgreementMember" xlink:label="lrmr_MergerAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_ChondrialMember" xlink:label="lrmr_ChondrialMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_AtTheMarketEquityOfferingProgramMember" xlink:label="lrmr_AtTheMarketEquityOfferingProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="lrmr_ZafgenMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lrmr_PrivateOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lrmr_MergerAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="lrmr_ChondrialMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lrmr_AtTheMarketEquityOfferingProgramMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="lrmr_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_FromExerciseOfWarrantsMember" xlink:label="lrmr_FromExerciseOfWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_SummaryOfSignificantAccountingPoliciesTable" xlink:label="lrmr_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_EquipmentFurnitureAndFixturesAndOfficeEquipmentMember" xlink:label="lrmr_EquipmentFurnitureAndFixturesAndOfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_LikelihoodPercentageMinimum" xlink:label="lrmr_LikelihoodPercentageMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="lrmr_FromExerciseOfWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lrmr_SummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lrmr_EquipmentFurnitureAndFixturesAndOfficeEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lrmr_LikelihoodPercentageMinimum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_InterestReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_AssetImpairmentCharges" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_USGovernmentSecuritiesMember" xlink:label="lrmr_USGovernmentSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lrmr_USGovernmentSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_USGovernmentSecuritiesMember" xlink:label="lrmr_USGovernmentSecuritiesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lrmr_USGovernmentSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_PrepaidResearchAndDevelopmentExpenses" xlink:label="lrmr_PrepaidResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_PayrollTaxesReceivable" xlink:label="lrmr_PayrollTaxesReceivable"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_OtherPrepaidExpenseAndOtherCurrentAssets" xlink:label="lrmr_OtherPrepaidExpenseAndOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="lrmr_PrepaidResearchAndDevelopmentExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_PrepaidInsurance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="lrmr_PayrollTaxesReceivable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="lrmr_OtherPrepaidExpenseAndOtherCurrentAssets" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureFixedAssetsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_DepreciationExpenseExcludingLeasedAssets" xlink:label="lrmr_DepreciationExpenseExcludingLeasedAssets"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_DepreciationExpensesRelatedToSubletAssets" xlink:label="lrmr_DepreciationExpensesRelatedToSubletAssets"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="lrmr_DepreciationExpenseExcludingLeasedAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="lrmr_DepreciationExpensesRelatedToSubletAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_AccruedResearchAndDevelopmentExpenseCurrent" xlink:label="lrmr_AccruedResearchAndDevelopmentExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="lrmr_AccruedResearchAndDevelopmentExpenseCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_EmployeesAndDirectorsMember" xlink:label="lrmr_EmployeesAndDirectorsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_FirstAnniversaryMember" xlink:label="lrmr_FirstAnniversaryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="lrmr_TwoThousandTwentyEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_MTSHealthPartnersMember" xlink:label="lrmr_MTSHealthPartnersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_EmployeesMember" xlink:label="lrmr_EmployeesMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_VestOneYearMember" xlink:label="lrmr_VestOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_TwoThousandFourteenEquityIncentivePlanMember" xlink:label="lrmr_TwoThousandFourteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_InducementStockMember" xlink:label="lrmr_InducementStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_AtTheMarketEquityDistributionAgreementMember" xlink:label="lrmr_AtTheMarketEquityDistributionAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_VestOverFourYearsMember" xlink:label="lrmr_VestOverFourYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_TwoThousandSixteenEquityAndIncentivePlanMember" xlink:label="lrmr_TwoThousandSixteenEquityAndIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_VestAnnuallyOverFourYearsMember" xlink:label="lrmr_VestAnnuallyOverFourYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_TwoThousandFourteenStockOptionAndIncentivePlanMember" xlink:label="lrmr_TwoThousandFourteenStockOptionAndIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_AtTheMarketEquityOfferingProgramMember" xlink:label="lrmr_AtTheMarketEquityOfferingProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_FromPriorPlansMember" xlink:label="lrmr_FromPriorPlansMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_PercentageOfCompensationForServicesEqualToGrossProceeds" xlink:label="lrmr_PercentageOfCompensationForServicesEqualToGrossProceeds"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_SalesAgreementDescription" xlink:label="lrmr_SalesAgreementDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_WarrantsIssuedPricePerShare" xlink:label="lrmr_WarrantsIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_StockAndWarrantIssuanceTransactionCosts" xlink:label="lrmr_StockAndWarrantIssuanceTransactionCosts"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts" xlink:label="lrmr_ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_AggregateGrossSalesProceedsUnderSalesAgreement" xlink:label="lrmr_AggregateGrossSalesProceedsUnderSalesAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lrmr_EmployeesAndDirectorsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="lrmr_FirstAnniversaryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lrmr_TwoThousandTwentyEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="lrmr_MTSHealthPartnersMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lrmr_EmployeesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="lrmr_VestOneYearMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lrmr_TwoThousandFourteenEquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="lrmr_InducementStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lrmr_AtTheMarketEquityDistributionAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="lrmr_VestOverFourYearsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lrmr_TwoThousandSixteenEquityAndIncentivePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="lrmr_VestAnnuallyOverFourYearsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lrmr_TwoThousandFourteenStockOptionAndIncentivePlanMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lrmr_AtTheMarketEquityOfferingProgramMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lrmr_FromPriorPlansMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_PercentageOfCompensationForServicesEqualToGrossProceeds" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_SalesAgreementDescription" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_WarrantsIssuedPricePerShare" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DividendsPayableCurrentAndNoncurrent" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_StockAndWarrantIssuanceTransactionCosts" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_AggregateGrossSalesProceedsUnderSalesAgreement" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="38" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="39" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsAssumptionsUsedToDetermineFairValueOfStockOptionsGrantedDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockbasedCompensationExpenseDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_PA" xlink:label="stpr_PA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_WakeForestUniversityHealthSciencesMember" xlink:label="lrmr_WakeForestUniversityHealthSciencesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_FirstSubleaseYearMember" xlink:label="lrmr_FirstSubleaseYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_OfficeMember" xlink:label="lrmr_OfficeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_MilestonePaymentAmount" xlink:label="lrmr_MilestonePaymentAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_MA" xlink:label="country_MA"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_IndianaUniversityResearchAndTechnologyCorporationMember" xlink:label="lrmr_IndianaUniversityResearchAndTechnologyCorporationMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_FinalSubleaseYearMember" xlink:label="lrmr_FinalSubleaseYearMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_OfficeSubleaseMember" xlink:label="lrmr_OfficeSubleaseMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_PaymentForLicenseAgreements" xlink:label="lrmr_PaymentForLicenseAgreements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_MA" xlink:label="stpr_MA"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember" xlink:label="lrmr_WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_SixthSubleaseYearMember" xlink:label="lrmr_SixthSubleaseYearMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_OfficeAndLabMember" xlink:label="lrmr_OfficeAndLabMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_MinimumAnnualRoyaltyObligation" xlink:label="lrmr_MinimumAnnualRoyaltyObligation"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_AdditionalOfficeMember" xlink:label="lrmr_AdditionalOfficeMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_LicenseAgreementConsiderationDeductionPercentage" xlink:label="lrmr_LicenseAgreementConsiderationDeductionPercentage"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_LabSpaceMember" xlink:label="lrmr_LabSpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_MilestoneExpenses" xlink:label="lrmr_MilestoneExpenses"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_MilestoneLiability" xlink:label="lrmr_MilestoneLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_LeaseTermCommencementDate" xlink:label="lrmr_LeaseTermCommencementDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_AreaOfOfficeSpace" xlink:label="lrmr_AreaOfOfficeSpace"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_SubleaseAnnualBaseRent" xlink:label="lrmr_SubleaseAnnualBaseRent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDepositLiability" xlink:label="us-gaap_SecurityDepositLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_PA" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OtherCommitmentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="lrmr_WakeForestUniversityHealthSciencesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="lrmr_FirstSubleaseYearMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="lrmr_OfficeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_LetterOfCreditMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lrmr_MilestonePaymentAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_MA" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="lrmr_IndianaUniversityResearchAndTechnologyCorporationMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="lrmr_FinalSubleaseYearMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="lrmr_OfficeSubleaseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lrmr_PaymentForLicenseAgreements" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_MA" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="lrmr_WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="lrmr_SixthSubleaseYearMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="lrmr_OfficeAndLabMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lrmr_MinimumAnnualRoyaltyObligation" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_StatementGeographicalAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="lrmr_AdditionalOfficeMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lrmr_LicenseAgreementConsiderationDeductionPercentage" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="lrmr_LabSpaceMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lrmr_MilestoneExpenses" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lrmr_MilestoneLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lrmr_LeaseTermCommencementDate" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsLineItems" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_RestrictedCash" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lrmr_AreaOfOfficeSpace" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lrmr_SubleaseAnnualBaseRent" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_SecurityDepositLiability" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_IncomeTaxesDisclosureTable" xlink:label="lrmr_IncomeTaxesDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_PerformedInUsMember" xlink:label="lrmr_PerformedInUsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_IncomeTaxesDisclosureLineItems" xlink:label="lrmr_IncomeTaxesDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_ZafgenMember" xlink:label="lrmr_ZafgenMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_NoExpirationMember" xlink:label="lrmr_NoExpirationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_PerformedOutsideUsMember" xlink:label="lrmr_PerformedOutsideUsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarliestTaxYearMember" xlink:label="us-gaap_EarliestTaxYearMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_NetOperatingLossCarryForwardExpirationYearBegin" xlink:label="lrmr_NetOperatingLossCarryForwardExpirationYearBegin"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_OperatingLossCarryforwardsMinimumPercentageOfTaxableIncomeInTaxPeriod" xlink:label="lrmr_OperatingLossCarryforwardsMinimumPercentageOfTaxableIncomeInTaxPeriod"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_DomesticAndStateLocalJurisdictionMember" xlink:label="lrmr_DomesticAndStateLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_Ircsection174Member" xlink:label="lrmr_Ircsection174Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_TaxCreditCarryForwardExpirationYearStart" xlink:label="lrmr_TaxCreditCarryForwardExpirationYearStart"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_TaxCutsAndJobsActOf2017CapitalizationOfResearchAndDevelopmentCostsUnderIrcSection174" xlink:label="lrmr_TaxCutsAndJobsActOf2017CapitalizationOfResearchAndDevelopmentCostsUnderIrcSection174"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_ResearchAndDevelopmentCostsCapitalized" xlink:label="lrmr_ResearchAndDevelopmentCostsCapitalized"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_CapitalizedResearchAndDevelopmentAmortizationPeriod" xlink:label="lrmr_CapitalizedResearchAndDevelopmentAmortizationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_NetCapitalizedRDDeferredTaxAssetsRealizationDescription" xlink:label="lrmr_NetCapitalizedRDDeferredTaxAssetsRealizationDescription"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_NetOperatingLossCarryforwardsAnnualUtilizationLimitChangeInOwnership" xlink:label="lrmr_NetOperatingLossCarryforwardsAnnualUtilizationLimitChangeInOwnership"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance" xlink:label="lrmr_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="lrmr_PerformedInUsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lrmr_ZafgenMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="lrmr_NoExpirationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lrmr_IncomeTaxesDisclosureTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureTable" xlink:to="us-gaap_TaxPeriodAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="lrmr_PerformedOutsideUsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_EarliestTaxYearMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="lrmr_NetOperatingLossCarryForwardExpirationYearBegin" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureTable" xlink:to="srt_StatementScenarioAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="lrmr_OperatingLossCarryforwardsMinimumPercentageOfTaxableIncomeInTaxPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="lrmr_DomesticAndStateLocalJurisdictionMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureTable" xlink:to="lrmr_IncomeTaxesDisclosureLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="lrmr_Ircsection174Member" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="lrmr_TaxCreditCarryForwardExpirationYearStart" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="lrmr_TaxCutsAndJobsActOf2017CapitalizationOfResearchAndDevelopmentCostsUnderIrcSection174" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="lrmr_ResearchAndDevelopmentCostsCapitalized" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="lrmr_CapitalizedResearchAndDevelopmentAmortizationPeriod" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="lrmr_NetCapitalizedRDDeferredTaxAssetsRealizationDescription" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="lrmr_NetOperatingLossCarryforwardsAnnualUtilizationLimitChangeInOwnership" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="lrmr_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_OpenTaxYear" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfLossBeforeIncomeTaxesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate" xlink:label="lrmr_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_EffectiveIncomeTaxRateReconciliationStockCompensationForfeituresPercent" xlink:label="lrmr_EffectiveIncomeTaxRateReconciliationStockCompensationForfeituresPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lrmr_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lrmr_EffectiveIncomeTaxRateReconciliationStockCompensationForfeituresPercent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="lrmr_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_DeferredTaxAssetsFixedAssetsAndIntangibleAssets" xlink:label="lrmr_DeferredTaxAssetsFixedAssetsAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="lrmr_DeferredTaxAssetsOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lrmr_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lrmr_DeferredTaxAssetsFixedAssetsAndIntangibleAssets" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lrmr_DeferredTaxAssetsOperatingLeaseLiabilities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfChangesInValuationAllowanceForDeferredTaxAssetsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_IncomeTaxesDisclosureTable" xlink:label="lrmr_IncomeTaxesDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_IncomeTaxesDisclosureLineItems" xlink:label="lrmr_IncomeTaxesDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureTable" xlink:to="lrmr_IncomeTaxesDisclosureLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lrmr_IncomeTaxesDisclosureTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_LaboratoryEquipmentMember" xlink:label="lrmr_LaboratoryEquipmentMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lrmr_LaboratoryEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.larimartx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="lrmr_StockIssuedDuringPeriodValueExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_StockIssuedDuringPeriodValueExerciseOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.larimartx.com/20231231/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_ZafgenMember" xlink:label="lrmr_ZafgenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_PrivateOfferingMember" xlink:label="lrmr_PrivateOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_MergerAgreementMember" xlink:label="lrmr_MergerAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_ChondrialMember" xlink:label="lrmr_ChondrialMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_AtTheMarketEquityOfferingProgramMember" xlink:label="lrmr_AtTheMarketEquityOfferingProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="lrmr_ZafgenMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lrmr_PrivateOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lrmr_MergerAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="lrmr_ChondrialMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lrmr_AtTheMarketEquityOfferingProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="lrmr_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_SummaryOfSignificantAccountingPoliciesTable" xlink:label="lrmr_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_FromExerciseOfWarrantsMember" xlink:label="lrmr_FromExerciseOfWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_EquipmentFurnitureAndFixturesAndOfficeEquipmentMember" xlink:label="lrmr_EquipmentFurnitureAndFixturesAndOfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_LikelihoodPercentageMinimum" xlink:label="lrmr_LikelihoodPercentageMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lrmr_SummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="lrmr_FromExerciseOfWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lrmr_EquipmentFurnitureAndFixturesAndOfficeEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lrmr_LikelihoodPercentageMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_USGovernmentSecuritiesMember" xlink:label="lrmr_USGovernmentSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lrmr_USGovernmentSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_USGovernmentSecuritiesMember" xlink:label="lrmr_USGovernmentSecuritiesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lrmr_USGovernmentSecuritiesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_EmployeesAndDirectorsMember" xlink:label="lrmr_EmployeesAndDirectorsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_FirstAnniversaryMember" xlink:label="lrmr_FirstAnniversaryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="lrmr_TwoThousandTwentyEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_FromPriorPlansMember" xlink:label="lrmr_FromPriorPlansMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_MTSHealthPartnersMember" xlink:label="lrmr_MTSHealthPartnersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_EmployeesMember" xlink:label="lrmr_EmployeesMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_VestOneYearMember" xlink:label="lrmr_VestOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_TwoThousandFourteenEquityIncentivePlanMember" xlink:label="lrmr_TwoThousandFourteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_InducementStockMember" xlink:label="lrmr_InducementStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_AtTheMarketEquityDistributionAgreementMember" xlink:label="lrmr_AtTheMarketEquityDistributionAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_VestOverFourYearsMember" xlink:label="lrmr_VestOverFourYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_TwoThousandSixteenEquityAndIncentivePlanMember" xlink:label="lrmr_TwoThousandSixteenEquityAndIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_VestAnnuallyOverFourYearsMember" xlink:label="lrmr_VestAnnuallyOverFourYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_TwoThousandFourteenStockOptionAndIncentivePlanMember" xlink:label="lrmr_TwoThousandFourteenStockOptionAndIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_AtTheMarketEquityOfferingProgramMember" xlink:label="lrmr_AtTheMarketEquityOfferingProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_PercentageOfCompensationForServicesEqualToGrossProceeds" xlink:label="lrmr_PercentageOfCompensationForServicesEqualToGrossProceeds"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_SalesAgreementDescription" xlink:label="lrmr_SalesAgreementDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_WarrantsIssuedPricePerShare" xlink:label="lrmr_WarrantsIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_StockAndWarrantIssuanceTransactionCosts" xlink:label="lrmr_StockAndWarrantIssuanceTransactionCosts"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts" xlink:label="lrmr_ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_AggregateGrossSalesProceedsUnderSalesAgreement" xlink:label="lrmr_AggregateGrossSalesProceedsUnderSalesAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lrmr_EmployeesAndDirectorsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="lrmr_FirstAnniversaryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lrmr_TwoThousandTwentyEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lrmr_FromPriorPlansMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="lrmr_MTSHealthPartnersMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lrmr_EmployeesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="lrmr_VestOneYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lrmr_TwoThousandFourteenEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="lrmr_InducementStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lrmr_AtTheMarketEquityDistributionAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="lrmr_VestOverFourYearsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lrmr_TwoThousandSixteenEquityAndIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="lrmr_VestAnnuallyOverFourYearsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lrmr_TwoThousandFourteenStockOptionAndIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lrmr_AtTheMarketEquityOfferingProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_PercentageOfCompensationForServicesEqualToGrossProceeds" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_SalesAgreementDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_WarrantsIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockVotingRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DividendsPayableCurrentAndNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_StockAndWarrantIssuanceTransactionCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_AggregateGrossSalesProceedsUnderSalesAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="35" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="36" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="37" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="38" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="39" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockbasedCompensationExpenseDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_PA" xlink:label="stpr_PA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_WakeForestUniversityHealthSciencesMember" xlink:label="lrmr_WakeForestUniversityHealthSciencesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_FirstSubleaseYearMember" xlink:label="lrmr_FirstSubleaseYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_OfficeMember" xlink:label="lrmr_OfficeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_MilestonePaymentAmount" xlink:label="lrmr_MilestonePaymentAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_MA" xlink:label="country_MA"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_IndianaUniversityResearchAndTechnologyCorporationMember" xlink:label="lrmr_IndianaUniversityResearchAndTechnologyCorporationMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_FinalSubleaseYearMember" xlink:label="lrmr_FinalSubleaseYearMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_OfficeSubleaseMember" xlink:label="lrmr_OfficeSubleaseMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_PaymentForLicenseAgreements" xlink:label="lrmr_PaymentForLicenseAgreements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_MA" xlink:label="stpr_MA"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember" xlink:label="lrmr_WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_SixthSubleaseYearMember" xlink:label="lrmr_SixthSubleaseYearMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_OfficeAndLabMember" xlink:label="lrmr_OfficeAndLabMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_MinimumAnnualRoyaltyObligation" xlink:label="lrmr_MinimumAnnualRoyaltyObligation"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_AdditionalOfficeMember" xlink:label="lrmr_AdditionalOfficeMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_LicenseAgreementConsiderationDeductionPercentage" xlink:label="lrmr_LicenseAgreementConsiderationDeductionPercentage"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_LabSpaceMember" xlink:label="lrmr_LabSpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_MilestoneExpenses" xlink:label="lrmr_MilestoneExpenses"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_MilestoneLiability" xlink:label="lrmr_MilestoneLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_LeaseTermCommencementDate" xlink:label="lrmr_LeaseTermCommencementDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_AreaOfOfficeSpace" xlink:label="lrmr_AreaOfOfficeSpace"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_SubleaseAnnualBaseRent" xlink:label="lrmr_SubleaseAnnualBaseRent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDepositLiability" xlink:label="us-gaap_SecurityDepositLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_PA" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="lrmr_WakeForestUniversityHealthSciencesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="lrmr_FirstSubleaseYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="lrmr_OfficeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_LetterOfCreditMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lrmr_MilestonePaymentAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_MA" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="lrmr_IndianaUniversityResearchAndTechnologyCorporationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="lrmr_FinalSubleaseYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="lrmr_OfficeSubleaseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lrmr_PaymentForLicenseAgreements" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_MA" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="lrmr_WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="lrmr_SixthSubleaseYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="lrmr_OfficeAndLabMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lrmr_MinimumAnnualRoyaltyObligation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="lrmr_AdditionalOfficeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lrmr_LicenseAgreementConsiderationDeductionPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="lrmr_LabSpaceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lrmr_MilestoneExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_LeaseContractualTermAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lrmr_MilestoneLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lrmr_LeaseTermCommencementDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_RestrictedCash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lrmr_AreaOfOfficeSpace" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LeaseExpirationDate1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lrmr_SubleaseAnnualBaseRent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_SecurityDepositLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_IncomeTaxesDisclosureLineItems" xlink:label="lrmr_IncomeTaxesDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_IncomeTaxesDisclosureTable" xlink:label="lrmr_IncomeTaxesDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_PerformedInUsMember" xlink:label="lrmr_PerformedInUsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_ZafgenMember" xlink:label="lrmr_ZafgenMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_NoExpirationMember" xlink:label="lrmr_NoExpirationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_PerformedOutsideUsMember" xlink:label="lrmr_PerformedOutsideUsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarliestTaxYearMember" xlink:label="us-gaap_EarliestTaxYearMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_NetOperatingLossCarryForwardExpirationYearBegin" xlink:label="lrmr_NetOperatingLossCarryForwardExpirationYearBegin"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_OperatingLossCarryforwardsMinimumPercentageOfTaxableIncomeInTaxPeriod" xlink:label="lrmr_OperatingLossCarryforwardsMinimumPercentageOfTaxableIncomeInTaxPeriod"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_DomesticAndStateLocalJurisdictionMember" xlink:label="lrmr_DomesticAndStateLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_Ircsection174Member" xlink:label="lrmr_Ircsection174Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_TaxCreditCarryForwardExpirationYearStart" xlink:label="lrmr_TaxCreditCarryForwardExpirationYearStart"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_TaxCutsAndJobsActOf2017CapitalizationOfResearchAndDevelopmentCostsUnderIrcSection174" xlink:label="lrmr_TaxCutsAndJobsActOf2017CapitalizationOfResearchAndDevelopmentCostsUnderIrcSection174"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_ResearchAndDevelopmentCostsCapitalized" xlink:label="lrmr_ResearchAndDevelopmentCostsCapitalized"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_CapitalizedResearchAndDevelopmentAmortizationPeriod" xlink:label="lrmr_CapitalizedResearchAndDevelopmentAmortizationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_NetCapitalizedRDDeferredTaxAssetsRealizationDescription" xlink:label="lrmr_NetCapitalizedRDDeferredTaxAssetsRealizationDescription"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_NetOperatingLossCarryforwardsAnnualUtilizationLimitChangeInOwnership" xlink:label="lrmr_NetOperatingLossCarryforwardsAnnualUtilizationLimitChangeInOwnership"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance" xlink:label="lrmr_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="lrmr_IncomeTaxesDisclosureTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lrmr_IncomeTaxesDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="lrmr_PerformedInUsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lrmr_ZafgenMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="lrmr_NoExpirationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lrmr_IncomeTaxesDisclosureTable" xlink:to="us-gaap_TaxPeriodAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="lrmr_PerformedOutsideUsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_EarliestTaxYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lrmr_IncomeTaxesDisclosureTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="lrmr_NetOperatingLossCarryForwardExpirationYearBegin" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lrmr_IncomeTaxesDisclosureTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="lrmr_OperatingLossCarryforwardsMinimumPercentageOfTaxableIncomeInTaxPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="lrmr_DomesticAndStateLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="lrmr_Ircsection174Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="lrmr_TaxCreditCarryForwardExpirationYearStart" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="lrmr_TaxCutsAndJobsActOf2017CapitalizationOfResearchAndDevelopmentCostsUnderIrcSection174" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="lrmr_ResearchAndDevelopmentCostsCapitalized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="lrmr_CapitalizedResearchAndDevelopmentAmortizationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="lrmr_NetCapitalizedRDDeferredTaxAssetsRealizationDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="lrmr_NetOperatingLossCarryforwardsAnnualUtilizationLimitChangeInOwnership" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="lrmr_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_OpenTaxYear" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfChangesInValuationAllowanceForDeferredTaxAssetsDetail">
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_IncomeTaxesDisclosureLineItems" xlink:label="lrmr_IncomeTaxesDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_IncomeTaxesDisclosureTable" xlink:label="lrmr_IncomeTaxesDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="lrmr_IncomeTaxesDisclosureTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_LaboratoryEquipmentMember" xlink:label="lrmr_LaboratoryEquipmentMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lrmr_LaboratoryEquipmentMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UsefulLifeDescriptionOfTermDomain" xlink:label="us-gaap_UsefulLifeDescriptionOfTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember" xlink:label="us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lrmr_ProceedsFromExerciseOfStockOptionsAndWarrants" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lrmr_CashAndNonCashOperatingLeaseExpense" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="9" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="10" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="11" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="12" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="13" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="14" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="15" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_ProceedsFromExerciseOfStockOptionsAndWarrants" xlink:label="lrmr_ProceedsFromExerciseOfStockOptionsAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_CashAndNonCashOperatingLeaseExpense" xlink:label="lrmr_CashAndNonCashOperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lrmr_PrepaidResearchAndDevelopmentExpenses" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lrmr_PayrollTaxesReceivable" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lrmr_OtherPrepaidExpenseAndOtherCurrentAssets" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_PrepaidResearchAndDevelopmentExpenses" xlink:label="lrmr_PrepaidResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_PayrollTaxesReceivable" xlink:label="lrmr_PayrollTaxesReceivable"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_OtherPrepaidExpenseAndOtherCurrentAssets" xlink:label="lrmr_OtherPrepaidExpenseAndOtherCurrentAssets"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="lrmr_AccruedResearchAndDevelopmentExpenseCurrent" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_AccruedResearchAndDevelopmentExpenseCurrent" xlink:label="lrmr_AccruedResearchAndDevelopmentExpenseCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfLossBeforeIncomeTaxesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lrmr_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20231231.xsd#lrmr_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate" xlink:label="lrmr_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="lrmr_DepreciationExpenseExcludingLeasedAssets" name="DepreciationExpenseExcludingLeasedAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lrmr_PercentageOfCompensationForServicesEqualToGrossProceeds" name="PercentageOfCompensationForServicesEqualToGrossProceeds" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lrmr_IncomeTaxesDisclosureTable" name="IncomeTaxesDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_NetOperatingLossCarryForwardExpirationYearBegin" name="NetOperatingLossCarryForwardExpirationYearBegin" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lrmr_OtherPrepaidExpenseAndOtherCurrentAssets" name="OtherPrepaidExpenseAndOtherCurrentAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lrmr_FromExerciseOfWarrantsMember" name="FromExerciseOfWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_Ircsection174Member" name="Ircsection174Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_SalesAgreementDescription" name="SalesAgreementDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_USGovernmentSecuritiesMember" name="USGovernmentSecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_DepreciationExpensesRelatedToSubletAssets" name="DepreciationExpensesRelatedToSubletAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lrmr_OfficeSubleaseMember" name="OfficeSubleaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lrmr_CapitalizedResearchAndDevelopmentAmortizationPeriod" name="CapitalizedResearchAndDevelopmentAmortizationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lrmr_NetCapitalizedRDDeferredTaxAssetsRealizationDescription" name="NetCapitalizedRDDeferredTaxAssetsRealizationDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lrmr_MergerAgreementMember" name="MergerAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_TwoThousandFourteenStockOptionAndIncentivePlanMember" name="TwoThousandFourteenStockOptionAndIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_ProceedsFromExerciseOfStockOptionsAndWarrants" name="ProceedsFromExerciseOfStockOptionsAndWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lrmr_ChondrialMember" name="ChondrialMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_LeaseTermCommencementDate" name="LeaseTermCommencementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lrmr_NetOperatingLossCarryforwardsAnnualUtilizationLimitChangeInOwnership" name="NetOperatingLossCarryforwardsAnnualUtilizationLimitChangeInOwnership" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lrmr_TwoThousandTwentyEquityIncentivePlanMember" name="TwoThousandTwentyEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_LabSpaceMember" name="LabSpaceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_LikelihoodPercentageMinimum" name="LikelihoodPercentageMinimum" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lrmr_TwoThousandSixteenEquityAndIncentivePlanMember" name="TwoThousandSixteenEquityAndIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_EmployeesMember" name="EmployeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_PaymentForLicenseAgreements" name="PaymentForLicenseAgreements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lrmr_MTSHealthPartnersMember" name="MTSHealthPartnersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_SixthSubleaseYearMember" name="SixthSubleaseYearMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_DeferredTaxAssetsFixedAssetsAndIntangibleAssets" name="DeferredTaxAssetsFixedAssetsAndIntangibleAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lrmr_LicenseAgreementConsiderationDeductionPercentage" name="LicenseAgreementConsiderationDeductionPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="lrmr_TaxCutsAndJobsActOf2017CapitalizationOfResearchAndDevelopmentCostsUnderIrcSection174" name="TaxCutsAndJobsActOf2017CapitalizationOfResearchAndDevelopmentCostsUnderIrcSection174" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lrmr_OperatingLossCarryforwardsMinimumPercentageOfTaxableIncomeInTaxPeriod" name="OperatingLossCarryforwardsMinimumPercentageOfTaxableIncomeInTaxPeriod" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants" name="StockIssuedDuringPeriodSharesExerciseOfWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lrmr_TaxCreditCarryForwardExpirationYearStart" name="TaxCreditCarryForwardExpirationYearStart" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lrmr_TwoThousandFourteenEquityIncentivePlanMember" name="TwoThousandFourteenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_VestOneYearMember" name="VestOneYearMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="lrmr_DomesticAndStateLocalJurisdictionMember" name="DomesticAndStateLocalJurisdictionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_MilestoneLiability" name="MilestoneLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lrmr_OfficeAndLabMember" name="OfficeAndLabMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_EffectiveIncomeTaxRateReconciliationStockCompensationForfeituresPercent" name="EffectiveIncomeTaxRateReconciliationStockCompensationForfeituresPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lrmr_WakeForestUniversityHealthSciencesMember" name="WakeForestUniversityHealthSciencesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_InducementStockMember" name="InducementStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lrmr_IndianaUniversityResearchAndTechnologyCorporationMember" name="IndianaUniversityResearchAndTechnologyCorporationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lrmr_NoExpirationMember" name="NoExpirationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_PayrollTaxesReceivable" name="PayrollTaxesReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lrmr_IncomeTaxesDisclosureLineItems" name="IncomeTaxesDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_MilestonePaymentAmount" name="MilestonePaymentAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lrmr_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember" name="WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_PrivateOfferingMember" name="PrivateOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="lrmr_MilestoneExpenses" name="MilestoneExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lrmr_FromPriorPlansMember" name="FromPriorPlansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_StockIssuedDuringPeriodValueExerciseOfWarrants" name="StockIssuedDuringPeriodValueExerciseOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lrmr_StockAndWarrantIssuanceTransactionCosts" name="StockAndWarrantIssuanceTransactionCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lrmr_AccruedResearchAndDevelopmentExpenseCurrent" name="AccruedResearchAndDevelopmentExpenseCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lrmr_DeferredTaxAssetsOperatingLeaseLiabilities" name="DeferredTaxAssetsOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lrmr_PrepaidResearchAndDevelopmentExpenses" name="PrepaidResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lrmr_AtTheMarketEquityDistributionAgreementMember" name="AtTheMarketEquityDistributionAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_FirstAnniversaryMember" name="FirstAnniversaryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lrmr_OfficeMember" name="OfficeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_AdditionalOfficeMember" name="AdditionalOfficeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_AreaOfOfficeSpace" name="AreaOfOfficeSpace" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lrmr_EquipmentFurnitureAndFixturesAndOfficeEquipmentMember" name="EquipmentFurnitureAndFixturesAndOfficeEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_PerformedInUsMember" name="PerformedInUsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_ZafgenMember" name="ZafgenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_PrepaidExpensesAndOtherCurrentAssetsTextBlock" name="PrepaidExpensesAndOtherCurrentAssetsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lrmr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" name="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lrmr_VestAnnuallyOverFourYearsMember" name="VestAnnuallyOverFourYearsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_VestOverFourYearsMember" name="VestOverFourYearsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_CashAndNonCashOperatingLeaseExpense" name="CashAndNonCashOperatingLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lrmr_AtTheMarketEquityOfferingProgramMember" name="AtTheMarketEquityOfferingProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_ProceedsFromExerciseOfStockOptionsIncludedInOtherCurrentAssets" name="ProceedsFromExerciseOfStockOptionsIncludedInOtherCurrentAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lrmr_EmployeesAndDirectorsMember" name="EmployeesAndDirectorsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_FinalSubleaseYearMember" name="FinalSubleaseYearMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_PerformedOutsideUsMember" name="PerformedOutsideUsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_MinimumAnnualRoyaltyObligation" name="MinimumAnnualRoyaltyObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lrmr_ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts" name="ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lrmr_FirstSubleaseYearMember" name="FirstSubleaseYearMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_ResearchAndDevelopmentCostsCapitalized" name="ResearchAndDevelopmentCostsCapitalized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lrmr_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance" name="DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lrmr_AggregateGrossSalesProceedsUnderSalesAgreement" name="AggregateGrossSalesProceedsUnderSalesAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lrmr_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" name="DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lrmr_SubleaseAnnualBaseRent" name="SubleaseAnnualBaseRent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lrmr_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate" name="EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lrmr_WarrantsIssuedPricePerShare" name="WarrantsIssuedPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299738811584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 12, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LRMR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">LARIMAR THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001374690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,800,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-3857670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Three Bala Plaza East<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Bala Cynwyd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">511-9056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,218,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Part III of this Annual Report on Form 10-K incorporates certain information by reference from the registrant&#8217;s proxy statement for the 2024 annual meeting of shareholders to be filed no later than 120 days after the end of the registrant&#8217;s fiscal year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">.</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">PricewaterhouseCoopers LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Philadelphia, Pennsylvania, USA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299738518400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 26,749<span></span>
</td>
<td class="nump">$ 26,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">60,041<span></span>
</td>
<td class="nump">91,603<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,385<span></span>
</td>
<td class="nump">2,311<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">90,175<span></span>
</td>
<td class="nump">120,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">684<span></span>
</td>
<td class="nump">831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">3,078<span></span>
</td>
<td class="nump">2,858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,339<span></span>
</td>
<td class="nump">1,339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">659<span></span>
</td>
<td class="nump">638<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">95,935<span></span>
</td>
<td class="nump">126,405<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,283<span></span>
</td>
<td class="nump">1,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">7,386<span></span>
</td>
<td class="nump">8,408<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">837<span></span>
</td>
<td class="nump">611<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">9,506<span></span>
</td>
<td class="nump">10,705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">4,709<span></span>
</td>
<td class="nump">4,797<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">14,215<span></span>
</td>
<td class="nump">15,502<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (See Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock; $0.001 par value per share; 5,000,000 shares authorized as of December 31, 2023 and December 31, 2022; no shares issued and outstanding as of December 31, 2023 and December 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value per share; 115,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 43,909,069 and 43,269,200 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">270,150<span></span>
</td>
<td class="nump">262,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(188,554)<span></span>
</td>
<td class="num">(151,605)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive gain (loss)</a></td>
<td class="nump">81<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">81,720<span></span>
</td>
<td class="nump">110,903<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 95,935<span></span>
</td>
<td class="nump">$ 126,405<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299738549872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">115,000,000<span></span>
</td>
<td class="nump">115,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">43,909,069<span></span>
</td>
<td class="nump">43,269,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">43,909,069<span></span>
</td>
<td class="nump">43,269,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299734592736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 27,670<span></span>
</td>
<td class="nump">$ 24,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">14,088<span></span>
</td>
<td class="nump">12,276<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">41,758<span></span>
</td>
<td class="nump">36,526<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(41,758)<span></span>
</td>
<td class="num">(36,526)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">4,809<span></span>
</td>
<td class="nump">1,171<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (36,949)<span></span>
</td>
<td class="num">$ (35,355)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (0.84)<span></span>
</td>
<td class="num">$ (1.37)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (0.84)<span></span>
</td>
<td class="num">$ (1.37)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic</a></td>
<td class="nump">43,901,241<span></span>
</td>
<td class="nump">25,761,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted</a></td>
<td class="nump">43,901,241<span></span>
</td>
<td class="nump">25,761,394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (36,949)<span></span>
</td>
<td class="num">$ (35,355)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="nump">112<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive gain (loss)</a></td>
<td class="nump">112<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (36,837)<span></span>
</td>
<td class="num">$ (35,386)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299738633408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2021</a></td>
<td class="nump">$ 64,413<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 180,645<span></span>
</td>
<td class="num">$ (116,250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,710,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Common Stock. Net</a></td>
<td class="nump">75,257<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">75,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Common Stock. Net, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,558,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">6,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="num">(31)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(35,355)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,355)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2022</a></td>
<td class="nump">$ 110,903<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
<td class="nump">262,496<span></span>
</td>
<td class="num">(151,605)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,269,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="nump">11,466<span></span>
</td>
<td class="nump">11,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">628,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_StockIssuedDuringPeriodValueExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">7,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="nump">112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(36,949)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,949)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2023</a></td>
<td class="nump">$ 81,720<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
<td class="nump">$ 270,150<span></span>
</td>
<td class="num">$ (188,554)<span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,909,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_StockIssuedDuringPeriodValueExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_StockIssuedDuringPeriodValueExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299738702160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (36,949)<span></span>
</td>
<td class="num">$ (35,355)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">7,615<span></span>
</td>
<td class="nump">6,619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_CashAndNonCashOperatingLeaseExpense', window );">Lease expense</a></td>
<td class="num">(82)<span></span>
</td>
<td class="num">(46)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">311<span></span>
</td>
<td class="nump">318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of discount on marketable securities</a></td>
<td class="num">(1,843)<span></span>
</td>
<td class="num">(774)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,065)<span></span>
</td>
<td class="num">(204)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(403)<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(1,022)<span></span>
</td>
<td class="nump">1,816<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="num">(21)<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities:</a></td>
<td class="num">(33,459)<span></span>
</td>
<td class="num">(27,569)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(164)<span></span>
</td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchase of marketable securities</a></td>
<td class="num">(101,233)<span></span>
</td>
<td class="num">(133,610)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Maturities and sales of marketable securities</a></td>
<td class="nump">134,750<span></span>
</td>
<td class="nump">42,750<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">33,353<span></span>
</td>
<td class="num">(90,960)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_ProceedsFromExerciseOfStockOptionsAndWarrants', window );">Proceeds from exercise of stock options and warrants</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">75,257<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(76)<span></span>
</td>
<td class="num">(43,272)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">28,164<span></span>
</td>
<td class="nump">71,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">28,088<span></span>
</td>
<td class="nump">$ 28,164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Leased assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_ProceedsFromExerciseOfStockOptionsIncludedInOtherCurrentAssets', window );">Proceeds from exercise of stock options included in other current assets</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_CashAndNonCashOperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of lease expense, both cash and non-cash, related to operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_CashAndNonCashOperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_ProceedsFromExerciseOfStockOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of options under share-based payment arrangements and exercise of stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_ProceedsFromExerciseOfStockOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_ProceedsFromExerciseOfStockOptionsIncludedInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from exercise of stock options included in other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_ProceedsFromExerciseOfStockOptionsIncludedInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299740522800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (36,949)<span></span>
</td>
<td class="num">$ (35,355)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299734581136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299741549520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of Business and Basis of Presentation</a></td>
<td class="text"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Description of Business and Basis of Presentation </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Larimar Therapeutics, Inc., together with its subsidiary (the &#8220;Company&#8221; or &#8220;Larimar&#8221;), is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Larimar's lead product candidate, nomlabofusp (nomlabofusp is the International Nonproprietary Name ("INN") and the United States Adopted Name ("USAN") for CTI-1601), is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin ("FXN"), an essential protein, to the mitochondria of patients with Friedreich&#8217;s ataxia ("FA"). FA is a rare, progressive and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has completed two phase 1 studies of nomlabofusp and a Phase 2 dose exploration study in patients with FA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2021, after reporting positive top-line data from the Company&#8217;s Phase 1 FA program, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) placed a clinical hold on the Company&#8217;s nomlabofusp clinical program after the Company notified the FDA of mortalities at the highest dose levels of a 26-week non-human primate toxicology study that was designed to support extended dosing of patients with nomlabofusp. In August 2022, the Company submitted a complete response to the clinical hold following a Type C Meeting with the FDA, and proposed as nomlabofusp's next clinical trial a Phase 2, four-week, dose exploration study in FA patients starting at the lower dose levels tested in the Company&#8217;s Phase 1 multiple-ascending dose clinical trial. In September 2022, the FDA lifted its full clinical hold on the nomlabofusp program and imposed a partial clinical hold.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2023, the Company announced top-line data from its completed 25 mg cohort of a Phase 2, four-week, dose exploration trial of nomlabofusp in patients with FA and provided a complete response to the FDA in June 2023, which included unblinded safety, pharmacokinetic ("PK"), and pharmacodynamic ("PD") data from the Phase 2 trial&#8217;s completed 25 mg cohort. Data from the completed 25 mg cohort (n = 13) indicated that nomlabofusp was generally well tolerated and showed increases in FXN levels from baseline compared to placebo in all evaluated tissues (skin and buccal cells) at day 14 (the final day of daily dosing in the trial).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2023, the Company met with the FDA. Following that meeting, the Company submitted a complete response to the FDA&#8217;s partial clinical hold that included unblinded safety, PK and frataxin data from the Phase 2 trial&#8217;s completed 25 mg cohort.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2023, following the FDA&#8217;s review of the Company's complete response to the partial clinical hold, the FDA cleared initiation of a second cohort at 50 mg of our four-week, placebo-controlled, Phase 2 dose exploration trial and initiation of the OLE trial with daily dosing of 25 mg.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2024, the Company reported positive top-line data and successful completion of their four-week, placebo-controlled Phase 2 dose exploration study of nomlabofusp in participants with FA. Nomlabofusp was generally well tolerated and demonstrated dose dependent increases in FXN levels in all evaluated tissues (skin and buccal cells) after daily dosing of 14 days followed by every other day dosing until day 28 in the 25 mg and 50 mg cohorts. Participants in the 25 mg (n=13) and 50 mg (n=15) cohorts were randomized 2:1 to receive subcutaneous injections of nomlabofusp or placebo. The initiation of additional U.S. clinical trials evaluating nomlabofusp are contingent on FDA review of data under the partial clinical hold.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2024, the Company initiated an OLE trial evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver, with the first patient dosed in March 2024. Participants who complete treatment in the Phase 2 dose exploration trial, or who previously completed a prior clinical trial of nomlabofusp are potentially eligible to screen for the OLE. The OLE will evaluate the safety, tolerability and PK and measures of frataxin levels in peripheral tissues as well as other exploratory PD (lipid profiles and gene expression data) following long-term subcutaneous administration of nomlabofusp. Clinical measures collected during the trial will be compared to data from a synthetic control arm derived from participants in the Friedreich&#8217;s Ataxia Clinical Outcome Measures Study (FACOMS) database. Dose escalation in the OLE trial will be considered based on safety, tolerability, PK, and tissue FXN levels from the Phase 2 trial&#8217;s 50 mg cohort as well as available data from the 25 mg dose of nomlabofusp in the OLE trial and is contingent on FDA review as part of the partial clinical hold. Initial data from the OLE trial is expected in the fourth quarter of 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to risks and uncertainties common to pre-commercial companies in the biotechnology industry, including, but not limited to, development and commercialization by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with governmental</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulations, failure to secure regulatory approval for its drug candidates or any other product candidates and the ability to secure additional capital to fund its operations. Product candidates under development will require extensive non-clinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, infrastructure and extensive compliance-reporting capabilities. Even if the Company's drug development efforts are successful, it is uncertain when, if ever, it will realize significant revenue from product sales.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consolidated financial statements include the accounts of Larimar and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated. The accompanying consolidated financial statements have been prepared in conformity with GAAP.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity and Capital Resources</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s consolidated financial statements have been presented on the basis that it will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since its inception, the Company has incurred significant recurring operating losses and negative cash flows from operations. The Company has incurred net losses of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">36.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">35.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the years ended December 31, 2023, and 2022, respectively. In addition, as of December 31, 2023, the Company had an accumulated deficit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">188.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company expects to continue to generate operating losses for the foreseeable future. As of December 31, 2023, the Company had approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">86.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of cash, cash equivalents and marketable securities available for use to fund its operations and capital requirements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has funded its operations to date primarily with proceeds from sales of common stock and proceeds from the sale of prefunded warrants for the purchase of common stock, the acquisition in 2020 of cash, cash equivalents and marketable securities upon the merger with Zafgen, Inc. ("Zafgen") and, prior to the 2020 merger with Zafgen, capital contributions from Chondrial Holdings, LLC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2024, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">19,736,842</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock in an underwritten public offering at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.74</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and received net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">161.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In accordance with Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-15, "Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern", the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. As of the issuance date of these consolidated financial statements, the Company expects its cash, cash equivalents and marketable securities, including its net proceeds from the February 2024 public offering, will be sufficient to fund its forecasted operating expenses and capital expenditure requirements into 2026. If the timing of the Company's clinical assumptions are delayed or if there are other forecasted assumption changes that negatively impact its operating plan, the Company would reduce expenditures in order to further extend cash resources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has not yet commercialized any products and does not expect to generate revenue from the commercial sale of any products for several years, if at all. The Company expects that its research and development and general and administrative expenses will continue to increase and, as a result, that it will need additional capital to fund its future operating and capital requirements. Unless and until the Company can generate substantial revenue, management continuously evaluates different strategies to obtain the required funding for future operations. These strategies include seeking additional funding through a combination of public or private equity offerings, debt or royalty financings, collaborations and licensing arrangements, strategic partnerships with pharmaceutical and/or larger biotechnology companies, or other sources. The incurrence of indebtedness would result in increased fixed payment obligations and the Company may be required to agree to certain restrictive covenants, such as limitations on its ability to incur additional debt, limitations on its ability to acquire, sell or license intellectual property rights, minimum required cash balances and other operating restrictions that could adversely impact the Company's ability to conduct its business. Any additional fundraising efforts may divert the Company's management from their day-to-day activities, which may adversely affect its ability to develop and commercialize its product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There can be no assurance that the Company will be able to raise sufficient additional capital on acceptable terms, if at all. If such additional financing is not available on satisfactory terms, or is not available in sufficient amounts, or if the Company does not have sufficient authorized shares, the Company may be required to delay,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">limit, or eliminate the development of business opportunities and its ability to achieve its business objectives, its competitiveness, and its business, financial condition, and results of operations will be materially adversely affected. The Company could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable and it may be required to relinquish rights to some of its technologies or product candidates or otherwise agree to terms unfavorable to it, any of which may have a material adverse effect on the Company's business, operating results and prospects. In addition, geopolitical tensions, volatility of capital markets, and other adverse macroeconomic events, including those due to inflationary pressures, rising interest rates, bank instability and the ability of the U.S. government to manage federal debt limits as well as the potential impact of other health crises on the global financial markets may reduce the Company's ability to access capital, which could negatively affect its liquidity and ability to continue as a going concern.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the Company is unable to obtain sufficient funding when needed and/or on acceptable terms, the Company may be required to significantly curtail, delay or discontinue one or more of its research and development programs, the manufacture of clinical and commercial supplies, product portfolio expansion, pre commercialization efforts and/or commercial operations, which could adversely affect its business prospects, or the Company may be unable to continue operations.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299741694208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Summary of Significant Accounting Policies </span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. This process involves reviewing open contracts and purchase orders, communicating with our personnel and outside vendors to identify services that have been performed on our behalf and estimating the level of service performed and the associated costs incurred for the services when we have not yet been invoiced or otherwise notified of the actual costs. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expense, the recording as prepaid expense of payments made in advance of the actual provision of goods or services, valuation of stock-based awards and valuation of leases. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk and Significant Suppliers</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and marketable securities. Cash balances may be held in financial institutions which may exceed federally insured limits. The Company has not experienced realized losses related to its cash, cash equivalents or marketable securities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is highly dependent on third-party manufacturers to supply products for research and development activities in its programs, to scale and optimize their manufacturing processes and, ultimately, to provide commercial supply. The Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for drug substance and formulated drugs related to these programs. The drug substance which is in frozen liquid form for nomlabofusp is currently manufactured for the Company by a third-party manufacturer, and the frozen liquid form of drug product is made at another manufacturer. The Company is undertaking a program with a third manufacturer to begin to produce a lyophilized version of the drug product from the same drug substance, that, once available, the Company intends to use in certain of its future planned clinical trials. The Company&#8217;s research and development programs could be adversely affected by a significant interruption in these manufacturing services or in the supply of drug substance and formulated drugs.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company considers all highly liquid investments with maturities of three months or less at the date of purchase to be cash equivalents. Cash equivalents consisted of money market funds as of December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Marketable securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Marketable securities consist of debt investments with original maturities greater than ninety days. The Company classifies its marketable securities as available-for-sale. Accordingly, these investments are recorded at fair value, which is based on quoted market prices. When the fair value is below the amortized cost the amount of the expected credit loss is estimated. The credit-related impairment amount, if any, would be recognized in net income; the remaining impairment amount and unrealized gains are reported as a component of accumulated other comprehensive income in stockholders&#8217; equity. Credit losses, if any, are recognized through the use of an allowance for credit losses account and subsequent improvements in expected credit losses are recognized as a reversal of the allowance account. If the Company has the intent to sell the security or if it is more likely than not that the Company would be required to sell the security prior to recovery of its amortized cost basis, the allowance for credit loss would be written off and the excess of the amortized cost basis of the asset over its fair value is recorded in net income.</span></p></div><div style="font-size:11pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_79196bf3-be5b-4806-9ec5-5fed79d1cfbe;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> or</span><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seven-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> estimated useful life for equipment, furniture and fixtures and office equipment. Leasehold improvements are amortized over the shorter of the asset life or the term of the lease agreement. Expenditures for repairs and maintenance of assets are charged to expense as incurred. Upon retirement or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain or loss is included in loss from operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Long-lived assets consist of property and equipment, net&#184; and right-of-use assets. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. Any impairment loss, if indicated, is measured as the amount by which the carrying amount of the asset exceeds the estimated fair value of the asset.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions. The Company&#8217;s focus is on the research, development and commercialization of novel therapeutics for the treatment of rare diseases.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Costs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Costs associated with internal research and development and external research and development services, including drug development, clinical studies and non-clinical studies, are expensed as incurred. Research and development expenses include costs for salaries, employee benefits, subcontractors, facility-related expenses, depreciation, stock-based compensation, third-party license fees, laboratory supplies, and external costs of outside vendors engaged to conduct discovery, non-clinical and clinical development activities and clinical trials as well as to manufacture clinical trial materials, and other costs. The Company recognizes external research and development costs based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its key service providers.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such prepaid expenses are recognized as an expense when the goods have been delivered or the related services have been performed, or when it is no longer expected that the goods will be delivered, or the services rendered.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upfront payments, milestone payments and annual maintenance fees under license agreements are currently expensed in the period in which they are incurred.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent Costs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company measures all stock-based awards granted to employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model. Compensation expense of those awards is recognized over the requisite service period, which is the vesting period of the respective award. Typically, the Company issues awards with only service-based vesting conditions and records the expense for these awards using the straight-line method. The Company accounts for forfeitures as they occur.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to May 28, 2020, the Company had been a private company and lacked company-specific historical and implied volatility information for its common stock. Prior to January 1, 2023, the Company estimated its expected common stock price volatility solely based on the historical volatility of publicly traded peer companies. Beginning on January 1, 2023, based on the availability of sufficient historical trading data of the Company's own common stock on the Nasdaq Global Market to calculate accurately its volatility, the Company began blending its volatility starting from June 2020 (following its merger with Zafgen in 2020) to the date of each stock-based award, and weighing the volatility of its peer group for the amount of time from May 31, 2020 backwards so that the blended volatility equals the expected term of the related stock-based award. The expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield considers the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comprehensive Gain (Loss)</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comprehensive gain (loss) includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and economic events other than those with stockholders. For the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company&#8217;s only element of other comprehensive loss was unrealized loss on marketable securities.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss Per Share</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Prior to August 11, 2023, basic shares outstanding includes the weighted average effect of the Company&#8217;s prefunded warrants issued in June 2020, the exercise of which requires little or no consideration for the delivery of shares of common stock. These prefunded warrants were exercised on August 11, 2023 and the Company received cash proceeds of less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Accordingly, the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">628,403</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares were issued upon the exercise of these warrants and are included in issued and outstanding common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares, including potentially dilutive common stock equivalents assuming the dilutive effect of outstanding stock options, outstanding restricted stock units, and unvested restricted common shares, as determined using the treasury stock method. For periods in which the Company has reported net losses (all periods since inception), diluted net loss per common share attributable to common stockholders is the same as basic net loss per common share attributable to common stockholders, since dilutive common stock equivalents are not assumed to have been issued if their effect is antidilutive.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company excluded </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,888,502</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,071,528</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> options to purchase common stock, outstanding as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 respectively, from the computation of diluted net loss per share for the twelve months ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, because they had an anti-dilutive impact due to the net loss incurred for the periods.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently Issued and Adopted Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, new accounting guidance is issued by the FASB or other standard setting bodies that is adopted by us as of the effective date or, in some cases where early adoption is permitted, in advance of the effective date. We have assessed the recently issued guidance that is not yet effective and believe the new guidance will not have a material impact on the consolidated results of operations, cash flows or financial position.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299741634000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Cash Equivalents/Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements and Cash Equivalents/Marketable Securities</a></td>
<td class="text"><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair Value Measurements and Cash Equivalents/Marketable Securities</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value Measurements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2023 and December 31, 2022 are measured in accordance with the standards of ASC 820, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value Measurements and Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which establishes a three-level valuation hierarchy for measuring fair value and expands financial statement disclosures about fair value measurements. The valuation hierarchy is based on upon the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:11.54%;"></td>
      <td style="width:88.46%;"></td>
     </tr>
     <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level &#8211; 1</span></p></td>
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></p></td>
     </tr>
     <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:middle;"><p style="font-size:1pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:middle;"><p style="font-size:1pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level &#8211; 2</span></p></td>
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.</span></p></td>
     </tr>
     <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
      <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level &#8211; 3</span></p></td>
      <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inputs to the valuation methodology are unobservable and significant to the fair value measurement.</span></p></td>
     </tr>
    </table><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s financial instruments consist primarily of cash and cash equivalents, marketable securities, accounts payable and accrued liabilities. For accounts payable and accrued liabilities, the carrying amounts of these financial instruments as of December 31, 2023 and 2022 were considered representative of their fair values due to their short term to maturity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables summarize the Company&#8217;s cash equivalents and marketable securities as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted<br/>Prices in<br/>Active<br/>Markets <br/>(Level 1)</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs <br/>(Level 2)</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs <br/>(Level 3)</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds invested in government securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,701</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,701</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,701</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,701</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury Bills</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,334</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,334</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Government securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,719</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,719</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,988</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,988</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">60,041</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,334</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,707</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Total cash equivalents and marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84,742</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,035</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,707</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds invested in government securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,184</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,184</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,184</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,184</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Government securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">91,603</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">91,603</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">91,603</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">91,603</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Total cash equivalents and marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">113,787</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,184</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">91,603</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accrued interest receivable related to the Company&#8217;s investments was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, respectively, and is included in prepaid expenses and other current assets on the consolidated balance sheet.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company classifies its money market funds and U.S. treasury bills, which are valued based on quoted market prices in active markets with no valuation adjustment, as Level 1 assets within the fair value hierarchy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company classifies its investments in U.S. government and agency securities, corporate commercial paper, and corporate bonds, if any, as Level 2 assets within the fair value hierarchy. The fair values of these investments are estimated by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2022, the unrealized loss for available-for-sale investments were non-credit related, and the Company does not intend to sell the investments that were in an unrealized loss position, nor will it be required to sell those investments before recovery of their amortized cost basis, which may be maturity. As of December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> allowances for credit losses for the Company&#8217;s investments were recorded. During the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">twelve months ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recognize any impairment losses related to investments.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company's cash equivalents and marketable securities consisted of a U.S. government money market fund, U.S. Treasury Bills, U.S. government and agency securities and corporate bonds, all held in our name in a separate custody account with U.S. Bank. The U.S. government money market fund has same-day liquidity access and the U.S. government and agency securities all have maturities of 90 days or less.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Marketable Securities</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables summarize the Company&#8217;s marketable securities as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized <br/>Losses</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury Bills</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,330</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,334</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Government securities (due within 1 year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,653</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,719</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper (due within 1 year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,977</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,988</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">59,960</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">81</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">60,041</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Government securities (due within 1 year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">91,634</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">91,603</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">91,634</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">91,603</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299740078672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Prepaid Expense and Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_PrepaidExpensesAndOtherCurrentAssetsTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prepaid Expenses and Other Current Assets</span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prepaid expenses and other current assets consisted of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid research and development expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,994</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,394</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid insurance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">682</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">679</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other prepaid expenses and other assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">709</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">238</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total prepaid expenses and other assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,385</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,311</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_PrepaidExpensesAndOtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_PrepaidExpensesAndOtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299738575280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Fixed Assets</a></td>
<td class="text"><div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">5.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fixed Assets</span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fixed assets, net consisted of the following:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.477%;"></td>
        <td style="width:1.399%;"></td>
        <td style="width:12.775%;"></td>
        <td style="width:1.399%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.776%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.399%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.776%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Useful Life</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5 years</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">117</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lab equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5 years</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,192</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,192</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7 years</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">555</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">456</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="-sec-ix-hidden:F_1743f7c9-4f07-468e-8ed1-5de01b765813;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">lease term</span></span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Total property, plant and equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,909</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,745</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Accumulated depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,225</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">914</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Property, plant and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">684</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">831</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation expense was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, respectively. In addition, for the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of depreciation related to sublet assets recorded as other expense.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299740104608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">6.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued Expenses</span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses consisted of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued research and development expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,594</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,921</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued payroll and related expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,365</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,046</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">427</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">441</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Total accrued expenses and other current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,386</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,408</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299744820720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity and Stock Options<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity and Stock Options</a></td>
<td class="text"><div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">7.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stockholders&#8217; Equity and Stock Options</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Common Stock and Prefunded warrants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 28, 2020, the Company entered into a securities purchase agreement with certain accredited investors (the &#8220;Purchasers&#8221;) for the sale by the Company in a private placement of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,105,359</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock and prefunded warrants to purchase an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">628,403</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock, for a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.88</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share of the common stock and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.87</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per prefunded warrant. The prefunded warrants were exercisable at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.01</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and were exercisable indefinitely. In August 2023, the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">628,403</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of prefunded warrants were exercised and the Company received cash proceeds of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_8cb91d11-91f9-408e-87be-ef7e83759a47;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six thousand two hundred and eighty-four dollars</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The private placement closed on June 1, 2020. The aggregate gross proceeds for the issuance and sale of the common stock and prefunded warrants were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">80.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, transaction costs totaled $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and resulted in net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">75.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company&#8217;s Registration Statement on Form S-3, filed with the SEC on June 26, 2020, registered the resale of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,105,359</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock sold and the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">628,403</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock underlying the prefunded warrants. MTS Health Partners served as placement agent to the Company in connection with the private placement. As partial compensation for these services, the Company issued MTS Health Partners </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">35,260</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company&#8217;s Amended and Restated Certificate of Incorporation, authorized the Company to issue up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">115,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> par value common stock, of which </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">43,909,069</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares were issued and outstanding, and up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> par value undesignated preferred stock, of which </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares were issued or outstanding. The voting, dividend and liquidation rights of the holders of the Company&#8217;s common stock are subject to and qualified by the rights, powers and preferences of the holders of the preferred stock. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Common stockholders are entitled to receive dividends, as may be declared by the board of directors of the Company (the &#8220;Board&#8221;), if any. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cash dividends have been declared or paid to date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2022, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25,558,750</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock in an underwritten public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and received net proceeds, net of underwriting discounts and commissions and offering costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">75.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2024, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">19,736,842</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock in an underwritten public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.74</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and received net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">161.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2022 ATM Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2022, the Company entered into a sales agreement (the "ATM Agreement") with a Guggenheim Securities, LLC in connection with the establishment of an &#8220;at-the-market&#8221; offering program under which the Company could sell up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of shares of common stock (the &#8220;ATM Shares&#8221;) from time to time.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2024, in connection with the underwritten public offering described above, the Company terminated the ATM Agreement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ATM Shares were ever sold pursuant to the ATM Agreement.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2020 Equity Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Board adopted the 2020 Equity Incentive Plan (the "2020 Plan") on July 16, 2020 and the stockholders of the Company approved the 2020 Plan on September 29, 2020. The 2020 Plan replaced the predecessor plans (the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">"Prior Plans") that the Company assumed following its merger with Zafgen in May 2020. Options outstanding under the Prior Plans will remain outstanding, unchanged, and subject to the terms of the Prior Plans and the respective award agreements, and no further awards will be made under the Prior Plans. However, if any award previously granted under the Prior Plans, expires, terminates, is canceled, or is forfeited for any reason after the approval of the 2020 Plan, the shares subject to that award will be added to the 2020 Plan share pool so that they can be utilized for new grants under the 2020 Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2020 Plan provides for the grant of incentive stock options (&#8220;ISOs&#8221;), nonstatutory stock options (&#8220;NSOs&#8221;), stock appreciation rights, restricted stock awards, restricted stock unit awards, and cash or other stock-based awards. ISOs may be granted only to the Company&#8217;s employees, including the Company&#8217;s officers, and the employees of the Company&#8217;s affiliates. All other awards may be granted to the Company&#8217;s employees, including the Company&#8217;s officers, the Company&#8217;s non-employee directors and consultants, and the employees and consultants of the Company&#8217;s affiliates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The maximum number of shares that may be issued in respect of any awards under the 2020 Plan is the sum of: (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,700,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares plus (ii) an annual increase on January 1, 2021 and each anniversary of such date thereafter through January 1, 2030, equal to the lesser of (A) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the shares issued and outstanding on the last day of the immediately preceding fiscal year, or (B) such smaller number of shares as determined by the Board (collectively, the &#8220;Plan Limit&#8221;).</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The maximum aggregate number of shares that may be issued under the 2020 Plan is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> over the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> term of the 2020 Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As permitted by the 2020 Plan, the Company added </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,756,363</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,730,768</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares available for grant to the 2020 Plan on January 1, 2024 and January 1, 2023, respectively, increasing the maximum number of shares of the Company&#8217;s common stock that may be issued under the 2020 Plan as of January 1, 2024 to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,042,968</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the twelve months ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, options to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">224,437</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">148,623</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares issued under the Prior Plans were canceled and became available for grant under the 2020 Plan. In addition, as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,286,605</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock were available for grant under the 2020 Plan.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Valuation</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted to employees:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.72</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.15</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.23</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.21</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">94</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.00</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.00</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Options</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the Company&#8217;s stock option activity for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">twelve months ended December 31, 2023 (amounts in millions, except for share and per share data):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.11%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.662%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.942%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.662%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Average</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Average</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Remaining</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Intrinsic</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exercise</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Contractual</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Value (a)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Term (in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in millions)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Outstanding as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,071,528</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.13</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.6</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,748,200</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.68</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,466</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.93</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited/Expired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">534,760</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.52</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,273,502</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.06</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.8</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exercisable as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,930,100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.55</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.6</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Vested and expected to vest as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,273,502</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.06</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.8</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(a)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were in the money at December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></div></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2023 Option Grants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the twelve months ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company granted options to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,388,200</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock to employees under the 2020 Plan. The options have an exercise price equal to the closing stock price as of the grant date, and vest over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% vesting on the first anniversary of the grant and the remainder vesting in equal monthly installments thereafter. The weighted-average grant date fair value of options granted under the 2020 Plan during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">twelve months ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.70</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.21</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, total unrecognized compensation expense related to unvested stock options granted under the 2020 Plan was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which is expected to be recognized over a weighted average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.91</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inducement Stock Option Grant</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the twelve months ended December 31, 2023, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Company granted options to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">360,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock granted outside of the 2020 Plan. These grants were made pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq listing rule 5635(c)(4). The options issued under this inducement grant have an exercise price equal to the closing stock price as of the grant date, and vest over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% vesting on the first anniversary of the grant and the remainder vesting in equal monthly installments thereafter. The weighted-average grant date fair value of options granted under this inducement grant during the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> twelve months ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.59</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> inducement grants in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">twelve months ended December 31, 2022.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, total unrecognized compensation expense related to unvested inducement options granted under the 2020 Plan was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which is expected to be recognized over a weighted average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3.28</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock Units</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2023, RSUs were granted under the 2020 Plan to the Company's employees in order to maintain retention of key employees. The value of an RSU award is based on the Company's stock price on the date of the grant. The shares underlying the RSUs are not issued until the RSUs vest.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Activity with respect to the Company's RSUs during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">twelve months ended December 31, 2023 was as follows (in millions, except share, contractual term, and per share data):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.11%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.662%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.942%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.662%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Average</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Average</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Remaining</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Intrinsic</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Grant Date</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Contractual</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Value (a)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Term (in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in millions)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Outstanding as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted stock units granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">650,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.94</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted stock units forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.94</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">615,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.94</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.6</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unvested and expected to vest as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">615,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.94</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.6</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock Unit Grants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The RSUs vest annually over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and have a weighted-average grant date fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.94</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per unit.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, total unrecognized compensation expense for RSUs was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which is expected to be recognized over a weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3.09</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">January 2024 Option and Restricted Stock Unit Grants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 17, 2024, the Company granted options to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,472,175</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">245,363</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of restricted stock to employees under the 2020 Plan. The options have an exercise price equal to the closing stock price as of the grant date, and vest over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">vesting on the first anniversary of the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">grant </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and the remainder vesting in equal monthly installments thereafter. The shares of restricted stock will vest annually over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense was classified in the consolidated statements of operations as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.92%;"></td>
        <td style="width:1.6%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.64%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.6%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.64%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.6%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,077</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,771</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,538</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,848</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,615</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,619</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299741694208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">8.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commitments and Contingencies </span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intellectual Property Licenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is party to an exclusive License Agreement (the &#8220;WFUHS License&#8221;), dated November 30, 2016, as amended, with Wake Forest University Health Sciences (&#8220;WFUHS&#8221;) and an exclusive License Agreement (the &#8220;IU License&#8221;), dated November 30, 2016, as amended, with Indiana University (&#8220;IU&#8221;). Such agreements provide for a transferable, worldwide license to certain patent rights regarding technology used by the Company with respect to the development of nomlabofusp. Both agreements continue from their effective date through the last to date of expiration of the licensed patents, unless earlier terminated by either party in accordance with their terms.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In partial consideration for the right and license granted under these agreements, the Company will pay each of WFUHS and IU a royalty of a low single digit percentage of net sales of licensed products depending on whether there is a valid patent covering such products. As additional consideration for these agreements, the Company is obligated to pay each of WFUHS and IU certain milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in the aggregate upon the achievement of certain developmental milestones, which commenced with the enrollment of the first patient in a Phase 1 clinical trial. The Company enrolled the first patient in its SAD trial on December 11, 2019 and paid WFUHS and IU less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company will also pay each of WFUHS and IU sublicensing fees ranging from a high-single digit to a low double-digit percentage of sublicense consideration depending on the Company&#8217;s achievement of certain regulatory milestones as of the time of receipt of the sublicense consideration. The Company is also obligated to reimburse WFUHS and IU for patent-related expenses. In the event that the Company disputes the validity of any of the licensed patents, the royalty rate would be tripled during such dispute. The Company is also obligated to pay to IU a minimum annual royalty of less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million per annum.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the event that the Company is required to pay IU consideration, then the Company may deduct </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of such IU consideration on a dollar-for-dollar basis from the consideration due to WFUHS. In the event that the Company is required to pay WFUHS consideration, then the Company may deduct </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">60</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of such WFUHS consideration on a dollar-for-dollar basis from the consideration due to IU.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2022, the Company initiated dosing of a Phase 2 study. Pursuant to the terms of both the WFUHS License and the IU License, the company recognized milestone expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million within research and development expenses.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Both agreements continue from their effective date through the last date of expiration of the licensed patents, unless earlier terminated by either party in accordance with their terms.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Bala Cynwyd Office Space</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 8, 2019, the Company entered into an operating lease for office space in Bala Cynwyd, Pennsylvania, effective as of December 15, 2019, for a period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three years and six months</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> with an option to extend the lease for </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_1adadb6d-a5ef-4cd0-b448-c546eec4b594;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> additional years. Due to required tenant improvements to be completed by the landlord, the Company did not take immediate possession of the leased property and the lease term commenced on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">February 15, 2020</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 9, 2023, the Company executed a lease extension agreement on its original </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,642</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square footage of office space in Bala Cynwyd, Pennsylvania (which was set to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_54780bae-ad9f-44bf-b3f5-82dab5b666a1;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">August 2023</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) and agreed to lease an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,462</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of office space from the same landlord.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The lease extension on the original </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,642</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square footage commenced on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 1, 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and the Company recorded a right of use asset and lease liability of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of that date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The new lease on </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,462</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> additional square footage commenced on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">October 1, 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and the Company recorded a right of use asset and lease liability of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of that date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The right of use assets and lease liabilities with both these leases are reflected in the financial statements for the year ended December 31, 2023 as are the right of use asset and lease liability of the Company's Boston office space discussed below.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Boston Office Lease</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Company's 2020 merger with Zafgen described in footnote 1, on May 28, 2020, the Company acquired a non-cancellable operating lease for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">17,705</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of office space (the &#8220;Premises&#8221;). The lease expires on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">October 30, 2029</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. As part of the agreement, the Company is required to maintain a letter of credit, which upon signing was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and is classified as restricted cash within the condensed consolidated financial statements. In addition to the base rent, the Company is also responsible for its share of operating expenses, electricity and real estate taxes, which costs are not included in the determination of the leases&#8217; right-of-use assets or lease liabilities. The right-of-use asset is being amortized to other income/(expense) over the remaining lease term as a result of the sublease described below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 27, 2020, the Company entered into a sublease agreement (the &#8220;Sublease&#8221;) with Massachusetts Municipal Association, Inc. (the &#8220;Subtenant&#8221;), whereby the Company sublet the entire Premises to the Subtenant. The initial term of the Sublease commenced on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 4, 2020</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and continues until </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">October 30, 2029</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In connection with the Sublease, the Company evaluated the need for impairment under ASC 360 "Impairment Testing: Long-Lived Assets Classified as Held and Used," and determined there was no impairment.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Sublease provided for an initial annual base rent of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which increases annually up to a maximum annual base rent of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Subtenant also is responsible for paying to the Company future increases in operating costs (commencing on January 1, 2022), future increases in annual tax costs (commencing July 1, 2021) and all utility costs (commencing March 1, 2021) attributable to the Premises during the term of the Sublease. As part of the Sublease, the subtenant deposited a letter of credit in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to assure their performance under the sublease. If there are no uncured events of default under the sublease, the amount of this security deposit decreases over time to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million on the sixth anniversary of the Sublease. The Company records sublease income on this sublease on a straight-line basis as a component of other income/(expense).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Lab Space</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 5, 2018, the Company entered into an operating lease for office and lab space in Philadelphia, Pennsylvania, effective as of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 1, 2019</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and expiring on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2020</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> with an option to extend the lease for </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_ed24bfd5-a8ef-478d-bee3-0b02edde6a19;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">two</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> additional years. On August 4, 2020, the Company executed the first option to extend the lease for an additional year, expiring on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2021</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. On August 9, 2021, the Company executed the remaining option to extend the lease for an additional year, expiring on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2022</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In January 2023, the Company executed an extension of this lease for an additional year, expiring on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company has determined this lease extension qualifies as a short-term lease and have applied the accounting policy election to not record the related right-of-use asset and lease liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 16, 2023, the Company entered into an operating lease for lab space in King of Prussia, Pennsylvania for a period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Due to required tenant improvements to be completed by the landlord, the Company did not take immediate possession of the leased property and the lease term is expected to commence in the second quarter of 2024, no right of use asset or lease liability will be recorded until the lease commencement date.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Lease Expense</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expense arising from operating leases was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">twelve months ended December 31, 2023 and 2022, respectively. For operating leases, the weighted-average remaining lease term for leases at December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5.5</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6.8</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">respectively. For operating leases, the weighted</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">average </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">discount rate for leases at December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%. The Company has not entered into any financing leases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Maturities of lease liabilities due under these lease agreements as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 are as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.1%;"></td>
        <td style="width:1.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.96%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">Year Ending December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Operating</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Leases</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,380</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,403</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,328</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,118</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,136</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">959</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,324</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,778</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Present value of lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,546</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Legal Proceedings</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is not currently a party to any litigation, nor is management aware of any pending or threatened litigation against the Company, that it believes would materially affect the Company&#8217;s business, operating results, financial condition or cash flows.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299739951776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">9.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income Taxes </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the years ended December 31, 2023, and 2022</span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company recorded </span><span style="font-size:10pt;font-family:Times New Roman;color:#333333;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> income tax benefits for the net operating losses incurred in each year due to its uncertainty of realizing a benefit from those items.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The domestic and foreign components of loss before income taxes are as follows.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Domestic</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,948</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,339</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,949</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,355</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A</span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.343%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.343%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal statutory income tax rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State taxes, net of federal benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in state tax rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal and state research and development tax credit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nondeductible permanent differences</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock compensation forfeitures - DTA Write Off</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in deferred tax asset valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29.6</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19.3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Effective income tax rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net deferred tax assets as of </span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 consisted of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized R&amp;D - acquired in merger with Zafgen</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66,678</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66,941</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized R&amp;D - Section 174 Costs post 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,411</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,019</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,490</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,709</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45,195</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,204</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax credit carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,319</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,284</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other temporary differences</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accruals &amp; reserves</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fixed assets &amp; intangibles</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">107</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">81</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,298</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,355</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">142,538</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">131,632</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating right of use asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">768</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">801</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">768</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">801</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">141,770</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">130,831</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets / (liabilities)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in the valuation allowance for deferred tax assets during the year ended December 31, 2023 and 2022</span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> related primarily to the increase in net operating loss carryforwards and tax credit carryforwards and a decrease other deferred tax assets associated with a reduction in the Company&#8217;s effective state rate. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes to the valuation allowance were as follows:</span></span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valuation allowance as of the beginning of the year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">130,831</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">124,016</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increases recorded to income tax provision</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,939</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,815</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valuation allowance at end of year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">141,770</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">130,831</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had net operating loss carryforwards that expire for federal, foreign and state income tax purposes of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#333333;white-space:pre-wrap;min-width:fit-content;">179.0</span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#333333;white-space:pre-wrap;min-width:fit-content;">1.2</span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#333333;white-space:pre-wrap;min-width:fit-content;">148.1</span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. The federal and state operating losses begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2026</span></span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2030</span></span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, while the foreign net loss carryforward can be carried forward indefinitely. As of </span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had federal net operating loss carryforwards that were generated after December 31, 2017 of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#333333;white-space:pre-wrap;min-width:fit-content;">140.3</span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million that do not expire, however these </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">carryforwards are limited to </span><span style="font-size:10pt;font-family:Times New Roman;color:#333333;white-space:pre-wrap;min-width:fit-content;">80</span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the taxable income in any one tax period.</span></span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> As of </span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company also had available tax credit carryforwards for federal and state income tax purposes of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#333333;white-space:pre-wrap;min-width:fit-content;">16.3</span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million which begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2039</span></span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Utilization of the pre-Merger net operating loss carryforwards attributable to Zafgen, of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#333333;white-space:pre-wrap;min-width:fit-content;">33.5</span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, are subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986 due to ownership changes occurred during the tax year associated with the Merger. In addition to the limitation of the pre-Merger NOL&#8217;s of Zafgen, the net capitalized R&amp;D deferred tax assets in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#333333;white-space:pre-wrap;min-width:fit-content;">66.9</span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">is subject to the built-in loss rules under Section 382 and may not be realized if the underlying asset associated with the R&amp;D is disposed within five years of the Merger, or May 28, 2025</span></span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. The ownership changes will limit the amount of pre-merger Zafgen carryforwards that can be utilized annually to offset future taxable income with an annual limitation of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#333333;white-space:pre-wrap;min-width:fit-content;">35</span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thousand per year. The Company has reduced their NOL and R&amp;D tax credit deferred tax assets associated with the pre-Merger Zafgen operations as a result of the 382 analysis.</span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company believes that as a result of its merger with Zafgen, its ability to utilize NOLs acquired in the transaction and our other NOLs is expected to be severely limited by Section 382 of the Code. Additionally, the Company&#8217;s July 2021, September 2022 and February 2023 equity transactions could also limit its ability to utilize NOLs in the future. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception. If the Company experienced a change of control, as defined by Section 382, at any time since inception, utilization of its net operating loss carryforwards or tax credit carryforwards would be subject to an annual limitation under Section 382, which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, our July 2021, September 2022 and February 2024 equity transactions could also limit our ability to utilize NOLs in the future. </span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any limitation may result in expiration of a portion of the net operating loss carryforwards or tax credit carryforwards before utilization. Further, until a study is completed, and any limitation is known, no amounts are being presented as an uncertain tax position.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Tax Cuts and Jobs Act ("TCJA") requires taxpayers to capitalize and amortize research and experimental expenditures under IRC Section 174 for tax years beginning after December 31, 2021. This rule became effective for the Company during the year ended December 31, 2022 and resulted in the capitalization of research and development costs in both 2023 and 2022. The Company is amortizing these costs for tax purposes over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> if the research and development was performed in the U.S. and over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15 years</span></span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> if the research and development was performed outside the U.S.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023 and 2022</span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company&#8217;s net deferred tax asset balance before the valuation allowance was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#333333;white-space:pre-wrap;min-width:fit-content;">141.8</span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#333333;white-space:pre-wrap;min-width:fit-content;">130.8</span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, and was comprised principally of net operating loss carryforwards, capitalized research and development expenses and tax credit carryforwards. During the years ended </span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, gross deferred tax assets increased due to deferred tax assets acquired as a result of additional net operating loss carryforwards and research and development tax credits generated.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets. Management has considered the Company&#8217;s history of cumulative net losses incurred since inception and its lack of commercialization of any products or generation of any revenue from product sales since inception and has concluded that it is more likely than not that the Company will not realize the benefits of the deferred tax assets. Accordingly, a full valuation allowance has been established against the deferred tax assets as of December 31, 2023 and 2022. Management reevaluates the positive and negative evidence at each reporting period.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#333333;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t recorded any amounts for unrecognized tax benefits as of </span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending income tax examinations. The Company&#8217;s tax years are still open under statute from </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2019</span></span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to the present. Earlier years may be examined to the extent that tax credit or net operating loss carryforwards are used in future periods. The Company&#8217;s policy is to record interest and penalties related to income taxes as part of its income tax provision.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299738507616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consolidated financial statements include the accounts of Larimar and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated. The accompanying consolidated financial statements have been prepared in conformity with GAAP.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityReserveEstimatePolicy', window );">Liquidity and Capital Resources</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity and Capital Resources</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s consolidated financial statements have been presented on the basis that it will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since its inception, the Company has incurred significant recurring operating losses and negative cash flows from operations. The Company has incurred net losses of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">36.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">35.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the years ended December 31, 2023, and 2022, respectively. In addition, as of December 31, 2023, the Company had an accumulated deficit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">188.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company expects to continue to generate operating losses for the foreseeable future. As of December 31, 2023, the Company had approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">86.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of cash, cash equivalents and marketable securities available for use to fund its operations and capital requirements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has funded its operations to date primarily with proceeds from sales of common stock and proceeds from the sale of prefunded warrants for the purchase of common stock, the acquisition in 2020 of cash, cash equivalents and marketable securities upon the merger with Zafgen, Inc. ("Zafgen") and, prior to the 2020 merger with Zafgen, capital contributions from Chondrial Holdings, LLC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2024, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">19,736,842</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock in an underwritten public offering at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.74</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and received net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">161.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In accordance with Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-15, "Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern", the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. As of the issuance date of these consolidated financial statements, the Company expects its cash, cash equivalents and marketable securities, including its net proceeds from the February 2024 public offering, will be sufficient to fund its forecasted operating expenses and capital expenditure requirements into 2026. If the timing of the Company's clinical assumptions are delayed or if there are other forecasted assumption changes that negatively impact its operating plan, the Company would reduce expenditures in order to further extend cash resources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has not yet commercialized any products and does not expect to generate revenue from the commercial sale of any products for several years, if at all. The Company expects that its research and development and general and administrative expenses will continue to increase and, as a result, that it will need additional capital to fund its future operating and capital requirements. Unless and until the Company can generate substantial revenue, management continuously evaluates different strategies to obtain the required funding for future operations. These strategies include seeking additional funding through a combination of public or private equity offerings, debt or royalty financings, collaborations and licensing arrangements, strategic partnerships with pharmaceutical and/or larger biotechnology companies, or other sources. The incurrence of indebtedness would result in increased fixed payment obligations and the Company may be required to agree to certain restrictive covenants, such as limitations on its ability to incur additional debt, limitations on its ability to acquire, sell or license intellectual property rights, minimum required cash balances and other operating restrictions that could adversely impact the Company's ability to conduct its business. Any additional fundraising efforts may divert the Company's management from their day-to-day activities, which may adversely affect its ability to develop and commercialize its product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There can be no assurance that the Company will be able to raise sufficient additional capital on acceptable terms, if at all. If such additional financing is not available on satisfactory terms, or is not available in sufficient amounts, or if the Company does not have sufficient authorized shares, the Company may be required to delay,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">limit, or eliminate the development of business opportunities and its ability to achieve its business objectives, its competitiveness, and its business, financial condition, and results of operations will be materially adversely affected. The Company could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable and it may be required to relinquish rights to some of its technologies or product candidates or otherwise agree to terms unfavorable to it, any of which may have a material adverse effect on the Company's business, operating results and prospects. In addition, geopolitical tensions, volatility of capital markets, and other adverse macroeconomic events, including those due to inflationary pressures, rising interest rates, bank instability and the ability of the U.S. government to manage federal debt limits as well as the potential impact of other health crises on the global financial markets may reduce the Company's ability to access capital, which could negatively affect its liquidity and ability to continue as a going concern.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the Company is unable to obtain sufficient funding when needed and/or on acceptable terms, the Company may be required to significantly curtail, delay or discontinue one or more of its research and development programs, the manufacture of clinical and commercial supplies, product portfolio expansion, pre commercialization efforts and/or commercial operations, which could adversely affect its business prospects, or the Company may be unable to continue operations.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. This process involves reviewing open contracts and purchase orders, communicating with our personnel and outside vendors to identify services that have been performed on our behalf and estimating the level of service performed and the associated costs incurred for the services when we have not yet been invoiced or otherwise notified of the actual costs. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expense, the recording as prepaid expense of payments made in advance of the actual provision of goods or services, valuation of stock-based awards and valuation of leases. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk and Significant Suppliers</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk and Significant Suppliers</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and marketable securities. Cash balances may be held in financial institutions which may exceed federally insured limits. The Company has not experienced realized losses related to its cash, cash equivalents or marketable securities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is highly dependent on third-party manufacturers to supply products for research and development activities in its programs, to scale and optimize their manufacturing processes and, ultimately, to provide commercial supply. The Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for drug substance and formulated drugs related to these programs. The drug substance which is in frozen liquid form for nomlabofusp is currently manufactured for the Company by a third-party manufacturer, and the frozen liquid form of drug product is made at another manufacturer. The Company is undertaking a program with a third manufacturer to begin to produce a lyophilized version of the drug product from the same drug substance, that, once available, the Company intends to use in certain of its future planned clinical trials. The Company&#8217;s research and development programs could be adversely affected by a significant interruption in these manufacturing services or in the supply of drug substance and formulated drugs.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company considers all highly liquid investments with maturities of three months or less at the date of purchase to be cash equivalents. Cash equivalents consisted of money market funds as of December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Marketable securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Marketable securities consist of debt investments with original maturities greater than ninety days. The Company classifies its marketable securities as available-for-sale. Accordingly, these investments are recorded at fair value, which is based on quoted market prices. When the fair value is below the amortized cost the amount of the expected credit loss is estimated. The credit-related impairment amount, if any, would be recognized in net income; the remaining impairment amount and unrealized gains are reported as a component of accumulated other comprehensive income in stockholders&#8217; equity. Credit losses, if any, are recognized through the use of an allowance for credit losses account and subsequent improvements in expected credit losses are recognized as a reversal of the allowance account. If the Company has the intent to sell the security or if it is more likely than not that the Company would be required to sell the security prior to recovery of its amortized cost basis, the allowance for credit loss would be written off and the excess of the amortized cost basis of the asset over its fair value is recorded in net income.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_79196bf3-be5b-4806-9ec5-5fed79d1cfbe;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> or</span><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seven-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> estimated useful life for equipment, furniture and fixtures and office equipment. Leasehold improvements are amortized over the shorter of the asset life or the term of the lease agreement. Expenditures for repairs and maintenance of assets are charged to expense as incurred. Upon retirement or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain or loss is included in loss from operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Long-lived assets consist of property and equipment, net&#184; and right-of-use assets. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. Any impairment loss, if indicated, is measured as the amount by which the carrying amount of the asset exceeds the estimated fair value of the asset.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions. The Company&#8217;s focus is on the research, development and commercialization of novel therapeutics for the treatment of rare diseases.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Costs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Costs associated with internal research and development and external research and development services, including drug development, clinical studies and non-clinical studies, are expensed as incurred. Research and development expenses include costs for salaries, employee benefits, subcontractors, facility-related expenses, depreciation, stock-based compensation, third-party license fees, laboratory supplies, and external costs of outside vendors engaged to conduct discovery, non-clinical and clinical development activities and clinical trials as well as to manufacture clinical trial materials, and other costs. The Company recognizes external research and development costs based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its key service providers.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such prepaid expenses are recognized as an expense when the goods have been delivered or the related services have been performed, or when it is no longer expected that the goods will be delivered, or the services rendered.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upfront payments, milestone payments and annual maintenance fees under license agreements are currently expensed in the period in which they are incurred.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Patent Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent Costs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company measures all stock-based awards granted to employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model. Compensation expense of those awards is recognized over the requisite service period, which is the vesting period of the respective award. Typically, the Company issues awards with only service-based vesting conditions and records the expense for these awards using the straight-line method. The Company accounts for forfeitures as they occur.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to May 28, 2020, the Company had been a private company and lacked company-specific historical and implied volatility information for its common stock. Prior to January 1, 2023, the Company estimated its expected common stock price volatility solely based on the historical volatility of publicly traded peer companies. Beginning on January 1, 2023, based on the availability of sufficient historical trading data of the Company's own common stock on the Nasdaq Global Market to calculate accurately its volatility, the Company began blending its volatility starting from June 2020 (following its merger with Zafgen in 2020) to the date of each stock-based award, and weighing the volatility of its peer group for the amount of time from May 31, 2020 backwards so that the blended volatility equals the expected term of the related stock-based award. The expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield considers the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Gain (Loss)</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comprehensive Gain (Loss)</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comprehensive gain (loss) includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and economic events other than those with stockholders. For the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company&#8217;s only element of other comprehensive loss was unrealized loss on marketable securities.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss Per Share</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Prior to August 11, 2023, basic shares outstanding includes the weighted average effect of the Company&#8217;s prefunded warrants issued in June 2020, the exercise of which requires little or no consideration for the delivery of shares of common stock. These prefunded warrants were exercised on August 11, 2023 and the Company received cash proceeds of less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Accordingly, the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">628,403</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares were issued upon the exercise of these warrants and are included in issued and outstanding common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares, including potentially dilutive common stock equivalents assuming the dilutive effect of outstanding stock options, outstanding restricted stock units, and unvested restricted common shares, as determined using the treasury stock method. For periods in which the Company has reported net losses (all periods since inception), diluted net loss per common share attributable to common stockholders is the same as basic net loss per common share attributable to common stockholders, since dilutive common stock equivalents are not assumed to have been issued if their effect is antidilutive.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company excluded </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,888,502</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,071,528</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> options to purchase common stock, outstanding as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 respectively, from the computation of diluted net loss per share for the twelve months ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, because they had an anti-dilutive impact due to the net loss incurred for the periods.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued and Adopted Accounting Pronouncements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently Issued and Adopted Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, new accounting guidance is issued by the FASB or other standard setting bodies that is adopted by us as of the effective date or, in some cases where early adoption is permitted, in advance of the effective date. We have assessed the recently issued guidance that is not yet effective and believe the new guidance will not have a material impact on the consolidated results of operations, cash flows or financial position.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityReserveEstimatePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for estimating its liability as of the balance sheet date for the ultimate cost of settling reported and unreported claims incurred and claims adjustment expenses (including effects of inflation and other societal and economic factors).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//944-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityReserveEstimatePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299743610992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Cash Equivalents/Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Cash Equivalents and Marketable Securities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables summarize the Company&#8217;s cash equivalents and marketable securities as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted<br/>Prices in<br/>Active<br/>Markets <br/>(Level 1)</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs <br/>(Level 2)</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs <br/>(Level 3)</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds invested in government securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,701</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,701</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,701</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,701</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury Bills</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,334</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,334</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Government securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,719</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,719</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,988</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,988</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">60,041</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,334</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,707</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Total cash equivalents and marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84,742</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,035</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,707</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds invested in government securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,184</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,184</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,184</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,184</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Government securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">91,603</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">91,603</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">91,603</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">91,603</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Total cash equivalents and marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">113,787</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,184</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">91,603</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary of Marketable Securities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables summarize the Company&#8217;s marketable securities as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized <br/>Losses</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury Bills</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,330</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,334</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Government securities (due within 1 year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,653</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,719</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial paper (due within 1 year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,977</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,988</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">59,960</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">81</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">60,041</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Government securities (due within 1 year)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">91,634</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">91,603</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">91,634</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">91,603</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299743611552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Prepaid Expense and Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prepaid expenses and other current assets consisted of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid research and development expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,994</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,394</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid insurance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">682</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">679</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other prepaid expenses and other assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">709</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">238</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total prepaid expenses and other assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,385</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,311</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299739969328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Fixed Assets, Net</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fixed assets, net consisted of the following:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.477%;"></td>
        <td style="width:1.399%;"></td>
        <td style="width:12.775%;"></td>
        <td style="width:1.399%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.776%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.399%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.776%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Useful Life</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5 years</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">117</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lab equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5 years</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,192</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,192</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7 years</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">555</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">456</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="-sec-ix-hidden:F_1743f7c9-4f07-468e-8ed1-5de01b765813;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">lease term</span></span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Total property, plant and equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,909</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,745</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Accumulated depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,225</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">914</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Property, plant and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">684</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">831</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299734704528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses consisted of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued research and development expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,594</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,921</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued payroll and related expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,365</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,046</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">427</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">441</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Total accrued expenses and other current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,386</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,408</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299744458576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity and Stock Options (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions used to Determine Fair Value of Stock Options Granted</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted to employees:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.72</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.15</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.23</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.21</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">94</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.00</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.00</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the Company&#8217;s stock option activity for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">twelve months ended December 31, 2023 (amounts in millions, except for share and per share data):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.11%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.662%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.942%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.662%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Average</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Average</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Remaining</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Intrinsic</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exercise</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Contractual</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Value (a)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Term (in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in millions)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Outstanding as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,071,528</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.13</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.6</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,748,200</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.68</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,466</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.93</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited/Expired</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">534,760</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.52</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,273,502</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.06</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.8</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exercisable as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,930,100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.55</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.6</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Vested and expected to vest as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,273,502</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.06</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.8</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">(a)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were in the money at December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Restricted Stock Units</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Activity with respect to the Company's RSUs during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">twelve months ended December 31, 2023 was as follows (in millions, except share, contractual term, and per share data):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.11%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.662%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.942%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.662%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted Average</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Average</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Remaining</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Intrinsic</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Grant Date</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Contractual</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Value (a)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Term (in years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in millions)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Outstanding as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted stock units granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">650,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.94</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted stock units forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.94</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">615,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.94</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.6</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unvested and expected to vest as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">615,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.94</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.6</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-Based Compensation Expense</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense was classified in the consolidated statements of operations as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.92%;"></td>
        <td style="width:1.6%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.64%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.6%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.64%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.6%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,077</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,771</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,538</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,848</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,615</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,619</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299739910960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Lease Liabilities Due Under Lease Agreements</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Maturities of lease liabilities due under these lease agreements as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 are as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.1%;"></td>
        <td style="width:1.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.96%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">Year Ending December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Operating</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Leases</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,380</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,403</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,328</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,118</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,136</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">959</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,324</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,778</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Present value of lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,546</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299738775376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Domestic and Foreign Components of Loss Before Income Taxes</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The domestic and foreign components of loss before income taxes are as follows.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Domestic</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,948</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,339</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,949</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,355</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Federal Statutory Income Tax Rate</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A</span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.343%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.343%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal statutory income tax rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State taxes, net of federal benefit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in state tax rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal and state research and development tax credit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nondeductible permanent differences</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock compensation forfeitures - DTA Write Off</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in deferred tax asset valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29.6</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19.3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Effective income tax rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Net Deferred Tax Assets</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net deferred tax assets as of </span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022 consisted of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized R&amp;D - acquired in merger with Zafgen</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66,678</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66,941</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized R&amp;D - Section 174 Costs post 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,411</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,019</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,490</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,709</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45,195</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,204</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax credit carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,319</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,284</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other temporary differences</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accruals &amp; reserves</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fixed assets &amp; intangibles</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">107</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">81</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,298</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,355</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">142,538</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">131,632</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating right of use asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">768</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">801</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">768</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">801</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">141,770</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">130,831</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets / (liabilities)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Summary of Changes in Valuation Allowance for Deferred Tax Assets</a></td>
<td class="text"><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes to the valuation allowance were as follows:</span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Years ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valuation allowance as of the beginning of the year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">130,831</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">124,016</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increases recorded to income tax provision</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,939</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,815</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valuation allowance at end of year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">141,770</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">130,831</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299737636592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Organization - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,949<span></span>
</td>
<td class="nump">$ 35,355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(188,554)<span></span>
</td>
<td class="num">$ (151,605)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,558,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">19,736,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price per share</a></td>
<td class="nump">$ 8.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds net of issuance costs</a></td>
<td class="nump">$ 161,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299738427424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 11, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_LikelihoodPercentageMinimum', window );">Percentage of likelihood to be realized upon ultimate settlement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,909,069<span></span>
</td>
<td class="nump">43,269,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,909,069<span></span>
</td>
<td class="nump">43,269,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=lrmr_FromExerciseOfWarrantsMember', window );">From Exercise of Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">628,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">628,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,888,502<span></span>
</td>
<td class="nump">3,071,528<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Cash proceeds from exercises of warrants</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=lrmr_EquipmentFurnitureAndFixturesAndOfficeEquipmentMember', window );">Equipment, Furniture and Fixtures and Office Equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=lrmr_EquipmentFurnitureAndFixturesAndOfficeEquipmentMember', window );">Equipment, Furniture and Fixtures and Office Equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_LikelihoodPercentageMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum likelihood percentage threshold used to determine the amount of tax benefit to be recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_LikelihoodPercentageMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=lrmr_FromExerciseOfWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=lrmr_FromExerciseOfWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=lrmr_EquipmentFurnitureAndFixturesAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=lrmr_EquipmentFurnitureAndFixturesAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299738473920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Cash Equivalents/Marketable Securities - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Accrued interest receivable</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for credit loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment losses on investment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480833/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299737996432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Cash Equivalents/Marketable Securities - Summary of Cash Equivalents and Marketable Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 24,701<span></span>
</td>
<td class="nump">$ 22,184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">60,041<span></span>
</td>
<td class="nump">91,603<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">84,742<span></span>
</td>
<td class="nump">113,787<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury Bills [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">17,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=lrmr_USGovernmentSecuritiesMember', window );">U.S. Government Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">35,719<span></span>
</td>
<td class="nump">91,603<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate Bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">6,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">24,701<span></span>
</td>
<td class="nump">22,184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets, (Level 1) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">24,701<span></span>
</td>
<td class="nump">22,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">17,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">42,035<span></span>
</td>
<td class="nump">22,184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets, (Level 1) [Member] | U.S. Treasury Bills [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">17,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets, (Level 1) [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">24,701<span></span>
</td>
<td class="nump">22,184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">42,707<span></span>
</td>
<td class="nump">91,603<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">42,707<span></span>
</td>
<td class="nump">91,603<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) [Member] | U.S. Government Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">35,719<span></span>
</td>
<td class="nump">$ 91,603<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) [Member] | Corporate Bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">$ 6,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=lrmr_USGovernmentSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=lrmr_USGovernmentSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299734155376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Cash Equivalents/Marketable Securities - Summary of Marketable Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 59,960<span></span>
</td>
<td class="nump">$ 91,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Value</a></td>
<td class="nump">60,041<span></span>
</td>
<td class="nump">91,603<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury Bills [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">17,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Value</a></td>
<td class="nump">17,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper (due within 1 year) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">6,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Value</a></td>
<td class="nump">6,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=lrmr_USGovernmentSecuritiesMember', window );">U.S. Government securities (due within 1 year) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">35,653<span></span>
</td>
<td class="nump">91,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Value</a></td>
<td class="nump">$ 35,719<span></span>
</td>
<td class="nump">$ 91,603<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=lrmr_USGovernmentSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=lrmr_USGovernmentSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299738772560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Prepaid Expense and Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_PrepaidResearchAndDevelopmentExpenses', window );">Prepaid research and development expenses</a></td>
<td class="nump">$ 1,994<span></span>
</td>
<td class="nump">$ 1,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">682<span></span>
</td>
<td class="nump">679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_OtherPrepaidExpenseAndOtherCurrentAssets', window );">Other prepaid expenses and other assets</a></td>
<td class="nump">709<span></span>
</td>
<td class="nump">238<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other assets</a></td>
<td class="nump">$ 3,385<span></span>
</td>
<td class="nump">$ 2,311<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_OtherPrepaidExpenseAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_OtherPrepaidExpenseAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_PrepaidResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs related to research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_PrepaidResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299734160672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fixed Assets - Schedule of Fixed Assets, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">$ 1,909<span></span>
</td>
<td class="nump">$ 1,745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">(1,225)<span></span>
</td>
<td class="num">(914)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">684<span></span>
</td>
<td class="nump">831<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">$ 117<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Fixed assets, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">$ 1,192<span></span>
</td>
<td class="nump">1,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Fixed assets, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">$ 555<span></span>
</td>
<td class="nump">456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Fixed assets, useful life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration', window );">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</a></td>
<td class="text">us-gaap:UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482190/360-10-35-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299734700160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_DepreciationExpenseExcludingLeasedAssets', window );">Depreciation expense</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_DepreciationExpensesRelatedToSubletAssets', window );">Depreciation expenses related to sublet assets</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_DepreciationExpenseExcludingLeasedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation expenses recognized in the period, excluding depreciation for leased assets as part of a sublease agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_DepreciationExpenseExcludingLeasedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_DepreciationExpensesRelatedToSubletAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation expense recognized in the period related to leased assets as part of a sublease agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_DepreciationExpensesRelatedToSubletAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299739552016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_AccruedResearchAndDevelopmentExpenseCurrent', window );">Accrued research and development expenses</a></td>
<td class="nump">$ 4,594<span></span>
</td>
<td class="nump">$ 5,921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and related expenses</a></td>
<td class="nump">2,365<span></span>
</td>
<td class="nump">2,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">427<span></span>
</td>
<td class="nump">441<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 7,386<span></span>
</td>
<td class="nump">$ 8,408<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_AccruedResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for expenses related to research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_AccruedResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299729188480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders Equity and Stock Options - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 17, 2024</div></th>
<th class="th"><div>Jan. 01, 2024</div></th>
<th class="th"><div>Aug. 11, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>May 28, 2020</div></th>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Undesignated preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Undesignated preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Undesignated preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Undesignated preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,000,000<span></span>
</td>
<td class="nump">115,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,909,069<span></span>
</td>
<td class="nump">43,269,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,909,069<span></span>
</td>
<td class="nump">43,269,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrentAndNoncurrent', window );">Dividend paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options to purchase shares of common stock granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,748,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Options to purchase shares of stock granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognized period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 1 month 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Restricted stock units granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,558,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">628,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=lrmr_InducementStockMember', window );">Inducement Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options to purchase shares of common stock granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.59<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=lrmr_InducementStockMember', window );">Inducement Stock [Member] | First Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock option vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,736,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 161,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lrmr_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward', window );">Share-based compensation arrangement by share-based payment award, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The maximum number of shares that may be issued in respect of any awards under the 2020 Plan is the sum of: (i) 1,700,000 shares plus (ii) an annual increase on January 1, 2021 and each anniversary of such date thereafter through January 1, 2030, equal to the lesser of (A) 4% of the shares issued and outstanding on the last day of the immediately preceding fiscal year, or (B) such smaller number of shares as determined by the Board (collectively, the &#8220;Plan Limit&#8221;).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue', window );">Minimum level of maximum number of shares allowed to be issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock', window );">Percentage of outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration', window );">Term of plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognized period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 10 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.7<span></span>
</td>
<td class="nump">$ 5.21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lrmr_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan [Member] | From Prior Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">224,437<span></span>
</td>
<td class="nump">148,623<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lrmr_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan [Member] | Employees [Member] | Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Restricted stock units granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lrmr_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,286,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,730,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lrmr_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan [Member] | Common Stock [Member] | Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options to purchase shares of common stock granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,388,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lrmr_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan [Member] | Common Stock [Member] | First Anniversary [Member] | Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock option vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lrmr_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan [Member] | Inducement Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognized period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 3 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lrmr_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan [Member] | Subsequent Event [Member] | Employees [Member] | Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Options to purchase shares of stock granted</a></td>
<td class="nump">245,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of stock option</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lrmr_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan [Member] | Subsequent Event [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,042,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,756,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lrmr_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan [Member] | Subsequent Event [Member] | Common Stock [Member] | Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options to purchase shares of common stock granted</a></td>
<td class="nump">1,472,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of stock option</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lrmr_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan [Member] | Subsequent Event [Member] | Common Stock [Member] | First Anniversary [Member] | Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock option vesting percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Cash proceeds from exercises of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | 2020 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum number of shares that may be issued under stock option incentive plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_WarrantsIssuedPricePerShare', window );">Warrants price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_StockAndWarrantIssuanceTransactionCosts', window );">Transaction cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts', window );">Proceeds from issuance common stock and warrants net offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,105,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Issuance of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">628,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">628,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Cash proceeds from exercises of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | MTS Health Partners [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lrmr_AtTheMarketEquityOfferingProgramMember', window );">ATM Offering Program [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lrmr_AtTheMarketEquityOfferingProgramMember', window );">ATM Offering Program [Member] | Maximum [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_AggregateGrossSalesProceedsUnderSalesAgreement', window );">Aggregate sale of shares of our common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwritten Public Offering [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,558,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwritten Public Offering [Member] | Subsequent Event [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,736,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 161,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_AggregateGrossSalesProceedsUnderSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The potential aggregate gross sales proceeds available under a sales agreement to sell shares of the Company's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_AggregateGrossSalesProceedsUnderSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock and prefunded warrants to purchase common stock, net of offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares that may be added annually to the threshold number of shares issued under the Plan, as a percentage of the shares issued and outstanding on the last day of the immediately preceding fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The term of the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum threshold number of shares used to determine the maximum number of shares that may be issued under the Plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_StockAndWarrantIssuanceTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs incurred during the period related to the issuance of stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_StockAndWarrantIssuanceTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_WarrantsIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per unit amount of prefunded warrant issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_WarrantsIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 405<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480191/946-405-45-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=lrmr_InducementStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=lrmr_InducementStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=lrmr_FirstAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=lrmr_FirstAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lrmr_TwoThousandTwentyEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lrmr_TwoThousandTwentyEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=lrmr_FromPriorPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=lrmr_FromPriorPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=lrmr_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=lrmr_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=lrmr_MTSHealthPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=lrmr_MTSHealthPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lrmr_AtTheMarketEquityOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lrmr_AtTheMarketEquityOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299737975216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders Equity and Stock Options - Assumptions used to Determine Fair Value of Stock Options Granted (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.72%<span></span>
</td>
<td class="nump">2.15%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 2 months 23 days<span></span>
</td>
<td class="text">6 years 2 months 15 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">94.00%<span></span>
</td>
<td class="nump">89.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299744347968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders Equity and Stock Options - Summary of Stock Option Activity (Detail) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Outstanding</a></td>
<td class="nump">3,071,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Granted</a></td>
<td class="nump">1,748,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares, Exercised</a></td>
<td class="num">(11,466)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of shares, Forfeited/Expired</a></td>
<td class="num">(534,760)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Outstanding</a></td>
<td class="nump">4,273,502<span></span>
</td>
<td class="nump">3,071,528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of shares, Exercisable as of December 31, 2023</a></td>
<td class="nump">1,930,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of shares, Vested and expected to vest as of December 31, 2023</a></td>
<td class="nump">4,273,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, balance</a></td>
<td class="nump">$ 12.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted</a></td>
<td class="nump">4.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercised</a></td>
<td class="nump">2.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Forfeited/Expired</a></td>
<td class="nump">12.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, balance</a></td>
<td class="nump">9.06<span></span>
</td>
<td class="nump">$ 12.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercisable as of December 31, 2023</a></td>
<td class="nump">12.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Vested and expected to vest as of December 31, 2023</a></td>
<td class="nump">$ 9.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term, outstanding</a></td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, Exercisable as of December 31, 2023</a></td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, Vested and expected to vest as of December 31, 2023</a></td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, outstanding as of December 31, 2023</a></td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, exercisable as of December 31, 2023</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value, Vested and expected to vest as of December 31, 2023</a></td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299733825824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders Equity and Stock Options - Summary of Restricted Stock Units (Details) - Restricted Stock Units (RSUs)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, Outstanding</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, Restricted stock units granted</a></td>
<td class="nump">650,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of shares, Restricted stock units forfeited</a></td>
<td class="num">(35,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, Outstanding</a></td>
<td class="nump">615,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber', window );">Number of shares, Unvested and expected to vest as of December 31, 2023</a></td>
<td class="nump">615,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Restricted stock units granted | $ / shares</a></td>
<td class="nump">$ 4.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Restricted stock units forfeited | $ / shares</a></td>
<td class="nump">4.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, balance | $ / shares</a></td>
<td class="nump">4.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Unvested and expected to vest as of December 31, 2023 | $ / shares</a></td>
<td class="nump">$ 4.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual term, Outstanding as of December 31, 2023</a></td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual term, Unvested and expected to vest as of December 31, 2023</a></td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate intrinsic value, Outstanding as of December 31, 2023 | $</a></td>
<td class="nump">$ 2.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue', window );">Aggregate intrinsic value, Unvested and expected to vest as of December 31, 2023 | $</a></td>
<td class="nump">$ 2.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of awards that are unvested and expected to vest under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that are unvested and expected to vest as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of awards that are unvested and expected to vest under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options that are unvested and expected to vest, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299835408928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders Equity and Stock Options - Summary of Stock-Based Compensation Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 7,615<span></span>
</td>
<td class="nump">$ 6,619<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">3,077<span></span>
</td>
<td class="nump">2,771<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 4,538<span></span>
</td>
<td class="nump">$ 3,848<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299731821968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 01, 2023 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 01, 2023 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 09, 2023 </div>
<div>ft&#178;</div>
</th>
<th class="th"><div>Aug. 09, 2021</div></th>
<th class="th">
<div>Oct. 27, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Aug. 04, 2020</div></th>
<th class="th">
<div>May 28, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 11, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Aug. 08, 2019</div></th>
<th class="th"><div>Nov. 05, 2018</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th">
<div>Oct. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Oct. 16, 2023</div></th>
<th class="th">
<div>Nov. 30, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,078<span></span>
</td>
<td class="nump">$ 2,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,709<span></span>
</td>
<td class="nump">$ 4,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_PA', window );">Pennsylvania [Member] | Office [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease extension period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_LeaseTermCommencementDate', window );">Lease term commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep.  01,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 15,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_AreaOfOfficeSpace', window );">Area of office space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,642<span></span>
</td>
<td class="nump">4,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease term expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_PA', window );">Pennsylvania [Member] | Office and Lab [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease extension period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_LeaseTermCommencementDate', window );">Lease term commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease term expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_PA', window );">Pennsylvania [Member] | Additional Office [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_LeaseTermCommencementDate', window );">Lease term commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct.  01,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_AreaOfOfficeSpace', window );">Area of office space | ft&#178;</a></td>
<td class="nump">3,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_PA', window );">Pennsylvania [Member] | Lab Space [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_MA', window );">Massachusetts [Member] | Office [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_AreaOfOfficeSpace', window );">Area of office space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease term expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 30,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_MA', window );">Massachusetts [Member] | Office [Member] | Letter of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Letter of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_MA', window );">Massachusetts [Member] | Office Sublease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_LeaseTermCommencementDate', window );">Lease term commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec.  04,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease term expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 30,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_MA', window );">Massachusetts [Member] | Office Sublease [Member] | First Sublease Year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_SubleaseAnnualBaseRent', window );">Annual base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_MA', window );">Massachusetts [Member] | Office Sublease [Member] | First Sublease Year [Member] | Letter of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDepositLiability', window );">Lease security deposits letters of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_MA', window );">Massachusetts [Member] | Office Sublease [Member] | Final Sublease Year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_SubleaseAnnualBaseRent', window );">Annual base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_MA', window );">Massachusetts [Member] | Office Sublease [Member] | Sixth Sublease Year [Member] | Letter of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDepositLiability', window );">Lease security deposits letters of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=lrmr_WakeForestUniversityHealthSciencesMember', window );">WFUHS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_LicenseAgreementConsiderationDeductionPercentage', window );">License agreement consideration deduction percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=lrmr_WakeForestUniversityHealthSciencesMember', window );">WFUHS [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_MilestonePaymentAmount', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=lrmr_IndianaUniversityResearchAndTechnologyCorporationMember', window );">IU [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_LicenseAgreementConsiderationDeductionPercentage', window );">License agreement consideration deduction percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=lrmr_IndianaUniversityResearchAndTechnologyCorporationMember', window );">IU [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_MilestonePaymentAmount', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_MinimumAnnualRoyaltyObligation', window );">Annual royalty pay obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=lrmr_WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember', window );">WFUHS and IU [Member] | Research and Development Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_MilestoneExpenses', window );">Milestone expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=lrmr_WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember', window );">WFUHS and IU [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_PaymentForLicenseAgreements', window );">Payment for license agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_AreaOfOfficeSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of office space.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_AreaOfOfficeSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_LeaseTermCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease term commencement date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_LeaseTermCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_LicenseAgreementConsiderationDeductionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that may be deducted from consideration due to Licensor 2 as a percentage of consideration paid to Licensor 1, whereby Licensor 1 is the identified party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_LicenseAgreementConsiderationDeductionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_MilestoneExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized during the period related to milestones. Such amount may include, but is not limited to, amounts due for attainment of milestones as well as deductions granted as part of a license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_MilestoneExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_MilestonePaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment due upon reaching milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_MilestonePaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_MinimumAnnualRoyaltyObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum annual royalty payment that is required under a contractual arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_MinimumAnnualRoyaltyObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_PaymentForLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment for license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_PaymentForLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_SubleaseAnnualBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sublease annual base rent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_SubleaseAnnualBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDepositLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents money paid in advance to protect the provider of a product or service, such as a lessor, against damage or nonpayment by the buyer or tenant (lessee) during the term of the agreement. Such damages may include physical damage to the property, theft of property, and other contractual breaches. Security deposits held may be interest or noninterest bearing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDepositLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_PA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_PA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=lrmr_OfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=lrmr_OfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=lrmr_OfficeAndLabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=lrmr_OfficeAndLabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=lrmr_AdditionalOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=lrmr_AdditionalOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=lrmr_LabSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=lrmr_LabSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=lrmr_OfficeSubleaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=lrmr_OfficeSubleaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=lrmr_FirstSubleaseYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=lrmr_FirstSubleaseYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=lrmr_FinalSubleaseYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=lrmr_FinalSubleaseYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=lrmr_SixthSubleaseYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=lrmr_SixthSubleaseYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=lrmr_WakeForestUniversityHealthSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=lrmr_WakeForestUniversityHealthSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=lrmr_IndianaUniversityResearchAndTechnologyCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=lrmr_IndianaUniversityResearchAndTechnologyCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=lrmr_WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=lrmr_WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299738767984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Maturities of Lease Liabilities Due Under Lease Agreements (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 1,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">1,403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">1,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">1,118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">1,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">959<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">7,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(1,778)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 5,546<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299729125952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Net capitalized R&amp;D deferred tax assets</a></td>
<td class="nump">66,678,000<span></span>
</td>
<td class="nump">66,941,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance', window );">Net deferred tax assets before the valuation allowance</a></td>
<td class="nump">141,800,000<span></span>
</td>
<td class="nump">130,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lrmr_ZafgenMember', window );">Zafgen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">33,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Net capitalized R&amp;D deferred tax assets</a></td>
<td class="nump">$ 66,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_NetCapitalizedRDDeferredTaxAssetsRealizationDescription', window );">Net capitalized R&amp;D deferred tax assets realization description</a></td>
<td class="text">is subject to the built-in loss rules under Section 382 and may not be realized if the underlying asset associated with the R&D is disposed within five years of the Merger, or May 28, 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_NetOperatingLossCarryforwardsAnnualUtilizationLimitChangeInOwnership', window );">Net operating loss carryforwards, change in ownership, annual utilization limit</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember', window );">Earliest Tax Year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 179,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_NetOperatingLossCarryForwardExpirationYearBegin', window );">Net operating loss carryforwards, beginning of expiration period</a></td>
<td class="text">2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member] | No Expiration [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 140,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_OperatingLossCarryforwardsMinimumPercentageOfTaxableIncomeInTaxPeriod', window );">Operating loss carryforwards, minimum percentage of taxable income in tax period</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Operating loss carryforwards, description</a></td>
<td class="text">carryforwards are limited to 80% of the taxable income in any one tax period.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 148,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_NetOperatingLossCarryForwardExpirationYearBegin', window );">Net operating loss carryforwards, beginning of expiration period</a></td>
<td class="text">2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=lrmr_DomesticAndStateLocalJurisdictionMember', window );">Federal and State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">$ 16,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_TaxCreditCarryForwardExpirationYearStart', window );">Research and development tax credit carry forwards, beginning of expiration period</a></td>
<td class="text">2039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=lrmr_Ircsection174Member', window );">IRC Section 174 [Member] | Performed in US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_CapitalizedResearchAndDevelopmentAmortizationPeriod', window );">Capitalized research and development amortization period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=lrmr_Ircsection174Member', window );">IRC Section 174 [Member] | Performed outside US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_CapitalizedResearchAndDevelopmentAmortizationPeriod', window );">Capitalized research and development amortization period</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_CapitalizedResearchAndDevelopmentAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization period for capitalized research and development costs, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_CapitalizedResearchAndDevelopmentAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of deferred tax liability but before allocation of valuation allowances, of deferred tax asset attributable to deductible differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_IncomeTaxesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Taxes Disclosure [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_IncomeTaxesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_NetCapitalizedRDDeferredTaxAssetsRealizationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the limitation that a capitalized research and development deferred tax asset may be subject to.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_NetCapitalizedRDDeferredTaxAssetsRealizationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_NetOperatingLossCarryForwardExpirationYearBegin">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The first year in which a net operating loss carryforward begins to expire.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_NetOperatingLossCarryForwardExpirationYearBegin</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_NetOperatingLossCarryforwardsAnnualUtilizationLimitChangeInOwnership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The annual limitation amount of net operating loss carryforwards that can be utilized to offset taxable income due to changes in ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_NetOperatingLossCarryforwardsAnnualUtilizationLimitChangeInOwnership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_OperatingLossCarryforwardsMinimumPercentageOfTaxableIncomeInTaxPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of limitation on operating loss carryforwards as a percentage of taxable income in any one tax period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_OperatingLossCarryforwardsMinimumPercentageOfTaxableIncomeInTaxPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_TaxCreditCarryForwardExpirationYearStart">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The first year in which a tax credit carryforward begins to expire.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_TaxCreditCarryForwardExpirationYearStart</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lrmr_ZafgenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lrmr_ZafgenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=lrmr_NoExpirationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=lrmr_NoExpirationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=lrmr_DomesticAndStateLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=lrmr_DomesticAndStateLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=lrmr_Ircsection174Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=lrmr_Ircsection174Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=lrmr_PerformedInUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=lrmr_PerformedInUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=lrmr_PerformedOutsideUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=lrmr_PerformedOutsideUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299738692848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Domestic and Foreign Components of Loss Before Income Taxes (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (36,948)<span></span>
</td>
<td class="num">$ (35,339)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">$ (36,949)<span></span>
</td>
<td class="num">$ (35,355)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299734159584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Federal Statutory Income Tax Rate (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="nump">4.90%<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate', window );">Change in state tax rate</a></td>
<td class="num">(1.70%)<span></span>
</td>
<td class="num">(7.90%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Federal and state research and development tax credit</a></td>
<td class="nump">8.20%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Nondeductible permanent differences</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_EffectiveIncomeTaxRateReconciliationStockCompensationForfeituresPercent', window );">Stock compensation forfeitures - DTA Write Off</a></td>
<td class="num">(1.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in deferred tax asset valuation allowance</a></td>
<td class="num">(29.60%)<span></span>
</td>
<td class="num">(19.30%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to a change in the state tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_EffectiveIncomeTaxRateReconciliationStockCompensationForfeituresPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deferred tax asset write-offs from stock compensation forfeitures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_EffectiveIncomeTaxRateReconciliationStockCompensationForfeituresPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299733894192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Net Deferred Tax Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized R&amp;D - acquired in merger with Zafgen</a></td>
<td class="nump">$ 66,678<span></span>
</td>
<td class="nump">$ 66,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts', window );">Capitalized R&amp;D - Section 174 Costs post 2021</a></td>
<td class="nump">9,411<span></span>
</td>
<td class="nump">5,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="nump">3,490<span></span>
</td>
<td class="nump">2,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">45,195<span></span>
</td>
<td class="nump">42,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">16,319<span></span>
</td>
<td class="nump">13,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other temporary differences</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves', window );">Accruals &amp; reserves</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_DeferredTaxAssetsFixedAssetsAndIntangibleAssets', window );">Fixed assets &amp; intangibles</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liability</a></td>
<td class="nump">1,298<span></span>
</td>
<td class="nump">1,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">142,538<span></span>
</td>
<td class="nump">131,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Operating right of use asset</a></td>
<td class="num">(768)<span></span>
</td>
<td class="num">(801)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(768)<span></span>
</td>
<td class="num">(801)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation allowance</a></td>
<td class="num">$ (141,770)<span></span>
</td>
<td class="num">$ (130,831)<span></span>
</td>
<td class="num">$ (124,016)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_DeferredTaxAssetsFixedAssetsAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible fixed assets and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_DeferredTaxAssetsFixedAssetsAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140299737634512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Changes in the Valuation Allowance for Deferred Tax Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance as of the beginning of the year</a></td>
<td class="nump">$ 130,831<span></span>
</td>
<td class="nump">$ 124,016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increases recorded to income tax provision</a></td>
<td class="nump">10,939<span></span>
</td>
<td class="nump">6,815<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance at end of year</a></td>
<td class="nump">$ 141,770<span></span>
</td>
<td class="nump">$ 130,831<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_IncomeTaxesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Taxes Disclosure [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_IncomeTaxesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>75
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M&8&4K'"9R2]L_RNI#0JUOH1EPOP%^THVCD8@*85D>;U8(<AI4?W'S[4C#A;
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M4K+<7&X(3@G7 NKW%6/R]49OT'SQFO\/4$L#!!0    ( #6#;EB=.X=?2@(
M *0%   8    >&PO=V]R:W-H965T<R]S:&5E=#<N>&ULK51M;],P$/XK5IC0
M)K'EO;"21%I;$),8JE8&G]WDVEB+[6 [S?;OL9TT=%-:(<27QG>^Y[E[KKY+
M6BX>90F@T!.MF$R=4JEZZKHR+X%B><5K8/IFPP7%2IMBZ\I: "XLB%9NX'D3
MEV+"G"RQOJ7($MZHBC!8"B0;2K%XGD'%V]3QG;WCGFQ+91QNEM1X"RM0#_52
M:,L=6 I"@4G"&1*P29T;?SJ/3+P-^$&@E0=G9)2L.7\TQFV1.IXI""K(E6'
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MLM"O4W2=KYLH7MMNL^=*]RX[+/7/ H0)T,]SSM5Q8C88?C_)&U!+ P04
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M+!LO>O*QJT*GG6([GYC;_61"=>,.5LJK">Z\[1)C%IU6SLC+XAZS5#SCV?'
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M:^KC0'G^-Y!* K_B_7T6\<[Q]+>6M.FP/\;!*DUY1D3EZ,IH>^4%*@EP0UL
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MT[87()$;X:N8PB<%L8@5.I5LR^CA!6^,3"F(@NET</*#2K%BPN-DO$'ZME<
MX1JC8#R<8?AL-#MY(:8!,@VF3? Y%UV7H"\;E]CY')BNZM.F,.J@O<]>/:W^
M-\"5O01?#[?_E>"#S%<PJ4C4$E/[O>GXU)[*^1]%MN4K\8NL*+(-?UTK(/N<
M!N#],LL*_X,6J/Z/Q-O_ U!+ P04    "  U@VY8O4_YN[P-  #F)P  &0
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M3P4.=%Z#B[=*&CR]@1A%!E8/VN=5Y[#$7\'LU:<_PNE5D6M9R#:7!S7ABN!
MW)390LCJ?&C5V5N=*X$T+*2 7Q9^IIR<&M6GO&?R-3TUB7%H/X.1D)-ACD "
M.,I.'FET+ET.TXJ@LD5AC9UO1.G!^Q0V:QF2>84Z5S [D:-GN;I%$E^Q0NQ,
M%'9IY-3.2K\:B-<V=/C-V(-*,.SLDG9K)]1LIC@)L[IPT]EROF#21GH^AA^
MMKI;:2<Y;^,7KXBBY4D@WQ=E893W0DEG-'0>E$-^9#M %@7^<3,ZHZ;LGUF7
M2WA!%"UR1'O\ #;AA1KN#;X]-)G.)FW3X:P]]I-*PW-8@(XJ85I>@WN-^/TM
M71J# \"4A%$A3W1W(@=?DL+9#=QT0T^D0)44'@8RT)*>ZR 0;3@RH$*RTE&G
MO83@]*/1B;-YF4'MN4*U9ON"^_5"L1+HCZ+0E.)6&EVI$++" VFM)V>K: S$
M!5;FN28-/*21/=+B'#LU>LZ6@$D?%+SRT*6&.,$6BI9&[\'2<D6;'XOQX)16
M&#H<B^DD.9^3'\-3RI5-M[*%AG=6KEF1;GDL)*D/ L?KA09+&?(>98:\=@JA
M"F>-J0C1G9EV<$[H3---\B5QO0 0$".1(9?J#*2#@_,,.JDP$B(=[**A(>7-
MQ9NXD8R%.A=SQXAKW>@IJVDE8:Z.UMCGPP+YZK$8#D:5;KIGL\=)X_=HWY?3
MZ#[D #,%AX)'S_D'1:P4"_C\8<<3*:>S?^86F]7A+O^LR:HMQ^EX9LM?*.6-
MSI[[ATP(2Y=&!NLV+?M16DW6"8"(=.V@/[VJC?80'X/M<L5:ZCBL4WHY+1UV
M=A1&GA\#Y] IPXN1I;@$<@9AY[DE[F&=T F)7/M5&93GFQR".H5[L7DXOW'B
M2:G!D;>O;6F0W!0YS8H\*R^;\$UG?(%\Y!+XQZD'&5,O2YB[**BXMS+1 WY&
MYN;5R]\36E.U^:W4KCF5@KYM#):QXPV ME"7HD2$(!#?1Y>">-M;R8LD'-$8
MZ0YAFL-X20@=!U=%9]L'2RZ-;-9O8#^ZPU=(<-J68,?N/R+$U2>6X$,6+&4-
MH./Q5AXND,'9YKGE(.?R$C/76/A0YIN!N(:?E[*H2SP71%HYM2D?=J 9QP+=
M;3!0/[$8#T44VGFA_X-3F[2>PH3(DB]-:E^BI,LA[E'$">^ >AMD-/'U9\"+
M_PVV>*<D@>37TDAQN2G6FUQ\F,UPH+BA!D%\*,1%.4>C)\YCWN]:$>PH<D%=
M1$1-X%L2-D> DB4I*]E(CQL.XJ=U5E]<JZ+P&W,K"RW[+1W%#-I4G9/J](@P
M<8RV>500M"XV4$7L#;R^$\O8X[&TS!1K$QRJ.R@PNDC#7Z30@A1,;"#>1$]N
MPDP5Y(IZ26 W&1K/I]&]C H-3#7@Q$#I_:T\FP.5PIFI&] H[3D%@%A9#Q/X
MML&)-X9-L9>1'9[)<BUH@&T_J:DK)4I05!,RTX ,]YZ]]FGL3;?L=J>RDAB6
MB2AKAGFHW9@H$PZP@)>:]'+</SU&:/Z&HTASMBJJ7VQ@<1!QS1K6]2I$B\#;
M>5=R,^)5I*:'..'T%GF$*5M6FO2/3QMN:$"TS4J=H3QZG-HFL01M2YVJ_GY9
M.TJ_4:N0G#-JN#;392O;N)R5'!$ZX4:2PY/P#->9"Z/E5)M4<RD%G=0IJ (2
M,N:'R'NAUFDG5D0UM/2RC^<J'?_I'$_V<WR?F-]!C9IYCMDJN_MD)RR&1$[-
MJ,OG;)-0*P(R(X#J XZ*$5GU1!3$@CO;)HM,:KDCQ;"3M8?D;"GJ+\B8EJI'
MU^$ <K+2<[M*X\1!M2AE5,ZU5!51'HHT]JN!?4.9 WBIW!P<\^-_RME<$43U
MF=/3*#^9%[E$D2DMA?I&C,]C\'<C768I?4GDGN(PHSJ *@Z O#-9RQ6RSIU>
M0I\&^>2L?S8\V1MD[='#M5-+#7,U<X)VJ%&@^[87QC'$^*G@GH[J5:7F.@?=
MZ]W:H(>&N@S"*8D%I$4&YGBH0]5!<0?F-6H^I*2T\UB,VLX*2X-HA@+L]4R3
MEN@(#P3+CI9)OZA@0((Z>2S%!'HLD#(7W5V.R/"G"LL*O]" %O1WR,4XF 8:
M!*;(.&0,RKY^0:HGK=?6JG 'ZB4%!'C5J4@X!1X4,X$J<]?N)'V(/D\%2!>9
M*?,FD')5(8CM(N13_Q/#Y-#.#EL1# [O!7 KWCNK2<:I(N[ETKK $ Q*L0Q5
MP(]=JJ.#)-@309U_C$Y%1FY<E&L?12_IJC2=?HH7-$&20O!#"X2>[0J0+H1I
M*,F=T[6;]+B>SG&$OH>,:! A;8!>WI?HNO4*IKCPWL(O(A2_*K+!-JV(*9I!
MW9IF(5NS+N8HI.X_4+6LXJQRJYI0U'Z$UB8J*RFHXKM;#^K,>)QP SE1!5X]
M8&;09E>X/I##JD.V%(R6LHS='1<O"AAR;CS5CA4<IU07-Y=B@IZD=]4\^0AG
MAO6?B7>VF!^^ S+,2:GD?9>=H'VK3,[<?T)T]GL)JT>WCB=#;Y0 "MLZ.>JK
MUDV:8D;^9%$K,K6?=?165>^\2B15F,&172I8O 4I- Z*)+T4:;>R6[1&@V%W
M5%*;-&8&SGS=Y("6CP>EMJ/L61E*QE,5([H-RF,:.$@^D*8=/\LB@D<V[QA>
MN(M(XAM990>5GTM3[1\E[&:,*$.LG??71V3:; A(8M,R<%5* M4^GJ8(5?NW
M[=#W:D?7"7VMQUP!:.L*\W;+13VZ6]IRAWG9@IY?N\3F"0KE%X[44]4CUCIU
M(#YFR>-BQL6:K*0<P\T\ Z3T9F['[OX6)R@^A)9!@'29I,#_RC8Q5]*8B0>2
MP\%QS78"M6B)N!&*(WTR]3T=MJ<R$03Z)A/&]!RIZ=9]'@_02RC.]O3>)HT&
M.$%34X3V.@JQ.\^C_933IM&LWT_$9N_\FUM-!G"@7'<DUPMM9*[,:D%=YOZ>
MLQ,.HZ>BS^08OJ2 V<:3PR_N--=V1Y_9M-C'.^M3U:HU@]K?.:;;)]$I_;W\
MCT2;B=@OCO8PT13E/YF1<2PME07VM:U%NW=+0?+M!T]$-P06TG>K1TV].168
MV%#Y2>[N%X UAYRAJFXU!QURJ]7*Z*0ZFL64_/(2;;_1V4;4'P! B83-8O0E
M/<<Y[@XTM;-YZH =>KNW0X%?$$2=R/EK&LU=.S0VV\%S;Q@SLZ5+LYC_\_D)
M#$I9*$M#YPH5584 ^190GVSL4J& +A&>R.4[&L9[0#B]XIBJIJ..6*KAHCJ1
M84[LE&-_^&,:1U;_I=.^?N^Q92^?>IIVTB=ANRUYNX*NE8%+I@'9@^TQ2,2)
M;7K%BNQH-@-Z@WV/@VBB-7]>HO)#.+RCL<-.X#ZK%(6 "7O.9:E.!B=\XQ1U
MF%WJZ[D1%3?4F',]Y1<57\7&B*#9]_?3 SGB5C1MJD:P9F< I!.H<.OT1O3>
MO(/&Y>V7M%N]A]\>A#9,.BY8,VO0YOAGC_Y!\XX?XRNLSNH/E8H>';!SV])#
M0/\DC7X?D6,3 NU/SH?TXP27Q\,)79[2W?$Y79[A<C3BRW.ZG)P^^D@(1\XH
M/IZ>/'WTT=)+S 2DJS>E9]A__.@=PO,9!7X9IS>D-52: Q Z.SL73QY=TXP=
MYJ%.0>U6U&.@@I/C4W ]CY]Y9&@D(-6]#SS(, !+A*T!2F7[@X^-(&+SU(\5
MU(1X /,"+L)A*->IUZ:E]?O ."&FT;O*6P1@)'BX[[R6Z<?!%_ 9ND]Z7>C3
M6S&:I]"K5.*(\<;.=XS3$I$.7?5;?AW[7-QJA@R4FN)8 ;SQB&)&/C#8]>W.
M4>O;*YXIT1=F](("T1 _PZKOUA^Q7<1OMYKE\0LX@/8Y!(9M9M@Z')R=]&(R
MK'X$N^(ON:8V!+ODRX4"['*T ,]I9E7]H /J3_M>_1=02P,$%     @ -8-N
M6*?!H/$]#0  (B4  !D   !X;"]W;W)K<VAE971S+W-H965T,3<N>&ULI5I;
M<]LV%G[7K\"HV4XZP\BB;I:<RXQC-]-TFJ23I.WL[NP#1$$6&HI4 ="R^NOW
M.P?@31=;L_M@622!@W/YSI5ZM<W--[M2RHF'=9K9U]V5<YNKBPN;K-1:VEZ^
M41F>+'.SE@Z7YN[";HR2"]ZT3B\&_?[D8BUUUGWSBN_]:MZ\R@N7ZDS]:H0M
MUFMI=F]5FF]?=^-N>>.SOELYNG'QYM5&WJDOROVV^=7@ZJ*BLM!KE5F=9\*H
MY>ON=7SU=D3K><'O6FUMX[L@2>9Y_HTNWB]>=_O$D$I5XHB"Q+][=:/2E B!
MC;\"S6YU)&UL?B^IOV/9(<M<6G63IW_HA5N][DZ[8J&6LDC=YWS[DPKRC(E>
MDJ>6/\76KQT.NR(IK,O783,X6.O,_Y</00^-#=/^B0V#L&' ?/N#F,M;Z>2;
M5R;?"D.K08V^L*B\&\SIC(SRQ1D\U=CGWKS/DGRMQ%?YH.RK"P>*=/\B";O?
M^MV#$[OC@?B09VYEQ8_90BW:!"[ 2L7/H.3G[>!1BK<JZ8EA'(E!?S!\A-ZP
MDF_(](9/RB=NM4W2W!9&B7]?SZTS0,1_CLGL*8Z.4R0ON;(;F:C77;B!5>9>
M==]\_UT\Z;]\A-]1Q>_H,>I/VN/QW;.>:!(0MX71V9UP*R5V2AHK%)E)0,EJ
M/5>F4G0D9+:@;P,1\>J;?+V1V0YNE^2&MF2YT)ZR@RKG*E-+[:Q 5.#U&<('
M H61CLZ#EBU.QX;"&&S6F5 R63$/8E& !JAA=Y$ERCA$#K<3^1*'R53_301D
M>8)8FGR-$W*KL$.M;4]\Q7$+,&*=3IAM\ #?RP2XV^29RD 8Q(@'4*&'#<[!
ME<0-29RG"$BVU_GG"<5T2#&LD\YM>=PS\5P,)]%L-!4_^(MQ-!S.Q ^==X&)
MYR+&(WQ.<+-:/FLL'X]Q<<V:S1*=:LG1"1R3'G_K?>F)I5I DZFP3KK"Y6;7
M5#U4S/IK6.G[[Z:#^/(EA%@N%4>Y@PW:-F2^8IF]RYX2^=V3/ SB7E_\(_SK
M?'',%VDX\FA85G*4MASU9F+2&W1N5C*[(QZ9>H,DU-:[9/5=]EBI@0!9V2\E
MAY,&4*);"W6/I+)!BG!,(P'6<,RT-P"=N/,Q)P$+*&2>*@%PKB6A0RPTU&04
ML&?YQ+XW&/V'&'GRC9&$O.,M P0ME78(&U:\$+=?K\4?!E 4GY9+WD908 L,
M7C8D0V)0C'UB3,(=G+B7:>%)2C*#! ,@,)CU)IZ!66\(#GX\:<,^Z]M_?@2]
MPR/8R%#\@7_7[@W066T==@7$>4S Z:Z:@#\D?=6YD1OMR$-Q__/W<KUY>0N%
MR.2O0@<G7RMSAU.WVJW$O^3R3F5 _60232ZG_LML%)\@\R5DZ?AR!%A;B++!
M)W$3BUDTBF,QCOKQ+!B(\O"B;:9A-)KUQ2"Z[,\Z'P^BD4BD,3N8<BO-PHK1
M.(IG8S$:1(/^J/.UQDY[63R)AO%,Q,-H,!UU/D%=B'8*4<:@?FGA"%P.^IWK
M)#&%3*U@L43(#J #&K/.._T IH.A_ I$/@"&\(E%_4LQC3N?:KX5I!0($'-$
M"43(.!K,IOA$!.E\S:'"HPAX)F*(-1Z2QF/8?S+<,V=)4"O8M#[-4/E"H"BL
M"H"%&TZFC,UI'U'MV*$-8AS@_(9GU99?E+57XO<CR*<U\2B.+B_[84<\[$?3
M(>TZA>X+\;QQ(.T*CM?XYEV0D@_#^YC34=(Z1G[1SI:GDF7M3$:EDEQI8S0J
M6IWNRL ,US5L/7!QF!KW4$;DW"D(TD,);@.]G#%XW/-MGFAFA_U/@CL.?A ]
MZ.)TN@C!%1^]2H%!E&,*W*I6#KTZ)X<>PX"/5G3*7-WI+",%A1ML@&<5)O!M
M,$( F'3>!]7:NC9QK=ID8_)[S3U#W(]F2,Z3:!J/CY_OB&<ZLCPN +(^^/I$
M0&V722NY>-K.;D7G/6P0+1F"(3U&50%3I[FF.(5!)%3,!MBZG"'^KW6:0I*(
M;B#9A4O>3S),>W&]!$%HXZV<[GSQM#S(J@>5&YN#]!K8Q06DG@3D#_L0?[O2
MR*H^@WCV20$'8N,B SF^IQ47:WQ; RM+G2&1$EOG:[ED_CQM,U"1AF@=Q=ZE
M _6]8^++H-I1'PFXU"5O7^2H>TN;16*5;U%Q<,%KU;Z?&@K5:^T\'J>4I .4
M845)%4@PJB9#H=[-@GV5T?GB7!4@N>2L!WDO=<ID3X:.!L;.@M:D(3ZLBR+K
M* S@43WQFT,0_KM5NJ(9>O'!%P!/ASSGC)X7S@N0AV(A(E)R P=^0#PE9("M
MX; WKM%,:K;%_$\@FO9)NH!<F=,L9(;LZ\W@62N ,E/5%L/IH&3V?08D9%C\
M&1;-"E+P0M'#>#:=E"U*O@5P[$IO1!)B8IZ$CJ:1*DB3'#[V(S ]] JAKDS(
M!4S$T/*!M<'FH08_?OJE"M-X6NJG;+62(S74L:00 K]<YT7FO)DG$Y36I9G1
M%C2TR8&XT*E[@7UL-5-097*H18+36N[8.^8J-&Y4 WI!>$.ZXTZ.*XECJBGY
M!@\+;0F(_B'.7E).\@UK4(U7"P!BQ ><.YBR=XP%:]8[>$I-[('-(DHR'&I
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ML=1Y84*)Q\OA&HB\0*Q/*K"8I01$VBUS31O2I4@4S9!20L0AR[;22!5:?BY
MBGJL"%0VSJ<>+FV)FW=JCG;&['PB4F"=1&JZ29(7Z<(G)8_%QX0/,GM@'>*
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M6PJ?\5/7JD7;M0/4KQ4<>EA?K#M:I_',8G1$%^?F9+)H798R_+$%D!F_XXE
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MM15+'5&]KS#$$K1RWHC\2R!G'M=[L-,?(V6V2GB7\NU@9EAM6ANXW$)OAC8
MW[\7RVO2X]GU]?7LR<45\_31[.+9Y>S)U74LI:'T$HY3E%<TYG+RV?,1^4V@
ML^*B+]*NV"V?9)20,\ZX4!CQ,1X N8?O+E=>Z%KQ)9KH:X3K18E*YY$'_CZ(
MK#D8L3DXG.Q%[J373J<_+D^?VWBG:^GI_I0LVTU#?, 097;KLZ6 !QG8YM@)
MG7_'.M5K9AFJB: *_8OIS+N0%_)\Z]@V(3/V(NG-W>N;VQ?9S5?^=D@.W?ED
MKN'!&LFS2&@]+O3R&$[>I(@=+)*"MYUQ\(CXOE9.3HC#MRG+]]28;<B,MC!
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MU+TL7WC[X^4[F;)[S5,%,:Y(U3D+*(ME^?8L)UIDQ7MO*32]'@MQ0\]UE.8
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ME] +.A!VP]X97N^0:*_B]3[@-2G^6:R-U?0M_#V59(WHGT:X^IB8@L4X\Z@
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MNB8#@Z1Q<UZ["9YQXP?LLRS,2K/+(H7TL8$!QMP%'K2!GP=[+5Y TF>A[[+
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MJF3'%'.5P +7 U3_FC%YJ.@)VI1X]B]02P,$%     @ -8-N6*\\J4P!!0
M_!T  !D   !X;"]W;W)K<VAE971S+W-H965T,C<N>&ULO5G;;N,V$/T50ET4
MNT :77R)G=H&$BM! ]1(L.YV'XH^,-+8)D*)6I**DZ(?7U)2),N5Z1@@\I*(
M$N=PYE SFF-.MHP_B0V 1"\)3<74V4B97;JNB#:08''.,DC5DQ7C"99JR->N
MR#C@N#!*J!MXWM!-,$F=V:2X]\!G$Y9+2E)XX$CD28+YZS50MITZOO-VXRM9
M;Z2^X<XF&5[#$N2W[(&KD5NCQ"2!5!"6(@ZKJ7/E7X9!H V*&7\2V(J=:Z1#
M>63L20_NXJGC:8^ 0B0U!%;_GF$.E&HDY<>/"M2IU]2&N]=OZ+=%\"J81RQ@
MSNAW$LO-U!DY*(85SJG\RK:_01700.-%C(KB+]I6<ST'1;F0+*F,E0<)2<O_
M^*4B8L? [Q\P""J#8-]@>,"@5QGTWKM"OS+H%\R4H10\A%CBV82S+>)ZMD+3
M%P69A;4*GZ1ZWY>2JZ=$V<G9LMQOQ%9H2=8I69$(IQ)=11'+4TG2-7I@E$0$
M!/H%7<4QT;N%*;I+RW=.[]WG$"0F](N:\6T9HL^?OJ!/B*1H02A5S\7$E<I3
MO9X;55[-2Z^" U[Y 5JP5&X$NDECB-L K@JQCC-XB_,Z,")>Y>MSY/MG*/""
M7I=#9O,0HG/4.VP>OM\\,$33JW>M5^#UCNS:_?%=^^MW98ON)"3B[P['K\N%
M^MT+Z:IS*3(<P=11944 ?P9G]O-/_M#[M8M$FV"A); 6P?V:X+X)??8 /()4
MJLJG,X.2)Z!DPUB,)$./H H>IN0?B%&>J?=?E1BB4@&0 "DIJ*HHSU3M$1$G
MF4Z0+MJ-RY]*>PDV+L!TH7^>>>>#B?N\RZ:E!5ML#FHV!T8VYRQ)%$^JF$5/
M9TALL%H"$2'R_=0NN3&"G<I-"3;8X:;?&WMC;SC>(ZAK8C <JP]H/;$5_+ .
M?GAZ\.H++"1.8Y6J70P8$4]E8/A>!KHFFABXJ!FX,#)PRUF";EY42A%1Y--W
MS+FJ5ZHX+2!Y!-Y9F(R8IW)@$RRT!-;B<E1S.?JHRC^R2;!-L- 26(O@<4WP
MV&:M&O\O9X;!J._UVJDU-ZYY*CV6P%KT^%[3,'K6ZUD%>90F\]*G\F0+K4W4
M3F?M&XFZ23+*7@'04E.%[@_V F:<4S/1*EIH"ZW-8=!P&'Q4N:M6LL6R3;30
M%EJ;Y49-^,9>>O8'DTK294RJSI5@2E]13&BN!7F5WYU\6E4.%5JK^1B-1@,O
MV&M2.B;VO M_$(RZFQ2_:?E]<\^_P"\DR1-C4V*&.#EHFVBA+;0V?4V/[P\^
M+%6M*@"K:*$MM#;+C9CPCZ@)+#8HXRP"B 5:Z<X:JLY:Z-9Z6[76G;26T/JS
MN",4_?UOL$WQ$=I":]/5* _?+#UN?N0D*P7Y;<Y3(G,.2/4IZ):\Z&M1#.Y7
MZF4%5$^N2P#Z%RU(>KPJ6-4J5M%"6VCM#6CDBO]A>L6W*EBLHH6VT-HL-YK%
M-XN6&U'^ A6C7, JIXB2%71R:%.(S(]X-4"O@'E7*0IM^='^+;C1,(%9PU@H
M"^]H%LQ.G$JV5;30%EI[ QIM%/@?518"J^K)*EIH"ZW-<J.> J-N>']9,..<
MS*'9JXO#9<&6'R5?[LZQ6 )\71PO"E2\8N7)47VW/L*\*@[N]N[/_<NP/(AL
M8,IST07F:Y(*1&&E(+WS"]4=\O*HL1Q(EA6';X],2I84EQO ,7 ]03U?,:6Z
MJH%>H#[PG?T'4$L#!!0    ( #6#;EC/;38JR (  # '   9    >&PO=V]R
M:W-H965T<R]S:&5E=#(X+GAM;*U5WV_:,!#^5ZQLFEII:T("V=1!)'ZT6A\J
M547M'J8]&.<@5AT[M1WH_ON=G9 !I6P/XX'8Y[O/W^<[GX<;I9], 6#)2RFD
M&06%M=5E&!I60$G-A:I XLI2Z9):G.I5:"H--/=!I0CC*$K#DG(99$-ON]/9
M4-56< EWFIBZ+*G^-0&A-J.@%VP-]WQ56&<(LV%%5S '^U#=:9R%'4K.2Y"&
M*TDT+$?!N'<Y39V_=WCDL#$[8^*4+)1Z<I.;?!1$CA (8-8A4/RL80I".""D
M\=QB!MV6+G!WO$6_]MI1RX(:F"KQG>>V& 5? I+#DM;"WJO--VCU#!P>4\+X
M?[)I?:. L-I85;;!R*#DLOG2E_8<=@)ZZ1L!<1L0'P;TWPA(VH#$"VV8>5DS
M:FDVU&I#M/-&-#?P9^.C40V7+HMSJW&58YS-KBG7Y)&*&L@M4%-KP!190ZC,
MR92:@EP]UWQ-A3.&MU0_@:4+ 60.K-;<<C#D$QGG.7=)H8+<R*:R7(K.9NC,
MQ3EZ/,QGY.S]^3"TR-GM'+*6WZ3A%[_!KQ>36R5M8<B5S"'?!PA1;*<XWBJ>
MQ"<19\ N2-+[2.(H3HX0FOY[>'R"3M(E(/%XR=\3,..&">5R8,B/\<)8C47^
M\]B9-9#]XY#NXE^:BC(8!7BS#>@U!-F'=[TT^GI,[W\"VU/?[]3W3Z%G8\9T
M#3GAT@*B6VP,#+#>L,2.Z6[ 4@_F^M,Z2R+W&X;K746OW7K[;GM<!QW7P6FN
M EL>E0P(ECAA&K#H">;+'&/:0 UV*!R2/.6QQR_M^*4G^=V4%=:2N[Z>%181
MWD$NUWBLSGB,9?KJH Y9GO)H6(8[S:<$O?(]V1"F:FF;6]E9N[8_]MWNP#[!
MYZ#IWG]@FK<$^\Z*2T,$+!$RNOB,IZ:;_MQ,K*I\BULHBPW3#PM\TD [!UQ?
M*F6W$[=!]TAFOP%02P,$%     @ -8-N6-&<9S^$!0  LB<  !D   !X;"]W
M;W)K<VAE971S+W-H965T,CDN>&ULS9K;;N,V$(9?A7 710)L(Y&4#TD= SDT
M;8"DFZZ3[471"]JF8R*2Z"5I9Q?HPY>2M:)D,XQET(!O$DLF?\X,9Z1/8_5?
MN7B1,TH5^);$J3QOS92:GP6!',]H0N0)G]-4?S/E(B%*'XKG0,X%)9-\4A('
M* P[04)8VAKT\W,/8M#G"Q6SE#X((!=)0L3W2QKSU_,6;/TX\9D]SU1V(ACT
MY^29#JEZFC\(?124*A.6T%0RG@)!I^>M"WAVA7O9A'S$%T9?9>4SR%P9<?Z2
M'=Q.SEMA9A&-Z5AE$D3_6](K&L>9DK;C:R':*M?,)E8__U"_R9W7SHR(I%<\
M_IM-U.R\U6N!"9V21:P^\]<_:.%0.],;\UCF?\%K,39L@?%"*IX4D[4%"4M7
M_\FW(A"5"3!Z8P(J)J!M)^!B LX=75F6NW5-%!GT!7\%(ANMU;(/>6SRV=H;
MEF;;.%1"?\OT/#6X(4R +R1>4'!/B5P(JO=(24#2";@B<@9^^[I@2Q)G)X-[
M(EZH(J.8@B$=+P13C$KP"QBN<@#PZ<:<7,@^[^A:GV/QL19X&EZ#HP_'X -@
M*7B<\874TV0_4-K#S,Y@7'ASN?(&O>'--1V?  P_ A0B;)E^M?UT5)\>Z+B6
MP45E<%&NA]\/[H645$?C0D?CCI$1BU<Q*&(^ 9]2\#D+C6#I<S[J3YZ*\L0E
MD4R"?^ZT/KA5-)'_VF*S,B:R&Y-=#\[DG(SI>4L7O*1B25N#GW^"G?!76Z0\
MB=7BALNX89?Z($\B:I+(YNQ*H9,K9->JY0!%W1#V@V75"\LH!'M1.:IF7E2:
M%SG-JZ2S+-/99N-*IEU9O1.&T;J-FZ-.=1RQW<9V:6/;:>,C5R0&X[5 YM68
M;&M^>\.P7M2-T)KYFZ,@Q-U>UVY_I[2_X[3_Z61X AY%7A[?P26+8YW_]S09
M46'-?:=:T]SW)%9SO%LZWCVD:T;79]P\B=7BUBOCUO-3E+W-?.UB'*UEM7.Q
M'5TY+5TY?3_W?^=+*M+L9ER]9[I*P"G:="L]B=7\AZ&!DO"0BJ"PQE/H?*G5
M8U<!.NBG$ J=:B7@=A>>KE6"99CC_@0-&T$G0@RNN)AS010%EUS#GC.UW5*-
M-V@?; ,-W$!\4,GM9*W&L?.D5H^=(2_H";V@A;U.>[WUW':NMJLWAM&@&]+N
M>4J_%T]'X&;Q;A4XU1KOI">UNN^&[V#GH*K *R#Z4JO'SB B=)+45L]'A42U
M &P/2+9A;S\A04-CT(UC?RVXTEOW(-A8;Z5^JK_(^S5%LLN/X.B.+FD,X+$[
MY3UQ6.'L/J@.&JR#IP>5\EZ!T)=:O9%BB! YJ6FKE"\DWDMYV["W4QX9\$*>
MP MM$I7M$<2]W*X1K_2NW'SFHX-0+%'U-$(A;J][NCG,M2.&M)"[C[3#10C\
M!YJV'MQ&-.Z[[0.PD $L%!W2-0IY K B=OO .61P#KV#<UN7A:5G9KL [(/0
MD"$TY&[![58]#9G6;4/C!-@'ER'#9>B@>G?(:_/.EUH]=@88D1L8M[K!;_;N
MK#=XRS#'[<3P&W+WY8;L.653-B:I I_4C KP:90%(J_XVW2^T!M>U 1R8ZU[
MH<8[MP\TPP;-\$$UZ[#79ITOM7KL##-B3\R(-YDQ0MVPN_Y[5Z-F'38PB/</
M@]@&@Q87-H>Y7*C\INB&P=VJ]P</-F_'N\UIG*?[P$)LL! ?%!9BKUCH2ZT>
M.X.%V!,6XDTLM#7DBV&=+0O$\!YV\][.!=*DD^^VH?'.[H/WL.$]?%"\A[WR
MGB^U>NP,[V%/O]<6.M5TMW3RW:LU]2:HO%"5O<VFC7UFJ00QG6KY\*2K2U"L
M7A!;'2@^S]^Q&G&E>))_G%$RH2(;H+^?<OTL51QDKVV5K^D-_@=02P,$%
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MGK$<+E5;#UP;J/<Q8_)EHAO'^A\%H_\!4$L#!!0    ( #6#;E@,<6#A=P(
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M)00<<F,1*+[6, 7.+1#2^-E@!NV6MG!_O$._<=I1RYQJF$K^C16F' 6? E+
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MKI"8\H[F R-K9PIS:=!BW+#$GP HFX#K"RG-+K ;M+^5[#=02P,$%     @
M-8-N6/B%7\NJ @  .P<  !D   !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL
MK55=;YLP%/TK%JNF5MH*X:MI1Y#:9-7V,"EJVNUAVH,#-\&JP<QVDO;?[]H0
ME":DRL->P!_W',ZY7%\G&R&?50&@R4O)*S5R"JWK&]=560$E59>BA@IW%D*6
M5.-4+EU52Z"Y!97<]3TO=DO**B=-[-I4IHE8:<XJF$JB5F5)Y>L=<+$9.0-G
MN_# EH4V"VZ:U'0),]!/]53BS.U8<E9"I9BHB(3%R+D=W(QC$V\#?C+8J)TQ
M,4[F0CR;R?=\Y'A&$'#(M&&@^%K#&#@W1"CC;\OI=)\TP-WQEOW>>D<O<ZI@
M+/@OENMBY P=DL."KKA^$)MOT/J)#%\FN+)/LFEC/8=D*Z5%V8)10<FJYDU?
MVCSL  ;A$8#? OQ3 4$+"*S11IFU-:&:IHD4&R)--+*9@<V-1:,;5IF_.-,2
M=QGB='J;97(%.?GZ@G6A0)'/9(:5DJ\X$+$@!]OG$]"4\0N,>YI-R/G9!3DC
MK"*/A5@I6N4J<37*,N1NUDJX:R3X1R1,(+LDP> 3\3T_Z(&/3X?[;^$N)J/+
MB-]EQ+=\P1&^*7VE<XY6T4WCGW)%?M_.E998='_Z##:,83^C.8@WJJ89C!P\
M:0KD&ISTXX=!['WIL_N?R-Z8#SKSP7OL73D89BJSPB8AAS6>]AK/KB;0%D)?
M%AKJV%*;[K%.P^@Z3-SUKKO#H.C:'W1!;U2'G>KP)-4U?96"<RM: J<:U]X3
MW+!&.UK\(([V!/<$>6'<+SCJ!$<G"1:Z -FG+#KX:.A?[0GKB0F/)#+N=,7O
MZGH4FF+Z6G7;U-E\6JG8D:0T9< 9G3/.-.M/;'SPDZ^"8;RG_S!H&'K#/0/N
M3FLSU\H/*I>L4H3# F'>Y17ZETVK;B9:U+;;S87&WFF'!=YN($T [B^$T-N)
M::#=?9G^ U!+ P04    "  U@VY8T6@QW"48  "59P$ &0   'AL+W=O<FMS
M:&5E=',O<VAE970S-2YX;6RUW6MSFUB"QO&O0GEVISI5:5N@>SI)53IPX #9
M274ZTR^V]@61L$VU)-R G/;6?O@%A(V.A(Y%\L^\Z'%L\3OX\NAP>8#77]/L
MS_PVC@OC[_5JD[^YN"V*NU=75_GB-EY'^65Z%V_*KURGV3HJRG]F-U?Y719'
MRWJA]>K*&@PF5^LHV5R\?5U_[F/V]G6Z+5;))OZ8&?EVO8ZRAU_C5?KUS85Y
M\?B)WY*;VZ+ZQ-7;UW?13?PI+C[??<S*?UT]*<MD'6_R)-T867S]YN*=^2J<
M3ZL%ZE?\.XF_YGL?&]6W\B5-_ZS^(9=O+@;5&L6K>%%41%3^WWW\/EZM*JE<
MC[\:].)IS&K!_8\?=5%_\^4W\R7*X_?IZH]D6=R^N9A=&,OX.MJNBM_2KU[<
M?$/CRENDJ[S^K_&U>>W@PEAL\R)=-PN7:[!.-KO_C_YN?A!["YBC$PM8S0+6
MN0L,FP6&YRXP:A88G;O N%E@?+C \,0"DV:!R>$"XQ,+3)L%IN>NTJQ98';N
M O-F@?FY"YB#Q]_<X&"1T[_KIU_VV;]M\_'7;=:_[ZO='U;]5VE'1?3V=99^
M-;+J]:57?5#_:=?+EW^,R:9*X:<B*[^:E,L5;S\5Z>+/VW2UC+/<</[:)L6#
M$6V61OUYXU]W551RXV?CW7*95!]'*T-N=N&O0O23'1=1LGI1ON+S)]OXZ3]>
MO+XJRM6J\*M%LPKN;A6L$ZM@&A_237%;#K]9QLN.Y8-GEK<TP%7Y\WCZH5B/
M/Y1?+:WH1YM+PYR^-*R!->I8H?=G+#XP3RYNZQ=_M[TI1]\M/NQ8W#E_]*[%
MA7[Q#]&#8<WJI0==OTO]TB+^<FE8\Y/?NG?&MSX\O>Y2O_A_I??EXH-Z<:MC
M<5^_^*?X3KMXH%_<CA?:E0_/7]S2_!$/GY(]K+W1">]S&88\N=E$1;PTRAGZ
M.LZR\J.\"O9+([^-LC@WHFUQFV;)_W;F[E?M -7VP:O\+EK$;RY*/H^S^_CB
M[3__84X&OW1EAL1L$G-(3)"82V(>B4D2\TDLV&'C&JNV0>_?C@?U_UY?W>^G
M\?G7*;$;/<5N]!VQNXLRXSY:;>.NN&GAOG$C,9O$'!(3).:2F$=BDL1\$@MV
MV'0O1H/+P< \"-MSKU*B-GZ*VOC[9[@DS[?=LYL6[QLW$K-)S"$Q06(NB7DD
M)DG,)[%@?#1K'<YKNE<H,9L\Q6SR_3%+MT5>E#N.R>:F*VO:$?IFC<1L$G-(
M3)"82V(>B4D2\TDLF#R;-=TKE*Q-G[(VU6;M?;I>IYM>.VE:L&^T2,PF,8?$
M!(FY).:1F"0QG\2"Z5%P3+-[-^V<5RI1FSU%;=8C:MH=,RW4-V(D9I.80V*"
MQ%P2\TA,DIA/8L'LK!VSYUZE1&O^%*UY_UGL](Z8%NL;+Q*S2<PA,4%B+HEY
M)"9)S">Q8'XT+XV&\\%\,)D?)*SKA=9D;IV:O\Q!>^INT#]FS^R(Z<F^84,U
M&]4<5!.HYJ*:AVH2U7Q4"QKMC-1UOE(;N[TSYN;9L3/NTZ),FI%598^\,W!:
MK'?@2,U&-0?5!*JYJ.:AFD0U']6"9Z+@1(O;W<1CI-?&8C\8\:9(BE4Y(16W
ML;$KF!A%:J2;N,I,^?J-$:U6QCHJBJIZDF^_K).B.L)8OBAJ7G)=+USF[2[:
M//SS'S/+G/Z2[_RFLM)UFIWZ":AO#U;[]F!I?R9V<I\LX\VRW*5,.C=W]<OW
M?D<@-1O5'%03J.:BFH=J$M5\5 L:;:(Y*DH-J :P[;V8^N++8VFM?".YVV:+
MVRB/GS:.#]ZD;K)H4W3OE.H'Z9U2M/V":@ZJ"51S4<U#-8EJ/JH%YG&[Q9R.
M9M;1X55J6#6K;5G&U+=E_JA;TN6L']W'6703&_'?<;9(RL3>9<DB?FFXFH2B
M?1E4LU'-036!:BZJ>:@F4<U'M:#19OL[J)>3V6$\H3'5>+8%&U/?L/DMSHLR
MAU5 =X7PSYNDR(W__A"OO\39_W2F$JW5H)J-:@ZJ"51S4<U#-8EJ/JH%J!92
MFIK>MK=CZHL[^@WAY[> T=(.JMFHYJ":0#47U3Q4DZCFHUI@'G=S)N..?@$U
MJIK1MN]CZ@L_GS=9O$AO-E6[I]HWO8LW^>[2JOCOZN/./H+>[)U,M/2#:@ZJ
M"51S4<U#-8EJ/JH%C;9_!,D:=E5_J&'5:+;](%-?$'HVFL;>U^_B+$F[IU&T
M/81J-JHYJ"90S44U#]4DJOFH%CR3D:'Q$$=9;IC&NKH$U[",9?30?58&6BTU
MS&TCR=17DHX.--4;ON7:%K%Q'25-^>^EL;?'N]M WM9[O+K-9+2^A&HVJCFH
M)E#-134/U22J^:@6-)IZ&&H^.IR)H3'5J_';HI-U5M%I=PA*=_!)[_3-(JK9
MJ.:@FD U%]4\5).HYJ-:@&HAI:F9;5M2EKX:(O-\&VT61\60SMBB'2E4LU'-
M036!:BZJ>:@F4<U'M0#5PD;;/VYEC<?CV71\HKAHM<TD2]],<A[/K9:1_!IE
MU29M_M@;[HPE6E1"-1O5'%03J.:BFH=J$M5\5 L:33D ;,U&@^'!MBTUJAK*
MMJUDZ=M*<K/<+N)U7.Z,GK%]BY:24,U&-0?5!*JYJ.:AFD0U']4"5 LI3<UM
MVURR],TEIF6H'Z1WH-$.$ZHYJ"90S44U#]4DJOFH%C3:_A0[G'2<R*%&5:/:
MMI@L?8OIWW%>7Z2S.T?3=A_2.L*=L41+3*AFHYJ#:@+57%3S4$VBFH]JP3-Q
M&.W.V73.J3^BL&2UA25+7UAZ/$GSL_8D317@M)E]=5,K6E]"-1O5'%03J.:B
MFH=J$M5\5 L:;?^\S/!R?'B5:_.J[HMQU!"VC21+WT@ZN4-J_)\ADBPOC'>;
M35(&-(^R!_W>*EI30C4;U1Q4$ZCFHIJ':A+5?%0+4"VD-#74;9?)TO<T/NUM
M\!KW[?;PHHQY.=%VIA?M+:&:C6H.J@E4<U'-0S6):CZJ!8TVWY\9+ZWQX?SY
M(TI)5EM*LO2EI$_;+WG\U[:::IW[ZK][4^WYG0>T?X1J-JHYJ"90S44U#]4D
MJOFH%J!:2&GJ Q?:GM)0WU/JTWG04WUCBVHVJCFH)E#-'1[?)LB<3X>3V<A2
MIPH/'5>BFH]J :J%E*9&LJTA#?4UI$_US6GJB\FK[=W=*9K./*(=)%2S4<U!
M-8%J;J/M'_:874Y'AUE$NT6HYJ-:@&HAI:E9;/M'0WW_Z&.6+N)XF1N;N*BF
MR.1QNERD>??-T_1@[U"B#214<U!-H)H[/+[ECSDQ)QV7;'GHP!+5?%0+4"VD
M-#69>X\*TY>0JH>]/3[]3VZJ@T+)?6Q\7$4;[:ZG7NT=3_8)8>PCPMAGA+$/
M"6.?$L8^)HQ]3AC[H#"TCD1I:H+;.M)07T>JMW-_KIY'>W"M:MWSO=F=S_GR
ML-O^;5YW%SW4GXZ^1MGRI;&,\T66G.Q$Z%>@=]C1JA*J.:@F4,U%-0_5)*KY
MJ!8\$Y_?;^/JL;K)>KLV-MMJPJMK0KL^7W$;%>57'XPO<7,7>R.I'D&=W\6+
M>D,VVCSL0I0;VTU]H].2J^?4>@I-=C=!S4L[O7YE_)2\,,R7T\'@9;G]]#C&
MW6J;EU\IOU0N$&TVVVA5#K+(XJI76,;8C\I/90_&[OF@9OV,WKBZ^VJT=S*V
M6N5M^;FZ,%$.62Y]7=2KDZ7;FUL5J1YT&O]5C5.D]?JMXCS??=\_O7MAC/[S
M\?ZKROW[ZX'W[C%>K5N]<)1718V'QX62]3I>)N5ZK!ZJ9T8MXOK%UTF^* >L
M^B<OC30S?OKUQ6Z-\W6T6I6#'_WLH[Q\7RJ_AW7Y"UM6;V 5_FM:_JR-GQ;I
MJGZ8]WTYR,OZ"]4]8JW!+_5//4S625%_POSEQ67G6_:/J*4-VUK:4-_#^9!L
MZK^W55Q^ ]6W?/(/L/S9I%]WM\9]^A/L?(M&:VNH9J.:@VH"U5Q4\U!-HIJ/
M:L'P^,EUYK3SR:T_HJ4V;%MJ0WU+[>/3:?.ZB;;W7GCZ4BH]V3N9:!D-U1Q4
M$ZCFHIJ':A+5?%0+&DT]F3XXO$D -:8:R[:W-M3WUGXO-Q*J0-Z5DW]G!-$V
M&JK9J.:@FD U%]4\5).HYJ-:\,P?OSDX7>JF5D3-95L]&W[G;;0ZPXJ6SU#-
M1C4'U02JN:CFH9I$-1_5@D;;/V$RFW5NR?Z(_MFP[9\-]?TSZ YW^E%ZAQ5M
MH*&:@VH"U5Q4\U!-HIJ/:L$S&3'KB=4H)]CZ#G>Y8<U.WN..6C$ESJ.V?C;2
MU\_0RZ?T8_4--:K9J.:@FD U%]4\5).HYJ-:T&C54P"+]OJIZ<'TV[QJOVTT
MOK1.//QVU';.1OK.V1EGTZMKJ;)T;7PLY]2L_I+^J0KZ$7NG$6VGH9J#:@+5
M7%3S4$VBFH]J :J%E*:FNVVQC?0M-OEX5B[9/)Z?:899&M=EF*^WQ3:+G\IM
MG6E&:VVH9J.:@VH"U5Q4\U!-HIJ/:L'H^,9:EC4:#8]FU^/7F:/9Q!J>F%_;
MMMKHN]MJY?SJK.]6Z4,<Y_N?_*W_ XWT*],[K&C)#=4<5!.HYJ*:AVH2U7Q4
M"U MI#0U^&W);:1OZ?2_D8\>[!U>M+2&:@ZJ"51S4<U#-8EJ/JH%S\1!<R,?
M:CW4H+;5II&^VO3CGK:@'[AWH-&*$ZHYJ"90S44U#]4DJOFH%C3:,T];H,94
MP]OVFT;Z?M-YF]=GWY] /UKOQ*+5)U1S4$V@FHMJ'JI)5/-1+4"UD-+49+<5
MJ9&^)?*IJ1/?1\DJ^K**Z^-5]63;&5RT,(5J-JHYJ"90S44U#]4DJOFH%C2:
M<O3)FDTF@\-[ %'#JIELZU$C?3V*.)R,EJ50S48UI]'4BOAP,#U\;KI AW51
MS4,UB6H^J@6H%E*:&M2V+#72%T&^8[.X\VAT9Y+1)A6JV:CFH)I -1?5/%23
MJ.:C6H!J(:4I<1^W9:JQODS%/-]!/TC?0*.:C6H.J@E4<U'-0S6):CZJ!>..
MNZ,-9S/KJ,=,#:MFM2U<C?6%J_[GA?1@[URB?2I4<U!-H)J+:AZJ253S42UX
M)@Z:\T+4>JA!;;M38WUWZONVH4_???[L#6S]^O7./=J\0C4'U02JN:CFH9I$
M-1_5 E0+*4U]+VA;7&-]B^L;;DFO%WNG%ZUBH9J#:@+57%3S4$VBFH]J0:,]
M<TMZ:DPUE6W%:JSOE)PW0_=Z:*E^Q-ZI13M8J.:@FD U%]4\5).HYJ-:@&HA
MI:GI;GM98WTOZYNNQ=>;O?.+5JY0S4$U@6HNJGFH)E'-1[6@T92;%YM=U^)3
MPZK1;%M78WWK"KH67S]*[["B;2M4<U!-H)J+:AZJ253S42UX)B/#W8$M8_AX
M+;XY.'DM/K5B:IS;JM587[4Z;SM:]P"H\ZY?TFYXHP4N5+-1S4$U@6HNJGFH
M)E'-1[4 U4)*4]\.VI;76-_RTI]-?OXT\G'OR1J-AY.AN@WS7K\6O3.*=K=0
M3:":BVH>JDE4\U$M0+60TM2,M@6OL;[@]0UGD?7@Z?-P[_5+]@XJ6LU"-8%J
M+JIYJ"91S4>U -5"2E.".FFK61-]->O[MZW/OGA)OR9]-Z%1S48U!]4$JKFH
MYJ&:1#4?U0)4"RE-37U;\IJ<\23'LR]>TF.]@VL>;7\/!R-K?GC=@8T.ZZ":
M0#47U3Q4DZCFHUJ :B&EJ9EL^UR3'WXO+/T(O8/:<<^AZ7ARM*=LH\,ZJ"90
MS44U#]4DJOFH%J!:2&EJ4-NRU82X95;O3>:S>Y?ZU>N=<K2YA6H.J@E4<U'-
M0S6):CZJ!:@64IKZ5M VO";ZAA=S85,SB'ISOZE53K8'AZ3U:],[JVA?"]4$
MJKFHYJ&:1#4?U0)4"RE-S6K;UYKH^UK]#TD_ VH.2>N7[!U4M)B%:@+57%3S
M4$VBFH]J :J%E*8&M6UO38A[9GW+]C5PT9-^W7MO?*.=,%1S4$V@FHMJ'JI)
M5/-1+4"UD-+4]XFV%C9YY@Y<_2]Z:D3]92/O]>/V3B7:SD(U@6HNJGFH)E'-
M1[4 U4)*4U/9MK,F^G;6A^;!V]I)%+W)%JK9J.:@FD U%]4\5).HYJ-:@&HA
MI:EQ;8M:$WVOZGV4WQIW6;J(XV5N7%?/48K_+N?0)-\=P_H:9=6!J\X'<>OI
MWC%&:UR-IERJTG&EBH..*E#-134/U22J^:@6H%I(:4I IVU!:ZHO:!W.I^6>
MZAD[R%UQU0_4-ZZH9J.:@VH"U5Q4\U!-HIJ/:@&JA92FAKKM7TWU_:O'4&^V
M55KK8]&[LT;%;508Z^C!^+)K>L1+8[M9EB_9/U9M)$^AORM#WYEUM+*%:C:J
M.:@F4,U%-0_5)*KYJ!9,CRN"NT=^'UYG3 VKQKBM;$WUE:V/67)?/8:EG'J;
M.WAHYU^TG85J-JHYJ"90S44U#]4DJOFH%J!:2&EJ<-L*UU1?X?JCV:LM]WR3
M15P=--Y-P)VQ1>M6J&:CFH-JHM'VG\]CFI>S@R=;NNB@'JI)5/-1+4"UD-+4
M/+8]JJF^1_64Q\=C3[M@=L:1[*2\1S4;U1Q4$XVV'\?!Y< \3"/:E$(UB6H^
MJ@6H%E*:FL:V*375%YO<+,WSIX/"G2%$;V.%:C:J.:@FIL<W4&IV; :'042;
M4*@F4<U'M0#50DI3@]@VH:;Z)M3OY:281XOZF,\BS3LOSM,3O:.(%I)0S4$U
MT6C[QQA&D\XDHETC5).HYJ-:@&HAI:E);+M&4WW7Z*-RAO3Q&CRUX1]MED^G
M2XU-7!CI]76<5:6D*KO=\RAZ5RE4LU'-0371:/OSZ'0\ZDPOVDE"-8EJ/JH%
MJ!92FIK>MI,TU7>23A^G[7/_"OT@O<.*MI90S4$U@6HNJGFH)E'-1[4 U4)*
M4P/=MI:F^M:2?)R #ZZRZXPMVE)"-1O5'%03C;:_@3PQ!^/A>'XXQ:(U)523
MJ.:C6H!J(:4IB9RU-:69OJ:TGTA=9U#/]$TCJMFHYJ":F!T_/FYBS4:#@WMQ
MN.BH'JI)5/-1+4"UD-+4,+;UHMD9MW<ZY]RFWNF=1K0FA&H.JHE&.SRW.3L,
M(]K_036):CZJ!:@64IH:QK8D--.7A)S'4YI[,^/+IN_7F4FT)H1J-JHYJ"90
MS44U;W9\*ZVNV5NBH_JH%J!:2&EJ*-L"T$Q? /J>RU[T=.^ HH4@5'-03:":
MBVI>HTT. GH83[0/A&H!JH64IL:S[0/-]'T@[0';#[]_,KPX6A6WQL<H*S9Q
MEG_3\5S].O3.,=HD0C4'U02JN:CFH9I$-1_5 E0+*4W->]LXFND;1WV.Y^JI
MWK%%NT>HYJ"::#3EOLMC:W)XPA0=U$,UB6H^J@6H%E*:FL>V>#33%X_>_?[!
M^-=C>^%CEMYDT?K;YEBTG81J-JHYJ"90S44U#]4DJOFH%J!:2&EJIML*TTQ?
M87J_-Z\^'G]JKC'M3"Y:34(U&]4<5!.HYJ*:AVH2U7Q4"QIM?V/G\-I1:D U
MCFTG::;O)#TWQ7;<]^'\61=M*J&:C6H.J@E4<U'-0S6):CZJ!:@64IH:\[:I
M--,WE=[=W&3Q374L*X]6\=Z='LJ/TFWV_-XNVEY"-1O5'%03J.:BFH=J<G9\
MIZMQYS5%/CIN@&HAI2DQG;?UI;F^OO2YNLG*URPIBGAC?-Q^626+=G;^EBE8
M/U[?W**:C6H.J@E4<U'-0S6):CZJ!:@64IJ:[;8--=>WH?H<7-93O6.+%J)0
MS4$U@6HNJGFH)E'-GQ_?Z<@:C\>SZ?A@\@[0<4-*4R/9=J+F^D[4V05%O=,[
MCV@9"M4<5!.HYJ*:AVH2U?Q&VR]V#B_-\6$6T2H4I:E9;*M0<WT5ZNG2UMTE
MJ_L7MYZX:E4/]@XE6H!"-0?5!*JYJ.:AFD0U?WY<SIJ.K8X]W  =-Z0T-9AM
M"6JN+T&=NT^*/)Q=ORZ],XV6H5#-036!:BZJ>:@F4<U'M0#50DI3<]^6H>9<
M&4I/]8XM6H9"-0?5!*JY\^-JE3F?#B>SD:5.4!XZKD0U']4"5 LI38UDVX>:
MZ_M0Y^^OHGTG5+-1S4$U@6INH^WOQ<TNIZ/#+*(])E3S42U M9#2U"RV/:;Y
MF;=B.G]_%:TRH9J-:@ZJ"51SY\?W;#(G9M<MUSQT8(EJ/JH%J!92VBZ95_EM
M'!=V5$1O7Z_C["9^'Z]6>1FS[:;DJ^-+3Y\ULOBZ3*[YZIUU<77T>==\Y9L=
MGP_,5V']^:N6?_OZ+KJ)/T393;+)C55\70XUN*SNPY@E-[=/_RC2NS<7YH7Q
M)2V*=%U_>!M'Y?YR]8+RZ]=I6CS^HQK@:YK]67\[;_\?4$L#!!0    ( #6#
M;EA&\O=HYP(  "$(   9    >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;*U6
MWV_:,!#^5ZQ,VCII);\*E XB 6VW/72K6JU[F/9@DH-8.'%J.U#^^YWCD %+
M$9/& ]C.W>?ON[O<,5P+N50I@"8O&<_5R$FU+JY<5\4I9%1U1 $Y/ID+F5&-
M6[EP52&!)I53QMW \WIN1EGN1,/J[%Y&0U%JSG*XET2564;E9@)<K$>.[VP/
M'M@BU>; C88%7< CZ._%O<2=VZ D+(-<,9$3"?.1,_:OIGUC7QD\,5BKG34Q
M2F9"+,WF2S)R/$,(.,3:(%#\6<$4.#= 2..YQG2:*XWC[GJ+?EMI1RTSJF J
M^ ^6Z'3D7#HD@3DMN7X0Z\]0Z^D:O%AP57V3=6WK.20NE199[8P,,I;;7_I2
MQV''(>B^XA#4#L&I#F'M$%9"+;-*UC75-!I*L2;26".:652QJ;Q1#<M-%A^U
MQ*<,_73TJ$6\3 5/0"IR\UPRO2$T3TAU3KX5)M:*G).QPCS7NU)!0K0@UZ!!
M(B<@MY1)\D1Y"43,#WP_29IK=#A#<\KX^Z&KD;>YW8UKCA/+,7B%HQ^0.Y'K
M% GF"23[ "X*;E0'6]63X"CB-<0=$OH?2. %80NAZ>GNP1$Z89.$L,(+3TC"
MNVT6O@H-Y.=XIK3$6O_5%C:+>M&.:M[_*U70&$8.ON *Y J<Z.T;O^=];)/\
MG\#V G#1!.#B&'KTP-3R?"X!",-:07Q-)-70IMD"^;:>38]:15['"_N8A]6N
MG':[P.\V=GM,NPW3[E&F-R\%-B!3_UCZY(SE9 -4JM:J/H[4LYXD()DM[B D
M"=VHMMS\(Y+?;4':D]MKY/9.D[L2G&K&L3#;E%J0P5ZL!^%@[W.0GS:7RT%[
M<OH-V_Y1MM=LQ1+ [K5AP),VHOV_;SW@=<S"DG)WNFT&<E$-(45B4>;:MJ#F
MM)ESXZJ]'YQ/</[9<?4'Q@[/.RH7#'LGASE">IT^%H"T \ENM"BJGCX3&B=$
MM4QQAH,T!OA\+K![U!MS0?.O(/H-4$L#!!0    ( #6#;EC8Q6+9R00  !$8
M   9    >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;+696W/:.!3'OXK&V]EM
M9U)LR9A+%IC)K;O[D#;33-J'G7T0Y@":VA:5!"3??B7;V& 3 2YY"98L'9W?
M.;K\K0S67/R0<P"%GN,HD4-GKM3BTG5E.(>8RA9?0*+?3+F(J=)%,7/E0@"=
MI)WBR"6>UW%CRA)G-$CK'L1HP)<J8@D\""27<4S%RS5$?#UTL+.I^,IF<V4J
MW-%@06?P".II\2!TR2VL3%@,B60\00*F0^<*7]X0WW1(6WQCL)9;S\B@C#G_
M80K_3(:.9SR""$)E3%#]LX(;B")C2?OQ,S?J%&.:CMO/&^N?4G@-,Z82;GCT
MG4W4?.CT'#2!*5U&ZBM?_PTY4&#LA3R2Z5^TSMMZ#@J74O$X[ZP]B%F2_=+G
M/!!;'4CP2@>2=R#5#NU7.OAYAS1R;N99BG5+%1T-!%\C85IK:^8AC4W:6].P
MQ*3Q40G]ENE^:O2H>/ACSJ,)"(GN?BZ9>D$TF:"T'GU9F%A+]!$]9FE&?+KS
M"EV9-)A.[V]!419]T&V?'F_1^W<?T#OD(CFG B1B"7I*F)(7NE(_W[,H,H8'
MKM(,QA,WS/V]SOPEK_B+";KGB9IK9Y,)3'8-N!J^B #91.":6"W>0MA"/KY
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M=(*B%-V%9,D$..OI7%"7!'2_H#G,:5H':)H6NB$I#P7'-(!@%T 7,9>!6]O
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MLAI<S& Y7SW_-_U1O1%[ _KC(P/ZU8#^N0,&U8#!P0#SZLB 835@>#A@=&3
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M$M44JH6H%J%:C&H)I37B=%#7=0;T'78&:&T'U2Q4LU'-0347U3Q4$ZCFHUJ
M:A+5%*J%J!:A6HQJ":4U([2N\@R8.^SHF<[!B59X4,U&-0?57%3S4$V@FH]J
M :I)5%.H%J):A&KQB2@:'FV=)M0\FB'9KT-27T10Z7:;3A^>MEF^V\;L=!M<
M/=TY.-$B#ZK9J.:@FHMJ'JH)5/-1+4 UB6H*U4)4BU M1K6$TIIA6I=_!@-Z
MIQTM^J":A6HVJCFHYJ*:AVH"U7Q4"U!-HII"M1#5(E2+42VAM&:$UD6?XB%\
MZEPO=LY04K-0S48U!]5<5/,J;?_2!',RZ8V:UR8(=*$^J@6H)E%-H5J(:A&J
MQ:B64%HS'.L*S^#L"L\9W[.AQSKG(EK@034;U1Q4<U'-._$/I"P^#7K/O:>V
M[^L1Z'1\5 M03:*:0K40U2)4BU$MH;1F8M;]G8&^OW/NX<W=A4K%4XJ]]V+;
M\\LFF\US_:%/]+X^J&:AFHUJ#JJYJ.:AFD U']4"5).HIE M1+4(U6)42RBM
M&;1U$V@PH0]]HO<*0C4+U6Q4<U#-134/U02J^:@6H)I$-85J(:I%J!:C6D)I
MS0BM6T,#?6NHW@"=EAN@K:&)WAD(U2Q4LU'-0347U;Q*VV_%FF]JL0)=IH]J
M :I)5%.H%J):A&HQJB64U@S#NDXTT->)3NVX?WVZ?;ZJ4[N7CK:*4,U"-1O5
M'%1S4<U#-8%J/JH%J"913:%:B&H1JL6HEE!:(U6'=:MH2+>*AFBK"-4L5+-1
MS4$U%]4\5!.HYJ-:@&H2U12JA:@6H5J,:@FE-2.T;A4-V1L$Z;G. 8JVBU#-
M1C7GQ&HH;Z!@](;';\'@HO/Q4$V@FH]J :I)5%.H%J):A&HQJB64U@S-?AV:
MY V"]%CGR$1[1:AFHYIS8B6<O#C(1:?CH9I -1_5 E23J*90+42U"-5B5$LH
MK9F8=95HJ+^/4.?CG\6?G/EFF]=_^9\LW6@/C^JGT#EGT?(1JMFHYJ":BVH>
MJ@E4\U$M0#6):@K50E2+4"U&M832FJ%;EX^*A_#AT2$:H:1FH9J-:@ZJN:CF
MH9I -1_5 E23J*90+42U"-5B5$LHK1FA=45IJ&^@?%JMGM*%<5O>+*.(T-;0
M1(M)J&:AFHUJ3J7M7RAT=7B=D(LNTD,U@6H^J@6H)E%-H5J(:A&JQ:B64%HS
M"^ORT?!?*Q]UW8?O6E+23Z]SSJ(E)52S4<U!-1?5/%03J.:C6H!J$M44JH6H
M%J%:C&H)I34#N2XI#>F2TA M*:&:A6HVJCFHYJ*:AVH"U7Q4"U!-HII"M1#5
M(E2+42VAM&:$UB6EX:F2TFZS=)M-GS;S_*<QRQ[7VWD1I(MRPW2K;R_I[<YI
MBK:74,U&-6?X]D9-+3O^:"D)U02J^:@6H)I$-85J(:I%J!:C6D)IS9"LRTM#
MN+Q4[OBOTD67D_=HMPG5+%2S4<U!-1?5/%03J.:C6H!J$M44JH6H%J%:C&H)
MI35"=U1WFT9TMVF$=IM0S4(U&]4<5'-1S4,U@6H^J@6H)E%-H5J(:A&JQ:B6
M4%HS0NMNTTA?JCGGY+V>Z!R::)\)U6Q4<RJM\8W&O3<[\>@R/503J.:C6H!J
M$M44JH6H%J%:C&H)I37#L%^'X;]V9Z2VG?BO\Q_Y W3V7C^]SD&+MJ!0S48U
M!]5<5/-03:":CVH!JDE44Z@6HEJ$:C&J)936#.2Z$C6B[ZXT0@M.J&:AFHUJ
M#JJYJ.:AFD U']4"5).HIE M1+4(U6)42RBM&:%UP:EX^/]V]EYO=TY34K-0
MS48UI]+V+]L?OMWQ)Q?IH9I -1_5 E23J*90+42U"-5B5$LHK1F2=85II*\P
M_>[\YGW5[YJC!294LU#-1C4'U5Q4\U!-H)J/:@&J2513J!:B6H1J,:HEE-:,
MS+KI-!K3N^9H-PG5+%2S4<U!-1?5/%03J.:C6H!J$M44JH6H%J%:C&H)I34C
MM.XFC;07[M_(^31;%3OGZ?TF>_Y&T>EZM9W/LI<OR\MF3]/RT6.V*9Z:I_>M
M7YZG7TSG8$4;2ZAFHYJ#:BZJ>:@F4,U'M0#5)*HI5 M1+4*U&-622KO>._[5
M>S=^/?[5S,NZB#32%Y&:>^G&'X9*?\R73TO]CCM:0$(U"]5L5'-0S44U#]4$
MJOFH%J":1#6%:B&J1:@6HUI":<T4K9M*HVMZQQWM':&:A6HVJCFHYJ*:AVH"
MU7Q4"U!-HII"M1#5(E2+42VAM$:$CNO>T5A[4?Z-FB^R;;XN0O,Q_5EF:%ML
MZI&NL8EJ%JK9J.:@FHMJ'JH)5/-1+4 UB6H*U4)4BU M1K6DTO8O2^F/]ZY+
M:<9AW2$:ZSM$XC?M'KA^=.<<1.M#J&:CFH-J+JIYJ"90S4>U -4DJBE4"U$M
M0K48U1)*:^9EO\[+/KP'/D:+0:AFH9J-:@ZJN:CFH9I -1_5 E23J*90+42U
M"-5B5$LHK1FA=3%HK+]7$G7J7+^8SL&*UH50S48U!]5<5/-03:":CVH!JDE4
M4Z@6HEJ$:C&J)976/'7>/[*+7K> BH=G[J*?>=Y<#W9.1E*S4,U&-0?57%3S
M4$V@FH]J :I)5%.H%J):A&HQJB64UHS0NB,T'M%[[6AG"-4L5+-1S4$U%]4\
M5!.HYJ-:@&H2U12JA:@6H5J,:@FE-2.T[@R-3]P=Z;SSYFA/"-4L5+-1S4$U
M%]4\5!.HYJ-:@&H2U12JA:@6H5J,:DFEG7G>O.[_C/7]G^J[-S?KG^DB_[G+
M1&-]NYC?EX<P6Y,1+?J@FH5J-JHYJ.:BFH=J M5\5 M03:*:0K40U2)4BU$M
MJ;3]9#2/!F-=]!F?4_1)5S.C>=SRUV)"Z6;Z4/[)RKYEB_5C>?+'_O&X.QVT
MU1_11)M J&:AFHUJ#JJYJ.:AFD U']4"5).HIE M1+4(U6)42RBM&;-U$VA,
M-X'&:!,(U2Q4LU'-0347U3Q4$ZCFHUJ :A+5%*J%J!:A6HQJ":4U(G12-X$F
MYS:!LFH3M"TV]4C7V$0U"]5L5'-0S44U#]4$JOFH%J":1#4U>=MH&1Q^T6J(
M+C)"M1C5$DIKIF%=!)KHBT#']MO/N=Y(3W?.2+0EA&HVJCFHYJ*:AVH"U7Q4
M"U!-HII"M1#5(E2+42VAM&:8]NLPI5M"$[0EA&H6JMFHYJ":BVH>J@E4\U$M
M0#6):@K50E2+4"U&M832FA%:MX0F^I90_'R5D7&WWAB+P\90^YXZV@="-0O5
M;%1S4,U%-0_51*4=.^-9)2-:\T$UB6H*U4)4BU M1K6$TIZ3\7+[D&6YE>;I
MS8=EMKG/OF2+Q=:8KI]6^6X+<^^WQB:[*Y+3?/^I?W'YYO?2?*_,EM^'YONH
M_/UES=]\>$SO,Y5N[N>KW?V$[HI%]=Y-1A?&9G[_\/I#OG[\>%%L2M^N\WR]
M+!\^9.DLV^R>4/S];KW.7W[8+>#[>O//\N7<_!]02P,$%     @ -8-N6)0V
M7![> @  _0<  !D   !X;"]W;W)K<VAE971S+W-H965T-#$N>&ULA95M;YLP
M$,>_BL6JJ9/6\A0@R1*D-M&T2:T4->WV8MH+!R[!JL',-DG[[6<;2K/%2=Z
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M#$F>]$7ZN_+<+;;S%.^"" -#A$'839ZWNK;7EEHS" 8' S>R:92).(Z);&2
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M"N02G/CC!S_ROG1)_D]@6PGHM0GH'4*/7QN,M@U&E>E$TWXS6##.&5^L#2]
M95<^ZD,B>X@98<O8#[WST!^XRTVE'6Y!S_.CUFU+0[_5T#^H 8N(HU1A!24D
M0F*C$BVP\VUI-?X@I11+9B9@%_4:N[_)R;L(+W:8O_6*SOU^-^^HY1W]>^XU
M 9Z:=.]+=?0VASW_[,S;(=SAMEV1FK*[,<0*D L[VQ5)1,5U_5>WUO;Z&-FI
MN6._PFNEO@5>8>H[Z89*[")%<I@CI'=ZAEF4]9RO-UJ4=E3.A,;!:Y<97HT@
MC0-^GPNAUQMS0'O9QG\!4$L#!!0    ( #6#;E@2L2!010,  ,H4   -
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M*^JM!'H;ZFT$>AOJ;01Z&^IM!'I;9[.$0&]#O8U ;T.]C4!O0[V-0&]#O8U
M;T.]C4!O0[V-0&^/>GL"O3WJ[0GT]JBW)]#;H]Z>0&_?V>PFT-NCWIY ;X]Z
M^W?J'=.U"O'9\UCC\]])=;K=&YZ/OR\?)SOO^!UG!W_L%K]02P,$%     @
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M              "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
M  @ -8-N6(3QLM6="   N#4  !@              ("!#@@  'AL+W=O<FMS
M:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( #6#;EC-RNJEI 4  )47   8
M              " @>$0  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"
M% ,4    "  U@VY8XWRZ4N("  #S"0  &               @(&[%@  >&PO
M=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ -8-N6,'C!A-5!
MF!   !@              ("!TQD  'AL+W=O<FMS:&5E=',O<VAE970T+GAM
M;%!+ 0(4 Q0    ( #6#;ECNIDPT@@4  "LA   8              " @5X>
M  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    "  U@VY8_[PT
M42D&  #]&@  &               @($6)   >&PO=V]R:W-H965T<R]S:&5E
M=#8N>&UL4$L! A0#%     @ -8-N6)T[AU]* @  I 4  !@
M ("!=2H  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( #6#
M;EAD.J)K0P(  (H&   8              " @?4L  !X;"]W;W)K<VAE971S
M+W-H965T."YX;6Q02P$"% ,4    "  U@VY8D8>D'"D3  "Q-   &
M        @(%N+P  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%
M  @ -8-N6-\A;OK[%0  "S\  !D              ("!S4(  'AL+W=O<FMS
M:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    "  U@VY8!.BY;NP(  !U&@
M&0              @('_6   >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+
M 0(4 Q0    ( #6#;EA*&R&ZF (  $,&   9              " @2)B  !X
M;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ -8-N6-Y:17TT
M P  &@<  !D              ("!\60  'AL+W=O<FMS:&5E=',O<VAE970Q
M,RYX;6Q02P$"% ,4    "  U@VY8'X:UGIL"  #>!0  &0
M@(%<:   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( #6#
M;EACEBR MP\  "\Q   9              " @2YK  !X;"]W;W)K<VAE971S
M+W-H965T,34N>&UL4$L! A0#%     @ -8-N6+U/^;N\#0  YB<  !D
M         ("!''L  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
M    "  U@VY8I\&@\3T-   B)0  &0              @($/B0  >&PO=V]R
M:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( #6#;EAP, >*81X  /1?
M   9              " @8.6  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL
M4$L! A0#%     @ -8-N6-+:HJX"!   # P  !D              ("!&[4
M 'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    "  U@VY8_!I'
M1:4"   K!@  &0              @(%4N0  >&PO=V]R:W-H965T<R]S:&5E
M=#(P+GAM;%!+ 0(4 Q0    ( #6#;E@)B3<&Y (  #L&   9
M  " @3"\  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @
M-8-N6->,C2JG @  WP4  !D              ("!2[\  'AL+W=O<FMS:&5E
M=',O<VAE970R,BYX;6Q02P$"% ,4    "  U@VY8V:8J4>P%   K#P  &0
M            @($IP@  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4
M Q0    ( #6#;EC;OH7&Y (  %0&   9              " @4S(  !X;"]W
M;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ -8-N6 %:OX6K!0
M+ X  !D              ("!9\L  'AL+W=O<FMS:&5E=',O<VAE970R-2YX
M;6Q02P$"% ,4    "  U@VY8-QK>-- #   >#P  &0              @(%)
MT0  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( #6#;EBO
M/*E, 04  /P=   9              " @5#5  !X;"]W;W)K<VAE971S+W-H
M965T,C<N>&UL4$L! A0#%     @ -8-N6,]M-BK( @  , <  !D
M     ("!B-H  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #6#;E@,<6#A=P(  &(&   9              "
M@:'N  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ -8-N
M6/B%7\NJ @  .P<  !D              ("!3_$  'AL+W=O<FMS:&5E=',O
M<VAE970S-"YX;6Q02P$"% ,4    "  U@VY8T6@QW"48  "59P$ &0
M        @($P]   >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0
M   ( #6#;EA&\O=HYP(  "$(   9              " @8P, 0!X;"]W;W)K
M<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ -8-N6-C%8MG)!   $1@
M !D              ("!J@\! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q0
M2P$"% ,4    "  U@VY8]KC6%7\#   ;#0  &0              @(&J% $
M>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( #6#;ECT2=#
M.@,  .0+   9              " @6 8 0!X;"]W;W)K<VAE971S+W-H965T
M,SDN>&UL4$L! A0#%     @ -8-N6!X!:F4O%   ]'L! !D
M ("!T1L! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    "  U
M@VY8E#9<'MX"  #]!P  &0              @($W, $ >&PO=V]R:W-H965T
M<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( #6#;E@GKSP-" <  %\K   9
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M970T-BYX;6Q02P$"% ,4    "  U@VY8$K$@4$4#  #*%   #0
M    @ 'R2 $ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( #6#;EB7BKL<P
M !,"   +              "  6), 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M #6#;EC$(U@=!P0  "T?   /              "  4M- 0!X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    "  U@VY8_2S5I:X!  #!&P  &@
M@ %_40$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  U
M@VY8)OJ'I[4!  #<&P  $P              @ %E4P$ 6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     -@ V +$.  !+50$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>141</ContextCount>
  <ElementCount>299</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>58</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="lrmr-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="lrmr-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="lrmr-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="lrmr-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="lrmr-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="lrmr-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="lrmr-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="lrmr-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="lrmr-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995455 - Disclosure - Description of Business and Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20231231/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganization</Role>
      <ShortName>Description of Business and Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="lrmr-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995465 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="lrmr-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995475 - Disclosure - Fair Value Measurements and Cash Equivalents/Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecurities1</Role>
      <ShortName>Fair Value Measurements and Cash Equivalents/Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="lrmr-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995485 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="lrmr-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995495 - Disclosure - Fixed Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureFixedAssets</Role>
      <ShortName>Fixed Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="lrmr-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995505 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="lrmr-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995515 - Disclosure - Stockholders??? Equity and Stock Options</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptions</Role>
      <ShortName>Stockholders??? Equity and Stock Options</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="lrmr-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995525 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="lrmr-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995535 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="lrmr-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995555 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="lrmr-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995565 - Disclosure - Fair Value Measurements and Cash Equivalents/Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesTables</Role>
      <ShortName>Fair Value Measurements and Cash Equivalents/Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecurities1</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="lrmr-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995575 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="lrmr-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995585 - Disclosure - Fixed Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureFixedAssetsTables</Role>
      <ShortName>Fixed Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureFixedAssets</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="lrmr-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995595 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureAccruedExpenses</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="lrmr-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995605 - Disclosure - Stockholders??? Equity and Stock Options (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsTables</Role>
      <ShortName>Stockholders??? Equity and Stock Options (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptions</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="lrmr-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995615 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="lrmr-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995625 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="lrmr-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995635 - Disclosure - Description of Business and Organization - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20231231/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail</Role>
      <ShortName>Description of Business and Organization - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="lrmr-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995645 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="lrmr-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995655 - Disclosure - Fair Value Measurements and Cash Equivalents/Marketable Securities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesAdditionalInformationDetail</Role>
      <ShortName>Fair Value Measurements and Cash Equivalents/Marketable Securities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="lrmr-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995665 - Disclosure - Fair Value Measurements and Cash Equivalents/Marketable Securities - Summary of Cash Equivalents and Marketable Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail</Role>
      <ShortName>Fair Value Measurements and Cash Equivalents/Marketable Securities - Summary of Cash Equivalents and Marketable Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="lrmr-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995675 - Disclosure - Fair Value Measurements and Cash Equivalents/Marketable Securities - Summary of Marketable Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail</Role>
      <ShortName>Fair Value Measurements and Cash Equivalents/Marketable Securities - Summary of Marketable Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="lrmr-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995685 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail</Role>
      <ShortName>Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="lrmr-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995695 - Disclosure - Fixed Assets - Schedule of Fixed Assets, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail</Role>
      <ShortName>Fixed Assets - Schedule of Fixed Assets, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="lrmr-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995705 - Disclosure - Fixed Assets - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureFixedAssetsAdditionalInformationDetail</Role>
      <ShortName>Fixed Assets - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="lrmr-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995715 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail</Role>
      <ShortName>Accrued Expenses - Schedule of Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="lrmr-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995725 - Disclosure - Stockholders Equity and Stock Options - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail</Role>
      <ShortName>Stockholders Equity and Stock Options - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="lrmr-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995735 - Disclosure - Stockholders Equity and Stock Options - Assumptions used to Determine Fair Value of Stock Options Granted (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsAssumptionsUsedToDetermineFairValueOfStockOptionsGrantedDetail</Role>
      <ShortName>Stockholders Equity and Stock Options - Assumptions used to Determine Fair Value of Stock Options Granted (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="lrmr-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995745 - Disclosure - Stockholders Equity and Stock Options - Summary of Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail</Role>
      <ShortName>Stockholders Equity and Stock Options - Summary of Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="lrmr-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995755 - Disclosure - Stockholders Equity and Stock Options - Summary of Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails</Role>
      <ShortName>Stockholders Equity and Stock Options - Summary of Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="lrmr-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995765 - Disclosure - Stockholders Equity and Stock Options - Summary of Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockbasedCompensationExpenseDetail</Role>
      <ShortName>Stockholders Equity and Stock Options - Summary of Stock-Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="lrmr-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995775 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="lrmr-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995785 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Lease Liabilities Due Under Lease Agreements (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail</Role>
      <ShortName>Commitments and Contingencies - Schedule of Maturities of Lease Liabilities Due Under Lease Agreements (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="lrmr-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995795 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="lrmr-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995805 - Disclosure - Income Taxes - Schedule of Domestic and Foreign Components of Loss Before Income Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfLossBeforeIncomeTaxesDetail</Role>
      <ShortName>Income Taxes - Schedule of Domestic and Foreign Components of Loss Before Income Taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="lrmr-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995815 - Disclosure - Income Taxes - Reconciliation of Federal Statutory Income Tax Rate (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail</Role>
      <ShortName>Income Taxes - Reconciliation of Federal Statutory Income Tax Rate (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="lrmr-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995825 - Disclosure - Income Taxes - Schedule of Net Deferred Tax Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail</Role>
      <ShortName>Income Taxes - Schedule of Net Deferred Tax Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="lrmr-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995835 - Disclosure - Income Taxes - Summary of Changes in the Valuation Allowance for Deferred Tax Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfChangesInValuationAllowanceForDeferredTaxAssetsDetail</Role>
      <ShortName>Income Taxes - Summary of Changes in the Valuation Allowance for Deferred Tax Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="lrmr-20231231.htm">lrmr-20231231.htm</File>
    <File>lrmr-20231231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img131876768_0.jpg</File>
    <File>img131876768_1.jpg</File>
    <File>img131876768_10.jpg</File>
    <File>img131876768_11.jpg</File>
    <File>img131876768_12.jpg</File>
    <File>img131876768_13.jpg</File>
    <File>img131876768_14.jpg</File>
    <File>img131876768_2.jpg</File>
    <File>img131876768_3.jpg</File>
    <File>img131876768_4.jpg</File>
    <File>img131876768_5.jpg</File>
    <File>img131876768_6.jpg</File>
    <File>img131876768_7.jpg</File>
    <File>img131876768_8.jpg</File>
    <File>img131876768_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="491">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="40">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>82
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "lrmr-20231231.htm": {
   "nsprefix": "lrmr",
   "nsuri": "http://www.larimartx.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "lrmr-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "lrmr-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    }
   },
   "keyStandard": 255,
   "keyCustom": 44,
   "axisStandard": 24,
   "axisCustom": 0,
   "memberStandard": 31,
   "memberCustom": 27,
   "hidden": {
    "total": 13,
    "http://xbrl.sec.gov/dei/2023": 3,
    "http://fasb.org/us-gaap/2023": 10
   },
   "contextCount": 141,
   "entityCount": 1,
   "segmentCount": 58,
   "elementCount": 570,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 491,
    "http://xbrl.sec.gov/dei/2023": 40,
    "http://xbrl.sec.gov/ecd/2023": 4
   },
   "report": {
    "R1": {
     "role": "http://www.larimartx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_888f9f57-5a7b-41a2-9fd9-4778351dfedb",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_888f9f57-5a7b-41a2-9fd9-4778351dfedb",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "100030 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_888f9f57-5a7b-41a2-9fd9-4778351dfedb",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R4": {
     "role": "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "100040 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.larimartx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity",
     "longName": "100050 - Statement - Consolidated Statements of Changes in Stockholders' Equity",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_cb46581b-8c63-4fee-b4c7-cc9ee9a93a21",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cb46581b-8c63-4fee-b4c7-cc9ee9a93a21",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
     "longName": "100060 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_f1669ee1-0407-437f-848e-7c1d63a35e33",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1669ee1-0407-437f-848e-7c1d63a35e33",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.larimartx.com/20231231/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganization",
     "longName": "995455 - Disclosure - Description of Business and Organization",
     "shortName": "Description of Business and Organization",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "995465 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecurities1",
     "longName": "995475 - Disclosure - Fair Value Measurements and Cash Equivalents/Marketable Securities",
     "shortName": "Fair Value Measurements and Cash Equivalents/Marketable Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets",
     "longName": "995485 - Disclosure - Prepaid Expenses and Other Current Assets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "lrmr:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "lrmr:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureFixedAssets",
     "longName": "995495 - Disclosure - Fixed Assets",
     "shortName": "Fixed Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureAccruedExpenses",
     "longName": "995505 - Disclosure - Accrued Expenses",
     "shortName": "Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptions",
     "longName": "995515 - Disclosure - Stockholders\u2019 Equity and Stock Options",
     "shortName": "Stockholders\u2019 Equity and Stock Options",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingencies",
     "longName": "995525 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "longName": "995535 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995555 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesTables",
     "longName": "995565 - Disclosure - Fair Value Measurements and Cash Equivalents/Marketable Securities (Tables)",
     "shortName": "Fair Value Measurements and Cash Equivalents/Marketable Securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables",
     "longName": "995575 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "lrmr:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "lrmr:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "lrmr:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "lrmr:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureFixedAssetsTables",
     "longName": "995585 - Disclosure - Fixed Assets (Tables)",
     "shortName": "Fixed Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesTables",
     "longName": "995595 - Disclosure - Accrued Expenses (Tables)",
     "shortName": "Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsTables",
     "longName": "995605 - Disclosure - Stockholders\u2019 Equity and Stock Options (Tables)",
     "shortName": "Stockholders\u2019 Equity and Stock Options (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables",
     "longName": "995615 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "longName": "995625 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.larimartx.com/20231231/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail",
     "longName": "995635 - Disclosure - Description of Business and Organization - Additional Information (Detail)",
     "shortName": "Description of Business and Organization - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_888f9f57-5a7b-41a2-9fd9-4778351dfedb",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LiabilityReserveEstimatePolicy",
       "div",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
     "longName": "995645 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "lrmr:LikelihoodPercentageMinimum",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "lrmr:LikelihoodPercentageMinimum",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesAdditionalInformationDetail",
     "longName": "995655 - Disclosure - Fair Value Measurements and Cash Equivalents/Marketable Securities - Additional Information (Detail)",
     "shortName": "Fair Value Measurements and Cash Equivalents/Marketable Securities - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_888f9f57-5a7b-41a2-9fd9-4778351dfedb",
      "name": "us-gaap:InterestReceivable",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_888f9f57-5a7b-41a2-9fd9-4778351dfedb",
      "name": "us-gaap:InterestReceivable",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail",
     "longName": "995665 - Disclosure - Fair Value Measurements and Cash Equivalents/Marketable Securities - Summary of Cash Equivalents and Marketable Securities (Detail)",
     "shortName": "Fair Value Measurements and Cash Equivalents/Marketable Securities - Summary of Cash Equivalents and Marketable Securities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_888f9f57-5a7b-41a2-9fd9-4778351dfedb",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_888f9f57-5a7b-41a2-9fd9-4778351dfedb",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail",
     "longName": "995675 - Disclosure - Fair Value Measurements and Cash Equivalents/Marketable Securities - Summary of Marketable Securities (Detail)",
     "shortName": "Fair Value Measurements and Cash Equivalents/Marketable Securities - Summary of Marketable Securities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_888f9f57-5a7b-41a2-9fd9-4778351dfedb",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_888f9f57-5a7b-41a2-9fd9-4778351dfedb",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail",
     "longName": "995685 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail)",
     "shortName": "Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_888f9f57-5a7b-41a2-9fd9-4778351dfedb",
      "name": "lrmr:PrepaidResearchAndDevelopmentExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "lrmr:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "div",
       "lrmr:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_888f9f57-5a7b-41a2-9fd9-4778351dfedb",
      "name": "lrmr:PrepaidResearchAndDevelopmentExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "lrmr:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "div",
       "lrmr:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail",
     "longName": "995695 - Disclosure - Fixed Assets - Schedule of Fixed Assets, Net (Detail)",
     "shortName": "Fixed Assets - Schedule of Fixed Assets, Net (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_888f9f57-5a7b-41a2-9fd9-4778351dfedb",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_888f9f57-5a7b-41a2-9fd9-4778351dfedb",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureFixedAssetsAdditionalInformationDetail",
     "longName": "995705 - Disclosure - Fixed Assets - Additional Information (Detail)",
     "shortName": "Fixed Assets - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "lrmr:DepreciationExpenseExcludingLeasedAssets",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "lrmr:DepreciationExpenseExcludingLeasedAssets",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail",
     "longName": "995715 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)",
     "shortName": "Accrued Expenses - Schedule of Accrued Expenses (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_888f9f57-5a7b-41a2-9fd9-4778351dfedb",
      "name": "lrmr:AccruedResearchAndDevelopmentExpenseCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_888f9f57-5a7b-41a2-9fd9-4778351dfedb",
      "name": "lrmr:AccruedResearchAndDevelopmentExpenseCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
     "longName": "995725 - Disclosure - Stockholders Equity and Stock Options - Additional Information (Detail)",
     "shortName": "Stockholders Equity and Stock Options - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_888f9f57-5a7b-41a2-9fd9-4778351dfedb",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:CommonStockVotingRights",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsAssumptionsUsedToDetermineFairValueOfStockOptionsGrantedDetail",
     "longName": "995735 - Disclosure - Stockholders Equity and Stock Options - Assumptions used to Determine Fair Value of Stock Options Granted (Detail)",
     "shortName": "Stockholders Equity and Stock Options - Assumptions used to Determine Fair Value of Stock Options Granted (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail",
     "longName": "995745 - Disclosure - Stockholders Equity and Stock Options - Summary of Stock Option Activity (Detail)",
     "shortName": "Stockholders Equity and Stock Options - Summary of Stock Option Activity (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_cf75de90-0aaa-46d6-bc15-445c359ea784",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails",
     "longName": "995755 - Disclosure - Stockholders Equity and Stock Options - Summary of Restricted Stock Units (Details)",
     "shortName": "Stockholders Equity and Stock Options - Summary of Restricted Stock Units (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_79fb8102-e267-43bc-9f8f-f08e3d54c866",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_79fb8102-e267-43bc-9f8f-f08e3d54c866",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockbasedCompensationExpenseDetail",
     "longName": "995765 - Disclosure - Stockholders Equity and Stock Options - Summary of Stock-Based Compensation Expense (Detail)",
     "shortName": "Stockholders Equity and Stock Options - Summary of Stock-Based Compensation Expense (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
     "longName": "995775 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_888f9f57-5a7b-41a2-9fd9-4778351dfedb",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_888f9f57-5a7b-41a2-9fd9-4778351dfedb",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail",
     "longName": "995785 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Lease Liabilities Due Under Lease Agreements (Detail)",
     "shortName": "Commitments and Contingencies - Schedule of Maturities of Lease Liabilities Due Under Lease Agreements (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_888f9f57-5a7b-41a2-9fd9-4778351dfedb",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_888f9f57-5a7b-41a2-9fd9-4778351dfedb",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
     "longName": "995795 - Disclosure - Income Taxes - Additional Information (Detail)",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfLossBeforeIncomeTaxesDetail",
     "longName": "995805 - Disclosure - Income Taxes - Schedule of Domestic and Foreign Components of Loss Before Income Taxes (Detail)",
     "shortName": "Income Taxes - Schedule of Domestic and Foreign Components of Loss Before Income Taxes (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail",
     "longName": "995815 - Disclosure - Income Taxes - Reconciliation of Federal Statutory Income Tax Rate (Detail)",
     "shortName": "Income Taxes - Reconciliation of Federal Statutory Income Tax Rate (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail",
     "longName": "995825 - Disclosure - Income Taxes - Schedule of Net Deferred Tax Assets (Detail)",
     "shortName": "Income Taxes - Schedule of Net Deferred Tax Assets (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_888f9f57-5a7b-41a2-9fd9-4778351dfedb",
      "name": "us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_888f9f57-5a7b-41a2-9fd9-4778351dfedb",
      "name": "lrmr:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfChangesInValuationAllowanceForDeferredTaxAssetsDetail",
     "longName": "995835 - Disclosure - Income Taxes - Summary of Changes in the Valuation Allowance for Deferred Tax Assets (Detail)",
     "shortName": "Income Taxes - Summary of Changes in the Valuation Allowance for Deferred Tax Assets (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_cf75de90-0aaa-46d6-bc15-445c359ea784",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2066b280-00da-4f34-bd69-b3d154d32fd8",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20231231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity of Counterparty, Type",
        "label": "Legal Entity of Counterparty, Type [Axis]",
        "documentation": "Information by legal entity of counterparty. A counterparty is the other party that participates in a financial transaction."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureAccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "totalLabel": "Accounts Payable, Current, Total",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r645"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Accrued Liabilities, Current",
        "totalLabel": "Total accrued expenses and other current liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "lrmr_AccruedResearchAndDevelopmentExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "AccruedResearchAndDevelopmentExpenseCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued research and development expenses",
        "label": "Accrued Research And Development Expense Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for expenses related to research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r127",
      "r489"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accumulated other comprehensive gain (loss)",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "terseLabel": "Accumulated other comprehensive loss",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r71",
      "r130",
      "r485",
      "r505",
      "r506"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Loss [Member]",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r11",
      "r24",
      "r386",
      "r389",
      "r429",
      "r501",
      "r502",
      "r756",
      "r757",
      "r758",
      "r765",
      "r766",
      "r767"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "lrmr_AdditionalOfficeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "AdditionalOfficeMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Office [Member]",
        "label": "Additional Office [Member]",
        "documentation": "Additional office."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance",
        "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital [Member]",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r516",
      "r765",
      "r766",
      "r767",
      "r818",
      "r841"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r298"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_AggregateGrossSalesProceedsUnderSalesAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "AggregateGrossSalesProceedsUnderSalesAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Aggregate sale of shares of our common stock",
        "label": "Aggregate Gross Sales Proceeds Under Sales Agreement",
        "documentation": "The potential aggregate gross sales proceeds available under a sales agreement to sell shares of the Company's common stock.",
        "terseLabel": "Aggregate sale of shares of our common stock"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r669",
      "r681",
      "r691",
      "r717"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r672",
      "r684",
      "r694",
      "r720"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r676",
      "r685",
      "r695",
      "r712",
      "r721",
      "r725",
      "r733"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r731"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockbasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r338"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment",
        "verboseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of discount on marketable securities",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r51",
      "r77",
      "r269"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total potentially dilutive shares",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "lrmr_AreaOfOfficeSpace": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "AreaOfOfficeSpace",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Area of office space",
        "label": "Area Of Office Space",
        "documentation": "Area of office space."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Asset Impairment Charges, Total",
        "label": "Asset Impairment Charges",
        "terseLabel": "Impairment losses on investment",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r35"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r129",
      "r150",
      "r180",
      "r189",
      "r191",
      "r229",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r375",
      "r379",
      "r407",
      "r481",
      "r548",
      "r645",
      "r658",
      "r781",
      "r782",
      "r825"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r131",
      "r150",
      "r229",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r375",
      "r379",
      "r407",
      "r645",
      "r781",
      "r782",
      "r825"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents and marketable debt securities",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total cash equivalents and marketable securities",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "lrmr_AtTheMarketEquityDistributionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "AtTheMarketEquityDistributionAgreementMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At the market equity distribution agreement.",
        "label": "At The Market Equity Distribution Agreement [Member]",
        "terseLabel": "At The Market Equity Distribution Agreement [Member]",
        "verboseLabel": "Prior ATM Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_AtTheMarketEquityOfferingProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "AtTheMarketEquityOfferingProgramMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ATM Offering Program [Member]",
        "label": "At The Market Equity Offering Program [Member]",
        "documentation": "At-the-market equity offering program."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r663",
      "r664",
      "r677"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r663",
      "r664",
      "r677"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r663",
      "r664",
      "r677"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r244",
      "r480"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair Value",
        "label": "Debt Securities, Available-for-Sale, Current",
        "totalLabel": "Debt Securities, Available-for-sale, Current, Total",
        "terseLabel": "Marketable securities",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r244"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r300",
      "r301",
      "r302",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Acquiree",
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r637",
      "r638"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition",
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49",
      "r370",
      "r637",
      "r638"
     ]
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganization"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of Business and Basis of Presentation",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r82",
      "r83"
     ]
    },
    "lrmr_CapitalizedResearchAndDevelopmentAmortizationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "CapitalizedResearchAndDevelopmentAmortizationPeriod",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized research and development amortization period",
        "label": "Capitalized Research and Development Amortization Period",
        "documentation": "Amortization period for capitalized research and development costs, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r125",
      "r619"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "lrmr_CashAndNonCashOperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "CashAndNonCashOperatingLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease expense",
        "label": "Cash and Non Cash Operating Lease Expense",
        "documentation": "The amount of lease expense, both cash and non-cash, related to operating leases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash, Cash Equivalents, and Short-Term Investments, Total",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash, cash equivalents and marketable securities",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r79",
      "r147"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r79"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]",
        "documentation": "Indicates (true false) whether accounting standards update was adopted."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r119",
      "r120",
      "r157",
      "r195",
      "r196",
      "r230",
      "r231",
      "r232",
      "r235",
      "r236",
      "r251",
      "r359",
      "r371",
      "r372",
      "r381",
      "r382",
      "r383",
      "r393",
      "r394",
      "r400",
      "r405",
      "r406",
      "r408",
      "r409",
      "r410",
      "r418",
      "r419",
      "r420",
      "r421",
      "r428",
      "r474",
      "r475",
      "r499",
      "r500"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date",
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r119",
      "r120",
      "r195",
      "r196",
      "r230",
      "r231",
      "r232",
      "r235",
      "r236",
      "r237",
      "r251",
      "r359",
      "r371",
      "r372",
      "r373",
      "r381",
      "r382",
      "r383",
      "r384",
      "r393",
      "r394",
      "r395",
      "r396",
      "r400",
      "r405",
      "r406",
      "r408",
      "r409",
      "r410",
      "r418",
      "r419",
      "r420",
      "r421",
      "r428",
      "r474",
      "r475",
      "r499",
      "r500",
      "r742"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]",
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r158",
      "r168",
      "r234",
      "r362"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "lrmr_ChondrialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "ChondrialMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chondrial [Member]",
        "label": "Chondrial [Member]",
        "documentation": "Chondrial."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants exercise price",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Warrant exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of warrants",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "verboseLabel": "Warrant issued",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial Paper [Member]",
        "label": "Commercial Paper [Member]",
        "verboseLabel": "Commercial paper (due within 1 year) [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r651",
      "r652",
      "r653",
      "r654"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (See Note 8)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r54",
      "r482",
      "r535"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r253",
      "r254",
      "r605",
      "r779"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r647",
      "r648",
      "r649",
      "r651",
      "r652",
      "r653",
      "r654",
      "r765",
      "r766",
      "r818",
      "r839",
      "r841"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, par value",
        "terseLabel": "Common stock, par value per share",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r536"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, shares issued",
        "terseLabel": "Common stock, shares issued",
        "label": "Common Stock, Shares, Issued",
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r65",
      "r536",
      "r554",
      "r841",
      "r842"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.001 par value per share; 115,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 43,909,069 and 43,269,200 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively",
        "label": "Common Stock, Value, Issued",
        "totalLabel": "Common Stock, Value, Issued, Total",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r484",
      "r645"
     ]
    },
    "us-gaap_CommonStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockVotingRights",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock voting rights",
        "label": "Common Stock, Voting Rights",
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r134",
      "r136",
      "r141",
      "r476",
      "r495"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Comprehensive loss:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Gain (Loss)",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer Equipment [Member]",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentrations of Credit Risk and Significant Suppliers",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r108"
     ]
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities",
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "auth_ref": [
      "r153",
      "r375",
      "r376",
      "r379",
      "r380",
      "r436",
      "r615",
      "r780",
      "r783",
      "r784"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities",
        "label": "Consolidated Entities [Domain]"
       }
      }
     },
     "auth_ref": [
      "r153",
      "r375",
      "r376",
      "r379",
      "r380",
      "r436",
      "r615",
      "r780",
      "r783",
      "r784"
     ]
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateBondSecuritiesMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate Bonds [Member]",
        "label": "Corporate Bond Securities [Member]",
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount)."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for credit loss",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss",
        "periodEndLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Ending Balance",
        "periodStartLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Beginning Balance",
        "totalLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Total",
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r244",
      "r248",
      "r249"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities Available For Sale [Table]",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "totalLabel": "Deferred Tax Liabilities, Gross, Total",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r99",
      "r353"
     ]
    },
    "lrmr_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Capitalized Research and Development Costs",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development costs.",
        "terseLabel": "Capitalized R&amp;D - Section 174 Costs post 2021"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_DeferredTaxAssetsFixedAssetsAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "DeferredTaxAssetsFixedAssetsAndIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed assets &amp; intangibles",
        "label": "Deferred Tax Assets Fixed Assets And Intangible Assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible fixed assets and intangible assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGrossAbstract",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized R&amp;D - acquired in merger with Zafgen",
        "verboseLabel": "Net capitalized R&amp;D deferred tax assets",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r816"
     ]
    },
    "lrmr_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net deferred tax assets before the valuation allowance",
        "label": "Deferred Tax Assets Net Of Liabilities Before Valuation Allowance",
        "documentation": "Amount, after allocation of deferred tax liability but before allocation of valuation allowances, of deferred tax asset attributable to deductible differences and carryforwards."
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability",
        "label": "Deferred Tax Assets Operating Lease Liabilities",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r816"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other temporary differences",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r816"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforwards",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "totalLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Total",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r47",
      "r816"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r816"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accruals &amp; reserves",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves, classified as other."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r816"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfChangesInValuationAllowanceForDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Valuation allowance at end of year",
        "negatedLabel": "Less: Valuation allowance",
        "periodStartLabel": "Valuation allowance as of the beginning of the year",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Deferred Tax Liabilities, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Operating right of use asset",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r816"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation",
        "totalLabel": "Depreciation, Total",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r36"
     ]
    },
    "lrmr_DepreciationExpenseExcludingLeasedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "DepreciationExpenseExcludingLeasedAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureFixedAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation Expense Excluding Leased Assets",
        "documentation": "The amount of depreciation expenses recognized in the period, excluding depreciation for leased assets as part of a sublease agreement."
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_DepreciationExpensesRelatedToSubletAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "DepreciationExpensesRelatedToSubletAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureFixedAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of depreciation expense recognized in the period related to leased assets as part of a sublease agreement.",
        "label": "Depreciation Expenses Related to Sublet Assets",
        "terseLabel": "Depreciation expenses related to sublet assets"
       }
      }
     },
     "auth_ref": []
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "DirectorMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Director [Member]",
        "label": "Director [Member]"
       }
      }
     },
     "auth_ref": [
      "r769",
      "r840"
     ]
    },
    "us-gaap_DividendsPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend paid",
        "label": "Dividends Payable",
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61",
      "r100",
      "r655",
      "r836"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r663",
      "r664",
      "r677"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r663",
      "r664",
      "r677",
      "r713"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "lrmr_DomesticAndStateLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "DomesticAndStateLocalJurisdictionMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Domestic and state local jurisdiction.",
        "label": "Domestic And State Local Jurisdiction [Member]",
        "terseLabel": "Federal and State [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarliestTaxYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarliestTaxYearMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earliest Tax Year [Member]",
        "label": "Earliest Tax Year [Member]",
        "documentation": "Earliest identified tax year."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, basic",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r170",
      "r172",
      "r174",
      "r175",
      "r176",
      "r178",
      "r398",
      "r399",
      "r477",
      "r496",
      "r623"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, diluted",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r172",
      "r174",
      "r175",
      "r176",
      "r178",
      "r398",
      "r399",
      "r477",
      "r496",
      "r623"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal statutory income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r346",
      "r366"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in deferred tax asset valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r814",
      "r817"
     ]
    },
    "lrmr_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to a change in the state tax rate.",
        "terseLabel": "Change in state tax rate",
        "label": "Effective Income Tax Rate Reconciliation Change in State Tax Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nondeductible permanent differences",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent, Total",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r814",
      "r817"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State taxes, net of federal benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r814",
      "r817"
     ]
    },
    "lrmr_EffectiveIncomeTaxRateReconciliationStockCompensationForfeituresPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationStockCompensationForfeituresPercent",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deferred tax asset write-offs from stock compensation forfeitures.",
        "terseLabel": "Stock compensation forfeitures - DTA Write Off",
        "label": "Effective Income Tax Rate Reconciliation, Stock Compensation Forfeitures, percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Federal and state research and development tax credit",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "terseLabel": "Federal and state research and development tax credit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r814",
      "r817"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued payroll and related expenses",
        "label": "Employee-related Liabilities, Current",
        "totalLabel": "Employee-related Liabilities, Current, Total",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense recognized period",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_EmployeesAndDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "EmployeesAndDirectorsMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employees and Directors [Member]",
        "label": "Employees and Directors [Member]",
        "documentation": "Employees and directors."
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_EmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "EmployeesMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employees [Member]",
        "label": "Employees [Member]",
        "documentation": "Employees."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation State Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "lrmr_EquipmentFurnitureAndFixturesAndOfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "EquipmentFurnitureAndFixturesAndOfficeEquipmentMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equipment, Furniture and Fixtures and Office Equipment [Member]",
        "label": "Equipment Furniture And Fixtures And Office Equipment [Member]",
        "documentation": "Equipment, furniture and fixtures and office equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquipmentMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab Equipment [Member]",
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r121",
      "r138",
      "r139",
      "r140",
      "r154",
      "r155",
      "r156",
      "r159",
      "r165",
      "r167",
      "r179",
      "r233",
      "r238",
      "r286",
      "r331",
      "r332",
      "r333",
      "r360",
      "r361",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r397",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r429",
      "r501",
      "r502",
      "r503",
      "r516",
      "r578"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r669",
      "r681",
      "r691",
      "r717"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r666",
      "r678",
      "r688",
      "r714"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r403",
      "r404"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r403",
      "r404"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]",
        "terseLabel": "Summary of Cash Equivalents and Marketable Securities",
        "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r97"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r403",
      "r441",
      "r442",
      "r443",
      "r630",
      "r631",
      "r634",
      "r635",
      "r636"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecurities1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements and Cash Equivalents/Marketable Securities",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Quoted Prices in Active Markets, (Level 1) [Member]",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r288",
      "r293",
      "r403",
      "r441",
      "r634",
      "r635",
      "r636"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Other Observable Inputs (Level 2) [Member]",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r288",
      "r293",
      "r403",
      "r442",
      "r630",
      "r631",
      "r634",
      "r635",
      "r636"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Unobservable Inputs (Level 3) [Member]",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r403",
      "r443",
      "r630",
      "r631",
      "r634",
      "r635",
      "r636"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r441",
      "r442",
      "r443",
      "r630",
      "r631",
      "r634",
      "r635",
      "r636"
     ]
    },
    "lrmr_FinalSubleaseYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "FinalSubleaseYearMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Final Sublease Year [Member]",
        "label": "Final Sublease Year [Member]",
        "documentation": "Final sublease year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r245",
      "r246",
      "r247",
      "r270",
      "r283",
      "r391",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r494",
      "r628",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r771",
      "r772",
      "r773",
      "r774"
     ]
    },
    "lrmr_FirstAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "FirstAnniversaryMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Anniversary [Member]",
        "label": "First Anniversary [Member]",
        "documentation": "First anniversary."
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_FirstSubleaseYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "FirstSubleaseYearMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Sublease Year [Member]",
        "label": "First Sublease Year [Member]",
        "documentation": "First sublease year member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Tax Authority [Member]",
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r673",
      "r685",
      "r695",
      "r721"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r673",
      "r685",
      "r695",
      "r721"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r673",
      "r685",
      "r695",
      "r721"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r673",
      "r685",
      "r695",
      "r721"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r673",
      "r685",
      "r695",
      "r721"
     ]
    },
    "lrmr_FromExerciseOfWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "FromExerciseOfWarrantsMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "From Exercise of Warrants [Member]",
        "documentation": "From exercise of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_FromPriorPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "FromPriorPlansMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "From Prior Plans [Member]",
        "label": "From Prior Plans [Member]",
        "documentation": "From Prior Plans [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and Fixtures [Member]",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnDispositionOfAssets1",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gain (Loss) on Disposition of Assets, Total",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedLabel": "Gain on disposal of fixed asset",
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee."
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "totalLabel": "General and Administrative Expense, Total",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r558"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockbasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative [Member]",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IPOMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "terseLabel": "IPO [Member]",
        "verboseLabel": "Public Offering [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r663",
      "r664",
      "r677"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r87"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfLossBeforeIncomeTaxesDetail": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfLossBeforeIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r365"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfLossBeforeIncomeTaxesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfLossBeforeIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r72",
      "r102",
      "r180",
      "r188",
      "r190",
      "r192",
      "r478",
      "r491",
      "r625"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfLossBeforeIncomeTaxesDetail": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfLossBeforeIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r365"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockbasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r252",
      "r563"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockbasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r563"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority",
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r341",
      "r347",
      "r350",
      "r357",
      "r363",
      "r367",
      "r368",
      "r369",
      "r511"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax benefit",
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Income Tax Expense (Benefit), Total",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r118",
      "r166",
      "r167",
      "r181",
      "r345",
      "r364",
      "r497"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r343",
      "r344",
      "r350",
      "r351",
      "r356",
      "r358",
      "r508"
     ]
    },
    "lrmr_IncomeTaxesDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "IncomeTaxesDisclosureLineItems",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfChangesInValuationAllowanceForDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes Disclosure [Line Items]",
        "label": "Income Taxes Disclosure [Line Items]",
        "documentation": "Income Taxes Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_IncomeTaxesDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "IncomeTaxesDisclosureTable",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfChangesInValuationAllowanceForDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes Disclosure [Table]",
        "label": "Income Taxes Disclosure [Table]",
        "documentation": "Income Taxes Disclosure [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "lrmr_IndianaUniversityResearchAndTechnologyCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "IndianaUniversityResearchAndTechnologyCorporationMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indiana University Research and Technology Corporation.",
        "label": "Indiana University Research And Technology Corporation [Member]",
        "terseLabel": "IU [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r676",
      "r685",
      "r695",
      "r712",
      "r721",
      "r725",
      "r733"
     ]
    },
    "lrmr_InducementStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "InducementStockMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inducement Stock [Member]",
        "documentation": "Inducement Stock."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r731"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r665",
      "r737"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r665",
      "r737"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r665",
      "r737"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patent Costs",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r469",
      "r470",
      "r471",
      "r473",
      "r621"
     ]
    },
    "us-gaap_InterestReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Receivable",
        "terseLabel": "Accrued interest receivable",
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable."
       }
      }
     },
     "auth_ref": [
      "r754",
      "r843"
     ]
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment Type",
        "label": "Investment Type [Axis]",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r520",
      "r521",
      "r523",
      "r525",
      "r585",
      "r587",
      "r589",
      "r592",
      "r593",
      "r594",
      "r595",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r649"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investments [Domain]",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r520",
      "r521",
      "r523",
      "r525",
      "r585",
      "r587",
      "r589",
      "r592",
      "r593",
      "r594",
      "r595",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r649"
     ]
    },
    "lrmr_Ircsection174Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "Ircsection174Member",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IRC Section 174 [Member]",
        "label": "IRCSection174 [Member]",
        "documentation": "IRCSection174."
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_LabSpaceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "LabSpaceMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lab Space [Member]",
        "documentation": "Lab space."
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory Equipment [Member]",
        "label": "Laboratory Equipment [Member]",
        "documentation": "Laboratory equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Contractual Term",
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Contractual Term",
        "label": "Lease Contractual Term [Domain]",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "us-gaap_LeaseExpirationDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseExpirationDate1",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease term expiration date",
        "label": "Lease Expiration Date",
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_LeaseTermCommencementDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "LeaseTermCommencementDate",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease term commencement date",
        "label": "Lease Term Commencement Date",
        "documentation": "Lease term commencement date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalEntityTypeOfCounterpartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LegalEntityTypeOfCounterpartyDomain",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity Type of Counterparty [Domain]",
        "documentation": "Nature of the other party participating in a financial transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturities of Lease Liabilities Due Under Lease Agreements",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease extension period",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease term",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "us-gaap_LetterOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LetterOfCreditMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Letter of Credit [Member]",
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r150",
      "r229",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r376",
      "r379",
      "r380",
      "r407",
      "r534",
      "r624",
      "r658",
      "r781",
      "r825",
      "r826"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders' equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r101",
      "r487",
      "r645",
      "r763",
      "r775",
      "r819"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and Stockholders' Equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r124",
      "r150",
      "r229",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r376",
      "r379",
      "r380",
      "r407",
      "r645",
      "r781",
      "r825",
      "r826"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityReserveEstimatePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityReserveEstimatePolicy",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liquidity and Capital Resources",
        "label": "Liability Reserve Estimate, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for estimating its liability as of the balance sheet date for the ultimate cost of settling reported and unreported claims incurred and claims adjustment expenses (including effects of inflation and other societal and economic factors)."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "lrmr_LicenseAgreementConsiderationDeductionPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "LicenseAgreementConsiderationDeductionPercentage",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License agreement consideration deduction percentage",
        "label": "License Agreement Consideration Deduction Percentage",
        "documentation": "The amount that may be deducted from consideration due to Licensor 2 as a percentage of consideration paid to Licensor 1, whereby Licensor 1 is the identified party."
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_LikelihoodPercentageMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "LikelihoodPercentageMinimum",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of likelihood to be realized upon ultimate settlement, description",
        "label": "Likelihood Percentage Minimum",
        "documentation": "The minimum likelihood percentage threshold used to determine the amount of tax benefit to be recognized."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "country_MA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "MA",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Massachusetts [Member]",
        "label": "MOROCCO"
       }
      }
     },
     "auth_ref": []
    },
    "stpr_MA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "localname": "MA",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Massachusetts [Member]",
        "label": "MASSACHUSETTS"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_MTSHealthPartnersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "MTSHealthPartnersMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MTS Health Partners [Member]",
        "label": "M T S Health Partners [Member]",
        "documentation": "MTS Health Partners."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r255",
      "r256",
      "r257",
      "r258",
      "r294",
      "r468",
      "r498",
      "r526",
      "r527",
      "r586",
      "r588",
      "r590",
      "r591",
      "r596",
      "r616",
      "r617",
      "r627",
      "r632",
      "r639",
      "r646",
      "r785",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "lrmr_MergerAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "MergerAgreementMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger Agreement [Member]",
        "label": "Merger Agreement [Member]",
        "documentation": "The number of common stock shares issued in exchange for one share of the other company's common stock as part of a merger agreement."
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_MilestoneExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "MilestoneExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone expenses",
        "label": "Milestone Expenses",
        "documentation": "The amount of expense recognized during the period related to milestones. Such amount may include, but is not limited to, amounts due for attainment of milestones as well as deductions granted as part of a license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_MilestoneLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "MilestoneLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payments due",
        "label": "Milestone Liability",
        "documentation": "Amount of payment due for milestones that have been achieved"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_MilestonePaymentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "MilestonePaymentAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payments",
        "label": "Milestone Payment Amount",
        "documentation": "Amount of payment due upon reaching milestone."
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_MinimumAnnualRoyaltyObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "MinimumAnnualRoyaltyObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual royalty pay obligation",
        "label": "Minimum Annual Royalty Obligation",
        "documentation": "The minimum annual royalty payment that is required under a contractual arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r255",
      "r256",
      "r257",
      "r258",
      "r294",
      "r468",
      "r498",
      "r526",
      "r527",
      "r586",
      "r588",
      "r590",
      "r591",
      "r596",
      "r616",
      "r617",
      "r627",
      "r632",
      "r639",
      "r646",
      "r785",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money Market Funds [Member]",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Real Estate, Type of Property [Axis]"
       }
      }
     },
     "auth_ref": [
      "r604",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614"
     ]
    },
    "srt_MortgageLoansOnRealEstateNamePropertyTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MortgageLoansOnRealEstateNamePropertyTypeDomain",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Real Estate [Domain]"
       }
      }
     },
     "auth_ref": [
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "lrmr_NetCapitalizedRDDeferredTaxAssetsRealizationDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "NetCapitalizedRDDeferredTaxAssetsRealizationDescription",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net capitalized R&amp;D deferred tax assets realization description",
        "label": "Net Capitalized R D Deferred Tax Assets Realization Description",
        "documentation": "Description of the limitation that a capitalized research and development deferred tax asset may be subject to."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80",
      "r81"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.larimartx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "negatedLabel": "Net loss",
        "totalLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r81",
      "r103",
      "r122",
      "r132",
      "r135",
      "r140",
      "r150",
      "r158",
      "r160",
      "r161",
      "r162",
      "r163",
      "r166",
      "r167",
      "r173",
      "r180",
      "r188",
      "r190",
      "r192",
      "r229",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r399",
      "r407",
      "r493",
      "r556",
      "r576",
      "r577",
      "r625",
      "r656",
      "r781"
     ]
    },
    "lrmr_NetOperatingLossCarryForwardExpirationYearBegin": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "NetOperatingLossCarryForwardExpirationYearBegin",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards, beginning of expiration period",
        "label": "Net Operating Loss Carry Forward Expiration Year Begin",
        "documentation": "The first year in which a net operating loss carryforward begins to expire."
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_NetOperatingLossCarryforwardsAnnualUtilizationLimitChangeInOwnership": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "NetOperatingLossCarryforwardsAnnualUtilizationLimitChangeInOwnership",
     "crdr": "credit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The annual limitation amount of net operating loss carryforwards that can be utilized to offset taxable income due to changes in ownership.",
        "label": "Net Operating Loss Carryforwards Annual Utilization Limit Change In Ownership",
        "terseLabel": "Net operating loss carryforwards, change in ownership, annual utilization limit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Issued and Adopted Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_NoExpirationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "NoExpirationMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "No Expiration [Member]",
        "label": "No Expiration [Member]",
        "documentation": "No expiration."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r673",
      "r685",
      "r695",
      "r712",
      "r721"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense), net",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Nonoperating Income (Expense), Total",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "lrmr_OfficeAndLabMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "OfficeAndLabMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office and Lab.",
        "label": "Office And Lab [Member]",
        "terseLabel": "Office and Lab [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_OfficeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "OfficeMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office [Member]",
        "label": "Office [Member]",
        "documentation": "Office."
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_OfficeSubleaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "OfficeSubleaseMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office Sublease",
        "label": "Office Sublease [Member]",
        "terseLabel": "Office Sublease [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OpenTaxYear": {
     "xbrltype": "gYearListItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OpenTaxYear",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Open tax year",
        "label": "Open Tax Year",
        "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r188",
      "r190",
      "r192",
      "r625"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Lease expense",
        "terseLabel": "Lease expenses",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Present value of lease liabilities",
        "terseLabel": "Operating lease liability",
        "label": "Operating Lease, Liability",
        "totalLabel": "Operating Lease, Liability, Total",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, current",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r644"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term in years",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r644"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "totalLabel": "Operating Loss Carryforwards, Total",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLimitationsOnUse": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLimitationsOnUse",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards, description",
        "label": "Operating Loss Carryforwards, Limitations on Use",
        "documentation": "A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income."
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_OperatingLossCarryforwardsMinimumPercentageOfTaxableIncomeInTaxPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "OperatingLossCarryforwardsMinimumPercentageOfTaxableIncomeInTaxPeriod",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards, minimum percentage of taxable income in tax period",
        "label": "Operating Loss Carryforwards Minimum Percentage Of Taxable Income In Tax Period",
        "documentation": "The amount of limitation on operating loss carryforwards as a percentage of taxable income in any one tax period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "totalLabel": "Other Assets, Noncurrent, Total",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Line Items]",
        "label": "Other Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Table]",
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.larimartx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain (loss) on marketable securities",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent, Total",
        "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r10",
      "r96"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other comprehensive gain (loss)",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Total other comprehensive income",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r10",
      "r96",
      "r133",
      "r136"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive loss:",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "lrmr_OtherPrepaidExpenseAndOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "OtherPrepaidExpenseAndOtherCurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other prepaid expenses and other assets",
        "label": "Other Prepaid Expense And Other Current Assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, not separately disclosed."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r671",
      "r683",
      "r693",
      "r719"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r674",
      "r686",
      "r696",
      "r722"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r674",
      "r686",
      "r696",
      "r722"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Underwritten Public Offering [Member]",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "stpr_PA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "localname": "PA",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pennsylvania [Member]",
        "label": "PENNSYLVANIA"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_PaymentForLicenseAgreements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "PaymentForLicenseAgreements",
     "crdr": "credit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment for license agreements.",
        "label": "Payment For License Agreements",
        "terseLabel": "Payment for license agreements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedLabel": "Purchase of marketable securities",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r143",
      "r197"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "lrmr_PayrollTaxesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "PayrollTaxesReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payroll tax receivable",
        "label": "Payroll Taxes Receivable",
        "documentation": "Carrying amount as of the balance sheet date of payroll taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "lrmr_PercentageOfCompensationForServicesEqualToGrossProceeds": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "PercentageOfCompensationForServicesEqualToGrossProceeds",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Percentage of compensation for services equal to gross proceeds",
        "label": "Percentage Of Compensation For Services Equal To Gross Proceeds",
        "documentation": "The fee for services as a percentage of gross proceeds resulting from the sale of shares of common stock under a sales agreement."
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_PerformedInUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "PerformedInUsMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performed in US [Member]",
        "documentation": "Performed in US."
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_PerformedOutsideUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "PerformedOutsideUsMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performed outside US [Member]",
        "documentation": "Performed outside US."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Undesignated preferred stock, par value",
        "terseLabel": "Preferred stock, par value per share",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r272"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Undesignated preferred stock, shares authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r536"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Undesignated preferred stock, shares issued",
        "terseLabel": "Preferred stock, shares issued",
        "label": "Preferred Stock, Shares Issued",
        "totalLabel": "Preferred Stock, Shares Issued, Total",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r272"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Undesignated preferred stock, shares outstanding",
        "terseLabel": "Preferred stock, shares outstanding",
        "label": "Preferred Stock, Shares Outstanding",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r536",
      "r554",
      "r841",
      "r842"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock; $0.001 par value per share; 5,000,000 shares authorized as of December 31, 2023 and December 31, 2022; no shares issued and outstanding as of December 31, 2023 and December 31, 2022",
        "label": "Preferred Stock, Value, Issued",
        "totalLabel": "Preferred Stock, Value, Issued, Total",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r483",
      "r645"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "totalLabel": "Total prepaid expenses and other assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "lrmr_PrepaidExpensesAndOtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "PrepaidExpensesAndOtherCurrentAssetsTextBlock",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid Expenses and Other Current Assets",
        "label": "Prepaid Expenses And Other Current Assets [Text Block]",
        "documentation": "The entire disclosure for prepaid expenses and other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid insurance",
        "label": "Prepaid Insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r620",
      "r629",
      "r776"
     ]
    },
    "lrmr_PrepaidResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "PrepaidResearchAndDevelopmentExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid research and development expenses",
        "label": "Prepaid Research And Development Expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs related to research and development."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassification",
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error."
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "lrmr_PrivateOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "PrivateOfferingMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Offering [Member]",
        "label": "Private Offering [Member]",
        "documentation": "Private offering of securities, as part of a merger agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement [Member]",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_ProceedsFromExerciseOfStockOptionsAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "ProceedsFromExerciseOfStockOptionsAndWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of stock options and warrants",
        "label": "Proceeds From Exercise Of Stock Options And Warrants",
        "documentation": "The cash inflow from the exercise of options under share-based payment arrangements and exercise of stock warrants."
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_ProceedsFromExerciseOfStockOptionsIncludedInOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "ProceedsFromExerciseOfStockOptionsIncludedInOtherCurrentAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of stock options included in other current assets",
        "label": "Proceeds From Exercise Of Stock Options Included In Other Current Assets",
        "documentation": "Proceeds from exercise of stock options included in other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from issuance common stock and warrants net offering costs",
        "label": "Proceeds From Issuance Common Stock And Warrants Net Offering Costs",
        "documentation": "Proceeds from issuance of common stock and prefunded warrants to purchase common stock, net of offering costs.",
        "terseLabel": "Net proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "verboseLabel": "Proceeds from issuance of common stock",
        "terseLabel": "Proceeds from sale of common stock, net of issuance costs",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Gross proceeds",
        "label": "Proceeds from Issuance of Private Placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "totalLabel": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale, Total",
        "terseLabel": "Maturities and sales of marketable securities",
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144",
      "r770"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash proceeds from exercises of warrants",
        "label": "Proceeds from Warrant Exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r132",
      "r135",
      "r145",
      "r150",
      "r158",
      "r166",
      "r167",
      "r180",
      "r188",
      "r190",
      "r192",
      "r229",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r374",
      "r377",
      "r378",
      "r399",
      "r407",
      "r478",
      "r492",
      "r515",
      "r556",
      "r576",
      "r577",
      "r625",
      "r642",
      "r643",
      "r657",
      "r758",
      "r781"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureFixedAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed Assets",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r109",
      "r112",
      "r113"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "totalLabel": "Property, Plant and Equipment, Gross, Total",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "terseLabel": "Total property, plant and equipment",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r126",
      "r490"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "totalLabel": "Property, plant and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r479",
      "r490",
      "r645"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r109",
      "r112",
      "r488"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureFixedAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fixed Assets, Net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed assets, useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "verboseLabel": "Estimated useful life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]",
        "documentation": "Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value."
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r255",
      "r256",
      "r257",
      "r258",
      "r287",
      "r294",
      "r325",
      "r326",
      "r327",
      "r444",
      "r468",
      "r498",
      "r526",
      "r527",
      "r586",
      "r588",
      "r590",
      "r591",
      "r596",
      "r616",
      "r617",
      "r627",
      "r632",
      "r639",
      "r646",
      "r649",
      "r778",
      "r785",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r255",
      "r256",
      "r257",
      "r258",
      "r287",
      "r294",
      "r325",
      "r326",
      "r327",
      "r444",
      "r468",
      "r498",
      "r526",
      "r527",
      "r586",
      "r588",
      "r590",
      "r591",
      "r596",
      "r616",
      "r617",
      "r627",
      "r632",
      "r639",
      "r646",
      "r649",
      "r778",
      "r785",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r666",
      "r678",
      "r688",
      "r714"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction",
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r433",
      "r434",
      "r824"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction",
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Line Items]",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r559",
      "r560",
      "r563"
     ]
    },
    "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionPurchasesFromRelatedParty",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchased of equipment",
        "label": "Related Party Transaction, Purchases from Related Party",
        "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r431",
      "r432",
      "r434",
      "r435",
      "r512",
      "r513",
      "r514",
      "r561",
      "r562",
      "r563",
      "r582",
      "r584"
     ]
    },
    "lrmr_ResearchAndDevelopmentCostsCapitalized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "ResearchAndDevelopmentCostsCapitalized",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of research and development costs capitalized during the period.",
        "label": "Research And Development Costs Capitalized",
        "terseLabel": "Capitalization of research and development costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development expense",
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "totalLabel": "Research and Development Expense, Total",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r340",
      "r833"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockbasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development [Member]",
        "label": "Research and Development Expense [Member]",
        "verboseLabel": "Research and Development Expenses [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Costs",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r667",
      "r679",
      "r689",
      "r715"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r668",
      "r680",
      "r690",
      "r716"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r675",
      "r687",
      "r697",
      "r723"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Letter of credit",
        "label": "Restricted Cash",
        "totalLabel": "Restricted Cash, Total",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r752",
      "r762",
      "r834",
      "r837"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash, Noncurrent",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r753",
      "r762"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restricted Stock Units [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r91",
      "r486",
      "r504",
      "r506",
      "r510",
      "r537",
      "r645"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit [Member]",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r154",
      "r155",
      "r156",
      "r159",
      "r165",
      "r167",
      "r233",
      "r238",
      "r331",
      "r332",
      "r333",
      "r360",
      "r361",
      "r385",
      "r387",
      "r388",
      "r390",
      "r397",
      "r501",
      "r503",
      "r516",
      "r841"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leased assets obtained in exchange for new operating lease liabilities",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r644"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Consideration Received on Transaction",
        "verboseLabel": "Proceeds net of issuance costs",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_SalesAgreementDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "SalesAgreementDescription",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Sales agreement, description",
        "label": "Sales Agreement Description",
        "documentation": "Description of sales agreement.."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r169",
      "r295",
      "r740",
      "r768"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Available For Sale Securities [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Marketable Securities",
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Net Deferred Tax Assets",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Federal Statutory Income Tax Rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Stock-Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Domestic and Foreign Components of Loss Before Income Taxes",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "lrmr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets",
        "label": "Schedule Of Prepaid Expenses And Other Current Assets Table [Text Block]",
        "documentation": "Tabular disclosure of the carrying amounts of prepaid expenses and other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r53",
      "r559",
      "r560",
      "r563"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockbasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r41"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assumptions used to Determine Fair Value of Stock Options Granted",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Restricted Stock Units",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "us-gaap_SecurityDepositLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SecurityDepositLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Deposit Liability",
        "terseLabel": "Lease security deposits letters of credit",
        "documentation": "This element represents money paid in advance to protect the provider of a product or service, such as a lessor, against damage or nonpayment by the buyer or tenant (lessee) during the term of the agreement. Such damages may include physical damage to the property, theft of property, and other contractual breaches. Security deposits held may be interest or noninterest bearing."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r193",
      "r194",
      "r519",
      "r522",
      "r524",
      "r587",
      "r589",
      "r593",
      "r597",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r618",
      "r633",
      "r649",
      "r786",
      "r838"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r193",
      "r626"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Percentage of outstanding shares",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Additional Shares Percentage Of Outstanding Stock",
        "documentation": "The maximum number of shares that may be added annually to the threshold number of shares issued under the Plan, as a percentage of the shares issued and outstanding on the last day of the immediately preceding fiscal year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period of stock option",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of plan",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Duration",
        "documentation": "The term of the plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of shares, Restricted stock units forfeited",
        "terseLabel": "Number of shares, Restricted stock units forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value, Restricted stock units forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of shares, Restricted stock units granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Options to purchase shares of stock granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value, Restricted stock units granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of shares, Outstanding",
        "periodStartLabel": "Number of shares, Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r313"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted average grant date fair value, balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodStartLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Beginning Balance",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r313"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual term, Outstanding as of December 31, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, Unvested and expected to vest as of December 31, 2023",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options Unvested And Expected To Vest, Aggregate Intrinsic Value",
        "documentation": "Intrinsic value of awards that are unvested and expected to vest under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares, Unvested and expected to vest as of December 31, 2023",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options Unvested And Expected To Vest, Outstanding Number",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that are unvested and expected to vest as of the balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value, Unvested and expected to vest as of December 31, 2023",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options Unvested And Expected To Vest, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of awards that are unvested and expected to vest under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual term, Unvested and expected to vest as of December 31, 2023",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options Unvested And Expected To Vest, Weighted Average Remaining Contractual Terms",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options that are unvested and expected to vest, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsAssumptionsUsedToDetermineFairValueOfStockOptionsGrantedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsAssumptionsUsedToDetermineFairValueOfStockOptionsGrantedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsAssumptionsUsedToDetermineFairValueOfStockOptionsGrantedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockbasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Increase in shares reserved for future issuance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum number of shares that may be issued under stock option incentive plan",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "verboseLabel": "Minimum level of maximum number of shares allowed to be issued",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares available for grant",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares, Exercisable as of December 31, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Exercisable as of December 31, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of shares, Forfeited/Expired",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "totalLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Total",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Forfeited/Expired",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of shares, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options to purchase shares of common stock granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value of options granted",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, outstanding as of December 31, 2023",
        "periodStartLabel": "Aggregate intrinsic value, outstanding",
        "periodEndLabel": "Aggregate intrinsic value, outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of shares, Outstanding",
        "periodEndLabel": "Number of shares, Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r305"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, balance",
        "periodEndLabel": "Weighted average exercise price, balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r305"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, Vested and expected to vest as of December 31, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares, Vested and expected to vest as of December 31, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Vested and expected to vest as of December 31, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based compensation arrangement by share-based payment award, description",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award",
        "documentation": "Description of terms of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Threshold Number Of Shares Allowed To Issue",
        "documentation": "The minimum threshold number of shares used to determine the maximum number of shares that may be issued under the Plan.",
        "terseLabel": "Minimum level of maximum number of shares allowed to be issued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r300",
      "r301",
      "r302",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Exercised",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r309"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r296",
      "r303",
      "r322",
      "r323",
      "r324",
      "r325",
      "r328",
      "r334",
      "r335",
      "r336",
      "r337"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Award vesting",
        "terseLabel": "Stock option vesting percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, Outstanding as of December 31, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsAssumptionsUsedToDetermineFairValueOfStockOptionsGrantedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, exercisable as of December 31, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual term, Exercisable as of December 31, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual term, outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual term, Vested and expected to vest as of December 31, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price per share",
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, shares",
        "periodEndLabel": "Ending balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Axis]",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Domain]",
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r148"
     ]
    },
    "lrmr_SixthSubleaseYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "SixthSubleaseYearMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sixth sublease year member",
        "label": "Sixth Sublease Year [Member]",
        "terseLabel": "Sixth Sublease Year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r21",
      "r121",
      "r138",
      "r139",
      "r140",
      "r154",
      "r155",
      "r156",
      "r159",
      "r165",
      "r167",
      "r179",
      "r233",
      "r238",
      "r286",
      "r331",
      "r332",
      "r333",
      "r360",
      "r361",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r397",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r429",
      "r501",
      "r502",
      "r503",
      "r516",
      "r578"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r193",
      "r194",
      "r519",
      "r522",
      "r524",
      "r587",
      "r589",
      "r593",
      "r597",
      "r604",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r618",
      "r633",
      "r649",
      "r786",
      "r838"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r179",
      "r472",
      "r507",
      "r517",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r536",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r555",
      "r557",
      "r558",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r578",
      "r650"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r169",
      "r295",
      "r740",
      "r741",
      "r768"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r179",
      "r472",
      "r507",
      "r517",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r536",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r555",
      "r557",
      "r558",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r578",
      "r650"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r670",
      "r682",
      "r692",
      "r718"
     ]
    },
    "lrmr_StockAndWarrantIssuanceTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "StockAndWarrantIssuanceTransactionCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction cost",
        "label": "Stock And Warrant Issuance Transaction Costs",
        "documentation": "Costs incurred during the period related to the issuance of stock and warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesExerciseOfWarrants",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of warrants, shares",
        "label": "Stock Issued During Period Shares Exercise of Warrants",
        "documentation": "Number of shares of issued as a result of the exercise of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Common Stock. Net, shares",
        "verboseLabel": "Issuance of common stock",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r64",
      "r65",
      "r91",
      "r509",
      "r578",
      "r602"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of shares, Exercised",
        "verboseLabel": "Number of shares, Exercised",
        "terseLabel": "Exercise of stock options, shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r64",
      "r65",
      "r91",
      "r309"
     ]
    },
    "lrmr_StockIssuedDuringPeriodValueExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "StockIssuedDuringPeriodValueExerciseOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of warrants",
        "label": "Stock Issued During Period Value Exercise of Warrants",
        "documentation": "Value of stock issued as a result of the exercise of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Common Stock. Net",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r64",
      "r65",
      "r91",
      "r516",
      "r578",
      "r602",
      "r657"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r21",
      "r91"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.larimartx.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' equity",
        "periodStartLabel": "Balances",
        "periodEndLabel": "Balances",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r68",
      "r69",
      "r84",
      "r538",
      "r554",
      "r579",
      "r580",
      "r645",
      "r658",
      "r763",
      "r775",
      "r819",
      "r841"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity and Stock Options",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r149",
      "r271",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r284",
      "r286",
      "r392",
      "r581",
      "r583",
      "r603"
     ]
    },
    "lrmr_SubleaseAnnualBaseRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "SubleaseAnnualBaseRent",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual base rent",
        "documentation": "Sublease annual base rent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Member]",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r437"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r437"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r437"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_SummaryOfSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "documentation": "Summary of significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_SummaryOfSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary Of Significant Accounting Policies [Table]",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "documentation": "Summary of significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Changes in Valuation Allowance for Deferred Tax Assets",
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "lrmr_TaxCreditCarryForwardExpirationYearStart": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "TaxCreditCarryForwardExpirationYearStart",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development tax credit carry forwards, beginning of expiration period",
        "label": "Tax Credit Carry Forward Expiration Year Start",
        "documentation": "The first year in which a tax credit carryforward begins to expire."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforward",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "lrmr_TaxCutsAndJobsActOf2017CapitalizationOfResearchAndDevelopmentCostsUnderIrcSection174": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "TaxCutsAndJobsActOf2017CapitalizationOfResearchAndDevelopmentCostsUnderIrcSection174",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax cuts and jobs act of 2017, capitalization of research and development costs under irc section 174.",
        "label": "Tax Cuts and Jobs Act of 2017, Capitalization of Research and Development Costs Under IRC Section 174",
        "terseLabel": "Capitalization of research and development costs under IRC Section 174"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Period",
        "label": "Tax Period [Axis]",
        "documentation": "Information about the period subject to enacted tax laws."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Period",
        "label": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual",
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r769",
      "r823"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual",
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r731"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r270",
      "r283",
      "r391",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r494",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r771",
      "r772",
      "r773",
      "r774"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "lrmr_TwoThousandFourteenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "TwoThousandFourteenEquityIncentivePlanMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2014 Equity Incentive Plan [Member]",
        "documentation": "Two thousand fourteen equity incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_TwoThousandFourteenStockOptionAndIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "TwoThousandFourteenStockOptionAndIncentivePlanMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2014 Stock Option and Incentive Plan [Member]",
        "label": "Two Thousand Fourteen Stock Option And Incentive Plan [Member]",
        "documentation": "Two thousand fourteen stock option and incentive plan.",
        "terseLabel": "2014 Stock Option and Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_TwoThousandSixteenEquityAndIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "TwoThousandSixteenEquityAndIncentivePlanMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2016 Equity and Incentive Plan [Member]",
        "label": "Two Thousand Sixteen Equity And Incentive Plan [Member]",
        "documentation": "Two thousand sixteen equity and incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_TwoThousandTwentyEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "TwoThousandTwentyEquityIncentivePlanMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2020 Equity Incentive Plan [Member]",
        "terseLabel": "2020 Equity Incentive Plan [Member]",
        "label": "Two Thousand Twenty Equity Incentive Plan [Member]",
        "documentation": "Two thousand twenty equity incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Government Securities [Member]",
        "verboseLabel": "U.S. Government and agency securities (due within 1 year) [Member]",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac)."
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "lrmr_USGovernmentSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "USGovernmentSecuritiesMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Government securities (due within 1 year) [Member]",
        "label": "U.S. Government Securities [Member]",
        "documentation": "U.S. Government securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Treasury Bills [Member]",
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r622",
      "r634",
      "r636",
      "r835"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits",
        "label": "Unrecognized Tax Benefits",
        "periodStartLabel": "Unrecognized Tax Benefits, Beginning Balance",
        "periodEndLabel": "Unrecognized Tax Benefits, Ending Balance",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r349"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r33",
      "r106",
      "r107",
      "r110",
      "r111"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfChangesInValuationAllowanceForDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increases recorded to income tax provision",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "lrmr_VestAnnuallyOverFourYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "VestAnnuallyOverFourYearsMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vest annually over four years.",
        "label": "Vest Annually Over Four Years [Member]",
        "terseLabel": "Vest Annually Over 4 Years [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_VestOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "VestOneYearMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vest one year.",
        "label": "Vest One Year [Member]",
        "terseLabel": "Vest 1 Year [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_VestOverFourYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "VestOverFourYearsMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vest over four years,",
        "label": "Vest Over Four Years [Member]",
        "terseLabel": "Vest Over 4 Years [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting",
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting",
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813"
     ]
    },
    "lrmr_WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Wake forest university health sciences and indiana university research and technology corporation.",
        "label": "Wake Forest University Health Sciences And Indiana University Research And Technology Corporation [Member]",
        "terseLabel": "WFUHS and IU [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_WakeForestUniversityHealthSciencesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "WakeForestUniversityHealthSciencesMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Wake Forest University Health Sciences (WFUHS) [Member]",
        "label": "Wake Forest University Health Sciences [Member]",
        "terseLabel": "WFUHS [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_WarrantsIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "WarrantsIssuedPricePerShare",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants price per share",
        "label": "Warrants Issued Price Per Share",
        "documentation": "Per unit amount of prefunded warrant issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common shares outstanding, diluted",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r176"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common shares outstanding, basic",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r176"
     ]
    },
    "lrmr_ZafgenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20231231",
     "localname": "ZafgenMember",
     "presentation": [
      "http://www.larimartx.com/20231231/taxonomy/role/DisclosureDescriptionOfBusinessAndOrganizationAdditionalInformationDetail",
      "http://www.larimartx.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Zafgen [Member]",
        "label": "Zafgen [Member]",
        "documentation": "Zafgen."
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//944-40/tableOfContent"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "SubTopic": "20",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-3"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-3"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-4"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-3"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-5"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-5"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-4"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "405",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480191/946-405-45-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482190/360-10-35-3"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>83
<FILENAME>0000950170-24-031529-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-031529-xbrl.zip
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M.P'BC/P[\V;X3?)W<E.0QS>Y$1QTVOJGF :_';PM72#XX.+CY>H%_>$Q*L*
M"9Z3!@R)A'EZP+R@WU4H?XP0*/PB/_I#;N(*=?EU@.+' )[;3S$A<XAGOW$@
MKL?) (@ 1#_>][/JY/X8U1\K4 O_ID5R=+]+V/$!^WV6GWWV?:O+^_W#/_2
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MDYIHZ:@>P2_XQZ<4?Y?7__EV '( <@!R '( <@!R '( <@!R '( <@!R '(
M<@!R '( <@!R '( <@!R '( <@!R '( <@!R '( <@!R '( <@!R '( <@!R
M '( <@!R '( <@!R '( <@!R /(?!CGRQ__]0[S *MS^W&JJ>T, 30#PWVP$
M(_^N#>"WGV>K!6X0 VE__#Q;$X =  0 28B!O_Q,(Y#PPVM$Q"2'C^#'W6D
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M&?G)Q'&FW\"<9B6*09!>T._BC:'*5W?,$T5> :X=.7_H=>V3XP)'2!)'AJ\
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MM3C>@==I@;>KK=NO?N.(CZI&]+9PY?R6?$89BL$.[\!8 66 QNZ^[U,=%_<
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MO;?#O&]V\[.FJ9R/S/V[<K)_I3)(4G8EF/$*\-(K\&MD&ART9A;9G08U;D^
M13U3G:P[6"=))8/>#B<#Z8^@M&O*:>B#T^E9(;-!U>7V2&&G-0"R@Y[GX.K*
MUWCW7,_[X'9S]YP T_CM[1)X/^CAS>M\"?'4)[0XGR<EA6_))&8_/^,[3&*]
MM3N'.02[W'G)-^XV%+9"3F[BIB%K:QXO$UY5:!WC)\<Q&^^1U)L"-C6P-O^
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M^X51>D2H@PKM'H]$KO3\/('=TX6"Z:[!05]NK]96T5X!41&=BNTKY^>=>[<
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M7[;FUGI,.I\>==SOO6C.)D;G!U^2:F?U<(>\]C6\UKQZ%?5INC,;[Z@;W=_
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M1#$-B:]4@1(PJ<YZ;%5;Z[XQ(;9W%Y?]4CXO4&MKEA[_JB%>'Z :!0P&<
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M>B1SW]Y6 ]=%E:U+MH^:>"3* 8D/BHD)?]M3D\N-%LQ0QU,_&R\#-ORP432
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M>(O9PVMU3O(DB*$2SSTC/S%,/T4CN30U,>-AV(/L32PIH,W-2=71Z)NE6[X
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MB8-(7SL?H=7Q._2PWCP6F7:CQR*%*C@VQ]Z;&M1\H*P)IZSF\ 4\7(PB^N4
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M &&GW1.ZP2;*7^SP_\@40TQ-%^B6T[TK%HX6@PH(^CM"AC5?I..7IV:;G.1
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M\_>(_<6*$^:X)%?T -VG72ZWI.,:_-</WH2G.YJG:;0 ((8PQUK!I!% +J&
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MN$![*HE#1OC$>?U(&M_J\VU+@IVEX1=V(@_ZMB$W7 _6VN/S>^:*=\?NBV)
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MM[0GK4Z,A?+1(L8D./),&92;1"$4I7A^6K3V*''(AB8/TIN/4C-C5) ^%IH
MTFM KAY;N3:)O8]$U6.8"EI-\_+"D2IB05_+%;YA0O).BX5&CQ!8YI3!N,)
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MUBE[I[WF[QO?FY2',HUR2X-S!4RCM<A#Z5:U%JN60HIJ/:7/[>SW^&0&(V2
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M[WB3JA0SJNQ7ZG.'SJVQ)BG95\.#Z)@M([O_](5'-XGB%$J[-U1G]L@+QZ3
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MAGI(:P RT.3KD+#;!E"[$_Q8+Z1@S_)026"X?0+_EA@E6Y%E_5L'[QI)'B?
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MV3KB\>!5DFIDNC>P,"K/;[M[!01V6]U-#*KHEF!,3R,Q%0T#4%($SF=M45\
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M[=8#E.CLPIK5>_I_EAGARS&N9+(RK/)<K\E'V9JT)Z6%Q62T0U4EP"K26\K
M*<T1DM6?>DYR"?Y3J/CT \5+L(OS@.-ZW@(=^S\PD-*[TLC-I4/;CM8CVS+F
MA$)5+9J4:Q.;.Z- $)@@K2]08AX%-U_CRPB=XEO:TE8N,RV;HRI8:1WE**-Z
MRA%+;G=8('Z<^8/ 59<-=%AKD:US._)3.R HG.HSEEI,$1UX7D,<CR/-4^*;
M%!ARX]6OCY9AO9Z(*' :RSB6X6#,6%(%CZ?+)B;UPL!',E&C#6XBM6:7K_N"
MV:":"3YL#/(:P&K=I;BN+)]/374-S[5Y_RQT)2==G=$7Y68K=+;MY3]7[F!R
M1WVD3TC1NM=&-1HR0.T(+EMLI=X.P,X6#2AJ]UGN4YFQ9(<Q[7_EN9#AT2,R
M8*QY__4'7H_17NZ=9&]IOT>PBK8BAPDU47/?!^XU41(N-P31$]B+TZG5$#6[
M/Z1GZVRE^@]9^8JMR#\="EG%MVSB_F>AVG(G-%GB*9$'/:^3.U,FP8UA\FL5
M^OA4!,H5UD",?#8) NJQN]GZ_,CQ$"':3/\92F9?0Q'L<NAYH6K#82JVD%YX
MPG5MFB6&RKX.314I0;Y#^>)&?4-#4JWCFF<[DBR,*99J_<SZ(:HLEV7\!-0Z
M9;AL/Y)E_K=5=*@&HA3<HQ1740YHW)C@*_[HX14E)Q]7%GF9#H-$0AD&Z21D
M.II-6^0)B$BY!LPNNW=O9U30]?"X^)K*C5)SIF2%VH+OI/D#=Y $BXKT_A;H
MJ7LUD#?HQK^)J6O6KYVNMR6 M$<V_<Z2]/L]OUNB:I&QN\I(F<BP*X@(*")I
MFVOHQOS9V:-,E"/+U']*\Z5S^*CIK@EEGH$/%=I4<WD?:/%4@OD]K0&O4II(
M0/EJ^9F7K\2E[Z%),A0P'0D0&R7F'/<%QWYB?WN@S<>;U9[?)#J7M&?G-B9^
M<,#OY@T+DO4. TZMVKB%*4%6T=1;MH<YFIW:C)0K-R0HPJ8;Z-_!6!,%S<VL
MY3I^J<":(CWB8,>4:ZHMN&ZVDG8-?J'8%*XN3$7?L(N+45O(#+.6T!WPM.65
M#2QCBQ:KT9">=/B[D/V4)GB:5T- 7KYW+%CIHI0N&X8SB&I'"-H&,5"A,=CE
M=WR?-.MG-RXI%>NCK)L,^33FC:LJ/X%2IWF"!7_BP&IA$MQ7LL=Y0PL-HM,I
M8.VSN+EOUDIA]E4YTW5-_C+3&C/:[Q._Y8FPHT-;Y45X^<' ]V]93$]9E;$N
M;JN#B(*9U'J3=V8W>JQ!!3<'_BU%L3)RC_6Z89X6' R1#X=1J;9/:=LL(/<9
M/HLTBX7H5!\*.<[&WII4X>S:IGY&$_,F1V6_HQ,:LREMK\>C])*D5:*!5VQ!
MH[5S\NDB_L[9%E_Y28<K2-ZIUJPQ1K+C;*$<*L19MRD3(Y7\OUSUC[8?\9J3
MD)0D-@JR9*%M&-(3T\=D%GX4<T340R)$?.!0#.,Y0T27D*A<:;@S\@(E,LE+
M)AUOM@:85K$P(IG4(^+$%#+_DUYPF/JFTL+>3NUK>5]PAJX<>KUMOM1C61%;
ME0A+$"FV6,A\X1(21%3RI<= I +&%ED?+O#=FZWMQKMYQ#^^E\S?!/Z45V?
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MUOLZY\3\XM6/(W\#;_\U]FX$70_B@-OK>/TR%O#RD)#M2)7$2%$WX<M5TZQ
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M[X"&A@.:&W?QCC6I=S=?NJQ-//MJ=6KA?2#6:N%2Z0*=BD57NDFXL7F3/^Z
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M7*BCH>_.E@,?/LH=OE)=_;)GSO?G=KO>*W+,Y)J5HLGAU.CA),(5!$R:FE[
M$IGQ! -SPJ5U#"\,8[;@7.M@LK3^_TU&!C@  %!+ P04    "  V@VY8;I#J
MD0QL   %OP  $@   &EM9S$S,3@W-C<V.%\Q+FIP9^R\!UA3V_(WG-![[S52
M!:7WWIM([P(J)*&3A"3T*MBH4@2D*R(=E"I%%"Q4*=*[=*1*1U#@ SQZ/.=X
M_^]]WWN_]_F^YV$TR9Z9-?.;-6OV6FOO'7(T>#0!(+NDKJ4.  (Q@-Y ;P#@
M:(6A2]\!CH:C'. (D B_($!264L'"PMP3 SE+QW$_V0!-DS *P!,1DX-)@P
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MTY/?4X0?CK07$)*2DCIQ(RS,=]R"#^4-0]MX\<%0[-^=_/"C"D6!D8ZG3XI
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M=^_I.S@G.;F,)T2^('K"97=)W  ?GW=,C/"F4N8R(E\R*B8BR6XOF!M]EZN
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M8/"X(FWG!X%80J%56\X[ K5.>H8-]4+QH+KW"-$ZX'835_L_QK#5.$'X1ZR
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MKK1A*"H[LKFF*5J('F'W* _9+N"0/(U+U 0[(+EN0U$J_716"]+1:$.F2AK
MSM%F)+L4SI#RT8,XFV'5*1(D(."@3E-XA9+A2N:5W#A-O4EI=[8J<H+39L,;
M, P-O$2-!#!UPYL]OXL_2X17WRU9.V2!Z#!AC(O.R_)N>]5@W[#NF3IH[2=*
M+^*4!E\@KG[-IDN\><F>_7#;)H?!$[21KBBV8VPG02UBGN$89:^=^@K8QI06
M'YO4/;!>[<\"C'3AW[%^F.\N7%9P;/A(#&0P+SS)..9$!DIO-*%@2?4G69:5
MA6E((I2]3P3_GI):AH14K/1(MV&1H]:P]L[CZQ#LR<UTL%5S+2[Z"Q".1(YJ
M\NJ(:$R>B-@4$4HZ@Q;C;Q,HS9Q> 9/\^HN@E#:1&6HZ6SDIRWBTW(15;!.>
MAXLC3=S<X!/9;Z-B<T'%%HZ[]%&5GR+#YJ5XE9.#K#3*Z8O!<W;'.RQB.G-B
M>WCFCL^M3Q+20NZ#":;Z^;GY^P3WI+:!(6#6A2\*#5EZ9K1W%>P;FZR/X.-9
MC9127@DVY9OI&-MM:P=:/Z]>B56"^R\3OP$;@00[^,;Q]^=))"XH;")C@I;'
M$6DQQ:^/[YVTE-7N09.!Q9'9XP_+9@?$KFHLLT":6-4@K57\*L3Q!$D)IOV\
M=(B6%#@)6#!9+>WH@"<1=>ZF2-"^QSNY9T"J*BE$ 3)+?C O2'=? (WN1I!9
M)*W&GVF2'(&'(T7[>SJ]7@&A!DB^";%O@FZC"/<<WA<44AN&YAX:F[@=^OVD
M;YRX*N#WD(2XH3/HN+[D:+J<PCL=);S/5T7+)&"J5JK^V8,#NI7B!Z),7-5)
MT>UT92LK.R0HDGXLFJ<L*S$P##.N+ 35FL;/;\:4Q*P+<,V#6,(.9YGAV=X2
M]K+L3#8YL:%UF#K*-Z%]=/#;_>EM9&$D\#T"83MEQ*Q?9XM1^7]#]OZMD%G?
M:II/JYL;\B0-C__N09KN)M+^BZO_+6+'OHN@_/I+]V.' !<"/IFA6T*O^XY(
MZO7!57'AFGIX8\%!2FI!/'62"O"H@*XDF)*:^%*UGO>3;S1LHK?[K3.M#$QZ
MH;64TKU<4*;>"9=%TTB2HDB![VG'O8#-K8/5F95M= 4D,(DA=;)S*DZ7TS^9
MY*LK6O/Q7O5H+P,8,^\XKT;*S>2+F9/A8B1!"M/2]UA)4N1- Z1B-*@2R[(A
MT>\@AV:4HJ2)-&5MH*5U.N?'KRMB,S7;,EVJ<PRS'M$WBY/28L4^!VK$-/0H
MWD-!>>\NK8A^>C\!OO0H-T2R>/H3AG+FV^"X>M_EG=E.L&;.P6)62I$S:+S<
MC&QTFG#W38,EN/'YN1BZ3I(J2T<M^1-OG1;+C)U1Y1G]M9:9;L\Z'@NJ94OS
MW$JF>HTQQRNYXN<&8$LP8@=BCT'GDF_DJ_BU6O^*L0ZM@<5BZESV?,W.+K,Q
M/2@7/C0I!,$&+[C71"X(G\R9I$DUP-ZQ7V"B\8".R!9^713>F'M"5EJ1!';:
M*3IF^I22/(:-G45944+#Q=9PO*(G#"X<QL++C!R=981$P@C(#_R0;JL-IX2I
M.#I\0[@).>GOP.\G\U1U58E12.4UHBW">:A)I#XF+&%$ZY0TQ-B6.8Z4WW(*
M^XQ4SQR1"7>ZO8RX[0,M7<[Z5;)]@'ML;:@+<;FFQ)36PL5TH'V+R&W@BMK@
MN2U+!MEY/N!XH7"ZT>$@#\W((*.48_Y-U(/YM$-\8DJF6 HR:V_MZ8IL&*C)
MO"1&;2+.&QVD')P=&QXN7\D_\2@VUTS@I1K5,NHH6Z_H2NTX/4K+-H/CN!:0
M:LK;0(KO7$QT%_5II:U^F<"-M!X5KSV21^.GJ@SL"9X1D ]'?)+2V[B5G)8Z
MVY8GR%%VZO*NGM_GMHZ;]A/\*!)IU,[IW7OSYN4<G=8<A2:KFIEL6J*.Q=/Q
MF9FY(".;-"-R =294_7+HLP5PTRD$75>B>+KEN-%WOHV1*'W12,?#%"RV:/;
MIZ9=>=5710\(CN_"AY&HRSF9X-/J45S 37U!4N'2V8:7AJT9T3,N!5Y5N'<*
MGKL&@(]4?5UCN6J+V\]V*>:S 3)\!8WAY>X%FDC2H=0$R .TUQ(E#M8*_6 X
M-,SD0V.MF7WSKOOYW?=2@C:G@YR.E2;!:0P)R%\JK8-,QM;\(8ILE9./*&6%
M:<\[JF!@8YC8J,Z<XL '0WUQH[[O#$-JNT.$F\S<&=,3M5*QJH+U>=Q^"#R-
M=!;2&P9$YKK>GV4=WEH=9%TOY==,W"36T+>+<4TK/Y58AVT;T1!S&?89\/M&
M-7^D*JH[(G%5&6/X%A(=DY"(>UE*]>9@K<7[3#O%;#M1DOH3YOB6.'%+B85&
M_U:F[W287R+>(HQ^$*EPMJ65+E2Q;_&^=J*5@:@Q91R"*F'2\J4V5<QI6"WM
M] #Y3>I=Y88:"=+BGG03O@''FNTU>IBB8BX&<Q!/60MT<Y43P5.!:^Q]Q=%3
M5\)N52@PM64NEGV>9NU;G':!]E>0^_ONQ1M<C-9)+0N&)C8%%789UD@XYTXO
M?JI(!7$JF?G]79R2A)P0&S"QE0R[8G>I@<;!-^0#?2.V,NKS3A2A6$R4*^ZJ
M+3!,L$&6H69PRC)/X%0K-]D _T#,S*<@SU5JPS S&&X%5+R9(0Z4)3X7,UQ3
M=LO@!)C,8"=2+DD*B(DYV7*.,%:]'$IY=J!4Y&<["ETX.L-2LI93"Q&"/4P\
MY !3JHAQ+4DR$QB^A\(O:!8$<WPM(P#<""B[7N0 (N@?MDT/<*P9+0BGZ-N=
MC*!#TDK+Q;0.B-Q+#;*/)N;&OSQ@)_A**77<^^L65JH 1/PG C3,-A\Z29IJ
M6EX?!1JZU^-TJ?6ZF+1;^GIX6X.3%AL6ISR;#Y3PNA0]8B!?"/QZ.XFN#LS&
M7F03GT&^@ZR6+2(M$48R&A3>F#(7&:2-RF2V8SODDD^0SH3O/E4)2N,V=O1
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M. -T7V#]M[:\+OR7.RS^ U!+ P04    "  V@VY8O%U+=9M@  !#>   $P
M &EM9S$S,3@W-C<V.%\Q,"YJ<&?LNW507-N7/]H$@A,"@>#N[JZ!X.X.P=U=
M&PGN$""X6W!W#^[:.,'=W9I'QK[WSF_N_<U,3;UZ]6I.U_JC^^RSU_JLO73W
M/B_S+[\ [R5%)40!$&\  (C7#^!E"2 ,@(6&AH%^"PL# P,'!PN/B(:$B("
MB(7Z 1D-#YL 'P\;%Y>0E)Z"D)B6!!>7DH.*EI&)E965@(*+CY.9EYZ%E?GW
M)!!P<'"("(B82$B8S$2X1,S_Y>NE$X ""\']Q@X2@ACP!@4"$@7BY2> X%7.
MMQ#_= '^Y8)X PGU%AH&%@X>X75 W7O &PA(R#=0D&_?0D&]WO5^O0^ 0GF+
M2L3T"?J#@CX,L3T:LU]L-BR)4%47NN+D&2F+@8,_'/Q'#$PL;#)R"DHJ:E8V
M=@Y.+F[ASR*B8N(2DDK**JIJZAJ:AD;&)J9FYA:.3LXNKF[N'@%? X."0T+#
MXN*_)20F?4].R<G-RR\H+"K^45U36U??T-C4W-WSL[>O?V!P:&IZ9G8.-+^P
MN+ZQN;6]L[NW?W!^<7EU?7-[=__P&Q<$ !+B7Z__$!?**ZXW4%"04#"_<4&\
M<?T]  7J+1$3-.HG!1A]^P_$S'ZP:$*QV55=<"0LBF?H!@Z3\!])6=?)SG]#
M^R=D_SE@_O\M9/\&[!^X%@&(D!"OBP>) A  W)2Q2%=:4T^DTCA(4\49X <L
ME@&-]U\ EYO6+P"?I"?*J1? U@?3%X#VAQ? )W2; B9539R9$G[7DN7BYZ3"
M%\!X9,/S@]Y9[B.#W L@$\?V\:IC776O<*@%ZU'CUECNJ$T [&7=<?HZ32#!
M@@?PZ6X)N);_ H!O$,$MJ?3\WR'_.^1_A_SOD/_?#5&9N1I^.U4^4-T );2%
M\OZ*?[9$A4WN'FH5"()Y 4S(4(EH&4JJF([CZ:Z_3C) /@YNI #[4Z\H_[MX
MF^8BZNS#<< L81@"2?(#<B6*"G4#"\=",L(;W:_<LT^8G3WKB@4H:=*0K;%@
M7N%N%+3J9M>5$'U=EBM+1],V1@5*,R9#=_Y0E%.9#UI$(A]20$YW=@"(=_7)
ME='5U[CBYZ(G%II5\O;<VD3&R.4SF-)H=Y0J->O-%6RCCS:$,)33EZ/V36&(
MJQ>C2@1;><"W>)?Q)6;:TBQ6-J<=BV->V3J*52>&?"1/E;G2%6V#^F4T1Q=4
MY; 84CE#%X>5[BJJ< M=9OX"V%S5NT6^*+:W=S'NSC.I0.FPK']-%B$=IU5*
M;V 'N-#[[VQ%*V=8!TF; KPR].670@A5(E&/]JL/$N/%QVW-I(AX8_AH)!0E
M]_D4 GFE,VE2JF-G%+0'SLD.1/".YBCK4=DGNBXZ/3;*]0[CEBP8%Y860Q?-
M;HE6HH#=A0N2-W0&Q76>8+P;]J)2+20+T_:48?D&=8I(5_^R&!$E?K(V,]T;
M&C1VV'E:O7=BY90WBFU^&\7YP.FJ:07UI(<7P(+F\$##Y=R>L=T\_TRBYNB2
MQ>MOMS?%B!'Y$[FF4;5M:67VSP:9''2CW7;,YL7$DBVYSOH'A6SC_$V>KF2+
M"^JE]1/;.L._,O-5)MDHKSH0AQT.M&Y_4C_$JQSIM X\S'"5UH/TA,MR*NGJ
MA@=.K7_-6*.B-[T 5 ?NNZY87R<ASW?6-S6H'H9;C_B.><W:]BW\891';[NF
MJ4/$$;C4H):"M#RI==3T]9L=SLGY;?!4Z9VN9W)M_H>?0@S+W^JEDRG(@V7R
MEM#L4=)F#&>UY\T-Q91-Y4<G/@P6@EC*@0.3>=YRE\5+.FVI\BW5-94:I'Z5
MF(-^T4IR"^SQ0@\CRFG&DTMGK[P,U._\3*=L&.B)+Q:78P[>.7C_:-4\R>,-
MW9T6K$VOS,=QA#@083 F;J^1'5QSS,VIM'5>*JK38'V4(F+-%J9:.6 9R-G4
M;'W45%_4[">;ZL.W'@\4CDK.71#')T_I2$QUYB@J]>2S+Z\]# TL2?T.I^;'
M1?JH(@*J0_ L4>ZHCN(\P;$X]JI^%MM\-;K.<]8IN=P+;FZ:-Y?:+=AY]>RJ
M9S6?H3=I4QVO2NA*!ZUSV8Z/2X2)T]M5?<Z/ Z06AN682D78UY+V+.5EH64<
MSRQ!L2M:Y-EFL2(.]CBYNS"K#2:$PD0DA%0#U_F4G"?*U'WFC5?HI!)J3C:E
M?,H[Z=IMB17H2<'X%XN]) KL:Y3BXOSW;+091&U^QP6-E>K'%(0TML/>%BM4
M>L)D885&:P=.SG M]5 !O(+1-[TRVD@!Y@B.GL^%'\17[1<"#?WB]R73N.*]
M@W5;"C9J04W+SP5(J4][-[LX#8@F&5/$Y#?.*N!S7M7/FC:IP&Q6=OOOQSMD
M281;'-*7XQ:[UCX+/Y8_Y2R+\Y:8\.O#)$+6*9L7>KL0NX4*#8':YTY<P%Z"
M],9RF2=//9GY7%OBOLS<1118AF';O!J06+5[=""DH3X8_.\_'C+RG_/7ETQ\
M*,+6%55N 9>RK#;Q)]+G7G'?-&=]*"RE-0Q=C-54C0\@!M&V'P/VM4'!'5L"
MI2^ =H'DTDV<@D>\#\7#E/T=]WALZ')*,R33M+H[@EJV$&(.'O!# ;JM43L+
M; B?PVCB0U8(./EJ/NM3T62ENPEIE^Z9E;;0J8][NYO;OP\\OA\["M+3+,H@
M?0&$:H-.K>N@,K2I<9*1KW(7!N109&C6.M:;.F0T#$TIR_.3BF!BU5T6MQ?U
M/ED7+9(2__(YCKT<S_Z1^*&L(82M:1ZUJM@ QDO%DZ)LP.W[OLW-U=2NDHBC
M2_--H1.JVQ%Q'(R5=91V(X'D7M< #&;1-UQ7MD)5-O0-XD&<&NKF*MTLW(UT
M[>/(*Q3M0\4>HZI!:(UY+GYSG.8'IV>+C^=D]]-SSZQ;'SO7YP<'N8Z/3]6.
M\E9?1?=72\H [8WEI%STOQ^)*N)3WTBU96QLB#+&?)?M^P B*X4*_TE'7V)+
M.R<""+=QB;X<I11.GO\QVY:FG*14H::F,]25-(,;AOHYY@-."437HJ/VCA]>
MSK@S>:9G^P)(P/2+0S H97RR3K]0?1A-P?U623L65W"3_UIWV!.K5%&[7,=V
MMVJA-C:7NN9'C5U6FDFZ.G9Z-WEV'MW*-UO>.$3&&/#>EM-UH4RY3GV)8Z&F
M>FEU'X0J\Q<G&(K+XAOK,@2WD(+IJ\/%G6/TA!R+\>)^QA04M(GV.<"6BAZ:
MSBAZ75OI.X5RHWEU#V"\A)+7<FFQ6EC^\<>B)8T-T_GJ;-N3(*QBFC>V\!K>
MR:H+&3B!71]L2'=7"V;8)&I_UM5$BHP>Y4(*O/J4^05%GGI;:4YJ4=E=*AO!
M(A%3,N_,_#L$&\S2,@&UE)V-C;Z+MT$'K"N!5D'HH[TO &(5T+,74$$%6^9T
M^RYY'"VN5>4*Z+?Z!O,-+.$5<6+3PG6R%>'T,=VZ6(J9'[388I;A7*U3R_!2
M//&J)JSD,TATN>R*[5VJY$Y5!994@HW9I @Z=)<(FCS$;_I3/M;ZD5+XY&\K
M<!CP M@C_U;/FG_>/PN=] (@3!5X^)7Y %OBK"3U HB1R7RVDWN&4FDFJ4;7
MBWSXCD]3G[$SMJS5?5$]W!B(5Z5RC5 FIU['SKCOL!0*BTQ:ROC6Z4JUJM@H
MH9YS-W@GWFNN?9>KV.SVO7"AC$&&5:+Z6[C'GL44XO8YYW"IY-+5.02EEEW>
M&C4I$0&+(V0DG+VK:3GAJ)G2G<0#H,!G!B:*X8R%2N1LUL<R'/EXX:I+Y5%[
MF^T4XN4$OAH=9[3GFJF?WK)(+6W/[RPE:E MI#AN>#3S#(DEC,AJCJ@OS!26
M1FZI[!U.@XBPA92W/%3;T.ESK>8PW40T#I_=<8,B'8%Y"VQ-4S9&!ML!B!"J
MI4Y:Q:775.6=43M7N RWGI=W("D1#I66VI H=-)OZ5/S&W17^U\5%J6R6^,A
M@V.WB6"O2S139:PWPC]8P\9.X<)>SB">(3G7B>K08SFKUT&[0U713V1%%A2K
MMK2PN,FJ+R+_.)X8J*MIG;D.K3BQ3ID3H/P9UA\?&S82+-U8%[$XFM,VTE59
M#0<KQ'?8F!-7"A):?<?@6M[6G#8+SF1>W1M&:D+I%/V5]O7)POW8U!9S:1GV
M>R<1M1XN9(#6C/*CJM[LIO=#X2UN?JU'8BS9<9X+DEU-E=F6DB_+H7Q/KJ[<
MNFD#$UJCQ(@?3N3L_*3*<:8!?R%>JLNL]RZ%OI%)>P WB=![_XMAJE_1DBWY
MB^,8H742>:&)5$Q5 ^LE/F&R):[4F&9]8X\\5\>&2=.LC]GZI9_/JGE'5M5M
M..PL;H,B?WI8+"YK2D $^(X^N9.>:RDK)HB13@L7!LN;%]8'"Y1JCG.$U#;E
MABYR7K;YKKN?2N6],@EQ_LV$"WG@I]WR3=D#Y4UTTC?^\J;[T[G7LC)*=EB\
M*5-ZMBPO,L?=> 4?S!*0DK)XJ?7Q9HYQ?X>*A$C7G%'-K#PES*;L]G,I=623
M$>B);P36V@8FHJ#)+'60\2VJH;\==49)@=3'!K+]*L]A]V_&AE;HA(8/:FHB
M\"6R8%7<RLEOFAU::<WJJP6!3G,N>H:-L4$HVHG&3Q[88^P8]#=*Y$F\NMKA
M.RWM-T!@OBNKDDK*WN=*>Q?0!9>UR:*$,PP'-L>B <FM0^>2WGE1SJ0SW!,;
M7VO+UR %4B8>(U\>D^8#2I44">(,5'I9F5/@SRTK*TW+$B=KI)SY3W$:QIQ0
MKNBS(W#^@M 22M%#F2*?=[9.S"7#"E)TO 6$PV6XS]Q$M8 U$KM8MU#]G"4/
MQ^DC#[+IN/(MS=R)  ?.\L2P#JM33RQ:4F5MVTF&1IJ,L^UOE5)%."'P,-\3
M5MO$V"8F-8HUV)97E6?RL?B#;&KX1NO3!@TA>2^\2BJ]UY34F>\\=F6KZ]IJ
MEF\GV?>5<4_&+8XH?T2*H1N9*B%C1UWX9(AQ%?4[>GOF+I?5AJ%?$I*<.!TJ
M>XED+R.<VYM^:'5D-$>!$<4[K,I)L^2L,S -C)A6] SI</*FB:^-NY6:O<8*
M2K7GEGT!4,ER0KT (IUKE?N\&E27I_+I75)<S'8K N?:\N3>5\<MJB]H?%3D
M]\@U-IC6T<HUL\7O1HP;INHD:2QO#\M7R3>*V Y2C/N6OI;#%8UJ?FMR3']$
M8N)NR#B$,54P<\4!?-=E:@4I82-LO=]Z"S9IQJ94,8J[P.GN:N*XB5*2JV;1
MZTI'R5;>WDY4ZL+W+]58U.DO.[@HQ17O:&%&3AC/=W*2/ZA'Z>[5TDE_<*GJ
MEBE8'JW[,KE=U[8R4M5.@ON@9@_?W(,]L)1&B>@M2W6EF"[&7+0^2[[HF=96
MEC TN/%F@O,#U<4%_PL :2K^2$WO[*MWZ@!0 .R^F=FF(X/V7/+4\>;C1RK-
M9^S'E:%F"U8/XVKN!..(-\@6@\U)*E4S.XXVMW.ODF 0D#FA*1<O-!AJ*+8J
MRLYQ1=)W[^B86(L<@?M1A$HP7,AKRFIYZJI2;CCSHAZP;D61S^E<T50>S3%;
M<;$EVE\ GEQM0CRIARL?M[3$6[19LZ*;!L8L+'$TIGM3OAY_@-4!J)$$=)8=
M4'L7)%8!U;271P\]P1\9>?DL^=IV\J8_#U30*U<>4/>'L#:QX7QFWT((T?(P
M[:BSG)28\5KNI4:Y\1D]<E3##FKPM*+3G\YK2*_$-^B!7%9R+B/?7^S;-=3]
M_L%HX!W6\V%A3K%*S>3[L^7!XL&..QB>7(W,VE'[YV_6:$3*IC%)ME:J5IK>
MO\X21IOJ8Z2GM\BY2,*.*0N/TT^?S2B^AJMV^*S(6BK6-UKRD'DST?]2[[1[
M1ZH4->/FT'>P^N#N%6I=NF 7,_08Y0U,=ZI5O*E(^F:)A._,<X2F(&+D%(BF
M(/CV-RG/"FQ]<']M+PE>VTLVFQ\6F1=PK2^ <N070%:*XOQ44C^!,K;>D[_5
M"^#0'[A'7#8KPP#^Q Z\[A*X0E'=BQI0>>U&[7VH9QGH6B7,3=&OKUN1+2Y0
M3 $)PT&=OP)Z1<$TLTY Y$6I8JU.4,Y*03)IO%4$Y!=]95Q<!XG.\JJK8=/9
MG)D%K6.FG_I*C9OF7+P^Z'(J9V/II;*7.K1=6\$#,;U4,N>[/%IXHN8Q7P[P
M:6<SZ$P?^8=6#"L#]<;BE#*3(9&3\$3-7@!?RR]^5K4T7-+S]T/2FE/.3XG/
MXS7><CW19(7WI#@IK(F2N&AM*:>QQ#>^7>1/4T981R+\1,J 6UT:4PHU2,.T
M6$@3,!^PZDNU?*B9AYR?_QQ3GV)Y2EC* 9&0I,_UV-2/Q_EC$1AQ2L'NH&M>
MV67M4?V<(=(XIL$L;N7G*WBH.>FF).//*02WL)YY#'LA/=(GD^\@P1N!GR L
M<L87F!"'L,V!@:\=VW"*F?5.5K)X3_Q4$.T%L,Z3;N5,%9F&.F@6,]"NG)<;
M;-TX"%E8]&N:#1G]T$<Z1L34UM;3MDC8FO+2E4H-"Y/S"3G?*AK:G!@KQ[:V
M>137GLM]/KW((?>L5[WUK#W9^Z:'6:KY1'TG-E$1U@E3L7%?$.O&ASH#B()'
M[VE&-Q";NT ;:,2)M9P5P<C?S_H">'_G_S!UX2T@7:MA$C98GA^[M53E#FG6
M3T'"YL[+5EAVI2:S.S#1D8PMP<),LHGCR[?O;(MDWCRSS[8HM4-K0CPI*5]-
ML&[EC 8QUK.)<U?[,XZ'R(WV:+.Q/7D+UD<_\YMAO*^<16L&HSG;5M4C+V/W
MB3^+W3:^BO'8UJ;Y880IFPT0VJP!7]#-^*<"+2EM*51(&^3F*7*9>E*/IM-M
MB2-ALO] =2FYTG:P7K/0%686(H)M"+$&>8H4Y T1[CA.W\_*B\O;/L:FKG[R
M4K/%U0K@AAM1>R!=5F+/,1RB PQ2(B;I)N%FG:76G994?88[B42]-"XK$@NF
MKVW;US%H<]8*^/T4OMW%X\]@N^@A:(GDL^0Q:$]X0!?H2:'X!5#87[!4JGKC
MRJ0UZ&2$<QO7U!T[#4,0J8M/&P]&A9J69F1UX(T-#E,<R5?CLF%DV4\+:_)>
M1R)1:(\[,=M!%1\Z(4E(T$C*?<\YWL8M +=OKT>V;.!LE+#S^0-[KPFF 48A
M*\2(\,:H)&>I;:RFF6P:"+7S!(XSR=RZ2U0<O[MYA42#NZWW/HCLD:S5GS(?
M*9/U^&T'1)J*!"^#K?D7#*E(GTGT$LV>FV"#5,RM75!Q23O>9+S@1)G3UI<^
MLOME1!O#05:(X7T?TCD$9E;B@X>+"[.R#7>A7FRQ]&6_# '<V6$@YNJ:[OZ<
MBX>5KG=_&CGJJ-^'SUUZ4._$>%5+V]&F\FL_[G IPRVN&TE(-O,X$P63["LN
MNME*5S759*Q^%*N)W C?Y>R)4<]4%#\P>Q,<:7MMS2-B&<G:CYJM1#OB,(1
MV1WAS'5@2?-SE2$.I%LU77JR$4C4&*+;@A*'<R?(5S7(O]'\+"7;,%M[;U4^
MFP+'U$ACS?M>3$">&DGXT[0S>V"Y=6P&E:K*%P!94H&<_;$@^G6;Q4;W3O=8
M]RQ]>056/4R\0:!"G$2OHZHNTPR=%P?>RG@L7Y=GHG.B-#O* 'SVIW%<TT)<
MD,Z/O43-$;NR*4XS+2^Y#]^,./NA/%7MSF0C$B>[L.6PB27P%5W>QH[M*'KZ
MF[W)=1O2Z7M;_<F91NLYD3W^V4*2);X?QWU\*G_Z285N-T1/)G$5QTM\CR11
MJ#JF#?,-8^<C=AP#(LJ&%L_M16!YNO669M&@8R>6@S=7_UPYL)OM"T/BY>TI
MK=74YVK)D:H61-3<.@!%6,7)U3B2[JKZT>6&=+%/0$;=Z.B&MZ/L# -IRB+5
M+__%58G<2T&4DU\)G(/DS;63F_&?P$-ML2>&9D]->-]/;/M^1,/M TT;_1)=
MM4+BJ!"D?R8()^SXLB!'AIY#JO<:M\_2?US8@DJ&?,]OG65H-C XBBT6?FI[
M38-IPSJ_4=^:Z):30+[L*I*V95B(7LG+45A>\ISC[[9#BY= ;BSVA1&!DI,"
M3<O-5J;6DCR4%'I,PCB8^4-0/$_-X<P$M&K')L84FTN5_X VIH%&P7V( 5S?
M>X"#VSAG(4=X'L8+X,LC=GBN4U4.!@DCVMJ.TQ&/QUQ!]OH2DN0U _GE9KHR
MD9N)V6T1%T2E.U9Q5.@7Y]K9$8']4+BO_++LSWS>>Y!)#>=/\;W.G-/!<?67
M<A!J%,_J%%9I^@XPF.2EP&Y#=W.;^(/$]YU)'V6<;;>'U*L [X.C\E T[=W$
M) /I<S[9$35%;IAYW<S_6'$IMZN#+EN/+Y;)74(F-6_V+/W*+AU9^X62C^GP
M*@N!.[&)/SE;<V78#/MB.S>44*W[/GKB(U_;(?1CK^;8HZ5X&:'_ Y\HC^4W
M9AM51 [ZN7XA[O-8'9?\@L6#.1ES=_R[[P%=75!.A%%?56V?B+GE;MQJ+W;Z
M,^@1VQW=@SY-ACO?9"'2L?1JIG$<HQ_1L.4UY\V5\)]A\R+ZHKT3!%S.)2YM
M0#6\UY9[3N/-MB4]8VXA:/8Y/ ^D*.JSS([NP38R(:X:_%Z^>.Y()-"F[R_7
M4">"\=6IR+ I]&UGT 9[1.]NU6=5+B(U3KUNWX]\#AO("%)E%NRA*.H1W9AY
MRY*;A!_\1K_T;%@;\!GL5VSXK[).Q[G]8HEFH+V#:F=^Q]F_K1-:66_-\<BW
MB6QE<!'&P:5M"'-6*OZ$E$,L6< 3S"Q:E>B^$ +OT$AZ'C#E2[7HMK!E9)EJ
M%K=BBSWE/CLVR\-! Q#DY./J-1>I&%M%3M6)FU1(Q$@G6G57B&OB/ $(1"K,
M>N$V8.OT91K\$O/F'G:EZZGIP+Q/>BY%5),@BVQM]E1O%5QB]5&07;*/\%&&
M&-&]&[,4+T]3S[W'MN+(<O]J0S^_--U0IC3CI56&(/7=L+JAH<U_8T7KMF4F
M+RW*'E15%M**DBO\=N03/9:-OCHI P_3?"'A&SG,$C5=C&D&?M!./[G-3P,A
M4L)HAI/8/1& ODR%7KHLYD?1D$@#&G-EQB]#AH,*G9WCFYH>X#9/<^_G](*%
MTNGGA!-2U_@O(KCV_11LYKP,!7G%Y M2^4,K;Z;BD]%=_('P\:IG)^EE4F@-
MYH2);)3X5/"HA3_2G/%G((9[-K5*\""E&QO5;72.#1(-I@S4:.W$53 )E'P]
M56MUJ5)T)/DXCLP89 X%S^^#MT/H3UD*LW&5X]Q(1#V=?<FZ/Q.)8RFZ0,R^
M4W(M1B<+"J#UH6J;.XD@6V6"0L#D@D5>-0"&G'%>9<%G,#;-6&U*'#L+6[3
M]]@B?MIN_)Z98 <,GJNRJ3MV8$#IQ4T2(8Z2,MM6CI2&U?8Z.)[A** IF?5B
M,2Q9Z_&TNY7@I51D#W*1R;KNHXI>IR/7NCO%Y](4H1Q!+*L7U6L>X6;"+_#E
MH,P) _Q7B+J@^/=>R?C#KQ?  UR)LY+R[\V2W6<[X#/45&+?MW;.AZQ_]]?&
M#W/@!5S-:^T)]UI[AC5\=A$J.>^0SVF,#M5,.$G-7VA+&(GAD1;&'&-FTK5\
M <#)MKT^9EGQ>-)B]FM;%7<PS=F>J9!>-3K+K"*S8YT*U+%'Y_P"\)[\X]!:
M\%BFD^GU_ V_7TZ[SVO-6*C[RJP.]'PK]D3&??O\MKSCM%F@IG %!F0X_P =
M=O\(1DWW!/N#]&Y7",Z^':Y=?6Q^ ;3O_9Z&0"?:< ^;9O?T3M+Y] %!![CF
M!.Q6J@!.:!Z"'W,?N;TGO%WX_E::Z*/]VT__>6'.]AEXS=&#E_)2%;5TLENG
MW+KVO.U53M@ZT#17RLIZG[?4$"%06GT_9'Q+?-N6%W0>:OO1<Q3]%^I=ZL_W
MDI,2)=HEQ5WX)G864CK GZ &.%O+(MU1EK.BR#CS%X#I$&A'Z.'(I8;O).PL
M]5FK-T4['.]Y^[F%<2@4I^B&#;V];<.R<2=N3;XUEDA^BKD#'JZ3XCS_&D[S
M:0"HK=9 \_LYGHKW=W%]V\?E=30#IK)8>/?H&/\  ERX!)HC'%8=>4.*>#W_
M20U_4*"I7#-R>7_5%1+ZY>T?E/ '!3ZG\^_QM^#W3["JC:_]84G^I+\;I\>L
MAR-/ L%)/8$_+,H?%G-A^B3@?U08B+-QY8Z9W!FDX^6&MUCL]Y%I]CK/]K,%
M^Z-=Z<H[A?A&:&J!%F"RN?6YBHUHY29EJ61T90$ -">ZW#^D<BYMM];=VW&;
M+[3\:]$%7JU&Z/]E</Z:AZOD[4U2ECI"%^9;ZRAZ\:L5K1F<82*16S.0U8DJ
MEQ"D[]H>%=T^UCH(J]=>*YC6*^CB(-U&E$-!8UW#/ K5] 1MSWK$\/UH.6RG
MB)JTR0!?6R^,6!+Y(+S+/12;(;@D?-@ JWK.HO^*?V54'X5%/L-@* 'RDA[O
MJ9 ."P"CMKF"_6\%;B]2AG? 4QB__0$^[/X6C%KV^_=7R'*V%7>)^^2>WJ(7
M(GZ\@Y(=RWI*QV(W7J#%WP[VVSAA6V4VL+;5LV<92&.CWN0:Q2NFN_X<=J'3
MDF^3&%S:;CGF>C(#CR==$CV[\"6?*JN-GVY$>G!A<\R6"U-UX9MZ5!F7N14J
M9@Y4M[=G:-LL1DYX3%S<D[F2$NB$3XW<AM'TD,_P&MJ2GH_:%Y$L%293FCR&
M'WC_R#HG"(FL:L3.!\7AF-NR.C\XYU6B>DI ]I'=:)S.J(WG]FKN[Y>L$-SA
MO38O;E,/$RN:H\4R-BR/O;SV(/R.0&0(LM886@-/D8Q-$:\'+Y7R@("2%<@]
MW0J98K?V58P4RY*K*#8U%X;N$N_INXDS5*W!-WTB5Z;-"GK\T>B6A0453L#C
M?(8_>N'T2>#_]^+?GW;;6RG^P=1C+-"1;[=G.V-'-5&M+J:F:I 7NP<E, '3
MD=UIW1Z^3#F.PZGC'FKA!0"">@%,B&C]2/GC;@6(UD7TVH?CP/VV-_H><AX(
M<GPJ&:*9!=,"!_![P"V9V[H*NCL(=Y3G5<!>?1$T-8TQ--7$R%RI,AF[V&7A
M-UTH*6*IG/#\OK/?O=CHMD#OU?4T5V40=<VBZ#H'6 :T_0:*G(G34ZF$9'0P
MOZF)\F(52=@#;1%OIN4,X8=9S22X!#HY'WO0$X#YHX4BIJ3E$?3K'PBUSU@B
M"#S0Q0<7&.WB9G,BT3U5IPJFV)"KI/=)4U$N\>V#L/#,C2:NS=)19=CW-2::
M ["VQ4C!:/>YELO:%99HE"4QYMR1PT*5ZLOBIHKG;X5<BSA)/55"KA#V:6UL
M/AOQM1[:S&W+?==I_F(0S%F>E;,F3.\/@<E'8S#>@UVVFI-(9V6]XT3?#AR"
MC\KSF+7$PS]Y :AP.Q'Q;M.UA7L589RB>K_%/3_AEW#AD6HZMJEUWVIOKW:@
M]>]UM>22,/K"&;DQ.)ZO/G=:NU1C16=#)]QK;P5*399+:Q'$Y _S"-O^T*TT
M[FZ,5)ZM[Y!D,YDWR45=FA4'V^?IH6JYYY'G*F'QX-R9(:CQOL^ATYEDL4F%
MDB.OHV(?ISFNH=NU?C$_LFVEE8HN.-:^9)GVT1]E*V$S8SCC>N3.9&<124JY
M@0-EL6T&M<>6!Y>ZBA?Q!LJU]/L5G:K&5D.T3)-Y;M\52EJYA^FA3+CHS.YK
M@S-]HBO^CDPE(BY33[).%H[->] QWGS^X.I[F=.*E%R \AQABW.8$J[NES@:
M5P'772XL@9@2#-=Z'Y-*!,U>EGFA\LFQ"')[0JY[09RJ&?A-M<^S6*8TA=JQ
M-O;L) (M_-?DT3ERI8/<W8.X=I^-X\2@ B'GWS@*%Q*$#C^T=<GJP8ME>==W
M6XO)*SF:X]K:231+&!I&^GH-K+E[,^GJ$:HD=%<:(]IU&I+,5;PZ03^I^*+U
MF#%G^*W8[FG_^BCQGD?-BH15L_5D!B-"'PG/-_RO83\4(OF2V<BHKB@5U.B=
M(B7'H%-VNC<P$VXPW 8@VOCK@')GFVOFH3X/D?FE<E2!GY>JU;TARK0W$DZ$
M(E+K(B1I5('O+";6=#3)TFK::JQCLW6&WK& ]E7B)6>,:BQ_5J>7?4.=^LHC
MB"<#;^\M,DS?RTU]L;<8-&Q.6IM"2:^CR)4G]#Y^.J7.<;U-"$X7<],R677]
M^*8'!V\DES0@ I_'.3>#KW^8OH\/W;W66H9^L]::?TM;LB6.!&NY9P:^QGJ]
M3'*#!L1$2V?$0NO(WD?@=[-[QLK5Z_Q.@S](!#W_QYZK!_,2VV1(^-?5#*V@
MS:?-R])%"TG)/1G6H^XPR@*2Z7;4%\"/F1? JMR6Y53)J,^?OG;W ;$RVG'N
MQ.]!6J\%)SC_!:"G^!I33(IFCVW!P@])S]Y2+X#LE%S=97XT=^:50#0%9<*<
M,$K /U%=[<H;:Z'!"J.6NNI:5-BO#;2"KN"]3O("_@^S6 S2E VHFM*QK':H
MV[>(0=KV$<K<,;*CW[+)*_2]L%A5P?33.QG*860NRR==@O=RBA:K\9Y(+X"0
M8QL%Z]KOKWT+:2@5C^\1![[$OM^A>JS9P[=]FEY]NT,4&B*4S&]16<]4HN'%
M=9E+T)D.UOZGEY]-;=:T'Y0EF:Q;[M&Q)$C+=EP-U>I3>^4M;T 39:V)'VCM
MA@X*8%36)1\SO ])>C$>G&\#:^^/,E@3-]8+,Y891VR4H3<K!]A&@08')A,Z
MKR6>]O/W8GN&1)=CO,M]Z:9IAM)?41L[8V[Z2<_:45^A'[!#)OWCS(^T?PP6
MI"SO7=/Q'C1_#+NY320YNLDWDJ!7P,3[N0DUUU=8O%_?C,NB0996V1?#"K=#
MZ+:%VS#88#].N+711-G*5"27UP5$\]%O=*CL#!DEV2S^94@0J:8#H^J:K";=
M;!+\;(9"$!]Q*4:*?[$0S)LX[-A@V8&\9)GB7&MK=5/3FE2^:ZX<VX>B?K-T
M>JBPLKIPW_S=I49C28KRI"87;LF-$"\+<9/WW6RO2(Y%S>)S 1[[CCCL^/>J
MN#RG(OI2^E(;* R7*:TA.R'Q1DX^)#(ACKN@@Z$EO(:0:]B<*O^;L1U8F^Q&
MU;!5]B@52%LR+)\ON9,E&5-UT!WG@9$G^;36S4[,K=\1_ XSJ'O[ ^BMP1/A
M11I2CE#\7C%$7Y;L,_(,LZ]+W5G316G,3DBK&M5).\68TM@]?)R5-^42!^,Y
M^"UK76]2$C.QJFJ9U;TS#-UW3Q:F*;Y0--0Y@%$:+3U;9J3"65&%:[O<7/HY
MQU=6,K_=EA8[Z<C"Z8?I<*^3?M]@8TIKND*GU7S[6'<@AU(?-X;,+[ZKF%?N
MJ:C\*UYM[:EOEWPN%1B[U..<K7Z 8<L[2$LA]XFMLNE21<O'A00_MYV:TZ1:
MZL8R=1BKP>)<O/J-KSN9++^O'9+]^'J;TK'B)UM#>P?#I<9^!$149FA8*'N5
MG"DVK(T,]5)Z?$XXU.H^<2'N ,6BGOO@8^.G@M/0BHT9)RD)B;I'R=5E<B(5
M16*8[0&\MH,7P'#QTIZK:LH6MQ>[JC_5)?L@B?.8AM)=S;&V<W[DRE,!#X\Y
MA1VS*ML@Y%SY"Z";IQAHHGV ;#&(7INA[1>$B?_DJ=)L+R%Z\P+PETQ+M5F;
MXIZWN<I>?U^5JC'11=DD822^Y0[':85.*R?$:*]*[XQ#8DOQ()+6/UB%KQT7
M6:YV"ADM"TX8, ?C6!XST]RST="(YZ=U^O^J).L<_R+FX:_WSF)R57NQ[.O4
MH-62$1/]+V3=#ED+OF_TSQO/>4>U'%[F9*4W-]6]CEA)(W;6/6)$(M?OTM4F
M\"VC2X2E.NA#: M6S]V'V!T,P;?3JZ5FS>@G;4Y?:N7?((W3G!7Q'9HY3 =6
MY# G[-)%+-*H29T]GY0G37VJ,JB.S$L4&^,<[+SE+,UR8-&D(C\*,<^WRPFC
M"OG7WIAF\8GE!4"ZR/!P'?\ "E.KNS,%2]3J71]27%<(,(-1>2[6-BL.BR?_
MW ^KL/ZISJD@YB&9>FV0E<;;_UC,/&_((6FYI<QATINFD(7>!GQDEF5:QMYY
M :PKF^M=O6]_FGX!A%8H(845RJ9$9!2FZB%SC:=0Q$WJUKT X',E7SD%WNYD
M/LD0G/U@K7B U?-Y[0U_@L1 1;=,#_FZ_9#K929\Z-=8FF(2QK5F648R\UX1
MIHNE9JO$4E*/D9;RL2?.GR/(?J!UQT_3BL) UKFL_7&>R3_S,*65Q5>S+;8(
M-+9TXOIZSIY:.%ZB:QXGA]=[T$LM.IE&FEU](&</9LO<.+;HUVJN3NEC#R7Q
MI>E3@U!/B^$38UMZ-:NBJ8X](N_[PA? ![$GZD@:L#_&6@KPG#57#QG+46?9
M)M*DR<K!H[PP6^?P_2&3KC;K68AXO:4!)%J?Z-%MK_:,EZ'YS:'YD:D[\:-^
M8R)YP[PR2A!...X6*F=G>0 8733AM51%.!T5N$L1^*,&BV_FO>E7 VY4ZJK%
M> C"KJI*]$31-Z9):Z6T3"_"T> =A[;P93TGVAGJ4%<D;HH3U5J"Q'>DOKS[
MJ9B7,,8R+GVI@_%':8%_PE'7XZI_='C#"42QN,'PG]EOB7-"WN65G"0Q.@^D
MB/:R5_'B*>G/MZB6<2H_T_Y\-J*6"!&\BE_0AO#7\I:HI^"V)AEYPB\OSW$^
MT[\ >E+PJPJT-0==!6))6F\9/D[7%D,(^?!9>-J^WW>8-S];&[2[Z$(:JJFN
MH72U*OCU3L=^1DWI;TQDIOG.M<3VH>/^6]&<)FE'Q9UAVHR72N%(T@O .,79
M_?@X1Z@*;1MY=,TO;*ZJ(^ G!D;0G%1CSJ,7QQOURM)Y>=@OXIV;%6RN?X(
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M3&9$TO?71=L V\S?2%Q.T$)04[& "\[=.$0H,38S<C*7QO>"7CH)&1@C<&W
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M*G-[)Q9:YN:W]3Y(.)7V%E!J,Y+&,(H?A^DA&;EY3%-0(,5'F.ZP0I@>'[\
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M^0* 6'JB$0H#9#77(A$3!>US5,KK0D/R[Z*3__% 4'['"T"%X-E9;U?B!W"
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M7@DQZ^EG!O?-H2!R?;/CAF>X:AS?!@-CUM<W&)PP+@Y %"W4SW%%:O*=N+]
M+'E#]+SF19*EDO<\XD2-1%5K#>@M/Z1<D>+Y(OBMEKY9#V!B;5T>"Z)4^VW
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MT&9G-H V/1[SHLKPCL7[?^1.TB+%FRMF:7_KPNIV>C3>!%(J;8 X-':+%#R
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MWEZL>],Q,/J78>U0@SM90&?KH$0WQ+1O"U*6#(VDM2\*GY>6=H%G# LE=E$
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MS;(9R?C.,3F3$#QYEG>)S7[)@9P8 _UD!JWI[8NM-FK:.]Y&=$^U5/<ZQ27
M0B%WD!/HC'35K"P4I(L,O8%,!"/)@M2&><^WJXH:1)Y4N;^L][+?.WBUFB!#
M7S:& )WAJY]I7Y:B[750SK77T)XJ(K>%R:M21^GX!>N^D/6Y> \RB D%P*T@
M8B:^@4I>+@EM/G=CVO5VM V<#V.,MRVI"MP%C!',-L!JM>HZN> +3,7W>IX$
M]W'$0P13RM%I?(%B! 6LYDQ<(@5;%J[?3TNJ&[CT$8(K"$]-)X]$>T'+0E
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MH%7!SW[XI$C9VP<)N[;2CW33THB)_?VAX*@E7\_#=P\ABJ<>]%RL.).RS5;
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MJ&CH&)A8CPKU^  B A(2(C(2"@HR\N-=_\?[ #(!"N$S;BE4(G53-#IG8I[
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M6/9UZTONQXY8_E20VBU,FT;!T&F8U57BO\P;3<W)_2>*;::6#N@A_73/MNU
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M[%M3!3NY?HH&9%OMI+IX8?;;\;?4)3?R&/]TX:"0KO/.?Z96#FRXJ$Y//Y'
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MX8BV14J3.9_&1S9YU ">.85/+;N.>@3TI)\F[K 7X4D?5#(^$'PP(!3[5B\
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MEXL=(CTEVN*[%;I!1G<H,5\_N/*U,U83W=ZIY<[ZY+8XD90]E!:9748O7MW
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MW_9Y-K)E^+IF-+-H8W'V\19 T2,2P5R41,_L"B7Y/Z4CSO81&"U(.U1H?XM
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MFYVXF]+U8*A6_INH*+39,!R6G^(-$1239Z6#?Z;X%!5\7E"9 Z(-/&'..=?
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M!=ZL 3LC?_M<-BY%?T@&RK\0;OXKB+1;>@$+JA"SF]BVBLLV\+-Y*&#E"Q2
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MVD4AG,!.)Q<H0,2'& J 0[R=+1Y1N0.^&-H*NO!%9/JOC1G_->3Y_^L1KI[
M,%OF\NQ .4HIE([@GN]C* KE-6ID?(T4Y(=_'SBF?+WU(!Y//G)+4OMK$%P[
M16 '24#R/G"-KQ$F#Z%P*.!3P(,Y+'79/H!\ O- X#'/LI/SSR$OAS"W'S!L
MUX^M&L)F>;#EZ/;/^4R%@POJ6 H>#@K_[ ]YD5(.1MA=N442[HVPS!BZ#6(4
M3CGELQG:%W[#\[_?OY@[G;T^F;_6AE)J6)$0'R^@;(ODXD0\3>(:^%SIEQ")
M_U<5]:\1__,C\MP1,YY8M!WS0 *M<DH,D/5KL]>\B.L"";0E/BKC@ *V*?U
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M[!-TOO[$8OXINGDVIA)1 [_B;G%9KZSJ]S)B35,LN%%#@3.:G*&>-#^:P!^
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MY%Z*[W2[LB*[XA(EP=U*&KI#'@:H;XC4YZD@$R_%:+O.LM6F61K.RD[]''3
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M"]%)R_X\1TL]8H)[^+SN?2*[15T!I=\_\GMI0 >;/6?JPMH>UL^1*OMN7C=
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M\ H&?$RB9\P]P 6<63M(=7U NG+$_F= !+ V/HK> QK!\BZ'@G,\\.3U"/
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M !' 52GG^PI;AM$41J?W=-+LZ&+JK5474,#M:2T4T"H+P;8$GB%60P%E+Z"
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M*V@E3@U)G'Q>%! )X#/D5-R#O&SR.YM?$K1..L0:YOL0O8B33  SP#LH,:[
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M7"\4T-Y_LOUPG0%Y2!99-75WAG@]K2(^RY%I%#^4"(-$MB3UQ)U$3JJ:^:$
MX6THH)4FXN]FF=J# AC1;15NHV:4="-^G?-7X)>>K?T=8!6(B<ND!N4O4EA
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M4'KQ:M*EL,BPUOCF5X>F %:,;DF%EB\9[=47K3AZ%M.*.IIMQ#HTYV:?-D;
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M,AY8L_6T3C3WR/A$'6SK T!&P1+%IUV8Q+36;GX&0U2/0=E#=N3)^+@ZT:)
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M=EO&:FD[VSF_DK%H3T![WI-5Y3LD6P(5Z^*EV()68J*ZK*VO-/"N*CK@Q*
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MD^4K5$? ,E%4<1B9)G4I7  K7PTRN&QT>_0NA_A-96O-E]\M"D)^S#R%4RO
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MTX^H*&30:(D@K6Z1&";K%CG#"X'41VQ9IY<%_O*AO&J@=?'#CNO8#>83_:&
M]>%UR(_6*S']P*>JB.8_JB+KD=<X4$!/6L^C-_# KP7]"6:D^/:C _ 1;J9[
MF^PX3J0LZ*(""L#^#P<0_Y<.4!BRYI/]-BW4YK8]K40"7C)?V&<]60&=(C\@
M\Z4-A$)2$6U]_]$RG<'ZND)6A]'#]"4/M7LD)X4?.H$AAZ=;L:<9V!M':"J>
M6E$,#ZG@I_D/OCRQP%7W\O3'S4;>WLJRWFD7?,<1!X6"NQ4- UV-KT/CRT5Z
MTM[U/9'A&)G$)P[.Z9[7:TW:@&!!BP_Q6L9A:IODO1W%F#W<*7G 7C>=)T6/
M 7=R2SU[)T0V!$N?:CZ+U@OE4?B6OQ0 S['5Y-Y<6%Z5.NRA6%]_LS'Z6D8O
M+:X7OY\X!D*F;S8M%\=9P)+Z%$K1^X)/WOVJ\,/TAU.2EN$,@#NA9A+R<0<=
M)5'@!/?F#_0;6:\\]]NM!(VWI D,4MK4KW(7>&$.C_7+$-#??+06F.+7UF;4
MORN?'M@R*BK,V=V+^/@]F+&?]ZG,]/E;"S!+<]R4"!4\LE&=#+M6&/?E_J@,
M:HEW-TZ66@^G&:&^Q;$>"8Q8RA<Y1!JIJJEK&<L,WL*)%XH!!1+TE=BC[]QY
M[7E.[TN-Q'D%G3]06J4S?L=>I>N7 ]FS"KI1I'PJ_)&O(XZMP9_YQ^X?!8TG
MRPH?/QE]PVK^<>SBG]=(^/KD3<V57AZ9"1B]^T0,8(] JDM:(22=JNQ.-O2J
MWC:?@9"TS*C16V!7A/:7SLHVX2D_@BSIM3@#FVJXA:_G,^64==RDWX<A/.,^
M<-U!M^UD+>';]EF7)'>C" I_ETG&2@XU'NW2H  #ZR?/ @$LQO[KCJ7_VO2!
M10\*(;)3927R<50!+Y#LL7Q3O8P*H8#VI4"(SS@4L+P*P=GIH>^6IJ>S>)BY
MC3JD\#3%:1-;DQV2AVL)EB8/_]!@M)CV8ZX0""J' K:/%(8;J-\HV7$L$I>3
MP!V:N6%KO'@L_"1-<V1POQ=Q*'A\>Y\ N<L]2!(Q"#1SY=A3=Y QCE_%[%&T
MS)B_ SX\]NB^C^[C"I F;DK/N<R;N)+J6]_VQH ",#[)>%-J)?<O=3,&1:)(
M;V&FAMZIFS\P@S/NX+J>R@^%&PV2M8A;] 5OO%NDGO**]DU-Z=&ON:C:>@:W
M:>S%]%1#!IC6$6O,9G+B*YI:42I&M9+/J@H15"YSR_4QPO@*Q+5>Z:^AY>_+
M2@EDE#(KAF\_)?PSQ!A(8_+.4Q !/OA1/?E!7B/2S:>.Q[W\PJVIF[F.FU^R
MYNBO'RX]W.Y+A-'V1)X)O_U=EO38;F^].:^' LK+'R,ULOZN2KI96'\\R[\<
M(XTG6XLH^+M_U%6G]O<KKW(!08H_%EMLGW3P!1C[*>)RWSP3$M/*[B,0U/3Q
M%B%T"S1*=#?"-J-0QL_@AI>D+4 @N,IW]S?!Z.+4$[<WQ;>OX2IL<7! ("#8
M"H%W.]GC2>)N:>L[ W_XAKC8^Q.!V"SIN0*2@:2G72<'GF8B C-A^:#7LTP3
MQ]V;&5G=0%]CS-(SQJ-Y8V6X\%5Y=#(V_/WQQCL (^7[)]<XJH,"]+Y# 6.R
MVI=1?X02W;^$DDQ4S[_Z:[FW*7R6Q=4,DC;/_A<_X;TN[!>YU&:&[E[B-57G
M+"I>L@W9*#V9\&&,$(E%(&01"KC0L]@U.-V# BZ?TFB:N:7!&<]3;7)U_)3]
M]_-2[+A9P5" W;<P? F,X.#*UB=?9:__E>_*O(LB,MH2]_F[HOB\/'?^RU]8
MF"^*?>V!5"P5,D#_*@?K_A_X[N;=M:3<Z6M7:U(E*U'1-]*OH0#^VA/VF)C>
M_]7.=T<UN6QOAV8H"H)TJ0:E2Y$F15"D1) JO2E%>N\(A"*@M" ("BJ]0^@=
M)(KT%J2)H-1 1$!Z3_F%4]5U[KGGKG777>M;Z_MC_GCSSCNS9\_>>Y[]3&:N
MEML.0Y ,5 OH@?M^OM@; 3@ !@)9C3&O.\<J+>4PFD,[V@SSK=]=ND=:P%B=
MB0]0/;\$*%Z\Q%O UR<3C(XSL6BZEJS[4_3()#D!<\#V<V_O"=:.UBW+J*\
MC "3TB^W9Y:US*\3!XM5>*FV5Y7(/@QOCG@#VF$MFN9[I36AW,FQ)EUSKZ<'
M5"8ENR6R6WC9)3NC2]^=@6_O:U^H6[!3&61L1TZ%>SA$NGAP##*^/+.[!S^B
MT"NI2Q;DLCME311JF!;W>5XQKR4E8E/*UWDN@'\3:JH%5%+RP $V4@LP1/GX
MS#%&!7W)'@=06(:OSP\!M7]]Q_WG._!W[SPA&RE41\ ^O%/20P_4@!BBQ9-:
M>CV7.^6-\M!=X']50X6KF6)%#/Y\F:=<QC4F+:"2_:/!2Y8@) [ K'E@T@3!
M$);+K^?BGU:Q_9T01)TC@@V5_=ZT-%@\7O5]YRL)1D)Y/[R&F7W_E.<#A?Y0
M3F%VHXC_@E%4*DG*LT7Y_A=Y3@MU05^.5>+AJ#Y5?,<P,W8#[-9QAZ>EYEG[
MREN;+>VB-+E.<DJ26)K;5[ /,HYG/TA@V<91/BF&@NWQ:L)&?CTKT9H'RK60
MPP4J#*;,1_1!G.7:-QL[E]RM&)J,6[$.'PYQ &B1O+3' 41?#_"6@7UG2!=>
M(6YQ.,> P= UN5<B;Z6#4B=1B2N)LDV+*\WT]Y\F:@8@RK9P@+GZ1Y?+4:](
M"HU8*DYI.,#1?.O4 9.0&02V-BB/!4'&[*Z1_1Y4)9R<_+X@$])]"H'I'2ZJ
M05 XTAL[T0\K4H@YAMUL8:['A!;C  A2^/J7\L1R'9H27NX<UVVIBU'%2,R(
ME+8Q^P1S.7HC!HN-ME@]8X#UPX-GB)(-@@V),2[?2FV+'L*^&8.@'EKL;^C@
M '<=X-MM0L='/"BHVU&MQ:)L?0?[%GO#D= 6'=0\HC10YL,NJX;)\X[BG 6"
M7%3H'<B<@5_,^ @6"]DM6=EH3*&AY62Z;<;E.U)PD39-*FL48^]8S4X1J)(T
M4(#!X),\?!=M99L,L (,&O]DH+)71H4-OG!X<6(^"A^>R_H#!3?9-"4R]O=Q
M !@>3)$WMYO79>SCTT[8KU4YD,\L+8 GN$KSZ*MC9KZ=.>5X33-]F.'L_<LF
M_((.D-\'P(^LK,V2O;G(X/7QK2Z5WD -5&(3BHZ8QWLEZ# -53(LO@Y8F81M
M:9)/\97><QOV?)F&M]$(LWDA$\UC_)2.EV>_69(R]O.[H0O.]1XN$"=.D_S7
M,)!S-H/*X=KY@=='[8'+L='O6]TCB.@^_!#G#P,'<_GF;:5D"K JP:S&VG"W
M8?B?-_W0N13C0S_9GZ'?5.17N!@UWZ@M=OX1<O C0$N1.J6;PYI093Q[6&B^
M:B/6U_,T3[?\-0\UJZ(NS]'15J$G.1MC/=1B(<E N\%3<Z/6-#)NG@/<D<F7
M-MH)Y@@HUS]WDW7UNR>TIUDS8?%*U'OP6/N=: 7%*%&Z)C?PZL(0^8IC\H;>
MYS6DI*9?;*[3&SN=:_Z#$KML2TW%@*Z179.^DJE'^15^P^)<D@V6A!DZ"D"H
ML4O\TFU;D_MQ"8?O V$?,#KC8];V&5NLX_CIK;$XXK4C,O\].7I6-7T#*D!(
MQ,QIR?)R<R>W*N6;WT**38CR%T9B;A!([JO:^L$&?I$L<T87"9 R>Y>ILC=I
M(GD(\S(;I9W@UB)D+1\F;8C++1P0]<.[*\X:>X<N7EO[#R1Y5=K63-T'');5
MK_6BH;OE,]/EX^]A/&9<M5NB^>7$'(.GW-,/\K*CVT>_3_[S'@0)/O7H=3::
MB_-EH)0.XHNO]"R!W)<Q,J[QL+:./.VS_Z8D[0,ZU%5^Y4G)S-L#78U!Y!VH
MF*FKXTO$0YO1:5Z2(=>JT.-\]_"7VU"'C'?PK7-X:+9RC$^>C6L=A$QNAACV
M$-Y.ZO]BY)XT07VG!L-M5M'<_-S<_MMEU'8NF^+F&V*J%T,&=ZZ:<OLDXP #
M3/=FYS3X]J6E>;(;*4_H#L)T/,;B>#!S-(LW][':XYQE/7'((=$T'@X L<JP
MDXLT ,;XY>9J!D,?>=DKVAC0%=-36HE5;#+(TVROJ6"&KUM3V&DG/F9W7DBF
M:.21/+>+YI-G,#G<L,<$F^1)$6CXR7JBC^](&M15^2T-GGFW1LUIZG+[4^P.
MM\^U\%J -UT2OO_"6OQ\X #'H/%::_S:^U40L@+'=N\0M,6'A0^'#H</XY?V
M3 \%UB_G)NJ5[..(M#C8!:4A 4_](%K=F$EO[*[7]F54Q"H?A)\WYGP5\$@,
MOC_ ?K>Y"_T []V!'WQ"'FH%A&J48DID6K/84&G0ARF#DJ^,W4R60+WF5TX"
M0.0';-C)Z8"\<G!V,Z1V$XXX$-J2"7JI7@*ALJ\P4:*N4Q')U.DJN6LE+K1'
MGXH#7'/'UF8I^0]\_IPB3FVE=)-1CY%H^)42;<A_P@R5>.( ["D9^M@[:>5_
MTB I**R\X#48NNC[@W"\3O9J"]#B,_Q_\E9?\T_.P<7\=@[.2\6:#\[R6CWC
MG(#@W$J6>W7OH:^K%+N?-PY B>%+#T=!R13WZ&(&#A\9:="BNT#\([L=)IN
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MQ:FL@@:&[V:2S_PAP,'W K"-E?@LR8#-S!(BCGM?=!]1[E*^X+]MQYJ?:-6
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MC)5O16JB%LTE4/+:$;([L(.YVA3Q)YR/G[RQX01R#)T*+BF::$WR*_$ELZ(
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MJ82D9O,S6*S^@M*]D%9#T].;B$ MDN*N$4YA!TERYVG!]I>I:JXHF;H=UHH
MK%[EG;N5:?PC;ON:'#)5I< ;?D1#Y(#7__ NT=^)$.\^^VF!2JAZK>*93GTZ
M('EK^'0I#M!F<0\'D'6!K"?C ,S/!R64QX3'_*=?:81%HW" .:$*_+HA*;_?
MBP/$L6\\FX @SF<<+T(Z,V15CVK-NZXK>>( W_T,/5!;E4?%(3!;\ 456<6O
M8P]82>@0/W4B_T.K+)M4)7JK7K0&\C@ 65 4>K,1'_L-T'8XP,/6=UB_3SC
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MH$#*>1?ESPOXSPL%%>W.772,>_<?8"(;5#T"4%'0T%#OH-V]>^<.\E-OY.?
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M"#P:62,\%>69Z60&/RQM0*_6)-$IZSH\ PN*BH+/$].FKDQNT=XB@/WO"""
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M%Q.)'\[*7C@>TDOK2]F'N+[!+] J(*QNV+RT56NTJ?@9:# 6]4;VP;O6;I1
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MC<S6E8T*]0=O?$^1N48,,M?@[>1W'GSMI^B@5(]- 9>(HSC=I8#[,>VJ#R.
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MCARG<_K1D\HL>L4-NR8[GM"4R"#W.H&%!A*/SA=.>O-T'K;L)[L\\L/M]@A
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MG%9E/]6N[*IR@_*$HN.-[N7(IO >%-T@1<170@;7D>09",!X!+)!5_+K/O6
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MBXY]UQ:W!*8,I;GH/=$+GDI 30;OWR^&QQ<STB!<OH#U6=$KQ<CZ3BOF3&%
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M5X^ )_6P$KT[81Z51.Q-!BNTY;X!K4"D4S*:?-J]G6H/];E6%HB%;O@V[>Q
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M'%99F<I)O4I.Y0FX,6E_2FH"XWA3/<7GSB>W?S")!GH^JH7E)%Q6+E8T!K1
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M@\X(+)<QJ\O=5=_G#X !DID'P-[DK\HOTC8.YD];R_4V5#T]42>IPD7:3W
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M$NVPA5/QFXC[3C)P<EEZGL-H\@=LUT."JZRPJQSB:4Z^7;XWXPC<Z^CQTB=
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M;I!''@ Y]H:2.[4*WRTU7-'W=VP17Q0O:3'[QU]IDA7=LI?/W-I*A&Y,VYF
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M8MP^<\*T^F6M1*FA.@"JH&J?&97DE3>#T:6;F^. X^.1;N@B!FZO\4=D1+\
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MC=H:;._"'78;RTXE'N;^'U!+ P04    "  V@VY8"ROB\8U;  !:K   $@
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M/H-8O^N=#>>;'P!_\@G/3U&^9QYTDO/268=BG)?/Z@,(3?\(6,;IQ_;T] T
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MC,'O%TURYL$K[<$/ HR6"[#[,;(ZI%9PP1TFS#,'L)B%7@^=.I%U%2BO)XP
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M^]U]H)6XU?=^E?K-W#FP#LCY=^X/ =A.ZL>C^N^NGS)^5^?YN[X$SS^"G;F
ML$. 0?_@P"TPXE\Y<-9@<; %Q$:2WHWKCV<.]%+_T[\9T*25@UF<:@MP"W#S
M\_Z[MOWNVGG;_MJ*LY990V&.%@@I.T<+&Q /R EN?5[S#^[_=N^?3@UU]7^?
M11P=>?Y)$XZ0=T'\>TWXV=,:'FT0'(J$68'D74[CQ?#/IK1!_V("_;.IT^H,
M?TUNZNKBRA XP@)R]JA/ZI3!;6<'%)<1EE,0$>%7D.43DI._Q<<GQB<D<$M!
M5D[T%K^"H(+L]SSUN^K?S,I!K9!G??V'6>"96<'_G-E?5/]F]ONS10OP_\#\
M/YCX&XS2:6*!PMS_:W/U?-@X6<#@YP\U)>E_!)[^;PIG.N=#0=S"ZGP@PBU<
M0$ )GM]X_UK)[A^Z[#]L_-]4_[5]5UL0Y*]+@Y"XT,^U[I=:_]K(679PM8"!
M;MF<QECJ^Y;ASS]:DM41_C59_Y/*OS9M97N:CT! *9X?BC\8?^N8?TPL_R_I
M,:'_AWOLU\7\HL<@4E90R-ES]?]"KYWB6)SN?4^W:%+6,*@CK863$]C.RN),
MB\<% OPCXSK]#!$"2OOK O0W(_\7&PL$P>S^*P/T%R]_QHGV_VN-_I_/R?]P
MX;N8D[]S_[KU_%?+YX]=P?=AJ7 VL/YS_2QQOL_Y[R;0OZC^DV7@?V<G\3?5
M?[(,_9_L5?ZEB;]'^Y>@_N]?I/T8:__B4NV'^.^7SC]%XN=_@W1Z00J2$I3@
M^2?VOW7Z.U=;3D$*Y[3!/^Y2_-.X_M^G"Y +D N0"Y +D N0"Y +D N0"Y +
MD N0"Y +D N0"Y +D N0"Y +D N0"Y +D N0"Y +D N0"Y +D N0"Y +D N0
M"Y +D N0"Y +D N0"Y +D N0"Y +D N0"Y#_91"</__?/P@"E*1WI;\I=3(-
MD 6@_ _IS,C_U ;*]]=BUJ*0HZ$0_G@M9@O@.@ %@(**]>O;<2]AXZ!\?^WE
MY=,*!@0  "8*&BHJ)CK69<S+V # 'T+ )4)L.B(^8A+26UK..&06Y5?IQ?RB
MG]224_ +B^K W6)>#3(P,C&S?!"04532UC>T= U,8%6PLH8-C2WLG!JF0?GQ
MNLV?R-_?Q(EVZL"I7.S4R[/W;:*CG6*A8'R7HZ$38M!A$O'=PB+6^D!OX4QR
MBEC^ZA(IO_;@P@X9@X",)>SWEU2^6)(61)/6$2DF'68:\/!8326C[=#'U8N6
MGA@CJXRR[].WNV'@:MTM:+_XD9,4DLF>U )B7Q&*PM#!PAO10TO+UFS.8,-2
MWDA^IO)(9R9;2LVR#5]D<4^8L*K[V)Q1*BUH.H*]GT*5?R7-%3H##TAF'919
MO-P+W["6"_8BV"FL*+:V)W6-B2Z*'L[U59[RT7&<6RXZH&Y&L)=./9X"\>M_
M9'._S9[_A59IL8'4P9:H;JLG9_RR0$BT1.R0&3W7MH.2@EI7DPT:PGJOT)"&
M-]"PK'G^C6*-I*7K5#SV(Z/4MB]&U]Q=AFMZI[ME%$KBE>_B>J74XM'5KGXZ
MDEQ*#B(\ 9AX"<C,4AI?5;-\HMP*4F+;,9CN0'DV S60Z!>(<GU2NR$1C\$.
M9IYS72X5Z7*;Y#AV.93N2#4J;A/1)7TZ3=W"8?64B8^#,6XX"8>*R[*1CWP@
MWB1^_1G/?";FT;N1VIMOUC:W/TE5+'9S:PDO")\ @OB\1?OU'7K>%9>!FK9X
MT,P2H&IW$HUSX*1C;QA+=!)F\AP3$>DRF!0L9%?EM"%&#<J\DOHL12[+6K,8
MB41*EN#;T$RKA\EWW&%'X4Z1(,>JR7>I=Z7<8SHF"AST;T'9G',T;K-LIJ1+
ML="H]K]HUY"E37BYN0/37/>;>(;8%K@)275O]XFM4&!+R)_V<+,$KV"'/S4M
M;>?0S.I9IJJUX7<^O%3?B<TC'WOW3<?<"P'.F4T9]53]^36W 5;&#!**/LH/
M\]4>Y8U@!O,9:Y!*=Q3<^TTM11#_#>5UZ:@V<A:[SY3(_>+>T"*=%4()70OS
MQ1F2P3![=L+ZK KBD:@K!#!-U!+2V9WW 1';Y9+"C5'D@JW;(KUU]SQCWKFR
MW:!^9D/_VBH]<2DLZZIN7@D=:PPRD3_B[=O[B3KW!0S;Q=A:O7;'8%QDT9&(
M(__T+&16__@U"31_?>&I^$1^>?#[<;GGLE-;%9]2H<Z>#1V[>XBUZ7A8T9@V
M<\?$*YR/34,.^ SZ#A:54I?TKAD0V"MJ-,^_\-D.[SV6%GFHVEE@K0:/.IB-
M9MAQ5=M<?\Q?HO'8N4/_N'Z.F7=LA7R,&>B<&:9ZF75NBP^?K-%1[.'H/'\.
M:]6>5GPU?:A!'R ZPJ-P97OV$ND!,HTS@=NA@0I4=54T?#^P)7>=B8F?F[%T
MN:SY.:,V-_$#'0JY(J"\8%8_>GWVQH"+*NMD$O>HZ!/4FW+(N-E[F+3,9AT3
ME6A2D1T-/+40<S*YX<?+PO)Y/;J':*JOV+U)0:"9#O^NNT^\PCOT6>(/RDO?
M$0P,:X&03&N7!>D.O1\O+_(%'KL.)+R!M='DS[D,)U<H&,Y7D<USZ+L2?R8S
MA^SA[%UYG5DI,9*#*D7DHO*ZI92EL *:QQX0%RW-I1WKO-X9IV;$B.ZQ.G]\
M#!^]NV'$41QQ=]H1NR(^<^E=R7T!WO?>9CO*'41&*I/(J/9JO(W>NVZN42Z=
MV)>N!= 4LA+)9[,E/KV39Z0N?+]8VHIAO*.J7N[+X?8>B]P5I^XRE]"Q^VO@
M4(A0XI55TQ59RX<Y+-2/%&E>Z[H<1X+U# M3,]-T']J9)\6XLQ'%^F ;WT04
M=J+@PJ_X^B4/NTW/UBTD.3;U]PH^[!H4<\U1<3KH;02^2^"H,L^??JTQ-.1
M8\0O&?^\.<F3;T[;7##VA4"(AM!VC5;\M6ZHSKZ>]/;T<L>-PDGO:>&I7>+E
MF5W"AG77&_YV0GXE% J*;OPQGXR,6V,,&%8FC7AT<[,LW6OMOP(Q=3*4/-FB
M^R46J+23F</OTBMZ'FX/#] PU#4NKFY5+X.KHSZ4+GS4=Y_T(LXUPXJH,B1Y
MJCK+Y5SIZ1?2'TW>[#Y081?2WR^$'VV/2)ADLL9[U6R?7KT\%2Y=E4D[<CGI
M(-(BI<;1!^+B0%7U8"NPU6\'=V^O)RN>1DE5776 8WN%<>Z93JRHV^>/[ZG%
M=5^S:"%U-8][)[!),ZZA_.U \R\?XS @#R(@V]ACRL58F&9]3]1*T@:A&PJ;
MR=Q/GFGKI%U)6;7=:7!U#"MD(:&F#7WP("1;-NY*D4C0CF3<V.[$3CSJO<^8
MW.)7/F6/RJ!J'AH:.AF6$Y(U-T7>&6.MRZQS,APC6MPI(C"]:Q\C_>0S"D90
MN9!I-2C>AGSI:%=<5[<*3ZR86NH%R5P>MM0E]$U)1V:^-:(KW ZC)IY&#RR,
MJV-("*\^Y&1+]!7V\=WDVCP! +]=VDEJ]3)_6/"%U[;:+_*H"(7;$YW49B20
MT\3+/."1EG)=$E1^<VT=GJ*<"C2[5)(AZN_X LJ27F&,?__IY\U:NEA*Y(.)
MJ32[;J5>A0(\@?T00XN KP.J+>S%=Y*!=\0X/NW'6V^20@H?)N%1*DS6++GN
MA \#%CS=\O<8(_>SK@Z!:<2(6EJEXS\WEES:;OGTU,GI::N+1!VGKAS0C16/
MO$:95DPI#,.?XZ"C8?G*M=:HQ&#Q)?M[7&W,?GH157*ZR8HQ3.F6_%YIVOS%
M')N+PQI"Q0(&RHHBD704F3/A(;HO\7H9L"S P&\*.I2+:G:1RRL=*V)&[.HT
MU7H^C*GM&RH-ZE\Z1-NX37/?:ND!#>@W\N7-6;,J_1+%X@@8(NX]W2)&^8(M
MD1IFJR+6(&\=MTBW6(Z$O.)A,8[(UUCI6=YI\7"6R1@S5S#0BV_D7%9K\_96
M(*PJ-U=1K6#W1>:*W0:)7-:88P"RDM#&]I$?67E\RK5L#W, )[4I#MYU'@[Z
M+&-I+R-*4#!/=[<,L3R0[/1,(#RIUI1>*?O![0<9K@/(X6/VRRVOY@:U6C]_
M:]LL>_A.U(^=QK;F:,BND<%W+Z!LF8-<4IVH-/FXA-G@@6J+IA,Z-<HP[#UP
M?;ZVC2_^3J3E-!>?"%.IXV0XG7X<!I!29OF&!.,-7,ABQJNBH!V$HH!.-!'Q
M3ME2RO"3J4+E]0_ GOM[@'U<_D>3\+38GG<*[77?%#ZK/:Y?*+B<'8"*$J&>
MWZG)/#?*B0BJY&@+".3+DI],5E#3\5 Z?,I/.,2)4W4G%92(-OXPX,.1&F&(
M*NE2]N*T'BB_=TDG9USI52.SUVO(JMV:(*.3B$*9X!9CNJHT<[)E]IU<1?QK
MG 4J3F@6.B]%N1\H9:]-V) .*Z,QIO70V4]\*S"_Y/X@ U]'Q9AG4DM=4D9=
MO*)0_R'M^. -3M00V?NOJ.#"!,+$J8[3K>DM\ ;F2\T)6%HXD_HASB+A;#%%
M"B4(6,/T_1X2+]SZ% X'C_7A[FOAK0*]#;"5GJAZ(Z2&TXW7AAN^<_S]EP+H
MLQ]PS?:$3J?)"$W$+6Z5,9,_H>!^WTNC$& GOJ$O5&G[680H^)G1%^8U(012
M4UZP"XLFE['5X8;&+;"#C-X1QX@I_6?C,-1((F1DWX(Q9=S,(XGNZ%8F14B_
MEF$>AH/U:2>W ;E)=_QZZ[.''QE1WDD?=2@MV5RX,S9EG":K6 )T,/58$2FC
M-=%@G1FRE;WA%L(]*Y^]%I8FILPT)KV1>Y8MJ/T_/)>3*T;78&R+=A*HCEO7
M<8JNLN\F?QABSY*@Q1Y7[&#8DMRA3Z3MX;3^\H:\;2:-M6&K+1K]!WVT <M%
M*SJ&2;EFQ8J'H>&V<U+BPF(5G%E+$P)RX5/\EKWUQ.#!+/UU9G^7WF%U$D*U
MAXPR43FL*!VVF+[__L@^^%KS)1H6L7"P"RYH:X@K4WV#M^OH EHG;_*AE*U\
M+T*I938 U9GKNS4<G#)>50Z,UX X;<7+9XXI6;\E2E]7>DI =#QP3[]=]*C\
MP6J16^G0HV9H*KQ;&+15+S,S-9O ,G-7.?@SF5:"$79"^:?W]JIDTQE;Q9E:
M]W5'BZ!%.:A?'QQXWCW<_L;0)5 FW[NT,L,\?DU:?:LKD,PE>7V_24CDDEJ'
M]#0,96=B)/<:T)6<@JV>/!&/;\-Q"WD/CO;@6EVJUU4K[V\=AHF#PP"5>^%#
M4N-60?WC!R.-]=.[?=+S"O.'REKQS^5%#<OX(AA _D-IS6.J0R.31>B"2+^Q
MF[44^CO1L(%^RFYAK5VTTIU.2I2;1YY6JCE<C[9Y$EDIV&/<3P >[JY<(^PQ
MX=2*HB$YU:4#?')J097F(O8[,?J'ADTJ&RVE!-)]F6"M,C_T5_T/I=DI_VF5
M^5<'FKI<2(83-!A? DO"]V 7WS7JGL37+VNXK:P$&9H?\7EX(J7> (Y1,@1L
M<='%4% ^$A <BZ/1VY'2$K &?Y0X7-H[NXK!>@E >Z38HRAM_Q_V^'_UR'19
MXTD6ONXNI"9[M9YJ-I*X R7RN@$^98R3OD3NN,D=+I[UW.#,(4Y*S9Z827L/
MH1[^(1=A"M0=4X9$8J?!ZGW+0:?L.#<B-*_4T)YI4-#T,H2O_N[G&V-R+YJU
MVG+B%VWTJZTI,*AET(?%9?2^A+._B#1L';\-?F[Z4?UAS[%W-#7^=:J^9$LO
M,:J7&=JEK\9X$,$UM>UM_-/W3/8W8NL+2RS2"^?NO!RPVV^CG/=NFO\HH)]L
MR6=W;US8]%%K]M1BEWYNE^ DW<M GEB<:9G^X*\WU4\ 4DT?#8BRGG>1'&BU
M?=*&)284BF$Q#TV;.."S..>4/Q))T[M&(BQ=?FN\PBJIA7TW9C2_X/X3SL&B
M#-/* V@R9XI&*OM#N5@ 5A3*)U_\]2M>7_$W\% B_BN!O>Q::VH%FR]XBYUC
MU>7@(*95L5!@DE6-GT:&$[85R\J;D%!NU$EL$1$HX;$7;&.[]'&<WGJ#S0CS
M[B15R9-,4^89R2^'^QPE4;Q-U-W<=VE $NKA_"9=F>^I1M.7<9B,E]]6K4R%
MC2(643RI=&.>OJO7E[Q?2AIQ T2F%2J0;T5102\M_FZKRK%+*SY0^#:*A1WY
M.^2K4MGJIUZA!5<FC;8WW?<Y6@.*@H4(4FHKE^5+8I0BK$V"@[/W4E#%5Q<)
M&B;7]\XR#->S*%0_:1P N>5-7U1?)P#-&\"2]&W+SU@=4EO_/AY=5BAHT:L1
M;EL?";]MR=I!OIFGOI1H9[9^KAQ(/ZD!>AZNVA95<;N;]#J7>T6SWM)C98IG
MI7[^!K$\1AD-Y>"0;G]$'TB>44_S$B-=& 7>3=61??N*)SGKARGA'DZ[[-H5
MM07.VND2'S_'!HAVJ3P6GIEH,U;*1+(-*8^DV>4-]BY(3:BG#S6"_&I>-1L5
M$>WL[D_C.K E470$V2K)J\EUBJC/W$MS."ADGWR'5:*GWFR@/J)%.J@9D@TG
M:"6L+%$IJ;:O.20IU"R3*5X;R](GRM..-X8YIXN]5E;A?Y"YQ-K)G-)L(J&;
M8B<XK X2&LSJX6D(?5WW>J OWN-%RTN3Y7Y5!>:*"GZ-5>MTH-ADX2Q?&,D=
M^-5(&T8;IB(7(CIJHM#VDLE;W=V-MXKEX.T= \JC!5^:IDN./+2KM3JVF',L
MWY0FP$C);]QP$<9Y+Y8,-6WJ'<R9>UWSL",Z'GL\S)*3QQ8*MI7O4&H3=D&,
MQ$9B2;N24[^R"!5L^$0.?FCLS'?M8P[Y^OWM4)JGW68;)9!]5GU_1CSBJ/24
M_$:0)12+QI5_O>6Y]58W(Y'+A!Y:1 '$'-V<XVG"AHMZL:$#\=9R>N6C<#=0
M9G)MD/]1-VM.P(=<_?V;6GY$*J6J*E&K'$):NCA2\;R\5 U4AX'9Q;<WPBKD
MY>T^+6KU%1&F6$:;>A,E]W9H*A/L@&(MQ*O+PR'(&0XW@]OC+E-<4ZUJQ"S!
MTOLO"7@!05%!=!\'R-=.TY#&^XRXN W9VIK8R]-/*,0C7_-7F:C12)2;62>K
MCGP<C;%?-6[7=S-IM'C$9 4+X12DN1>7D+>L+SQC^*EGALV4T>#SFX@30%[_
MG)2/LXDC]C54# C:9\>]+]\>(V^6!Q^C2%Y>OD[[I0I3_-_E:F5O2?+@W9=.
MD#FOH-I/+MOSNGT2G5Q#;]673@!%;\U39$6[]]1\&SY,Z(O/;Z%F1?)+MNVK
MAN;?T:DO]Y'3?_X@-*\U,"Z [#:>E=]3H7UBH013*U0\;1@WL9Q*O?8.@>L5
M["5'53^D:KB.6DU50XFK?7&13J,>2$4PWEQ,A3W<6$!')T1Y5R(O3+";2^9U
M1):*8%&75HASS,<YJ@2QVNF:JYU>V.H/=L*D2%HFNO$-S)0Z7BYN2%KZX=-Q
M6W>I2(47- L$ -_+;:946-N44@JH&]"/IBK,);7ONW1DHJL]>U]0,#Z&E%34
M>_: #N[C W<W%HS5'55-&2IBPF!A4Q!+54U1WQJMV(@7'<K#T>SG$FWCD'2*
MV9Y?W64@NS<A?U7,9NK]ZFWKN$+KYTB=S/%RC#$^?QNH<]%1_&*G75ILI'SW
M@VD5@8[J+W)M(@W-DFH/?)1CXB-M]U.&5.H4>HJ7G@JW&C0;2$#9.!+?\B!P
ML10Z1%>AAONC"E<P5+@,F)0-J-5RG&OX$.L'2O$!#PM;]>QC5!1'!VT =AA@
M7,X#E@>/P5B^4FLG@ C0"0!UVT;@BGS:4\OGE;:=.@G8@%L-/1&OC0U(,,P:
MK&0P-AGNND:N?6(A6/*8.7K%K&-@S^+*@/O>=$DQ6AJ9,'N5+Y:\8VUBLT3B
M9312Y0Z[/%2EP)^-$H/F6B]-6^]-(LL4<2<6\_X:3TAPE+PNI]9@T .7M9)E
M4B,"L1LG $5Q,K4.P;1(^^XQHFX]JYUEN3 N[2RTR/5A+40M% @T$2@<F!VS
M?'.;<U]I&TA!\EBHI-KR#9G%W9@HP2*GP^T"(]T01F5^<G<^)4W"3\$ P+=&
ME(*,:ZA!U KT+O?[G0A<.3OK[LP&?"21=,!0S6]BGP;F6H<'X@1:IC]J%HBI
M#;SAW!.0T=6Y;!$5'O'PLOK=F@&@X:J6=G!:SAT<WQ7'L:$/7 [0;I68+_'$
M?5?3+,(V$E(<G6*B'5)I50S>#2;CO+,"S_'G&)<]@UL\=&,FG6I(]F0-96_A
M6&1>*W\C(Y)NSYL<TQ5BX,QL4L<16B$E_:3@NNG3NZYP_> 9^<N)X$F5+Q1F
MPN9,(?5:Q6,?2FIDF-3\B#7C&TLWJ'.N";OA<3Y7HIF.A>6*O]CVR>L6#Q^J
M%>(U=&R9HAF;[%4HL0WVKWIC*Q9\=3=^9);&C(Y"='5S5NC&03 A,"T#$0;C
M3([ 4/]]NJ+)P\FS46@/=[ F^RVV^J=7=C^Y^Q*Z0E/+LB#\\RD%(T=M^GYQ
M+UV!SJ/[=_PCF>V<S4W&@FTL+R5A4\B04HP.%W>/<Q;YW_Y$KJH'DWX-!)F0
MOU0)!PS@_7Y<XPA&M>I/E/SV$D!X?>1:8$7*OB'=@D73PY5OC^O5(5G367W3
MQFV(!@V,=L9.,HIW==*JBAP&E5.=U_$WV=A0O#;T=$@W9'B,:>?'KO(*L[*S
M1;*G2R&O\(X)<9%U!9CR3\[JE1C$:(7=6:$^6F2KC?^X=V/\PY>%>4RW^%:/
MP,BVKPIU-FI5PTSN,OOC65#VZJ\3,H)9XB> (Z^5I,:I/I%WO!\PYKJCGXXQ
M-YE:M-4ZUVL6CJE*WKLF%<DIM]G"(3+DO'"=$2/*6K]TW(ADJA'@XGMUL [%
M,&^L-4^_R*QMJ-%-)=Y^Q$([AVV+53<.+KI4>5OLW7"FF B978VX(M&[%+-4
ME[*]8QZ]Y^65C6%/A.!0A:H%A<IXX24>?L(^J_@-:<<Y2"SL4Q$B7LU9+EB&
M [)D\"HA;#BYJ;1M$LC'*-G-9<[&'Y'E$'$GXVU;3LXFDOD%'S,CDC1DO<_1
MB%X^+J8\S(K&_-KGX9JRAGL[,0(YW-7@CH%:C-*GT_[1O75\I6*.AM&3S3-0
M:,3#]K#<$JXN93O4_HQUE=U,TP38*OUS4?.=^BR[<J*P$51R%>3UN7>!)'9@
MDYO:7<BT():Z8N2=1%52VO 0\6TVRXS%XPHC&#HN>G:VHPK_#8[I02\+7\["
M[2 2C7'&]]CM4RF&2>5HC,R?CC+4+3<CTVDY-M1'G?<M?:NJ=&ND6@=&.XU4
M->:<]!;(G]\K%)Y_[3_CQQ /XWP SB0["L5UP--"?.TP0H5@8(;X&1U'KX05
M)/*!OS8Y[]O>:\6(*1N]\S"2HIF.]'I([A-F+^)K@E0A]IS5;ZOFFJKD>EV9
M.)]@?B;F'VM1^B0X%X/*BAU[-LRYCN<]D)Z/M:E((TJC$;OZ3 Z&\I4U%<2B
MK^O>T66!NA(-VWDK=\9[FC42.K+S"U]EAU/%'3%5=-^J4!.++R&E5'L@'H#O
M?7S (13U05^R \F.O&;)U,S>B+,2SH,,+CSZU@&EY G>="8+T9'3@40/<=Z@
M(&<=B0^EM\MH(%$;CR%XE4%;4IGM/0&)Y-H5%BO>9@#6B@H05',EY%)-%HE^
M[A)SS&ZC+U:5L%]PF1CS2D!V;3(SY.#Q6.A+3>&E3%Y+:- CY[VA8-0V\2VQ
MR=&W4\\.&4SARC<=Z>LI0HE-,P:3N?;"G]Z*=HDQ-Q9"%,.Y:#51:?T*JV^&
MM-*Z9%#UM9P.JI]VS.^[RXXG2I8?G-](?$8A^@S8G9'J\S:S>.E[Q3>OK2,D
M&K:MO; ,D/5YY^<9A#@!.&MT/\#Z=LC,]XEPV:MUD\H6YX&O;Q M+=U\G;L+
M#=;^&BX"[>S9SI\'IG^$)#G,G,#-/^J*.P$! 8WH]@36HRGP 92BZVOJ<7"B
M8J47?^(=X=AC5XFWJ\B,@<DG+%[5^H71$-/D5)L$HT!"]:LNK&EO)IF 5+0Q
MH2&L^7!&68];] JB5WUY \)GM\+36?4;RV3B!:?R]*N>D.]"J^ZDW)G8;'K!
M/[>K63W\Y-IA;178HG=%I\CX.:M. NWRXBJ; E?>CM4-Y'J:2YT=:X$U7X73
M^TFE-J5:^67XI_UHV."24 <.[5;F.G:T:44+GT9,1UIG6B!;+"%W*=MHGI%.
MNIA,-@NI=MSI+E6TNBISV-UDB6-U3_*)/NG"M9%"A1+Q MUP0]44(0:FI)&P
ML>&PA U5=N55GA?)0(GM0.>63_K;[JCE)N7<X1+YMSJ?B79W>'D_/=V?EEA9
M1BG;5/2#=0:)=@;5&*)A.T@&(-D>$V00J;JICPS!?"N\'U.!%WE-DU_/^)5/
M@(:CLE+2WER&NR#;\*7QK=!;W6+ *9K%<'[W8?O]:ON6N"FD<J*C)4N@V,>U
M&MTK8A'O:EX?C]T$4:?P%=6*:2M,4D1T=7F%/)RYKK79;T\&7!A3:I-_*3]M
M:6Z \I(UU9VB)B\L1&NX55/Z#4+NR&\S;5 3MGE(',[(P(40+[U=1D.]FQQO
M8UOKN6%8F&,5$1%B_?'6.U5,>2.<.RJL@@*'9&@)$N$M;VAI73W>?CAH!L$!
MX>9"6LSST\OV4=5):P_1).,>QS^+::MV$>?F0L>GW?J2;9<P^CA#(= 8N]$2
MV;/AW-'R@NR-RH,P*V99<E'>./17[527@IR6>D1I9O"=!BCVT*1-RD>$QZ.=
M<O><E[P:>$ME0?<B7ON[9$DW1L\P;M2_[B9TCK*),Q0OT'35"N6[H8^8\;I,
M2F_8$,%2T;N,,5=V)U_EP6)P=G#DY\\V*X\;OL9_R^[J[QTITA[+E]$OKM#[
MI'B LP$)_O14(-+J6GUB(,=RB[:'83W&'3Z.JD_JKS0Q@FF(?8-CJ]8N4=1=
M7ZD=/CSR&O%N2U[#7C:G_8PUF\'WQ[I'$%J@MS@?=N0#Y:'7Y.2/YVAD<)QT
M&=2I?"TF(.9V&9V+W6)/M\HATUO M=B,/C9P(S&:_F&<VW4N%(O(P?[YIH^P
M;3U[S!N=)J%=!N(:9@8<0-QTX[2*!B]2MV<M%K!7"D:<ZGK$S-_TTB29L\C]
M<P!7%.(GLGUE1WWE\'.4T>[[NM*@R[[H<3_$FMTEW!V@J/HY0=%-9]O>#DQ9
MLQAP=UA^.= +M+$I',M><.XL?")&+D*!X(@:>J\,J1A=ZB?W9 SCI'\Y^7%;
M!\D["M4E4VZ 36#CF\2[BZ'A\WXC/7;>3+N#\*_#UJG0UB8<'E,2=R9DMEV]
MG=7SC0\4T3F9).71\2X37N6R4A]K^ ;N@9(A:'!%B<:GF?7@B]CUP??4.IR<
MPD<2QRX.UQ]YOQG3,6MT_NA^'&SR7#WKU?N/3\P+-*:9[94,.-DGC)\]N!5;
M*7'':I:7['V,]_TU#_[HSK['#QY%%:'(B7VU$"YI^2J@^I#51#-]9 L$U=:Y
M\["+JWO!WDZTZK //LY6DRIXG< -I[^%BSDB/M_,S$BKNMX@+@^X6*BA0G0_
MK#YSG"-LI4E\Z3H;=G ^7KF9V!,K%VB:"G^V_I-WN,MSS-%4SZ&XK63*W.4$
M]';,F:U*5QCE^1DU[C&R$@"PA'(-2Z2ZQH8?Z7EWRI#M%-W<2+M;GM!@0]%F
M-M$-A8,']]9LC_0"XS6J"F5>#\T-I6U(C!9H!+ .AV4/M0MH?2H?YP'*I;\&
M\U>FBES5F^5P2,NYS;]XE(-Y]4I_M?W[6P'7C M<JB? ,&@&IG,8TY,(F?P9
M%K[T@+0L?-MV/6OKR#O)P3Z,1=D?F946/D Z<G?DWY$U/>HJ+C5\ =5*AN&C
M:9L,#/I6M/+W\*N3)>(^<;U,]5IDE=06067@@$9LE)/[.6N4&6([N=D[J2:"
MUFN,>%ZJV+<X*>RN(1\FB;D#KNF7%LAKJX5:VB^YC!TO6'48&LA%HXVD#L/P
MDEG% @@=V<,+<]M'0KJPI^\_AZ##VB4OE[=>XN@EZ:T58^W0*W]'QW@'$4"#
MO%9"R>.X*\JA7VJ2?U!W&21?%7&K10S50UP%U>)Y*^@ E (GV.)_Q<L0Q80N
MHOI<-?(0#:WNZTU)MHAMP:C6J!&24>-.1ZNKBJ5LT:G6./%1X(3V,BA6'^%G
M87T9[W[Q%0>PU]MK)2[Z9J"9FX7/4 L+ *A  "$OBC1 L<?3/7(Z0^AT^&O=
M=)N^.=,'ZR,RP-'SH @3R%Q<7B@1<NQ27-Q-!LO#D3$[>S4*^88U0<DKI,DY
M<]EIG:^?Y9H:V##.8LI[DG5X\1NC%JMO[H@N/KE]F^E.!OU<O:1&DD"-<L?:
M@^)$.Q^=@+"PNV]E)^V4^HQ623C<DMZ61'FR?AZDK(QDWXBON(M0IIYVC* .
M2-$W<2:GX>>.=0.%<<? */RO5T;F ^NOW(J0K&R$2\7:4C;,7PH5SZXH7IT)
M^DKB[-_"A-92N=.5>^!Q+RT3DSWT?>)KRV!LN;QF7#5,UB#:NP0B%BAO9.OP
MO5 D57_;Z*,^IC8\ 3#K']\L#'0^?MQGBY^.-1A,(][JN.QY4&CM+4J _YFK
M\I[;ULX5;W,\E'T03^+U*[)UN\L2[K^N[ACQYBJA^7WO7(IB>5WFGC;.T;P(
MY9]CMHOF_A!#\BS';R8\,S1QNFO<3#@I)<23A2K48#18+]ZZM0O/%$TG=X'I
MTH*3:-#TVQ. ]0G LM[KDBL\S;5Y..CJ>P9G?07AGAR;9R"WA^[Y4YMX>IF;
M[..32:S V,"2IV$/Y4S:!6XQ%(<*CL(L0_IP,]O$>AB+]7UM\4A/ +Y46/3,
M;] >B5W'KEO=7-T_/+2G-.&JM8-N-'$U0<D/[U\ORS7W.G"@]%C./=12GP"E
MYUH9.W83+>DG,ULW(YD\C/SSOS!FN04O!,3%7EV<JHA."PIW^U@K7O30A%DV
M[:THI8DYINTU5P+[J_HIX;O#2S)CKH)O\V12BL0,'E")%55C?K9>SJSDS(F4
MKW6*>)CW+E%OS5Y$H$;7<4$[C:V/)$=?.S^!I+ JQ4B]F'ELED;WY<OQAYN)
M0<X:LE6O,2#=KIEZ6P+5R\-N,4X5L>5X0/.V(PK4Z(_RUNM(350).JJH2QB&
M 9JXU\;W58V%C7-6<G JZK*@KJ<7$17.<?9#6=K. 7:B]_!3^-1%:U(\A<-H
MBAP4NC4;JVL+W@[4UA<II!M$V.5WV\1->2??QK\'LH@B=C5YW2<*1XQ\5=0K
M:GGZJM\^26,P<;>G6-6H[BLEMGOWU12&3@I#0)6<:A]&EP;SX]L1<0Y4C:X4
MY?&5RZ&5.4_>I#9W3B4MY6_IN$_J\-J$D(I[?P[CO@PD3SOZPO)&W,MF,IG!
M^OV.:04_43IU;(ZR0U*,EBHJ)*Y()6;:M*@,6,T]]4J:?52APK$#*Q'"DL]M
MWF;4[?2IK3[N QC)'5.#K\9/'1/ O5XS-5P[%Z[SG%*0GH+M?FE'L<6[75(C
M#C[G--T/=PBCBVB&4>ZD1RGA XJ1NG.Z8^"V3XL^I-H;/17"EA-KW(,K"B,V
MH[BW$\J_8<O"]3Z+1#"IW#<(@9C/:+ _++KAC?NJBNM))[5"M_@#[V>WMN='
M!G*1^!L>@<2O/FOK &2!\B+8)G[I[3N=PP75+!_9RVIZFI.@0P,#U<\_>\4G
M96E1Z^7O"@7"'PY56"M=C4&0"6$*$#DR9_G6A1).39B5NTC4MYID\>PDI.A9
MO^S:Q6FASRS)5VVNNJ>*?D])U(U/'70+>D>!2Q%"%J%N66D$TI-;Y:4)/9VJ
MDV&U%!&Y1Y4O61Q"FBLGV2\++$Y*P -H=YJT<M[6!V?5!B/IZBX+%:*R*8%K
M#?/*+7@$Y[S-:66L5)(=@('IN3VSQ\&#;TA3YF@FIB!BI83W!L,U#SEY'CL=
MF):J3P6LW\=D3XYZIW^Y?W1>%\2P<>#>E2V[=FE<P=XWF0U+*[2SK:VS(S^?
M1/_1VM:S',*J%V$5CC4R\CG<<$Q=NK?%D]C9I.W44PR';:W?(!T1)I:33 N[
M$D:U82%;!8/E-77N?NW=\?<>$PAG]YN=7C1E9@B'L=QMFSZ8H&H)M.MTM8TO
MF'SV^'K$)G-^X,U"'O7I7GO"V9#"4)RL&R&PL?@LO834HU;G<N']=9&7G9CY
M:+H#J*4!'_&CO*;0J+_?3D"Y'5'L$\OA_7A45O1;_ZH@5I__6@N6I.7!]LI7
MO9ZE^=DVKDI\NH.ODO/4IWGLRJMO)X"BS4]>*3_TSTSLOCZROMZU9.NW?+/^
M=?M\?S]+E_.$I\L)X/ )?NWX :CYA7RV^]J*?_M2#'SB6UHY\/KVDHQJ\&D*
MM,NG\O4*1#F6S7=3Y;*A+"M[\9'_B^ODL>2;C5V=#TXMI"R,#%8$X@'*3#G4
MPK8A7:F]_*S+G8DM*!T[BU<\(YU0EJY[%1BN/\V[L24SUCEF)V.@9Z62ZO[)
M0&"::V^]8=JK._6&0W?G2'AZ26]+06M-24%?CH9>(AOLE4V\E<N!G4<Q514\
M\/UT+6Q4-Q%<KU*$C!97H<]D02'IBWE(WIDND.@?M<P7PD04?&FWKW1=+Z!5
M'&G;1Y0GU$LQ')/&KE@8!WR6]_'=>&[?G%8:"ZONJH[ZKD*FO;/[K++D<+_N
M":!;XNUNRM,#J5CXY7N-(QRP5D<=_L'*F##C%WJ4O0]G]9-"P DB)1*2"7V=
M>X(,^FNE50]";5B%Y66SR_PG_(L&#BEJ/=_*U2V%^<2RDJG%ZF&]K3.XFY-E
MD&9KB-4AIY;NK/2&7]F R90.7SQ+:"[F!?LSPIC,SL5U^KO"S@T%T[A?GL')
M-SM#&:^#V"XS2K*EN.1CF,XRKG/'15:TRPOO1YO)SU".Z +77V3Q#<&T:^G4
M"H;I?#=X7 <KF7G+7?(\ YN?8-]0\NU\.M12\[I>0S_(MKZFO;K( =] "Y0N
MJVZ.DJ/"M\$H9FH8\L"21H3-[Q*6L_^L]12GD@%IZ5L)&^'T\'TI[GPE3T'9
MW1XE\Z$T' =RA2U2+5?(ZO18<9#M9*:B8;C#;J$H/:M<!T4=$1U C5"-D$Y;
MZ9*Y0C(..AMV^V)<-BN !"#A"Q#]A)7@.WHZW*"S-7U+5/NXMVFLGQ/63C-!
MF=\&4J &0/57_1WJDQ*P+S/3^KX2H\9L\VCGR#?&<1+SKBHB'=F?UF*>?-7*
MPD0P)>^+XH3OFTG/3(?NOBD!B*1Y+R?[R$=T#=>+XN8:<?_C-T&/V[O[I:5[
M3@!?:YYYG0!N/WL\T>+M^^@_FCH^:RV[7W9,W)<>[:OU4051U[?60.3<5Y]Z
M?G&WQ2_B=?=V_M)>^_;C;S?XT5:#]KH_X<TX$LC=\'[[A>4Q@.H;\4H=C:+O
MUO36)]>MTRG4^:VG#KY6]4V1DPI58B=&8, =X(/%8=A%-]TCAO)&L2[(>?N)
MU/&7B3I_:4',D#=2 (+5<E]/EX\H;]"]![?RO1(/03=CFCV]UK$&JT<AB67=
MU$=[GPE-X-..T'J5;"[0UI-63;H\54&#WBSM6/Z7N&9\9&W*>M-N2I8-Q"$!
MFNI=WC3HN=2P?I)[@CF+"M%VN=WZ=4-,=O#5HE3;^I%'3!0*:5E)!=RV):F?
MS'::Q:\'27CJ-!];-Y7@<8_KZVWFV'&HUG:K2%EIZ)$\G8HQ,F%Z%&G=#VD;
M1<\G\4#270V,4BDP>UB6_:DC'DU<@RV&LZ,^BC4I'Z=5"7\MQ(I02CJ'UQ=V
MHQW?SKQC+UQ$^8N\28X%2&6ZOX@4>S1>,#8M9K(SIVF^P0-2YO5U7&=$Z"9]
M>NTTE....TE.+PY?B=:([N)4/R?QZWXP4QA!GK,).C1-A$UK5E=?WEFSRS"S
M)(+AZ<>0ITF)I?K%<5]F7[L,\H"*&$"AOO4"SP?>'W#:PI04LVYHAZ2F)A88
MTN< <2O<FZF0/6)/0VMNUBP]X*JW+K=L)2>J3-^8T""KE?8QZL2R> 0T8>.N
M,7@N63=![]C/$=7)1=5I?*R1K4K5%3R]N2Z99#W+[[<0UQ>3H-(RQA+M6L=<
M$5U5)'&G\1&UO7KRYQD9+?YE8=O6_1ZDB&WGZ9)BS[GU02GPEK-E5!.+8T32
M(Y"YC3+$#?CDY4Z8Z8!?@CB77OTA->=Z]=VD-HK,_:GL')IF"I7VSV50BAWC
M:OU1D^=":47Q;7*M]6;VJ'JAU>:CLV^1)-;(@4+:(4-)KR_;&RKV)P 5=FZA
M&5-/YT^0;3K5R@'2UNBZ;\R.#@$;?-7B3'>RI\5?WU&W>E9OMG0S):NBJO@)
MM%^>TLOX'89YFD3<IIBU YQ6KX3_(3&=8D\.@$:*]G3#[+^2(;"&Z?ODO?'S
MK5B:[>?MM8N];WF[8\9+GCUUC^+XTM TYHS>#?:+:LI<Q-)P>@[9R%C,<SZZ
M:B 0EEWP*BB;X?(Z&)+C<(5<_8:9',Z"NRT>OI'BBZ4#'HE@0# 6JL1GK"0
MC.XMRLO()!@Z8?]ING7(F]_[4G <IKB&O?;[W0.23QOMG_EKUX]U!2(WO\&E
M[ZU)A2E>?W&UUD\D2D] ]/!3(&>E\]'7IEF4?>LKDG/OY[-J_GQ0#$/KGY#
M[_>]7B<K?>^#=W*0UXPCB>1\?5L;U;V/]_+$"8[*RC:[@YI"E78'V[%<44X
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MYVS0S+7Q[--=;-7134Q =48N]+NXA-D"PTMPZ\D4M4:QFN)(L;0O_40D=)B
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M08\'=E[1W1'M;'>[*\Y *'8;U=FRNR-SXBPTBC,4/YO?1G>V\.[HW-#8VF<
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M0K_S)TY/=FVIZF4[H!$B #F$@#V857>HB.M$=;!LAD4.KDX!W^.Q$09J8"8
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M2!HSM6EW"Q0=Z*$[/\A#")>&L;'HXA%!I(; 6M0R$2N#L46AG<\=<(INMIK
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M]P 77_KUV-1'AC4*+*-M6,P;0-FGX3ECB__$%S:B@9ZQ%:MA']6?\5+BZ!5
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M*89I7VD<;QER-(TYZJRTU5>=+NK)D;<U(P115JYB+-KJ61OI@T&:6L1%/[.
M<O(8QE*0\-^%'::C?S58A[ H]XTU^^NF=LC7'+O;^_/N3I.-.I]G]!8'4/6M
M/S<-J;-8SA5[[7HEM2QYA^%Q]%2=7S4)A<S8"'.4\2T,K> 6G]P.5#B6_7E2
MB?D9!$(G0*[?4E+30(F4N4F0_LS0<SLD]#-06IJGR5?8;FCGBB+=#YM/_?2T
MF%'/8)W+QTV6%7)#362&9P_*LRWHU,NHN\"+0"'.;5NNHZ+=E<U /.@U(_S
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MPN/QHQ]KR'@#-KQM,XCBP9I>_JR:[\ZF?5N*83U?$<MM](,LF8F;V^_H55Z
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MU]\#_J23'V8)OD:>8Y2'I8,!/7Y8/GVHPNP?!GN"/Z3PV7<  .(W/+T%<!%
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M)C($8W V2<V9^JL"F+TEP>E!2%^I%C;F4BI)P.DW#: GXR$:R9D^]3<K(QM
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M_.R)9<5.ATC4L ).J!B\[1G%187LZ1A<[KLU&J6V-UP)\[3GJ]72+M)5F\=
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M;PC02M^.F),#M:SJKVQXB&G*9G\9V^C=I4R^UV#JJM!4.][*_K7G0*T%^,Q
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M+?"TT:= &Z(B[56(*<&EBDEHXP?J&TD3\Z))!^'3WG>U'-9M8>Y*\8T'![3
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M\IML92M]T\=5RZGY[PIG0+J,)N@G\/M9M@XK8?\N6[;G3MF.(O_0GK_Q*5W
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MO*6L<G !_53-N[9_GFG[PD#&=(R$;]S@L1O#\1:]?&F>]CM7'6-PXGJO(I-
M,N&OKC:^T<\RLXN0%^[C6N_;U\N&PXA69TWQ,9.H.0:7VY9+1%:>G\8#T7<
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MDCP "0D9R1O)&P X72.QU[0'P\!0>[ K#2\'%T!(6DD-%16 :"2J3;K:/TF
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M7ACGA)+L+[8Q["!@=]??6.A@",@.]*,JRNF<*6F<\Q TGJ4[#*P = %"+&%
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MFUDN3<] HOW*BI</<KM?!H,Q3F=S>LL:RG\EJ^(.DVR\KHW<ZVR8P-7W>C/
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MS<AW.[) J#4$='[WDN:,MD1<K\/$Z>BP:7YIWX!LK'_@N"*NNL]1;*PY@4Y
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M06F\+1G,;T>EQLES0DMTU>]@>!3>!''1MSUK+1F]EFC."*Z\AGM?R[)77(&
M.Z,YRU7B;I28 M57,M>N VV,UJP58+9WMF4M;O,>#F-8I>G6X;KG2Q0CWPW*
M3Z@4+F.%J(N?[8!9+K,M/KOCIOES#U:KU6O?/%#Z(,3CN/.4KCA0A0%:5D9
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M5#Y>:._V@X)^:[. S[O!VTN)KP7NXT5]22U+'?FBTWLSEE.5U2ICCW#GVON
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MF:I55VU5=+<U[]Z: [_"(GX_F_!,S)H^F!7U)*4:XY'];,H [WUH3I6N"IC
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MRRA>[V9VY)+;Z[T7!"R=VGG+UUQ;?4/JS3;=)QD>>@>=$I!!<UF^.>5*>$6
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M$2>AY%MQ!M&'>F,Q@=.U]3:WNHCA]TS,6[I*BB,']V*#6[PW"@8>*#&4A36
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M4RE0T,ED'I*P=T?UQHO9"5K4A@NHQAQJ$FI@T?8+$FWDDY-%WQ2/#IZ7K@\
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MD/U9.&XY\1_A7'IIV1]\0V)LS@>?[SKV=M+[VW5.FV94A>4G&U&0X2.6W#X
M1ML]I1.@],K(%R(X:_Q>UP*)-+21!EUZI1%1XD>(Z)AX/J-JQ##M.@ZK2-RG
M0Y]<)*)L,LEU::7S+9ZV1^OOKL7#)),%KA&\^KY,#OEPW+]. SJXK^T.=%P=
M++1J1CR,/Z-#"^ _P)L=4"FA-\=&XE\PWA'(WR0-V,#_JX\T0&/<966K]=CN
M)"1KX%'V7R[-9IKG]&67;5(@+ L<D!5*LR]!O?TQLQP+FNVTLA1O]%!"*ZR
M;7!B2<'!FTQO^JS28WZ04I_ W5F(PF6N]RQ!-#,\V-G"(]:*!>_QCJU'M\+;
M[$FK9U*5OJ'QLM 6=/.GM>-8ZGG8@IKP5URU0;2'NW'49C,A-RWM+T0"'W[%
M<J^7F!F(.8A^ +FLDV#SEO#3BLWV8+!PIIQCN/=BEO(-&4>)]OKBV>)N(-D7
M*>7BR95#8+*6-RTTCU,-MKDIHWC6',U5G:0Q]T!_FWA+:W\VA0P"!L&VV+2N
M2XI-4_B6=XN\0V7XD8Y=M/L#Y+*XH#HO+QFWB+61R"\A4&V+K1Q\IO:V9!HS
M6X/3O]^@1J/>)>#K=.I2M@ ZTJ58[>%!&H4B%X./C2$C'=7<\D-) 2M0!:Q:
M$7J!Q9@>J)6T?[[F5P0.OOL+RYV MQ1^^7*5-V^RXHQS)=(E,8^NT*X6F&"(
MA(G!S-"OKN3]%)-!T7SB!?2)<MJPE>B$:=>"C3F)FS]IEN#I6XM85PAG*I$8
M8UV<['+M_4'D[MHYEM])%BLQ6%91C:EUEU3:]D8M$&Y<J(K^4Z_@D2*:YO&;
MB>N84/@ZO&'%XD_UJ(NR8[A&,1P>[:.AB%!*RVG#RNZNT/Q,:?K%PXOS817S
M40ROQU/Y#/WHU;KDH^,^[*?,];4!FOES;E]DI:3I<!4S= >\Q:'23K9L713L
ML)V\0B;#,D?4YDU+!TDXRA&(^OP\^^F3/8&^C'W.FR$?3MJ83^^0"&^)W*\%
M'-IJZO_BQ<4?UO4DCA26HZSAYLM^^1CV$03>; /1EZ6E$LH65@@/2# 1&#LK
MUE/TQRRHE9Q+8D]\2M?YMBSS6FN!E;]YKW;_* QQ8;>9H43/)I<3CQQM?  6
MT**F8(R-:1/,V)H^ '7U([3IG9=]BFW@$Z?3Z+HYQ[ J1)8';AUED[RJH)7V
MHB3DCH9ORZW1?8%J0)=SH=G$**F+>8XV4/QD,T#>&!8!_P,PM=HH KQ5J0,K
M-E:LJ?,<5,W.0>]Z6+CEO+I,,K$WA:__*1 W@3[_C,2,AS<%B<695SKHJJ7P
M"MD<\PQCHPL9R=\7E9>8V8V.GH&@Q]SLF4[>9OW'LPZ;T;697>B)TG#$QNR*
M?03?9/XU[AJ*5@4Z5)%;N)?&"*2/!B%M",V"S)6V-#<[?[ OG$$Z^_"C-)KY
M>$=2JYX=7[=IT%(+I[$I C1O0TN+AJXHKZ!?;I"=%FM(A>UAB1T\$O8U,G8>
M;[_V%*J9[*4:I^)X8U!ORW;A-.2R^=%*Q[4%?/*#EG%1\U@483"_MDY%CP[]
M(<.I8>#VJH^51X5@VFLBX9:G,196GS=_V=1;UD?M/[.(*/>:![0=H$'']3\3
MF\Y2WONCA-\:E;7?=+XWYU.N[ 4GUW_5R._K#<$B-=1]E3$H+1"-6X4JMT(M
M')@=[GKL;_MD85YY@XV";R%]L!<Q#:E"=N/?T:(!HIK+PBY2I0X4#HQ^DY*.
M EZ2^_=K"".#TOH*^?I&G$64)E$8PD/<;5[UWW%\+\P\/P )\I37!"U_F?_0
MOUJU<GPS=XUO?;;$>@T$Q3]M+T/B</'BDO9)@0VH--NI. ]I1D,9Y"Q>1^GF
MVNZQU/NK+PU;XQ(1^#C77T0"=RK?T"'YEN^?G%0=CO%=':Q@1#;QV99;^<T\
M*))9,0\^MX2*6HD:?*4G]+Q;JF[5RMS6-'0R!W'>=THU0FA,LQZ-Q&"/ITWV
M6$UH24)[TS0X$PM#"PN362O+RCVP$PUT KEWDOZJ&S[V)7[O/C^-H]_HT@7K
M"Z]302=X0QZO=^-'>M*=BE/2E?B/J*LP65HG5K0Z/D8B+[IXC-1B*_+0.HT=
MMQ[[#T H.R$RR<BQMV>\2^Z='9)1E:#9)(-#KY!"< ;:2*)DHH],6EP.I&6"
M-?)23U&5HJ). 3H%G)8\.:L-:G TO#>-BE.^VI\OM%'U\KS2X-GMLW50OJ2)
MHU86B'6**!+!"&"D"4-]=K[5H"Z5,;$P7UU=Y:BG\"R%3>U$[ZD!<@E.WI"7
ME1HA1=A(%NM=G*#.H:GRJG:,&KMB'M[25?]5KFZ#(E^O6 #.9;YS/A$QTXB#
MVM6(0S'V9Q-)[=M'0_W>6^<,DIY$A--^$BSF.51\OJ_/;@Q1$_[W6A6Z!,4:
M?2JM;X.]/N_P21%X.I3-SZ+)"A*_C^@ZT8>G3PMUZ_@QX=*^L1Y>W^&V#_O1
M#LY\E[M?&94;[H A[E+C&A]Y@TE[@I<]7=TB(02A<85011E71S;#RV73J;J4
M%Z8E(&LD*&&JU'PC*\?][(HW;*_Q5&Z_[6$T1?@Z?Q&H:/,2>7.>Z5%BT/YY
MN55E:S'NT]9P_ 78..+PKG'^K&\L$O2>6BFDG^6 OYR85 3D:&P&_M"Z(R[$
M$^ZEQVGI#NZ24O-7T&IKV* [?@@M?D'!6@L'\?631+4J5TMCF!]6+<E$V-:J
M5:A;+33!C$4N&0AN#844WR<!K;T68.AL/4,O+RYOM'"A7[_@O%#Z/HG]RA_=
M^O?[]CKX]#=T\!K79B.H7N\"ZM;YH;#XC*EL QBQPP%YPM_;/ F]1^4G;#*B
MF[&-@^H:X=,:X5<BJ1^BO.:,3U_811NUE%GKM[J8. W"_*GF>**"\^'<3T*,
M37W\.[YW#G3/QKH0-K^H'VUL@Q8^ "AT&[TQ6S;DL^*Z8SHFM":R6L<TO>$4
M(*V3D])3SM)'C68\LIAO@M_P9]0_4_49VY)J84P558]+_F<M)^@K>F>JIILO
MM$39 E(VICU+&W0D(=<R,^M6)*+!%Y>_0[O8N75);L:LYOMD]>P$CIGU@E=M
MHIG>5V-*/7;Z?VTMIA?(M\SI>1TL53AN(>RSYH0% MGG/;H]<J; LEX;;L>K
MPP_T.7.CPSX&%!(A6/K06K$:OU)G#4.MQU'J8$8LF;\L%T#C_""BN=HIF1H1
MOMNM(E?YSUT4^?_Y+LI_*_,VYD%$JE&2!+\O$0A\\\G+6>AA-NQD42]IW@A=
M(<@IZ6KWQ6MR#0UV/F5JS8$:9ZI6V%Y>6>H0EA+)A&+?WP-[YOJ,X.:SOAI"
M=I-LH,2!T^@5-*.+9[XI%7H%-M]D/J!X'1>HS%(TED_XRB:9/ [@3-L_"V)>
META1D(4-S_M:-QFC9K%YGG67()\NQQ=Q)/&\5/S\K@28V4Y548PEBHYL1=VG
MXL$<[S=0.AAQL3Z2LN3"L7,@E_%^<L@&^QB'T7.]E&M5T6H1G_]/=$FW&]42
M&#XVR-EQW*Z9JANQ*T]Z>!78+A0VOXWMD<90JR%<<B/N(4]-X1Z6;Q[ Z?P\
MD/2B?"YD*4$89"HJ+1%2=2>^].@-\>JH,!6$@2/\+G+'?%^[%Y5Q+G#,36&
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M#G@![\\O&3GELQK.A;\8C@*J0PB@_3O=T[8WN(NY/6I=Y8QRPRLU;/+!?LY
M66JC;^HO&:;\"%&"(L.,C&%YX7 R'."54?I/^A-'S,3#%OFI\XB^SJ3)Y[@.
M76TD;(AY0I 4)<5PK;O":C4!9*NWDELSN>\X4716\ICS9:(#PB8*2L^XJ3)>
M(C^4R =M9BDKD=+>.5<\/)YHV8OFS^[=9@+&B1_A=80$[*\BQ8Z4^)VY1(.I
M1F20JWX:F/80XCH4"QT++">$-# ;EWPUH]I\.'HZ45V+VJ>(9I8<-J10+QP%
MBI6P.WKF#S6JZ1Y(A)XUJA3"O"K,!(F]BA2T"4M@7'=.LKS V2RTW-A0EFA<
MG!2L5BKX;\>$8SNA,.[[8P:@I09\,A4GILE='B>6(88LZ;<_K#>0B3QQ(!Z-
M/(F4,.GGFHL0B@?&&?^_OQ!<EE4@W*H2RS4)3U,A9<A_<'"EL"'NUJ1D^$H\
MU\X:RIK-@#+4VWB24[KMFBW!*H47,]*JO.@BJBIU+LJ]9X>%JT8/VH*VKJ16
M2V>PF(X2B_[;]XUG-+_&M!G$)(9OH @,&V^G>N<&]SW[.BNDFNG@8T%9CD'X
M6>7'<!STAM_%Q1*(V-;J;U>>CO +M&R8.[57CD..(+6.WBEL4&HCV)\%"=WX
MQST_>PF&2I"AW)-UPV9MM1F?,FG8MQ&\B<9\+S=0OB*8G^1?V>!NI5VCX-_H
M:_?$NIRQQJ]6AY&NABL'Y5F;(\>Q?M'&&\W@MB\@L]+4>LYG(IOPG9&C]E )
MHZN>\]EP;98$-6"7IYU0D967^5KPG&\D;46:WH0"LH;!@^P"+%8"%X-J@I56
MFI@SP7Z_F>1@TD;X"H$_%WU0>:8QE7M(G<>>B(I;)SS3:R8'%W?(NTCU8C#6
MH6S-H;S2$(1S;%6OY04YFS,2QT"*OS24;7M7TJ9;=W?Q+QUST FE'SW04Y#'
M/@"WD:T##9HFF@=:UB3EA .$*TT9 Y]O3[]OAI%\4HB-DLYG0]2&V ,GRK7I
M6K.',3-^(6S6\>9)X#J '&L/YO YR67?"A,.&<MU>-+A6F3"Y1H?+0A1^@JE
MC/IY=-N[/;3($ZQP:KI;@].4P)9UE#2H^*M6^78D@DM9,G68\.$P8XCT^?7/
MB]&(IX_?Y7N%DV)4/_,<7=0D_0@7 7VWO'+\^&"]Y"&3^]:RVF]BFOUH@5SO
M\HT) $Z 4E7)I?\0CUC;95:O=W-:63R'\]!U@; O?%O<;]:>V+8\*L]8ZL7-
M[_[S4GB657)+$Y=)J1W#UT5#\:]!?B(OQ.LYNK7\5I&J2Q;99<@3LMF:@LQW
MPXLA>W)X+WW^^ +RV_UR+A42&)QL?V1):3@HN8 Z4XO Q(S<FYL>ZPC%(5GK
M1EKD6' VY;B"V5>1WZG&ZL@=2@'RUIZE ]7!6>A2E=$9LS:HEOZ42N;!O\6_
MHGDEG XC[0XC)%NO>K\IA(VB[^$MH**.H<:^]FR2%\D 6T,3&/MT\757^2*2
MKQ:G^%IA3FL?Y(-+)Z-PW:FG+/GUVV'7'"1>/I4Z74'P=0')AGOGA?(AA0I0
M\?=T#OPFPY]8)CV,5MC1.L@&\3XA*/-EOW>^O;U+_<-MW'#B;S0I&*LM@%!Y
MJD*JT&=^??U,I0:$S- EV-_)>10#8O?3GL*"/C$SDECHD07/@K]54G;>_[_M
M^"*0]-,U?KG?"$*_BFAR<VDC=]N'4YPCODQGU3]@I:MH=(6"5Y]BK"PVZE>>
M%RJ/2KUJ^T@V0[;)K1QQ\0H,SO#BGCW%_4$6"2E?S3N;EBB/K<IR6]0_ #0%
M22^-Z/O)EC,R$XOXT[,](G,^N:#S0==NM0> T$(%OIJ[?S<5QKCJ('(YL;5\
MS/0$='*(,RP @_?'&^G9!Z /YS8)R/U $'=;(?\F+_FT KK9M5Y!:.$V/>%<
MOGHM5.GB?P/KBQC&CL*VI7BAC*>^%^\?848BO/-7D[[_I8Y0&:\$MB"$]E]@
M$NOHPH57)T0SVY/8$E+K4K,;@]1Z@M[[SGHY4[I5> O]?71";*@Y@WM 0RC8
MX9>-?*2R4:&=)6C'NY<\X;ON')#"ES7+J_-,-_WN]FZJJN?).)A] JEO=#^
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MOC>,= OWW[/5.9P&R/W+WU!+ P04    "  V@VY8!RF.RL=N 0":O $ $@
M &EM9S$S,3@W-C<V.%\V+FIP9^R[!U@4W;8F7 B"HH(H2 8E2 8)3886D"RT
MY R2:9J<<XM(3I*5*))SSDG).><H67+.T#WM.6?.=^\W9\9OPOW_.\\S!?6P
MJWKWVGN]:^VUWE6[0$XB?P /922D)0 T-#3 !?4#(!=O'8J[0$T 0$X.8 0
MX Z @28 W$*U'@  FHP_%,! M=%0O^J)2;_^ B0 <&MPDPS 0MV[C[H61IT
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M[?&.998<A1OJ%$['Z =K.>>P9AL]#9;=K^KI_F>V#.TO4=1YC_B1!X17* 9
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M!UQ49M>?D^691JUI=N[E[IDP^TU8!+T=]WQ6 9^JBF+0F5O31L(8>5^]FM/
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MP9,$BJ@":6LKK>YI8AZRB @$R#9-NJM%Z[-RVU*J/"A>NRCU9WQ[CG7&9-D
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MQ@;^\0A),)O+!=GDPWR4T03-YZ$9/9#TUK&I9PK9SQ:_\&;>41,1WB'J\YF
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M:G_E92> P-GH]LLW]ZE1"F'MR()5&+J^(LW ,6J?;/K$B^PM:[,JZV?1*A>
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MH2,)SD%91>0^5;:W860W%4JQHT^)#??G@9GOVW$M14SOGE.)7O$3)$!"R"4
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MCE7IZ0.'0S,/6ZJ=%T7J=Q*#"PEY,S?;Q'3E5N /ECPAR*H,Y.X<2]+!-'P
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M'O,]:-%6>T.,G[F9G8(ZT1;G'.O3\:A?GHK42RG[ZE#M![>>;E^#V>2<;M\
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M\OY6> BAE"5+P>E@O)->;URB,FU#Z(?[J3A6]*=I&L_5=F-_TCTU=8VMIR:
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M3WBA3/)SKS_6;"7@XE:=PK]T/2SWX<G]L;^ES4IK YU5M[D^@54[TOCLP$N
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M1E(&!J/)D=P:E?#SE0_3?M$V]A_J;3_7Z<54_4XJ&/3"QNAUG:G@[CXR?H_
M3[/8X'ZZ:*/GT].Y,+\<C3S&2E]Q9]2E>P74OJ'<*)!+7KL'='S8)P^T,Z"F
MTWQ)>!.U%R!Z#^CG[FB[%)Q[P&M>C:<[D0'TB[:M;^*[:,G&F!&D=1]NW\,+
M.V$]8$+AITH&+YX?\F3_M<H.EV1=!)F_:%LCF/(3<"VP(S24&.[/<G>*H9!Z
M7O-)[E45->%8C![7SY)Y)-_E%X0YBO'*:5YNG=U8Z?R@Z1=A[SHC*R)<_.G
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M"P"X]Q])T02D(%14ZY$?@;&U3:Z_YCL8*YO963+^:LF08SLU<$BU;T#,+GX
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M?[D*E\!ZK"^1!UM>V;\Q[QBJ9$R]86X06()5]OM+<J@\<[2V!5RVYQ#DN*G
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M+YS]<P\81@)/"?[;Z/\V^K^-_F^C_W\9K?]?/J\V:OO7;%."$$F:P$Z&LJ'
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ME%AUPZBN;I-1UI6UV)';^R*=C<.D/YV^T5_Q6"E754=!&+$A[8B2\,47&-7
M+:F//SU]4!QJ\]*Q\T _W6M34HLEB(7+5[>NR-5H6$LE5\C>\[$5_%#-\.V
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M)1>IHX:1"G&:W-,=6;E=K&4[%'H$G$;!][(VPCHQDEFE.-71)?3J%V3*4\W
MU8=24]Z?%/75PEJ_MRPL$V+?[@(*:M=B5^=ED')9\80%1T0O#&A-3037CC]5
M3Z)6I7O/"[(L-U.Z\.E^$C&%CE-^'&D/QBH':-?T:^J3G'*2;_VJ5#+T;*;'
M!.KP^(X-N(#H]X[F5,RKAXLK?1V=KAJ^:$[4KK(#1QRL!'>)2 _5K;LH44U
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M+UXH#F&=J<H=QOVUWI8)HN!!;K;K4@D-:13$PTIK1$&&)8VVZ=/0MJ&V*=G
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MV1JO8&+-K'A+^-V1,)DI8M/5S#?/J#KY N@-2//]"$^CH%^3/BL\N#Y#[*]
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M<_;$T8SAF"B"?')V,VODL6OIDE49,BV$%11<E>0>YY;O>-I1=J*N-^$,.TD
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MGRC[6+<MG7>I^(.CGR>8J496O?]&:T1N8L2C_^0)@Q(A;S* -B<'D4:*_;9
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M:F5J9FF:<B_V.$;LF4WMTH);RCIL T7\WQN0Q$4.'' ^\3J23948KG*"/]"
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M<U_K87[7ZF];3DZ_(XB8$<B]V^_[<;$;/W[P/87T%IJ3/?3_3J$)1 _IMD^
MR!QA\Z\W>N,7+6Q_'PH6V*V_6%2A8%+CXDPZD=BFVURIY\ F9E%= Q9@N(^]
M"DP!]U'6F<PHP:VH Q GN'3^]^! 9:[CDE%1^/J=)BZ5U0@R<+]Y(,G>R1'S
M'Q ;*@S'69<IJ-3SE!'2E&CY,(/KWN(= N%!?S4D_%P/9?!=P_7.@+?MA%.E
M9>.Q+G+VU7V[==+$5T0R3B>,P+/"]M82^1M%A@=PHK_4>PC5,+4V?R0DB4O.
M=Y?9%BVXPSL3)&?Q"FV6D(0<)NJ>%3&56&X]@]8!'0K%?[]\XLH=(DK)2)3U
M_,<4[H%]H^SPYN>B'=F19LFL8,C%Z^Q402VQAD^U&S4CTXO^99_0DFV%NROU
MO-VMFJ*_^9L%TG4<0_$C#;%#KJD:%&*_1?I-K68*,&_+[0-8+>AW0)QM#9->
M3YR]=W?7S9[7,%DF1JA'K VF'AT, SS/ ZFQ4JX(?RG3QJ8O+T/U786Z2*5?
MI"S)RRAK-3-R;C$>Z6Z#Y"=.*U2.-)L:VL<;^*5!DX)I)<0QBA1NFR%,J>E
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MPL7H/Q=C*:1 #T+P*+9/I-DG? &=B:-QA-S6YSBO&F0'A2/74XR]BSB+G9
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M1HM,></+&V3@RN3=3Y=?P*A[8NX:QMF8?5K]P'P@<+*W<94CP:9<?D@8B_G
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M\Z9RVY43]<1QV,\VFHNBU\_3?.C19@Y#//#DGL$ZX8^W-[@AW4!K?8,(SZ6
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M[6Y$1"F"2&]!04$!$>D(!"P@(B(HO8M($Y >FJ$(2 U%0&D!03I!D4ZHH8B
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MUN)JW%9T4S6VR[4N.XJ#^6;<]&F#P%5JHV]8K1!GI$P!Y,/<H;'W>8-A@8:
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M@T(EW^\:EI1_U9O3-!+"//-O;?*#U[ZN[K*AC3U[9J5U&[+1@9KFD-J>X_'
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MKNN6;:P]U8MW"0E;5K*":4X=%1Y3S-@A>#!!S#IS)5Y+M"2>.7J#72+6H$H
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MTBZEQ:=V)^=$FT:W%'+0K2CHV_<PA[*6H<,!H[IP 'T.'+!J@>A/XE:H;K%
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MS.^/SJ;ZH\RR-&N[E\<M1T'I;4GCNDZZC%W1&(F^U'YN/X"+8K$IC!EGM9[
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M]326M"1F9&I1[3"IAA)7Q6/>UBB>)/8J;T<?S!L'N2],Z^; )HJJI82.)8'
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MVE:X)T!;867WI\M0#:H_\"EZ ZQF=$\)_ZL@,@[@5C/5U3HB"C3 H [S?$3
MDAG>;;1=%P+_P$?S&\A"^4R8XJ^"^ Q (V[ HSY$9!>%(Z;?$41LIO*U70V
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M@YM> S=4]B14:-%;P&?-UY6U9>ZJN@3O[2?L#6*G(5+[2V2;2$S2A %L\^I
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MP;7IK>LILG=ZN$IH@E),Z 3(QS" AFP$<''CK&XA^)^%>#G:&$!"C2@:#<0
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MA/AQQK%A^'E"'NVZ==S0T;V]0L)UI9D3=T.EFM#(S5HDJ#R1N/6\)5SR VS
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M:R@22"2[B3MQ)0$WHTUZC8<C>374.VED+2E:((6U1VB.6::@SZO1X;*]Q86
M/@$B/GF_.9,)B*>^B87P5-O U$5AH1&^H%8JF$3%UJ2O!=*P-$'%R$L]FD6%
M$'JOH!Y_?G=C.!+(X!@O=,O3#KP]HY--PR],U<H,ZVK--\;-+^C;K7EJC&8Q
M$S4<0*Z],CM4(R?]S$1UDFC''#YY4\HI[FO#S(I)D\G5T._[TCPYX;$XWRXO
MZS;94\03F%]Y*M\G,) ;9:T(-A;2_C#:_9LRHBS/NAAG*7(K=0)_\^VSY&K+
M'/-7>B%U;=_Q',A+R&M#76855!3#9?JGB_N3^5J8BCO;1J7E+YZL"#)^))';
MX4>4"*WEY@XO7M506!S-B(0S+0IWWW,2)Y82%I/*D<FK+8C*CUJW[L_.'&_A
M 5,QN;?<Q>U-D.DK"927KAK@X+1(_1K(HZ7Q)N^.%#[1#CON>S?);IL>>OY;
MP7+2F\-Y1F9IU5\F8NRCAWL;J?%X1)_'SI'7&1S:P>Y'M4C<B'GN_2Q<)63\
M81K3RVSR!ROWW<L2,O266+G%#&"3GP*[D[>I,K1\NIMIF7$! <3X92!3P"Z1
M]'J;AF..:L*C_L7XEBV]8-?RHUHK0=X54%=X6S?;MX%=V6I5XL!3]XQ<\+'#
M2%J(U X[XT<\]-14O&CLWNI"M'>  %)MV,5L=.,^=8,O97N@PT51[YL/5I_4
M<B$H5;R5*;]5>9%\28U_!F%DH1H-6HQ][2:.*]M?+9RQI,E9,T?1WYZE]=D0
M/#!7'J__G(S)=O[^^V\N>^W9,;9YUQI%WO09#PL&<Z5Q%H1MCW(9D G-725>
MPT%DI$'4&+@0NUT"Q2?B<NIY09)*UR/:%LU((U $]8MYS\UME%TE1NKS94M+
M/W9=OJX;T<X<.\L2YAP-V%.E.":<$"@K'EBK]F$*FF=R+*)]:_A1;QP'SW-)
MD&;N'16/)67'5QZBW%1/9-NR>I_C0--54P>: &=?K1S/YQ&HU,:+R]O(5H;R
M;!K[DDP3P1X7 V"XU4I'-ZGB@]5ZJD3B[%&MS=/T")MD8\B*2XDLDY>&Y??[
M+:E3(=?W%C$ 6 M[.H(?3EAOGK6L:U0F75(RSAB:UO'Z@V>;PR?#>UAMP<^:
M0H2HS2.P_L<E#0,PTC:UKLE2\I3+?(U;^%*0L6E'DOYT<O\5W*^8DU@<7VX[
M?\I/(\U,E0LD1MRXOH,0SLWB?,,OSJ(]/-/_9B.?4BVRSR"><W.TM0IHDY&(
M7RI3+F8;SSR4/L1IQ\JUXV3J(62X/3"O'$MH@)^UPKK/P#:\VSD:4R5ZX&>6
M;A0S_RR_:2XNU;S;9<9-G 1-BKQ%N[P7FMJX2'3C12 KXFY8J4W$[BQ5"TX/
M;H"A8_8&<I*PV"S)@"CJLWUKN_M]::%WS^WQ8;/: >]8AE.&@_(K/\ M7C[O
ML+(FV40R4>VW7!15VU(LR1^]79OF;.3+^%65-WFZ,*@.*ZC6LRW&G_[A3KZC
M@[9YID-'=4]I]GHS_BPRR'>9;D7Y:!K]_F((3.?R'P5L@$*IZTHXOW@5Y+^/
MQI2-V&@Y:0IZ]?N3@E;S5R^SKD/N],J.5P3GT!%B ,>KW=G(2)AKQL@+S9&>
M^49'=Q8=/X?,'FHFIBQLM@+S2!GD$,@C+Y'7\DVJE*$Q;%FT'O7(@#S'"WI
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M\F5>96C(T$4_J>(]>GMMYT(Y>KJNC7RQ%C<&R4CZQFA[UO]K&/9_G>R*P&[
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M'E1S8'MQQM\%.,$1I.#XUFJ.%KHU\E4CQ1LM2'S=<5Q\CP8-$:FW^U?OO99
MT"UG63>TA5;714F&.;LE6-:3/4U30Y ^3D;XV8X?^Y9>;3;46S&5@OM@AZJB
MV'PE* <IL(%ZA=Q!VEFC"+NT_80]^=..U*Z#^]:H:(A!8V!GDC IO?B'^N0/
ML7TBQUP?OZZ1>VD9@!YHW&]+^P_HSPN]!VPA%3ZH,/*,50-X@8Q E=Y56KC+
M]-Y,GA&<"/'Z$!G\$_A'(2A0\AC0R'?U1KZ$MJ:BN2:AZSM9GT^W-@6QD]"*
MG^;"Y8W$]$'SB]4GMM4+!1LU5<=Y$.*(:MM*F@!4<".8Y>0>\'<)K;8W\G0R
M#Y?\0GP>><.3R_*,&^1^55E:4F@ \BKIR?5J+V6R'=)XC_420.D/$']VX!I]
M16-(]<^Z5&]G:?X^>L./11Y@;7 @*7N 59V2)^9JG*)K:#*!HF* AO.MXM6T
MB;6Z<ER$EKI1/(7GI.$P8W7<;3)L'BW4[E;$G>V\HIU;"4^*E^A%JY#JN7G?
MZ-7%=U#C/BS4E;-V^4E"P),)P;?6,H'?\D]WU<'_9R%J9XWN<Y0M;K50VGD7
MI?G]Q0.[YI+FM2M3._6^#D*H?^-L^R(&]U7Z;H#0]68+MOP1HC0#U;4);=(N
M[AC4SN:VCX/+'4@H9]C6\2O!\Q[PMPGO9)RGH%P8K[5YAS/Z2N-7M3H(>H>3
ME>-QJ#7N\F6/?;423#=$.(O;WJAO>P_P-K6(3/=$.X;6(?[[")0;>8Z3S81:
M.O^ ^3$5A@.\.6N@VC9>SY' DG>7WGIUT[:X3.F8"UJJ"FD#&NN/L%]YCV?N
M:C_PV9(S_==AL$"WZ<^X>4X)0H# L?0S@;\]SE]',O="->%@IG#4,&/2XJU+
MKG=-:8C1[WLG#5%N!XK8H:1IZY)O$J]S*C,=8Q0&Y$;K"!9NZ<=J? 6Z+MP%
MYLTWBAG[L[&![,1L!D^0J2W\08EPV:"S*Q_=HD'"L/Q!_*2XOCA9F[WBXO6
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M=\ES'RC-D#5EXT*@+^)4QVF^.>J;P/3, X53XF4O_1C:AV6&\7@I)<N=Y_<
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M>T:Q54IEW[Q=MI47';50;9K90GKRO+*P%E.4CS0X2U>O.WNAT[EPJ6\0A3M
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MQO$Z2Y>Q%.;<#V2T@NUTYE:X[^=6DFD^=L;S1463-J'F8$V=U$C/4*(A9,J
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M1<D>>S8H'2&K'T4<R#849U./21S[JG0OJU==?D=P5WUNEQ4,->!1TQ>,T\_
M;($VL.DB>:1:&-3#)H&N)7+5Z#EM\#>;<FX["T#_IP-0))*E7G+('+3 *IV@
MM;)^(B=.WXD=*'Z7Q#AC9S[D Q$[[//<G0P'C%3#W</$RZOMGQLN6&7,74Q(
MXI>_IAJ6I$%OYK)Q%5J A!R^Y0#*S./ I9=:$JKM&JM?RHMX!N'S.F[JRJ@
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MDU<DB[ASUO.FN.KV2D=BU#)]HXRJZNLL]_FW'72R_I2W;!I%8#\K-'P15H,
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M@:F<4[%W2LGET>39O#YK_?.-XE^>XC>:.]94H-SA2:.I@Y#UINV;OD$Q5J[
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M!T22]H\ZETF^8)R$K28%+^\H:XWYR0YPFKPL)E@G3,RH^!EWB^EXK91=X@S
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MTE9T%TD>S'S%2VTMT]5@==I1SYD@,?B,61>/1VTK2I-FD9J97AF41N\%+$$
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M21 4C!2V)E1A]%6/?_!A6Q49^^O:>7/>#J1'/51FTG'*TGJ?969EKLW11(9
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MZO+K?74^/9UAG[XY_,2J[SEVRD"9-5\+@.!^2RVE%%-Q2Q))PD55]P7@SML
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M=7P>)=%_3,O#=/Q'3?Y8"+=_E\=WX(R?"$[VC.^<P=@_&K95/;=>.C[3PO=
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M*,Q4)JZS=CU+$X5[3[@.P5C0K&7H57 3^):*X^^H3HP3,6 E,HV"=ZJ]-.S
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M^/Q5V"$0=%Q[9NV?1N?<@N'J+>/TYTQ57J6O6/?&2P8%60B,M?=MT/CE$4.
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M[ GGZ&@ARF+[]+QBOG[WD]IIIXZ#Z^\.MB>#;H4=/'T:NA+&<AUH[43A+^$
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M4CJSU5%^L-">N9T\=1B.-L_W?2O5![(V<X[D1H_1J$9\ X=%VAFN$O:V1DY
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M9*>E'J$C ROTRU?-3>YK4S$!&NNPMN6-L3;S1#C@;:P1(K$>@@-@*/R78W
M!G4C(IJDPP&WZ$Y'90.LN?&B43X;\W,3MU+E8H56L:5+P-JC(.R]("Q<1 "9
M'A9RN@TI ^VNBM^AZXY-;EKAR_?T'73P332>#)?[>#8-79)X ;!2)>[IK&V)
MG6GN@;-/KMS@ %#ZK9VQ*4S*-^PN0!$.^)16:)*A42URQ>\*JE\$C6R,W,&<
MCLKM ^B,&L<GU!5'D_=)BY-OS/DF@E^KJ"IT5KQID1GS-AE4J)<;_)CJB#W*
MZKP7]SE+EFQ;DY==4%VMOJ7+U5;H5B=T;RO1T,>EKR:@:,]Y"Y-P*V$/FNF2
MZQTZY==@%>\1/ST(Q*NCN;)Q;A#<>E)A9-_TO F;',C0%S%B,:HBHS@4;P3<
M0E+Q/BU-:X]FKV,7UGE-G^-C)67-)8$>)1!0/D(J2%=IT)N6#Z/9E5(Q\)S?
M<G3P*%56LZWN=W?"NH]/OQ'.^'%YZFT;Y1&;+M\A3X7!RC>;?I]&J=?R&I++
MR^1#$[RI91Z[RAJN%YS(07-S;%])>U3]=89B2E>&&'6KFZMAX^]EG4\4)LPW
M[LMA$E(^C!>S:VPL3U%9D(\(7OCP:*?G);J#Q(#,"K7%O&R%T.I;H=IWP]%%
MP HI8"HZZ6ZVDJ[RR]5FII4:^T8.Z#Z%3GA!AS\XO<7"D2)48.NU'WF&]_"
MJ RSF5]M\(V*86.2+D6NQ1<4ZX0L2,;6;:Y:V GENP2MISZKBB>X&"?(8O.X
M+:<%_6*YN$M\]C,7T8.M"UYXZEDYS75MX?[ BQ$Z>D8E.0)(7^@3C_?N2#4-
M)^]E*4_T3-B.J"K A/)VE6^XO_GW#23. Z 8YME?D=]T/RC:8'7]3A 4T3K
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M0)+O9Q:T/JCJ[#/NK#H7Q?&H\AX?5JSQ B[,D>ZO-S[X@F289 DED(J;0,[
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MS3W S9#WWX/V@)&WN4Q*3Y6Q:)25SIL*BH3@1Y9([[:S[$O+$%:**\"[/DZ
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MUAEGSKKGGI=[[GV8A_]AKU5[U;=WU?ZKOJJ]Z_9TIYT$7M3&<'78#BG#D0E
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MQI:EH,4WT4]*^9QLU<@4-63W3$0N9_\&4$L#!!0    ( #:#;EB%?W3/^7D
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MC$F6=D>6(0)61C^RL= ?_MO=<XVV-2%F5H]'8[1L"_T94EN+PV2L$*!L^S=
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M%&$@CT_K&\5R]@7;)!%%?.?1LN1]&TP?FJ.OV^:KQ/];D_-<'YPK(U""16
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MJ6_$R>5YQL]Y<P#C';-V5N;-S4JCO_R$$\.,^W4) 8<Q9D70&WE]-=%#558
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M?Z8S">01SA;)V%7X+G3"8_:QN1>PC1/6>W]>6%>99X&V4_>ANIK\[7?&\ P
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M$W3KE^B&V(2I$S2:"MJ':5_ K(T0"W6]42%@FE3'M'VQ+S);Z".D1*O'(G!
M7O?LU2L'$1?&6+/P[C3\7-K4->@YTT8]P64:LQD$BOK:FB2&;XNT7ZW[1S]0
ML0, @*0'<#W9,HNN>]0D]_,IUS^J>,X!K [^6=SU@V1KE7GK&4&<B#F)5Z(S
M6M0"3S9K#$-YS5&"XF>UX]L4RC C:%'G,K^YN9RLZK%SO3_Q'^KK&4015D!Y
M\MZ3;GGB'#/%,JN^O@#/V!5Y64+'00DE@0/_B0\#S SBOHQG?=^G[G/*17ND
M%LZ6QX >]&,M.^:@)J<PMZ;E(E<P*AV^!9%1Y!A3#U'TB[ZGP:HIPETR$V7J
M&K#O39?[<.AH@[,Y*=T#(_KPRP;Y?',@%EIIH5V2)GDQ3H/5T71"IP7QCEC@
M8(V90EW,>Z"[TA'\6U+4MB(4VSJ0_S<'I179+78&)OW5V@:1'^B$&N(N=",A
MP?]XY^'_E:Y[ ''#6>\>"#SA5B=5-W";/:B+YA?6<L[QYQ&&C6 +I"\SF=%0
MZS.W*K!Z'8SCDA91?DMZ4S/@XJ0:FCFR7>GH4W-$<(H @Q53@'?WA45$7;G=
MKL(*00%^_3TVSRJ<KTB3MTU:>2A%?143&==;_793L'9BN1<[DD$YC_1*V/-M
M,,6$2-)X8,XT[S>Q*,37^;U9U9&O _)N4B?;OW$U@*>^552-QNQ0K=18JH8J
M((T**3'=-B,7S7)T<K*6-!GRNVP\<I-2G"@A'UU8D-+D=BLA#=U18V/&H5#'
M<H3E/A&\::Q=2E351O$SEH7=B1?==2MV?ORE/$-\BZ"32:K,<)8R+,N(O5VJ
MW-RJ:D:NMLDE9<"'D7B:9$8RO!M'+4 G SJ/(S.EDRND.,U-=S.(YE-1>*ER
M:Y=9Y =#GW?'/)NG::>E6KE-##X;D;-*@HY S(ZE^@H%D^JKET Q=QX5"%J)
MGH](1UO$971^!N%@_Q"C.7@O5.([2B]_W2/'N:AX3[<;N5 *'VD*BB;WU% R
M?[$(1EI1^43Z/>],O2=[%07?60DH)D\TU>F,XE_MPP30X? *YMG8X\H;$\"]
MCA*KF2 S)S5JJ%6/D+<OA1]Y!3J,GTD/\C_04(',?'AKKB7[%*Y- OE 9<Y,
M$E=>N&A^X_=0%,"QF7)8^3HG;YHOS8(DZ&)C4,1NE[4>: YM?R9(F.I#7=3>
MOW@EX;BTU2 0[]R?+0[39XF)\X. >1A%<?J=LL9JIUP+7$!WA3O%Q Q^9U%'
MG4187"BO#-R;TVU5J[?LL"DY;$E/YX>F!_*J3[[D 9$=F8/,-3&<^V-!6?9+
MO+@[=!SBY>Z3)(_58X1P10(."@R#G;>X$PWR',XI%[@\J-)32__XR@ 4=K2"
M4 RQ*71>(3^*F[^UB;008@)*V9 Q2>9'"E2'OGH<X&U;6J>H!YJF W$DFY :
M+(RQ#/PUX81?SI66^>53!U;+'\7:*Z<4T>$5$9WP:K/K:V^[* _1%O(T9@(7
MUL4;='D'$PH6Q+*]$LW+K2(8LD_"8DB1M98UX6#>-O5EV9A=QN*&AIF[.YM8
M;20SDFK&SAD.$:.]'V2<*3]HH#%WM2X0.!U$4TJB3("QKR">X=@20MH<GSQ'
MGH<I&8<$ULA@W9]?[1X![9$3@;W/7?]W=V&Q;!YA"5\53&!SK1=U'+;IEL^T
MGKZY"/<+@96XR0DZ*;D2X1&^!P0L%V\N=38S(#X"M0W<^/,QOHAV<3#;2R7]
MW@A_!N1\E2C;IHVW]Y"\ 3[G(VCKJ><]\&X+XH05V_G/8"'>N,GY[#%&TT7P
M#6G"COS!?[@1'60V]!4E3ZSV]!ZX)4E^ <D]6 _O;C+ SV4A,@[C7H+OIH;1
MY>\R^+KYL@@WXV[YZC^UN5Q'%Y=OJ&NQ[.SBEU5)[N$?T7R%T*V&<)]R#J%K
M"\:H%'%0RLVAI*CFTH>#S\TV@.1,FA"(AJXAV5_U/?#$\"JA[>LKT[K CUL:
MF/RCU6:Y#9X@77N5"/^W\LLG-P-KQO= XSH;*!J2-NLB_[ FFDF?[B)_&]/"
M_T;E'%V'MZFDAHX4Z2JC;6UM02R9\R2A6F8\Y2CJRA/[1DMMMII0T>EL&T(U
M_?AGDF^._6FE\3'ZRT5BN5= 2"F_I.Z5E!/_#XBCO+F I/>:2O)N%^!O2Q7!
M#Z^+W9+7$=U"RM2[&]!143[53P[M/#L9?KV< 4:=1P&#IL!W35<J$[\SQKN*
M]<O5G\F^3< ]P+\+@7_QEL8BB(%P<6J.\/C3PP:J?T$0*PQ2.:"X=3QL0 <]
M1'(F_5,7I("":_@7C/F7Z8;O@<T[T.'L/>!G+2^R.GM]X[O "'IPG>@H9@MT
M"FZZW(?TK\K]';%#[*9?+X?])5Z7_PV\"IN>705(?ALAKZJL/S6)6'GR"<\(
M?.Q54)P>;R]S 9N@4J/ZXIA(MF&\@1N)365T3I)>.4BTEMC:!J2QNY6>.$>6
M60>S.H2%^9_T?_:GQJY=?_9,X8?P3[U"= VM X&ECG\9_1CE#JH$=#CO!25"
M-,.\Y_O?-I+BFV:-I&S?U ']_.[)6"GG%V:9(5^A.KE5T^3553KJRM8C67+\
ME=;[X_[C3#O^IC>+"QPW>6\1O?*>BAXLM'H.*_TXT8AY6R(C>='!6?SVV:7B
M7 4;A7L;@M8L?HT^)+,9M!]P'E?<T &Y.92'FS<@7<BK5V#26:/%H3);B2-Y
MI-2/CX]:\"%'SZ]A%HYBF5+ _OA$+#I$,/Z8;V)\1(SI]*:U?VVC\4B[GZF#
M2;T'/PTF:'+/U0I;9C[@44G;BBV*9FMXFRNZO6B:/"H%E, 6T(51#]')L];^
M_ZB1T?\7:-K_JY:)7YQ5;#Z3=!'R.'HHB;A)[.5S?T"L9TWEX&\^;\C*;-XE
MK(&0']'DY%X4&W2>NT>W*C7WLCT5A9H#0+%( :/N.X)!32>HH&,6>1V%/&Z;
MH;ID-)3^>\#EVQK14:QERND=),A%_3P3\<&]LC.R]90[;J ?ET2U<+?D,YL0
M]$%K9#^/6(-@4P_)>5,.;S^DW$JCR^]3S@>,']T#IP?\#BA74I5#/\"0$"?Q
M\R@X"-PNM1"X%W\@\%_%4V5 B*+D+4. F'OWMZ.+5:2X$"FV08"MN>OF7Z:?
MXM^\N0=>4-X#:&(/F4D/,^?;X\N!S&F*_4TXJ%6[&#1T"1:2!5.$/61%A'#4
M:]I+%N4>X%N])'XHPT-6TH-X,V]*KY.)P%Y=!X(/17C(BPBZI\2E_CD/_^U-
MV)SOKQ+\RD@0U4740=O_8/D_6/X/EO^#Y?^U6*8V'JM4TOFUVWI&F\6)GT2%
M"UZD!\ED[M>_Q'[#SW0W<Q-Q__U_ 5!+ P04    "  V@VY8Z56>F!6> P!-
M$", $0   &QR;7(M,C R,S$R,S$N:'1M[+UI<]M(LB[\_?P*O#[GW'%'J&3L
MB[NG;]"RU*W;MN2K99;[Q5&KA&D0X "@EO/KW\PJ@ 076;)$29",B8ZQ2 *%
M0E4N3V;E\LO_OAIGUH4LJ[3(__H79]O^BR5S7H@T/_OK7T;'._O[?_G?O_['
M+^<U7 :7YM5?WYS7]>3]NW>7EY?;E]YV49Z]<Y(D>7>%U[PQ%[V_8F4FTMFU
M^%%?Z=IV^,[\N'!IO?;2P%Q:=R]-%R;0O=I[E^9537,NV^NS-/_S&Y?CSXQ6
ML\NO5JY?>#_\M;TTO;II7 >G 9?*?WPX^M1>GA?YP70LRY2OOTW4Y;OZ>B+?
MP84D-U?.9E6EZ^8$;^"\^\?G3\?\7(XI67[UJIZ4BVM:2;Y]5ER\PU_@;M=K
M+YU6Y(S2R>QJ12NF']'\L' QS)3@3*M;7@3N<8GM$<]I[^3%-*_+Z_63:GY<
M>%1Z51/X?>%![?7S)7Y7ES2O5%&.:0TTC#L0$#ON/%AR0:HI6__@YL>%!U=E
MO;H8\.7BJM7EC:25O(-?9RLFT_6/AA\6W[<J?->)OD7?YHK.B]WX4@LC2R I
M=QV'N?8[>57+O$I9)HG4E*>7L2+NMCUCHW*\^*X9+=,Q+>NK;5Z,]9,<=[[>
ML&_KW^%;FX;4XA(G?//K?UB_G$LJX%_KESJM,_FK8Y,_?GEG_L9OQ[*F%CZ
MR']/TXN_OMDI<GB)FIP Y;VQN/GTUS<UO-L[+97>X:COFF%_886XMJKZ.I-_
M?0.O<9;F[RTZK8O_+QU/BA+8J/YY0@6*P/=6/+GZ^8U^JD@OVIM$6DTR>HUL
M+>'77]*K]SBV+,V?J1 RUW_.^=Y*8:_VOD:!QVT6<6+[+"9^Z 8DH9R3T$^<
M, FISSWWC973,3Y%IN\_%ASNS^N]M.(T^P(C%6(/OJN:U[RJCZ2"!?CJVF'(
MW-@FMBTH\97G$R;"A#!/.($O/%>)^,VO>__\Y=W"M-;/TI.Q&[)8D=!5,,O
M2TAL!PY)/$\Y82 =5\CN+'=SV)SK'9AG2;/]7,BK/^3U_69H@UCS(C],[#O-
MU(\2X4G?)BR.8:8V#PE3D4.X<+TP]JBKHK [TQ$LIM +FM&S>\W0,E3[US=
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MM 3@4.]>R9*GU:JT\(4M;>E+ BL =&I[ L:7#HD$!W'D.,R1?)5.A>0 9S*
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MJ>*)2+A^Z%)7]$[^#<'3KRUXVDL\R?P04)'K"TRR$23!8O(B48%D("JHW;N
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M);Z#;>("7\%?0>SXMHR4W=N3FSNRSI&L:9I+T7KT7@J*53X5L8H$":6C7?X
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MOD=MDCB!@'V-_)@J)^9);YV&?9#5/=C") FH\CR;,(79M1*,FB3T ^)0'L?
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M]LWNY]&;GSI*K:-32GDV!6B"H]$I<$^#,1&LC77G4GQ_.H&)7,!+XM=Y,<Y
M*JMI-;'>=C^DE9[-/EI'N09V<,=!D<.]DS*56)G?.J!C@^GPRM,\14FK,3G,
M5A03_*@OP0?MG.P3,/"<GW"=:7[=3!Z&$U.0(X#[A.[G9Q8'=!UJ" '*+BLF
M5H.F&T&#3YSF!@!)E#55NU-XC]DZO!X4(4B1N4F)YN3<J!P$P@\E$(2$&6A)
M (@@1<NNE+R<IO586WF-.3,3 #7JH<IZ:S"*9AO0;"UQ->8<*"-JC#5@VCE?
MP6>=PEVG&@LV)&[8$&\#,$+-8_%.8"912D!4?X$'U/0JI<#C>\#B6TCH[YI[
MYH]JF'YIHC<\$P9I7GQI^K/[D9D6Q&!'C>/#X<W^@ICRWU.P1/0KM$ 5KNW4
M!-5@M(:E@MUX>WDN%V>I)<W\(3"MIH0];LCL*IAU7>#1Q5:7OZFX 'S2HN^M
MKI"#N<+[\\:*[>S5?(JSP<^+#)&ZEN$HA>LB;T1C1^P-PF(0%O!(;6 T*AS4
M\APQ@,XW91JD%A>@HW,+:$=F\#7<BQ:EX4CK;6.U'7[:;<RUG[H4JN4 V&[&
M-P0V,WJO@&8-+R&1:E !O[7B2N8E@'(4&X:(E^8XF9;55%I"(^8*"%Z/--#S
M0,\K:!@L\@*,:I2MZ*K4M#@3DPWDTNI)DV$'4MX '+MT/?/R6'.%J\<OQC D
MEX9^Y[3<6(M@U4FC1=2R:MM:XA7:><:'%/TG*4<W*@?VD]9H O8A-US4LN"'
M3Z.6!=%C,4ZUY\?H,F!LA.M:SS2OUWV=%4$ PW>1N@7&JE:.:0DC8 =J/2S^
M@CX1>9'"WFAG!#QH@F^[_,AVMEL/QL4#KP^\#H]$@D!_2LH!QJ4=WSVPQRKO
MS\UB#8Q01#2?[\#XMY'LMZAU:V8X-E[65N]I=8H3T'XI/;[Q[C>3&,A\('-X
MY'EQ:64%D,FEU(=&[>D+RETU;?!1YU#*4/L4??]II?T@G%;G6_K_+13@0%HS
M[[YQEFB72C4_JFM15WLD@V;1&2VUHECR@:*=-GOV5M>/W9R/H!E325HB8<.P
M7:VK_1DXL4E:TYEV&<\FIW62!J3&>)-25,N&6?/ _&S@EH%;%@V:N>!M@8WV
M9J2E()A-=PW$GT_1)PGT7.*Y,*"U,WHFT;,)1(U ['^,#PZM#/D=^J#I!%]U
MGJ A(W99:H@9'M%Y/ A^U&/:_&G:+2,?=C&B1F2I-(8](#?5Z D)'S3F+#7;
MM9?AO=^AP.[FBUP"B:T2U=\OU%!IS[_K4@<5S$32G_+:NI"YP-.59A5F9^#=
M6\P=-#,N6:E=+A+/T]$9VQED8/J!Z5>]&*6$]=:L"X1",U"5^I"MRPZ-S^^^
MF X_91@0A6R6YNB!1S\KG@P;+=>%I6E^4607YBAOP<'"4"HT@F'QX95A+]3-
M,R&&H\_/+5=O69()&"R@8W\H/\>C='A:0<5L4&VEX2'S'5AH T&4SF.%4#XD
MGNMA$7$/(UEW"*A\BH#*01'\R(I N]NN#9A8.$SI&AK&,Z4#E8K%2+_YR7/G
MYHX!,_/Y+9X(=P^LIX!G0 <,.&4@S\9C5;5&11/+U9RPSEV]1D.O'-@MJ?>'
MXGGC;-9'+\8LQ\[:.)D5@+!D27S7/+;N9UA@E; VG*I9CH&#!@Z"1YZE8/FU
M 0#F=!%&;GU6MP0@C+:6"<TXA1<\PI8)6&Z<:3 .[/Y9VMR"XZ*'66AYW]$*
M\.2SDHZ;8W>C>AJ3'/F]C;'O!-3>"N#?+IZASN,BYJ*"T1*T2ZFM!?@*YH$C
MS.(C,(H00U&-:I,5^OG2"NQJ#"!%CV+#ZZVKSF(8EZ\M'XS9:F]<?!4=-M\&
M70Q<.7#E*NQ:QU48G0P,@($OQHQLU(Z2C?C'X/T,P[FG)CYF(M%%IU,D@8;/
M8(RJ-MX[2]?"&D#50'PS4+6:>H/1T_KC[."_G&:-FFCD=AN&WYYPO]7'UUFV
MBOD[(:8_S9S(+1E:TPE0LTD5 ,DIY$1J!VU'>L]=SC,'Y^Q0I"C/:)[^3S.=
MMV]VC@XK#(F#*_&$A;:'(=U1&B=OJ=,+.C[L+4R5 H.#33%^W>@B#!N ;>85
M,M5%BA'P ^,,C+/.:ZJC1!L.T4(;/>V5/I5(5<H!S$M^KD\CND<.3:0AS>F9
M-JF1&:LBSV768J%F-',FV;3^L=J&:0,Q#L2X2HQSW*"1 !YT<W/BVR8;M&U2
MVD2JU,3O9UKV3VL=4"$6XG:KZPHWOK$4=)"M-E\OBA0TQC63):%U3?F?6JQF
M*4^+*;IXZG):Z8-L[8X5Q66.L<8@9Z?<''!G1:45B8Z*FF#F*[^>I_^@-8'L
M@YE%L-+E=#+$*PYDWP$O.J!6IQ8:$'$FBTD!=&Y" TVL;=7!$P!,FHCO(E=
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M8'RJIW)ML,.V];F]R<QM5M9FS:TWK/"ZY6U-ORVX>5[_,M?N1]ADF+IV/6A
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MF%&BHV]8FL]*6TSGWI3OSO77\M;4$9B?=:8Y( !X^7 ;IV)XICG4H=J%U$G
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M8^;/!$@<DK! @"^6*M%7_^63F6<#P:K2YBJIT-'=5I'$P5GRY)Y/PN'R]@D
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MA>*[V\H($4)XF;0/E)M%PN)-N"O1CV^7_W%T<B=X!A_<NV,?%?6FIJ^K-3O
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M<ZDQEO*%Z3DS%D=#,^ ,L6#PD7_8M<GCUF]()L1QA(WTV"9?;8M*3X<-<[C
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M3Y7XY@JU"Z*)LA,%#E=QHKQY=L'3LZUJW:S!G^=I2>=SVK1\5AC]73-)2C(
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M/7@_,1?3T/W&I<,D:2KTO^UV(^GZ"ST1RX=\=0IR?9$%1ZIB3DK>0=H02X%
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MXBLA+7=8ODLZ<Z?]HU7P*=(5=I UFT6>B>[+1<@U('5.F=S\_/2,HW$%\49
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M#;A./=KL_]#JY-##)-WC(#-%SF@]:-;(IK%3X[<C+5^)7+^ / !W6)TUMAV
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M_7R*JO^<A3\SQ[.*[K+F"]MB.S0V40(P4F2GEW_"@HO#Z1SWDZ=^?/6F84B
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MS_GZP='TY+SOC]QW__-?;=V?J.4O. AO7!XHJ2_X?QZ?T4X($_M>6!D^&+X
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MED/HZ!<P28U3!JJB2S5)(6+*S*J@O9K_/6<B,8D8FS,HXXR*F&]P5.&9Y,?
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M, _IF.7ILJQ(P$X" T@:&X<^.#11AIA$_9%5MEWL*^P6TP0Z&M^U5-=5A/6
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M- WQV[!W/QSDUV4#"8[V;[M>40RC?_B8I,4!?XLW\V='C^] ^<LZM(P_T 0
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M[T:AX7-ELS1E< I(7N\% &";$T3.9<'GB#R2)Z4'#5.@1"%UD"C]9-$543!
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MBS7@&#L,..Y:16KIU.,M-K .Y/:1-CN'LNR<^Q=M-R8Y:;K 56=<S2/KNI]
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MJ);%;&Z_V'M*D+V-/O220D(TTC13L@%^&&VROHO&<HB]Z#=!@U/F)MR'%]Q
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M-DM>D"<]O0?&6O$PMMP"Q>5T)&QJ8C\U_[DO*F$R('92-32UM.IA&NSI(><
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MB<Z=U)L3B;>-9Q\\X1<]@@3BQG%6S;7W"[/#J#[4D)]!5BV269'MKL*J&[&
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M^,N2*N*H8F+&Y :(HUKI*&@/=WB__,R8@E 8E;ZEA+G)!!0OI<W.K[J_!]>
MK-@Y_^*U"'UK=/+R[^>O-3I1J8-BQV%Z..HC#L/P#.$ #6V2JEP?!Z9FD]2^
MVFF7U&:LI6^*>ZKR48:]<>:Y'LL9\V/$_JNDI49'2LH1EJN26Y2,D_Q3'9[&
M_X4FJL>_JG5JJ6*\C-(1K[UK!!B ):MCW_/F+QK6WN3@E+XA[[=7Q/Y$42:
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M@)MH)"%+VBZ^_QZ$4J%9N7+;^E H>;N/T<KHIX!PA3'G_MSS7Q;L#4 <6I3
MZ;40>1;!"2'/2SHG/$]TB@8;U_9)L%Z3Q?P.5\ _GQ$#NK\94?6=F'+/ KZ)
MWX8^&B3)K7 WW",**(3C:L/,J-3E?%B<G8GPROVO5(&%"LDT^ =H$(%20<FK
MWV\E&C,7-GA^D!L(1;DP:VN9J@.#VME],4*O3*(C4RLY;/KDU%N'<.'>P<BS
M8,3Y2+"+A4S\^R;MD@\>"'__RTP2W]?>\3NCBL/\%-NBTBM\Y!V_1KXH+LW'
M&1:>576A;N]J\-!CJTG5R\+KZ;T7ORGIXABTWJ$_U%W^OMAU_BC-BT:]6?^6
MW[K] 5"@J HCI(RM^NKY/N1%F#:'<&=0&-.=X7>U*^*VR7@DVYKE@F1>!OI
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MCAA'+TS;\BIB"E@L'5'\DH'PUZ"9O<,[X:=ZP:63JS"!!Q'[@=))=1R9SU.
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M0&.7/!*WLKM8]EG7UY:_\;DL-+YX/ZUMB%?0U;!P%2AB(EQ*GZWW/!.UIQ"
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MBE,95=+K1^[\!R5=A;EK::#(V\@X^)0"8=1:WID<@6&$](B"]HC8E=Y=>(C
MY,$U.P\T2(%TB2Z3S&.FY<>JONDAL#;#2G554[.(#[0>Z3],=?<6Q9A_?-OB
M]X=)6B54#F)B9,=>;SQ^0G*$UKW@C\BM1?3@M[[P,YKV8MI;E\X;CM(OM6?Y
M(8^+E:^"JAVAMR0YQZ"4NI,T#'6QDW=7;FAQTMBUT9_OK4WO"N"5'NFHN9&8
M@[BQ#$VYOX16?BF!=X>/GQ[CQR,$0(,9'9OJH;48F^I).WR5MX&>2M4+TC<7
MC*SM_Z/EA/5C[7A;EZ)XDUP!:=.8\_0;(8XP!W:4#C"S+, RL/CIN'>+IXN=
MDW9]H>_SXP5:2&*S"U=B*>H&>Z1W"S>X>=80<$D%( 7+%A4":6;2Y8%ROCH0
M[?-FD4%:!53[4SE%J=>QII2H[N+%>;?M_+,GBW\VS;_MODN+"-2@0UZW[H5T
M%09X*!98VYH>Y@_9G&'5T!W$ZV,??%5?U(UTV;P&*!,CZ1H<"!F[9\OZ1#3
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M0**$$B#B@]%!%F3]!CDJL' #6%]MG21%#$0#*"WMM#:PWN+@/>96T$FBDLY
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M$/I",&H-A(KBEDJ8V 2,)LSC4BMX@OQB$'>G$5888:3C98*-/%7"/W!I6X?
M_)9*X(I%COH_D_$UZ0'RWJ"(ID&&[1@?*R6H Y%5R^#@2*I>/0-WF>*$SR2T
M))W^"!,^#)3J1.?$M(KF0VR&JMJ^W S)2RZ+;-I09XX\FD&$2!%=GHR$?E %
M[)2^TPY"&P)@&<%.R%FXMVC[1T!)'ZBKLVX>'YKVJMH(:$@9RAB6)(/XTDOF
M7GWICS74K=NSKELS_<!T%$K*2&4?:D-$F)PBI4JZE-J)II(AMRVE,67V& .7
MFSSO@I@,ZUK4@@JM):L08:'U9&YG.VJ"U#2%%<'=4Y.[@8FBKIL!2[SEB*#;
M287%7RE"!?J_X6\MNT0]@4\CC?O(/,% "%,?+/U_3IUP#TEN1*5$ /4[G<@N
MF8-A"&#?TN=(/3[D31=N0'F:E7;;8#=C'UL7;4+838Q:52WZ&?_6V-AO1WSX
M )ODN?$52H^FYEGI2K#6[@TN6QBZ+LZN@ZC"%3\VMU1$-U!( 5([!?E+U;WA
M#UNF!=DZ(W:4Y7*XG60VE[B\=&493KXX@X:)R#O7W\7JU?V?#0;X6T<1P'LL
MO90$(EUD0M!J[C*BYT,9=^2S ,:*NHNJGY--ZH@53+N];J<E&2**)M4-VC.E
MER;BHMFE@H U/K_OU8,HG$H]B:H,O(\50DLDGE+BI23 N2_!P&10D4*:/L;)
MV(\#Y'FG8[POQO/WN+>/9I/Z86C#Z".@8 1'O)$L4'%A/BH4KT&"*#QUM_$+
MAGP*>/GD]V%,*B@Z0H)3E14Y)4%HH7G@0J#WFR[ISY\L8/&%0.]7?0JS'!]*
MY2'9\S3?!Y&$W7">"\J/L4_YA&9 %>'U2$9HVI(TRGV"W<JXN(\!?[@O:P?I
MTR77 &=5#R05-+0"< #LI[?4ZSK='"9_:V$ 0=*K>E"8\.U '@;V/?6G(9.?
M4)Y(&5$PQ[/7?+MVMP\8;&LF#*G&&$> Z64,-<#(==R_\"8#$X0EKDFUPV@<
M, R4FU'J,J>K%>&P(GZ?][C5]5"2>H:3Z8,$""SJTV%TT(J'8#S^^\MBE2!X
M9V8G'NY[?YEBJ_$@E;K#!]2Z @MO _3J4N#ZGO#4-P +3,^*V 7+T79U9)XV
MKA;"G^VKOL<!,*!9,&59D505TR+IKQGTIW7%QL9HPBO?=($9<,2%1CQ#@2'R
M0'P&1,D\XF)NRZIS"?RK/%*TN()F3,,H=WPM<'S*@NO]&JMI:@83++]%H74I
M(08IVEE50B4%%ZXLX682;E7SWN->Q[RHG,$:K8)T,_3OW*^<@VQ?L4H0207S
M@95LC"3,X$MU^$Y119[<'I7[$ZG5T6I[P-[RIYU]9ZA691E;A#%/B1FD'TX8
M/(G;C!:[*/Q:FV*=Z@IT,-85LB7UE3!_J5/A]@?SL+[BETLG350LXK3+0&0G
M/B3RSD;:7PPNW O(-:>M#;7B*?&"5"8P]B!G"4V3QQ''#D*A3&E$QY.1F1S1
M97"NQ+*E]+]7X(BBMGT@U4<]'<^V$%AD\CKQ]N*GZXGF';+OS,GSC7>8A1-)
MJ(S[F*FBDZ-3)<S_^62O 9-QS &'5F+D59FD_DA8[E"0#(2Z_QS(2G0:7DFE
M:"$G(V\TQUD>.A9L]%NPX:31N*JP[Y0.9%@Y/Z)BV8-P/ZI]-:$*QD,1Z]Z:
M4\L:84+E31U>63>9V4\L%,3A32>1W*81*3")N2UGI"7H9L9QQX2[?:OBI_Y4
MY$$JH;C>4RKYN/.>(Q2HH$_^\X[:F[?$9K87_<E +*?1OC'QSENS$%^S64I[
MB]X+24UO3VD3(W-/=O$40M0NJU;TJ$,S(Z0:&9,Y\SRJ_K0-\3BS]!'5KCH*
MQQ]/\/(U"X<N/:RR/16)^H4TA,E)0OM"E(Z4N8H87KK@<;K@M7P"ZVV#M&C$
M'ZAD:L%#YQ"3IRN@1U7!-(*\F=R6/$6$#V$6UCPQ(JGK,G9O,2@&2W#@P6JA
MU@SUT1Z<XP_A2$S[T?F'PR514(O[VZMY2-(>@-,#;3BHT*3EY1CQ>\</\1"2
MU<D1;EML$H?8NX@!.CW9!QSH7'9!,6'CNG5;7?'.)!RHU+H+>L^9.VF[:8=R
M&+J>M]Z3+ <,9>U)5M;[!$IZUG_]_E6V*C$@QB[$;5R+A74=!9_-$'Z4<35;
MXNW.U6;K9+IJ$E,FOT?1#P>[@$6-O"=C?:[+6B)K20)W,G],I?EF/4C'T=]7
M58I(=$Z<E5R2X%:E4E]&)HA 6&,(&//H2P)[VK*#W4[K2"6I 95T"E&;5O+;
M.("L(M/R)-)WJ<K3]LV%(HL66,X55U 9&)'Q^T<E\WCH>58'GB2@=F/"/4\$
MTL+B(-_P.TMUXZ_IZ/Q"Y1-P@D2A=P?T. \$ZBRLJ&+)RJ?OZZ/:^=P13XH)
M?$/Z--(2^)9RI<_^_"EM$W$.D1JC_9XHJUSOC] 5]@G0PQ]J:0-WX6L&2NJ#
MX:%/.!)DGP@"7@6>2XL\CRH1+60?A@[7Y _A[Q5PK&8M9(6=J_Y%O>8"I,2U
M/"^FQ/<;22?ZBA/Y7CBCE *RL<F"*&$/E4A==:3@A-M">^K*9XB.!?.HWL<@
M+'3Q\:*^]9?K5B_V9>6WK4LZAX]NCTW+S/Z]NX8(#&@$9=$W8I_PY&O_^TZ5
M?2W)?=H)9J7VK! B6]T\QU,7D.%GZR7SNN2ZGJ_<N8K,@^9QH':!L)]+GP"U
MC^'8U$K/H IG650Z\\JB@O/YPM?D^SJC0# EQ1"0D3-:A%*JF<]3&Q/8&9T5
M!#AH3"P5MPAF*HG4P._";X0VE#UR2H)DF.*H_K&I!&&+/=%\+1(0Q[UV6W80
M_8P)<)'NTX1_65D]<I50 M<ZI4&N8X9="]0%/+O:-8TP88NSFC%?49.:(R]Y
MP)Y".YSR<#9X7V(0J1I!5(ZW9:49H40MR11IT:A 8'CBQB "F#OL*6"PR!(_
MT3H?>OC*E"%7^6BJXC4KWW.Q^CJ[*0ZS0VVFXL! "\"5#\B='4'QUY-IFSHA
MC#6I=%Y_F[T>)&F,,4WTLLRS0-#_\92 %BS+A\6R/%VP+ OQX;^!41:V<+\*
M$>5']>+JV+-BL?7JNFW;XLYXX]:=N9C:M5G:A><M0@&"4HIJ0Y0<+(V@'R;7
M2IF8S "=WP.X3%YCBT?)JX@Q@0@[:@5]BL4QZS?#3=/9K_,1E4Z4E=)-,'?!
M@8B=V?^4$H)BD(JP$D*O?P^/+@G.38,>MM]-#"44;XZQ]3G>9N<ECSD[,F,M
M9B1)8=J_WCZ?/%S>_GB/%\PY/:ZXW:>;^SMLV.;98TR/7OXUH52X\F./J[65
M&&J@Y.ES:8)4Q1V^#O4K*-.W^IS?Y9*H6)\:*W0XPR7Z'!57&9$R,]1-""OH
M:.%:K,X;%2YNM)F]8 \^2"8TJ6DS)6B#F%3-^NXU,K=."U($ 808$@SWR9PR
M]NT[<J?[)4[::3F3'>EZ@EZD]BUR%3HN064B0"0<=%N>PH#,# /%&9:F*W=J
MTK;8+0L>N0,A*EPJPIC<*?-:<%5#)2=IZZ+1W/Q1I)\1T?C8D>^I$'>=?2JT
MDB:>V4-N9+R+.-0[KJ7+\VI2JOBR.=7^DM>S$C._@[(4^>BHKW)5-;"9"'V[
M6/TCU'#]\XB^8NJIR1Z6QB,"':#(KAU0+ \-(9:E4HI@:@976_?8)]#^V3K4
MR'7B%BN,CD/DSZ"<]'\E3+%!"ZLN,TO&RO@[QBK<6Y+AAMQK$#%B\C]4'LLI
M52V.G#J1E@4V(X[>"T0UOD0Y-7= $@WN](#4CZ;Z,(LM;2*3-*'_JI;FJ5L&
M3>HT\DGFX6B3Z*$F?8_K(CT7V8/O==C8N!G?D7 Y^5MH@$89:E%-HH/BDEB[
MO5#MCW+OS.1[NMF/&UF$ /"Q'H7^IM\;7Y0/-_82%M]*30A"5K"\D78>&1U
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MVQ<@Q^\"U$KHW@0-R%J T]Y&IX&2L0$9V!J3IH51%QQ&@T[Z!7B+0*.A8..
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MA8-MH\@4,E7JU9]MJ ^NYWL0K:'5)[V1@F5-)\C.G*A*OV.NO'LT>Z:M3QK
M>HI">BFWX3$*W5/+VQ]W?7O#/180(X^4Y^K$=YQ63FTVP#*BDD>XJ5N^.D%W
MF1X@.FFX'KK7;A5.SWHQ!P#*ZVM38ZU!U:GO5;CF^]-1BK-7H7[JWA[W),$!
MJ9*$YI (I1@'E%L/#H92VI&DZVC R7X[#$93_571$2" R1Z&3Q@J,.>))G5
M6X3GSFS[W<QS:S*U)[\J^1(G'B?Z78SF$DY'W@[+^(Q" E.N2W^M_KU2CME
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M+I9Y7V=()5QN E'7'[7>N8UV9+55W0W42JHP-7.^1C1& ,0>LI#LPNH!<()
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MOQC1*-C"9/JH1HJ0Z10Z1$EKSA EA;_/,= OF/8/BVG_:L&T_Z:8]C]^AY@
M<V:%5_4- <>N([WG?N^N?=84.F^ .A!_:2I<)"X%>@ )_+&O L!+! %60+1U
M1^K*"/R$CJ2B=30<)42>PQ4-V_8G1EDU:Z99%9X,?^' 7@!2@3HFT;C3Z-85
M,4Y<-3=.F+QVU=5X)#N=!YR?Q61\RKLR[<V0O]V3Y^V/;W8)HDD014&856>L
M"T$U-0PQ)4N[*?<R:X%"P(0(0V'U6/CEA8$&8^B66$NPF<HS)=-G9)-'H!+[
M0J?Z6Q'QF)JM2X$0=C+8'V6C229$-*I=TWC3JDL6SJ PKA=@UN0E&JZJEA(*
MI J"KS:T>!-4B-QV+%:N E)KDN^,OB5T9R^#LD-'<0):\SI-6V[*(Q,P1GJU
MP%:6H$2"Z%\3N=VA>Y-^)KYF!C7)F3$!+.><$E^)O=(P5[A'MZ,^3:'N%4%
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M4@OT.XZZS7*,A?I8F9>:-TN$(1; 'CGX]?B0(\Z?I4I;IRU>;3RD01J'':>
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M\K;4I1:!ZK+E*N2HDB.5!WB\%!R$_0Q.<*I2(>WJL[GY=/[-Z0NNBJ=%A,@
MA4I6XFEM%39@LO&PQZ@#OQK1.Z"%"N^":>Z,275\<?&X] )E\]:"B(51A3M$
MI3[P97!Q:]N6WK4-:_9/V'QOO+.3=L1,_J2FXO82.LS?E!9JWN5V)!7VMQ/K
MO(JE5W(B6P\Z4A520Q2[1NP^/723* QB5TW,?]/@Z\Q9',5YZ"9F.RE;[DX'
MMIV9ZA95CEHIE1\LL::P.B.&T.\)D6OFL1F*)I7(1,JJDI%FSLPILZ)4OL5#
MHEW@0%T%718^\""3H ="PZG8L62IE"?O(A]OT"B+!A9%&^@FFU@"2(ITR3G
MU:*S5G+7M%'&$86'Z\M39*;E>DU\N 9L+FI.3#)"<3@H_X[$F4F!)^6Q#.4H
M8J.XJ1BCV;.,<JARVR69'S.+2JC8$^+R$>$WF:-W$.I3-X[6'B/[\G/&PE8$
M;'.CYWCD0:Q>0+GV25VLOJXZ$UU=N?Z6 IK0@VU&A3P;&,<YZ-F9F['#.M B
M(E9O;SQ[5PJ%/!IETKC/MIVUZ![:0^DC.%=RDNZ([$7K$H(Q_ 1-"=G-WU^
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MT9\F%'OO48E6U"^@$3AL#@GDDZ.,L,,;'7IO5_\"-(X!4T9CS8Q@:/3)F.9
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M.FOD"6-BFIP-]TG0##]B3(*4ZA]Q/2ORNLUB>HOID>F=XV[72I>% \0^\&)
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MH^H]$6Y4;:?.Q;B=P,G'=)%\MZ!S870/=VXF^CJ3[:)[K)%;UE1DR)T_7<G
MGZDK!"$;H[4LI#(NTX!J>Q[)5Z8?NMQ&3]J#YVP1V8L>'BK:X5U05_[_9^]M
MF-PVDBW1OX)P[(TG1T ]EBS9GGMC-Z)''Q[=D2P]M;S>>2]>3(!DL0F+!#@
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M'9#!5F&X$9$ABD4:(QY\H*! +3"_&.QF?#C8"#[+\'TA:A&"DC!N&!W4F)'
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MS+GXIE"<# <698!=$UN>HPL;.,;(I&?.5?(PQ,9Z(=7+V]U&O,*Z;'G.59I
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M@[OR/^RM\ KB=FL1"]EV/H?T\7UC4<_T5OD2(4]$#3GZ$=J/1V8%OOR3^$U
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M2TKO-#!5\P*D> ,)A$>3<N,M,"R!<<3P%AF1YI+<+0%,T33/>ED"+:'QM_E
M;BR!0I/YRK414L["R]WPFO%+TKZ7GNQ2(N*:!_JI<''))8D579%:!+8ZTCIY
M4C:""'B1O^V7U. JQ#$O7#MORAF%ZS/,,>O3*?E]'1,-_0X56'K?RS-3F!]0
M#>M]2''>N%NI<'V8W'F*S#]N9/[]%)E_*9%Y5B[^YU>D]W-O1CH7+76G%Z M
MQ<GESY-_W/_NX;U[WW_:BN+!(_S-DQ?9O;^<93__]/K)Q<OG__O)X^SBS?G3
MI]FCER]>//GIS<7IAC<_U=4?0B$236@^W],@-J-']Y^3Q3PZRQ[]_2]/7E\\
M>?3SZV=O_OYO4Y'_T 7X1[1"/*CS(H6I7H HX')_NAM(,2X!]"NURX#VU232
M0G+4VAG&#."(#XG\@SBIKM)+SI*-(<W!OMK\O)$&**5S'<7ZE=M=U\U;Q.-E
MLV#)%!_Z8>I.,SL@Z#8=H7\X;I3,) >C$[@\ /"IESNF!M%8*_P>@>!L-D)I
M".@S.D;L^CB+2O"' 6K0L6HMJ"W/F'?BTJ<@DJ 2?DV@.#Z=ZO1.@, S DNX
MLQ3,I-4-= .S.\_,3U](%D:?>.RO]/4)I[<$$7@L[!D4']OW]"90B]/ 0\MS
MF\+]H?BG U3D8F>*^6Q,"<M:9?]CWOZXP[!R2J@:QBJ'N\%BYL-&HMJ1-ZO+
MINZV&3;" $4F)3S>4,AITFOO5CX*99H3P>]KE<]=%>NN"" C_F#FJJNRJ:O@
M%,?N'O<+Y2.?LW:87U;'L'&[5<W$&<HWA_5YMTM[__YI:6_MZIJ@>C0'0#F4
M^ (A?5-8'I=O>(_IHX\^9"Y4;5S!P./P3B8H,(9AXW67SD=YN6+W4*"<%YQS
MZHV;5R$P+EETU^X^2U6B+W^'_V+.IO&3"?N67&>>;5?[EO\+:]=<%E7Y+ZUC
M;5S1<@4U[+:\-QI @)QY.7Z<W;C?Q)$?<]4\>17!X<P4*?4CC,!' TQ/ISGV
M@>! C709<00YE&<+(IJD'B.A'O=_"H5P83W <2V/E^LI&T_R9#H)YU/K+HW^
MB!2G]&/Q58=+Y$PRW)\$HO+/6S@ K1Y&I\3+%/"PJ':71B1DVFB?^"CEH\5L
MM;"4 =YU9 .P,'@0\!P<(C4:Y^MCA]_MSG,Y& $<3@5\?"Q64XBGW)V'?HD?
MCX>Y^I%JV,\Z(X<RL-!IT R8@ B,K)C46GO0M\F._Z #@X!WB-/N'HC31.NI
M!%[;!EBY;('<V/^-AJ_]ON,_R6@4GF(:"U5&@LGTUS FOMYQOR/])TUT[)<U
MQ.U]<O@K[/']87#M9C9BU#CLA-,+E=IDEFMJ>:[+=H51$'$E/,? ,R^+4M>R
MCK%PS!<HKIA!%CF.',KL0ZW6DP6P7>08XG\L=L"9JEK>C^]>V3"&09W6Q(IX
MMD>O?MI+B56D_HWL]A*UCGYFH;&6$#>9LR#I[UC(>2<-<\HWBK8FB<N].3 &
M7P&T($9W"917:@C[_ #T/6FEAS;1?V6K^MI!$YI^=PR^QZ)V"BJ]=J$F8MW6
ME0]'19<[EWZ9C&;3_^9&3CJ>^DC9!B^O7^DY\FM*RI>4F$SD[/^^\=%M0QK1
MC6-T'LYD\P4?D*X=N*><.?JU:<=XB%<4F]S+GOD+9_?.SQ+JGG\?O/*'KH[^
M&/@#3M<YO!SEL(7$/8>M+=7G(R>K,!VK%LS[U7J\4]<HF0;D=-0D_HP*X2&N
M&(@U'N97'F&-Q46=4X#';RQ*)<XJW.:!*#_&V$OLTZ0"90<21^K#4\3\1UG_
MB"4<3@9-&M4<;AUPM57CH$=!?D$OTS\";U/'O5Y1,"9RT_>^B>(2!PJYYJ;C
MT359V1_%PW2K4CT-SO5S^WS,N:W<>BL1!F52E\TPEX<A*[]X'.2OWZL^H2&9
M>+#0>/(__=;M0\W!">?DVI'Z322_.;-=QW%F;TK&B-VQ6UP"&:E/YM__%L00
M=7^'AD K-]]//V+<-Q<+2:V7$SO^Q%UM0:GDRK0O_L#$9+R7*J.949CK4+("
M;-\()_RPQCPOFWFWH<)WC[>+G/#_IN+ *V^B7&]^[BX%=?DH,"3E_0\]C=J^
MGX\%37BXCXN'^V'"PWTI>+@_PG[.%\1<C),5V?NC5>F66>3;?$F@:VF\WQPU
M#'5!!H=[:*%ITXR[8:%@UIJ:WK*VPF$2+=P^#\-I?=Q=GW A;BRGE<G(-O3K
M11,GD4OIKZ@YXV2>X5":FRB=CK>NE/0O\O#H:6PNB-3#ICO41E@L&M2!5V[3
M:^]^CO'4I\!$WA?\E(^(_W'_NP??_O#-9P2+O'^6O7K]\M63UV^>/3EAX.PO
M5AF4*Z?W\N\??I.U_^R0<6!.9)FMBQD-(8,\"^2:WJ>]6I7K8N%3E%59Y-FK
M<S!EI5JCD%W>^%];^5=T%_\AOX(@U&=!]B+T*WQYNE3.8X<^$2MX4''M-Z5_
M)XL<0@ T6^./B9W0ZN.BR!:7 ';13V%*HYR?LF2/9A4($0%T0\>:7Q<=4-_F
M?[[_?7^UB31U;,7_)B(HKQKPSM"B6UTK6HCQ]62&-"PX_S1Y4&K![!W[?ZK'
MB"XYC_W1U,U\WOD7-@^CA2W-6"XRNE?"N(#]]_Z#TUY=!5OL6:_4S'/%-4X%
MV^]]GW__S</^DM<(M.)2_Z5N=Q1#O2C:MIBONM;M=J'!>$U'-2FWH7^.M>'/
M^T31_R@7K.W?T**6HL#[TD='!,3V:_?GL^RE^8OOH=;^#;I2/8-MNQD_3QA.
M);8?S.E=N_"OH':[S0/*IR,W=7*S1)RX3N_SI&TL2@T:D2_B6>*2&\L)LXOF
MWAO=Q U!SW+Y\8.>3_^RQ%%5KFBD94G'E%M )I'^$V=D\C[]:J_L%+T:*F8^
M^SXXB@ 4BY+ZR&& M*[,O"V8J:0#+5.H?^ATS+=KJA\AEG:4X[?_>/#GAP\_
MIW#PV[/L^9,?SY]34/CHR9/'SW[Z\;2C0B$2-02;C"7 2F9F*;D:OB[*31C!
MKVF4G/@A(D=K5/,;"F,S(7, .02&3:K,=3NM6_O4?%M*M!=)U>MN1W),0H?@
MWA&ZGU$)_G!  52EKZHPB=N'Z_FMTP4!\068>80;TX(*"?\ V/U.:(YM>)H2
M#ZAV0QCLX.%"YI W#_:'[LD'&UJ08NEV^ZA5T/[CX??W?GCP&6W,!V?9BV<_
M/<DNSI\^>?/W[/&SBT?/7U[\_#HF;9_!G9YPV^(G(AH<ECJFZOLGJ;[_>:J^
M?]+JN]W/=^\]//OVAX?_$<R6;O8_[WU[]NWQ;?X^+P.&.6)L\.+ B);_^.[[
M^_>_^^'S<-FOSE^_R9X]>_]S[7=:2#C5'C*KD,]Z&W>)OD*U:UM64B2]C]W^
M'W_^/%X53K>'_G0[?_VW)V^RIR]?9Z^?_/CLXLWK\Y_>2,GZ J/]+W_*GOS?
M/S][\_?<?^+Y^1O,_;]\]+>_OGS^^,GKS^D8?''^YLV3UQ?9^4^/LV<7%S\_
M>9V]^OGUH[^>7SRYR%X^E<?(9!+]V9.+?Q^XY0=^52(H:]I8IQM"O.QKSM(\
M-93."#?=%$+G;-1.?V3R;7F)L8K3[C=^@3)AOWO^^L7K,Z&_.ZT6S&=AXG]E
MA>#3M>MSI+/>2'W*=^\!:IL/4-M<%8M>3?:[^YC8;!:9ZBJ/:#&?K+-\7-*,
M4K4X85NR8RM$(%<T3$NV+4H>7EGH.\K:$J-''8OX@*O1?ZTAD>UK)57$C&1A
MOZ7LB77C6N>$DPYS%J=J=:\=1=O9!422_';\N>*0$FV)**UYNC;YAFIL;)8S
M$J.H:E&4\B^KLR_+:&HJ>4:!\AEI&-'LOI$(6XALNTPJ/1*2U]<""/&V_)18
M3G^X^S>Z /%0+**LFP\L3]9<G[5M1\--G3]NBI97X0DRGLE8/P>&L.]:MT9?
MFV#H]1KR)HM0,R:JA7]\]YE8$F6FWYUE_^]K1[._;G'V_TUEO4]IJW_^9BKK
M?2:@V@]5E_H^MI):.NHZ""X2YPSQ%K5E^X\']SZCW?\]U:5^.O_Q"?%*AF(4
M-5]^OKAX]O(G5'C\!Y[__>(9*CM/G_UT_M.C9^?/LT<O?WK\[(U\YG,J3KU^
M<O'S\S>X6\+]G=,]GD"/ES]ZFPG@O]==UJZ$TUOHRY;U>EUC6BA:+;=!Q6XU
M41WC+!9NHI'I]5U]Z1 )AM -4&"'R=!P.EK*<:* -CK?:!ES?]6G1  6 ;Z]
MR-RZ=8 &<4KC[_"\ N,8AY A@KSWS=V_)7AQRHG\QVE*==[3=3'CY0=?"KU'
MDGZD%.JZ:!9WUW4- G%SZS-&'6V% UH5#/Q12?39*=\]*=D23F2I!&@BGRH$
MWUTET'*6JF<^N&ZS%;%,L/@PBZ&NP ;YWI)@6X:)0,BP:X@'*9UU";YI0CB7
M') SP?:1)R/ LU)Y<^,\B"FD\I,U9O-!HNY7WI3NA,]J5^XHI)<2GAW-ETJ>
MX&I47KUH5!WH^$J?:EKP\HKH6]SUE^_H;@!)%H%:TWM#HO.9E;69$)X+M']9
M^PW-!6<1TV)18E?LHD3?UF]2QW(=M)\"J3R4;-V[K"D@&- Z)&+,DT@;OJK]
M%;,Y@4:VKG([06INJ4JS<-F=KQZ]>O75UW9PV;L&:F9M>$>#<FH@DDBZ8!N"
MBBV[=IO=L7\H&9KR+!%R\*F0U>#^J=CXG\Z^>O;33_ZWU;NFNN+G(GW,G_WJ
MYXMS^BR]BD=OGMWU =:]KS&:"Z#FO-L5E>.TOI#Y'JH#0*B]WLS(L1*[ =PF
M-(;+*I'57GB_!TZ%DG):TNG=%>_\9^Y\]?3_^-\E/%!&0QD, 9(KY#J@LREW
M]7SE#R'OX2"*K8N%L^:I?^Q%X\KYZO_RMTO7+;(@EW,>Q7*>GO/S-."-A0BV
M_\GR2JA;EP4)3LH21SG%\%MD )W [VI9,@=S(>8]&I;\/S\IY*@ ]\.NG&?%
MK**3AE@ESK3T02)I0#.)CG"T17^@RFD*AK(X@.+MD.S/T6_!'3\]SS-_8GG[
M\?8'=^E__LP;0K24QFVI\L>Z<01F:MJ=P5G1'13;?3*3&I"?]"QR:5*-3M_W
M^82=#5A/5+1>O0J[6O'4#I9"YL;OV75D#9MZ[>8=6]"\J4G?DWT'#40U!4N(
M(&=CC%GAKU1"9\-_J".Q"K^_99!<,&IF06OY5?R]L:FE:E\H>W+=;*E<I^X,
M"#[>K701%3>U'D4?#SL2MV#56N5Z?N$#;?-\59 ZB/>D_^)X@VW757,E+?+1
MS'H7R8^6O0>55\[R*2R%?L)F=S'L $C?Z0H2D34XM+L9S7[OA)"*!6)KEEH6
M>1FXXG &FG.%QCG*=1@6'R7-SB@&\Y%R6>?)26IXGX@*F(+$#B?HO-BR0 UX
MSP(1%@7'%4A"2?=7/DB93*[<V%<E[D0)=! +F['2*Q<8T^C  @+S%MJCGYU-
M?.# T#K_5W2\%9OLYRW%$Q_[C7R78IH^IQ3XD;*OOP'[^L='#=S^UDX88ZK-
M3PZO@:F^KK-7*TPKCC+F%_*O][-%S=-':]%0Y4\=C5,^(XS(E[^VSZKL10%-
MW7LYSY61IW;$P=VR:()_M+L03 ,=-?(L.G1T^7V@OA7WA5JX6@G*,W4K$XLH
M,?C_7I/TY5R(4& ;=[ZZ.'],29?:Q6,WQ\ Y9M$X N+O;T@_;#MVA1?I%1CR
M08]T!KKOH#A&#)YLI NW85U'/&I3U\N[_O]A?GV[HPBH77&%"7'CHJ!A'YM:
M^9_YE2LFB(9LS@=YNBT=WO>^]=_<J_09UW7HCN\R%PQXB"2&1Y1EXGC<,96K
M\.:1'#<<]6/4<U9#OLX'#:(E0/^&;*W-[LRZ.:0\?$Q !*9O*3?#44WU.K\R
M[=<8$/3A)921J6WLF,)=)S1$#+-HVWI>XN(\&5I*]]AE_HU3L.>73M[H"8=[
M<0M]V]M"C2,-1(SB=-5L74J"/=A/]$;O/\PV)*6XJIF3,.ZQ^QBI]O&'>YOK
M\M]5!C]*ZP_XV)Y=DH&=!Z_;VQGZPY(5H*P;OWI=M%$SG(=N=CXYXMT#XE&B
M/5U\%&LF^^5JK#'KKS/LRGUV[\%T;/Q!-O_?G5_+8/0;GV2&9L+3Q^=$#ZM5
M>OA04KQ$&L'SPF <H4!!@XI(""-U)'^12&9)4'M:?(TU"*:G=7EI/,0=QE-5
M>?;J;UPKTOI5NN%T<V&S1"K.$./8#7G:WNV_N[6ZMZ59U'2)F-?.X";'5W5T
M)7.]FO]K5_#8N0\^V)G12*)2#XB7NO/P&[\V7X?>UW'W>$,H6E123<,O<M[^
M\OD3^5?8-)__,9J!:9RX39",4+./H%I]?UR^CB_0B!W=&$;QENN=6_[46-ZU
M=6Q4F>R??;CF_4A!B#=0;P<_)%54/O*P_HLD/GQP!C+J<EYN"V0BJSI:;JS)
M"3;SN!U!]I8N8$!UT9D43$_92Y;ZCPHR"2T1^N_[\_*RE!IVZX]65R&ZE!?,
M- _TIC&6KF<GQ]IP@6+;=%(+5S+]A;A%U>&!V*^Z2%-&]C'A=H6*CI[%E@\&
MD:"^!!J0?_4XN[,NM^5"]:DX$Z2P@3Z'ZGW-/OAKXT:(9?0N3<BG=E$DO&2]
M]W26A3I!>(AYO69X5[;@<A:757D+\]"^C3OB4>!]R[[R'Z:*KW@-OPX;GR$T
MWIH6_*&MM1(QA]C)"#[PG/L9X>Y>\G1T]D+O\F+7+?;41SE_]/+%A<]9Z#YF
MH.QX#*MBFDEZ9/D5ZXGP&)]/N#.AT#XN"NW>A$+[3%!H_Y:'M-(MTP%92$M=
M(V-[)E"<S 4"Z??V$[?#P3+", W*S.D0:5'&<ER<G\/D-/5V0)FH:MHE>DL5
M(D2),PU[_\&PDN!%)?XZO8WX*_X7 MU5F,#H"!DSD5R98.^IFS5IM'=3F1!%
M@0YB=<MN'6J"?)3C:+ZNQ7!\CL]V0=]ABX+L9GN[^/YP6-;BL!T:6G*8:_$Y
M:<;?6.](RH<+!F_=5-)[_Q('RJG]W./> RXJ<@C%T2\ISNPE)J.JB'R:>;3H
M+^[_H.;=?]6R!KU ./GPG>I_WOOV:_,=^HN'7X?E0Q6Q\?]<;] _OO^?][@A
M#C+1VY9-"=;#BSM5=/Z(1^=QJ_4^3$A&;&6;5';\PEX6S4)C[(Z=^?#L "21
M$5<^^&UJ2/SY/;*MRVK'N0M=C: 1Q?QM55_[S7SII*H3:S:*1-C3R"9D)KQM
M432O$M*AL+!;U7[3$G##S5>%SQXVBKUA4%6Q$R"/2'$ZO91_U5U%!2QPJB'#
M2O%FIFXZ!/L 0[G>"QP5@!S<"Y0YA18Y@6QLNX9>%8U@>0<9W KD _SS,%PM
MOLA<V^>TF7R6Q7Q/<LPEV%@X74[\A@<>O&$BZV P(55=W0W7W*Y\_E/,&0!G
M!3WH]7#ZI U]D*T=6&)^HF*^"KRD,Y^@5Y5P.1.N@-D16=V;?@1$:_#::"+Z
MKS!\!;(UV5^>GW/ED#/)E)1R5:R7<E@_/.'#VIYBM+,P&'A)+!Q^X5XR\N=Q
MTWD?_O/9Q1E>\Y..$"-?Y]EK>N&O0);7^%WT6(P9G_3__+1H=]D;DI$-?X5J
MPNMG+YYD=^0J E 3G!#O':P_DX"1B)^W@JYB_-,EX4!AB]ZG=.L"M-V,+[YR
M+51!Z6_J;D>1+.,B<=MTZ 15#KK4NVV0E@]F+%U))H=62[]T]+?;50DD5:G<
M?V$2_/N'_\'P)HSF=M0KE! A6Y=7C+A)[R:/BH2 P3 W0J_08\$U%'66&]H_
MP&&BF@5WHBYUJW^(7BFP;_O[$.F3(Q"KS\ZH/S!V1OCI_1LZ9[09($O/ LQ=
M1H=?*-%<^/P)#V#J'EQVZ)'05DD&0NC((-/S&Z&AB!-6+SR#D@B&Z6++BI#W
M/L35QS6" G__\G/710,JH%"_W,J<[/!RF$:9_[,KVU(+84 "T >+=I7C_V9$
M)N1/2P?I'28=0L)I9IUE_(6<&29;Z&N8_0"8P/F#1>9?_I]BZ0,'&-!9=N<K
M_B-CL7.IVTJ0@1L9^ZI@XKB"6,XZ\7_T0AX)%GJ=$2,'&6&>/7_^:(IR_Z!D
M]L)M=P%@<I_[D=1-O/\P?_CP!R9?]Q'0T-*1P54<[UTWU+^D;%;G#[R15&X7
M-X/_\O_X_N'9_<S?WYK#,^1S%"=#I@<LE2<<JHS6%; 2]_Z<?__M=_D/#^Z_
MQTHP8U%8D'QT1=*S_G_<^^[>V7>Z0"=[FC[23.I\/J\[U-NR5R3*HD[TPNAV
M_'>WN(QS@$]\D$8O\X3/56;/NG%HL@GQ*BJ-/O.KFP7\ ,Z1'\_/7W%.S)\*
M;:_Z=I?'4<?SF(9-UO^=/R8;S$"Q O);Z&?SFO6G%B6U96EDGO"4(E^Q(;O
M!FI;##2L2X,59[Y=NAH54RLC=3>XHR'_-GB##]Z23%V&ZFP1372K)AKG)OV%
MZ^O(.4Q?N*1,WB6S-)%V^-8O5T: B)TG#SJ&BBA$#0&7THTT<I=X<-NB;8\]
M-H9W_?^]K*%'6+3EC3.E!N,8K\OSG?P)!\W;^!NB \N9T;\1#O]# [N)90.
M &A<\:0$VOY/V)A/U[4]PKZV,EJ-?5<+\ZX*DX=APJ-HT_&2/*TQ495'CY<!
M@-S[REA]IYE%?_S\R[:QX#,$5Q);"CHD*-&":3BT6S>G RS;%>U;'0BUE2T\
M#I7,>)R%J^JTI56(G3?+.@@"B(=C-TZX9BJM<6E1FVY4W_/.![]O#M!?Y0#M
MB?F.X*B.O;_DO:G7I0.D#,K/ZCOUDJA=^ ]RCN*ORT\5$S'J^\*;6V55G$X8
M,%,=59&0YR*(OA\"4-%.*)=[0A-?E9A?(O\>^:G\%>B-\Q+2)6<.53L<'.RR
MM *"RB?>'%_+?%<'9 TXF<^?LL(\_R*DF.$^KE?^UZ\-@QNIWN"6Z!65<X84
MH7UR7;;XB%\M%X#GXG0Y8"<_?ETW;_G-6/N@HJ@_V/AM^ 7I&C-V&'UR'/,:
MWTJZFK"G*"/!!TA@CTMD/[A<IEBE@U>VXXK%X@K1AVW![%9-W5TFA>'>WCS+
MSB/10&[Y[/0Y;WXLX%C"[1_DO=,B'Q?+PWW82_;14]7B3U1,J[05-IC4QA7E
M"A-5^J=%L]R?T"P3FN5#QFT7J 20)*3W*WR,GWS$1L(QC#4$U@#%DKL<-A5$
M'=.&7A =43Y$JO=.HK"HFYJ$6<NB]%&0#[6<_LV"19+X2A)+0<)K7?@?NYBO
M:E2)D67<W38EZO2;>D$*[&]N];F8MIH&\\IO;T8/ T%PY9)DAN?X%XY5"=W@
MUI<C[X)OQUZE$X P%\=';TQ8&L8BMQFEF>&<Q]73)*_1$<IW>: 3*K*J0S'2
MW^)5X0]9(B*X@5XHQD L_*%A[L@]:;2I/?".;Z.L5DXD(N,+/<N>+94TB"@!
MJDLGEC&:/C98&I\:T]NR;W=NMZ0<^R1%M*8$W7(?Q0MK%'"<\?;+W[^OM-F
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M#8G#FH^U?)A]=D"*<%!F:"RM[-*T.FON&D^R<9I+*U.R#&<91->JK5F1*FG
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MF#'?C<[L&>ZF&GGN!VZ\L)#6YA&AA1.<"^"!DZ/Q;3V](;M7:9RQ$,^ZX@G
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MTHRG=PA-OK<"$;C4*9F3/Y/AKXG0JQ?<\74'T91;;)-DFGVYP,^#&+X[PTT
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M8PFH%R.X@-\IB.?+47R9@^/9?:%X]D79:>J5,"Q.+1@2AG<!ACMUI%7"\.'
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MD7]190G]%*3WN!?P_:, T(ME\)C[-;=+-^#O5H\;/ZNT!Q_.HZ]?B2;FS$[
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MEL +AK#:<)V-"_%=?.8?25R[#/EPCGE*))%BHPNP^RO)8['_I0"10J(#0@+
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M=W\?U(M*.\4(A>Y^RH5ZGN<5D*,;X39F=]R<A?<(,Y*$)>:#D0K(CE8JYH/
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M*1U2.J0\8*1\]K[GC(>^C .?I)'V 8G3E'"1@^+*&4XNDD$>+JFK0N>:AQR
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M"^#76GUJ6?C3F)>3XU*^Z[AX4QEGB:O+=@"XDZ?I '"' %#%\+\@CTD:90$
MH!^2/&,QR8,HE;&D">/Q)GQ,CP^ ON\ \#$R;W<853>D;E_>9\K$#F^+$S9.
MV#R-MIWE 9.I3T!Z4! VV$G"#W.B69;H*(H"F6RDH=R2L#G^QHLQ,O#[JCX#
M87+6LS&V1=^8Q E&8>1:2C@DW,G3=$BX0T@8^5S)7$:$JB@A-('_Y"'@6Q;[
MC%.9^+Y8RK[9B-K].$@81:,D</JW<W??FVU^YY.6+HV3NP$J;)PN[A*47(+2
M0QH=I1GW)2C<J>(:=.E088$$2!U?*!Y3RE2L-J)_UY502C;OZ^H2A<QQ*5M^
MOC[5ZR70QJ0/':7QMJ3/CF85/0[G.(!T +G/ *ESJG.=)D1P[1/*_(AD.D])
MS/,@BG/&<G\C961/"Y T=/BX8RTKGG62_28JRJ[:Y&,OO_9>MN5EOZY,S'2U
M"T[R.<FW\=9RRH]$F@F2)0E(L8#GA#-?$ZX8#?T\ETJ)+9:#G72,?I]:@]NJ
MP*)X6T[YO1%V#D =@#H W:4(09HGP@_]@.2:*T*IT"23,2<)"T))XSR/XJ7,
MQ T6?ST(D.]6_)7YHRPY,#-D=P()KOBK+?[21<E+X8J_7&G-?ASDWB[,4>CS
M/TB7C7K/^<C67VPE%@;#,18NJLO+"F]?B3]'7JDF^,>B::8@SQ1\VMS>!':'
MM\OE9KG<K*7M8&$0NF-VO+KWA_CL>76U5X/10&4QCPGWHY10F7#" I43D&Z4
M41VFJ5YR,S\TP'K22L13_<8(S#.4EQOR+J?Q*(S3_4ET=.7\3Z+1J1^J%H6M
M-C+JG%==(2'9Y,?OO*YYZ90YYXIWKO@[U;32*/%]Q8ADPB<4! 3)!1<DE#K2
M6NDDBI.'Q#+']64])V'>M>Q[JHUL.;6\>US*?[2<NZE8YH%YRYV^[.#0P>$3
MV<=[@PDND>^I$OE6A=9<]HG#>(?QFU9YPYAE>1YQHH(H)#2/!,E\*8D4-,F8
M3D6>/TCEO25;Y'W'Z)M/WW,JKTO=<^#IP'.+X.GG*O"C0!,6B B 4 KL_Z>(
M3E1"=1ZD2D9;3+7;'GANU3N]-P#J/-B;2:Q#$T"V<]%P.!2: R-K%&"/VF]
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MV2/FA2XQS5K9+&DKXF>!!=N9ST2AX(^-YKW1/&C UQG_-H,7;CJMK2,J;RL
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MY.X),1MELDV2V5+\9=-H\_@QF<TJ6+=RU8SDM[EZ$YUY4F%R@$MV%+W7QWN
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MRAKR@U_H&0!4?1UAI6YB__:L^;R78<GW)Z&!M H&<FU[H8I?K^.@CNT!T!#
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MX\@E:I#@6.$8C9>KL4Y; +/=U@^A!=T*NI4M/29T^WZV(%M%2T>U$8E[Y&,
MU2^EB*R-'G%"'.B! )^K71]WB9;_A+\VWO7Q^!I</"VBNEBXA[BW!39?#W.6
M4L>3U,@)I1 W-%<V\1PQ["43Q/MH5]KV; +F=A, GPU<?'R@UIG(D%.J75(5
M&?' I*<I(,UPUQ2&*DE9+UFIDK/UD,@2D>94>8LTJ.8@?GA VAB&$C8)>\6H
MX>2^R/))B1 -1MA:B[@,$CE/!.)<> 8BRRK-#]\I^Q!YS=.P3C6KJT!T@>@"
MT;N#Z$0X$2(PI 7VB <ID*-*(R%8S$X58Z+< 40?@JNY8';![(+9!;./SH'.
M%!.4@X9NC 498(-"+O+<G8RP9 R11JZ4#-RE#.B0 _T$9$#QPQ=A4(1!!X7!
M _5>17 2.XVDEAJ .$ED!5'Y"%1:D831?BL^ELX?"YP 5+_^= %^SWOZ]]D*
M_S:YBJ.>A[]#[^:!3^'6NYDNAE/S<\'8=[N*J7XX6;1YMX17?_-M3UV[/%V8
M]@-;^ZU7S%EVNGXS=4L&%@@%_4I8!29W$LAR@A$A5"N5&)5VI1DLQ5(ZJH%C
M<>XHE1A'+DB#'#Q)\,!H"GK&L?W1U>CB]U&\MKWP\]?K.*A!N1J$#^/+.)IR
M9YLJ^PF>_V-_Z/]\4T7@SNN\G:-)A&$OS#?TZNN^O;U(_?AU>2__/:G'O70[
M6[OF"E2/[6C\MMDU!/MS55\X6\=^;Q!7]O=N!S+AJ.^VD2O\C-U:&<YLYKU!
M'CYJ%N ;<P:=\GQ&-@OKUSZ28'S_@7N;WC*]3PFEFE%*90>A:FBEFA)+U5++
MG"5:9&A^KN<+^C*^H,DP%VA"-&'@"QD=2#+,$(U.1\F8MVK%#'DV7WSTES%,
M^O%#>A*'9'!\F$U>AH*/(M-V4N@W0R9QD4R&#9GX*9G89LGR!M6]&JRX:I@J
MN  $?+\__-(;?+YXH36[@>$O'0EWPM!X!K\\1U2U2E#;76,U \I.QL.9.I/'
MDS<%AI\O1X!,PPD@6N]K#&_GJ'4.N#6] 7:J;Z_K>%$#*8S 3I^M0Z/HML]^
MLRYLX:97]UROWQO?7LR>\5 \0O-:*<^- 19Z\]=O7$3.)7WLDL>^I^=:,WSW
MWZ,W='Y,CT2.Z%V6%/FF9:\/S[ _UNF])'MW-JXM3OW.2'^MEO24BI<;2?#=
MVZH4BB\47RA^.PGM1686!'DY@CRK&^=18 S%E+V<-)[2@[(+*[93?GEI4]O"
M4<?"4:\HQGZ"'%4D>I'H+\8?>6(VP?>]036^'$YJ.PCUD\(ZNKLNAUCFZCAS
ML&;G!:-81SORE\UY08@WL3^\;NI8S0X22AS1 :8U[J?[U9%&\+B@M7$Q("$,
M0]S[@+1*$FGB6, *6QW":SI;+<8#_#%EQW>#\-,=,\[.0#<57W]F3*E556"L
M\UM:8&R#,!:#8IYX#!@4 8B<\\@* ">!DT@!>Z'-2@6^YP0B[@'&6(&Q5VG#
MI2+!/6VX-Z@G(SOP\?#%Q2[K,QP'#Q5QL52PU5)"-2B\%%.0&81%I+FPR(>D
M0 66.-J5:+^7]'.=LMZO,\[;5,-67>H5%L@J>WM*D*6%)=$(CZ1Q"7'J.=*)
M4*2-(#IBS%3:2)[DMB!+F0)9Q;?[>NYHLP.N'XX(M\L) P<K,/;M$GGIN7\'
M6>Z%F_ZLP_YCDC5&!^DTYXB;7)<E!HRLPPDYRX,T6$?X_-5.X8:1E_-@UJ;!
M;$@ *;QE ?244(=CYY@"DP4F3P<F95#82D\1XSH[G7,A*TH28MX9+ZR@6OA7
M.YUW#).4Z0*3W?-,+^9XGFX[LD_#L>T7W7_70NT8R[^4^BY/*M!H5>+")91
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MQ323N)[T6Y=C;B:_)'LZ1QHA@9DE D79DD9<*X^L\ ;1P$&+\=X3&U]-&NL
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M9V"JV20W(A^7M[V(R"41F=T--5@KC>Y]/5NISHM,+RWG%O1HX7)A,@)JM19
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M81C4O9PM,8/V?JSKEBV^?]<] J8Z:8()1D3D,MT6,^2PQ8@Q;KV1+@%-[X^
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MU:J P.9:U6#8(<I:P?LL 3I^-$W7NX..W]5Q9,<9"Z1WL&<:1-B@B9 H8.E
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M+:06YU4#1EXI0W1)";-)6'@@MA#!,@Q=R=!/9[%L?2E7EP')YA9.]9)P8*[
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M:$I1B#B:?#IL<&*?(][:M>F"W0H4/%/B?SO.H#IN3\0O$ZXOR2C'&50@VC\
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MRE2[],;-I(O+K;,[Z_B][[Y>U0$LBNO?@*BL/P/RF@,A_@TPRM=3H'TP_2?
MB&T>]MNQ/[WZK#8$^[(DX*=<?^Q*5;TRHGE7K&B>(WB6ZLJ2CU</:LF]334=
MM=394>1RW _AZ/3:*:X8X'I2!G$;03EAFH*D,$1'K8A,6\JK-$F29#'"/JKV
M!-4)*W,U72L<\W"3?P*.SI4YSGL:9EUP>YD!V8"TG=?W#JVXADRPM4[Z() 0
M.=@A,(PTUAR!9NLY#9XZOY45]#5D,NB]A]-[K['MERAS!6$_VM&B+594CMFR
MBI+5"?BVGA6$;4M#OGK_NF(25]^\O?SF-U ?<F!T]=-D_ ']5'^$FU^U\O[U
MAIKTGW$4"O'^#OK0R3==EG.K2+1O!N#,FO1XLO;FY^R87(F$KDQLNRMVO)(?
M70VIE9;8RS.,$ 5+E"ED<^L?[BC)I6YRMSZ2P!1F2N M.T1B'*@D'"R6Q,#B
M!@%EE0#K.:A N:26!K,A;)9+U1:/RDTF?MUGJ,#UW?N.9XPL5750AF>='[I,
M?G31U1NU8,=^7J\UUF\Z\49QS6-$5I?D+^J0P1$D!]71&QN456$K!Q4;KHV,
M2'L+TB9'-#L")J\2S"?)<PE#^7!T0D[[5#]FLT[A2@-M+<?B\-@T'J?VHE20
MGFR(AK28+TI(^I+(ZO6LY]9,_*Y36;M2@W^UXS93K0A'"DKSKH=T- E6YXZG
M_'4Q6MY/NO#KT:A:S-OCCNWKVV2-RQOF8.2Z16G3L9S02B7O2O@MJ[=<U;^W
M7$:;(K-9K6.(TTE3+]- -KU$J\*HI2AL+]D-1\:LXAAQ:1,"SK/(&441U8;&
M*!+Q>HO=?,(X)N!)Z5DN_LL!R@4HA,'R*#AFE,4MY>Y]]+#@\XLW[7*MSI:?
M-#87^&URKY"N'@AP3)E&+A.R*K.],F5!74N= M2Z7. :6+5<[_)C[&I(AYAL
M=F!LWWURA=3F9W7.*&F7?4FF>4T[YFN=);F(9Q^+4B='03/ "E&32TU&H$NM
M/0%UP<,727&+M^*H$K4V4N>0-CDBV"F+3") H1P#?5+"<3(/3I>\CW39Q>0W
M,.9<*:#M5I#!>@L%UXN:ML$TS:7KI77 M4^KUSXO5<F:^<P6?U[NUM)5)"LN
MN)RT/AEW^L=N3]ZS/97^R;KG7GAEU6>C+7ZB[UQZI81(P'HVRQR\7\[JD0UQ
M-#W+55>^7(/E0$>(V ?#3$*2D9Q_0&/.MA1($U!Z;:#.T*W0PJ QUH8Y)"@!
MA3@FC+2-+BO$WID0B([Q"7C<-M1%TC]?RDFAIW+(W"FXAR$1)PSA^8C8:0T*
M&;8::68\2L1)ZS5-7FQ%P7T-B3Q:;]O5"*D>^F3[47@G!LI=KKAM=2Z\HW1
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M*^C<]#.N7@>B?20VU_9P.=$?S&P'!K<.S%/L#$UINW43EM)1L(8P#KF^-N,
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M/;?(1$)02IYX3RSF:JN]XMT/2?L!H>*$L0,G;O>6S?:<&S DRRT[1;>'CH.
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MT6=+*N3#P[JDE);CX^ELDL^%)N-!E#S)L/"A:M:#2"'E%&,RH2@C2"$90;:
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M5EG:EFA97X=MR(T9LI8%N[X(Y2%9:(&^_^DLEI6QG5Y7U$O8MMED5.Y?^1=
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M>+G7;7ELY-NA9H6&C]9LF'WK<B9&[O48ZFR]T]/@#+Z*8F\.Y\5%$%)OZ:-
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MT>VH->OO3H&+X:NSII6ALKE&HQ+FIVZPB<LC55I0-!T8U:@>39E3["@2XQ,
M:H.K#D?;*4_W&](8!P#_@,51:O-\2IOW;,(KR"6O-.,5M1^(Z:QIC$O=4P,R
MB#<VA-L5LT <O72A5WZ4\FSNHBCR^O8]0Q4@UO-%&*P%@N06UEZ:#N LVL.
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MR;F@87\JNA][+L*X@OZ8YGN?/Z/+B+JB_/-ZLU7A\'D$V$I,!3.TNZYA-%N
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M$.#K.[2JVLB*Z/*?*\^G'TMUG**V W$X5XD 12VMSO'MVF%,N<M*9S?;RNX
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M6?'I/-1?Q@_YRYC_!Q,_/7_)*P5%,D3(6;;$G1#RX:,@_9O@?[\PJ\2%DI.
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M"$<Z'ZI!"0WQLGFX,] 6\S R9I1I116.3/CH3<SZXC$:Q: #&*FUD5!#E48
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MJ#*,EH QDF%T(+M-$V0&DOX-!"6?Z4\-XS0Y_@H:?7]P?)\E61K@N2'CK=B
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M]%N8#0/^NU4^X:J8<<+*XL2O&%P3X&#_/8V\V/6VO5FE^_S"D'%7_,#3I9Q
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M)H%/V3R4 -.9".\5!C0)T8[JL.CRN)Q>$_#QTV+(KR,G@_:I"OL[,=K^+UG
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MD/\=N/HO8?(/!/4"PGT P?HBI(PVF16HK!LEJF(P2\-8)[-=Q[ "\/OG,$J
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M%-<[?+_!R>8:BPMBFM!A($M0X$#VFU(:017MD[6V!!C%-C K9G/ :(=AS$M
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MKQ+M[E: "^X0VW ?@$,$7C,K-"("3=+4"C!T<LC@+ZFY)F;OK_ B=AK)_*O
M><$6;-DG:>U%=7,K]C3W[\A\.<B[D'_Y-P_?*XQYA6=4JP&L !D3"SA<P&U(
M2"G[V8KE]M4&9>%IH' <3^54F\0*U-U&Z.AXK-P3R]74G.=0IY\5 -XAXG,'
M@;4GSF8LOZW*#E: 5*34O\5;<!-D1=\:,CHV][("N,?[AXB0R9,J7J&YM17
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MLTB><J*  YO;W65-0W%':IQE!S7>1MY1J)?N.(X5>\Y<B5ARTD^J>A[2QE:
M(N',,M>PGOR=8A0K@.>2H5Z"VCTDU#*C+O)*#QK=K  O=^N3&Y1++>Q8=(.-
MF\]!DATKC3IF_4>U##D2;47\\53ZI=F3H,5 EJ% K(KC=[)(V1/'Z8%^U^VL
M=)_!N+JAT(C$$-N4.<!MT])CI6QHQ;[KUI44RT!Z?<US5X19$"?:*VD(:NR4
M;D?S((I?3W#6C#F&L :@7C<KCJJ,I&IFO6_1W0IP=6\71)(\? O[7-!L""O
MSGDG)?=?;V7%XM=!XKF0YQM+TT4&BJM7, DB%TP=P!VE+%*DFB)<G@AFD('-
M$ZE:#<+-#HNG$*46A?O($3@NMNAFQ0DHN)R:Y%UV%FG#,+4:R@HT<*I%N0ZU
MULB*I5<5"U)F7]C0_!WC59H9RT+I!'L!7 FOH]O1BET2)_%8)R2% EZPU =.
MJZ,5(!;W7RMN!_(:;3/Z7XW,(?R<)K$9>#(K4,DJ\:"/8>#J9$-6=K "I+ZQ
M-5S>A;)%;I1('OELQ@5YFM")>XMJ)H*J1-_<PXH3(N89(=>CW,VSJ8\5@!4!
MQI3QA?IE*<9Z)NB E@WMP@CQ%3&RQ%8BF'L,9_ZUYZ-'B@ 97I=&'1*)7TBS
MOJ/?<,;O\D4(:6D%%I7:CU8<9 AF!#..)"*#^]G\0=.IHD/.2:6>X@YY25KX
M;M9.W$#C&C]Z934O:%0TM,%Y,RN.(WZ9\7/NX3>:7N=K+_ 2] GOC2NWVC5V
ML@(T+FD7/&:;G58!D^9>5@#'TE1#5<:8)'?& DYN),97"6$Q!_R,/YX^H;WC
M4_X%*I]"[N#HZ&1IGV5T:,CQK4"86*:A#QRI[@D4!9]@\/B)Y4>_PS 6@S]\
M?N2*"P[Y$4H=YT%4^D@UL#CC+TK&?Y]8( F0H.IS(FICQ1EC''*6%E<N:0L;
M6@&"3F:C6W 3Q,<SP3+M4YH016QXZU2+6 PTI!5H^8*^90\"5< '^".-48^U
M<P>V'<,*P&^C3 W/R?PTTYX(1'EK:X%1)Q91][ $*(FG+@GO% .EZF$%4)60
MXS9!QLH[.,2X5B"(>*UO=H\QA63SE&#&'!04[%'$TJ+$!B[T$^@^G!7H^)C&
M>+UQO-[2D'UX2^!CA!1ZO\9.5H"69U8LN#R9S")I:@48%4\X0;(%%G%,LTSS
M,<CDFT<L8G?WTAQT/CL0JDAZV[=$GWP0XP("E;.O#BC:X^7B%^M;\@S[Z@0E
MPM;0U#@8:WPY7:(3$P2>EGZTXK#EI<+Y;/URSQU%<RO *8@#"4%'77U4FGJ;
MUV _? L?GL,T=@+W.DRC!*& Z0PX18W$!:E-9ROV]>9V(Q>Z\Q^M6&JU0E.E
M?E,1K4>8\D?,D5*O5)":J6E.EJ9XB(&M0!'AO<DE8T*SKJBMU],*(#DW-[YX
MK%X>'T$/*X!B;K8/8<905P]E<2#A> J%U'9#6 $V$8R4>U=N8<6B\X(Z<D&I
MTL0X\T09NVO/EU3>J?YN_AG.3C,^NI^\+0FH8)6>!.X(\K;F ?GD_8I\[SD,
MW2(O4986L@:(HJT5)U^<$*V!Y'(MS>]&L^<*EFNE95-:];9SQ_ ']EWFO0NQ
M/=%+*;T4^TIK9UN-: 52*@6;!>7$U2VM &(\"VB>VM\RRZS^NJS8H-I%*<)5
M66U9K?M5[V:>C#+O;UF"R<KO5NQ'KHUGV9^$IM=J(_.XSD(1\.F'3V6;@B!]
MBVX?\X"-1RD>66V2:DT(S4(0@H)I]J[5N'"Q3ETOP;QW%NI1T\V6?[:"%G0.
M5.#-H2SE0+YM@Q<X:9S-^-Y3P7'MNA&8!>D_G[P ?1!+F(*&5IR'LM>"E+<1
M-+-D!^X/CN\S\ZP8]Z4FMBS[&?F^TAC%MS!>..7!2\"(<1.XWHOG8@)<M2M+
M&UEQRF_(4T,R#BG\>.NMK%C\A>_$<5[491,1!XQ2\=^BXDOV:RRDQIT&L@,%
M)'@?1;G[D3)H6M34"C#ZUH+FPCHHT^1E 5C,:7=0L51W4BM0"]&&<)"A6@=F
M^M5!];6&ECP*=2;AO2XW8<D]%0:/Y\Q<D4I&N#.ZG<T+<* &Q00SC$CH@J(F
M5[61%;O4,UG*QY-X &EXS'C3F3\)F]T.OYN2$\#_:,7.EVMUB#:KW,**1=^G
M3S'Z5PJY+E\RWDP1DB9K; 4H-)JA2,Z4:0;D#*FTN?F3WYFON$PC<<VXWB-:
ML<=\:FQ(3?24P,L%QA0L1!^\LO%3NY,5H'7>()4ZYQ*$112X$-8\*/^J.ZD5
MJ+V-PIV7?)*'862_FK_W]%&##%O.D_+=XYM8@>,VZ?ZN,:\A]LII-X85@&<)
M.F\"S#W+K&_5-E8L7%2D\D.[FI8?+#B I@PI7,:=NO>3-8LR+GRS(.'W'YZ(
M"K,J<U=_-W^6/GL^QF08()%%5]S"_*)K]GTQ%?4$T.AW-0\FJ+^=P"GJ2W(I
MA!_0]CD(_7!_8@G4\%61/*(=Q[&";I-=J9AK94*.K*T5@)1- A>86]Q#/*]D
MW_1[60&<3FJA+V'@(C?%S9Y\5<V<KF.9OZ_X5</M?)*WK,C54KN.XF96[*.D
M# H]A7V+J2A&L0)XHAT!42/<.O[?\3L=N]Y6?3T;NM@!%MH#_;A#1U ,M(AG
MT>IH_M;Q19B$*?9+%<9JQJVN8UBQM]*D"FK5ID8W\_N*N9:49BJ1)+>6M[)B
M;SH+1,0C;;,CGP=58_$#F]_?O$PE"6N X*J8Q08\XM>=A%O%>11*;>/;=;?G
M1 R3VE?3L7'L#,.ZR[ "_;J)AW7:6P'0H/KL.R_^]1K?EAM()(CYM$F4Z*))
MYXW:1FT6YP1C66Q(FY69?SX@[8Q_GV(BA $%';G,=T+<SHI3QL?"9>YRS(E.
M9KR1MK<"((F96<Z)*CM8 5+C?8L;O-Z4R3!+/I.=KOMPTYN_T[D<<IU& :%$
M)/WM*W,9I-9 A>MF]U&,FPY8NFH0P:IF _XW\[LDJ%X39R7?'D)":64Y[[5[
M6G'S]=58_91@YG>TG#GIFF9.*OQSX=7$)#JJ"V&Z'<V#"#E?<TL/%ACE"_Z(
M]IZPVG>;_E8<X-%913C0([B+MY_>"G3KUQ!O02\$O:T MO/F4DO]9K=V79+\
M$C/G&BEQ1YS.^,M?)(Z),@.?)(ZKU,2*4P G]MH/OWW!3?''XG'CJA84![?P
MNU=9C_J.:05BL%P3@<!YB>B_60T?@$E6%:AE5TO!K"<GU(.QWL\* (NLBU12
MK=2G8BGUX6SB[[U]T":18Z<AK4 +/HPAXX;HRA4&?6EC*T 1Y>*IIQ'53N,C
MZ&J>^>7U1I!W%[PR.>TVEW")E$:@%7])<<FZ\T+GH:S8[0:Z9 OYB9-C]/7S
MFE]B]I7YPU399W8(N()-XI.CV<^*8T*N\\WAZ'@1<)(7F&7<BT^,N*450.1&
M%:$KDKR5%8LGI^4Y]%T4Q50>%/O?5%L9SV]P@>73T/=<4&H1MET0SZAJ9UP<
M8<I&J#_):O-B<?0.'CL$%U;$W+3J:)Z&414PLPHI8T_*C:RX&_AE+8H9270)
M10,KELQRIERB>!MYK&Y;EC'Y%M,?2-0)WZHS++<>Q?Q1TW%GO2#53FX"8@?+
M6M3-&AT'LF+_]6J/<LZ47 E@T4GH,YX5",E-GIM=7D#E-LSJP2BT(SK]K "P
M8FED>KA+B+Y'KI8#3LLAK "[D.YUCF@;;4'[\<P3O_OT<'"BTV9W[^T##S^G
MX&]:SH_/RE?4Y07]OG;L/%=XCMC36=H)J3Y;U-@*4,1'[4)0KUV?-HMZ6P%L
M0^D*ZO@-=H<X(9R&4 IL.885@)<CWV2NG.1'J2]IVS&L /P1,HY?Q8EWP.=2
MN)_E%E8LNE 0YQ8/Y<.A:F\%0'VSB7$O_^!.5<-,;?[]K6FHK[U7O%;RD=3-
M+E>4%SCLM.IOQ;DBQ 9T0C>'8Q2^4"<Y>0B7HKD5X.3W.+-8)R=UCI]J2RN
M$*1>4T80JMK;!=#'4_[Q;QXF ='V^42R14C+96KUM +(6C4D:=R8"%#]WG8
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MC]%L\)6Y"(,87PB:_8'6'T#N)N#VH-EM1F.,H759>RRE0'8F(CP1N87MPV.
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MMTXC9\LB3I=&GA<>;PT7=Q$HTRB^)S^*R\+0)W7I('6:FX5('8($.3R6*LJ
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MC?PBIT(Z?<W=BNTV/:2$ZR.>ND!K(O2,@CA/[:*^(=K];=L]>CDZ;E^ULYW
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MA]*::0VL!^*E9!>'_OW^D(!6R?1.Z>'(9F ^G1N2KI/@4)3)79%D?TM5V#0
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M! PT^"BEZ.P(J>4U;L2HF926)M,+B5#K"8X_:8]&BJ:6X:9G@=8.#5B?IQ0
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MF.)V1-.981BAW9_B,D<@XH1;65=[[@Q[!JT%[M??XU=0JK+EYN<_?OG+M7<
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MJ$A"PHTY K,O<ML\!KYKI*I+C+6FKO;V)3RT-/FX,/X>+9 :*M C+6,%>\I
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M6?3'BQ?2>QH:TO5V&5H,J3['K'OFI/1O<LK^B_T67LSATUK-?,=.P^< K6.
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MPGX=K?*BSKPXV#HX^&[5Y>WBF[[B3)>SLS7HL6**9@:"M^5\K1)ZCI%EDW_
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MF8Y5D@6IG(YX"_GTA.Y$M[;OG1366AXDW 6N*!^\^#(+T5/WD]0Y3=6\P(*
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M?/L5ZI$%+7BLPNA.%VCC24A?@KUA%P' @F9PDP?RW?Q/JD^1 #4/I6#;Y9C
M+Y'7MZ,C6%1E@[EB'@)L!CN<$G#-FVE#: #C"#\IEIL;O]-L YQ<?L^\$$!J
M2B;J(;(@A];2T>=D<1%X,0I8;'$&^-1WB9>"\>ZA+W&0O%RESW%ZV61Z+/K0
MR0V[B8VW)[QA]=8$22R?_ G2?H,;&V7Q$V$G/[/FGF[V?L69R&?6K."# T<B
M_.LGMR7#13237ARF(3 :P#)HCNC =N;PBJS]XT]P*W@T"+$$T<1@(@23@W7<
M^C0/$6(UERW-PH>H)Y@J,3H,)$MN:RQ\41$L6:1B\.HC4@\F@@$F$3&BP-/B
M.+KGPQUL$_@:T27DHXXF?+LC;9T4[E^V1<S72)O36\#4:4L!30NX$ .8QB8\
M<N[=Y)8)&]S/]"]<ZI(]AB] "D<JDDCKBS[V$V.HX$U0J?*&@9GRK3BCZ'9Z
MP2":?G+0K@5ECK-B &[%C42IN]SE0%L2)@@M.Y6:96?C[LC\7AB/60VT1]U-
M.M]8,?(1DEO$L_QD!#MQ G:BG] 9!K().@JKBK0?%1KKU#A.M(9T@O)1#E_S
M-O$ CMWY0IMW8, 'D>OE1X!E5:(U2O:#3<=#):K(6I_/-KZ )6BRD#K8+I+H
M)TF&W[=.9G+&P/OQM,EA'Z?6F9<?=2<J\&DM,93W27P?+3]Y/H)$BS' %2\C
ME;[9:Z_>O,U>M3 -&^2&9#D8PZ#.A98_4C&GV*-HF]KY"+Y0ZDNQ3)+U(FF"
M4 5%MQ5[_N9F%7CG9+]&8!DIR[PL!G03*Z*;] M&8^AI84Z-FI \BWX/SO(0
M*ML\2LRX@ID)OQ3'C=6<>M@P9 Q4D]0CE!;UZ1=$G:W9UBE_XI*AAL(S["F<
MYU)LM6?;7"DGW9V-1.+H)O*PR>8"MR*.<KP^6W92S%"JZ:,U( 6&SH@U,Z #
M%94T9-1/N7XPQAZ2]LA28BC.<_F6;"-6S234S0N-/+9^T6M#+T@@83&XM"6+
M9X\4(I*!":\")QDFNTI/9FQO5__7I1*^[Z,/NE3"^J02?D(3@?V#AH.G&+?*
MSTQ+IY./62F"$/1J;.%B&3Y&.-!B&5V23>:^J=MWG0G&E#H+3BPX965U4G\*
MS@W809\4QDUB+I;)@Q.>HM ,17@BX=/Q<8:LN$B,[F>L"_[8N)&C5:)65I4;
M&%!75*\I-]:^G9Q5S 2"CI:B,*(.G@DQQCQ+?:8%$-N)G04A*@&#S2\D$VSK
MKS1J?KY];ZS02XG]SR.7@<>G(XFZJ(CB,&0I$L,!W42_;H$MP@TQEY&!.Q$3
MK]MM%&!,3(<WL8!3&Y,F*V,306!]%&9D*!6#A2#BL/2=6S*"DEL>O9T6,B\K
M Z,X$*W)C0_3B9:;";#+.IA'F[#F(HNGMT2@D6_!XGUU_@1F@ )0?7J(<:CT
MDEI/+2;<1,(DC#OG?C88D8P2DC1XG1E%Z.K7KB2LXG76"56L,&S)#OORISO^
M?*X\'Q8_>! WM?3.^<T",(UI!=(H4#HNC7(R(Q[*B&>FL/@P6+/RL!-G?C)U
MM7CCXL%'U(>F)"1)SF@%>RE!E@J&79T5AZ"'R .HQ+OSI-]C$T/UN-0+1V\?
MF:;B]#1*K6'?H?0E144(HD.K94MN<AME@8Z0@H8& 7^%KJ#X2##YB>7!V4,L
M2<VZ*_,9N.,61#R1ZO2ZM+JDF#GV9H>5$W>F0$O#N,#CYMR,J+0L44^)^,N:
MY)Y[ >P'_J.G=&X#67)N(@J&8UY%4I4WF3"ZH/:_5WB'A+UL*]U:>SW"%[/@
MII()OF$G60R"I[T'2G:*03>JJH:]%?$.I9GU2B$\(^H@J=E<2;P]6<"@I*E+
MF?T)G6G4<)CB$/VBO$+(0O(?^"$%#MP@/T.#:)H'HORP+T<R7>V'_\CP  9)
MY(0#YNG-73@A \L0"<W"\BD8<?B2T!)PN$H!+RIP5Q)=I+DH]9RC_@TQ &>+
MS'6@P@+-$E@ Q!:R2A*.Z!L* 9'I4%Y0?C4:)RP8*<PW0!7(^%K(DZ5+D. Z
M+I$O8%YY\'T>'!Q?@BHMQ$&L,F(Z1*-[6Y+HX;-*)J28Z'EZ=7Y7XS!R5DA[
MT\(:A^.+\Y/3Z].+<^?BO7/]Z\C1U*0=3+D6IKRW->@=:[AX&\H<T(#W0TR&
MB-8N%FK):8V)'%3Y4]*Y2_CF*JQWZC,8UQ:M0+4,4^=X<"")3N](_F:RR<>9
MY*HT#KJ690W3(-/8G[2?9/IX=:O>+T+.,2>2,[XP1(2 #WAPW%-CRB0CG#A[
ML2FYK@12)% -NE:<ON( RB<V, @:H4D#T6E!GDQ!H)&3@-WGBEBW1YD/&S];
M6A=35SBHD+*3 OIHO=U@CB,U%2)%ZPGGZ"J;($U3RLE"9MO7>^4Q08PZ06S*
M$FP0ES"E9LNDBIOB<+JI'69@Y;.<U!,V/CH35#[$O+&II8NLW!YA%3BCE=_M
M'EL>@ R'_?J*55/%=(^)17((;[3QG< R)6"@@E?X8#\R<>IY/\LV5I<E^3FS
M)(==EJ3+DGRA);O_DOVC%588M= _&IY=C\9#=) ZCZC>(]H'CZALVPUS^[&%
M_5C6)6;KFIAM7K!>9^+W3?C3+K.X?4@0GX\ WO!&PZVMZ)ZVKNQRDVK;*HD;
MLI7-M1P.#A.O0O^$V2A=KZ8TO]EAV, VUDQ@&CSTG3:R;K5A [21=&N5?$!<
M981Y3NV7@3-IK13[$RZ&5WTD*"!8+_6?N*/&:T(-$41(CF#^UGYA/*E]VQ;(
M94X$6L79<7T1$EA0YE?8@?G78A>+++2 [WC#6Q5X6*M!RVFO+W4CH$1[^$H#
M'UW&>GJ1S?^,2LLXBU>F%(XX=OD*P?"6HVV2Q<?T(G6#P,PBO%^"F:F2KTOW
M@QL6GTRT$BI-&5A E!4^ 5H$H*PC:&9TAEE WY7Y/>_,C1G0K,H<'64VDQL4
M#Q,WP2\2^Q)MEWUX7(( _\0Y 0=#+Y(F[#"E8!)\TH0BM7*GEU*^JSN\"$V'
MA%X6!<[MVONL_>D^V>RU2,=<!KK,\DJJ1$WKC-4IFDLMF&#U:*$<VG;/<EJ9
M%DWO"CE-0441SJV G2,]A%/F+C T[ 9]Y,MW?2JG,:*0%$2AF\^V<L32YEWU
MC'1V:LY;224K",F(L!0M5UG.AF7$UIMUFSF'.N%$!-=55'UB;6B=6#)U^B;#
M8C%!YM_%6/Y$*=T&G0+C?:YIN//5O<#-6#'(AU7SSBIY4B&<L4K%QK;AP2FO
M.BZRP#28"XF_F)FK;]20\'EAIVW2.ZH8OL>7_840.V@"@>DW9.P<$PJP/3;+
MXM!/;@O:SLNH(C[%+)D/HT7 3 1_\1E@4G@>+!\ZMG:%&)IQ<+#($FK70;^!
M9O% BGH&GEC8NGXMO09W%YFFND<\*&C[3S68FI(MO"F,\3&6T#DW*E1H".?5
MWAMV-S]!!@F\B(8//W"29Z(-0\0782(:+&H4',-R:L_#&*O#]?>%M,-*^1JZ
MT,$FS0W\B8:--F7?>@V<3C>D)3-UHDP9;&CKV9.3AA9VGP*ND#?N@@A'WPE=
M,EMS;'A-9X0;QJ""#)W!&T>QP>=^B.+T!EZ)6B)84#*:#N791GF==%GC*62A
MS"ZL00!9S4VFDM&4@D5IUXC4RF9V"D[0XRJDVJ*/<):#[:(?( 2KL9HJL-B-
M?T/'OQ0("YE"I-6!(W6W^C?K*VMOT$];9= 7U:16KRU O#18ZPP&P),/<\=:
MZ?=SWDDY-LJZFNAD) @P(\VNSQ+C?]J[YTFGR8,%4=4;WFPHIN*)%CXS83 >
M,8UN%&U+^C1'U+P"!>L'J2F:YLU5NZ\%E"' <!Q+=#P\(;Q#AMMTF"0^U3J<
MQ+!O^>B'7^@<E@.66CI:;5ZX3IR0(<KSLWE%DW)*'PX39@H5)0HKAG!]!OAR
MV$)0N4,X<6#J0\);("\IJ8!A/$6)F:9T<OTM"V%-!V_>;)>'4W/[A@%)/0<8
M)W"BD(*D*2!LN5E69)+ LSUV[TUPK^2Q4'K.%(*<O/^=SB(NVW5#'I7\A9_,
M751SW=ZQ?38EC79Z'[@ 'Z?]?Y >@@MX+)%>J;(9PMXMQ(9-01D'N4 D$%17
M!)&@X0<W#?Q/IFL.Z14D5:=8H*=F).>\7[(0YR)P)U',! I) :J$]YZBC))%
M96JM20>P23%Y*)J"N<UM5[FA[3'=%%XZ'4]DI'40E)EI##%N$6Y-I@Y'ZCAR
MBB.WF,C*>'E"\&#-LYAWA1$9X[)?DS'J:P!B_IQZ2'ZBNB:I'?SG.S_Z=0?_
MZ> _+]BKX%X<+8>Q_KI*/#4=C]ZF8\"J=<P^: T8]#03W!GJCYPY=B9$B/\4
M<T;PJEB8E$KG/V%KRBD6'6HA2T6FE=P>':(-5%X\\#"2;D=F; 56$MO7K^-1
MQ;C.9OX"5ATH4=#Y*LP!(2J<9O,)17<ZJ[;)JMWMC7-BEZ89;X$371W4\K+Z
M"M5OF6J2RL)=SIP3-ILK]B?(A,!7E+HQPR1<5!L+EB[2V6UE^A43%0.7O2L7
M%!'QQC9VQBTR/F4A-Q0RI7=LI%7V5:,B,"Q0^)97S#^6%E**''XF2LMLP:Q+
M8-Z#SP">J+ZDW!"BE(AG%DO-K0MV/?<E7>IE].WZ3YE*NP*RH%6([LH*,=L4
MD$9V2ZE2IP:/922'>:B8!BI*++Z[RKNSTJ)F'^ )N5F0YB&0TB3X\PG2/!8S
MCM6@[)0JU&<R:SJJP1-'S!/<M!LG1NKMZ]=MV?L1 UXD:^_EZM)#1DX/"2U#
M+PHE[U&*-%/,2?,]L1N%GD#$Y9W,+,HC+J^ZO:2R9"GW!Z\549H(G?FA[KE3
M:IEK!8KY*W*:L5*O\W"1[;P6D"/30<NG\HTJ-;*-V[ [+9I.B[W>!X7P2G^:
M3_,9'+HM#K-2^QXA8K9,!/D3A]28*')&8 !=GE5@%ZZK^99Z-0=W$MT1RZR9
M.8*2#YQQQ \GI'&(RA9&-'-0>5#QFC:!).3*PZB]3WX%4OOI%Y:<Q6";N: Y
MNU'5D2;;H?O8"\?=Y$$3!F&O@$!S DPBVM-YV#APBTQX=7$>N*;;-DW;9K]W
MAB$S9ZR"E@0*Z4167* VERV=E.%PMJXE@A22=Q\3ZO$\"A_$H$]S@D4M"_BR
M=FIX69;2C@?RP9P3&%A<^LQC:5V,9D@DQ;K8B+UB+.5<"R561NGSSNP\M2%3
MO6VM>"=N1D.CA;8C\3109C<EZ"1?Z\YP)[FZ%(]?0\\VY25J)IOFU387GGF>
MD);&LG2M7NQ,3:W3F@6HF59PRP9>^I*!D\K]:)ZJ\\)TG4@$),F'DEPQ=;F6
MJ?Z/%"II!"<>+V?5J#%)28J,<6)\8.V*%C8-4_7B^#%I$Q9N05;)WFOG%I>@
M3T()(S,Z.JK!4XB IE9O+U?37-G/Q1R["8)K^Y1MM(*A+89WH7B4RN<1%&=[
M.5.[AKXFR]BI_B;5?U I-3I& MD6V$M61VN3<BZ0#8K7 W?R6%6"D?XJFKU:
M1--/*A4B7!<I;#GW4T^!6[:;EE1>V84Y?'=STYH;83*KKBD 0KIJ%)J-$,HO
M$D(]:4.I=[P82)L6)01%%Q ES\Z"\4US(F-+JXJ&= 4*4SQ+,7<N//;*48&Z
M<[66LBAV(DT]E'<@KYVR<L.>RM(N65'\'H@(;'=!U,P4FW:A )'R".#^G_6,
M<ELB[<26]4#?&=:51L@LEX;G,?EX/;)($0T$LB ATUPTS0BQP 0?C#+2DPV'
MAA3$1[.T+#<YY9NOX7_:Y<X3=E5SIZN57X]DV9LN6;8^R;*UMT4.*[;(2"=>
M6F2/X#'K*<L.-H>#,4F%5!^5]JUR[Y G:'KKARI^Z,L?3$:ICU@6G,^^,\F"
M3T0IE#)WW<S_3+T.F@HBS>08N#\Z)1&=U)GQ<8PED-O:I7/7R=L&?(FU1$8(
M6CKLP-%1:X:DXS.)[BH"QR#<A;S:(NVE$&FQX\15@!K"C:2J&M8-3P7OV8T?
M\D[2%CD3/9S9F:AMBD00+&A1P]A-N5S>R5IW I9LHHWF,<@?\[R22T[#%T.+
M_*:&?H>=/]*D U[WSHA0]]@ JU:[]6U'&W:40,7R0MJRUYT2N_,G*V=3,#\-
M^:AI)%^7&8@5-[<0@Y)B2"1RC%:-BFF&@O 6:U*3*O!<:GRQ,B&PW/@B>S@3
M<]8X-=6QVK.#-\AGJ#;J07-FGFHE0QI#>WGGEF+HPJL+7)N@A.B?PMH\E8VM
MS)UF5*C=(&_9K-?X.:QE$M$AD@)H;LQ26VVR9-B=0FE2*&]Z[XE?X"QRO?98
M$=1"*W"QKH?Z<;'KBW+$; AE&C?#^:B\Q'F][2R0,)QVC9. $TP<YG!+;1J@
MXTKWU:;!XVTCK9H9<V9I=GS?]%&$H>=G/->BR'O=8_J'#V5Z+ZNA7;&4WER1
M(U03S87)4J#C&QWK[A)6J14VFVDAJ]1X=#D\'7>,4O5:\&!KT*N>QN,<(?$A
M;_2R4AU9LE4D"MGG1C14HXJ10>&^=1/MC-&1F;_LCJ,A,'SB%]P'W=-V U80
MSM4B:4FH8V[X%_)+D.&D8 ,8\A*N0)2/C[D__1"UJ#2L#TV(E4]P@TJTG MX
M !JZ+G<GT<_H3O-&.=ZIA A:*,7E> 'E+LKP#UU86ZX@T36[^[;TVF)I)+@,
M2].DK#INT+=PJU) GL4R/XEN1V"G'?!1"@,-,?&4X7<603:?V'WO>0^66BQJ
MCC'3N#'R.0]GN]Q1[3[:-(4PM3"R(V>2D>%C,B/T[OU":RJ!>Z%1H1. V+R5
MHC'WL%NB>]RN\%;9//_=7"&M;PE9@CE),\);Y7(:GHKCK!ZF+N=D.:=A3XYN
M]5"Q>ZHW#_R9Z=_QR->U9GI5-T-P(]AIDRR8P&,";/3*=4S(O8S>1N.0V'BS
M6AWCQ&)]I]:U K^3B:7V3KD6M=T5TLFE[M-6PWO.SUKYF*>L86):Z;!X\AM<
MT'F TS?2#E3[R<)$&[R77=FQ@A2K!58W'W9Y<PB.E?2'%O>H0J--:&&,^3%)
MF">EB$81]&U.?BM/>*]<OC+5/P@&%:\KN% ^AX9,,YI %TH4<<@%IC*)5A3;
ML5B?E*1/XB+<0LZ<*'!YW1%C 9OIE71S5]+S%$>98G\_Z=B'/6!N J)RD]@$
M>J<X/=DTY79^,IA+5T#.%"SC6/D2=#]>F3N=&.(VR,)BJ-NL%L)I"@_K5Q7=
M$E1ZI2.P%9GI"B2[G._W??1@NTOZKD_2MY7NVS>>JS4E]MB'2[<=U;4EQ:YK
MR-Z1*#H],:(^B>[TZ2>J6+L]=G4@G<FZ.!!;C)(XP4%T7ZQW-U#VSK-N\JRQ
MT XAF RU^@WLG'9$@NJCU<8U%C+M?@/]=K^0)>D;(2)[QO(VRJ:58=LJA'PL
M^!\^5CO ;ASC('0/>UO2%2)W0VG$B[TQ08&BQL1,H.8:PY_X;[!O8M\CF*\!
MWO4Q<D3N4AKY@4HM1G$[Z/0"'*&R?'6>4(L\H9R93V$H(O?TD5],)7[,SKPD
M<%*]_?(:(8*>%*QP4Z*C(>@EV"D% \I"T<]CNI3S(G@(43B#7.L<L]F9%(8R
MI,?H/'EJ&A.TW/29Y@$:ZD83I.([FD%:K:XY6)(SM< V%>_'.%AV'3CH!O"_
M<*XL9O_"F.E-9:S)(T#<VEG)D;Y%5]%3B]B_X]$C7U)2B0I6 0 (R+?<4S7#
M$Y>^AV#;.0A27MM@SO"RIY1) +/0<ZRP^LUO6?N&W D\MOK,AQ$UD,=JT-3H
M5NKG23<J5CBXCH<]1+/<PB#^L#LWR)"+,!)DDP9NL&' G<^F^CL:.D L>U&@
MN,J#D !TBU@%OIKEWF^-R\I2D3>0JW82-2P#.36DY#XUXL LUT03*U+O]I!9
MNGSITQ:&T0-/:*R[R"+CI2&/C/W$N.HYP#KW:FFD-NR"^]*Z4F9GH%5] 3>4
M5JO+S#9G9E?8X*J%F=G3\^/Q:'@UNG).SYWKX>_PP_#\Q+FXI"Y Y[\XH]\O
M1^==?]0FR_QP:] [43/J^++JRLSW^B#/8BRXSRG-=-+JD,/]LPC5-"D28CZS
M*$\IY*?<D @"<W]OHN +;]>=L-3=[+70;A]2.T@P,OX.IRD=:ZNWW%LT/2O<
MC[RO<#NQ'\I547E>H<@1@.2>LI++N59GQ6U.YL?<AH%=NY]51R\\:>5N?8<N
M2S51VFW95F[9FHRV(2W#A?Q#N?':;[1I>S<::<)N;[5R;]':(/B>XAQ1J F<
M#*R_VV"RP;Q6;K!C-U (F:0UZO98Z_88]=29ZD5Z('1+$.A"(@U)P>XM9(QB
MJ# NQ 6OP3FD<)@6/L;"^ACRPC4W)/W60_'6!<'0W!_,33=)L)2?2XRZ/6[O
M<=7*/=X9JB]@HY-O>7,3JQO-%5I?S+9P?8_CT7E16[D^;UF1&SXGN@]5G-SZ
MB[Z@_PE99I$YVJ!1DW-@%[? @X^X86JZB55&PDM7B$T]*=JTL_US:@-_LS=U
M%S[Z_87J1[-T3-]44*%<W:S;P-9\W5$^Y3\VAIL8;; JRFC)!& IF31B8(4G
M"4*C =WKLC^D/KO8DJF/U7+(L_4J8;(SZ^&;)G'8MX,AC\"')5-GO2.?7J63
MR$HP<A%>'0D-,XK=4633>G?L/C'U%VY:>'V3AD0R1P1K&W2Y$7N=*^L@AQWD
M\/L^>C#H((<=Y/ %GV?6.4 )]K^ &M]X1Z<0$0583L>CJKZF)JO$J'#5</Y9
MV$0X&\#]^1?V-*([$*)"(:%TFH]B#&?")@4F$(SOHJ"^PDX06"H$(\?@O-V+
ML=";2[,F6D7;S!>M03K?Z0C$GIJ%O@MAB+_E[\L//<)!K+6!A186F<APBNN2
M*HTLC,PJ6-5WA&_,<3DV@B4G_&-ZD= 5M"&9W]+ME:LH9@@QZJ.5YB)1:;D#
M1J,;+'.)NJK56?;G=C<MRT[V"0G_Z+/L&7W=BP<.?R.*8Z9UJ(1X"OPHCZB.
M?AT'C6[CJ,E6_&D6H/9-U7PCV=1-?_&.&N2WP7&D^R@+/(N+TF+2<6L4W*9I
MO@)[BW:61*:2"KW+3(;/NY"I=GD+V8 ';GZ(US<D;RR5_26N2.FKN;Z%[Q&D
M4=*VM7Y'C3=.\$F>K)RGO>"3U5#/R"+;X_ MI_W6]2RJ=[IJR8*ETDO'"@46
M=!%Q@^ISRX"IYSI&_Y3<6*/$P:B);IL0FF]R?E"SV*1?41Q<F!,T% C*Z$MK
M3:%@;F"E+CR>7K'R?*)I;E0WU.M"SFNO_JWJ;BM-K1MD@-J7F.6W-TN(Z$ND
M=9OP!5/Q15FX6 IP:;DUJ(%TDL3@W*6W<93=4!.,)XV3*9L$@5MY!ZL>>(%H
MT6S."YOWNC8=K<M-UV'*X@CNA<TX1-XIK$Q(5>R-:BUZI>[8/,S>B WI<DME
M(4EVDDV(@9O=]H;O-*V+Y\\TEE8WTJZ\OQ7$SOF>RK.Z[B'L62M#V%>IX).[
MR'7K(M?H6&GT.%Z@;7#NB\!;"]'\PN)2S!A7U3*UGFTZ<=#EU'0PS1K":X)]
MV$^MN?_:;_Z;5F[^EN _[ PI"K/$!@+J=8@\;CC,ON#_I!0N4?="87"/-3)D
M$,&?W^D2@E,KL'^").S^-+7OP.P'U*9(V)"X^N'&!A4&R&3/57B"'TSR[D;$
M0L)=VF]4"#LBZ&NZ6-Q.8*:YR)@+$AB[^:_8_RY1W/0C"_5OFM!$6EIHI&.?
M1^ ))T&$5C13[5F9:LN5L3D'&C)4TM""RX L\ART$[$8P4_[PF#K!J;'%[R8
M&R@J0,1YP?[NJN_<Q%%B&B Q:69N?<F:W5%3-XD&Y+-,GS(;3;XDFQ8K%9'Y
MF#R*W5O A!A<V.9QJ!X27<""#/N);JE&W>+RE<9[Q6E^:3X4F!D4&%6\S6:Y
M.4(*LJ@G2F8;%^\FTE06V ^A C6N+,P&)O;(/,I-73_G-:W8=JS3_5D^G+(A
M#U>0BMW$&B2ZNAH3V/B\F<?PT"$$!R&@FN5:-\HN&;.2GGFA4("[4II;&41M
MW]EXV 03$Y;_UD?YX.(6[$9XX\^H,@GFVT]=*@&2K8W<'8H&BEWF6"P*DIY7
M_^ )]:]-K/#SK%OKGZA<%=8IFOM3\ZY2*4L%W<PP0M!?QWEO>\6:;DTK:'H;
MHYO,B5: ;92;_K$[DI_"O)V1V7+97C9.<_'FF*J./>ZW-&.&%R]3'+?PO9Q1
MEA]E/X3#L3,_008LPK1LP$EM:OW<XH,V*Z$-4^1@2I4Q=IQR)I"+X!6/F)\=
M5>[)T5\>H[DYT7(QNZ;+V.U\V[.C16%822;FK>?Y..BRB%T6\0=D$7>Z+&*7
M17S!/H:E4FM.ISR(FD1@'W&-NM3#3Y3QWR2=-G<_^_-L[H39?,)GJZV;B[W_
M O>^2"=JET'+ &R[AD\.PL6X=4'"'%7"#],!,.O]J"DM]8>28=N!WVHP,[I1
MVM2S<IE/^"Z>;QPFM@=$MB/;X(6_IWGC.#- /+=MIE<S7]BF(3%P).O=,))9
M6J=JCT&N0TQO(X_S .YGMF] GNZD"%KJLD>F538UT,Y3O$@X@E%P:?+H(Q>C
MRARF7W,Y'"@\)#H4:.K*;;]#;+_2NB^S>C8&8-_CF&V7CBY\Z!=*M4P?V8DK
MM@T+!]F*D?A\[( @BX !)1EK6_MGQ!"7TOB#!YW_\2FF3+:NSH;C$ JMPL"F
MW?G2P8(;FV0Y?I#'7E.5_S1/CGA6ZPWBC5T<FC04H?9B]J,Y(1N*8[:QMVGW
M:'SL=?KZ99 0QGK ;72O,*_OJ60:^Y/"NMH$,Z:2W\;7>=H-M]UILO)P$F@?
MU'GZ-4ZX'EY2&I]I;DY3J=U<$'$S,69!Z@WXIY<&MCE9^MUJN:O\Q>A]7K(C
MN#KS:>VCB^YF[W36$ .N2V()"M2.(:BZMA]VFZ4Z?DO.C.*Y<G6+;J@^JO'^
ML/DWC$?=+#6&S$B\\CJ;H.*FZNQ[SJ)BA\H3E::2$*_M^6+3Q\"JS046OF20
MEJ->FLD-G$,K<.",Y([V>RV=5SG5!F"1>"[%EF@*YK"ZMTMMDYI\W> O@QU]
M@MB#:1Q_R4_7R7$\$RO?=ZN8JDK!2J&3;:H#*\:3SY")NORZ3*.*;VL1+YB_
MT<&IJ\$+8_*30M]V0X#SE-D^=6JGNR$%2A\&F$>=FZV5DZS:M[?X<BRM:<?L
MD-=:GB;OOD #AD[-BMB316W:Q^:@]B?, Y/HBN&;ZH9AE9UT@Y9AN2DR[B6R
M(;7]5&>3UVT7,R:T0_TH2X('1C V[I][M!IO8$=*U[AB OR+GLDG^/+'^5Q&
M6>9WM.\CO@Q&3&<5JQ:LA9D_11:CASI!RP$@VO80IM_!=IZ9. '/7=:2F\7R
MQ3!FMM0>*D_.?3>8%\Q/2.BULII3,''\M&X<[HV+DVEO6;D)32Q15:&O@I>3
M$!N7SM^L45'/O6?%I6I6A)9O58)SQ KQB1Y[J?4.X%*-\ 5J=.WMC,EF;YB
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M*+!&6*GADBR(#2J1M^8[VJUR+>ITBNOSUV99Z)EL0S.*L=ZD^BKGI^(5/#$
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MG]#S>QZ\Z^[7XUTGM7#7)YX5WPIY3;\4\EHU+G\0[K7ZX&\ OY9G5R,_5P:
M]:N/7B$"=OJ-^-<G&SKMQ, ^+GH(&0Q-N6'9-%WW6-H$@3N4&Z(XO?,!IG[
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M].+5S*;9OP6ZTL=?T'H[_'3)6S%*\8DO]>C;<&Q+BQ.%RA/G4QC=!\J[45K
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M$A57A<W)>1;Z4V,!2"O0(E=]&954LNCR[&?-*_6UX81?G :N/Q>+QJ_/>MN
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M4HY&A.PJ5#,_+9X=Y"MD3#EW'W(@JER47'0?ZLX+W9H3W.= _&KFU,JM%BH
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M\V^B76L%P@+.1#Z;A"KLT\\FLM[.<N=S8@)/2VH#!8_L%HN\<Y*^H"24.2S
MD4$1M9R[-91'*[[^+T_<CQD_VVM[)W6V6'$5F-X2P@KS21[ZR\RPU]/'NP8I
MK"0ZOCNEG=5_ZB]E LZER6K>I%Q9;6DO-DX=5LN<=Y46GBF33?8\H;Q(6G-9
MG[/,MVE>L-ID["VIC%ZT*DI-WI+@&^_J9,#N22$"=/I3PGGEJFA($%I^*,A=
M8VY'7198?JE*_00]19>W3"8"-KW#R.\V<;!>IEV;F#Q=?5\$.:9TUSXW_(-I
M%"1-^S."]R&=1[<(]354S+4YSCP1)J?/T*%O\H^Z_L"=KY9P#XJZZ167DD)V
MEE]*&UBKHE49K<6G_E8S>JN6\1Q?J>?$Q,WNDI(-'H#46S@KJJJ.(Z:G/I>S
M9WNV'"=E4'8=D  TGX]7=6-*MX3SH888+\TEG#B8$,%T%$6??G^TUWA4B;9Y
M(YN38J%/XL;70S-U]4[I)1)=7D43^8U.'5 PS@*B9ZTNFG/"#;5G"U+^79FQ
M2Y>-RJ:^N<P!=Y"C:/!?SY.7\)[POD]\25VWC&Z0LU,FD?Y#$B9UFH/7C E"
M8GUIJEML4+LND=45"[[WB8##""P KT@[E.-%X- #U*HFI?\'KQUP9T8,NN(O
MXTV)GJK!9>^34G^LZKR9YH',PJ1:H7*=4CP=T=E^EZ4%K#7XR+NL+)O[XC8M
M\_3)U^C&P[TX:4W&F^ Q5.GRU3)311,!"V-3"#!Q&]FB . 7-RN2%_ZX].WW
MW^;DY\,]SF4K)O.AXB7MKU;JWQ#Z.'O;P'YK.(4>%"L?=_Y^J_,-$UY6'1/'
M8%J"$&<,4,',LH"KL.L8<=J.U1K?TPBA8UQ0>0T??>+3RO/:.H&6""V"Y=Q@
MAL0H.'?B\U=P3A6<4<DF*S[Y5YBCU8\'R.Z^36$LDHL.I&C//=@!(UFGT4H-
M*AR\%0,X^?EIO^;;(68#.@@T*!ZNFW"'N.Z-L%7B85!&PO'=FBY9#$:0YS&?
M$>%:7JV03$8@'(G?UI:37EHPL/OB@Z [$/.N;:YMV1<J"K<&'>%'N#N ,A^T
MU'S;[8-L"0$#N5ED/R5\3[H4[YLVK8D;?DL'2]KJ)7G"G *N^/7(-]#!FN(F
MJO7N74M_ER^^*R-]HV6D@UT9Z>F4D9["Z0:'&P4^;>=0 U**4E>X"J0OI[+5
M!(%$X\D'L>X2>;PP#*:B4TA/@Z;67%NO%]#LDT7'X;1\*M]-J"EW\G\$8^/$
M=^A$9J%V8D/V?6'"G^H8<;K.<T/3HKS_HM_HN/]#;XK/G5!,#8;CNS8222"U
MSU.$RV-^BQL<O<0IB<TCN-OSS:1,.A%&E[%;6%US:H+"6KQR -]/?#L:X[Y@
MCK*[M&@\<0 Z'WB"TH$J;[WC33S0C EKH*K+P..,)4<$^HK>+D9I88@</9:R
MS78 J23/LW\XM$0YY&B+<X1@'N+54(?"3VGG'.Z_&MHT#/.$DR].W.$)MJPV
MS- TS6:8BZ1!>%X_ZS]'U]8=02[<#'/(L##J5>9U(H)\$@M?J$^V?S0<C"ND
MH16\C7M"^Y+;;: X.G&[^$;6WZ]J<S5#;>L3W!@!4C7!PJMH/*]U/$33NUS5
M9?P,_BL-O&@BY9UF$!,A:2!YT_<]5,(]@B+P*E=I$455G&?CR_:OV)A7F$L?
M-&C3/ATV1@17]ND<[GZQ1##T<K'K<C34LBO?A?I+..SCJ44BG!JK!.,,1C7S
M"F0&*,EAA*OH(A=T57_0PHS><"KUFDA*E4M[GD*:F?$7:9WY;ROQS,PS7DU0
M #*[KXPA,]MZ'>?48'#9G>*RS0K[XR$<,L;T8WN-<)-IBSL$T>IGX[JO"=%I
M\SM>F(PX3\1&Z4GD1A!#+SOSPQ)G\_G (7(4(-^;430/ 4<I=8CWU#-'VK#<
M5I2#+J]8%H8-)%YZU^+2V^+RP]ZKG!-2E?+=_3(X9J)O:^Z<<,$F6T8[FKP>
M$VR*T0G)Z@AD;:VT*#K?!V:BDS*NBBCC**WJS;KCBY]*LX;[3$AB1PFL&X\"
M%9751M>V-AZU98P$7E*V&_>HLX^H):HQ4_]Q!R'?.1,W"I]R*IX8VQJ5,DL\
M)I7)7$7T(NR&E-/L,N@:$?I$.L!QUOG"].AUM;J^B;_2X6UBOV<TL/"NEYT=
MA[DL5S"OY"TP,'RISM5-11F4>AXVHGH%;_$!:(U(D?&$3C^1]J#&35T=]'P-
M6SUI6R9QCY:$EC#R?]XD>==A7%<?T.=7&C3!,C3^6BF!3-0!0X@";*Z4H"=8
MSN6MW%,=?5Q+$Y=S:RGEX/E@*G61.T''!_EODP(6KSM1\#R/V.@^X>9,DA#=
MRO4[$D!Z9H*"IKN3:W<>])X'+UMD;V_2O,">%GA91])UMFGF-_?^92$Q^=OC
MUY$-A&?P>(WP=:SU5A[9;<] H7:_?*1*JUM C@8A<W4 (1,<A8'&;5HCSA-Y
MQ%WT</#]WY00$AOZ86^BI.Y4G5G)/+,HK]?=Z L<P\9H&1\2SOI\.YV=JH9B
M KP+'27L-C*VC-Z![[]-ZP]P"?C =[4VBI2A%2<#RHV-]SZV;E/11J<C?$!&
MW/"0T16F#Z%W ^:90T!Z;ZILKE3!H0IYY#5(N-)52]K9CU[[\2-VY,)?-RN>
MZ=DA*7O>*+_# ^XBR;:Z HO+40T\KWTKN ]=Q$3W_X^R_SO[\\WQ]RBCDG1'
M3^""VN159V<6#*:>?H=K^'[7^K.KV7SAFLWS7<WFZ=1LMO)@^\P6$8JQL'=S
ME@GS'Z--Z4=E'^) E7[J@\):XK9]9=R_S1 +N:UD C+:(\35[C@%MH93("PV
MN2-?7./XY'=*J;Q&C29&1_%#LLJMMV_(MU!.!\8_)?*Q%!Z]3G%JOZ.(?IPV
M.;;KW)J4O2*P#%]IX.1W.3(NIZN^OD^E^1$' V052 @3?'C5I',8;\W[DDGK
ME28R+-GT(6VB7-\B#5"-CT*1?LLPWG2X=USZ[C4NZW8SO3JFNC9 JTTOX;_T
M$J)86=G-2K*@G.D*7R097L\#V$ZSS;A/<ZPUA)Y7[SQM3^':J[E9W>3C?,DP
M/@UVGO_X[/GW"8^5QJ1IWB8M,FYBTZ:?OFV:4)2<^%KM+,WKP9QC97\%%D=>
M.NZWH.]AFC'97(@Q',K6F.5U@Y3Q)$^J2JSQ?OH%[O74U_>XO;Y-_*5KD_6L
M@\5HDR"V=+AVB7*-FAM-&K:M"TRB>"9BMJ[TO3?Y1WBY5%' /7$H0M2I5!FH
MNAU1\RXS#_AV V(]( +A1W_2,N=^<-S\F=W MO]KVQ%4>L?C1,\[DX]K[18Y
M-N4IP]>?-\JRZ\Y0FHCNK)N[+1N[.WQ>_;B\GJ7[EI0^_M<S3\]_^$HR3S_M
MZ0;;297NI$HSD;4K""4R0E!*GFTZ*;E%,[/!>1!+2(3F'%YS,[98?>>6H393
MF3D>?/U#,^QO-'3RJM28WU1%/A42WK4:?0F?]_/T#Q8UU^-Q64T^^(+K."LS
M9(? $^RNA('<Y L/(LRM7*!'.X$-1[@"\MX6][:B <YH1CV$^K7MSQ.<N:<^
MEJ?>90JV95.UM1R1\0N<I?J^+^X),!V_.$!7,KBI[K S,_'0KL>(XA(+ RM4
M5N%.AJ]T+!VS8PBF"$YH-2@JK+PYJ4:$G(&/"C>ZQ\LAW(R<949YT9:"K5]=
ME^2T\7X%I_4F+:\Q]? &ZW>KFK4*XH$[/WD+=]IR\YZ,[J\MFI4MVE[$3<YD
MD?L?A[26\@9+Z)S&*N&"74N>XSY&%37*;!@>.NMWRCC#F(44L1$7U"8]X3LX
M"D/"/GWJ321],W+IF]>IX"+V[X<:%-HFQG%65'=)$.K9S?_)1V%>MD_^5&K\
MVI?/Y[R69MU)'UR%@<"<.BWE$%<&2IZO3F2M"2H..HV;'8\D9J/KAC?GE^)M
M&HU]&HX]T]H"?WC=G,7!L\Q?6D^"C*\QI\@>[0L3^%I0%8)(5A"[YN+T"EZ>
M&$QZ<8] 30AM+<>K$Z1/X,<P;1TIP4?NB# 3\1W4>YN3>C"$P;1G:)JNP<&J
M^4$)JHG'V(3Z D23OISDBP(+,TMBP%P.LO\@5%W.&W\3OP8ZE[(RV.*XX<UC
M!N$1C>V)RR/Z&^5-7^^OCO! @  /=*ZZWLD>][7["/?9]3F)+C25T+WPW7S+
MJ7\&(Y<:+UE>>)]!:,5]074.P2F\%75KTVT\8(/ <(/0B)T7&Y6[I"*S ZOL
MP"I?&*SR8@=6V8%5ON)4ZQI\JNO/C.G-3=-6-@C/0"%4?Q3/.Z?+(,Q&<G$F
M:^KA>7><N%U\N)X*5QW0@ MW1F1>SH=EN3 >*W?BH&<9/H1J"T0]UM+ ZF.W
M6\G8.;<KF@LBB".91DHP^A2?00N7KLTZ1Y&%(L^PR0[5!;A-8K[ TA5V0.0-
M3M6UZT^(_7?;^N= IY*^H.R+IC"TWK6%#I7X@9OWI+9H3K8K7X$TQB9QC5F*
M:FE@^@9_L29+X/L78$UJ1MUER%O!==RQ)VQDV775AMP0UT!9R<9[M.(:]7,\
M3G/M\70Y<7/M3YBC] $\,45BSJ?,2=%.@UTD'BP'93KG:+XS/P//-9$NV]@0
M]%@:,JD64MC%*K6)RN/++3H.$<&Q17O_<+$H\HFPF6ZT[(CYK2('-R#M$R\)
MUKDTXVBNRX-6]ILA'<O7JQ1YL*H:?Q&)H2K?@#:9NGTK38SV#(>[L\"*[2_M
M& HUA;H+Q=^RN;HGOP4F6[4%WH:T*)?IAXRPHH=*I[?9<OQA>1^0>B16_+6V
MHN(6"^:(29T63\ .:!>\)'('CDZ&+C16%[<2?MLTY (GCQ.SN8ZYW'/>PH&X
MFG/EROJ,,=E*2X[8E@7=@\QB[S+.?+.WN>MUZT4<_;QWB"]DH;;HS+^3#=,D
M/*KD:U!IGKW%9:9%MQDM.1-G1A!&:9=%K>K)A[*Z*[+IM?1,2$J\B<@^S$XA
M%H5ZKHQ7#;,R/"()CR YXHB*1H,JW+P[FK7A56N#4"5@/'2;["9E(O# :UV#
M'DXZZN,=N\C/\%CH-BA/GR\C5"9^:+8B#4%_/REZ:4UXMR-[=^0_6MWK)_FV
M^&!_0,@CW$F(KH"HH<@-V[WA91-/B6MI#;S1[[JHRJ0.BB0C$;'()VV ,$.B
MJ8JIRV10(,/)#*]"%])$+_/%2CPR*B<&[;%R5C)W:N89=+- O%I8TUR,N(2)
M3;@ /'7"ZZY\W2F-'KFBGCF#F.(I$S,3*H/@QH\=(%($E$J'^@E#V6W7WNUZ
M\/W>2=Y@=9<2A,X%>DTU%C#]&]^T!0]/2[08V8>.6VKWI%2;IQ7*BK;XIP,O
M;ZJ/2+YFT61W1@"%Q"<SH:1Y* _)5&3AK3 W&21_#-/NVG[TL$5^C>_ Q6S;
MZM7*N/AZ]XJ_X&C0%+F/.Y1F$_VE0XT/=<X[.((7=7Z;%]EU1C3+$]5U:C\2
M&K(ZHW4&]XBYEW=;LG]+'NSQ"WZ=-QB"Z*E2#\ZS/_AC&T37#P8[$+54?]@X
MX#DIC2UA/Y[W[3D;R:G)9! RQ1*LB=ZRG/-8[L'7+(4<1(FDY8=ZM5A.[ED>
M)=,@E?:^4$SYO]!Y2KXMRQTH(5]H/=!I<>8#J<C-]SN'+<K-S -HCF5AM>$9
M$#$8LVX3>1S)4ML![9.GQ5R7:A^4H-7$&V):,R6P3<,;<$^2N47T^1V.88=C
M^,(XAA]V.(8=CN$KQC$$IX1WK3%XFP2V?JC"&YCLB?KS/>FF:1NG2+9Q-)S5
M'9Y<DCMR,9Z]2"LXIC-J:A3LR+VW:B.//&X2GVAJ7/F>FSL3K5PS5Y5051&$
MO-NO)OQ$*-_'C0P(R<S*B9"Y=@--/^F,9%S'U%PP4B4BBG)'O^#FWY'$1P3D
M%"Q[BM'',IV&Y.3[@C:FN,@FOZW'8!JR_43V*< )U36.T%\T6"2=:</>KWKU
MV,95?I&TSS%U*MDGNDJ>/<^G'2AU<9O7RY4'!R]3BH&DN0P3$/4T<S^0(IU
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M[=[$N3OAGD[X_V^K>HDH_\R5J46* /F%P>'!^"5=QFJG'"KE]<#H!L@.CWQ
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M8@3>H280XO?8EK]H0T5^@>G<U>*?1BW^IUTM_NG4XI_*(3QN'\+5&)D=B:-
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MNII@Y< N&1XXU\5+O;2V?Q>O.<W8CF<]E(]E99HO*,4R(9 E/[V@-699R*M
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M]>X;]%? ZE8S1Z=M/ 1'"J;ZR^!6)$1KG$M> FQQG8]7)<IFA&=5)PM;3%+
M3#WV1/A"[D3/>$(_NF9>'9*\LMQ)GMLEUGF'T'^>PD$.QUUB') '3W;WE&FM
MLMTJW!#S4"N=D7@\(9E"YL?VY/.PVT4YNAW<9\>Q![EF5XYE,<$ZON;0A3Q+
M[8V#H2DYA)(Z);("T>?T_AUYS;J'' %+M)$T"RI4VTTW.9<)K;&'#?8142;R
M]LZ,L5C5R+?DJ3VLY^C),M8*J78\1I@'Y ]Y/J<POG/,:TW@Z/O,@I^4(#61
M#$XK5!*Y)DT\%N."#QCF]=CF( TF<EXPT90T"/*+H)3#?6A/3<)!3,8\_9C/
M(;Y3^2SI&63S58UE$*GA!KN/.714<(9?V;P)&"0KL=I!VL_..*;_))[S:5/^
M<B0F$+_*76VPKS;XP]ZQA'&;-CAL7URNC16.&^YGQ;2MU_1U@:>DO":3>D4*
M'U8#.(FT=0)]X'$VP3"0*/I(G)CN(&PN.B$4MWHKD$X^E-4=K,-KI7XI\+KN
MDO=FNXAZ,+)4I4BH9P7I\G*R0JJ)9LD/1Y,P7Q2I!+EVC[.I0SDR[VW0@_#7
M.6"'58:["VS<-$=^&10%(!K=^:)&FMF)TKC.\H\(\/;?%P+'))1:$44U8<M5
MJRM"!F1Q;F"M*Q<.38+\AJ=%MBW<GKCLX+VXQZ?'8T?$F6Z8 Q$N%&[;P5O8
MR->PK8F;PWDOEDQ)R&99',7:!%T:6AS0>>M>2*D=O4]CO/R;FV=5/U1;F@HS
MUB^N>)8,;AS1(CX]TA9A&WO*Z0AQOW H1VD!(79:#W[/TCIT,J,L'ZG%M*1B
MV,NV:ZZE]$$.;JI.,'SG)>>WEYX6J:72'6T,RH40L:"9&I3SDR?7%>0V86L1
M8&MZDX&K0"D>^&O4IYX*EY5Y;6'[^A3Y6_+F1EC/) .5LBH9,ZAI:MFPI49Y
MZ<;) 6%*R1_%*N@G":.0Z65W4/0>%"_IH"@YF0JVYHS9J+<<0/(TW]6/>V>T
MRL]E(_A-LNE#7NGG5'<6:Q.X*^,\O;?1024OM!D]ZE])S Q"*5\Q"L(?SE8A
M==*9Q,-&O'LJJ^//<_F(\4V\=TXI9/=!YI"MP=363<?7N% H'Q;FO4X4AR]M
MDS0O2H6*)J$@#K1*S);<>$[(S#>UE>*4V8E-N3DBW,?3&@O8]VLO(_/-=_>G
M%;+@P3M&ZL7KM)Y2BE^.=>0!QN/!7<,2.DM,8X@'K0^BA+9>+\V*K;G\C9ZK
M1/C%*IOPEWK%1,/*X"*\V<T"A;AFJQH/%J';964"*="[.]T;E<LY3'N=8Y*J
M2,=(# UWI:%YY51F J6XKD0WP#\D2GTS535'27)S?V=3=%K:J-8*:<)"V$?*
MPJHLN*#:5,03"&MWV+ONX"WB4YW0T:S9,3KG^06&XNDSG*ZVCC*YSQU*REPZ
M5*_,+&]VF'@4P;YH[?9@BWLLD\G7N:_,5D7!14AD3"_NG9X\4<LZ)O"F#;H)
M5GE67K-:&<P3V/*ZS/HIF86/NZ.*2JD]$?CCR-FEZ?2JC6[EP2PC3FGB,PJK
M5^%FT82 7S<EV#A4+A7F1)&*>&"X.]VO)U(U>KZK&NVJ1I_GN'9O'?K LD[+
M!@WL/U<+,+7H%_VR*4CR^>7QT<EH</#CYE;\_QG7_+_^$3Q(K/=7ZZ5(KX0>
M-!?<\D3-:E?GHU\&;Y#7"-LK1O]^-SJ]&%U\[8'27Q5UB&OO77-V)5)A&WS(
MH["QB#JCZ,4[#-!4*0K1IU8_A554S&73MK"L^'W_' SVTV&H=V4]7]6@BF(6
MB&;J:\)J(6^?*.Q*%(.<]>K$$@(2_HGJ*(T7ZUTQ0-F'4\L@Z^^+-D11_\#%
M,D=P'3'01Q>"*\'W]&6D@]N\*MRGNXH&Q+2N7ZEJ3J[RSWR%";[&(KP(Q$BK
MFE[OHBKR"0J$Y%HL"8CIB<M]/%16;A&]P?G-9\&[I6QM7JXR=9:-H);XS9SQ
MJK44S<4SN(S*O4AR+C>H4T;;#PXZ1>&=7WA- ://!YKWC&E6M\10898TB!N)
M=UVQK-,;[? K747-[I QAG].1*%]=:O/8!QCS!HW6<'NL&A_C5=UHR*_?6.B
MY&V'2!JL!"\#4:+J29'>092 RD'X9NUGAXX@WUZ\,DE0&ZRE5-Z\9Y)25:^^
MMW)#+B[KC#90CMI)1-M'\2A_7U!U&>5^\+K%:=)K<2E7KL"6G06+:/5T32\L
MD-%'5DTBVP/?;0C1*.T@,EA<ZK5HUP3"!]V+BR8TB:!Y?G[J[K&P5)\43.W#
M&X)OM^9<W4$ BZPP.&_67\ EB_]$7/_ 8Z$F$0%9EG1[CK$*D[GP-GXE(2DR
MW"Y2LM819(/KL@V1W\J;]3:3=0\YZ.3$2KI.93JA"?<U"LD]:)D=5V]L W5%
MDG:Y]B^L;3V@59F3W7JU:F#O-=A7Z/((")#-%\ON'#URT5*603,3_$Y[D[H[
M1Q@<X9]VCK 9TBE2KR(G[>B461PN+%GA+X.VHTQ$G?\Z//G:'>(O53GXZ=G!
MWFD%OI?%0F^V$[3KH/)@#SP'\S()3Y.VL1$Q62H(4&(;?#$1,J+FKCI\X(1$
M5S)I\R&'@BTTG<+PR04UNU0=H*9W*C]:1>*RTI##58AD@(>'NSXXD'R$HLU.
M)UZ?3TPN>EYS<C/5'7*)4@]/@".)C!GZ1> HA(<OV6-,I:+=A<-#'1J""7!I
MO(9P@]J5G&2ASD%0AN7O:77 S3M>(9N/JVFKAVI7INO=;,]QL[VM,!>]#4W7
M[W$WW:H<J5L\[>V$=199%Q#^@(^1%KB*5/F1BA8FV3U;B>3S-2F'"7ZE=8D6
M-,XG[]W.E[8C EKT74>PO@+76Y4N%KFG_7N3%=,HM8\?12A$8@$5@5)78@I-
M7#S!EZ;@LR@BX8_1=\G) W/U736;)0-NJZFE7E63WA<,?XBM/@H<CMU&]V'$
M7S \.>PB['Q OGJ1WF>LIMTQ3<YR^'N1JJ4H GC$2]D=AIDHB4-%150D^.@2
MVDYL!(FQWA^KTEULFL'#U>FRJKW*'-:-2C24++W*H_ NO55NM6\K"64%X9$S
MD1LD45Y:5?)>WT&,1T8_DF*S[S>1[ '[\ZSNR0V,J/- *G%8H[G-?.N;7P)%
MQ74=F)!9S@9^K-YQ12!4_#*F=NJ\<0VB$I7&D7B_'=W5=[[1^LZ+77WGZ=1W
M=D[0B[USGRP<L=KT1MV@-ZP"&C8&2+;':R;& ME..]%ZQ=Z]4*ET.$U#^7)$
M_E;WDFN;H)PM1028E<*$#P)@23+>):86&%&LYH1'J DEH.JR""OVV6OW34[5
MX>4\QLHD[=)E4Z'7M\N\K,N\_+S+O-B@7&031N=O=]%=MV'[^=G!WLBI$&^'
MGF:HBJS%ODASV1N[($8B%6#.M]<&O>;R&S8M?)M.R"<?UU4U!Z\Z2R734 ZN
MD0:%3GNNDZG@)B:XP6/ :L,=HN,)8:7_8">; J] T-ME+AIXPB:WU$NFQ\"$
MLADEDQ0"&3P?/ ?)JF&X,&M%1BZMX[_G_WC!^F_PU\-B*47/Q\G</LV-\7SO
M-[@HL=P(A'9S>Z-+KQK[X:Y+N&P8:?L7KG$_EY\QA#/=<OYC LRC1"%C%_W>
MZ>=H<[K/V.R04L3)@ )N#^R@\ FXQS"JI4V@T &.XJD9A[<(0GE199%I3.:P
M,1 ].!@<3B:T!Z\1=I#/U@U1-IY['*X9VKHE?MR;O\%KH@Q!\&I5KC<ZZT'>
M85-'@&&FY*Y[>JF7%>E=9,<08!$SN<U(@=Z1*NUKN;#2? OUNPZUER>P03>P
ME!MRMA26X5.^E'7]TS,1D^G<\3)JVN^\58S6LF"1-DM.^TZT]X@?,6@^0N"#
MSZS$$[-_, Q;\VKN=X<]-)'ET=VVJ>E UV@DKU/A)>,V$(,KM441M!O'BV\_
M=6[X%O5MXR=X26S.F&D,LE5\P)N;#D)>T,[ Z&BZTDRE?U5DQ7!O.59,3-@5
MRMG(49XN0-SIF-.@O1ZA$]8\Y,L#_']?CK[@^7"C_*09YSLW-P'P=C;[_)M[
M]'%69O";#3[_^LG_PH__P.1_X4<?@_.-A*2;>W[I<,8/;FX: N?JL^WH_@0Q
MF--L7D+DTD&*BIX,%FFXA2GBF?!V';S9TZKW1J4CT6&/)G!=9\;!MKR@I+JM
M("G&MI)'0X2PGIEYP+ZBY.2R!G%AV/.5BN.%OA![8#971R[1Y)Z&S:0>#&PP
MW!X=;!X+G&T%$S-W*%'DKG'</]<E91 #A \01BLHU,Z=:Q^T]"&?==.N!T>Z
M$9XW;%]#N(*'OYGPB#\9X2MS_G0]I>$[W')((!@2B$#$NDN.KDN._F.7'#5#
M^G^OCD>7@]'I?Y_]CA(S7WL>Z/,FXYW#%/L=S>VJ%)8JRGJ*910$58F%&=U*
M3^EK@=T3/C[[F#<(GI*MS%T6,&+F=X)O0L"9(?PV*_^H[D/+IST48%VG==MT
M2;R9U7A0,:"\$$  =[H2CAP_Q\&V@<VNQG\8.!BG'8/<9IR%I-QF18?9Q8JZ
M 6K^"W]/V4_Z4X@[HS,:/-^@]-T6&IW3L\'%U?GY"&6I?B$!7U3*.H]6T XS
M\HUB1G[8849VF)%M\QR^4 7I^?>,4K]PQ90*"TD4;6ZTEG2*D9'0LA*1.D0V
ML9?1BTW'$@1!0;!-SG"V4E 9QT"$R70Q&-'6^-)2B_U=?*H>RJNN ,L3[1(Z
M,FH46I5$74&Y5/I[+2[=79T[DDYL;X0U%#6>?>W.\)=;TH0%?T^SN=%%?,DT
MQ%2XQ-[BG$%'VAC99-F'09U-$8]-.1C;N)LX*%(#CCKCF8GB9EGGL#'"=FN!
M5%>W4@ZJO<,<IQT\UQN5OE:%>,KGV?6J<"T;EJ15F("8CC3554JEJR(O(4QH
M;BCUHX6RV6HI';NV(;S5NAUN'/ENSW@JMQ.=3$KV$7QG9+>A"V>%O'VD]W%,
M0/P8VF6L=%68UNF-F>*NE$AR!<]>[& 4VU0)!S?3*+HFO2B1XUAZM,;8T]89
MI+&H%9-&XY@R=0YX$'IE_]8[+)&\0C5U[N7)^^ K<8:O@WNS[GTB$J! W(ED
MAS!W1+2V%>NGT.-*W@V,Q&+%C)P/YI]27QIM9:*RM"YR8BKU%SS7EO8TJF!G
MA;Y HN,*R4PQ:2ETIR4&N--*6J@IB>9;=;AW9W*333[HRT'J87SN"8J+P"]<
MGX)^R-%)-CP)\4&C^(@&UG8S2X56J\TB1D>2]&7$U];XV^L)F;1KAZ20U4$:
MIT6P)<_EL6E-9A8CP+T+5M?N$8U(NW :PND-:E%L83C-T3-A',]19?;5[X/_
MOCK__1>2O+X<G1^='![OH(\]SLP!^.?_O:K!)F.+_38X-5TH+]O^@V(4,-(Q
M]B$QWX%GGTALTQ-Y*::)R]!+!)Z2%JS0>K%IZF'9F*=HFQN])7:,:5L06DNN
M),D7LVG<$Z1$^N)TW.2+@'K"]D=UT1&@-]#'1L#NV?4JQ9X]^JO%Y7BAC/BZ
MRM[H27?;'I/TC2EO(+-%DN4VO/]PI*V6\(0!NXWO>]UMOK[-]WSOO?.8CLQB
MW33UJUN6J .#)!?<=*<\G10!8R:=71'^G>ZC<!4SJI';*N#IL%-#W$K;7RGL
MXBEY]M1NV$QJ< R%2]%SW!AJ&0EM#7+3WT'Z3<TMN-'4:2DHVPB6/J5;DWJQ
M,3IW=-@3A11*MR%CYW+1<91:@F=Y]W<;&D G@2\Q$B/MQ;*IBMQPW/OG<6:&
M;9#<7(1-%3-)<;XR*HTS9]-"+B24\#%<KE_8EWKY5?M2&V1HW$)?ZO0,IN6I
MD]!Y&@O/<=O!O-3)M$2MVTTBS%_P#R:%(MX*H@+"PUJZNAO?V8%F=E4*:41#
M[&%E^TAVX6V4OXO#WF:ES&XP7KZ691+*9]AOCL<.9_QN",WCGBO59* &Y\2-
MS-"6H?"C-1+)U]EUWBSI0NC[H!DE!,X<C/)@O\[ GI?N.C(#<A52CV 4"3'4
M.23_E!#:)067,LY[I7A"<#)SEM$E4;Z,/T%=XNF4<ET1PCTM-TA\O].'?")5
MO9>[JM[3J>I]@X>>XO\B>2ZG498X* SXF0I[(5_]!$PN=?M5KCV/FDG@4%OD
MW)8MIR$[Q3<4 K"IQK/%4ADZAI":E0!4%U(_OY\U0YN+34PNN6]@Z#Q[70:4
MD4 Q)Y@0>TU';2?=Y'@\"7LG'Z "&7()@D<"$W7^GC_'KBT-8SR-CG@,B>.+
M51))90[L=A'6%P+ER"\]LR0)7T9'YGW"?#_<LB0)87?@TAM%TG_]18[J$34"
M>Y<H@44"6*CPD)92!"">*>0BQ*LA_V/))05]U;XEM*QT;O/&^R?+FSK+.LD)
M\T RB1X1'0RN&+7\,3_E"=\ODZHG)_AWS?-KXZ$-,IIL83QT?G4B_-SGHU^O
M3IBY\&E'1TA7'-(S*=!^3#HQ@J><+X3B:EW=%4\;6/H%I1<YADCG&*:(IB5Q
M8DA+[D.2-*TOD)A,.JTPE#.*15TC<6?;7/L#NC]&R%:P,US,-2T @:YG*V)C
M=3VNL9NPY#ZF%Q&*KO[[5PR^;Q)7E6V"8GP3)H*XJ<,U9+C?*PVBM'=&Y<&@
MLNL;30T_;T  [JKA';SD"9VU#BN3"( F&> QZ?A3F%&1"/5,%TF-X!KI^7MX
M9D@A![$+Y36'O6$V4JJ_\CL[Q":F/"?F@ZS,ZK38G13K3HH-XABW\*1X=7[V
M/RT,[Q,[&D8"&^DF:A!24HD"F-&U"?UJXG HI3J7+PE(@1;$<L).L[18^FSY
MN*X^=)?L;"W+(T#:,(;#:RIB=)"%O.)KT^% (ZOD2GQ3.'-RQ306^0<1/Z8,
M(0ND(C=F=EV10-0TJJTQ!6R@3CWCL 4=?8;]1$^%55!\,J2$7S/3<N9H9U["
MU)53JHTNM6\#^^W,Q',E]":MYUQ3H;)(.0W.#F5H/*&6-14F19D[N14F_OA"
M&'(QQU7041@(P-&D&?4X_S);\TJO?[#_66]Q&-=J\7ZXEN!7PMQIPB@LM3+[
M?;:\PWC#/B>!<J1V+.X"?5]:UOK78:+* ]3XADV*,5<OBP3/TJ()_!VO:O8G
MEB_<+*\5<X8%=+_ *"82KV7-]K%X,E\=PQ.:&@AW!:9UQ^0&$X-;>$P>G[X>
MO3T]OOS]:S\IOQ0FX.6S@[UX(Q^SX5G>;Q9M'-,P3RL"]G%G,T,M"48O>!P/
MKG?@8BN?$?C<OLRM974K9DG 2'=65+5G$>/?S(B/%^% B>LSYY[K1J*FA:5Z
MCR_8.J/6"QSYBEN($29:R*H8."BD[^0VZIAZ"+?[Y34YZ ;FI5_$2:+^=7=X
ML48H/?; -=A[GJM=S6M7\_K"-:\-:OWM:EZ[FM=G+R*GOG5=(R\2&7:DU8>@
M#09'VDZ"M4+-,K#EF&A;34+-L,<VBB6?'I^Y>$S[,5A C)T!DO->%Z<)^0KE
M]BAD2V(21!>/-:0]:(&P]BX:.+GOI,BSK[TI$N6Z"6/P:9@A%CW"3[C!))_2
M8=LZW^3TENY_K];F3_B9_8"J>-6BM4(IYG$E73QAWQU+'?8-LF/NM%O'^ NH
MAE%&K4FVBR:QG5.U#Z+B=B75HZ^-3ICX6+ 69[ DD1GU S@'B2;>I^*-X:VS
M7?M>OX/]?*^]8;?#Q8X"_I:-Z# - 9"U#.F7)%-CI?RTS/]9.ZY_N\4;[*B:
MSRM$$<"J'NRKT CAO;*/*L)A=^(P\G4#R3[Y$UOK3S72026"]][:Y,5NG[S8
M>\VB-[2P+K+ED@MUFP:GNV,KZ5:[R1O&(E2UPT?;\]$;=9%RI?"4<1=<Q H^
MXBC/EK2$R$% FG[NZF1N_L0A7ZB95N6"IA(8KAMK&1TTWB256%3;1S':#,E;
MT_I^2'(]L"6JNLP0'4$P$M[8X54$^>!UEH*B7K<,T;Z_, ;4<1*"]'FSNMW?
MKH.8=6DQV.4TY((IWA#9DMW>AR]FUQ7)L@5S3_D X4DC<9Z[TCP\!OCH74SR
MA="3I0W-?E[*[ <:3[WS?UL5I J]J'"%86N1SPQ@J??C)&M<D5#Z4=/;-"\,
MG6]?8XU5-9ZDX(.@<A1]PQ&6'3P[\. C3HZW<OG$@4S-0T[)HENAUS4CN&E"
MC2;G/V"K!$W<-"?3B7526:B5JE'7&<OK%MEU2H#F69%/ AB2_F;F-&YE'P4-
MIO+>7+I8I87[%;4[5@>\O1Z*O4CV-N"9XOQ"M",X=XTFS*Z)!IGRC5R'6Q<>
ME(:%'R2BIGEMG!%T1S2N'Q(IM-K#H?L6C<34,2RU(7R0I,J8Y-G0.#?B^)%1
M"W+QG4-2'CWM0:>#MLEOD4'<>  \0028B*]#^G#@V:*+B2R/W?=A.G^&^K7G
M.IW.\V68:!,O>SJ,/V[ 7812N^5NYE7I?.44;2O#&5S0YBM7.>?[K+'M>[&[
MDOZZ6L4&$SI;6*MX>WQQ-#HY.3P=G5U]]:"O+^4F_OCL -Q$QHANF REFYMB
MG/-9$J*OG(.C##EHFN!HSXNXZDIF*?N835;+C ,PWSR32E+?_7E2+>ZC4-Y!
MIW:11N\2>KYW2=:0&F&WH'"Q!;.C*C9;D8_POIIEV.GI3^O:=WA>>_WA%.,&
M<>D\X7"3%AFEQVZS>Y8@18?^NE3BE*4ND7UX^(*Q#"A_XB4F=!$Y;052-UU9
MO0O4"_&JR9YXIW#E.#<>MR3U(AT?'XJ"J7.%-:!SE<U*:X'\.@GS2IXK3ABK
M;[!?)%_,E$W5E?AT'$8Y>Y\R/65[7"=N7,X7Q* &]:+!<<K$@"&Q4D8)PYFT
M+2J8E-*E(8F2NZG7:XFR1W;2M-O 39XB9/3M99F]J TO90+W*\&!:2S3]7A;
M8"-VQ<UON[CYTZZXN2MN?DE_Z\%PYK,5=3[](.IK*X.3>$7)/NKS6.,"?,+1
ML/.'>_WA%WLG^3Q?NF32B8$$;9(SM2<[ERX665J+T+Q-R\4<":5IRW]' %J?
MLJ("$E6&O&R\@'3'2T.5T.>>$ ;,42M:M''CTO\>=!7(N<>R&<ZSHELGX2UK
MO:@;.E/M86X7BP/P ((P9LRPN#5VJ-'6%'Y$F8#!'ZOI=9C.:[B(@5.@0FRV
MH!%.Z6Y;]6ZK'_8VKF&)W7,J6*-TG3XINR1$)>' X=W/@D737JIW-QGOB)IB
M+D]1 J^X8FV?Z>!-_M'Q6,:)]\OT(ZP9(:V,_WA&NCFX2=Q'#DT;G01E?&%'
MA HO'IG 6'50"5MM44C?QLOOG^^/A_L_#G6C7&$J>#JX6)),]JNT_%"O%LO)
M_>"HFNX8Q/K7],N]$05X@]?59+7QZJQ)PNVSC+H6X1HL)[C6O>SC33[&N+G.
MP!,0X4G-" A^R7>&XDGBVPU\;087&']IJ*6A1DCK:$H\NL:V<6C%H,ZNT[H%
M0'"W7Y#6A_;ON"Y1,XZTG@R(\ XM>D"UB[W^+$Y,B8WN1T^72ZJQT"-@Q01+
M;^6D@LU2T]:5N:"R3VJ*2=X"A%6JK@P"7I 8GHF5STZ#%S_IH"TPXB=K/]K[
M</Q,R6/OY)F4ZZJ_[7*WVW_<^Y7)D6#5GJ1WV[+7G:=R3:.3M<N "'3'&D4H
M%.F=6SF,#;K#=CX"-[[+RK*Y+V[3,D\'^\@MP:R!%B8TN:ER!M7!E08UK;NE
M2/[NEDWOLOEI[ZJ4'NIM""0$P],C<I H6@NIM97OI 5"F^0UG'?-DC/%TH]!
MXH&H+%TH]W=>WL*[F;(8E)N"0J$_"/!(*<>().]D.!EH@2SN3J AYD2U ],L
MI7^80 G;#]CP,YJA!UV-2Z;&H6*V<$V:**#O489AWGTI9+DI<11@"9\,<QJ,
M490/%;5$G/5\=?JPO[A&=%CGPC!&8'G<]+-DZ!%LQ=W>Z]U[/^_QVGF=-PMP
MC9O-;;M'O:2#%\]>O'BQI6_I\YY_/QWN*?J%Z27(;<(M,)67HXF!1$!$Q3WG
M%?2GQ# ],Y6S)CVB# *&>1,A#;'\%?YC)M5F&MKAJU/BW%</D-,IJWKYN'-3
M+%083<'28U6/(V*&U;ALE")U8^G_'%\,AS/3<HP28XEY\=$F%:_ A[^M)@0H
M;%;C.97$EDT&,:P8D#]6,+-3I0_VG+GP8*ANT7XM3368I22\@!QASMY(!8HM
M,!HHL#X)3ZQP:?G6/TJFF-OZA H,[#L6ALV%L:;$!KU:V+U0CT3+CLHL;NRT
MDE&BB"HBBQKB7<'61WE%L I+9 KWDK11(HP5)3R]:&Q/S?)PZ,^!U4A'&![\
M*W@\JFOFC@S8S_"3W_ACV/@!K)Q6F)++IY35PW7-R6K6QV!@&\501+R&?::8
MU(X7LI!9U[18')Z>X9.Z.O8U5:/:E&X%U8[XC<-!6G4<>L);UE1@\%=\O3G5
M;AEV0JO3_3-@7A^V]&9D4XJ'M7#% )D+NX^);5^DH]P4A"E60N6N*0?$"V]7
M+/U&BZ4_[XJE3Z=8NO/I_]'1048\+!L-JZ\8R>@J!H)3;(@K'#ZCI)N>S*V%
MHN^CE\&6@!6$IS7Q<R]9/-'PL$:=K]U\,BW-MMAK#IH>!+JD!$D$82(/9U+5
MS/\PI>8OAQBGL[?_O:B+.7%Z9^)HKGOF"3GX4M9+]>EFIN>W[U%=4\LO[%X*
MJ57?S4JOFT>'*A*XPZO3.*2J#7D>S!_\$W]CF?6H%Z36_F$-67 RZPQ;!ND+
MF$0NZ5_S;#[&M4&(KSOR5O?](.CN_N9R;W?KQ#O8EL#H%M,J-6Q:)K+2T3FV
M)1Z1":CLZ-S@=&SDR>#(N@%C-&]#"](-63W\*O^LQ2A>4%=C=4?/M<L&28TA
MY)Q*I$BMZD&A5E 2#&$==F.7;>D'HW^_-VK@Z199L5%;_#Y':,3@X/O!-*6&
MNJ*H[EBY@'F= VO% DX!>345]HG .B(.$*L>2AP,O*I@ %4WULZT_R;4&P1K
M?V#Z )U@8%7?VXLGW/VTE%R')"#0]-+M7J=+6:U4$F[]S1611A\7><TY4_Z.
MH]4S"=;<<ZQVZV=2 W3:2+(3B:"K*4?8^]S"IC\GU+!$4"3B,L>IX[^)R,:0
M^ZS"3SF<DLO XF]\#=W!0^)2N&>FQMXKI)Z]YHC/F1MI'>0N+Q*QC"X;7Y(F
M0C "TH<E+R$L_"=ZC(\%9Q)7\MT2L)1RK (\S6;IJEAVXV 2G,_N+\2S2Y5
MZ>YV,DXS*>,2D(:^AD00TW Q^6FA:\#:K:E5+*<S(^D8V7[6G@EN7$PE8&]6
M8^H5:[0KE$'DC>3$XY(O7'(6#4HHRP/J!>FHY4R[H[./E%MTN%E<&6.6=VJ
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M[E%$"\1*J<@6W9I&BJ7]&CT&Q":Q.?0MJ,'>T=]\]?O4I8!J%<;E]C+_1"?
M_SL \ES?&?Y< ,QG0/["93;U[['WPQ0[5TR)59^$< P@1!+-P\17U;LZ[8S8
M_$#&A#8*!-'DZ80B%73V'8NWE]\JU#\89[:1/ 1TL\4F]-F>4&-EX@^=\*-X
M-,+F6B%,"80V@$.?IOPQ(?? =Z 8<\?P%_V#/T\F"TJ7)\DDP$_#*'STJ<"
M[RT3K!*@5QD@8Q+'\/TH]G%803R^3^5N@I-XZR?\?H?J2 <%EM_]1/Q5]P-N
M;G[7&SZ<2< ?)+J'0<JK\N42Q)\%($W@VX<$#[5B%(1XN(='VAXN730V<%$:
M:\"_$NPK;&3"00^2DU7Z?D9Q=I/=--G-]=[Z^,AD-TUV<X>SF^3:L+2='!RQ
M\HH0T$=2$RL?M'/;MVJMC,&N)!<!D'%N"1ND-QF%Z*)T1NTM]SZR21T+'R="
MRX&[YP6%(C(2Z*/@A<,9;KY(1K(NK#A^A?\APT",0F@PR?')6(7BM:<JG^BY
M1Z$^3S>JQUXJBN*PVY]4%BJ)ED)Y'EU'7+10(DDU=MP\2@C 'TF>OXANY?5Y
MRVPC->WBC/[TS!L8OKJCQ=$K4->$T^V"+X/L9YC+,^04X@&H!_4253CY0M[_
M=L:OE!8+QPIELI+3/19D_U'V,**.5$\2*BBF'Z?9G_SM@XBXCUR%B(5XJ@6%
M*_X3KE<L(TUS12EB=E/V_OB$A7R6PC_KF29.(+,*4.("@77$G"($%<5I%@W"
ML&E*U5\D]C4.)P\YQ<0I$/,3K"H6>C.KY<KHED$<4E&:E@&7Q/T$3_DX"_BT
M4G5#T?</I,Z/3V_>DW-R6,N.('""F#[$Z42F4&CPD*J<^1$5R<AH\=S_BP_Q
M %/_?#.4@ZM0RQ,K@)J D#F0_]C>"Z&ZAU1H:K:X/TSPS9GZ< "CCH!C$(W*
ME9_*3I>EO0#:#^JJI,5Z3RGQ+4A,5*$RY<>7N=!%':&X3A349/U7_#"9B<4N
M6PKF$A+4IEDTHH6Z#:2SY):6"K-G<>MQ3&I0(<6A];"N4H#%S!OS^3@#J0VE
M%Y2J0C*<#733OE03I.B@OB\*GDZ.G9OC<RUG<8&6&!7"4IO'58,! 5I(O:P<
M[,IJOZQ@$6'1(D%9<VDX;D=NHGA*T0&HZ"PMA(P8K],05M#GL[LM1I!A@0!E
ME&6X<' @.I:&<U%IFF?N2^A'6KZJ">!3\U)B4XATZI)>1QBQ$0^@95?%5-7R
M7@Z3&\L<BJAPE30(?;[*[1/DFR12)<NH6:N-FO=+Q8R*$";X,LWI860Z;DMR
MZ>324,!.L0[U MM\?:U*8&/H)!74\7S23^8&5<O3!19I2@"-$)S#UVCR/WJD
MD9]2S.[S'<1M*'=#4L@S458VERX[QD:/-YB'$=Y;EJB2"J=J':FZ5^-3\%V#
M2O-P&%@[KD:!A>59G@ZG'\U) P.8#GG($*. $+F CMEQHOV6"E8E+ G$^=#G
M2GKQK"(7C0/UB5@8M6*"U>OBC](X6F#4'K".B)_3UH"*=E!3E;72DDN1$HF4
MZ,Q5U3Y@I_ 45_57+")KIK3>INJX8YIK/M%<<XL-A2K87'/@M(9]U_O(;.>J
M-W"]S2Z=[59'YN4\$+\7<(>FC)!S?18TO.;[8(,=2  _D/0+FZZDX&N-JO2+
M\8M,*9"<S8B_NN53#1;FAJQX<4G9@QC/<NX'<IYJ6=;QQN</QG_+R>V,=#+4
M_)LDXG.-K('L@@K1,T)T\%5;*E,@U4)*]@AN2<[IRH:$.MDPSSW-.781Y ')
M45&6+5U1<1\LS=821DS1'#J#2S%>Q.QK=\ZY^"5W*D@I2"R:4=X$K:S *A/Q
M'@6#,L1#"K?3,/B2Y4(R*IUBUQ+W$]'I5!+V<CR[7&UX-.'?#!#<B\!7^8"P
MY.&PI"%8C 5]1L"&PM249'*6O5>?EQ5=* 5.Y=RU^C?,1Z9S26*F=9W3+"D.
MMTP15"5_&8J_#\.'Y0^K.J:O"-$)XB\?R2Q / %DR:S-T&S5F-P;K#!$D"3D
M10O5)HVW?*I0G$9+S<HT:T'P9Q:7WCP]Q@GP =IZ")GULM"+'*#)JYF\VIKS
M:@V35S-YM1V&BWGHA7Z$?*$O(!*$G\%A<-_XTYMWM:-W[VO-MY00DKMN"!%W
M^*>?WA[53AKOZL<-[A+.2? <6*Q?\PUO3C;O&]C_]>2-9NVX^4N]\6[5D]/4
MU)M-@:[P8@2\,HSMCZ L,E,@Q1/UPB_(;_'_.U]0%QY-3/5.&Z# G0#!Y-,(
M[,'_@,C#0?/HD$"(>&HU''PD$<"CUAQP'TTDZVMS!$,+-78K2..M4!>('P3Y
MA@P>^:!G*36OEJ#5?-Q  N9#^6PG.5R5W5U$Y<2%#U'![]&G'@=Z  &)N6,H
M0,5C@M+.H^,!'X\Z_[Q?=CK(72JS(7+'P"@4:B%")ZD%RB);_=OS,/LVA)82
MC!&Q1+0OI8YW3]@ L3<)I%&DB2Q''$MUO6)J&# B35!-L.YS2NY9]W/*4>7#
M-Z619(HD\GP";X363EU,'@69D/GT6%CBA._5A#>SUIC L.>'/,& 2V.M5X$\
M]4%0JA+1H"T%?3X-W(NNY0W[SH"=]SJ=WO5_-SL;6_7+!DZ_8#C]YJ7#Z8;!
MTKO%XGEFS5V77;M>UQD,V'7;Z3N]\^5:2XA=E;R"GK-3$"[PJ<0*2BO8S20!
M,(5X4A11;=@C5HL<U;&Z=J?7MT_7.PG-DZ\[PLTLK#.K8[&KCO4?_F>_=^7T
MO8\UYG9;=<C$^%CS^]E':0[J^,I]XWJGYJ@R[]S9E]/O9;3@(P0@4H,S=HHP
M%>1(?\2X7J>OV6 .D6AV'8[OTBA,7NV+3;K^-#RMHE$V;)%*.2</R+VG_'PW
M@[#,)73?@&" +?IR;/],L25GXK4=-NS:3A_.68[-/*=K=3UFM?[5[5UW'/N"
MG[N\MN4QUV/GPT[GH_BVQYT0?.*P5J][SGV^V^L.6.^<_3ZT+RX=N$379M>6
M^X%_&;[C62Y<GX.$@=/R\-N-X_J;@RW*'5:*ETB("6<-IM[M7G30RW&#P&Q9
M,/7PX8=>9\@GL^_RW_E',+O\2SUN"G? .HXU<(2=6KW+J[[3=KHVOQ9:JN]T
MW.X?0W?01@/QN[6X+^5V87WWHNT-V-E']L'M>T,'/AL,6^UO,>Y>8S%Z7;:W
MA/<& [;:O:[==ZT.K.2^=>4,/;<U(!A8,SBPRCBPY2= \QC4H5SCYTM_,H5
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M8<2R40I)LL% )$D46\!M0G<,M&#DAE<"!=;F* H]''4N^2!P%9[EA_"H:PV
M'[E^R%*N#1)-"K^QF-/(KN#0K'<HV=3>KQ&!H;56+.GY]IX!9L46C#D861HB
M [P%#P&.X=+:LP_VZE8,K[C]0%C)7QGRJ*$0*4(3K<4"1I6.X$M_".+S,(@
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M2"%J[_;M@W>XP>H:5LLM]][N;N_NKB&WK*[GQ[U%"*+X*/P;'7=/48CVP1E
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M6%"(]R9YJ,K,O@NGHH2_.PQQ&^YFT5%DQ@K,)IY1)A:E2TF;;K_T.L+T. 3
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M+Z%RTS\?CNY7;OK*3?\,<%8DK*W9E&6D(ECZZ"HBR]R,ELJ14KF(@>0TIY9
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MZ9(3=5W8;@[X!*5)>BC^Y=!,=?0& ]47[=K%QPA_436(!A(M42SB!G^2E($
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M2B:VAM97:F@=;["&W!I:K:&US8;6V?.^BF>O_W+V?)2/D]?_#U!+ P04
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M\DALHX\)+TB95RTHZ+D[M(,W0:^Z??L%4$L#!!0    ( #:#;E@!4E33[@(
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MNU?G*,D!>U71J'A4\)KQT,1NQ(T5$!)%[N3EGG-H>WXMUSWQ:QE]*4!%H!Y
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M@8^J4MUDX E/KIFT Q0HJQ<"\CO&$&-+ZQ5(6O^XC:TA;*:8<8<I&@T"(,/
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M.#<V-S8X7S N:G!G4$L! A0#%     @ -H-N6&Z0ZI$,;   !;\  !(
M         ( !% <! &EM9S$S,3@W-C<V.%\Q+FIP9U!+ 0(4 Q0    ( #:#
M;EB\74MUFV   $-X   3              "  5!S 0!I;6<Q,S$X-S8W-CA?
M,3 N:G!G4$L! A0#%     @ -H-N6*TD 'FNA@  JYL  !,
M ( !'-0! &EM9S$S,3@W-C<V.%\Q,2YJ<&=02P$"% ,4    "  V@VY8MTD:
M0=%U  !RF   $P              @ '[6@( :6UG,3,Q.#<V-S8X7S$R+FIP
M9U!+ 0(4 Q0    ( #:#;EACPDP?0ET  )%S   3              "  ?W0
M @!I;6<Q,S$X-S8W-CA?,3,N:G!G4$L! A0#%     @ -H-N6./5BXTQA
M<)T  !,              ( !<"X# &EM9S$S,3@W-C<V.%\Q-"YJ<&=02P$"
M% ,4    "  V@VY8"ROB\8U;  !:K   $@              @ '2L@, :6UG
M,3,Q.#<V-S8X7S(N:G!G4$L! A0#%     @ -H-N6/[ZT)BMD@  <,,  !(
M             ( !CPX$ &EM9S$S,3@W-C<V.%\S+FIP9U!+ 0(4 Q0    (
M #:#;EC_B6O!E'X  $70   2              "  6RA! !I;6<Q,S$X-S8W
M-CA?-"YJ<&=02P$"% ,4    "  V@VY8.M)F(8B)  !GVP  $@
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M,3@W-C<V.%\Y+FIP9U!+ 0(4 Q0    ( #:#;ECI59Z8%9X# $T0(P 1
M          "  :TR"0!L<FUR+3(P,C,Q,C,Q+FAT;5!+ 0(4 Q0    ( #:#
M;EC<T9MF4R,! $BH$  1              "  ?'0# !L<FUR+3(P,C,Q,C,Q
M+GAS9%!+ 0(4 Q0    ( #:#;EA5!UD\0?8  !\]"  0              "
M 7/T#0!L<FUR+65X,3!?,C N:'1M4$L! A0#%     @ -H-N6#,-![M?,0
M@9 ! !               ( !XNH. &QR;7(M97@Q,%\R,2YH=&U02P$"% ,4
M    "  V@VY8/;T6@K80   X>0  #P              @ %O' \ ;')M<BUE
M>#$P7S,N:'1M4$L! A0#%     @ -H-N6)X+(+YC%0  O+(   \
M     ( !4BT/ &QR;7(M97@Q,%\T+FAT;5!+ 0(4 Q0    ( #:#;EAM*\YE
M'0,  (03   /              "  >)"#P!L<FUR+65X,C%?,2YH=&U02P$"
M% ,4    "  V@VY8 5)4T^X"  #A$P  #P              @ $L1@\ ;')M
M<BUE>#(S7S$N:'1M4$L! A0#%     @ -H-N6.SX;VO0!P  /BD   \
M         ( !1TD/ &QR;7(M97@S,5\Q+FAT;5!+ 0(4 Q0    ( #:#;EA1
M,62$SP<  *$I   /              "  411#P!L<FUR+65X,S%?,BYH=&U0
M2P$"% ,4    "  V@VY8AC/C6Q,%  !T.@  #P              @ % 60\
M;')M<BUE>#,R7S$N:'1M4$L! A0#%     @ -H-N6-\=M?5Q$@  *IP   \
M             ( !@%X/ &QR;7(M97@Y-U\Q+FAT;5!+!08     &P ; *<&
(   ><0\    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>lrmr-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:lrmr="http://www.larimartx.com/20231231"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="lrmr-20231231.xsd" xlink:type="simple"/>
    <context id="C_e3617796-30ca-4ac0-abe2-0626ffe07078">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">lrmr:PerformedInUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">lrmr:Ircsection174Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_80781f96-9385-4dd5-8eb7-f026c92fd2c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_69cb0fb5-da69-40e6-80bc-099615cd64ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_dac4deed-8338-46b9-9588-adb96f059754">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">lrmr:WakeForestUniversityHealthSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-11-30</instant>
        </period>
    </context>
    <context id="C_a74f39df-acd1-4d8b-9dba-1fd17150fcb5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-28</instant>
        </period>
    </context>
    <context id="C_c9852892-0da8-479d-83c0-1ee02dd67583">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_783e630c-cae9-4de1-9bdf-0cc7dfa2bdb8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:AdditionalOfficeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-09</startDate>
            <endDate>2023-03-09</endDate>
        </period>
    </context>
    <context id="C_a2ca56a1-3b79-4526-a05b-9dc40fc95833">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b1cbaf6b-72b0-4de8-aef3-35073ff760cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">lrmr:NoExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5ea5486f-6817-49ce-bca9-bd58ccc45608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-28</instant>
        </period>
    </context>
    <context id="C_e9f9b4ac-b65e-40cf-8ab9-8f0d09a73535">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8bce919e-849a-4aa5-be5e-b7af4b9b190d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-01</instant>
        </period>
    </context>
    <context id="C_bb598509-13da-4a32-959a-d65c251e001c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_095c643d-76db-4c04-8cbb-33eef107ab9e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-28</startDate>
            <endDate>2020-05-28</endDate>
        </period>
    </context>
    <context id="C_79fb8102-e267-43bc-9f8f-f08e3d54c866">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_df56d690-57ac-45e5-928f-f00b6eb9e578">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_78ca8c58-4724-4fdd-b217-9f4c3b5b885f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lrmr:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9e62e2a7-281f-4efe-9952-2af3980d814c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d735f0e0-bd1f-4ef9-b8c9-2c828c14ca2f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:LabSpaceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-16</instant>
        </period>
    </context>
    <context id="C_8f177c92-7fde-43e5-bb65-ae7ee79f52cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lrmr:ZafgenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4df7afcb-4d0e-4162-9cf0-4e8b3712bbec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_cf00efe6-6c32-4b41-a584-da4e540323ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeSubleaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lrmr:FirstSubleaseYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-27</instant>
        </period>
    </context>
    <context id="C_4e7af380-9c31-42f4-a857-43c89ba539c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_bcdb66fd-e3ec-478b-b8b2-8edf5a625608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lrmr:EquipmentFurnitureAndFixturesAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1f994bce-c827-41bc-8923-a0b663b5dccb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-01</endDate>
        </period>
    </context>
    <context id="C_c10d75ec-25a9-4bc3-b1d5-100a6af3fb57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-08</startDate>
            <endDate>2019-08-08</endDate>
        </period>
    </context>
    <context id="C_71666c3b-3ed8-4c95-870d-c95adde92612">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_cb46581b-8c63-4fee-b4c7-cc9ee9a93a21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7a4395b1-58c4-4b3b-bac0-3280e7df8802">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-01</instant>
        </period>
    </context>
    <context id="C_4d0e0e4e-6b0a-403d-87e1-7dc7a011b1ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="C_89695345-0b21-49a0-8d47-0e33cf4abec6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeAndLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-04</startDate>
            <endDate>2020-08-04</endDate>
        </period>
    </context>
    <context id="C_fe994e7e-b8ca-4866-b2b8-f68f8a9ef323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lrmr:InducementStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_24df9b26-5847-47e5-b4ad-c48348d08414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="C_a8e69aee-3f52-42fe-9a00-5c7054b2ba1f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-01</endDate>
        </period>
    </context>
    <context id="C_8cd23ff2-fd7c-4814-976b-44a4de8fb1e2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-28</startDate>
            <endDate>2020-05-28</endDate>
        </period>
    </context>
    <context id="C_d4d4aee3-9c3b-49c7-bff2-63ffe90e6e2e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f93fcf7c-172c-4854-bab6-8d8a70725f95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ccc62b5b-71d4-486d-aec0-66d4350d7baf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lrmr:ZafgenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c597ff2c-39de-40dd-b55f-1bcc76bd4dc7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">lrmr:MTSHealthPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-28</startDate>
            <endDate>2020-05-28</endDate>
        </period>
    </context>
    <context id="C_f1c3acf0-ab7f-4fb7-b405-7bbdf99bfc05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_32800e6f-ee7b-44d6-a810-966628d6e119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_cf8be5df-f0b1-4821-a7e8-f9b1795798f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lrmr:FromExerciseOfWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-11</instant>
        </period>
    </context>
    <context id="C_0899eeab-0bfd-49a2-8a22-1c41967d8084">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_2a37f99b-d107-4e6e-89a3-1dc033f729cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-11</startDate>
            <endDate>2023-08-11</endDate>
        </period>
    </context>
    <context id="C_600d2614-95f3-40e4-a75b-3d7d2462a2d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeSubleaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lrmr:FirstSubleaseYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-27</instant>
        </period>
    </context>
    <context id="C_393eb466-a24d-43ed-9e90-d9f5eb33fa0b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b8fdf4b9-43b7-4ab7-8542-b3d410371289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="C_6dc50be6-f9ce-45f0-896b-c14acf174567">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_039998c9-136d-4c84-92be-a69133fb0a75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lrmr:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="C_510b971c-d3fe-4984-9d53-6865328abecd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e619f4e9-77cd-449f-8ab2-c55b57519206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a9f53337-4c5c-4958-98a5-a81a54dd3435">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d800893b-5211-4ef0-8aeb-b28cb9dd18ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeAndLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-05</startDate>
            <endDate>2018-11-05</endDate>
        </period>
    </context>
    <context id="C_530aece5-55e1-42ca-83b2-fdd8cc766346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="C_4b113e78-3130-4612-8c3b-467b2bc9cf25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8ad4ebd6-202a-41f5-854f-4158140e7f04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f4ad8f7d-6e13-40e8-9f2e-5b7b5f6addd0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeAndLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-09</startDate>
            <endDate>2021-08-09</endDate>
        </period>
    </context>
    <context id="C_7edb1b10-e53a-422a-9a1e-e81b7d59c086">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_73fffb18-77da-4d3d-8982-345e143a5dd4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">lrmr:NoExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a82c95f9-c18c-445c-a45f-cb3e1f90d580">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ce01a5a3-0bd6-4643-a592-16b822a79946">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_faa2d74d-3a2d-47fb-a723-778c940b635d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lrmr:EquipmentFurnitureAndFixturesAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_47c297aa-bca8-4b02-b5a1-b4f42c32fbc2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lrmr:USGovernmentSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7461d392-dc75-45e2-93a6-6a4655ad44cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lrmr:FromPriorPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b6f1f981-2a41-46ca-88f7-657876f052f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c1455b06-7113-45cb-ac47-8e1eb7003ee1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_026fc58b-40b7-41a5-a024-519b8180c981">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0042b997-c48a-4b61-bc0b-c18adeff5e3f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_69f61fa0-0ce7-4f9f-b5a6-b3da5b3c716c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeSubleaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-27</startDate>
            <endDate>2020-10-27</endDate>
        </period>
    </context>
    <context id="C_a3c09498-0d4a-46e4-b3c4-1c97a4ae24dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c1f2a4df-aa2f-4030-a1d3-a3da85f2634e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_3d5bafd5-20d4-4026-a715-daa85bdc64bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">lrmr:IndianaUniversityResearchAndTechnologyCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-11-30</instant>
        </period>
    </context>
    <context id="C_41a0d33b-53ab-4ae8-bdba-87ffec128add">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_112cf294-81d1-4c4c-ba37-b763be85def2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_786b0fcb-721f-4485-992a-f6eb8aa02bf3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3e015593-165f-45fc-9cb4-52b758b04a99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="C_196f20b7-7250-4fea-befc-99827d01c86b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lrmr:InducementStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_5c533b45-4872-44aa-8eba-29efd92ddf96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">lrmr:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e779eef1-f227-4303-a5d4-03032bdb61b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="C_26cd9754-8143-4a1f-93ac-b42a31563c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeAndLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="C_485ac229-ff1e-4d6d-89fa-970087d282fe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:AdditionalOfficeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-01</instant>
        </period>
    </context>
    <context id="C_bdabb33a-7162-4c37-8a9a-3a553319cde1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">lrmr:WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-11</startDate>
            <endDate>2019-12-11</endDate>
        </period>
    </context>
    <context id="C_e5052803-8e24-4b5c-bf1d-feeb356d8445">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_25c4d6a9-6524-4f9f-84fa-c1a37a44ade0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-09</startDate>
            <endDate>2023-03-09</endDate>
        </period>
    </context>
    <context id="C_d39d1e4b-8b4a-4b1b-9377-433018f6afff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_02732bcd-6e0a-478e-b53c-e115414d242b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">lrmr:WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="C_a4f1b737-b155-4ae3-9c2f-2c7f4437ce11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4d67c562-0e3a-4233-a627-82c574413619">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">lrmr:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-17</startDate>
            <endDate>2024-01-17</endDate>
        </period>
    </context>
    <context id="C_f2aae2bb-8999-4b7a-9f12-440a582140f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeSubleaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lrmr:SixthSubleaseYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-27</instant>
        </period>
    </context>
    <context id="C_cfbfa2af-4b87-40ab-a789-900833fd126d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c68ae4ef-38ed-4e5e-950b-6c460b173668">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_8d3107c2-8938-4cdd-a26e-1dde989d7e23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2066b280-00da-4f34-bd69-b3d154d32fd8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_04fe8bd0-766a-4741-afc3-501f8a39c817">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">lrmr:DomesticAndStateLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b59bebb3-ca2d-4a96-ba24-a2513f6be665">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-08</instant>
        </period>
    </context>
    <context id="C_94e051e5-07aa-4e1e-a62e-12871b5fe6b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_860248e3-56cf-4688-98a3-19daf6e5ff6f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">lrmr:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">lrmr:FirstAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_5b2496bb-0283-4097-be94-f3832f36eb00">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lrmr:InducementStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9592d411-a0cd-4a54-9714-8ba1a249205b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1efd9ede-f9a2-45c2-93a1-636a41f2a1f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:AdditionalOfficeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-01</endDate>
        </period>
    </context>
    <context id="C_17f828a8-cd38-4b18-ac31-c79bc0508443">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_fa925083-1371-4656-ab14-7ea6e7f54fb3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">lrmr:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-17</startDate>
            <endDate>2024-01-17</endDate>
        </period>
    </context>
    <context id="C_5c3f05e5-8f01-4df5-a495-e7063f7dcbec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_953fc3f7-0bdc-46a5-a81f-b24a2a0ecad9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lrmr:InducementStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_740659e5-2866-4797-81d2-afb8bf9c13fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4b5e3f0d-190b-43a0-915d-81748af18c9f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_995af330-bf27-4e38-9645-1ac883fd043e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lrmr:USGovernmentSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b9dcce0a-1f1b-450f-80d2-41ae1be44f56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_cf75de90-0aaa-46d6-bc15-445c359ea784">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0247df73-9c90-49d2-a664-08a0e4028d55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
        </entity>
        <period>
            <instant>2024-03-12</instant>
        </period>
    </context>
    <context id="C_b312098e-3ef4-4545-b143-2d83afce1c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0bbb406f-e95b-44a2-aa20-069ec9f8367d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b094896e-8ca7-4bae-b10c-753cf6471626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeSubleaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lrmr:FinalSubleaseYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-27</instant>
        </period>
    </context>
    <context id="C_88192957-9603-4bc3-a321-f4c70d5a065f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5baad777-d068-4ce3-be35-c76ec7ffb655">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">lrmr:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">lrmr:FirstAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-17</startDate>
            <endDate>2024-01-17</endDate>
        </period>
    </context>
    <context id="C_a3395847-e949-4251-a28f-6484e3b7556e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lrmr:InducementStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">lrmr:FirstAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b696efd6-314c-4861-aaea-8e43ed271ae6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f0f9091f-cf20-4767-8991-bfab4c73cc6d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_846f3ecc-8d1c-4bc9-aa46-2d08b1bb1e55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3b388c97-79fa-4717-81b4-abd04c453ac4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_59823e91-6700-4233-b1ac-e431259ec4c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lrmr:USGovernmentSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d76e4f25-f643-4f25-bc71-be694bd78953">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7c80164a-e618-431e-908f-17026b8e4ae2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_37911699-3824-4881-9471-81254e29f4ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7812fd06-a01a-48d2-ab1b-3ad1ddddf263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5602ff77-c44f-4314-9ff2-70c3f8d3ba31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e879db45-fbcf-422c-84ea-f7c96123af6f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">lrmr:DomesticAndStateLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_26ed7eb8-3335-4a45-993d-30b861b1ef11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-28</instant>
        </period>
    </context>
    <context id="C_c656e41d-74c1-416b-8d9c-5d87a8f0183d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeAndLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-05</instant>
        </period>
    </context>
    <context id="C_279e75b7-f67a-4ee0-b268-adff2a559757">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">lrmr:IndianaUniversityResearchAndTechnologyCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-11-30</instant>
        </period>
    </context>
    <context id="C_064057be-fcdf-4308-890d-a8ada4719458">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lrmr:FromPriorPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3beedc45-1504-486d-95b7-175808b52042">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_9d1af696-7d08-4f42-87a7-b186b43ac50d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-28</startDate>
            <endDate>2020-05-28</endDate>
        </period>
    </context>
    <context id="C_22aa2b7d-3358-4d02-ae96-34174231f4a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lrmr:USGovernmentSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_95b87097-23b2-4be8-a5a4-68ffcb45d537">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">lrmr:WakeForestUniversityHealthSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-11-30</instant>
        </period>
    </context>
    <context id="C_f1669ee1-0407-437f-848e-7c1d63a35e33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a0d3bc37-c2c5-449e-9b72-d46590f710ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ba0cb289-2a01-465c-bc0c-d7869d54c786">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">lrmr:PerformedOutsideUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">lrmr:Ircsection174Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4a47b017-2508-45fe-a4d9-e2f06dcde4b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1c1b0f6e-ec81-493a-a1e1-b384f3fff492">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">lrmr:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_753c0b7c-04b8-4625-9acc-6491696a4c32">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_3e826b8f-62f8-4539-8051-933f165e12de">0001374690</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_479d3e40-b888-40c6-bf71-cd23683a2f76">false</dei:AmendmentFlag>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      id="F_68573a87-9368-4180-b1d5-870fdebccda7"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      id="F_5793ff2a-5e93-4e6d-badc-77a0ddfc5bbb"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      id="F_b02ed5cb-0a60-495a-a92c-8887d3f31d3b"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      id="F_9e6f1fc1-938c-4d9f-b37c-b85697a3850a"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_bcdb66fd-e3ec-478b-b8b2-8edf5a625608"
      id="F_79196bf3-be5b-4806-9ec5-5fed79d1cfbe">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration
      contextRef="C_786b0fcb-721f-4485-992a-f6eb8aa02bf3"
      id="F_1743f7c9-4f07-468e-8ed1-5de01b765813">http://fasb.org/us-gaap/2023#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember</us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_4d0e0e4e-6b0a-403d-87e1-7dc7a011b1ec"
      decimals="0"
      id="F_8cb91d11-91f9-408e-87be-ef7e83759a47"
      unitRef="U_USD">6284</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_b59bebb3-ca2d-4a96-ba24-a2513f6be665"
      id="F_1adadb6d-a5ef-4cd0-b448-c546eec4b594">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_25c4d6a9-6524-4f9f-84fa-c1a37a44ade0"
      id="F_54780bae-ad9f-44bf-b3f5-82dab5b666a1">2023-08-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_c656e41d-74c1-416b-8d9c-5d87a8f0183d"
      id="F_ed24bfd5-a8ef-478d-bee3-0b02edde6a19">P2Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <dei:DocumentType
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_b98e6082-3d13-4fd6-9232-c9585c8e9c72">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_0c3fc938-3933-4b12-825f-44d07629e7bf">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_fb500297-b998-40fb-bcb1-73678eedc0bd">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_2637af49-1bb6-4a66-b19d-11539426bcac">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_3ace50fb-f126-46da-b935-85db70e4a6f2">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_7d9dde10-6809-4bba-92b6-4f8c783710a3">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_8f1edc67-46ff-4a62-b699-4d9b9c2c7c05">001-36510</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_d3489c83-1a01-46c3-b7d1-e43424924498">LARIMAR THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_adf7578f-92eb-4f63-ab9b-a5ce87e37e8d">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_420e8e5a-d83a-49e1-8876-29791c7ec8a0">20-3857670</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_c36a549d-2fab-4e11-bf69-bea85e1c8cfd">Three Bala Plaza East</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_69761ab6-49b1-4410-9142-85523e058f77">Suite 506</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_76ef918c-fa2a-4f9b-9510-04b01270508e">Bala Cynwyd</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_b9507bfd-de3e-487e-9f52-75aa829e9875">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_fa873981-2a3e-4b29-9e96-f395ff4ace33">19004</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_8bb275aa-a6b0-4904-b9da-61e38787b955">844</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_6c74f906-ad39-4af9-9df8-c5ef31805312">511-9056</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_343b3a00-9e09-4fba-83c2-7323c588098b">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_2845f6f3-0b25-4497-85db-39eb45a0091d">LRMR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_8aebbd9b-93d9-4ddb-acb8-8e333f293b09">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_067a50c5-8ac0-4010-8871-0bce984ce18a">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_189824df-86bc-41d7-9b39-f66d38948d4a">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_2b5a366e-3069-48fe-8727-c4d416ba7c93">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_da285eff-2238-41da-9a41-5446ef9f1fe3">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_539c227f-5815-40b0-b5ce-14321b71ccc4">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_949a7a64-9fcb-408d-9d9e-309432cb5399">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_795e25dc-771f-4c85-900d-da3e71efb3af">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_d9b4c90b-bce4-4d3d-aec3-764eb6cd5575">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_a90156c2-442d-49e0-8062-b21b9025df47">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_081f134e-fbc7-4045-b9ec-995b95b3688c">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_c68ae4ef-38ed-4e5e-950b-6c460b173668"
      decimals="-3"
      id="F_e30fbad2-51dc-4112-8671-a4ccc1f80872"
      unitRef="U_USD">80218629000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_0247df73-9c90-49d2-a664-08a0e4028d55"
      decimals="INF"
      id="F_39852e52-2a46-416f-9dbc-b2776b6363f6"
      unitRef="U_shares">63800017</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_d0b6873f-1276-49d7-90b8-3b954fb8dee6">&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;Part III of this Annual Report on Form 10-K incorporates certain information by reference from the registrant&#x2019;s proxy statement for the 2024 annual meeting of shareholders to be filed no later than 120 days after the end of the registrant&#x2019;s fiscal year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_f1669ee1-0407-437f-848e-7c1d63a35e33"
      id="F_45bce1aa-6082-4606-8a7a-92a065c00edf">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_f1669ee1-0407-437f-848e-7c1d63a35e33"
      id="F_76f715a8-955e-452d-a468-0ed5fa1f47ea">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_f1669ee1-0407-437f-848e-7c1d63a35e33"
      id="F_b92fa2ca-85d5-4b95-8753-a8d31193fb23">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_f1669ee1-0407-437f-848e-7c1d63a35e33"
      id="F_5f166b7e-d5cd-4976-9a1e-d9fe39fab658">false</ecd:NonRule10b51ArrTrmntdFlag>
    <dei:AuditorName
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_f1855b0b-3ca7-4a7b-8855-ffed8b4570f3">PricewaterhouseCoopers LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_f242e56a-b88f-40b4-81c8-131db9a5e644">Philadelphia, Pennsylvania, USA</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_c0fc958d-7725-48b9-a820-d4a9d5562e01">238</dei:AuditorFirmId>
    <dei:AuditorFirmId
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_7b60c641-7d69-4e20-a393-d202db5b3b10">238</dei:AuditorFirmId>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_dfaa878d-5bc2-462f-b591-fb10c89d4d67"
      unitRef="U_USD">26749000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_7f124128-b4cc-47ea-ab13-8ca4f6c6f8f3"
      unitRef="U_USD">26825000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_95c01a93-2c9a-44bf-b1f5-72a4e4d143d9"
      unitRef="U_USD">60041000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_54270f3c-f6e0-4956-8699-8cc5d7e17274"
      unitRef="U_USD">91603000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_86a858b6-8ac6-4c76-bc63-f174acc58def"
      unitRef="U_USD">3385000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_dc1c6733-8fe1-4174-99ea-d1865309d15b"
      unitRef="U_USD">2311000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_cd19c352-460c-4179-9de9-70dd1bd083cd"
      unitRef="U_USD">90175000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_7c045896-df20-4935-a754-c37ca5779469"
      unitRef="U_USD">120739000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_92451b4d-f1c3-4b10-9da5-ae8fdfcbc984"
      unitRef="U_USD">684000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_d0181589-5ff3-4c86-af29-f1a0c27a009d"
      unitRef="U_USD">831000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_2a9d3d5f-96fd-41bd-b000-973ef5ea239a"
      unitRef="U_USD">3078000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_34b828a6-c496-4956-9d17-a91b8d5e60d6"
      unitRef="U_USD">2858000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_75238b7f-bd0a-44f5-b47c-6fe5bb1fb79c"
      unitRef="U_USD">1339000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_85f2bb5b-2c51-4bc8-9b42-d349a39dbb03"
      unitRef="U_USD">1339000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_e643ddba-2f99-48f8-bab3-6ebe330628b9"
      unitRef="U_USD">659000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_be8c00cd-b0fe-4390-84c0-57324f431338"
      unitRef="U_USD">638000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_3d3a1b56-d3ca-4710-b8d1-5a7b70001f1a"
      unitRef="U_USD">95935000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_a65aa946-2896-4691-b2c5-4eb7887eed26"
      unitRef="U_USD">126405000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_53bc8a20-de14-4c50-b4bf-c4a5c470ed47"
      unitRef="U_USD">1283000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_7db7ca2a-0859-45b6-9721-000f98d14cb3"
      unitRef="U_USD">1686000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_23d7e63e-5437-4b0f-b3ba-c73374a19578"
      unitRef="U_USD">7386000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_5b5619c7-d573-4e2e-aae9-b3de0ee48c39"
      unitRef="U_USD">8408000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_a33b8df1-cc46-4749-b39b-696b68bfe45f"
      unitRef="U_USD">837000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_f7f11077-e90a-446f-b9e7-381e9fe6492b"
      unitRef="U_USD">611000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_3590a564-05e3-4215-a751-8d953e4959f4"
      unitRef="U_USD">9506000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_66511f24-c4d7-4097-999e-385daaf50bcf"
      unitRef="U_USD">10705000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_06e6eaeb-1cc2-4d67-8327-2c375fb9c6d2"
      unitRef="U_USD">4709000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_be934d7b-e80a-4a39-be6b-c36e706b68fc"
      unitRef="U_USD">4797000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_457c1c10-195d-4194-acf1-c38ac2e5e2a6"
      unitRef="U_USD">14215000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_1182dd4d-c964-43a1-92e9-4eceb2f30f5e"
      unitRef="U_USD">15502000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="INF"
      id="F_de52b56d-15e8-499b-8782-d487729c50a2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="INF"
      id="F_22e53b8d-74b9-4abb-b2b2-0d717eb2de2c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="INF"
      id="F_613d8687-10da-4b7f-bccb-9be0ff18aa38"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="INF"
      id="F_105bd887-fc19-4854-863b-449627f2d879"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="INF"
      id="F_0fab3a0c-babc-4966-b945-b2721b61f137"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="INF"
      id="F_81cae4ed-c208-4f42-869e-2edabd042b89"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="INF"
      id="F_156d7866-c581-45e1-9c93-96e6ba68c6c9"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="INF"
      id="F_3a45f377-0560-41cd-995b-0f7361e024c0"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="INF"
      id="F_e2fa6ea5-9223-4cc3-9096-7f80e957ad97"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="INF"
      id="F_b41e191b-6811-4d6b-90cb-60724b5a65bd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="INF"
      id="F_996c550a-7074-4535-b71a-63dec6a67a5d"
      unitRef="U_shares">115000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="INF"
      id="F_5505976f-7dc5-41ae-b7bb-2670c2eda425"
      unitRef="U_shares">115000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="INF"
      id="F_8cb3ed0d-c5dd-4d49-9a0b-c87088e7402e"
      unitRef="U_shares">43909069</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="INF"
      id="F_df58f490-55b8-422f-a128-fb6c8737de45"
      unitRef="U_shares">43909069</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="INF"
      id="F_1ea3ea2e-31c4-42bd-9d9c-53ed4d8d603e"
      unitRef="U_shares">43269200</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="INF"
      id="F_4349e05e-d30f-4eb4-9484-d3510a0d1905"
      unitRef="U_shares">43269200</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_19082c79-4363-4152-bc8e-d65b00bb53e7"
      unitRef="U_USD">43000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_079049b3-0a79-4603-9cdb-c9515fb8499c"
      unitRef="U_USD">43000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_71f8fc97-83ff-4ebd-a710-a8a9c6e3aeef"
      unitRef="U_USD">270150000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_ca472570-c1c9-485b-a92d-71497a72af43"
      unitRef="U_USD">262496000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_85a801cf-ec43-46f8-9146-1a7d80e05746"
      unitRef="U_USD">-188554000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_1692723b-bda1-4bfc-bbce-afe219e07df9"
      unitRef="U_USD">-151605000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_115ceedf-6940-4669-907b-b49030210ff6"
      unitRef="U_USD">81000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_4109db41-21af-47bb-81d4-faf451e46807"
      unitRef="U_USD">-31000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_9021bdf2-9444-4efe-8acd-9ff34d5d54dc"
      unitRef="U_USD">81720000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_750df9ed-3449-41ec-bbe1-612ba603a02d"
      unitRef="U_USD">110903000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_9dc3ef48-ba59-46f9-a6ac-6d4769eb05b0"
      unitRef="U_USD">95935000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_890308ad-c6dc-48d6-8acf-58a4c610fdf1"
      unitRef="U_USD">126405000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="-3"
      id="F_e5c4502c-3d7d-4d35-892b-828449eacd22"
      unitRef="U_USD">27670000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="-3"
      id="F_4bfe56de-dd62-48f9-8923-fd0d5f1e6a0c"
      unitRef="U_USD">24250000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="-3"
      id="F_a07bf621-2467-4fa5-a8d4-08117dfdafe4"
      unitRef="U_USD">14088000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="-3"
      id="F_8e1fc070-0e6e-4e4e-8541-b19aecc199f0"
      unitRef="U_USD">12276000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="-3"
      id="F_9fc8feca-83fb-4985-a18b-16d5ccae9832"
      unitRef="U_USD">41758000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="-3"
      id="F_604df18e-9da7-4047-8bd1-345064119460"
      unitRef="U_USD">36526000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="-3"
      id="F_093c07c8-a971-46ea-8b00-1329019cc009"
      unitRef="U_USD">-41758000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="-3"
      id="F_50b61f38-6fbd-42b0-bdb5-743ee8a9aa81"
      unitRef="U_USD">-36526000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="-3"
      id="F_85c9ce68-3dbd-4a26-aa68-364bf330e1e0"
      unitRef="U_USD">4809000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="-3"
      id="F_34b6af8d-4872-4637-befe-2ebd3134762b"
      unitRef="U_USD">1171000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="-3"
      id="F_9869b22e-af9a-4e21-a007-293715151054"
      unitRef="U_USD">-36949000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="-3"
      id="F_75273e31-44f1-4243-a5d5-f2942c64d59f"
      unitRef="U_USD">-35355000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="2"
      id="F_d5f72b20-727d-429f-8b46-b068f6e884c2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.84</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="2"
      id="F_922c9206-1887-4d8a-88e3-89a685071165"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.84</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="2"
      id="F_594bb64b-2347-410a-9645-814ca4f241dd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="2"
      id="F_cff1cbd2-bb26-4d63-b1d1-4bb4cc8ebf32"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="0"
      id="F_3cfdf0af-35de-4304-8280-a04c6e79a088"
      unitRef="U_shares">43901241</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="0"
      id="F_2477610f-ed1f-4eab-941c-aa58211add59"
      unitRef="U_shares">43901241</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="0"
      id="F_5b0e8153-225c-4e23-a0f9-9d1ac006ea62"
      unitRef="U_shares">25761394</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="0"
      id="F_2e0815f4-3289-4cd8-87c1-eaad9c3aa082"
      unitRef="U_shares">25761394</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="-3"
      id="F_c04e520e-c9c5-4a86-87d5-0c37646e2e02"
      unitRef="U_USD">-36949000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="-3"
      id="F_edbe7dcb-ba1c-4f5e-adb0-06328c7f76c4"
      unitRef="U_USD">-35355000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="-3"
      id="F_27f0ea33-ecce-4220-9bf4-e2a14d37972f"
      unitRef="U_USD">112000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="-3"
      id="F_6db9509d-a0fa-4dd7-b6ef-eb1698c72255"
      unitRef="U_USD">-31000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="-3"
      id="F_703428ee-fe16-4ef4-88a8-16e6e0d0f540"
      unitRef="U_USD">112000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="-3"
      id="F_f7fed643-f2c7-4c41-8a34-6e0cfea6c537"
      unitRef="U_USD">-31000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="-3"
      id="F_c20f0e88-87fe-453d-bb15-268d4481f507"
      unitRef="U_USD">-36837000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="-3"
      id="F_ebce6160-e757-44d0-84c4-1814afa940d0"
      unitRef="U_USD">-35386000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_7edb1b10-e53a-422a-9a1e-e81b7d59c086"
      decimals="INF"
      id="F_0ee5e293-662d-46e6-bb52-fc1b7e9f56ae"
      unitRef="U_shares">43269200</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_7edb1b10-e53a-422a-9a1e-e81b7d59c086"
      decimals="-3"
      id="F_11bfc6b9-bd7f-47e9-b7d9-ee402a164902"
      unitRef="U_USD">43000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b312098e-3ef4-4545-b143-2d83afce1c16"
      decimals="-3"
      id="F_16517f5f-07c9-480f-baa6-6416639150b6"
      unitRef="U_USD">262496000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_88192957-9603-4bc3-a321-f4c70d5a065f"
      decimals="-3"
      id="F_4787f92e-3aef-4090-aa5f-7715855965e8"
      unitRef="U_USD">-151605000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_8d3107c2-8938-4cdd-a26e-1dde989d7e23"
      decimals="-3"
      id="F_68a7dd57-672f-44e4-aa54-0ffd8b8f456e"
      unitRef="U_USD">-31000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_447b6ee2-f238-4563-ba85-08fbd807b8ab"
      unitRef="U_USD">110903000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_df56d690-57ac-45e5-928f-f00b6eb9e578"
      decimals="-3"
      id="F_fd21daff-b46d-4e67-9d93-a65b552edced"
      unitRef="U_USD">7615000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="-3"
      id="F_2dd44e6d-0709-4ff1-83c9-9bbc5f2333e2"
      unitRef="U_USD">7615000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_9592d411-a0cd-4a54-9714-8ba1a249205b"
      decimals="0"
      id="F_6a3564b8-741a-48bd-aba8-33dc3d6c5f6a"
      unitRef="U_shares">11466</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_df56d690-57ac-45e5-928f-f00b6eb9e578"
      decimals="-3"
      id="F_3ff6d0b8-25dd-4468-8ce9-b21eab46a2bf"
      unitRef="U_USD">33000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="-3"
      id="F_aed69174-2077-44b3-8beb-1792de8da006"
      unitRef="U_USD">33000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <lrmr:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="C_9592d411-a0cd-4a54-9714-8ba1a249205b"
      decimals="INF"
      id="F_f3fc9b6e-5463-4e32-99b9-0cbaa0b654ce"
      unitRef="U_shares">628403</lrmr:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <lrmr:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="C_df56d690-57ac-45e5-928f-f00b6eb9e578"
      decimals="-3"
      id="F_2a0c2069-2a82-4418-9320-f20d9efe7e41"
      unitRef="U_USD">6000</lrmr:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <lrmr:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="-3"
      id="F_d432360a-f11a-4640-9482-efdac3581d16"
      unitRef="U_USD">6000</lrmr:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_7c80164a-e618-431e-908f-17026b8e4ae2"
      decimals="-3"
      id="F_b3646b6a-e581-4478-9e60-ce7f6983e0ff"
      unitRef="U_USD">112000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="-3"
      id="F_143ccab9-a094-45c9-9c2d-1dfac4859641"
      unitRef="U_USD">112000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="C_5602ff77-c44f-4314-9ff2-70c3f8d3ba31"
      decimals="-3"
      id="F_14ab6502-1582-487a-b528-431e3fd2247a"
      unitRef="U_USD">-36949000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="-3"
      id="F_a78c2291-e72f-4eec-ae52-7b33cd812d61"
      unitRef="U_USD">-36949000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_69cb0fb5-da69-40e6-80bc-099615cd64ea"
      decimals="INF"
      id="F_83b53ca4-f27a-4b75-87c0-060f0f69e2df"
      unitRef="U_shares">43909069</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_69cb0fb5-da69-40e6-80bc-099615cd64ea"
      decimals="-3"
      id="F_71e4aaa8-f057-47a2-86d2-cb4b0a469ebc"
      unitRef="U_USD">43000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b9dcce0a-1f1b-450f-80d2-41ae1be44f56"
      decimals="-3"
      id="F_92c4ce5e-467f-42fe-a4eb-b69deecd64cf"
      unitRef="U_USD">270150000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_cfbfa2af-4b87-40ab-a789-900833fd126d"
      decimals="-3"
      id="F_9a20d510-73f0-4277-acb7-4a8d691d1b2c"
      unitRef="U_USD">-188554000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_41a0d33b-53ab-4ae8-bdba-87ffec128add"
      decimals="-3"
      id="F_886255c1-5abe-431f-ae38-77e1e3bfda7b"
      unitRef="U_USD">81000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_2b9a128e-092d-46f1-ab0c-a3cf4d3c2552"
      unitRef="U_USD">81720000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_f93fcf7c-172c-4854-bab6-8d8a70725f95"
      decimals="INF"
      id="F_c297dec2-847c-4e50-bab9-8f9840bb02f9"
      unitRef="U_shares">17710450</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_f93fcf7c-172c-4854-bab6-8d8a70725f95"
      decimals="-3"
      id="F_85c98b8e-a5c1-48d0-acc5-e565e8b65e92"
      unitRef="U_USD">18000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_510b971c-d3fe-4984-9d53-6865328abecd"
      decimals="-3"
      id="F_517bc8dc-5165-4459-a2b9-5e151a2e5c76"
      unitRef="U_USD">180645000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_8ad4ebd6-202a-41f5-854f-4158140e7f04"
      decimals="-3"
      id="F_3ea54650-900b-461b-8465-48fcd746f647"
      unitRef="U_USD">-116250000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_cb46581b-8c63-4fee-b4c7-cc9ee9a93a21"
      decimals="-3"
      id="F_32ae919f-867a-4bf7-a69b-b903f9b93967"
      unitRef="U_USD">64413000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_4b5e3f0d-190b-43a0-915d-81748af18c9f"
      decimals="INF"
      id="F_4d9cc242-e715-4b97-b3e4-c729e7059f7d"
      unitRef="U_shares">25558750</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_4b5e3f0d-190b-43a0-915d-81748af18c9f"
      decimals="-3"
      id="F_881a1ef8-6e55-4fb1-8a2d-5c31a149467d"
      unitRef="U_USD">25000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_e5052803-8e24-4b5c-bf1d-feeb356d8445"
      decimals="-3"
      id="F_6ff26bd5-4388-472a-80f0-b80a8178d40b"
      unitRef="U_USD">75232000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="-3"
      id="F_0b94d19c-9320-40c4-9cd6-cda49bdc6c7c"
      unitRef="U_USD">75257000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_e5052803-8e24-4b5c-bf1d-feeb356d8445"
      decimals="-3"
      id="F_ef674291-af7f-4c30-82c5-89c59a4f06d0"
      unitRef="U_USD">6619000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="-3"
      id="F_e200929c-a99c-4186-8b6b-0aefc91e785e"
      unitRef="U_USD">6619000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_e9f9b4ac-b65e-40cf-8ab9-8f0d09a73535"
      decimals="-3"
      id="F_cc7748e6-46d8-422e-bf69-58a7f1d180ce"
      unitRef="U_USD">-31000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="-3"
      id="F_80b45e78-7feb-48f3-bce0-53cbc45edbea"
      unitRef="U_USD">-31000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="C_7812fd06-a01a-48d2-ab1b-3ad1ddddf263"
      decimals="-3"
      id="F_1281c0b1-8f11-4256-8ff8-13ea06dec0b6"
      unitRef="U_USD">-35355000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="-3"
      id="F_e44cc253-9574-4dd2-8eb1-fe2d3b659887"
      unitRef="U_USD">-35355000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_7edb1b10-e53a-422a-9a1e-e81b7d59c086"
      decimals="INF"
      id="F_f5b0447e-0b68-4c31-96f8-83030c545fba"
      unitRef="U_shares">43269200</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_7edb1b10-e53a-422a-9a1e-e81b7d59c086"
      decimals="-3"
      id="F_7f74d457-637e-4aab-899d-a7197070fbd8"
      unitRef="U_USD">43000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b312098e-3ef4-4545-b143-2d83afce1c16"
      decimals="-3"
      id="F_66049c01-aa36-4100-9984-284ee69d3b37"
      unitRef="U_USD">262496000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_88192957-9603-4bc3-a321-f4c70d5a065f"
      decimals="-3"
      id="F_e46b3686-1add-4d33-897b-cb354ff7d797"
      unitRef="U_USD">-151605000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_8d3107c2-8938-4cdd-a26e-1dde989d7e23"
      decimals="-3"
      id="F_96d8f92d-3137-493f-a578-466e99f82ea3"
      unitRef="U_USD">-31000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_bdf25206-ab3a-4756-81f2-f77ab18e1bf7"
      unitRef="U_USD">110903000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="-3"
      id="F_27c1b753-4ac2-4f45-8144-f7ec9c1efd41"
      unitRef="U_USD">-36949000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="-3"
      id="F_dca4a8a7-65c6-4960-8903-0434d2254c1b"
      unitRef="U_USD">-35355000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="-3"
      id="F_f8cb40ac-c2b3-4fdc-bd3d-0b0ec1750f13"
      unitRef="U_USD">7615000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="-3"
      id="F_a5c69306-475e-4dcb-aea8-ddd0f5a008ae"
      unitRef="U_USD">6619000</us-gaap:ShareBasedCompensation>
    <lrmr:CashAndNonCashOperatingLeaseExpense
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="-3"
      id="F_a207d581-e53f-462b-98f4-e839778637d6"
      unitRef="U_USD">-82000</lrmr:CashAndNonCashOperatingLeaseExpense>
    <lrmr:CashAndNonCashOperatingLeaseExpense
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="-3"
      id="F_70c72613-7dc1-4068-a1f3-3be17c8123ec"
      unitRef="U_USD">-46000</lrmr:CashAndNonCashOperatingLeaseExpense>
    <us-gaap:Depreciation
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="-3"
      id="F_3f2fff81-2ae4-40d9-812c-a4d956bef6d8"
      unitRef="U_USD">311000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="-3"
      id="F_971ca7e3-c0be-47ae-88c8-7c2fe4527e49"
      unitRef="U_USD">318000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="-3"
      id="F_29fe295a-8c62-46e1-8e06-6c8bda20818b"
      unitRef="U_USD">-1843000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="-3"
      id="F_8108fbcd-dc13-469f-8a04-62dcb666d143"
      unitRef="U_USD">-774000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="-3"
      id="F_11816cbb-3edc-4dc1-b397-ccd7b54608f2"
      unitRef="U_USD">1065000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="-3"
      id="F_f37ffd55-827a-4448-a89f-69a1f10fff91"
      unitRef="U_USD">204000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="-3"
      id="F_5ef7fb04-acc6-4efd-ab9a-3c5f8e53b753"
      unitRef="U_USD">-403000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="-3"
      id="F_ade19061-aa90-43ea-b19e-7f4325fdbce3"
      unitRef="U_USD">26000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="-3"
      id="F_c8964aea-cd95-4871-8705-2874f2dc022f"
      unitRef="U_USD">-1022000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="-3"
      id="F_149da19d-124e-4add-aa83-98613f8a514f"
      unitRef="U_USD">1816000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="-3"
      id="F_52e78546-a047-4247-9440-ba78549af8f8"
      unitRef="U_USD">21000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="-3"
      id="F_e23efc6e-9785-4b97-a661-a7f5d8820358"
      unitRef="U_USD">-31000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="-3"
      id="F_d4a6213e-eeb6-4a63-9831-cea7ef850d70"
      unitRef="U_USD">-33459000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="-3"
      id="F_d074ad88-bb2b-4cc9-8e34-5c56379203cf"
      unitRef="U_USD">-27569000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="-3"
      id="F_d7759c14-e778-49e8-b856-a42a734e1607"
      unitRef="U_USD">164000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="-3"
      id="F_e55551b5-7391-4902-b985-b137d5d468a5"
      unitRef="U_USD">100000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="-3"
      id="F_d9b18d70-6c34-49fd-a02b-f896f3331d62"
      unitRef="U_USD">101233000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="-3"
      id="F_30aedbd3-4e36-4636-b2da-9508a4d600c0"
      unitRef="U_USD">133610000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="-3"
      id="F_a79a0d2b-7eaf-4f2e-a7fa-90cea5448e5e"
      unitRef="U_USD">134750000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="-3"
      id="F_fb4fbf76-caf0-4803-9fb7-5ab135b88b08"
      unitRef="U_USD">42750000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="-3"
      id="F_ce03c79c-9668-41ab-a80f-ae8420bbdeec"
      unitRef="U_USD">33353000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="-3"
      id="F_7b6c0201-bfae-44cf-9d5a-6812d45bb357"
      unitRef="U_USD">-90960000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="-3"
      id="F_841e95a5-a037-4d6a-81eb-cee484f277fc"
      unitRef="U_USD">75257000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <lrmr:ProceedsFromExerciseOfStockOptionsAndWarrants
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="-3"
      id="F_e43600e8-d8c0-4926-bcac-2df3ffef6356"
      unitRef="U_USD">30000</lrmr:ProceedsFromExerciseOfStockOptionsAndWarrants>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="-3"
      id="F_2589bb3a-e132-4b3c-90dd-dc4698f7cbb6"
      unitRef="U_USD">30000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="-3"
      id="F_0be1031f-81c3-4fdc-a42e-f6e64fb17ed3"
      unitRef="U_USD">75257000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="-3"
      id="F_cd745cc2-94dd-4526-b2ee-13beaaa99ccb"
      unitRef="U_USD">-76000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="-3"
      id="F_b3d483f6-0016-44bb-813a-f54033542417"
      unitRef="U_USD">-43272000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_535f6701-d8f3-49ef-9236-0577e8a23769"
      unitRef="U_USD">28164000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_cb46581b-8c63-4fee-b4c7-cc9ee9a93a21"
      decimals="-3"
      id="F_60616a61-e970-4bb7-a67b-7beac17cda2a"
      unitRef="U_USD">71436000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_f8a0ed2a-2650-422c-bd67-79eea518e25c"
      unitRef="U_USD">28088000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_9e738841-7031-43c5-9b97-15536a6f2231"
      unitRef="U_USD">28164000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="-3"
      id="F_cefd22bf-4508-42ce-a635-9ad6f12673b3"
      unitRef="U_USD">790000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <lrmr:ProceedsFromExerciseOfStockOptionsIncludedInOtherCurrentAssets
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="-3"
      id="F_3937e938-0e13-47cb-9fc5-315df4619ea5"
      unitRef="U_USD">9000</lrmr:ProceedsFromExerciseOfStockOptionsIncludedInOtherCurrentAssets>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_31f51cb1-d352-4c6f-8a31-050841828027">&lt;div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;1.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Description of Business and Basis of Presentation &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Larimar Therapeutics, Inc., together with its subsidiary (the &#x201c;Company&#x201d; or &#x201c;Larimar&#x201d;), is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Larimar's lead product candidate, nomlabofusp (nomlabofusp is the International Nonproprietary Name ("INN") and the United States Adopted Name ("USAN") for CTI-1601), is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin ("FXN"), an essential protein, to the mitochondria of patients with Friedreich&#x2019;s ataxia ("FA"). FA is a rare, progressive and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has completed two phase 1 studies of nomlabofusp and a Phase 2 dose exploration study in patients with FA.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In May 2021, after reporting positive top-line data from the Company&#x2019;s Phase 1 FA program, the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) placed a clinical hold on the Company&#x2019;s nomlabofusp clinical program after the Company notified the FDA of mortalities at the highest dose levels of a 26-week non-human primate toxicology study that was designed to support extended dosing of patients with nomlabofusp. In August 2022, the Company submitted a complete response to the clinical hold following a Type C Meeting with the FDA, and proposed as nomlabofusp's next clinical trial a Phase 2, four-week, dose exploration study in FA patients starting at the lower dose levels tested in the Company&#x2019;s Phase 1 multiple-ascending dose clinical trial. In September 2022, the FDA lifted its full clinical hold on the nomlabofusp program and imposed a partial clinical hold.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In May 2023, the Company announced top-line data from its completed 25 mg cohort of a Phase 2, four-week, dose exploration trial of nomlabofusp in patients with FA and provided a complete response to the FDA in June 2023, which included unblinded safety, pharmacokinetic ("PK"), and pharmacodynamic ("PD") data from the Phase 2 trial&#x2019;s completed 25 mg cohort. Data from the completed 25 mg cohort (n = 13) indicated that nomlabofusp was generally well tolerated and showed increases in FXN levels from baseline compared to placebo in all evaluated tissues (skin and buccal cells) at day 14 (the final day of daily dosing in the trial).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In June 2023, the Company met with the FDA. Following that meeting, the Company submitted a complete response to the FDA&#x2019;s partial clinical hold that included unblinded safety, PK and frataxin data from the Phase 2 trial&#x2019;s completed 25 mg cohort.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In July 2023, following the FDA&#x2019;s review of the Company's complete response to the partial clinical hold, the FDA cleared initiation of a second cohort at 50 mg of our four-week, placebo-controlled, Phase 2 dose exploration trial and initiation of the OLE trial with daily dosing of 25 mg.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In February 2024, the Company reported positive top-line data and successful completion of their four-week, placebo-controlled Phase 2 dose exploration study of nomlabofusp in participants with FA. Nomlabofusp was generally well tolerated and demonstrated dose dependent increases in FXN levels in all evaluated tissues (skin and buccal cells) after daily dosing of 14 days followed by every other day dosing until day 28 in the 25 mg and 50 mg cohorts. Participants in the 25 mg (n=13) and 50 mg (n=15) cohorts were randomized 2:1 to receive subcutaneous injections of nomlabofusp or placebo. The initiation of additional U.S. clinical trials evaluating nomlabofusp are contingent on FDA review of data under the partial clinical hold.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In January 2024, the Company initiated an OLE trial evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver, with the first patient dosed in March 2024. Participants who complete treatment in the Phase 2 dose exploration trial, or who previously completed a prior clinical trial of nomlabofusp are potentially eligible to screen for the OLE. The OLE will evaluate the safety, tolerability and PK and measures of frataxin levels in peripheral tissues as well as other exploratory PD (lipid profiles and gene expression data) following long-term subcutaneous administration of nomlabofusp. Clinical measures collected during the trial will be compared to data from a synthetic control arm derived from participants in the Friedreich&#x2019;s Ataxia Clinical Outcome Measures Study (FACOMS) database. Dose escalation in the OLE trial will be considered based on safety, tolerability, PK, and tissue FXN levels from the Phase 2 trial&#x2019;s 50 mg cohort as well as available data from the 25 mg dose of nomlabofusp in the OLE trial and is contingent on FDA review as part of the partial clinical hold. Initial data from the OLE trial is expected in the fourth quarter of 2024.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is subject to risks and uncertainties common to pre-commercial companies in the biotechnology industry, including, but not limited to, development and commercialization by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with governmental&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;regulations, failure to secure regulatory approval for its drug candidates or any other product candidates and the ability to secure additional capital to fund its operations. Product candidates under development will require extensive non-clinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, infrastructure and extensive compliance-reporting capabilities. Even if the Company's drug development efforts are successful, it is uncertain when, if ever, it will realize significant revenue from product sales.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The consolidated financial statements include the accounts of Larimar and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated. The accompanying consolidated financial statements have been prepared in conformity with GAAP.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Liquidity and Capital Resources&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s consolidated financial statements have been presented on the basis that it will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Since its inception, the Company has incurred significant recurring operating losses and negative cash flows from operations. The Company has incurred net losses of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for the years ended December 31, 2023, and 2022, respectively. In addition, as of December 31, 2023, the Company had an accumulated deficit of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;188.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Company expects to continue to generate operating losses for the foreseeable future. As of December 31, 2023, the Company had approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;86.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of cash, cash equivalents and marketable securities available for use to fund its operations and capital requirements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has funded its operations to date primarily with proceeds from sales of common stock and proceeds from the sale of prefunded warrants for the purchase of common stock, the acquisition in 2020 of cash, cash equivalents and marketable securities upon the merger with Zafgen, Inc. ("Zafgen") and, prior to the 2020 merger with Zafgen, capital contributions from Chondrial Holdings, LLC.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In February 2024, the Company sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,736,842&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of its common stock in an underwritten public offering at a price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.74&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share and received net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;161.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In accordance with Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2014-15, "Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern", the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. As of the issuance date of these consolidated financial statements, the Company expects its cash, cash equivalents and marketable securities, including its net proceeds from the February 2024 public offering, will be sufficient to fund its forecasted operating expenses and capital expenditure requirements into 2026. If the timing of the Company's clinical assumptions are delayed or if there are other forecasted assumption changes that negatively impact its operating plan, the Company would reduce expenditures in order to further extend cash resources.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has not yet commercialized any products and does not expect to generate revenue from the commercial sale of any products for several years, if at all. The Company expects that its research and development and general and administrative expenses will continue to increase and, as a result, that it will need additional capital to fund its future operating and capital requirements. Unless and until the Company can generate substantial revenue, management continuously evaluates different strategies to obtain the required funding for future operations. These strategies include seeking additional funding through a combination of public or private equity offerings, debt or royalty financings, collaborations and licensing arrangements, strategic partnerships with pharmaceutical and/or larger biotechnology companies, or other sources. The incurrence of indebtedness would result in increased fixed payment obligations and the Company may be required to agree to certain restrictive covenants, such as limitations on its ability to incur additional debt, limitations on its ability to acquire, sell or license intellectual property rights, minimum required cash balances and other operating restrictions that could adversely impact the Company's ability to conduct its business. Any additional fundraising efforts may divert the Company's management from their day-to-day activities, which may adversely affect its ability to develop and commercialize its product candidates.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;There can be no assurance that the Company will be able to raise sufficient additional capital on acceptable terms, if at all. If such additional financing is not available on satisfactory terms, or is not available in sufficient amounts, or if the Company does not have sufficient authorized shares, the Company may be required to delay,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;limit, or eliminate the development of business opportunities and its ability to achieve its business objectives, its competitiveness, and its business, financial condition, and results of operations will be materially adversely affected. The Company could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable and it may be required to relinquish rights to some of its technologies or product candidates or otherwise agree to terms unfavorable to it, any of which may have a material adverse effect on the Company's business, operating results and prospects. In addition, geopolitical tensions, volatility of capital markets, and other adverse macroeconomic events, including those due to inflationary pressures, rising interest rates, bank instability and the ability of the U.S. government to manage federal debt limits as well as the potential impact of other health crises on the global financial markets may reduce the Company's ability to access capital, which could negatively affect its liquidity and ability to continue as a going concern.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;If the Company is unable to obtain sufficient funding when needed and/or on acceptable terms, the Company may be required to significantly curtail, delay or discontinue one or more of its research and development programs, the manufacture of clinical and commercial supplies, product portfolio expansion, pre commercialization efforts and/or commercial operations, which could adversely affect its business prospects, or the Company may be unable to continue operations.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_48b38935-2f3d-476d-bfbe-e541f7df1b87">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The consolidated financial statements include the accounts of Larimar and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated. The accompanying consolidated financial statements have been prepared in conformity with GAAP.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:LiabilityReserveEstimatePolicy
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_f3261750-8be3-4ee8-91b7-c077f28eed06">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Liquidity and Capital Resources&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s consolidated financial statements have been presented on the basis that it will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Since its inception, the Company has incurred significant recurring operating losses and negative cash flows from operations. The Company has incurred net losses of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for the years ended December 31, 2023, and 2022, respectively. In addition, as of December 31, 2023, the Company had an accumulated deficit of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;188.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Company expects to continue to generate operating losses for the foreseeable future. As of December 31, 2023, the Company had approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;86.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of cash, cash equivalents and marketable securities available for use to fund its operations and capital requirements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has funded its operations to date primarily with proceeds from sales of common stock and proceeds from the sale of prefunded warrants for the purchase of common stock, the acquisition in 2020 of cash, cash equivalents and marketable securities upon the merger with Zafgen, Inc. ("Zafgen") and, prior to the 2020 merger with Zafgen, capital contributions from Chondrial Holdings, LLC.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In February 2024, the Company sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,736,842&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of its common stock in an underwritten public offering at a price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.74&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share and received net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;161.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In accordance with Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2014-15, "Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern", the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. As of the issuance date of these consolidated financial statements, the Company expects its cash, cash equivalents and marketable securities, including its net proceeds from the February 2024 public offering, will be sufficient to fund its forecasted operating expenses and capital expenditure requirements into 2026. If the timing of the Company's clinical assumptions are delayed or if there are other forecasted assumption changes that negatively impact its operating plan, the Company would reduce expenditures in order to further extend cash resources.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has not yet commercialized any products and does not expect to generate revenue from the commercial sale of any products for several years, if at all. The Company expects that its research and development and general and administrative expenses will continue to increase and, as a result, that it will need additional capital to fund its future operating and capital requirements. Unless and until the Company can generate substantial revenue, management continuously evaluates different strategies to obtain the required funding for future operations. These strategies include seeking additional funding through a combination of public or private equity offerings, debt or royalty financings, collaborations and licensing arrangements, strategic partnerships with pharmaceutical and/or larger biotechnology companies, or other sources. The incurrence of indebtedness would result in increased fixed payment obligations and the Company may be required to agree to certain restrictive covenants, such as limitations on its ability to incur additional debt, limitations on its ability to acquire, sell or license intellectual property rights, minimum required cash balances and other operating restrictions that could adversely impact the Company's ability to conduct its business. Any additional fundraising efforts may divert the Company's management from their day-to-day activities, which may adversely affect its ability to develop and commercialize its product candidates.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;There can be no assurance that the Company will be able to raise sufficient additional capital on acceptable terms, if at all. If such additional financing is not available on satisfactory terms, or is not available in sufficient amounts, or if the Company does not have sufficient authorized shares, the Company may be required to delay,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;limit, or eliminate the development of business opportunities and its ability to achieve its business objectives, its competitiveness, and its business, financial condition, and results of operations will be materially adversely affected. The Company could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable and it may be required to relinquish rights to some of its technologies or product candidates or otherwise agree to terms unfavorable to it, any of which may have a material adverse effect on the Company's business, operating results and prospects. In addition, geopolitical tensions, volatility of capital markets, and other adverse macroeconomic events, including those due to inflationary pressures, rising interest rates, bank instability and the ability of the U.S. government to manage federal debt limits as well as the potential impact of other health crises on the global financial markets may reduce the Company's ability to access capital, which could negatively affect its liquidity and ability to continue as a going concern.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;If the Company is unable to obtain sufficient funding when needed and/or on acceptable terms, the Company may be required to significantly curtail, delay or discontinue one or more of its research and development programs, the manufacture of clinical and commercial supplies, product portfolio expansion, pre commercialization efforts and/or commercial operations, which could adversely affect its business prospects, or the Company may be unable to continue operations.&lt;/span&gt;&lt;/p&gt;</us-gaap:LiabilityReserveEstimatePolicy>
    <us-gaap:NetIncomeLoss
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="-5"
      id="F_38bce3ab-557b-44aa-8cc7-b263438ddf8e"
      unitRef="U_USD">-36900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="-5"
      id="F_dd03d9a8-6a4e-4c83-a787-0387c160548d"
      unitRef="U_USD">-35400000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-5"
      id="F_31c6dc8a-94d7-4e88-a1fa-ae5df80c870d"
      unitRef="U_USD">-188600000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-5"
      id="F_c434db06-28cb-4c03-bf4c-db1c2b57fb83"
      unitRef="U_USD">86800000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_3e015593-165f-45fc-9cb4-52b758b04a99"
      decimals="INF"
      id="F_6baff0d9-449a-4e12-a0c2-acbe00269041"
      unitRef="U_shares">19736842</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_530aece5-55e1-42ca-83b2-fdd8cc766346"
      decimals="2"
      id="F_e496e3b9-4d03-4209-987f-3feaefc5f392"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.74</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_3e015593-165f-45fc-9cb4-52b758b04a99"
      decimals="-5"
      id="F_aed7f46d-3a49-426c-907a-38ab6394698d"
      unitRef="U_USD">161600000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_b6a41464-d5f3-4dff-a896-eb06dd677789">&lt;div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;2.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Summary of Significant Accounting Policies &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. This process involves reviewing open contracts and purchase orders, communicating with our personnel and outside vendors to identify services that have been performed on our behalf and estimating the level of service performed and the associated costs incurred for the services when we have not yet been invoiced or otherwise notified of the actual costs. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expense, the recording as prepaid expense of payments made in advance of the actual provision of goods or services, valuation of stock-based awards and valuation of leases. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Concentrations of Credit Risk and Significant Suppliers&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and marketable securities. Cash balances may be held in financial institutions which may exceed federally insured limits. The Company has not experienced realized losses related to its cash, cash equivalents or marketable securities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is highly dependent on third-party manufacturers to supply products for research and development activities in its programs, to scale and optimize their manufacturing processes and, ultimately, to provide commercial supply. The Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for drug substance and formulated drugs related to these programs. The drug substance which is in frozen liquid form for nomlabofusp is currently manufactured for the Company by a third-party manufacturer, and the frozen liquid form of drug product is made at another manufacturer. The Company is undertaking a program with a third manufacturer to begin to produce a lyophilized version of the drug product from the same drug substance, that, once available, the Company intends to use in certain of its future planned clinical trials. The Company&#x2019;s research and development programs could be adversely affected by a significant interruption in these manufacturing services or in the supply of drug substance and formulated drugs.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company considers all highly liquid investments with maturities of three months or less at the date of purchase to be cash equivalents. Cash equivalents consisted of money market funds as of December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Marketable securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Marketable securities consist of debt investments with original maturities greater than ninety days. The Company classifies its marketable securities as available-for-sale. Accordingly, these investments are recorded at fair value, which is based on quoted market prices. When the fair value is below the amortized cost the amount of the expected credit loss is estimated. The credit-related impairment amount, if any, would be recognized in net income; the remaining impairment amount and unrealized gains are reported as a component of accumulated other comprehensive income in stockholders&#x2019; equity. Credit losses, if any, are recognized through the use of an allowance for credit losses account and subsequent improvements in expected credit losses are recognized as a reversal of the allowance account. If the Company has the intent to sell the security or if it is more likely than not that the Company would be required to sell the security prior to recovery of its amortized cost basis, the allowance for credit loss would be written off and the excess of the amortized cost basis of the asset over its fair value is recorded in net income.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:11pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_79196bf3-be5b-4806-9ec5-5fed79d1cfbe;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;five&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; or&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;seven-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; estimated useful life for equipment, furniture and fixtures and office equipment. Leasehold improvements are amortized over the shorter of the asset life or the term of the lease agreement. Expenditures for repairs and maintenance of assets are charged to expense as incurred. Upon retirement or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain or loss is included in loss from operations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Long-lived assets consist of property and equipment, net&#xb8; and right-of-use assets. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. Any impairment loss, if indicated, is measured as the amount by which the carrying amount of the asset exceeds the estimated fair value of the asset.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions. The Company&#x2019;s focus is on the research, development and commercialization of novel therapeutics for the treatment of rare diseases.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Research and Development Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Costs associated with internal research and development and external research and development services, including drug development, clinical studies and non-clinical studies, are expensed as incurred. Research and development expenses include costs for salaries, employee benefits, subcontractors, facility-related expenses, depreciation, stock-based compensation, third-party license fees, laboratory supplies, and external costs of outside vendors engaged to conduct discovery, non-clinical and clinical development activities and clinical trials as well as to manufacture clinical trial materials, and other costs. The Company recognizes external research and development costs based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its key service providers.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such prepaid expenses are recognized as an expense when the goods have been delivered or the related services have been performed, or when it is no longer expected that the goods will be delivered, or the services rendered.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Upfront payments, milestone payments and annual maintenance fees under license agreements are currently expensed in the period in which they are incurred.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Patent Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company measures all stock-based awards granted to employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model. Compensation expense of those awards is recognized over the requisite service period, which is the vesting period of the respective award. Typically, the Company issues awards with only service-based vesting conditions and records the expense for these awards using the straight-line method. The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#x2019;s payroll costs are classified or in which the award recipient&#x2019;s service payments are classified.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prior to May 28, 2020, the Company had been a private company and lacked company-specific historical and implied volatility information for its common stock. Prior to January 1, 2023, the Company estimated its expected common stock price volatility solely based on the historical volatility of publicly traded peer companies. Beginning on January 1, 2023, based on the availability of sufficient historical trading data of the Company's own common stock on the Nasdaq Global Market to calculate accurately its volatility, the Company began blending its volatility starting from June 2020 (following its merger with Zafgen in 2020) to the date of each stock-based award, and weighing the volatility of its peer group for the amount of time from May 31, 2020 backwards so that the blended volatility equals the expected term of the related stock-based award. The expected term of the Company&#x2019;s stock options has been determined utilizing the &#x201c;simplified&#x201d; method for awards that qualify as &#x201c;plain-vanilla&#x201d; options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield considers the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#x2019;s tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Comprehensive Gain (Loss)&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Comprehensive gain (loss) includes net loss as well as other changes in stockholders&#x2019; equity that result from transactions and economic events other than those with stockholders. For the years ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company&#x2019;s only element of other comprehensive loss was unrealized loss on marketable securities.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Prior to August 11, 2023, basic shares outstanding includes the weighted average effect of the Company&#x2019;s prefunded warrants issued in June 2020, the exercise of which requires little or no consideration for the delivery of shares of common stock. These prefunded warrants were exercised on August 11, 2023 and the Company received cash proceeds of less than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. Accordingly, the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;628,403&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares were issued upon the exercise of these warrants and are included in issued and outstanding common stock.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares, including potentially dilutive common stock equivalents assuming the dilutive effect of outstanding stock options, outstanding restricted stock units, and unvested restricted common shares, as determined using the treasury stock method. For periods in which the Company has reported net losses (all periods since inception), diluted net loss per common share attributable to common stockholders is the same as basic net loss per common share attributable to common stockholders, since dilutive common stock equivalents are not assumed to have been issued if their effect is antidilutive.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company excluded &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,888,502&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,071,528&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; options to purchase common stock, outstanding as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 respectively, from the computation of diluted net loss per share for the twelve months ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively, because they had an anti-dilutive impact due to the net loss incurred for the periods.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recently Issued and Adopted Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;From time to time, new accounting guidance is issued by the FASB or other standard setting bodies that is adopted by us as of the effective date or, in some cases where early adoption is permitted, in advance of the effective date. We have assessed the recently issued guidance that is not yet effective and believe the new guidance will not have a material impact on the consolidated results of operations, cash flows or financial position.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_aa283011-7f49-4ee3-bbc0-c285b7082a8e">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. This process involves reviewing open contracts and purchase orders, communicating with our personnel and outside vendors to identify services that have been performed on our behalf and estimating the level of service performed and the associated costs incurred for the services when we have not yet been invoiced or otherwise notified of the actual costs. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expense, the recording as prepaid expense of payments made in advance of the actual provision of goods or services, valuation of stock-based awards and valuation of leases. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_74409b8f-c929-4a68-8b03-12a423787164">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Concentrations of Credit Risk and Significant Suppliers&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and marketable securities. Cash balances may be held in financial institutions which may exceed federally insured limits. The Company has not experienced realized losses related to its cash, cash equivalents or marketable securities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is highly dependent on third-party manufacturers to supply products for research and development activities in its programs, to scale and optimize their manufacturing processes and, ultimately, to provide commercial supply. The Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for drug substance and formulated drugs related to these programs. The drug substance which is in frozen liquid form for nomlabofusp is currently manufactured for the Company by a third-party manufacturer, and the frozen liquid form of drug product is made at another manufacturer. The Company is undertaking a program with a third manufacturer to begin to produce a lyophilized version of the drug product from the same drug substance, that, once available, the Company intends to use in certain of its future planned clinical trials. The Company&#x2019;s research and development programs could be adversely affected by a significant interruption in these manufacturing services or in the supply of drug substance and formulated drugs.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_1079a47e-b891-4960-96aa-735d43f27e2c">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company considers all highly liquid investments with maturities of three months or less at the date of purchase to be cash equivalents. Cash equivalents consisted of money market funds as of December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_4c1cce6c-7107-4a88-a8d9-c13d03c02ea4">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Marketable securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Marketable securities consist of debt investments with original maturities greater than ninety days. The Company classifies its marketable securities as available-for-sale. Accordingly, these investments are recorded at fair value, which is based on quoted market prices. When the fair value is below the amortized cost the amount of the expected credit loss is estimated. The credit-related impairment amount, if any, would be recognized in net income; the remaining impairment amount and unrealized gains are reported as a component of accumulated other comprehensive income in stockholders&#x2019; equity. Credit losses, if any, are recognized through the use of an allowance for credit losses account and subsequent improvements in expected credit losses are recognized as a reversal of the allowance account. If the Company has the intent to sell the security or if it is more likely than not that the Company would be required to sell the security prior to recovery of its amortized cost basis, the allowance for credit loss would be written off and the excess of the amortized cost basis of the asset over its fair value is recorded in net income.&lt;/span&gt;&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_6d53943c-13f0-48ff-a90d-8bd2dec39051">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_79196bf3-be5b-4806-9ec5-5fed79d1cfbe;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;five&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; or&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;seven-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; estimated useful life for equipment, furniture and fixtures and office equipment. Leasehold improvements are amortized over the shorter of the asset life or the term of the lease agreement. Expenditures for repairs and maintenance of assets are charged to expense as incurred. Upon retirement or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain or loss is included in loss from operations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_faa2d74d-3a2d-47fb-a723-778c940b635d"
      id="F_0e90f192-a118-4d6a-a6c7-8084f45f8c70">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_e9f289ab-6a4d-4ea9-a17a-e58d14b7f551">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Long-lived assets consist of property and equipment, net&#xb8; and right-of-use assets. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. Any impairment loss, if indicated, is measured as the amount by which the carrying amount of the asset exceeds the estimated fair value of the asset.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_87793d10-8884-4e70-8fac-c2532b3943d8">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions. The Company&#x2019;s focus is on the research, development and commercialization of novel therapeutics for the treatment of rare diseases.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_875981ff-a58a-4e90-9ebb-c2e21152eee8">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Research and Development Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Costs associated with internal research and development and external research and development services, including drug development, clinical studies and non-clinical studies, are expensed as incurred. Research and development expenses include costs for salaries, employee benefits, subcontractors, facility-related expenses, depreciation, stock-based compensation, third-party license fees, laboratory supplies, and external costs of outside vendors engaged to conduct discovery, non-clinical and clinical development activities and clinical trials as well as to manufacture clinical trial materials, and other costs. The Company recognizes external research and development costs based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its key service providers.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such prepaid expenses are recognized as an expense when the goods have been delivered or the related services have been performed, or when it is no longer expected that the goods will be delivered, or the services rendered.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Upfront payments, milestone payments and annual maintenance fees under license agreements are currently expensed in the period in which they are incurred.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_8c4cb1cd-7cf3-417b-b92f-e1e027404b2e">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Patent Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.&lt;/span&gt;&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_e4853bca-806c-4cdf-9338-270f611e3749">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company measures all stock-based awards granted to employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model. Compensation expense of those awards is recognized over the requisite service period, which is the vesting period of the respective award. Typically, the Company issues awards with only service-based vesting conditions and records the expense for these awards using the straight-line method. The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#x2019;s payroll costs are classified or in which the award recipient&#x2019;s service payments are classified.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prior to May 28, 2020, the Company had been a private company and lacked company-specific historical and implied volatility information for its common stock. Prior to January 1, 2023, the Company estimated its expected common stock price volatility solely based on the historical volatility of publicly traded peer companies. Beginning on January 1, 2023, based on the availability of sufficient historical trading data of the Company's own common stock on the Nasdaq Global Market to calculate accurately its volatility, the Company began blending its volatility starting from June 2020 (following its merger with Zafgen in 2020) to the date of each stock-based award, and weighing the volatility of its peer group for the amount of time from May 31, 2020 backwards so that the blended volatility equals the expected term of the related stock-based award. The expected term of the Company&#x2019;s stock options has been determined utilizing the &#x201c;simplified&#x201d; method for awards that qualify as &#x201c;plain-vanilla&#x201d; options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield considers the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_fa71842c-da21-45ef-9af4-70cca577afb5">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#x2019;s tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <lrmr:LikelihoodPercentageMinimum
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="2"
      id="F_2a134382-473b-4518-af46-067f55096911"
      unitRef="U_pure">0.50</lrmr:LikelihoodPercentageMinimum>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_affe2350-e55d-4c2a-b63c-8fb692320df6">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Comprehensive Gain (Loss)&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Comprehensive gain (loss) includes net loss as well as other changes in stockholders&#x2019; equity that result from transactions and economic events other than those with stockholders. For the years ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company&#x2019;s only element of other comprehensive loss was unrealized loss on marketable securities.&lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_75cbd8e2-565d-4fe8-a1dd-addd219308a0">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Prior to August 11, 2023, basic shares outstanding includes the weighted average effect of the Company&#x2019;s prefunded warrants issued in June 2020, the exercise of which requires little or no consideration for the delivery of shares of common stock. These prefunded warrants were exercised on August 11, 2023 and the Company received cash proceeds of less than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. Accordingly, the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;628,403&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares were issued upon the exercise of these warrants and are included in issued and outstanding common stock.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares, including potentially dilutive common stock equivalents assuming the dilutive effect of outstanding stock options, outstanding restricted stock units, and unvested restricted common shares, as determined using the treasury stock method. For periods in which the Company has reported net losses (all periods since inception), diluted net loss per common share attributable to common stockholders is the same as basic net loss per common share attributable to common stockholders, since dilutive common stock equivalents are not assumed to have been issued if their effect is antidilutive.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company excluded &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,888,502&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,071,528&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; options to purchase common stock, outstanding as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 respectively, from the computation of diluted net loss per share for the twelve months ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively, because they had an anti-dilutive impact due to the net loss incurred for the periods.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_2a37f99b-d107-4e6e-89a3-1dc033f729cc"
      decimals="-5"
      id="F_0d8e9634-c02a-4379-bdb2-d1188ebfec6a"
      unitRef="U_USD">100000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_cf8be5df-f0b1-4821-a7e8-f9b1795798f9"
      decimals="INF"
      id="F_ede818e7-2b40-4dcc-be53-36f8ecf595c3"
      unitRef="U_shares">628403</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_cf8be5df-f0b1-4821-a7e8-f9b1795798f9"
      decimals="INF"
      id="F_1a72dc75-2c0f-4dc2-97c4-319a1f79b0d8"
      unitRef="U_shares">628403</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_9e62e2a7-281f-4efe-9952-2af3980d814c"
      decimals="INF"
      id="F_fca4116a-e6d7-44bd-961b-1e0587d04615"
      unitRef="U_shares">4888502</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_393eb466-a24d-43ed-9e90-d9f5eb33fa0b"
      decimals="INF"
      id="F_c88a8d00-f9e6-4bb4-bc66-c2e3fe04654b"
      unitRef="U_shares">3071528</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_c2f6075a-d1c8-41d8-95a9-d3230a21448a">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recently Issued and Adopted Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;From time to time, new accounting guidance is issued by the FASB or other standard setting bodies that is adopted by us as of the effective date or, in some cases where early adoption is permitted, in advance of the effective date. We have assessed the recently issued guidance that is not yet effective and believe the new guidance will not have a material impact on the consolidated results of operations, cash flows or financial position.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_41dcfb5b-84f9-4cfd-b0bb-8798c6974563">&lt;div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;3.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair Value Measurements and Cash Equivalents/Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2023 and December 31, 2022 are measured in accordance with the standards of ASC 820, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, which establishes a three-level valuation hierarchy for measuring fair value and expands financial statement disclosures about fair value measurements. The valuation hierarchy is based on upon the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:11.54%;"&gt;&lt;/td&gt;
      &lt;td style="width:88.46%;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level &#x2013; 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:1pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:1pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level &#x2013; 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level &#x2013; 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Inputs to the valuation methodology are unobservable and significant to the fair value measurement.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s financial instruments consist primarily of cash and cash equivalents, marketable securities, accounts payable and accrued liabilities. For accounts payable and accrued liabilities, the carrying amounts of these financial instruments as of December 31, 2023 and 2022 were considered representative of their fair values due to their short term to maturity.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following tables summarize the Company&#x2019;s cash equivalents and marketable securities as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Quoted&lt;br/&gt;Prices in&lt;br/&gt;Active&lt;br/&gt;Markets &lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs &lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs &lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds invested in government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury Bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,988&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,988&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;60,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42,707&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;84,742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42,035&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42,707&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds invested in government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;91,603&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;91,603&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;91,603&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;91,603&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;113,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;91,603&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accrued interest receivable related to the Company&#x2019;s investments was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022, respectively, and is included in prepaid expenses and other current assets on the consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company classifies its money market funds and U.S. treasury bills, which are valued based on quoted market prices in active markets with no valuation adjustment, as Level 1 assets within the fair value hierarchy.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company classifies its investments in U.S. government and agency securities, corporate commercial paper, and corporate bonds, if any, as Level 2 assets within the fair value hierarchy. The fair values of these investments are estimated by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2022, the unrealized loss for available-for-sale investments were non-credit related, and the Company does not intend to sell the investments that were in an unrealized loss position, nor will it be required to sell those investments before recovery of their amortized cost basis, which may be maturity. As of December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; allowances for credit losses for the Company&#x2019;s investments were recorded. During the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;twelve months ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t recognize any impairment losses related to investments.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, the Company's cash equivalents and marketable securities consisted of a U.S. government money market fund, U.S. Treasury Bills, U.S. government and agency securities and corporate bonds, all held in our name in a separate custody account with U.S. Bank. The U.S. government money market fund has same-day liquidity access and the U.S. government and agency securities all have maturities of 90 days or less.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following tables summarize the Company&#x2019;s marketable securities as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized &lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury Bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Government securities (due within 1 year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,653&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper (due within 1 year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,988&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;60,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Government securities (due within 1 year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;91,634&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;91,603&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;91,634&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;91,603&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_75168287-982c-422a-85fc-4cb77832509e">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following tables summarize the Company&#x2019;s cash equivalents and marketable securities as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Quoted&lt;br/&gt;Prices in&lt;br/&gt;Active&lt;br/&gt;Markets &lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs &lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs &lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds invested in government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury Bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,988&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,988&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;60,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42,707&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;84,742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42,035&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42,707&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds invested in government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;91,603&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;91,603&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;91,603&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;91,603&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;113,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22,184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;91,603&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_b696efd6-314c-4861-aaea-8e43ed271ae6"
      decimals="-3"
      id="F_da05cfd5-9611-4e81-ad79-3ba10527b26a"
      unitRef="U_USD">24701000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_80781f96-9385-4dd5-8eb7-f026c92fd2c7"
      decimals="-3"
      id="F_37d2b70a-60de-402f-8d46-0d46cce05968"
      unitRef="U_USD">24701000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_3ff4e4f3-12e8-430f-b448-0dbf42c2e9c5"
      unitRef="U_USD">24701000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_a9f53337-4c5c-4958-98a5-a81a54dd3435"
      decimals="-3"
      id="F_d7bccad0-6ccd-4762-94cc-a2b6cb412bfd"
      unitRef="U_USD">24701000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_e619f4e9-77cd-449f-8ab2-c55b57519206"
      decimals="-3"
      id="F_08439506-756c-4fdd-bf7b-b46dd6ef1ada"
      unitRef="U_USD">17334000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_f0f9091f-cf20-4767-8991-bfab4c73cc6d"
      decimals="-3"
      id="F_b95f1cf4-ff2f-4dd7-89cd-40162ba6fb92"
      unitRef="U_USD">17334000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_47c297aa-bca8-4b02-b5a1-b4f42c32fbc2"
      decimals="-3"
      id="F_47ec9e13-74b1-49fc-a944-dd93a0cf0322"
      unitRef="U_USD">35719000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_22aa2b7d-3358-4d02-ae96-34174231f4a5"
      decimals="-3"
      id="F_d70b75e5-f6a7-481f-a6fc-8b18321365bd"
      unitRef="U_USD">35719000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_112cf294-81d1-4c4c-ba37-b763be85def2"
      decimals="-3"
      id="F_cbc61258-54ea-4f90-b434-23af7ec7911a"
      unitRef="U_USD">6988000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_846f3ecc-8d1c-4bc9-aa46-2d08b1bb1e55"
      decimals="-3"
      id="F_3857454f-4628-4995-9e46-16c01b63d7c9"
      unitRef="U_USD">6988000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_ba107f7e-e247-457b-89f1-ab7591aadf0a"
      unitRef="U_USD">60041000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_a9f53337-4c5c-4958-98a5-a81a54dd3435"
      decimals="-3"
      id="F_ceff5667-31b2-456d-9a11-46090d6e9c4d"
      unitRef="U_USD">17334000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_a4f1b737-b155-4ae3-9c2f-2c7f4437ce11"
      decimals="-3"
      id="F_0abc302c-23c3-43c7-8a2a-62ebe9f22c73"
      unitRef="U_USD">42707000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_584ac7db-b800-43d9-a1e1-db5a2d91950e"
      unitRef="U_USD">84742000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a9f53337-4c5c-4958-98a5-a81a54dd3435"
      decimals="-3"
      id="F_2a7833c7-fc00-49d7-9f5e-287ffc501747"
      unitRef="U_USD">42035000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a4f1b737-b155-4ae3-9c2f-2c7f4437ce11"
      decimals="-3"
      id="F_2efd4645-616a-435d-8803-790467f9434c"
      unitRef="U_USD">42707000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_b6f1f981-2a41-46ca-88f7-657876f052f8"
      decimals="-3"
      id="F_acd03ac6-2dee-4701-b876-8382fc5bd506"
      unitRef="U_USD">22184000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_3b388c97-79fa-4717-81b4-abd04c453ac4"
      decimals="-3"
      id="F_88465c87-4e61-4e8a-9413-4b42da093791"
      unitRef="U_USD">22184000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_78c39102-d351-4b19-ab9a-6d7451eec5da"
      unitRef="U_USD">22184000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_d4d4aee3-9c3b-49c7-bff2-63ffe90e6e2e"
      decimals="-3"
      id="F_62b11e40-2b4b-42e8-8590-083c8e506ea2"
      unitRef="U_USD">22184000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_59823e91-6700-4233-b1ac-e431259ec4c1"
      decimals="-3"
      id="F_c2f2fd77-1047-4955-a693-748be4af8cfc"
      unitRef="U_USD">91603000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_995af330-bf27-4e38-9645-1ac883fd043e"
      decimals="-3"
      id="F_91e56672-b297-4a69-bbfb-c8efc7403b26"
      unitRef="U_USD">91603000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_62c6ffb8-4fe1-49c5-b62a-359886c34bd8"
      unitRef="U_USD">91603000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_ce01a5a3-0bd6-4643-a592-16b822a79946"
      decimals="-3"
      id="F_22cf74c5-2959-40ed-abd8-4b733d848f80"
      unitRef="U_USD">91603000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_a4768bea-78c5-43ad-930c-8b18b7fb4417"
      unitRef="U_USD">113787000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d4d4aee3-9c3b-49c7-bff2-63ffe90e6e2e"
      decimals="-3"
      id="F_882e19b5-a606-4843-9828-c206d5ff95a6"
      unitRef="U_USD">22184000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_ce01a5a3-0bd6-4643-a592-16b822a79946"
      decimals="-3"
      id="F_e49a62b2-6145-4340-b630-4db2e9078c22"
      unitRef="U_USD">91603000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InterestReceivable
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-5"
      id="F_aa01df17-67b5-4e9b-afbb-ea1a9be8045f"
      unitRef="U_USD">300000</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-5"
      id="F_9de88772-8aa8-462c-b084-9445c1433db9"
      unitRef="U_USD">100000</us-gaap:InterestReceivable>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="INF"
      id="F_038f9d0b-a66a-49e8-97a8-2d5202ed75fe"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="INF"
      id="F_629330aa-4c1e-4a3f-840a-674b2f1dc7d2"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="INF"
      id="F_df44f736-51d6-4836-a9e4-f1b4a1eb3e49"
      unitRef="U_USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="INF"
      id="F_a96a60e8-1276-4221-8383-e16674976f12"
      unitRef="U_USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_a92628a0-f6f8-41b6-94db-3bd2490e964a">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following tables summarize the Company&#x2019;s marketable securities as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized &lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury Bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Government securities (due within 1 year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,653&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial paper (due within 1 year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,988&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;60,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Government securities (due within 1 year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;91,634&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;91,603&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;91,634&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;91,603&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_e619f4e9-77cd-449f-8ab2-c55b57519206"
      decimals="-3"
      id="F_d963915b-b433-4c7a-968d-d3738a689244"
      unitRef="U_USD">17330000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_e619f4e9-77cd-449f-8ab2-c55b57519206"
      decimals="-3"
      id="F_827a6a67-f4de-446f-b46d-ae5718c88f2a"
      unitRef="U_USD">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_e619f4e9-77cd-449f-8ab2-c55b57519206"
      decimals="-3"
      id="F_bc424484-ed3f-4109-b93c-686c34b0ea5d"
      unitRef="U_USD">17334000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_47c297aa-bca8-4b02-b5a1-b4f42c32fbc2"
      decimals="-3"
      id="F_b096e49b-f9d6-484a-9dd6-f0736d6fbb2f"
      unitRef="U_USD">35653000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_47c297aa-bca8-4b02-b5a1-b4f42c32fbc2"
      decimals="-3"
      id="F_05aaee7d-05eb-46e2-bd12-f6e94d4f6619"
      unitRef="U_USD">66000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_47c297aa-bca8-4b02-b5a1-b4f42c32fbc2"
      decimals="-3"
      id="F_9e323b63-4d7a-493a-b467-0be2a9228e82"
      unitRef="U_USD">35719000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_f1c3acf0-ab7f-4fb7-b405-7bbdf99bfc05"
      decimals="-3"
      id="F_fd25d45d-e48d-483b-ad70-4233ae00ed39"
      unitRef="U_USD">6977000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_f1c3acf0-ab7f-4fb7-b405-7bbdf99bfc05"
      decimals="-3"
      id="F_225018bc-7fda-4470-91ba-b33c3d64de23"
      unitRef="U_USD">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_f1c3acf0-ab7f-4fb7-b405-7bbdf99bfc05"
      decimals="-3"
      id="F_d813c27a-dc7c-4c9c-b28c-83af4c108aab"
      unitRef="U_USD">6988000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_6b39e1d4-afbb-4816-bb40-cdb58eeb2c85"
      unitRef="U_USD">59960000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_43519dc9-7b56-42f8-b038-7d8fdabcb72c"
      unitRef="U_USD">81000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_09bc7d2a-4c5f-4882-82d1-b9f083766aeb"
      unitRef="U_USD">60041000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_59823e91-6700-4233-b1ac-e431259ec4c1"
      decimals="-3"
      id="F_73e8e9fb-a9cd-48db-826f-f7f7f6aa345e"
      unitRef="U_USD">91634000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_59823e91-6700-4233-b1ac-e431259ec4c1"
      decimals="-3"
      id="F_4e40e3e9-7865-48d4-bf29-54070ee9c6eb"
      unitRef="U_USD">12000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_59823e91-6700-4233-b1ac-e431259ec4c1"
      decimals="-3"
      id="F_b2895f4c-cedd-4ffe-aaec-411b8db48d2a"
      unitRef="U_USD">43000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_59823e91-6700-4233-b1ac-e431259ec4c1"
      decimals="-3"
      id="F_a22b4f68-b577-492c-83c4-30c6351cceaf"
      unitRef="U_USD">91603000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_5e2b72ca-8ced-424d-8993-f09f0c732941"
      unitRef="U_USD">91634000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_f14155d3-850c-4d65-b278-553e5f4c99e6"
      unitRef="U_USD">12000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_373524ed-99ac-4ad7-be47-0b13f9916965"
      unitRef="U_USD">43000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_65db60b8-6868-46f6-a517-aae6a5f598c1"
      unitRef="U_USD">91603000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <lrmr:PrepaidExpensesAndOtherCurrentAssetsTextBlock
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_36d3d127-05a7-4df5-a410-112877f326a2">&lt;div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;4.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prepaid expenses and other current assets consisted of the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,994&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,394&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;679&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other prepaid expenses and other assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;709&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total prepaid expenses and other assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,311&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</lrmr:PrepaidExpensesAndOtherCurrentAssetsTextBlock>
    <lrmr:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_2f93bd2f-2f07-46eb-a503-2eb8e633ca75">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prepaid expenses and other current assets consisted of the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,994&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,394&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;679&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other prepaid expenses and other assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;709&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total prepaid expenses and other assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,311&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</lrmr:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock>
    <lrmr:PrepaidResearchAndDevelopmentExpenses
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_bd889bed-5593-4ccd-87f6-81b3d070a8dd"
      unitRef="U_USD">1994000</lrmr:PrepaidResearchAndDevelopmentExpenses>
    <lrmr:PrepaidResearchAndDevelopmentExpenses
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_ed73c1c0-47e9-4bbc-a57b-50f5fd0c589e"
      unitRef="U_USD">1394000</lrmr:PrepaidResearchAndDevelopmentExpenses>
    <us-gaap:PrepaidInsurance
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_7a212893-2020-413e-845a-cdf7ccd60ea5"
      unitRef="U_USD">682000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_85a1e95c-69bf-42c4-8f12-89518e0037f5"
      unitRef="U_USD">679000</us-gaap:PrepaidInsurance>
    <lrmr:OtherPrepaidExpenseAndOtherCurrentAssets
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_98d6b844-490c-4ed0-ab0f-ba4d6908e490"
      unitRef="U_USD">709000</lrmr:OtherPrepaidExpenseAndOtherCurrentAssets>
    <lrmr:OtherPrepaidExpenseAndOtherCurrentAssets
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_6d70a6c2-3489-4bd3-821f-3cb9c5a5285c"
      unitRef="U_USD">238000</lrmr:OtherPrepaidExpenseAndOtherCurrentAssets>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_fa7f45bf-f08e-4a79-b049-f3b1744d4a26"
      unitRef="U_USD">3385000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_e6c11938-9862-4a3a-9db9-cc13a3e596dc"
      unitRef="U_USD">2311000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_95e31d73-1d7f-4231-b533-f5831e6ba3a3">&lt;div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;5.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fixed Assets&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fixed assets, net consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.477%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.775%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;555&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_1743f7c9-4f07-468e-8ed1-5de01b765813;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;lease term&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;Total property, plant and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,745&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;914&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;Property, plant and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Depreciation expense was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022, respectively. In addition, for the years ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, there was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of depreciation related to sublet assets recorded as other expense.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_36600fc8-b485-4400-9cee-5d2d273ffca4">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fixed assets, net consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.477%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.775%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;555&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_1743f7c9-4f07-468e-8ed1-5de01b765813;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;lease term&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;Total property, plant and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,745&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;914&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;Property, plant and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_4a47b017-2508-45fe-a4d9-e2f06dcde4b3"
      id="F_3f2b881d-39b4-4757-9c54-41e8a1a4a4f1">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_4a47b017-2508-45fe-a4d9-e2f06dcde4b3"
      decimals="-3"
      id="F_27f77186-6d9d-491c-ae00-b30aa9e1bb35"
      unitRef="U_USD">117000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_a2ca56a1-3b79-4526-a05b-9dc40fc95833"
      decimals="-3"
      id="F_e472ad16-4bb2-4273-98ae-91775106ebee"
      unitRef="U_USD">66000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_026fc58b-40b7-41a5-a024-519b8180c981"
      id="F_a69265d9-5c33-49e9-958f-fa03ae2c9b63">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_026fc58b-40b7-41a5-a024-519b8180c981"
      decimals="-3"
      id="F_b43a8c0e-7adb-466a-8d65-7ca02146fb31"
      unitRef="U_USD">1192000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_32800e6f-ee7b-44d6-a810-966628d6e119"
      decimals="-3"
      id="F_bfc3e6ef-646f-4790-b320-13f25af51c25"
      unitRef="U_USD">1192000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_4b113e78-3130-4612-8c3b-467b2bc9cf25"
      id="F_fea2306c-389a-475f-8394-2373bb2ba54c">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_4b113e78-3130-4612-8c3b-467b2bc9cf25"
      decimals="-3"
      id="F_7c51e21f-e27f-47bc-9490-a69ee68a19c5"
      unitRef="U_USD">555000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_4df7afcb-4d0e-4162-9cf0-4e8b3712bbec"
      decimals="-3"
      id="F_7462da63-e8b8-466d-9ee4-753ca09d8793"
      unitRef="U_USD">456000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_786b0fcb-721f-4485-992a-f6eb8aa02bf3"
      decimals="-3"
      id="F_af25b1e8-32b2-4e36-85a5-933c17096276"
      unitRef="U_USD">45000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_a3c09498-0d4a-46e4-b3c4-1c97a4ae24dd"
      decimals="-3"
      id="F_835437f5-831b-43ac-8bbb-748f831f5348"
      unitRef="U_USD">31000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_d1cdc41e-1344-4b9d-b512-d00d3ca635f6"
      unitRef="U_USD">1909000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_ed034083-f856-494f-b382-82cad0da49ad"
      unitRef="U_USD">1745000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_ffa6d2e5-50a9-4292-9cff-c3ffd52f51f3"
      unitRef="U_USD">1225000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_5007f546-ca58-4a69-ad35-c17b61b1adb0"
      unitRef="U_USD">914000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_553d891a-90b4-4812-aead-c90ee8cdb258"
      unitRef="U_USD">684000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_59146f0b-ce30-45f2-b9fa-06171b799089"
      unitRef="U_USD">831000</us-gaap:PropertyPlantAndEquipmentNet>
    <lrmr:DepreciationExpenseExcludingLeasedAssets
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="-5"
      id="F_8fa60bec-2d97-4889-a706-16299e0923a2"
      unitRef="U_USD">200000</lrmr:DepreciationExpenseExcludingLeasedAssets>
    <lrmr:DepreciationExpenseExcludingLeasedAssets
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="-5"
      id="F_4d597278-77b1-4536-baf9-65e947f0f1bb"
      unitRef="U_USD">200000</lrmr:DepreciationExpenseExcludingLeasedAssets>
    <lrmr:DepreciationExpensesRelatedToSubletAssets
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="-5"
      id="F_4bbbe297-f55a-40ea-9ff5-c88264289a99"
      unitRef="U_USD">100000</lrmr:DepreciationExpensesRelatedToSubletAssets>
    <lrmr:DepreciationExpensesRelatedToSubletAssets
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="-5"
      id="F_39bcd4fb-1515-46f3-a46f-6f184d20ee2a"
      unitRef="U_USD">100000</lrmr:DepreciationExpensesRelatedToSubletAssets>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_6d2d1cba-af8b-4dc0-acc3-a12c265c78b3">&lt;div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;6.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued Expenses&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued expenses consisted of the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued payroll and related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,046&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;427&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;441&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,408&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_a7d2ba33-b563-47fa-88f9-fb2759771797">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued expenses consisted of the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued payroll and related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,046&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;427&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;441&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,408&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <lrmr:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_84cbfd71-1ede-4cb3-9041-d4198ac8c7e7"
      unitRef="U_USD">4594000</lrmr:AccruedResearchAndDevelopmentExpenseCurrent>
    <lrmr:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_44730009-215e-4f98-97fa-8555fa6beeca"
      unitRef="U_USD">5921000</lrmr:AccruedResearchAndDevelopmentExpenseCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_43346046-9053-4b16-810c-276a4efd6145"
      unitRef="U_USD">2365000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_de4750a9-77d2-434f-8229-36aea391c785"
      unitRef="U_USD">2046000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_273ebda0-afdd-4fbd-a43c-682ce143f331"
      unitRef="U_USD">427000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_80992495-1a8f-40f2-a1a8-aa70f27840f5"
      unitRef="U_USD">441000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_bc7f1165-5f2f-4084-b81a-1e98486b7d14"
      unitRef="U_USD">7386000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_8272fdaf-499e-441f-8884-7b2675273ccd"
      unitRef="U_USD">8408000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_b061d5be-fa65-4cfd-b66c-5d1fa2418584">&lt;div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;7.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stockholders&#x2019; Equity and Stock Options&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Common Stock and Prefunded warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On May 28, 2020, the Company entered into a securities purchase agreement with certain accredited investors (the &#x201c;Purchasers&#x201d;) for the sale by the Company in a private placement of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,105,359&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock and prefunded warrants to purchase an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;628,403&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock, for a price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.88&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share of the common stock and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.87&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per prefunded warrant. The prefunded warrants were exercisable at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.01&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and were exercisable indefinitely. In August 2023, the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;628,403&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of prefunded warrants were exercised and the Company received cash proceeds of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_8cb91d11-91f9-408e-87be-ef7e83759a47;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;six thousand two hundred and eighty-four dollars&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The private placement closed on June 1, 2020. The aggregate gross proceeds for the issuance and sale of the common stock and prefunded warrants were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;80.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, transaction costs totaled $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and resulted in net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The Company&#x2019;s Registration Statement on Form S-3, filed with the SEC on June 26, 2020, registered the resale of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,105,359&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock sold and the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;628,403&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock underlying the prefunded warrants. MTS Health Partners served as placement agent to the Company in connection with the private placement. As partial compensation for these services, the Company issued MTS Health Partners &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,260&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company&#x2019;s Amended and Restated Certificate of Incorporation, authorized the Company to issue up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;115,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; par value common stock, of which &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43,909,069&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares were issued and outstanding, and up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; par value undesignated preferred stock, of which &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares were issued or outstanding. The voting, dividend and liquidation rights of the holders of the Company&#x2019;s common stock are subject to and qualified by the rights, powers and preferences of the holders of the preferred stock. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#x2019;s stockholders&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Common stockholders are entitled to receive dividends, as may be declared by the board of directors of the Company (the &#x201c;Board&#x201d;), if any. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; cash dividends have been declared or paid to date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In September 2022, the Company sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,558,750&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock in an underwritten public offering price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share and received net proceeds, net of underwriting discounts and commissions and offering costs of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In February 2024, the Company sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,736,842&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of its common stock in an underwritten public offering price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.74&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share and received net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;161.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2022 ATM Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2022, the Company entered into a sales agreement (the "ATM Agreement") with a Guggenheim Securities, LLC in connection with the establishment of an &#x201c;at-the-market&#x201d; offering program under which the Company could sell up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of shares of common stock (the &#x201c;ATM Shares&#x201d;) from time to time.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In February 2024, in connection with the underwritten public offering described above, the Company terminated the ATM Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ATM Shares were ever sold pursuant to the ATM Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2020 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Board adopted the 2020 Equity Incentive Plan (the "2020 Plan") on July 16, 2020 and the stockholders of the Company approved the 2020 Plan on September 29, 2020. The 2020 Plan replaced the predecessor plans (the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;"Prior Plans") that the Company assumed following its merger with Zafgen in May 2020. Options outstanding under the Prior Plans will remain outstanding, unchanged, and subject to the terms of the Prior Plans and the respective award agreements, and no further awards will be made under the Prior Plans. However, if any award previously granted under the Prior Plans, expires, terminates, is canceled, or is forfeited for any reason after the approval of the 2020 Plan, the shares subject to that award will be added to the 2020 Plan share pool so that they can be utilized for new grants under the 2020 Plan.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The 2020 Plan provides for the grant of incentive stock options (&#x201c;ISOs&#x201d;), nonstatutory stock options (&#x201c;NSOs&#x201d;), stock appreciation rights, restricted stock awards, restricted stock unit awards, and cash or other stock-based awards. ISOs may be granted only to the Company&#x2019;s employees, including the Company&#x2019;s officers, and the employees of the Company&#x2019;s affiliates. All other awards may be granted to the Company&#x2019;s employees, including the Company&#x2019;s officers, the Company&#x2019;s non-employee directors and consultants, and the employees and consultants of the Company&#x2019;s affiliates.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The maximum number of shares that may be issued in respect of any awards under the 2020 Plan is the sum of: (i) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,700,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares plus (ii) an annual increase on January 1, 2021 and each anniversary of such date thereafter through January 1, 2030, equal to the lesser of (A) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the shares issued and outstanding on the last day of the immediately preceding fiscal year, or (B) such smaller number of shares as determined by the Board (collectively, the &#x201c;Plan Limit&#x201d;).&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; The maximum aggregate number of shares that may be issued under the 2020 Plan is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; over the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ten-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; term of the 2020 Plan.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As permitted by the 2020 Plan, the Company added &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,756,363&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,730,768&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares available for grant to the 2020 Plan on January 1, 2024 and January 1, 2023, respectively, increasing the maximum number of shares of the Company&#x2019;s common stock that may be issued under the 2020 Plan as of January 1, 2024 to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,042,968&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the twelve months ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively, options to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;224,437&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;148,623&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares issued under the Prior Plans were canceled and became available for grant under the 2020 Plan. In addition, as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,286,605&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock were available for grant under the 2020 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock Valuation&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted to employees:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.72&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.23&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.21&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;94&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s stock option activity for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;twelve months ended December 31, 2023 (amounts in millions, except for share and per share data):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.11%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.942%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Remaining&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Intrinsic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Exercise&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Contractual&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Value (a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in millions)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,071,528&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,748,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,466&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited/Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;534,760&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,273,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Exercisable as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,930,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Vested and expected to vest as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,273,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;"&gt;(a)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were in the money at December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2023 Option Grants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the twelve months ended December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company granted options to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,388,200&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock to employees under the 2020 Plan. The options have an exercise price equal to the closing stock price as of the grant date, and vest over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% vesting on the first anniversary of the grant and the remainder vesting in equal monthly installments thereafter. The weighted-average grant date fair value of options granted under the 2020 Plan during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;twelve months ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.70&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.21&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, total unrecognized compensation expense related to unvested stock options granted under the 2020 Plan was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which is expected to be recognized over a weighted average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1.91&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Inducement Stock Option Grant&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the twelve months ended December 31, 2023, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the Company granted options to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;360,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock granted outside of the 2020 Plan. These grants were made pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq listing rule 5635(c)(4). The options issued under this inducement grant have an exercise price equal to the closing stock price as of the grant date, and vest over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% vesting on the first anniversary of the grant and the remainder vesting in equal monthly installments thereafter. The weighted-average grant date fair value of options granted under this inducement grant during the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; twelve months ended December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.59&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; inducement grants in &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;twelve months ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, total unrecognized compensation expense related to unvested inducement options granted under the 2020 Plan was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which is expected to be recognized over a weighted average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;3.28&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In January 2023, RSUs were granted under the 2020 Plan to the Company's employees in order to maintain retention of key employees. The value of an RSU award is based on the Company's stock price on the date of the grant. The shares underlying the RSUs are not issued until the RSUs vest.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Activity with respect to the Company's RSUs during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;twelve months ended December 31, 2023 was as follows (in millions, except share, contractual term, and per share data):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.11%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.942%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Remaining&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Intrinsic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Grant Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Contractual&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Value (a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in millions)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted stock units granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;650,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted stock units forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;615,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unvested and expected to vest as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;615,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Restricted Stock Unit Grants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The RSUs vest annually over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and have a weighted-average grant date fair value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.94&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per unit.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, total unrecognized compensation expense for RSUs was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which is expected to be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;3.09&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;January 2024 Option and Restricted Stock Unit Grants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On January 17, 2024, the Company granted options to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,472,175&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;245,363&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of restricted stock to employees under the 2020 Plan. The options have an exercise price equal to the closing stock price as of the grant date, and vest over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;vesting on the first anniversary of the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;grant &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and the remainder vesting in equal monthly installments thereafter. The shares of restricted stock will vest annually over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-based compensation expense was classified in the consolidated statements of operations as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.64%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.64%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,077&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,538&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,615&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,619&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_8cd23ff2-fd7c-4814-976b-44a4de8fb1e2"
      decimals="INF"
      id="F_70db5bb7-16e3-40e3-a4e1-a18e2a0506e3"
      unitRef="U_shares">6105359</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_a74f39df-acd1-4d8b-9dba-1fd17150fcb5"
      decimals="INF"
      id="F_07461840-c97a-4f49-8465-11e396e260d3"
      unitRef="U_shares">628403</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_a74f39df-acd1-4d8b-9dba-1fd17150fcb5"
      decimals="INF"
      id="F_7c523676-4bd3-4a1b-b4d9-34f4549806ca"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.88</us-gaap:SharesIssuedPricePerShare>
    <lrmr:WarrantsIssuedPricePerShare
      contextRef="C_26ed7eb8-3335-4a45-993d-30b861b1ef11"
      decimals="INF"
      id="F_06f0a520-9277-404b-92aa-88f08b828958"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.87</lrmr:WarrantsIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_26ed7eb8-3335-4a45-993d-30b861b1ef11"
      decimals="INF"
      id="F_31f715c0-6549-4afb-b4e8-0b4bd6948614"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <lrmr:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="C_4d0e0e4e-6b0a-403d-87e1-7dc7a011b1ec"
      decimals="0"
      id="F_5dbde661-40b3-4eaa-894b-b6d3e35e5643"
      unitRef="U_shares">628403</lrmr:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_9d1af696-7d08-4f42-87a7-b186b43ac50d"
      decimals="-5"
      id="F_0231dd17-0ec3-47f6-bf4f-6d33890d27af"
      unitRef="U_USD">80000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <lrmr:StockAndWarrantIssuanceTransactionCosts
      contextRef="C_9d1af696-7d08-4f42-87a7-b186b43ac50d"
      decimals="-5"
      id="F_34cff39c-f214-4ae4-a2aa-34534cace9f9"
      unitRef="U_USD">4600000</lrmr:StockAndWarrantIssuanceTransactionCosts>
    <lrmr:ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts
      contextRef="C_9d1af696-7d08-4f42-87a7-b186b43ac50d"
      decimals="-5"
      id="F_df9275d2-d171-487c-a5c9-2d45e5ccc1ae"
      unitRef="U_USD">75400000</lrmr:ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_8cd23ff2-fd7c-4814-976b-44a4de8fb1e2"
      decimals="INF"
      id="F_f9b16062-a8e6-4bfb-813a-f6b25a86c7b9"
      unitRef="U_shares">6105359</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_a74f39df-acd1-4d8b-9dba-1fd17150fcb5"
      decimals="INF"
      id="F_5f8def0f-a4ee-45fd-8149-c0649d1706d7"
      unitRef="U_shares">628403</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_c597ff2c-39de-40dd-b55f-1bcc76bd4dc7"
      decimals="INF"
      id="F_e06e73cb-14bb-4f5a-9cfc-0dc17e2cbc0c"
      unitRef="U_shares">35260</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="INF"
      id="F_8ee458a5-ed00-42ab-8745-7a37f38f77bd"
      unitRef="U_shares">115000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="INF"
      id="F_3cab3754-c043-4310-99dc-ceb35d6335ad"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="INF"
      id="F_4f0e354a-1c0b-4872-80c7-9c431a45c973"
      unitRef="U_shares">43909069</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="INF"
      id="F_f29bed71-dceb-4138-bfb0-901617746638"
      unitRef="U_shares">43909069</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="INF"
      id="F_c0631842-5e57-4290-9cf2-dd34df4f59fc"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="INF"
      id="F_3f46ebd5-cbeb-4a35-8125-fd5c36e7af6d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="INF"
      id="F_c6a44aab-5bd2-4100-857b-bb8d214e33c7"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="INF"
      id="F_9ee1d560-fc38-42b2-b060-473af60c2e2d"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockVotingRights
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_8f8f9b17-9a46-4515-9b95-89fc295fd606">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#x2019;s stockholders</us-gaap:CommonStockVotingRights>
    <us-gaap:DividendsPayableCurrentAndNoncurrent
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_cc70025d-27ea-47ee-bb70-1a39f09ffb7e"
      unitRef="U_USD">0</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_94e051e5-07aa-4e1e-a62e-12871b5fe6b5"
      decimals="INF"
      id="F_d912091a-ddfb-4586-a626-1e76fced428f"
      unitRef="U_shares">25558750</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_5c3f05e5-8f01-4df5-a495-e7063f7dcbec"
      decimals="INF"
      id="F_f4c329b9-a407-4fe9-8b97-0bdd74ab7b46"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.15</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_94e051e5-07aa-4e1e-a62e-12871b5fe6b5"
      decimals="-5"
      id="F_ec4f3ff2-1cc6-469c-ae02-debc5310245c"
      unitRef="U_USD">75200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_e779eef1-f227-4303-a5d4-03032bdb61b2"
      decimals="INF"
      id="F_b0c73161-b062-4ede-8612-a5c189cbbea2"
      unitRef="U_shares">19736842</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_24df9b26-5847-47e5-b4ad-c48348d08414"
      decimals="INF"
      id="F_08231669-60b5-475d-b31d-708ee571a40a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.74</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_e779eef1-f227-4303-a5d4-03032bdb61b2"
      decimals="-5"
      id="F_cad30f38-6977-496e-b97d-870797617cee"
      unitRef="U_USD">161600000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <lrmr:AggregateGrossSalesProceedsUnderSalesAgreement
      contextRef="C_039998c9-136d-4c84-92be-a69133fb0a75"
      decimals="-5"
      id="F_9eb2be57-27aa-4520-b52c-a6f16393853d"
      unitRef="U_USD">50000000</lrmr:AggregateGrossSalesProceedsUnderSalesAgreement>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_78ca8c58-4724-4fdd-b217-9f4c3b5b885f"
      decimals="INF"
      id="F_9dd8c17a-bebd-4061-9c0a-2d5d37fe4fc5"
      unitRef="U_shares">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
      contextRef="C_37911699-3824-4881-9471-81254e29f4ad"
      id="F_f18d22f0-5bfd-46a7-addb-3133c98688d3">The maximum number of shares that may be issued in respect of any awards under the 2020 Plan is the sum of: (i) 1,700,000 shares plus (ii) an annual increase on January 1, 2021 and each anniversary of such date thereafter through January 1, 2030, equal to the lesser of (A) 4% of the shares issued and outstanding on the last day of the immediately preceding fiscal year, or (B) such smaller number of shares as determined by the Board (collectively, the &#x201c;Plan Limit&#x201d;).</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
    <lrmr:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue
      contextRef="C_37911699-3824-4881-9471-81254e29f4ad"
      decimals="INF"
      id="F_d2903e25-3ec4-43ad-a7f1-a2377cf9adab"
      unitRef="U_shares">1700000</lrmr:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue>
    <lrmr:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock
      contextRef="C_37911699-3824-4881-9471-81254e29f4ad"
      decimals="2"
      id="F_28f81010-1576-4a03-b0a0-334ac96bf43a"
      unitRef="U_pure">0.04</lrmr:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_4e7af380-9c31-42f4-a857-43c89ba539c2"
      decimals="INF"
      id="F_cf1fa9ce-36ec-4b0d-9485-009dc54e3df5"
      unitRef="U_shares">8000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <lrmr:ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration
      contextRef="C_37911699-3824-4881-9471-81254e29f4ad"
      id="F_97bf7aa3-a084-410a-aa85-f296a4494185">P10Y</lrmr:ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_a8e69aee-3f52-42fe-9a00-5c7054b2ba1f"
      decimals="INF"
      id="F_4425ddf1-a359-4299-b637-d0797cb7bcef"
      unitRef="U_shares">1756363</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_b8fdf4b9-43b7-4ab7-8542-b3d410371289"
      decimals="INF"
      id="F_d92c5d01-ed74-42a6-ac25-31bd0e3f42a8"
      unitRef="U_shares">1730768</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_7a4395b1-58c4-4b3b-bac0-3280e7df8802"
      decimals="INF"
      id="F_5c6e6c73-3c2d-4121-b310-ce170bcb6b77"
      unitRef="U_shares">3042968</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_7461d392-dc75-45e2-93a6-6a4655ad44cb"
      decimals="INF"
      id="F_9e13290b-0388-4f64-9e28-bf5733d51afb"
      unitRef="U_shares">224437</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_064057be-fcdf-4308-890d-a8ada4719458"
      decimals="INF"
      id="F_7dbe08af-399a-4873-bf10-07b1baced462"
      unitRef="U_shares">148623</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_6dc50be6-f9ce-45f0-896b-c14acf174567"
      decimals="INF"
      id="F_ed9bb3df-0f78-46e6-b66b-9d821bcbb7ef"
      unitRef="U_shares">1286605</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_4ae884be-8e5b-47a6-b682-14fc58cc4d8d">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted to employees:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.72&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.23&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.21&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;94&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="4"
      id="F_5c87bd4b-2e9a-47db-9935-22deeb78ba79"
      unitRef="U_pure">0.0372</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="4"
      id="F_b014603d-0ad2-4151-9420-a61b60eed52e"
      unitRef="U_pure">0.0215</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_6f899d2c-b3df-40c3-b593-89da9c1ff437">P6Y2M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      id="F_25883e93-bb09-4f15-8006-f01eeb60881a">P6Y2M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="2"
      id="F_9a3dbab5-6204-4842-bda2-4baf9330d23d"
      unitRef="U_pure">0.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="2"
      id="F_5928f1e7-8a8e-464d-9806-d49700b9b550"
      unitRef="U_pure">0.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="4"
      id="F_92a8f7c5-9437-4721-b8c9-da03d09cbeea"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="4"
      id="F_74186fcc-764b-4da5-a907-1bf513f784cb"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_dbfb4874-9d4a-423a-8aa3-3d65a34889b4">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s stock option activity for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;twelve months ended December 31, 2023 (amounts in millions, except for share and per share data):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.11%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.942%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Remaining&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Intrinsic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Exercise&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Contractual&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Value (a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in millions)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,071,528&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,748,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,466&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited/Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;534,760&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,273,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Exercisable as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,930,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Vested and expected to vest as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,273,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;"&gt;(a)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were in the money at December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="INF"
      id="F_b143184e-0985-45c0-a230-1d37fefe7e3b"
      unitRef="U_shares">3071528</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="2"
      id="F_d15d83a6-fe64-47ba-9c70-5b90ce0f82f6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      id="F_2ea5d8e9-bb66-4a87-823d-4c07ec12ed76">P7Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="INF"
      id="F_d40b75a1-3be1-4151-9e90-c755832ea9b0"
      unitRef="U_shares">1748200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="2"
      id="F_3f530709-a4b1-45b7-aad4-8efe105b4bb0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.68</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="INF"
      id="F_dd5c3775-94f0-4ce9-9728-7ea7baabeeb6"
      unitRef="U_shares">11466</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="2"
      id="F_607a5230-ccb1-49c8-a22f-43a7b93940d4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="INF"
      id="F_2b960c3d-7a84-4a5a-a011-c3c13d78629b"
      unitRef="U_shares">534760</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="2"
      id="F_84aba926-5bc7-415e-921b-12c0508c7334"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="INF"
      id="F_d4f0f69e-978d-4828-9010-5f2f6216382a"
      unitRef="U_shares">4273502</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="2"
      id="F_74327eba-9a4f-4542-a40d-8f87bbada95a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_cdf3657f-4e52-4191-9366-4c66de7d93c4">P7Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-5"
      id="F_a0e901be-0e80-445c-8eab-603fcfba7fa0"
      unitRef="U_USD">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="INF"
      id="F_cef4d872-6ecb-4055-81bb-d20a947864b4"
      unitRef="U_shares">1930100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="2"
      id="F_9d9a2d4a-a35a-4c35-9e23-8d9dc176ddb3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_bcc4a2b4-5a28-484b-8670-abe99547aaaa">P6Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-5"
      id="F_3a7a8494-b1c0-4bf7-990c-2815f6ffb81b"
      unitRef="U_USD">200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="INF"
      id="F_5f8c9ccf-0df1-4df1-a537-d8a184c1f8e2"
      unitRef="U_shares">4273502</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="2"
      id="F_1e1a33dd-a87b-413b-99bc-548adf783af1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_79bde6e8-0607-47e8-a44c-ca008348af2f">P7Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-5"
      id="F_a5e0733a-0fcb-411e-a311-de741fa48d8d"
      unitRef="U_USD">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_1c1b0f6e-ec81-493a-a1e1-b384f3fff492"
      decimals="INF"
      id="F_d0c1d712-36e6-476f-89c5-6d9ce73f85cd"
      unitRef="U_shares">1388200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_1c1b0f6e-ec81-493a-a1e1-b384f3fff492"
      id="F_ac4bb259-73f7-4ea3-9dcb-aca75a2b4901">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_860248e3-56cf-4688-98a3-19daf6e5ff6f"
      decimals="2"
      id="F_f2f807e2-7da4-417f-89ae-a66b82dee8ea"
      unitRef="U_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_37911699-3824-4881-9471-81254e29f4ad"
      decimals="2"
      id="F_cb0157a6-91f0-43e4-b13e-63ff5bd94b4e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_c1455b06-7113-45cb-ac47-8e1eb7003ee1"
      decimals="2"
      id="F_1159bf4f-a7dc-42e1-85c6-bb37788e5f3a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_a82c95f9-c18c-445c-a45f-cb3e1f90d580"
      decimals="-5"
      id="F_7ae4fdb7-6274-4de9-9c55-33def823a20d"
      unitRef="U_USD">8800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_37911699-3824-4881-9471-81254e29f4ad"
      id="F_34d9408e-f94a-4508-b450-4ed2610bf3d6">P1Y10M28D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_196f20b7-7250-4fea-befc-99827d01c86b"
      decimals="INF"
      id="F_d221071c-a1c9-4bf5-8912-adb75a44eda1"
      unitRef="U_shares">360000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_196f20b7-7250-4fea-befc-99827d01c86b"
      id="F_2b3fbd19-4960-45ca-bed0-e446244eb169">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_a3395847-e949-4251-a28f-6484e3b7556e"
      decimals="2"
      id="F_9f55fb8a-6909-469e-91fc-c96e364b5b6a"
      unitRef="U_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_196f20b7-7250-4fea-befc-99827d01c86b"
      decimals="2"
      id="F_e8908944-ad14-48e7-b865-c95c519b475f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_fe994e7e-b8ca-4866-b2b8-f68f8a9ef323"
      decimals="0"
      id="F_999a1b73-d798-41c0-8e57-142d6dfa0eaa"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_5b2496bb-0283-4097-be94-f3832f36eb00"
      decimals="-5"
      id="F_15ad8156-d06b-463c-ac45-6ec87155e743"
      unitRef="U_USD">1100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_953fc3f7-0bdc-46a5-a81f-b24a2a0ecad9"
      id="F_c77e89b1-c6fa-4d4a-aaf4-2b30533c23e4">P3Y3M10D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_66aab9fb-b891-4635-b595-c42bee288355">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Activity with respect to the Company's RSUs during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;twelve months ended December 31, 2023 was as follows (in millions, except share, contractual term, and per share data):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.11%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.942%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Remaining&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Intrinsic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Grant Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Contractual&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Value (a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in millions)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted stock units granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;650,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted stock units forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;615,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unvested and expected to vest as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;615,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_79fb8102-e267-43bc-9f8f-f08e3d54c866"
      decimals="INF"
      id="F_deab8a33-8043-4470-8c4f-945c451ff751"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_0899eeab-0bfd-49a2-8a22-1c41967d8084"
      decimals="INF"
      id="F_1ed8847f-796a-4af6-bc3a-ce841d942629"
      unitRef="U_shares">650000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0899eeab-0bfd-49a2-8a22-1c41967d8084"
      decimals="2"
      id="F_85870ae7-74d1-4029-87da-21b6300ba4d3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_0899eeab-0bfd-49a2-8a22-1c41967d8084"
      decimals="INF"
      id="F_02a19866-7357-4d03-8727-4c59b020782c"
      unitRef="U_shares">35000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_0899eeab-0bfd-49a2-8a22-1c41967d8084"
      decimals="2"
      id="F_1e9b7a6f-8e2e-49b9-bd5b-ff1ff6989781"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_a0d3bc37-c2c5-449e-9b72-d46590f710ec"
      decimals="INF"
      id="F_855faaee-0fb2-4175-bc7c-180e6424cdc6"
      unitRef="U_shares">615000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_a0d3bc37-c2c5-449e-9b72-d46590f710ec"
      decimals="2"
      id="F_6100e162-f6c5-4b7b-8231-906351e67849"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="C_0899eeab-0bfd-49a2-8a22-1c41967d8084"
      id="F_cbb1e5ce-131e-42ac-9d92-1bf7bcdb39d5">P1Y7M6D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="C_a0d3bc37-c2c5-449e-9b72-d46590f710ec"
      decimals="-5"
      id="F_164c7670-1773-4ea0-bc96-16940116e0b8"
      unitRef="U_USD">2800000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <lrmr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber
      contextRef="C_a0d3bc37-c2c5-449e-9b72-d46590f710ec"
      decimals="INF"
      id="F_8d583880-1d75-4ccc-90cb-0e737264cde1"
      unitRef="U_shares">615000</lrmr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber>
    <lrmr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue
      contextRef="C_a0d3bc37-c2c5-449e-9b72-d46590f710ec"
      decimals="2"
      id="F_853a574b-7dd6-4f18-a82e-c3cca649617c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.94</lrmr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue>
    <lrmr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms
      contextRef="C_0899eeab-0bfd-49a2-8a22-1c41967d8084"
      id="F_8d9f46fd-08e9-4322-bb3b-a1501cd61914">P1Y7M6D</lrmr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms>
    <lrmr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue
      contextRef="C_a0d3bc37-c2c5-449e-9b72-d46590f710ec"
      decimals="-5"
      id="F_5b764b46-9a7b-4714-a785-c5f83160ea55"
      unitRef="U_USD">2800000</lrmr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_5c533b45-4872-44aa-8eba-29efd92ddf96"
      id="F_027e1196-c40b-455e-bcc7-21b958be9295">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_5c533b45-4872-44aa-8eba-29efd92ddf96"
      decimals="2"
      id="F_64b4ba6b-e999-49a8-88d5-bb5c604ddac1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_a0d3bc37-c2c5-449e-9b72-d46590f710ec"
      decimals="-5"
      id="F_8da64e55-294f-4481-951a-804ff5fa70d1"
      unitRef="U_USD">2300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_0899eeab-0bfd-49a2-8a22-1c41967d8084"
      id="F_1eecdf9c-db5b-4ebe-b51f-12bb2f30ebb0">P3Y1M2D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_fa925083-1371-4656-ab14-7ea6e7f54fb3"
      decimals="INF"
      id="F_50656af7-151c-4ad6-af56-c0719a743fc1"
      unitRef="U_shares">1472175</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_4d67c562-0e3a-4233-a627-82c574413619"
      decimals="INF"
      id="F_d2406cf0-1faa-4615-80e3-162ef73a387f"
      unitRef="U_shares">245363</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_fa925083-1371-4656-ab14-7ea6e7f54fb3"
      id="F_4d3f23e6-1522-4b97-9640-918a1f88d2e5">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_5baad777-d068-4ce3-be35-c76ec7ffb655"
      decimals="2"
      id="F_5a3c0704-d9a0-4fc7-a2fa-8b7c8bf3e0e8"
      unitRef="U_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_4d67c562-0e3a-4233-a627-82c574413619"
      id="F_0f96c300-547e-45ee-9b5c-b5ce5992dcc0">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_d75b0896-eda6-4467-ac4f-7c7168217753">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-based compensation expense was classified in the consolidated statements of operations as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.64%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.64%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,077&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,538&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,615&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,619&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c9852892-0da8-479d-83c0-1ee02dd67583"
      decimals="-3"
      id="F_f74923b1-cff2-41f0-b611-532d7187359f"
      unitRef="U_USD">3077000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_740659e5-2866-4797-81d2-afb8bf9c13fd"
      decimals="-3"
      id="F_5b074bd9-f704-49b7-81d3-62f9a9be68a6"
      unitRef="U_USD">2771000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_d39d1e4b-8b4a-4b1b-9377-433018f6afff"
      decimals="-3"
      id="F_9b99a8d9-6214-4297-bbf4-8d13828bf996"
      unitRef="U_USD">4538000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0042b997-c48a-4b61-bc0b-c18adeff5e3f"
      decimals="-3"
      id="F_894eec86-e005-4cf9-833e-8fcbb2f9fa31"
      unitRef="U_USD">3848000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="-3"
      id="F_4c6c3c64-d6dd-4863-ba5d-a7ed2dd11398"
      unitRef="U_USD">7615000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="-3"
      id="F_e6145afa-f3a4-4349-99de-779e1e774285"
      unitRef="U_USD">6619000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_abe5ea53-4227-46eb-a3ed-3ee74991f954">&lt;div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;8.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Commitments and Contingencies &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Intellectual Property Licenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is party to an exclusive License Agreement (the &#x201c;WFUHS License&#x201d;), dated November 30, 2016, as amended, with Wake Forest University Health Sciences (&#x201c;WFUHS&#x201d;) and an exclusive License Agreement (the &#x201c;IU License&#x201d;), dated November 30, 2016, as amended, with Indiana University (&#x201c;IU&#x201d;). Such agreements provide for a transferable, worldwide license to certain patent rights regarding technology used by the Company with respect to the development of nomlabofusp. Both agreements continue from their effective date through the last to date of expiration of the licensed patents, unless earlier terminated by either party in accordance with their terms.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In partial consideration for the right and license granted under these agreements, the Company will pay each of WFUHS and IU a royalty of a low single digit percentage of net sales of licensed products depending on whether there is a valid patent covering such products. As additional consideration for these agreements, the Company is obligated to pay each of WFUHS and IU certain milestone payments of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in the aggregate upon the achievement of certain developmental milestones, which commenced with the enrollment of the first patient in a Phase 1 clinical trial. The Company enrolled the first patient in its SAD trial on December 11, 2019 and paid WFUHS and IU less than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The Company will also pay each of WFUHS and IU sublicensing fees ranging from a high-single digit to a low double-digit percentage of sublicense consideration depending on the Company&#x2019;s achievement of certain regulatory milestones as of the time of receipt of the sublicense consideration. The Company is also obligated to reimburse WFUHS and IU for patent-related expenses. In the event that the Company disputes the validity of any of the licensed patents, the royalty rate would be tripled during such dispute. The Company is also obligated to pay to IU a minimum annual royalty of less than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million per annum.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In the event that the Company is required to pay IU consideration, then the Company may deduct &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of such IU consideration on a dollar-for-dollar basis from the consideration due to WFUHS. In the event that the Company is required to pay WFUHS consideration, then the Company may deduct &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;60&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of such WFUHS consideration on a dollar-for-dollar basis from the consideration due to IU.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In October 2022, the Company initiated dosing of a Phase 2 study. Pursuant to the terms of both the WFUHS License and the IU License, the company recognized milestone expense of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million within research and development expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Both agreements continue from their effective date through the last date of expiration of the licensed patents, unless earlier terminated by either party in accordance with their terms.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Bala Cynwyd Office Space&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On August 8, 2019, the Company entered into an operating lease for office space in Bala Cynwyd, Pennsylvania, effective as of December 15, 2019, for a period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;three years and six months&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; with an option to extend the lease for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_1adadb6d-a5ef-4cd0-b448-c546eec4b594;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; additional years. Due to required tenant improvements to be completed by the landlord, the Company did not take immediate possession of the leased property and the lease term commenced on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;February 15, 2020&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On March 9, 2023, the Company executed a lease extension agreement on its original &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,642&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; square footage of office space in Bala Cynwyd, Pennsylvania (which was set to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_54780bae-ad9f-44bf-b3f5-82dab5b666a1;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;August 2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;) and agreed to lease an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,462&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; square feet of office space from the same landlord.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The lease extension on the original &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,642&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; square footage commenced on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;September 1, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and the Company recorded a right of use asset and lease liability of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as of that date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The new lease on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,462&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; additional square footage commenced on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;October 1, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and the Company recorded a right of use asset and lease liability of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as of that date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The right of use assets and lease liabilities with both these leases are reflected in the financial statements for the year ended December 31, 2023 as are the right of use asset and lease liability of the Company's Boston office space discussed below.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Boston Office Lease&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In connection with the Company's 2020 merger with Zafgen described in footnote 1, on May 28, 2020, the Company acquired a non-cancellable operating lease for approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,705&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; square feet of office space (the &#x201c;Premises&#x201d;). The lease expires on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;October 30, 2029&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. As part of the agreement, the Company is required to maintain a letter of credit, which upon signing was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and is classified as restricted cash within the condensed consolidated financial statements. In addition to the base rent, the Company is also responsible for its share of operating expenses, electricity and real estate taxes, which costs are not included in the determination of the leases&#x2019; right-of-use assets or lease liabilities. The right-of-use asset is being amortized to other income/(expense) over the remaining lease term as a result of the sublease described below.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On October 27, 2020, the Company entered into a sublease agreement (the &#x201c;Sublease&#x201d;) with Massachusetts Municipal Association, Inc. (the &#x201c;Subtenant&#x201d;), whereby the Company sublet the entire Premises to the Subtenant. The initial term of the Sublease commenced on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 4, 2020&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and continues until &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;October 30, 2029&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. In connection with the Sublease, the Company evaluated the need for impairment under ASC 360 "Impairment Testing: Long-Lived Assets Classified as Held and Used," and determined there was no impairment.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Sublease provided for an initial annual base rent of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which increases annually up to a maximum annual base rent of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The Subtenant also is responsible for paying to the Company future increases in operating costs (commencing on January 1, 2022), future increases in annual tax costs (commencing July 1, 2021) and all utility costs (commencing March 1, 2021) attributable to the Premises during the term of the Sublease. As part of the Sublease, the subtenant deposited a letter of credit in the amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million to assure their performance under the sublease. If there are no uncured events of default under the sublease, the amount of this security deposit decreases over time to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million on the sixth anniversary of the Sublease. The Company records sublease income on this sublease on a straight-line basis as a component of other income/(expense).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Lab Space&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On November 5, 2018, the Company entered into an operating lease for office and lab space in Philadelphia, Pennsylvania, effective as of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;January 1, 2019&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, and expiring on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2020&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; with an option to extend the lease for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_ed24bfd5-a8ef-478d-bee3-0b02edde6a19;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; additional years. On August 4, 2020, the Company executed the first option to extend the lease for an additional year, expiring on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. On August 9, 2021, the Company executed the remaining option to extend the lease for an additional year, expiring on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. In January 2023, the Company executed an extension of this lease for an additional year, expiring on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Company has determined this lease extension qualifies as a short-term lease and have applied the accounting policy election to not record the related right-of-use asset and lease liabilities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On October 16, 2023, the Company entered into an operating lease for lab space in King of Prussia, Pennsylvania for a period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Due to required tenant improvements to be completed by the landlord, the Company did not take immediate possession of the leased property and the lease term is expected to commence in the second quarter of 2024, no right of use asset or lease liability will be recorded until the lease commencement date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Lease Expense&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Expense arising from operating leases was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;twelve months ended December 31, 2023 and 2022, respectively. For operating leases, the weighted-average remaining lease term for leases at December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;6.8&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;respectively. For operating leases, the weighted&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;average &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;discount rate for leases at December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%. The Company has not entered into any financing leases.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Maturities of lease liabilities due under these lease agreements as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 are as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;"&gt;Year Ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Operating&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,380&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,403&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,136&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,778&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Legal Proceedings&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is not currently a party to any litigation, nor is management aware of any pending or threatened litigation against the Company, that it believes would materially affect the Company&#x2019;s business, operating results, financial condition or cash flows.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <lrmr:MilestonePaymentAmount
      contextRef="C_95b87097-23b2-4be8-a5a4-68ffcb45d537"
      decimals="-5"
      id="F_0464cf26-8788-4e39-ad32-38bad4829e7c"
      unitRef="U_USD">2600000</lrmr:MilestonePaymentAmount>
    <lrmr:MilestonePaymentAmount
      contextRef="C_3d5bafd5-20d4-4026-a715-daa85bdc64bd"
      decimals="-5"
      id="F_1a54c308-4d82-48b6-873e-c242fc35f91a"
      unitRef="U_USD">2600000</lrmr:MilestonePaymentAmount>
    <lrmr:PaymentForLicenseAgreements
      contextRef="C_bdabb33a-7162-4c37-8a9a-3a553319cde1"
      decimals="-5"
      id="F_a955a41b-7003-47b0-9a7d-6fd2dc508095"
      unitRef="U_USD">100000</lrmr:PaymentForLicenseAgreements>
    <lrmr:MinimumAnnualRoyaltyObligation
      contextRef="C_3d5bafd5-20d4-4026-a715-daa85bdc64bd"
      decimals="-5"
      id="F_ee09bc3a-c8c6-4890-8638-e9bedf9a6e05"
      unitRef="U_USD">100000</lrmr:MinimumAnnualRoyaltyObligation>
    <lrmr:LicenseAgreementConsiderationDeductionPercentage
      contextRef="C_279e75b7-f67a-4ee0-b268-adff2a559757"
      decimals="2"
      id="F_13bf1c34-09fe-4b36-afea-0522acfd3c64"
      unitRef="U_pure">0.20</lrmr:LicenseAgreementConsiderationDeductionPercentage>
    <lrmr:LicenseAgreementConsiderationDeductionPercentage
      contextRef="C_dac4deed-8338-46b9-9588-adb96f059754"
      decimals="2"
      id="F_1134c9be-02d1-4d55-a025-8868e3883624"
      unitRef="U_pure">0.60</lrmr:LicenseAgreementConsiderationDeductionPercentage>
    <lrmr:MilestoneExpenses
      contextRef="C_02732bcd-6e0a-478e-b53c-e115414d242b"
      decimals="-5"
      id="F_d73b9865-c289-41f6-8d98-122b5e8b3fa3"
      unitRef="U_USD">300000</lrmr:MilestoneExpenses>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_b59bebb3-ca2d-4a96-ba24-a2513f6be665"
      id="F_20dae8a3-cdaa-4f76-b746-185e6628cc24">P3Y6M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <lrmr:LeaseTermCommencementDate
      contextRef="C_c10d75ec-25a9-4bc3-b1d5-100a6af3fb57"
      id="F_18d98bc9-dfd1-44f7-83e9-a80a54b1af3c">2020-02-15</lrmr:LeaseTermCommencementDate>
    <lrmr:AreaOfOfficeSpace
      contextRef="C_25c4d6a9-6524-4f9f-84fa-c1a37a44ade0"
      decimals="INF"
      id="F_c0c10150-0a35-4236-ab1b-7eb3355286e7"
      unitRef="U_sqft">4642</lrmr:AreaOfOfficeSpace>
    <lrmr:AreaOfOfficeSpace
      contextRef="C_783e630c-cae9-4de1-9bdf-0cc7dfa2bdb8"
      decimals="INF"
      id="F_741cae72-c104-48df-920f-f82c0d405b36"
      unitRef="U_sqft">3462</lrmr:AreaOfOfficeSpace>
    <lrmr:AreaOfOfficeSpace
      contextRef="C_1f994bce-c827-41bc-8923-a0b663b5dccb"
      decimals="INF"
      id="F_650c29a6-9a07-4a96-bb65-caf7769f9bc1"
      unitRef="U_sqft">4642</lrmr:AreaOfOfficeSpace>
    <lrmr:LeaseTermCommencementDate
      contextRef="C_25c4d6a9-6524-4f9f-84fa-c1a37a44ade0"
      id="F_29abee27-b299-4925-bcc8-257ee8fa2492">2023-09-01</lrmr:LeaseTermCommencementDate>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_8bce919e-849a-4aa5-be5e-b7af4b9b190d"
      decimals="-5"
      id="F_5d8c25d1-4604-42e8-9ff9-0e0ce505573e"
      unitRef="U_USD">500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_8bce919e-849a-4aa5-be5e-b7af4b9b190d"
      decimals="-5"
      id="F_f0f9e090-e96b-4429-ab7b-7de236846746"
      unitRef="U_USD">500000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <lrmr:AreaOfOfficeSpace
      contextRef="C_1efd9ede-f9a2-45c2-93a1-636a41f2a1f2"
      decimals="INF"
      id="F_b237ab66-00dd-414d-951e-c1976dc22cd7"
      unitRef="U_sqft">3462</lrmr:AreaOfOfficeSpace>
    <lrmr:LeaseTermCommencementDate
      contextRef="C_783e630c-cae9-4de1-9bdf-0cc7dfa2bdb8"
      id="F_e292e4fd-bf2e-45f4-bc00-b6584585b691">2023-10-01</lrmr:LeaseTermCommencementDate>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_485ac229-ff1e-4d6d-89fa-970087d282fe"
      decimals="-5"
      id="F_4cfb248e-cd80-4090-8447-f549bea9af3a"
      unitRef="U_USD">300000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_485ac229-ff1e-4d6d-89fa-970087d282fe"
      decimals="-5"
      id="F_d3dcabe2-db31-49c1-8a75-d70349fa51a2"
      unitRef="U_USD">300000</us-gaap:OperatingLeaseRightOfUseAsset>
    <lrmr:AreaOfOfficeSpace
      contextRef="C_095c643d-76db-4c04-8cbb-33eef107ab9e"
      decimals="INF"
      id="F_162157b3-8b8c-4fbd-bb48-421948038faa"
      unitRef="U_sqft">17705</lrmr:AreaOfOfficeSpace>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_095c643d-76db-4c04-8cbb-33eef107ab9e"
      id="F_182d1e70-b5d2-403b-936e-62b190151118">2029-10-30</us-gaap:LeaseExpirationDate1>
    <us-gaap:RestrictedCash
      contextRef="C_5ea5486f-6817-49ce-bca9-bd58ccc45608"
      decimals="-5"
      id="F_2fa88c0c-f0ad-44cd-95df-a798c9f3c81f"
      unitRef="U_USD">1300000</us-gaap:RestrictedCash>
    <lrmr:LeaseTermCommencementDate
      contextRef="C_69f61fa0-0ce7-4f9f-b5a6-b3da5b3c716c"
      id="F_c8b74739-bf79-4ae4-8382-f0918e8716fa">2020-12-04</lrmr:LeaseTermCommencementDate>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_69f61fa0-0ce7-4f9f-b5a6-b3da5b3c716c"
      id="F_0aab6cd5-5527-4d30-8084-5c6c42dc2bc4">2029-10-30</us-gaap:LeaseExpirationDate1>
    <lrmr:SubleaseAnnualBaseRent
      contextRef="C_600d2614-95f3-40e4-a75b-3d7d2462a2d9"
      decimals="-5"
      id="F_de53f237-aa5d-4b21-afe7-c41fef13750f"
      unitRef="U_USD">800000</lrmr:SubleaseAnnualBaseRent>
    <lrmr:SubleaseAnnualBaseRent
      contextRef="C_b094896e-8ca7-4bae-b10c-753cf6471626"
      decimals="-5"
      id="F_c97484ee-a8d1-442b-90e6-b28ec9ad7a7d"
      unitRef="U_USD">1000000</lrmr:SubleaseAnnualBaseRent>
    <us-gaap:SecurityDepositLiability
      contextRef="C_cf00efe6-6c32-4b41-a584-da4e540323ec"
      decimals="-5"
      id="F_0e33a740-46af-484a-b972-2892ee5f1c8d"
      unitRef="U_USD">800000</us-gaap:SecurityDepositLiability>
    <us-gaap:SecurityDepositLiability
      contextRef="C_f2aae2bb-8999-4b7a-9f12-440a582140f9"
      decimals="-5"
      id="F_fb2c4107-29c6-4e4a-88c1-c4c2c4f74a07"
      unitRef="U_USD">400000</us-gaap:SecurityDepositLiability>
    <lrmr:LeaseTermCommencementDate
      contextRef="C_d800893b-5211-4ef0-8aeb-b28cb9dd18ee"
      id="F_10cd939f-6314-4f2e-ab15-81748ad2b921">2019-01-01</lrmr:LeaseTermCommencementDate>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_d800893b-5211-4ef0-8aeb-b28cb9dd18ee"
      id="F_b5914cbb-b88f-40a8-839c-f1b6ac82fc52">2020-12-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_89695345-0b21-49a0-8d47-0e33cf4abec6"
      id="F_63119ee8-d7be-4bc2-ae8b-8a9fcbe819de">2021-12-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_f4ad8f7d-6e13-40e8-9f2e-5b7b5f6addd0"
      id="F_9a247719-3080-489e-ac75-32c8c364fcb9">2022-12-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_26cd9754-8143-4a1f-93ac-b42a31563c34"
      id="F_c0ae6d51-bfef-4a5e-b3e0-18bf06197721">2023-12-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_d735f0e0-bd1f-4ef9-b8c9-2c828c14ca2f"
      id="F_b6a273c4-8c30-4808-9b8e-f68f9d080813">P4Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="-5"
      id="F_8d18ce1a-0e0b-4142-abbe-8d3c20b92ff4"
      unitRef="U_USD">400000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="-5"
      id="F_d7e064f7-1e14-4806-97aa-808e8209231c"
      unitRef="U_USD">300000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      id="F_ac057305-b916-4b0c-9161-9a72aca16a87">P5Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      id="F_5e274e9f-e5e3-4fa1-bcad-e66db0051d4b">P6Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="3"
      id="F_acc06655-4300-4f18-ae16-10a819c64062"
      unitRef="U_pure">0.11</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="3"
      id="F_6699385d-ee4b-4268-b8d4-4152e8bd3acf"
      unitRef="U_pure">0.11</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_69b513e9-5b5c-4a44-83a4-9f110b4d9c28">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Maturities of lease liabilities due under these lease agreements as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 are as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;"&gt;Year Ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Operating&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,380&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,403&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,136&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,778&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_c4c34187-45f0-4feb-a5d9-a77505d2984a"
      unitRef="U_USD">1380000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_a50a5ddd-64d1-4e37-b297-d39ffff2d3c3"
      unitRef="U_USD">1403000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_2d08e7df-7ae0-4738-b663-525232d4939b"
      unitRef="U_USD">1328000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_afc7dff9-53a7-436d-94c1-42881075282b"
      unitRef="U_USD">1118000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_df222110-d8f3-45ff-929f-8c62b8ce32b1"
      unitRef="U_USD">1136000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_15f3ff11-d2ca-451c-9599-055139efe9c8"
      unitRef="U_USD">959000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_47f1018c-d571-4870-bd9c-c12a043ca6b3"
      unitRef="U_USD">7324000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_7c9e56b8-5590-46c6-9017-3efa1a55eb82"
      unitRef="U_USD">1778000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_f75888c7-e637-48fd-9e0e-e992ab1615d3"
      unitRef="U_USD">5546000</us-gaap:OperatingLeaseLiability>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_65e10f47-5b92-4c7c-91ad-5c21a5d81a2d">&lt;div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;9.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the years ended December 31, 2023, and 2022&lt;/span&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company recorded &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#333333;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; income tax benefits for the net operating losses incurred in each year due to its uncertainty of realizing a benefit from those items.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The domestic and foreign components of loss before income taxes are as follows.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Years ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Domestic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,339&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,949&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,355&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A&lt;/span&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; reconciliation of the U.S. federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.343%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.343%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal statutory income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in state tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal and state research and development tax credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Nondeductible permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock compensation forfeitures - DTA Write Off&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in deferred tax asset valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Effective income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Net deferred tax assets as of &lt;/span&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Capitalized R&amp;amp;D - acquired in merger with Zafgen&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;66,678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;66,941&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Capitalized R&amp;amp;D - Section 174 Costs post 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,709&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45,195&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other temporary differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accruals &amp;amp; reserves&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Fixed assets &amp;amp; intangibles&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;107&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,298&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,355&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;142,538&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;131,632&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating right of use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;141,770&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;130,831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred tax assets / (liabilities)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Changes in the valuation allowance for deferred tax assets during the year ended December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; related primarily to the increase in net operating loss carryforwards and tax credit carryforwards and a decrease other deferred tax assets associated with a reduction in the Company&#x2019;s effective state rate. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Changes to the valuation allowance were as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Years ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Valuation allowance as of the beginning of the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;130,831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;124,016&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Increases recorded to income tax provision&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,815&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Valuation allowance at end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;141,770&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;130,831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company had net operating loss carryforwards that expire for federal, foreign and state income tax purposes of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#333333;white-space:pre-wrap;min-width:fit-content;"&gt;179.0&lt;/span&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#333333;white-space:pre-wrap;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#333333;white-space:pre-wrap;min-width:fit-content;"&gt;148.1&lt;/span&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively. The federal and state operating losses begin to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2030&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, while the foreign net loss carryforward can be carried forward indefinitely. As of &lt;/span&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company had federal net operating loss carryforwards that were generated after December 31, 2017 of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#333333;white-space:pre-wrap;min-width:fit-content;"&gt;140.3&lt;/span&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million that do not expire, however these &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;carryforwards are limited to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#333333;white-space:pre-wrap;min-width:fit-content;"&gt;80&lt;/span&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the taxable income in any one tax period.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; As of &lt;/span&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company also had available tax credit carryforwards for federal and state income tax purposes of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#333333;white-space:pre-wrap;min-width:fit-content;"&gt;16.3&lt;/span&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million which begin to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2039&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Utilization of the pre-Merger net operating loss carryforwards attributable to Zafgen, of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#333333;white-space:pre-wrap;min-width:fit-content;"&gt;33.5&lt;/span&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, are subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986 due to ownership changes occurred during the tax year associated with the Merger. In addition to the limitation of the pre-Merger NOL&#x2019;s of Zafgen, the net capitalized R&amp;amp;D deferred tax assets in the amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#333333;white-space:pre-wrap;min-width:fit-content;"&gt;66.9&lt;/span&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;is subject to the built-in loss rules under Section 382 and may not be realized if the underlying asset associated with the R&amp;amp;D is disposed within five years of the Merger, or May 28, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. The ownership changes will limit the amount of pre-merger Zafgen carryforwards that can be utilized annually to offset future taxable income with an annual limitation of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#333333;white-space:pre-wrap;min-width:fit-content;"&gt;35&lt;/span&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; thousand per year. The Company has reduced their NOL and R&amp;amp;D tax credit deferred tax assets associated with the pre-Merger Zafgen operations as a result of the 382 analysis.&lt;/span&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company believes that as a result of its merger with Zafgen, its ability to utilize NOLs acquired in the transaction and our other NOLs is expected to be severely limited by Section 382 of the Code. Additionally, the Company&#x2019;s July 2021, September 2022 and February 2023 equity transactions could also limit its ability to utilize NOLs in the future. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception. If the Company experienced a change of control, as defined by Section 382, at any time since inception, utilization of its net operating loss carryforwards or tax credit carryforwards would be subject to an annual limitation under Section 382, which is determined by first multiplying the value of the Company&#x2019;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Additionally, our July 2021, September 2022 and February 2024 equity transactions could also limit our ability to utilize NOLs in the future. &lt;/span&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Any limitation may result in expiration of a portion of the net operating loss carryforwards or tax credit carryforwards before utilization. Further, until a study is completed, and any limitation is known, no amounts are being presented as an uncertain tax position.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Tax Cuts and Jobs Act ("TCJA") requires taxpayers to capitalize and amortize research and experimental expenditures under IRC Section 174 for tax years beginning after December 31, 2021. This rule became effective for the Company during the year ended December 31, 2022 and resulted in the capitalization of research and development costs in both 2023 and 2022. The Company is amortizing these costs for tax purposes over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; if the research and development was performed in the U.S. and over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;15 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; if the research and development was performed outside the U.S.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company&#x2019;s net deferred tax asset balance before the valuation allowance was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#333333;white-space:pre-wrap;min-width:fit-content;"&gt;141.8&lt;/span&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#333333;white-space:pre-wrap;min-width:fit-content;"&gt;130.8&lt;/span&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively, and was comprised principally of net operating loss carryforwards, capitalized research and development expenses and tax credit carryforwards. During the years ended &lt;/span&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022, gross deferred tax assets increased due to deferred tax assets acquired as a result of additional net operating loss carryforwards and research and development tax credits generated.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets. Management has considered the Company&#x2019;s history of cumulative net losses incurred since inception and its lack of commercialization of any products or generation of any revenue from product sales since inception and has concluded that it is more likely than not that the Company will not realize the benefits of the deferred tax assets. Accordingly, a full valuation allowance has been established against the deferred tax assets as of December 31, 2023 and 2022. Management reevaluates the positive and negative evidence at each reporting period.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#333333;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t recorded any amounts for unrecognized tax benefits as of &lt;/span&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022&lt;/span&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending income tax examinations. The Company&#x2019;s tax years are still open under statute from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2019&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; to the present. Earlier years may be examined to the extent that tax credit or net operating loss carryforwards are used in future periods. The Company&#x2019;s policy is to record interest and penalties related to income taxes as part of its income tax provision.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="INF"
      id="F_5b38321f-5207-4f1a-af92-c3af61a152b5"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="INF"
      id="F_93c09c5c-f301-4cc9-a822-cf3b9db4d30a"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_40358b79-ed06-44fe-aebd-84aaa67863b5">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The domestic and foreign components of loss before income taxes are as follows.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Years ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Domestic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,339&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,949&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,355&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="-3"
      id="F_dfb6a0f6-0cc4-48ef-83b2-12250336e388"
      unitRef="U_USD">-36948000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="-3"
      id="F_6ecff1b5-e3e3-4c4a-9e11-ffc1cc1a047f"
      unitRef="U_USD">-35339000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="-3"
      id="F_1e8fd37f-5490-4bf4-8949-ea7fe1a3d5e8"
      unitRef="U_USD">-1000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="-3"
      id="F_9beae1ce-47a6-4702-a43a-9c859cb5c120"
      unitRef="U_USD">-16000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="-3"
      id="F_9d30f437-e8e8-4fd0-851b-2efb606bb6e9"
      unitRef="U_USD">-36949000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="-3"
      id="F_07c67a87-67c9-4774-aa39-537946bf1a9f"
      unitRef="U_USD">-35355000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_27362e81-d24a-4e0f-8f68-30dc93e68a77">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A&lt;/span&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; reconciliation of the U.S. federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.343%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.343%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal statutory income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in state tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal and state research and development tax credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Nondeductible permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock compensation forfeitures - DTA Write Off&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in deferred tax asset valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Effective income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="3"
      id="F_28bf7cc8-d8b4-450f-a584-8f75249b56a3"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="3"
      id="F_1e3a2760-87e0-4a56-a79b-7eb21612b767"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="3"
      id="F_eb93b7ae-174b-4aa1-8ace-370103378546"
      unitRef="U_pure">0.049</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="3"
      id="F_0b1b8f80-6c4c-499f-be27-6842153e9307"
      unitRef="U_pure">0.062</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <lrmr:EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="3"
      id="F_9a860ff1-cce8-4113-ac69-e83476cc6765"
      unitRef="U_pure">-0.017</lrmr:EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate>
    <lrmr:EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="3"
      id="F_fefd4e00-bee3-4b5e-ad82-d2f6d5343579"
      unitRef="U_pure">-0.079</lrmr:EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="3"
      id="F_85de52cf-fa02-41c7-82cc-374e3cc9c00b"
      unitRef="U_pure">0.082</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="3"
      id="F_4ab1816b-4140-4951-b523-2cce43d11788"
      unitRef="U_pure">0.011</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="3"
      id="F_a8d6d0c6-6323-467a-be45-e6412d3cdaca"
      unitRef="U_pure">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="3"
      id="F_d7dc10fa-a1a7-4ba4-8a22-45690bbe51a4"
      unitRef="U_pure">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <lrmr:EffectiveIncomeTaxRateReconciliationStockCompensationForfeituresPercent
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="3"
      id="F_589ca90a-3678-49a0-9273-c72657623766"
      unitRef="U_pure">-0.018</lrmr:EffectiveIncomeTaxRateReconciliationStockCompensationForfeituresPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="3"
      id="F_01b3b85f-6255-4fe6-b86a-e6b24d00a4ce"
      unitRef="U_pure">-0.296</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="3"
      id="F_04b2bcf2-8b55-4320-93b7-ce317aa740c6"
      unitRef="U_pure">-0.193</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="3"
      id="F_813d097e-63b8-42dd-9a4d-3766ae2d9da6"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="3"
      id="F_626334ba-6f38-4180-af92-4e8d6795e381"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_c6dac32b-c8b9-42e1-8236-e5cb94ad399d">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Net deferred tax assets as of &lt;/span&gt;&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022 consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Capitalized R&amp;amp;D - acquired in merger with Zafgen&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;66,678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;66,941&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Capitalized R&amp;amp;D - Section 174 Costs post 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,709&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45,195&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other temporary differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accruals &amp;amp; reserves&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Fixed assets &amp;amp; intangibles&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;107&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,298&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,355&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;142,538&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;131,632&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating right of use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;141,770&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;130,831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred tax assets / (liabilities)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_cd1368a9-7218-4c00-a63d-7f89c95d166f"
      unitRef="U_USD">66678000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_dd9c85cd-10f6-4b6c-8917-86551421d8b2"
      unitRef="U_USD">66941000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <lrmr:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_81fd4183-1843-4b95-a991-120d36d1a9ea"
      unitRef="U_USD">9411000</lrmr:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts>
    <lrmr:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_5d8ed426-2d97-49ea-beb6-fb5d524e7b3a"
      unitRef="U_USD">5019000</lrmr:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_27abb52f-d60a-4183-8b54-1e1dafaef8de"
      unitRef="U_USD">3490000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_a5cca039-6a9e-42f1-8096-8b254b337d05"
      unitRef="U_USD">2709000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_f0b29fab-0a7b-4dc4-80b6-341d061aad34"
      unitRef="U_USD">45195000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_6497b23a-faa7-4b29-bb22-202fc6c0497a"
      unitRef="U_USD">42204000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_b28dab93-d5d3-4ac8-ae8c-bebb55e23a7f"
      unitRef="U_USD">16319000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_ba15aabd-a451-43d2-ae82-ff74d90682cf"
      unitRef="U_USD">13284000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_1422d989-c73c-490b-9272-12a928835bd9"
      unitRef="U_USD">21000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_1807014c-e7e4-477e-8e03-e905d8a482db"
      unitRef="U_USD">20000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_f4277ef4-a187-4b3e-a017-31068256315b"
      unitRef="U_USD">19000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_fdf1f1d1-0619-44c6-879d-7bcf942623c3"
      unitRef="U_USD">19000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves>
    <lrmr:DeferredTaxAssetsFixedAssetsAndIntangibleAssets
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_db5088f8-2300-4786-a720-570b65d7eb5c"
      unitRef="U_USD">107000</lrmr:DeferredTaxAssetsFixedAssetsAndIntangibleAssets>
    <lrmr:DeferredTaxAssetsFixedAssetsAndIntangibleAssets
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_bfce9afa-5d2f-496a-a8f2-5fd3cc8df034"
      unitRef="U_USD">81000</lrmr:DeferredTaxAssetsFixedAssetsAndIntangibleAssets>
    <lrmr:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_569c8978-34bb-4a7c-8025-a80f5a13e158"
      unitRef="U_USD">1298000</lrmr:DeferredTaxAssetsOperatingLeaseLiabilities>
    <lrmr:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_2c2949e0-341e-40c2-af10-d0209cd66a37"
      unitRef="U_USD">1355000</lrmr:DeferredTaxAssetsOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_2db2b1a4-e50c-4980-a2b2-191001d43b92"
      unitRef="U_USD">142538000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_1dc795e0-11b4-4e99-89e7-e25a36b901d6"
      unitRef="U_USD">131632000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_88c9fc52-d523-4ee0-b400-1c5897f6273f"
      unitRef="U_USD">768000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_05152b9f-8505-40d8-bfe8-65bad7ad42b5"
      unitRef="U_USD">801000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_c357bfdc-f30f-4cff-9bef-756aecd97187"
      unitRef="U_USD">768000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_f4c9677f-e014-4bf6-96be-a694cf2b9cfe"
      unitRef="U_USD">801000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_c8cf427e-d809-46f2-a399-5999bd3a265c"
      unitRef="U_USD">141770000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_7307a544-756f-4f94-bdbe-0dce56d49155"
      unitRef="U_USD">130831000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:SummaryOfValuationAllowanceTextBlock
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      id="F_cf9213d8-36c6-4c13-9c53-755f3e465d7a">&lt;span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Changes to the valuation allowance were as follows:&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Years ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Valuation allowance as of the beginning of the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;130,831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;124,016&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Increases recorded to income tax provision&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,815&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Valuation allowance at end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;141,770&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;130,831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_3325cd8a-e598-4ccf-b8fc-e3029648c2f7"
      unitRef="U_USD">130831000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_cb46581b-8c63-4fee-b4c7-cc9ee9a93a21"
      decimals="-3"
      id="F_21be415b-6787-435f-9448-00fae66d3a94"
      unitRef="U_USD">124016000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_2066b280-00da-4f34-bd69-b3d154d32fd8"
      decimals="-3"
      id="F_27b7336f-e6e7-46eb-88c2-f7873f642a1a"
      unitRef="U_USD">10939000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_71666c3b-3ed8-4c95-870d-c95adde92612"
      decimals="-3"
      id="F_814ef94a-baa3-4f24-98ab-6ddc1ed62e64"
      unitRef="U_USD">6815000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-3"
      id="F_66ad2a29-d680-44d8-a3b3-af4b1b007bfc"
      unitRef="U_USD">141770000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-3"
      id="F_ee98ab93-3722-4a80-ae88-d34d85e1d369"
      unitRef="U_USD">130831000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0bbb406f-e95b-44a2-aa20-069ec9f8367d"
      decimals="-5"
      id="F_34707822-016a-4241-b464-e7a8343743e5"
      unitRef="U_USD">179000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_bb598509-13da-4a32-959a-d65c251e001c"
      decimals="-5"
      id="F_86ab5acc-90b5-4e6c-b765-fa34d3529691"
      unitRef="U_USD">1200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_d76e4f25-f643-4f25-bc71-be694bd78953"
      decimals="-5"
      id="F_ddd1b745-b3c4-4b3a-a34f-dd02562ccab4"
      unitRef="U_USD">148100000</us-gaap:OperatingLossCarryforwards>
    <lrmr:NetOperatingLossCarryForwardExpirationYearBegin
      contextRef="C_17f828a8-cd38-4b18-ac31-c79bc0508443"
      id="F_f2abf064-a220-4237-b1d7-8d506373100b">2026</lrmr:NetOperatingLossCarryForwardExpirationYearBegin>
    <lrmr:NetOperatingLossCarryForwardExpirationYearBegin
      contextRef="C_c1f2a4df-aa2f-4030-a1d3-a3da85f2634e"
      id="F_d7fb0ec4-b9c8-4605-836b-27d7f20212c5">2030</lrmr:NetOperatingLossCarryForwardExpirationYearBegin>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_b1cbaf6b-72b0-4de8-aef3-35073ff760cf"
      decimals="-5"
      id="F_00f2111d-a00e-4d90-a159-7b5756c9ac7d"
      unitRef="U_USD">140300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse
      contextRef="C_73fffb18-77da-4d3d-8982-345e143a5dd4"
      id="F_76b7936f-06fd-44d8-b31c-b34748172b71">carryforwards are limited to 80% of the taxable income in any one tax period.</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <lrmr:OperatingLossCarryforwardsMinimumPercentageOfTaxableIncomeInTaxPeriod
      contextRef="C_73fffb18-77da-4d3d-8982-345e143a5dd4"
      decimals="2"
      id="F_5c7cb695-3546-44a1-acba-8da764123c04"
      unitRef="U_pure">0.80</lrmr:OperatingLossCarryforwardsMinimumPercentageOfTaxableIncomeInTaxPeriod>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_e879db45-fbcf-422c-84ea-f7c96123af6f"
      decimals="-5"
      id="F_95ac9944-1097-4636-b3a9-e4814b1b1888"
      unitRef="U_USD">16300000</us-gaap:TaxCreditCarryforwardAmount>
    <lrmr:TaxCreditCarryForwardExpirationYearStart
      contextRef="C_04fe8bd0-766a-4741-afc3-501f8a39c817"
      id="F_245637dc-6dc1-4f6a-972f-df290bc3bd37">2039</lrmr:TaxCreditCarryForwardExpirationYearStart>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_8f177c92-7fde-43e5-bb65-ae7ee79f52cb"
      decimals="-5"
      id="F_3ce8c0e9-737b-45cf-b779-54a27a3fbdaa"
      unitRef="U_USD">33500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_8f177c92-7fde-43e5-bb65-ae7ee79f52cb"
      decimals="-5"
      id="F_d1611073-2c69-4100-8ff1-bd607485684e"
      unitRef="U_USD">66900000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <lrmr:NetCapitalizedRDDeferredTaxAssetsRealizationDescription
      contextRef="C_ccc62b5b-71d4-486d-aec0-66d4350d7baf"
      id="F_373c08e7-3af1-4fea-af88-25958810a79a">is subject to the built-in loss rules under Section 382 and may not be realized if the underlying asset associated with the R&amp;D is disposed within five years of the Merger, or May 28, 2025</lrmr:NetCapitalizedRDDeferredTaxAssetsRealizationDescription>
    <lrmr:NetOperatingLossCarryforwardsAnnualUtilizationLimitChangeInOwnership
      contextRef="C_ccc62b5b-71d4-486d-aec0-66d4350d7baf"
      decimals="-3"
      id="F_0d1b1e5f-8bee-4ba6-94ae-45c187869da5"
      unitRef="U_USD">35000</lrmr:NetOperatingLossCarryforwardsAnnualUtilizationLimitChangeInOwnership>
    <lrmr:CapitalizedResearchAndDevelopmentAmortizationPeriod
      contextRef="C_e3617796-30ca-4ac0-abe2-0626ffe07078"
      id="F_e7f8a078-9e40-465b-aa1c-7a4f231b7056">P5Y</lrmr:CapitalizedResearchAndDevelopmentAmortizationPeriod>
    <lrmr:CapitalizedResearchAndDevelopmentAmortizationPeriod
      contextRef="C_ba0cb289-2a01-465c-bc0c-d7869d54c786"
      id="F_a5fbc33e-6f7d-464a-910a-a7bab8eb420d">P15Y</lrmr:CapitalizedResearchAndDevelopmentAmortizationPeriod>
    <lrmr:DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="-5"
      id="F_9a32a0ef-cef6-4886-a8ec-88bcaa184298"
      unitRef="U_USD">141800000</lrmr:DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance>
    <lrmr:DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="-5"
      id="F_f8d08d42-4ee5-4a4f-b955-69aa59acad5c"
      unitRef="U_USD">130800000</lrmr:DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_888f9f57-5a7b-41a2-9fd9-4778351dfedb"
      decimals="INF"
      id="F_5d7a2ea2-782f-4eb8-af0c-184c42fe8e2b"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_cf75de90-0aaa-46d6-bc15-445c359ea784"
      decimals="INF"
      id="F_1b6b2159-68d4-4378-81b4-06b2f19d1d48"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:OpenTaxYear
      contextRef="C_3beedc45-1504-486d-95b7-175808b52042"
      id="F_3121b984-6f0a-44ed-9156-cfd2472adee9">2019</us-gaap:OpenTaxYear>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
